PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Asano, S; Yoshida, A; Yashiro, H; Kobayashi, Y; Morisato, A; Ogawa, H; Takeguchi, N; Morii, M				Asano, S; Yoshida, A; Yashiro, H; Kobayashi, Y; Morisato, A; Ogawa, H; Takeguchi, N; Morii, M			The cavity structure for docking the K+-competitive inhibitors in the gastric proton pump	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; MUTATIONAL ANALYSIS; BINDING-SITES; TRANSMEMBRANE SEGMENT; FUNCTIONAL EXPRESSION; CALCIUM-PUMP; H+,K+-ATPASE; H,K-ATPASE; SUBUNIT; OMEPRAZOLE	2-Methyl-8-(phenylmethoxy) imidazo[1,2-a] pyridine-3-acetonitrile (SCH 28080) is a reversible inhibitor specific for the gastric proton pump. The inhibition pattern is competitive with K+. Here we studied the binding sites of this inhibitor on the putative three-dimensional structure of the gastric proton pump alpha-subunit that was constructed by homology modeling based on the structure of sarcoplasmic reticulum Ca2+ pump. Alanine and serine mutants of Tyr(801) located in the fifth transmembrane segment of the gastric proton pump alpha-subunit retained the Rb-86 transport and K+-dependent ATPase (K+-ATPase) activities. These mutants showed 60 - 80-times lower sensitivity to SCH 28080 than the wild type in the 86Rb transport activity. The K+-ATPase activities of these mutants were not completely inhibited by SCH 28080. The sensitivity to SCH 28080 was dependent on the bulkiness of the side chain at this position. Therefore, the side chain of Tyr(801) is important for the interaction with this inhibitor. In the three-dimensional structure of the E-2 form (conformation with high affinity for K+) of the gastric proton pump, Tyr(801) faces a cavity surrounded by the first, fourth, fifth, sixth, and eighth transmembrane segments and fifth/sixth, seventh/ eighth, and ninth/tenth loops. SCH 28080 can dock in this cavity. However, SCH 28080 cannot dock in the same location in the E-1 form ( conformation with high affinity for proton) of the gastric proton pump due to the drastic rearrangement of the transmembrane helices between the E-1 and E-2 forms. These results support the idea that this cavity is the binding pocket of SCH 28080.	Toyama Med & Pharmaceut Univ, Life Sci Res Ctr, Toyama 9300194, Japan; Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Toyama 9300194, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bukyo Ku, Tokyo 1130032, Japan	University of Toyama; University of Toyama; University of Tokyo	Asano, S (corresponding author), Toyama Med & Pharmaceut Univ, Life Sci Res Ctr, 2630 Sugitani, Toyama 9300194, Japan.	shinji@ms.toyama-mpu.ac.jp		Asano, Shinji/0000-0003-1443-8970				Asano S, 2000, J BIOCHEM, V127, P993, DOI 10.1093/oxfordjournals.jbchem.a022716; ASANO S, 1994, BIOCHEM J, V299, P59, DOI 10.1042/bj2990059; Asano S, 1997, J BIOL CHEM, V272, P17668, DOI 10.1074/jbc.272.28.17668; Asano S, 1996, J BIOL CHEM, V271, P2740, DOI 10.1074/jbc.271.5.2740; Asano S, 2001, J BIOL CHEM, V276, P31265, DOI 10.1074/jbc.M103698200; Asano S, 1999, J BIOL CHEM, V274, P6848, DOI 10.1074/jbc.274.11.6848; BEIL W, 1986, BRIT J PHARMACOL, V88, P19, DOI 10.1111/j.1476-5381.1986.tb09466.x; Besancon M, 1997, J BIOL CHEM, V272, P22438, DOI 10.1074/jbc.272.36.22438; Brady GP, 2000, J COMPUT AID MOL DES, V14, P383, DOI 10.1023/A:1008124202956; Farley RA, 2001, J BIOL CHEM, V276, P2608, DOI 10.1074/jbc.M008784200; FARLEY RA, 1985, J BIOL CHEM, V260, P3899; Grishin AV, 1996, AM J PHYSIOL-RENAL, V271, pF539, DOI 10.1152/ajprenal.1996.271.3.F539; Hermsen HPH, 2000, BIOCHEMISTRY-US, V39, P1330, DOI 10.1021/bi991396y; Hermsen HPH, 1998, BIOCHEM J, V331, P465, DOI 10.1042/bj3310465; HERSEY SJ, 1988, BIOCHIM BIOPHYS ACTA, V956, P49, DOI 10.1016/0167-4838(88)90296-8; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KEELING DJ, 1989, J BIOL CHEM, V264, P5545; KEELING DJ, 1988, BIOCHEM PHARMACOL, V37, P2231, DOI 10.1016/0006-2952(88)90586-2; Kimura T, 2002, J BIOL CHEM, V277, P20671, DOI 10.1074/jbc.M200523200; Kimura T, 2002, J BIOCHEM, V131, P923, DOI 10.1093/oxfordjournals.jbchem.a003183; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambrecht N, 2000, J BIOL CHEM, V275, P4041, DOI 10.1074/jbc.275.6.4041; MOLLER M, 1986, ADV PINEAL RES, V1, P51; MORII M, 1993, J BIOL CHEM, V268, P21553; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; MUNSON KB, 1991, J BIOL CHEM, V266, P18976; Munson KB, 2000, BIOCHEMISTRY-US, V39, P2997, DOI 10.1021/bi991837d; Ogawa H, 2002, P NATL ACAD SCI USA, V99, P15977, DOI 10.1073/pnas.202622299; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Rost B, 1996, METHOD ENZYMOL, V266, P525; Rulli SJ, 2001, ARCH BIOCHEM BIOPHYS, V387, P27, DOI 10.1006/abbi.2000.2243; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sanner M F, 1999, Pac Symp Biocomput, P401; SHULL GE, 1986, J BIOL CHEM, V261, P6788; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Tsukimi Y, 2000, JPN J PHARMACOL, V82, P21, DOI 10.1254/jjp.82.21; Ushiro T, 1997, JPN J PHARMACOL, V75, P303; Vagin O, 2002, BIOCHEMISTRY-US, V41, P12755, DOI 10.1021/bi025921w; Vagin O, 2001, BIOCHEMISTRY-US, V40, P7480, DOI 10.1021/bi0105328; WALLMARK B, 1985, J BIOL CHEM, V260, P3681; YODA A, 1970, BIOCHEM BIOPH RES CO, V40, P880, DOI 10.1016/0006-291X(70)90985-X; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	46	38	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13968	13975		10.1074/jbc.M308934200	http://dx.doi.org/10.1074/jbc.M308934200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14699149	hybrid			2022-12-25	WOS:000220478500084
J	Lin, SH; Nishino, M; Luo, WP; Aumais, JP; Galfione, M; Kuang, J; Yu-Lee, LY				Lin, SH; Nishino, M; Luo, WP; Aumais, JP; Galfione, M; Kuang, J; Yu-Lee, LY			Inhibition of prostate tumor growth by overexpression of NudC, a microtubule motor-associated protein	ONCOGENE			English	Article						NudC; dynein; microtubule; mitosis; prostate cancer	NUCLEAR MIGRATION GENE; CARCINOMA CELL-LINE; CYTOPLASMIC DYNEIN; MOVEMENT PROTEIN; ASPERGILLUS-NIDULANS; DYNACTIN REVEALS; HUMAN HOMOLOG; LIS1; LOCALIZATION; EXPRESSION	Microtubules play a central role in coordinating various cellular functions that are orchestrated by their interaction with molecular motors. Anticancer drugs that target microtubule dynamics have been shown to be effective in cancer treatment. However, the effect of microtubule motor-associated molecules on cancer cell proliferation is not clear. Here, we investigated the role of NudC, a nuclear movement protein associated with the microtubule motor dynein, on prostate tumorigenesis. Recombinant adenovirus expressing NudC (Ad-NudC) was used to examine the effects of NudC on the tumorigenicity of prostate cancer cells. Expression of NudC in LNCaP cells inhibited their anchorage-independent growth in a soft agar colony assay. Expression of NudC in DU145 or PC-3 cells inhibited tumor growth in a subcutaneous xenograft model. At the cellular level, expression of NudC in DU145 and PC-3 cells inhibited cell proliferation at 48 h after Ad-NudC infection. FACS analysis of cell cycle distribution showed that 50-60% of Ad-NudC-infected PC-3 cells have a G2/M-phase DNA content compared to about 16-19% in Ad-Luciferase (Ad-Luc)-infected control cells, suggesting that NudC overexpression resulted in aberrant cell cycle progression. Immunofluorescence microscopy revealed a significant increase in cells with a single enlarged nucleus and cells exhibiting multiple nuclei, along with a concomitant increase in cell size in Ad-NudC-infected cells. These results suggest that NudC overexpression led to a block in cell division of prostate cancer cells, and that Ad-NudC may provide a new anticancer drug approach targeting the function of a microtubule motor-associated protein.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Baylor Coll Med, Cell & Mol Biol Program, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Yu-Lee, LY (corresponding author), Baylor Coll Med, Dept Med, Houston, TX 77030 USA.	yulee@bcm.tmc.edu		Nishino, Michiya/0000-0003-4692-4981	NCI NIH HHS [R01 CA86342] Funding Source: Medline; NIDDK NIH HHS [R01 DK53176] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086342] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053176] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Angus SP, 2002, EXP CELL RES, V276, P201, DOI 10.1006/excr.2002.5510; Aumais JP, 2003, J CELL SCI, V116, P1991, DOI 10.1242/jcs.00412; Aumais JP, 2000, MOL BIOL CELL, V11, p353A; Aumais JP, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-24-j0002.2001; AXTELL SM, 1995, MOL ENDOCRINOL, V9, P312, DOI 10.1210/me.9.3.312; Baas PW, 1999, NEURON, V22, P23, DOI 10.1016/S0896-6273(00)80675-3; Banks JD, 2001, CURR BIOL, V11, pR128, DOI 10.1016/S0960-9822(01)00059-8; Beaudouin J, 2002, CELL, V108, P83, DOI 10.1016/S0092-8674(01)00627-4; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Chen JG, 2002, CANCER RES, V62, P1935; Chiu YH, 1997, MOL BIOL CELL, V8, P1735, DOI 10.1091/mbc.8.9.1735; Coquelle FM, 2002, MOL CELL BIOL, V22, P3089, DOI 10.1128/MCB.22.9.3089-3102.2002; Dujardin DL, 2002, CURR OPIN CELL BIOL, V14, P44, DOI 10.1016/S0955-0674(01)00292-7; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Estrera VT, 2001, J BIOL CHEM, V276, P15547, DOI 10.1074/jbc.M008156200; Faulkner NE, 2000, NAT CELL BIOL, V2, P784, DOI 10.1038/35041020; Gartel AL, 2002, MOL CANCER THER, V1, P639; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Gocke CD, 2000, HISTOCHEM CELL BIOL, V114, P293; Gocke CD, 2000, LEUKEMIA LYMPHOMA, V39, P447, DOI 10.3109/10428190009113375; Han GS, 2001, CURR BIOL, V11, P719, DOI 10.1016/S0960-9822(01)00200-7; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; KAIGHN ME, 1979, INVEST UROL, V17, P16; Karki S, 1998, J CELL BIOL, V142, P1023, DOI 10.1083/jcb.142.4.1023; Karki S, 1999, CURR OPIN CELL BIOL, V11, P45, DOI 10.1016/S0955-0674(99)80006-4; Ligon LA, 2003, MOL BIOL CELL, V14, P1405, DOI 10.1091/mbc.E02-03-0155; Lin SH, 1999, ANTICANCER RES, V19, P337; Miller BA, 1999, EXP HEMATOL, V27, P742, DOI 10.1016/S0301-472X(98)00074-5; Moreau N, 2001, INT J DEV BIOL, V45, P839; Morris NR, 2000, J CELL BIOL, V148, P1097, DOI 10.1083/jcb.148.6.1097; Morris SM, 1998, EXP CELL RES, V238, P23, DOI 10.1006/excr.1997.3822; Morris SM, 1997, MOL ENDOCRINOL, V11, P229, DOI 10.1210/me.11.2.229; Morris SM, 1998, CURR BIOL, V8, P603, DOI 10.1016/S0960-9822(98)70232-5; Niethammer M, 2000, NEURON, V28, P697, DOI 10.1016/S0896-6273(00)00147-1; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; OSMANI AH, 1990, J CELL BIOL, V111, P543, DOI 10.1083/jcb.111.2.543; Peterson JR, 2002, CHEM BIOL, V9, P1275, DOI 10.1016/S1074-5521(02)00284-3; Quintyne NJ, 1999, J CELL BIOL, V147, P321, DOI 10.1083/jcb.147.2.321; Quintyne NJ, 2002, J CELL BIOL, V159, P245, DOI 10.1083/jcb.200203089; ROCKWELL SC, 1972, J NATL CANCER I, V49, P735; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; Salina D, 2002, CELL, V108, P97, DOI 10.1016/S0092-8674(01)00628-6; Smith DS, 2000, NAT CELL BIOL, V2, P767, DOI 10.1038/35041000; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; Straight AF, 2000, CURR BIOL, V10, pR760, DOI 10.1016/S0960-9822(00)00746-6; Tai CY, 2002, J CELL BIOL, V156, P959, DOI 10.1083/jcb.200109046; Talcott B, 2000, J BIOL CHEM, V275, P10099, DOI 10.1074/jbc.275.14.10099; Wood Kenneth W., 2001, Current Opinion in Pharmacology, V1, P370, DOI 10.1016/S1471-4892(01)00064-9; Yan XM, 2003, MOL CELL BIOL, V23, P1239, DOI 10.1128/MCB.23.4.1239-1250.2003; Zhang MY, 2002, EXP CELL RES, V273, P73, DOI 10.1006/excr.2001.5414; Zhou T, 2003, DEV CELL, V5, P127, DOI 10.1016/S1534-5807(03)00186-2	52	26	28	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2499	2506		10.1038/sj.onc.1207343	http://dx.doi.org/10.1038/sj.onc.1207343			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14676831				2022-12-25	WOS:000220558000007
J	Huai, Q; Liu, YD; Francis, SH; Corbin, JD; Ke, HM				Huai, Q; Liu, YD; Francis, SH; Corbin, JD; Ke, HM			Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determinant of inhibitor selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; CAMP PHOSPHODIESTERASES; CATALYTIC DOMAIN; PDE4; AMP; DIVERSITY; MECHANISM	Cyclic nucleotide phosphodiesterases (PDEs) are a superfamily of enzymes controlling cellular concentrations of the second messengers cAMP and cGMP. Crystal structures of the catalytic domains of cGMP-specific PDE5A1 and cAMP-specific PDE4D2 in complex with the nonselective inhibitor 3-isobutyl-1-methylxanthine have been determined at medium resolution. The catalytic domain of PDE5A1 has the same topological folding as that of PDE4D2, but three regions show different tertiary structures, including residues 79 - 113, 208 - 224 (H-loop), and 341 - 364 (M-loop) in PDE4D2 or 535 - 566, 661 - 676, and 787 - 812 in PDE5A1, respectively. Because H- and M-loops are involved in binding of the selective inhibitors, the different conformations of the loops, thus the distinct shapes of the active sites, will be a determinant of inhibitor selectivity in PDEs. IBMX binds to a subpocket that comprises key residues Ile-336, Phe-340, Gln-369, and Phe-372 of PDE4D2 or Val-782, Phe-786, Gln-817, and Phe-820 of PDE5A1. This subpocket may be a common site for binding nonselective inhibitors of PDEs.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Vanderbilt University	Ke, HM (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.	hke@med.unc.edu	, PEP-MX Core/AGV-4051-2022		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058277, R01DK040029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059791] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA016086] Funding Source: Medline; NIDDK NIH HHS [DK 40029, DK 58277] Funding Source: Medline; NIGMS NIH HHS [GM 59791] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alvarez R, 1996, PHOSPHODIESTERASE IN, P161; Antoni FA, 2000, FRONT NEUROENDOCRIN, V21, P103, DOI 10.1006/frne.1999.0193; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barnard A, 2000, J ROY ANTHROPOL INST, V6, P164; Barnette M S, 1999, Prog Drug Res, V53, P193; BEAVO JA, 1970, MOL PHARMACOL, V6, P597; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carvajal JA, 2000, J CELL PHYSIOL, V184, P409, DOI 10.1002/1097-4652(200009)184:3<409::AID-JCP16>3.3.CO;2-B; Chin KV, 2002, ANN NY ACAD SCI, V968, P49, DOI 10.1111/j.1749-6632.2002.tb04326.x; Conti M, 2003, J BIOL CHEM, V278, P5493, DOI 10.1074/jbc.R200029200; Corbin JD, 1999, J BIOL CHEM, V274, P13729, DOI 10.1074/jbc.274.20.13729; Corbin JD, 2002, INT J CLIN PRACT, V56, P453; Dal Piaz V, 2000, EUR J MED CHEM, V35, P463, DOI 10.1016/S0223-5234(00)00179-3; Degerman E, 1996, BIOCHEM SOC T, V24, P1010, DOI 10.1042/bst0241010; Fink TL, 1999, J BIOL CHEM, V274, P34613, DOI 10.1074/jbc.274.49.34613; Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1; FRANCIS SH, 1994, J BIOL CHEM, V269, P22477; Francis SH, 2000, BIOCHEMISTRY-US, V39, P9591, DOI 10.1021/bi000392m; Giembycz M A, 2002, Monaldi Arch Chest Dis, V57, P48; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; Houslay MD, 2003, BIOCHEM J, V370, P1, DOI 10.1042/BJ20021698; Huai Q, 2003, BIOCHEMISTRY-US, V42, P13220, DOI 10.1021/bi034653e; Huai Q, 2003, STRUCTURE, V11, P865, DOI 10.1016/S0969-2126(03)00123-0; Huang Z, 2001, CURR OPIN CHEM BIOL, V5, P432, DOI 10.1016/S1367-5931(00)00224-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Klein C, 2002, CELL SIGNAL, V14, P493, DOI 10.1016/S0898-6568(01)00283-2; Lee ME, 2002, FEBS LETT, V530, P53, DOI 10.1016/S0014-5793(02)03396-3; Liu YG, 2001, CARDIOVASC DRUG REV, V19, P369, DOI 10.1111/j.1527-3466.2001.tb00076.x; Lucas KA, 2000, PHARMACOL REV, V52, P375; MANGANIELLO VC, 1995, CELL SIGNAL, V7, P445, DOI 10.1016/0898-6568(95)00017-J; MANGANIELLO VC, 1995, ARCH BIOCHEM BIOPHYS, V322, P1, DOI 10.1006/abbi.1995.1429; Mehats C, 2002, TRENDS ENDOCRIN MET, V13, P29, DOI 10.1016/S1043-2760(01)00523-9; Movsesian MA, 2000, EXPERT OPIN INV DRUG, V9, P963, DOI 10.1517/13543784.9.5.963; Muller T, 1996, TRENDS PHARMACOL SCI, V17, P294, DOI 10.1016/0165-6147(96)10035-3; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pelligrino DA, 1998, PROG NEUROBIOL, V56, P1, DOI 10.1016/S0301-0082(98)00009-4; Rotella DP, 2002, NAT REV DRUG DISCOV, V1, P674, DOI 10.1038/nrd893; SEKHAR KR, 1996, PHOSPHODIESTERASE IN, P135; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; Souness JE, 2000, IMMUNOPHARMACOLOGY, V47, P127, DOI 10.1016/S0162-3109(00)00185-5; Sturton G, 2002, CHEST, V121, p192S, DOI 10.1378/chest.121.5_suppl.192S; Sung BJ, 2003, NATURE, V425, P98, DOI 10.1038/nature01914; Torphy TJ, 1998, AM J RESP CRIT CARE, V157, P351, DOI 10.1164/ajrccm.157.2.9708012; Truss MC, 2001, WORLD J UROL, V19, P344, DOI 10.1007/s003450100221; Xu RX, 2000, SCIENCE, V288, P1822, DOI 10.1126/science.288.5472.1822	46	96	104	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13095	13101		10.1074/jbc.M311556200	http://dx.doi.org/10.1074/jbc.M311556200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14668322	hybrid, Green Published			2022-12-25	WOS:000220334900130
J	Zhao, M; Qiao, M; Harris, SE; Oyajobi, BO; Mundy, GR; Chen, D				Zhao, M; Qiao, M; Harris, SE; Oyajobi, BO; Mundy, GR; Chen, D			Smurf1 inhibits osteoblast differentiation and bone formation in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E3 UBIQUITIN LIGASE; RECEPTOR; DEGRADATION; EXPRESSION; TARGETS; SMAD7; SCLEROSTIN; NOGGIN; ROLES; CELLS	Bone morphogenetic proteins (BMPs) are required for normal postnatal bone formation and osteoblast differentiation. There is evidence from recent studies that BMP signaling in osteoblasts is controlled by an ubiquitin-proteasome regulatory mechanism involving a cascade of enzymatic reactions. The specificity of protein ubiquitination is determined by E3 ubiquitin ligases, which play a crucial role in defining substrate specificity and subsequent protein degradation by 26S proteasomes. We have examined the role of the E3 ubiquitin ligase (Sm) under bar ad (u) under bar biquitin (r) under bar egulatory factor 1 (Smurf1), a member of the Hect domain family of E3 ubiquitin ligases in osteoblast function. Smurf1 has been found to interact with BMP-activated Smad1 and -5 and to mediate degradation of these Smad proteins. Recently we have found that Smurf1 mediates the protein degradation of the osteoblast-specific transcription factor Runx2/Cbfa1. To determine the role of Smurf1 in osteoblast differentiation, in the present studies we transfected a Smurf1 expression plasmid into 2T3 osteoblast precursor cells and found that Smurf1 overexpression inhibits BMP signaling and osteoblast differentiation. To further investigate the role of Smurf1 in bone formation in vivo, we generated transgenic mice in which expression of the epitope-tagged Smurf1 transgene was targeted to osteoblasts using the murine 2.3-kb osteoblast-specific type I collagen promoter. In these transgenic mice, bone formation was significantly reduced during postnatal life. Our results demonstrate for the first time that Smurf1 plays a specific role in osteoblast differentiation and bone formation in vivo.	Univ Rochester, Med Ctr, Ctr Musculoskeletal Res, Rochester, NY 14642 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Univ Missouri, Dept Oral Biol, Kansas City, MO 64108 USA	University of Rochester; University of Texas System; University of Texas Health San Antonio; University of Missouri System; University of Missouri Kansas City	Chen, D (corresponding author), Univ Rochester, Med Ctr, Ctr Musculoskeletal Res, 601 Elmwood Ave, Rochester, NY 14642 USA.	di_chen@urmc.rochester.edu		Oyajobi, Babatunde/0000-0002-1064-3072	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051189, R03AR048920] Funding Source: NIH RePORTER; NIAMS NIH HHS [R03 AR048920, R01 AR051189-01, AR 051189, R03 AR048920-04, AR 048920, R01 AR051189, R03 AR048920-03] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Devlin RD, 2003, ENDOCRINOLOGY, V144, P1972, DOI 10.1210/en.2002-220918; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Feng JQ, 2003, J BIOL CHEM, V278, P29130, DOI 10.1074/jbc.M212296200; Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198; Groppe J, 2002, NATURE, V420, P636, DOI 10.1038/nature01245; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HERSHKO A, 1983, CELL, V34, P11, DOI 10.1016/0092-8674(83)90131-9; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kusu N, 2003, J BIOL CHEM, V278, P24113, DOI 10.1074/jbc.M301716200; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Murakami G, 2003, MOL BIOL CELL, V14, P2809, DOI 10.1091/mbc.E02-07-0441; Podos SD, 2001, DEV CELL, V1, P567, DOI 10.1016/S1534-5807(01)00057-0; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; Suzuki C, 2002, J BIOL CHEM, V277, P39919, DOI 10.1074/jbc.M201901200; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Wozney JM, 1998, CLIN ORTHOP RELAT R, P26; Ying SX, 2003, J BIOL CHEM, V278, P39029, DOI 10.1074/jbc.M301193200; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200; Zhao M, 2002, J CELL BIOL, V157, P1049, DOI 10.1083/jcb.200109012; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	28	168	183	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12854	12859		10.1074/jbc.M313294200	http://dx.doi.org/10.1074/jbc.M313294200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14701828	Green Accepted, hybrid			2022-12-25	WOS:000220334900101
J	Wolfger, H; Mamnun, YM; Kuchler, K				Wolfger, H; Mamnun, YM; Kuchler, K			The yeast Pdr15p ATP-binding cassette (ABC) protein is a general stress response factor implicated in cellular detoxification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLEIOTROPIC DRUG-RESISTANCE; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; NUCLEAR-LOCALIZATION; OSMOTIC REGULATION; PLASMA-MEMBRANE; BUDDING YEAST; ELEMENT STRE; IN-VIVO; PDR3	ATP-binding cassette (ABC) transporters play important roles in drug efflux, but some may also function in cellular detoxification. The Pdr15p ABC protein is the closest homologue of the multidrug efflux transporter Pdr5p, which mediates pleiotropic drug resistance to hundreds of unrelated compounds. In this study, we show that the plasma membrane protein Pdr15p displays limited drug transport capacity, mediating chloramphenicol and detergent tolerance. Interestingly, Pdr15p becomes most abundant when cells exit the exponential growth phase, whereas its closest homologue, Pdr5p, disappears after exponential growth. Furthermore, in contrast to Pdr5p, Pdr15p is strongly induced by various stress conditions including heat shock, low pH, weak acids, or high osmolarity. PDR15 induction bypasses the Pdr1p/Pdr3p regulators but requires the general stress regulator Msn2p, which directly decorates the stress response elements in the PDR15 promoter. Remarkably, however, Pdr15p induction bypasses upstream components of the high osmolarity glycerol (HOG) pathway including the Hog1p and Pbs2p kinases as well as the dedicated HOG cell surface sensors. Our data provide evidence for a novel upstream branch of the general stress response pathway activating Msn2p. In addition, the results demonstrate a crosstalk between stress response and the pleiotropic drug resistance network.	Med Univ Vienna, Max F Perutz Labs, Div Mol Genet, Dept Biochem Med, A-1030 Vienna, Austria; Bioctr Vienna, A-1030 Vienna, Austria	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Vienna Biocenter (VBC)	Kuchler, K (corresponding author), Med Univ Vienna, Max F Perutz Labs, Div Mol Genet, Dept Biochem Med, Dr Bohr Gasse 9-2, A-1030 Vienna, Austria.	karl.kuchler@univie.ac.at	kuchler, karl/AAL-6937-2020	kuchler, karl/0000-0003-2719-5955				Alepuz PM, 2003, EMBO J, V22, P2433, DOI 10.1093/emboj/cdg243; BALZI E, 1994, J BIOL CHEM, V269, P2206; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; Boy-Marcotte E, 1998, J BACTERIOL, V180, P1044, DOI 10.1128/JB.180.5.1044-1052.1998; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Coleman ST, 1999, MOL CELL BIOL, V19, P8302; Cui Z, 1998, MOL MICROBIOL, V29, P1307, DOI 10.1046/j.1365-2958.1998.01027.x; Decottignies A, 1998, J BIOL CHEM, V273, P12612, DOI 10.1074/jbc.273.20.12612; DECOTTIGNIES A, 1994, J BIOL CHEM, V269, P12797; DELAVEAU T, 1994, MOL GEN GENET, V244, P501, DOI 10.1007/BF00583901; DeRisi J, 2000, FEBS LETT, V470, P156, DOI 10.1016/S0014-5793(00)01294-1; Egner R, 1996, FEBS LETT, V378, P177, DOI 10.1016/0014-5793(95)01450-0; ESTRUCH F, 1993, MOL CELL BIOL, V13, P3872, DOI 10.1128/MCB.13.7.3872; Fernandes L, 1997, MOL CELL BIOL, V17, P6982, DOI 10.1128/MCB.17.12.6982; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gorner W, 2002, EMBO J, V21, P135, DOI 10.1093/emboj/21.1.135; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Hallstrom TC, 1998, J BIOL CHEM, V273, P2098, DOI 10.1074/jbc.273.4.2098; Hanson PK, 2001, J BIOL CHEM, V276, P9861, DOI 10.1074/jbc.M009065200; Kaiser C., 1994, METHODS YEAST GENETI; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; Katzmann DJ, 1996, J BIOL CHEM, V271, P23049, DOI 10.1074/jbc.271.38.23049; Kean LS, 1997, J CELL BIOL, V138, P255, DOI 10.1083/jcb.138.2.255; Kolaczkowski M, 1996, J BIOL CHEM, V271, P31543, DOI 10.1074/jbc.271.49.31543; Kolaczkowski M, 1998, MICROB DRUG RESIST, V4, P143, DOI 10.1089/mdr.1998.4.143; Kontoyiannis DP, 2000, J ANTIMICROB CHEMOTH, V46, P199, DOI 10.1093/jac/46.2.199; Kren A, 2003, MOL CELL BIOL, V23, P1775, DOI 10.1128/MCB.23.5.1775-1785.2003; Le Crom S, 2002, MOL CELL BIOL, V22, P2642, DOI 10.1128/MCB.22.8.2642-2649.2002; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mahe Y, 1996, MOL MICROBIOL, V20, P109, DOI 10.1111/j.1365-2958.1996.tb02493.x; Mahe Y, 1996, J BIOL CHEM, V271, P25167, DOI 10.1074/jbc.271.41.25167; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; Reiser V, 1999, MOL BIOL CELL, V10, P1147, DOI 10.1091/mbc.10.4.1147; Rep M, 2000, J BIOL CHEM, V275, P8290, DOI 10.1074/jbc.275.12.8290; Rep M, 1999, MOL CELL BIOL, V19, P5474; Rep M, 2001, MOL MICROBIOL, V40, P1067, DOI 10.1046/j.1365-2958.2001.02384.x; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; SERVOS J, 1993, MOL GEN GENET, V236, P214, DOI 10.1007/BF00277115; SIKORSKI RS, 1989, GENETICS, V122, P19; WEMMIE A, 1994, J BIOL CHEM, V269, P14690; Wolfger H, 1997, FEBS LETT, V418, P269, DOI 10.1016/S0014-5793(97)01382-3; Wolfger H, 2001, RES MICROBIOL, V152, P375, DOI 10.1016/S0923-2508(01)01209-8	48	45	48	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11593	11599		10.1074/jbc.M311282200	http://dx.doi.org/10.1074/jbc.M311282200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699125	hybrid			2022-12-25	WOS:000220157600092
J	Bondar, T; Ponomarev, A; Raychaudhuri, P				Bondar, T; Ponomarev, A; Raychaudhuri, P			Ddb1 is required for the proteolysis of the Schizosaccharomyces pombe replication inhibitor Spd1 during S phase and after DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COP9 SIGNALOSOME; FISSION YEAST; CULLIN 4A; PROTEIN; DEGRADATION; SCF; COP9/SIGNALOSOME; EXPRESSION; PATHWAY; COMPLEX	Recently we showed that the Schizosaccharomyces pombe ddb1 gene plays a role in S phase progression. A mutant S. pombe strain lacking expression of the ddb1 gene exhibited slow replication through both early and late regions causing a slow S phase phenotype. We attributed the phenotypes in the ddb1 strain to an increased activity of the replication checkpoint kinase Cds1. However, the basis for a high basal Cds1 activity in the ddb1 strain was not clear. It was shown that Ddb1 associates with the Cop9/signalosome. Moreover, the phenotypes of the Deltaddb1 strain are remarkably similar to the Deltacsn1 (or Deltacsn2) strain that lacks expression of the Csn1 (or Csn2) subunit of the Cop9/signalosome. Cop9/signalosome cooperates with Pcu4 to induce proteolysis of Spd1, which inhibits DNA replication by inhibiting ribonucleotide reductase. Therefore, we investigated whether Ddb1 is required for the proteolysis of Spd1. Here we show that a S. pombe strain lacking expression of Ddb1 fails to induce proteolysis of Spd1 in S phase and after DNA damage. Moreover, deletion of the spd1 gene attenuates the Cds1 kinase activity in cells lacking the expression of ddb1, suggesting that an accumulation of Spd1 results in the increase of Cds1 activity in the Deltaddb1 strain. In addition, the double mutant lacking spd1 and ddb1 no longer exhibits the growth defects and DNA damage sensitivity observed in the Deltaddb1 strain. Our results establish an essential role of Ddb1 in the proteolysis of Spd1. In addition, the observation provides evidence for a functional link between Ddb1 and the Cop9/signalosome.	Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raychaudhuri, P (corresponding author), Univ Illinois, Dept Biochem & Mol Genet, 900 S Ashland Ave,M-C 696, Chicago, IL 60607 USA.	Pradip@uic.edu	Bondar, Tanya/T-5576-2017	Bondar, Tanya/0000-0003-4765-8910	NCI NIH HHS [CA88863] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088863] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMIC M, 1991, J BIOL CHEM, V266, P22493; BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; Bondar T, 2003, J BIOL CHEM, V278, P37006, DOI 10.1074/jbc.M303003200; Borgne A, 2000, J CELL SCI, V113, P4341; Chabes A, 2000, J BIOL CHEM, V275, P17747, DOI 10.1074/jbc.M000799200; Chabes A, 2003, CELL, V112, P391, DOI 10.1016/S0092-8674(03)00075-8; Chaboute ME, 2002, J BIOL CHEM, V277, P17845, DOI 10.1074/jbc.M200959200; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; Cope GA, 2003, CELL, V114, P663, DOI 10.1016/S0092-8674(03)00722-0; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; Hayes S, 1998, MOL CELL BIOL, V18, P240, DOI 10.1128/MCB.18.1.240; HWANG BJ, 1993, BIOCHEMISTRY-US, V32, P1657, DOI 10.1021/bi00057a033; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Liu C, 2003, GENE DEV, V17, P1130, DOI 10.1101/gad.1090803; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Mundt KE, 1999, CURR BIOL, V9, P1427, DOI 10.1016/S0960-9822(00)80091-3; Nag A, 2001, MOL CELL BIOL, V21, P6738, DOI 10.1128/MCB.21.20.6738-6747.2001; Osterlund MT, 1999, TRENDS CELL BIOL, V9, P113, DOI 10.1016/S0962-8924(99)01499-3; Otrin VR, 1998, MOL CELL BIOL, V18, P3182, DOI 10.1128/MCB.18.6.3182; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; Schroeder DF, 2002, CURR BIOL, V12, P1462, DOI 10.1016/S0960-9822(02)01106-5; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Shiyanov P, 1999, J BIOL CHEM, V274, P35309, DOI 10.1074/jbc.274.50.35309; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Woollard A, 1996, EMBO J, V15, P4603, DOI 10.1002/j.1460-2075.1996.tb00838.x; Yang XM, 2002, CURR BIOL, V12, P667, DOI 10.1016/S0960-9822(02)00791-1; Zhou CS, 2001, BMC BIOCHEM, V2, DOI 10.1186/1471-2091-2-7; Zolezzi F, 2002, J BIOL CHEM, V277, P41183, DOI 10.1074/jbc.M207890200	31	39	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9937	9943		10.1074/jbc.M312570200	http://dx.doi.org/10.1074/jbc.M312570200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701809	hybrid			2022-12-25	WOS:000220050400035
J	Cheon, YP; DeMayo, FJ; Bagchi, MK; Bagchi, IC				Cheon, YP; DeMayo, FJ; Bagchi, MK; Bagchi, IC			Induction of cytotoxic T-lymphocyte antigen-2 beta, a cysteine protease inhibitor in decidua - A potential regulator of embryo implantation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATHEPSIN-L; PLASMINOGEN-ACTIVATOR; CELL SELECTION; EXPRESSION; PURIFICATION; INVASION	During early pregnancy, the steroid hormone progesterone induces differentiation of uterine stroma to decidual cells, which regulate embryo-uterine interactions. The progesterone-induced signaling molecules that participate in the formation and function of decidua remain poorly understood. We recently utilized high-density oligonucleotide microarrays to identify several genes whose expression is markedly altered in pregnant uterus in response to RU486, a well characterized antagonist of the progesterone receptor (PR). Our study revealed that the gene encoding cytotoxic T-lymphocyte antigen-2beta (CTLA-2beta), a cysteine protease inhibitor, is expressed during PR-induced decidualization. The spatio-temporal expression of CTLA-2beta mRNA precisely overlapped with the decidual phase of pregnancy. Interestingly, administration of progesterone to estrogen-primed ovariectomized mice failed to induce CTLA-2beta expression. A concomitant artificial decidual stimulation was necessary to trigger this expression. Uteri of PR knockout mice failed to express this mRNA, even after a combined administration of steroid hormones and artificial stimulation. The uterine expression of CTLA-2beta was, therefore, dependent on PR as well as other unknown factor(s) associated with decidual response. To identify the molecular target( s) of CTLA-2beta, we analyzed its interaction with proteins present in soluble extracts prepared from day 7 pregnant uteri containing implanted embryos. A protein affinity strategy employing recombinant CTLA-2beta helped us to determine that cathepsin L, a cysteine protease, is one of its targets in the pregnant uterus. Consistent with this finding, expression of cathepsin L was detected in the giant trophoblast cells of the ectoplacental cone on day 7 of pregnancy. Collectively, our results support the hypothesis that expression of CTLA-2beta in the decidua may regulate implantation of the embryo by neutralizing the activities of one or more proteases generated by the proliferating trophoblast.	Univ Illinois, Dept Vet Biosci, Urbana, IL 61802 USA; Univ Illinois, Dept Mol Integrat Physiol, Urbana, IL 61802 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Baylor College of Medicine	Bagchi, IC (corresponding author), Univ Illinois, Dept Vet Biosci, Urbana, IL 61802 USA.	ibagchi@uiuc.edu	DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD044611, R01HD043381, R01HD039291, R01HD034527] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050257] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-44611, R01 HD-39291, R01 HD-34527, R01 HD-43381] Funding Source: Medline; NIDDK NIH HHS [R01-DK-50257] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Afonso S, 1997, DEVELOPMENT, V124, P3415; Alexander CM, 1996, DEVELOPMENT, V122, P1723; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BAULIEU EE, 1991, TRENDS ENDOCRIN MET, V2, P233, DOI 10.1016/1043-2760(91)90030-Q; Benavides F, 2001, IMMUNOGENETICS, V53, P233, DOI 10.1007/s002510100320; BEVILACQUA EMAF, 1989, ARCH BIOL MED EXP, V22, P107; BRUNET JF, 1988, IMMUNOL REV, V103, P21, DOI 10.1111/j.1600-065X.1988.tb00747.x; Carson DD, 2000, DEV BIOL, V223, P217, DOI 10.1006/dbio.2000.9767; Cheon YP, 2002, MOL ENDOCRINOL, V16, P2853, DOI 10.1210/me.2002-0270; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; Croy BA, 2002, J REPROD IMMUNOL, V57, P151, DOI 10.1016/S0165-0378(02)00005-0; DEFEO VJ, 1967, CELLULAR BIOL UTERUS, P191; DELARIA K, 1994, J BIOL CHEM, V269, P25172; DENIZOT F, 1989, EUR J IMMUNOL, V19, P631, DOI 10.1002/eji.1830190409; FAZLEABAS AT, 1982, J BIOL CHEM, V257, P6886; FINN CA, 1977, BIOL UTERUS, P246; GU Y, 1999, ENCY REPROD, P836; HAMILTON R T, 1990, Journal of Cell Biology, V111, p357A; Honey K, 2002, J EXP MED, V195, P1349, DOI 10.1084/jem.20011904; Irwin J. C., 1999, ENCY REPROD, V1, P823; LEFEBVRE O, 1995, DEVELOPMENT, V121, P947; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Makrigiannakis A, 2001, NAT IMMUNOL, V2, P1018, DOI 10.1038/ni719; Mellor AL, 2001, NAT IMMUNOL, V2, P64, DOI 10.1038/83183; Moffett-King A, 2002, NAT REV IMMUNOL, V2, P656, DOI 10.1038/nri886; MULLINS DE, 1980, CELL, V20, P865, DOI 10.1016/0092-8674(80)90333-5; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; PARIA BC, 1993, P NATL ACAD SCI USA, V90, P10159, DOI 10.1073/pnas.90.21.10159; Parr MB., 1989, BIOL UTERUS, P233; Philibert D, 1985, ANTIPROGESTIN STEROI, P49; Psychoyos A, 1976, J Reprod Fertil Suppl, P17; PSYCHOYOS A, 1986, ANN NY ACAD SCI, V476, P36, DOI 10.1111/j.1749-6632.1986.tb20920.x; PSYCHOYOS A, 1973, HDB PHYSL, P187; ROBERTS RM, 1995, MOL CELLULAR ASPECTS, P253; STALLINGSMANN ML, 1994, J BIOL CHEM, V269, P24090; STRICKLAND S, 1992, CELL, V71, P355, DOI 10.1016/0092-8674(92)90503-5; Teesalu T, 1996, MECH DEVELOP, V56, P103, DOI 10.1016/0925-4773(96)00515-1; Thellin O, 2003, TOXICOLOGY, V185, P179, DOI 10.1016/S0300-483X(02)00607-8; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Weitlauf H. M., 1994, P391; YOSHINAGA K, 1988, ANN NY ACAD SCI, V541, P424, DOI 10.1111/j.1749-6632.1988.tb22279.x; Yoshinaga K., 1980, PROGR REPRODUCTIVE B, V7, P189; Zhang X, 1996, BIOL REPROD, V54, P1052, DOI 10.1095/biolreprod54.5.1052	43	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10357	10363		10.1074/jbc.M309434200	http://dx.doi.org/10.1074/jbc.M309434200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14681235	hybrid			2022-12-25	WOS:000220050400085
J	Del Carpio, RV; Gonzalez-Nilo, FD; Jayaram, H; Spencer, E; Prasad, BVV; Patton, JT; Taraporewala, ZF				Del Carpio, RV; Gonzalez-Nilo, FD; Jayaram, H; Spencer, E; Prasad, BVV; Patton, JT; Taraporewala, ZF			Role of the histidine triad-like motif in nucleotide hydrolysis by the rotavirus RNA-packaging protein NSP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPERATURE-SENSITIVE MUTANTS; VIRUS NONSTRUCTURAL PROTEIN; CASEIN KINASE-II; SIMIAN ROTAVIRUS-SA11; BINDING ACTIVITY; IN-VITRO; PHOSPHORYLATION; LOCALIZATION; MULTIMERS; RESIDUES	Octamers formed by the nonstructural protein NSP2 of rotavirus are proposed to function as molecular motors in the packaging of the segmented double-stranded RNA genome. The octamers have RNA binding, helix unwinding, and Mg2+-dependent NTPase activities and play a crucial role in assembly of viral replication factories (viroplasms). Comparison of x-ray structures has revealed significant structural homology between NSP2 and the histidine triad ( HIT) family of nucleotidyl hydrolases, which in turn has suggested the location of the active site for NTP hydrolysis in NSP2. Consistent with the structural predictions, we show here using site-specific mutagenesis and ATP docking simulations that the active site for NTP hydrolysis is localized to residues within a 25-Angstrom-deep cleft between the C- and N-terminal domains of the NSP2 monomer. Although lacking the precise signature HIT motif (HOHOHOO where O is a hydrophobic residue), our analyses demonstrate that histidines (His(221) and His(225)) represent critical residues of the active site. Similar to events occurring during nucleotide hydrolysis by HIT proteins, NTP hydrolysis by NSP2 was found to produce a short lived phosphorylated intermediate. Evaluation of the biological importance of the NTPase activity of NSP2 by transient expression in mammalian cells showed that such activity has no impact on the ability of NSP2 to induce the hyperphosphorylation of NSP5 or to interact with NSP5 to form viroplasm-like structures. Hence the NTPase activity of NSP2 probably has a role subsequent to the formation of viroplasms, consistent with its suspected involvement in RNA packaging and/or replication.	NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA; Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Santiago Chile, Fac Quim & Biol, Dept Ciencias Quim, Santiago, Chile; Univ Santiago Chile, Virol Lab, Santiago, Chile	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Baylor College of Medicine; Universidad de Santiago de Chile; Universidad de Santiago de Chile	Taraporewala, ZF (corresponding author), NIAID, Infect Dis Lab, NIH, 50 South Dr,MSC 8026,Rm 6314, Bethesda, MD 20892 USA.	ztarapore@niaid.nih.gov	González-Nilo, Fernando/M-5671-2016; Patton, John T/P-1390-2014; González Nilo, Fernando Danilo/M-5368-2017; Patton, John/V-7651-2018	González-Nilo, Fernando/0000-0001-6857-3575; González Nilo, Fernando Danilo/0000-0001-6857-3575; Prasad, B.V.Venkataram/0000-0002-1172-2071; Patton, John/0000-0003-1572-0732; Spencer, Eugenio/0000-0001-6109-140X	NCRR NIH HHS [P41 RR002250, P41 RR007707] Funding Source: Medline; NIAID NIH HHS [P01 AI057788, AI36040, R37 AI036040, R01 AI036040] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR007707, P41RR002250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI036040, R01AI036040, Z01AI000754, P01AI057788] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACCELRYS, 1997, INSIGHT 2 DELPHI USE; Afrikanova I, 1998, J GEN VIROL, V79, P2679, DOI 10.1099/0022-1317-79-11-2679; Afrikanova I, 1996, J GEN VIROL, V77, P2059, DOI 10.1099/0022-1317-77-9-2059; Blackhall J, 1997, J VIROL, V71, P138, DOI 10.1128/JVI.71.1.138-144.1997; Brenner C, 2002, BIOCHEMISTRY-US, V41, P9003, DOI 10.1021/bi025942q; Brenner C, 1999, J CELL PHYSIOL, V181, P179, DOI 10.1002/(SICI)1097-4652(199911)181:2<179::AID-JCP1>3.0.CO;2-8; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CHEN DY, 1990, VIROLOGY, V178, P143, DOI 10.1016/0042-6822(90)90387-7; Eichwald C, 2002, J VIROL, V76, P3461, DOI 10.1128/JVI.76.7.3461-3470.2002; Fabbretti E, 1999, J GEN VIROL, V80, P333, DOI 10.1099/0022-1317-80-2-333; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GALLEGOS CO, 1989, VIROLOGY, V172, P616, DOI 10.1016/0042-6822(89)90204-3; Gonzalez RA, 1998, ARCH VIROL, V143, P981, DOI 10.1007/s007050050347; GONZALEZ SA, 1991, VIROLOGY, V182, P8, DOI 10.1016/0042-6822(91)90642-O; HELMBERGERJONES M, 1986, VIROLOGY, V155, P655, DOI 10.1016/0042-6822(86)90225-4; HILDEBRANDT E, 1989, ANAL BIOCHEM, V177, P407, DOI 10.1016/0003-2697(89)90075-4; HINRICHS MV, 1993, BIOCHEMISTRY-US, V32, P7310, DOI 10.1021/bi00079a030; Horscroft NJ, 2000, J GEN VIROL, V81, P1961, DOI 10.1099/0022-1317-81-8-1961; Jayaram H, 2002, NATURE, V417, P311, DOI 10.1038/417311a; Kapikian A. Z., 2001, FIELDS VIROLOGY, V2, P1787; KATTOURA MD, 1992, VIROLOGY, V191, P698, DOI 10.1016/0042-6822(92)90245-K; KATTOURA MD, 1994, VIROLOGY, V202, P803, DOI 10.1006/viro.1994.1402; Klumpp S, 2002, EUR J BIOCHEM, V269, P1067, DOI 10.1046/j.1432-1033.2002.02755.x; Lima CD, 1997, SCIENCE, V278, P286, DOI 10.1126/science.278.5336.286; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; McIntosh DB, 2003, ANN NY ACAD SCI, V986, P101, DOI 10.1111/j.1749-6632.2003.tb07145.x; MITCHELL DB, 1988, NUCLEIC ACIDS RES, V16, P6244, DOI 10.1093/nar/16.13.6244; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Parashar UD, 2003, EMERG INFECT DIS, V9, P565, DOI 10.3201/eid0905.020562; PETRIE BL, 1982, J GEN VIROL, V63, P457, DOI 10.1099/0022-1317-63-2-457; PETRIE BL, 1984, VIRUS RES, V1, P133, DOI 10.1016/0168-1702(84)90069-8; Poncet D, 1997, J VIROL, V71, P34, DOI 10.1128/JVI.71.1.34-41.1997; RAMIG RF, 1984, J VIROL, V49, P665, DOI 10.1128/JVI.49.3.665-673.1984; Schuck P, 2001, J BIOL CHEM, V276, P9679, DOI 10.1074/jbc.M009398200; Taraporewala Z, 1999, J VIROL, V73, P9934, DOI 10.1128/JVI.73.12.9934-9943.1999; Taraporewala ZF, 2001, VIROLOGY, V280, P221, DOI 10.1006/viro.2000.0764; Taraporewala ZF, 2001, J VIROL, V75, P4519, DOI 10.1128/JVI.75.10.4519-4527.2001; Vende P, 2002, J VIROL, V76, P5291, DOI 10.1128/JVI.76.10.5291-5299.2002	38	31	34	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10624	10633		10.1074/jbc.M311563200	http://dx.doi.org/10.1074/jbc.M311563200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699117	hybrid			2022-12-25	WOS:000220050400116
J	Koch, J; Guntrum, R; Heintke, S; Kyritsis, C; Tampe, R				Koch, J; Guntrum, R; Heintke, S; Kyritsis, C; Tampe, R			Functional dissection of the transmembrane domains of the transporter associated with antigen processing (TAP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; MOLECULAR-MECHANISM; PEPTIDE BINDING; TAPASIN; GLYCOPROTEIN; SUBUNITS; COMPLEX; REGION; IDENTIFICATION; TRANSLOCATION	The transporter associated with antigen processing (TAP1/2) translocates cytosolic peptides of proteasomal degradation into the endoplasmic reticulum ( ER) lumen. A peptide-loading complex of tapasin, major histocompatibility complex class I, and several auxiliary factors is assembled at the transporter to optimize antigen display to cytotoxic T-lymphocytes at the cell surface. The heterodimeric TAP complex has unique N-terminal domains in addition to a 6 + 6-transmembrane segment core common to most ABC transporters. Here we provide direct evidence that this core TAP complex is sufficient for (i) ER targeting, (ii) heterodimeric assembly within the ER membrane, (iii) peptide binding, (iv) peptide transport, and ( v) specific inhibition by the herpes simplex virus protein ICP47 and the human cytomegalovirus protein US6. We show for the first time that the translocation pore of the transporter is composed of the predicted TM-(5 - 10) of TAP1 and TM-( 4 - 9) of TAP2. Moreover, we demonstrate that the N-terminal domains of TAP1 and TAP2 are essential for recruitment of tapasin, consequently mediating assembly of the macromolecular peptide-loading complex.	Goethe Univ Frankfurt, Bioctr, Inst Biochem, D-69439 Frankfurt, Germany	Goethe University Frankfurt	Tampe, R (corresponding author), Goethe Univ Frankfurt, Bioctr, Inst Biochem, Marie Curie Str 9, D-69439 Frankfurt, Germany.	tampe@em.uni-frankfurt.de	Tampé, Robert/H-2953-2015	Tampé, Robert/0000-0002-0403-2160				Abele R, 1999, BBA-BIOMEMBRANES, V1461, P405, DOI 10.1016/S0005-2736(99)00171-6; Ahn K, 1997, IMMUNITY, V6, P613, DOI 10.1016/S1074-7613(00)80349-0; Ahn K, 1996, EMBO J, V15, P3247, DOI 10.1002/j.1460-2075.1996.tb00689.x; ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; Antoniou AN, 2003, CURR OPIN IMMUNOL, V15, P75, DOI 10.1016/S0952-7915(02)00010-9; Antoniou AN, 2002, IMMUNOLOGY, V106, P182, DOI 10.1046/j.1365-2567.2002.01415.x; Babenko AP, 2002, J BIOL CHEM, V277, P43997, DOI 10.1074/jbc.M208085200; Bangia N, 1999, EUR J IMMUNOL, V29, P1858, DOI 10.1002/(SICI)1521-4141(199906)29:06<1858::AID-IMMU1858>3.0.CO;2-C; Barnden MJ, 2000, J IMMUNOL, V165, P322, DOI 10.4049/jimmunol.165.1.322; Brocke P, 2002, CURR OPIN IMMUNOL, V14, P22, DOI 10.1016/S0952-7915(01)00294-1; Chan KW, 2003, EMBO J, V22, P3833, DOI 10.1093/emboj/cdg376; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Chen M, 2003, J BIOL CHEM, V278, P29686, DOI 10.1074/jbc.M302757200; FRUH K, 1995, NATURE, V375, P415, DOI 10.1038/375415a0; Garbi N, 2003, EUR J IMMUNOL, V33, P264, DOI 10.1002/immu.200390029; Grandea AG, 1997, IMMUNOGENETICS, V46, P477, DOI 10.1007/s002510050308; Heintke S, 2003, FEBS LETT, V533, P42, DOI 10.1016/S0014-5793(02)03746-8; Hengel H, 1997, IMMUNITY, V6, P623, DOI 10.1016/S1074-7613(00)80350-7; Hewitt EW, 2003, IMMUNOLOGY, V110, P163, DOI 10.1046/j.1365-2567.2003.01738.x; Hewitt EW, 2001, EMBO J, V20, P387, DOI 10.1093/emboj/20.3.387; Knittler MR, 1999, CURR BIOL, V9, P999, DOI 10.1016/S0960-9822(99)80448-5; Kyritsis C, 2001, J BIOL CHEM, V276, P48031, DOI 10.1074/jbc.M108528200; Lauvau G, 1999, J BIOL CHEM, V274, P31349, DOI 10.1074/jbc.274.44.31349; Lehner PJ, 1998, IMMUNITY, V8, P221, DOI 10.1016/S1074-7613(00)80474-4; Lehner PJ, 1997, P NATL ACAD SCI USA, V94, P6904, DOI 10.1073/pnas.94.13.6904; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; Neumann L, 1997, J MOL BIOL, V272, P484, DOI 10.1006/jmbi.1997.1282; Nijenhuis M, 1996, J IMMUNOL, V157, P5467; Nijenhuis M, 1996, J IMMUNOL, V156, P2186; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Park B, 2003, J BIOL CHEM, V278, P14337, DOI 10.1074/jbc.M212882200; Peh CA, 2000, J IMMUNOL, V164, P292, DOI 10.4049/jimmunol.164.1.292; Raghuraman G, 2002, J BIOL CHEM, V277, P41786, DOI 10.1074/jbc.M207128200; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; Schoenhals GJ, 1999, EMBO J, V18, P743, DOI 10.1093/emboj/18.3.743; TAMPE R, 1997, UNUSUAL SECRETORY PA, P115; Tan P, 2002, J IMMUNOL, V168, P1950, DOI 10.4049/jimmunol.168.4.1950; Turnquist HR, 2002, IMMUNOL RES, V25, P261, DOI 10.1385/IR:25:3:261; Turnquist HR, 2001, J IMMUNOL, V167, P4443, DOI 10.4049/jimmunol.167.8.4443; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; Vos JC, 1999, J IMMUNOL, V163, P6679; Vos JC, 2000, CURR BIOL, V10, P1, DOI 10.1016/S0960-9822(99)00257-2; Williams AP, 2002, IMMUNITY, V16, P509, DOI 10.1016/S1074-7613(02)00304-7; Zarling AL, 2003, J IMMUNOL, V171, P5287, DOI 10.4049/jimmunol.171.10.5287	47	136	141	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10142	10147		10.1074/jbc.M312816200	http://dx.doi.org/10.1074/jbc.M312816200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14679198	hybrid			2022-12-25	WOS:000220050400060
J	Kouchi, Z; Fukami, K; Shikano, T; Oda, S; Nakamura, Y; Takenawa, T; Miyazaki, S				Kouchi, Z; Fukami, K; Shikano, T; Oda, S; Nakamura, Y; Takenawa, T; Miyazaki, S			Recombinant phospholipase C zeta has high Ca2+ sensitivity and induces Ca2+ oscillations in mouse eggs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE; SPATIOTEMPORAL DYNAMICS; FERTILIZATION; ACTIVATION; RECEPTOR; OOCYTES; EMBRYO; DOMAIN; CELL; INVOLVEMENT	Sperm-specific phospholipase Czeta (PLCzeta) is known to induce intracellular Ca2+ oscillations and subsequent early embryonic development when expressed in mouse eggs by injection of RNA encoding PLCzeta (Saunders, C. M., Larman, M. G., Parrington, J., Cox, L. J., Royse, J., Blayney, L. M., Swann, K., and Lai, F. A. (2002) Development 129, 3533-3544). The present study addressed characteristics of purified mouse PLCzeta protein that was synthesized using the baculovirus/ Sf9 cell expression system. Microinjection of recombinant PLCzeta protein into mouse eggs induced serial Ca2+ spikes quite similar to those produced by the injection of sperm extract, probably because of repetitive Ca2+ release from the endoplasmic reticulum caused by continuously produced inositol 1,4,5-trisphosphate. Recombinant PLCzeta1 also induced Ca2+ oscillations, but a 20-fold higher concentration was required compared with PLCzeta. In the enzymatic assay of phosphatidylinositol 4,5-bisphosphate hydrolyzing activity in vitro at various calcium ion concentrations ([Ca2+]), PLCzeta exhibited a significant activity at [Ca2+] as low as 10 nM and had 70% maximal activity at 100 nM [Ca2+] that is usually the basal intracellular calcium ion concentration level of cells. On the other hand, the activity of PLCdelta1 increased at a [Ca2+] between 1 and 30 muM. EC50 was 52 nM for PLCzeta and 5.7 muM for PLCdelta1. Thus, PLCzeta has an similar to100-fold higher Ca2+ sensitivity than PLCdelta1. The ability of purified PLCzeta protein to induce Ca2+ oscillations qualifies PLCzeta as a proper candidate of the mammalian egg-activating sperm factor. Furthermore, such a high Ca2+ sensitivity of PLC activity as PLCzeta that can be active in cells at the resting state is thought to be an appropriate characteristic of the sperm factor, which is introduced into the ooplasm upon sperm-egg fusion, triggers Ca2+ release first, and maintains Ca2+ oscillations.	Tokyo Womens Med Univ, Dept Physiol, Sch Med, Shinjuku Ku, Tokyo 1628666, Japan; Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 1088639, Japan; Tokyo Univ Pharm & Life Sci, Lab Genome & Biosignal, Tokyo 1920392, Japan	Tokyo Women's Medical University; University of Tokyo; Tokyo University of Pharmacy & Life Sciences	Kouchi, Z (corresponding author), Tokyo Womens Med Univ, Dept Physiol, Sch Med, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.	zkouchi@research.twmu.ac.jp		Nakamura, Yoshikazu/0000-0001-8355-1091				Allen V, 1997, BIOCHEM J, V327, P545, DOI 10.1042/bj3270545; Deguchi R, 2000, DEV BIOL, V218, P299, DOI 10.1006/dbio.1999.9573; Ducibella T, 2002, DEV BIOL, V250, P280, DOI 10.1006/dbio.2002.0788; Dupont G, 1996, BIOCHEM J, V316, P583, DOI 10.1042/bj3160583; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; Fukami K, 2001, SCIENCE, V292, P920, DOI 10.1126/science.1059042; Grobler JA, 1998, BIOCHEMISTRY-US, V37, P5020, DOI 10.1021/bi972952w; Jones KT, 2000, BIOCHEM J, V346, P743, DOI 10.1042/0264-6021:3460743; Jones KT, 1998, INT J DEV BIOL, V42, P1; Jones KT, 2000, DEV BIOL, V225, P1, DOI 10.1006/dbio.2000.9826; Katan M, 1998, BBA-MOL CELL BIOL L, V1436, P5, DOI 10.1016/S0005-2760(98)00125-8; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Kumakiri J, 2003, DEV BIOL, V260, P522, DOI 10.1016/S0012-1606(03)00273-2; Lee WK, 1999, BIOCHEM BIOPH RES CO, V261, P393, DOI 10.1006/bbrc.1999.1035; Lomasney JW, 1999, J BIOL CHEM, V274, P21995, DOI 10.1074/jbc.274.31.21995; Mehlmann LM, 1998, DEV BIOL, V203, P221, DOI 10.1006/dbio.1998.9051; MIYAZAKI S, 1993, JPN J PHYSIOL, V43, P409, DOI 10.2170/jjphysiol.43.409; MIYAZAKI S, 1993, DEV BIOL, V158, P62, DOI 10.1006/dbio.1993.1168; Nagano K, 1999, J BIOL CHEM, V274, P2872, DOI 10.1074/jbc.274.5.2872; Nakano Y, 1997, MOL HUM REPROD, V3, P1087, DOI 10.1093/molehr/3.12.1087; Oda S, 1999, DEV BIOL, V209, P172, DOI 10.1006/dbio.1999.9233; Pawelczyk T, 1998, EUR J BIOCHEM, V257, P169, DOI 10.1046/j.1432-1327.1998.2570169.x; Rice A, 2000, DEV BIOL, V228, P125, DOI 10.1006/dbio.2000.9929; Sato Y, 1998, BIOL REPROD, V58, P867, DOI 10.1095/biolreprod58.3.867; Saunders CM, 2002, DEVELOPMENT, V129, P3533; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; Swann K, 1996, Rev Reprod, V1, P33, DOI 10.1530/ror.0.0010033	27	183	191	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10408	10412		10.1074/jbc.M313801200	http://dx.doi.org/10.1074/jbc.M313801200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701816	hybrid			2022-12-25	WOS:000220050400091
J	Pagans, S; Pineyro, D; Kosoy, A; Bernues, J; Azorin, F				Pagans, S; Pineyro, D; Kosoy, A; Bernues, J; Azorin, F			Repression by TTK69 of GAGA-mediated activation occurs in the absence of TTK69 binding to DNA and solely requires the contribution of the POZ/BTB domain of TTK69	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; PLZF-RAR-ALPHA; TRANSCRIPTIONAL REPRESSION; HISTONE DEACETYLASE; POZ DOMAIN; ECTOPIC EXPRESSION; BTB/POZ DOMAIN; DROSOPHILA EYE; FUSHI-TARAZU; CELL FATE	tramtrack 69 (TTK69) is known to repress GAGA-mediated activation of the eve promoter in S2 cells. Here, we show that repression by TTK69 occurs in the absence of bona fide TTK69-binding sites on the template, indicating that it does not require the binding of TTK69 to DNA. Consistent with this interpretation, the POZ/BTB domain of TTK69, which does not bind DNA, is sufficient for repression. Moreover, a fusion protein in which the POZ/BTB domain of GAGA is replaced by that of TTK69 is not capable of activating the eve promoter but efficiently represses GAGA-dependent activation. Repression involves GAGA-TTK69 interaction because TTK69 is not capable of repressing basal transcription. Most probably, GAGA-TTK69 interaction occurs at the promoter because GAGA . TTK69 complexes are fully competent in binding DNA in vitro. Our results also show that repression by TTK69 of GAGA-dependent activation of the eve promoter is not mediated by any of the co-repressors known to interact with TTK69 (dMi2 or C-terminal binding protein) or by trichostatin A-sensitive histone deacetylases. Altogether, these observations strongly suggest that the binding of TTK69 prevents the interaction of GAGA with the transcription machinery and, therefore, compromises its activation potential.	Consejo Super Invest Cient, Inst Biol Mol Barcelona, Dept Mol & Cellular Biol, Barcelona 08034, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB)	Azorin, F (corresponding author), Consejo Super Invest Cient, Inst Biol Mol Barcelona, Dept Mol & Cellular Biol, Jordi Girona Salgado 18-26, Barcelona 08034, Spain.	fambmc@cid.csic.es	Pagans, Sara/G-3407-2015; Azorin, Fernando/N-4388-2014; Bernues, Jordi/ABE-8360-2021	Pagans, Sara/0000-0003-0772-6982; Azorin, Fernando/0000-0002-8426-7858; Bernues, Jordi/0000-0001-6218-8254; Pineyro, David/0000-0001-5633-3339				Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; Benyajati C, 1997, NUCLEIC ACIDS RES, V25, P3345, DOI 10.1093/nar/25.16.3345; BROWN JL, 1991, EMBO J, V10, P665, DOI 10.1002/j.1460-2075.1991.tb07995.x; BROWN JL, 1993, DEVELOPMENT, V117, P45; Courey AJ, 2001, GENE DEV, V15, P2786; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Espinas ML, 1999, J BIOL CHEM, V274, P16461, DOI 10.1074/jbc.274.23.16461; Giesen K, 1997, DEVELOPMENT, V124, P2307; Greenberg AJ, 2001, MOL CELL BIOL, V21, P8565, DOI 10.1128/MCB.21.24.8565-8574.2001; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GUO M, 1995, NEURON, V14, P913, DOI 10.1016/0896-6273(95)90330-5; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; Kosoy A, 2002, J BIOL CHEM, V277, P42280, DOI 10.1074/jbc.M207505200; Lai ZC, 1999, GENETICS, V152, P299; Li XM, 1999, CANCER RES, V59, P5275; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Murawsky CM, 2001, EMBO REP, V2, P1089, DOI 10.1093/embo-reports/kve252; Pagans S, 2002, NUCLEIC ACIDS RES, V30, P4406, DOI 10.1093/nar/gkf570; Pointud JC, 2001, DEV BIOL, V237, P368, DOI 10.1006/dbio.2001.0358; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; READ D, 1990, MOL CELL BIOL, V10, P4334, DOI 10.1128/MCB.10.8.4334; READ D, 1992, MECH DEVELOP, V38, P183, DOI 10.1016/0925-4773(92)90052-L; READ D, 1992, EMBO J, V11, P1035, DOI 10.1002/j.1460-2075.1992.tb05142.x; Ryu JR, 2001, P NATL ACAD SCI USA, V98, P12960, DOI 10.1073/pnas.231394998; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961; Vaquero A, 2000, J BIOL CHEM, V275, P19461, DOI 10.1074/jbc.M000967200; Wen Y, 2000, GENETICS, V156, P195; Wilkins RC, 1997, NUCLEIC ACIDS RES, V25, P3963, DOI 10.1093/nar/25.20.3963; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; XIONG WC, 1993, GENE DEV, V7, P1085, DOI 10.1101/gad.7.6.1085	36	15	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9725	9732		10.1074/jbc.M313200200	http://dx.doi.org/10.1074/jbc.M313200200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701830	hybrid			2022-12-25	WOS:000220050400010
J	Zou, J; Zhu, F; Liu, JJ; Wang, WY; Zhang, RM; Garlisi, CG; Liu, YH; Wang, SH; Shah, H; Wan, YT; Umland, SP				Zou, J; Zhu, F; Liu, JJ; Wang, WY; Zhang, RM; Garlisi, CG; Liu, YH; Wang, SH; Shah, H; Wan, YT; Umland, SP			Catalytic activity of human ADAM33	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ALPHA-CONVERTING-ENZYME; METALLOPROTEINASE INHIBITORS; INTRACELLULAR MATURATION; PROTEOLYTIC ACTIVITY; MEMBRANE-PROTEINS; CYSTEINE SWITCH; CELL-CELL; DISINTEGRIN; CLEAVAGE	ADAM33 ( a disintegrin and metalloproteinase) is an asthma susceptibility gene recently identified through a genetic study of asthmatic families ( van Eerdewegh et al. ( 2002) Nature 418, 426 - 430). In order to characterize the catalytic properties of ADAM33, the metalloproteinase domain of human ADAM33 was expressed in Drosophila S2 cells and purified. The N-terminal sequence of the purified metalloproteinase was exclusively (204)EARR, indicating utilization of one of three furin recognition sites. Of many synthetic peptides tested as potential substrates, four peptides derived from beta-amyloid precursor protein (APP), Kit-ligand-1 (KL-1), tumor necrosis factor-related activation-induced cytokine, and insulin B chain were cleaved by ADAM33; mutation at the catalytic site, E346A, inactivated catalytic activity. Cleavage of APP occurred at His(14)down arrowGln(15), not at the alpha-secretase site and was inefficient (k(cat)/K-m (1.6 +/- 0.3) x 10(2) M-1 s(-1)). Cleavage of a juxtamembrane KL-1 peptide occurred at a site used physiologically with a similar efficiency. Mutagenesis of KL-1 peptide substrate indicated that the P3, P2, P1, and P3' residues were critical for activity. In a transfected cell-based sheddase assay, ADAM33 functioned as a negative regulator of APP shedding and mediated some constitutive shedding of KL-1, which was not regulated by phorbol 12-myristate 13-acetate activation. ADAM33 activity was sensitive to several hydroxamate inhibitors (IK682, K-i = 23 +/- 7 nM) and to tissue inhibitors of metalloproteinase (TIMPs). Activity was inhibited moderately by TIMP-3 and TIMP-4 and weakly inhibited by TIMP-2 but not by TIMP-1, a profile distinct from other ADAMs. The identification of ADAM33 peptide substrates, cellular activity, and a distinct inhibitor profile provide the basis for further functional studies of ADAM33.	Schering Plough Corp, Res Inst, Dept Allergy, Kenilworth, NJ 07033 USA; Schering Plough Corp, Res Inst, Dept Struct Chem, Kenilworth, NJ 07033 USA	Merck & Company; Schering Plough Corporation; Merck & Company; Schering Plough Corporation	Zou, J (corresponding author), Schering Plough Corp, Res Inst, Dept Allergy, 2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA.	jun.zou@spcorp.com		Zhang, Rumin/0000-0002-6590-6036				Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 2002, FEBS LETT, V524, P154, DOI 10.1016/S0014-5793(02)03047-8; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Becherer JD, 2003, CURR TOP DEV BIOL, V54, P101, DOI 10.1016/S0070-2153(03)54006-6; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Chesneau V, 2003, J BIOL CHEM, V278, P22331, DOI 10.1074/jbc.M302781200; Duan JJW, 2002, J MED CHEM, V45, P4954, DOI 10.1021/jm0255670; Fourie AM, 2003, J BIOL CHEM, V278, P30469, DOI 10.1074/jbc.M213157200; Garlisi CG, 2003, BIOCHEM BIOPH RES CO, V301, P35, DOI 10.1016/S0006-291X(02)02976-5; Gong WM, 1998, J MOL BIOL, V283, P657, DOI 10.1006/jmbi.1998.2110; Gunn TM, 2002, BMC GENET, V3, DOI 10.1186/1471-2156-3-2; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Howard L, 2001, FEBS LETT, V498, P82, DOI 10.1016/S0014-5793(01)02506-6; HOWARD L, 1995, METHOD ENZYMOL, V248, P388; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; Jin GX, 2002, ANAL BIOCHEM, V302, P269, DOI 10.1006/abio.2001.5549; Kang TB, 2002, J BIOL CHEM, V277, P48514, DOI 10.1074/jbc.M208961200; Kuzmic P, 2000, ANAL BIOCHEM, V286, P45, DOI 10.1006/abio.2000.4685; LEHNINGER AL, 1975, BIOCHEMISTRY-US, P189; Loechel F, 2000, BIOCHEM BIOPH RES CO, V278, P511, DOI 10.1006/bbrc.2000.3835; Loechel F, 1999, J BIOL CHEM, V274, P13427, DOI 10.1074/jbc.274.19.13427; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; Loechel F, 2001, FEBS LETT, V506, P65, DOI 10.1016/S0014-5793(01)02873-3; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; Mohan MJ, 2002, BIOCHEMISTRY-US, V41, P9462, DOI 10.1021/bi0260132; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Mullberg J, 2000, EUR CYTOKINE NETW, V11, P27; Nagase H, 2002, ARTHRITIS RES THER, V4, pS51, DOI 10.1186/ar573; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; Park HI, 2002, J BIOL CHEM, V277, P35168, DOI 10.1074/jbc.M205071200; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Rasmussen HS, 1997, PHARMACOL THERAPEUT, V75, P69, DOI 10.1016/S0163-7258(97)00023-5; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Schlomann U, 2002, J BIOL CHEM, V277, P48210, DOI 10.1074/jbc.M203355200; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schlondorff J, 2001, J BIOL CHEM, V276, P14665, DOI 10.1074/jbc.M010741200; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shirakabe K, 2001, J BIOL CHEM, V276, P9352, DOI 10.1074/jbc.M007913200; Stone AL, 1999, J PROTEIN CHEM, V18, P447, DOI 10.1023/A:1020692710029; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; Umland SP, 2003, AM J RESP CELL MOL, V29, P571, DOI 10.1165/rcmb.2003-0028OC; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Williams J W, 1979, Methods Enzymol, V63, P437; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Yoshinaka T, 2002, GENE, V282, P227, DOI 10.1016/S0378-1119(01)00818-6; Zhang LL, 1999, J BIOL CHEM, V274, P8966, DOI 10.1074/jbc.274.13.8966; Zhang RM, 1999, ANAL BIOCHEM, V270, P268, DOI 10.1006/abio.1999.4109	63	89	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9818	9830		10.1074/jbc.M309696200	http://dx.doi.org/10.1074/jbc.M309696200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14676211	hybrid			2022-12-25	WOS:000220050400021
J	Kwon, G; Pappan, KL; Marshall, CA; Schaffer, JE; McDaniel, ML				Kwon, G; Pappan, KL; Marshall, CA; Schaffer, JE; McDaniel, ML			cAMP dose-dependently prevents palmitate-induced apoptosis by both protein kinase A- and cAMP-guanine nucleotide exchange factor-dependent pathways in beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCAGON-LIKE PEPTIDE-1; INDEPENDENT SIGNALING PATHWAY; CYCLIC-AMP; GENE-TRANSCRIPTION; EPAC; RAP1; POLYPEPTIDE; ACTIVATION; RELEASE; OBESITY	Lipid accumulation in pancreatic beta-cells is thought to cause its dysfunction and/or destruction via apoptosis. Our studies show that incubation of the beta-cell line RINm5F with the saturated free fatty acids (FFA) palmitate caused apoptosis based on increases in caspase 3 activity, Annexin V staining, and cell death. Furthermore, exposure of RINm5F cells to cAMP-increasing agents, 3-isobutyl-1-methylxanthine (IBMX), and forskolin completely abolished palmitate-mediated caspase 3 activity and significantly inhibited Annexin V staining and cell death. The cyclic AMP analogs cpt-cAMP and dibutyryl-cAMP mimicked the protective effects of IBMX and forskolin, suggesting that cAMP is the mediator of the anti-apoptotic effects. The protective action of IBMX and forskolin was rapid and did not appear to require gene transcription or new protein synthesis. However, these protective effects were clearly independent of protein kinase A (PKA) because of the lack of inhibition by the PKA inhibitors H-89 and KT5720. In attempts to identify this PKA-independent mechanism, we found that the newly developed cAMP analog 8CPT-2Me-cAMP, which selectively activates the cAMP-dependent guanine nucleotide exchange factor (cAMP-GEF) pathway, mimicked the protective effects of IBMX and forskolin, suggesting that the cAMP-GEF pathway is involved. In addition, both glucagon-like peptide (GLP-1) and its receptor agonist, Exenatide, inhibited palmitate-mediated caspase 3 activation in a dose-dependent manner. Unexpectedly, H-89 partially reversed the protective effects of GLP-1 and Exenatide, suggesting that PKA may play a role in the protective effects of these incretins. To explain these seemingly conflicting results, we demonstrated that low concentrations of cAMP produced by GLP-1 and Exenatide preferentially activate the PKA pathway, whereas higher cAMP concentrations produced by IBMX and forskolin activate the more dominant cAMP-GEF pathway. Taken together, these results indicate that intracellular concentrations of cAMP may play a key role in determining divergent signaling pathways that lead to antiapoptotic responses.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	McDaniel, ML (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, Campus Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA.	mcdaniel@pathology.wustl.edu	Pappan, Kirk/AAV-5946-2021	Pappan, Kirk/0000-0002-2341-8798	NIDDK NIH HHS [DK-06181] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK006181, R56DK006181] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boden G, 2002, EUR J CLIN INVEST, V32, P14, DOI 10.1046/j.1365-2362.32.s3.3.x; Bok J, 2003, J NEUROSCI, V23, P777; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Ding WQ, 2003, CELL SIGNAL, V15, P27, DOI 10.1016/S0898-6568(02)00051-7; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Farilla L, 2002, ENDOCRINOLOGY, V143, P4397, DOI 10.1210/en.2002-220405; FEHMANN HC, 1995, ENDOCR REV, V16, P390, DOI 10.1210/er.16.3.390; Gasperini S, 2002, EUR CYTOKINE NETW, V13, P47; Grbovic O, 2002, CANCER INVEST, V20, P972, DOI 10.1081/CNV-120005913; Hamelink C, 2002, J NEUROSCI, V22, P5310; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hecquet C, 2002, ONCOGENE, V21, P6101, DOI 10.1038/sj.onc.1205765; Holst JJ, 2002, DIABETES-METAB RES, V18, P430, DOI 10.1002/dmrr.328; HOLZ GG, 1995, J BIOL CHEM, V270, P17749, DOI 10.1074/jbc.270.30.17749; Kang G., 2002, J PHYSL, V546, P175; Kang GX, 2003, J BIOL CHEM, V278, P8279, DOI 10.1074/jbc.M211682200; Kashima Y, 2001, J BIOL CHEM, V276, P46046, DOI 10.1074/jbc.M108378200; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Leech CA, 2000, BIOCHEM BIOPH RES CO, V278, P44; Lewis SE, 2001, J BIOL CHEM, V276, P37042, DOI 10.1074/jbc.M105556200; Listenberger LL, 2001, J BIOL CHEM, V276, P14890, DOI 10.1074/jbc.M010286200; Martin MC, 2001, J BIOL CHEM, V276, P45041, DOI 10.1074/jbc.M105197200; NAUCK MA, 1993, DIABETOLOGIA, V36, P741, DOI 10.1007/BF00401145; Sakamoto C, 2003, INT J HEMATOL, V77, P60, DOI 10.1007/BF02982604; Sandal T, 2002, J BIOL CHEM, V277, P20783, DOI 10.1074/jbc.M112248200; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Tsuboi T, 2003, BIOCHEM J, V369, P287, DOI 10.1042/BJ20021288; Webster CRL, 2002, AM J PHYSIOL-GASTR L, V283, pG727, DOI 10.1152/ajpgi.00410.2001; WEIR GC, 1989, DIABETES, V38, P338, DOI 10.2337/diabetes.38.3.338	29	100	110	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8938	8945		10.1074/jbc.M310330200	http://dx.doi.org/10.1074/jbc.M310330200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14688288	hybrid			2022-12-25	WOS:000189265900052
J	Cohen, L; Karbat, I; Gilles, N; Froy, O; Corzo, G; Angelovici, R; Gordon, D; Gurevitz, M				Cohen, L; Karbat, I; Gilles, N; Froy, O; Corzo, G; Angelovici, R; Gordon, D; Gurevitz, M			Dissection of the functional surface of an anti-insect excitatory toxin illuminates a putative "hot spot" common to all scorpion beta-toxins affecting Na+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSECT SODIUM-CHANNELS; CENTRUROIDES-NOXIUS HOFFMANN; SELECTIVE NEUROTOXINS; ANDROCTONUS-AUSTRALIS; MOLECULAR-MECHANISMS; RECEPTOR-SITES; BACULOVIRUS; EXPRESSION; BINDING; VENOM	Scorpion beta-toxins affect the activation of voltage-sensitive sodium channels (NaChs). Although these toxins have been instrumental in the study of channel gating and architecture, little is known about their active sites. By using an efficient system for the production of recombinant toxins, we analyzed by point mutagenesis the entire surface of the beta-toxin, Bj-xtrIT, an anti-insect selective excitatory toxin from the scorpion Buthotus judaicus. Each toxin mutant was purified and analyzed using toxicity and binding assays, as well as by circular dichroism spectroscopy to discern the differences among mutations that caused structural changes and those that specifically affected bioactivity. This analysis highlighted a functional discontinuous surface of 1405 Angstrom(2), which was composed of a number of non-polar and three charged amino acids clustered around the main alpha-helical motif and the C-tail. Among the charged residues, Glu(30) is a center of a putative "hot spot" in the toxin-receptor binding-interface and is shielded from bulk solvent by a hydrophobic "gasket" (Tyr(26) and Val(34)). Comparison of the Bj-xtrIT structure with that of other beta-toxins that are active on mammals suggests that the hot spot and an adjacent non-polar region are spatially conserved. These results highlight for the first time structural elements that constitute a putative "pharmacophore" involved in the interaction of beta-toxins with receptor site-4 on NaChs. Furthermore, the unique structure of the C-terminal region most likely determines the specificity of excitatory toxins for insect NaChs.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Plant Sci, IL-69978 Tel Aviv, Israel; Ctr Etud Saclay, Dept Ingn & Etud Prot, Commissariat Energie Atom, F-91191 Gif Sur Yvette, France; Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual, Inst Biochem Food Sci & Nutr, IL-76100 Rehovot, Israel	Tel Aviv University; CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite Paris Saclay; Hebrew University of Jerusalem	Gordon, D (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Plant Sci, IL-69978 Tel Aviv, Israel.	dgordon@post.tau.ac.il; mamgur@post.tau.ac.il	Corzo, Gerardo/B-3778-2014; Froy, Oren/C-3550-2009	Corzo, Gerardo/0000-0002-9513-1622; 				BARHANIN J, 1982, J BIOL CHEM, V257, P2553; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; BOUGIS PE, 1989, J BIOL CHEM, V264, P19259; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; CATTERALL WA, 1992, PHYSIOL REV, V72, P15; Cestele S, 1998, NEURON, V21, P919, DOI 10.1016/S0896-6273(00)80606-6; Cestele S, 2000, BIOCHIMIE, V82, P883, DOI 10.1016/S0300-9084(00)01174-3; Froy O, 1999, J BIOL CHEM, V274, P5769, DOI 10.1074/jbc.274.9.5769; Gershburg E, 1998, FEBS LETT, V422, P132, DOI 10.1016/S0014-5793(97)01614-1; Gilles N, 2003, FEBS LETT, V540, P81, DOI 10.1016/S0014-5793(03)00226-6; Gilles N, 2000, J NEUROCHEM, V75, P1735, DOI 10.1046/j.1471-4159.2000.0751735.x; GORDON D, 1992, BIOCHEMISTRY-US, V31, P7622, DOI 10.1021/bi00148a025; Gordon D, 2003, EUR J BIOCHEM, V270, P2663, DOI 10.1046/j.1432-1033.2003.03643.x; Gordon D, 1998, J TOXICOL-TOXIN REV, V17, P131, DOI 10.3109/15569549809009247; Gordon Dalia, 1997, Invertebrate Neuroscience, V3, P103, DOI 10.1007/BF02480365; Gurevitz M, 2001, FASEB J, V15, P1201, DOI 10.1096/fj.00-0571hyp; JOVER E, 1980, BIOCHEM BIOPH RES CO, V95, P1607, DOI 10.1016/S0006-291X(80)80082-9; Krimm I, 1999, J MOL BIOL, V285, P1749, DOI 10.1006/jmbi.1998.2418; Lee D, 2000, J INSECT PHYSIOL, V46, P499, DOI 10.1016/S0022-1910(99)00136-5; LIMA ME, 1989, INSECT BIOCHEM, V19, P413; LIMA ME, 1986, BIOCHEM BIOPH RES CO, V139, P296; MAEDA S, 1991, VIROLOGY, V184, P777, DOI 10.1016/0042-6822(91)90451-G; Marcotte P, 1997, CIRC RES, V80, P363, DOI 10.1161/01.RES.80.3.363; MARTINEAUCLAIRE MF, 1994, EUR J BIOCHEM, V223, P637, DOI 10.1111/j.1432-1033.1994.tb19036.x; MOSKOWITZ H, 1994, INSECT BIOCHEM MOLEC, V24, P13, DOI 10.1016/0965-1748(94)90118-X; Oren DA, 1998, STRUCTURE, V6, P1095, DOI 10.1016/S0969-2126(98)00111-7; PANG SZ, 1992, GENE, V116, P165, DOI 10.1016/0378-1119(92)90512-N; PELHATE M, 1982, J EXP BIOL, V97, P67; Pinheiro CB, 2003, ACTA CRYSTALLOGR D, V59, P405, DOI 10.1107/S090744490202111X; Pintar A, 1999, J MOL BIOL, V287, P359, DOI 10.1006/jmbi.1999.2611; Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x; REED L. J., 1938, AMER JOUR HYG, V27, P493; Regev A, 2003, FEBS LETT, V537, P106, DOI 10.1016/S0014-5793(03)00104-2; Selisko B, 1996, EUR J BIOCHEM, V242, P235, DOI 10.1111/j.1432-1033.1996.0235r.x; Shichor I, 2002, J NEUROSCI, V22, P4364, DOI 10.1523/JNEUROSCI.22-11-04364.2002; Sobolev V, 1999, BIOINFORMATICS, V15, P327, DOI 10.1093/bioinformatics/15.4.327; STEWART LMD, 1991, NATURE, V352, P85, DOI 10.1038/352085a0; ZLOTKIN E, 1985, ARCH BIOCHEM BIOPHYS, V240, P877, DOI 10.1016/0003-9861(85)90098-0; ZLOTKIN E, 1991, BIOCHEMISTRY-US, V30, P4814, DOI 10.1021/bi00233a025; ZLOTKIN E, 1997, TOXINS SIGNAL TRANSD, P95	40	64	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8206	8211		10.1074/jbc.M307531200	http://dx.doi.org/10.1074/jbc.M307531200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14672947	hybrid			2022-12-25	WOS:000189103300102
J	Lewis, A; McCrossan, ZA; Abbott, GW				Lewis, A; McCrossan, ZA; Abbott, GW			MinK, MiRP1, and MiRP2 diversify Kv3.1 and Kv3.2 potassium channel gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED K+ CHANNELS; PROTEIN-KINASE-C; FAST-SPIKING; RAT-BRAIN; PHARMACOLOGICAL CHARACTERIZATION; FUNCTIONAL-CHARACTERIZATION; NEOCORTICAL INTERNEURONS; CARDIAC-ARRHYTHMIA; AUDITORY NEURONS; GLOBUS-PALLIDUS	High frequency firing in mammalian neurons requires ultra-rapid delayed rectifier potassium currents generated by homomeric or heteromeric assemblies of Kv3.1 and Kv3.2 potassium channel alpha subunits. Kv3.1 alpha subunits can also form slower activating channels by coassembling with MinK-related peptide 2 (MiRP2), a single transmembrane domain potassium channel ancillary subunit. Here, using channel subunits cloned from rat and expressed in Chinese hamster ovary cells, we show that modulation by MinK, MiRP1, and MiRP2 is a general mechanism for slowing of Kv3.1 and Kv3.2 channel activation and deactivation and acceleration of inactivation, creating a functionally diverse range of channel complexes. MiRP1 also negatively shifts the voltage dependence of Kv3.1 and Kv3.2 channel activation. Furthermore, MinK, MiRP1, and MiRP2 each form channels with Kv3.1-Kv3.2 heteromers that are kinetically distinct from one another and from MiRP/homomeric Kv3 channels. The findings illustrate a mechanism for dynamic expansion of the functional repertoire of Kv3.1 and Kv3.2 potassium currents and suggest roles for these alpha subunits outside the scope of sustained rapid neuronal firing.	Cornell Univ, Weill Med Coll, Div Cardiol, Dept Med, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA	Cornell University; Cornell University	Abbott, GW (corresponding author), Cornell Univ, Weill Med Coll, Div Cardiol, Dept Med, Starr 463,520 E 70th St, New York, NY 10021 USA.	gwa2001@med.cornell.edu		Abbott, Geoffrey/0000-0003-4552-496X				Abbott GW, 2002, FASEB J, V16, DOI 10.1096/fj.01-0520hyp; Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Abbott GW, 2001, CIRC RES, V88, P981, DOI 10.1161/hh1001.091869; Abbott GW, 2001, CELL, V104, P217, DOI 10.1016/S0092-8674(01)00207-0; Baranauskas G, 1999, J NEUROSCI, V19, P6394; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Betancourt L, 2000, J NEUROSCI RES, V61, P646, DOI 10.1002/1097-4547(20000915)61:6<646::AID-JNR8>3.0.CO;2-B; Bianchi L, 2003, J BIOL CHEM, V278, P12415, DOI 10.1074/jbc.M212788200; Chow A, 1999, J NEUROSCI, V19, P9332; Coetzee WA, 1999, ANN NY ACAD SCI, V868, P233, DOI 10.1111/j.1749-6632.1999.tb11293.x; CRITZ SD, 1993, J NEUROCHEM, V60, P1175, DOI 10.1111/j.1471-4159.1993.tb03273.x; Deutsch C, 2002, ANNU REV PHYSIOL, V64, P19, DOI 10.1146/annurev.physiol.64.081501.155934; Erisir A, 1999, J NEUROPHYSIOL, V82, P2476, DOI 10.1152/jn.1999.82.5.2476; Fernandez FR, 2003, J BIOL CHEM, V278, P40890, DOI 10.1074/jbc.M304235200; FREEMAN LC, 1993, CIRC RES, V73, P968, DOI 10.1161/01.RES.73.5.968; Gan L, 1998, J NEUROBIOL, V37, P69, DOI 10.1002/(SICI)1097-4695(199810)37:1<69::AID-NEU6>3.0.CO;2-6; GRISSMER S, 1992, J BIOL CHEM, V267, P20971; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hernandez-Pineda R, 1999, J NEUROPHYSIOL, V82, P1512, DOI 10.1152/jn.1999.82.3.1512; Isbrandt D, 2002, J MOL MED-JMM, V80, P524, DOI 10.1007/s00109-002-0364-0; Kaczmarek LK, 1997, PHYSIOL REV, V77, P627, DOI 10.1152/physrev.1997.77.3.627; KANEMASA T, 1995, J NEUROPHYSIOL, V74, P207, DOI 10.1152/jn.1995.74.1.207; Lau D, 2000, J NEUROSCI, V20, P9071; Lien CC, 2003, J NEUROSCI, V23, P2058; Macica CM, 2003, J NEUROSCI, V23, P1133, DOI 10.1523/JNEUROSCI.23-04-01133.2003; Martina M, 1998, J NEUROSCI, V18, P8111; McCrossan ZA, 2003, J NEUROSCI, V23, P8077; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; Melman YF, 2002, J BIOL CHEM, V277, P25187, DOI 10.1074/jbc.M200564200; Melman YF, 2001, J BIOL CHEM, V276, P6439, DOI 10.1074/jbc.M010713200; MORENO H, 1995, J NEUROSCI, V15, P5486; Ohya S, 2002, AM J PHYSIOL-CELL PH, V283, pC866, DOI 10.1152/ajpcell.00099.2002; Ohya S, 2002, AM J PHYSIOL-GASTR L, V282, pG277, DOI 10.1152/ajpgi.00200.2001; RETTIG J, 1992, EMBO J, V11, P2473, DOI 10.1002/j.1460-2075.1992.tb05312.x; Rudy B, 2001, TRENDS NEUROSCI, V24, P517, DOI 10.1016/S0166-2236(00)01892-0; Rudy B, 1999, ANN NY ACAD SCI, V868, P304, DOI 10.1111/j.1749-6632.1999.tb11295.x; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Schroeder BC, 2000, NATURE, V403, P196, DOI 10.1038/35003200; SCHROTER KH, 1991, FEBS LETT, V278, P211, DOI 10.1016/0014-5793(91)80119-N; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Tansey EP, 2002, HIPPOCAMPUS, V12, P137, DOI 10.1002/hipo.1104; Tinel N, 2000, EMBO J, V19, P6326, DOI 10.1093/emboj/19.23.6326; Tinel N, 2000, FEBS LETT, V480, P137, DOI 10.1016/S0014-5793(00)01918-9; Tyson J, 1997, HUM MOL GENET, V6, P2179, DOI 10.1093/hmg/6.12.2179; VARNUM MD, 1993, P NATL ACAD SCI USA, V90, P11528, DOI 10.1073/pnas.90.24.11528; Wang LY, 1998, J PHYSIOL-LONDON, V509, P183, DOI 10.1111/j.1469-7793.1998.183bo.x; Yu H, 2001, CIRC RES, V88, pE84, DOI 10.1161/hh1201.093511; Yue L, 2000, J PHYSIOL-LONDON, V527, P467, DOI 10.1111/j.1469-7793.2000.00467.x; Zhang M, 2001, CIRC RES, V88, P1012, DOI 10.1161/hh1001.090839; ZHANG ZJ, 1994, P NATL ACAD SCI USA, V91, P1766, DOI 10.1073/pnas.91.5.1766	52	61	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7884	7892		10.1074/jbc.M310501200	http://dx.doi.org/10.1074/jbc.M310501200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14679187	hybrid			2022-12-25	WOS:000189103300065
J	Mehle, A; Strack, B; Ancuta, P; Zhang, CS; McPike, M; Gabuzda, D				Mehle, A; Strack, B; Ancuta, P; Zhang, CS; McPike, M; Gabuzda, D			Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; HIV-1 VIF; REVERSE TRANSCRIPTION; ENZYME APOBEC3G; SOR GENE; PROTEIN; DNA; HYPERMUTATION; STABILITY; COMPLEX	Viruses must overcome diverse intracellular defense mechanisms to establish infection. The Vif (virion infectivity factor) protein of human immunodeficiency virus 1 (HIV-1) acts by overcoming the antiviral activity of APOBEC3G (CEM15), a cytidine deaminase that induces G to A hypermutation in newly synthesized viral DNA. In the absence of Vif, APOBEC3G incorporation into virions renders HIV-1 non-infectious. We report here that Vif counteracts the antiviral activity of APOBEC3G by targeting it for destruction by the ubiquitin-proteasome pathway. Vif forms a complex with APOBEC3G and enhances APOBEC3G ubiquitination, resulting in reduced steady-state APOBEC3G levels and a decrease in protein half-life. Furthermore, Vif-dependent degradation of APOBEC3G is blocked by proteasome inhibitors or ubiquitin mutant K48R. A mutation of highly conserved cysteines or the deletion of a conserved SLQ(Y/F)LA motif in Vif results in mutants that fail to induce APOBEC3G degradation and produce non-infectious HIV-1; however, mutations of conserved phosphorylation sites in Vif that impair viral replication do not affect APOBEC3G degradation, suggesting that Vif is important for other functions in addition to inducing proteasomal degradation of APOBEC3G. Vif is mon-oubiquitinated in the absence of APOBEC3G but is poly-ubiquitinated and rapidly degraded when APOBEC3G is coexpressed, suggesting that coexpression accelerates the degradation of both proteins. These results suggest that Vif functions by targeting APOBEC3G for degradation via the ubiquitin-proteasome pathway and implicate the proteasome as a site of dynamic interplay between microbial and cellular defenses.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Gabuzda, D (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, JF816,44 Binney St, Boston, MA 02115 USA.	dana_gabuzda@dfci.harvard.edu		Mehle, Andrew/0000-0001-6060-4330	NIAID NIH HHS [AI28691, AI36186] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028691, R01AI036186] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ancuta P, 2003, J EXP MED, V197, P1701, DOI 10.1084/jem.20022156; BLANC D, 1993, VIROLOGY, V193, P186, DOI 10.1006/viro.1993.1114; Brown HEV, 1999, J VIROL, V73, P9011, DOI 10.1128/JVI.73.11.9011-9020.1999; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453; Fouchier RAM, 1996, J VIROL, V70, P8263, DOI 10.1128/JVI.70.12.8263-8269.1996; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; GONCALVES J, 1995, J VIROL, V69, P7196, DOI 10.1128/JVI.69.11.7196-7204.1995; GONCALVES J, 1994, J VIROL, V68, P704, DOI 10.1128/JVI.68.2.704-712.1994; Goncalves J, 1996, J VIROL, V70, P8701, DOI 10.1128/JVI.70.12.8701-8709.1996; Harris RS, 2003, NAT IMMUNOL, V4, P641, DOI 10.1038/ni0703-641; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; MA XY, 1994, J VIROL, V68, P1714, DOI 10.1128/JVI.68.3.1714-1720.1994; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; Ohagen A, 2000, J VIROL, V74, P11055, DOI 10.1128/JVI.74.23.11055-11066.2000; SAKAI H, 1993, J VIROL, V67, P1663, DOI 10.1128/JVI.67.3.1663-1666.1993; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Simon JHM, 1996, J VIROL, V70, P5297, DOI 10.1128/JVI.70.8.5297-5305.1996; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; Tsirigotis M, 2001, J BIOL CHEM, V276, P46073, DOI 10.1074/jbc.M109023200; Ulrich HD, 2002, CURR TOP MICROBIOL, V268, P137; VARTANIAN JP, 1994, P NATL ACAD SCI USA, V91, P3092, DOI 10.1073/pnas.91.8.3092; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; Vecchione A, 2003, MOL CELL BIOL, V23, P3363, DOI 10.1128/MCB.23.9.3363-3372.2003; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; YAMANAKA S, 1995, P NATL ACAD SCI USA, V92, P8483, DOI 10.1073/pnas.92.18.8483; Yang X, 1996, J BIOL CHEM, V271, P10121, DOI 10.1074/jbc.271.17.10121; Yang XY, 1998, J BIOL CHEM, V273, P29879, DOI 10.1074/jbc.273.45.29879; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707	39	377	397	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7792	7798		10.1074/jbc.M313093200	http://dx.doi.org/10.1074/jbc.M313093200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14672928	hybrid			2022-12-25	WOS:000189103300053
J	Hinton, PR; Johlfs, MG; Xiong, JM; Hanestad, K; Ong, KC; Bullock, C; Keller, S; Tang, MT; Tso, JY; V squez, M; Tsurushita, N				Hinton, PR; Johlfs, MG; Xiong, JM; Hanestad, K; Ong, KC; Bullock, C; Keller, S; Tang, MT; Tso, JY; V squez, M; Tsurushita, N			Engineered human IgG antibodies with longer serum half-lives in primates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEONATAL FC RECEPTOR; AMINO-ACID-RESIDUES; I-RELATED RECEPTOR; CRYSTAL-STRUCTURE; CONSTANT REGION; BINDING; COMPLEX; MOUSE; ANTIGEN; SITE	The neonatal Fe receptor (FcRn) plays an important role in regulating the serum half-lives of IgG antibodies. A correlation has been established between the pH-dependent binding affinity of IgG antibodies to FcRn and their serum half-lives in mice. In this study, molecular modeling was used to identify Fe positions near the FcRn binding site in a human IgG antibody that, when mutated, might alter the binding affinity of IgG to FcRn. Following mutagenesis, several IgG, mutants with increased binding affinity to human FcRn at pH 6.0 were identified at Fc positions 250 and 428. These mutants do not bind to human FcRn at pH 7.5. A pharmacokinetics study of two mutant IgG(2) antibodies with increased FcRn binding affinity indicated that they had serum half-lives in rhesus monkeys similar to2-fold longer than the wild-type antibody.	Prot Design Labs Inc, Fremont, CA 94555 USA		Hinton, PR (corresponding author), Prot Design Labs Inc, Fremont, CA 94555 USA.	phinton@pdl.com						BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; CARAS IW, 1987, NATURE, V325, P545, DOI 10.1038/325545a0; CO MS, 1992, J IMMUNOL, V148, P1149; Cole MS, 1997, J IMMUNOL, V159, P3613; Dall'Acqua WF, 2002, J IMMUNOL, V169, P5171, DOI 10.4049/jimmunol.169.9.5171; EHRLICH P H, 1992, Human Antibodies and Hybridomas, V3, P2; Ghetie V, 1997, NAT BIOTECHNOL, V15, P637, DOI 10.1038/nbt0797-637; Ghetie V, 2000, ANNU REV IMMUNOL, V18, P739, DOI 10.1146/annurev.immunol.18.1.739; Ghetie V, 1996, EUR J IMMUNOL, V26, P690, DOI 10.1002/eji.1830260327; Higuchi R., 1989, PCR TECHNOLOGY, P61; Hoogenboom HR, 2000, IMMUNOL TODAY, V21, P371, DOI 10.1016/S0167-5699(00)01667-4; Idusogie EE, 2001, J IMMUNOL, V166, P2571, DOI 10.4049/jimmunol.166.4.2571; Israel EJ, 1996, IMMUNOLOGY, V89, P573, DOI 10.1046/j.1365-2567.1996.d01-775.x; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; Junghans RP, 1996, P NATL ACAD SCI USA, V93, P5512, DOI 10.1073/pnas.93.11.5512; Kabat EA, 1991, SEQUENCES PROTEINS I; Kim JK, 1999, EUR J IMMUNOL, V29, P2819, DOI 10.1002/(SICI)1521-4141(199909)29:09<2819::AID-IMMU2819>3.0.CO;2-6; KIM JK, 1994, EUR J IMMUNOL, V24, P542, DOI 10.1002/eji.1830240308; LEVITT M, 1983, J MOL BIOL, V168, P595, DOI 10.1016/S0022-2836(83)80304-0; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; Martin WL, 2001, MOL CELL, V7, P867, DOI 10.1016/S1097-2765(01)00230-1; Medesan C, 1997, J IMMUNOL, V158, P2211; MORRISON SL, 1984, P NATL ACAD SCI-BIOL, V81, P6851, DOI 10.1073/pnas.81.21.6851; RAGHAVAN M, 1995, BIOCHEMISTRY-US, V34, P14649, DOI 10.1021/bi00045a005; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; Shields RL, 2001, J BIOL CHEM, V276, P6591, DOI 10.1074/jbc.M009483200; SIMISTER NE, 1989, NATURE, V337, P184, DOI 10.1038/337184a0; Simmons LC, 2002, J IMMUNOL METHODS, V263, P133, DOI 10.1016/S0022-1759(02)00036-4; TAO MH, 1989, J IMMUNOL, V143, P2595; Waldmann TA, 2003, NAT MED, V9, P269, DOI 10.1038/nm0303-269; Weng ZP, 1998, J MOL BIOL, V282, P217, DOI 10.1006/jmbi.1998.2020; West AP, 2000, BIOCHEMISTRY-US, V39, P9698, DOI 10.1021/bi000749m; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	33	203	530	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6213	6216		10.1074/jbc.C300470200	http://dx.doi.org/10.1074/jbc.C300470200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14699147	hybrid			2022-12-25	WOS:000188969200003
J	Izard, T; Sygusch, J				Izard, T; Sygusch, J			Induced fit movements and metal cofactor selectivity of class II aldolases - Structure of thermus aquaticus fructose-1,6-bisphosphate aldolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ACTIVE-SITE; MUSCLE ALDOLASE; MECHANISM; MOLSCRIPT; COMPLEX; RESIDUE	Fructose-1,6-bisphosphate (FBP) aldolase is an essential glycolytic enzyme that reversibly cleaves its ketohexose substrate into triose phosphates. Here we report the crystal structure of a metallo-dependent or class II FBP aldolase from an extreme thermophile, Thermus aquaticus (Taq). The quaternary structure reveals a tetramer composed of two dimers related by a 2-fold axis. Taq FBP aldolase subunits exhibit two distinct conformational states corresponding to loop regions that are in either open or closed position with respect to the active site. Loop closure remodels the disposition of chelating active site histidine residues. In subunits corresponding to the open conformation, the metal cofactor, Co2+, is sequestered in the active site, whereas for subunits in the closed conformation, the metal cation exchanges between two mutually exclusive binding loci, corresponding to a site at the active site surface and an interior site vicinal to the metal-binding site in the open conformation. Cofactor site exchange is mediated by rotations of the chelating histidine side chains that are coupled to the prior conformational change of loop closure. Sulfate anions are consistent with the location of the phosphate-binding sites of the FBP substrate and determine not only the previously unknown second phosphate-binding site but also provide a mechanism that regulates loop closure during catalysis. Modeling of FBP substrate into the active site is consistent with binding by the acyclic keto form, a minor solution species, and with the metal cofactor mediating keto bond polarization. The Taq FBP aldolase structure suggests a structural basis for different metal cofactor specificity than in Escherichia coli FBP aldolase structures, and we discuss its potential role during catalysis. Comparison with the E. coli structure also indicates a structural basis for thermostability by Taq FBP aldolase.	Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38111 USA	Universite de Montreal; St Jude Children's Research Hospital	Sygusch, J (corresponding author), Univ Montreal, Dept Biochem, CP 6128,Succ Centreville, Montreal, PQ H3C 3J7, Canada.	jurgen.sygusch@umontreal.ca		Sygusch, Jurgen/0000-0002-6629-2128	NCI NIH HHS [CA21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANAI M, 1973, ARCH BIOCHEM BIOPHYS, V156, P712, DOI 10.1016/0003-9861(73)90324-X; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bairoch A, 1997, J MOL MED-JMM, V75, P312; Barbas CF, 1997, SCIENCE, V278, P2085, DOI 10.1126/science.278.5346.2085; BERTHIAUME L, 1993, J BIOL CHEM, V268, P10826; BERTHIAUME L, 1991, J BIOL CHEM, V266, P17099; Blom NS, 1996, NAT STRUCT BIOL, V3, P856, DOI 10.1038/nsb1096-856; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Choi KH, 1999, BIOCHEMISTRY-US, V38, P12655, DOI 10.1021/bi9828371; Chudzik DM, 2000, J MOL BIOL, V300, P697, DOI 10.1006/jmbi.2000.3910; Cooper SJ, 1996, STRUCTURE, V4, P1303, DOI 10.1016/S0969-2126(96)00138-4; Dalby AR, 2001, ACTA CRYSTALLOGR D, V57, P1526, DOI 10.1107/S0907444901012719; DeMontigny C, 1996, EUR J BIOCHEM, V241, P243; DOBELI H, 1991, ACT LEIDENS, V60, P135; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; FREEZE H, 1970, J BACTERIOL, V101, P541, DOI 10.1128/JB.101.2.541-550.1970; GAMBLIN SJ, 1990, FEBS LETT, V262, P282, DOI 10.1016/0014-5793(90)80211-Z; Hall DR, 1999, J MOL BIOL, V287, P383, DOI 10.1006/jmbi.1999.2609; Hall DR, 2002, J BIOL CHEM, V277, P22018, DOI 10.1074/jbc.M202464200; HANNAPPEL E, 1982, ARCH BIOCHEM BIOPHYS, V214, P293, DOI 10.1016/0003-9861(82)90033-9; HESTER G, 1991, FEBS LETT, V292, P237, DOI 10.1016/0014-5793(91)80875-4; IZARD T, 1994, STRUCTURE, V2, P361, DOI 10.1016/S0969-2126(00)00038-1; Izard T, 2000, EMBO J, V19, P3849, DOI 10.1093/emboj/19.15.3849; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karshikoff A, 2001, TRENDS BIOCHEM SCI, V26, P550, DOI 10.1016/S0968-0004(01)01918-1; Kim H, 1998, BIOCHEMISTRY-US, V37, P4388, DOI 10.1021/bi972233h; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KYTE J, 1995, MECH PROTEIN CHEM, P353; LAI CY, 1965, J BIOL CHEM, V240, P1347; Maurady A, 2002, J BIOL CHEM, V277, P9474, DOI 10.1074/jbc.M107600200; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Plater AR, 1999, J MOL BIOL, V285, P843, DOI 10.1006/jmbi.1998.2376; Qamar S, 1996, PROTEIN SCI, V5, P154; ROSSMANN MG, 1973, J MOL BIOL, V76, P533, DOI 10.1016/0022-2836(73)90491-9; Sauve V, 2001, PROTEIN EXPRES PURIF, V21, P293, DOI 10.1006/prep.2000.1380; Sauve V, 2001, ACTA CRYSTALLOGR D, V57, P310, DOI 10.1107/S0907444900019727; Schoevaart R, 2001, J ORG CHEM, V66, P4559, DOI 10.1021/jo001766k; SYGUSCH J, 1987, P NATL ACAD SCI USA, V84, P7846, DOI 10.1073/pnas.84.22.7846; Szilagyi A, 2000, STRUCTURE, V8, P493, DOI 10.1016/S0969-2126(00)00133-7; Takayama S, 1997, ANNU REV MICROBIOL, V51, P285, DOI 10.1146/annurev.micro.51.1.285; Terwilliger TC, 1996, ACTA CRYSTALLOGR D, V52, P743, DOI 10.1107/S0907444996001473; VONDEROSTEN CH, 1989, J AM CHEM SOC, V111, P3924, DOI 10.1021/ja00193a025; WAGNER J, 1995, SCIENCE, V270, P1797, DOI 10.1126/science.270.5243.1797; Wong C. -H., 1994, ENZYMES SYNTHETIC OR, V1st	46	32	33	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11825	11833		10.1074/jbc.M311375200	http://dx.doi.org/10.1074/jbc.M311375200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699122	hybrid			2022-12-25	WOS:000220157600119
J	Pell, G; Szabo, L; Charnock, SJ; Xie, HF; Gloster, TM; Davies, GJ; Gilbert, HJ				Pell, G; Szabo, L; Charnock, SJ; Xie, HF; Gloster, TM; Davies, GJ; Gilbert, HJ			Structural and biochemical analysis of Cellvibrio japonicus xylanase 10C - How variation in substrate-binding cleft influences the catalytic profile of family GH-10 xylanases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-FLUORESCENS; ALPHA-GLUCURONIDASE; CELLULOSA XYLANASE; LINKER SEQUENCES; ACTIVE-SITE; DOMAINS; SPECIFICITY; COMPLEX; CRYSTALLOGRAPHY; HEMICELLULASES	Microbial degradation of the plant cell wall is the primary mechanism by which carbon is utilized in the biosphere. The hydrolysis of xylan, by endo-beta-1,4-xylanases (xylanases), is one of the key reactions in this process. Although amino acid sequence variations are evident in the substrate binding cleft of "family GH10" xylanases (see afmb.cnrs-mrs.fr/CAZY/), their biochemical significance is unclear. The Cellvibrio japonicus GH10 xylanase CjXyn10C is a bi-modular enzyme comprising a GH10 catalytic module and a family 15 carbohydrate-binding module. The three-dimensional structure at 1.85 Angstrom, presented here, shows that the sequence joining the two modules is disordered, confirming that linker sequences in modular glycoside hydrolases are highly flexible. CjXyn10C hydrolyzes xylan at a rate similar to other previously described GH10 enzymes but displays very low activity against xylooligosaccharides. The poor activity on short substrates reflects weak binding at the -2 subsite of the enzyme. Comparison of CjXyn10C with other family GH10 enzymes reveals "polymorphisms" in the substrate binding cleft including a glutamate/glycine substitution at the -2 subsite and a tyrosine insertion in the -2/-3 glycone region of the substrate binding cleft, both of which contribute to the unusual properties of the enzyme. The CjXyn10C-substrate complex shows that Tyr-340 stacks against the xylose residue located at the -3 subsite, and the properties of Y340A support the view that this tyrosine plays a pivotal role in substrate binding at this location. The generic importance of using CjXyn10C as a template in predicting the biochemical properties of GH10 xylanases is discussed.	Newcastle Univ, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England	Newcastle University - UK; University of York - UK	Gilbert, HJ (corresponding author), Newcastle Univ, Sch Cell & Mol Biosci, Agr Bldg, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	H.J.Gilbert@Newcastle.ac.uk	Davies, Gideon J/A-9042-2011	Davies, Gideon J/0000-0002-7343-776X				Andrews SR, 2000, J BIOL CHEM, V275, P23027, DOI 10.1074/jbc.M000128200; Armand S, 2001, BIOCHEMISTRY-US, V40, P7404, DOI 10.1021/bi002704r; ATKINS EDT, 1992, PROGR BIOTECHNOL, V7, P39; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beylot MH, 2001, BIOCHEM J, V358, P599, DOI 10.1042/0264-6021:3580599; Biely P, 1997, J BIOTECHNOL, V57, P151, DOI 10.1016/S0168-1656(97)00096-5; BIELY P, 1981, EUR J BIOCHEM, V119, P559, DOI 10.1111/j.1432-1033.1981.tb05644.x; Black GW, 1996, BIOCHEM J, V319, P515, DOI 10.1042/bj3190515; Black GW, 1997, J BIOTECHNOL, V57, P59, DOI 10.1016/S0168-1656(97)00089-8; BRETT CT, 1996, PHYSL BIOCH PLANT CE, V1; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CARPITA NC, 1993, PLANT J, V3, P1, DOI 10.1111/j.1365-313X.1993.tb00007.x; Charnock SJ, 1998, J BIOL CHEM, V273, P32187, DOI 10.1074/jbc.273.48.32187; Charnock SJ, 1997, J BIOL CHEM, V272, P2942, DOI 10.1074/jbc.272.5.2942; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; Ducros V, 2000, J BIOL CHEM, V275, P23020, DOI 10.1074/jbc.275.30.23020; Emami K, 2002, J BACTERIOL, V184, P4124, DOI 10.1128/JB.184.15.4124-4133.2002; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FERREIRA LMA, 1990, BIOCHEM J, V269, P261, DOI 10.1042/bj2690261; Fujimoto Z, 2000, J MOL BIOL, V300, P575, DOI 10.1006/jmbi.2000.3877; GILKES NR, 1991, MICROBIOL REV, V55, P303, DOI 10.1128/MMBR.55.2.303-315.1991; HARRIS GW, 1994, STRUCTURE, V2, P1107, DOI 10.1016/S0969-2126(94)00112-X; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; KELLETT LE, 1990, BIOCHEM J, V272, P369, DOI 10.1042/bj2720369; Lo Leggio L, 1999, PROTEINS, V36, P295; MATSUI I, 1991, J BIOCHEM-TOKYO, V109, P566, DOI 10.1093/oxfordjournals.jbchem.a123420; MILLWARDSADLER SJ, 1994, MOL MICROBIOL, V11, P375, DOI 10.1111/j.1365-2958.1994.tb00317.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagy T, 2002, J BACTERIOL, V184, P4925, DOI 10.1128/JB.184.17.4925-4929.2002; Notenboom V, 1998, NAT STRUCT BIOL, V5, P812, DOI 10.1038/1852; Notenboom V, 1998, BIOCHEMISTRY-US, V37, P4751, DOI 10.1021/bi9729211; Nurizzo D, 2002, STRUCTURE, V10, P547, DOI 10.1016/S0969-2126(02)00742-6; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pell G, 2004, J BIOL CHEM, V279, P9597, DOI 10.1074/jbc.M312278200; Receveur V, 2002, J BIOL CHEM, V277, P40887, DOI 10.1074/jbc.M205404200; SOMOGYI M, 1952, J BIOL CHEM, V195, P19; SUGANUMA T, 1978, J BIOCHEM-TOKYO, V84, P293, DOI 10.1093/oxfordjournals.jbchem.a132130; Szabo L, 2001, J BIOL CHEM, V276, P49061, DOI 10.1074/jbc.M109558200; TULL D, 1994, BIOCHEMISTRY-US, V33, P6363, DOI 10.1021/bi00186a041; White A, 1996, NAT STRUCT BIOL, V3, P149, DOI 10.1038/nsb0296-149; Williams SJ, 2000, J AM CHEM SOC, V122, P4229, DOI 10.1021/ja0002870; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Xie HF, 2001, BIOCHEMISTRY-US, V40, P5700, DOI 10.1021/bi010034z	44	83	87	2	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11777	11788		10.1074/jbc.M311947200	http://dx.doi.org/10.1074/jbc.M311947200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14670951	hybrid			2022-12-25	WOS:000220157600115
J	Pettus, BJ; Bielawska, A; Subramanian, P; Wijesinghe, DS; Maceyka, M; Leslie, CC; Evans, JH; Freiberg, J; Roddy, P; Hannun, YA; Chalfant, CE				Pettus, BJ; Bielawska, A; Subramanian, P; Wijesinghe, DS; Maceyka, M; Leslie, CC; Evans, JH; Freiberg, J; Roddy, P; Hannun, YA; Chalfant, CE			Ceramide 1-phosphate is a direct activator of cytosolic phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MOLECULAR-CLONING; BINDING DOMAIN; C2 DOMAIN; TRANSLOCATION; PROTEIN; MEMBRANE; KINASE; CELLS; DIACYLGLYCEROL	Recently, we demonstrated that ceramide kinase, and its product, ceramide 1-phosphate (Cer-1-P), were mediators of arachidonic acid released in cells in response to interleukin-1beta and calcium ionophore (Pettus, B. J., Bielawska, A., Spiegel, S., Roddy, P., Hannun, Y. A., and Chalfant, C. E. (2003) J. Biol. Chem. 278, 38206-38213). In this study, we demonstrate that down-regulation of cytosolic phospholipase A(2) (cPLA(2)) using RNA interference technology abolished the ability of Cer-1-P to induce arachidonic acid release in A549 cells, demonstrating that cPLA(2) is the key phospholipase A(2) downstream of Cer-1-P. Treatment of A549 cells with Cer-1-P (2.5 muM) induced the translocation of full-length cPLA(2) from the cytosol to the Golgi apparatus/perinuclear regions, which are known sites of translocation in response to agonists. Cer-1-P also induced the translocation of the CaLB/C2 domain of cPLA(2) in the same manner, suggesting that this domain is responsive to Cer-1-P either directly or indirectly. In vitro studies were then conducted to distinguish these two possibilities. In vitro binding studies disclosed that Cer-1-P interacts directly with full-length cPLA(2) and with the CaLB domain in a calcium- and lipid-specific manner with a K-Ca of 1.54 muM. Furthermore, Cer-1-P induced a calcium- dependent increase in cPLA(2) enzymatic activity as well as lowering the EC50 of calcium for the enzyme from 191 to 31 nM. This study identifies Cer-1-P as an anionic lipid that translocates and directly activates cPLA(2), demonstrating a role for this bioactive lipid in the mediation of inflammatory responses.	Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Natl Jewish Med & Res Ctr, Cell Biol Program, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pathol, Denver, CO 80262 USA; Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA 23249 USA	Virginia Commonwealth University; Medical University of South Carolina; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Hunter Holmes McGuire Veterinary Affairs Medical Center	Chalfant, CE (corresponding author), Virginia Commonwealth Univ, Dept Biochem, Med Coll Virginia Campus,Rm 2-003,Sanger Hall,110, Richmond, VA 23298 USA.	cechalfant@vcu.edu	Maceyka, Michael/B-9277-2008	, Preeti/0000-0002-6062-6158	NATIONAL CANCER INSTITUTE [R01CA087584] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072925, F32HL010507, R01HL061378, P01HL034303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER; NCI NIH HHS [CA87584] Funding Source: Medline; NHLBI NIH HHS [HL34303, HL10507, HL61378, HL072925] Funding Source: Medline; NIGMS NIH HHS [GM43825, GM08716] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bayburt T, 1997, BIOCHEMISTRY-US, V36, P3216, DOI 10.1021/bi961659d; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; DIEZ E, 1992, J BIOL CHEM, V267, P18342; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; GomezMunoz A, 1997, BIOCHEM J, V325, P435, DOI 10.1042/bj3250435; HANNUN YA, 1986, J BIOL CHEM, V261, P7184; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; Hinkovska-Galcheva VT, 1998, J BIOL CHEM, V273, P33203, DOI 10.1074/jbc.273.50.33203; Hixon MS, 1998, BIOCHEMISTRY-US, V37, P8516, DOI 10.1021/bi980416d; Hogback S, 2003, BIOCHEM J, V370, P111, DOI 10.1042/bj20020970; Kawano Y, 2001, AM J REPROD IMMUNOL, V46, P393, DOI 10.1034/j.1600-0897.2001.d01-30.x; Kitatani K, 2000, ARCH BIOCHEM BIOPHYS, V382, P296, DOI 10.1006/abbi.2000.2028; Klapisz E, 2000, J LIPID RES, V41, P1680; Kramer RM, 1997, FEBS LETT, V410, P49, DOI 10.1016/S0014-5793(97)00322-0; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; LASSUS P, 2002, SCI STKE; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Luberto C, 2002, J BIOL CHEM, V277, P41128, DOI 10.1074/jbc.M206747200; Maceyka M, 1997, J CELL BIOL, V139, P1411, DOI 10.1083/jcb.139.6.1411; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Pettus BJ, 2003, J BIOL CHEM, V278, P38206, DOI 10.1074/jbc.M304816200; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; Rile G, 2003, ACTA HAEMATOL-BASEL, V109, P76, DOI 10.1159/000068491; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SCHUTZE S, 1994, J LEUKOCYTE BIOL, V56, P533, DOI 10.1002/jlb.56.5.533; SHARP JD, 1991, J BIOL CHEM, V266, P14850; Sugiura M, 2002, J BIOL CHEM, V277, P23294, DOI 10.1074/jbc.M201535200; TAY A, 1995, GENOMICS, V26, P138, DOI 10.1016/0888-7543(95)80093-2; Xu GY, 1998, J MOL BIOL, V280, P485, DOI 10.1006/jmbi.1998.1874	34	280	290	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11320	11326		10.1074/jbc.M309262200	http://dx.doi.org/10.1074/jbc.M309262200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14676210	hybrid			2022-12-25	WOS:000220157600060
J	Christinger, HW; Fuh, G; de Vos, AM; Wiesmann, C				Christinger, HW; Fuh, G; de Vos, AM; Wiesmann, C			The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-KINASE; ANGSTROM RESOLUTION; ANGIOGENESIS; VEGF; FLT-1; RECEPTOR; BINDING; PROTEIN; PIGF	Placental growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family and plays an important role in pathological angiogenic events. PlGF exerts its biological activities through binding to VEGFR1, a receptor tyrosine kinase that consists of seven immunoglobulin-like domains in its extracellular portion. Here we report the crystal structure of PlGF bound to the second immunoglobulin-like domain of VEGFR1 at 2.5 Angstrom resolution and compare the complex to the closely related structure of VEGF bound to the same receptor domain. The two growth factors, PlGF and VEGF, share a sequence identity of similar to50%. Despite this moderate sequence conservation, they bind to the same binding interface of VEGFR1 in a very similar fashion, suggesting that both growth factors could induce very similar if not identical signaling events.	Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA	Roche Holding; Genentech	Wiesmann, C (corresponding author), Genentech Inc, Dept Prot Engn, 1 DNA Way, San Francisco, CA 94080 USA.	chw@gene.com		Wiesmann, Christian/0000-0002-4092-9880				Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, XPLOR MANUAL VERSION; Cao YH, 1997, BIOCHEM BIOPH RES CO, V235, P493, DOI 10.1006/bbrc.1997.6813; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; Eriksson A, 2002, CANCER CELL, V1, P99, DOI 10.1016/S1535-6108(02)00028-4; Farrara N, 2000, CURR OPIN BIOTECH, V11, P617, DOI 10.1016/S0958-1669(00)00153-1; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Iyer S, 2001, J BIOL CHEM, V276, P12153, DOI 10.1074/jbc.M008055200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LECOUTER J, 2003, NATURE, V299, P890; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Luttun A, 2002, BIOCHEM BIOPH RES CO, V295, P428, DOI 10.1016/S0006-291X(02)00677-0; MAGLIONE D, 1993, ONCOGENE, V8, P925; Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Neufeld G, 2002, ADV EXP MED BIOL, V515, P81; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARK JE, 1994, J BIOL CHEM, V269, P25646; Starovasnik MA, 1999, J MOL BIOL, V293, P531, DOI 10.1006/jmbi.1999.3134; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0	31	112	123	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10382	10388		10.1074/jbc.M313237200	http://dx.doi.org/10.1074/jbc.M313237200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14684734	hybrid			2022-12-25	WOS:000220050400088
J	Das, TK; Samuni, U; Lin, Y; Goldberg, DE; Rousseau, DL; Friedman, JM				Das, TK; Samuni, U; Lin, Y; Goldberg, DE; Rousseau, DL; Friedman, JM			Distal heme pocket conformers of carbonmonoxy derivatives of Ascaris hemoglobi - Evidence of conformational trapping in porous sol-gel matrices	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SCATTERING; MYCOBACTERIUM-TUBERCULOSIS; LIGAND-BINDING; ENCAPSULATED HEMOGLOBIN; OXYGEN AVIDITY; TYROSINE B10; MYOGLOBIN; HISTIDINE; MUTANTS; IRON	We report the ligand dependence of the conformer distribution in the distal heme pocket of Ascaris suum hemoglobin (Hb) studied by resonance Raman spectroscopy. The heme-bound CO is used as a spectroscopic antenna to probe the original distribution of conformers in the dioxygen derivative of Ascaris Hb, by utilizing sol-gel encapsulation. The first step is to encapsulate the dioxygen derivative in the porous sol-gel and let the gel age, thus trapping the equilibrium conformational distribution of Ascaris dioxygen Hb. In the second step, the dioxygen ligand is replaced by CO. The sol-gel environment impedes any large scale movements, drastically slowing down the conformational relaxation triggered by the ligation change, essentially "locking in" the initial quaternary and even tertiary structure of the protein. Studying the Fe-CO frequencies of the latter sample allows evaluation of the distribution of the distal heme pocket conformers that was originally associated with the dioxygen derivative. Extending the study to the Ascaris mutants allows for examination of the effect of specific residues in the distal pocket on the conformational distribution. The choice of mutants was largely based on the anticipated variation in hydrogen bonding patterns. The results show that the sol-gel encapsulation can slow or prevent re-equilibration within the distal heme pocket of Ascaris Hb and that the distribution of distal heme pocket conformers for the CO derivative of Ascaris Hb in the sol-gel is highly dependent on the history of the sample. Additionally, we report a detailed study of the CO complex of the mutants in solution for assignment of the various heme pocket conformers, and we present a comparison of the sol-gel data with solution data. The results support a picture in which the dioxygen derivative biases the population strongly toward a tightly packed configuration that favors the network of strong hydrogen bonding interactions, and suggest that Ascaris Hb is uniquely designed for dioxygen capture.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Pfizer Global Res & Dev, Chesterfield, MO 63017 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA	Yeshiva University; Albert Einstein College of Medicine; Pfizer; Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL)	Friedman, JM (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	jfriedma@aecom.yu.edu		Das, Tapan/0000-0002-3641-3988	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM058890, R01GM054812, R01GM067814] Funding Source: NIH RePORTER; NIBIB NIH HHS [EB00296] Funding Source: Medline; NIGMS NIH HHS [GM54812, GM67814, GM58890] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ArredondoPeter R, 1997, PLANT PHYSIOL, V115, P1259, DOI 10.1104/pp.115.3.1259; BARRICK D, 1994, BIOCHEMISTRY-US, V33, P6546, DOI 10.1021/bi00187a023; Bettati S, 1997, J BIOL CHEM, V272, P32050, DOI 10.1074/jbc.272.51.32050; Couture M, 1999, J BIOL CHEM, V274, P6898, DOI 10.1074/jbc.274.11.6898; Couture M, 2000, EUR J BIOCHEM, V267, P4770, DOI 10.1046/j.1432-1327.2000.01531.x; Das TK, 2000, BIOCHEMISTRY-US, V39, P837, DOI 10.1021/bi9922087; Das TK, 1998, J AM CHEM SOC, V120, P10268, DOI 10.1021/ja982127i; Das TK, 2001, P NATL ACAD SCI USA, V98, P479, DOI 10.1073/pnas.98.2.479; Das TK, 1999, J BIOL CHEM, V274, P4207, DOI 10.1074/jbc.274.7.4207; Das TK, 2000, BIOCHEMISTRY-US, V39, P14330, DOI 10.1021/bi001681d; Das TK, 1999, BIOSPECTROSCOPY, V5, pS64, DOI 10.1002/(SICI)1520-6343(1999)5:5+<S64::AID-BSPY7>3.0.CO;2-W; DAVENPORT HE, 1949, PROC R SOC SER B-BIO, V136, P255, DOI 10.1098/rspb.1949.0024; DEBAERE I, 1994, P NATL ACAD SCI USA, V91, P1594, DOI 10.1073/pnas.91.4.1594; Draghi F, 2002, J BIOL CHEM, V277, P7509, DOI 10.1074/jbc.M109206200; GIBSON QH, 1965, PROC R SOC SER B-BIO, V163, P206, DOI 10.1098/rspb.1965.0067; Guarrera L, 1998, BIOCHEMISTRY-US, V37, P5608, DOI 10.1021/bi972380f; Hirota S, 1996, J AM CHEM SOC, V118, P7845, DOI 10.1021/ja9608297; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; Huang SC, 1996, J BIOL CHEM, V271, P958, DOI 10.1074/jbc.271.2.958; Juszczak LJ, 1999, J BIOL CHEM, V274, P30357, DOI 10.1074/jbc.274.43.30357; Khan I, 2000, BIOCHEMISTRY-US, V39, P16099, DOI 10.1021/bi000536x; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; KLOEK AP, 1994, J BIOL CHEM, V269, P2377; KLOEK AP, 1993, J BIOL CHEM, V268, P17669; Kundu S, 2002, PROTEINS, V46, P268, DOI 10.1002/prot.10048; Milani M, 2003, P NATL ACAD SCI USA, V100, P5766, DOI 10.1073/pnas.1037676100; Milani M, 2001, EMBO J, V20, P3902, DOI 10.1093/emboj/20.15.3902; Mukai M, 2002, BIOCHEMISTRY-US, V41, P3897, DOI 10.1021/bi0156409; Navati MS, 2003, P NATL ACAD SCI USA, V100, P3832, DOI 10.1073/pnas.262526399; OKAZAKI T, 1965, BIOCHIM BIOPHYS ACTA, V111, P503, DOI 10.1016/0304-4165(65)90060-7; ONDRIAS MR, 1982, BIOCHEMISTRY-US, V21, P3428, DOI 10.1021/bi00257a028; Peterson ES, 1998, BIOCHEMISTRY-US, V37, P12301, DOI 10.1021/bi980752u; Peterson ES, 1997, BIOCHEMISTRY-US, V36, P13110, DOI 10.1021/bi971156n; Phillips GN, 1999, J PHYS CHEM B, V103, P8817, DOI 10.1021/jp9918205; ROUSSEAU DG, 1992, J STRUCT BIOL, V109, P13; ROUSSEAU DL, 1983, ANNU REV BIOPHYS BIO, V12, P357, DOI 10.1146/annurev.bb.12.060183.002041; ROUSSEAU DL, 1988, BIOL APPLICATIONS RA, V3, P133; Royer WE, 1996, P NATL ACAD SCI USA, V93, P14526, DOI 10.1073/pnas.93.25.14526; Samuni U, 2002, J BIOL CHEM, V277, P25783, DOI 10.1074/jbc.M200301200; Scherlis DA, 2001, J AM CHEM SOC, V123, P8436, DOI 10.1021/ja015665v; Shibayama N, 1999, J AM CHEM SOC, V121, P444, DOI 10.1021/ja983652k; SHIBAYAMA N, 1995, J MOL BIOL, V251, P203, DOI 10.1006/jmbi.1995.0427; SHIRO Y, 1994, BIOCHEMISTRY-US, V33, P14986, DOI 10.1021/bi00254a006; SMERDON SJ, 1993, BIOCHEMISTRY-US, V32, P5132, DOI 10.1021/bi00070a023; SONG SH, 1993, BIOCHEMISTRY-US, V32, P6330, DOI 10.1021/bi00076a005; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; STAVROV SS, 1993, BIOPHYS J, V65, P1942, DOI 10.1016/S0006-3495(93)81265-7; YANG J, 1995, P NATL ACAD SCI USA, V92, P4224, DOI 10.1073/pnas.92.10.4224	48	13	14	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10433	10441		10.1074/jbc.M309590200	http://dx.doi.org/10.1074/jbc.M309590200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688246	hybrid			2022-12-25	WOS:000220050400094
J	O'Brien, PJ; Ellenberger, T				O'Brien, PJ; Ellenberger, T			Dissecting the broad substrate specificity of human 3-methyladenine-DNA glycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYLADENINE DNA GLYCOSYLASE; DEOXYRIBONUCLEIC-ACID; ESCHERICHIA-COLI; EXCISION-REPAIR; BASE EXCISION; HYPOXANTHINE; BINDING; PURIFICATION; CATALYSIS; 1,N(6)-ETHENOADENINE	Human alkyladenine-DNA glycosylase (AAG) catalyzes the excision of a broad range of modified bases, protecting the genome from many types of alkylative and oxidative DNA damage. We have investigated how AAG discriminates against normal DNA bases, while accommodating a structurally diverse set of lesioned bases, by measuring the rates of AAG-catalyzed (k(st)) and spontaneous N-glycosidic bond hydrolysis (k(non)) for damaged and undamaged DNA oligonucleotides. The rate enhancements for excision of different bases reveal that AAG is most adept at excising the deaminated lesion hypoxanthine (k(st)/k(non) = 10(8)), suggesting that enzymatic activity may have evolved in response to this lesion. Comparisons of the rate enhancements for excision of normal and modified purine nucleobases provide evidence that AAG excludes the normal purines via steric clashes with the exocyclic amino groups of adenine and guanine. However, methylated purines are more chemically labile, and only modest rate enhancements are required for their efficient excision. Base flipping also contributes to specificity as destabilized mismatched base pairs are better substrates than stable Watson-Crick pairs, and many of the lesions recognized by AAG are compromised in their ability to base pair. These findings suggest that AAG reconciles a broad substrate tolerance with the biological imperative to avoid normal DNA by excluding normal bases from the active site rather than by specifically recognizing each lesion.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Ellenberger, T (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	tome@hms.harvard.edu			NIGMS NIH HHS [R01 GM52504, GM65043] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM065043, R01GM052504] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AAMODT RM, 2004, IN PRESS J BIOL CHEM; Abner CW, 2001, J BIOL CHEM, V276, P13379, DOI 10.1074/jbc.M010641200; Allan BW, 1999, BIOCHEMISTRY-US, V38, P5308, DOI 10.1021/bi9900020; Berdal KG, 1998, EMBO J, V17, P363, DOI 10.1093/emboj/17.2.363; Biswas T, 2002, J MOL BIOL, V320, P503, DOI 10.1016/S0022-2836(02)00519-3; Branum ME, 2001, J BIOL CHEM, V276, P25421, DOI 10.1074/jbc.M101032200; Bruskov VI, 2002, NUCLEIC ACIDS RES, V30, P1354, DOI 10.1093/nar/30.6.1354; Connor EE, 2002, CHEM BIOL, V9, P1033, DOI 10.1016/S1074-5521(02)00215-6; DUNCAN BK, 1981, ENZYMES, V14, P565; Engelward BP, 1997, P NATL ACAD SCI USA, V94, P13087, DOI 10.1073/pnas.94.24.13087; GALLAGHER PE, 1982, BIOCHEMISTRY-US, V21, P6404, DOI 10.1021/bi00268a013; GONZALEZ FJ, 1992, TRENDS PHARMACOL SCI, V13, P346, DOI 10.1016/0165-6147(92)90107-H; Hanawalt PC, 2002, ONCOGENE, V21, P8949, DOI 10.1038/sj.onc.1206096; Hang B, 1997, P NATL ACAD SCI USA, V94, P12869, DOI 10.1073/pnas.94.24.12869; HENDLER S, 1970, BIOCHEMISTRY-US, V9, P4141, DOI 10.1021/bi00823a017; IKUTA S, 1987, BIOCHEMISTRY-US, V26, P5646, DOI 10.1021/bi00392a010; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; Jiang YL, 2002, BIOCHEMISTRY-US, V41, P11236, DOI 10.1021/bi026226r; KARRAN P, 1980, BIOCHEMISTRY-US, V19, P6005, DOI 10.1021/bi00567a010; Kartalou M, 2000, BIOCHEMISTRY-US, V39, P8032, DOI 10.1021/bi000417h; Lau AY, 2000, P NATL ACAD SCI USA, V97, P13573, DOI 10.1073/pnas.97.25.13573; Law SM, 1996, BIOCHEMISTRY-US, V35, P12329, DOI 10.1021/bi9614545; LEONARD GA, 1994, BIOCHEMISTRY-US, V33, P4755, DOI 10.1021/bi00182a002; LIENHARD GE, 1973, SCIENCE, V180, P149, DOI 10.1126/science.180.4082.149; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; MARTIN FH, 1985, NUCLEIC ACIDS RES, V13, P8927, DOI 10.1093/nar/13.24.8927; MCKAY GA, 1994, BIOCHEMISTRY-US, V33, P6936, DOI 10.1021/bi00188a024; Miao F, 1998, NUCLEIC ACIDS RES, V26, P4034, DOI 10.1093/nar/26.17.4034; O'Brien PJ, 2003, BIOCHEMISTRY-US, V42, P12418, DOI 10.1021/bi035177v; OCONNOR TR, 1991, BIOCHEM BIOPH RES CO, V176, P1170, DOI 10.1016/0006-291X(91)90408-Y; OCONNOR TR, 1993, NUCLEIC ACIDS RES, V21, P5561; OIVANEN M, 1993, TRENDS ORG CHEM, V4, P397; Osborne MR, 2000, CHEM RES TOXICOL, V13, P257, DOI 10.1021/tx990182e; Peyret N, 1999, BIOCHEMISTRY-US, V38, P3468, DOI 10.1021/bi9825091; RADIKA K, 1984, BIOCHEMISTRY-US, V23, P5118, DOI 10.1021/bi00317a006; RADZICKA A, 1995, SCIENCE, V267, P90, DOI 10.1126/science.7809611; Roberts RJ, 1998, ANNU REV BIOCHEM, V67, P181, DOI 10.1146/annurev.biochem.67.1.181; Salinas AE, 1999, CURR MED CHEM, V6, P279; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; SINGER B, 1992, P NATL ACAD SCI USA, V89, P9386, DOI 10.1073/pnas.89.20.9386; Stivers JT, 2001, ARCH BIOCHEM BIOPHYS, V396, P1, DOI 10.1006/abbi.2001.2605; Wong I, 2002, J BIOL CHEM, V277, P19424, DOI 10.1074/jbc.M201198200; WOOD SG, 1986, NUCLEIC ACIDS RES, V14, P6591, DOI 10.1093/nar/14.16.6591	44	138	141	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9750	9757		10.1074/jbc.M312232200	http://dx.doi.org/10.1074/jbc.M312232200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688248	hybrid			2022-12-25	WOS:000220050400013
J	Schneider, D; Engelman, DM				Schneider, D; Engelman, DM			Involvement of transmembrane domain interactions in signal transduction by alpha/beta integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAINS; BIOLOGICAL MEMBRANE; HELIX ASSOCIATION; ESCHERICHIA-COLI; LIGAND-BINDING; BETA-SUBUNITS; GXXXG MOTIF; ACTIVATION; ALPHA(IIB)BETA(3); ALPHA-IIB-BETA-3	The alpha and beta subunits of alpha/beta heterodimeric integrins function together to bind ligands in the extracellular region and transduce signals across cellular membranes. A possible function for the transmembrane regions in integrin signaling has been proposed from structural and computational data. We have analyzed the capacity of the integrin alpha(2), alpha(IIb), alpha(4), beta(1), beta(3), and beta(7) transmembrane domains to form homodimers and/or heterodimers. Our data suggest that the integrin transmembrane helices can help to stabilize heterodimeric integrins but that the interactions do not specifically associate particular pairs of alpha and beta subunits; rather, the alpha/beta subunit interaction constrains the extramembranous domains, facilitating signal transduction by a promiscuous transmembrane helix-helix association.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Univ Freiburg, Dept Biochem & Mol Biol, D-79104 Freiburg, Germany	Yale University; University of Freiburg	Engelman, DM (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 208114, New Haven, CT 06520 USA.	donald.engelman@yale.edu						Adair BD, 2002, P NATL ACAD SCI USA, V99, P14059, DOI 10.1073/pnas.212498199; Armulik A, 1999, J BIOL CHEM, V274, P37030, DOI 10.1074/jbc.274.52.37030; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; Carman CV, 2003, CURR OPIN CELL BIOL, V15, P547, DOI 10.1016/j.ceb.2003.08.003; CHEN HF, 1995, J BIOL CHEM, V270, P14115, DOI 10.1074/jbc.270.23.14115; Daines DA, 2000, J BACTERIOL, V182, P5267, DOI 10.1128/JB.182.18.5267-5270.2000; Dawson JP, 2002, J MOL BIOL, V316, P799, DOI 10.1006/jmbi.2001.5353; Dmitrova M, 1998, MOL GEN GENET, V257, P205; Fleming KG, 1997, J MOL BIOL, V272, P266, DOI 10.1006/jmbi.1997.1236; FRACHET P, 1992, BIOCHEMISTRY-US, V31, P2408, DOI 10.1021/bi00123a028; Gottschalk KE, 2002, PROTEIN SCI, V11, P1800, DOI 10.1110/ps.4120102; Haas TA, 1996, J BIOL CHEM, V271, P6017, DOI 10.1074/jbc.271.11.6017; Hantgan RR, 1999, BIOCHEMISTRY-US, V38, P14461, DOI 10.1021/bi9907680; HEMLER M, 1999, EXTRACELLULAR MATRIX, P196; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Kleiger G, 2002, BIOCHEMISTRY-US, V41, P5990, DOI 10.1021/bi0200763; Langosch D, 1996, J MOL BIOL, V263, P525, DOI 10.1006/jmbi.1996.0595; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LEMMON MA, 1994, FEBS LETT, V346, P17, DOI 10.1016/0014-5793(94)00467-6; Li RH, 2003, SCIENCE, V300, P795, DOI 10.1126/science.1079441; Li RH, 2001, P NATL ACAD SCI USA, V98, P12462, DOI 10.1073/pnas.221463098; Lu CF, 2001, J BIOL CHEM, V276, P14642, DOI 10.1074/jbc.M100600200; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; Mehta RJ, 1998, BIOCHEM J, V330, P861; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Peterson JA, 1998, BLOOD, V92, P2053, DOI 10.1182/blood.V92.6.2053.418k14_2053_2063; Porter JC, 1998, TRENDS CELL BIOL, V8, P390, DOI 10.1016/S0962-8924(98)01344-0; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Schneider D, 2003, J BIOL CHEM, V278, P3105, DOI 10.1074/jbc.M206287200; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2001, P NATL ACAD SCI USA, V98, P11175, DOI 10.1073/pnas.201420198; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Travis MA, 2003, TRENDS PHARMACOL SCI, V24, P192, DOI 10.1016/S0165-6147(03)00069-5; Ulmer TS, 2001, BIOCHEMISTRY-US, V40, P7498, DOI 10.1021/bi010338l; Vallar L, 1999, J BIOL CHEM, V274, P17257, DOI 10.1074/jbc.274.24.17257; Vinogradova O, 2000, P NATL ACAD SCI USA, V97, P1450, DOI 10.1073/pnas.040548197; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535	45	88	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9840	9846		10.1074/jbc.M312749200	http://dx.doi.org/10.1074/jbc.M312749200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14681217	hybrid			2022-12-25	WOS:000220050400023
J	Sun, XX; Hodge, JJL; Zhou, Y; Nguyen, M; Griffith, LC				Sun, XX; Hodge, JJL; Zhou, Y; Nguyen, M; Griffith, LC			The eag potassium channel binds and locally activates calcium/calmodulin-dependent protein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CURRENTS; CAM KINASE; DROSOPHILA; CALMODULIN; MODULATION; PLASTICITY; DENDRITES; SUBUNIT; AUTOPHOSPHORYLATION; AUTOREGULATION	Ca2+/calmodulin-dependent protein kinase II ( CaMKII) has been implicated in the regulation of neuronal excitability in many systems. Recent studies suggest that local regulation of membrane potential can have important computational consequences for neuronal function. In Drosophila, CaMKII regulates the eag potassium channel, but if and how this regulation was spatially restricted was unknown. Using coimmunoprecipitation from head extracts and in vitro binding assays, we show that CaMKII and Eag form a stable complex and that association with Eag activates CaMKII independently of CaM and autophosphorylation. Ca2+/CaM is necessary to initiate binding of CaMKII to Eag but not to sustain association because binding persists when CaM is removed. The Eag CaMKII-binding domain has homology to the CaMKII autoregulatory region, and the constitutively active CaMKII mutant, T287D, binds Eag Ca2+-independently in vitro and in vivo. These results favor a model in which the CaMKII-binding domain of Eag displaces the CaMKII autoinhibitory region. Displacement results in autophosphorylation-independent activation of CaMKII which persists even when Ca2+ levels have gone down. Activity-dependent binding to this potassium channel substrate allows CaMKII to remain locally active even when Ca2+ levels have dropped, providing a novel mechanism by which CaMKII can regulate excitability locally over long time scales.	Brandeis Univ, Dept Biol, Waltham, MA 02454 USA; Brandeis Univ, Ctr Complex Syst, Waltham, MA 02454 USA; Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA	Brandeis University; Brandeis University; University of Pennsylvania	Griffith, LC (corresponding author), Brandeis Univ, Dept Biol, Ms008,415 South St, Waltham, MA 02454 USA.	griffith@brandeis.edu		Griffith, Leslie/0000-0003-3164-9876; Hodge, James/0000-0003-4741-2363	NCRR NIH HHS [S10 RR16780] Funding Source: Medline; NIGMS NIH HHS [R01 GM54408, R01 GM054408, R01 GM054408-08] Funding Source: Medline; NINDS NIH HHS [R01 NS17910] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR016780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054408] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017910] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bayer KU, 2001, NATURE, V411, P801, DOI 10.1038/35081080; BUTLER LS, 1995, P NATL ACAD SCI USA, V92, P6852, DOI 10.1073/pnas.92.15.6852; Cook EP, 1999, J NEUROPHYSIOL, V81, P535, DOI 10.1152/jn.1999.81.2.535; DRYSDALE R, 1991, GENETICS, V127, P497; Estes PS, 2000, J NEUROGENET, V13, P233, DOI 10.3109/01677060009084496; GRIFFITH LC, 1993, J NEUROCHEM, V61, P1534, DOI 10.1111/j.1471-4159.1993.tb13650.x; GRIFFITH LC, 1994, P NATL ACAD SCI USA, V91, P10044, DOI 10.1073/pnas.91.21.10044; Hansel C, 2001, NAT NEUROSCI, V4, P467, DOI 10.1038/87419; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HASHIMOTO Y, 1988, P NATL ACAD SCI USA, V85, P7001, DOI 10.1073/pnas.85.18.7001; Hoffman DA, 1997, NATURE, V387, P869, DOI 10.1038/43119; Hudmon A, 2002, ANNU REV BIOCHEM, V71, P473, DOI 10.1146/annurev.biochem.71.110601.135410; Hudmon A, 2003, BIOPHYS J, V84, p329A; Jin R, 1998, J NEUROSCI, V18, P8955; Johnston D, 2003, PHILOS T ROY SOC B, V358, P667, DOI 10.1098/rstb.2002.1248; KAPLAN WD, 1969, GENETICS, V61, P399; Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; Long XM, 2000, J BIOL CHEM, V275, P40765, DOI 10.1074/jbc.M003949200; Marder E, 1996, P NATL ACAD SCI USA, V93, P13481, DOI 10.1073/pnas.93.24.13481; Park D, 2002, J NEUROBIOL, V52, P24, DOI 10.1002/neu.10066; Pedarzani P, 1996, PFLUG ARCH EUR J PHY, V431, P723, DOI 10.1007/s004240050057; Peretz A, 1998, J NEUROSCI, V18, P9153; Putkey JA, 1996, J BIOL CHEM, V271, P29619, DOI 10.1074/jbc.271.47.29619; Reiner DJ, 1999, NATURE, V402, P199, DOI 10.1038/46072; Roeper J, 1997, J NEUROSCI, V17, P3379; Schonherr R, 2000, EMBO J, V19, P3263, DOI 10.1093/emboj/19.13.3263; Smith MR, 2002, J NEUROPHYSIOL, V87, P2031, DOI 10.1152/jn.00821.2001; SODERLING TR, 1993, BIOTECHNOL APPL BIOC, V18, P185; Sola C, 1999, PROG NEUROBIOL, V58, P207, DOI 10.1016/S0301-0082(98)00082-3; Takamatsu Y, 2003, BRAIN RES, V974, P99, DOI 10.1016/S0006-8993(03)02562-9; Turrigiano GG, 1999, TRENDS NEUROSCI, V22, P221, DOI 10.1016/S0166-2236(98)01341-1; Varga AW, 2000, LEARN MEMORY, V7, P321, DOI 10.1101/lm.35300; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002; Wang Z, 1998, J NEUROCHEM, V71, P378; Wang Z, 2002, J BIOL CHEM, V277, P24022, DOI 10.1074/jbc.M201949200; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Willis WD, 2001, ANN NY ACAD SCI, V933, P142; WU CF, 1983, SCIENCE, V220, P1076, DOI 10.1126/science.6302847; Yang EY, 1999, J BIOL CHEM, V274, P26199, DOI 10.1074/jbc.274.37.26199; Yao WD, 1999, ANN NY ACAD SCI, V868, P450, DOI 10.1111/j.1749-6632.1999.tb11312.x; Yuan LL, 2002, J NEUROSCI, V22, P4860, DOI 10.1523/JNEUROSCI.22-12-04860.2002	43	77	81	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10206	10214		10.1074/jbc.M310728200	http://dx.doi.org/10.1074/jbc.M310728200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699099	hybrid			2022-12-25	WOS:000220050400067
J	Woodworth, A; Pesheva, P; Fiete, D; Baenziger, JU				Woodworth, A; Pesheva, P; Fiete, D; Baenziger, JU			Neuronal-specific synthesis and glycosylation of tenascin-R	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX GLYCOPROTEIN; CELL-ADHESION MOLECULE; LONG-TERM POTENTIATION; CIRCULATORY HALF-LIFE; DEVELOPMENTAL EXPRESSION; HNK-1-REACTIVE ANTIGENS; PERISOMATIC INHIBITION; N-ACETYLGALACTOSAMINE; CHONDROITIN SULFATES; HNK-1 CARBOHYDRATE	Tenascin-R (TN-R) is a member of the tenascin family of multidomain matrix glycoproteins that is expressed exclusively in the central nervous system by oligodendrocytes and small neurons during postnatal development and in the adult. TN-R contributes to the regulation of axon extension and regeneration, neurite formation and synaptogenesis, and neuronal growth and migration. TN-R can be modified with three distinct sulfated oligosaccharide structures: HNK-1 (SO4-3-GlcUAbeta1,3Galbeta1,4,GlcNAc), GalNAc-4-SO4, and chondroitin sulfate. We have determined that TN-R expressed in dendrite-rich regions of the rat cerebellum, hippocampus, and cerebral cortex is one of the major matrix glycoproteins that bears N-linked carbohydrates terminating with beta1,4-linked GalNAc-4-SO4. The syntheses of these unique sulfated structures on TN-R are differentially regulated. Levels of HNK-1 on TN-R rise and fall in parallel to the levels of TN-R during postnatal development of the cerebellum. In contrast, levels of GalNAc-4-SO4 are regulated independently from those of TN-R, rising late in cerebellar development and continuing into adulthood. As a result, the pattern of TN-R modification with distinct sulfated carbohydrate structures changes dramatically over the course of postnatal cerebellar development in the rat. Because TN-R interacts with a number of different matrix components and, depending on the circumstances, can either activate or inhibit neurite outgrowth, the highly regulated addition of these unique sulfated structures may modulate the adhesive properties of TN-R over the course of development and during synapse maintenance. In addition, the 160-kDa form of TN-R is particularly enriched for terminal GalNAc-4-SO4 later in development and in the adult, suggesting additional levels of regulation.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Univ Bonn, Neuro & Tumor Cell Biol Grp, Dept Nucl Med, D-53105 Bonn, Germany	Washington University (WUSTL); University of Bonn	Baenziger, JU (corresponding author), Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA.	Baenziger@pathology.wustl.edu	Baenziger, Jacques U/E-9430-2012		NCI NIH HHS [R37-CA21923] Funding Source: Medline; NIDDK NIH HHS [R01-DK41738] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA021923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041738] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTMAN J, 1972, J COMP NEUROL, V145, P399, DOI 10.1002/cne.901450402; Altman J, 1997, DEV CEREBELLAR SYSTE; BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; BAENZIGER JU, 1988, BIOCHIM BIOPHYS ACTA, V947, P287, DOI 10.1016/0304-4157(88)90012-3; BIEDLER JL, 1973, CANCER RES, V33, P2643; BIEDLER JL, 1978, CANCER RES, V38, P3751; Chou DKH, 2002, J NEUROCHEM, V82, P1239, DOI 10.1046/j.1471-4159.2002.01066.x; Chou DKH, 2000, J NEUROSCI RES, V59, P188, DOI 10.1002/(SICI)1097-4547(20000115)59:2<188::AID-JNR5>3.0.CO;2-M; CHOU DKH, 1991, J NEUROCHEM, V57, P852, DOI 10.1111/j.1471-4159.1991.tb08229.x; DHARMESH SM, 1993, J BIOL CHEM, V268, P17096; Fawcett JW, 1997, CELL TISSUE RES, V290, P371, DOI 10.1007/s004410050943; FUSS B, 1991, J NEUROSCI RES, V29, P299, DOI 10.1002/jnr.490290305; FUSS B, 1993, J CELL BIOL, V120, P1237, DOI 10.1083/jcb.120.5.1237; GARY SC, 1998, MICROSC RES TECHNIQ, V43, P576; Hooper LV, 1996, FASEB J, V10, P1137, DOI 10.1096/fasebj.10.10.8751716; Jones FS, 2000, DEV DYNAM, V218, P235, DOI 10.1002/(SICI)1097-0177(200006)218:2<235::AID-DVDY2>3.3.CO;2-7; Kang HG, 2001, J BIOL CHEM, V276, P10861, DOI 10.1074/jbc.M011560200; KRUSE J, 1985, NATURE, V316, P146, DOI 10.1038/316146a0; Manzella SM, 1996, J BIOL CHEM, V271, P12117, DOI 10.1074/jbc.271.21.12117; Mi YL, 2002, J CLIN INVEST, V109, P269, DOI 10.1172/JCI13997; NORENBERG U, 1995, J CELL BIOL, V130, P473, DOI 10.1083/jcb.130.2.473; PESHEVA P, 1994, J CELL SCI, V107, P2323; Pesheva P, 2000, PROG NEUROBIOL, V61, P465, DOI 10.1016/S0301-0082(99)00061-1; PESHEVA P, 1989, J CELL BIOL, V109, P1765, DOI 10.1083/jcb.109.4.1765; PESHEVA P, 1993, NEURON, V10, P69, DOI 10.1016/0896-6273(93)90243-K; PRASADARAO N, 1990, J NEUROCHEM, V55, P2024, DOI 10.1111/j.1471-4159.1990.tb05791.x; Probstmeier R, 2001, J NEUROSCI RES, V64, P70, DOI 10.1002/jnr.1055; Probstmeier R, 2000, J NEUROSCI RES, V60, P21, DOI 10.1002/(SICI)1097-4547(20000401)60:1<21::AID-JNR3>3.0.CO;2-H; Probstmeier R, 2000, BRAIN RES, V863, P42, DOI 10.1016/S0006-8993(00)02075-8; ROSS RA, 1983, J NATL CANCER I, V71, P741; Saghatelyan AK, 2000, EUR J NEUROSCI, V12, P3331, DOI 10.1046/j.1460-9568.2000.00216.x; Saghatelyan AK, 2001, MOL CELL NEUROSCI, V17, P226, DOI 10.1006/mcne.2000.0922; SCHACHNER M, 1994, PERSPECT DEV NEUROBI, V2, P33; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; Woodworth A, 2002, J BIOL CHEM, V277, P50941, DOI 10.1074/jbc.M209876200; Xiao ZC, 1997, J NEUROSCI RES, V49, P698, DOI 10.1002/(SICI)1097-4547(19970915)49:6<698::AID-JNR4>3.0.CO;2-2; Zamze S, 1999, GLYCOBIOLOGY, V9, P823, DOI 10.1093/glycob/9.8.823	37	34	35	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10413	10421		10.1074/jbc.M312466200	http://dx.doi.org/10.1074/jbc.M312466200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14681222	hybrid			2022-12-25	WOS:000220050400092
J	Ko, JS; Shin, SM; Oh, YM; Lee, YS; Ryoo, ZY; Lee, YH; Na, DS; Kim, JW				Ko, JS; Shin, SM; Oh, YM; Lee, YS; Ryoo, ZY; Lee, YH; Na, DS; Kim, JW			Transgenic mouse model for breast cancer: induction of breast cancer in novel oncogene HCCR-2 transgenic mice	ONCOGENE			English	Article						breast cancer; HCCR-2; p53; transgenic mouse	EMBRYO FIBROBLASTS; C-MYC; IDENTIFICATION; AMPLIFICATION; INVOLVEMENT; GENES; CELLS; DNA	Transgenic mice containing novel oncogene HCCR-2 were generated to analyse the phenotype and to characterize the role of HCCR-2 in cellular events. Mice transgenic for HCCR-2 developed breast cancers and metastasis. The level of p53 in HCCR-2 transgenic mice was elevated in most tissues including breast, brain, heart, lung, liver, stomach, kidney, spleen, and lymph node. We examined whether stabilized p53 is functional in HCCR-2 transgenic mice. Defective induction of p53 responsive genes including p21(WAF1), MDM2, and bax indicates that stabilized p53 in HCCR-2 transgenic mice exists in an inactive form. These results suggest that HCCR-2 represents an oncoprotein that is related to breast cancer development and regulation of the p53 tumor suppressor.	Catholic Univ Korea, Coll Med, Mol Genet Lab, Seoul 137040, South Korea; Univ Ulsan, Coll Med, Asan Inst Life Sci, Seoul 138736, South Korea; Univ Ulsan, Coll Med, Dept Internal Med, Seoul 138736, South Korea; Catholic Univ Korea, Coll Med, Dept Obstet & Gynecol, Seoul 137040, South Korea; Catholic Univ Korea, Coll Med, Dept Clin Pathol, Seoul 137040, South Korea; Catholic Univ Korea, Coll Med, Lab Anim Sci, Seoul 137040, South Korea; Yeungnam Univ, Coll Med, Dept Biochem & Mol Biol, Taegu 705717, South Korea; Univ Ulsan, Coll Med, Dept Biochem & Mol Biol, Seoul 138736, South Korea	Catholic University of Korea; University of Ulsan; University of Ulsan; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Yeungnam University; University of Ulsan	Kim, JW (corresponding author), Catholic Univ Korea, Coll Med, Mol Genet Lab, Seoul 137040, South Korea.	jinwoo@catholic.ac.kr	RYOO, ZAEYOUNG/AAQ-1573-2020					BERNS EMJJ, 1992, CANCER RES, V52, P1107; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BYRNE JA, 1995, CANCER RES, V55, P2896; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; Dickson C, 2000, ONCOGENE, V19, P1097, DOI 10.1038/sj.onc.1203267; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; Kim J, 1996, AM J PHYSIOL-RENAL, V270, pF575, DOI 10.1152/ajprenal.1996.270.4.F575; Ko J, 2003, ONCOGENE, V22, P4679, DOI 10.1038/sj.onc.1206624; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; NEBERT DW, 1991, MUTAT RES, V247, P267, DOI 10.1016/0027-5107(91)90022-G; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Proux V, 1996, J BIOL CHEM, V271, P30790, DOI 10.1074/jbc.271.48.30790; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHUURING E, 1992, CANCER RES, V52, P5229; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Smith JB, 1998, J NATL CANCER I, V90, P1146, DOI 10.1093/jnci/90.15.1146	19	32	45	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1950	1953		10.1038/sj.onc.1207356	http://dx.doi.org/10.1038/sj.onc.1207356			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14691448				2022-12-25	WOS:000220129500017
J	Eickhoff, J; Hanke, M; Stein-Garlach, M; Kiang, TP; Herzberger, K; Habenberger, P; Muller, S; Klebl, B; Marschall, M; Stamminger, T; Cotten, M				Eickhoff, J; Hanke, M; Stein-Garlach, M; Kiang, TP; Herzberger, K; Habenberger, P; Muller, S; Klebl, B; Marschall, M; Stamminger, T; Cotten, M			RICK activates a NF-kappa B-dependent anti-human cytomegalovirus response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE CYTOMEGALOVIRUS; TRANSCRIPTION FACTORS; SIGNALING PATHWAYS; ALPHA PROTEOLYSIS; VIRUS REPLICATION; PROTEIN-KINASE; ADENOVIRUS; INDUCTION; INFECTION; PROMOTER	The adapter kinase receptor interacting protein-like interacting caspase-like apoptosis regulatory protein kinase (RICK, also called RIP2 and CARDIAK) was found to be elevated at both the protein and RNA levels during human cytomegalovirus ( HCMV) replication, suggesting either that the virus may require RICK for replication or that RICK is part of an unsuccessful host attempt to inhibit HCMV replication. It is demonstrated here that forced expression of RICK in either a kinase active or inactive form activates nuclear factor (NF)-kappaB by means of its intermediate domain and potently blocks HCMV replication in human fibroblasts. Importantly, NF-kappaB activation, which exerted a modestly positive effect on the early phase of infection, clearly had a strongly negative impact during later viral steps. A stable inhibitor of NF-kappaB (IkappaB) reverses the RICK inhibitory effect, and activation of NF-kappaB by IkappaB kinase beta expression is inhibitory to HCMV, demonstrating that NF-kappaB activation is part of a potent anti-HCMV response. Supernatant transfer experiments identified interferon-beta as a downstream component of the RICK inhibitory pathway. RICK expression was found to synergize with HCMV infection in the induction of interferon-beta expression. This study identifies an endogenous RICK-activated, NF-kappaB- and interferon-beta-dependent antiviral pathway that is either inhibited or faulty under normal HCMV replication conditions; efforts to bolster this pathway may lead to novel anti-viral approaches.	Axxima Pharmaceut AG, D-81377 Munich, Germany; Univ Erlangen Nurnberg, Inst Klin & Mol Virol, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Cotten, M (corresponding author), Axxima Pharmaceut AG, Max Lebsche Pl 32, D-81377 Munich, Germany.	Matt.Cotten@axxima.com		Stamminger, Thomas/0000-0001-9878-3119; Cotten, Matthew/0000-0002-3361-3351				Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Benedict CA, 2001, IMMUNITY, V15, P617, DOI 10.1016/S1074-7613(01)00222-9; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Browne EP, 2003, P NATL ACAD SCI USA, V100, P11439, DOI 10.1073/pnas.1534570100; Browne EP, 2001, J VIROL, V75, P12319, DOI 10.1128/JVI.75.24.12319-12330.2001; Carlquist JF, 1999, J INFECT DIS, V179, P1094, DOI 10.1086/314734; Casarosa P, 2001, J BIOL CHEM, V276, P1133, DOI 10.1074/jbc.M008965200; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a; Chiocca S, 1997, J VIROL, V71, P3168, DOI 10.1128/JVI.71.4.3168-3177.1997; Compton T, 2003, J VIROL, V77, P4588, DOI 10.1128/JVI.77.8.4588-4596.2003; COTTEN M, 1996, CURRENT PROTOCOLS HU; Efferth T, 2002, J MOL MED-JMM, V80, P233, DOI 10.1007/s00109-001-0300-8; Falvo JV, 2000, MOL CELL BIOL, V20, P4814, DOI 10.1128/MCB.20.13.4814-4825.2000; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; FORBES BA, 1990, J INFECT DIS, V162, P39, DOI 10.1093/infdis/162.1.39; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Inohara N, 2000, J BIOL CHEM, V275, P27823; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jiang HY, 2002, J VIROL, V76, P5737, DOI 10.1128/JVI.76.11.5737-5747.2002; Johnson RA, 2001, J VIROL, V75, P6022, DOI 10.1128/JVI.75.13.6022-6032.2001; JORDAN MC, 1977, J GEN VIROL, V37, P419, DOI 10.1099/0022-1317-37-2-419; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; KOMENT RW, 1989, J MED VIROL, V27, P44, DOI 10.1002/jmv.1890270110; KOMENT RW, 1985, J MED VIROL, V15, P149, DOI 10.1002/jmv.1890150207; LATHEY JL, 1991, J VIROL, V65, P6371, DOI 10.1128/JVI.65.11.6371-6375.1991; LEMAY P, 1980, VIROLOGY, V101, P131, DOI 10.1016/0042-6822(80)90490-0; Marschall M, 2000, ANTIMICROB AGENTS CH, V44, P1588, DOI 10.1128/AAC.44.6.1588-1597.2000; Marschall M, 2002, J GEN VIROL, V83, P1013, DOI 10.1099/0022-1317-83-5-1013; Martin Seamus J., 2001, Trends in Cell Biology, V11, P188, DOI 10.1016/S0962-8924(01)01971-7; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Michou AI, 1999, J VIROL, V73, P1399, DOI 10.1128/JVI.73.2.1399-1410.1999; Miller DM, 1999, J IMMUNOL, V162, P6107; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Orange JS, 2002, J CLIN INVEST, V109, P1501, DOI 10.1172/JCI200214858; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PROSCH S, 1995, VIROLOGY, V208, P197, DOI 10.1006/viro.1995.1143; Russell WC, 2000, J GEN VIROL, V81, P2573, DOI 10.1099/0022-1317-81-11-2573; SAMBUCETTI LC, 1989, EMBO J, V8, P4251, DOI 10.1002/j.1460-2075.1989.tb08610.x; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; TANAKA J, 1984, J GEN VIROL, V65, P1759, DOI 10.1099/0022-1317-65-10-1759; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VELASCO N, 1984, J INFECTION, V9, P69, DOI 10.1016/S0163-4453(84)94576-6; Waldhoer M, 2002, J VIROL, V76, P8161, DOI 10.1128/JVI.76.16.8161-8168.2002; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yurochko AD, 1997, J VIROL, V71, P5051, DOI 10.1128/JVI.71.7.5051-5059.1997; YUROCHKO AD, 1995, J VIROL, V69, P5391, DOI 10.1128/JVI.69.9.5391-5400.1995; Yurochko AD, 1997, J VIROL, V71, P4638, DOI 10.1128/JVI.71.6.4638-4648.1997	56	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9642	9652		10.1074/jbc.M312893200	http://dx.doi.org/10.1074/jbc.M312893200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14670961	hybrid			2022-12-25	WOS:000189265900132
J	James, MJ; Zomerdijk, JCBM				James, MJ; Zomerdijk, JCBM			Phosphatidylinositol 3-kinase and mTOR signaling pathways regulate RNA polymerase I transcription in response to IGF-1 and nutrients	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL GENE-TRANSCRIPTION; GROWTH-FACTOR STIMULATION; SACCHAROMYCES-CEREVISIAE; RDNA TRANSCRIPTION; CELL-GROWTH; AMINO-ACID; FACTOR UBF; DEPENDENT PHOSPHORYLATION; MAMMALIAN TARGET; FACTOR SL1	Regulation of ribosomal RNA gene transcription by RNA polymerase I (Pol I) is fundamental to ribosome biogenesis and therefore protein translation capacity and cell growth, yet little is known of the key signaling cascades involved. We show here that insulin-like growth factor-1 (IGF-1)-induced Pol I transcription in HEK293 cells is entirely dependent on phosphatidylinositol 3-kinase (PI3K) activity and, additionally, is modulated by the mammalian target of rapamycin ( mTOR), which coordinates Pol I transcription with the availability of amino acids. The mitogen-activated protein kinase ( MAPK) pathway is weakly stimulated by IGF-1 in these cells and partly contributes to Pol I transcription regulation. Activation of Pol I transcription by IGF-1 results from enhancement of the activity of the Pol I transcription machinery and increased occupancy by SL1 of the endogenous tandemly repeated ribosomal promoters in vivo. The inputs from PI3K, mTOR, and MAPK pathways converge to direct appropriate rRNA gene expression by Pol I in the nucleolus of mammalian cells in response to environmental cues, such as growth factors and nutrients.	Univ Dundee, Fac Life Sci, Wellcome Trust Bioctr, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland	University of Dundee	Zomerdijk, JCBM (corresponding author), Univ Dundee, Fac Life Sci, Wellcome Trust Bioctr, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland.	j.zomerdijk@dundee.ac.uk	Zomerdijk, Joost/A-5142-2008	James, Martyn John/0000-0001-5094-0314; Zomerdijk, Joost/0000-0003-1865-729X				Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BECKMANN H, 1995, SCIENCE, V270, P1506, DOI 10.1126/science.270.5241.1506; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; Brandenburger Y, 2001, FASEB J, V15, P2051, DOI 10.1096/fj.00-0853fje; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Cavanaugh AH, 2002, J BIOL CHEM, V277, P27423, DOI 10.1074/jbc.M201232200; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Claypool JA, 2004, MOL BIOL CELL, V15, P946, DOI 10.1091/mbc.E03-08-0594; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; CRAIG N, 1987, P NATL ACAD SCI USA, V84, P629, DOI 10.1073/pnas.84.3.629; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; Damelin M, 2002, MOL CELL, V9, P563, DOI 10.1016/S1097-2765(02)00475-6; DAMMANN R, 1993, NUCLEIC ACIDS RES, V21, P2331, DOI 10.1093/nar/21.10.2331; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fath S, 2001, P NATL ACAD SCI USA, V98, P14334, DOI 10.1073/pnas.231181398; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; GLIBETIC M, 1993, MOL CELL ENDOCRINOL, V94, P243, DOI 10.1016/0303-7207(93)90173-H; GRUMMT I, 1976, CELL, V7, P439, DOI 10.1016/0092-8674(76)90174-4; GRUMMT I, 1976, CELL, V7, P447, DOI 10.1016/0092-8674(76)90175-6; Grummt I, 1999, PROG NUCLEIC ACID RE, V62, P109; HAAF T, 1991, EXP CELL RES, V193, P78, DOI 10.1016/0014-4827(91)90540-B; Hannan KM, 1998, AM J PHYSIOL-CELL PH, V275, pC130, DOI 10.1152/ajpcell.1998.275.1.C130; Hannan KM, 2003, MOL CELL BIOL, V23, P8862, DOI 10.1128/MCB.23.23.8862-8877.2003; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Jordan P, 1996, J CELL BIOL, V133, P225, DOI 10.1083/jcb.133.2.225; Kabler RL, 1996, J STEROID BIOCHEM, V59, P431, DOI 10.1016/S0960-0760(96)00126-4; Kenyon C, 2001, CELL, V105, P165, DOI 10.1016/S0092-8674(01)00306-3; KERMEKCHIEV M, 1993, NUCLEIC ACIDS RES, V21, P447, DOI 10.1093/nar/21.3.447; KIEF DR, 1981, MOL CELL BIOL, V1, P1007, DOI 10.1128/MCB.1.11.1007; LEARNED R M, 1982, Journal of Molecular and Applied Genetics, V1, P575; LEARNED RM, 1986, CELL, V45, P847, DOI 10.1016/0092-8674(86)90559-3; Leicht M, 1996, CELL GROWTH DIFFER, V7, P1199; Luyken J, 1996, CIRC RES, V78, P354, DOI 10.1161/01.RES.78.3.354; Magee T, 1999, CELL, V98, P9, DOI 10.1016/S0092-8674(00)80601-7; MAHAJAN PB, 1994, INT J IMMUNOPHARMACO, V16, P711, DOI 10.1016/0192-0561(94)90091-4; Miller G, 2001, EMBO J, V20, P1373, DOI 10.1093/emboj/20.6.1373; Moss T, 2002, CELL, V109, P545, DOI 10.1016/S0092-8674(02)00761-4; O'Sullivan AC, 2002, MOL CELL BIOL, V22, P657, DOI 10.1128/MCB.22.2.657-668.2002; OCHS RL, 1989, EXP CELL RES, V184, P552, DOI 10.1016/0014-4827(89)90354-6; Oldham S, 2000, GENE DEV, V14, P2689, DOI 10.1101/gad.845700; OMAHONY DJ, 1992, J BIOL CHEM, V267, P35; Panov KI, 2001, MOL CELL BIOL, V21, P2641, DOI 10.1128/MCB.21.8.2641-2649.2001; Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002; Powers T, 1999, MOL BIOL CELL, V10, P987, DOI 10.1091/mbc.10.4.987; Proud CG, 2002, EUR J BIOCHEM, V269, P5338, DOI 10.1046/j.1432-1033.2002.03292.x; Reeder R. H., 1995, NUCL ACIDS MOL BIOL, V9, P251; Reeder RH, 1999, PROG NUCLEIC ACID RE, V62, P293; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; Roussel P, 1996, J CELL BIOL, V133, P235, DOI 10.1083/jcb.133.2.235; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Shigemitsu K, 1999, J BIOL CHEM, V274, P1058, DOI 10.1074/jbc.274.2.1058; Stefanovsky VY, 2001, MOL CELL, V8, P1063, DOI 10.1016/S1097-2765(01)00384-7; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Tsang CK, 2003, EMBO J, V22, P6045, DOI 10.1093/emboj/cdg578; Tu X, 2002, J BIOL CHEM, V277, P44357, DOI 10.1074/jbc.M208001200; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; WHITE MF, 1994, J BIOL CHEM, V269, P1; Zaragoza D, 1998, MOL CELL BIOL, V18, P4463, DOI 10.1128/MCB.18.8.4463; ZATSEPINA OV, 1993, CHROMOSOMA, V102, P599, DOI 10.1007/BF00352307; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000; Zhao J, 2003, MOL CELL, V11, P405, DOI 10.1016/S1097-2765(03)00036-4; ZOMERDIJK JCB, 1998, TRANSCRIPTION EUKARY, V1, P67; ZOMERDIJK JCBM, 1994, SCIENCE, V266, P2015, DOI 10.1126/science.7801130	76	90	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8911	8918		10.1074/jbc.M307735200	http://dx.doi.org/10.1074/jbc.M307735200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14688273	hybrid			2022-12-25	WOS:000189265900049
J	Papanikolopoulou, K; Forge, V; Goeltz, P; Mitraki, A				Papanikolopoulou, K; Forge, V; Goeltz, P; Mitraki, A			Formation of highly stable chimeric trimers by fusion of an adenovirus fiber shaft fragment with the foldon domain of bacteriophage T4 fibritin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-2 FIBER; CRYSTAL-STRUCTURE; SEROTYPE-2 FIBER; TERMINAL DOMAIN; BINDING DOMAIN; COILED-COIL; BETA-HELIX; PROTEIN; REVEALS; RESOLUTION	The folding of beta-structured, fibrous proteins is a largely unexplored area. A class of such proteins is used by viruses as adhesins, and recent studies revealed novel beta-structured motifs for them. We have been studying the folding and assembly of adenovirus fibers that consist of a globular C-terminal domain, a central fibrous shaft, and an N-terminal part that attaches to the viral capsid. The globular C-terminal, or "head" domain, has been postulated to be necessary for the trimerization of the fiber and might act as a registration signal that directs its correct folding and assembly. In this work, we replaced the head of the fiber by the trimerization domain of the bacteriophage T4 fibritin, termed "foldon." Two chimeric proteins, comprising the foldon domain connected at the C-terminal end of four fiber shaft repeats with or without the use of a natural linker sequence, fold into highly stable, SDS-resistant trimers. The structural signatures of the chimeric proteins as seen by CD and infrared spectroscopy are reported. The results suggest that the foldon domain can successfully replace the fiber head domain in ensuring correct trimerization of the shaft sequences. Biological implications and implications for engineering highly stable, beta-structured nanorods are discussed.	Inst Biol Struct, F-38027 Grenoble, France; CEA Grenoble, Dept Reponse & Dynam Cellulaires, Unite Mixte Rech 5090, Lab Biophys Mol & Cellulaire, F-38054 Grenoble, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); CEA	Mitraki, A (corresponding author), Inst Biol Struct, 41 Rue Jules Horowitz, F-38027 Grenoble, France.	mitraki@ibs.fr	MITRAKI, Anna/A-6034-2014	MITRAKI, Anna/0000-0001-5072-1939				Ambriovic-Ristov A, 2003, VIROLOGY, V312, P425, DOI 10.1016/S0042-6822(03)00238-1; Barnett BG, 2002, BBA-GENE STRUCT EXPR, V1575, P1, DOI 10.1016/S0167-4781(02)00249-X; Beck K, 1998, J STRUCT BIOL, V122, P17, DOI 10.1006/jsbi.1998.3965; BLACKWELL JR, 1991, FEBS LETT, V295, P10, DOI 10.1016/0014-5793(91)81372-F; Chappell JD, 2002, EMBO J, V21, P1, DOI 10.1093/emboj/21.1.1; CHEN BL, 1991, BIOCHEMISTRY-US, V30, P6260, DOI 10.1021/bi00239a026; Cohen C, 1998, J STRUCT BIOL, V122, P180, DOI 10.1006/jsbi.1998.3983; DEVAUX C, 1987, VIROLOGY, V161, P121, DOI 10.1016/0042-6822(87)90177-2; Frank S, 2001, J MOL BIOL, V308, P1081, DOI 10.1006/jmbi.2001.4644; GREEN NM, 1983, EMBO J, V2, P1357, DOI 10.1002/j.1460-2075.1983.tb01592.x; HENRY LJ, 1994, J VIROL, V68, P5239, DOI 10.1128/JVI.68.8.5239-5246.1994; Hong JS, 1996, J VIROL, V70, P7071, DOI 10.1128/JVI.70.10.7071-7078.1996; Hulmes DJS, 2002, J STRUCT BIOL, V137, P2, DOI 10.1006/jsbi.2002.4450; Hyman P, 2002, P NATL ACAD SCI USA, V99, P8488, DOI 10.1073/pnas.132544299; Jenkins J, 2001, PROG BIOPHYS MOL BIO, V77, P111, DOI 10.1016/S0079-6107(01)00013-X; Khurana R, 2000, BIOPHYS J, V78, P994, DOI 10.1016/S0006-3495(00)76657-4; KING J, 1971, J MOL BIOL, V62, P465, DOI 10.1016/0022-2836(71)90148-3; Krasnykh V, 2001, J VIROL, V75, P4176, DOI 10.1128/JVI.75.9.4176-4183.2001; Letarov AV, 1999, BIOCHEMISTRY-MOSCOW+, V64, P817; Lortat-Jacob H, 2001, J BIOL CHEM, V276, P9009, DOI 10.1074/jbc.M009304200; LOUIS N, 1994, J VIROL, V68, P4104, DOI 10.1128/JVI.68.6.4104-4106.1994; Luckey M, 2000, FEBS LETT, V468, P23, DOI 10.1016/S0014-5793(00)01184-4; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; Miroshnikov KA, 1998, PROTEIN ENG, V11, P329, DOI 10.1093/protein/11.4.329; Mitraki A, 2002, J STRUCT BIOL, V137, P236, DOI 10.1006/jsbi.2002.4447; Mitraki A, 1999, EUR J BIOCHEM, V264, P599, DOI 10.1046/j.1432-1327.1999.00683.x; NOVELLI A, 1991, VIROLOGY, V185, P365, DOI 10.1016/0042-6822(91)90784-9; RUIGROK RWH, 1990, J MOL BIOL, V215, P589, DOI 10.1016/S0022-2836(05)80170-6; Scheibel T, 2003, P NATL ACAD SCI USA, V100, P4527, DOI 10.1073/pnas.0431081100; Seki T, 2002, J VIROL, V76, P1100, DOI 10.1128/JVI.76.3.1100-1108.2002; Seshadri S, 1999, METHOD ENZYMOL, V309, P559; Smith TAG, 2003, HUM GENE THER, V14, P777, DOI 10.1089/104303403765255165; Stehle T, 2003, REV MED VIROL, V13, P123, DOI 10.1002/rmv.379; TABOR S, 1990, CURRENT PROTOCOLS MO; Tao YZ, 1997, STRUCTURE, V5, P789, DOI 10.1016/S0969-2126(97)00233-5; van Raaij MJ, 1999, NATURE, V401, P935, DOI 10.1038/44880; van Raaij MJ, 1999, VIROLOGY, V262, P333, DOI 10.1006/viro.1999.9849; Weigele PR, 2003, J BACTERIOL, V185, P4022, DOI 10.1128/JB.185.14.4022-4030.2003; XIA D, 1994, STRUCTURE, V2, P1259, DOI 10.1016/S0969-2126(94)00126-X; Yang XZ, 2002, J VIROL, V76, P4634, DOI 10.1128/JVI.76.9.4634-4642.2002; Zhang SG, 2002, CURR OPIN CHEM BIOL, V6, P865, DOI 10.1016/S1367-5931(02)00391-5	41	43	61	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8991	8998		10.1074/jbc.M311791200	http://dx.doi.org/10.1074/jbc.M311791200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14699113	hybrid			2022-12-25	WOS:000189265900058
J	Vadseth, C; Souza, JM; Thomson, L; Seagraves, A; Nagaswami, C; Scheiner, T; Torbet, J; Vilaire, G; Bennett, JS; Murciano, JC; Muzykantov, V; Penn, MS; Hazen, SL; Weisel, JW; Ischiropoulos, H				Vadseth, C; Souza, JM; Thomson, L; Seagraves, A; Nagaswami, C; Scheiner, T; Torbet, J; Vilaire, G; Bennett, JS; Murciano, JC; Muzykantov, V; Penn, MS; Hazen, SL; Weisel, JW; Ischiropoulos, H			Pro-thrombotic state induced by post-translational modification of fibrinogen by reactive nitrogen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; MYOCARDIAL-INFARCTION; ATHEROSCLEROTIC LESIONS; TYROSINE NITRATION; IN-VIVO; CARDIOVASCULAR-DISEASE; PLASMA-PROTEINS; CLOT FORMATION; HEART-DISEASE; OXIDATION	Formation of nitric oxide-derived oxidants has been linked to development of atherosclerosis and associated thrombotic complications. Although systemic levels of protein nitrotyrosine predict risk for coronary artery disease, neither specific proteins targeted for modification nor functional consequences that might contribute to disease pathogenesis have been defined. Here we report a selective increase in circulating levels of nitrated fibrinogen in patients with coronary artery disease. Exposure of fibrinogen to nitrating oxidants, including those produced by the myeloperoxidase-hydrogen peroxide-nitrite system, significantly accelerates clot formation and factor XIII cross-linking, whereas exposure of fibrinogen to non-nitrating oxidants decelerates clot formation. Clots formed with fibrinogen exposed to nitrating oxidants are composed of large bundles made from twisted thin fibrin fibers with increased permeation and a decrease in storage modulus G' value, suggesting that these clots could be easily deformed by mechanical stresses. In contrast, clots formed with fibrinogen exposed to non-nitrating oxidants showed decreased permeation with normal architecture. Fibrinogen modified by exposure to physiologic nitration systems demonstrated no difference in the rate of plasmin-induced clot lysis, platelet aggregation, or binding. Thus, increased levels of fibrinogen nitration may lead to a pro-thrombotic state via acceleration in formation of fibrin clots. The present results may account, in part, for the association between nitrative stress and risk for coronary artery disease.	Childrens Hosp Philadelphia, Stokes Res Inst, Abramson Res Ctr 416D, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; Univ Penn, Inst Environm Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, Dept Cardiovasc Med, Cleveland, OH 44195 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Ischiropoulos, H (corresponding author), Childrens Hosp Philadelphia, Stokes Res Inst, Abramson Res Ctr 416D, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	ischirop@mail.med.upenn.edu	Murciano, Juan Carlos/AAG-6253-2021; Hazen, Stanley L/ABD-5845-2021; Thomson, Leonor/C-4684-2008	Murciano, Juan Carlos/0000-0002-4894-046X; Thomson, Leonor/0000-0002-2574-8520	NCRR NIH HHS [RM01 RR018390] Funding Source: Medline; NHLBI NIH HHS [HL62526, P50 HL70128, HL70621] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR018390] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062526, P50HL070128, R01HL070621] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aulak KS, 2001, P NATL ACAD SCI USA, V98, P12056, DOI 10.1073/pnas.221269198; Baker CSR, 1999, ARTERIOSCL THROM VAS, V19, P646, DOI 10.1161/01.ATV.19.3.646; Baldus S, 2001, J CLIN INVEST, V108, P1759; Bdeir K, 2000, BLOOD, V96, P1820, DOI 10.1182/blood.V96.5.1820.h8001820_1820_1826; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; Belisario MA, 1997, BIOCHIMIE, V79, P449, DOI 10.1016/S0300-9084(97)86155-X; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; BINI A, 1987, BLOOD, V69, P1038; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; Buttery LDK, 1996, LAB INVEST, V75, P77; Collet JP, 2000, ARTERIOSCL THROM VAS, V20, P1354, DOI 10.1161/01.ATV.20.5.1354; Cromheeke KM, 1999, CARDIOVASC RES, V43, P744, DOI 10.1016/S0008-6363(99)00148-0; Diaz MN, 1997, NEW ENGL J MED, V337, P408, DOI 10.1056/NEJM199708073370607; FATAH K, 1992, THROMB HAEMOSTASIS, V68, P130; Fatah K, 1996, THROMB HAEMOSTASIS, V76, P535; Gaut JP, 2002, J CLIN INVEST, V109, P1311, DOI 10.1172/JCI200215021; Gole MD, 2000, AM J PHYSIOL-LUNG C, V278, pL961, DOI 10.1152/ajplung.2000.278.5.L961; INADA Y, 1978, BIOCHIM BIOPHYS ACTA, V532, P161, DOI 10.1016/0005-2795(78)90459-2; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; LANGER BG, 1988, J BIOL CHEM, V263, P15056; LASSILA R, 1993, ARTERIOSCLER THROMB, V13, P1738, DOI 10.1161/01.ATV.13.12.1738; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P1433, DOI 10.1074/jbc.272.3.1433; Lupidi G, 1999, FEBS LETT, V462, P236, DOI 10.1016/S0014-5793(99)01500-8; Murciano JC, 2002, AM J PHYSIOL-LUNG C, V282, pL529, DOI 10.1152/ajplung.00112.2001; Murthy SNP, 2000, P NATL ACAD SCI USA, V97, P44, DOI 10.1073/pnas.97.1.44; PHILIPS MH, 1973, BIOCHEMISTRY-US, V12, P3642; Pignatelli B, 2001, CANCER RES, V61, P778; Ryan EA, 1999, BIOPHYS J, V77, P2813, DOI 10.1016/S0006-3495(99)77113-4; SALOMAA V, 1995, CIRCULATION, V91, P284, DOI 10.1161/01.CIR.91.2.284; SCRUTTON MC, 1994, BLOOD COAGUL FIBRIN, V5, P719, DOI 10.1097/00001721-199410000-00007; SHACTER E, 1995, FREE RADICAL BIO MED, V18, P815, DOI 10.1016/0891-5849(95)93872-4; Shishehbor MH, 2003, JAMA-J AM MED ASSOC, V289, P1675, DOI 10.1001/jama.289.13.1675; SMITH EB, 1990, ARTERIOSCLEROSIS, V10, P263, DOI 10.1161/01.ATV.10.2.263; STIEF TW, 1991, THROMB RES, V61, P191, DOI 10.1016/0049-3848(91)90095-E; THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003; Turko IV, 2002, PHARMACOL REV, V54, P619, DOI 10.1124/pr.54.4.619; Veklich Y, 1998, BLOOD, V92, P4721, DOI 10.1182/blood.V92.12.4721.424k13_4721_4729; WEISEL JW, 1992, BIOPHYS J, V63, P111, DOI 10.1016/S0006-3495(92)81594-1; WEISEL JW, 1985, SCIENCE, V230, P1388, DOI 10.1126/science.4071058; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804	43	179	190	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8820	8826		10.1074/jbc.M306101200	http://dx.doi.org/10.1074/jbc.M306101200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14681238	hybrid			2022-12-25	WOS:000189265900037
J	Lim, CC; Zuppinger, C; Guo, XX; Kuster, GM; Helmes, M; Eppenberger, HM; Suter, TM; Liao, RL; Sawyer, DB				Lim, CC; Zuppinger, C; Guo, XX; Kuster, GM; Helmes, M; Eppenberger, HM; Suter, TM; Liao, RL; Sawyer, DB			Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CARDIAC MYOCYTES; MUSCLE-SPECIFIC CALPAIN; SKELETAL-MUSCLE; CA2+-DEPENDENT PROTEOLYSIS; DOXORUBICIN ADRIAMYCIN; INTERMEDIATE FILAMENTS; MYOCARDIAL-INFARCTION; MYOFIBRILLAR PROTEINS; STUNNED MYOCARDIUM; ALZHEIMERS-DISEASE	Titin, the largest myofilament protein, serves as a template for sarcomere assembly and acts as a molecular spring to contribute to diastolic function. Titin is known to be extremely susceptible to calcium-dependent protease degradation in vitro. We hypothesized that titin degradation is an early event in doxorubicin-induced cardiac injury and that titin degradation occurs by activation of the calcium-dependent proteases, the calpains. Treatment of cultured adult rat cardiomyocytes with 1 or 3 mumol/liter doxorubicin for 24 h resulted in degradation of titin in myocyte lysates, which was confirmed by a reduction in immunostaining of an antibody to the spring-like (PEVK) domain of titin at the I-band of the sarcomere. The elastic domain of titin appears to be most susceptible to proteolysis because co-immunostaining with an antibody to titin at the M-line was preserved, suggesting targeted proteolysis of the springlike domain of titin. Doxorubicin treatment for 1 h resulted in similar to3-fold increase in calpain activity, which remained elevated at 48 h. Co-treatment with calpain inhibitors resulted in preservation of titin, reduction in myofibrillar disarray, and attenuation of cardiomyocyte necrosis but not apoptosis. Co-treatment with a caspase inhibitor did not prevent the degradation of titin, which precludes caspase-3 as an early mechanism of titin proteolysis. We conclude that calpain activation is an early event after doxorubicin treatment in cardiomyocytes and appears to target the degradation of titin. Proteolysis of the spring-like domain of titin may predispose cardiomyocytes to diastolic dysfunction, myofilament instability, and cell death by necrosis.	Boston Univ, Med Ctr, Dept Med,Sch Med, Div Cardiovasc,Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Univ Bern, Inselspital, Swiss Cardiovasc Ctr Bern, CH-3010 Bern, Switzerland; Swiss Fed Inst Technol, Inst Cell Biol, CH-8093 Zurich, Switzerland	Boston University; University of Bern; University Hospital of Bern; Swiss Federal Institutes of Technology Domain; ETH Zurich	Sawyer, DB (corresponding author), Boston Univ, Med Ctr, Dept Med,Sch Med, Div Cardiovasc,Whitaker Cardiovasc Inst, 650 Albany St, Boston, MA 02118 USA.	douglas.sawyer@bmc.org	Zuppinger, Christian/H-4452-2019; Kuster, Gabriela M/AAB-5478-2022	Zuppinger, Christian/0000-0003-1786-0800; Kuster, Gabriela M/0000-0002-8209-4631	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068144, T32HL007224] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 03878-02, R01 HL068144, T32 HL07224-27] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andersson M, 1998, OPHTHALMIC RES, V30, P157, DOI 10.1159/000055469; Andersson M, 1996, OPHTHALMIC RES, V28, P51, DOI 10.1159/000267944; Antoku K, 1997, LEUKEMIA, V11, P1665, DOI 10.1038/sj.leu.2400805; Averna M, 2001, J BIOL CHEM, V276, P38426, DOI 10.1074/jbc.M101936200; BUGAISKY LB, 1989, CIRC RES, V64, P493, DOI 10.1161/01.RES.64.3.493; Cazorla O, 2000, CIRC RES, V86, P59, DOI 10.1161/01.RES.86.1.59; Cazorla O, 2001, CIRC RES, V88, P1028, DOI 10.1161/hh1001.090876; Chen M, 2002, J BIOL CHEM, V277, P29181, DOI 10.1074/jbc.M204951200; Clark KA, 2002, ANNU REV CELL DEV BI, V18, P637, DOI 10.1146/annurev.cellbio.18.012502.105840; Communal C, 2002, P NATL ACAD SCI USA, V99, P6252, DOI 10.1073/pnas.092022999; Costelli P, 2001, BRIT J CANCER, V84, P946, DOI 10.1054/bjoc.2001.1696; DALLEDONNE I, 1992, EXP MOL PATHOL, V56, P229, DOI 10.1016/0014-4800(92)90039-E; de Jonge N, 2002, J AM COLL CARDIOL, V39, P963, DOI 10.1016/S0735-1097(02)01713-8; DOROSHOW JH, 1983, CANCER RES, V43, P460; Enns D., 2002, Molecular and Cellular Biochemistry, V241, P29, DOI 10.1023/A:1020861120368; Fukuda N, 2001, CIRCULATION, V104, P1639, DOI 10.1161/hc3901.095898; Gamen S, 2000, EXP CELL RES, V258, P223, DOI 10.1006/excr.2000.4924; Gao WD, 1996, CIRC RES, V78, P455; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Gotthardt M, 2003, J BIOL CHEM, V278, P6059, DOI 10.1074/jbc.M211723200; GRANZIER HL, 1995, BIOPHYS J, V68, P1027, DOI 10.1016/S0006-3495(95)80278-X; Gregorio CC, 1999, CURR OPIN CELL BIOL, V11, P18, DOI 10.1016/S0955-0674(99)80003-9; Grynspan F, 1997, BRAIN RES, V763, P145, DOI 10.1016/S0006-8993(97)00384-3; Guttmann RP, 1998, J BIOL CHEM, V273, P13331, DOI 10.1074/jbc.273.21.13331; HEIN S, 1994, J MOL CELL CARDIOL, V26, P1291, DOI 10.1006/jmcc.1994.1148; Helmes M, 2003, J GEN PHYSIOL, V121, P97, DOI 10.1085/jgp.20028652; Helmes M, 1996, CIRC RES, V79, P619, DOI 10.1161/01.RES.79.3.619; Huang J, 1998, P NATL ACAD SCI USA, V95, P12100, DOI 10.1073/pnas.95.21.12100; HUFFLONERGAN E, 1995, J ANIM SCI, V73, P1064; ITO H, 1990, P NATL ACAD SCI USA, V87, P4275, DOI 10.1073/pnas.87.11.4275; KEUNG EC, 1991, J CLIN INVEST, V87, P2108, DOI 10.1172/JCI115241; KIM DH, 1989, J MOL CELL CARDIOL, V21, P433, DOI 10.1016/0022-2828(89)90782-7; Kinbara K, 1997, ARCH BIOCHEM BIOPHYS, V342, P99, DOI 10.1006/abbi.1997.0108; Kostin S, 2003, CIRC RES, V92, P715, DOI 10.1161/01.RES.0000067471.95890.5C; Kuramochi Y, 2004, AM J PHYSIOL-CELL PH, V286, pC222, DOI 10.1152/ajpcell.00312.2003; Lim CC, 2000, J MOL CELL CARDIOL, V32, P2075, DOI 10.1006/jmcc.2000.1239; Linke WA, 1998, J CELL SCI, V111, P1567; Matsumura Y, 1996, CIRC RES, V79, P447, DOI 10.1161/01.RES.79.3.447; MORANO I, 1994, J MOL CELL CARDIOL, V26, P361, DOI 10.1006/jmcc.1994.1045; PAPOIAN T, 1990, AM J PATHOL, V136, P1201; Papp Z, 2000, CARDIOVASC RES, V45, P981, DOI 10.1016/S0008-6363(99)00374-0; Person V, 2000, J CELL SCI, V113, P3851; Ray SK, 2002, J NEUROSCI RES, V69, P197, DOI 10.1002/jnr.10265; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; Saeki K, 2002, LIFE SCI, V70, P2377, DOI 10.1016/S0024-3205(02)01524-2; Sandmann S, 2002, EUR J PHARMACOL, V453, P99, DOI 10.1016/S0014-2999(02)02384-1; Sandmann S, 2001, BRIT J PHARMACOL, V132, P767, DOI 10.1038/sj.bjp.0703860; SASAKI T, 1984, J BIOL CHEM, V259, P2489; Sawyer DB, 1999, CIRC RES, V84, P257, DOI 10.1161/01.RES.84.3.257; Sawyer DB, 2002, CIRCULATION, V105, P1551, DOI 10.1161/01.CIR.0000013839.41224.1C; Shi YX, 2000, AM J PHYSIOL-RENAL, V279, pF509, DOI 10.1152/ajprenal.2000.279.3.F509; SINGAL PK, 1987, J MOL CELL CARDIOL, V19, P817, DOI 10.1016/S0022-2828(87)80392-9; Solomon V, 1996, J BIOL CHEM, V271, P26690, DOI 10.1074/jbc.271.43.26690; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; Sorimachi H, 1995, J BIOL CHEM, V270, P31158, DOI 10.1074/jbc.270.52.31158; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Sussman MA, 1997, CIRC RES, V80, P52, DOI 10.1161/01.RES.80.1.52; Suzuki A, 1996, ADV BIOPHYS, V33, P53; TATSUMI R, 1995, ANAL BIOCHEM, V224, P28, DOI 10.1006/abio.1995.1004; TOKUYASU KT, 1987, J CELL BIOL, V105, P2781, DOI 10.1083/jcb.105.6.2781; Tsuji T, 1998, NEUROSCI LETT, V248, P109, DOI 10.1016/S0304-3940(98)00348-6; UYTTERHAEGEN L, 1994, J ANIM SCI, V72, P1209, DOI 10.2527/1994.7251209x; WANG K, 1984, ADV EXP MED BIOL, V170, P285; WANG SM, 1988, J CELL BIOL, V107, P1075, DOI 10.1083/jcb.107.3.1075; WANG SM, 1985, J MUSCLE RES CELL M, V6, P293, DOI 10.1007/BF00713171; Xu XL, 2002, NAT GENET, V30, P205, DOI 10.1038/ng816; YOSHIDA K, 1993, BIOCHIM BIOPHYS ACTA, V1182, P215, DOI 10.1016/0925-4439(93)90143-O; Zima T, 2001, EXP MOL PATHOL, V70, P154, DOI 10.1006/exmp.2000.2353; Zima T, 2001, TOXICOL APPL PHARM, V171, P135, DOI 10.1006/taap.2000.9084	69	208	215	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8290	8299		10.1074/jbc.M308033200	http://dx.doi.org/10.1074/jbc.M308033200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14676206	hybrid			2022-12-25	WOS:000189103300111
J	Dow, LE; Brumby, AM; Muratore, R; Coombe, ML; Sedelies, KA; Trapani, JA; Russell, SM; Richardson, HE; Humbert, PO				Dow, LE; Brumby, AM; Muratore, R; Coombe, ML; Sedelies, KA; Trapani, JA; Russell, SM; Richardson, HE; Humbert, PO			hScrib is a functional homologue of the Drosophila tumour suppressor Scribble	ONCOGENE			English	Article						hScrib; Scribble; polarity; cell cycle; tumour suppressor; Drosophila; discs large	CELL POLARITY; GENE-EXPRESSION; PROTEIN; DLG; IDENTIFICATION; PROLIFERATION; PROGRESSION; EPITHELIA; GROWTH; CANCER	Scribble (scrib), discs large (dlg) and lethal giant larvae (lgl) encode proteins that regulate cell polarity and have been identified as neoplastic tumour suppressor genes in Drosophila melanogaster. Here, we have used the Drosophila model system to provide the first functional evidence that human Scribble (hScrib) can act as a tumour suppressor. We show that hScrib protein displays highly polarized localization in mammalian epithelial cells and colocalizes with mammalian Dlg, similar to D. melanogaster Scribble (DmScrib) distribution in Drosophila epithelium. Furthermore, hScrib can rescue the polarity and tumorous overgrowth defects of scrib mutant Drosophila. hScrib therefore can act as an effective tumour suppressor in vivo, regulating both apical-basal polarity and cellular proliferation in a manner similar to that of DmScrib in Drosophila. These data demonstrate that hScrib is a functional homologue of DmScrib and therefore predict an important role for hScrib in the suppression of mammalian tumorigenesis.	Peter MacCallum Canc Ctr, Cell Cycle & Canc Genet Lab, Melbourne, Vic 3002, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3005, Australia; Peter MacCallum Canc Ctr, Cell Cycle & Dev Lab, Melbourne, Vic 3002, Australia; Peter MacCallum Canc Ctr, Canc Cell Death Lab, Melbourne, Vic 3002, Australia; Univ Melbourne, Dept Pathol, Parkville, Vic 3005, Australia; Peter MacCallum Canc Ctr, Immune Signaling Lab, Melbourne, Vic 3002, Australia; Univ Melbourne, Dept Anat & Cell Biol, Parkville, Vic 3005, Australia	Peter Maccallum Cancer Center; University of Melbourne; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; Peter Maccallum Cancer Center; University of Melbourne	Humbert, PO (corresponding author), Peter MacCallum Canc Ctr, Cell Cycle & Canc Genet Lab, St Andrews Pl, Melbourne, Vic 3002, Australia.		Richardson, Helena E/A-8080-2013; Russell, Sarah M/B-9341-2009; Humbert, Patrick O/L-4264-2016	Richardson, Helena E/0000-0003-3852-4953; Russell, Sarah M/0000-0001-5826-9641; Humbert, Patrick O/0000-0002-1366-6691; Trapani, Joseph/0000-0003-0983-1532; Dow, Lukas/0000-0001-7048-1418				BEHRENS J, 1985, J CELL BIOL, V101, P1307, DOI 10.1083/jcb.101.4.1307; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Boussioutas A, 2003, CANCER RES, V63, P2569; BRAND AH, 1993, DEVELOPMENT, V118, P401; GATEFF E, 1994, INT J DEV BIOL, V38, P565; Huang JHY, 2003, GENE EXPR PATTERNS, V3, P3, DOI 10.1016/s1567-133X(02)00096-0; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Liu LX, 2002, WORLD J GASTROENTERO, V8, P580, DOI 10.3748/wjg.v8.i4.580; Ludford-Menting MJ, 2002, J BIOL CHEM, V277, P4477, DOI 10.1074/jbc.M108479200; Makino K, 1997, ONCOGENE, V14, P2425, DOI 10.1038/sj.onc.1201087; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Mathew D, 2002, CURR BIOL, V12, P531, DOI 10.1016/S0960-9822(02)00758-3; Montcouquiol M, 2003, NATURE, V423, P173, DOI 10.1038/nature01618; Murdoch JN, 2003, HUM MOL GENET, V12, P87, DOI 10.1093/hmg/ddg014; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thomas U, 1997, MECH DEVELOP, V62, P161, DOI 10.1016/S0925-4773(97)00658-8; Woodhouse E, 1998, DEV GENES EVOL, V207, P542, DOI 10.1007/s004270050145; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	25	93	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	2003	22	58					9225	9230		10.1038/sj.onc.1207154	http://dx.doi.org/10.1038/sj.onc.1207154			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755JU	14681682				2022-12-25	WOS:000187400400004
J	Wolff, L; Garin, MT; Koller, R; Bies, J; Liao, W; Malumbres, M; Tessarollo, L; Powell, D; Perella, C				Wolff, L; Garin, MT; Koller, R; Bies, J; Liao, W; Malumbres, M; Tessarollo, L; Powell, D; Perella, C			Hypermethylation of the Ink4b locus in murine myeloid leukemia and increased susceptibility to leukemia in p15(Ink4b)-defficient mice	ONCOGENE			English	Article						tumor suppressor; myeloid leukemia; hypermethylation; retrovirus; Ink4b	KINASE INHIBITOR P15(INK4B); TUMOR-SUPPRESSOR; C-MYB; METHYLATION; INACTIVATION; P16(INK4A); EXPRESSION; P19(ARF); CELLS; ASSAY	The Ink4b gene (Cdkn2b) encodes p15(Ink4b), a cyclin-dependent kinase inhibitor. It has been implicated in playing a role in the development of acute myeloid leukemia (AML) in man, since it is hypermethylated with high frequency. We provide evidence that the gene is a tumor suppressor for myeloid leukemia in mice. The evidence is twofold: (1) retrovirus-induced myeloid leukemias of the myelomonocytic phenotype were found to have hypermethylation of the 5' CpG island of the Ink4b gene, and this could be correlated with reduced mRNA expression, as demonstrated by TaqMan real-time PCR. p15(Ink4b) mRNA expression in a leukemia cell line, with hypermethylation at the locus, was induced following treatment with 5-aza-2'-deoxycytidine.(2) Targeted deletion of one allele in mice by removal of exon 2 increases their susceptibility to retrovirus-induced myeloid leukemia. Mice deficient in both alleles were not more susceptible to myeloid disease than those deficient in one allele, raising the possibility that there are opposing forces related to the development of myeloid leukemia in Ink4b null mice.	NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Ctr Nacl Invest Oncol, E-28029 Madrid, Spain; NCI, SAIC Frederick, Bethesda, MD 20892 USA; NCI, Data Management Serv, Frederick, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wolff, L (corresponding author), NCI, Ctr Canc Res, NIH, Bldg 37,Room 4124A,37 Convent Dr MSC 4255, Bethesda, MD 20892 USA.	lwolff@helix.nih.gov	Malumbres, Marcos/E-8834-2011	Malumbres, Marcos/0000-0002-0829-6315				Amanullah A, 2000, BLOOD, V96, P475; Bonin A, 2000, METH MOL B, V158, P121; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Fekete E, 1938, AM J PATHOL, V14, P557; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Haviernik P, 2003, ONCOGENE, V22, P1600, DOI 10.1038/sj.onc.1206268; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P16; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Malumbres M, 1997, ONCOGENE, V14, P1361, DOI 10.1038/sj.onc.1200969; NAZAROV V, 1994, VIROLOGY, V205, P479, DOI 10.1006/viro.1994.1668; ROWE WP, 1970, VIROLOGY, V42, P1136, DOI 10.1016/0042-6822(70)90362-4; Ruas M, 1998, BIOCHIM BIOPHYS ACTA, V1378, P115, DOI 10.1016/s0304-419x(98)00017-1; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Schmidt M, 2001, ONCOGENE, V20, P6205, DOI 10.1038/sj.onc.1204821; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Stirewalt DEREK L., 2000, Hematology, V5, P15; Teofili L, 2000, EXP HEMATOL, V28, P519, DOI 10.1016/S0301-472X(00)00139-9; Tessarollo L, 2000, METH MOL B, V158, P47; Wolff L, 2003, J VIROL, V77, P4965, DOI 10.1128/JVI.77.8.4965-4971.2003; Wolff L, 2001, BLOOD CELL MOL DIS, V27, P483, DOI 10.1006/bcmd.2001.0409	31	35	35	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2003	22	58					9265	9274		10.1038/sj.onc.1207092	http://dx.doi.org/10.1038/sj.onc.1207092			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755JU	14681685				2022-12-25	WOS:000187400400008
J	Burrows, JF; McGrattan, MJ; Rascle, A; Humbert, M; Baek, KH; Johnston, JA				Burrows, JF; McGrattan, MJ; Rascle, A; Humbert, M; Baek, KH; Johnston, JA			DUB-3, a cytokine-inducible deubiquitinating enzyme that blocks proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-SPECIFIC PROTEASE; T-CELL LEUKEMIA; CANCER-CELLS; INTERLEUKIN-4; PATHWAY; GROWTH; APOPTOSIS; PROTEINS; DEGRADATION; INTERACTS	Previous studies have identified the DUB family of cytokine-regulated murine deubiquitinating enzymes, which play a role in the control of cell proliferation and survival. Through data base analyses and cloning, we have identified a human cDNA (DUB-3) that shows significant homology to the known murine DUB family members. Northern blotting has shown expression of this gene in a number of tissues including brain, liver, and muscle, with two transcripts being apparent (1.6 and 1.7 kb). In addition, expression was observed in cell lines including those derived from a number of hematopoietic tumors such as the Burkitt's lymphoma cell line RAJI. We have also demonstrated that DUB-3, which was shown to be an active deubiquitinating enzyme, is induced in response to interleukin-4 and interleukin-6 stimulation. Finally, we have demonstrated that constitutive expression of DUB-3 blocks proliferation and can initiate apoptosis in both IL-3-dependent Ba/F3 cells and NIH3T3 fibroblasts. These findings suggest that human DUB-3, like the murine DUB family members, is transiently induced in response to cytokines and can, when constitutively expressed, block growth factor-dependent proliferation.	Queens Univ Belfast, Dept Microbiol & Immunol, Belfast BT9 7BL, Antrim, North Ireland; DNAX Res Inst Mol & Cellular Biol Inc, Palo Alto, CA 94304 USA; Pochon CHA Univ, Coll Med, Cell & Gene Therapy Res Inst, Seoul, South Korea	Queens University Belfast; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Pochon Cha University	Johnston, JA (corresponding author), Queens Univ Belfast, Dept Microbiol & Immunol, Whitla Med Bldg,97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	jim.johnston@qub.ac.uk	Rascle, Anne/AAC-1904-2019	Rascle, Anne/0000-0001-7464-8545; Baek, Kwang-Hyun/0000-0001-7662-7190				Baek KH, 2003, EXP MOL MED, V35, P1; Baek KH, 2001, BLOOD, V98, P636, DOI 10.1182/blood.V98.3.636; Blanchette P, 2001, ONCOGENE, V20, P5533, DOI 10.1038/sj.onc.1204823; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Cai SY, 1999, P NATL ACAD SCI USA, V96, P2828, DOI 10.1073/pnas.96.6.2828; D'Andrea A, 1998, CRIT REV BIOCHEM MOL, V33, P337, DOI 10.1080/10409239891204251; DeSalle LM, 2001, ONCOGENE, V20, P5538, DOI 10.1038/sj.onc.1204824; DeSalle LM, 2001, FEBS LETT, V490, P179, DOI 10.1016/S0014-5793(01)02121-4; Diehl S, 2002, MOL IMMUNOL, V39, P531, DOI 10.1016/S0161-5890(02)00210-9; Donaldson KM, 2003, CURR BIOL, V13, P258, DOI 10.1016/S0960-9822(03)00043-5; Evans PC, 2003, J BIOL CHEM, V278, P23180, DOI 10.1074/jbc.M301863200; Gewies A, 2003, CANCER RES, V63, P682; Gondo Y, 1998, GENOMICS, V54, P39, DOI 10.1006/geno.1998.5545; Gooch JL, 1998, CANCER RES, V58, P4199; GRAY DA, 1995, ONCOGENE, V10, P2179; GUPTA K, 1994, ONCOGENE, V9, P1729; Henchoz S, 1996, MOL CELL BIOL, V16, P5717; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; Hirano T, 1998, Int Rev Immunol, V16, P249; HOWARD M, 1982, P NATL ACAD SCI USA, V85, P6107; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; KAWANO F, 1992, LEUKEMIA, V6, P66; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li ZB, 2002, J BIOL CHEM, V277, P4656, DOI 10.1074/jbc.M108269200; MADDEN KB, 1991, J IMMUNOL, V147, P1387; Malakhov MP, 2002, J BIOL CHEM, V277, P9976, DOI 10.1074/jbc.M109078200; Malakhova OA, 2003, GENE DEV, V17, P455, DOI 10.1101/gad.1056303; Migone TS, 2001, BLOOD, V98, P1935, DOI 10.1182/blood.V98.6.1935; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; Mulloy JC, 1998, J VIROL, V72, P4408, DOI 10.1128/JVI.72.5.4408-4412.1998; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; NAKAMURA T, 1992, ONCOGENE, V7, P733; O'Garra A, 2000, TRENDS CELL BIOL, V10, P542, DOI 10.1016/S0962-8924(00)01856-0; OBIRI NI, 1993, J CLIN INVEST, V91, P88, DOI 10.1172/JCI116205; Pantaleon M, 2001, MECH DEVELOP, V109, P151, DOI 10.1016/S0925-4773(01)00551-2; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; Taya S, 1999, GENES CELLS, V4, P757, DOI 10.1046/j.1365-2443.1999.00297.x; TOI M, 1992, CANCER RES, V52, P275; TOPP MS, 1995, CANCER RES, V55, P2173; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Vugmeyster Y, 2002, MOL IMMUNOL, V39, P431, DOI 10.1016/S0161-5890(02)00123-2; Ward AC, 2000, BLOOD, V95, P19; Watanabe T, 1997, INT J HEMATOL, V66, P257; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zhu Y, 1996, P NATL ACAD SCI USA, V93, P3275, DOI 10.1073/pnas.93.8.3275; Zhu Y, 1996, MOL CELL BIOL, V16, P4808; Zhu YA, 1997, J BIOL CHEM, V272, P51	54	72	77	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13993	14000		10.1074/jbc.M311291200	http://dx.doi.org/10.1074/jbc.M311291200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14699124	hybrid			2022-12-25	WOS:000220478500087
J	Kroczynska, B; Evangelista, CM; Samant, SS; Elguindi, EC; Blond, SY				Kroczynska, B; Evangelista, CM; Samant, SS; Elguindi, EC; Blond, SY			The SANT2 domain of the murine tumor cell DnaJ-like protein 1 human homologue interacts with alpha(1)-antichymotrypsin and kinetically interferes with its serpin inhibitory activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONES; BINDING DOMAIN; GENETIC INTERACTIONS; MEMBRANE-PROTEINS; ATPASE ACTIVITY; MOUSE CDNA; IN-VITRO; YEAST; ER	The murine tumor cell DnaJ-like protein 1 or MTJ1/ ERdj1 is a membrane J-domain protein enriched in microsomal and nuclear fractions. We previously showed that its lumenal J-domain stimulates the ATPase activity of the molecular chaperone BiP/GRP78 (Chevalier, M., Rhee, H., Elguindi, E. C., and Blond, S. Y. (2000) J. Biol. Chem. 275, 19620-19627). MTJ1/ERdj1 also contains a large carboxyl-terminal cytosolic extension composed of two tryptophan-mediated repeats or SANT domains for which the function(s) is unknown. Here we describe the cloning of the human homologue HTJ1 and its interaction with alpha(1)-antichymotrypsin (ACT), a member of the serine proteinase inhibitor (serpin) family. The interaction was initially identified in a two-hybrid screening and further confirmed in vitro by dot blots, native electrophoresis, and fluorescence studies. The second SANT domain of HTJ1 (SANT2) was found to be sufficient for binding to ACT, both in yeast and in vitro. Single tryptophan-alanine substitutions at two strictly conserved residues significantly (Trp-497) or totally (Trp-520) abolished the interaction with ACT. SANT2 binds to human ACT with an intrinsic affinity equal to 0.5 nM. Preincubation of ACT with nearly stoichiometric concentrations of SANT2 wild-type but not SANT2: W520A results in an apparent loss of ACT inhibitory activity toward chymotrypsin. Kinetic analysis indicates that the formation of the covalent inhibitory complex ACT-chymotrypsin is significantly delayed in the presence of SANT2 with no change on the catalytic efficiency of the enzyme. This work demonstrates for the first time that the SANT2 domain of MTJ1/HTJ1/ERdj1 mediates stable and high affinity protein-protein interactions.	Univ Illinois, Coll Pharm, Dept Med Chem & Pharmacognosy, Ctr Pharmaceut Biotechnol MC 870, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Blond, SY (corresponding author), Univ Illinois, Coll Pharm, Dept Med Chem & Pharmacognosy, Ctr Pharmaceut Biotechnol MC 870, Mol Biol Res Bldg,900 S Ashland Ave, Chicago, IL 60607 USA.	blond@uic.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058107] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM058107-05, R01 GM058107-04, R01 GM058107-03, GM 58107] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aasland R, 1996, TRENDS BIOCHEM SCI, V21, P87, DOI 10.1016/S0968-0004(96)30009-1; Andres ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873; Bies C, 1999, BIOL CHEM, V380, P1175, DOI 10.1515/BC.1999.149; BLACQUE OE, 2002, J BIOL CHEM, V272, P9950; Boyer LA, 2002, MOL CELL, V10, P935, DOI 10.1016/S1097-2765(02)00634-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braun EL, 2001, MOL BIOL EVOL, V18, P1401, DOI 10.1093/oxfordjournals.molbev.a003924; BRIGHTMAN SE, 1995, GENE, V153, P249, DOI 10.1016/0378-1119(94)00741-A; Brizzio V, 1999, MOL BIOL CELL, V10, P609, DOI 10.1091/mbc.10.3.609; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; Chevalier M, 2000, J BIOL CHEM, V275, P19620, DOI 10.1074/jbc.M001333200; Corsi AK, 1997, J CELL BIOL, V137, P1483, DOI 10.1083/jcb.137.7.1483; Corsi AK, 1996, J BIOL CHEM, V271, P30299, DOI 10.1074/jbc.271.48.30299; Cunnea PM, 2003, J BIOL CHEM, V278, P1059, DOI 10.1074/jbc.M206995200; Dudek J, 2002, EMBO J, V21, P2958, DOI 10.1093/emboj/cdf315; Duranton J, 1998, BIOCHEMISTRY-US, V37, P11239, DOI 10.1021/bi980223q; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Gooptu B, 2000, P NATL ACAD SCI USA, V97, P67, DOI 10.1073/pnas.97.1.67; Grigoryev SA, 1999, J BIOL CHEM, V274, P5626, DOI 10.1074/jbc.274.9.5626; Haigh NG, 2002, J CELL BIOL, V156, P261, DOI 10.1083/jcb.200110074; Hanaoka S, 2001, J MOL BIOL, V312, P167, DOI 10.1006/jmbi.2001.4924; Hook VYH, 1999, J NEUROCHEM, V73, P59, DOI 10.1046/j.1471-4159.1999.0730059.x; HUGHES R, 1995, GENOMICS, V29, P546, DOI 10.1006/geno.1995.9969; Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200; Hwang SR, 2002, BIOCHEMISTRY-US, V41, P10397, DOI 10.1021/bi020088o; Inoue T, 2000, GENES CELLS, V5, P699, DOI 10.1046/j.1365-2443.2000.00362.x; Irving JA, 2002, J BIOL CHEM, V277, P13192, DOI 10.1074/jbc.M108460200; JEPPSSON JO, 1978, EUR J BIOCHEM, V83, P143, DOI 10.1111/j.1432-1033.1978.tb12078.x; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; Kalsheker NA, 1996, INT J BIOCHEM CELL B, V28, P961, DOI 10.1016/1357-2725(96)00032-5; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; Kelley WL, 1999, CURR BIOL, V9, pR305, DOI 10.1016/S0960-9822(99)80185-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamande SR, 1999, SEMIN CELL DEV BIOL, V10, P455, DOI 10.1006/scdb.1999.0317; Lievremont JP, 1997, J BIOL CHEM, V272, P30873, DOI 10.1074/jbc.272.49.30873; Luo Y, 1999, J BIOL CHEM, V274, P17733, DOI 10.1074/jbc.274.25.17733; Mahadeva R, 2002, J BIOL CHEM, V277, P6771, DOI 10.1074/jbc.C100722200; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; NAIDOO N, 1995, J BIOL CHEM, V270, P14548, DOI 10.1074/jbc.270.24.14548; Nishikawa S, 1998, BIOCHEM BIOPH RES CO, V244, P785, DOI 10.1006/bbrc.1998.8342; Nishikawa S, 2001, J CELL BIOL, V153, P1061, DOI 10.1083/jcb.153.5.1061; Nishikawa S, 1997, J BIOL CHEM, V272, P12889, DOI 10.1074/jbc.272.20.12889; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; Shen Y, 2002, J BIOL CHEM, V277, P15947, DOI 10.1074/jbc.M112214200; SHOJI W, 1995, J BIOL CHEM, V270, P24818, DOI 10.1074/jbc.270.42.24818; Silberstein S, 1998, J CELL BIOL, V143, P921, DOI 10.1083/jcb.143.4.921; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Skowronek MH, 1999, BIOL CHEM, V380, P1133, DOI 10.1515/BC.1999.142; Sterner DE, 2002, J BIOL CHEM, V277, P8178, DOI 10.1074/jbc.M108601200; Stronge VS, 2001, J BIOL CHEM, V276, P39779, DOI 10.1074/jbc.M107091200; TAHARA E, 1984, HUM PATHOL, V15, P957, DOI 10.1016/S0046-8177(84)80125-2; TAKADA S, 1986, CANCER RES, V46, P3688; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; TOWNSLEY FM, 1994, EUR J CELL BIOL, V64, P211; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; Tyedmers J, 2000, P NATL ACAD SCI USA, V97, P7214, DOI 10.1073/pnas.97.13.7214; Vincent MJ, 1998, J BIOL CHEM, V273, P950, DOI 10.1074/jbc.273.2.950; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Yan W, 1998, EMBO J, V17, P4809, DOI 10.1093/emboj/17.16.4809; Yu JJ, 2003, EMBO J, V22, P3403, DOI 10.1093/emboj/cdg326; Yu M, 2000, J BIOL CHEM, V275, P24984, DOI 10.1074/jbc.M000739200; Zargarian L, 1999, BIOCHEMISTRY-US, V38, P1921, DOI 10.1021/bi981199j; Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9; ZHANG SG, 1992, EMBO J, V11, P3787, DOI 10.1002/j.1460-2075.1992.tb05464.x; Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303; Zhou AW, 2001, J BIOL CHEM, V276, P27541, DOI 10.1074/jbc.M102594200; Zupicich J, 2001, GENOME BIOL, V2	72	30	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11432	11443		10.1074/jbc.M310903200	http://dx.doi.org/10.1074/jbc.M310903200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14668352	hybrid, Green Accepted			2022-12-25	WOS:000220157600074
J	Steckelbroeck, S; Jin, Y; Gopishetty, S; Oyesanmi, B; Penning, TM				Steckelbroeck, S; Jin, Y; Gopishetty, S; Oyesanmi, B; Penning, TM			Human cytosolic 3 alpha-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3 beta-hydroxysteroid dehydrogenase activity - Implications for steroid hormone metabolism and action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN 20-ALPHA-HYDROXYSTEROID DEHYDROGENASE; SITE-DIRECTED MUTAGENESIS; ANDROGEN METABOLISM; NEUROACTIVE STEROIDS; HUMAN PROSTATE; DIHYDRODIOL DEHYDROGENASE; HUMAN BRAIN; MALE RATS; HYDROXYSTEROID DEHYDROGENASES; SUBSTRATE-SPECIFICITY	The source of NADPH-dependent cytosolic 3beta-hydroxysteroid dehydrogenase (3beta-HSD) activity is unknown to date. This important reaction leads e. g. to the reduction of the potent androgen 5alpha-dihydrotestosterone (DHT) into inactive 3beta-androstanediol (3beta-Diol). Four human cytosolic aldo-keto reductases (AKR1C1 AKR1C4) are known to act as non-positional-specific 3alpha- / 17beta- /20alpha-HSDs. We now demonstrate that AKR1Cs catalyze the reduction of DHT into both 3alpha- and 3beta-Diol ( established by H-1 NMR spectroscopy). The rates of 3alpha-versus 3beta-Diol formation varied significantly among the isoforms, but with each enzyme both activities were equally inhibited by the nonsteroidal anti-inflammatory drug flufenamic acid. In vitro, AKR1Cs also expressed substantial 3alpha[17beta]-hydroxysteroid oxidase activity with 3alpha-Diol as the substrate. However, in contrast to the 3-ketosteroid reductase activity of the enzymes, their hydroxysteroid oxidase activity was potently inhibited by low micromolar concentrations of the opposing cofactor ( NADPH). This indicates that in vivo all AKR1Cs will preferentially work as reductases. Human hepatoma (HepG2) cells (which lack 3beta-HSD/Delta(5-4) ketosteroid isomerase mRNA expression, but express AKR1C1 - AKR1C3) were able to convert DHT into 3alpha- and 3beta-Diol. This conversion was inhibited by flufenamic acid establishing the in vivo significance of the 3alpha/ 3beta-HSD activities of the AKR1C enzymes. Molecular docking simulations using available crystal structures of AKR1C1 and AKR1C2 demonstrated how 3alpha/3beta-HSD activities are achieved. The observation that AKR1Cs are a source of 3beta-tetrahydrosteroids is of physiological significance because: (i) the formation of 3beta-Diol ( in contrast to 3alpha-Diol) is virtually irreversible, (ii) 3beta-Diol is a pro-apoptotic ligand for estrogen receptor beta, and (iii) 3beta-tetrahydrosteroids act as gamma-aminobutyric acid type A receptor antagonists.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Penning, TM (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 130C John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	penning@pharm.med.upenn.edu		Penning, Trevor/0000-0002-3937-1066	NATIONAL CANCER INSTITUTE [R01CA090744] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047015] Funding Source: NIH RePORTER; NCI NIH HHS [CA90744] Funding Source: Medline; NIDDK NIH HHS [DK47015] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECKER H, 1973, ACTA ENDOCRINOL-COP, V73, P407, DOI 10.1530/acta.0.0730407; Biswas MG, 1997, J BIOL CHEM, V272, P15959, DOI 10.1074/jbc.272.25.15959; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burczynski ME, 1998, BIOCHEMISTRY-US, V37, P6781, DOI 10.1021/bi972725u; Chetyrkin SV, 2001, J BIOL CHEM, V276, P22278, DOI 10.1074/jbc.M102076200; Chetyrkin SV, 2001, ARCH BIOCHEM BIOPHYS, V386, P1, DOI 10.1006/abbi.2000.2203; CLAIR P, 1984, J STEROID BIOCHEM, V20, P377, DOI 10.1016/0022-4731(84)90237-1; Couture JF, 2003, J MOL BIOL, V331, P593, DOI 10.1016/S0022-2836(03)00762-9; Dufort I, 1999, ENDOCRINOLOGY, V140, P568, DOI 10.1210/en.140.2.568; GEMZIK B, 1992, ARCH BIOCHEM BIOPHYS, V296, P374, DOI 10.1016/0003-9861(92)90587-M; Gingras S, 1999, ENDOCRINOLOGY, V140, P4573, DOI 10.1210/en.140.10.4573; Gough WH, 1998, J BIOL CHEM, V273, P19778, DOI 10.1074/jbc.273.31.19778; HABRIOUX G, 1978, STEROIDS, V32, P61, DOI 10.1016/0039-128X(78)90100-9; He XY, 2000, BBA-MOL CELL BIOL L, V1484, P267, DOI 10.1016/S1388-1981(00)00014-7; Higaki Y, 2003, CHEM-BIOL INTERACT, V143, P503, DOI 10.1016/S0009-2797(02)00206-5; HORST HJ, 1975, ACTA ENDOCRINOL-COP, V79, P394, DOI 10.1530/acta.0.0790394; Huang XF, 2000, J BIOL CHEM, V275, P29452, DOI 10.1074/jbc.M000562200; JACOBI GH, 1977, J CLIN ENDOCR METAB, V44, P107, DOI 10.1210/jcem-44-1-107; Ji Q, 2003, PROSTATE, V54, P275, DOI 10.1002/pros.10192; Jin Y, 2001, BEST PRACT RES CL EN, V15, P79, DOI 10.1053/beem.2001.0120; Jin Y, 2001, BIOCHEMISTRY-US, V40, P10161, DOI 10.1021/bi010919a; KAO LWL, 1977, J STEROID BIOCHEM, V8, P1109; KINOSHITA Y, 1981, ENDOCRINOL JAPON, V28, P499; Krebs H A, 1973, Symp Soc Exp Biol, V27, P299; KRIEG M, 1975, J ENDOCRINOL, V64, P529, DOI 10.1677/joe.0.0640529; Lambert JJ, 2001, BRAIN RES REV, V37, P68, DOI 10.1016/S0165-0173(01)00124-2; Lin HK, 1997, MOL ENDOCRINOL, V11, P1971, DOI 10.1210/me.11.13.1971; LORENCE MC, 1990, ENDOCRINOLOGY, V126, P2493, DOI 10.1210/endo-126-5-2493; Maitra R, 1998, CAN J PHYSIOL PHARM, V76, P909, DOI 10.1139/cjpp-76-9-909; Matsuura K, 1997, BIOCHEM J, V323, P61, DOI 10.1042/bj3230061; MAUVAISJ.P, 1965, J CLIN ENDOCR METAB, V25, P1167, DOI 10.1210/jcem-25-9-1167; MORFIN RF, 1977, BIOCHIMIE, V59, P637, DOI 10.1016/S0300-9084(77)80173-9; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Nahoum V, 2001, J BIOL CHEM, V276, P42091, DOI 10.1074/jbc.M105610200; OFFNER P, 1983, J STEROID BIOCHEM, V18, P415; PAUL SM, 1992, FASEB J, V6, P2311, DOI 10.1096/fasebj.6.6.1347506; PAWLOWSKI JE, 1994, J BIOL CHEM, V269, P13502; Penning TM, 1997, ENDOCR REV, V18, P281, DOI 10.1210/er.18.3.281; Penning TM, 2000, BIOCHEM J, V351, P67, DOI 10.1042/0264-6021:3510067; PENNING TM, 1983, P NATL ACAD SCI-BIOL, V80, P4504, DOI 10.1073/pnas.80.14.4504; Pirog EC, 1999, J CLIN ENDOCR METAB, V84, P3217, DOI 10.1210/jc.84.9.3217; PRINCE RJ, 1992, NEUROSCI LETT, V135, P273, DOI 10.1016/0304-3940(92)90454-F; Ratnam K, 1999, BIOCHEMISTRY-US, V38, P7856, DOI 10.1021/bi982838t; REICH JG, 1981, ENERGY METABOLISM CE; RHEAUME E, 1991, MOL ENDOCRINOL, V5, P1147, DOI 10.1210/mend-5-8-1147; Rizner TL, 2003, ENDOCRINOLOGY, V144, P2922, DOI 10.1210/en.2002-0032; Rupprecht R, 1999, TRENDS NEUROSCI, V22, P410, DOI 10.1016/S0166-2236(99)01399-5; SAARTOK T, 1984, ENDOCRINOLOGY, V114, P2100, DOI 10.1210/endo-114-6-2100; Shaw G, 2000, P NATL ACAD SCI USA, V97, P12256, DOI 10.1073/pnas.220412297; Simard J, 1996, J ENDOCRINOL, V150, pS189; Steckelbroeck S, 2001, J CLIN ENDOCR METAB, V86, P1324, DOI 10.1210/jc.86.3.1324; Steckelbroeck S, 2001, MOL CELL ENDOCRINOL, V171, P165, DOI 10.1016/S0303-7207(00)00432-9; STENSTAD P, 1981, BIOCHIM BIOPHYS ACTA, V663, P169, DOI 10.1016/0005-2760(81)90203-4; STEWART ME, 1977, J ENDOCRINOL, V72, P385, DOI 10.1677/joe.0.0720385; Stoffel-Wagner B, 2003, EPILEPSY RES, V54, P11, DOI 10.1016/S0920-1211(03)00036-6; TALALAY P, 1959, 2 CIBA FDN STUD GROU, P53; THOMAS JL, 1992, BIOCHEMISTRY-US, V31, P5522, DOI 10.1021/bi00139a014; TRAPP T, 1992, J STEROID BIOCHEM, V42, P321, DOI 10.1016/0960-0760(92)90135-6; Trauger JW, 2002, BIOCHEMISTRY-US, V41, P13451, DOI 10.1021/bi026109w; Usami N, 2002, BIOL PHARM BULL, V25, P441, DOI 10.1248/bpb.25.441; VANDOORN EJ, 1975, J STEROID BIOCHEM, V6, P1549, DOI 10.1016/0022-4731(75)90213-7; WALSH PC, 1976, J CLIN INVEST, V57, P1093, DOI 10.1172/JCI108353; Wang J, 1999, BIOCHEM J, V338, P23, DOI 10.1042/0264-6021:3380023; Wang MD, 2000, ACTA PHYSIOL SCAND, V169, P333, DOI 10.1046/j.1365-201x.2000.00744.x; Wang MD, 2002, J NEUROSCI, V22, P3366; Weihua Z, 2002, P NATL ACAD SCI USA, V99, P13589, DOI 10.1073/pnas.162477299; Weihua Zhang, 2001, Proceedings of the National Academy of Sciences of the United States of America, V98, P6330, DOI 10.1073/pnas.111150898; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; WRIGHT F, 1980, J STEROID BIOCHEM, V13, P639, DOI 10.1016/0022-4731(80)90030-8; Zhang Y, 2000, J MOL ENDOCRINOL, V25, P221, DOI 10.1677/jme.0.0250221	70	229	234	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10784	10795		10.1074/jbc.M313308200	http://dx.doi.org/10.1074/jbc.M313308200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14672942	hybrid, Green Submitted			2022-12-25	WOS:000220050400134
J	Zhou, WB; Freed, CR				Zhou, WB; Freed, CR			Tyrosine-to-cysteine modification of human alpha-synuclein enhances protein aggregation and cellular toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BETA COMPONENT; PARKINSONS-DISEASE; OXIDATIVE STRESS; PRECURSOR PROTEIN; WILD-TYPE; MUTANT; SUSCEPTIBILITY; EXPRESSION; MUTATIONS; OVEREXPRESSION	The deposition of alpha-synuclein and other cellular proteins in Lewy bodies in midbrain dopamine neurons is a pathological hallmark of Parkinson's disease. Nitrative and oxidative stress can induce alpha-synuclein protein aggregation, possibly initiated by the formation of stable cross-linking dimers. To determine whether enhanced dimer formation can accelerate protein aggregation and increase cellular toxicity, we have substituted cysteine for tyrosine at positions 39, 125, 133, and 136 in human wild-type (WT) alpha-synuclein, and in A53T and A30P mutant alpha-synuclein. To reduce the likelihood of cross-linking, phenylalanine was substituted for tyrosine at the same sites. We have found that overexpression of Y39C or Y125C mutant proteins leads to increased intracellular inclusions and apoptosis in a rat dopaminergic cell line (N27 cells) and in human embryonic kidney 293 cells. Expression of Y133C, Y136C, and all four Tyr-to-Phe mutations were not more cytotoxic than WT control. Exposure to oxidative stress increased Y39C and Y125C alpha-synuclein aggregation and toxicity. Dimers and oligomers were found in Triton X-100-soluble fractions from adenovirus-mediated overexpression of Y39C and Y125C in N27 cells. In contrast, WT beta-synuclein and all four Tyr-to-Cys mutant beta-synucleins did not cause protein aggregation and cell death. We conclude that cysteine substitution at critical positions in the alpha-synuclein molecule can increase dimer formation and accelerate protein aggregation and cellular toxicity of alpha-synuclein.	Univ Colorado, Hlth Sci Ctr, Dept Med, Div Clin Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Neurosci Program, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Freed, CR (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Div Clin Pharmacol, Campus Box C-237,4200 E 9th Ave, Denver, CO 80262 USA.	curt.freed@uchsc.edu						Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Clarkson ED, 1998, P NATL ACAD SCI USA, V95, P1265, DOI 10.1073/pnas.95.3.1265; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Dawson TM, 2003, J CLIN INVEST, V111, P145, DOI 10.1172/JCI200317575; Dawson TM, 2002, NEURON, V35, P219, DOI 10.1016/S0896-6273(02)00780-8; Duda JE, 2000, AM J PATHOL, V157, P1439, DOI 10.1016/S0002-9440(10)64781-5; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745; Hsu LJ, 1998, J NEUROCHEM, V71, P338; Hsu LJ, 2000, AM J PATHOL, V157, P401, DOI 10.1016/S0002-9440(10)64553-1; Ischiropoulos H, 2003, J CLIN INVEST, V111, P163, DOI 10.1172/JCI200317638; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Junn E, 2002, NEUROSCI LETT, V320, P146, DOI 10.1016/S0304-3940(02)00016-2; Kanda S, 2000, NEUROSCIENCE, V97, P279, DOI 10.1016/S0306-4522(00)00077-4; Kessler JC, 2003, BIOCHEMISTRY-US, V42, P672, DOI 10.1021/bi020429y; Ko LW, 2000, J NEUROCHEM, V75, P2546, DOI 10.1046/j.1471-4159.2000.0752546.x; Krishnan S, 2003, BIOCHEMISTRY-US, V42, P829, DOI 10.1021/bi026528t; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lang AE, 1998, NEW ENGL J MED, V339, P1130, DOI 10.1056/NEJM199810153391607; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Lee FJS, 2001, FASEB J, V15, P916, DOI 10.1096/fj.00-0334com; Lee M, 2001, J NEUROCHEM, V76, P998, DOI 10.1046/j.1471-4159.2001.00149.x; Lee MK, 2002, P NATL ACAD SCI USA, V99, P8968, DOI 10.1073/pnas.132197599; Lewy F., 1914, DEUT Z NERVENHEILKD, V50, P50; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Norris EH, 2003, J BIOL CHEM, V278, P27230, DOI 10.1074/jbc.M212436200; OLANOW CW, 1990, NEUROLOGY, V40, P32; Paxinou E, 2001, J NEUROSCI, V21, P8053, DOI 10.1523/JNEUROSCI.21-20-08053.2001; Perez RG, 2002, J NEUROSCI, V22, P3090, DOI 10.1523/JNEUROSCI.22-08-03090.2002; Perrin RJ, 2000, J BIOL CHEM, V275, P34393, DOI 10.1074/jbc.M004851200; PICARD V, 1996, METHOD MOL BIOL, V67, P81; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Tabrizi SJ, 2000, HUM MOL GENET, V9, P2683, DOI 10.1093/hmg/9.18.2683; Takahashi T, 2002, BRAIN RES, V938, P73, DOI 10.1016/S0006-8993(02)02498-8; Turnbull S, 2001, FREE RADICAL BIO MED, V30, P1163, DOI 10.1016/S0891-5849(01)00513-5; Uversky VN, 2002, FEBS LETT, V517, P239, DOI 10.1016/S0014-5793(02)02638-8; van der Putten H, 2000, J NEUROSCI, V20, P6021, DOI 10.1523/JNEUROSCI.20-16-06021.2000; Zhou WB, 2000, BRAIN RES, V866, P33, DOI 10.1016/S0006-8993(00)02215-0; Zhou WB, 2002, BRAIN RES, V926, P42, DOI 10.1016/S0006-8993(01)03292-9	48	64	68	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10128	10135		10.1074/jbc.M307563200	http://dx.doi.org/10.1074/jbc.M307563200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699135	hybrid			2022-12-25	WOS:000220050400058
J	Kebache, S; Cardin, E; Nguyen, DT; Chevet, E; Larose, L				Kebache, S; Cardin, E; Nguyen, DT; Chevet, E; Larose, L			Nck-1 antagonizes the endoplasmic reticulum stress-induced inhibition of translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED-PROTEIN RESPONSE; HERPES-SIMPLEX VIRUS-1; KAR2 BIP GENE; ER STRESS; GAMMA(1)34.5 PROTEIN; CELLS; INITIATION; KINASE; ADAPTER; EIF2-ALPHA	Eukaryotic cells have developed specific mechanisms to overcome environmental stress. Here we show that the Src homology 2/3 (SH2/SH3) domain-containing protein Nck-1 prevents the unfolded protein response normally induced by pharmacological endoplasmic reticulum ( ER) stress agents. Overexpression of Nck-1 enhances protein translation, whereas it abrogates eukaryotic initiation factor 2alpha(eIF2alpha) phosphorylation and inhibition of translation in response to tunicamycin or thapsigargin treatment. Nck-1 overexpression also attenuates induction of the ER chaperone, the immunoglobulin heavy chain-binding protein (BiP), and impairs cell survival in response to thapsigargin. We provided evidence that in these conditions, the effects of Nck on the unfolded protein response (UPR) involve its second SH3 domain and a calyculin A-sensitive phosphatase activity. In addition, we demonstrated that protein translation is reduced in mouse embryonic fibroblasts lacking both Nck isoforms and is enhanced in similar cells expressing high levels of Nck-1. In these various mouse embryonic fibroblasts, we also provided evidence that Nck modulates the activation of the ER resident eIF2alpha kinase PERK and consequently the phosphorylation of eIF2alpha on Ser-51 in response to stress. Our study establishes that Nck is required for optimal protein translation and demonstrates that, in addition to its adaptor function in mediating signaling from the plasma membrane, Nck also mediates signaling from the ER membrane compartment.	McGill Univ, Fac Med,Polypeptide Lab, Dept Expt Med, Div Endocrinol, Montreal, PQ H3A 2B2, Canada; McGill Univ, Dept Surg, Organelle Signaling Lab, Montreal, PQ H3A 2B2, Canada	McGill University; McGill University	Larose, L (corresponding author), McGill Univ, Fac Med,Polypeptide Lab, Dept Expt Med, Div Endocrinol, Strathcona Bldg,3640 Univ St,Rm W315, Montreal, PQ H3A 2B2, Canada.	louise.larose@mcgill.ca	chevet, eric/E-4992-2016	chevet, eric/0000-0001-5855-4522				Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bladt F, 2003, MOL CELL BIOL, V23, P4586, DOI 10.1128/MCB.23.13.4586-4597.2003; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; Buday L, 2002, CELL SIGNAL, V14, P723, DOI 10.1016/S0898-6568(02)00027-X; CHOU J, 1994, P NATL ACAD SCI USA, V91, P5247, DOI 10.1073/pnas.91.12.5247; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gotoh T, 2002, J BIOL CHEM, V277, P12343, DOI 10.1074/jbc.M107988200; Gulow K, 2002, J CELL SCI, V115, P2443; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; He B, 1996, J VIROL, V70, P84, DOI 10.1128/JVI.70.1.84-90.1996; He B, 1998, J BIOL CHEM, V273, P20737, DOI 10.1074/jbc.273.33.20737; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Jousse C, 2003, J CELL BIOL, V163, P767, DOI 10.1083/jcb.200308075; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; Kebache S, 2002, P NATL ACAD SCI USA, V99, P5406, DOI 10.1073/pnas.082483399; Kimball SR, 1998, J BIOL CHEM, V273, P30945, DOI 10.1074/jbc.273.47.30945; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Li W, 2001, ONCOGENE, V20, P6403, DOI 10.1038/sj.onc.1204782; Li W, 2000, HISTOL HISTOPATHOL, V15, P947, DOI 10.14670/HH-15.947; Lussier G, 1997, J BIOL CHEM, V272, P2688, DOI 10.1074/jbc.272.5.2688; McCarty JH, 1998, BIOESSAYS, V20, P913, DOI 10.1002/(SICI)1521-1878(199811)20:11<913::AID-BIES6>3.0.CO;2-T; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Poulin F, 1998, J BIOL CHEM, V273, P14002, DOI 10.1074/jbc.273.22.14002; PROSTKO CR, 1993, MOL CELL BIOCHEM, V128, P255, DOI 10.1007/BF01076776; Siomi MC, 1996, MOL CELL BIOL, V16, P3825; Sood R, 2000, BIOCHEM J, V346, P281, DOI 10.1042/0264-6021:3460281; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; van Huizen R, 2003, J BIOL CHEM, V278, P15558, DOI 10.1074/jbc.M212074200; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Yan W, 2002, P NATL ACAD SCI USA, V99, P15920, DOI 10.1073/pnas.252341799; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200	42	45	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9662	9671		10.1074/jbc.M310535200	http://dx.doi.org/10.1074/jbc.M310535200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676213	hybrid			2022-12-25	WOS:000189265900134
J	Lenoir, G; Picard, M; Gauron, C; Montigny, C; Le Marechal, P; Falson, P; le Maire, M; Moller, JV; Champeil, P				Lenoir, G; Picard, M; Gauron, C; Montigny, C; Le Marechal, P; Falson, P; le Maire, M; Moller, JV; Champeil, P			Functional properties of sarcoplasmic reticulum Ca2+-ATPase after proteolytic cleavage at Leu(119)-Lys(120), close to the A-domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENERGY TRANSDUCTION MECHANISM; SITE-DIRECTED MUTAGENESIS; MEMBRANE CALCIUM-PUMP; PHOSPHOENZYME INTERMEDIATE; ADENOSINE-TRIPHOSPHATASE; TRANSMEMBRANE SEGMENTS; LIMITED PROTEOLYSIS; INORGANIC-PHOSPHATE; OXIDATIVE CLEAVAGE; PROTEINASE-K	By measuring the phosphorylation levels of individual proteolytic fragments of SERCA1a separated by electrophoresis after their phosphorylation, we were able to study the catalytic properties of a p95C-p14N complex arising from SERCA1a cleavage by proteinase K between Leu(119) and Lys(120), in the loop linking the A-domain with the second transmembrane segment. ATP hydrolysis by the complex was very strongly inhibited, although ATP-dependent phosphorylation and the conversion of the ADP-sensitive E1P form to E2P still occurred at appreciable rates. However, the rate of subsequent dephosphorylation of E2P was inhibited to a dramatic extent, and this was also the case for the rate of "backdoor" formation of E2P from E2 and P-i. E2P formation from E2 at equilibrium nevertheless indicated little change in the apparent affinity for P-i or Mg2+, while binding of orthovanadate was weaker. The p95C-p14N complex also had a slightly reduced affinity for Ca2+ and exhibited a reduced rate for its Ca2+-dependent transition from E2 to Ca(2)E1. Thus, disruption of the N-terminal link of the A-domain with the transmembrane region seems to shift the conformational equilibria of Ca2+-ATPase from the E1/E1P toward the E2/E2P states and to increase the activation energy for dephosphorylation of Ca2+-ATPase, reviving the old idea of the A-domain being a phosphatase domain as part of the transduction machinery.	CEA, Dept Biol Joliot Curie, Serv Biophys Fonct Membranaires,CNRS, Unite Rech Associee 2096,Lab Rech Associe 17V, F-91191 Gif Sur Yvette, France; Univ Paris Sud, CEA Saclay, Inst Federat Rech 46, F-91191 Gif Sur Yvette, France; Univ Paris 11, IFR46, F-91405 Orsay, France; Univ Paris 11, Inst Biochim & Biophys Mol & Cellulaire, Equipe Chim Prot, CNRS,Unite Mixte Rech 8619, F-91405 Orsay, France; Aarhus Univ, Dept Biophys, DK-8000 Aarhus C, Denmark	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Aarhus University	Champeil, P (corresponding author), CEA, Dept Biol Joliot Curie, Serv Biophys Fonct Membranaires,CNRS, Unite Rech Associee 2096,Lab Rech Associe 17V, F-91191 Gif Sur Yvette, France.	champeil@dsvidf.cea.fr	Picard, Martin/A-3236-2016; Lenoir, Guillaume/I-4002-2019	Picard, Martin/0000-0002-6518-8900; Lenoir, Guillaume/0000-0002-8759-5179; Falson, Pierre/0000-0002-9760-4577				ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; Andersen JP, 2001, J BIOL CHEM, V276, P23312, DOI 10.1074/jbc.M102384200; ANDERSEN JP, 1993, BIOCHEMISTRY-US, V32, P10015, DOI 10.1021/bi00089a017; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; Champeil P, 1998, J BIOL CHEM, V273, P6619, DOI 10.1074/jbc.273.12.6619; Champeil P, 2000, J BIOL CHEM, V275, P18623, DOI 10.1074/jbc.M000470200; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Clausen JD, 2003, BIOCHEMISTRY-US, V42, P2585, DOI 10.1021/bi0271897; Daiho T, 2003, J BIOL CHEM, V278, P39197, DOI 10.1074/jbc.M305200200; Daiho T, 1999, FEBS LETT, V444, P54, DOI 10.1016/S0014-5793(99)00027-7; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; Danko S, 2001, FEBS LETT, V489, P277, DOI 10.1016/S0014-5793(01)02111-1; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; Echarte MM, 2001, ANAL BIOCHEM, V289, P267, DOI 10.1006/abio.2000.4950; Goldshleger R, 1999, J BIOL CHEM, V274, P16213, DOI 10.1074/jbc.274.23.16213; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HENAO F, 1991, EUR J BIOCHEM, V202, P559, DOI 10.1111/j.1432-1033.1991.tb16408.x; JENCKS WP, 1989, J BIOL CHEM, V264, P18855; JUUL B, 1995, J BIOL CHEM, V270, P20123, DOI 10.1074/jbc.270.34.20123; Kato S, 2003, J BIOL CHEM, V278, P9624, DOI 10.1074/jbc.M208861200; Ma HL, 2003, J BIOL CHEM, V278, P28938, DOI 10.1074/jbc.M304120200; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MAKINOSE M, 1973, FEBS LETT, V37, P140, DOI 10.1016/0014-5793(73)80443-0; MEDDA P, 1983, EUR J BIOCHEM, V137, P7, DOI 10.1111/j.1432-1033.1983.tb07788.x; Menguy T, 1998, J BIOL CHEM, V273, P20134, DOI 10.1074/jbc.273.32.20134; Moller JV, 2003, ANN NY ACAD SCI, V986, P82, DOI 10.1111/j.1749-6632.2003.tb07142.x; Moller JV, 2002, J BIOL CHEM, V277, P38647, DOI 10.1074/jbc.M204603200; Patchornik G, 2000, P NATL ACAD SCI USA, V97, P11954, DOI 10.1073/pnas.220332897; PORTILLO F, 1988, EMBO J, V7, P1793, DOI 10.1002/j.1460-2075.1988.tb03010.x; PORTILLO F, 1996, BIOMEMBR, V5, P225; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SARKADI B, 1988, BIOCHIM BIOPHYS ACTA, V939, P40, DOI 10.1016/0005-2736(88)90044-2; SCOTT TL, 1982, J MEMBRANE BIOL, V64, P137, DOI 10.1007/BF01870879; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shin JM, 2001, J BIOL CHEM, V276, P48440, DOI 10.1074/jbc.M106864200; SHOSHANBARMATZ V, 1987, J BIOL CHEM, V262, P11559; Sorensen T, 1997, J BIOL CHEM, V272, P30244, DOI 10.1074/jbc.272.48.30244; Soulie S, 1996, ANAL BIOCHEM, V236, P363, DOI 10.1006/abio.1996.0183; TONG SW, 1977, BIOCHEM BIOPH RES CO, V74, P1242, DOI 10.1016/0006-291X(77)91651-5; TOROK K, 1988, EUR J BIOCHEM, V173, P361, DOI 10.1111/j.1432-1033.1988.tb14006.x; Toustrup-Jensen M, 2003, J BIOL CHEM, V278, P11402, DOI 10.1074/jbc.M212136200; Toyoshima C, 2003, FEBS LETT, V555, P106, DOI 10.1016/S0014-5793(03)01086-X; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Tsivkovskii R, 2002, J BIOL CHEM, V277, P976, DOI 10.1074/jbc.M109368200; VILSEN B, 1989, J BIOL CHEM, V264, P21024; Xu C, 2002, J MOL BIOL, V316, P201, DOI 10.1006/jmbi.2001.5330; Yamasaki K, 2004, J BIOL CHEM, V279, P2202, DOI 10.1074/jbc.M309398200	51	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9156	9166		10.1074/jbc.M311411200	http://dx.doi.org/10.1074/jbc.M311411200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14672956	Green Submitted, hybrid			2022-12-25	WOS:000189265900077
J	Rump, A; Morikawa, Y; Tanaka, M; Minami, S; Umesaki, N; Takeuchi, M; Miyajima, A				Rump, A; Morikawa, Y; Tanaka, M; Minami, S; Umesaki, N; Takeuchi, M; Miyajima, A			Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; GENE-EXPRESSION; TUMOR-MARKER; MONOCLONAL-ANTIBODY; GASTRIC-CANCER; CA 125; EXTRACELLULAR SUPERSTRUCTURE; GYNECOLOGIC-ONCOLOGY; HUMAN CARCINOMAS; CA-125 GENE	Mesothelin is a glycosylphosphatidylinositol-linked cell surface molecule expressed in the mesothelial lining of the body cavities and in many tumor cells. Based on the finding that a soluble form of mesothelin specifically binds to ovarian carcinoma cell line OVCAR-3, we isolated cDNAs encoding a mesothelin-binding protein by expression cloning. The polypeptides encoded by the two cloned cDNA fragments matched to portions of CA125, an ovarian cancer antigen and a giant mucin-like glycoprotein present at the surface of tumor cells. By flow cytometric analysis and immunoprecipitation, we demonstrate that CA125 binds to mesothelin in a specific manner. Binding of CA125 to membrane-bound mesothelin mediates heterotypic cell adhesion as anti-mesothelin antibody blocks binding of OVCAR-3 cells expressing CA125 to an endothelial-like cell line expressing mesothelin. Finally, we show that CA125 and mesothelin are co-expressed in advanced grade ovarian adenocarcinoma. Taken together, our data indicate that mesothelin is a novel CA125-binding protein and that CA125 might contribute to the metastasis of ovarian cancer to the peritoneum by initiating cell attachment to the mesothelial epithelium via binding to mesothelin.	Univ Tokyo, Inst Mol & Cellular Biosci, Lab Cell Growth & Differentiat, Bunkyo Ku, Tokyo 1130032, Japan; Wakayama Med Univ, Dept Anat & Neurobiol, Wakayama 6410012, Japan; Wakayama Med Univ, Dept Obstet & Gynecol, Wakayama 6410012, Japan; Japan Sci & Technol Corp, CREST, Tokyo, Japan	University of Tokyo; Wakayama Medical University; Wakayama Medical University; Japan Science & Technology Agency (JST)	Miyajima, A (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Cell Growth & Differentiat, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1130032, Japan.	miyajima@ims.u-tokyo.ac.jp						Argani P, 2001, CLIN CANCER RES, V7, P3862; BAST RC, 1983, NEW ENGL J MED, V309, P883, DOI 10.1056/NEJM198310133091503; Bera TK, 2000, MOL CELL BIOL, V20, P2902, DOI 10.1128/MCB.20.8.2902-2906.2000; Bon GG, 1996, AM J OBSTET GYNECOL, V174, P107, DOI 10.1016/S0002-9378(96)70381-2; Boussioutas A, 2003, CANCER RES, V63, P2569; Bresalier RS, 1996, CANCER RES, V56, P4354; CANNISTRA SA, 1993, NEW ENGL J MED, V329, P1550, DOI 10.1056/NEJM199311183292108; CANNISTRA SA, 1993, CANCER RES, V53, P3830; CHANG K, 1992, INT J CANCER, V50, P373, DOI 10.1002/ijc.2910500308; Chang K, 1996, P NATL ACAD SCI USA, V93, P136, DOI 10.1073/pnas.93.1.136; Fernandez-Rodriguez J, 2002, TUMOR BIOL, V23, P193, DOI 10.1159/000067252; FLEUREN GJ, 1987, CANCER, V60, P2437, DOI 10.1002/1097-0142(19871115)60:10<2437::AID-CNCR2820601015>3.0.CO;2-K; Frierson HF, 2003, HUM PATHOL, V34, P605, DOI 10.1016/S0046-8177(03)00177-1; FUKS A, 1975, BIOCHIM BIOPHYS ACTA, V417, P123, DOI 10.1016/0304-419X(75)90002-5; Fukuda M, 2002, BBA-GEN SUBJECTS, V1573, P394, DOI 10.1016/S0304-4165(02)00409-9; FUKUDA MN, 1995, GENE DEV, V9, P1199, DOI 10.1101/gad.9.10.1199; Gaetje R, 2002, Clin Exp Obstet Gynecol, V29, P34; Gaetje R, 1999, J SOC GYNECOL INVEST, V6, P278, DOI 10.1016/S1071-5576(99)00027-1; Gimmi CD, 1996, NAT MED, V2, P1367, DOI 10.1038/nm1296-1367; Ginath S, 2002, INT J GYNECOL CANCER, V12, P372, DOI 10.1046/j.1525-1438.2002.01007.x; Gum JR, 2002, BIOCHEM BIOPH RES CO, V291, P466, DOI 10.1006/bbrc.2002.6475; Hara T, 1999, IMMUNITY, V11, P567, DOI 10.1016/S1074-7613(00)80132-6; HARADA N, 1990, P NATL ACAD SCI USA, V87, P857, DOI 10.1073/pnas.87.3.857; HARDARDOTTIR H, 1990, AM J OBSTET GYNECOL, V163, P1925, DOI 10.1016/0002-9378(90)90775-3; Heintz A P, 2001, J Epidemiol Biostat, V6, P107; Hellstrom I, 2003, CANCER RES, V63, P3695; Hilkens J, 1995, BIOCHEM SOC T, V23, P822, DOI 10.1042/bst0230822; Hippo Y, 2001, CANCER RES, V61, P889; HOLNESS CL, 1993, BLOOD, V81, P1607; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kim YJ, 1999, AM J PATHOL, V155, P461, DOI 10.1016/S0002-9440(10)65142-5; KOJIMA T, 1995, J BIOL CHEM, V270, P21984, DOI 10.1074/jbc.270.37.21984; Lash AE, 2000, GENOME RES, V10, P1051, DOI 10.1101/gr.10.7.1051; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; MacDonald TJ, 2001, NAT GENET, V29, P143, DOI 10.1038/ng731; Menczer J, 1997, INT J GYNECOL CANCER, V7, P304, DOI 10.1046/j.1525-1438.1997.00459.x; Miettinen M, 2003, AM J SURG PATHOL, V27, P150, DOI 10.1097/00000478-200302000-00002; Mills L, 2002, CANCER RES, V62, P5106; Morikawa Y, 1996, ARCH PATHOL LAB MED, V120, P490; O'Brien TJ, 1998, INT J BIOL MARKER, V13, P188, DOI 10.1177/172460089801300403; O'Brien TJ, 2002, TUMOR BIOL, V23, P154, DOI 10.1159/000064032; O'Brien TJ, 2001, TUMOR BIOL, V22, P348, DOI 10.1159/000050638; OMURA GA, 1991, J CLIN ONCOL, V9, P1138, DOI 10.1200/JCO.1991.9.7.1138; PARMLEY TH, 1974, AM J OBSTET GYNECOL, V120, P234, DOI 10.1016/0002-9378(74)90370-6; PETERS WA, 1986, CANCER, V58, P2625, DOI 10.1002/1097-0142(19861215)58:12<2625::AID-CNCR2820581213>3.0.CO;2-A; PRIEVE MG, 2003, BMC DEV BIOL; Rodriguez GC, 2001, GYNECOL ONCOL, V80, P245, DOI 10.1006/gyno.2000.6042; Sato N, 2003, CANCER RES, V63, P4158; Satoh S, 2000, INT J CANCER, V88, P507, DOI 10.1002/1097-0215(20001115)88:4<507::AID-IJC1>3.0.CO;2-0; Scholler N, 1999, P NATL ACAD SCI USA, V96, P11531, DOI 10.1073/pnas.96.20.11531; Seelenmeyer C, 2003, J CELL SCI, V116, P1305, DOI 10.1242/jcs.00312; SERS C, 1994, CANCER RES, V54, P5689; Sternberg LR, 1999, GASTROENTEROLOGY, V116, P363, DOI 10.1016/S0016-5085(99)70133-2; Strobel T, 1999, GYNECOL ONCOL, V73, P362, DOI 10.1006/gyno.1999.5388; Suwa T, 1998, INT J CANCER, V76, P377, DOI 10.1002/(SICI)1097-0215(19980504)76:3<377::AID-IJC15>3.0.CO;2-8; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; Wong NK, 2003, J BIOL CHEM, V278, P28619, DOI 10.1074/jbc.M302741200; Wreschner DH, 2002, PROTEIN SCI, V11, P698, DOI 10.1110/ps.16502; Yin BWT, 2001, J BIOL CHEM, V276, P27371, DOI 10.1074/jbc.M103554200; Zeimet AG, 1996, GYNECOL ONCOL, V62, P384, DOI 10.1006/gyno.1996.0253	60	383	436	3	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9190	9198		10.1074/jbc.M312372200	http://dx.doi.org/10.1074/jbc.M312372200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676194	hybrid			2022-12-25	WOS:000189265900080
J	Lubyova, B; Kellum, MJ; Frisancho, AJ; Pitha, PM				Lubyova, B; Kellum, MJ; Frisancho, AJ; Pitha, PM			Kaposi's sarcoma-associated herpesvirus-encoded vIRF-3 stimulates the transcriptional activity of cellular IRF-3 and IRF-7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON REGULATORY FACTOR; DOUBLE-STRANDED-RNA; VIRUS-MEDIATED INDUCTION; ACTIVATED PROTEIN-KINASE; IFN-BETA PROMOTER; GENE-EXPRESSION; I INTERFERON; ALPHA GENES; HISTONE ACETYLTRANSFERASE; FUNCTIONAL-ANALYSIS	Kaposi's sarcoma-associated herpesvirus has been linked to Kaposi's sarcoma, body cavity-based lymphoma, and Castleman's disease. The Kaposi's sarcoma-associated herpesvirus genome contains a cluster of open reading frames encoding proteins (vIRFs) with homology to the cellular transcription factors of the interferon regulatory factor family. vIRF-3, also called LANA2, is a latently expressed nuclear protein. Here we demonstrate that vIRF-3 directly interacts with cellular interferon regulatory factor (IRF) IRF-3, IRF-7, and the transcriptional co-activator CBP/p300. The mapping of the vIRF-3 binding domain revealed that vIRF-3 associates with both IRF-3 and IRF-7 through its C-terminal region. The p300 domain, which interacts with vIRF-3, is distinct from the previously identified IBiD domain, to which both vIRF-1 and IRF-3 bind. Thus, in contrast to vIRF-1, vIRF-3 neither blocks the interaction between IRF-3 and p300 nor inhibits the histone acetylation. Although vIRF-3 is not a DNA-binding protein, it is recruited to the IFNA promoters via its interaction with IRF-3 and IRF-7. The presence of vIRF-3 in the enhanceosome assembled on the IFNA promoters increases binding of IRF-3, IRF-7, and acetylated histone H3 to this promoter region. Consequently, vIRF-3 stimulates the IRF-3- and IRF-7-mediated activation of type I interferon (IFNA and IFNB) genes and the synthesis of biologically active type I interferons in infected B cells. These studies illustrate that vIRF-3 and vIRF-1 have clearly distinct functions. In addition to its co-repressor activity, vIRF-3 can also act as a transcriptional activator on genes controlled by cellular IRF-3 and IRF-7.	Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Pitha, PM (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, 1650 E Orleans St, Baltimore, MD 21231 USA.	parowe@jhmi.edu	Lubyova, Barbora/G-5921-2014	Lubyova, Barbora/0000-0002-8714-0414	NATIONAL CANCER INSTITUTE [R01CA076946, P01CA081400] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA76946, P01CA81400] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; AU WC, 1993, J BIOL CHEM, V268, P24032; Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; Au WC, 2001, J BIOL CHEM, V276, P41629, DOI 10.1074/jbc.M105121200; Au WC, 2001, VIROLOGY, V280, P273, DOI 10.1006/viro.2000.0782; Barnes BJ, 2002, MOL CELL BIOL, V22, P5721, DOI 10.1128/MCB.22.16.5721-5740.2002; Barnes BJ, 2001, J BIOL CHEM, V276, P23382, DOI 10.1074/jbc.M101216200; Burysek L, 1999, J VIROL, V73, P7334; Burysek L, 1999, J HUMAN VIROL, V2, P19; Burysek L, 2001, J VIROL, V75, P2345, DOI 10.1128/JVI.75.5.2345-2352.2001; Caillaud A, 2002, J BIOL CHEM, V277, P49417, DOI 10.1074/jbc.M207484200; Chatterjee M, 2002, SCIENCE, V298, P1432, DOI 10.1126/science.1074883; CHEUNG SC, 1991, J IMMUNOL, V146, P121; Deng HY, 2002, J VIROL, V76, P8252, DOI 10.1128/JVI.76.16.8252-8264.2002; Dent CL, 1996, EUR J BIOCHEM, V236, P895, DOI 10.1111/j.1432-1033.1996.t01-1-00895.x; Dent CL, 1996, J INTERF CYTOK RES, V16, P99, DOI 10.1089/jir.1996.16.99; Escalante CR, 1998, NATURE, V391, P103, DOI 10.1038/34224; Esteban M, 2003, J GEN VIROL, V84, P1463, DOI 10.1099/vir.0.19014-0; Fakhari FD, 2002, J VIROL, V76, P6213, DOI 10.1128/JVI.76.12.6213-6223.2002; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Flowers CC, 1998, MOL MED, V4, P402, DOI 10.1007/BF03401747; Gao SJ, 1997, ONCOGENE, V15, P1979, DOI 10.1038/sj.onc.1201571; Izaguirre A, 2003, J LEUKOCYTE BIOL, V74, P1125, DOI 10.1189/jlb.0603255; Jenner RG, 2001, J VIROL, V75, P891, DOI 10.1128/JVI.75.2.891-902.2001; Juang YT, 1998, P NATL ACAD SCI USA, V95, P9837, DOI 10.1073/pnas.95.17.9837; Juang YT, 1999, J BIOL CHEM, V274, P18060, DOI 10.1074/jbc.274.25.18060; Karpova AY, 2001, MOL CELL BIOL, V21, P4169, DOI 10.1128/MCB.21.13.4169-4176.2001; Katze MG, 2002, NAT REV IMMUNOL, V2, P675, DOI 10.1038/nri888; Kim TY, 2003, J BIOL CHEM, V278, P15272, DOI 10.1074/jbc.M205792200; Kirchhoff S, 2002, J IMMUNOL, V168, P1226, DOI 10.4049/jimmunol.168.3.1226; Leaman DW, 1998, P NATL ACAD SCI USA, V95, P9442, DOI 10.1073/pnas.95.16.9442; Li M, 2000, MOL CELL BIOL, V20, P8254, DOI 10.1128/MCB.20.21.8254-8263.2000; Li MT, 1998, J VIROL, V72, P5433, DOI 10.1128/JVI.72.7.5433-5440.1998; Lin CH, 2001, MOL CELL, V8, P581, DOI 10.1016/S1097-2765(01)00333-1; Lin RT, 1999, MOL CELL BIOL, V19, P959; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lin RT, 2001, ONCOGENE, V20, P800, DOI 10.1038/sj.onc.1204163; Lu RQ, 2000, J BIOL CHEM, V275, P31805, DOI 10.1074/jbc.M005288200; Lubyova B, 2000, J VIROL, V74, P8194, DOI 10.1128/JVI.74.17.8194-8201.2000; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Masumi A, 1999, MOL CELL BIOL, V19, P1810; Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4; Nakamura H, 2001, J VIROL, V75, P7572, DOI 10.1128/JVI.75.16.7572-7582.2001; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; Paulose-Murphy M, 2001, J VIROL, V75, P4843, DOI 10.1128/JVI.75.10.4843-4853.2001; Peters KL, 2002, P NATL ACAD SCI USA, V99, P6322, DOI 10.1073/pnas.092133199; Rivas C, 2001, J VIROL, V75, P429, DOI 10.1128/JVI.75.1.429-438.2001; Roan F, 1999, J GEN VIROL, V80, P2205, DOI 10.1099/0022-1317-80-8-2205; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Seo T, 2001, J VIROL, V75, P6193, DOI 10.1128/JVI.75.13.6193-6198.2001; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; TAKI S, 1997, IMMUNITY, V6, P1; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1996, NATURE, V382, P555; Taniguchi T, 1999, COLD SPRING HARB SYM, V64, P465, DOI 10.1101/sqb.1999.64.465; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Wang XP, 2003, J GEN VIROL, V84, P329, DOI 10.1099/vir.0.18653-0; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Yeow WS, 1998, J IMMUNOL, V160, P2932; Yeow WS, 1997, INT J BIOCHEM CELL B, V29, P513, DOI 10.1016/S1357-2725(96)00105-7; Yeow WS, 2000, J BIOL CHEM, V275, P6313, DOI 10.1074/jbc.275.9.6313; Yeow WS, 2001, J VIROL, V75, P3021, DOI 10.1128/JVI.75.6.3021-3027.2001; Yie JM, 1999, EMBO J, V18, P3074, DOI 10.1093/emboj/18.11.3074; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Yoneyama M, 2002, J INTERF CYTOK RES, V22, P73, DOI 10.1089/107999002753452674; Zhang LQ, 2002, SCIENCE, V298, P995, DOI 10.1126/science.1076185; Zhu FX, 2002, P NATL ACAD SCI USA, V99, P5573, DOI 10.1073/pnas.082420599; Zimring JC, 1998, J VIROL, V72, P701, DOI 10.1128/JVI.72.1.701-707.1998	74	74	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7643	7654		10.1074/jbc.M309485200	http://dx.doi.org/10.1074/jbc.M309485200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14668346	hybrid			2022-12-25	WOS:000189103300035
J	He, Q; Huang, Y; Sheikh, MS				He, Q; Huang, Y; Sheikh, MS			Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells	ONCOGENE			English	Article						Apo2L/TRAIL; death receptor 5; caspases; Bax; proteasome inhibitor cytochrome c; Smac	TRAIL-INDUCED APOPTOSIS; DEPLETION-INDUCED APOPTOSIS; DECOY RECEPTORS; HUMAN COLON; IN-VIVO; AGENTS; FAMILY; LIGAND; DOMAIN; MITOCHONDRIAL	Apo2L/TRAIL (tumor necrosis factor-related apoptosis inducing ligand ( TRAIL), also known as Apo2L) is a potentially important anticancer agent awaiting clinical trials. Unfortunately, however, some cancer cells exhibit resistance to Apo2L/TRAIL, which could limit the use of this potentially promising anticancer agent. Although the molecular basis of the inherent or acquired resistance to Apo2L/TRAIL remains unclear, previous studies indicate that Bax deficiency can confer resistance to Apo2L/TRAIL. Proteasome inhibition is also emerging as a promising therapeutic strategy to manage human malignancies. Here, we report that proteasome inhibitor MG132 upregulates Apo2L/TRAIL death receptor 5 expression in both Bax-proficient and -deficient HCT116 cells. MG132 effectively cooperated with Apo2L/TRAIL to induce apoptosis in both Bax-proficient and -deficient cells that was coupled with caspases-8 and -3 activation and Bid cleavage. Although both agents in combination also induced cytochrome c and Smac release from mitochondria into cytosol and activated caspase-9 in Bax-proficient cells, their effects on these events were significantly diminished in Bax-deficient cells. These results suggest that Bax is not absolutely required for death receptor 5-dependent apoptotic signals and MG132 by upregulating DR5 effectively cooperates with Apo2L/TRAIL to overcome Bax deficiency-induced resistance to Apo2L/TRAIL. Our results have important clinical implications in that the use of Apo2L/TRAIL and proteasome inhibitors in combination could prove to be a novel therapeutic strategy to manage the Apo2L/TRAIL-resistant tumors.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Sheikh, MS (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	sheikhm@mail.upstate.edu			NCI NIH HHS [CA89043, CA86945] Funding Source: Medline; NIDDK NIH HHS [DK062136] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA089043, R01CA086945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK062136] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams J, 2003, CANCER TREAT REV, V29, P3, DOI 10.1016/S0305-7372(03)00081-1; Adams J, 2000, ONCOGENE, V19, P6687, DOI 10.1038/sj.onc.1204088; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Burns TF, 2001, J BIOL CHEM, V276, P37879; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; He Q, 2003, ONCOGENE, V22, P2674, DOI 10.1038/sj.onc.1206363; He Q, 2002, ONCOGENE, V21, P6032, DOI 10.1038/sj.onc.1205897; He Q, 2002, ONCOGENE, V21, P2623, DOI 10.1038/sj.onc.1205345; Huang Y, 2001, CANCER RES, V61, P6918; Korsmeyer SJ, 1999, COLD SPRING HARB SYM, V64, P343, DOI 10.1101/sqb.1999.64.343; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lenz HJ, 2003, CANCER TREAT REV, V29, P41, DOI 10.1016/S0305-7372(03)00082-3; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nagane M, 2000, CANCER RES, V60, P847; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Nimmanapalli R, 2001, CANCER RES, V61, P759; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Singh A, 1998, J INTERF CYTOK RES, V18, P439, DOI 10.1089/jir.1998.18.439; Verhagen AM, 2002, APOPTOSIS, V7, P163, DOI 10.1023/A:1014318615955; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yamaguchi H, 2003, CANCER RES, V63, P1483; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	41	97	108	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2554	2558		10.1038/sj.onc.1207351	http://dx.doi.org/10.1038/sj.onc.1207351			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14691451				2022-12-25	WOS:000220558000013
J	Wu, L; Nicholson, W; Knobel, SM; Steffner, RJ; May, JM; Piston, DW; Powers, AC				Wu, L; Nicholson, W; Knobel, SM; Steffner, RJ; May, JM; Piston, DW; Powers, AC			Oxidative stress is a mediator of glucose toxicity in insulin-secreting pancreatic islet cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ADP-RIBOSE) POLYMERASE GENE; BETA-CELL; SUPEROXIDE-DISMUTASE; GLUCOKINASE ACTIVITY; CATALYTIC-ACTIVITY; RATS; DNA; OVEREXPRESSION; GLUTATHIONE; EXPRESSION	Pancreatic beta cells secrete insulin in response to changes in the extracellular glucose. However, prolonged exposure to elevated glucose exerts toxic effects on beta cells and results in beta cell dysfunction and ultimately beta cell death (glucose toxicity). To investigate the mechanism of how increased extracellular glucose is toxic to beta cells, we used two model systems where glucose metabolism was increased in beta cell lines by enhancing glucokinase (GK) activity and exposing cells to physiologically relevant increases in extracellular glucose (3.3 - 20 mM). Exposure of cells with enhanced GK activity to 20 mM glucose accelerated glycolysis, but reduced cellular NAD(P) H and ATP, caused accumulation of intracellular reactive oxygen species (ROS) and oxidative damage to mitochondria and DNA, and promoted apoptotic cell death. These changes required both enhanced GK activity and exposure to elevated extracellular glucose. A ROS scavenger partially prevented the toxic effects of increased glucose metabolism. These results indicate that increased glucose metabolism in beta cells generates oxidative stress and impairs cell function and survival; this may be a mechanism of glucose toxicity in beta cells. The level of beta cell GK may also be critical in this process.	Vanderbilt Univ, Med Ctr, Dept Med, Div Endocrinol Diabet & Metab, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Powers, AC (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Endocrinol Diabet & Metab, 715 PRB,2220 Pierce Ave, Nashville, TN 37232 USA.	al.powers@vanderbilt.edu			NIDDK NIH HHS [DK 64339, DK 20593, DK 55233, DK 50435] Funding Source: Medline; NIEHS NIH HHS [P30 ES 00267] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050435, R01DK055233, P60DK020593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; Bennett BD, 1996, J BIOL CHEM, V271, P3647; Berman HK, 1998, BIOCHEMISTRY-US, V37, P4543, DOI 10.1021/bi9726133; Brissova M, 2002, J BIOL CHEM, V277, P11225, DOI 10.1074/jbc.M111272200; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Burkart V, 1999, NAT MED, V5, P314, DOI 10.1038/6535; Cardinal JW, 2001, MOL CELL BIOL, V21, P5605, DOI 10.1128/MCB.21.16.5605-5613.2001; CHEN C, 1994, DIABETES, V43, P684, DOI 10.2337/diabetes.43.5.684; CHEN C, 1994, J CLIN INVEST, V94, P1616, DOI 10.1172/JCI117503; Cockburn BN, 1997, DIABETES, V46, P1434, DOI 10.2337/diabetes.46.9.1434; DeFronzo RA, 1997, DIABETES REV, V5, P177; DYPBUKT JM, 1994, J BIOL CHEM, V269, P30553; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Evans JL, 2003, DIABETES, V52, P1, DOI 10.2337/diabetes.52.1.1; HELLER B, 1995, J BIOL CHEM, V270, P11176, DOI 10.1074/jbc.270.19.11176; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Ihara Y, 1999, DIABETES, V48, P927, DOI 10.2337/diabetes.48.4.927; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; Kooptiwut S, 2002, ENDOCRINOLOGY, V143, P2085, DOI 10.1210/en.143.6.2085; Lenzen S, 1996, FREE RADICAL BIO MED, V20, P463, DOI 10.1016/0891-5849(96)02051-5; Levy H R, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P97; LIANG Y, 1990, J BIOL CHEM, V265, P16863; LIANG Y, 1994, J CLIN INVEST, V93, P2473, DOI 10.1172/JCI117256; Liu YQ, 2000, AM J PHYSIOL-ENDOC M, V279, pE68, DOI 10.1152/ajpendo.2000.279.1.E68; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; May JM, 2001, BIOCHEM PHARMACOL, V62, P873, DOI 10.1016/S0006-2952(01)00736-5; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MILBURN JL, 1995, J BIOL CHEM, V270, P1295, DOI 10.1074/jbc.270.3.1295; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; OPENSHAW P, 1995, J EXP MED, V182, P1357, DOI 10.1084/jem.182.5.1357; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; Robertson RP, 2003, DIABETES, V52, P581, DOI 10.2337/diabetes.52.3.581; Rong YQ, 1999, P NATL ACAD SCI USA, V96, P9897, DOI 10.1073/pnas.96.17.9897; Rosen P, 2001, DIABETES-METAB RES, V17, P189, DOI 10.1002/dmrr.196; ROSSETTI L, 1990, DIABETES CARE, V13, P610, DOI 10.2337/diacare.13.6.610; Sakuraba H, 2002, DIABETOLOGIA, V45, P85, DOI 10.1007/s125-002-8248-z; SESTILI P, 1990, J CANCER RES CLIN, V116, P615, DOI 10.1007/BF01637083; Sreenan SK, 1998, DIABETES, V47, P1881, DOI 10.2337/diabetes.47.12.1881; Such L, 1999, CYTOMETRY, V37, P140, DOI 10.1002/(SICI)1097-0320(19991001)37:2<140::AID-CYTO7>3.0.CO;2-7; TAKASU N, 1991, J BIOL CHEM, V266, P2112; Tanaka Y, 1999, P NATL ACAD SCI USA, V96, P10857, DOI 10.1073/pnas.96.19.10857; Tanaka Y, 2002, P NATL ACAD SCI USA, V99, P12363, DOI 10.1073/pnas.192445199; Tiedge M, 1997, DIABETES, V46, P1733, DOI 10.2337/diabetes.46.11.1733; VANGINKEL G, 1994, METHOD ENZYMOL, V233, P273; Wang HY, 1997, J BIOL CHEM, V272, P25731, DOI 10.1074/jbc.272.41.25731; Wang HY, 1997, P NATL ACAD SCI USA, V94, P4372, DOI 10.1073/pnas.94.9.4372; WEST DC, 1985, ANAL BIOCHEM, V147, P289, DOI 10.1016/0003-2697(85)90274-X; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; Wu L, 1998, ENDOCRINOLOGY, V139, P4205, DOI 10.1210/en.139.10.4205; YIN L, 1992, DIABETES, V41, P792; YU BP, 1994, PHYSIOL REV, V74, P139, DOI 10.1152/physrev.1994.74.1.139	53	86	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12126	12134		10.1074/jbc.M307097200	http://dx.doi.org/10.1074/jbc.M307097200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14688272	hybrid			2022-12-25	WOS:000220334900018
J	Gouffi, K; Gerard, F; Santini, CL; Wu, LF				Gouffi, K; Gerard, F; Santini, CL; Wu, LF			Dual topology of the Escherichia coli TatA protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEC-INDEPENDENT PROTEIN; TWIN-ARGININE TRANSLOCASE; SIGNAL PEPTIDE; MEMBRANE PROTEINS; TRANSPORT SYSTEM; EXPORT PATHWAY; COMPONENTS; BINDING; GENES; IDENTIFICATION	The Escherichia coli Tat system has unusual capacity of translocating folded proteins across the cytoplasmic membrane. The TatA protein is the most abundant known Tat component and consists of a transmembrane segment followed by an amphipathic helix and a hydrophilic C terminus. To study the operation mechanism of the Tat apparatus, we analyzed the topology of TatA. Intriguingly, alkaline phosphatase (PhoA)-positive fusions were obtained at positions Gly-38, Lys-40, Asp-51, and Thr-53, which are all located at the cytoplasmic C terminus of the TatA protein. Interestingly, replacing phoA with uidAat Thr-53 led to positive beta-glucuronidase fusion, implying cytoplasmic location of the TatA C terminus. To further determine cellular localization of the TatA C terminus, we deleted the phoA gene and left 46 exogenous residues, including the tobacco etch virus (Tev) protease cleavage site (Tcs) after Thr-53, yielding TatA(T53)::Tcs. Unlike the PhoA and UidA fusions, which abolished the TatA function, the TatA(T53)::Tcs construct was able to restore the growth of tatA mutants on the minimal trimethlyamine N-oxide media. In vitro and in vivo proteolysis assay showed that the Tcs site of TatA(T53):: Tcs was accessible from both the periplasm and cytoplasm, indicating a dual topology of the TatA C terminus. Importantly, growth conditions seemed to influence the protein level of TatA and the cytoplasmic accessibility of the Tcs site of TatA(T53):: Tcs. A function-linked change of the TatA topology is suggested, and its implication in protein transport is discussed.	Inst Biol Struct & Microbiol, CNRS, UPR 9043, Chim Bacterienne Lab, F-13402 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS)	Wu, LF (corresponding author), Inst Biol Struct & Microbiol, CNRS, UPR 9043, Chim Bacterienne Lab, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	wu@ibsm.cnrs-mrs.fr						Alami M, 2003, MOL CELL, V12, P937, DOI 10.1016/S1097-2765(03)00398-8; Alami M, 2002, J BIOL CHEM, V277, P20499, DOI 10.1074/jbc.M201711200; Allen SCH, 2002, J BIOL CHEM, V277, P10362, DOI 10.1074/jbc.M109135200; Barrett CML, 2003, FEBS LETT, V537, P42, DOI 10.1016/S0014-5793(03)00068-1; Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; Bolhuis A, 2001, J BIOL CHEM, V276, P20213, DOI 10.1074/jbc.M100682200; Bordi C, 2003, MOL MICROBIOL, V48, P211, DOI 10.1046/j.1365-2958.2003.03428.x; Chanal A, 1998, MOL MICROBIOL, V30, P674, DOI 10.1046/j.1365-2958.1998.01095.x; Cline K, 2001, J CELL BIOL, V154, P719, DOI 10.1083/jcb.200105149; Dalbey RE, 1999, TRENDS BIOCHEM SCI, V24, P17, DOI 10.1016/S0968-0004(98)01333-4; Danese PN, 1998, ANNU REV GENET, V32, P59, DOI 10.1146/annurev.genet.32.1.59; de Leeuw E, 2002, J MOL BIOL, V322, P1135, DOI 10.1016/S0022-2836(02)00820-3; De Leeuw E, 2001, FEBS LETT, V506, P143, DOI 10.1016/S0014-5793(01)02904-0; Drew D, 2002, P NATL ACAD SCI USA, V99, P2690, DOI 10.1073/pnas.052018199; Driessen AJM, 2001, NAT STRUCT BIOL, V8, P492, DOI 10.1038/88549; Ehrmann M, 1997, P NATL ACAD SCI USA, V94, P13111, DOI 10.1073/pnas.94.24.13111; Gouffi K, 2002, FEBS LETT, V525, P65, DOI 10.1016/S0014-5793(02)03069-7; Hicks MG, 2003, FEBS LETT, V539, P61, DOI 10.1016/S0014-5793(03)00198-4; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; INGLEDEW WJ, 1984, MICROBIOL REV, V48, P222, DOI 10.1128/MMBR.48.3.222-271.1984; Jack RL, 2001, J BACTERIOL, V183, P1801, DOI 10.1128/JB.183.5.1801-1804.2001; Lee PA, 2002, J BACTERIOL, V184, P5871, DOI 10.1128/JB.184.21.5871-5879.2002; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; Miller J. H., 1972, EXPT MOL GENETICS, P431; Mori H, 2002, J CELL BIOL, V157, P205, DOI 10.1083/jcb.200202048; Mori H, 2001, BBA-MOL CELL RES, V1541, P80, DOI 10.1016/S0167-4889(01)00150-1; Mori H, 1999, J CELL BIOL, V146, P45, DOI 10.1083/jcb.146.1.45; Mori H, 2001, TRENDS MICROBIOL, V9, P494, DOI 10.1016/S0966-842X(01)02174-6; Mori H, 2001, FEBS LETT, V501, P65, DOI 10.1016/S0014-5793(01)02626-6; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; Porcelli I, 2002, BIOCHEMISTRY-US, V41, P13690, DOI 10.1021/bi026142i; Rodrigue A, 1999, J BIOL CHEM, V274, P13223, DOI 10.1074/jbc.274.19.13223; Sargent F, 2001, EUR J BIOCHEM, V268, P3361, DOI 10.1046/j.1432-1327.2001.02263.x; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Sargent F, 1999, J BIOL CHEM, V274, P36073, DOI 10.1074/jbc.274.51.36073; Settles AM, 1997, SCIENCE, V278, P1467, DOI 10.1126/science.278.5342.1467; SIMON G, 1995, MOL MICROBIOL, V17, P971, DOI 10.1111/j.1365-2958.1995.mmi_17050971.x; Slatin SL, 2002, P NATL ACAD SCI USA, V99, P1286, DOI 10.1073/pnas.022480199; SLATIN SL, 1994, NATURE, V371, P158, DOI 10.1038/371158a0; Stanley NR, 2002, MOL MICROBIOL, V43, P1005, DOI 10.1046/j.1365-2958.2002.02797.x; Tian HP, 2002, J BACTERIOL, V184, P111, DOI 10.1128/JB.184.1.111-118.2002; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; Wexler M, 2000, J BIOL CHEM, V275, P16717, DOI 10.1074/jbc.M000800200; Wu LF, 2000, J MOL MICROB BIOTECH, V2, P179; Yahr TL, 2001, EMBO J, V20, P2472, DOI 10.1093/emboj/20.10.2472	48	58	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11608	11615		10.1074/jbc.M313187200	http://dx.doi.org/10.1074/jbc.M313187200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701831	hybrid			2022-12-25	WOS:000220157600094
J	He, G; George, A				He, G; George, A			Dentin matrix protein 1 immobilized on type I collagen fibrils facilitates apatite deposition in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-FORCE MICROSCOPY; BONE SIALOPROTEIN; HYDROXYAPATITE FORMATION; BINDING-PROPERTIES; X-RAY; PHOSPHOPHORYN; EXPRESSION; INVITRO; FIBRILLOGENESIS; MINERALIZATION	During bone and dentin mineralization, the crystal nucleation and growth processes are considered to be matrix regulated. Osteoblasts and odontoblasts synthesize a polymeric collagenous matrix, which forms a template for apatite initiation and elongation. Coordinated and controlled reaction between type I collagen and bone/dentin-specific noncollagenous proteins are necessary for well defined biogenic crystal formation. However, the process by which collagen surfaces become mineralized is not understood. Dentin matrix protein 1 (DMP1) is an acidic noncollagenous protein expressed during the initial stages of mineralized matrix formation in bone and dentin. Here we show that DMP1 bound specifically to type I collagen, with the binding region located at the N-telopeptide region of type I collagen. Peptide mapping identified two acidic clusters in DMP1 responsible for interacting with type I collagen. The collagen binding property of these domains was further confirmed by site-directed mutagenesis. Transmission electron microscopy analyses have localized DMP1 in the gap region of the collagen fibrils. Fibrillogenesis assays further demonstrated that DMP1 accelerated the assembly of the collagen fibrils in vitro and also increased the diameter of the reconstituted collagen fibrils. In vitro mineralization studies in the presence of calcium and phosphate ions demonstrated apatite deposition only at the collagen-bound DMP1 sites. Thus specific binding of DMP1 and possibly other noncollagenous proteins on the collagen fibril might be a key step in collagen matrix organization and mineralization.	Univ Illinois, Dept Oral Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	George, A (corresponding author), Univ Illinois, Dept Oral Biol, M-C 690, Chicago, IL 60612 USA.	anneg@uic.edu		GEORGE, ANNE/0000-0002-9008-7642	NIDCR NIH HHS [DE13836, DE 11657] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE011657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R56DE011657, R01DE013836] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Agarwal G, 2002, BIOCHEMISTRY-US, V41, P11091, DOI 10.1021/bi020087w; BERTHETCOLOMINAS C, 1979, J MOL BIOL, V134, P431, DOI 10.1016/0022-2836(79)90362-0; Boskey AL, 1996, CONNECT TISSUE RES, V35, P357, DOI 10.3109/03008209609029212; Bradt JH, 1999, CHEM MATER, V11, P2694, DOI 10.1021/cm991002p; BUTLER WT, 1995, INT J DEV BIOL, V39, P169; Camacho NP, 1999, BONE, V25, P287, DOI 10.1016/S8756-3282(99)00165-9; CHEN Y, 1992, J BIOL CHEM, V267, P24871; CLARKSON BH, 1993, ARCH ORAL BIOL, V38, P737, DOI 10.1016/0003-9969(93)90068-W; COCKINGJOHNSON D, 1983, BIOCHIM BIOPHYS ACTA, V742, P49, DOI 10.1016/0167-4838(83)90357-6; Dahl T, 1998, J STRUCT BIOL, V123, P162, DOI 10.1006/jsbi.1998.4025; Dahl T, 2003, CONNECT TISSUE RES, V44, P206, DOI 10.1080/03008200390181672; Dickeson SK, 1999, J BIOL CHEM, V274, P32182, DOI 10.1074/jbc.274.45.32182; FUJISAWA R, 1995, CALCIFIED TISSUE INT, V56, P140, DOI 10.1007/BF00296346; FUJISAWA R, 1992, CALCIFIED TISSUE INT, V51, P438; GEHRONROBEY P, 1996, PRINCIPLES BONE BIOL, P155; George A, 1999, P INDIAN AS-CHEM SCI, V111, P121; George A, 1995, Connect Tissue Res, V33, P67, DOI 10.3109/03008209509016984; GEORGE A, 1993, J BIOL CHEM, V268, P12624; GEORGE A, 1991, BIOCHEMISTRY-US, V30, P2372, DOI 10.1021/bi00223a011; He G, 2003, NAT MATER, V2, P552, DOI 10.1038/nmat945; He G, 2003, CONNECT TISSUE RES, V44, P240, DOI 10.1080/03008200390181726; Hoshi K, 2001, J ELECTRON MICROSC, V50, P33, DOI 10.1093/jmicro/50.1.33; Hunter GK, 1996, BIOCHEM J, V317, P59, DOI 10.1042/bj3170059; Hunter GK, 2001, J BIOMED MATER RES, V55, P496, DOI 10.1002/1097-4636(20010615)55:4<496::AID-JBM1042>3.0.CO;2-2; Jager I, 2000, BIOPHYS J, V79, P1737, DOI 10.1016/S0006-3495(00)76426-5; Kamiya N, 2001, HISTOCHEM J, V33, P545, DOI 10.1023/A:1014955925339; MACBEATH JRE, 1993, J BIOL CHEM, V268, P19826; Mizuno M, 2001, J BIOCHEM-TOKYO, V129, P133, DOI 10.1093/oxfordjournals.jbchem.a002824; NA GC, 1986, J BIOL CHEM, V261, P2290; Neame PJ, 2000, CELL MOL LIFE SCI, V57, P859, DOI 10.1007/s000180050048; Orgel JPRO, 2001, STRUCTURE, V9, P1061, DOI 10.1016/S0969-2126(01)00669-4; Paige MF, 1998, BIOPHYS J, V74, P3211, DOI 10.1016/S0006-3495(98)78027-0; PAYNE KJ, 1986, BIOPOLYMERS, V25, P1185, DOI 10.1002/bip.360250703; PAYNE KJ, 1988, BIOPOLYMERS, V27, P1749, DOI 10.1002/bip.360271105; Qin CL, 2001, EUR J ORAL SCI, V109, P133, DOI 10.1034/j.1600-0722.2001.00001.x; Saito T, 1997, BONE, V21, P305, DOI 10.1016/S8756-3282(97)00149-X; SANDBERG M, 1988, DEV BIOL, V130, P324, DOI 10.1016/0012-1606(88)90438-1; SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776; SCHONHERR E, 1995, J BIOL CHEM, V270, P8877, DOI 10.1074/jbc.270.15.8877; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; Sreenath T, 2003, J BIOL CHEM, V278, P24874, DOI 10.1074/jbc.M303908200; Srinivasan R, 1999, CONNECT TISSUE RES, V40, P251, DOI 10.3109/03008209909000703; STETLERSTEVENSON WG, 1987, CALCIFIED TISSUE INT, V40, P97, DOI 10.1007/BF02555712; TRAUB W, 1992, MATRIX, V12, P251, DOI 10.1016/S0934-8832(11)80076-4; TRAUB W, 1992, MATRIX, V12, P197, DOI 10.1016/S0934-8832(11)80062-4; TRAUB W, 1989, P NATL ACAD SCI USA, V86, P9822, DOI 10.1073/pnas.86.24.9822; Veis A., 1994, EXTRACELLULAR MATRIX, P15, DOI DOI 10.1016/B978-0-12-775170-2.50007-X; Wallwork ML, 2002, CALCIFIED TISSUE INT, V71, P249, DOI 10.1007/s00223-001-1011-4; Weiner S, 1998, ANNU REV MATER SCI, V28, P271, DOI 10.1146/annurev.matsci.28.1.271; WHITE SW, 1977, NATURE, V266, P421, DOI 10.1038/266421a0; Xiao SX, 2001, NAT GENET, V27, P201, DOI 10.1038/84848	51	170	185	1	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11649	11656		10.1074/jbc.M309296200	http://dx.doi.org/10.1074/jbc.M309296200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699165	hybrid			2022-12-25	WOS:000220157600099
J	Koedding, J; Howard, P; Kaufmann, L; Polzer, P; Lustig, A; Welte, W				Koedding, J; Howard, P; Kaufmann, L; Polzer, P; Lustig, A; Welte, W			Dimerization of TonB is not essential for its binding to the outer membrane siderophore receptor FhuA of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRICHROME-IRON RECEPTOR; C-TERMINAL DOMAIN; IN-VIVO EVIDENCE; CRYSTAL-STRUCTURE; EVOLUTIONARY RELATIONSHIP; NUCLEOTIDE-SEQUENCE; PERIPLASMIC DOMAIN; PROTEIN; TRANSPORT; FEPA	FhuA belongs to a family of specific siderophore transport systems located in the outer membrane of Escherichia coli. The energy required for the transport process is provided by the proton motive force of the cytoplasmic membrane and is transmitted to FhuA by the protein TonB. Although the structure of full-length TonB is not known, the structure of the last 77 residues of a fragment composed of the 86 C-terminal amino acids was recently solved and shows an intertwined dimer (Chang, C., Mooser, A., Pluckthun, A., and Wlodawer, A. (2001) J. Biol. Chem. 276, 27535-27540). We analyzed the ability of truncated C-terminal TonB fragments of different lengths ( 77, 86, 96, 106, 116, and 126 amino acid residues, respectively) to bind to the receptor FhuA. Only the shortest TonB fragment, TonB-77, could not effectively interact with FhuA. We have also observed that the fragments TonB-77 and TonB-86 form homodimers in solution, whereas the longer fragments remain monomeric. TonB fragments that bind to FhuA in vitro also inhibit ferrichrome uptake via FhuA in vivo and protect cells against attack by bacteriophage Phi80.	Univ Konstanz, Fak Biol, D-78457 Constance, Germany; Univ Saskatchewan, Dept Microbiol & Immunol, Saskatoon, SK S7N 5E5, Canada; Biozentrum Basel, CH-4056 Basel, Switzerland	University of Konstanz; University of Saskatchewan	Welte, W (corresponding author), Univ Konstanz, Fak Biol, Univ Str 10, D-78457 Constance, Germany.	wolfram.welte@uni-konstanz.de						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bonhivers M, 2001, BIOCHEMISTRY-US, V40, P2606, DOI 10.1021/bi001725i; BRADBEER C, 1993, J BACTERIOL, V175, P3146, DOI 10.1128/JB.175.10.3146-3150.1993; Braun M, 1999, MOL MICROBIOL, V33, P1037, DOI 10.1046/j.1365-2958.1999.01546.x; BRAUN V, 1993, MOL MICROBIOL, V8, P261, DOI 10.1111/j.1365-2958.1993.tb01570.x; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; Cadieux N, 1999, P NATL ACAD SCI USA, V96, P10673, DOI 10.1073/pnas.96.19.10673; Chang CS, 2001, J BIOL CHEM, V276, P27535, DOI 10.1074/jbc.M102778200; Chimento DP, 2003, NAT STRUCT BIOL, V10, P394, DOI 10.1038/nsb914; COULTON JW, 1986, J BACTERIOL, V165, P181, DOI 10.1128/jb.165.1.181-192.1986; Edelstein S J, 1973, Methods Enzymol, V27, P82; EVANS JS, 1986, FEBS LETT, V208, P211, DOI 10.1016/0014-5793(86)81020-1; Ferguson AD, 1998, PROTEIN SCI, V7, P1636, DOI 10.1002/pro.5560070719; Ferguson AD, 2002, BBA-BIOMEMBRANES, V1565, P318, DOI 10.1016/S0005-2736(02)00578-3; Ferguson AD, 2002, SCIENCE, V295, P1715, DOI 10.1126/science.1067313; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Ferguson AD, 2001, STRUCTURE, V9, P707, DOI 10.1016/S0969-2126(01)00631-1; Ferguson AD, 2000, PROTEIN SCI, V9, P956, DOI 10.1110/ps.9.5.956; GUNTER K, 1990, FEBS LETT, V274, P85, DOI 10.1016/0014-5793(90)81335-L; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HANTKE K, 1978, J BACTERIOL, V135, P190, DOI 10.1128/JB.135.1.190-197.1978; HELLER K, 1985, J BACTERIOL, V161, P904, DOI 10.1128/JB.161.3.904-908.1985; Howard SP, 2001, J BACTERIOL, V183, P5885, DOI 10.1128/JB.183.20.5885-5895.2001; INGHAM C, 1990, J BACTERIOL, V172, P3577, DOI 10.1128/jb.172.7.3577-3583.1990; JENSEN KF, 1993, J BACTERIOL, V175, P3401, DOI 10.1128/jb.175.11.3401-3407.1993; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Killmann H, 2002, MICROBIOL-SGM, V148, P3497, DOI 10.1099/00221287-148-11-3497; Killmann H, 2001, J BACTERIOL, V183, P3476, DOI 10.1128/JB.183.11.3476-3487.2001; LARSEN RA, 1994, MOL MICROBIOL, V12, P857; Larsen RA, 1997, J BACTERIOL, V179, P3213, DOI 10.1128/jb.179.10.3213-3221.1997; Larsen RA, 1999, MOL MICROBIOL, V31, P1809, DOI 10.1046/j.1365-2958.1999.01317.x; Larsen RA, 2001, J BIOL CHEM, V276, P8111, DOI 10.1074/jbc.M007479200; Lebowitz J, 2002, PROTEIN SCI, V11, P2067, DOI 10.1110/ps.0207702; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; Lubkowski J, 1999, STRUCTURE, V7, P711, DOI 10.1016/S0969-2126(99)80092-6; LUNDRIGAN MD, 1986, J BIOL CHEM, V261, P797; MOECK GS, 1994, J BACTERIOL, V176, P4250, DOI 10.1128/jb.176.14.4250-4259.1994; Moeck GS, 2001, J BACTERIOL, V183, P2755, DOI 10.1128/JB.183.9.2755-2764.2001; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; POSTLE K, 1988, J BIOL CHEM, V263, P11000; Postle K, 2003, MOL MICROBIOL, V49, P869, DOI 10.1046/j.1365-2958.2003.03629.x; POSTLE K, 1993, J BIOENERG BIOMEMBR, V25, P591; PRESSLER U, 1988, J BACTERIOL, V170, P2716, DOI 10.1128/jb.170.6.2716-2724.1988; Sauter A, 2003, J BACTERIOL, V185, P5747, DOI 10.1128/JB.185.19.5747-5754.2003; Scott DC, 2001, J BIOL CHEM, V276, P13025, DOI 10.1074/jbc.M011282200; Usher KC, 2001, P NATL ACAD SCI USA, V98, P10676, DOI 10.1073/pnas.181353398; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vakharia HL, 2002, J BACTERIOL, V184, P5508, DOI 10.1128/JB.184.19.5508-5512.2002; Witty M, 2002, EMBO J, V21, P4207, DOI 10.1093/emboj/cdf417	51	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9978	9986		10.1074/jbc.M311720200	http://dx.doi.org/10.1074/jbc.M311720200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14665631	hybrid			2022-12-25	WOS:000220050400041
J	Lee, HK; Dunzendorfer, S; Tobias, PS				Lee, HK; Dunzendorfer, S; Tobias, PS			Cytoplasmic domain-mediated dimerizations of toll-like receptor 4 observed by beta-lactamase enzyme fragment complementation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; TOLL-LIKE RECEPTOR-4; ADAPTER PROTEIN; CUTTING EDGE; RECOGNITION; ACTIVATION; DECTIN-1; FAMILY; MYD88; TLR1	Toll-like receptors (TLRs) detect the presence of microbial challenge and initiate innate immune defensive responses. In this work we have explored the mechanism and role of TLR dimerization in signal transduction using the newly developed technique of beta-lactamase protein fragment complementation, among others. We observed that TLR4 interactions with itself, with MyD88, or with TLR2 were accurately reported by the enzyme complementation technique. That technique, as well as co-immunoprecipitation, transfection-initiated cell activation, and site-directed mutagenesis all suggest an important role for TLR intracellular domains in receptor dimerization. These findings broaden our understanding of TLR self-interactions as well as heterodimer formation.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Tobias, PS (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd,IMM-12, La Jolla, CA 92037 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL023584] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL23584] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akira S, 2003, IMMUNOL LETT, V85, P85, DOI 10.1016/S0165-2478(02)00228-6; Akira S, 2003, BIOCHEM SOC T, V31, P637, DOI 10.1042/BST0310637; Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Correia JD, 2002, J BIOL CHEM, V277, P1845, DOI 10.1074/jbc.M109910200; DUNNE A, 2003, SCI STKE; Galarneau A, 2002, NAT BIOTECHNOL, V20, P619, DOI 10.1038/nbt0602-619; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Hajjar AM, 2001, J IMMUNOL, V166, P15, DOI 10.4049/jimmunol.166.1.15; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Lee HK, 2002, J IMMUNOL, V168, P4012, DOI 10.4049/jimmunol.168.8.4012; Matsuguchi T, 2003, EMBO J, V22, P4455, DOI 10.1093/emboj/cdg438; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Michnick SW, 2000, METHOD ENZYMOL, V328, P208, DOI 10.1016/S0076-6879(00)28399-7; Muhlradt PF, 1997, J EXP MED, V185, P1951, DOI 10.1084/jem.185.11.1951; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Re F, 2002, J BIOL CHEM, V277, P23427, DOI 10.1074/jbc.M202554200; Tapping RI, 2003, J ENDOTOXIN RES, V9, P264, DOI 10.1179/096805103225001477; Wehrman T, 2002, P NATL ACAD SCI USA, V99, P3469, DOI 10.1073/pnas.062043699; Xu YW, 2000, NATURE, V408, P111, DOI 10.1038/35040600; Zhang HF, 2002, FEBS LETT, V532, P171, DOI 10.1016/S0014-5793(02)03669-4	22	49	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10564	10574		10.1074/jbc.M311564200	http://dx.doi.org/10.1074/jbc.M311564200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699116	hybrid			2022-12-25	WOS:000220050400110
J	Wang, FS; Wang, CJ; Chen, YJ; Chang, PR; Huang, YT; Sun, YC; Huang, HC; Yang, YJ; Yang, KD				Wang, FS; Wang, CJ; Chen, YJ; Chang, PR; Huang, YT; Sun, YC; Huang, HC; Yang, YJ; Yang, KD			Ras induction of superoxide activates ERK-dependent angiogenic transcription factor HIF-1 alpha and VEGF-A expression in shock wave-stimulated osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; BONE MORPHOGENETIC PROTEINS; GENE-EXPRESSION; FACTOR 1-ALPHA; IN-VITRO; PATHWAY; CELLS; HYPERPOLARIZATION; DIFFERENTIATION	Vascular endothelial growth factor (VEGF) released by osteoblasts plays an important role in angiogenesis and endochondral ossification during bone formation. In animal studies, we have reported that shock waves (SW) can promote osteogenic differentiation of mesenchymal stem cells through superoxide-mediated signal transduction (Wang, F. S., Wang, C. J., Sheen-Chen, S. M., Kuo, Y. R., Chen, R. F., and Yang, K. D. (2002) J. Biol. Chem. 277, 10931-10937) and vascularization of the bone-tendon junction. Here, we found that SW elevation of VEGF-A expression in human osteoblasts to be mediated by Ras-induced superoxide and ERK-dependent HIF-1alpha activation. SW treatment (0.16 mJ/mm(2), 1 Hz, 500 impulses) rapidly activated Ras protein (15 min) and Rac1 protein ( 30 min) and increased superoxide production in 30 min and VEGF mRNA expression in 6 h. Early scavenging of superoxide, but not nitric oxide, peroxide hydrogen, or prostaglandin E-2, reduced SW-augmented VEGF-A levels. Inhibition of superoxide production by diphenyliodonium, an NADPH oxidase inhibitor, was found to suppress VEGF-A expression. Transfection of osteoblasts with a dominant negative (S17N) Ras mutant abrogated the SW enhancement of Rac1 activation, superoxide synthesis, and VEGF expression. Further studies demonstrated that SW significantly promoted ERK activation in 1 h and HIF-1alpha phosphorylation and HIF-1alpha binding to VEGF promoter in 3 h. In support of the observation that superoxide mediated the SW-induced ERK activation and HIF-1alpha transactivation, we further demonstrated that scavenging of superoxide by superoxide dismutase and inhibition of ERK activity by PD98059 decreased HIF-1alpha activation and VEGF-A levels. Moreover, culture medium harvested from SW-treated osteoblasts increased vessel number of chick chorioallantoic membrane. Superoxide dismutase pretreatment and anti-VEGF-A antibody neutralization reduced the promoting effect of conditioned medium on angiogenesis. Thus, modulation of redox reaction by SW may have some positive effect on angiogenesis during bone regeneration.	Chang Gung Mem Hosp, Dept Med Res, Kaohsiung 833, Taiwan; Chang Gung Mem Hosp, Dept Orthoped Surg, Kaohsiung, Taiwan; Chang Gung Univ, Dept Orthoped Surg, Linkou 244, Taiwan; Fooyin Univ, Kaohsiung, Taiwan	Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University; Fooyin University	Yang, KD (corresponding author), Chang Gung Mem Hosp, Dept Med Res, 123 Ta Pei Rd, Kaohsiung 833, Taiwan.	wangfs@ms33.hinet.net						ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; AROSON J, 1997, J ORTHOP RES, V15, P221; Azuma Y, 2001, J BONE MINER RES, V16, P671, DOI 10.1359/jbmr.2001.16.4.671; Bellahcene A, 2000, CIRC RES, V86, P885, DOI 10.1161/01.RES.86.8.885; Burger EH, 1999, FASEB J, V13, pS101, DOI 10.1096/fasebj.13.9001.s101; Chua CC, 2000, BBA-MOL CELL RES, V1497, P69, DOI 10.1016/S0167-4889(00)00040-9; Deckers MML, 2002, ENDOCRINOLOGY, V143, P1545, DOI 10.1210/en.143.4.1545; Deckers MML, 2000, ENDOCRINOLOGY, V141, P1667, DOI 10.1210/en.141.5.1667; Durot I, 2000, FREE RADICAL BIO MED, V29, P846, DOI 10.1016/S0891-5849(00)00382-8; Duyndam MCA, 2001, J BIOL CHEM, V276, P48066, DOI 10.1074/jbc.M106282200; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Ferguson C, 1999, MECH DEVELOP, V87, P57, DOI 10.1016/S0925-4773(99)00142-2; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Gao N, 2002, J BIOL CHEM, V277, P31963, DOI 10.1074/jbc.M200082200; Goad DL, 1996, ENDOCRINOLOGY, V137, P2262, DOI 10.1210/en.137.6.2262; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Hatton JP, 2003, J BONE MINER RES, V18, P58, DOI 10.1359/jbmr.2003.18.1.58; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962; KUROKI M, 1998, J CLIN INVEST, V10, P248; Liu XH, 2002, J BIOL CHEM, V277, P50081, DOI 10.1074/jbc.M201095200; Loew M, 1999, J BONE JOINT SURG BR, V81B, P863, DOI 10.1302/0301-620X.81B5.9374; Maes C, 2002, MECH DEVELOP, V111, P61, DOI 10.1016/S0925-4773(01)00601-3; MAIER M, 2003, CLIN ORTHOP RELAT R, V406, P237; Mayr-Wohlfart U, 2002, BONE, V30, P472, DOI 10.1016/S8756-3282(01)00690-1; Meadows KN, 2001, J BIOL CHEM, V276, P49289, DOI 10.1074/jbc.M108069200; Mottet D, 1994, J CELL PHYSL, V194, P30; Page EL, 2002, J BIOL CHEM, V277, P48403, DOI 10.1074/jbc.M209114200; Rivilis I, 2002, AM J PHYSIOL-HEART C, V283, pH1430, DOI 10.1152/ajpheart.00082.2002; Rompe JD, 2001, CLIN ORTHOP RELAT R, P102, DOI 10.1097/00003086-200106000-00014; Salter DM, 2000, J BONE MINER RES, V15, P1746, DOI 10.1359/jbmr.2000.15.9.1746; Shay-Salit A, 2002, P NATL ACAD SCI USA, V99, P9462, DOI 10.1073/pnas.142224299; Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099; Suhr D, 1996, ULTRASOUND MED BIOL, V22, P671, DOI 10.1016/0301-5629(96)00044-0; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Thannickal VJ, 2000, FASEB J, V14, P1741, DOI 10.1096/fj.99-0878com; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; Wadhwa S, 2002, J BONE MINER RES, V17, P266, DOI 10.1359/jbmr.2002.17.2.266; Wang CJ, 2003, J ORTHOP RES, V21, P984, DOI 10.1016/S0736-0266(03)00104-9; WANG CJ, 2001, CLIN ORTHOP RELAT R, V387, P95; Wang FS, 2003, BONE, V32, P387, DOI 10.1016/S8756-3282(03)00029-2; Wang FS, 2002, J BIOL CHEM, V277, P10931, DOI 10.1074/jbc.M104587200; Wang FS, 2001, BIOCHEM BIOPH RES CO, V287, P648, DOI 10.1006/bbrc.2001.5654; Yeh LH, 1999, AM J PHYSIOL-CELL PH, V276, pC838, DOI 10.1152/ajpcell.1999.276.4.C838	45	165	178	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10331	10337		10.1074/jbc.M308013200	http://dx.doi.org/10.1074/jbc.M308013200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14681237	hybrid			2022-12-25	WOS:000220050400082
J	Schneider, S; Campodonico, E; Schwer, B				Schneider, S; Campodonico, E; Schwer, B			Motifs IV and V in the DEAH box splicing factor Prp22 are important for RNA unwinding, and helicase-defective Prp22 mutants are suppressed by Prp8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; DOMINANT-NEGATIVE MUTANTS; SMALL NUCLEAR-RNA; DEPENDENT ATPASE; SACCHAROMYCES-CEREVISIAE; U5 SNRNA; MUTATIONAL ANALYSIS; PREMESSENGER RNA; IN-VITRO; NUCLEOSIDE TRIPHOSPHATASE	The yeast pre-mRNA splicing factor Prp22 is a member of the DEAH box family of nucleic acid-stimulated ATPases and RNA helicases. Here we report a mutational analysis of 16 conserved residues in motifs Ia ((534)TQPRRVAA(541)), IV ((695)LVFLTG(700)), and V ((TNI)-T-757-AETSIT(765)). Mutants T757A, I764A, and T765A were lethal, and F697A cells did not grow at less than or equal to30 degreesC. The mutant proteins failed to catalyze mRNA release from the spliceosome in vitro, and they were deficient for RNA unwinding. The F697A, I764A, and T765A proteins were active for ATP hydrolysis in the presence of RNA cofactor. The T757A mutant retained basal ATPase activity but was not stimulated by RNA, whereas ATP hydrolysis by T765A was strictly dependent on the RNA cofactor. Thus Thr-757 and Thr-765 in motif V link ATP hydrolysis to the RNA cofactor. To illuminate the mechanism of Prp22-catalyzed mRNA release, we performed a genetic screen to identify extragenic suppressors of the cold-sensitive growth defect of a helicase/release-defective Prp22 mutant. We identified one of the suppressors as a missense mutation of PRP8 (R1753K), a protein component of the U5 small nuclear ribonucleoprotein. We show that PRP8-R1753K suppressed multiple helicase-deficient prp22 mutations, including the lethal I764A mutation. Replacing Arg-1753 of Prp8 by either Lys, Ala, Gln, or Glu resulted in suppression of helicase-defective Prp22 mutants. Prp8-Arg1753 mutations by themselves caused temperature-sensitive growth defects in a PRP22 strain. These findings suggest a model whereby Prp22 disrupts an RNA/protein or RNA/RNA interaction in the spliceosome that is normally stabilized by Prp8.	Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	Cornell University	Schwer, B (corresponding author), Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, 1300 York Ave, New York, NY 10021 USA.	bschwer@med.cornell.edu			NIGMS NIH HHS [GM50288] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050288] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSARI A, 1995, EMBO J, V14, P4001, DOI 10.1002/j.1460-2075.1995.tb00071.x; Arenas JE, 1997, P NATL ACAD SCI USA, V94, P11798, DOI 10.1073/pnas.94.22.11798; Brow DA, 2002, ANNU REV GENET, V36, P333, DOI 10.1146/annurev.genet.36.043002.091635; BROWN JD, 1992, EMBO J, V11, P3721, DOI 10.1002/j.1460-2075.1992.tb05457.x; Burge CB, 1999, RNA WORLD, P525; Campodonico E, 2002, GENETICS, V160, P407; Chang TH, 1997, NUCLEIC ACIDS RES, V25, P5033, DOI 10.1093/nar/25.24.5033; Chao L, 1999, J VIROL, V73, P8798, DOI 10.1128/JVI.73.10.8798-8807.1999; Chen JYF, 2001, MOL CELL, V7, P227, DOI 10.1016/S1097-2765(01)00170-8; Collins CA, 2000, NAT STRUCT BIOL, V7, P850; Collins CA, 1999, GENE DEV, V13, P1970, DOI 10.1101/gad.13.15.1970; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6; Edwalds-Gilbert G, 2000, RNA, V6, P1106, DOI 10.1017/S1355838200992483; Fleckner J, 1997, GENE DEV, V11, P1864, DOI 10.1101/gad.11.14.1864; GARCIABLANCO MA, 1990, P NATL ACAD SCI USA, V87, P3082, DOI 10.1073/pnas.87.8.3082; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Gross CH, 1998, J VIROL, V72, P4729, DOI 10.1128/JVI.72.6.4729-4736.1998; Gross CH, 1996, J VIROL, V70, P1706, DOI 10.1128/JVI.70.3.1706-1713.1996; GROSS CH, 1995, J VIROL, V69, P4727, DOI 10.1128/JVI.69.8.4727-4736.1995; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; Heilek GM, 1997, J VIROL, V71, P6264, DOI 10.1128/JVI.71.8.6264-6266.1997; HODGES PE, 1995, YEAST, V11, P337; Jankowsky E, 2000, NUCLEIC ACIDS RES, V28, P333, DOI 10.1093/nar/28.1.333; Kim DH, 1999, RNA, V5, P959, DOI 10.1017/S135583829999012X; Kim DW, 1997, J VIROL, V71, P9400, DOI 10.1128/JVI.71.12.9400-9409.1997; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; KIM SH, 1993, P NATL ACAD SCI USA, V90, P888, DOI 10.1073/pnas.90.3.888; KIM SH, 1992, EMBO J, V11, P2319, DOI 10.1002/j.1460-2075.1992.tb05291.x; Kistler AL, 2001, GENE DEV, V15, P42, DOI 10.1101/gad.851301; Kuhn AN, 2002, P NATL ACAD SCI USA, V99, P9145, DOI 10.1073/pnas.102304299; Laggerbauer B, 1998, P NATL ACAD SCI USA, V95, P4188, DOI 10.1073/pnas.95.8.4188; Libri D, 2001, GENE DEV, V15, P36, DOI 10.1101/gad.852101; LOSSKY M, 1987, CELL, V51, P1019, DOI 10.1016/0092-8674(87)90588-5; MACMILLAN AM, 1994, GENE DEV, V8, P3008, DOI 10.1101/gad.8.24.3008; Martin A, 2002, J BIOL CHEM, V277, P17743, DOI 10.1074/jbc.M200762200; McConnell TS, 2001, EMBO J, V20, P3577, DOI 10.1093/emboj/20.13.3577; McPheeters DS, 2000, NUCLEIC ACIDS RES, V28, P1313, DOI 10.1093/nar/28.6.1313; McPheeters DS, 2003, MOL CELL BIOL, V23, P4174, DOI 10.1128/MCB.23.12.4174-4186.2003; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; Newman AJ, 1995, RNA, V1, P968; Newman AJ, 1997, EMBO J, V16, P5797, DOI 10.1093/emboj/16.19.5797; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; ODay CL, 1996, J BIOL CHEM, V271, P33261, DOI 10.1074/jbc.271.52.33261; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Raghunathan PL, 1998, CURR BIOL, V8, P847, DOI 10.1016/S0960-9822(07)00345-4; Reyes JL, 1999, RNA, V5, P167, DOI 10.1017/S1355838299981785; RUBY SW, 1993, GENE DEV, V7, P1909, DOI 10.1101/gad.7.10.1909; Schneider S, 2002, J BIOL CHEM, V277, P15452, DOI 10.1074/jbc.M112473200; Schneider S, 2001, J BIOL CHEM, V276, P21184, DOI 10.1074/jbc.M101964200; Schwer B, 1998, EMBO J, V17, P2086, DOI 10.1093/emboj/17.7.2086; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; Schwer B, 2001, NAT STRUCT BIOL, V8, P113, DOI 10.1038/84091; Schwer B, 2000, EMBO J, V19, P6582, DOI 10.1093/emboj/19.23.6582; Siatecka M, 1999, GENE DEV, V13, P1983, DOI 10.1101/gad.13.15.1983; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; Staley JP, 1999, MOL CELL, V3, P55, DOI 10.1016/S1097-2765(00)80174-4; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Stevens SW, 1999, P NATL ACAD SCI USA, V96, P7226, DOI 10.1073/pnas.96.13.7226; STRAUSS EJ, 1994, NUCLEIC ACIDS RES, V22, P3187, DOI 10.1093/nar/22.15.3187; Svitkin YV, 2001, RNA, V7, P1743; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; TEIGELKAMP S, 1995, NUCLEIC ACIDS RES, V23, P320, DOI 10.1093/nar/23.3.320; TEIGELKAMP S, 1995, EMBO J, V14, P2602, DOI 10.1002/j.1460-2075.1995.tb07258.x; Umen JG, 1996, GENETICS, V143, P723; UMEN JG, 1995, RNA, V1, P584; van Nues RW, 2001, GENETICS, V157, P1451; Wagner JDO, 1998, EMBO J, V17, P2926, DOI 10.1093/emboj/17.10.2926; Wang Y, 1998, CURR BIOL, V8, P441, DOI 10.1016/S0960-9822(98)70178-2; WHITTAKER E, 1991, NUCLEIC ACIDS RES, V19, P5483, DOI 10.1093/nar/19.20.5483; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542; Xu DM, 1996, NATURE, V381, P709, DOI 10.1038/381709a0; Zhang M, 2001, GENE DEV, V15, P30, DOI 10.1101/gad.851701	74	49	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8617	8626		10.1074/jbc.M312715200	http://dx.doi.org/10.1074/jbc.M312715200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14688266	hybrid			2022-12-25	WOS:000189265900013
J	Jang, ER; Lim, SJ; Lee, ES; Jeong, G; Kim, TY; Bang, YJ; Lee, JS				Jang, ER; Lim, SJ; Lee, ES; Jeong, G; Kim, TY; Bang, YJ; Lee, JS			The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen	ONCOGENE			English	Article						estrogen receptor alpha, beta; tamoxifen responsiveness; HDAC inhibitor; ER alpha-negative breast cancer	ER-BETA; TRANSCRIPTIONAL REPRESSION; ACTIVATION FUNCTION-2; BRCA1 INHIBITION; GENE-EXPRESSION; COACTIVATORS; ACETYLATION; MODULATION; PREVENTION; ESTRADIOL	Many cases of breast cancer show loss of estrogen receptor (ER) alpha expression, which leads to unresponsiveness to antihormonal treatment even though there is no loss of the structurally and biochemically similar ER beta. ER activity is positively and negatively regulated by transcriptional regulators such as histone deacetylase (HDAC), which is known to be a negative ER regulator. Here, we evaluated using ER beta as an alternative target for tamoxifen therapy by treating ER alpha-negative, beta-positive breast cancer cells with the HDAC inhibitor trichostatin A (TSA), and testing whether tamoxifen responsiveness increased following upregulation of ER beta. TSA enhanced the overall ER transcriptional activity in these cells, as visualized by estrogen response element-regulated reporter and the expression of progesterone receptor, a known ER target, without ER alpha restoration. Additionally, TSA induced the expression and nuclear translocation of ER beta but not alpha, suggesting that these actions leading to increase of ER transcriptional activity are mediated through ER beta rather than alpha. Furthermore, following treatment with TSA, the formerly unresponsive MDA-MB-231 and Hs578T breast cancer cells became responsive to tamoxifen. However, reduction of ER beta expression by short interfering RNA abrogated this TSA-induced sensitization effect in these cells. Together, these results show that the HDAC inhibitor TSA sensitized ER alpha-negative, antihormone-unresponsive breast cancer cells to tamoxifen treatment possibly by upregulating ER beta activity.	Natl Canc Ctr, Hosp, Goyang Si 411764, Gyeonggi Do, South Korea; Seoul Natl Univ, Coll Nat Sci, Seoul 110799, South Korea; Seoul Natl Univ, Natl Res Lab Canc Epigenet, Inst Canc Res, Coll Med, Seoul 110799, South Korea	National Cancer Center - Korea (NCC); Seoul National University (SNU); Seoul National University (SNU)	Lee, JS (corresponding author), Natl Canc Ctr, Res Inst, 809 Madu 1 Dong, Goyang Si 411764, Gyeonggi Do, South Korea.	leejs@ncc.re.kr	Kim, Tae-You/J-2750-2012; Bang, Yung Jue/J-2759-2012	Bang, Yung Jue/0000-0001-6000-4597				Acevedo ML, 2003, MOL CELL BIOL, V23, P335, DOI 10.1128/MCB.23.1.335-348.2003; An JP, 1999, P NATL ACAD SCI USA, V96, P15161, DOI 10.1073/pnas.96.26.15161; Bieche I, 2001, ONCOGENE, V20, P8109, DOI 10.1038/sj.onc.1204917; Bovenzi V, 2001, CANCER CHEMOTH PHARM, V48, P71, DOI 10.1007/s002800100294; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CARMICHAEL J, 1987, CANCER RES, V47, P936; Chang J, 2000, CLIN CANCER RES, V6, P616; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 2002, CANCER RES, V62, P141; Ghoshal K, 2002, MOL CELL BIOL, V22, P8302, DOI 10.1128/MCB.22.23.8302-8319.2002; Hager GL, 2000, J STEROID BIOCHEM, V74, P249, DOI 10.1016/S0960-0760(00)00100-X; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; HEDDEN A, 1995, ANN NY ACAD SCI, V761, P109, DOI 10.1111/j.1749-6632.1995.tb31373.x; Jensen EV, 2001, P NATL ACAD SCI USA, V98, P15197, DOI 10.1073/pnas.211556298; Jordan VC, 2001, ANN NY ACAD SCI, V949, P72; Jung DJ, 2001, J BIOL CHEM, V276, P37280, DOI 10.1074/jbc.M106860200; Kaaks R, 2002, CANCER EPIDEM BIOMAR, V11, P1531; Kawata M, 2001, ARCH HISTOL CYTOL, V64, P353, DOI 10.1679/aohc.64.353; Kim MY, 2001, EMBO J, V20, P6084, DOI 10.1093/emboj/20.21.6084; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; Levenson AS, 2002, CANCER RES, V62, P4419; Liu MM, 2002, J BIOL CHEM, V277, P24353, DOI 10.1074/jbc.M201829200; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; Mandlekar S, 2001, APOPTOSIS, V6, P469, DOI 10.1023/A:1012437607881; Matsuda KI, 2002, MOL ENDOCRINOL, V16, P2215, DOI 10.1210/me.2002-0110; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; Nilsson S, 2000, BREAST CANCER RES, V2, P360, DOI 10.1186/bcr81; Noh EJ, 2003, BIOCHEM BIOPH RES CO, V310, P267, DOI 10.1016/j.bbrc.2003.09.013; Norris JD, 2002, MOL ENDOCRINOL, V16, P459, DOI 10.1210/me.16.3.459; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Palmieri C, 2002, ENDOCR-RELAT CANCER, V9, P1, DOI 10.1677/erc.0.0090001; Park WC, 2002, TRENDS MOL MED, V8, P82, DOI 10.1016/S1471-4914(02)02282-7; Powles TJ, 2002, NAT REV CANCER, V2, P787, DOI 10.1038/nrc908; Scott GK, 2002, MOL CANCER THER, V1, P385; Shi YH, 2001, GENE DEV, V15, P1140, DOI 10.1101/gad.871201; Sun JM, 2001, J BIOL CHEM, V276, P49435, DOI 10.1074/jbc.M108364200; Weihua Z, 2002, P NATL ACAD SCI USA, V99, P13589, DOI 10.1073/pnas.162477299; Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1; Yang XW, 2001, CANCER RES, V61, P7025; Yang XW, 2000, CANCER RES, V60, P6890	42	138	147	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1724	1736		10.1038/sj.onc.1207315	http://dx.doi.org/10.1038/sj.onc.1207315			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	14676837				2022-12-25	WOS:000220029300008
J	Ohara-Imaizumi, M; Nishiwaki, C; Kikuta, T; Kumakura, K; Nakamichi, Y; Nagamatsu, S				Ohara-Imaizumi, M; Nishiwaki, C; Kikuta, T; Kumakura, K; Nakamichi, Y; Nagamatsu, S			Site of docking and fusion of insulin secretory granules in live MIN6 beta cells analyzed by TAT-conjugated anti-syntaxin 1 antibody and total internal reflection fluorescence microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; EVANESCENT-WAVE MICROSCOPY; LIPID RAFTS; CELLULAR UPTAKE; EXOCYTOSIS; MEMBRANE; PROTEIN; RELEASE; DELIVERY; IDENTIFICATION	To determine the site of insulin exocytosis in the pancreatic beta cell plasma membrane, we analyzed the interaction between the docking/fusion of green fluorescent protein-tagged insulin granules and syntaxin 1 labeled by TAT-conjugated Cy3-labeled antibody (Ab) using total internal reflection fluorescence microscopy (TIRFM). Monoclonal Ab against syntaxin 1 was labeled with Cy3 then conjugated with the protein transduction domain of HIV-1 TAT. TAT-conjugated Cy3-labeled anti-syntaxin 1 Ab was transduced rapidly into the subplasmalemmal region in live MIN6 beta cells, which enabled us to observe the spatial organization and distribution of endogenous syntaxin 1. TIRFM imaging revealed that syntaxin 1 is distributed in numerous separate clusters in the intact plasma membrane, where insulin secretory granules were docked preferentially to the sites of syntaxin 1 clusters, colocalizing with synaptosomal-associated protein of 25 kDa (SNAP-25) clusters. TIRFM imaging analysis of the motion of single insulin granules demonstrated that the fusion of insulin secretory granules stimulated by 50 mM KCl occurred exclusively at the sites of the syntaxin 1 clusters. Cholesterol depletion by methyl-beta-cyclodextrin treatment, in which the syntaxin 1 clusters were disintegrated, decreased the number of docked insulin granules, and, eventually the number of fusion events was significantly reduced. Our results indicate that 1) insulin exocytosis occurs at the site of syntaxin 1 clusters; 2) syntaxin 1 clusters are essential for the docking and fusion of insulin granules in MIN6 beta cells; and 3) the sites of syntaxin 1 clusters are distinct from flotillin-1 lipid rafts.	Kyorin Univ, Sch Med, Dept Biochem 2, Tokyo 1818611, Japan; Sophia Univ, Inst Life Sci, Chiyoda Ku, Tokyo 1028554, Japan	Kyorin University; Sophia University	Nagamatsu, S (corresponding author), Kyorin Univ, Sch Med, Dept Biochem 2, Shinkawa 6-20-2, Tokyo 1818611, Japan.	shinya@kyorin-u.ac.jp						Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Axelrod D, 2001, TRAFFIC, V2, P764, DOI 10.1034/j.1600-0854.2001.21104.x; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Bilderback TR, 1999, J BIOL CHEM, V274, P257, DOI 10.1074/jbc.274.1.257; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; Daniel S, 1999, DIABETES, V48, P1686, DOI 10.2337/diabetes.48.9.1686; DEAN PM, 1973, DIABETOLOGIA, V9, P115, DOI 10.1007/BF01230690; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; JACOBSSON G, 1994, P NATL ACAD SCI USA, V91, P12487, DOI 10.1073/pnas.91.26.12487; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; Lang T, 2002, J CELL BIOL, V158, P751, DOI 10.1083/jcb.200203088; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Lindsay MA, 2002, CURR OPIN PHARMACOL, V2, P587, DOI 10.1016/S1471-4892(02)00199-6; Nagamatsu S, 1999, J BIOL CHEM, V274, P8053, DOI 10.1074/jbc.274.12.8053; Nagamatsu S, 1996, J BIOL CHEM, V271, P1160, DOI 10.1074/jbc.271.2.1160; Niesner U, 2002, BIOCONJUGATE CHEM, V13, P729, DOI 10.1021/bc025517+; Ohara-Imaizumi M, 2002, J BIOL CHEM, V277, P3805, DOI 10.1074/jbc.C100712200; Ohara-Imaizumi M, 2002, J BIOL CHEM, V277, P50805, DOI 10.1074/jbc.M207988200; OHTANI Y, 1989, EUR J BIOCHEM, V186, P17, DOI 10.1111/j.1432-1033.1989.tb15171.x; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE145, DOI 10.1038/14097; Potocky TB, 2003, J BIOL CHEM, V278, P50188, DOI 10.1074/jbc.M308719200; REGAZZI R, 1995, EMBO J, V14, P2723, DOI 10.1002/j.1460-2075.1995.tb07273.x; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; SADOUL K, 1995, J CELL BIOL, V128, P1019, DOI 10.1083/jcb.128.6.1019; Salzer U, 2001, BLOOD, V97, P1141, DOI 10.1182/blood.V97.4.1141; Schmidt A, 1997, J CELL BIOL, V137, P445, DOI 10.1083/jcb.137.2.445; Steffen W, 2001, METH MOL B, V161, P141; Stein S, 1999, FEBS LETT, V458, P383, DOI 10.1016/S0014-5793(99)01186-2; Tsui-Pierchala BA, 2002, TRENDS NEUROSCI, V25, P412, DOI 10.1016/S0166-2236(02)02215-4; Wheeler MB, 1996, ENDOCRINOLOGY, V137, P1340, DOI 10.1210/en.137.4.1340; WOLLHEIM CB, 1996, DIABETES REV, V4, P276	35	85	91	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8403	8408		10.1074/jbc.M308954200	http://dx.doi.org/10.1074/jbc.M308954200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14676208	hybrid			2022-12-25	WOS:000189103300123
J	Zimmer, JSD; Voelker, DR; Bernlohr, DA; Murphy, RC				Zimmer, JSD; Voelker, DR; Bernlohr, DA; Murphy, RC			Stabilization of leukotriene A(4) by epithelial fatty acid-binding protein in the rat basophilic leukemia cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-GEL DIGESTION; CRYSTAL-STRUCTURE; SEQUENCE; 5-LIPOXYGENASE; PURIFICATION; B-4; IDENTIFICATION; LOCALIZATION; METABOLISM; EXPRESSION	Leukotriene A(4) ( LTA(4)) is a chemically unstable triene epoxide product of 5-lipoxygenase metabolism of arachidonic acid. Despite this chemical reactivity and its synthesis at the perinuclear membrane, LTA(4) is enzymatically converted into the cysteinyl leukotrienes and leukotriene B-4. Furthermore, LTA(4) participates in transcellular biosynthesis and is thus transferred between cells as an intact molecule. A cytosolic fatty acid-binding protein present in the rat basophilic leukemia cells was identified using mass spectrometry. This protein was determined to be the stabilizing factor present in the cell cytosol responsible for increasing the effective chemical half-life of LTA(4). Rat epithelial fatty acid-binding protein (E-FABP) was isolated using partial protein purification and immunoprecipitation. In-gel digestion with trypsin followed by peptide fingerprint analysis using matrix-assisted laser desorption ionization mass spectrometry and sequencing the major tryptic peptide obtained from liquid chromatography/mass spectrometry/mass spectrometry analysis identified E-FABP in the active fraction. Semi-quantitative Western blot analysis indicated that E-FABP in the cytosolic fraction of RBL-1 cells was present at similar to1-3 pmol/10(6) cells. E-FABP (9 muM) was tested for its ability to stabilize LTA(4), and at 37degreesC E-FABP was able to increase the half-life of LTA(4) from the previously reported half-life less than 3 s to a half-life of similar to7 min. These results present a novel function for the well studied fatty acid-binding protein as a participant in leukotriene biosynthesis that permits LTA(4) to be available for further enzymatic processing in various cellular regions.	Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Minnesota System; University of Minnesota Twin Cities	Murphy, RC (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, 1400 Jackson St, Denver, CO 80206 USA.	murphyr@njc.org			NHLBI NIH HHS [HL 25785] Funding Source: Medline; NIDDK NIH HHS [DK53189] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025785, R37HL025785] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053189] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1990, METHOD ENZYMOL, DOI 10.1016/0076-6879(90)82024-v; Bennaars-Eiden A, 2002, J BIOL CHEM, V277, P50693, DOI 10.1074/jbc.M209493200; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P3213, DOI 10.1073/pnas.76.7.3213; BROCK TG, 1994, J BIOL CHEM, V269, P22059; CARRIER DJ, 1988, PROSTAG LEUKOTR ESS, V34, P27, DOI 10.1016/0952-3278(88)90021-X; Dickinson JS, 2002, J AM SOC MASS SPECTR, V13, P1227, DOI 10.1016/S1044-0305(02)00456-7; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; Evans JF, 2002, PROSTAG OTH LIPID M, V68-9, P587, DOI 10.1016/S0090-6980(02)00057-6; FEINMARK SJ, 1986, J BIOL CHEM, V261, P6466; FITZPATRICK FA, 1982, J BIOL CHEM, V257, P4680; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; GLATZ JFC, 1983, ANAL BIOCHEM, V132, P89, DOI 10.1016/0003-2697(83)90429-3; GOETZE AM, 1985, PROSTAGLANDINS, V29, P689, DOI 10.1016/0090-6980(85)90130-3; Gutierrez-Gonzalez LH, 2002, BIOCHEM J, V364, P725, DOI 10.1042/BJ20020039; Haeggstrom JZ, 2000, AM J RESP CRIT CARE, V161, pS25, DOI 10.1164/ajrccm.161.supplement_1.ltta-6; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; Hertzel AV, 2002, J LIPID RES, V43, P2105, DOI 10.1194/jlr.M200227-JLR200; Hohoff C, 1999, BIOCHEMISTRY-US, V38, P12229, DOI 10.1021/bi990305u; JAKSCHIK BA, 1983, PROSTAG OTH LIPID M, V25, P767, DOI 10.1016/0090-6980(83)90002-3; Kane CD, 1996, BIOCHEMISTRY-US, V35, P2894, DOI 10.1021/bi952476e; KRIEG P, 1993, J BIOL CHEM, V268, P17362; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; MACLOUF JA, 1988, J BIOL CHEM, V263, P174; MCGEE JE, 1986, P NATL ACAD SCI USA, V83, P1349, DOI 10.1073/pnas.83.5.1349; Penrose JF, 1996, J BIOL CHEM, V271, P11356, DOI 10.1074/jbc.271.19.11356; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; PETERS P, 1996, ALL ALBUMIN, P76; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; Sala A, 1996, J BIOL CHEM, V271, P17944, DOI 10.1074/jbc.271.30.17944; SHIMIZU T, 1984, P NATL ACAD SCI-BIOL, V81, P689, DOI 10.1073/pnas.81.3.689; Storch J, 2000, BBA-MOL CELL BIOL L, V1486, P28, DOI 10.1016/S1388-1981(00)00046-9; Widstrom RL, 2003, BIOCHEMISTRY-US, V42, P11762, DOI 10.1021/bi034971d; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Zarini S, 2003, J BIOL CHEM, V278, P11190, DOI 10.1074/jbc.M208496200; Zimmerman AW, 2001, INT J BIOCHEM CELL B, V33, P865, DOI 10.1016/S1357-2725(01)00070-X	38	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7420	7426		10.1074/jbc.M311404200	http://dx.doi.org/10.1074/jbc.M311404200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14676186	hybrid			2022-12-25	WOS:000189103300008
J	Wang, W; Ungermannova, D; Jin, JP; Harper, JW; Liu, XD				Wang, W; Ungermannova, D; Jin, JP; Harper, JW; Liu, XD			Negative regulation of SCFSkp2 ubiquitin ligase by TGF-beta signaling	ONCOGENE			English	Article						Skp2; p27(Kip1); TGF-beta; protein degradation; ubiquitin; Cdc34 and Cks1	ANAPHASE-PROMOTING COMPLEX; CELL-CYCLE ARREST; BOX PROTEIN SKP2; DEPENDENT KINASE; GROWTH-INHIBITION; MAMMALIAN-CELLS; CDK INHIBITORS; HUMAN CUL-1; S-PHASE; DEGRADATION	TGF-beta is a multifunctional growth factor whose best-known function is to inhibit cell growth and suppress tumor formation. TGF-beta causes cells to accumulate in mid-to-late G1 phase by blocking the transition from G1 to S. It has been shown that TGF-beta inhibits Cdk2-cyclin E kinase activity by promoting the binding of cell cycle inhibitor p27(Kip1) to the kinase complexes. Here, we show that TGF-beta treatment leads to stabilization of p27(Kip1) during G1 to S transition. We found that TGF-beta negatively regulates components of the SCF complex, which degrades the p27(Kip1) during the G1 to S transition, through two distinct mechanisms. Using a pulse-chase analysis, we demonstrated that the stability of Skp2 decreases in the presence of TGF-beta. Destabilization of Skp2 by ubiquitin-mediated proteolysis was also demonstrated that in an in vitro degradation system, using cell extracts prepared from TGF-beta-treated cultured cells. In addition, TGF-beta treatment decreases the levels of Cks1 mRNA. The deficiency of Cks1 in TGF-beta-treated cells likely contributes to the stabilization of p27(Kip1) and destabilization of Skp2, because in the absence of Cks1, SCFSkp2 cannot ubiquitinate p27(Kip1); instead, self-ubiquitination of Skp2 occurs. Thus, stabilization of the cell cycle inhibitor p27(Kip1) and cell growth inhibition in response to TGF-beta occur in part through limiting the threshold of the SCFSkp2 ubiquitin ligase by transcriptional and post-transcriptional mechanisms.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA	University of Colorado System; University of Colorado Boulder; Baylor College of Medicine	Liu, XD (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.	xuedong.liu@colorado.edu	Jin, Jianping/K-5002-2018	Jin, Jianping/0000-0003-4175-9104; LIU, XUEDONG/0000-0001-7209-4964; Harper, Jeffrey/0000-0002-6944-7236	NCI NIH HHS [CA95527-01, R01 CA095527] Funding Source: Medline; NIA NIH HHS [R01 AG011085] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095527] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Blain SW, 2002, NAT MED, V8, P1076, DOI 10.1038/nm1002-1076; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Donnellan R, 1999, FASEB J, V13, P773, DOI 10.1096/fasebj.13.8.773; Dow R, 2001, J BIOL CHEM, V276, P45945, DOI 10.1074/jbc.M103593200; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Galan JM, 1999, P NATL ACAD SCI USA, V96, P9124, DOI 10.1073/pnas.96.16.9124; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harper JW, 2001, CURR BIOL, V11, pR431, DOI 10.1016/S0960-9822(01)00253-6; Iavarone A, 1997, NATURE, V387, P417; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Liu XD, 2000, ONCOGENE, V19, P5926, DOI 10.1038/sj.onc.1203991; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Liu XH, 2000, EMBO J, V19, P6759, DOI 10.1093/emboj/19.24.6759; Lyapina SA, 1998, P NATL ACAD SCI USA, V95, P7451, DOI 10.1073/pnas.95.13.7451; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nakayama K, 2001, BIOCHEM BIOPH RES CO, V282, P853, DOI 10.1006/bbrc.2001.4627; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; SIMON KE, 1995, CELL GROWTH DIFFER, V6, P1261; Sitry D, 2002, J BIOL CHEM, V277, P42233, DOI 10.1074/jbc.M205254200; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Stroschein SL, 2001, GENE DEV, V15, P2822; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Tsubari M, 1999, MOL CELL BIOL, V19, P3654; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Wang W, 2003, J BIOL CHEM, V278, P32390, DOI 10.1074/jbc.M305241200; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	59	39	40	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1064	1075		10.1038/sj.onc.1207204	http://dx.doi.org/10.1038/sj.onc.1207204			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14676846				2022-12-25	WOS:000188749900005
J	Nony, P; Gaude, H; Rossel, M; Fournier, L; Rouault, JP; Billaud, M				Nony, P; Gaude, H; Rossel, M; Fournier, L; Rouault, JP; Billaud, M			Stability of the Peutz-Jeghers syndrome kinase LKB1 requires its binding to the molecular chaperones Hsp90/Cdc37	ONCOGENE			English	Article						LKB1; Peutz-Jeghers; tumor suppressor; Hsp90	SERINE/THREONINE PROTEIN-KINASE; TUMOR-SUPPRESSOR; GENE LKB1; CANCER; HSP90; IDENTIFICATION; MUTATIONS; CHIP; LKB1/STK11; DESTABILIZATION	Peutz-Jeghers syndrome (PJS) is an autosomal dominant disorder characterized by the presence of multiple gastrointestinal polyps and an increased risk for various types of cancers. Inactivating germline mutations of the LKB1 gene, which encodes a serine/threonine kinase, are responsible for the majority of PJS cases. Here, we show that the heteromeric complex containing the molecular chaperones Hsp90 and Cdc37/p50 interacts with the kinase domain of LKB1. Treatment of cells with either geldanamycin or novobiocin, two pharmacological inhibitors of Hsp90 causes the destabilization of LKB1. Furthermore, geldanamycin treatment leads to the ubiquitination and the rapid degradation of LKB1 by the proteasome-dependent pathway. In addition, we found that a LKB1 point mutation identified in a sporadic testicular cancer, weakens the interaction of LKB1 with both Hsp90 and Cdc37/p50 and enhances its sensitivity to the destabilizing effect of geldanamycin. Collectively, our results demonstrate that the Hsp90/Cdc37 complex is a major regulator of the stability of the LKB1 tumor suppressor. Furthermore, these data draw attention to the possible adverse consequences of antitumor drugs that target Hsp90, such as antibiotics related to geldanamycin, which could disrupt LKB1 function and promote the development of polyps and carcinomatous lesions.	Lab Genet & Canc, FRE 2692, F-69373 Lyon 08, France; Hop Debrousse, INSERM, U418, INRA UA 953,Lab Commun Cellulaires & Differenciat, F-69322 Lyon 05, France; Ecole Prat Hautes Etud, INSERM, E0343, Lab Biol Cellulaire Quantit, F-34095 Montpellier 05, France	CHU Lyon; INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Universite de Montpellier	Billaud, M (corresponding author), Lab Genet & Canc, FRE 2692, Domaine Rockefeller,8 Ave Rockefeller, F-69373 Lyon 08, France.	billaud@univ-lvon1.fr	Billaud, Marc N/M-6954-2013	Rossel, Mireille/0000-0003-2275-0817				Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Blumer JB, 2003, J BIOL CHEM, V278, P23217, DOI 10.1074/jbc.C200686200; BOUDEAU J, 2002, BIOCHEM J, V19, P849; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; Collins SP, 2000, BIOCHEM J, V345, P673, DOI 10.1042/0264-6021:3450673; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hunter T, 1997, TRENDS CELL BIOL, V7, P157, DOI 10.1016/S0962-8924(97)01027-1; JEGHERS H, 1949, NEW ENGL J MED, V241, P993, DOI 10.1056/NEJM194912222412501; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Jishage K, 2002, P NATL ACAD SCI USA, V99, P8903, DOI 10.1073/pnas.122254599; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Liu WK, 2003, J BIOMED SCI, V10, P242, DOI 10.1159/000068708; Marcu MG, 2000, J BIOL CHEM, V275, P37181, DOI 10.1074/jbc.M003701200; Marignani PA, 2001, J BIOL CHEM, V276, P32415, DOI 10.1074/jbc.C100207200; Martin SG, 2003, NATURE, V421, P379, DOI 10.1038/nature01296; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Mehenni H, 1998, AM J HUM GENET, V63, P1641, DOI 10.1086/302159; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Miyata Y, 2001, J BIOL CHEM, V276, P21841, DOI 10.1074/jbc.M010944200; Miyoshi H, 2002, CANCER RES, V62, P2261; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Olschwang S, 2001, J MED GENET, V38, P356, DOI 10.1136/jmg.38.6.356; Pearl LH, 2000, CURR OPIN STRUC BIOL, V10, P46, DOI 10.1016/S0959-440X(99)00047-0; Perdew GH, 1997, BIOCHEMISTRY-US, V36, P3600, DOI 10.1021/bi9612529; Peutz JL, 1921, NEDERL MAANDSCHR GEN, V10, P134; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Rossi DJ, 2002, P NATL ACAD SCI USA, V99, P12327, DOI 10.1073/pnas.192301399; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sapkota GP, 2002, BIOCHEM J, V362, P481, DOI 10.1042/0264-6021:3620481; Sapkota GP, 2001, J BIOL CHEM, V276, P19469, DOI 10.1074/jbc.M009953200; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Shen Z, 2002, CLIN CANCER RES, V8, P2085; Smith DP, 1999, HUM MOL GENET, V8, P1479, DOI 10.1093/hmg/8.8.1479; Smith DP, 2001, HUM MOL GENET, V10, P2869, DOI 10.1093/hmg/10.25.2869; SPIGELMAN AD, 1989, GUT, V30, P1588, DOI 10.1136/gut.30.11.1588; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Su JY, 1996, J BIOL CHEM, V271, P14430, DOI 10.1074/jbc.271.24.14430; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Tiainen M, 2002, HUM MOL GENET, V11, P1497, DOI 10.1093/hmg/11.13.1497; TOFT DO, 1999, CONTROL HORMONE RECE; Watts JL, 2000, DEVELOPMENT, V127, P1467; Whitesell L, 1997, ONCOGENE, V14, P2809, DOI 10.1038/sj.onc.1201120; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Ylikorkala A, 1999, HUM MOL GENET, V8, P45, DOI 10.1093/hmg/8.1.45; Ylikorkala A, 2001, SCIENCE, V293, P1323, DOI 10.1126/science.1062074; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079	55	45	46	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2003	22	57					9165	9175		10.1038/sj.onc.1207179	http://dx.doi.org/10.1038/sj.onc.1207179			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	752FJ	14668798	Bronze			2022-12-25	WOS:000187149100007
J	Baron, S; Manin, M; Beaudoin, C; Leotoing, L; Communal, Y; Veyssiere, G; Morel, L				Baron, S; Manin, M; Beaudoin, C; Leotoing, L; Communal, Y; Veyssiere, G; Morel, L			Androgen receptor mediates non-genomic activation of phosphatidylinositol 3-OH kinase in androgen-sensitive epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; PROSTATE-CANCER CELLS; VAS-DEFERENS PROTEIN; ESTROGEN-RECEPTOR; PROGESTERONE-RECEPTOR; PHOSPHOINOSITIDE 3-KINASE; STEROID-HORMONES; SIGNAL-TRANSDUCTION; APOPTOSIS; ALPHA	Androgens are known to modulate many cellular processes such as cell growth and survival by binding to the androgen receptor (AR) and activating the transcription of target genes. Recent data suggested that AR can also mediate non-transcriptional actions outside the nucleus in addition to its ligand-inducible transcription factor function. Here, we describe a transcription-independent activation of the phosphatidylinositol 3-OH kinase (PI3-K) signaling pathway by androgens. Using non-transformed androgen-sensitive epithelial cells, we show that androgens enhance the PI3-K activity by promoting accumulation of phosphoinositide-3-P phospholipids in vitro. This activation is found in conjunction with an increased time-dependent phosphorylation of the downstream kinase AKT/protein kinase B on both Ser(473) and Thr(308) residues. Hormone-stimulated phosphorylation of AKT requires AR since incubation with the anti-androgen bicalutamide completely abolishes the androgen-stimulated AKT phosphorylation. Accordingly, we show that androgens increase AKT phosphorylation level in prostatic carcinoma PC3 cells only once they have been transfected with AR. Downstream, androgens enhance phosphorylation of transcription factor FKHR ( Forkhead in rhabdomyosarcoma)-L1 and proapoptotic Bad protein and promote cell survival as they can counteract an apoptotic process. We also report that non-genomic effects of androgens are based on direct interaction between AR and the p85alpha regulatory subunit of class I(A) PI3-K. Together, these novel findings point out an important and physiologically relevant link between androgens and the PI3-K/AKT signaling pathway in governing cell survival.	Univ Clermont Ferrand, CNRS, UMR 6547, F-63177 Clermont Ferrand, France; Ctr Jean Perrin, Immunol Lab, F-63011 Clermont Ferrand, France	Centre National de la Recherche Scientifique (CNRS); Universite Clermont Auvergne (UCA); UNICANCER; Centre Jean Perrin	Morel, L (corresponding author), Univ Clermont Ferrand, CNRS, UMR 6547, Campus Univ Cezeaux,24 Ave Landais, F-63177 Clermont Ferrand, France.	laurent.morel@univ-bpclermont.fr						Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Bagowski CP, 2001, J BIOL CHEM, V276, P37708, DOI 10.1074/jbc.M104582200; Bayaa M, 2000, P NATL ACAD SCI USA, V97, P12607, DOI 10.1073/pnas.220302597; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; BRANN DW, 1995, J STEROID BIOCHEM, V52, P113, DOI 10.1016/0960-0760(94)00160-N; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chambliss KL, 2000, CIRC RES, V87, pE44, DOI 10.1161/01.RES.87.11.e44; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; Cunha GR, 1996, PROSTATE, P22; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Falkenstein E, 2000, PHARMACOL REV, V52, P513; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Kurita T, 2001, CELL DEATH DIFFER, V8, P192, DOI 10.1038/sj.cdd.4400797; Li PF, 2003, MOL CELL BIOL, V23, P104, DOI 10.1128/MCB.23.1.104-118.2003; Lo Surdo P, 1999, J BIOL CHEM, V274, P15678, DOI 10.1074/jbc.274.22.15678; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Manin M, 2002, BIOCHEM J, V366, P729, DOI 10.1042/BJ20020585; MANIN M, 1995, BIOL REPROD, V52, P50, DOI 10.1095/biolreprod52.1.50; Manin M, 2000, J ANDROL, V21, P641; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Moss RL, 1999, STEROIDS, V64, P14, DOI 10.1016/S0039-128X(98)00092-0; Peterziel H, 1999, ONCOGENE, V18, P6322, DOI 10.1038/sj.onc.1203032; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Sun M, 2001, CANCER RES, V61, P5985; Ueki K, 2002, P NATL ACAD SCI USA, V99, P419, DOI 10.1073/pnas.012581799; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; Yao R, 1996, ONCOGENE, V13, P343; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	41	129	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14579	14586		10.1074/jbc.M306143200	http://dx.doi.org/10.1074/jbc.M306143200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14668339	hybrid			2022-12-25	WOS:000220594700015
J	Bruce, JIE; Giovannucci, DR; Blinder, G; Shuttleworth, TJ; Yule, DI				Bruce, JIE; Giovannucci, DR; Blinder, G; Shuttleworth, TJ; Yule, DI			Modulation of [Ca2+](i) signaling dynamics and metabolism by perinuclear mitochondria in mouse parotid acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC CA2+ SIGNALS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; ATOMIC-FORCE MICROSCOPY; NUCLEAR-PORE COMPLEX; ENDOPLASMIC-RETICULUM; CALCIUM OSCILLATIONS; RUTHENIUM RED; ATP; TRANSPORT; ENVELOPE	Parotid acinar cells exhibit rapid cytosolic calcium signals ([Ca2+](i)) that initiate in the apical region but rapidly become global in nature. These characteristic [Ca2+](i) signals are important for effective fluid secretion, which critically depends on a synchronized activation of spatially separated ion fluxes. Apically restricted [Ca2+](i) signals were never observed in parotid acinar cells. This is in marked contrast to the related pancreatic acinar cells, where the distribution of mitochondria has been suggested to contribute to restricting [Ca2+](i) signals to the apical region. Therefore, the aim of this study was to determine the mitochondrial distribution and the role of mitochondrial Ca2+ uptake in shaping the spatial and temporal properties of [Ca2+](i) signaling in parotid acinar cells. Confocal imaging of cells stained with MitoTracker dyes ( MitoTracker Green FM or MitoTracker CMXRos) and SYTO dyes ( SYTO- 16 and SYTO-61) revealed that a majority of mitochondria is localized around the nucleus. Carbachol ( CCh) and caged inositol 1,4,5- trisphosphate- evoked [Ca2+](i) signals were delayed as they propagated through the nucleus. This delay in the CCh- evoked nuclear [Ca2+](i) signal was abolished by inhibition of mitochondrial Ca2+ uptake with ruthenium red and Ru360. Likewise, simultaneous measurement of [Ca2+](i) with mitochondrial [Ca2+] ([Ca2+](m)), using fura- 2 and rhod- FF, respectively, revealed that mitochondrial Ca2+ uptake was also inhibited by ruthenium red and Ru360. Finally, at concentrations of agonist that evoke [Ca2+](i) oscillations, mitochondrial Ca2+ uptake, and a nuclear [Ca2+] delay, CCh also evoked a substantial increase in NADH autofluorescence. This autofluorescence exhibited a predominant perinuclear localization that was also sensitive to mitochondrial inhibitors. These data provide evidence that perinuclear mitochondria and mitochondrial Ca2+ uptake may differentially shape nuclear [Ca2+] signals but more importantly drive mitochondrial metabolism to generate ATP close to the nucleus. These effects may profoundly affect a variety of nuclear processes in parotid acinar cells while facilitating efficient fluid secretion.	Univ Rochester, Med Ctr, Sch Med & Dent, Dept Physiol & Pharmacol, Rochester, NY 14642 USA	University of Rochester	Bruce, JIE (corresponding author), Univ Rochester, Med Ctr, Sch Med & Dent, Dept Physiol & Pharmacol, 601 Elmwood Ave, Rochester, NY 14642 USA.	jason_bruce@urmc.rochester.edu	Giovannucci, David R/A-5657-2018		NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R56DE014756, P01DE013539] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 14756, DE 013539] Funding Source: Medline; NIGMS NIH HHS [GM 40457] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMOHANNA FA, 1994, NATURE, V367, P745, DOI 10.1038/367745a0; Assandri R, 1997, J MEMBRANE BIOL, V157, P301, DOI 10.1007/s002329900237; Atkinson L, 2002, NATURE, V420, P42, DOI 10.1038/420042a; Bading H, 2000, EUR J BIOCHEM, V267, P5280, DOI 10.1046/j.1432-1327.2000.01565.x; Badminton MN, 1996, J BIOL CHEM, V271, P31210, DOI 10.1074/jbc.271.49.31210; Badminton MN, 1998, CELL CALCIUM, V23, P79, DOI 10.1016/S0143-4160(98)90105-1; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Billups B, 2002, J NEUROSCI, V22, P5840; Bruce JIE, 2002, J BIOL CHEM, V277, P48172, DOI 10.1074/jbc.M208393200; Bruce JIE, 2002, J BIOL CHEM, V277, P1340, DOI 10.1074/jbc.M106609200; Bustamante JO, 2000, PFLUG ARCH EUR J PHY, V439, P433, DOI 10.1007/s004240050960; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; Chamero P, 2002, J BIOL CHEM, V277, P50226, DOI 10.1074/jbc.C200522200; Collins TJ, 2001, J BIOL CHEM, V276, P26411, DOI 10.1074/jbc.M101101200; DENTON RM, 1990, ANNU REV PHYSIOL, V52, P451, DOI 10.1146/annurev.ph.52.030190.002315; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; DUCHEN MR, 1992, BIOCHEM J, V283, P41, DOI 10.1042/bj2830041; Dzeja PP, 2002, P NATL ACAD SCI USA, V99, P10156, DOI 10.1073/pnas.152259999; Garner MH, 2002, J MEMBRANE BIOL, V187, P97, DOI 10.1007/s00232-001-0155-5; Gerasimenko OV, 1996, PFLUG ARCH EUR J PHY, V432, P1055, DOI 10.1007/s004240050234; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; Giovannucci DR, 2002, J PHYSIOL-LONDON, V540, P469, DOI 10.1113/jphysiol.2001.013453; GREBER UF, 1995, J CELL BIOL, V128, P5, DOI 10.1083/jcb.128.1.5; Hajnoczky G, 1999, J BIOL CHEM, V274, P14157, DOI 10.1074/jbc.274.20.14157; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hebbar PB, 2003, CHROMOSOMA, V111, P495, DOI 10.1007/s00412-003-0232-x; Heist EK, 1998, CELL CALCIUM, V23, P103; Jaggar JH, 2000, AM J PHYSIOL-CELL PH, V278, pC235, DOI 10.1152/ajpcell.2000.278.2.C235; Johnson PR, 2002, CELL CALCIUM, V32, P59, DOI 10.1016/S0143-4160(02)00091-X; Kargacin GJ, 1998, PFLUG ARCH EUR J PHY, V436, P338, DOI 10.1007/s004240050641; LANINI L, 1992, J BIOL CHEM, V267, P11548; MA JJ, 1993, J GEN PHYSIOL, V102, P1031, DOI 10.1085/jgp.102.6.1031; Maechler P, 2002, CELL MOL LIFE SCI, V59, P1803, DOI 10.1007/PL00012507; MARUYAMA Y, 1993, EMBO J, V12, P3017, DOI 10.1002/j.1460-2075.1993.tb05970.x; Matlib MA, 1998, J BIOL CHEM, V273, P10223, DOI 10.1074/jbc.273.17.10223; Mazzanti M, 2001, PHYSIOL REV, V81, P1, DOI 10.1152/physrev.2001.81.1.1; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; NAUNTOFTE B, 1992, AM J PHYSIOL, V263, pG823, DOI 10.1152/ajpgi.1992.263.6.G823; Oberleithner H, 1996, PFLUG ARCH EUR J PHY, V432, P839, DOI 10.1007/s004240050206; Park MK, 2001, EMBO J, V20, P1863, DOI 10.1093/emboj/20.8.1863; PerezTerzic C, 1996, SCIENCE, V273, P1875, DOI 10.1126/science.273.5283.1875; PETERSEN OH, 1995, CIBA F SYMP, V188, P85; Rakowska A, 1998, J MEMBRANE BIOL, V163, P129, DOI 10.1007/s002329900377; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Rizzuto Rosario, 2002, Trends in Pharmacological Sciences, V23, P348, DOI 10.1016/S0165-6147(02)02063-1; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; Santella L, 1998, BIOCHEM BIOPH RES CO, V244, P317, DOI 10.1006/bbrc.1998.8086; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835; Stoffler D, 1999, J MOL BIOL, V287, P741, DOI 10.1006/jmbi.1999.2637; Stoffler D, 1999, CURR OPIN CELL BIOL, V11, P391, DOI 10.1016/S0955-0674(99)80055-6; Straub SV, 2000, J GEN PHYSIOL, V116, P547, DOI 10.1085/jgp.116.4.547; Teruel MN, 2000, CURR BIOL, V10, P86, DOI 10.1016/S0960-9822(00)00295-5; Thomas D, 2000, CELL CALCIUM, V28, P213, DOI 10.1054/ceca.2000.0152; Tinel H, 1999, EMBO J, V18, P4999, DOI 10.1093/emboj/18.18.4999; Voronina S, 2002, J PHYSIOL-LONDON, V539, P41, DOI 10.1113/jphysiol.2001.013134; YING WL, 1991, BIOCHEMISTRY-US, V30, P4949, DOI 10.1021/bi00234a016; Zhou Z, 2002, PFLUG ARCH EUR J PHY, V445, P132, DOI 10.1007/s00424-002-0909-7	59	69	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12909	12917		10.1074/jbc.M309070200	http://dx.doi.org/10.1074/jbc.M309070200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14699167	hybrid			2022-12-25	WOS:000220334900108
J	Davis, CA; Hearn, AS; Fletcher, B; Bickford, J; Garcia, JE; Leveque, V; Melendez, JA; Silverman, DN; Zucali, J; Agarwal, A; Nick, HS				Davis, CA; Hearn, AS; Fletcher, B; Bickford, J; Garcia, JE; Leveque, V; Melendez, JA; Silverman, DN; Zucali, J; Agarwal, A; Nick, HS			Potent anti-tumor effects of an active site mutant of human manganese-superoxide dismutase - Evolutionary conservation of product inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MATRIX-METALLOPROTEINASE EXPRESSION; HYDROGEN-PEROXIDE; MALIGNANT PHENOTYPE; CELL-GROWTH; MITOCHONDRIAL; OVEREXPRESSION; PROLIFERATION; INVOLVEMENT; SUPPRESSION	Mn-SOD serves as the primary cellular defense against oxidative damage by converting superoxide radicals (O-2(radical anion)) to O-2 and H2O2. A unique characteristic of this mitochondrial anti-oxidant enzyme is the conservation from bacteria to man of a rapidly formed product inhibited state. Using site-directed mutagenesis, we have generated an active site mutant (H30N) of human Mn-SOD, which exhibits significantly reduced product inhibition and increased enzymatic efficiency. Overexpression of the H30N enzyme causes anti-proliferative effects in vitro and anti-tumor effects in vivo. Our results provide a teleological basis for the phylogenetically invariant nature of position His-30 and the evolutionary conservation of product inhibition. These data also provide more direct intracellular evidence for the signaling role associated with H2O2.	Univ Florida, Shands Canc Ctr, Dept Neurosci, Gainesville, FL 32610 USA; Univ Florida, Shands Canc Ctr, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Univ Florida, Shands Canc Ctr, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Shands Canc Ctr, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA; Univ Florida, McKnight Brain Inst, Gainesville, FL 32610 USA; Albany Med Coll, Ctr Immunol & Microbial Dis, Albany, NY 12208 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; Albany Medical College	Nick, HS (corresponding author), Univ Florida, J Hillis Miller Hlth Ctr, Dept Neurosci, Box 100244,1600 SW Archer Rd, Gainesville, FL 32610 USA.	hnick@ufl.edu		Melendez, Juan/0000-0001-8021-3097				Arnold RS, 2001, P NATL ACAD SCI USA, V98, P5550, DOI 10.1073/pnas.101505898; BORGSTAHL GEO, 1992, CELL, V71, P107, DOI 10.1016/0092-8674(92)90270-M; BRAVARD A, 1992, INT J CANCER, V51, P476, DOI 10.1002/ijc.2910510323; Burdon RH, 1996, FREE RADICAL RES, V24, P81, DOI 10.3109/10715769609088004; Cabelli DE, 1999, BIOCHEMISTRY-US, V38, P11686, DOI 10.1021/bi9909142; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Davis CA, 2001, J AM SOC NEPHROL, V12, P2683, DOI 10.1681/ASN.V12122683; Fletcher BS, 2002, LEUKEMIA, V16, P1507, DOI 10.1038/sj.leu.2402557; Fridovich I, 1998, J EXP BIOL, V201, P1203; Hearn AS, 2001, BIOCHEMISTRY-US, V40, P12051, DOI 10.1021/bi011047f; Hsu JL, 1996, J BIOL CHEM, V271, P17687, DOI 10.1074/jbc.271.30.17687; Leveque VJP, 2001, BIOCHEMISTRY-US, V40, P10586, DOI 10.1021/bi010792p; Li SJ, 2000, CANCER RES, V60, P3927; MCADAM ME, 1977, BIOCHEM J, V165, P71, DOI 10.1042/bj1650071; MITCHELL P, 1965, NATURE, V18, P1205; Nelson KK, 2003, CLIN CANCER RES, V9, P424; Oberley LW, 2001, ANTIOXID REDOX SIGN, V3, P461, DOI 10.1089/15230860152409095; Ramilo CA, 1999, J BIOL CHEM, V274, P27711, DOI 10.1074/jbc.274.39.27711; Ranganathan AC, 2001, J BIOL CHEM, V276, P14264, DOI 10.1074/jbc.M100199200; Rodriguez AM, 2000, FREE RADICAL BIO MED, V29, P801, DOI 10.1016/S0891-5849(00)00362-2; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SERREZE DV, 1995, DIABETES, V44, P1392, DOI 10.2337/diabetes.44.12.1392; Silverman DN, 2002, METHOD ENZYMOL, V349, P61, DOI 10.1016/S0076-6879(02)49321-4; SUN Y, 1989, INT J CANCER, V44, P1028, DOI 10.1002/ijc.2910440615; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; VISNER GA, 1991, AM J PHYSIOL, V260, pL444, DOI 10.1152/ajplung.1991.260.6.L444; VISNER GA, 1990, J BIOL CHEM, V265, P2856; Wartenberg M, 1999, J BIOL CHEM, V274, P27759, DOI 10.1074/jbc.274.39.27759; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Zhong WX, 1997, ONCOGENE, V14, P481, DOI 10.1038/sj.onc.1200852	32	38	38	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12769	12776		10.1074/jbc.M310623200	http://dx.doi.org/10.1074/jbc.M310623200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14688256	hybrid			2022-12-25	WOS:000220334900091
J	Angers, A; Ramjaun, AR; McPherson, PS				Angers, A; Ramjaun, AR; McPherson, PS			The HECT domain ligase itch ubiquitinates endophilin and localizes to the trans-Golgi network and endosomal system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; RECEPTOR DOWN-REGULATION; PROTEIN LIGASE; ENDOCYTIC PATHWAY; VESICLE FORMATION; PLASMA-MEMBRANE; CUE DOMAIN; SH3 DOMAIN; BINDING; MOTIF	Endophilin A1 is an SH3 domain-containing protein functioning in membrane trafficking on the endocytic pathway. We have identified the E3 ubiquitin ligase itch/AIP4 as an endophilin A1-binding partner. Itch belongs to the Nedd4/Rsp5p family of proteins and contains an N-terminal C2 domain, four WW domains and a catalytic HECT domain. Unlike other Nedd4/Rsp5p family members, itch possesses a short proline-rich domain that mediates its binding to the SH3 domain of endophilin A1. Itch ubiquitinates endophilin A1 and the SH3/ proline-rich domain interaction facilitates this activity. Interestingly, itch co-localizes with markers of the endosomal system in a C2 domain-dependent manner and upon EGF stimulation, endophilin A1 translocates to an EGF-positive endosomal compartment where it co-localizes with itch. Moreover, EGF treatment of cells stimulates endophilin A1 ubiquitination. We have thus identified endophilin A1 as a substrate for the endo-some-localized ubiquitin ligase itch. This interaction may be involved in ubiquitin-mediated sorting mechanisms operating at the level of endosomes.	McGill Univ, Montreal Neurol Inst, Dept Neurol, Montreal, PQ H3A 2B4, Canada; McGill Univ, Montreal Neurol Inst, Dept Neurosurg, Montreal, PQ H3A 2B4, Canada	McGill University; McGill University	Angers, A (corresponding author), Univ Montreal, Dept Sci Biol, POB 6128,Stn Ctr Ville, Montreal, PQ H3C 3J7, Canada.	Annie.Angers@umontreal.ca	Angers, Annie/P-1217-2018	Angers, Annie/0000-0003-0131-256X				Anan T, 1998, GENES CELLS, V3, P751, DOI 10.1046/j.1365-2443.1998.00227.x; Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; Barik S, 1993, Methods Mol Biol, V15, P277, DOI 10.1385/0-89603-244-2:277; Bishop N, 2002, J CELL BIOL, V157, P91, DOI 10.1083/jcb.200112080; Cestra G, 1999, J BIOL CHEM, V274, P32001, DOI 10.1074/jbc.274.45.32001; Chatellard-Causse C, 2002, J BIOL CHEM, V277, P29108, DOI 10.1074/jbc.M204019200; Chen X, 2001, GENOMICS, V73, P238, DOI 10.1006/geno.2001.6512; Courbard JR, 2002, J BIOL CHEM, V277, P45267, DOI 10.1074/jbc.M206460200; Davies BA, 2003, J BIOL CHEM, V278, P19826, DOI 10.1074/jbc.M301059200; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Dunn R, 2001, J BIOL CHEM, V276, P25974, DOI 10.1074/jbc.M104113200; Dunn R, 2001, MOL BIOL CELL, V12, P421, DOI 10.1091/mbc.12.2.421; EBNER R, 1991, CELL REGUL, V2, P599, DOI 10.1091/mbc.2.8.599; Fang DY, 2002, NAT IMMUNOL, V3, P281, DOI 10.1038/ni763; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; FIFIORE PP, 2003, NAT REV MOL CELL BIO, V4, P491; Gad H, 2000, NEURON, V27, P301, DOI 10.1016/S0896-6273(00)00038-6; Galinier R, 2002, BIOCHEMISTRY-US, V41, P14299, DOI 10.1021/bi020125b; Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; Guichet A, 2002, EMBO J, V21, P1661, DOI 10.1093/emboj/21.7.1661; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; HICKE L, 2003, MOL BIO CELL S, V14, pA360; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Ikeda M, 2000, VIROLOGY, V268, P178, DOI 10.1006/viro.1999.0166; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Lu Q, 2003, P NATL ACAD SCI USA, V100, P7626, DOI 10.1073/pnas.0932599100; Magnifico A, 2003, J BIOL CHEM, V278, P43169, DOI 10.1074/jbc.M308009200; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; Miaczynska M, 2002, EXP CELL RES, V272, P8, DOI 10.1006/excr.2001.5401; Micheva KD, 1997, J BIOL CHEM, V272, P27239, DOI 10.1074/jbc.272.43.27239; Otte L, 2003, PROTEIN SCI, V12, P491, DOI 10.1110/ps.0233203; Perry WL, 1998, NAT GENET, V18, P143, DOI 10.1038/ng0298-143; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Plant PJ, 2000, J CELL BIOL, V149, P1473, DOI 10.1083/jcb.149.7.1473; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Ramjaun AR, 2001, J BIOL CHEM, V276, P28913, DOI 10.1074/jbc.M103198200; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Ringstad N, 1999, NEURON, V24, P143, DOI 10.1016/S0896-6273(00)80828-4; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Sachse M, 2002, MOL BIOL CELL, V13, P1313, DOI 10.1091/mbc.01-10-0525; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Stang E, 2000, J BIOL CHEM, V275, P13940, DOI 10.1074/jbc.275.18.13940; Traweger A, 2002, J BIOL CHEM, V277, P10201, DOI 10.1074/jbc.M111384200; Verstreken P, 2002, CELL, V109, P101, DOI 10.1016/S0092-8674(02)00688-8; Wang GL, 2001, MOL CELL BIOL, V21, P3564, DOI 10.1128/MCB.21.10.3564-3575.2001; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563	64	94	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11471	11479		10.1074/jbc.M309934200	http://dx.doi.org/10.1074/jbc.M309934200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14684745	hybrid			2022-12-25	WOS:000220157600078
J	Brautigam, CA; Chelliah, Y; Deisenhofer, J				Brautigam, CA; Chelliah, Y; Deisenhofer, J			Tetramerization and ATP binding by a protein comprising the A, B, and C domains of rat synapsin I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI-B; GLUTATHIONE SYNTHETASE; NEUROTRANSMITTER RELEASE; CRYSTAL-STRUCTURES; FLEXIBLE LOOP; KINASE; LIGASE; COEFFICIENT; CALCIUM; ENZYMES	Synapsins are multidomain proteins that are critical for regulating neurotransmitter release in vertebrates. In the present study, two crystal structures of the C domain of rat synapsin I (rSynI-C) in complex with Ca2+ and ATP reveal that this protein can form a tetramer and that a flexible loop ( the "multifunctional loop") contacts bound ATP. Further experiments were carried out on a protein comprising the A, B, and C domains of rat synapsin I (rSynI-ABC). An ATP-stabilized tetramer of rSynI-ABC is observed during velocity sedimentation and size-exclusion chromatographic experiments. These hydrodynamic results also indicate that the A and B domains exist in an extended conformation. Calorimetric measurements of ATP binding to wild-type and mutant rSynI-ABC demonstrate that the multifunctional loop and a cross-tetramer contact are important for ATP binding. The evidence supports a view of synapsin I as an ATP-utilizing, tetrameric protein made up of monomers that have a flexible, extended N terminus.	Univ Texas, SW Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Deisenhofer, J (corresponding author), Univ Texas, SW Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA.	Johann.Deisenhofer@UTSouthwestern.edu		Brautigam, Chad/0000-0001-6563-1338				Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Bernstein HJ, 2000, TRENDS BIOCHEM SCI, V25, P453, DOI 10.1016/S0968-0004(00)01606-6; Bilwes AM, 2001, NAT STRUCT BIOL, V8, P353, DOI 10.1038/86243; Brautigam CA, 1998, J MOL BIOL, V277, P363, DOI 10.1006/jmbi.1997.1586; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DATTA AK, 1995, NUCLEIC ACIDS RES, V23, P4530, DOI 10.1093/nar/23.21.4530; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Esser L, 1998, EMBO J, V17, P977, DOI 10.1093/emboj/17.4.977; Feng J, 2002, J NEUROSCI, V22, P4372, DOI 10.1523/JNEUROSCI.22-11-04372.2002; Galperin MY, 1997, PROTEIN SCI, V6, P2639; Gushima H, 1983, J Appl Biochem, V5, P210; Hara T, 1996, BIOCHEMISTRY-US, V35, P11967, DOI 10.1021/bi9605245; Harrington W F, 1973, Methods Enzymol, V27, P306; Hibi T, 1996, NAT STRUCT BIOL, V3, P16, DOI 10.1038/nsb0196-16; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; Hosaka M, 1999, J BIOL CHEM, V274, P16747, DOI 10.1074/jbc.274.24.16747; Hosaka M, 1999, NEURON, V24, P377, DOI 10.1016/S0896-6273(00)80851-X; Hosaka M, 1998, J BIOL CHEM, V273, P13371, DOI 10.1074/jbc.273.22.13371; Hosaka M, 1998, J BIOL CHEM, V273, P1425, DOI 10.1074/jbc.273.3.1425; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kao HT, 1998, P NATL ACAD SCI USA, V95, P4667, DOI 10.1073/pnas.95.8.4667; KATO H, 1994, BIOCHEMISTRY-US, V33, P4995, DOI 10.1021/bi00183a001; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Machius M, 2001, P NATL ACAD SCI USA, V98, P11218, DOI 10.1073/pnas.201220098; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Philo JS, 2000, ANAL BIOCHEM, V279, P151, DOI 10.1006/abio.2000.4480; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; Ryan TA, 1996, J CELL BIOL, V134, P1219, DOI 10.1083/jcb.134.5.1219; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; TANAKA T, 1992, BIOCHEMISTRY-US, V31, P2259, DOI 10.1021/bi00123a007; Tanaka T, 1997, ARCH BIOCHEM BIOPHYS, V339, P151, DOI 10.1006/abbi.1996.9821; Thoden JB, 2002, J BIOL CHEM, V277, P23898, DOI 10.1074/jbc.M202251200; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSIEN RY, 1988, TRENDS NEUROSCI, V11, P419, DOI 10.1016/0166-2236(88)90192-0; VENDER AJ, 1990, HUMAN PHYSL, P108; Wang CR, 1997, PROTEIN SCI, V6, P2264	46	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11948	11956		10.1074/jbc.M312015200	http://dx.doi.org/10.1074/jbc.M312015200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14688264	hybrid			2022-12-25	WOS:000220157600132
J	Glowacki, R; Jakubowski, H				Glowacki, R; Jakubowski, H			Cross-talk between Cys(34) and lysine residues in human serum albumin revealed by N-homocysteinylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN HOMOCYSTEINYLATION; PATHOLOGICAL CONSEQUENCES; PLASMA HOMOCYSTEINE; POSSIBLE MECHANISM; ENDOTHELIAL-CELLS; HEART-DISEASE; THIOLACTONE; RISK; METABOLISM; ATHEROSCLEROSIS	Protein N-homocysteinylation involves a post-translational modification by homocysteine (Hcy)-thiolactone. In humans, about 70% of circulating Hcy is N-linked to blood proteins, mostly to hemoglobin and albumin. It was unclear what protein site(s) were prone to Hcy attachment and how N-linked Hcy affected protein function. Here we show that Lys(525) is a predominant site of N-homocysteinylation in human serum albumin in vitro and in vivo. We also show that the reactivity of albumin lysine residues, including Lys525, is affected by the status of Cys(34). The disulfide forms of circulating albumin, albumin-Cys(34)-S-S-Cys and albumin-Cys(34)-S-S-Hcy, are N-homocysteinylated faster than albumin-Cys(34)-SH. Although N-homocysteinylations of albumin-Cys(34)-SH and albumin-Cys(34)-S-S-Cys yield different primary products, subsequent thiol-disulfide exchange reactions result in the formation of a single product, N-(Hcy-S-S-Cys)-albumin-Cys(34)-SH. We also show that N-homocysteinylation affects the susceptibility of albumin to oxidation and proteolysis. The data suggest that a disulfide at Cys(34) of albumin promotes conversion of N-(Hcy-SH)-albumin-Cys(34)-SH to a proteolytically sensitive form N-(HcyS-S-Cys)-albumin-Cys(34)-SH, which would facilitate clearance of the N-homocysteinylated form of mercaptoalbumin.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Int Ctr Publ Hlth, Newark, NJ 07103 USA; Polish Acad Sci, Inst Bioorgan Chem, PL-61704 Poznan, Poland	Rutgers State University New Brunswick; Rutgers State University Medical Center; Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences	Jakubowski, H (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Int Ctr Publ Hlth, Newark, NJ 07103 USA.	jakubows@umdnj.edu	Jakubowski, Hieronim/A-2510-2017; Jakubowski, Hieronim/AAA-6834-2019	Jakubowski, Hieronim/0000-0001-5845-4409; 				Anderson JL, 2000, CIRCULATION, V102, P1227, DOI 10.1161/01.CIR.102.11.1227; Carballal S, 2003, BIOCHEMISTRY-US, V42, P9906, DOI 10.1021/bi027434m; Chambers JC, 2001, CIRC RES, V89, P187, DOI 10.1161/hh1401.093459; Chen P, 1999, ADV ENZYME REGUL, V39, P93, DOI 10.1016/S0065-2571(98)00029-6; CHRISTODOULOU J, 1994, EUR J BIOCHEM, V225, P363, DOI 10.1111/j.1432-1033.1994.00363.x; Clarke R, 2002, JAMA-J AM MED ASSOC, V288, P2015, DOI 10.1001/jama.288.16.2015; Daneshvar P, 2003, RAPID COMMUN MASS SP, V17, P358, DOI 10.1002/rcm.915; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; JAKUBOWSKI H, 1993, FEBS LETT, V317, P237, DOI 10.1016/0014-5793(93)81283-6; Jakubowski H, 2000, J BIOL CHEM, V275, P3957, DOI 10.1074/jbc.275.6.3957; Jakubowski H, 2000, CIRC RES, V87, P45, DOI 10.1161/01.RES.87.1.45; Jakubowski H, 1997, J BIOL CHEM, V272, P1935; Jakubowski H, 2002, J BIOL CHEM, V277, P30425, DOI 10.1074/jbc.C200267200; Jakubowski H, 2003, CLIN CHEM LAB MED, V41, P1462, DOI 10.1515/CCLM.2003.224; Jakubowski H, 2002, ANAL BIOCHEM, V308, P112, DOI 10.1016/S0003-2697(02)00224-5; Jakubowski H, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P21; Jakubowski H, 2001, FEBS LETT, V491, P35, DOI 10.1016/S0014-5793(01)02143-3; Jakubowski H, 2001, BIOMED PHARMACOTHER, V55, P443, DOI 10.1016/S0753-3322(01)00085-3; JAKUBOWSKI H, 1981, NUCLEIC ACIDS RES, V9, P3105, DOI 10.1093/nar/9.13.3105; Jakubowski H, 1999, FASEB J, V13, P2277, DOI 10.1096/fasebj.13.15.2277; Jakubowski H, 1997, DEV CARDIOVASC MED, P157; Jakubowski H, 2000, J BIOL CHEM, V275, P21813, DOI 10.1074/jbc.C000280200; Jakubowski H, 2000, J NUTR, V130, p377S, DOI 10.1093/jn/130.2.377S; JAKUBOWSKI H, 2004, IN PRESS CELL MOL LI, V60; JAKUBOWSKI H, 2004, IN PRESS AMINOACYL T; JAKUBOWSKI H, 2001, ENCY LIFE SCI, V18, P441; Klerk M, 2002, JAMA-J AM MED ASSOC, V288, P2023, DOI 10.1001/jama.288.16.2023; MANSOOR MA, 1992, ANAL BIOCHEM, V200, P218, DOI 10.1016/0003-2697(92)90456-H; Mattson MP, 2003, TRENDS NEUROSCI, V26, P137, DOI 10.1016/S0166-2236(03)00032-8; Mercie P, 2000, APOPTOSIS, V5, P403, DOI 10.1023/A:1009652011466; MUDD SH, 2001, METABOLIC MOL BASES, V2, P2007; Peters T, 1996, ALL ALBUMIN BIOCH GE, P51; ROSENBLATT D, 2001, METABOLIC MOL BASES, V2, P3897; Sengupta S, 2001, J BIOL CHEM, V276, P30111, DOI 10.1074/jbc.M104324200; Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613; Uji Y, 2002, CLIN CHEM, V48, P941; Zhang C, 2001, J BIOL CHEM, V276, P35867, DOI 10.1074/jbc.M100747200; Zunszain Patricia A, 2003, BMC Struct Biol, V3, P6, DOI 10.1186/1472-6807-3-6	38	107	109	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10864	10871		10.1074/jbc.M313268200	http://dx.doi.org/10.1074/jbc.M313268200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701829	hybrid			2022-12-25	WOS:000220157600007
J	Hormaeche, I; Iloro, I; Arrondo, JLR; Goni, FM; de la Cruz, F; Alkorta, I				Hormaeche, I; Iloro, I; Arrondo, JLR; Goni, FM; de la Cruz, F; Alkorta, I			Role of the transmembrane domain in the stability of TrwB, an integral protein involved in bacterial conjugation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; IV SECRETION SYSTEM; TRAG-LIKE PROTEINS; MEMBRANE-PROTEINS; ESCHERICHIA-COLI; COUPLING PROTEIN; PLASMID R388; DNA; BINDING; ORGANIZATION	TrwB is an integral membrane protein encoded by the conjugative plasmid R388. TrwB binds ATP and is essential for R388-directed bacterial conjugation. The protein consists of a cytosolic domain, which contains an ATP-binding site, and a transmembrane domain. The complete protein has been purified in the presence of detergents, and in addition, the cytosolic domain has also been isolated in the form of a soluble truncated protein, TrwBDeltaN70. The availability of intact and truncated forms of the protein provides a convenient system to study the role of the transmembrane domain in the stability of TrwB. Protein denaturation was achieved by heat, in the presence of guanidinium HCl, or under low salt conditions. In all three cases TrwB was significantly more stable than TrwBDeltaN70 with other conditions being the same. IR spectroscopy of the native and truncated forms revealed significant differences between them. In addition, it was found that TrwBDeltaN70 was stabilized in dispersions of non-ionic detergent, suggesting the presence of hydrophobic patches on the surface of the truncated protein. IR spectroscopy also confirmed the conformational stability provided by the detergent. These results suggest that in integral membrane proteins consisting of a transmembrane and a cytosolic domain, the transmembrane portion may have a role beyond the mere anchoring of the protein to the cell membrane. In addition, this study indicates that the truncated soluble parts of two-domain membrane proteins may not reflect the physiological conformation of their native counterparts.	Univ Basque Country, CSIC, Ctr Mixto, Unidad Biofis, E-48080 Bilbao, Spain; Univ Basque Country, Dept Bioquim, E-48080 Bilbao, Spain; Univ Cantabria, Dept Biol Mol, Santander 39011, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country; Universidad de Cantabria	Goni, FM (corresponding author), Univ Basque Country, CSIC, Ctr Mixto, Unidad Biofis, Apto 644, E-48080 Bilbao, Spain.	gbpgourf@lg.ehu.es	Goni, Felix M/M-5425-2015; Iloro, Ibon/L-6022-2014; Alkorta, Itziar/N-4374-2014; Alkorta, Itziar/Y-6267-2019; de la Cruz, Fernando/L-2812-2014	Goni, Felix M/0000-0001-6270-9216; Iloro, Ibon/0000-0002-9537-1714; Alkorta, Itziar/0000-0002-1976-8904; de la Cruz, Fernando/0000-0003-4758-6857; ALCORTA CALVO, MIREN ITZIAR/0000-0001-6978-389X				Arrondo JLR, 1999, PROG BIOPHYS MOL BIO, V72, P367, DOI 10.1016/S0079-6107(99)00007-3; ARRONDO JLR, 1993, PROG BIOPHYS MOL BIO, V59, P23, DOI 10.1016/0079-6107(93)90006-6; ARRONDO JLR, 1988, BIOCHIM BIOPHYS ACTA, V952, P261, DOI 10.1016/0167-4838(88)90125-2; Aussel L, 2002, CELL, V108, P195, DOI 10.1016/S0092-8674(02)00624-4; BANUELOS S, 1995, J BIOL CHEM, V270, P29910, DOI 10.1074/jbc.270.50.29910; BOLLAND S, 1990, J BACTERIOL, V172, P5795, DOI 10.1128/jb.172.10.5795-5802.1990; Bowie JU, 2001, CURR OPIN STRUC BIOL, V11, P397, DOI 10.1016/S0959-440X(00)00223-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; DATTA N, 1972, J GEN MICROBIOL, V72, P349, DOI 10.1099/00221287-72-2-349; DELACRUZ F, 1982, J BACTERIOL, V151, P222, DOI 10.1128/JB.151.1.222-228.1982; Echabe I, 1998, PROTEIN SCI, V7, P1172, DOI 10.1002/pro.5560070511; Garavito RM, 2001, J BIOL CHEM, V276, P32403, DOI 10.1074/jbc.R100031200; Gomis-Ruth FX, 2002, J BIOL CHEM, V277, P7556, DOI 10.1074/jbc.M110462200; Gomis-Ruth FX, 2001, NATURE, V409, P637, DOI 10.1038/35054586; Goni F. M., 2000, BIOCHIM BIOPHYS ACTA, V1508, P1; Goni FM, 2002, MOL MEMBR BIOL, V19, P237, DOI 10.1080/0968768021000035078; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; HALTIA T, 1995, BBA-BIOENERGETICS, V1228, P1, DOI 10.1016/0005-2728(94)00161-W; Hormaeche I, 2002, J BIOL CHEM, V277, P46456, DOI 10.1074/jbc.M207250200; LLOSA M, 1994, J MOL BIOL, V235, P448, DOI 10.1006/jmbi.1994.1005; Llosa M, 2002, MOL MICROBIOL, V45, P1, DOI 10.1046/j.1365-2958.2002.03014.x; Martinez A, 1996, J BIOL CHEM, V271, P19737, DOI 10.1074/jbc.271.33.19737; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Moncalian G, 1999, J BIOL CHEM, V274, P36117, DOI 10.1074/jbc.274.51.36117; MORO F, 1996, THESIS U BASQUE COUN; MUGA A, 1991, BIOCHEMISTRY-US, V30, P2629, DOI 10.1021/bi00224a010; RACKER E, 1985, RECONSTITUTIONS TRAN; SANDLER JR, 1980, GENE, V8, P279; Schroder G, 2003, J BACTERIOL, V185, P4371, DOI 10.1128/JB.185.15.4371-4381.2003; Schroder G, 2002, J BACTERIOL, V184, P2767, DOI 10.1128/JB.184.10.2767-2779.2002; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Tribet C, 1996, P NATL ACAD SCI USA, V93, P15047, DOI 10.1073/pnas.93.26.15047; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319	34	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10955	10961		10.1074/jbc.M310422200	http://dx.doi.org/10.1074/jbc.M310422200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699106	hybrid			2022-12-25	WOS:000220157600017
J	Mylonis, I; Drosou, V; Brancorsini, S; Nikolakaki, E; Sassone-Corsi, P; Giannakouros, T				Mylonis, I; Drosou, V; Brancorsini, S; Nikolakaki, E; Sassone-Corsi, P; Giannakouros, T			Temporal association of protamine 1 with the inner nuclear membrane protein lamin B receptor during spermiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE METHOD; RNA-BINDING; KINASE; PHOSPHORYLATION; RAT; IDENTIFICATION; LOCALIZATION; QUANTITATION; EXPRESSION; CHROMATIN	During mammalian spermiogenesis, histones are replaced by transition proteins, which are in turn replaced by protamines P1 and P2. P1 protamine contains a short arginine/serine-rich (RS) domain that is highly phosphorylated before being deposited into sperm chromatin and almost completely dephosphorylated during sperm maturation. We now demonstrate that, in elongating spermatids, this phosphorylation is required for the temporal association of P1 protamine with lamin B receptor (LBR), an inner nuclear membrane protein that also possesses a stretch of RS dipeptides at its nucleoplasmic NH2-terminal domain. Previous studies have shown that the cellular protein p32 also binds tightly to the unmodified RS domain of LBR. Extending those findings, we now present evidence that p32 prevents phosphorylation of LBR and furthermore that dissociation of this protein precedes P1 protamine association. Our data suggest that docking of protamine 1 to the nuclear envelope is an important intermediate step in spermiogenesis and reveal a novel role for SR protein kinases and p32.	Aristotle Univ Thessaloniki, Dept Chem, Biochem Lab, Thessaloniki 54124, Greece; Inst Genet & Biol Mol & Cellulaire, F-67404 Strasbourg, France	Aristotle University of Thessaloniki; Institut National de la Sante et de la Recherche Medicale (Inserm)	Giannakouros, T (corresponding author), Aristotle Univ Thessaloniki, Dept Chem, Biochem Lab, GR-54006 Thessaloniki, Greece.	giannako@chem.auth.gr	Sassone-Corsi, Paolo/H-6182-2011; Brancorsini, Stefano/L-8770-2015; GIANNAKOUROS, THOMAS/R-3204-2019	Brancorsini, Stefano/0000-0002-8410-7248; Mylonis, Ilias/0000-0002-0893-6618				Alsheimer M, 1998, J CELL SCI, V111, P2227; BIGGIOGERA M, 1992, MICROSC RES TECHNIQ, V20, P259, DOI 10.1002/jemt.1070200305; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; CHIRAT F, 1993, BIOCHIM BIOPHYS ACTA, V1203, P109, DOI 10.1016/0167-4838(93)90043-Q; Erez O, 2001, MOL CELL BIOL, V21, P175, DOI 10.1128/MCB.21.1.175-184.2001; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; HECHT NB, 1995, DEV GENET, V16, P95, DOI 10.1002/dvg.1020160202; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; Kuroyanagi H, 2000, MECH DEVELOP, V99, P51, DOI 10.1016/S0925-4773(00)00477-9; Lewis JD, 2003, CHROMOSOMA, V111, P473, DOI 10.1007/s00412-002-0226-0; MARUSHIGE Y, 1978, BIOCHIM BIOPHYS ACTA, V518, P440, DOI 10.1016/0005-2787(78)90162-4; Meistrich M., 1989, HISTONES OTHER BASIC, P165; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; Nikolakaki E, 1996, J BIOL CHEM, V271, P8365, DOI 10.1074/jbc.271.14.8365; Nikolakaki E, 2001, J BIOL CHEM, V276, P40175, DOI 10.1074/jbc.M104755200; OLIVA R, 1991, PROG NUCLEIC ACID RE, V40, P25; Papoutsopoulou S, 1999, NUCLEIC ACIDS RES, V27, P2972, DOI 10.1093/nar/27.14.2972; Papoutsopoulou S, 1999, BIOCHEM BIOPH RES CO, V255, P602, DOI 10.1006/bbrc.1999.0249; PARVINEN M, 1972, ANAT REC, V174, P435, DOI 10.1002/ar.1091740404; Petersen-Mahrt SK, 1999, EMBO J, V18, P1014, DOI 10.1093/emboj/18.4.1014; Raukas E, 1999, BIOESSAYS, V21, P440, DOI 10.1002/(SICI)1521-1878(199905)21:5<440::AID-BIES11>3.0.CO;2-V; Sassone-Corsi P, 2002, SCIENCE, V296, P2176, DOI 10.1126/science.1070963; SIMOS G, 1992, EMBO J, V11, P4027, DOI 10.1002/j.1460-2075.1992.tb05496.x; SIMOS G, 1994, FEBS LETT, V346, P225, DOI 10.1016/0014-5793(94)00479-X; Soltys BJ, 2000, HISTOCHEM CELL BIOL, V114, P245; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; Wu JY, 2000, NAT GENET, V25, P448, DOI 10.1038/78153; YU L, 1995, J VIROL, V69, P3017, DOI 10.1128/JVI.69.5.3017-3023.1995	32	58	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11626	11631		10.1074/jbc.M311949200	http://dx.doi.org/10.1074/jbc.M311949200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701833	hybrid			2022-12-25	WOS:000220157600096
J	Schunemann, V; Lendzian, F; Jung, C; Contzen, J; Barra, AL; Sligar, SG; Trautwein, AX				Schunemann, V; Lendzian, F; Jung, C; Contzen, J; Barra, AL; Sligar, SG; Trautwein, AX			Tyrosine radical formation in the reaction of wild type and mutant cytochrome P450cam with peroxy acids - A multifrequency EPR study of intermediates on the millisecond time scale	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; HIGH-FIELD EPR; HORSERADISH-PEROXIDASE COMPOUND; COLI RIBONUCLEOTIDE REDUCTASE; HIGH-FREQUENCY EPR; Q-BAND ENDOR; ESCHERICHIA-COLI; SPIN-RESONANCE; PHOTOSYSTEM-II; MAGNETIC-RESONANCE	We report a multifrequency (9.6-, 94-, 190-, and 285-GHz) EPR study of a freeze-quenched intermediate obtained from reaction of substrate-free cytochrome P450cam (CYP101) and its Y96F and Y96F/Y75F mutants with peroxy acids. It is generally assumed that in such a shunt reaction an intermediate [Fe(IV) = O, porphyrin-pi-cation radical] is formed, which should be identical to the species in the natural reaction cycle. However, for the wild type as well as for the mutant proteins, a porphyrin-pi-cation radical is not detectable within 8 ms. Instead, EPR signals corresponding to tyrosine radicals are obtained for the wild type and the Y96F mutant. Replacement of both Tyr-96 and Tyr-75 by phenylalanine leads to the disappearance of the tyrosine EPR signals. EPR studies at 285 GHz on freeze-quenched wild type and Y96F samples reveal g tensor components for the radical (stretched g(x) values from 2.0078 to 2.0064, g(y) = 2.0043, and g(z) = 2.0022), which are fingerprints for tyrosine radicals in a heterogeneous polar environment. The measurements at 94 GHz using a fundamental mode microwave resonator setup confirm the 285-GHz study. From the simulation of the hyperfine structure in the 94- GHz EPR spectra the signals have been assigned to Tyr-96 in the wild type and to Tyr-75 in the Y96F mutant. We suggest that a transiently formed Fe(IV) = O porphyrin-pi-cation radical intermediate in P450cam is reduced by intramolecular electron transfer from these tyrosines within 8 ms.	Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Med Univ Lubeck, Inst Phys, D-23538 Lubeck, Germany; Tech Univ Berlin, Max Volmer Lab Biophys Chem, D-10623 Berlin, Germany; CNRS, Grenoble High Magnet Field Lab, F-38042 Grenoble 9, France; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Lubeck; Technical University of Berlin; Centre National de la Recherche Scientifique (CNRS); University of Illinois System; University of Illinois Urbana-Champaign	Schunemann, V (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13125 Berlin, Germany.	schuenemann@uni-Luebeck.de; lendzian@struktur.chem.tu-berlin.de; cjung@mdc-berlin.de	Schünemann, Volker/C-6603-2016					AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; [Anonymous], 1990, ELECT PARAMAGNETIC R, DOI DOI 10.1007/978-3-642-74599-7; ATKINS WM, 1988, J BIOL CHEM, V263, P18842; Ballou D P, 1978, Methods Enzymol, V54, P85; Bar G, 2001, J AM CHEM SOC, V123, P3569, DOI 10.1021/ja003108n; Barra AL, 2001, APPL MAGN RESON, V21, P619, DOI 10.1007/BF03162434; BECKER D, 1988, INT J RADIAT BIOL, V53, P767, DOI 10.1080/09553008814551121; BEINERT H, 1982, BIOCHIM BIOPHYS ACTA, V683, P245, DOI 10.1016/0304-4173(82)90003-9; BENDER CJ, 1989, J AM CHEM SOC, V111, P8076, DOI 10.1021/ja00203a002; BENECKY MJ, 1993, BIOCHEMISTRY-US, V32, P11929, DOI 10.1021/bi00095a024; BIEFUSS G, 2001, BIOCHEMISTRY-US, V40, P1562; BURGHAUS O, 1993, J PHYS CHEM-US, V97, P7639, DOI 10.1021/j100131a037; CARRINGTON A, 1969, INTRO MAGNETIC RESON, P132; CHAMULITRAT W, 1989, J BIOL CHEM, V264, P7889; Chouchane S, 2002, J BIOL CHEM, V277, P42633, DOI 10.1074/jbc.M207916200; Davydov R, 2001, J AM CHEM SOC, V123, P1403, DOI 10.1021/ja003583l; Dorlet P, 2000, BIOCHEMISTRY-US, V39, P7826, DOI 10.1021/bi000175l; Dorlet P, 2002, BIOCHEMISTRY-US, V41, P6107, DOI 10.1021/bi015871f; Egawa T, 2001, J BIOL INORG CHEM, V6, P46, DOI 10.1007/s007750000181; EGAWA T, 1991, J BIOL CHEM, V266, P10246; EGAWA T, 1994, BIOCHEM BIOPH RES CO, V201, P1464, DOI 10.1006/bbrc.1994.1868; FASANELL.EL, 1969, P NATL ACAD SCI USA, V62, P299, DOI 10.1073/pnas.62.2.299; GERFEN GJ, 1993, J AM CHEM SOC, V115, P6420, DOI 10.1021/ja00067a071; Graslund A, 1996, ANNU REV BIOPH BIOM, V25, P259; Green MT, 1999, J AM CHEM SOC, V121, P7939, DOI 10.1021/ja991541v; Guallar V, 2003, P NATL ACAD SCI USA, V100, P6998, DOI 10.1073/pnas.0732000100; Himo F, 1997, BIOPHYS J, V72, P1556, DOI 10.1016/S0006-3495(97)78803-9; Hofbauer W, 2001, P NATL ACAD SCI USA, V98, P6623, DOI 10.1073/pnas.101127598; Hoganson CW, 1996, J AM CHEM SOC, V118, P4672, DOI 10.1021/ja953979a; HUYETT JE, 1995, J AM CHEM SOC, V117, P9033, DOI 10.1021/ja00140a021; Ivancich A, 1999, J AM CHEM SOC, V121, P5743, DOI 10.1021/ja990562m; Ivancich A, 2001, BIOCHEMISTRY-US, V40, P6860, DOI 10.1021/bi002826j; Ivancich A, 2001, J AM CHEM SOC, V123, P5050, DOI 10.1021/ja0036514; Ivancich A, 1997, BIOCHEMISTRY-US, V36, P9356, DOI 10.1021/bi970886s; Ivancich A, 1996, J AM CHEM SOC, V118, P12852, DOI 10.1021/ja9628361; Jayaraj K, 1997, INORG CHEM, V36, P4555, DOI 10.1021/ic970597s; JUNG C, 1992, BIOCHEMISTRY-US, V31, P12855, DOI 10.1021/bi00166a021; JUNG C, 1991, BIOCHIM BIOPHYS ACTA, V1076, P130, DOI 10.1016/0167-4838(91)90229-S; KALYANARAMAN B, 1983, J BIOL CHEM, V258, P3855; Kellner DG, 2002, J BIOL CHEM, V277, P9641, DOI 10.1074/jbc.C100745200; Kolberg M, 2002, ARCH BIOCHEM BIOPHYS, V397, P57, DOI 10.1006/abbi.2001.2658; Lendzian F, 1996, J AM CHEM SOC, V118, P8111, DOI 10.1021/ja960917r; LEWIS D.F.V, 1996, CYTOCHROMES P450 STR; MacMillan F, 1999, BIOCHEMISTRY-US, V38, P9179, DOI 10.1021/bi9911987; MILLER AF, 1991, BIOCHIM BIOPHYS ACTA, V1056, P1, DOI 10.1016/S0005-2728(05)80067-2; MOMBOURQUETTE MJ, 1992, J MAGN RESON, V99, P37, DOI 10.1016/0022-2364(92)90153-X; NELSON DJ, 1977, J CHEM SOC PERK T 2, P2005, DOI 10.1039/p29770002005; Nimz O, 1998, APPL MAGN RESON, V14, P255, DOI 10.1007/BF03161893; Ogliaro F, 2002, J INORG BIOCHEM, V91, P554, DOI 10.1016/S0162-0134(02)00437-3; Ort D.R., 1996, ADV PHOTOSYNTH, P1; PALCIC MM, 1980, BIOCHEM BIOPH RES CO, V94, P1123, DOI 10.1016/0006-291X(80)90535-5; POULOS TL, 1987, BIOCHEMISTRY-US, V26, P8165, DOI 10.1021/bi00399a022; POULOS TL, 1986, BIOCHEMISTRY-US, V25, P5314, DOI 10.1021/bi00366a049; RIEGER PH, 1982, J MAGN RESON, V50, P485, DOI 10.1016/0022-2364(82)90013-0; Rigby SEJ, 2000, BIOCHEMISTRY-US, V39, P5921, DOI 10.1021/bi992614q; RIGBY SEJ, 1994, BIOCHEMISTRY-US, V33, P1734, DOI 10.1021/bi00173a016; RUTTER R, 1983, BIOCHEMISTRY-US, V22, P4769, DOI 10.1021/bi00289a024; RUTTER R, 1982, J BIOL CHEM, V257, P7958; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; SCHULZ CE, 1979, FEBS LETT, V103, P102, DOI 10.1016/0014-5793(79)81259-4; Schunemann V, 2002, J INORG BIOCHEM, V91, P586, DOI 10.1016/S0162-0134(02)00476-2; Schunemann V, 2000, FEBS LETT, V479, P149, DOI 10.1016/S0014-5793(00)01886-X; SCHUNEMANN V, 2004, IN PRESS HYPERFINE I; Sligar SG, 1977, MICROSOMES DRUG OXID, P202; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; STESMANS A, 1989, REV SCI INSTRUM, V60, P2949, DOI 10.1063/1.1140633; STONE EW, 1962, J CHEM PHYS, V37, P1326, DOI 10.1063/1.1733281; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Tanaka M, 2003, BIOPHYS J, V84, P1998, DOI 10.1016/S0006-3495(03)75008-5; Un S, 1996, BIOCHEMISTRY-US, V35, P679, DOI 10.1021/bi9523769; Un S, 2001, J AM CHEM SOC, V123, P3048, DOI 10.1021/ja003650b; UNGER BP, 1986, J BIOL CHEM, V261, P1158; Urano Y, 1997, J AM CHEM SOC, V119, P12008, DOI 10.1021/ja972892h; van Dam PJ, 1998, J AM CHEM SOC, V120, P5080, DOI 10.1021/ja9737127; WAGNER GC, 1981, J BIOL CHEM, V256, P6262; WAGNER GC, 1982, BIOL CHEM IRON, P405; Weber S, 2002, P NATL ACAD SCI USA, V99, P1319, DOI 10.1073/pnas.032469399	77	83	83	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10919	10930		10.1074/jbc.M307884200	http://dx.doi.org/10.1074/jbc.M307884200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14688245	hybrid			2022-12-25	WOS:000220157600013
J	Shiflett, SL; Ward, DM; Huynh, D; Vaughn, MB; Simmons, JC; Kaplan, J				Shiflett, SL; Ward, DM; Huynh, D; Vaughn, MB; Simmons, JC; Kaplan, J			Characterization of Vta1p, a class E Vps protein in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIVESICULAR-BODY; YEAST; COMPLEX; ENDOSOME; UBIQUITIN; PATHWAY; TRANSPORT; MEMBRANE; CHITIN; ENDOCYTOSIS	We identified VTA1 in a screen for mutations that result in altered vacuole morphology. Deletion of VTA1 resulted in delayed trafficking of the lipophilic dye FM4-64 to the vacuole and altered vacuolar morphology when cells were exposed to the dye 5-(and 6)-carboxy-2',7'-dichlorofluorescein diacetate (CDCFDA). Deletion of class E vacuolar protein sorting (VPS) genes, which encode proteins that affect multivesicular body formation, also showed altered vacuolar morphology upon exposure to high concentrations of CDCFDA. These results suggest a VPS defect for Deltavta1 cells. Deletion of VTA1 did not affect growth on raffinose and only mildly affected carboxypeptidase S sorting. Turnover of the surface protein Ste3p, the a-factor receptor, was affected in Deltavta1 cells with the protein accumulating on the vacuolar membrane. Likewise the alpha-factor receptor Ste2p accumulated on the vacuolar membrane in Deltavta1 cells. We demonstrated that many class E VPS deletion strains are hyper-resistant to the cell wall disruption agent calcofluor white. Deletion of VTA1 or VPS60, another putative class E gene, resulted in calcofluor white hypersensitivity. A Vta1p-green fluorescent protein fusion protein transiently associated with a Pep12p-positive compartment. This localization was altered by deletion of many of the class E VPS genes, indicating that Vta1p binds to endosomes in a manner dependent on the assembly of the endosomal sorting complexes required for transport. Membrane-associated Vta1p co-purified with Vps60p, suggesting that Vta1p is a class E Vps protein that interacts with Vps60p on a prevacuolar compartment.	Univ Utah, Hlth Sci Ctr, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Kaplan, J (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA.	jerry.kaplan@path.utah.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007464] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29622] Funding Source: Medline; NIGMS NIH HHS [5T32GM07464] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amerik AY, 2000, MOL BIOL CELL, V11, P3365, DOI 10.1091/mbc.11.10.3365; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Bowers K, 2000, MOL BIOL CELL, V11, P4277, DOI 10.1091/mbc.11.12.4277; Brachmann CB, 1998, YEAST, V14, P115; Davies BA, 2003, J BIOL CHEM, V278, P19826, DOI 10.1074/jbc.M301059200; DAVIS NG, 1993, J CELL BIOL, V122, P53, DOI 10.1083/jcb.122.1.53; Garcia-Rodriguez LJ, 2000, J BACTERIOL, V182, P2428, DOI 10.1128/JB.182.9.2428-2437.2000; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Ketela T, 1999, J BACTERIOL, V181, P3330, DOI 10.1128/JB.181.11.3330-3340.1999; Kranz A, 2001, MOL BIOL CELL, V12, P711, DOI 10.1091/mbc.12.3.711; Lussier M, 1997, GENETICS, V147, P435; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; Odorizzi G, 2003, J CELL SCI, V116, P1893, DOI 10.1242/jcs.00395; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Reggiori F, 2001, EMBO J, V20, P5176, DOI 10.1093/emboj/20.18.5176; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; Valdivia RH, 2003, P NATL ACAD SCI USA, V100, P10287, DOI 10.1073/pnas.1834246100; Valdivieso MH, 2000, J BACTERIOL, V182, P4752, DOI 10.1128/JB.182.17.4752-4757.2000; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Yeo SCL, 2003, J CELL SCI, V116, P3957, DOI 10.1242/jcs.00751	27	63	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10982	10990		10.1074/jbc.M312669200	http://dx.doi.org/10.1074/jbc.M312669200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701806	hybrid			2022-12-25	WOS:000220157600020
J	Liu, WC; Shen, XY; Yang, YZ; Yin, XL; Xie, JH; Yan, J; Jiang, JH; Liu, WJ; Wang, HZ; Sun, MY; Zheng, Y; Gu, JX				Liu, WC; Shen, XY; Yang, YZ; Yin, XL; Xie, JH; Yan, J; Jiang, JH; Liu, WJ; Wang, HZ; Sun, MY; Zheng, Y; Gu, JX			Trihydrophobin 1 is a new negative regulator of A-Raf kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CELL-CYCLE ARREST; B-RAF; MAP KINASE; HEMATOPOIETIC-CELLS; INDUCED PROLIFERATION; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; DROSOPHILA-MELANOGASTER; BIOCHEMICAL-PROPERTIES	Our previous work indicated that instead of binding to B-Raf or C-Raf, trihydrophobin 1 (TH1) specifically binds to A-Raf kinase both in vitro and in vivo. In this work, we investigated its function further. Using confocal microscopy, we found that TH1 colocalizes with A-Raf, which confirms our former results. The region of TH1 responsible for the interaction with A-Raf is mapped to amino acids 1 - 372. Coimmunoprecipitation experiments demonstrate that TH1 is associated with A-Raf in both quiescent and serum-stimulated cells. Wild type A-Raf binds increasingly to TH1 when it is activated by serum and/or upstream oncogenic Ras/Src compared with that of "kinase-dead" A-Raf. The latter can still bind to TH1 under the same experimental condition. The binding pattern of A-Raf implies that this interaction is mediated in part by the A-Raf kinase activity. As indicated by Raf protein kinase assays, TH1 inhibits A-Raf kinase, whereas neither B-Raf nor C-Raf kinase activity is influenced. Furthermore, we observed that TH1 inhibited cell cycle progression in TH1 stably transfected 7721 cells compared with mock cells, and flow cell cytometry analysis suggested that the TH1 stably transfected 7721 cells were G(0)/G(1) phase-arrested. Taken together, our data provide a clue to understanding the cellular function of TH1 on Raf isoform-specific regulation.	Fudan Univ, Shanghai Med Coll, State Key Lab Genet Engn, Shanghai 200032, Peoples R China; Fudan Univ, Shanghai Med Coll, Ctr Gene Res, Shanghai 200032, Peoples R China	Fudan University; Fudan University	Gu, JX (corresponding author), Fudan Univ, Shanghai Med Coll, State Key Lab Genet Engn, 138 Yixeuyuan Rd, Shanghai 200032, Peoples R China.	Jxgu@shmu.edu.cn	yang, yanzhong/AAH-6132-2019; liu, weicheng/D-4173-2013; Sun, Maoyun/I-6622-2012; Wang, Hanzhou/G-9814-2012	Wang, Hanzhou/0000-0002-0493-827X				AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BANGA SS, 1995, MOL GEN GENET, V246, P148, DOI 10.1007/BF00294677; Barnard D, 1998, ONCOGENE, V17, P1539, DOI 10.1038/sj.onc.1202061; Boldyreff B, 1997, FEBS LETT, V403, P197, DOI 10.1016/S0014-5793(97)00010-0; Bonthron DT, 2000, HUM GENET, V107, P165, DOI 10.1007/s004390000344; Bosch E, 1997, ONCOGENE, V15, P1021, DOI 10.1038/sj.onc.1201270; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; Chang FM, 2001, ONCOGENE, V20, P4354, DOI 10.1038/sj.onc.1204564; Chen S, 2003, J BIOL CHEM, V278, P20029, DOI 10.1074/jbc.M300818200; Cioffi CL, 1997, MOL PHARMACOL, V51, P383; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; Guan KL, 2000, J BIOL CHEM, V275, P27354; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hagemann C, 1997, FEBS LETT, V403, P200, DOI 10.1016/S0014-5793(97)00011-2; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kuroda S, 1996, J BIOL CHEM, V271, P14680, DOI 10.1074/jbc.271.25.14680; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; McCubrey JA, 1998, LEUKEMIA, V12, P1903, DOI 10.1038/sj.leu.2401215; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MUSZYNSKI KW, 1995, J EXP MED, V181, P2189, DOI 10.1084/jem.181.6.2189; NETZKER R, 1992, J BIOL CHEM, V267, P6421; Pritchard CA, 1996, CURR BIOL, V6, P614, DOI 10.1016/S0960-9822(02)00548-1; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Rosario M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270; Rosario M, 2001, MOL CELL BIOL, V21, P3750, DOI 10.1128/MCB.21.11.3750-3762.2001; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Shinkai M, 1996, BIOCHEM BIOPH RES CO, V223, P729, DOI 10.1006/bbrc.1996.0964; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STORM SM, 1990, ONCOGENE, V5, P345; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Sutor SL, 1999, J BIOL CHEM, V274, P7002, DOI 10.1074/jbc.274.11.7002; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WADEWITZ AG, 1993, ONCOGENE, V8, P1055; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421; Wojnowski L, 2000, MECH DEVELOP, V91, P97, DOI 10.1016/S0925-4773(99)00276-2; Wojnowski L, 1998, MECH DEVELOP, V76, P141, DOI 10.1016/S0925-4773(98)00111-7; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Wu XY, 1996, J BIOL CHEM, V271, P3265, DOI 10.1074/jbc.271.6.3265; Yin XL, 2002, BBA-MOL CELL RES, V1589, P71, DOI 10.1016/S0167-4889(01)00188-4; Yin XL, 2002, MOL CELL BIOCHEM, V231, P69, DOI 10.1023/A:1014437024129; Yip-Schneider MT, 2000, BIOCHEM J, V351, P151, DOI 10.1042/0264-6021:3510151; Yuryev A, 1998, Cell Res, V8, P81; Yuryev A, 2000, MOL CELL BIOL, V20, P4870, DOI 10.1128/MCB.20.13.4870-4878.2000; Zhang SW, 2002, J BIOL CHEM, V277, P35314, DOI 10.1074/jbc.M202179200; Zhang SW, 2001, MOL CELL BIOCHEM, V221, P161, DOI 10.1023/A:1010932211745; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	67	16	17	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10167	10175		10.1074/jbc.M307994200	http://dx.doi.org/10.1074/jbc.M307994200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14684750	hybrid			2022-12-25	WOS:000220050400063
J	Paumann, M; Lubura, B; Regelsberger, G; Feichtinger, M; Kollensberger, G; Jakopitsch, C; Furtmuller, PG; Peschek, GA; Obinger, C				Paumann, M; Lubura, B; Regelsberger, G; Feichtinger, M; Kollensberger, G; Jakopitsch, C; Furtmuller, PG; Peschek, GA; Obinger, C			Soluble Cu-A domain of cyanobacterial cytochrome c oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SEQUENCE ALIGNMENT; BLUE-GREEN-ALGAE; SP. PCC 6803; PARACOCCUS-DENITRIFICANS; SUBUNIT-II; RHODOBACTER-SPHAEROIDES; ANABAENA-VARIABILIS; ANACYSTIS-NIDULANS; FOLD RECOGNITION; SURFACE MUTANTS	The genomes of several cyanobacteria show the existence of gene clusters encoding subunits I, II, and III of aa(3)-type cytochrome c oxidase. The enzyme occurs on both plasma and thylakoid membranes of these oxygenic phototrophic prokaryotes. Here we report the expression and purification of a truncated subunit II copper A (Cu-A) domain (i.e. the electron entry and donor binding site) of cytochrome c oxidase from the cyanobacterium Synechocystis PCC 6803 in high yield. The water-soluble purple redox-active bimetallic center displays a relatively low standard reduction potential of 216 mV. Its absorption spectrum at pH 7 is similar to that of other soluble fragments from aa(3)-type oxidases, but the insensitivity of both absorbance and circular dichroism spectra to pH suggests that it is less exposed to the aqueous milieu compared with other CuA domains. Oxidation of horse heart cytochrome c by the bimetallic center follows monophasic kinetics. At pH 7 and low ionic strength the bimolecular rate constant is (2.1 +/- 0.3) x 10(4) M-1 s(-1), and the rates decrease upon the increase of ionic strength. Sequence alignment and modeling of cyanobacterial CuA domains show several peculiarities such as: (i) a large insertion located between the second transmembrane region and the putative hydrophobic cytochrome c docking site, (ii) the lack of acidic residues shown to be important in the interaction between cytochrome c and Paracoccus CuA domain, and (iii) an extended C terminus similar to Escherichia coli ubiquinol oxidase.	BOKU, Univ Nat Resources & Appl Life Sci, Dept Chem, Div Biochem,Metalloprot Res Grp, A-1190 Vienna, Austria; Univ Vienna, Inst Phys Chem, Mol Bioenerget Grp, A-1090 Vienna, Austria	University of Natural Resources & Life Sciences, Vienna; University of Vienna	Obinger, C (corresponding author), BOKU, Univ Nat Resources & Appl Life Sci, Dept Chem, Div Biochem,Metalloprot Res Grp, Muthgasse 18, A-1190 Vienna, Austria.	christian.obinger@boku.ac.at	Furtmüller, Paul G./Y-5819-2018; Obinger, Christian/AAV-3173-2021	Furtmüller, Paul G./0000-0002-1199-2469; Obinger, Christian/0000-0002-7133-3430; Jakopitsch, Christa/0000-0002-5855-2057; Regelsberger, Gunther/0000-0002-3233-1491				Abramson J, 2000, NAT STRUCT BIOL, V7, P910; Abramson J, 2001, BBA-PROTEIN STRUCT M, V1544, P1, DOI 10.1016/S0167-4838(00)00241-7; ALGE D, 1993, BIOCHEM MOL BIOL INT, V29, P511; ALGE D, 1993, BIOCHEM BIOPH RES CO, V191, P9, DOI 10.1006/bbrc.1993.1177; ALGE D, 1994, GENE, V138, P127, DOI 10.1016/0378-1119(94)90794-3; BANCI L, 2001, HDB METALLOPROTEINS, V1, P33; Blankenship RE, 2001, TRENDS PLANT SCI, V6, P4, DOI 10.1016/S1360-1385(00)01831-8; BRODA E, 1979, J THEOR BIOL, V81, P201, DOI 10.1016/0022-5193(79)90160-7; Bronsted JN, 1924, J AM CHEM SOC, V46, P555, DOI 10.1021/ja01668a006; CALHOUN MW, 1994, TRENDS BIOCHEM SCI, V19, P325, DOI 10.1016/0968-0004(94)90071-X; CASTRESANA J, 1994, EMBO J, V13, P2516, DOI 10.1002/j.1460-2075.1994.tb06541.x; Drosou V, 2002, BIOCHEMISTRY-US, V41, P10629, DOI 10.1021/bi020094k; Dutton P L, 1978, Methods Enzymol, V54, P411; Fromwald S, 1999, ARCH BIOCHEM BIOPHYS, V367, P122, DOI 10.1006/abbi.1999.1236; FRY IV, 1988, METHOD ENZYMOL, V167, P450; Gupta S, 2001, BIOCHEMISTRY-US, V40, P6180, DOI 10.1021/bi002212e; HAFELE U, 1988, BIOCHIM BIOPHYS ACTA, V934, P186, DOI 10.1016/0005-2728(88)90181-8; Hennig L, 1999, BIOTECHNIQUES, V26, P1170, DOI 10.2144/99266bc02; Howitt CA, 1998, BIOCHEMISTRY-US, V37, P17944, DOI 10.1021/bi981486n; ISO GUM, 1995, GUID EXPR UNC MEAS, Vfirst; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; Jones DT, 1999, J MOL BIOL, V287, P797, DOI 10.1006/jmbi.1999.2583; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Jones DT, 1998, FEBS LETT, V423, P281, DOI 10.1016/S0014-5793(98)00095-7; Kaneko T, 1996, DNA Res, V3, P109; Komorowski L, 2001, J BIOENERG BIOMEMBR, V33, P27, DOI 10.1023/A:1005668522801; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAPPALAINEN P, 1993, J BIOL CHEM, V268, P26416; LARSSON S, 1995, P NATL ACAD SCI USA, V92, P7167, DOI 10.1073/pnas.92.16.7167; Lassmann T, 2002, FEBS LETT, V529, P126, DOI 10.1016/S0014-5793(02)03189-7; LOCKAU W, 1981, ARCH MICROBIOL, V128, P336, DOI 10.1007/BF00422541; Malatesta F, 1998, FEBS LETT, V434, P322, DOI 10.1016/S0014-5793(98)01006-0; MCGEOCH DJ, 1985, VIRUS RES, V3, P271, DOI 10.1016/0168-1702(85)90051-6; McGuffin LJ, 2003, BIOINFORMATICS, V19, P874, DOI 10.1093/bioinformatics/btg097; Morgenstern B, 1999, BIOINFORMATICS, V15, P211, DOI 10.1093/bioinformatics/15.3.211; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Navarro JA, 1997, J BIOL INORG CHEM, V2, P11, DOI 10.1007/s007750050101; NICHOLLS P, 1992, BIOCHIM BIOPHYS ACTA, V1098, P184, DOI 10.1016/S0005-2728(05)80335-4; NITSCHKE W, 1991, TRENDS BIOCHEM SCI, V16, P241, DOI 10.1016/0968-0004(91)90095-D; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PESCHEK GA, 1982, ARCH MICROBIOL, V131, P261, DOI 10.1007/BF00405890; Peschek GA, 1996, BIOCHEM SOC T, V24, P729, DOI 10.1042/bst0240729; Peschek GA, 1996, BBA-BIOENERGETICS, V1275, P27, DOI 10.1016/0005-2728(96)00045-X; PESCHEK GA, 1994, BBA-BIOENERGETICS, V1187, P369, DOI 10.1016/0005-2728(94)90011-6; PESCHEK GA, 1994, FEMS MICROBIOL LETT, V124, P431, DOI 10.1111/j.1574-6968.1994.tb07320.x; PETTGREW GW, 1987, CYTOCHROMES C BIOL A; Roberts VA, 1999, J BIOL CHEM, V274, P38051, DOI 10.1074/jbc.274.53.38051; Romero A, 1998, J MOL BIOL, V275, P327, DOI 10.1006/jmbi.1997.1455; SANDMANN G, 1980, PLANT SCI LETT, V17, P417, DOI 10.1016/0304-4211(80)90128-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Slutter CE, 1996, BIOCHEMISTRY-US, V35, P3387, DOI 10.1021/bi9525839; SONE N, 1993, BIOCHIM BIOPHYS ACTA, V1183, P130, DOI 10.1016/0005-2728(93)90012-5; Sorlie M, 2000, ANAL BIOCHEM, V287, P118, DOI 10.1006/abio.2000.4826; STANIER RY, 1971, BACTERIOL REV, V35, P171, DOI 10.1128/MMBR.35.2.171-205.1971; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Svensson-Ek M, 2002, J MOL BIOL, V321, P329, DOI 10.1016/S0022-2836(02)00619-8; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wang KF, 1999, J BIOL CHEM, V274, P38042, DOI 10.1074/jbc.274.53.38042; WASTYN M, 1987, BIOCHEM BIOPH RES CO, V149, P102, DOI 10.1016/0006-291X(87)91610-X; WIKSTROM M, 1989, NATURE, V338, P776, DOI 10.1038/338776a0; Wilmanns M, 1995, P NATL ACAD SCI USA, V92, P11955, DOI 10.1073/pnas.92.26.11955; Witt H, 1998, J BIOL CHEM, V273, P5132, DOI 10.1074/jbc.273.9.5132; Zhen YJ, 1999, J BIOL CHEM, V274, P38032, DOI 10.1074/jbc.274.53.38032	66	25	25	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10293	10303		10.1074/jbc.M308903200	http://dx.doi.org/10.1074/jbc.M308903200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14672950	hybrid			2022-12-25	WOS:000220050400078
J	Verhamme, IM; Bock, PE; Jackson, CM				Verhamme, IM; Bock, PE; Jackson, CM			The preferred pathway of glycosaminoglycan-accelerated inactivation of thrombin by heparin cofactor II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUANTITATIVE AFFINITY-CHROMATOGRAPHY; BLOOD-COAGULATION PROTEINASES; PEPTIDE CHLOROMETHYL KETONES; FIBRIN-BOUND THROMBIN; AMINO-ACID-RESIDUES; ANTITHROMBIN-III; DERMATAN SULFATE; ALPHA-THROMBIN; EXOSITE-I; PROTHROMBIN FRAGMENT-2	Thrombin ( T) inactivation by the serpin, heparin cofactor II (HCII), is accelerated by the glycosaminoglycans (GAGs) dermatan sulfate (DS) and heparin ( H). Equilibrium binding and thrombin inactivation kinetics at pH 7.8 and ionic strength ( I) 0.125 M demonstrated that DS and heparin bound much tighter to thrombin (K-T(DS) 1 - 5.8 muM; K-T(H) 0.02 - 0.2 muM) than to HCII (K-HCII(DS) 236 - 291 muM; K-HCII(H) 25 - 35 muM), favoring formation of T . GAG over HCII . GAG complexes as intermediates for T GAG . HCII complex assembly. At [GAG] << KHCII( GAG) the GAG and HCII concentration dependences of the first-order inactivation rate constants (k(app)) were hyperbolic, reflecting saturation of T . GAG complex and formation of the T . GAG . HCII complex from T . GAG and free HCII, respectively. At [GAG] >> K-HCII(GAG), HCII . GAG complex formation caused a decrease in k(app). The bell-shaped logarithmic GAG dependences fit an obligatory template mechanism in which free HCII binds GAG in the T . GAG complex. DS and heparin bound fluorescently labeled meizothrombin(des-fragment 1) (MzT(- F1)) with KMzT(-F1)(GAG) 10 and 20 muM, respectively, demonstrating a binding site outside of exosite II. Exosite II ligands did not attenuate the DS-accelerated thrombin inactivation markedly, but DS displaced thrombin from heparin-Sepharose, suggesting that DS and heparin share a restricted binding site in or nearby exosite II, in addition to binding outside exosite II. Both T . DS and MzT(- F1) . DS interactions were saturable at DS concentrations substantially below K-HCII( DS), consistent with DS bridging T . DS and free HCII. The results suggest that GAG template action facilitates ternary complex formation and accommodates HCII binding to GAG and thrombin exosite I in the ternary complex.	Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA; Hemosaga Diagnost Corp, San Diego, CA 92121 USA	Vanderbilt University	Verhamme, IM (corresponding author), Vanderbilt Univ, Sch Med, Dept Pathol, C3321A Med Ctr N, Nashville, TN 37232 USA.	Ingrid.Verhamme@vanderbilt.edu	Jackson, Craig M/AAC-6338-2020	Jackson, Craig/0000-0001-9484-4420	NHLBI NIH HHS [HL-38779, HL-32373] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032373, R29HL038779, R01HL038779] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; Baglin TP, 2002, P NATL ACAD SCI USA, V99, P11079, DOI 10.1073/pnas.162232399; BAHR V, 1993, MOL BIOCHEM PARASIT, V58, P107, DOI 10.1016/0166-6851(93)90095-F; Bauman SJ, 1999, J BIOL CHEM, V274, P34556, DOI 10.1074/jbc.274.49.34556; Becker DL, 1999, J BIOL CHEM, V274, P6226, DOI 10.1074/jbc.274.10.6226; Bock PE, 1997, J BIOL CHEM, V272, P19837, DOI 10.1074/jbc.272.32.19837; BOCK PE, 1992, J BIOL CHEM, V267, P14963; BOCK PE, 1992, J BIOL CHEM, V267, P14974; BODE W, 1992, PROTEIN SCI, V1, P426; CARLISLE TL, 1990, J BIOL CHEM, V265, P22044; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; CHURCH FC, 1989, J BIOL CHEM, V264, P3618; CHURCH FC, 1987, BIOCHEM BIOPH RES CO, V148, P362, DOI 10.1016/0006-291X(87)91119-3; CHURCH FC, 1987, ARCH BIOCHEM BIOPHYS, V259, P331, DOI 10.1016/0003-9861(87)90499-1; CHURCH FC, 1988, FEBS LETT, V237, P26, DOI 10.1016/0014-5793(88)80164-9; Colwell NS, 1999, BBA-PROTEIN STRUCT M, V1431, P148, DOI 10.1016/S0167-4838(99)00051-5; Colwell NS, 1998, BIOCHEMISTRY-US, V37, P15057, DOI 10.1021/bi980925f; Colwell NS, 1997, BRIT J HAEMATOL, V97, P219, DOI 10.1046/j.1365-2141.1997.d01-2145.x; Cooper ST, 2002, THROMB RES, V107, P67, DOI 10.1016/S0049-3848(02)00180-9; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; DUGGLEBY RG, 1977, BIOCHIM BIOPHYS ACTA, V481, P297, DOI 10.1016/0005-2744(77)90264-9; FENTON JW, 1977, J BIOL CHEM, V252, P3587; FENTON JW, 1989, ANN NY ACAD SCI, V556, P158; Fredenburgh JC, 2001, J BIOL CHEM, V276, P44828, DOI 10.1074/jbc.M108710200; GAN ZR, 1994, J BIOL CHEM, V269, P1301; GRIFFITH MJ, 1985, BIOCHEMISTRY-US, V24, P6777, DOI 10.1021/bi00345a008; Han JH, 1997, J BIOL CHEM, V272, P28660, DOI 10.1074/jbc.272.45.28660; HAYAKAWA Y, 1995, BLOOD COAGUL FIBRIN, V6, P643, DOI 10.1097/00001721-199510000-00004; Hayakawa Y, 2000, J BIOL CHEM, V275, P11379, DOI 10.1074/jbc.275.15.11379; HOGG PJ, 1990, J BIOL CHEM, V265, P248; HOGG PJ, 1989, P NATL ACAD SCI USA, V86, P3619, DOI 10.1073/pnas.86.10.3619; HOGG PJ, 1985, ARCH BIOCHEM BIOPHYS, V240, P70, DOI 10.1016/0003-9861(85)90009-8; Hogg PJ, 1996, J BIOL CHEM, V271, P26088, DOI 10.1074/jbc.271.42.26088; HORTIN GL, 1989, J BIOL CHEM, V264, P13979; Huntington JA, 2003, J THROMB HAEMOST, V1, P1535, DOI 10.1046/j.1538-7836.2003.00305.x; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; Liaw PCY, 1999, J BIOL CHEM, V274, P27597, DOI 10.1074/jbc.274.39.27597; Liaw PCY, 2001, J BIOL CHEM, V276, P20959, DOI 10.1074/jbc.M010584200; LINDAHL P, 1991, BIOCHEM J, V276, P387, DOI 10.1042/bj2760387; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P539, DOI 10.1016/0167-4838(83)90272-8; Maaroufi RM, 1997, BIOMATERIALS, V18, P359, DOI 10.1016/0142-9612(95)00355-X; MACHOVICH R, 1975, BIOCHIM BIOPHYS ACTA, V379, P193, DOI 10.1016/0005-2795(75)90022-7; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; Mitchell JW, 2002, J BIOL CHEM, V277, P19823, DOI 10.1074/jbc.M200630200; Munro PD, 2000, J THEOR BIOL, V203, P407, DOI 10.1006/jtbi.2000.1099; Myles T, 1998, J BIOL CHEM, V273, P31203, DOI 10.1074/jbc.273.47.31203; NICHOL LW, 1981, BIOCHEMISTRY-US, V20, P4856, DOI 10.1021/bi00520a008; NORDENMAN B, 1978, EUR J BIOCHEM, V90, P1, DOI 10.1111/j.1432-1033.1978.tb12567.x; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OLSON ST, 1988, J BIOL CHEM, V263, P1698; RAGG H, 1990, J BIOL CHEM, V265, P22386; ROGERS SJ, 1992, J BIOL CHEM, V267, P3613; SACHE E, 1982, THROMB RES, V25, P443, DOI 10.1016/0049-3848(82)90086-X; Segel I. H, 1975, ENZYME KINETICS, P178; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; SHEEHAN JP, 1994, J BIOL CHEM, V269, P32747; Shi F, 1998, BIOPHYS CHEM, V75, P187, DOI 10.1016/S0301-4622(98)00205-1; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; STREUSAND VJ, 1995, J BIOL CHEM, V270, P9043, DOI 10.1074/jbc.270.16.9043; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; Tasset DM, 1997, J MOL BIOL, V272, P688, DOI 10.1006/jmbi.1997.1275; TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031; TOLLEFSEN DM, 1982, J BIOL CHEM, V257, P2162; TOLLEFSEN DM, 1986, J BIOL CHEM, V261, P8854; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; VANBOECKEL CAA, 1994, NAT STRUCT BIOL, V1, P423, DOI 10.1038/nsb0794-423; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; Verhamme IM, 2002, J BIOL CHEM, V277, P6788, DOI 10.1074/jbc.M110257200; VERHAMME IMA, 1989, ARCH INT PHYSL BIOCH, V97, pB117; WINZOR DJ, 1995, QUANTITATIVE CHARACT, P62	71	41	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9785	9795		10.1074/jbc.M313962200	http://dx.doi.org/10.1074/jbc.M313962200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701814	hybrid			2022-12-25	WOS:000220050400017
J	Wang, AM; Hascall, VC				Wang, AM; Hascall, VC			Hyaluronan structures synthesized by rat mesangial cells in response to hyperglycemia induce monocyte adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SMOOTH-MUSCLE-CELLS; CARBOHYDRATE ELECTROPHORESIS FACE; EXPERIMENTAL DIABETIC-NEPHROPATHY; HIGH GLUCOSE CONDITIONS; GROWTH-FACTOR-BETA; PROSTAGLANDIN PRODUCTION; RENAL HYPERTROPHY; GLOMERULAR CELLS; EXPRESSION	Mesangial expansion, the principal glomerular lesion in diabetic nephropathy, is preceded by a phenotypic activation and transient proliferation of the glomerular mesangial cells and by a prominent glomerular infiltration of monocytes and macrophages. Because this infiltration seems to play a key role in the subsequent mesangial matrix expansion, we tested the response of cultures of rat mesangial cells (RMCs) for monocyte adhesion in response to hyperglycemia. Increasing the medium glucose concentration from 5.6 mM ( normal) to 25.6 mM ( hyperglycemic) significantly increased hyaluronan in the cell matrix, with a concurrent 3- to 4-fold increase in adhesion of U937 monocytic leukemic cells to cultures of near confluent RMCs. These responses were attributed directly to the high glucose concentration and not to increased extracellular osmolality. The monocytes primarily bind directly to hyaluronan-based structures in vitro. Abnormal deposits of hyaluronan were found in glomeruli of kidney sections from diabetic rats 1 week after streptozotocin treatment, often with closely associated monocytes/macrophages, suggesting that similar structures are relevant in vivo. The monocyte adhesion response to high glucose concentration required growth stimulation of RMCs by serum and activation of protein kinase C, and was inhibited by prior passage of the RMCs in the presence of heparin. These results suggest that the response may be cell growth state and protein kinase C-dependent. When incubated with the viral mimetic, poly I: C, in the presence of normal glucose, heparin-passaged RMCs still increased cell-associated hyaluronan and exhibited hyaluronan-mediated adhesion of monocytes, indicating that the two stimuli, high glucose and viral mimetic, induce the production of the hyaluronan structures that promote monocyte adhesion by distinctly different intracellular signaling mechanisms.	Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Wang, AM (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, 9500 Euclid Ave,ND20, Cleveland, OH 44195 USA.	wanga@bme.ri.ccf.org			NIDDK NIH HHS [K01 DK02847] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002847] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Babazono T, 1998, DIABETES, V47, P668, DOI 10.2337/diabetes.47.4.668; BARZU T, 1994, J CELL PHYSIOL, V160, P239, DOI 10.1002/jcp.1041600205; Calabro A, 2000, GLYCOBIOLOGY, V10, P273, DOI 10.1093/glycob/10.3.273; Calabro A, 2000, GLYCOBIOLOGY, V10, P283, DOI 10.1093/glycob/10.3.283; Calabro A, 2001, OSTEOARTHR CARTILAGE, V9, pS16, DOI 10.1053/joca.2001.0439; CALABRO A, 2000, PROTEOGLYCANS STRUCT, P5; Craven PA, 1995, J DIABETES COMPLICAT, V9, P241, DOI 10.1016/1056-8727(95)80012-4; CRAVEN PA, 1987, METABOLISM, V36, P95, DOI 10.1016/0026-0495(87)90070-9; de la Motte CA, 2003, AM J PATHOL, V163, P121, DOI 10.1016/S0002-9440(10)63636-X; de la Motte CA, 1999, J BIOL CHEM, V274, P30747, DOI 10.1074/jbc.274.43.30747; DERUBERTIS FR, 1994, DIABETES, V43, P1, DOI 10.2337/diabetes.43.1.1; DIAMOND JR, 1991, AM J PHYSIOL, V260, pF779, DOI 10.1152/ajprenal.1991.260.6.F779; DICORLETO PE, 1985, J CLIN INVEST, V75, P1153, DOI 10.1172/JCI111810; Dunlop ME, 1996, KIDNEY INT, V50, P40, DOI 10.1038/ki.1996.284; Erikstrup C, 2001, EUR J ENDOCRINOL, V145, P193, DOI 10.1530/eje.0.1450193; FURUTA T, 1993, AM J KIDNEY DIS, V21, P480, DOI 10.1016/S0272-6386(12)80393-3; GAMBARO G, 1992, KIDNEY INT, V42, P285, DOI 10.1038/ki.1992.288; GAMBARO G, 1994, KIDNEY INT, V46, P797, DOI 10.1038/ki.1994.335; Glogowski EA, 1999, KIDNEY INT, V55, P486, DOI 10.1046/j.1523-1755.1999.00284.x; Haneda M, 1997, DIABETES, V46, P847, DOI 10.2337/diabetes.46.5.847; Hascall VC, 2000, GLYCOCONJUGATE J, V17, P607, DOI 10.1023/A:1011082728155; HEGELE RG, 1989, CLIN INVEST MED, V12, P181; Jones S, 2001, KIDNEY INT, V59, P1739, DOI 10.1046/j.1523-1755.2001.0590051739.x; KIKKAWA R, 1994, DIABETOLOGIA, V37, P838, DOI 10.1007/BF00404342; KLEIN DJ, 1986, DIABETES, V35, P1130, DOI 10.2337/diabetes.35.10.1130; MAHADEVAN P, 1995, DIABETOLOGIA, V38, P298, DOI 10.1007/s001250050285; Majors AK, 2003, J BIOL CHEM, V278, P47223, DOI 10.1074/jbc.M304871200; MAUER SM, 1994, KIDNEY INT, V45, P612, DOI 10.1038/ki.1994.80; MENE P, 1989, PHYSIOL REV, V69, P1347, DOI 10.1152/physrev.1989.69.4.1347; Mene P, 1996, KIDNEY INT, V50, P417, DOI 10.1038/ki.1996.331; MENE P, 1995, NEPHROL DIAL TRANSPL, V10, P481, DOI 10.1093/ndt/10.4.481; Mene P, 2001, NEPHROL DIAL TRANSPL, V16, P913, DOI 10.1093/ndt/16.5.913; Mukhopadhyay D, 2001, ARCH BIOCHEM BIOPHYS, V394, P173, DOI 10.1006/abbi.2001.2552; NAKAMURA T, 1993, DIABETES, V42, P450, DOI 10.2337/diabetes.42.3.450; RADOUNIKLI A, 1995, NEPHROL DIAL TRANSPL, V10, P185; Rodriguez-Iturbe B, 2001, KIDNEY INT, V59, P1626, DOI 10.1046/j.1523-1755.2001.0590051626.x; SCHAMBELAN M, 1985, J CLIN INVEST, V75, P404, DOI 10.1172/JCI111714; SHANKLAND SJ, 1994, KIDNEY INT, V46, P430, DOI 10.1038/ki.1994.291; SHARMA K, 1995, DIABETES, V44, P1139, DOI 10.2337/diabetes.44.10.1139; SIMONSON MS, 1990, METHOD ENZYMOL, V187, P544; Takeda M, 2001, METABOLISM, V50, P789, DOI 10.1053/meta.2001.24207; TEMPLETON DM, 1990, J BIOL CHEM, V265, P21764; Templeton DM, 2000, CARDIOVASC RES, V45, P503, DOI 10.1016/S0008-6363(99)00357-0; TOOLE BP, 2000, PROTEOGLYCANS STRUCT, P61; Wang AM, 1996, KIDNEY INT, V49, P437, DOI 10.1038/ki.1996.63; WANG AM, 1994, J CELL PHYSIOL, V159, P295, DOI 10.1002/jcp.1041590213; Wolf G, 1999, KIDNEY INT, V56, P393, DOI 10.1046/j.1523-1755.1999.00590.x; Young B., 1992, Journal of the American Society of Nephrology, V3, P770; YOUNG BA, 1995, KIDNEY INT, V47, P935, DOI 10.1038/ki.1995.139	49	89	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10279	10285		10.1074/jbc.M312045200	http://dx.doi.org/10.1074/jbc.M312045200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14679194	hybrid			2022-12-25	WOS:000220050400076
J	Zhuang, SH; Nguyen, GT; Chen, YC; Gudi, T; Eigenthaler, M; Jarchau, T; Walter, U; Boss, GR; Pilz, RB				Zhuang, SH; Nguyen, GT; Chen, YC; Gudi, T; Eigenthaler, M; Jarchau, T; Walter, U; Boss, GR; Pilz, RB			Vasodilator-stimulated phosphoprotein activation of serum-response element-dependent transcription occurs downstream of RhoA and is inhibited by cGMP-dependent protein kinase phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REQUIRES NUCLEAR TRANSLOCATION; INTACT HUMAN PLATELETS; F-ACTIN BINDING; ENA/VASP PROTEINS; GENE-EXPRESSION; FOCAL ADHESION; FIBROBLAST MOTILITY; CELL-ADHESION; FOS PROMOTER; NITRIC-OXIDE	Vasodilator-stimulated phosphoprotein (VASP) associates with cytoskeletal structures and promotes F-actin formation. RhoA, a member of the Ras superfamily of proteins, activates serum response element (SRE)-dependent transcription through changes in actin dynamics. We now show that the F-actin binding region of VASP is required for VASP stimulation of SRE-dependent transcription, and that VASP is downstream of RhoA in stimulating SRE-dependent transcription. The isolated carboxyl-terminal coiled-coil region of VASP mediates protein tetramerization and has been used as a dominant negative form of VASP; we found that it forms complexes with endogenous VASP in vivo and inhibits in a dose-dependent fashion serum, RhoA-, and VASP-stimulatedSRE-dependent transcription. Cyclic GMP-dependent protein kinase (G-kinase) inhibits RhoA activation of SREdependent transcription (Gudi, T., Chen, J. C., Casteel, D. E., Seasholtz, T. M., Boss, G. R., and Pilz, R. B. (2002) J. Biol. Chem. 277, 37382-37393). We now show that the G-kinase inhibition that occurs downstream of RhoA can be explained, at least in part, by G-kinase phosphorylation of VASP on Ser(239) at the carboxyl-terminal end of the G-actin binding site, with some contribution by phosphorylation of Ser(157), which is proximal to the profilin binding site. A phosphorylation-deficient VASP mutant can partly prevent cGMP/G-kinase inhibition of serum- and RhoA- induced SRE-dependent transcription. These studies show that VASP, an important component of the cellular microfilament system, plays a major role in regulating SRE-dependent transcription, and that G-kinase regulates VASP activity.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Klinikum Univ Wurzburg, Inst Klin Biochem & Pathobiochem, D-97080 Wurzburg, Germany	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Wurzburg	Pilz, RB (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.	rpilz@ucsd.edu	Walter, ulrich/W-2478-2017	Walter, ulrich/0000-0001-6784-2307; Boss, Gerry/0000-0002-9758-8714	NCI NIH HHS [CA89828] Funding Source: Medline; NIGMS NIH HHS [GM55586] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R33CA089828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055586] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; Arguinzonis MIG, 2002, J BIOL CHEM, V277, P45604, DOI 10.1074/jbc.M202873200; Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; BUTT E, 1992, BIOCHEM PHARMACOL, V43, P2591, DOI 10.1016/0006-2952(92)90148-C; BUTT E, 1994, J BIOL CHEM, V269, P14509; Castellano F, 2001, EMBO J, V20, P5603, DOI 10.1093/emboj/20.20.5603; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; Geese M, 2002, MOL BIOL CELL, V13, P2383, DOI 10.1091/mbc.E02-01-0058; Geneste O, 2002, J CELL BIOL, V157, P831, DOI 10.1083/jcb.200203126; Gineitis D, 2001, J BIOL CHEM, V276, P24531, DOI 10.1074/jbc.M102678200; Grosse R, 2003, EMBO J, V22, P3050, DOI 10.1093/emboj/cdg287; Gudi T, 2002, J BIOL CHEM, V277, P37382, DOI 10.1074/jbc.M204491200; Gudi T, 2000, ONCOGENE, V19, P6324, DOI 10.1038/sj.onc.1204007; Gudi T, 1996, J BIOL CHEM, V271, P4597; Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244; Gudi T, 1999, FASEB J, V13, P2143, DOI 10.1096/fasebj.13.15.2143; HAFFNER C, 1995, EMBO J, V14, P19, DOI 10.1002/j.1460-2075.1995.tb06971.x; HALBRUGGE M, 1989, EUR J BIOCHEM, V185, P41, DOI 10.1111/j.1432-1033.1989.tb15079.x; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; Harbeck B, 2000, J BIOL CHEM, V275, P30817, DOI 10.1074/jbc.M005066200; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Howe AK, 2002, J BIOL CHEM, V277, P38121, DOI 10.1074/jbc.M205379200; Huttelmaier S, 1999, FEBS LETT, V451, P68, DOI 10.1016/S0014-5793(99)00546-3; Idriss SD, 1999, J BIOL CHEM, V274, P9489, DOI 10.1074/jbc.274.14.9489; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Krause M, 2002, J CELL SCI, V115, P4721, DOI 10.1242/jcs.00218; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; Kumar MS, 2003, ARTERIOSCL THROM VAS, V23, P737, DOI 10.1161/01.ATV.0000065197.07635.BA; Kwiatkowski AV, 2003, TRENDS CELL BIOL, V13, P386, DOI 10.1016/S0962-8924(03)00130-2; Loureiro JJ, 2002, MOL BIOL CELL, V13, P2533, DOI 10.1091/mbc.E01-10-0102; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Morissette MR, 2000, AM J PHYSIOL-HEART C, V278, pH1769, DOI 10.1152/ajpheart.2000.278.6.H1769; Pilz RB, 2003, CIRC RES, V93, P1034, DOI 10.1161/01.RES.0000103311.52853.48; Posern G, 2002, MOL BIOL CELL, V13, P4167, DOI 10.1091/mbc.02-05-0068; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; Reinhard M, 2001, TRENDS BIOCHEM SCI, V26, P243, DOI 10.1016/S0968-0004(00)01785-0; Sah VP, 1999, J CLIN INVEST, V103, P1627, DOI 10.1172/JCI6842; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; Smolenski A, 2000, J BIOL CHEM, V275, P25723, DOI 10.1074/jbc.M909632199; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Walders-Harbeck B, 2002, FEBS LETT, V529, P275, DOI 10.1016/S0014-5793(02)03356-2; Wang Y, 2000, ONCOGENE, V19, P1379, DOI 10.1038/sj.onc.1203443; Zimmermann J, 2002, BIOCHEMISTRY-US, V41, P11143, DOI 10.1021/bi020379x	50	34	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10397	10407		10.1074/jbc.M313048200	http://dx.doi.org/10.1074/jbc.M313048200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14679200	hybrid			2022-12-25	WOS:000220050400090
J	Cha, MK; Kim, WC; Lim, CJ; Kim, K; Kim, IH				Cha, MK; Kim, WC; Lim, CJ; Kim, K; Kim, IH			Escherichia coli periplasmic thiol peroxidase acts as lipid hydroperoxide peroxidase and the principal antioxidative function during anaerobic growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANISM; OXIDATION; PROTEINS; STRESS	To clarify the enzymatic property of Escherichia coli periplasmic thiol peroxidase (p20), the specific peroxidase activity toward peroxides was compared with other bacterial thiol peroxidases. p20 has the most substrate preference and peroxidase activity toward organic hydroperoxide. Furthermore, p20 exerted the most potent lipid peroxidase activity. Despite that the mutation of p20 caused the highest susceptibility toward organic hydroperoxide and heat stress, the cellular level of p20 did not respond to the exposure of oxidative stress. Expression level of p20 during anaerobic growth was sustained at the similar to50% level compared with that of the aerobic growth. Viability of aerobic p20Delta without glucose was reduced to the similar to65% level of isogenic strains, whereas viability of aerobic p20Delta with 0.5% glucose supplement was sustained. The deletion of p20 resulted in a gradual loss of the cell viability during anaerobic growth. At the stationary phase, the viability of p20Delta was down to similar to10% level of parent strains. An analysis of the protein carbonyl contents of p20Delta as a marker for cellular oxidation indicates that severe reduction of viability of anaerobic p20Delta was caused by cumulative oxidative stress. P20Delta showed hypersensitivity toward membrane-soluble organic hydroperoxides. An analysis of protein carbonyl and lipid hydroperoxide contents in the membrane of the stress-imposed p20Delta demonstrates that the severe reduction of viability was caused by cumulative oxidative stress on the membrane. Taken together, present data uncover in vivo function for p20 as a lipid hydroperoxide peroxidase and demonstrate that, as the result, p20 acts as the principal antioxidant in the anaerobic habitats.	Paichai Univ, Dept Biochem, Taejon 302735, South Korea; NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA; Kangwon Natl Univ, Dept Biochem, Chunchon 200701, South Korea; Chonnam Natl Univ, Dept Food & Nutr, Kwangjoo 50075, South Korea	Pai Chai University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Kangwon National University; Chonnam National University	Kim, IH (corresponding author), Paichai Univ, Dept Biochem, 439-6 Doma 2 Dong, Taejon 302735, South Korea.	ihkim@mail.paichai.ac.kr	Kim, Il-Han/W-1401-2019					Baker LMS, 2003, J BIOL CHEM, V278, P9203, DOI 10.1074/jbc.M209888200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; Cha MK, 1996, J BACTERIOL, V178, P5610, DOI 10.1128/jb.178.19.5610-5614.1996; CHA MK, 1995, J BIOL CHEM, V270, P28635, DOI 10.1074/jbc.270.48.28635; Choi JK, 2003, J BIOL CHEM, V278, P49478, DOI 10.1074/jbc.M309015200; CLARK DP, 1989, FEMS MICROBIOL LETT, V63, P223, DOI 10.1111/j.1574-6968.1989.tb03398.x; de Macario EC, 2000, FRONT BIOSCI-LANDMRK, V5, pD780; FERRI A, 1995, BIOCHEM MOL BIOL INT, V35, P691; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Holms H, 1996, FEMS MICROBIOL REV, V19, P85, DOI 10.1111/j.1574-6976.1996.tb00255.x; ISIKORSKI RS, 1989, GENETICS, V122, P19; Jeong W, 2000, J BIOL CHEM, V275, P2924, DOI 10.1074/jbc.275.4.2924; JIANG ZY, 1991, LIPIDS, V26, P853, DOI 10.1007/BF02536169; KIM KW, 1988, J BIOL CHEM, V263, P4704; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Link AJ, 1997, ELECTROPHORESIS, V18, P1259, DOI 10.1002/elps.1150180807; LYNCH AS, 1996, E COLI SALMONELLA CE, V6, P1526; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; Poole LB, 2000, EUR J BIOCHEM, V267, P6126, DOI 10.1046/j.1432-1327.2000.01704.x; POOLE LB, 2003, SIGNAL TRANSDUCTION, P80; ROSE M, 1983, METHOD ENZYMOL, V101, P167; Sambrook J, 2001, MOL CLONING LAB MANU; Seaver LC, 2001, J BACTERIOL, V183, P7173, DOI 10.1128/JB.183.24.7173-7181.2001; Storz G, 1999, CURR OPIN MICROBIOL, V2, P188, DOI 10.1016/S1369-5274(99)80033-2; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; Talent JM, 1998, ANAL BIOCHEM, V263, P31, DOI 10.1006/abio.1998.2752; TENHAKEN R, 1995, P NATL ACAD SCI USA, V92, P4158, DOI 10.1073/pnas.92.10.4158; Wan XY, 1997, FEBS LETT, V407, P32, DOI 10.1016/S0014-5793(97)00302-5; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8	30	53	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8769	8778		10.1074/jbc.M312388200	http://dx.doi.org/10.1074/jbc.M312388200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676195	hybrid			2022-12-25	WOS:000189265900031
J	Lu, X; Hansen, JC				Lu, X; Hansen, JC			Identification of specific functional subdomains within the linker histone H1(o)C-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OCTAPEPTIDE REPEAT MOTIF; SECONDARY STRUCTURE; NUCLEOSOMAL ARRAYS; ESCHERICHIA-COLI; CHROMATIN FIBER; TERMINAL DOMAIN; C-TERMINUS; N-TERMINI; DNA; H1	Linker histone binding to nucleosomal arrays in vitro causes linker DNA to form an apposed stem motif, stabilizes extensively folded secondary chromatin structures, and promotes self-association of individual nucleosomal arrays into oligomeric tertiary chromatin structures. To determine the involvement of the linker histone C-terminal domain (CTD) in each of these functions, and to test the hypothesis that the functions of this highly basic domain are mediated by neutralization of linker DNA negative charge, four truncation mutants were created that incrementally removed stretches of 24 amino acids beginning at the extreme C terminus of the mouse H1(0) linker histone. Native and truncated H1(0) proteins were assembled onto biochemically defined nucleosomal arrays and characterized in the absence and presence of salts to probe primary, secondary, and tertiary chromatin structure. Results indicate that the ability of H1(0) to alter linker DNA conformation and stabilize condensed chromatin structures is localized to specific C-terminal subdomains, rather than being equally distributed throughout the entire CTD. We propose that the functions of the linker histone CTD in chromatin are linked to the characteristic intrinsic disorder of this domain.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	Colorado State University; University of Texas System; University of Texas Health San Antonio	Hansen, JC (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Campus Delivery 1870, Ft Collins, CO 80523 USA.	Jeffrey.C.Hansen@colostate.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045916, R01GM045916] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45916] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN J, 1986, J MOL BIOL, V187, P591, DOI 10.1016/0022-2836(86)90337-2; ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; Bednar J, 1998, P NATL ACAD SCI USA, V95, P14173, DOI 10.1073/pnas.95.24.14173; Bharath MMS, 2002, BIOCHEMISTRY-US, V41, P7617, DOI 10.1021/bi025773+; Carruthers LM, 1998, BIOCHEMISTRY-US, V37, P14776, DOI 10.1021/bi981684e; Carruthers LM, 2000, J BIOL CHEM, V275, P37285, DOI 10.1074/jbc.M006801200; Carruthers LM, 2000, METHOD ENZYMOL, V321, P66; Carter GJ, 1998, ANAL BIOCHEM, V263, P79, DOI 10.1006/abio.1998.2775; CERF C, 1993, BIOCHEMISTRY-US, V32, P11345, DOI 10.1021/bi00093a011; CHURCHILL MEA, 1989, EMBO J, V8, P4189, DOI 10.1002/j.1460-2075.1989.tb08604.x; CLARK DJ, 1990, J MOL BIOL, V211, P883, DOI 10.1016/0022-2836(90)90081-V; CLARK DJ, 1988, EMBO J, V7, P69, DOI 10.1002/j.1460-2075.1988.tb02784.x; Dunker AK, 2002, ADV PROTEIN CHEM, V62, P25; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8; Fletcher TM, 1996, CRIT REV EUKAR GENE, V6, P149, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.40; GARCIA-RAMIREZ M, 1990, Protein Expression and Purification, V1, P40, DOI 10.1016/1046-5928(90)90043-X; GEORGEL P, 1993, J BIOL CHEM, V268, P1947; GERCHMAN SE, 1994, PROTEIN EXPRES PURIF, V5, P242, DOI 10.1006/prep.1994.1037; Hansen JC, 2002, ANNU REV BIOPH BIOM, V31, P361, DOI 10.1146/annurev.biophys.31.101101.140858; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; HARTMAN PG, 1977, EUR J BIOCHEM, V77, P45, DOI 10.1111/j.1432-1033.1977.tb11639.x; HILL CS, 1989, EMBO J, V8, P2591, DOI 10.1002/j.1460-2075.1989.tb08398.x; Horn PJ, 2002, NAT STRUCT BIOL, V9, P263, DOI 10.1038/nsb776; Khadake JR, 1997, BIOCHEMISTRY-US, V36, P1041, DOI 10.1021/bi961617p; Khadake JR, 1997, FEBS LETT, V400, P193, DOI 10.1016/S0014-5793(96)01393-2; PARSEGHIAN MH, 1994, PROTEIN SCI, V3, P575; PEHRSON J, 1980, NATURE, V285, P43, DOI 10.1038/285043a0; PEHRSON JR, 1981, BIOCHEMISTRY-US, V20, P2298, DOI 10.1021/bi00511a035; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHWARZ PM, 1994, J BIOL CHEM, V269, P16284; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; SUBIRANA JA, 1990, BIOPOLYMERS, V29, P1351, DOI 10.1002/bip.360291003; SUZUKI M, 1993, PROTEIN ENG, V6, P565, DOI 10.1093/protein/6.6.565; SUZUKI M, 1989, EMBO J, V8, P797, DOI 10.1002/j.1460-2075.1989.tb03440.x; Thomas JO, 1999, CURR OPIN CELL BIOL, V11, P312, DOI 10.1016/S0955-0674(99)80042-8; Tse C, 1997, BIOCHEMISTRY-US, V36, P11381, DOI 10.1021/bi970801n; van Holde K.E., 1988, CHROMATIN; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; Vila R, 2000, PROTEIN SCI, V9, P627; Vila R, 2001, J BIOL CHEM, V276, P46429, DOI 10.1074/jbc.M106952200; Vila R, 2001, J BIOL CHEM, V276, P30898, DOI 10.1074/jbc.M104189200; Wellman SE, 1997, BIOTECHNOL APPL BIOC, V26, P117; Wolffe A., 1998, CHROMATIN STRUCTURE; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110	46	112	116	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8701	8707		10.1074/jbc.M311348200	http://dx.doi.org/10.1074/jbc.M311348200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14668337	hybrid			2022-12-25	WOS:000189265900022
J	Schneiders, T; Barbosa, TM; McMurry, LM; Levy, SB				Schneiders, T; Barbosa, TM; McMurry, LM; Levy, SB			The Escherichia coli transcriptional regulator MarA directly represses transcription of purA and hdeA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE ANTIBIOTIC-RESISTANCE; NUCLEOID-ASSOCIATED PROTEIN; RNA-POLYMERASE; DNA-BINDING; COMPLEX-FORMATION; ACID-RESISTANCE; ACTIVATION; EXPRESSION; GENES; SUPEROXIDE	The Escherichia coli MarA protein mediates a response to multiple environmental stresses through the activation or repression in vivo of a large number of chromosomal genes. Transcriptional activation for a number of these genes has been shown to occur via direct interaction of MarA with a 20-bp degenerate asymmetric "marbox" sequence. It was not known whether repression by MarA was also direct. We found that purified MarA was sufficient in vitro to repress transcription of both purA and hdeA. Transcription and electrophoretic mobility shift experiments in vitro using mutant promoters suggested that the marbox involved in the repression overlapped the -35 promoter motif and was in the "backward" orientation. This organization contrasts with that of the class II promoters activated by MarA, in which the marbox also overlaps the -35 motif but is in the "forward" orientation. We conclude that MarA, a member of the AraC/XylS family, can act directly as a repressor or an activator, depending on the position and orientation of the marbox within a promoter.	Tufts Univ, Sch Med, Ctr Adaptat Genet & Drug Resistance, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA	Tufts University; Tufts University; Tufts University	Levy, SB (corresponding author), Tufts Univ, Sch Med, Ctr Adaptat Genet & Drug Resistance, 136 Harrison Ave, Boston, MA 02111 USA.	stuart.levy@tufts.edu		Barbosa, Teresa M./0000-0001-7151-3418; Schneiders, Thamarai/0000-0002-7758-7925	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051661] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51661/AI56021] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alekshun MN, 1997, ANTIMICROB AGENTS CH, V41, P2067, DOI 10.1128/AAC.41.10.2067; ANSARI AZ, 1995, NATURE, V374, P371; ARIZA RR, 1995, J BACTERIOL, V177, P1655, DOI 10.1128/jb.177.7.1655-1661.1995; ARNQVIST A, 1994, MOL MICROBIOL, V13, P1021, DOI 10.1111/j.1365-2958.1994.tb00493.x; Barbosa TM, 2002, MOL MICROBIOL, V45, P191, DOI 10.1046/j.1365-2958.2002.03006.x; Barbosa TM, 2000, J BACTERIOL, V182, P3467, DOI 10.1128/JB.182.12.3467-3474.2000; BERTRANDBURGGRAF E, 1987, J MOL BIOL, V193, P293, DOI 10.1016/0022-2836(87)90220-8; Caslake LF, 1997, J BACTERIOL, V179, P1787, DOI 10.1128/jb.179.5.1787-1795.1997; CHOY H, 1996, ESCHERICHIA COLI SAL, P1287; COHEN SP, 1988, J BACTERIOL, V170, P5416, DOI 10.1128/jb.170.12.5416-5422.1988; Dangi B, 2001, J MOL BIOL, V314, P113, DOI 10.1006/jmbi.2001.5106; Delihas N, 2001, J MOL BIOL, V313, P1, DOI 10.1006/jmbi.2001.5029; Dunstan SJ, 1998, INFECT IMMUN, V66, P732, DOI 10.1128/IAI.66.2.732-740.1998; Estrem ST, 1998, P NATL ACAD SCI USA, V95, P9761, DOI 10.1073/pnas.95.17.9761; Gajiwala KS, 2000, J MOL BIOL, V295, P605, DOI 10.1006/jmbi.1999.3347; Gallegos MT, 1997, MICROBIOL MOL BIOL R, V61, P393, DOI 10.1128/.61.4.393-410.1997; GEORGE AM, 1983, J BACTERIOL, V155, P531, DOI 10.1128/JB.155.2.531-540.1983; Gralla JD, 1996, ESCHERICHIA COLI SAL, P1232; GREENBERG JT, 1991, J BACTERIOL, V173, P4433, DOI 10.1128/JB.173.14.4433-4439.1991; Griffith KL, 2001, MOL MICROBIOL, V40, P1141, DOI 10.1046/j.1365-2958.2001.02456.x; HE B, 1994, J BACTERIOL, V176, P1009, DOI 10.1128/JB.176.4.1009-1013.1994; Hoffman JA, 2001, MICROB PATHOGENESIS, V31, P69, DOI 10.1006/mpat.2001.0451; Hommais F, 2001, MOL MICROBIOL, V40, P20, DOI 10.1046/j.1365-2958.2001.02358.x; JAIR KW, 1995, J BACTERIOL, V177, P7100, DOI 10.1128/jb.177.24.7100-7104.1995; Jair KW, 1996, MOL MICROBIOL, V19, P307, DOI 10.1046/j.1365-2958.1996.368893.x; Jair KW, 1996, J BACTERIOL, V178, P2507, DOI 10.1128/jb.178.9.2507-2513.1996; Kwon HJ, 2000, NAT STRUCT BIOL, V7, P424; Martin RG, 2000, MOL MICROBIOL, V35, P623, DOI 10.1046/j.1365-2958.2000.01732.x; Martin RG, 1999, MOL MICROBIOL, V34, P431, DOI 10.1046/j.1365-2958.1999.01599.x; Martin RG, 2002, MOL MICROBIOL, V43, P355, DOI 10.1046/j.1365-2958.2002.02748.x; Martin RG, 2002, MOL MICROBIOL, V44, P1611, DOI 10.1046/j.1365-2958.2002.02985.x; Martin RG, 2001, CURR OPIN MICROBIOL, V4, P132, DOI 10.1016/S1369-5274(00)00178-8; NUNOSHIBA T, 1993, J BACTERIOL, V175, P7492, DOI 10.1128/JB.175.22.7492-7494.1993; Pomposiello PJ, 2001, J BACTERIOL, V183, P3890, DOI 10.1128/JB.183.13.3890-3902.2001; Rhee S, 1998, P NATL ACAD SCI USA, V95, P10413, DOI 10.1073/pnas.95.18.10413; Sambrook J, 2001, MOL CLONING LAB MANU; Schwartz CJ, 2001, P NATL ACAD SCI USA, V98, P14895, DOI 10.1073/pnas.251550898; Smith TL, 1996, P NATL ACAD SCI USA, V93, P8868, DOI 10.1073/pnas.93.17.8868; TOUATI D, 1983, J BACTERIOL, V155, P1078, DOI 10.1128/JB.155.3.1078-1087.1983; Tucker DL, 2003, J BACTERIOL, V185, P3190, DOI 10.1128/JB.185.10.3190-3201.2003; Van Dyk TK, 1998, J BACTERIOL, V180, P785, DOI 10.1128/JB.180.4.785-792.1998; Waterman SR, 1996, MOL MICROBIOL, V21, P925, DOI 10.1046/j.1365-2958.1996.00058.x; WOLFE SA, 1988, J BIOL CHEM, V263, P19147	43	29	30	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9037	9042		10.1074/jbc.M313602200	http://dx.doi.org/10.1074/jbc.M313602200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14701822	hybrid			2022-12-25	WOS:000189265900064
J	Vinciguerra, M; Vivacqua, A; Fasanella, G; Gallo, A; Cuozzo, C; Morano, A; Maggiolini, M; Musti, AM				Vinciguerra, M; Vivacqua, A; Fasanella, G; Gallo, A; Cuozzo, C; Morano, A; Maggiolini, M; Musti, AM			Differential phosphorylation of c-Jun and JunD in response to the epidermal growth factor is determined by the structure of MAPK targeting sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE; JNK; ANTAGONIZES; SPECIFICITY; CONTAINS; PROTEINS; ELK-1; AP-1; FORM	MAPK phosphorylation of various substrates is mediated by the presence of docking sites, including the D domain and the DEF motif. Depending on the number and sequences of these domains, substrates are phosphorylated by specific subsets of MAPKs. For example, a D domain targets JNK to c-Jun, whereas a DEF motif is required for ERK phosphorylation of c-Fos. JunD, in contrast, contains both D and DEF domains. Here we show that these motifs mediate JunD phosphorylation in response to either ERK or JNK activation. An intact D domain is required for phosphorylation and activation of JunD by both subtypes of MAPK. The DEF motif acts together with the D domain to elicit efficient phosphorylation of JunD in response to the epidermal growth factor (EGF) but has no function on JunD phosphorylation and activation by JNK signaling. Furthermore, we show that conversion of a c-Jun sequence to a canonical DEF domain, as it is present in JunD, elicits c-Jun activation in response to EGF. Our results suggest that evolution of a particular modular system of MAPK targeting sequences has determined a differential response of JunD and c-Jun to ERK activation.	Univ Naples Federico II, CNR, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Univ Naples Federico II, CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Calabria, Dipartimento Farmacobiol, I-87036 Cosenza, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; University of Calabria	Musti, AM (corresponding author), Univ Naples Federico II, CNR, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy.	ammusti@yahoo.it	vivacqua, adele/I-2771-2015; Morano, Annalisa/K-6955-2012; Maggiolini, Marcello/Z-4729-2019; Musti, Anna Maria/M-2520-2019	vivacqua, adele/0000-0001-5333-8396; Morano, Annalisa/0000-0002-5609-4742; MUSTI, Anna Maria/0000-0003-1443-2739; Maggiolini, Marcello/0000-0002-7485-854X				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Barsyte-Lovejoy D, 2002, J BIOL CHEM, V277, P9896, DOI 10.1074/jbc.M108145200; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOUGLAS A, 2001, J BIOL CHEM, V29, P27256; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Galanis A, 2001, J BIOL CHEM, V276, P965, DOI 10.1074/jbc.M007697200; Gallo A, 2002, ONCOGENE, V21, P6434, DOI 10.1038/sj.onc.1205822; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Holland PM, 1999, CURR BIOL, V9, pR329, DOI 10.1016/S0960-9822(99)80205-X; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kockel L, 1997, GENE DEV, V11, P1748, DOI 10.1101/gad.11.13.1748; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; Maniatis T., 1989, MOL CLONING LAB MAN; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Musti AM, 1996, BIOL CHEM, V377, P619, DOI 10.1515/bchm3.1996.377.10.619; Peverali FA, 1996, EMBO J, V15, P3943, DOI 10.1002/j.1460-2075.1996.tb00768.x; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Yazgan O, 2002, J BIOL CHEM, V277, P29710, DOI 10.1074/jbc.M204552200	34	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9634	9641		10.1074/jbc.M308721200	http://dx.doi.org/10.1074/jbc.M308721200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676207	hybrid			2022-12-25	WOS:000189265900131
J	Vulsteke, V; Beullens, M; Boudrez, A; Keppens, S; Van Eynde, A; Rider, MH; Stalmans, W; Bollen, M				Vulsteke, V; Beullens, M; Boudrez, A; Keppens, S; Van Eynde, A; Rider, MH; Stalmans, W; Bollen, M			Inhibition of spliceosome assembly by the cell cycle-regulated protein kinase MELK and involvement of splicing factor NIPP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR INHIBITOR; PHOSPHATASE-1; PHOSPHORYLATION; POLYPEPTIDES; PEG3	NIPP1 is a ubiquitous nuclear protein that is required for spliceosome assembly. We report here that the phosphothreonine-binding Forkhead-associated domain of NIPP1 interacts with the cell cycle-regulated protein Ser/Thr kinase MELK ( maternal embryonic leucine zipper kinase). The NIPP1-MELK interaction was critically dependent on the phosphorylaton of Thr-478 of MELK and was increased in lysates from mitotically arrested cells. Recombinant MELK was a potent inhibitor of an early step of spliceosome assembly in nuclear extracts. This splicing defect was also seen with a kinase-dead mutant but was absent after mutation (T478A) of the NIPP1 binding site of MELK, indicating a mediatory role for NIPP1. Our data suggest that MELK has a role in the cell cycle-regulated control of pre-mRNA splicing.	Catholic Univ Louvain, Fac Geneeskunde, Afdeling Biochem, B-3000 Louvain, Belgium; Univ Louvain, Hormone & Metab Res Unit, B-1200 Brussels, Belgium	Universite Catholique Louvain; Universite Catholique Louvain	Bollen, M (corresponding author), Catholic Univ Louvain, Fac Geneeskunde, Afdeling Biochem, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	Mathieu.Bollen@med.kuleuven.ac.be						BERNDT N, 1990, EUR J BIOCHEM, V190, P291, DOI 10.1111/j.1432-1033.1990.tb15575.x; Bernstein HS, 1998, J BIOL CHEM, V273, P4666, DOI 10.1074/jbc.273.8.4666; BEULLENS M, 1993, J BIOL CHEM, V268, P13172; Beullens M, 2002, J BIOL CHEM, V277, P19855, DOI 10.1074/jbc.M200847200; BEULLENS M, 1992, J BIOL CHEM, V267, P16538; Beullens M, 1999, J BIOL CHEM, V274, P14053, DOI 10.1074/jbc.274.20.14053; Beullens M, 2000, BIOCHEM J, V352, P651, DOI 10.1042/0264-6021:3520651; Blencowe BJ, 2003, CURR BIOL, V13, pR149, DOI 10.1016/S0960-9822(03)00079-4; Blot J, 2002, DEV BIOL, V241, P327, DOI 10.1006/dbio.2001.0525; Boudrez A, 2000, J BIOL CHEM, V275, P25411, DOI 10.1074/jbc.M001676200; Boudrez A, 2002, J BIOL CHEM, V277, P31834, DOI 10.1074/jbc.M204427200; Davezac N, 2002, ONCOGENE, V21, P7630, DOI 10.1038/sj.onc.1205870; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Heyer BS, 1999, DEV DYNAM, V215, P344; Jagiello I, 2000, J CELL SCI, V113, P3761; Jin QM, 2003, J BIOL CHEM, V278, P30677, DOI 10.1074/jbc.M302273200; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Reed R, 2000, CURR OPIN CELL BIOL, V12, P340, DOI 10.1016/S0955-0674(00)00097-1; Rutter J, 2001, P NATL ACAD SCI USA, V98, P8991, DOI 10.1073/pnas.161284798; Shin CS, 2002, CELL, V111, P407, DOI 10.1016/S0092-8674(02)01038-3; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; Van Eynde A, 1995, J BIOL CHEM, V270, P28068, DOI 10.1074/jbc.270.47.28068; VAN EYNDE A, 1994, BIOCHEM J, V297, P447, DOI 10.1042/bj2970447; Vulsteke V, 1997, J BIOL CHEM, V272, P32972, DOI 10.1074/jbc.272.52.32972	27	68	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8642	8647		10.1074/jbc.M311466200	http://dx.doi.org/10.1074/jbc.M311466200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14699119	hybrid			2022-12-25	WOS:000189265900016
J	Yanagisawa, M; Kaverina, IN; Wang, AX; Fujita, Y; Reynolds, AB; Anastasiadis, PZ				Yanagisawa, M; Kaverina, IN; Wang, AX; Fujita, Y; Reynolds, AB; Anastasiadis, PZ			A novel interaction between kinesin and p120 modulates p120 localization and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-FAMILY GTPASES; TRANSCRIPTION FACTOR; CATENIN P120(CTN); CADHERIN FUNCTION; BINDING-PROTEIN; NUCLEAR IMPORT; CELL-ADHESION; PARTNER KAISO; P120-CATENIN; CANCER	p120-catenin exists in a membrane-associated cadherin-bound pool, a cytosolic pool that affects Rho GTPases, and a nuclear pool that is thought to associate with the methylation-relevant transcriptional repressor Kaiso. We show here that cytoplasmic p120 can also associate both directly and indirectly with the microtubule network, and that p120 traffics along microtubules toward their plus ends. The direct binding required most of the armadillo repeats and was mutually exclusive for interaction with E-cadherin. Perturbing the p120-microtubule interaction with nocodazole or taxol markedly affected both the tubulin interaction and the balance between cytoplasmic and nuclear p120. The indirect binding occurred via a novel interaction between a segment of the p120 N-terminal domain and conventional kinesin heavy chains. Selective uncoupling of the p120-kinesin interaction by overexpression of the respective p120 and kinesin-binding fragments promoted nuclear p120 accumulation. In addition, expression of full-length kinesin reduced the nuclear accumulation of p120 and blocked the branching phenotype associated with p120 overexpression. Taken together, the data suggest that kinesin affects both the targeting and activity of p120 at several cellular locations.	Mayo Clin, Ctr Canc, Jacksonville, FL 32224 USA; Austrian Acad Sci, Inst Mol Biol, Dept Cell Biol, A-5020 Salzburg, Austria; Univ Texas, Med Branch, Dept Pharmacol, Galveston, TX 77555 USA; UCL, MRC Lab, Mol Cell Biol & Cell Biol Unit, London WC1E 6BT, England; Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA	Mayo Clinic; Austrian Academy of Sciences; University of Texas System; University of Texas Medical Branch Galveston; University of London; University College London; Vanderbilt University	Anastasiadis, PZ (corresponding author), Mayo Clin, Ctr Canc, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	panos@mayo.edu	Fujita, Yasuyuki/A-4324-2012		NATIONAL CANCER INSTITUTE [R01CA055724] Funding Source: NIH RePORTER; MRC [MC_U122669938] Funding Source: UKRI; Medical Research Council [MC_U122669938] Funding Source: Medline; NCI NIH HHS [R01-CA55724] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aho S, 2002, J CELL SCI, V115, P1391; Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Anastasiadis PZ, 2001, CURR OPIN CELL BIOL, V13, P604, DOI 10.1016/S0955-0674(00)00258-1; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Cai YF, 2001, J BIOL CHEM, V276, P41594, DOI 10.1074/jbc.M104514200; Campbell EA, 2003, ADV DRUG DELIVER REV, V55, P761, DOI 10.1016/S0169-409X(03)00049-8; Daniel JM, 2002, NUCLEIC ACIDS RES, V30, P2911, DOI 10.1093/nar/gkf398; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; Grosheva I, 2001, J CELL SCI, V114, P695; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Kaverina I, 1999, J CELL BIOL, V146, P1033, DOI 10.1083/jcb.146.5.1033; Mary S, 2002, MOL BIOL CELL, V13, P285, DOI 10.1091/mbc.01-07-0337; Mayerle J, 2003, GASTROENTEROLOGY, V124, P949, DOI 10.1053/gast.2003.50142; Miki H, 2001, P NATL ACAD SCI USA, V98, P7004, DOI 10.1073/pnas.111145398; Myster SH, 2003, J CELL BIOL, V160, P433, DOI 10.1083/jcb.200211083; Nollet F, 1999, Mol Cell Biol Res Commun, V2, P77, DOI 10.1006/mcbr.1999.0155; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Prokhortchouk A, 2001, GENE DEV, V15, P1613, DOI 10.1101/gad.198501; Reynolds AB, 1996, EXP CELL RES, V225, P328, DOI 10.1006/excr.1996.0183; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; Roczniak-Ferguson A, 2003, J CELL SCI, V116, P4201, DOI 10.1242/jcs.00724; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; van Hengel J, 1999, P NATL ACAD SCI USA, V96, P7980, DOI 10.1073/pnas.96.14.7980; Verhey KJ, 1998, J CELL BIOL, V143, P1053, DOI 10.1083/jcb.143.4.1053; Wu J, 1998, HYBRIDOMA, V17, P175, DOI 10.1089/hyb.1998.17.175; Xia XB, 2003, BIOCHEMISTRY-US, V42, P9195, DOI 10.1021/bi034597h; Yap AS, 1998, CANCER INVEST, V16, P252, DOI 10.3109/07357909809039774; Yoon HG, 2003, MOL CELL, V12, P723, DOI 10.1016/j.molcel.2003.08.008	33	103	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9512	9521		10.1074/jbc.M310895200	http://dx.doi.org/10.1074/jbc.M310895200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676216	hybrid			2022-12-25	WOS:000189265900118
J	Brush, MH; Guardiola, A; Connor, JH; Yao, TP; Shenolikar, S				Brush, MH; Guardiola, A; Connor, JH; Yao, TP; Shenolikar, S			Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE H3 PHOSPHORYLATION; IN-VIVO; MITOTIC PHOSPHORYLATION; GROWTH-INHIBITION; CATALYTIC SUBUNIT; TRICHOSTATIN-A; ACETYLATION; KINASE; MICROTUBULES; FIBROBLASTS	Affinity isolation of protein serine/threonine phosphatases on the immobilized phosphatase inhibitor microcystin-LR identified histone deacetylase 1(HDAC1), HDAC6, and HDAC10 as novel components of cellular phosphatase complexes. Other HDACs, specifically HDAC2, -3, -4, and -5, were excluded from such complexes. In vitro biochemical studies showed that recombinant HDAC6, but not HDAC4, bound directly to the protein phosphatase ( PP) 1 catalytic subunit. No association was observed between HDAC6 and PP2A, another major protein phosphatase. PP1 binding was mapped to the second catalytic domain and adjacent C-terminal sequences in HDAC6, and treatment of cells with trichostatin A (TSA) disrupted endogenous HDAC6.PP1 complexes. Consistent with the inhibition of tubulin deactylase activity of HDAC6, TSA enhanced cellular tubulin acetylation, and acetylated tubulin was present in the PP1 complexes from TSA-treated cells. Trapoxin B, a weak HDAC6 inhibitor, and calyculin A, a cell-permeable phosphatase inhibitor, had no effect on the stability of the HDAC6.PP1 complexes or on tubulin acetylation. Mutations that inactivated HDAC6 prevented its incorporation into cellular PP1 complexes and suggested that when bound together both enzymes were active. Interestingly, TSA disrupted all the cellular HDAC.phosphatase complexes analyzed. This study provided new insight into the mechanism by which HDAC inhibitors elicited coordinate changes in cellular protein phosphorylation and acetylation and suggested that changes in these protein modifications at multiple subcellular sites may contribute to the known ability of HDAC inhibitors to suppress cell growth and transformation.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Shenolikar, S (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, LSRC C315,Res Dr, Durham, NC 27710 USA.	sheno001@mc.duke.edu		Connor, John/0000-0002-8867-7256	NIDDK NIH HHS [R01-DK52054] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052054] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ajuh PM, 2000, NUCLEIC ACIDS RES, V28, P678, DOI 10.1093/nar/28.3.678; Brinkmann H, 2001, J BIOL CHEM, V276, P22491, DOI 10.1074/jbc.M100206200; Brush MH, 2003, MOL CELL BIOL, V23, P1292, DOI 10.1128/MCB.23.4.1292-1303.2003; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Chang TH, 2002, CLIN CANCER RES, V8, P1206; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; Edmondson DG, 2002, J BIOL CHEM, V277, P29496, DOI 10.1074/jbc.M200651200; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Fass DM, 2003, J BIOL CHEM, V278, P43014, DOI 10.1074/jbc.M305905200; Furumai R, 2001, P NATL ACAD SCI USA, V98, P87, DOI 10.1073/pnas.011405598; Galasinski SC, 2002, J BIOL CHEM, V277, P19618, DOI 10.1074/jbc.M201174200; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Guardiola AR, 2002, J BIOL CHEM, V277, P3350, DOI 10.1074/jbc.M109861200; Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hook SS, 2002, P NATL ACAD SCI USA, V99, P13425, DOI 10.1073/pnas.172511699; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; Jin QM, 2003, J BIOL CHEM, V278, P30677, DOI 10.1074/jbc.M302273200; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Katayama H, 2001, J BIOL CHEM, V276, P46219, DOI 10.1074/jbc.M107540200; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Liao H, 1998, J BIOL CHEM, V273, P21901, DOI 10.1074/jbc.273.34.21901; Lim YM, 2002, J BIOL CHEM, V277, P12735, DOI 10.1074/jbc.M111011200; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Lu Q, 2003, J BIOL CHEM, V278, P15727, DOI 10.1074/jbc.M300546200; Matsuyama A, 2002, EMBO J, V21, P6820, DOI 10.1093/emboj/cdf682; Merienne K, 2001, MOL CELL BIOL, V21, P7089, DOI 10.1128/MCB.21.20.7089-7096.2001; Murnion ME, 2001, J BIOL CHEM, V276, P26656, DOI 10.1074/jbc.M102288200; Oliver CJ, 2002, MOL CELL BIOL, V22, P4690, DOI 10.1128/MCB.22.13.4690-4701.2002; Pflum MKH, 2001, J BIOL CHEM, V276, P47733, DOI 10.1074/jbc.M105590200; Salvador LM, 2001, J BIOL CHEM, V276, P40146, DOI 10.1074/jbc.M106710200; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Seigneurin-Berny D, 2001, MOL CELL BIOL, V21, P8035, DOI 10.1128/MCB.21.23.8035-8044.2001; SHENOLIKAR S, 1984, METHOD ENZYMOL, V107, P102; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Verdel A, 2000, CURR BIOL, V10, P747, DOI 10.1016/S0960-9822(00)00542-X; Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Yamagoe S, 2003, MOL CELL BIOL, V23, P1025, DOI 10.1128/MCB.23.3.1025-1033.2003; Zhang WZ, 2002, AM J PHYSIOL-RENAL, V283, pF904, DOI 10.1152/ajprenal.00156.2002; Zhang Y, 2003, EMBO J, V22, P1168, DOI 10.1093/emboj/cdg115; Zhao X, 2001, J BIOL CHEM, V276, P35042, DOI 10.1074/jbc.M105086200	52	112	119	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7685	7691		10.1074/jbc.M310997200	http://dx.doi.org/10.1074/jbc.M310997200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14670976	hybrid			2022-12-25	WOS:000189103300040
J	Cherny, I; Gazit, E				Cherny, I; Gazit, E			The YefM antitoxin defines a family of natively unfolded proteins - Implications as a novel antibacterial target	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMID ADDICTION SYSTEM; NUTRITIONAL STRESS; DISORDERED PROTEIN; ESCHERICHIA-COLI; DNA-BINDING; CELL-DEATH; TOXIN; PHD; P1; PROPHAGE	Although natively unfolded proteins are being observed increasingly, their physiological role is not well understood. Here, we demonstrate that the Escherichia coli YefM protein is a natively unfolded antitoxin, lacking secondary structure even at low temperature or in the presence of a stabilizing agent. This conformation of the protein is suggested to have a key role in its physiological regulatory activity. Because of the unfolded state of the protein, a linear determinant rather than a conformational one is presumably being recognized by its toxin partner, YoeB. A peptide array technology allowed the identification and validation of such a determinant. This recognition element may provide a novel antibacterial target. Indeed, a pair-constrained bioinformatic analysis facilitated the definite determination of novel YefM-YoeB toxin-antitoxin systems in a large number of bacteria including major pathogens such as Staphylococcus aureus, Streptococcus pneumoniae, and Mycobacterium tuberculosis. Taken together, the YefM protein defines a new family of natively unfolded proteins. The existence of a large and conserved group of proteins with a clear physiologically relevant unfolded state serves as a paradigm to understand the structural basis of this state.	Tel Aviv Univ, Dept Mol Microbiol & Biotechnol, George S Wise Fac Life Sci, IL-69978 Tel Aviv, Israel	Tel Aviv University	Gazit, E (corresponding author), Tel Aviv Univ, Dept Mol Microbiol & Biotechnol, George S Wise Fac Life Sci, Green Bldg,Rm 221, IL-69978 Tel Aviv, Israel.	ehudg@post.tau.ac.il	Gazit, Ehud/M-8026-2019; Gazit, Ehud/C-3715-2011; Gazit, Ehud/AHE-9332-2022	Gazit, Ehud/0000-0001-5764-1720; Gazit, Ehud/0000-0001-5764-1720; 				Aizenman E, 1996, P NATL ACAD SCI USA, V93, P6059, DOI 10.1073/pnas.93.12.6059; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Camacho AG, 2002, BIOL CHEM, V383, P1701, DOI 10.1515/BC.2002.191; Christensen SK, 2003, MOL MICROBIOL, V48, P1389, DOI 10.1046/j.1365-2958.2003.03512.x; Christensen SK, 2001, P NATL ACAD SCI USA, V98, P14328, DOI 10.1073/pnas.251327898; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8; Gazit E, 2002, CURR MED CHEM, V9, P1725; Gazit E, 1999, J BIOL CHEM, V274, P2652, DOI 10.1074/jbc.274.5.2652; Gazit E, 1999, J BIOL CHEM, V274, P16813, DOI 10.1074/jbc.274.24.16813; Gerdes K, 2000, J BACTERIOL, V182, P561, DOI 10.1128/JB.182.3.561-572.2000; Grady R, 2003, MOL MICROBIOL, V47, P1419, DOI 10.1046/j.1365-2958.2003.03387.x; HARIS PI, 1995, BIOPOLYMERS, V37, P251, DOI 10.1002/bip.360370404; JENNESS DD, 1976, BIOPOLYMERS, V15, P513, DOI 10.1002/bip.1976.360150308; LEHNHERR H, 1995, P NATL ACAD SCI USA, V92, P3274, DOI 10.1073/pnas.92.8.3274; LEHNHERR H, 1993, J MOL BIOL, V233, P414, DOI 10.1006/jmbi.1993.1521; Oberer M, 1999, BIOL CHEM, V380, P1413, DOI 10.1515/BC.1999.181; Pedersen K, 2002, MOL MICROBIOL, V45, P501, DOI 10.1046/j.1365-2958.2002.03027.x; Pedersen K, 2003, CELL, V112, P131, DOI 10.1016/S0092-8674(02)01248-5; Pomerantsev AP, 2001, PLASMID, V46, P210, DOI 10.1006/plas.2001.1548; RADIVOJAC P, 2003, PAC S BIOC, V8, P216; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; Romero P, 2001, PROTEINS, V42, P38, DOI 10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3; SCHWEERS O, 1994, J BIOL CHEM, V269, P24290; THI MHD, 2000, J MOL BIOL, V299, P1373; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uversky VN, 2002, EUR J BIOCHEM, V269, P2, DOI 10.1046/j.0014-2956.2001.02649.x; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; Uversky VN, 2002, PROTEIN SCI, V11, P739, DOI 10.1110/ps.4210102; VIHINEN M, 1994, PROTEINS, V19, P141, DOI 10.1002/prot.340190207	32	67	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8252	8261		10.1074/jbc.M308263200	http://dx.doi.org/10.1074/jbc.M308263200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14672926	hybrid			2022-12-25	WOS:000189103300107
J	Gomez-Merino, FC; Brearley, CA; Ornatowska, M; Abdel-Haliem, MEF; Zanor, MI; Mueller-Roeber, B				Gomez-Merino, FC; Brearley, CA; Ornatowska, M; Abdel-Haliem, MEF; Zanor, MI; Mueller-Roeber, B			AtDGK2, a novel diacylglycerol kinase from Arabidopsis thaliana, phosphorylates 1-stearoyl-2-arachidonoyl-sn-glycerol and 1,2-dioleoyl-sn-glycerol and exhibits cold-inducible gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH DOMAINS; PROTEIN-KINASE; PHORBOL ESTER; PHOSPHATIDIC-ACID; PHOSPHOLIPASE-C; BETA-GLUCURONIDASE; MOLECULAR-CLONING; PSAF GENE; CELLS; ACTIVATION	Diacylglycerol kinase (DGK) phosphorylates diacylglycerol (DAG) to generate phosphatidic acid (PA). Both DAG and PA are implicated in signal transduction pathways. DGKs have been widely studied in animals, but their analysis in plants is fragmentary. Here, we report the cloning and biochemical characterization of AtDGK2, encoding DGK from Arabidopsis thaliana. AtDGK2 has a predicted molecular mass of 79.4 kDa and, like AtDGK1 previously reported, harbors two copies of a phorbol ester/DAG-binding domain in its N-terminal region. AtDGK2 belongs to a family of seven DGK genes in A. thaliana. AtDGK3 to AtDGK7 encode similar to55-kDa DGKs that lack a typical phorbol ester/DAG-binding domain. Phylogenetically, plant DGKs fall into three clusters. Members of all three clusters are widely expressed in vascular plants. Recombinant AtDGK2 was expressed in Escherichia coli and biochemically characterized. The enzyme phosphorylated 1,2-dioleoyl-sn-glycerol to yield PA, exhibiting Michaelis-Menten type kinetics. Estimated K-m and V-max values were 125 muM for DAG and 0.25 pmol of PA min(-1) mug(-1), respectively. The enzyme was maximally active at pH 7.2. Its activity was Mg2+-dependent and affected by the presence of detergents, salts, and the DGK inhibitor R59022, but not by Ca2+. AtDGK2 exhibited substrate preference for unsaturated DAG analogues (i.e. 1-stearoyl-2-arachidonoyl-sn-glycerol and 1,2-dioleoyl-sn-glycerol). The AtDGK2 gene is expressed in various tissues of the Arabidopsis plant, including leaves, roots, and flowers, as shown by Northern blot analysis and promoter-reporter gene fusions. We found that AtDGK2 is induced by exposure to low temperature (4degreesC), pointing to a role in cold signal transduction.	Univ Potsdam, Inst Biochem & Biol, D-14476 Golm Potsdam, Germany; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Max Planck Inst Mol Plant Physiol, Cooperat Res Grp, D-14476 Golm Potsdam, Germany	University of Potsdam; University of East Anglia; Max Planck Society	Mueller-Roeber, B (corresponding author), Univ Potsdam, Inst Biochem & Biol, Karl Liebknecht Str 24-25,Haus 20, D-14476 Golm Potsdam, Germany.	bmr@rz.uni-potsdam.de	Gómez-Merino, Fernando Carlos/D-2224-2014; Abdel-Haliem, Mahmoud/AAD-3333-2019; Mueller-Roeber, Bernd/Z-4052-2019; Mohamed, Mahmoud/B-2262-2015	Mohamed, Mahmoud/0000-0002-1518-2340; Brearley, Charles/0000-0001-6179-9109				ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; BAKER SS, 1994, PLANT MOL BIOL, V24, P701, DOI 10.1007/BF00029852; Baudouin E, 2002, PLANTA, V214, P400, DOI 10.1007/s004250100630; Baudouin E, 1999, PLANT SCI, V142, P67, DOI 10.1016/S0168-9452(98)00241-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREARLEY CA, 1992, BIOCHEM J, V283, P255, DOI 10.1042/bj2830255; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; Chandok MR, 1996, MOL GEN GENET, V251, P599, DOI 10.1007/BF02173650; Chandok MR, 2001, MOL GEN GENET, V264, P819, DOI 10.1007/s004380000371; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Ding L, 1998, J BIOL CHEM, V273, P32746, DOI 10.1074/jbc.273.49.32746; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Gilroy S, 2001, NAT REV MOL CELL BIO, V2, P307, DOI 10.1038/35067109; GOMEZMERINO FC, 2003, IN PRESS P 12 C GEN; HAWKINS PT, 1986, BIOCHEM J, V238, P507, DOI 10.1042/bj2380507; HIRAYAMA T, 1995, P NATL ACAD SCI USA, V92, P3903, DOI 10.1073/pnas.92.9.3903; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; Houssa B, 1998, BIOCHEM J, V331, P677; Ishioka N., 1992, PLANT TISSUE CULT LE, V9, P86; JEFFERSON RA, 1987, EMBO J, V6, P3901; Jiang C, 1996, PLANT MOL BIOL, V30, P679, DOI 10.1007/BF00049344; Jiang Y, 2000, J BIOL CHEM, V275, P34092, DOI 10.1074/jbc.M004914200; Jiang Y, 2000, BIOCHEM PHARMACOL, V59, P763, DOI 10.1016/S0006-2952(99)00395-0; KAMADA Y, 1991, BIOCHIM BIOPHYS ACTA, V1093, P72, DOI 10.1016/0167-4889(91)90140-S; Kanoh H, 2002, J BIOCHEM, V131, P629, DOI 10.1093/oxfordjournals.jbchem.a003144; KANOH H, 1981, ARCH BIOCHEM BIOPHYS, V209, P266, DOI 10.1016/0003-9861(81)90280-0; Katagiri T, 1996, PLANT MOL BIOL, V30, P647, DOI 10.1007/BF00049339; Kim HJ, 2002, PLANT J, V29, P693, DOI 10.1046/j.1365-313X.2002.01249.x; Lee S, 2001, PLANT J, V26, P479, DOI 10.1046/j.1365-313x.2001.01037.x; LEE Y, 1991, P NATL ACAD SCI USA, V88, P2127, DOI 10.1073/pnas.88.6.2127; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; LIN CH, 1986, LIPIDS, V21, P206, DOI 10.1007/BF02534823; LUNDBERG GA, 1992, BIOCHIM BIOPHYS ACTA, V1123, P177, DOI 10.1016/0005-2760(92)90109-9; Martelli AM, 2002, CELL MOL LIFE SCI, V59, P1129, DOI 10.1007/s00018-002-8492-9; Matowe WC, 1996, PHARMACOLOGY, V53, P376, DOI 10.1159/000139453; Miller KG, 1999, NEURON, V24, P323, DOI 10.1016/S0896-6273(00)80847-8; MORITZ A, 1992, J BIOL CHEM, V267, P7207; Mueller-Roeber B, 2002, PLANT PHYSIOL, V130, P22, DOI 10.1104/pp.004770; Munnik T, 2001, TRENDS PLANT SCI, V6, P227, DOI 10.1016/S1360-1385(01)01918-5; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Ruelland E, 2002, PLANT PHYSIOL, V130, P999, DOI 10.1104/pp.006080; Sakane F, 2002, J BIOL CHEM, V277, P43519, DOI 10.1074/jbc.M206895200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; Shindo M, 2003, J BIOL CHEM, V278, P18448, DOI 10.1074/jbc.M300400200; Snedden WA, 2000, PLANT J, V24, P317, DOI 10.1046/j.1365-313x.2000.00877.x; Stockinger EJ, 1997, P NATL ACAD SCI USA, V94, P1035, DOI 10.1073/pnas.94.3.1035; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Wostemeyer A, 2003, J PLANT PHYSIOL, V160, P503, DOI 10.1078/0176-1617-00912; ZHAO ZH, 1993, P NATL ACAD SCI USA, V90, P4251, DOI 10.1073/pnas.90.9.4251	54	70	75	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8230	8241		10.1074/jbc.M312187200	http://dx.doi.org/10.1074/jbc.M312187200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14665624	hybrid			2022-12-25	WOS:000189103300105
J	Inuzuka, T; Yun, BG; Ishikawa, H; Takahashi, S; Hori, H; Matts, RL; Ishimori, K; Morishima, I				Inuzuka, T; Yun, BG; Ishikawa, H; Takahashi, S; Hori, H; Matts, RL; Ishimori, K; Morishima, I			Identification of crucial histidines for heme binding in the N-terminal domain of the heme-regulated eIF2 alpha kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EIF-2-ALPHA KINASE; PROTEIN-SYNTHESIS; RESONANCE RAMAN; REPLACEMENT; MYOGLOBIN; CYSTEINE; LIGAND	The heme-regulated eukaryotic initiation factor-2alpha (eIF2alpha) kinase (HRI) regulates the initiation of protein synthesis in reticulocytes. The binding of NO to the N-terminal heme-binding domain (NTD) of HRI positively modulates its kinase activity. By utilizing UV-visible absorption, resonance Raman, EPR and CD spectroscopies, two histidine residues have been identified that are crucial for the binding of heme to the NTD. The UV-visible absorption and resonance Raman spectra of all the histidine to alanine mutants constructed were similar to those of the unmutated NTD. However, the change in the CD spectra of the NTD construct containing mutation of His(78) to Ala (H78A) indicated loss of the specific binding of heme. The EPR spectrum for the ferric H78A mutant was also substantially perturbed. Thus, His(78) is one of the axial ligands for the NTD of HRL Significant changes in the EPR spectrum of the H123A mutant were also observed, and heme readily dissociated from both the H123A and the H78A NTD mutants, suggesting that His(123) was also an axial heme ligand. However, the CD spectrum for the Soret region of the H123A mutant indicated that this mutant still bound heme specifically. Thus, while both His(78) and His(123) are crucial for stable heme binding, the effects of their mutations on the structure of the NTD differed. His(78) appears to play the primary role in the specific binding of heme to the NTD, acting analogously to the "proximal histidine" ligand of globins, while His(123) appears to act as the "distal" heme ligand.	Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA; Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6158510, Japan; Osaka Univ, Grad Sch Engn Sci, Dept Bioengn, Osaka 5608531, Japan	Oklahoma State University System; Oklahoma State University - Stillwater; Kyoto University; Osaka University	Matts, RL (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA.	rmatts@biochem.okstate.edu; koichiro@scl.kyoto-u.ac.jp; morisima@mds.moleng.kyoto-u.ac.jp	Ishikawa, Haruto/B-1562-2012; Ishimori, Koichiro/S-1247-2016; Ishimori, Koichiro/AAQ-4434-2021	Ishikawa, Haruto/0000-0001-6362-5719; Ishimori, Koichiro/0000-0002-5868-0462; Ishimori, Koichiro/0000-0002-5868-0462				ADACHI S, 1993, BIOCHEMISTRY-US, V32, P241, DOI 10.1021/bi00052a031; BOISPOLTORATSKY R, 1967, EUR J BIOCHEM, V2, P361, DOI 10.1111/j.1432-1033.1967.tb00146.x; Chefalo PJ, 1998, EUR J BIOCHEM, V258, P820, DOI 10.1046/j.1432-1327.1998.2580820.x; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; Deinum G, 1996, BIOCHEMISTRY-US, V35, P1540; Hirst J, 2001, BIOCHEMISTRY-US, V40, P1274, DOI 10.1021/bi002090q; HSU MC, 1971, J AM CHEM SOC, V93, P3515; Ihara M, 2000, BIOCHEMISTRY-US, V39, P5961, DOI 10.1021/bi9922289; Ishikawa H, 2002, J AM CHEM SOC, V124, P13696, DOI 10.1021/ja0272336; LI XY, 1988, J AM CHEM SOC, V110, P6024, DOI 10.1021/ja00226a017; PAUL KG, 1953, ACTA CHEM SCAND, V7, P1284, DOI 10.3891/acta.chem.scand.07-1284; Rafie-Kolpin M, 2000, J BIOL CHEM, V275, P5171, DOI 10.1074/jbc.275.7.5171; RIVERA M, 1992, BIOCHEMISTRY-US, V31, P12233, DOI 10.1021/bi00163a037; Uma S, 2000, EUR J BIOCHEM, V267, P498, DOI 10.1046/j.1432-1327.2000.01021.x; Uma S, 2001, J BIOL CHEM, V276, P14875, DOI 10.1074/jbc.M011476200; Yoshioka S, 2001, EUR J BIOCHEM, V268, P252, DOI 10.1046/j.1432-1033.2001.01872.x	16	20	21	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6778	6782		10.1074/jbc.C300464200	http://dx.doi.org/10.1074/jbc.C300464200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14672943	hybrid			2022-12-25	WOS:000188969200071
J	Pollice, A; Nasti, V; Ronca, R; Vivo, M; Lo Iacono, M; Calogero, R; Calabro, V; La Mantia, G				Pollice, A; Nasti, V; Ronca, R; Vivo, M; Lo Iacono, M; Calogero, R; Calabro, V; La Mantia, G			Functional and physical interaction of the human ARF tumor suppressor with Tat-binding protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							26 S PROTEASOME; RETINOBLASTOMA PROTEIN; CELL-CYCLE; P19(ARF); P53; P14(ARF); GENE; MDM2; DEGRADATION; LOCUS	The p14(ARF) tumor suppressor is a key regulator of cellular proliferation, frequently inactivated in human cancer, whose mode of action is currently not completely understood. We report here that the so-called human immunodeficiency virus Tat-binding protein-1 (TBP-1), a component of the 19 S regulatory subunit of the proteasome 26 S, also involved in transcriptional regulation and with a supposed role in the control of cell proliferation, specifically interacts with ARF, both in yeast and mammalian cells. We present evidence that the overexpression of TBP-1 in various cell lines results in a sharp increase of both transfected and endogenous ARF protein levels. Moreover, this effect depends on the binding between the two proteins and, at least in part, is exerted at the post-translational level. We also show that the ARF increase following TBP-1 overexpression results in an increase in p53 protein levels and activity. Finally, our data underline a clear involvement of TBP-1 in the control of cell proliferation.	Univ Naples Federico II, Dept Genet Gen & Mol Biol, I-80134 Naples, Italy; S Luigi Hosp, Dept Clin & Biol Sci, I-10043 Turin, Italy	University of Naples Federico II	La Mantia, G (corresponding author), Univ Naples Federico II, Dept Genet Gen & Mol Biol, Via Mezzocannone 8, I-80134 Naples, Italy.	lamantia@unina.it	Lo Iacono, Marco/L-5453-2016; Calabro, Viola/H-6156-2013; Vivo, Maria/S-3390-2017; Calogero, Raffaele/K-9428-2019	Lo Iacono, Marco/0000-0002-3936-4472; Vivo, Maria/0000-0003-2458-4226; Calogero, Raffaele/0000-0002-2848-628X; Calabro, Viola/0000-0002-6508-8889; Ronca, Raffaele/0000-0003-2217-3378				Barak O, 2001, VIROLOGY, V283, P110, DOI 10.1006/viro.2001.0883; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BEPLER G, 1994, P NATL ACAD SCI USA, V91, P5513, DOI 10.1073/pnas.91.12.5513; Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; Boyer SN, 1996, CANCER RES, V56, P4620; Calabro V, 2002, J BIOL CHEM, V277, P2674, DOI 10.1074/jbc.M107173200; Calabro V, 1999, ONCOGENE, V18, P2157, DOI 10.1038/sj.onc.1202532; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Chen Y, 1997, J BIOL CHEM, V272, P24081, DOI 10.1074/jbc.272.38.24081; Datta A, 2002, MOL CELL BIOL, V22, P8398, DOI 10.1128/MCB.22.24.8398-8408.2002; David-Pfeuty T, 2002, ONCOGENE, V21, P6779, DOI 10.1038/sj.onc.1205871; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Ghee M, 2000, J NEUROCHEM, V75, P2221, DOI 10.1046/j.1471-4159.2000.0752221.x; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Ishizuka T, 2001, MOL ENDOCRINOL, V15, P1329, DOI 10.1210/me.15.8.1329; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kashuba Elena, 2003, Mol Cancer, V2, P18, DOI 10.1186/1476-4598-2-18; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Menendez S, 2003, J BIOL CHEM, V278, P18720, DOI 10.1074/jbc.M211007200; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; OHANA B, 1993, P NATL ACAD SCI USA, V90, P138, DOI 10.1073/pnas.90.1.138; Ottosen S, 2002, SCIENCE, V296, P479, DOI 10.1126/science.1071270; Parisi T, 2002, BIOCHEM BIOPH RES CO, V291, P1138, DOI 10.1006/bbrc.2002.6591; Park BW, 1999, P NATL ACAD SCI USA, V96, P6434, DOI 10.1073/pnas.96.11.6434; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rizos H, 2003, J BIOL CHEM, V278, P4981, DOI 10.1074/jbc.M210978200; Russell SJ, 1999, MOL CELL, V3, P687, DOI 10.1016/S1097-2765(01)80001-0; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Strickland E, 2000, J BIOL CHEM, V275, P5565, DOI 10.1074/jbc.275.8.5565; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Vivo M, 2001, J BIOL CHEM, V276, P14161, DOI 10.1074/jbc.M006845200; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Zhang SL, 1998, P NATL ACAD SCI USA, V95, P2429, DOI 10.1073/pnas.95.5.2429; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	43	33	34	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6345	6353		10.1074/jbc.M310957200	http://dx.doi.org/10.1074/jbc.M310957200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14665636	hybrid			2022-12-25	WOS:000188969200019
J	Reiter, R; Oh, AS; Wellstein, A; Riegel, AT				Reiter, R; Oh, AS; Wellstein, A; Riegel, AT			Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta 3 on estrogenic ligands with different intrinsic activity	ONCOGENE			English	Article						AIB1; coactivator; estrogen; ER	BREAST-CANCER; ER-ALPHA; TISSUE DISTRIBUTION; EXPRESSION; GROWTH; BETA; HORMONE; MAMMARY; COREGULATORS; SPECIFICITY	The nuclear receptor coactivator amplified in breast cancer 1 (AIB1) and its more active isoform AIB1-Delta3 are overexpressed in breast cancer and preneoplastic breast tissue. However, the impact of these proteins on the transcriptional activity of natural estrogens or selective estrogen receptor modulators (SERMs) has not been determined. Here we show that AIB1-Delta3 causes a significant increase in the efficacy of 17beta-estradiol at both estrogen receptor-alpha (ER-alpha) and ER-beta in ovarian, breast and endometrial cancer cell lines. AIB1-Delta3 also significantly increased the efficacy of the natural estrogen genistein at both ER-alpha and ER-beta, whereas AIB1 had no effect on either the potency or efficacy of genistein at either receptor. The estrogenic efficacy of the partial agonist tamoxifen was significantly increased in all cell lines at ER-alpha by overexpression of AIB1-Delta3 both on transfected and endogenous estrogen responsive genes. In contrast, overexpression of AIB1 or AIB1-Delta3 had no effect on the potency or efficacy of the SERM raloxifene. We conclude that overexpression of the AIB1-Delta3 isoform will increase the estrogenicity of a variety of natural and pharmacologic compounds in tissues that develop hormone-dependent neoplasias and overexpression of these cofactors may be a contributing factor to the hormone-driven development of neoplasia and to antiestrogen resistance of breast cancers.	Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20057 USA; Georgetown Univ, Dept Pharmacol, Washington, DC 20057 USA	Georgetown University; Georgetown University	Riegel, AT (corresponding author), Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Res Bldg,Room E307, Washington, DC 20057 USA.	ariege01@georgetown.edu		Wellstein, Anton/0000-0002-0570-4950; Oh, Annabell S./0000-0002-0676-1164	NCI NIH HHS [P50 CA58185] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058185] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; AUGEREAU P, 1994, MOL ENDOCRINOL, V8, P693, DOI 10.1210/me.8.6.693; Bautista S, 1998, CLIN CANCER RES, V4, P2925; Bouras T, 2001, CANCER RES, V61, P903; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Couse JF, 1997, ENDOCRINOLOGY, V138, P4613, DOI 10.1210/en.138.11.4613; Crews ST, 1999, CURR OPIN GENET DEV, V9, P580, DOI 10.1016/S0959-437X(99)00003-9; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; Glass CK, 2000, GENE DEV, V14, P121; Guan XY, 1996, CANCER RES, V56, P3446; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; Jordan VC, 2002, CANCER CELL, V1, P215, DOI 10.1016/S1535-6108(02)00050-8; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kurebayashi J, 2000, CLIN CANCER RES, V6, P512; Lamartiniere CA, 2002, J NUTR, V132, p552S, DOI 10.1093/jn/132.3.552S; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; List HJ, 2001, J BIOL CHEM, V276, P23763, DOI 10.1074/jbc.M102397200; List HJ, 2001, BREAST CANCER RES TR, V68, P21, DOI 10.1023/A:1017910924390; Liu H, 2002, J BIOL CHEM, V277, P9189, DOI 10.1074/jbc.M108335200; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Murphy LC, 2000, CANCER RES, V60, P6266; Nilsson S, 2002, CRIT REV BIOCHEM MOL, V37, P1, DOI 10.1080/10409230290771438; ONATE SA, 1995, SCIENCE, V270, P1354; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Ponting CP, 1997, CURR BIOL, V7, pR674, DOI 10.1016/S0960-9822(06)00352-6; Reiter R, 2001, J BIOL CHEM, V276, P39736, DOI 10.1074/jbc.M104744200; Roger P, 2001, CANCER RES, V61, P2537; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; Szapary D, 1999, MOL ENDOCRINOL, V13, P2108, DOI 10.1210/me.13.12.2108; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Tikkanen MK, 2000, P NATL ACAD SCI USA, V97, P12536, DOI 10.1073/pnas.220427297; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Watanabe T, 1998, MOL CELL BIOL, V18, P442, DOI 10.1128/MCB.18.1.442; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Zava DT, 1997, NUTR CANCER, V27, P31, DOI 10.1080/01635589709514498	39	40	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					403	409		10.1038/sj.onc.1207202	http://dx.doi.org/10.1038/sj.onc.1207202			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14691461				2022-12-25	WOS:000188098300010
J	Belevych, AE; Juranek, I; Harvey, RD				Belevych, AE; Juranek, I; Harvey, RD			Protein kinase C regulates functional coupling of beta(1)-adrenergic receptors to G(i/o)-mediated responses in cardiac myocytes	FASEB JOURNAL			English	Article						inhibitory G(i/o) proteins; L-type Ca2+ channels; dual coupling; beta-adrenergic regulation	PERTUSSIS-TOXIN; BETA(2)-ADRENERGIC RECEPTORS; VENTRICULAR MYOCYTES; ACTIVATION; EXPRESSION; ISOFORMS; PHOSPHORYLATION; DESENSITIZATION; MECHANISM; CHANNELS	The effect of protein kinase C (PKC) activation on beta(1)-adrenergic receptor (beta(1)-AR) regulation of the cardiac L-type Ca2+ current (I-Ca,I-L) was studied using the whole-cell patch clamp technique. Treatment of guinea pig ventricular myocytes with phorbol-12,13-dibutyrate (PDBu) caused a significant decrease in I-Ca,I-L sensitivity to stimulation by submaximal beta(1)-AR activation using isoproterenol (Iso). This decrease in sensitivity was also associated with the ability of higher concentrations of Iso to directly inhibit the stimulatory response. PDBu treatment produced similar effects on H-2 histamine receptor-mediated I-Ca,I-L responses. In the presence of PDBu, higher concentrations of Iso inhibited the histamine stimulated I-Ca,I-L, and this effect was blocked by a selective beta(1)-AR antagonist. Higher concentrations of histamine also inhibited the Iso stimulated I-Ca,I-L, and this effect was blocked by a selective H-2 receptor antagonist. The effects of PDBu were blocked by the PKC inhibitor bisindolylmaleimide I, and they were not mimicked by the inactive phorbol ester 4alpha-phorbol-12,13-didecanoate. The inhibitory effects of Iso and histamine were significantly reduced when G(i/o) mediated responses were blocked with pertussis toxin. These results suggest that PKC promotes coupling of cardiac beta(1)-adrenergic and H-2 histamine receptors to G(i/o) mediated inhibitory responses.	Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Case Western Reserve University	Harvey, RD (corresponding author), Case Western Reserve Univ, Dept Physiol & Biophys, 2109 Adelbert Rd, Cleveland, OH 44106 USA.	rdh3@cwru.edu	Harvey, Robert D/L-8496-2016	Harvey, Robert D/0000-0002-8499-8765; Belevych, Andriy/0000-0002-1272-5784				Akaishi Y, 1997, J MOL CELL CARDIOL, V29, P765, DOI 10.1006/jmcc.1996.0315; Belevych AE, 2003, BIOPHYS J, V84, p538A; Belevych AE, 2002, MOL PHARMACOL, V62, P554, DOI 10.1124/mol.62.3.554; Belevych AE, 2001, J PHYSIOL-LONDON, V536, P677, DOI 10.1111/j.1469-7793.2001.00677.x; BOHM M, 1992, BASIC RES CARDIOL, V87, P37; Bowling N, 1999, CIRCULATION, V99, P384, DOI 10.1161/01.CIR.99.3.384; Brodde OE, 1999, PHARMACOL REV, V51, P651; Bunemann M, 1999, ANNU REV PHYSIOL, V61, P169, DOI 10.1146/annurev.physiol.61.1.169; Cai JJ, 1996, MOL PHARMACOL, V49, P81; Chakraborti S, 2000, CELL SIGNAL, V12, P499, DOI 10.1016/S0898-6568(00)00087-5; Chen XW, 2002, CIRC RES, V91, P517, DOI 10.1161/01.RES.0000033988.13062.7C; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; Communal C, 1999, CIRCULATION, V100, P2210, DOI 10.1161/01.CIR.100.22.2210; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Dzimiri N, 1999, PHARMACOL REV, V51, P465; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Gauthier C, 2000, TRENDS PHARMACOL SCI, V21, P426, DOI 10.1016/S0165-6147(00)01562-5; Gauthier C, 1996, J CLIN INVEST, V98, P556, DOI 10.1172/JCI118823; Goldberg M, 1997, J CLIN INVEST, V99, P55, DOI 10.1172/JCI119133; Hemmings HC, 1998, TOXICOL LETT, V101, P89, DOI 10.1016/S0378-4274(98)00170-2; HESCHELER J, 1987, PFLUG ARCH EUR J PHY, V410, P23, DOI 10.1007/BF00581891; HESCHELER J, 1986, PFLUG ARCH EUR J PHY, V407, P182, DOI 10.1007/BF00580674; Hool LC, 1997, AM J PHYSIOL-HEART C, V273, pH1669, DOI 10.1152/ajpheart.1997.273.4.H1669; Kamp TJ, 2000, CIRC RES, V87, P1095, DOI 10.1161/01.RES.87.12.1095; Kaumann AJ, 1997, TRENDS PHARMACOL SCI, V18, P70, DOI 10.1016/S0165-6147(96)01033-4; Kilts JD, 2000, CIRC RES, V87, P705, DOI 10.1161/01.RES.87.8.705; Koch WJ, 1996, CIRC RES, V78, P511, DOI 10.1161/01.RES.78.4.511; Kuschel M, 1999, J BIOL CHEM, V274, P22048, DOI 10.1074/jbc.274.31.22048; NEUMANN J, 1988, LANCET, V2, P936; OUADID H, 1995, J CARDIOVASC PHARM, V25, P282, DOI 10.1097/00005344-199502000-00014; Paul K, 1997, CIRC RES, V81, P643; Richard S, 1998, CARDIOVASC RES, V37, P300, DOI 10.1016/S0008-6363(97)00273-3; Rohde S, 2000, J MOL CELL CARDIOL, V32, P1193, DOI 10.1006/jmcc.2000.1153; Schwartz DD, 1997, J CARDIOVASC PHARM, V29, P257, DOI 10.1097/00005344-199702000-00015; Shin HG, 2000, CARDIOVASC RES, V48, P285, DOI 10.1016/S0008-6363(00)00185-1; Takeishi Y, 1999, CIRC RES, V85, P264, DOI 10.1161/01.RES.85.3.264; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; van der Goot H, 2000, EUR J MED CHEM, V35, P5, DOI 10.1016/S0223-5234(00)00101-X; Wang JW, 1999, CAN J CARDIOL, V15, P683; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105; Xiao RP, 1999, CIRC RES, V84, P43; XIAO RP, 1995, MOL PHARMACOL, V47, P322; Zhang ZH, 1997, CIRC RES, V80, P720, DOI 10.1161/01.RES.80.5.720	43	14	15	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					367	+		10.1096/fj.03-0647fje	http://dx.doi.org/10.1096/fj.03-0647fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14688202				2022-12-25	WOS:000188067500008
J	Tomczak, KK; Marinescu, VD; Ramoni, MF; Sanoudou, D; Montanaro, F; Han, M; Kunkel, LM; Kohane, IS; Beggs, AH				Tomczak, KK; Marinescu, VD; Ramoni, MF; Sanoudou, D; Montanaro, F; Han, M; Kunkel, LM; Kohane, IS; Beggs, AH			Expression profiling and identification of novel genes involved in myogenic differentiation	FASEB JOURNAL			English	Article						C2C12 myoblasts; myogenesis; microarrays; cluster analysis; Expressed Sequence Tags	SKELETAL-MUSCLE REGENERATION; CELL-CYCLE WITHDRAWAL; TRANS-DIFFERENTIATION; MYOBLAST FUSION; MYOD; PROTEIN; PROSTAGLANDINS; TRANSCRIPTION; CAVEOLIN-3; INDUCTION	Skeletal muscle differentiation is a complex, highly coordinated process that relies on precise temporal gene expression patterns. To better understand this cascade of transcriptional events, we used expression profiling to analyze gene expression in a 12-day time course of differentiating C2C12 myoblasts. Cluster analysis specific for time-ordered microarray experiments classified 2895 genes and ESTs with variable expression levels between proliferating and differentiating cells into 22 clusters with distinct expression patterns during myogenesis. Expression patterns for several known and novel genes were independently confirmed by real-time quantitative RT-PCR and/or Western blotting and immunofluorescence. MyoD and MEF family members exhibited unique expression kinetics that were highly coordinated with cell-cycle withdrawal regulators. Among genes with peak expression levels during cell cycle withdrawal were Vcam1, Itgb3, Itga5, Vcl, as well as Ptger4, a gene not previously associated with the process of myogenesis. One interesting uncharacterized transcript that is highly induced during myogenesis encodes several immunoglobulin repeats with sequence similarity to titin, a large sarcomeric protein. These data sets identify many additional uncharacterized transcripts that may play important functions in muscle cell proliferation and differentiation and provide a baseline for comparison with C2C12 cells expressing various mutant genes involved in myopathic disorders.	Childrens Hosp Boston, Div Genet, Boston, MA 02115 USA; Childrens Hosp Boston, Genom Program, Boston, MA 02115 USA; Childrens Hosp, Informat Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Beggs, AH (corresponding author), Childrens Hosp Boston, Div Genet, 300 Longwood Ave, Boston, MA 02115 USA.	beggs@enders.tch.harvard.edu	Montanaro, Federica/GRJ-5139-2022; Sanoudou, Despina/AAD-8139-2019; Kohane, Isaac Kohane/K-3716-2012	Montanaro, Federica/0000-0002-3338-0498; Sanoudou, Despina/0000-0003-3704-1941; Kohane, Isaac Kohane/0000-0003-2192-5160; Beggs, Alan/0000-0001-8818-0568	NINDS NIH HHS [P01 NS040828] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS040828] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amthor H, 1996, DEV BIOL, V178, P343, DOI 10.1006/dbio.1996.0223; Anderson JE, 1998, BIOCHEM CELL BIOL, V76, P13, DOI 10.1139/bcb-76-1-13; Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BOBER E, 1991, J CELL BIOL, V6, P1255; Chambers R L, 1996, Can J Appl Physiol, V21, P155; Delgado I, 2003, GENOMICS, V82, P109, DOI 10.1016/S0888-7543(03)00104-6; ENTWISTLE A, 1986, J CELL BIOL, V103, P857, DOI 10.1083/jcb.103.3.857; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; Friday BB, 2003, DIFFERENTIATION, V71, P217, DOI 10.1046/j.1432-0436.2003.710303.x; Galbiati F, 2001, TRENDS MOL MED, V7, P435, DOI 10.1016/S1471-4914(01)02105-0; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; Granzier H, 2002, J PHYSIOL-LONDON, V541, P335, DOI 10.1113/jphysiol.2001.014381; Grimaldi PA, 1997, PROSTAG LEUKOTR ESS, V57, P71, DOI 10.1016/S0952-3278(97)90495-6; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Ikeda K, 2003, J BIOL CHEM, V278, P3514, DOI 10.1074/jbc.M204563200; Inoue C, 2001, GENES CELLS, V6, P977, DOI 10.1046/j.1365-2443.2001.00476.x; Kabashima K, 2003, NAT MED, V9, P744, DOI 10.1038/nm872; Liu GY, 2003, NUCLEIC ACIDS RES, V31, P82, DOI 10.1093/nar/gkg121; Liu LA, 1999, J BIOL CHEM, V274, P38171, DOI 10.1074/jbc.274.53.38171; Machwate M, 2001, MOL PHARMACOL, V60, P36, DOI 10.1124/mol.60.1.36; Maeda T, 2001, J BIOL CHEM, V276, P3628, DOI 10.1074/jbc.M007898200; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; McNally EM, 1998, HUM MOL GENET, V7, P871, DOI 10.1093/hmg/7.5.871; Megeney LA, 1995, BIOCHEM CELL BIOL, V73, P723, DOI 10.1139/o95-080; Moran JL, 2002, PHYSIOL GENOMICS, V10, P103, DOI 10.1152/physiolgenomics.00011.2002; Muntoni F, 2002, NEUROMUSCULAR DISORD, V12, P438, DOI 10.1016/S0960-8966(01)00326-1; Naya FJ, 1999, CURR OPIN CELL BIOL, V11, P683, DOI 10.1016/S0955-0674(99)00036-8; Ohyama M, 2002, J PERIODONTOL, V73, P543, DOI 10.1902/jop.2002.73.5.543; PATAPOUTIAN A, 1995, DEVELOPMENT, V121, P3347; Perry RLS, 2000, FRONT BIOSCI, V5, pD750, DOI 10.2741/Perry; Ramoni MF, 2002, P NATL ACAD SCI USA, V99, P9121, DOI 10.1073/pnas.132656399; ROSEN SD, 1992, TRENDS GLYCOSCI GLYC, V4, P1; ROSSI MJ, 1989, J CELL PHYSIOL, V141, P142, DOI 10.1002/jcp.1041410121; Rudiger M, 1998, BIOESSAYS, V20, P733; Sabourin LA, 2000, CLIN GENET, V57, P16, DOI 10.1034/j.1399-0004.2000.570103.x; Sanoudou D, 2003, P NATL ACAD SCI USA, V100, P4666, DOI 10.1073/pnas.0330960100; Shen X, 2003, DEV DYNAM, V226, P128, DOI 10.1002/dvdy.10200; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Taverna D, 1998, J CELL BIOL, V143, P849, DOI 10.1083/jcb.143.3.849; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAMAGUCHI A, 1995, SEMIN CELL BIOL, V6, P165, DOI 10.1006/scel.1995.0023; Yeow K, 2001, FEBS LETT, V506, P157, DOI 10.1016/S0014-5793(01)02900-3; Young P, 2001, J CELL BIOL, V154, P123, DOI 10.1083/jcb.200102110; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3; ZALIN RJ, 1977, DEV BIOL, V59, P241, DOI 10.1016/0012-1606(77)90258-5; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	50	145	147	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					403	+		10.1096/f.03-0568fje	http://dx.doi.org/10.1096/f.03-0568fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14688207				2022-12-25	WOS:000188067500013
J	Black, EJ; Clair, T; Delrow, J; Neiman, P; Gillespie, DAF				Black, EJ; Clair, T; Delrow, J; Neiman, P; Gillespie, DAF			Microarray analysis identifies Autotaxin, a tumour cell motility and angiogenic factor with lysophospholipase D activity, as a specific target of cell transformation by v-Jun	ONCOGENE			English	Article						v-Jun; autotaxin; microarray; lysophospholipase; angiogenesis	HYPOXIA-INDUCIBLE FACTOR-1; ESTROGEN RECEPTOR CHIMERA; C-JUN; TRANSCRIPTIONAL ACTIVATION; GROWTH; GENE; PROTEIN; DNA; FIBROBLASTS; EXPRESSION	We have used chicken cDNA microarrays to investigate gene-expression changes induced during transformation of chick embryo fibroblasts (CEF) by the viral Jun oncoprotein encoded by ASV17. This analysis reveals that v-Jun induces increases and decreases of varying magnitude in the expression of genes involved in diverse cellular functions, most of which have not been detected in previous screens for putative v-Jun targets. In all, 27 individual genes were identified, whose expression is increased threefold or more in v-Jun-transformed cells, including genes involved in energy generation, protein synthesis, and gene transcription. Interestingly, this group includes the hypoxia-inducible factor-1 alpha (Hif-1alpha) transcription factor and the glycolytic enzyme enolase, suggesting that adaptation to hypoxia could play a role in tumorigenesis by v-Jun. We also identified 32 genes whose expression is decreased threefold or more, including chaperones, components of the cytoskeleton, and, unexpectedly, DNA replication factors. The gene whose expression is upregulated most dramatically (similar to100-fold) encodes Autotaxin (ATX), a secreted tumor motility-promoting factor with lysophospholipase D activity. Strikingly, v-Jun-transformed CEF secrete catalytically active ATX and chemotactic activity, which can be detected in conditioned medium. ATX is not detectably expressed in normal CEF or CEF transformed by the v-Src or v-Myc oncoproteins, indicating that induction of this putative autocrine/paracrine factor is a specific consequence of cell transformation by v-Jun. ATX has been implicated in both angiogenesis and invasion, and could therefore play an important role in tumorigenesis by v-Jun in vivo.	Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Beatson Inst Canc Res, Canc Res Campaign Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Dept Human Biol, Seattle, WA 98109 USA	University of Glasgow; Beatson Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center	Gillespie, DAF (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland.	d.gillespie@beatson.gla.ac.uk	Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544	NATIONAL CANCER INSTITUTE [R01CA020068] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA20068] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alfranca A, 2002, MOL CELL BIOL, V22, P12, DOI 10.1128/MCB.22.1.12-22.2002; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Bader AG, 2001, ONCOGENE, V20, P7524, DOI 10.1038/sj.onc.1204938; Bates S, 1996, ONCOGENE, V13, P1103; Beere H M, 2001, Sci STKE, V2001, pre1, DOI 10.1126/stke.2001.93.re1; Bollen M, 2000, CRIT REV BIOCHEM MOL, V35, P393, DOI 10.1080/10409230091169249; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; Chen F, 2001, AM J PATHOL, V159, P387, DOI 10.1016/S0002-9440(10)61708-7; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Clair T, 1997, J BIOL CHEM, V272, P996, DOI 10.1074/jbc.272.2.996; Clark W, 2000, MOL CELL BIOL, V20, P2529, DOI 10.1128/MCB.20.7.2529-2542.2000; Clark W, 1997, CELL GROWTH DIFFER, V8, P371; Cohen SB, 2001, ONCOGENE, V20, P141, DOI 10.1038/sj.onc.1204077; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Dunn CA, 2003, BBA-GENE STRUCT EXPR, V1628, P147, DOI 10.1016/S0167-4781(03)00136-2; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Gao MH, 1996, CANCER RES, V56, P4229; Hadman M, 1996, ONCOGENE, V12, P135; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hartl M, 2001, P NATL ACAD SCI USA, V98, P13601, DOI 10.1073/pnas.241451198; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Inohara N, 1998, J BIOL CHEM, V273, P8705, DOI 10.1074/jbc.273.15.8705; Jones SE, 2002, INT J BIOCHEM CELL B, V34, P427, DOI 10.1016/S1357-2725(01)00155-8; Kilbey A, 1996, ONCOGENE, V12, P2409; Koh E, 2003, CANCER RES, V63, P2042; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Lee HY, 2002, FEBS LETT, V515, P137, DOI 10.1016/S0014-5793(02)02457-2; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; Moolenaar WH, 2002, J CELL BIOL, V158, P197, DOI 10.1083/jcb.200206094; MORGAN IM, 1993, ONCOGENE, V8, P1135; Nam SW, 2000, ONCOGENE, V19, P241, DOI 10.1038/sj.onc.1203263; Nam SW, 2001, CANCER RES, V61, P6938; Neiman PE, 2001, P NATL ACAD SCI USA, V98, P6378, DOI 10.1073/pnas.111144898; NISHIMURA T, 1988, ONCOGENE, V3, P659; Salnikow K, 2002, MOL CELL BIOL, V22, P1734, DOI 10.1128/MCB.22.6.1734-1741.2002; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Vial E, 2000, ONCOGENE, V19, P5020, DOI 10.1038/sj.onc.1203867; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; WONG WY, 1992, ONCOGENE, V7, P2077	46	58	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2357	2366		10.1038/sj.onc.1207377	http://dx.doi.org/10.1038/sj.onc.1207377			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14691447	Bronze			2022-12-25	WOS:000220427700010
J	Cartron, PF; Oliver, L; Juin, P; Meflah, K; Vallette, FM				Cartron, PF; Oliver, L; Juin, P; Meflah, K; Vallette, FM			The p18 truncated form of bax behaves like a Bcl-2 homology domain 3-only protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOTIC CELL-DEATH; DRUG-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; BH3 DOMAIN; INTRACELLULAR-LOCALIZATION; X-L; CLEAVAGE; MITOCHONDRIA; CALPAIN; CANCER	p21(Bax) is a pro-apoptotic member of the Bcl-2 family and is converted by calpain into a truncated form called p18(Bax). This proteolysis enhanced the apoptogenic properties of Bax by a mechanism not yet elucidated. We have shown recently that the first alpha helix (Halpha1) of p21(Bax) contained a mitochondrial addressing sequence, which appeared to be necessary for p21(Bax)-induced apoptosis (Cartron, P. F., Priault, M., Oliver, L., Meflah, K., Manon, S., and Vallette, F. M. (2003) J. Biol. Chem. 278, 11633 11641). This feature is in contradiction with the high apoptogenic profile of p18(Bax), because the Halpha1 is lost during the calpain cleavage of p21(Bax). We investigated the role of p18(Bax) in apoptosis and found that its activity required the presence of p21(Bax). In addition, p18(Bax) exhibited a higher affinity for Bcl-Xl than p21(Bax) did, a property that seems to be essential for the fulfillment of its pro-apoptotic role. In conclusion, calpain proteolysis converts the multi-domain p21(Bax) into a Bcl-2 homology 3-like protein capable of overcoming the inhibition of apoptosis due to Bcl-Xl.	Inst Fed Rech 26, INSERM, U419, F-44035 Nantes 01, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Vallette, FM (corresponding author), Inst Fed Rech 26, INSERM, U419, 9 Quai Moncousu, F-44035 Nantes 01, France.	fval@nantes.inserm.fr	JUIN, Philippe P/H-3636-2014; Vallette, Francois/N-2361-2018; Vallette, Francois M/K-9047-2015; Oliver, Lisa J/L-3070-2015; Cartron, Pierre Francois/K-9802-2015; JUIN, Philippe/Q-1338-2019	JUIN, Philippe P/0000-0002-4997-3888; Vallette, Francois M/0000-0002-3296-8572; Oliver, Lisa J/0000-0002-5588-7564; JUIN, Philippe/0000-0002-4997-3888; Cartron, Pierre-Francois/0000-0002-3393-784X; Vallette, Francois/0000-0003-0802-0519				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Amundson SA, 2000, CANCER RES, V60, P6101; Cao XF, 2003, BLOOD, V102, P2605, DOI 10.1182/blood-2003-01-0211; Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; Cartron PF, 2003, J BIOL CHEM, V278, P11633, DOI 10.1074/jbc.M208955200; Cartron PF, 2002, FEBS LETT, V512, P95, DOI 10.1016/S0014-5793(02)02227-5; Chan SL, 2003, J BIOL CHEM, V278, P20453, DOI 10.1074/jbc.C300138200; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Choi WS, 2001, J NEUROCHEM, V77, P1531, DOI 10.1046/j.1471-4159.2001.00368.x; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cuconati A, 2002, GENE DEV, V16, P2465, DOI 10.1101/gad.1012702; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Gao G, 2000, J CELL BIOCHEM, V80, P53; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Juin P, 1998, BIOCHEM BIOPH RES CO, V253, P185, DOI 10.1006/bbrc.1998.9742; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Mahajan NP, 1998, NAT BIOTECHNOL, V16, P547, DOI 10.1038/nbt0698-547; Moreau C, 2003, J BIOL CHEM, V278, P19426, DOI 10.1074/jbc.M209472200; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Toyota H, 2003, CANCER LETT, V189, P221, DOI 10.1016/S0304-3835(02)00552-9; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; Vieira Helena L. A., 2002, Oncogene, V21, P1963, DOI 10.1038/sj.onc.1205270; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wood DE, 2000, EXP CELL RES, V256, P375, DOI 10.1006/excr.2000.4859; Wood DE, 1999, J BIOL CHEM, V274, P8309, DOI 10.1074/jbc.274.12.8309; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101	40	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11503	11512		10.1074/jbc.M311922200	http://dx.doi.org/10.1074/jbc.M311922200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14681224	hybrid			2022-12-25	WOS:000220157600082
J	Lemrow, SM; Anderson, KA; Joseph, JD; Ribar, TJ; Noeldner, PK; Means, AR				Lemrow, SM; Anderson, KA; Joseph, JD; Ribar, TJ; Noeldner, PK; Means, AR			Catalytic activity is required for calcium/calmodulin-dependent protein kinase IV to enter the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; AMINO-ACID-SEQUENCE; IMMUNOHISTOCHEMICAL LOCALIZATION; MOLECULAR-CLONING; BRAIN CALMODULIN; RAT-BRAIN; KAPPA-B; PHOSPHORYLATION; ACTIVATION; TRANSPORT	Calcium/calmodulin-dependent protein kinase IV (CaMKIV) is a nuclear protein kinase that responds to acute rises in intracellular calcium by phosphorylating and activating proteins involved in transcription. Consistent with these roles, CaMKIV is found predominantly in the nucleus of cells in which it is expressed. Here we evaluate nuclear entry of CaMKIV and demonstrate that the protein kinase homology domain is both necessary and sufficient for nuclear localization. Unexpectedly, although catalytic activity is required for nuclear translocation, it is not required for CaMKIV to interact with the nuclear adaptor protein, importin-alpha. Because the catalytically inactive molecules remain in the cytoplasm, these data suggest that this interaction is not sufficient for nuclear entry. We evaluated a role for other proteins known to interact with CaMKIV in regulation of its nuclear entry. Although our data do not support a role for calmodulin or protein phosphatase 2A, the catalytically inactive CaMKIV proteins interact more avidly with CaM-dependent protein kinase kinase (CaMKK), which is restricted to the cytoplasm. We find that the catalytically inactive proteins do not inhibit nuclear entry of wild-type CaMKIV but do inhibit the ability of the wild-type protein kinase to stimulate cyclic AMP response element-binding protein-mediated transcription. Because activation loop phosphorylation is required for the transcriptional roles of CaMKIV, these data suggest that CaMKK phosphorylation of CaMKIV may occur in the cytoplasm. We propose that sequestration of CaMKK may be the molecular mechanism by which catalytically inactive mutants of CaMKIV exert their "dominant-negative" functions within the cell.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Means, AR (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.	means001@mc.duke.edu			NICHD NIH HHS [HD07503] Funding Source: Medline; NIGMS NIH HHS [GM-33976] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033976] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; Anderson KA, 1997, MOL ENDOCRINOL, V11, P725, DOI 10.1210/me.11.6.725; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Chatila T, 1996, J BIOL CHEM, V271, P21542, DOI 10.1074/jbc.271.35.21542; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; Fagerlund R, 2002, J BIOL CHEM, V277, P30072, DOI 10.1074/jbc.M202943200; FELDHERR CM, 1991, J CELL BIOL, V115, P933, DOI 10.1083/jcb.115.4.933; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNTER T, 1986, ENZYMES, P17; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; Ji RR, 1996, BRAIN RES, V721, P167, DOI 10.1016/0006-8993(95)01316-4; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; Kane CD, 2000, EMBO J, V19, P691, DOI 10.1093/emboj/19.4.691; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MCDONALD OB, 1993, J BIOL CHEM, V268, P10054; MIYANO O, 1992, J BIOL CHEM, V267, P1198; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; NAKAMURA Y, 1995, NEUROSCIENCE, V68, P181, DOI 10.1016/0306-4522(95)00092-W; Nakamura Y, 2001, NEUROSCI RES, V39, P175, DOI 10.1016/S0168-0102(00)00209-1; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OKUNO S, 1993, J BIOCHEM-TOKYO, V114, P167, DOI 10.1093/oxfordjournals.jbchem.a124149; OKUNO S, 1995, J BIOCHEM-TOKYO, V117, P686, DOI 10.1093/oxfordjournals.jbchem.a124764; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Sakagami H, 1996, BRAIN RES, V719, P154, DOI 10.1016/0006-8993(96)00088-1; Sakagami H, 2000, EUR J NEUROSCI, V12, P89, DOI 10.1046/j.1460-9568.2000.00883.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sorg G, 1999, BIOTECHNIQUES, V26, P858, DOI 10.2144/99265bm12; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Tokumitsu H, 1999, J BIOL CHEM, V274, P15803, DOI 10.1074/jbc.274.22.15803; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3; Zhao X, 2001, J BIOL CHEM, V276, P35042, DOI 10.1074/jbc.M105086200	42	48	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11664	11671		10.1074/jbc.M312613200	http://dx.doi.org/10.1074/jbc.M312613200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701808	hybrid			2022-12-25	WOS:000220157600101
J	Young, AP; Longmore, GD				Young, AP; Longmore, GD			Ras protects Rb family null fibroblasts from cell death - A role for AP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; C-JUN; RETINOBLASTOMA PROTEIN; ONCOGENIC RAS; G(1) CONTROL; DNA-BINDING; IN-VITRO; APOPTOSIS; KINASE; GENE	The retinoblastoma protein (Rb) controls cell proliferation, differentiation, and senescence and provides an essential tumor suppressive function that cells must eliminate to attain unlimited proliferative potential. Elimination of the Rb pathway also results in apoptosis, however, thereby providing an efficient surveillance mechanism to sense the loss of Rb. To become tumorigenic cells must thus overcome not only Rb function but also the apoptotic response caused by the loss of Rb function. We show that oncogenic Ras (RasV12) potently blocks cell death in Rb family member knockout mouse embryo fibroblasts (TKO cells). Activation of phosphatidylinositol 3-kinase and Raf by oncogenic Ras mediated this protection, implying that multiple Ras effector pathways are required, in concert, for this pro-survival signal. Although activation of Raf by selective Ras mutants protected TKO cells from cell death, pharmacologic inhibition of MEK had little effect on RasV12 protection, suggesting that a Raf-dependent, MEK-independent pathway was important for this effect. We show that this Raf-dependent protection occurred through activation of c-Jun and thus AP-1 activation. These observations could account for the dependence of Ras transformation on c-Jun activity and for the roles of AP-1 in oncogenesis. Our results support the concept of two oncogenic events cooperating to achieve a balance between immortalization and survival.	Washington Univ, Sch Med, Div Hematol, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Longmore, GD (corresponding author), Washington Univ, Sch Med, Div Hematol, Dept Med, 660 S Euclid Ave, St Louis, MO 63110 USA.	glongmor@im.wustl.edu			NCI NIH HHS [CA 85839] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085839] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Baccarini M, 2002, CELL DEATH DIFFER, V9, P783, DOI 10.1038/sj.cdd.4401070; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Chresta C M, 1996, Behring Inst Mitt, P232; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eferl R, 1999, J CELL BIOL, V145, P1049, DOI 10.1083/jcb.145.5.1049; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; FERNANDEZ A, 1994, ONCOGENE, V9, P2009; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; Gallo A, 2002, ONCOGENE, V21, P6434, DOI 10.1038/sj.onc.1205822; Ginsberg D, 2002, FEBS LETT, V529, P122, DOI 10.1016/S0014-5793(02)03270-2; GRUDA MC, 1994, ONCOGENE, V9, P2537; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HANAZAWA S, 1993, J BIOL CHEM, V268, P9526; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; Hilgers W, 2002, HEMATOL ONCOL CLIN N, V16, P17, DOI 10.1016/S0889-8588(01)00005-3; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; LAMB JA, 2003, GENE DEV, V11, P1479; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; Ma PH, 2002, MOL CELL BIOL, V22, P2928, DOI 10.1128/MCB.22.9.2928-2938.2002; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Orecchia R, 2000, J PATHOL, V190, P423; Peli J, 1999, EMBO J, V18, P1824, DOI 10.1093/emboj/18.7.1824; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Reed SI, 1997, CANCER SURV, V29, P7; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Walker GJ, 2002, J INVEST DERMATOL, V119, P783, DOI 10.1046/j.1523-1747.2002.00217.x; Webb CP, 2001, METHOD ENZYMOL, V333, P318; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White E, 2001, ONCOGENE, V20, P7836, DOI 10.1038/sj.onc.1204861; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Zenz R, 2003, DEV CELL, V4, P879, DOI 10.1016/S1534-5807(03)00161-8	55	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10931	10938		10.1074/jbc.M311814200	http://dx.doi.org/10.1074/jbc.M311814200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14688262	hybrid			2022-12-25	WOS:000220157600014
J	Gaudreau, R; Beaulieu, ME; Chen, ZG; Le Gouill, C; Lavigne, P; Stankova, J; Rola-Pleszczynski, M				Gaudreau, R; Beaulieu, ME; Chen, ZG; Le Gouill, C; Lavigne, P; Stankova, J; Rola-Pleszczynski, M			Structural determinants regulating expression of the high affinity leukotriene B-4 receptor - Involvement of dileucine motifs and alpha-helix VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; DI-LEUCINE MOTIF; CYTOPLASMIC TAIL; SORTING SIGNALS; MDCK CELLS; BETA(2)-ADRENERGIC RECEPTOR; CARBOXYL-TERMINUS; PLASMA-MEMBRANE; DOWN-REGULATION; HUMAN MONOCYTES	Mutational analysis of determinants located in the C-terminal (C) tail of the high affinity leukotriene (LT) B-4 receptor, BLT1, was performed to assess their significance in BLT1 trafficking. When expressed in COS-7 cells, a BLT1 deletion mutant lacking the C-tail (G291stop) displayed higher numbers of binding sites and increased signal transduction compared with wildtype (WT) BLT1. Addition of the C-tail from either the platelet-activating factor receptor or the LTD4 receptor, CysLT1, did not restore WT phenotype. Moreover, the number of LTB4 binding sites was higher in the chimeras than in the WT BLT1, suggesting the requirement for specific structural determinants within the BLT1 C-tail. Elimination of a distal C-tail dileucine motif (Leu(304)-Leu(305)), but not the proximal (Leu(292)-Leu(293)) motif, altered BLT1 pharmacological characteristics and caused a moderate constitutive receptor activation. Surprisingly, all mutant receptors were efficiently delivered to the plasma membrane, but not to a greater extent than WT BLT1, as assessed by flow cytometry. Furthermore, substitution of Leu(304)-Leu(305) prevented LTB4-induced BLT1 internalization. Molecular modeling of BLT1 on the bovine rhodopsin receptor scaffold strongly suggested the involvement of the distal dileucine motif (Leu(304)-Leu(305)) in a hydrophobic core, including intrahelical interactions within alpha-helix VIII and interhelical interactions with residues of helix I. Disruption of this hydrophobic core is proposed to increase the population of receptors in the active form, to restrain their trafficking and to facilitate the activation of BLT1 as indicated by the increased maximal level of binding of the ligand and constitutive activation of the receptor.	Univ Sherbrooke, Div Immunol, Dept Pediat, Fac Med, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, Dept Pharmacol, Fac Med, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke; University of Sherbrooke	Rola-Pleszczynski, M (corresponding author), Univ Sherbrooke, Div Immunol, Dept Pediat, Fac Med, 3001 N 12th Ave, Sherbrooke, PQ J1H 5N4, Canada.	marek.rola-pleszczynski@usherbrooke.ca	Chen, Zhangguo/AAW-2032-2021	Chen, Zhangguo/0000-0002-2741-0080				Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; Bockaert J, 2003, FEBS LETT, V546, P65, DOI 10.1016/S0014-5793(03)00453-8; Cai KW, 1999, BIOCHEMISTRY-US, V38, P7925, DOI 10.1021/bi9900119; Claeysen S, 1999, MOL PHARMACOL, V55, P910; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; Deraet M, 2002, CAN J PHYSIOL PHARM, V80, P418, DOI 10.1139/Y02-060; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; Fan GH, 2001, BIOCHEMISTRY-US, V40, P791, DOI 10.1021/bi001661b; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; Gaudreau R, 2002, J BIOL CHEM, V277, P31567, DOI 10.1074/jbc.M202723200; Gaudreau R, 1998, BIOCHEM J, V335, P15, DOI 10.1042/bj3350015; Geisler C, 1998, J BIOL CHEM, V273, P21316, DOI 10.1074/jbc.273.33.21316; Gether U, 2002, PHARMACOL TOXICOL, V91, P304, DOI 10.1034/j.1600-0773.2002.910607.x; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Hall DA, 2000, MOL PHARMACOL, V58, P1412, DOI 10.1124/mol.58.6.1412; Heilker R, 1999, BIOESSAYS, V21, P558, DOI 10.1002/(SICI)1521-1878(199907)21:7<558::AID-BIES4>3.0.CO;2-R; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Kraft K, 2001, J BIOL CHEM, V276, P34408, DOI 10.1074/jbc.M102782200; Kuang YN, 1996, J BIOL CHEM, V271, P3975; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Lavine N, 2002, J BIOL CHEM, V277, P46010, DOI 10.1074/jbc.M205035200; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; Martens AS, 2000, J CELL SCI, V113, P3593; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; Okamoto Y, 1997, J BIOL CHEM, V272, P21589, DOI 10.1074/jbc.272.34.21589; OKUNO T, 2003, J BIOL CHEM; Orsini MJ, 1999, J BIOL CHEM, V274, P31076, DOI 10.1074/jbc.274.43.31076; Paing MM, 2002, J BIOL CHEM, V277, P1292, DOI 10.1074/jbc.M109160200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parnot C, 2000, P NATL ACAD SCI USA, V97, P7615, DOI 10.1073/pnas.110142297; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; ROLAPLESZCZYNSKI M, 1992, BLOOD, V80, P1004; ROLAPLESZCZYNSKI M, 1985, IMMUNOL TODAY, V6, P302, DOI 10.1016/0167-5699(85)90181-1; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; STANKOVA J, 1992, BIOCHEM J, V282, P625; STANKOVA J, 1992, IMMUNOLOGY, V76, P258; Teuchert M, 1999, J BIOL CHEM, V274, P36781, DOI 10.1074/jbc.274.51.36781; Weiss JM, 1996, J THEOR BIOL, V178, P169, DOI 10.1006/jtbi.1996.0015; Yang K, 1996, BIOCHEMISTRY-US, V35, P14040, DOI 10.1021/bi962113u; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Yu HB, 1999, BIOCHEMISTRY-US, V38, P12033, DOI 10.1021/bi9909492	53	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10338	10345		10.1074/jbc.M309207200	http://dx.doi.org/10.1074/jbc.M309207200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688279	hybrid			2022-12-25	WOS:000220050400083
J	Guilherme, A; Soriano, NA; Bose, S; Holik, J; Bose, A; Pomerleau, DP; Furcinitti, P; Leszyk, J; Corvera, S; Czech, MP				Guilherme, A; Soriano, NA; Bose, S; Holik, J; Bose, A; Pomerleau, DP; Furcinitti, P; Leszyk, J; Corvera, S; Czech, MP			EHD2 and the novel EH domain binding protein EHBP1 couple endocytosis to the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; POLARIZED EPITHELIAL-CELLS; CLATHRIN-COATED PITS; ARP2/3 COMPLEX; 3T3-L1 ADIPOCYTES; MAMMALIAN-CELLS; PLASMA-MEMBRANE; GLUT4 ENDOCYTOSIS; N-WASP; INSULIN	Here we identified two novel proteins denoted EH domain protein 2 (EHD2) and EHD2-binding protein 1 (EHBP1) that link clathrin-mediated endocytosis to the actin cytoskeleton. EHD2 contains an N-terminal P-loop and a C-terminal EH domain that interacts with NPF repeats in EHBP1. Disruption of EHD2 or EHBP1 function by small interfering RNA-mediated gene silencing inhibits endocytosis of transferrin into EEA1-positive endosomes as well as GLUT4 endocytosis into cultured adipocytes. EHD2 localizes with cortical actin filaments, whereas EHBP1 contains a putative actin-binding calponin homology domain. High expression of EHD2 or EHBP1 in intact cells mediates extensive actin reorganization. Thus EHD2 appears to connect endocytosis to the actin cytoskeleton through interactions of its N-terminal domain with membranes and its C-terminal EH domain with the novel EHBP1 protein.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Czech, MP (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.	Michael.Czech@umassmed.edu			NIDDK NIH HHS [DK30898, DK60837, DK54479] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060837, R01DK030898, R37DK030898, R01DK054479] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Apodaca G, 2001, TRAFFIC, V2, P149, DOI 10.1034/j.1600-0854.2001.020301.x; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; Benmerah A, 1999, J CELL SCI, V112, P1303; Bose A, 2002, NATURE, V420, P821, DOI 10.1038/nature01246; Bose A, 2001, MOL CELL BIOL, V21, P5262, DOI 10.1128/MCB.21.15.5262-5275.2001; Caplan S, 2002, EMBO J, V21, P2557, DOI 10.1093/emboj/21.11.2557; Confalonieri S, 2002, FEBS LETT, V513, P24, DOI 10.1016/S0014-5793(01)03241-0; de Beer T, 2000, NAT STRUCT BIOL, V7, P1018, DOI 10.1038/80924; Duncan MC, 2001, NAT CELL BIOL, V3, P687, DOI 10.1038/35083087; Engqvist-Goldstein AEY, 1999, J CELL BIOL, V147, P1503, DOI 10.1083/jcb.147.7.1503; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Fujimoto LM, 2000, TRAFFIC, V1, P161, DOI 10.1034/j.1600-0854.2000.010208.x; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; Geli MI, 1998, J CELL SCI, V111, P1031; Gimona M, 2002, FEBS LETT, V513, P98, DOI 10.1016/S0014-5793(01)03240-9; Goode BL, 2001, J CELL BIOL, V153, P627, DOI 10.1083/jcb.153.3.627; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; Grant B, 2001, NAT CELL BIOL, V3, P573, DOI 10.1038/35078549; Guilherme A, 2000, J BIOL CHEM, V275, P38151, DOI 10.1074/jbc.M003432200; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; Hussain NK, 2001, NAT CELL BIOL, V3, P927, DOI 10.1038/ncb1001-927; JACKMAN MR, 1994, J CELL SCI, V107, P2547; Jeng RL, 2001, CURR BIOL, V11, pR691, DOI 10.1016/S0960-9822(01)00410-9; Jiang ZY, 2002, J BIOL CHEM, V277, P509, DOI 10.1074/jbc.M108280200; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; Lawe DC, 2002, J BIOL CHEM, V277, P8611, DOI 10.1074/jbc.M109239200; Li DL, 2001, J BIOL CHEM, V276, P22883, DOI 10.1074/jbc.M010143200; Lin SX, 2001, NAT CELL BIOL, V3, P567, DOI 10.1038/35078543; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Merrifield CJ, 1999, NAT CELL BIOL, V1, P72, DOI 10.1038/9048; Munn AL, 2001, BBA-MOL BASIS DIS, V1535, P236, DOI 10.1016/S0925-4439(01)00028-X; NATION JL, 1983, STAIN TECHNOL, V58, P347, DOI 10.3109/10520298309066811; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; Pohl U, 2000, GENOMICS, V63, P255, DOI 10.1006/geno.1999.6087; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Qualmann B, 2000, J CELL BIOL, V148, P1047, DOI 10.1083/jcb.148.5.1047; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Rao AW, 1998, J BIOL CHEM, V273, P25450, DOI 10.1074/jbc.273.39.25450; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rotem-Yehudar R, 2001, J BIOL CHEM, V276, P33054, DOI 10.1074/jbc.M009913200; Santolini E, 1999, EXP CELL RES, V253, P186, DOI 10.1006/excr.1999.4694; Schafer DA, 2002, CURR OPIN CELL BIOL, V14, P76, DOI 10.1016/S0955-0674(01)00297-6; Shao YF, 2002, J CELL BIOL, V157, P679, DOI 10.1083/jcb.200201063; Takei K, 2001, TRENDS CELL BIOL, V11, P385, DOI 10.1016/S0962-8924(01)02082-7; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; Volchuk A, 1998, J BIOL CHEM, V273, P8169, DOI 10.1074/jbc.273.14.8169; Wenk MR, 2001, NEURON, V32, P79, DOI 10.1016/S0896-6273(01)00456-1; Woodman PG, 2000, TRAFFIC, V1, P695, DOI 10.1034/j.1600-0854.2000.010902.x; Yang S, 1999, MOL BIOL CELL, V10, P2265, DOI 10.1091/mbc.10.7.2265	52	114	130	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10593	10605		10.1074/jbc.M307702200	http://dx.doi.org/10.1074/jbc.M307702200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14676205	hybrid			2022-12-25	WOS:000220050400113
J	Kunz, JB; Schwarz, H; Mayer, A				Kunz, JB; Schwarz, H; Mayer, A			Determination of four sequential stages during microautophagy in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-COMPLEX FORMATION; SACCHAROMYCES-CEREVISIAE; MEMBRANE-FUSION; CVT PATHWAY; AUTOPHAGIC VESICLES; TARGETING PATHWAY; PICHIA-PASTORIS; PROTEIN-KINASE; VACUOLE; YEAST	Microautophagy is the transfer of cytosolic components into the lysosome by direct invagination of the lysosomal membrane and subsequent budding of vesicles into the lysosomal lumen. This process is topologically equivalent to membrane invagination during multivesicular body formation and to the budding of enveloped viruses. Vacuoles are lysosomal compartments of yeasts. Vacuolar membrane invagination can be reconstituted in vitro with purified yeast vacuoles, serving as a model system for budding of vesicles into the lumen of an organelle. Using this in vitro system, we defined different reaction states. We identified inhibitors of microautophagy in vitro and used them as tools for kinetic analysis. This allowed us to characterize four biochemically distinguishable steps of the reaction. We propose that these correspond to sequential stages of vacuole invagination and vesicle scission. Formation of vacuolar invaginations was slow and temperature-dependent, whereas the final scission of the vesicle from a preformed invagination was fast and proceeded even on ice. Our observations suggest that the formation of invaginations rather than the scission of vesicles is the rate-limiting step of the overall reaction.	Max Planck Gesell, Friedrich Miescher Lab, D-72076 Tubingen, Germany; Max Planck Inst Entwicklungsbiol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Max Planck Society; Max Planck Society	Mayer, A (corresponding author), Univ Lausanne, Dept Biochim, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.	andreas.mayer@tuebingen.mpg.de	Mayer, Andreas/AAE-4315-2020	Mayer, Andreas/0000-0001-6131-313X				Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025; BAKER D, 1989, METHOD CELL BIOL, V31, P127; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; Barth H, 2001, FEBS LETT, V508, P23, DOI 10.1016/S0014-5793(01)03016-2; Barth H, 2001, GENE, V274, P151, DOI 10.1016/S0378-1119(01)00614-X; Bhuiyan MSA, 1999, BIOSCI BIOTECH BIOCH, V63, P1075, DOI 10.1271/bbb.63.1075; BOLARD J, 1986, BIOCHIM BIOPHYS ACTA, V864, P257, DOI 10.1016/0304-4157(86)90002-X; Botstein D, 1997, MOL BIOL CELL, V8, pR1, DOI 10.1091/mbc.8.1.i; CARDENAS ME, 1995, J BIOL CHEM, V270, P20997, DOI 10.1074/jbc.270.36.20997; Carminati JL, 1997, J CELL BIOL, V138, P629, DOI 10.1083/jcb.138.3.629; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; Eitzen G, 2001, EMBO J, V20, P5650, DOI 10.1093/emboj/20.20.5650; Epple UD, 2001, J BACTERIOL, V183, P5942, DOI 10.1128/JB.183.20.5942-5955.2001; FRYBERG M, 1974, ARCH BIOCHEM BIOPHYS, V160, P83, DOI 10.1016/S0003-9861(74)80011-1; GUPTA RS, 1983, CANCER RES, V43, P505; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; HOLEN I, 1993, EUR J BIOCHEM, V215, P113, DOI 10.1111/j.1432-1033.1993.tb18013.x; Hutchins MU, 2001, J BIOL CHEM, V276, P20491, DOI 10.1074/jbc.M101150200; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507; Kato M, 2001, EMBO J, V20, P4035, DOI 10.1093/emboj/20.15.4035; Khalfan WA, 2002, CURR OPIN CELL BIOL, V14, P468, DOI 10.1016/S0955-0674(02)00343-5; Kim J, 2001, J CELL BIOL, V152, P51, DOI 10.1083/jcb.152.1.51; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Knop M, 1993, CURR OPIN CELL BIOL, V5, P990, DOI 10.1016/0955-0674(93)90082-2; Komatsu M, 2001, J BIOL CHEM, V276, P9846, DOI 10.1074/jbc.M007737200; Kuma A, 2002, J BIOL CHEM, V277, P18619, DOI 10.1074/jbc.M111889200; Lang T, 2000, J BACTERIOL, V182, P2125, DOI 10.1128/JB.182.8.2125-2133.2000; Lang T, 1998, EMBO J, V17, P3597, DOI 10.1093/emboj/17.13.3597; LENTZ BR, 1987, BIOCHEMISTRY-US, V26, P5389, DOI 10.1021/bi00391a026; Meiling-Wesse K, 2002, FEBS LETT, V530, P174, DOI 10.1016/S0014-5793(02)03456-7; Meiling-Wesse K, 2002, FEBS LETT, V526, P71, DOI 10.1016/S0014-5793(02)03119-8; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mukaiyama H, 2002, GENES CELLS, V7, P75, DOI 10.1046/j.1356-9597.2001.00499.x; Muller O, 2000, J CELL BIOL, V151, P519, DOI 10.1083/jcb.151.3.519; Muller O, 2002, EMBO J, V21, P259, DOI 10.1093/emboj/21.3.259; Muller O, 2001, EMBO J, V20, P5657, DOI 10.1093/emboj/20.20.5657; Noda T, 2002, TRENDS CELL BIOL, V12, P231, DOI 10.1016/S0962-8924(02)02278-X; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; Peters C, 1999, SCIENCE, V285, P1084, DOI 10.1126/science.285.5430.1084; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; POSTE G, 1973, BIOCHIM BIOPHYS ACTA, V300, P421, DOI 10.1016/0304-4157(73)90015-4; ROSENTHAL MD, 1989, BIOCHIM BIOPHYS ACTA, V1001, P1, DOI 10.1016/0005-2760(89)90299-3; Sakai Y, 1998, J CELL BIOL, V141, P625, DOI 10.1083/jcb.141.3.625; Sattler T, 2000, J CELL BIOL, V151, P529, DOI 10.1083/jcb.151.3.529; Scott SV, 2000, J BIOL CHEM, V275, P25840, DOI 10.1074/jbc.M002813200; Shintani T, 2001, J BIOL CHEM, V276, P30452, DOI 10.1074/jbc.M102346200; Stockwell BR, 2000, NAT REV GENET, V1, P116, DOI 10.1038/35038557; Suriapranata I, 2000, J CELL SCI, V113, P4025; SUURKUUSK J, 1976, BIOCHEMISTRY-US, V15, P1393, DOI 10.1021/bi00652a007; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; TITORENKO VI, 1995, J BACTERIOL, V177, P357, DOI 10.1128/jb.177.2.357-363.1995; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Wang CW, 2002, J BIOL CHEM, V277, P47917, DOI 10.1074/jbc.M208191200; Wang CW, 2001, J BIOL CHEM, V276, P30442, DOI 10.1074/jbc.M102342200; WILSCHUT J, 1985, BIOCHEMISTRY-US, V24, P8, DOI 10.1021/bi00322a002; Yuan WP, 1997, J CELL SCI, V110, P1935	58	104	113	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9987	9996		10.1074/jbc.M307905200	http://dx.doi.org/10.1074/jbc.M307905200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14679207	hybrid			2022-12-25	WOS:000220050400042
J	London, M; London, E				London, M; London, E			Ceramide selectively displaces cholesterol from ordered lipid domains (rafts) - Implications for lipid raft structure and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PENETRATION DEPTH; GPI-ANCHORED PROTEINS; MODEL MEMBRANES; BIOLOGICAL-MEMBRANES; SIGNAL-TRANSDUCTION; HUMAN FIBROBLASTS; CELL-SURFACE; SPHINGOMYELINASE; BILAYERS; RESISTANCE	Ceramide is a membrane lipid involved in a number of crucial biological processes. Recent evidence suggests that ceramide is likely to reside and function within lipid rafts; ordered sphingolipid and cholesterol-rich lipid domains believed to exist within many eukaryotic cell membranes. Using lipid vesicles containing co-existing raft domains and disordered fluid domains, we find that natural and saturated synthetic ceramides displace sterols from rafts. Other raft lipids remain raft-associated in the presence of ceramide, showing displacement is relatively specific for sterols. Like cholesterol-containing rafts, ceramide-rich "rafts" remain in a highly ordered state. Comparison of the sterol-displacing abilities of natural ceramides with those of saturated diglycerides and an unsaturated ceramide demonstrates that tight lipid packing is critical for sterol displacement by ceramide. Based on these results, and the fact that cholesterol and ceramides both have small polar headgroups, we propose that ceramides and cholesterol compete for association with rafts because of a limited capacity of raft lipids with large headgroups to accommodate small headgroup lipids in a manner that prevents unfavorable contact between the hydrocarbon groups of the small headgroup lipids and the surrounding aqueous environment. Minimizing the exposure of cholesterol and ceramide to water may be a strong driving force for the association of other molecules with rafts. Furthermore, displacement of sterol from rafts by ceramide is very likely to have marked effects upon raft structure and function, altering liquid ordered properties as well as molecular composition. In this regard, certain previously observed physiological processes may be a result of displacement. In particular, a direct connection to the previously observed sphingomyelinase-induced displacement of cholesterol from plasma membranes in cells is proposed.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	London, E (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	Erwin.London@stonybrook.edu			NIGMS NIH HHS [GM48596] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMS FS, 1992, BIOCHEMISTRY-US, V31, P5312, DOI 10.1021/bi00138a010; Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; Al-Makdissy N, 2003, CELL SIGNAL, V15, P1019, DOI 10.1016/S0898-6568(03)00070-6; ALMEIDA PFF, 1992, BIOCHEMISTRY-US, V31, P6739, DOI 10.1021/bi00144a013; BECK A, 1993, CHEM PHYS LIPIDS, V66, P135, DOI 10.1016/0009-3084(93)90038-5; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; CHATTERJEE S, 1994, J BIOL CHEM, V269, P879; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; Cremesti AE, 2002, FEBS LETT, V531, P47, DOI 10.1016/S0014-5793(02)03489-0; Fastenberg ME, 2003, BIOCHEMISTRY-US, V42, P12376, DOI 10.1021/bi034718d; Grassme H, 2003, NAT MED, V9, P322, DOI 10.1038/nm823; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Gulbins E, 2003, PHARMACOL RES, V47, P393, DOI 10.1016/S1043-6618(03)00052-5; HALE JE, 1982, EUR J BIOCHEM, V122, P649; Heerklotz H, 2003, J MOL BIOL, V329, P793, DOI 10.1016/S0022-2836(03)00504-7; Huang JY, 1999, BIOPHYS J, V76, P2142, DOI 10.1016/S0006-3495(99)77369-8; Ito J, 2000, J LIPID RES, V41, P894; Jan JT, 2000, J VIROL, V74, P6425, DOI 10.1128/JVI.74.14.6425-6432.2000; Khan TK, 2003, BIOCHEMISTRY-US, V42, P4780, DOI 10.1021/bi0265877; Lange Y, 1997, J BIOL CHEM, V272, P13103, DOI 10.1074/jbc.272.20.13103; Lange Y, 1999, J LIPID RES, V40, P2264; Leventis R, 2001, BIOPHYS J, V81, P2257, DOI 10.1016/S0006-3495(01)75873-0; Loidl A, 2003, J BIOL CHEM, V278, P32921, DOI 10.1074/jbc.M306088200; London E, 2002, CURR OPIN STRUC BIOL, V12, P480, DOI 10.1016/S0959-440X(02)00351-2; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; Michael JM, 1997, CANCER RES, V57, P3600; Niu SL, 2002, BIOPHYS J, V83, P3408, DOI 10.1016/S0006-3495(02)75340-X; Ogretmen B, 2001, DRUG RESIST UPDATE, V4, P368, DOI 10.1054/drup.2001.0225; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Radhakrishnan A, 2000, BIOCHEMISTRY-US, V39, P8119, DOI 10.1021/bi0005097; Ridgway ND, 2000, BBA-MOL CELL BIOL L, V1484, P129, DOI 10.1016/S1388-1981(00)00006-8; Ridgway ND, 1998, J BIOL CHEM, V273, P31621, DOI 10.1074/jbc.273.47.31621; Rietveld A, 1998, BBA-REV BIOMEMBRANES, V1376, P467, DOI 10.1016/S0304-4157(98)00019-7; Ruvolo PP, 2003, PHARMACOL RES, V47, P383, DOI 10.1016/S1043-6618(03)00050-1; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; SLOTTE JP, 1989, BIOCHIM BIOPHYS ACTA, V985, P90, DOI 10.1016/0005-2736(89)90108-9; Subbaiah PV, 2003, J LIPID RES, V44, P1574, DOI 10.1194/jlr.M300103-JLR200; tenGrotenhuis E, 1996, BIOPHYS J, V71, P1389, DOI 10.1016/S0006-3495(96)79341-4; Tweten RK, 2001, CURR TOP MICROBIOL, V257, P15; Wang TY, 2003, BIOPHYS J, V84, P367, DOI 10.1016/S0006-3495(03)74857-7; Wang TY, 2001, BIOCHEMISTRY-US, V40, P13031, DOI 10.1021/bi0112311; Xu XL, 2001, J BIOL CHEM, V276, P33540, DOI 10.1074/jbc.M104776200; Xu XL, 2000, BIOCHEMISTRY-US, V39, P843, DOI 10.1021/bi992543v; Zitzer A, 2001, J BIOL CHEM, V276, P14628, DOI 10.1074/jbc.M100241200	46	303	310	3	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9997	10004		10.1074/jbc.M309992200	http://dx.doi.org/10.1074/jbc.M309992200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699154	hybrid			2022-12-25	WOS:000220050400043
J	Xu, J; Lai, YJ; Lin, WC; Lin, FT				Xu, J; Lai, YJ; Lin, WC; Lin, FT			TRIP6 enhances lysophosphatidic acid-induced cell migration by interacting with the lysophosphatidic acid 2 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; FOCAL ADHESION KINASE; LIM DOMAIN; GROWTH-FACTOR; CANCER CELLS; ZYXIN; IDENTIFICATION; EXPRESSION; PAXILLIN; NUCLEAR	Lysophosphatidic acid (LPA) induces actin rearrangement, focal adhesion assembly, and cell migration through the activation of small G protein Rho and its downstream effectors. These diverse cellular responses are mediated by its associated G protein-coupled receptors. However, the mechanisms and specificity by which these LPA receptors mediate LPA actions are still poorly understood. Here we show that LPA stimulation promotes the interaction of the LPA(2) receptor with a focal adhesion molecule, TRIP6 (thyroid receptor interacting protein 6)/ZRP-1 (zyxin-related protein 1). TRIP6 directly binds to the carboxyl-terminal tail of the LPA(2) receptor through its LIM domains. LPA-dependent recruitment of TRIP6 to the plasma membrane promotes its targeting to focal adhesions and co-localization with actin stress fibers. In addition, TRIP6 associates with the components of focal complexes including paxillin, focal adhesion kinase, c-Src, and p130(cas) in an agonist-dependent manner. Overexpression of TRIP6 augments LPA-induced cell migration; in contrast, suppression of endogenous TRIP6 expression by a TRIP6-specific small interfering RNA reduces it in SKOV3 ovarian cancer cells. Strikingly, the association with TRIP6 is specific to the LPA(2) receptor but not LPA(1) or LPA(3) receptor, indicating a specific role for TRIP6 in regulating LPA(2) receptor-mediated signaling. Taken together, our results suggest that TRIP6 functions at a point of convergence between the activated LPA(2) receptor and downstream signals involved in cell adhesion and migration.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Div Hematol & Oncol, Dept Med, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Lin, FT (corresponding author), MCLM 360A,1918 Univ Blvd, Birmingham, AL 35294 USA.	flin@uab.edu			NATIONAL CANCER INSTITUTE [R01CA100848, R01CA100857] Funding Source: NIH RePORTER; NCI NIH HHS [CA100848, R01 CA100857, R01 CA100848] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; Beckerle MC, 1997, BIOESSAYS, V19, P949, DOI 10.1002/bies.950191104; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; Contos JJA, 2000, GENOMICS, V64, P155, DOI 10.1006/geno.2000.6122; Cox EA, 1998, MICROSC RES TECHNIQ, V43, P412, DOI 10.1002/(SICI)1097-0029(19981201)43:5<412::AID-JEMT7>3.0.CO;2-F; Drees BE, 1999, J CELL BIOL, V147, P1549, DOI 10.1083/jcb.147.7.1549; Gorenne I, 2003, AM J PHYSIOL-CELL PH, V285, pC674, DOI 10.1152/ajpcell.00608.2002; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Hu YL, 2001, J NATL CANCER I, V93, P762, DOI 10.1093/jnci/93.10.762; Ishii I, 2000, MOL PHARMACOL, V58, P895, DOI 10.1124/mol.58.5.895; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Mills Gordon B, 2002, Cancer Treat Res, V107, P259; Murthy KK, 1999, J BIOL CHEM, V274, P20679, DOI 10.1074/jbc.274.29.20679; Nix DA, 2001, J BIOL CHEM, V276, P34759, DOI 10.1074/jbc.M102820200; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Panetti TS, 2001, PROSTAG OTH LIPID M, V64, P93, DOI 10.1016/S0090-6980(01)00102-2; Petit MMR, 2003, J BIOL CHEM, V278, P2157, DOI 10.1074/jbc.M206106200; Petit MMR, 1996, GENOMICS, V36, P118, DOI 10.1006/geno.1996.0432; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sengupta S, 2003, FASEB J, V17, P1570, DOI 10.1096/fj.02-1145fje; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; van Leeuwen FN, 2003, J BIOL CHEM, V278, P400, DOI 10.1074/jbc.M210151200; Wang Y, 2001, BBA-MOL CELL RES, V1538, P260, DOI 10.1016/S0167-4889(01)00077-5; Wang Y, 2003, BBA-MOL CELL RES, V1593, P115, DOI 10.1016/S0167-4889(02)00349-X; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; Yi JS, 2002, J BIOL CHEM, V277, P9580, DOI 10.1074/jbc.M106922200	34	76	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10459	10468		10.1074/jbc.M311891200	http://dx.doi.org/10.1074/jbc.M311891200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688263	Green Accepted, hybrid			2022-12-25	WOS:000220050400097
J	Fang, XJ; Yu, SX; Bast, RC; Liu, SY; Xu, HJ; Hu, SX; LaPushin, R; Claret, FX; Aggarwal, BB; Lu, YL; Mills, GB				Fang, XJ; Yu, SX; Bast, RC; Liu, SY; Xu, HJ; Hu, SX; LaPushin, R; Claret, FX; Aggarwal, BB; Lu, YL; Mills, GB			Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; PROTEIN-COUPLED RECEPTOR; KAPPA-B; LPA RECEPTORS; INTERLEUKIN-8 EXPRESSION; INHIBITS ANGIOGENESIS; PACLITAXEL RESISTANCE; CARCINOMA CELLS; GENE-TRANSFER; LYSOPHOSPHOLIPIDS	A potential role for lysophosphatidic acid (LPA) in human oncogenesis was first suggested by the observation that LPA is present at elevated levels in ascites of ovarian cancer patients. In the current study, we demonstrated that LPA is a potent inducer of interleukin-6 (IL-6) and interleukin-8 (IL-8) production in ovarian cancer cells. Both IL-6 and IL-8 have been implicated in ovarian cancer progression. We characterized the IL-8 gene promoter to ascertain the transcriptional mechanism underlying LPA - induced expression of these cytokines. LPA stimulated the transcriptional activity of the IL-8 gene with little effect on IL-8 mRNA stability. The optimal response of the IL-8 gene promoter to LPA relied on binding sites for NF-kappaB and AP-1, two transcription factors that were strongly activated by LPA in ovarian cancer cell lines. Positive regulators of the NF-kappaB and AP-1 pathways synergistically activated the IL-8 gene promoter. Further, the effect of LPA on IL- 6 and IL- 8 generation is mediated by the Edg LPA receptors as enforced expression of LPA receptors restored LPA-induced IL-6 and IL-8 production in non-responsive cells and enhanced the sensitivity to LPA in responsive cell lines. The LPA(2) receptor was identified to be the most efficient in linking LPA to IL-6 and IL-8 production although LPA(1) and LPA(3) were also capable of increasing the response to a certain degree. These studies elucidate the transcriptional mechanism and the Edg LPA receptors involved in LPA-induced IL-6 and IL-8 production and suggest potential strategies to restrain the expression of these cytokines in ovarian cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fang, XJ (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem, Sanger Hall 2-006,1101 E Marshall St, Richmond, VA 23298 USA.	xfang@vcu.edu	Bast, Robert C/E-6585-2011; Claret, Francois X/R-2104-2016; Aggarwal, Bharat B/G-3388-2013	Bast, Robert C/0000-0003-4621-8462; Claret, Francois X/0000-0003-4629-6495; 	NCI NIH HHS [CA82716, 5P30 CA016672, CA64602] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA064602, R01CA082716] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Baker DL, 2002, JAMA-J AM MED ASSOC, V287, P3081, DOI 10.1001/jama.287.23.3081; Bandoh K, 2000, FEBS LETT, V478, P159, DOI 10.1016/S0014-5793(00)01827-5; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Contos JJA, 2002, MOL CELL BIOL, V22, P6921, DOI 10.1128/MCB.22.19.6921-6929.2002; Daaka Y, 2002, BBA-MOL CELL BIOL L, V1582, P265, DOI 10.1016/S1388-1981(02)00180-4; Duan Z, 2002, CYTOKINE, V17, P234, DOI 10.1006/cyto.2001.1008; Duan ZF, 1999, CLIN CANCER RES, V5, P3445; DVORAK HF, 1995, AM J PATHOL, V146, P1029; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Fang XJ, 1997, J BIOL CHEM, V272, P13683, DOI 10.1074/jbc.272.21.13683; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Fang XJ, 1998, ONCOGENE, V16, P1, DOI 10.1038/sj.onc.1201525; Fang XJ, 2000, ANN NY ACAD SCI, V905, P188; Fischer DJ, 2001, MOL PHARMACOL, V60, P776; Fishman DA, 2001, CANCER RES, V61, P3194; Frankel A, 1996, CLIN CANCER RES, V2, P1307; Fritsche HA, 1998, CLIN CHEM, V44, P1379; Fujita T, 2003, CANCER LETT, V192, P161, DOI 10.1016/S0304-3835(02)00713-9; Fukushima N, 2001, PROSTAG OTH LIPID M, V64, P21, DOI 10.1016/S0090-6980(01)00105-8; Goetzl EJ, 1999, ADV EXP MED BIOL, V469, P259; Goetzl EJ, 1999, CANCER RES, V59, P5370; Goppelt-Struebe M, 2000, BIOCHEM J, V345, P217, DOI 10.1042/0264-6021:3450217; Hatzi E, 2002, ONCOGENE, V21, P3552, DOI 10.1038/sj.onc.1205440; Heise CE, 2001, MOL PHARMACOL, V60, P1173, DOI 10.1124/mol.60.6.1173; Hirota K, 2001, FEBS LETT, V489, P134, DOI 10.1016/S0014-5793(01)02094-4; Hooks SB, 2001, J BIOL CHEM, V276, P4611, DOI 10.1074/jbc.M007782200; Hu YL, 2003, J NATL CANCER I, V95, P733, DOI 10.1093/jnci/95.10.733; Hu YL, 2001, J NATL CANCER I, V93, P762, DOI 10.1093/jnci/93.10.762; Huang S, 2000, CANCER RES, V60, P5334; Imai A, 2000, J CLIN ENDOCR METAB, V85, P3370, DOI 10.1210/jc.85.9.3370; Ivarsson K, 2000, ACTA OBSTET GYN SCAN, V79, P777, DOI 10.1034/j.1600-0412.2000.079009777.x; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; Lee LF, 1996, CANCER RES, V56, P1303; MAHE Y, 1991, J BIOL CHEM, V266, P13759; Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0; Mayerhofer K, 2001, CANCER-AM CANCER SOC, V91, P388, DOI 10.1002/1097-0142(20010115)91:2<388::AID-CNCR1013>3.3.CO;2-2; MILLS GB, 1988, CANCER RES, V48, P1066; MILLS GB, 1989, OVARIAN CANCER BIOL, P55; Moolenaar WH, 2000, ANN NY ACAD SCI, V905, P1; MOTRO B, 1990, P NATL ACAD SCI USA, V87, P3092, DOI 10.1073/pnas.87.8.3092; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; O'Rourke JP, 2002, J VIROL, V76, P1510, DOI 10.1128/JVI.76.3.1510-1515.2002; Penson RT, 2000, INT J GYNECOL CANCER, V10, P33, DOI 10.1046/j.1525-1438.2000.00003.x; Pustilnik TB, 1999, CLIN CANCER RES, V5, P3704; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Roberts R, 1998, J BIOL CHEM, V273, P22059, DOI 10.1074/jbc.273.34.22059; Rosen E M, 1991, EXS, V59, P194; Sardar VM, 2002, BBA-MOL CELL BIOL L, V1582, P309, DOI 10.1016/S1388-1981(02)00185-3; Sawada K, 2002, CANCER RES, V62, P6015; Schulte KM, 2001, INT J CANCER, V92, P249, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1166>3.0.CO;2-D; Schwartz BM, 2001, GYNECOL ONCOL, V81, P291, DOI 10.1006/gyno.2001.6124; Shahrestanifar M, 1999, J BIOL CHEM, V274, P3828, DOI 10.1074/jbc.274.6.3828; Stassar MJJG, 2001, BRIT J CANCER, V85, P1372, DOI 10.1054/bjoc.2001.2074; Stracke ML, 1997, ADV ENZYME REGUL, V37, P135, DOI 10.1016/S0065-2571(96)00017-9; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; Tanyi JL, 2003, CANCER RES, V63, P1073; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; VANSNICK J, 1988, EUR J IMMUNOL, V18, P193; Vigna E, 2000, J GENE MED, V2, P308; WATSON JM, 1993, GYNECOL ONCOL, V49, P8, DOI 10.1006/gyno.1993.1077; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Xiao YJ, 2001, ANAL BIOCHEM, V290, P302, DOI 10.1006/abio.2001.5000; Xie YH, 2002, J BIOL CHEM, V277, P32516, DOI 10.1074/jbc.M203864200; Xu L, 2000, CANCER RES, V60, P4610; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; Xu Y, 1995, CLIN CANCER RES, V1, P1223; Yoneda J, 1998, JNCI-J NATL CANCER I, V90, P447, DOI 10.1093/jnci/90.6.447; Zondag GCM, 1998, BIOCHEM J, V330, P605, DOI 10.1042/bj3300605	72	151	161	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9653	9661		10.1074/jbc.M306662200	http://dx.doi.org/10.1074/jbc.M306662200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14670967	hybrid			2022-12-25	WOS:000189265900133
J	Morris, JB; Pham, TM; Kenney, B; Sheppard, KE; Woodcock, EA				Morris, JB; Pham, TM; Kenney, B; Sheppard, KE; Woodcock, EA			UTP transactivates epidermal growth factor receptors and promotes cardiomyocyte hypertrophy despite inhibiting transcription of the hypertrophic marker gene, atrial natriuretic peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC-HYPERTROPHY; ACTIVATION; APOPTOSIS; HEART; EXPRESSION; AGONIST; PATHWAY; ATP	In neonatal rat ventricular myocytes, activation of receptors that couple to the G(q) family of heterotrimeric G proteins causes hypertrophic growth, together with expression of "hypertrophic marker" genes, such as atrial natriuretic peptide (ANP) and myosin light chain 2 (MLC2). As reported previously for other G(q)-coupled receptors, stimulation of alpha(1)-adrenergic receptors with phenylephrine ( 50 muM) caused phosphorylation of epidermal growth factor (EGF) receptors as well as activation of ERK1/2, cellular growth, and ANP transcription. These responses depended on EGF receptor activation. In marked contrast, stimulation of G(q)-coupled purinergic receptors with UTP caused EGF receptor phosphorylation, ERK1/2 activation, and cellular growth but minimal increases in ANP transcription. UTP inhibited phenylephrine-dependent transcription from ANP and MLC2 promoters but not transcription from myoglobin promoters or from AP-1 elements. Myocardin is a muscle-specific transcription enhancer that activates transcription from ANP and MLC2 promoters but not myoglobin promoters or AP-1 elements. UTP inhibited ANP and MLC2 responses to overexpressed myocardin but did not inhibit responses to c-Jun, GATA4, or serum response factor, all of which are active in nonmuscle cells. Thus, UTP inhibits transcriptional responses to phenylephrine only at cardiac-specific promoters, and this may involve the muscle-specific transcription enhancer, myocardin. These studies show that EGF receptor activation is necessary but not sufficient for ANP and MLC2 responses to activation of G(q)-coupled receptors in ventricular myocytes, because inhibitory mechanisms can oppose such stimulation. ANP is a compensatory and protective factor in cardiac hypertrophy, and mechanisms that reduce its generation need to be defined.	Baker Heart Res Inst, Cellular Biochem Lab, Melbourne, Vic 8008, Australia; Baker Heart Res Inst, Gene Transcript Lab, Melbourne, Vic 8008, Australia	Baker Heart and Diabetes Institute; Baker Heart and Diabetes Institute	Woodcock, EA (corresponding author), Baker Heart Res Inst, Cellular Biochem Lab, POB 6492,St Kilda Rd Cent, Melbourne, Vic 8008, Australia.	liz.woodcock@baker.edu.au	Sheppard, Karen/P-5947-2019; Sheppard, Karen E/U-5360-2017	Sheppard, Karen/0000-0002-2798-4703; Sheppard, Karen E/0000-0002-2798-4703				Adams JW, 2001, ONCOGENE, V20, P1626, DOI 10.1038/sj.onc.1204275; Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Arthur JF, 2001, J BIOL CHEM, V276, P37341, DOI 10.1074/jbc.M106572200; Boluyt MO, 1997, CIRC RES, V81, P176, DOI 10.1161/01.RES.81.2.176; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; Calderone A, 2003, HEART FAIL REV, V8, P55, DOI 10.1023/A:1022147005110; CannonCarlson S, 1997, ANAL BIOCHEM, V246, P146, DOI 10.1006/abio.1997.2002; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Costello-Boerrigter LC, 2003, MED CLIN N AM, V87, P475, DOI 10.1016/S0025-7125(02)00181-5; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Dorn GW, 1999, TRENDS CARDIOVAS MED, V9, P26, DOI 10.1016/S1050-1738(99)00004-3; Esposito G., 2001, CARDIOVASC RES, V50, P65; Harrison SN, 1998, CIRC RES, V83, P1232, DOI 10.1161/01.RES.83.12.1232; Holtwick R, 2003, J CLIN INVEST, V111, P1399, DOI 10.1172/JCI200317061; Homcy CJ, 1998, CIRCULATION, V97, P1890, DOI 10.1161/01.CIR.97.19.1890; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Molkentin JD, 2003, J CLIN INVEST, V111, P1275, DOI 10.1172/JCI200318389; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Omura T, 2002, HYPERTENSION, V39, P81, DOI 10.1161/hy0102.100783; PETERSON GL, 1979, ANAL BIOCHEM, V100, P201, DOI 10.1016/0003-2697(79)90222-7; Pham TM, 2003, J MOL CELL CARDIOL, V35, P287, DOI 10.1016/S0022-2828(03)00009-9; Pu WT, 2003, CIRC RES, V92, P725, DOI 10.1161/01.RES.0000069211.82346.46; Sabri A, 2002, CIRC RES, V90, P850, DOI 10.1161/01.RES.0000016165.23795.1F; Schaub MC, 1997, J MOL MED, V75, P901, DOI 10.1007/s001090050182; Sesti C, 2003, J PHARMACOL EXP THER, V306, P238, DOI 10.1124/jpet.103.049874; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; Thomas WG, 2002, CIRC RES, V90, P135, DOI 10.1161/hh0202.104109; Vassort G, 2001, PHYSIOL REV, V81, P767, DOI 10.1152/physrev.2001.81.2.767; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Woodcock EA, 2002, J BIOL CHEM, V277, P22734, DOI 10.1074/jbc.M110405200	31	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8740	8746		10.1074/jbc.M310012200	http://dx.doi.org/10.1074/jbc.M310012200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676212	hybrid			2022-12-25	WOS:000189265900027
J	Ng, DS; Xie, CH; Maguire, GF; Zhu, XH; Ugwu, F; Lam, E; Connelly, PW				Ng, DS; Xie, CH; Maguire, GF; Zhu, XH; Ugwu, F; Lam, E; Connelly, PW			Hypertriglyceridemia in lecithin-cholesterol acyltransferase-deficient mice is associated with hepatic overproduction of triglycerides, increased lipogenesis, and improved glucose tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL REGULATORY ELEMENT; LIVER-X-RECEPTOR; PLASMA LIPOLYTIC-ACTIVITIES; FATTY-ACID-METABOLISM; APOLIPOPROTEIN-A-I; LIPOPROTEIN-LIPASE; BINDING PROTEIN-1; TRANSGENIC MICE; NUTRITIONAL REGULATION; TARGETED DISRUPTION	Lecithin-cholesterol acyltransferase deficiency is frequently associated with hypertriglyceridemia (HTG) in animal models and humans. We investigated the mechanism of HTG in the ldlr-/- x lcat-/- (double knockout (dko)) mice using the ldlr-/- x lcat-/- (knock-out (ko)) littermates as control. Mean fasting triglyceride (TG) levels in the dko mice were elevated 1.75-fold compared with their controls (p < 0.002). Both the very low density lipoprotein and the low density lipoprotein/intermediate density lipoprotein fractions separated by fast protein liquid chromatography were TG-enriched in the dko mice. In vitro lipolysis assay revealed that the dko mouse very low density lipoprotein (d < 1.019 g/ml) fraction separated by ultracentrifugation was a more efficient substrate for lipolysis by exogenous bovine lipoprotein lipase. Post-heparin lipoprotein lipase activity was reduced by 61% in the dko mice. Hepatic TG production rate, determined after intravenous Triton WR1339 injection, was increased 8-fold in the dko mice. Hepatic mRNA levels of sterol regulatory element binding protein-1 (srebp-1) and its target genes acetyl-CoA carboxylase-1 (acc-1), fatty acid synthase (fas), and stearoyl-CoA desaturase-1 (scd-1) were significantly elevated in the dko mice compared with the ko control. The hepatic mRNA levels of LXRalpha (lxralpha) and its target genes including angiopoietin-like protein 3 (angptl-3) in the dko mice were unchanged. Fasting glucose and insulin levels were reduced by 31 and 42%, respectively in the dko mice, in conjunction with a 49% reduction in hepatic pepck-1 mRNA (p = 0.014). Both the HTG and the improved fasting glucose phenotype seen in the dko mice are at least in part attributable to an up-regulation of the hepatic srebp-1c gene.	St Michaels Hosp, Dept Med, Toronto, ON M5B 1A6, Canada	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Ng, DS (corresponding author), St Michaels Hosp, Dept Med, W Annex 2-015,38 Shuter St, Toronto, ON M5B 1A6, Canada.	ngd@smh.toronto.on.ca	Connelly, Philip W/B-7583-2012	Connelly, Philip W/0000-0001-7244-6843				Alexander CM, 2003, DIABETES, V52, P1210, DOI 10.2337/diabetes.52.5.1210; APPEL B, 1992, AM J PHYSIOL, V262, pE695, DOI 10.1152/ajpendo.1992.262.5.E695; Ayyobi AF, 2003, ARTERIOSCL THROM VAS, V23, P1289, DOI 10.1161/01.ATV.0000077220.44620.9B; BLOMHOFF JP, 1978, SCAND J CLIN LAB INV, V38, P177, DOI 10.3109/00365517809104922; Brinton Eliot A, 2003, Curr Diab Rep, V3, P65, DOI 10.1007/s11892-003-0056-3; Cao GQ, 2003, J BIOL CHEM, V278, P1131, DOI 10.1074/jbc.M210208200; Chakravarty K, 2001, J BIOL CHEM, V276, P34816, DOI 10.1074/jbc.M103310200; Fere P, 2001, BIOCHEM SOC T, V29, P547; Field FJ, 2002, BIOCHEM J, V368, P855, DOI 10.1042/BJ20020731; Forte TM, 1999, J LIPID RES, V40, P1276; FRANCONE OL, 1995, J CLIN INVEST, V96, P1440, DOI 10.1172/JCI118180; FROHLICH J, 1988, METABOLISM, V37, P3, DOI 10.1016/0026-0495(88)90021-2; Furbee JW, 2002, J LIPID RES, V43, P428; Ginsberg HN, 2003, AM J CARDIOL, V91, p29E, DOI 10.1016/S0002-9149(02)03386-6; GJONE E, 1974, SCAND J CLIN LAB INV, V33, P73, DOI 10.3109/00365517409100633; Grefhorst A, 2002, J BIOL CHEM, V277, P34182, DOI 10.1074/jbc.M204887200; Groener JEM, 1996, J LIPID RES, V37, P2271; HA YC, 1985, J CHROMATOGR, V341, P154, DOI 10.1016/S0378-4347(00)84020-7; Haffner SM, 1999, AM J CARDIOL, V83, p17F; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HERZ J, 1995, P NATL ACAD SCI USA, V92, P4611, DOI 10.1073/pnas.92.10.4611; Hoeg JM, 1996, J BIOL CHEM, V271, P4396; Hogan JC, 2001, BIOCHEM BIOPH RES CO, V287, P484, DOI 10.1006/bbrc.2001.5606; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Ide T, 2003, MOL ENDOCRINOL, V17, P1255, DOI 10.1210/me.2002-0191; Inaba T, 2003, J BIOL CHEM, V278, P21344, DOI 10.1074/jbc.M213202200; Jong MC, 1999, ARTERIOSCL THROM VAS, V19, P472, DOI 10.1161/01.ATV.19.3.472; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Knutson VP, 2000, ENDOCRINOLOGY, V141, P693, DOI 10.1210/en.141.2.693; Laffitte BA, 2003, P NATL ACAD SCI USA, V100, P5419, DOI 10.1073/pnas.0830671100; Luo Y, 2000, J CLIN INVEST, V105, P513, DOI 10.1172/JCI8573; Marshall BA, 1999, J BIOL CHEM, V274, P27426, DOI 10.1074/jbc.274.39.27426; Maugeais C, 2000, J LIPID RES, V41, P1673; Mensenkamp AR, 1999, J BIOL CHEM, V274, P35711, DOI 10.1074/jbc.274.50.35711; Merkel M, 2002, J LIPID RES, V43, P1997, DOI 10.1194/jlr.R200015-JLR200; Ng DS, 2002, J BIOL CHEM, V277, P11715, DOI 10.1074/jbc.M112320200; Ng DS, 1997, J BIOL CHEM, V272, P15777, DOI 10.1074/jbc.272.25.15777; NG DS, 1994, J CLIN INVEST, V93, P223, DOI 10.1172/JCI116949; Olivecrona T, 1997, P NUTR SOC, V56, P723, DOI 10.1079/PNS19970072; Ou JF, 2001, P NATL ACAD SCI USA, V98, P6027, DOI 10.1073/pnas.111138698; Pawar A, 2003, J BIOL CHEM, V278, P40736, DOI 10.1074/jbc.M307973200; Plump AS, 1996, J CLIN INVEST, V97, P2660, DOI 10.1172/JCI118716; Sakai N, 1997, J BIOL CHEM, V272, P7506, DOI 10.1074/jbc.272.11.7506; SASAKI A, 1992, J BIOL CHEM, V267, P15198; Schoonjans K, 2000, J MOL BIOL, V304, P323, DOI 10.1006/jmbi.2000.4218; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; SCHUMAKER VN, 1970, J THEOR BIOL, V26, P89, DOI 10.1016/S0022-5193(70)80034-0; SEMENKOVICH CF, 1989, J BIOL CHEM, V264, P9030; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Tontonoz P, 2003, MOL ENDOCRINOL, V17, P985, DOI 10.1210/me.2003-0061; Voyiaziakis E, 1998, J LIPID RES, V39, P313; WANG CS, 1987, BIOCHIM BIOPHYS ACTA, V920, P9, DOI 10.1016/0005-2760(87)90305-5; WANG CS, 1981, CLIN CHEM, V27, P663; Worgall TS, 2002, J BIOL CHEM, V277, P3878, DOI 10.1074/jbc.M102393200; Xu J, 2001, J BIOL CHEM, V276, P9800, DOI 10.1074/jbc.M008973200; Yoshikawa T, 2003, MOL ENDOCRINOL, V17, P1240, DOI 10.1210/me.2002-0190; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001; Zhang Y, 2001, J BIOL CHEM, V276, P43018, DOI 10.1074/jbc.M107823200	59	38	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7636	7642		10.1074/jbc.M309439200	http://dx.doi.org/10.1074/jbc.M309439200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14668345	hybrid			2022-12-25	WOS:000189103300034
J	Abhyankar, MM; Reddy, JM; Sharma, R; Bullesbach, E; Bastia, D				Abhyankar, MM; Reddy, JM; Sharma, R; Bullesbach, E; Bastia, D			Biochemical investigations of control of replication initiation of plasmid R6K	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; COLE1 DNA-REPLICATION; ESCHERICHIA-COLI; COPY NUMBER; NEGATIVE CONTROL; IN-VITRO; BINDING-SITES; ORIGIN GAMMA; PROTEIN; REPA	The mechanistic basis of control of replication initiation of plasmid R6K was investigated by addressing the following questions. What are the biochemical attributes of mutations in the pi initiator protein that caused loss of negative control of initiation? Did the primary control involve only initiator protein-ori DNA interaction or did it also involve protein-protein interactions between pi and several host-encoded proteins? Mutations at two different regions of the pi-encoding sequence individually caused some loss of negative control as indicated by a relatively modest increase in copy number. However, combinations of the mutation P42L, which caused loss of DNA looping, with those located in the region between the residues 106 and 113 induced a robust enhancement of copy number. These mutant forms promoted higher levels of replication in vitro in a reconstituted system consisting of 22 purified proteins. The mutant forms of pi were susceptible to pronounced iteron-induced monomerization in comparison with the WT protein. As contrasted with the changes in DNA-protein interaction, we found no detectable differences in protein-protein interaction between wild type pi with DnaA, DnaB helicase, and DnaG primase on one hand and between the high copy mutant forms and the same host proteins on the other. The DnaG-pi interaction reported here is novel. Taken together, the results suggest that both loss of negative control due to iteron-induced monomerization of the initiator and enhanced iteron-initiator interaction appear to be the principal causes of enhanced copy number.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Bastia, D (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.	bastia@muse.edu						Abhyankar MM, 2003, J BIOL CHEM, V278, P45476, DOI 10.1074/jbc.M308516200; ABLES AL, 1991, P NATL ACAD SCI USA, V88, P9011; CESARENI G, 1982, P NATL ACAD SCI-BIOL, V79, P6313, DOI 10.1073/pnas.79.20.6313; CHATTORAJ D, 1984, P NATL ACAD SCI-BIOL, V81, P6456, DOI 10.1073/pnas.81.20.6456; CHATTORAJ DK, 1988, CELL, V52, P551, DOI 10.1016/0092-8674(88)90468-0; DASGUPTA S, 1987, CELL, V51, P1113, DOI 10.1016/0092-8674(87)90597-6; Datta HJ, 1999, P NATL ACAD SCI USA, V96, P73, DOI 10.1073/pnas.96.1.73; Diaz-Lopez T, 2003, J BIOL CHEM, V278, P18606, DOI 10.1074/jbc.M212024200; Fang LH, 1999, MOL CELL, V4, P541, DOI 10.1016/S1097-2765(00)80205-1; FILUTOWICZ M, 1985, NUCLEIC ACIDS RES, V13, P103, DOI 10.1093/nar/13.1.103; FILUTOWICZ M, 1988, NUCLEIC ACIDS RES, V16, P3829, DOI 10.1093/nar/16.9.3829; Filutowicz M., 1985, PLASMIDS BACTERIA, P125; GERMINO J, 1983, CELL, V34, P125, DOI 10.1016/0092-8674(83)90142-3; GERMINO J, 1983, CELL, V32, P131, DOI 10.1016/0092-8674(83)90503-2; Ingmer H, 2001, MOL MICROBIOL, V42, P519, DOI 10.1046/j.1365-2958.2001.02661.x; INUZUKA M, 1978, P NATL ACAD SCI USA, V75, P5381, DOI 10.1073/pnas.75.11.5381; INUZUKA M, 1985, EMBO J, V4, P2301, DOI 10.1002/j.1460-2075.1985.tb03930.x; INUZUKA M, 1975, BIOCHEMISTRY-US, V17, P2567; INUZUKA N, 1980, J BIOL CHEM, V255, P1071; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; Jiang Y, 2003, P NATL ACAD SCI USA, V100, P8692, DOI 10.1073/pnas.1532393100; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; KELLEY W, 1985, P NATL ACAD SCI USA, V82, P2574, DOI 10.1073/pnas.82.9.2574; KELLEY WL, 1991, J BIOL CHEM, V266, P15924; KELLEY WL, 1992, NEW BIOL, V4, P569; Kim SY, 2002, J BIOL CHEM, V277, P44778, DOI 10.1074/jbc.M206176200; KITTELL BL, 1991, P NATL ACAD SCI USA, V88, P1389, DOI 10.1073/pnas.88.4.1389; Konieczny I, 1997, P NATL ACAD SCI USA, V94, P14378, DOI 10.1073/pnas.94.26.14378; Kruger R, 2001, J MOL BIOL, V306, P945, DOI 10.1006/jmbi.2000.4426; Lu YB, 1998, EMBO J, V17, P5192, DOI 10.1093/emboj/17.17.5192; Lu YB, 1996, P NATL ACAD SCI USA, V93, P12902, DOI 10.1073/pnas.93.23.12902; MACALLISTER TW, 1991, J BIOL CHEM, V266, P16056; MASUKATA H, 1990, CELL, V62, P331, DOI 10.1016/0092-8674(90)90370-T; MCEACHERN MJ, 1989, P NATL ACAD SCI USA, V86, P7942, DOI 10.1073/pnas.86.20.7942; MESSER W, 1991, RES MICROBIOL, V142, P119, DOI 10.1016/0923-2508(91)90018-6; MIRON A, 1994, P NATL ACAD SCI USA, V91, P6438, DOI 10.1073/pnas.91.14.6438; MIRON A, 1992, EMBO J, V11, P1205, DOI 10.1002/j.1460-2075.1992.tb05161.x; MUKHERJEE S, 1988, P NATL ACAD SCI USA, V85, P6287, DOI 10.1073/pnas.85.17.6287; MUKHERJEE S, 1988, CELL, V52, P375, DOI 10.1016/S0092-8674(88)80030-8; Nishihara K, 2000, APPL ENVIRON MICROB, V66, P884, DOI 10.1128/AEM.66.3.884-889.2000; Park K, 2001, EMBO J, V20, P7323, DOI 10.1093/emboj/20.24.7323; POLISKY B, 1988, CELL, V55, P929, DOI 10.1016/0092-8674(88)90235-8; Ratnakar PVAL, 1996, P NATL ACAD SCI USA, V93, P5522, DOI 10.1073/pnas.93.11.5522; Sharma R, 2001, EMBO J, V20, P4577, DOI 10.1093/emboj/20.16.4577; SKOWYRA D, 1993, J BIOL CHEM, V268, P25296; VOCKE C, 1985, P NATL ACAD SCI USA, V82, P2252, DOI 10.1073/pnas.82.8.2252; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; Zhong ZP, 2003, J BIOL CHEM, V278, P45305, DOI 10.1074/jbc.M306058200	49	30	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6711	6719		10.1074/jbc.M312052200	http://dx.doi.org/10.1074/jbc.M312052200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14665626	hybrid			2022-12-25	WOS:000188969200063
J	Afaq, F; Ahmad, N; Mukhtar, H				Afaq, F; Ahmad, N; Mukhtar, H			Suppression of UVB-induced phosphorylation of mitogen-activated protein kinases and nuclear factor kappa B by green tea polyphenol in SKH-1 hairless mice	ONCOGENE			English	Article						photochemopreventive; UVB; GTP; MAPKs; NF-kappa B; SKH-1	HUMAN EPIDERMAL-KERATINOCYTES; C-JUN; GROWTH-FACTOR; MOUSE SKIN; GENE-EXPRESSION; (-)-EPIGALLOCATECHIN-3-GALLATE TREATMENT; SIGNAL-TRANSDUCTION; MEDIATED ACTIVATION; DENDRITIC CELLS; MAP KINASES	Studies from our laboratory have shown that epigallocatechin-3-gallate, the major polyphenol present in green tea, inhib its ultraviolet (UV)B-exposure-mediated phosphorylation of mitogen-activated protein kinases (MAPKs) (Toxicol. Appl. Pharmacol. 176: 110-117, 2001) and activation of nuclear factor kappa B (NF-kappaB) (Oncogene 22: 1035-1044,2003) pathways in normal human epidermal keratinocytes. This study was designed to investigate the relevance of these findings to the in vivo situations in SKH-1 hairless mouse model, which is regarded to have relevance to human situations. SKH-1 hairless mice were topically treated with GTP (5 mg/0.2 ml acetone/mouse) and were exposed to UVB 30 min later (180 mJ/cm(2)). These treatments were repeated every alternate day for 2 weeks, for a total of seven treatments. The animals were killed 24 h after the last UVB exposure. Topical application of GTP resulted in significant decrease in UVB-induced bifold-skin thickness, skin edema and infiltration of leukocytes. Employing Western blot analysis and immunohistochemical studies, we found that GTP resulted in inhibition of UVB-induced: (i) phosphorylation of extracellular-signal-regulated kinases (ERK1/2),(ii) c-Jun N-terminal kinases, and (iii) p38 protein expression. Since NF-kappaB plays a major role in inflammation and cell proliferation, we assessed the effect of GTP on UVB-mediated modulations in the NF-kappaB pathway. Our data demonstrated that GTP inhibited UVB-induced: (i) activation of NF-kappaB,(ii) activation of IKKalpha, and (iii) phosphorylation and degradation of IkappaBalpha. Our data suggest that GTP protects against the adverse effects of UV radiation via modulations in MAPK and NF-kappaB signaling pathways, and provides molecular basis for the photochemopreventive effect of GTP in an in vivo animal model system.	Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Mukhtar, H (corresponding author), Univ Wisconsin, Med Sci Ctr, Dept Dermatol, B25,1300 Univ Ave, Madison, WI 53706 USA.	hmukhtar@wisc.edu	Ahmad, Nihal/AAR-4249-2021	Ahmad, Nihal/0000-0002-4239-9887				Adderley SR, 1999, J BIOL CHEM, V274, P5038, DOI 10.1074/jbc.274.8.5038; Afaq F, 2003, ONCOGENE, V22, P1035, DOI 10.1038/sj.onc.1206206; Afaq F, 2003, TOXICOL APPL PHARM, V186, P28, DOI 10.1016/S0041-008X(02)00014-5; Afaq F, 2002, SKIN PHARMACOL APPL, V15, P297, DOI 10.1159/000064533; Afaq F, 2002, FRONT BIOSCI-LANDMRK, V7, pD784, DOI 10.2741/afaq; AGARWAL R, 1992, CANCER RES, V52, P3582; Ahmad N, 2000, ARCH BIOCHEM BIOPHYS, V376, P338, DOI 10.1006/abbi.2000.1742; Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; Bachelor MA, 2002, ONCOGENE, V21, P7092, DOI 10.1038/sj.onc.1205855; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Balasubramanian S, 1999, ONCOGENE, V18, P1297, DOI 10.1038/sj.onc.1202417; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; Chen WX, 1998, J BIOL CHEM, V273, P32176, DOI 10.1074/jbc.273.48.32176; Chen WX, 2001, ONCOGENE, V20, P3921, DOI 10.1038/sj.onc.1204530; Chen YC, 2002, J CELL BIOCHEM, V86, P331, DOI 10.1002/jcb.10230; Chouinard N, 2002, BIOCHEM J, V365, P133, DOI 10.1042/BJ20020072; Clydesdale GJ, 2001, IMMUNOL CELL BIOL, V79, P547, DOI 10.1046/j.1440-1711.2001.01047.x; de Gruijl FR, 2002, SKIN PHARMACOL APPL, V15, P316, DOI 10.1159/000064535; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dhar A, 2002, MOL CELL BIOCHEM, V234, P185, DOI 10.1023/A:1015948505117; Dubois B, 2001, CELL IMMUNOL, V214, P173, DOI 10.1006/cimm.2001.1898; Elmets CA, 2001, J AM ACAD DERMATOL, V44, P425, DOI 10.1067/mjd.2001.112919; F'guyer S, 2003, PHOTODERMATOL PHOTO, V19, P56, DOI 10.1034/j.1600-0781.2003.00019.x; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; GENSLER HL, 1992, CARCINOGENESIS, V13, P9, DOI 10.1093/carcin/13.1.9; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Hildesheim J, 2002, CANCER RES, V62, P7305; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Iordanov MS, 2002, MOL CELL BIOL, V22, P5380, DOI 10.1128/MCB.22.15.5380-5394.2002; Jemal A, 2000, JNCI-J NATL CANCER I, V92, P811, DOI 10.1093/jnci/92.10.811; Kang S, 2003, J INVEST DERMATOL, V120, P835, DOI 10.1046/j.1523-1747.2003.12122.x; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Katiyar SK, 2000, CLIN CANCER RES, V6, P3864; Katiyar SK, 2001, TOXICOL APPL PHARM, V176, P110, DOI 10.1006/taap.2001.9276; Katiyar SK, 2001, CARCINOGENESIS, V22, P287, DOI 10.1093/carcin/22.2.287; KATIYAR SK, 1995, PHOTOCHEM PHOTOBIOL, V62, P855; Katiyar SK, 2001, J LEUKOCYTE BIOL, V69, P719; Katiyar SK, 1997, JNCI-J NATL CANCER I, V89, P556, DOI 10.1093/jnci/89.8.556; KATIYAR SK, 1992, CANCER RES, V52, P6890; Kaufman CK, 2000, J CELL BIOL, V149, P999, DOI 10.1083/jcb.149.5.999; Kim J, 2001, SKIN PHARMACOL APPL, V14, P11, DOI 10.1159/000056329; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LEARN DB, 1993, PHOTODERMATOL PHOTO, V9, P147; Lefort K, 2001, ONCOGENE, V20, P7375, DOI 10.1038/sj.onc.1204923; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; Mittal A, 2003, CARCINOGENESIS, V24, P1379, DOI 10.1093/carcin/bgg095; Mukhtar H, 1996, PHOTOCHEM PHOTOBIOL, V63, P355, DOI 10.1111/j.1751-1097.1996.tb03040.x; Nghiem DX, 2002, J INVEST DERMATOL, V119, P600, DOI 10.1046/j.1523-1747.2002.01845.x; Nomura M, 2001, J BIOL CHEM, V276, P46624, DOI 10.1074/jbc.M107897200; Potapova O, 2001, J BIOL CHEM, V276, P28546, DOI 10.1074/jbc.M102075200; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Scharffetter-Kochanek K, 1997, BIOL CHEM, V378, P1247; She QB, 2002, J BIOL CHEM, V277, P24039, DOI 10.1074/jbc.M109907200; Stahl W, 2002, SKIN PHARMACOL APPL, V15, P291, DOI 10.1159/000064532; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Vink AA, 1997, P NATL ACAD SCI USA, V94, P5255, DOI 10.1073/pnas.94.10.5255; WANG ZY, 1991, CARCINOGENESIS, V12, P1527, DOI 10.1093/carcin/12.8.1527; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamazaki S, 2001, J BIOL CHEM, V276, P27657, DOI 10.1074/jbc.M103426200; Yang TY, 2002, IEEE T ADV PACKAGING, V25, P54, DOI 10.1109/TADVP.2002.1017686; Zhu WH, 2002, AM J PATHOL, V161, P823, DOI 10.1016/S0002-9440(10)64242-3	72	105	107	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2003	22	58					9254	9264		10.1038/sj.onc.1207035	http://dx.doi.org/10.1038/sj.onc.1207035			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755JU	14681684				2022-12-25	WOS:000187400400007
J	Cid, C; Alvarez-Cermeno, JC; Camafeita, E; Salinas, M; Alcazar, A				Cid, C; Alvarez-Cermeno, JC; Camafeita, E; Salinas, M; Alcazar, A			Antibodies reactive to heat shock protein 90 induce oligodendrocyte precursor cell death in culture. Implications for demyelination in multiple sclerosis	FASEB JOURNAL			English	Article						cell surface antigen expression; demyelinating diseases; O-2A progenitor cells; terminal complement complex; remyelination	HEAT-SHOCK PROTEINS; PROGENITOR CELLS; T-CELL; IDENTIFICATION; EXPRESSION; LESIONS; ASTROCYTE; DAMAGE; SERUM	Oligodendrocyte precursor cells (OPCs) are extremely efficient at remyelination. These cells persist in the adult human central nervous system and can proliferate. However, the failure to remyelinate is a pathological characteristic of the human demyelinating disease multiple sclerosis (MS), which suggests that these cells are ineffective in this disorder. This paper reports that IgG antibodies in the cerebrospinal fluid (CSF) of MS patients specifically recognize an antigen on OPCs in culture. Control patients were found not to possess these antibodies. The antigen was immunoprecipitated in cell extracts from cultures with purified IgG from MS CSF. Peptide mass fingerprinting identified it as the beta type of heat shock protein 90 (Hsp90). Two-dimensional electrophoresis and immunoblot showed that this antigen in fact corresponds to two specific isoforms of Hsp90beta. Several control assays using monoclonal and polyclonal anti-Hsp90 antibodies confirmed the specific expression of Hsp90 on OPCs. Labeling OPCs in vivo with MS CSF and anti-Hsp90 antibodies and subsequent immunofluorescence confocal microscopy located the antigen on the cell surface. The binding of CSF antibodies from MS patients to the OPC surface led to complement activation and significant extinction of the OPC population. These results suggest that OPCs may be a target of anti-Hsp90 antibodies in MS patients and that this could prevent remyelination.	Hosp Ramon & Cajal, Serv Bioquim Invest, E-28034 Madrid, Spain; Hosp Ramon & Cajal, Serv Neurol, E-28034 Madrid, Spain; Ctr Nacl Biotecnol, Madrid, Spain	Hospital Universitario Ramon y Cajal; Hospital Universitario Ramon y Cajal; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Alcazar, A (corresponding author), Hosp Ramon & Cajal, Serv Bioquim Invest, Ctra Colmenar Km 9-1, E-28034 Madrid, Spain.	alberto.alcazar@hrc.es	Messier, Claude/A-2322-2008; Alvarez-Cermeño, José/E-6432-2013	Messier, Claude/0000-0002-4791-1763; 				Alcazar A, 1996, MOL BRAIN RES, V38, P101, DOI 10.1016/0169-328X(95)00335-P; Alcazar A, 2000, J NEUROIMMUNOL, V104, P58, DOI 10.1016/S0165-5728(99)00225-8; Aquino DA, 1997, J NEUROPATH EXP NEUR, V56, P664; ARMSTRONG RC, 1992, J NEUROSCI, V12, P1538; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BARRES BA, 1993, NATURE, V361, P258, DOI 10.1038/361258a0; Blakemore WF, 1999, J NEUROIMMUNOL, V98, P69, DOI 10.1016/S0165-5728(99)00083-1; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; Brosnan CF, 1996, J NEUROPATH EXP NEUR, V55, P389, DOI 10.1097/00005072-199604000-00001; Chang A, 2002, NEW ENGL J MED, V346, P165, DOI 10.1056/NEJMoa010994; Conroy SE, 1996, BRIT J CANCER, V74, P717, DOI 10.1038/bjc.1996.427; EISENBARTH GS, 1979, P NATL ACAD SCI USA, V76, P4913, DOI 10.1073/pnas.76.10.4913; Fanarraga ML, 1999, EUR J NEUROSCI, V11, P517; FFRENCHCONSTANT C, 1986, NATURE, V319, P499, DOI 10.1038/319499a0; Franklin RJM, 2002, NAT REV NEUROSCI, V3, P705, DOI 10.1038/nrn917; FREEDMAN MS, 1992, J NEUROIMMUNOL, V41, P231, DOI 10.1016/0165-5728(92)90074-U; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Genain CP, 1999, NAT MED, V5, P170, DOI 10.1038/5532; Harlow E., 1999, USING ANTIBODIES LAB; Hayem G, 1999, ANN RHEUM DIS, V58, P291, DOI 10.1136/ard.58.5.291; HOVANESSIAN AG, 1987, EMBO J, V6, P1273, DOI 10.1002/j.1460-2075.1987.tb02364.x; Kakimura J, 2002, FASEB J, V16, P601, DOI 10.1096/fj.01-0530fje; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; LUBETZKI C, 1991, J NEUROCHEM, V56, P671, DOI 10.1111/j.1471-4159.1991.tb08202.x; Mycko MP, 2003, BRAIN, V126, P1048, DOI 10.1093/brain/awg107; Niehaus A, 1999, J NEUROSCI, V19, P4948; Niehaus A, 2000, ANN NEUROL, V48, P362, DOI 10.1002/1531-8249(200009)48:3<362::AID-ANA11>3.0.CO;2-6; Noseworthy JH, 2000, NEW ENGL J MED, V343, P938, DOI 10.1056/NEJM200009283431307; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; RAFF MC, 1983, J NEUROSCI, V3, P1289; Roy NS, 1999, J NEUROSCI, V19, P9986, DOI 10.1523/jneurosci.19-22-09986.1999; Sadatipour BT, 1998, ANN NEUROL, V44, P980, DOI 10.1002/ana.410440621; Sapozhnikov AM, 1999, CELL PROLIFERAT, V32, P363, DOI 10.1111/j.1365-2184.1999.tb01354.x; Scolding NJ, 1999, NEUROSCIENCE, V89, P1, DOI 10.1016/S0306-4522(98)00548-X; SCOLDING NJ, 1995, NEUROREPORT, V6, P441, DOI 10.1097/00001756-199502000-00009; Shi JY, 1998, J NEUROSCI, V18, P4627; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; SPIEGEL K, 1998, NEUROINFLAMMATION ME, P129; SUN JP, 1991, EUR J IMMUNOL, V21, P1461, DOI 10.1002/eji.1830210620; TAKENAKA IM, 1992, J CELL PHYSIOL, V152, P568, DOI 10.1002/jcp.1041520317; TEMPLE S, 1986, CELL, V44, P773, DOI 10.1016/0092-8674(86)90843-3; Wolswijk G, 2002, BRAIN, V125, P338, DOI 10.1093/brain/awf031; Wolswijk G, 1998, J NEUROSCI, V18, P601; WREN DR, 1989, P NATL ACAD SCI USA, V86, P9025, DOI 10.1073/pnas.86.22.9025; WUCHERPFENNIG KW, 1992, P NATL ACAD SCI USA, V89, P4588, DOI 10.1073/pnas.89.10.4588	46	40	42	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					409	+		10.1096/fj.03-0606fje	http://dx.doi.org/10.1096/fj.03-0606fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14688203				2022-12-25	WOS:000188067500009
J	McArdle, A; Dillmann, WH; Mestril, R; Faulkner, JA; Jackson, MJ				McArdle, A; Dillmann, WH; Mestril, R; Faulkner, JA; Jackson, MJ			Overexpression of HSP70 in mouse skeletal muscle protects against muscle damage and age-related muscle dysfunction	FASEB JOURNAL			English	Article						lengthening contractions; regeneration; maximum tetanic force; transgenic	CONTRACTION-INDUCED INJURY; OXIDATIVE STRESS; HEAT-SHOCK; MICE; YOUNG; STRETCHES; INCREASES; PROTEINS; ANIMALS; RELEASE	Ageing is associated with skeletal muscle atrophy, a deficit in force generation, an increased susceptibility to contraction-induced injury, and a permanent force deficit following severe injury. Muscles of young mice adapt rapidly following exercise by an increase in the production of heat shock proteins (HSPs), whereas muscles of old mice show a severely diminished response. We hypothesized that overexpression of HSP70 in muscle throughout life would reduce age-related changes in function. The maximum tetanic force of extensor digitorum longus (EDL) muscles of adult and old wild-type (WT) and HSP70 overexpressor transgenic mice was determined. EDL muscles were subjected to damaging lengthening contractions and the ability to generate force was assessed for up to 28 days following the contractions. Overexpression of HSP70 in muscles of old transgenic mice prevented the specific force deficit observed in muscles of old WT mice. The complete recovery of muscles of old HSP70 transgenic mice by 14 days following the contraction protocol was in contrast to the 44% force deficit, which remained in muscles of old WT mice at 28 days following the protocol. These data indicate that a diminished production of HSP70 in muscles of old mammals has a major effect on age-related functional deficits.	Univ Liverpool, Dept Med, Liverpool L69 3GA, Merseyside, England; Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA; Loyola Univ, Dept Physiol, Chicago, IL 60611 USA; Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA	University of Liverpool; University of California System; University of California San Diego; Loyola University Chicago; University of Michigan System; University of Michigan	McArdle, A (corresponding author), Univ Liverpool, Dept Med, Liverpool L69 3GA, Merseyside, England.	mdcr02@liv.ac.uk		Mestril, Ruben/0000-0003-3631-2236; Jackson, Malcolm/0000-0003-3683-8297				BALON TW, 1994, J APPL PHYSIOL, V77, P2519, DOI 10.1152/jappl.1994.77.6.2519; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BROOKS SV, 1990, AM J PHYSIOL, V258, pC436, DOI 10.1152/ajpcell.1990.258.3.C436; BROOKS SV, 1988, J PHYSIOL-LONDON, V404, P71, DOI 10.1113/jphysiol.1988.sp017279; Brooks SV, 2001, J APPL PHYSIOL, V91, P661, DOI 10.1152/jappl.2001.91.2.661; Brooks SV, 2001, J GERONTOL A-BIOL, V56, pB163, DOI 10.1093/gerona/56.4.B163; Brooks SV, 1996, J PHYSIOL-LONDON, V497, P573, DOI 10.1113/jphysiol.1996.sp021790; CARLSON BM, 1989, AM J PHYSIOL, V256, pC1262; Carlson BM, 2001, J GERONTOL A-BIOL, V56, pB224, DOI 10.1093/gerona/56.5.B224; CARLSON BM, 1988, EXP NEUROL, V102, P50, DOI 10.1016/0014-4886(88)90077-5; Cederna PS, 2001, J GERONTOL A-BIOL, V56, pB254, DOI 10.1093/gerona/56.6.B254; FLANAGAN SW, 1995, AM J PHYSIOL-REG I, V268, pR28, DOI 10.1152/ajpregu.1995.268.1.R28; GOLDSPINK G, 1994, STRENGTH POWER SPORT, P211; HADLEY EC, 1993, J GERONTOL, V48, pR7, DOI 10.1093/geronj/48.Special_Issue.vii; Khassaf M, 2001, J APPL PHYSIOL, V90, P1031, DOI 10.1152/jappl.2001.90.3.1031; LEXELL J, 1988, J NEUROL SCI, V84, P275, DOI 10.1016/0022-510X(88)90132-3; LOPEZ ME, 2000, HDB OXIDANTS ANTIOXI; Manzerra P, 1997, J CELL PHYSIOL, V170, P130, DOI 10.1002/(SICI)1097-4652(199702)170:2<130::AID-JCP4>3.0.CO;2-P; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; McArdle A, 2001, AM J PHYSIOL-CELL PH, V280, pC621, DOI 10.1152/ajpcell.2001.280.3.C621; MCCULLY KK, 1985, J APPL PHYSIOL, V59, P119, DOI 10.1152/jappl.1985.59.1.119; Moseley PL, 1998, ANN NY ACAD SCI, V856, P206, DOI 10.1111/j.1749-6632.1998.tb08327.x; Nosek TM, 2000, PHYSIOL GENOMICS, V4, P25, DOI 10.1152/physiolgenomics.2000.4.1.25; ONeill CA, 1996, J APPL PHYSIOL, V81, P1197, DOI 10.1152/jappl.1996.81.3.1197; PHILLIPS SK, 1991, J PHYSIOL-LONDON, V437, P63, DOI 10.1113/jphysiol.1991.sp018583; Porter M. M., 1995, Scandinavian Journal of Medicine and Science in Sports, V5, P129; REID MB, 1992, J APPL PHYSIOL, V73, P1805, DOI 10.1152/jappl.1992.73.5.1805; SALO DC, 1991, FREE RADICAL BIO MED, V11, P239, DOI 10.1016/0891-5849(91)90119-N; SKELDON P, 1994, MANUF CHEMIST, V65, P23; SOHAL RS, 1992, ANN NY ACAD SCI, V663, P74, DOI 10.1111/j.1749-6632.1992.tb38651.x; Vasilaki A, 2003, BIOCHEM SOC T, V31, P455, DOI 10.1042/BST0310455; Vasilaki A, 2002, MUSCLE NERVE, V25, P902, DOI 10.1002/mus.10094; WARNER HR, 1994, FREE RADICAL BIO MED, V17, P249, DOI 10.1016/0891-5849(94)90080-9; ZERBA E, 1990, AM J PHYSIOL, V258, pC429, DOI 10.1152/ajpcell.1990.258.3.C429	34	196	198	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					355	+		10.1096/fj.03-0395fje	http://dx.doi.org/10.1096/fj.03-0395fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14688209	Green Submitted			2022-12-25	WOS:000188067500015
J	Deshayes, F; Lapree, G; Portier, A; Richard, Y; Pencalet, P; Mahieu-Caputo, D; Horellou, P; Tsapis, A				Deshayes, F; Lapree, G; Portier, A; Richard, Y; Pencalet, P; Mahieu-Caputo, D; Horellou, P; Tsapis, A			Abnormal production of the TNF-homologue APRIL increases the proliferation of human malignant glioblastoma cell lines via a specific receptor	ONCOGENE			English	Article						glioblastomas; APRIL; proliferation; APRIL receptor; malignancy	NECROSIS-FACTOR FAMILY; MATURATION ANTIGEN; BCMA GENE; GROWTH; MEMBER; TACI; LIGAND; SUPERFAMILY; SYSTEM; DEATH	A proliferation-inducing ligand (APRIL) of the tumour necrosis factor (TNF) family is produced in small amounts in many tissues and more abundantly in tumours. APRIL has been reported to promote cell growth in vivo and in vitro. It was recently shown that the production of APRIL in some glioblastoma cell lines does not lead to an increase in cell growth. In this study, we investigated the production of APRIL and its ability to increase the proliferation of eight human glioblastoma cell lines. We found that APRIL was produced in the eight human glioblastoma cell lines tested but not in the normal embryonic astrocyte counterparts of glioblastomas. Flow cytometry demonstrated the presence of a specific APRIL-binding receptor on the cell surface in all the glioblastoma cell lines tested. This receptor was also present on normal embryonic and adult astrocytes and embryonic neural progenitor cells. Moreover, the addition of recombinant human APRIL resulted in an increase in proliferation rate of normal adult astrocytes and in four of eight cell lines tested. Addition of the soluble recombinant TNF-receptor-homologue B-cell maturation (BCMA) chimeric protein, which binds APRIL, confirmed the involvement of APRIL in the growth of malignant glioblastoma cell lines.	INSERM, U131, F-92140 Clamart, France; Hop Foch, Serv Neurochirurg, F-92150 Suresnes, France; Hop Antoine Beclere, INSERM, F-92140 Clamart, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Hospital Foch; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Tsapis, A (corresponding author), INSERM, U131, 32 Rue Carnets, F-92140 Clamart, France.	andreas.tsapis@ipsc.u-psud.fr	Horellou, Philippe/B-4290-2019; RICHARD, Yolande/B-7926-2008	Horellou, Philippe/0000-0003-2467-8177; RICHARD, Yolande/0000-0001-8560-9250				Barbero S, 2003, CANCER RES, V63, P1969; CHAMAK B, 1989, DEVELOPMENT, V106, P483; DAVIES LG, 1986, BASIC METHODS MOL BI; Goswami S, 1998, J NEUROCHEM, V71, P1837; Gravestein LA, 1998, SEMIN IMMUNOL, V10, P423, DOI 10.1006/smim.1998.0144; Gross JA, 2000, NATURE, V404, P995, DOI 10.1038/35010115; Hahne M, 1998, J EXP MED, V188, P1185, DOI 10.1084/jem.188.6.1185; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Held-Feindt J, 2003, J NEURO-ONCOL, V63, P117, DOI 10.1023/A:1023943405292; Kelly K, 2000, CANCER RES, V60, P1021; LAABI Y, 1992, EMBO J, V11, P3897, DOI 10.1002/j.1460-2075.1992.tb05482.x; LAABI Y, 1994, NUCLEIC ACIDS RES, V22, P1147, DOI 10.1093/nar/22.7.1147; Lopez-Fraga M, 2001, EMBO REP, V2, P945, DOI 10.1093/embo-reports/kve198; Madry C, 1998, INT IMMUNOL, V10, P1693, DOI 10.1093/intimm/10.11.1693; Marsters SA, 2000, CURR BIOL, V10, P785, DOI 10.1016/S0960-9822(00)00566-2; MILOUX B, 1994, GENE, V149, P341, DOI 10.1016/0378-1119(94)90173-2; Rennert P, 2000, J EXP MED, V192, P1677, DOI 10.1084/jem.192.11.1677; Ridet JL, 1999, HUM GENE THER, V10, P271, DOI 10.1089/10430349950019057; Roth W, 2001, CELL DEATH DIFFER, V8, P403, DOI 10.1038/sj.cdd.4400827; Schneider P, 1999, J EXP MED, V189, P1747, DOI 10.1084/jem.189.11.1747; Shu HB, 1999, J LEUKOCYTE BIOL, V65, P680, DOI 10.1002/jlb.65.5.680; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Thompson JS, 2000, J EXP MED, V192, P129, DOI 10.1084/jem.192.1.129; Thompson JS, 2001, SCIENCE, V293, P2108, DOI 10.1126/science.1061965; Wu YM, 2000, J BIOL CHEM, V275, P35478, DOI 10.1074/jbc.M005224200; Xia XZ, 2000, J EXP MED, V192, P137, DOI 10.1084/jem.192.1.137; Yu G, 2000, NAT IMMUNOL, V1, P252, DOI 10.1038/79802	27	47	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3005	3012		10.1038/sj.onc.1207350	http://dx.doi.org/10.1038/sj.onc.1207350			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	14691452				2022-12-25	WOS:000220845200004
J	Hekman, M; Wiese, S; Metz, R; Albert, S; Troppmair, J; Nickel, J; Sendtner, M; Rapp, UR				Hekman, M; Wiese, S; Metz, R; Albert, S; Troppmair, J; Nickel, J; Sendtner, M; Rapp, UR			Dynamic changes in C-raf phosphorylation and 14-3-3 protein binding in response to growth factor stimulation - Differential roles of 14-3-3 protein binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-RAF; MONOCLONAL-ANTIBODIES; BIOLOGICAL-ACTIVITY; SIGNALING PROTEINS; PHOSPHATIDIC-ACID; ACTIVATES RAF-1; LIPID RAFTS; V-RAF; A-RAF; KINASE	Phosphorylation events play a crucial role in Raf activation. Phosphorylation of serines 259 and 621 in C-Raf and serines 364 and 728 in B-Raf has been suggested to be critical for association with 14-3-3 proteins. To study the functional consequences of Raf phosphorylations at these positions, we developed and characterized phosphospecific antibodies directed against 14-3-3 binding epitopes: a monoclonal phosphospecific antibody (6B4) directed against pS621 and a polyclonal antibody specific for B-Raf-pS364 epitope. Although 6B4 detected both C- and B-Raf in Western blots, it specifically recognizes the native form of C- Raf but not B-Raf. Contrary to B-Raf, a kinase-dead mutant of C- Raf was found to be only poorly phosphorylated in the Ser-621 position. Moreover, serine 259 to alanine mutation prevented the Ser-621 phosphorylation suggesting an interdependence between these two 14-3-3 binding domains. Direct C- Raf . 14-3-3 binding studies with purified proteins combined with competition assays revealed that the 14-3-3 binding domain surrounding pS621 represents the high affinity binding site, whereas the pS259 epitope mediates lower affinity binding. Raf isozymes differ in their 14-3-3 association rates. The time course of endogenous C- Raf activation in mammalian cells by nerve growth factor (NGF) has been examined using both phosphospecific antibodies directed against 14-3-3 binding sites (6B4 and anti-pS259) as well as phosphospecific antibodies directed against the activation domain (anti-pS338 and anti-pY340/pY341). Time course of Ser-621 phosphorylation, in contrast to Ser-259 phosphorylation, exhibited unexpected pattern reaching maximal phosphorylation within 30 s of NGF stimulation. Phosphorylation of tyrosine 340/341 reached maximal levels subsequent to Ser-621 phosphorylation and was coincident with emergence of kinase activity. Taken together, we found substantial differences between C- Raf . 14-3-3 binding epitopes pS259 and pS621 and visualized for the first time the sequence of the essential C- Raf phosphorylation events in mammalian cells in response to growth factor stimulation.	Univ Wurzburg, Inst Med Radiat & Cell Res, D-97078 Wurzburg, Germany; Univ Wurzburg, Inst Clin Neurobiol, D-97080 Wurzburg, Germany; Univ Wurzburg, Biozentrum, Theodor Boveri Inst Biowissensch, D-97074 Wurzburg, Germany	University of Wurzburg; University of Wurzburg; University of Wurzburg	Rapp, UR (corresponding author), Univ Wurzburg, Inst Med Radiat & Cell Res, D-97078 Wurzburg, Germany.	rappur@mail.uni-wuerzburg.de	Sendtner, Michael/M-8137-2014; Sendtner, Michael/J-1542-2012	Sendtner, Michael/0000-0002-4737-2974; Sendtner, Michael/0000-0002-4737-2974; Troppmair, Jakob/0000-0002-0611-3837				Afanassiev V, 1998, HYBRIDOMA, V17, P383, DOI 10.1089/hyb.1998.17.383; Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; Chong HR, 2003, J BIOL CHEM, V278, P36269, DOI 10.1074/jbc.M212803200; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Dumaz N, 2003, J BIOL CHEM, V278, P29819, DOI 10.1074/jbc.C300182200; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hekman M, 2002, J BIOL CHEM, V277, P24090, DOI 10.1074/jbc.M200576200; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; KOLCH W, 1990, ONCOGENE, V5, P713; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kubicek M, 2002, J BIOL CHEM, V277, P7913, DOI 10.1074/jbc.M108733200; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; MARTIN H, 1993, FEBS LETT, V331, P296, DOI 10.1016/0014-5793(93)80356-Y; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; Papin C, 1996, ONCOGENE, V12, P2213; Raabe T, 2003, CURR BIOL, V13, pR635, DOI 10.1016/S0960-9822(03)00568-2; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; SCHULTZ AM, 1988, ONCOGENE, V2, P187; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; SUEN KL, 1995, ONCOGENE, V11, P825; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Weber CK, 2001, CANCER RES, V61, P3595; Wixler V, 1996, FEBS LETT, V385, P131, DOI 10.1016/0014-5793(96)00363-8; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yuryev A, 2000, MOL CELL BIOL, V20, P4870, DOI 10.1128/MCB.20.13.4870-4878.2000; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	47	45	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14074	14086		10.1074/jbc.M309620200	http://dx.doi.org/10.1074/jbc.M309620200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14688280	hybrid			2022-12-25	WOS:000220478500097
J	Kadaja, L; Laos, S; Maimets, T				Kadaja, L; Laos, S; Maimets, T			Overexpression of leukocyte marker CD43 causes activation of the tumor suppressor proteins p53 and ARF	ONCOGENE			English	Article						CD43; p53; p19ARF	WISKOTT-ALDRICH SYNDROME; T-CELL-ACTIVATION; SURFACE SIALOGLYCOPROTEIN; MONOCLONAL-ANTIBODIES; COLON ADENOMA; FEEDBACK LOOP; MDM2; PHOSPHORYLATION; LEUKOSIALIN; EXPRESSION	CD43 or leukosialin is a transmembrane sialoglycoprotein, whose extracellular domain participates in cell adhesiveness and the cytoplasmic tail regulates a variety of intracellular signal transduction pathways involved in cell proliferation. CD43 is abundantly expressed on the surface of hematopoietic cells, but CD43 expression is also frequently found in the tumor cells of nonhematopoietic origin. In the early stages of some tumors, the accumulation of tumor suppressor protein p53 has been described. Here, we show that the expression of CD43 causes the induction of functionally active p53 protein. Moreover, we found that the activation of p53 by CD43 is mediated by tumor suppressor protein ARF. The coexpression of CD43 and ARF in ARF-null mouse embryonic fibroblasts resulted in programmed cell death, but that was not the case when CD43 alone was expressed in these cells. These data provide the first evidence of the connection between p53- and CD43-dependent pathways.	Univ Tartu, Inst Mol & Cell Biol, Dept Cell Biol, EE-51010 Tartu, Estonia; Gothenburg Univ, Dept Med Biochem, S-41390 Gothenburg, Sweden	University of Tartu; University of Gothenburg	Kadaja, L (corresponding author), Univ Tartu, Inst Mol & Cell Biol, Dept Cell Biol, 23 Riia St, EE-51010 Tartu, Estonia.	lkadaja@ebc.ee	Maimets, Toivo/E-9268-2017	Maimets, Toivo/0000-0001-6461-3365				ANDERSSON LC, 1978, BLOOD, V52, P57; ARDMAN B, 1992, P NATL ACAD SCI USA, V89, P5001, DOI 10.1073/pnas.89.11.5001; AXELSSON B, 1988, J IMMUNOL, V141, P2912; BAECKSTROM D, 1991, J BIOL CHEM, V266, P21537; BAECKSTROM D, 1995, J BIOL CHEM, V270, P13688, DOI 10.1074/jbc.270.23.13688; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DRAGONE LL, 1995, P NATL ACAD SCI USA, V92, P626, DOI 10.1073/pnas.92.2.626; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fernandez-Rodriguez J, 2002, TUMOR BIOL, V23, P193, DOI 10.1159/000067252; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HARPER JW, 1993, CELL, V75, P805; Joers A, 1998, ONCOGENE, V17, P2351, DOI 10.1038/sj.onc.1202146; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; MAZARS R, 1991, ONCOGENE, V6, P1685; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; MENTZER SJ, 1987, J EXP MED, V165, P1383, DOI 10.1084/jem.165.5.1383; Miura Y, 2001, BIOCHEM BIOPH RES CO, V288, P80, DOI 10.1006/bbrc.2001.5729; Ostberg JR, 1996, J IMMUNOL, V157, P4876; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; PARK JK, 1991, NATURE, V350, P706, DOI 10.1038/350706a0; Pedraza-Alva G, 1998, J BIOL CHEM, V273, P14218, DOI 10.1074/jbc.273.23.14218; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1999, J PATHOL, V187, P112; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REMOLDODONNELL E, 1984, J EXP MED, V159, P1705, DOI 10.1084/jem.159.6.1705; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; Rosenstein Y, 1999, IMMUNOL RES, V20, P89, DOI 10.1007/BF02786465; Sambrook J., 2002, MOL CLONING LAB MANU; Santamaria M, 1996, CANCER RES, V56, P3526; Santana MA, 2000, J BIOL CHEM, V275, P31460, DOI 10.1074/jbc.M005231200; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sikut R, 1999, INT J CANCER, V82, P52, DOI 10.1002/(SICI)1097-0215(19990702)82:1<52::AID-IJC10>3.0.CO;2-C; Sikut R, 1997, BIOCHEM BIOPH RES CO, V238, P612, DOI 10.1006/bbrc.1997.7334; Stewart ZA, 2001, BREAST CANCER RES, V3, P5, DOI 10.1186/bcr261; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Wang SW, 2001, CARCINOGENESIS, V22, P757, DOI 10.1093/carcin/22.5.757; Wang WM, 2000, CELL IMMUNOL, V205, P34, DOI 10.1006/cimm.2000.1716; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	53	11	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 1	2004	23	14					2523	2530		10.1038/sj.onc.1207359	http://dx.doi.org/10.1038/sj.onc.1207359			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14676827				2022-12-25	WOS:000220558000009
J	Audero, E; Cascone, I; Maniero, F; Napione, L; Arese, M; Lanfrancone, L; Bussolino, F				Audero, E; Cascone, I; Maniero, F; Napione, L; Arese, M; Lanfrancone, L; Bussolino, F			Adaptor ShcA protein binds tyrosine kinase Tie2 receptor and regulates migration and sprouting but not survival of endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIDDLE T-ANTIGEN; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; COLORIMETRIC ASSAY; DOCKING PROTEIN; SH2 DOMAIN; ANGIOPOIETIN-1; ACTIVATION; PHOSPHORYLATION	Angiopoietin-1 can promote migration, sprouting, and survival of endothelial cells through activation of different signaling pathways triggered by the Tie2 tyrosine kinase receptor. ShcA adapter proteins are targets of activated tyrosine kinases and are implicated in the transmission of activation signals to the Ras/mitogen-activated protein kinase pathway. Here we report the identification of an interaction between the adapter protein ShcA and the cytoplasmic domain of Tie2 through in vitro co-immunoprecipitation analysis. Stimulation of endogenous Tie2 in endothelial cells with its ligand angiopoietin-1 increased its association with ShcA and phosphorylation of the adapter protein. The interaction requires the SH2 domain of ShcA and the tyrosine phosphorylation of Tie2 as shown by pull-down experiments. Furthermore, Tyr-1101 of Tie2 was identified as the primary binding site for the SH2 domain of ShcA. Overexpression of a dominant-negative form of ShcA affects angiopoietin-1-induced chemotaxis and sprouting, although it has no effect on survival of endothelial cells. Furthermore, this mutant partially reduces the tyrosine phosphorylation of the regulatory p85 subunit of phosphatidylinositol 3-kinase. Together, our results identified a novel interaction between Tie2 with the adapter molecule ShcA and suggested that this interaction may play a role in the regulation of migration and three-dimensional organization of endothelial cells induced by angiopoietin-1.	Univ Turin, Sch Med, Inst Canc Res & Treatment, Div Mol Angiogeneis, I-10060 Candiolo, Italy; Univ Turin, Dept Oncol Sci, I-10060 Candiolo, Italy; European Inst Oncol, I-20141 Milan, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; University of Turin; IRCCS European Institute of Oncology (IEO)	Bussolino, F (corresponding author), Inst Canc Res & Treatment, Div Mol Angiogenesis, Sp 142,Km 3-95, I-10060 Turin, Italy.	federico.bussolino@ircc.it	Bussolino, Federico/AES-3951-2022; Cascone, Ilaria/Q-7844-2018; Napione, Lucia/K-3927-2016; arese, marco/J-6119-2013; Lanfrancone, Luisa/AAC-8671-2019; Bussolino, Federico/K-2500-2016	Cascone, Ilaria/0000-0003-4903-8926; Napione, Lucia/0000-0003-2648-1466; arese, marco/0000-0002-7384-9406; Lanfrancone, Luisa/0000-0002-4523-3815; Bussolino, Federico/0000-0002-5348-1341; Audero, Enrica/0000-0002-6138-244X				Audero E, 2001, ARTERIOSCL THROM VAS, V21, P536, DOI 10.1161/01.ATV.21.4.536; BALDARI CT, 1995, ONCOGENE, V10, P1141; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Borges E, 2000, J BIOL CHEM, V275, P39867, DOI 10.1074/jbc.M007040200; Bussolino F, 1997, TRENDS BIOCHEM SCI, V22, P251, DOI 10.1016/S0968-0004(97)01074-8; Bussolino F, 2001, EMBO REP, V2, P763, DOI 10.1093/embo-reports/kve181; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; CARMICHAEL J, 1987, CANCER RES, V47, P936; Cascone I, 2003, BLOOD, V102, P2482, DOI 10.1182/blood-2003-03-0670; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Collins LR, 1999, J CELL BIOL, V147, P1561, DOI 10.1083/jcb.147.7.1561; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Faisal A, 2002, J BIOL CHEM, V277, P30144, DOI 10.1074/jbc.M203229200; Fournier E, 1996, J BIOL CHEM, V271, P12956, DOI 10.1074/jbc.271.22.12956; Goalstone ML, 2001, J BIOL CHEM, V276, P12805, DOI 10.1074/jbc.M009443200; Gotoh N, 1995, ONCOGENE, V11, P2525; Grignani F, 1998, CANCER RES, V58, P14; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; HUANG LW, 1995, ONCOGENE, V11, P2097; Jones N, 1999, J BIOL CHEM, V274, P30896, DOI 10.1074/jbc.274.43.30896; Jones N, 1998, ONCOGENE, V17, P1097, DOI 10.1038/sj.onc.1202115; Jones N, 2001, NAT REV MOL CELL BIO, V2, P257, DOI 10.1038/35067005; Kim I, 2000, CIRC RES, V86, P952, DOI 10.1161/01.RES.86.9.952; Kim I, 2002, FASEB J, V16, P1126, DOI 10.1096/fj.01-0805fje; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Kontos CD, 1998, MOL CELL BIOL, V18, P4131, DOI 10.1128/MCB.18.7.4131; Korff T, 1998, J CELL BIOL, V143, P1341, DOI 10.1083/jcb.143.5.1341; Korpelainen EI, 1999, ONCOGENE, V18, P1, DOI 10.1038/sj.onc.1202288; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Kwak HJ, 1999, FEBS LETT, V448, P249, DOI 10.1016/S0014-5793(99)00378-6; Kwak HJ, 2000, CIRCULATION, V101, P2317, DOI 10.1161/01.CIR.101.19.2317; Lai KMV, 2000, GENE DEV, V14, P1132; LANFRANCONE L, 1995, ONCOGENE, V10, P907; Luzi L, 2000, CURR OPIN GENET DEV, V10, P668, DOI 10.1016/S0959-437X(00)00146-5; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; Mauro L, 1999, EXP CELL RES, V252, P439, DOI 10.1006/excr.1999.4639; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NEHLS V, 1995, MICROVASC RES, V50, P311, DOI 10.1006/mvre.1995.1061; Nolan MK, 1997, INT J CANCER, V72, P828, DOI 10.1002/(SICI)1097-0215(19970904)72:5<828::AID-IJC20>3.0.CO;2-3; OKADA S, 1995, J BIOL CHEM, V270, P20737, DOI 10.1074/jbc.270.35.20737; OKKENHAUG K, 2001, SCI STKE; Ong SH, 2001, EMBO J, V20, P6327, DOI 10.1093/emboj/20.22.6327; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Papapetropoulos A, 1999, LAB INVEST, V79, P213; Pelicci G, 1996, ONCOGENE, V13, P633; PELICCI G, 1995, ONCOGENE, V10, P1631; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Primo L, 2000, ONCOGENE, V19, P3632, DOI 10.1038/sj.onc.1203708; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Roca C, 2003, CANCER RES, V63, P1500; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sakai R, 2000, NEURON, V28, P819, DOI 10.1016/S0896-6273(00)00156-2; Sasaoka T, 1996, J BIOL CHEM, V271, P20082, DOI 10.1074/jbc.271.33.20082; Sato A, 1998, INT IMMUNOL, V10, P1217, DOI 10.1093/intimm/10.8.1217; Sato K, 2002, J BIOL CHEM, V277, P29568, DOI 10.1074/jbc.M203179200; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Stupack D. G., 2002, SCI STKE, ppe7; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; TRUB T, 1995, J BIOL CHEM, V270, P18205; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; Ventura A, 2004, J BIOL CHEM, V279, P2299, DOI 10.1074/jbc.M307655200; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	79	42	47	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13224	13233		10.1074/jbc.M307456200	http://dx.doi.org/10.1074/jbc.M307456200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14665640	hybrid			2022-12-25	WOS:000220334900144
J	Picossi, S; Valladares, A; Flores, E; Herrero, A				Picossi, S; Valladares, A; Flores, E; Herrero, A			Nitrogen-regulated genes for the metabolism of cyanophycin, a bacterial nitrogen reserve polymer - Expression and mutational analysis of two cyanophycin synthetase and cyanophycinase gene clusters in the heterocyst-forming cyanobacterium Anabaena sp PCC 7120	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP-STRAIN PCC-7120; CLONING; ENZYME; SEQUENCES; GROWTH; NTCA; DIFFERENTIATION; TRANSCRIPTION; BIOSYNTHESIS; PROTEINS	Two gene clusters each encoding the cyanophycin-metabolism enzymes cyanophycin synthetase and cyanophycinase are found in the heterocyst-forming cyanobacterium Anabaena sp. PCC 7120. In cluster cph1, the genes cphB1 and cphA1 were expressed in media containing ammonium, nitrate, or N-2 as nitrogen sources, but expression was higher in the absence of combined nitrogen taking place both in vegetative cells and heterocysts. Both genes were cotranscribed from three putative promoters located upstream of cphB1, and, additionally, the cphA1 gene was expressed monocistronically from at least two promoters located in the intergenic cphB1-cphA1 region. Both constitutive promoters and promoters dependent on the global nitrogen control transcriptional regulator NtcA were identified. In cluster cph2, the cphB2 and cphA2 genes, which are found in opposite orientations, were expressed as monocistronic messages in media containing ammonium, nitrate, or N-2, but expression was higher in the absence of ammonium. Expression of the cph2 genes was lower than that of cph1 genes. Analysis of cph gene insertional mutants indicated that cluster cph1 genes contributed more than cluster cph2 genes to cyanophycin accumulation in the whole filament as well as in heterocysts. Diazotrophic growth was more severely impaired in cyanophycinase than in cyanophycin synthetase mutants, indicating that cyanophycin, although normally synthesized in the heterocysts, is not required for heterocyst function and that the inability to degrade this polymer is detrimental for the diazotrophic growth of the cyanobacterium.	Univ Seville, CSIC, Inst Bioquim Vegetal & Fotosintesis, E-41092 Seville, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF)	Herrero, A (corresponding author), Ctr Invest Cient Isla de la Cartuja, Inst Bioquim Vegetal & Fotosintesis, C Amer Vespucio S-N, E-41092 Seville, Spain.	herrero@cica.es	Herrero, Antonia/B-7246-2015; Valladares, Ana/B-7611-2015; Picossi, Silvia/I-5623-2012; Flores, Enrique/M-8407-2019; Flores, Enrique/L-2007-2014	Herrero, Antonia/0000-0003-1071-6590; Valladares, Ana/0000-0002-6683-1355; Picossi, Silvia/0000-0003-1175-6228; Flores, Enrique/0000-0001-7605-7343; Flores, Enrique/0000-0001-7605-7343				ALLEN MM, 1984, ANNU REV MICROBIOL, V38, P1, DOI 10.1146/annurev.mi.38.100184.000245; Ausubel FM, 2003, CURRENT PROTOCOLS MO; BLACK TA, 1993, MOL MICROBIOL, V9, P77, DOI 10.1111/j.1365-2958.1993.tb01670.x; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; CAI YP, 1990, J BACTERIOL, V172, P3138, DOI 10.1128/jb.172.6.3138-3145.1990; ElhaI J, 1997, J BACTERIOL, V179, P1998, DOI 10.1128/jb.179.6.1998-2005.1997; ELHAI J, 1988, METHOD ENZYMOL, V167, P747; ELHAI J, 1988, GENE, V68, P119, DOI 10.1016/0378-1119(88)90605-1; ELHAI J, 1994, J BACTERIOL, V176, P5059, DOI 10.1128/jb.176.16.5059-5067.1994; Flores E., 1994, MOL BIOL CYANOBACTER, VVol 1, P487; FRIAS JE, 1994, MOL MICROBIOL, V14, P823, DOI 10.1111/j.1365-2958.1994.tb01318.x; GOLDEN JW, 1991, J BACTERIOL, V173, P7098, DOI 10.1128/jb.173.22.7098-7105.1991; GUPTA M, 1981, J GEN MICROBIOL, V125, P17; Hejazi M, 2002, BIOCHEM J, V364, P129, DOI 10.1042/bj3640129; Herrero A, 2001, J BACTERIOL, V183, P411, DOI 10.1128/JB.183.2.411-425.2001; Kaneko T, 1996, DNA Res, V3, P109; Kaneko T, 2001, DNA RES, V8, P205, DOI 10.1093/dnares/8.5.205; Krehenbrink M, 2002, ARCH MICROBIOL, V177, P371, DOI 10.1007/s00203-001-0396-9; LAWRY NH, 1982, J PHYCOL, V18, P391; LUQUE I, 1994, EMBO J, V13, P2862, DOI 10.1002/j.1460-2075.1994.tb06580.x; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MAZODIER P, 1985, NUCLEIC ACIDS RES, V13, P195, DOI 10.1093/nar/13.1.195; MESSINEO L, 1966, ARCH BIOCHEM BIOPHYS, V117, P534, DOI 10.1016/0003-9861(66)90094-4; MONTESINOS ML, 1995, J BACTERIOL, V177, P3150, DOI 10.1128/jb.177.11.3150-3157.1995; Muro-Pastor AM, 1999, J BACTERIOL, V181, P6664, DOI 10.1128/JB.181.21.6664-6669.1999; Muro-Pastor AM, 2002, MOL MICROBIOL, V44, P1377, DOI 10.1046/j.1365-2958.2002.02970.x; Obst M, 2002, J BIOL CHEM, V277, P25096, DOI 10.1074/jbc.M112267200; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; Richter R, 1999, EUR J BIOCHEM, V263, P163, DOI 10.1046/j.1432-1327.1999.00479.x; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Sherman DM, 2000, J PHYCOL, V36, P932, DOI 10.1046/j.1529-8817.2000.99132.x; Sherman LA, 1998, PHOTOSYNTH RES, V58, P25, DOI 10.1023/A:1006137605802; Simon R.D., 1987, CYANOBACTERIA, P199; SIMON RD, 1976, BIOCHIM BIOPHYS ACTA, V422, P407, DOI 10.1016/0005-2744(76)90151-0; TUMER NE, 1983, NATURE, V306, P337, DOI 10.1038/306337a0; Vioque A, 1997, NUCLEIC ACIDS RES, V25, P3471, DOI 10.1093/nar/25.17.3471; Wolk C.P., 1994, MOL BIOL CYANOBACTER, P769, DOI DOI 10.1007/978-94-011-0227-8_27; Ziegler K, 2001, FEMS MICROBIOL LETT, V196, P13, DOI 10.1111/j.1574-6968.2001.tb10533.x; Ziegler K, 2002, Z NATURFORSCH C, V57, P522; Ziegler K, 1998, EUR J BIOCHEM, V254, P154, DOI 10.1046/j.1432-1327.1998.2540154.x	40	46	52	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11582	11592		10.1074/jbc.M311518200	http://dx.doi.org/10.1074/jbc.M311518200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14679189	hybrid			2022-12-25	WOS:000220157600091
J	Haidar, B; Denis, M; Marcil, M; Krimbou, L; Genest, J				Haidar, B; Denis, M; Marcil, M; Krimbou, L; Genest, J			Apolipoprotein A-I activates cellular cAMP signaling through the ABCA1 transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; REVERSE CHOLESTEROL TRANSPORT; FAMILIAL HDL DEFICIENCY; PROTEIN-KINASE-A; TANGIER-DISEASE; APOA-I; DEPENDENT PATHWAY; PHOSPHOLIPASE-C; CYCLIC-AMP; EFFLUX	It has been suggested that the signal transduction pathway initiated by apoA-I activates key proteins involved in cellular lipid efflux. We investigated apoA-I-mediated cAMP signaling in cultured human fibroblasts induced with (22R)-hydroxycholesterol and 9-cis-retinoic acid (stimulated cells). Treatment of stimulated fibroblasts with apoA-I for short periods of time (<45 min) increased ATP binding cassette A1 (ABCA1) phosphorylation in a concentration-dependent manner. Concomitantly, apoA-I increased the intracellular level of cAMP in a concentration- and time-dependent manner. The maximal cAMP level was reached within 10 min at 10 mu g/ml apoA-I representing a 1-fold increase. The ability of apoA-I to mediate cAMP production was only observed in stimulated fibroblasts. Furthermore, overexpression of ABCA1 in Chinese hamster ovary cells resulted in a 1.5-fold increase in apoA-I-mediated cAMP accumulation as compared with untransfected cells. In contrast, forskolin increased cAMP production significantly in unstimulated fibroblasts as well as in untransfected Chinese hamster ovary cells. Pharmacological inhibition of protein kinase A (H89) completely blocked apoA-I-mediated ABCA1 phosphorylation. Naturally occurring mutations of ABCA1 associated with Tangier disease (C1477R, 2203X, and 2145X) severely reduced apoA-I-mediated cAMP production, ABCA1 phosphorylation, I-125-apoA-I binding, and lipid efflux, without affecting forskolin-mediated cAMP elevation. In contrast, the protein kinase A catalytic subunit was able to phosphorylate ABCA1 similarly from mutant and normal cell lines in vitro. Together, our results indicate that apoA-I activates ABCA1 phosphorylation through the cAMP/protein kinase A-dependent pathway, apoA-I-mediated cAMP production required high level expression of functional ABCA1, and Tangier disease mutants have defective apoA-I-mediated cAMP signaling. These findings suggest that apoA-I may activate cAMP signaling through G protein-coupled ABCA1 transporter.	McGill Univ, Royal Victoria Hosp, Ctr Hlth, Div Cardiol,Cardiovasc Genet Lab, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital	Genest, J (corresponding author), McGill Univ, Royal Victoria Hosp, Ctr Hlth, Div Cardiol,Cardiovasc Genet Lab, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	jacques.genest@muhc.mcgill.ca						Allouche S, 1996, J NEUROCHEM, V67, P2461; ALVAREZ R, 1992, ANAL BIOCHEM, V203, P76, DOI 10.1016/0003-2697(92)90045-9; Batal R, 1998, ARTERIOSCL THROM VAS, V18, P655, DOI 10.1161/01.ATV.18.4.655; Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; Brewer HB, 2003, AM J CARDIOL, V91, p3E, DOI 10.1016/S0002-9149(02)03382-9; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Buechler C, 2002, J BIOL CHEM, V277, P41307, DOI 10.1074/jbc.C200436200; Cockerill GW, 1999, INT REV CYTOL, V188, P257; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Deeg MA, 1997, ARTERIOSCL THROM VAS, V17, P1667, DOI 10.1161/01.ATV.17.9.1667; Denis M, 2004, J BIOL CHEM, V279, P7384, DOI 10.1074/jbc.M306963200; Fidge NH, 1999, J LIPID RES, V40, P187; FIELDING CJ, 1995, J LIPID RES, V36, P211; Goodfellow HR, 1996, J BIOL CHEM, V271, P13668, DOI 10.1074/jbc.271.23.13668; Haidar B, 2002, CIRCULATION, V106, P219; Haidar B, 2002, J LIPID RES, V43, P2087, DOI 10.1194/jlr.M200235-JLR200; Haidar B, 2001, J LIPID RES, V42, P249; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Herrlich A, 1996, J BIOL CHEM, V271, P16764, DOI 10.1074/jbc.271.28.16764; Krimbou L, 2003, J LIPID RES, V44, P884, DOI 10.1194/jlr.M200273-JLR200; Krimbou L, 2001, J BIOL CHEM, V276, P33241, DOI 10.1074/jbc.M100326200; Li QQ, 1997, BIOCHEMISTRY-US, V36, P12045, DOI 10.1021/bi970079t; Li XA, 2002, J BIOL CHEM, V277, P11058, DOI 10.1074/jbc.M110985200; Marcil M, 1999, LANCET, V354, P1341, DOI 10.1016/S0140-6736(99)07026-9; Marcil M, 2003, CIRCULATION, V107, P1366, DOI 10.1161/01.CIR.0000056764.53152.F9; Marcil M, 1999, ARTERIOSCL THROM VAS, V19, P159, DOI 10.1161/01.ATV.19.1.159; Martinez LO, 2003, J BIOL CHEM, V278, P37368, DOI 10.1074/jbc.M307161200; MENDEZ AJ, 1991, T ASSOC AM PHYSICIAN, V104, P48; Nofer JR, 2003, J BIOL CHEM, V278, P53055, DOI 10.1074/jbc.M305673200; Nofer JR, 2002, ATHEROSCLEROSIS, V161, P1, DOI 10.1016/S0021-9150(01)00651-7; Nofer JR, 2001, THROMB HAEMOSTASIS, V85, P730; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; See RH, 2002, J BIOL CHEM, V277, P41835, DOI 10.1074/jbc.M204923200; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; TALL AR, 1993, J LIPID RES, V34, P1255; Tsukamoto K, 2001, BIOCHEM BIOPH RES CO, V287, P757, DOI 10.1006/bbrc.2001.5575; Utech M, 2001, BIOCHEM BIOPH RES CO, V280, P229, DOI 10.1006/bbrc.2000.4061; von Eckardstein A, 2001, ARTERIOSCL THROM VAS, V21, P13, DOI 10.1161/01.ATV.21.1.13; Walter M, 1996, J CLIN INVEST, V98, P2315, DOI 10.1172/JCI119043; Wang N, 2003, ARTERIOSCL THROM VAS, V23, P1178, DOI 10.1161/01.ATV.0000075912.83860.26; Witting SR, 2003, J BIOL CHEM, V278, P40121, DOI 10.1074/jbc.M305193200; Wu V, 1997, J BIOL CHEM, V272, P9037; Yamauchi Y, 2003, J BIOL CHEM, V278, P47890, DOI 10.1074/jbc.M306258200	44	77	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9963	9969		10.1074/jbc.M313487200	http://dx.doi.org/10.1074/jbc.M313487200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701824	hybrid			2022-12-25	WOS:000220050400039
J	Laprise, P; Viel, A; Rivard, N				Laprise, P; Viel, A; Rivard, N			Human homolog of disc-large is required for adherens junction assembly and differentiation of human intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR BINDS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASE; ADHESION; ACTIVATION; CADHERINS; DOMAINS; SAP97; HDLG	We and others have shown that phosphatidylinositol 3-kinase (PI3K) is recruited to and activated by E-cadherin engagement. This PI3K activation is essential for adherens junction integrity and intestinal epithelial cell differentiation. Here we provide evidence that hDlg, the homolog of disc-large tumor suppressor, is another key regulator of adherens junction integrity and differentiation in mammalian epithelial cells. We report the following. 1) hDlg co-localizes with E-cadherin, but not with ZO-1, at the sites of cell-cell contact in intestinal epithelial cells. 2) Reduction of hDlg expression levels by RNA(i) in intestinal cells not only severely alters adherens junction integrity but also prevents the recruitment of p85/PI3K to E-cadherin-mediated cell-cell contact and inhibits sucrase-isomaltase gene expression. 3) PI3K and hDlg are associated with E-cadherin in a common macromolecular complex in living differentiating intestinal cells. 4) This interaction requires the association of hDlg with E-cadherin and with Src homology domain 2 domains of the p85/PI3K subunit. 5) Phosphorylation of hDlg on serine and threonine residues prevents its interaction with the p85 Src homology domain 2 in subconfluent cells, whereas phosphorylation of hDlg on tyrosine residues is essential. We conclude that hDlg may be a determinant in E-cadherin-mediated adhesion and signaling in mammalian epithelial cells.	Univ Sherbrooke, Fac Med, Dept Anat & Biol Cellulaire, Canadian Inst Hlth Res Grp Funct Dev & Physiopath, Sherbrooke, PQ J1H 5N4, Canada; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	University of Sherbrooke; Harvard University	Rivard, N (corresponding author), Univ Sherbrooke, Fac Med, Dept Anat & Biol Cellulaire, Canadian Inst Hlth Res Grp Funct Dev & Physiopath, Sherbrooke, PQ J1H 5N4, Canada.	Nathalie.Rivard@USherbrooke.ca						Calzado MA, 2000, CLIN EXP IMMUNOL, V120, P317, DOI 10.1046/j.1365-2249.2000.01203.x; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; Caruana G, 2002, INT J DEV BIOL, V46, P511; Donze O, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e46; Firestein BL, 2001, MOL BIOL CELL, V12, P3465, DOI 10.1091/mbc.12.11.3465; Hanada T, 1997, J BIOL CHEM, V272, P26899, DOI 10.1074/jbc.272.43.26899; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; Houde M, 2001, J BIOL CHEM, V276, P21885, DOI 10.1074/jbc.M100236200; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; Koh YH, 1999, CELL, V98, P353, DOI 10.1016/S0092-8674(00)81964-9; Laprise P, 2002, J BIOL CHEM, V277, P8226, DOI 10.1074/jbc.M110235200; Lue RA, 1996, J CELL BIOL, V135, P1125, DOI 10.1083/jcb.135.4.1125; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; McLaughlin M, 2002, J BIOL CHEM, V277, P6406, DOI 10.1074/jbc.M108724200; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; Perreault N, 1996, EXP CELL RES, V224, P354, DOI 10.1006/excr.1996.0145; Perreault N, 1998, EXP CELL RES, V245, P34, DOI 10.1006/excr.1998.4221; Reuver SM, 1998, J CELL SCI, V111, P1071; Somasiri A, 2000, DIFFERENTIATION, V66, P116, DOI 10.1046/j.1432-0436.2000.660206.x; Tepass U, 2002, BIOESSAYS, V24, P690, DOI 10.1002/bies.10129; Vleminckx K, 1999, BIOESSAYS, V21, P211, DOI 10.1002/(SICI)1521-1878(199903)21:3<211::AID-BIES5>3.3.CO;2-G; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	25	101	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10157	10166		10.1074/jbc.M309843200	http://dx.doi.org/10.1074/jbc.M309843200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699157	hybrid			2022-12-25	WOS:000220050400062
J	Lin, Y; Choksi, S; Shen, HM; Yang, QF; Hur, GM; Kim, YS; Tran, JH; Nedospasov, SA; Liu, ZG				Lin, Y; Choksi, S; Shen, HM; Yang, QF; Hur, GM; Kim, YS; Tran, JH; Nedospasov, SA; Liu, ZG			Tumor necrosis factor-induced nonapoptotic cell death requires receptor-interacting protein-mediated cellular reactive oxygen species accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DOMAIN KINASE RIP; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; TERMINAL KINASE; JNK ACTIVATION; TNF; PATHWAY; TRAF2; CYTOTOXICITY	The mechanism of tumor necrosis factor (TNF)-induced nonapoptotic cell death is largely unknown, although the mechanism of TNF-induced apoptosis has been studied extensively. In wild-type mouse embryonic fibroblast cells under a caspase-inhibited condition, TNF effectively induced cell death that morphologically resembled necrosis. In this study, we utilized gene knockout mouse embryonic fibroblasts cells and found that tumor necrosis factor receptor ( TNFR) I mediates TNF-induced necrotic cell death, and that RIP, FADD, and TRAF2 are critical components of the signaling cascade of this TNF-induced necrotic cell death. Inhibitors of NF-kappaB facilitated TNF-induced necrotic cell death, suggesting that NF-kappaB suppresses the necrotic cell death pathway. JNK, p38, and ERK activation seem not to be required for this type of cell death because mitogen-activated protein kinase inhibitors did not significantly affect TNF-induced necrotic cell death. In agreement with the previous reports that the reactive oxygen species (ROS) may play an important role in this type of cell death, the ROS scavenger butylated hydroxyanisole efficiently blocked TNF-induced necrotic cell death. Interestingly, during TNF-induced necrotic cell death, the cellular ROS level was significantly elevated in wild type, but not in RIP-/-, TRAF2(-/-), and FADD(-/-) cells. These results suggest that RIP, TRAF2, and FADD are crucial in mediating ROS accumulation in TNF-induced necrotic cell death.	NCI, Cell & Canc Biol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; NCI, Basic Res Program, Sci Applicat Int Corp, LMI,CCR,NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Lin, Y (corresponding author), NCI, Cell & Canc Biol Branch, Ctr Canc Res, NIH, Bldg 10,Rm 6N105,9000 Rockville Pike, Bethesda, MD 20892 USA.	linyo@mail.nih.gov	Nedospasov, Sergei/J-5936-2013; Nedospasov, Sergei/C-3043-2018; Nedospasov, Sergei/L-1990-2015; Hur, Gang-min/ABF-9263-2021; SHEN, Han-Ming/B-5942-2011; Nedospasov, Sergei/Q-7319-2016	Hur, Gang-min/0000-0003-4870-6574; SHEN, Han-Ming/0000-0001-7369-5227; 	DIVISION OF BASIC SCIENCES - NCI [Z01BC010601] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [ZIASC010376, Z01SC010376] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Barnhart BC, 2003, SEMIN IMMUNOL, V15, P185, DOI 10.1016/S1044-5323(03)00031-9; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chan FKM, 2003, J BIOL CHEM, V278, P51613, DOI 10.1074/jbc.M305633200; Chandel NS, 2001, J BIOL CHEM, V276, P42728, DOI 10.1074/jbc.M103074200; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Denecker G, 2001, CELL DEATH DIFFER, V8, P829, DOI 10.1038/sj.cdd.4400883; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Devin A, 2003, EMBO REP, V4, P623, DOI 10.1038/sj.embor.embor854; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Garg AK, 2002, MOL IMMUNOL, V39, P509, DOI 10.1016/S0161-5890(02)00207-9; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Goossens V, 1996, J BIOL CHEM, V271, P192, DOI 10.1074/jbc.271.1.192; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Izban KF, 2000, HUM PATHOL, V31, P1482, DOI 10.1053/hupa.2000.20370; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; Lee TH, 2003, MOL CELL BIOL, V23, P8377, DOI 10.1128/MCB.23.22.8377-8385.2003; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li JJ, 1997, CANCER RES, V57, P1991; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Lin Y, 2003, MOL CELL BIOL, V23, P5849, DOI 10.1128/MCB.23.16.5849-5856.2003; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Los M, 2002, MOL BIOL CELL, V13, P978, DOI 10.1091/mbc.01-05-0272; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacEwan DJ, 2002, CELL SIGNAL, V14, P477, DOI 10.1016/S0898-6568(01)00262-5; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	47	333	345	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10822	10828		10.1074/jbc.M313141200	http://dx.doi.org/10.1074/jbc.M313141200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701813	hybrid			2022-12-25	WOS:000220050400138
J	Shang, J; Lehrman, MA				Shang, J; Lehrman, MA			Metformin-stimulated mannose transport in dermal fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CONGENITAL DISORDERS; N-GLYCOSYLATION; LINKED OLIGOSACCHARIDES; GLUCOSE-TRANSPORT; CORRECTS; SUPPLEMENTATION; DEFICIENCY; DEFECT	The biguanide drug metformin stimulates AMP-activated protein kinase, a master regulator of cellular energy metabolism, and has antihyperglycemic activity due to attenuation of gluconeogenesis in hepatocytes and 2-fold stimulation of glucose transport by skeletal muscle. Here we identify a metformin-stimulated D-mannose transport (MSMT) activity in dermal fibroblasts. MSMT increased mannose uptake 1.8-fold and had greater affinity for mannose than basal mannose transport activity. It was attributed to robust stimulation of a transporter expressed weakly in untreated cells. MSMT was not explained by greater glucose transporter activity because metformin unexpectedly decreased transport of 2-deoxy-D-glucose and 3-O-methyl-D-glucose by fibroblasts. Effective inhibitors of MSMT retained specificity for the 3-, 4-, and 6-OH groups of the mannose ring but not the 2-OH group. Thus, MSMT could be strongly inhibited by glucose and 2-deoxy-D-glucose even though the latter was not a good transport substrate. MSMT was significant because in the presence of 2.5 muM mannose, metformin corrected experimentally induced deficiencies in the synthesis of glucose(3)mannose(9)GlcNAc(2)-P-P-dolichol and N-linked glycosylation. MSMT was also identified in congenital disorder of glycosylation types Ia and Ib fibroblasts, and metformin acted synergistically with 100 muM mannose to correct lipid-linked oligosaccharide synthesis and N-glycosylation in the Ia cells. In conclusion, metformin activates a novel fibroblast mannose-selective transport system. This suggests that AMP-activated protein kinase may be a regulator of mannose metabolism and implies a therapy for congenital disorders of glycosylation-Ia.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Lehrman, MA (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	mark.lehrman@utsouthwestern.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM038545, R01GM038545] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM038545, GM38545] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alton G, 1998, GLYCOBIOLOGY, V8, P285, DOI 10.1093/glycob/8.3.285; Babovic-Vuksanovic D, 1999, J PEDIATR-US, V135, P775, DOI 10.1016/S0022-3476(99)70103-4; Davis S., 2001, GOODMAN GILMANS T PH, P1679; Doerrler WT, 1999, P NATL ACAD SCI USA, V96, P13050, DOI 10.1073/pnas.96.23.13050; Dupre T, 2000, GLYCOBIOLOGY, V10, P1277, DOI 10.1093/glycob/10.12.1277; Fryer LGD, 2000, DIABETES, V49, P1978, DOI 10.2337/diabetes.49.12.1978; Gao NG, 2002, GLYCOBIOLOGY, V12, P353, DOI 10.1093/glycob/12.5.353; Harms HK, 2002, ACTA PAEDIATR, V91, P1065, DOI 10.1080/080352502760311566; Jaeken J, 2001, ANNU REV GENOM HUM G, V2, P129, DOI 10.1146/annurev.genom.2.1.129; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Korner C, 1998, GLYCOBIOLOGY, V8, P165, DOI 10.1093/glycob/8.2.165; Korner C, 1998, GLYCOCONJUGATE J, V15, P499, DOI 10.1023/A:1006939104442; KOSOWER NS, 1969, BIOCHEM BIOPH RES CO, V37, P593, DOI 10.1016/0006-291X(69)90850-X; Marquardt T, 2001, BIOL CHEM, V382, P161, DOI 10.1515/BC.2001.024; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Niehues R, 1998, J CLIN INVEST, V101, P1414, DOI 10.1172/JCI2350; Panneerselvam K, 1996, J CLIN INVEST, V97, P1478, DOI 10.1172/JCI118570; Panneerselvam K, 1996, J BIOL CHEM, V271, P9417, DOI 10.1074/jbc.271.16.9417; Panneerselvam K, 1997, J BIOL CHEM, V272, P23123, DOI 10.1074/jbc.272.37.23123; REBRIN K, 1992, J BIOMED ENG, V14, P33, DOI 10.1016/0141-5425(92)90033-H; Rush JS, 2000, GLYCOBIOLOGY, V10, P829, DOI 10.1093/glycob/10.8.829; Shang J, 2002, GLYCOBIOLOGY, V12, P307, DOI 10.1093/glycob/12.5.307; Spiro RG, 2002, GLYCOBIOLOGY, V12, p43R, DOI 10.1093/glycob/12.4.43R; STUMVOLL M, 1995, NEW ENGL J MED, V333, P550, DOI 10.1056/NEJM199508313330903; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Witters LA, 2001, J CLIN INVEST, V108, P1105, DOI 10.1172/JCI200114178; ZENG Y, 1991, ANAL BIOCHEM, V193, P266, DOI 10.1016/0003-2697(91)90020-T; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505	28	20	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9703	9712		10.1074/jbc.M310837200	http://dx.doi.org/10.1074/jbc.M310837200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14681228	hybrid			2022-12-25	WOS:000220050400008
J	Wittamer, V; Gregoire, F; Robberecht, P; Vassart, G; Communi, D; Parmentier, M				Wittamer, V; Gregoire, F; Robberecht, P; Vassart, G; Communi, D; Parmentier, M			The C-terminal nonapeptide of mature chemerin activates the chemerin receptor with low nanomolar potency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; AGONIST; ANAPHYLATOXIN; PEPTIDE; BINDING; IDENTIFICATION; NEUROPEPTIDE; CHEMOTAXIS; RESIDUES; ANALOGS	Chemerin is a novel protein identified as the natural ligand of ChemR23 (chemerinR), a previously orphan G protein-coupled receptor expressed in immature dendritic cells and macrophages. Chemerin is synthesized as a secreted precursor, prochemerin, which is poorly active, but converted into a full agonist of chemerinR by proteolytic removal of the last six amino acids. In the present work, we have synthesized a number of peptides derived from the C-terminal domain of human prochemerin and have investigated their functional properties as agonists or antagonists of human chemerinR. We found that the nonapeptide (149)YFPGQFAFS(157) (chemerin-9), corresponding to the C terminus of processed chemerin, retained most of the activity of the full-size protein, with regard to agonism toward the chemerinR. Extension of this peptide at its N terminus did not increase the activity, whereas further truncations rapidly resulted in inactive compounds. The C-terminal end of the peptide appeared crucial for its activity, as addition of a single amino acid or removal of two amino acids modified the potency by four orders of magnitude. Alanine- scanning mutagenesis identified residues Tyr(149), Phe(150), Gly(152), Phe(154), and Phe(156) as the key positions for chemerinR activation. A modified peptide (YHSFFFPGQFAFS) was synthesized and iodinated, and a radioligand binding assay was established. It was found that the ability of the various peptides to activate the chemerin receptor was strictly correlated with their affinity in the binding assay. These results confirm that a precise C-terminal processing is required for the generation of a chemerinR agonist. The possibility to restrict a medium sized protein to a nonapeptide, while keeping a low nanomolar affinity for its receptor is unusual among G protein-coupled receptors ligands. The identification of these short bioactive peptides will considerably accelerate the pharmacological analysis of chemerin-chemerinR interactions.	Free Univ Brussels, Inst Rech Interdisciplinaire Biol Humaine & Mol, B-1070 Brussels, Belgium; Free Univ Brussels, Lab Chim Biol & Nutr, B-1070 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Parmentier, M (corresponding author), Free Univ Brussels, Inst Rech Interdisciplinaire Biol Humaine & Mol, Campus Erasme,808 Route Lennik, B-1070 Brussels, Belgium.	mparment@ulb.ac.be		Wittamer, Valerie/0000-0003-0003-2646; Parmentier, Marc/0000-0001-8081-4685; Gregoire, Francoise/0000-0003-0452-8868				CAPORALE LH, 1980, J BIOL CHEM, V255, P758; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; Detheux M, 2000, J EXP MED, V192, P1501, DOI 10.1084/jem.192.10.1501; Drews J, 2000, SCIENCE, V287, P1960, DOI 10.1126/science.287.5460.1960; EMBER JA, 1992, J IMMUNOL, V148, P3165; Heveker N, 1998, CURR BIOL, V8, P369, DOI 10.1016/S0960-9822(98)70155-1; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; Katugampola S, 2003, TRENDS PHARMACOL SCI, V24, P30, DOI 10.1016/S0165-6147(02)00007-X; KAWAI M, 1991, J MED CHEM, V34, P2068, DOI 10.1021/jm00111a022; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Kotani M, 2001, J BIOL CHEM, V276, P34631, DOI 10.1074/jbc.M104847200; Laurence JS, 2001, BIOCHEMISTRY-US, V40, P4990, DOI 10.1021/bi002593w; Loetscher P, 1998, J BIOL CHEM, V273, P22279, DOI 10.1074/jbc.273.35.22279; Luck MD, 1999, MOL ENDOCRINOL, V13, P670, DOI 10.1210/me.13.5.670; Marchese A, 1999, TRENDS PHARMACOL SCI, V20, P370, DOI 10.1016/S0165-6147(99)01366-8; Martin L, 2001, BIOCHEMISTRY-US, V40, P6303, DOI 10.1021/bi002670n; Methner A, 1997, BIOCHEM BIOPH RES CO, V233, P336, DOI 10.1006/bbrc.1997.6455; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; MOSER B, 1993, J BIOL CHEM, V268, P7125; Nufer O, 1999, BIOCHEMISTRY-US, V38, P636, DOI 10.1021/bi981294s; Ohtaki T, 2001, NATURE, V411, P613, DOI 10.1038/35079135; RAWLINGS ND, 1990, J MOL EVOL, V30, P60, DOI 10.1007/BF02102453; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; SALVESEN G, 1986, BIOCHEM J, V234, P429, DOI 10.1042/bj2340429; Samson M, 1998, EUR J IMMUNOL, V28, P1689, DOI 10.1002/(SICI)1521-4141(199805)28:05<1689::AID-IMMU1689>3.0.CO;2-I; Stables J, 1997, ANAL BIOCHEM, V252, P115, DOI 10.1006/abio.1997.2308; Struyf S, 1998, EUR J IMMUNOL, V28, P1262, DOI 10.1002/(SICI)1521-4141(199804)28:04<1262::AID-IMMU1262>3.0.CO;2-G; WILLIAMSON MP, 1990, BIOCHEMISTRY-US, V29, P2895, DOI 10.1021/bi00464a002; Wittamer V, 2003, J EXP MED, V198, P977, DOI 10.1084/jem.20030382; ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O; ZHANG YJ, 1994, J BIOL CHEM, V269, P15918	33	147	164	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9956	9962		10.1074/jbc.M313016200	http://dx.doi.org/10.1074/jbc.M313016200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701797	hybrid			2022-12-25	WOS:000220050400038
J	Jayachandran, R; Shaila, MS; Karande, AA				Jayachandran, R; Shaila, MS; Karande, AA			Analysis of the role of oligosaccharides in the apoptotic activity of glycodelin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL PROTEIN-14; HUMAN ERYTHROPOIETIN; N-GLYCOSYLATION; SIALIC-ACID; CELLS; EXPRESSION; GLYCOPROTEIN; REPRODUCTION; GAMMA; SITES	Glycodelin A, also known as placental protein-14, is a multifunctional glycosylated protein secreted by the uterine endometrium during the early phases of pregnancy. It is a known suppressor of T cell proliferation, inducer of T cell apoptosis, and inhibitor of sperm zona binding. Unlike in contraceptive activity, where the glycans on the molecule have been shown to play a crucial role, mutagenesis of the asparagines at sites of N-linked glycosylation (Asn(28) and Asn(63)) to glutamine shows that the apoptogenic activity of glycodelin A is executed by the protein backbone. Glycosylation at Asn(28) appears to play a role in the extracellular secretion of the molecule, as mutation of Asn(28) resulted in a significant decrease in the amount of secreted protein, and loss of both glycosylation sites reduced the secretion drastically. Our results also suggest that the loss of glycosylation does not affect the dimerization status of the molecule.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India; Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore	Karande, AA (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	anjali@biochem.iisc.ernet.in	Karande, Anjali/C-4880-2009					BOLTON AE, 1987, LANCET, V1, P593; BOYUM A, 1964, NATURE, V204, P793, DOI 10.1038/204793a0; CANTELL K, 1992, J INTERFERON RES, V12, P177, DOI 10.1089/jir.1992.12.177; Chotigeat W, 2000, J BIOTECHNOL, V81, P55, DOI 10.1016/S0168-1656(00)00268-6; DELL A, 1995, J BIOL CHEM, V270, P24116, DOI 10.1074/jbc.270.41.24116; GOLDWASSER E, 1974, J BIOL CHEM, V249, P4202; Grossmann M, 1997, ENDOCR REV, V18, P476, DOI 10.1210/er.18.4.476; Hooker AD, 1999, BIOTECHNOL BIOENG, V63, P559, DOI 10.1002/(SICI)1097-0290(19990605)63:5<559::AID-BIT6>3.0.CO;2-L; IMAI N, 1990, EUR J BIOCHEM, V194, P457, DOI 10.1111/j.1432-1033.1990.tb15639.x; JENKINS N, 1994, ENZYME MICROB TECH, V16, P354, DOI 10.1016/0141-0229(94)90149-X; JULKUNEN M, 1986, ENDOCRINOLOGY, V118, P1782, DOI 10.1210/endo-118-5-1782; Julkunen M, 1984, Arch Androl, V12 Suppl, P59; Karri T, 2000, HISTOCHEM J, V32, P711, DOI 10.1023/A:1004144909714; Koistinen H, 1996, MOL HUM REPROD, V2, P759, DOI 10.1093/molehr/2.10.759; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Morais VA, 2001, BIOCHEM J, V353, P719, DOI 10.1042/0264-6021:3530719; Morris HR, 1996, J BIOL CHEM, V271, P32159, DOI 10.1074/jbc.271.50.32159; Mukhopadhyay D, 2004, J BIOL CHEM, V279, P8577, DOI 10.1074/jbc.M306673200; Mukhopadhyay D, 2001, J BIOL CHEM, V276, P28268, DOI 10.1074/jbc.M010487200; RECNY MA, 1992, J BIOL CHEM, V267, P22428; RINDERKNECHT E, 1984, J BIOL CHEM, V259, P6790; Seppala M, 1997, CLIN ENDOCRINOL, V46, P381, DOI 10.1046/j.1365-2265.1997.1510943.x; SEPPO A, 1998, CELLS LAB MANUAL, V1; Wester L, 2000, GLYCOBIOLOGY, V10, P891, DOI 10.1093/glycob/10.9.891; WITTWER AJ, 1990, BIOCHEMISTRY-US, V29, P4175, DOI 10.1021/bi00469a021; YAMAGUCHI K, 1991, J BIOL CHEM, V266, P20434	26	21	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8585	8591		10.1074/jbc.M310480200	http://dx.doi.org/10.1074/jbc.M310480200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14679202	hybrid			2022-12-25	WOS:000189265900009
J	Jenkins, J; Shevchik, VE; Hugouvieux-Cotte-Pattat, N; Pickersgill, RW				Jenkins, J; Shevchik, VE; Hugouvieux-Cotte-Pattat, N; Pickersgill, RW			The crystal structure of pectate lyase Pel9A from Erwinia chrysanthemi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; PROTON ABSTRACTION; CARBON ACIDS; ENZYMES; ARCHITECTURE; PECTIN; FAMILY; MECHANISM; MOLSCRIPT; COMPLEX	The "family 9 polysaccharide lyase" pectate lyase L (Pel9A) from Erwinia chrysanthemi comprises a 10-coil parallel beta-helix domain with distinct structural features including an asparagine ladder and aromatic stack at novel positions within the superhelical structure. Pel9A has a single high affinity calcium-binding site strikingly similar to the "primary" calcium-binding site described previously for the family Pel1A pectate lyases, and there is strong evidence for a common second calcium ion that binds between enzyme and substrate in the "Michaelis" complex. Although the primary calcium ion binds substrate in subsite -1, it is the second calcium ion, whose binding site is formed by the coming together of enzyme and substrate, that facilitates abstraction of the C5 proton from the sacharride in subsite +1. The role of the second calcium is to withdraw electrons from the C6 carboxylate of the substrate, thereby acidifying the C5 proton facilitating its abstraction and resulting in an E1cb-like anti-beta-elimination mechanism. The active site geometries and mechanism of Pel1A and Pel9A are closely similar, but the catalytic base is a lysine in the Pel9A enzymes as opposed to an arginine in the Pel1A enzymes.	Univ London, Queen Mary, Sch Biol Sci, London E1 4NS, England; Univ Lyon 1, CNRS, UMR 5122, Unite Microbiol & Genet, F-69622 Villeurbanne, France; Inst Food Res, Norwich NR4 7UA, Norfolk, England	University of London; Queen Mary University London; Centre National de la Recherche Scientifique (CNRS); Institut National des Sciences Appliquees de Lyon - INSA Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia	Pickersgill, RW (corresponding author), Univ London, Queen Mary, Sch Biol Sci, Mile End Rd, London E1 4NS, England.	r.w.pickersgill@qmul.ac.uk		COTTE-PATTAT, Nicole/0000-0002-4322-160X; Shevchik, Vladimir/0000-0002-8031-8638	Biotechnology and Biological Sciences Research Council [BBS/B/07896] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Akita M, 2001, ACTA CRYSTALLOGR D, V57, P1786, DOI 10.1107/S0907444901014482; Anderson VE, 1998, COMPREHENSIVE BIOL C, V2, P115; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Charnock SJ, 2002, P NATL ACAD SCI USA, V99, P12067, DOI 10.1073/pnas.182431199; Coutinho PM, 1999, ROY SOC CH, P3; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GERLT JA, 1993, BIOCHEMISTRY-US, V32, P11943, DOI 10.1021/bi00096a001; GERLT JA, 1992, J AM CHEM SOC, V114, P5928, DOI 10.1021/ja00041a004; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; Herron SR, 2000, P NATL ACAD SCI USA, V97, P8762, DOI 10.1073/pnas.97.16.8762; Herron SR, 2003, J BIOL CHEM, V278, P12271, DOI 10.1074/jbc.M209306200; Huang WJ, 1999, J MOL BIOL, V294, P1257, DOI 10.1006/jmbi.1999.3292; JENCKS WP, 1980, ACCOUNTS CHEM RES, V13, P161, DOI 10.1021/ar50150a001; Jenkins J, 2001, PROG BIOPHYS MOL BIO, V77, P111, DOI 10.1016/S0079-6107(01)00013-X; Jenkins J, 2001, J MOL BIOL, V305, P951, DOI 10.1006/jmbi.2000.4324; JENKINS J, 1995, FEBS LETT, V362, P281, DOI 10.1016/0014-5793(95)00252-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lietzke SE, 1996, PLANT PHYSIOL, V111, P73, DOI 10.1104/pp.111.1.73; LOJKOWSKA E, 1995, MOL MICROBIOL, V16, P1183, DOI 10.1111/j.1365-2958.1995.tb02341.x; Mayans O, 1997, STRUCTURE, V5, P677, DOI 10.1016/S0969-2126(97)00222-0; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Murzin AG, 2001, PROTEINS, P76; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; OFERRALL RA, 1970, J CHEM SOC B, P274, DOI 10.1039/j29700000274; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OTWINOWSKI Z, 1991, DARESBURY STUDY WEEK, P80; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Petersen TN, 1997, STRUCTURE, V5, P533, DOI 10.1016/S0969-2126(97)00209-8; PICKERSGILL R, 1994, NAT STRUCT BIOL, V1, P717, DOI 10.1038/nsb1094-717; Pickersgill R, 1998, J BIOL CHEM, V273, P24660, DOI 10.1074/jbc.273.38.24660; Rigden DJ, 2002, FEBS LETT, V530, P225, DOI 10.1016/S0014-5793(02)03490-7; Roy C, 1999, J BACTERIOL, V181, P3705, DOI 10.1128/JB.181.12.3705-3709.1999; Scavetta RD, 1999, PLANT CELL, V11, P1081, DOI 10.1105/tpc.11.6.1081; Shevchik V, 1998, ACTA CRYSTALLOGR D, V54, P419, DOI 10.1107/S0907444997012043; Shevchik VE, 1999, J BACTERIOL, V181, P3912, DOI 10.1128/JB.181.13.3912-3919.1999; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994	40	64	65	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9139	9145		10.1074/jbc.M311390200	http://dx.doi.org/10.1074/jbc.M311390200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14670977	hybrid			2022-12-25	WOS:000189265900075
J	Magnusson, U; Salopek-Sondi, B; Luck, LA; Mowbray, SL				Magnusson, U; Salopek-Sondi, B; Luck, LA; Mowbray, SL			X-ray structures of the leucine-binding protein illustrate conformational changes and the basis of ligand specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-DENSITY MAPS; ESCHERICHIA-COLI; TRANSPORT-SYSTEMS; D-ALLOSE; PROGRAM; RECEPTOR; PRODUCE; MODELS; MOTION	The periplasmic leucine-binding protein is the primary receptor for the leucine transport system in Escherichia coli. We report here the structure of an open ligand-free form solved by molecular replacement and refined at 1.5-Angstrom resolution. In addition, two closed ligand-bound structures of the same protein are presented, a phenylalanine-bound form at 1.8 Angstrom and a leucine-bound structure at a nominal resolution of 2.4 Angstrom. These structures show the basis of this protein's ligand specificity, as well as illustrating the conformational changes that are associated with ligand binding. Comparison with earlier structures provides further information about solution conformations, as well as the different specificity of the closely related leucine/isoleucine/valine-binding protein.	Swedish Univ Agr Sci, Ctr Biomed, Dept Mol Biosci, Div Struct Biol, S-75124 Uppsala, Sweden; Uppsala Univ, Ctr Biomed, Dept Cell & Mol Biol, S-75124 Uppsala, Sweden; Clarkson Univ, Dept Chem, Potsdam, NY 13699 USA	Swedish University of Agricultural Sciences; Uppsala University; Clarkson University	Mowbray, SL (corresponding author), Swedish Univ Agr Sci, Ctr Biomed, Dept Mol Biosci, Div Struct Biol, Box 590, S-75124 Uppsala, Sweden.	mowbray@xray.bmc.uu.se	Sondi, Branka Salopek/AAG-1614-2019; Mowbray, Sherry L/D-2141-2013	Sondi, Branka Salopek/0000-0001-8202-8960; 	NATIONAL CANCER INSTITUTE [R03CA089705] Funding Source: NIH RePORTER; NCI NIH HHS [R03-CA 89705] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS MD, 1991, J BIOL CHEM, V266, P6209; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Bjorkman AJ, 1998, J MOL BIOL, V279, P651, DOI 10.1006/jmbi.1998.1785; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BOHL E, 1995, J THEOR BIOL, V172, P83, DOI 10.1006/jtbi.1995.0006; BOOS W, 1996, ESCHERICHIA COLI SAL, P1175; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chaudhuri BN, 1999, J MOL BIOL, V286, P1519, DOI 10.1006/jmbi.1999.2571; *COLL COMP PROJ, 1984, ACTA CRYSTALLOGR D, V50, P760; GERSTEIN M, 1993, J MOL BIOL, V234, P357, DOI 10.1006/jmbi.1993.1592; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; Harris M, 2001, ACTA CRYSTALLOGR D, V57, P1201, DOI 10.1107/S0907444901007697; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P826, DOI 10.1107/S0907444995014983; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDICK R, 1985, J BIOL CHEM, V260, P8257; Luck LA, 2000, PROTEIN SCI, V9, P2573, DOI 10.1110/ps.9.12.2573; Magnusson U, 2002, J BIOL CHEM, V277, P14077, DOI 10.1074/jbc.M200514200; McPherson A, 1982, PREPARATION ANAL PRO; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; OLAH GA, 1993, J BIOL CHEM, V268, P16241; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAHMANIAN M, 1973, J BACTERIOL, V116, P1258, DOI 10.1128/JB.116.3.1258-1266.1973; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SACK JS, 1989, J MOL BIOL, V206, P193, DOI 10.1016/0022-2836(89)90532-9; Salopek-Sondi B, 2002, PROTEIN ENG, V15, P855, DOI 10.1093/protein/15.11.855; Salopek-Sondi B, 2002, J BIOMOL STRUCT DYN, V20, P381, DOI 10.1080/07391102.2002.10506856; SHILTON BH, 1995, PROTEIN SCI, V4, P1346, DOI 10.1002/pro.5560040710; Shilton BH, 1996, J MOL BIOL, V264, P364, DOI 10.1006/jmbi.1996.0646; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; Tatusov RL, 1996, CURR BIOL, V6, P279, DOI 10.1016/S0960-9822(02)00478-5; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; ZOU JY, 1993, J MOL BIOL, V233, P739, DOI 10.1006/jmbi.1993.1549	40	60	60	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8747	8752		10.1074/jbc.M311890200	http://dx.doi.org/10.1074/jbc.M311890200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14672931	hybrid			2022-12-25	WOS:000189265900028
J	Pell, G; Taylor, EJ; Gloster, TM; Turkenburg, JP; Fontes, CMGA; Ferreira, LMA; Nagy, T; Clark, SJ; Davies, GJ; Gilbert, HJ				Pell, G; Taylor, EJ; Gloster, TM; Turkenburg, JP; Fontes, CMGA; Ferreira, LMA; Nagy, T; Clark, SJ; Davies, GJ; Gilbert, HJ			The mechanisms by which family 10 glycoside hydrolases bind decorated substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-GLUCURONIDASE; PSEUDOMONAS-FLUORESCENS; CELLULOSA XYLANASE; ACTIVE-SITE; XYLOOLIGOSACCHARIDES; INTERMEDIATE; SPECIFICITY; MOLSCRIPT; FAMILIES; SEQUENCE	Endo-beta-1,4-xylanases (xylanases), which cleave beta-1,4 glycosidic bonds in the xylan backbone, are important components of the repertoire of enzymes that catalyze plant cell wall degradation. The mechanism by which these enzymes are able to hydrolyze a range of decorated xylans remains unclear. Here we reveal the three-dimensional structure, determined by x-ray crystallography, and the catalytic properties of the Cellvibrio mixtus enzyme Xyn10B (CmXyn10B), the most active GH10 xylanase described to date. The crystal structure of the enzyme in complex with xylopentaose reveals that at the +1 subsite the xylose moiety is sandwiched between hydrophobic residues, which is likely to mediate tighter binding than in other GH10 xylanases. The crystal structure of the xylanase in complex with a range of decorated xylooligosaccharides reveals how this enzyme is able to hydrolyze substituted xylan. Solvent exposure of the O-2 groups of xylose at the +4, +3, +1, and -3 subsites may allow accommodation of the alpha-1,2-linked 4-O-methyl-D-glucuronic acid side chain in glucuronoxylan at these locations. Furthermore, the uronic acid makes hydrogen bonds and hydrophobic interactions with the enzyme at the +1 subsite, indicating that the sugar decorations in glucuronoxylan are targeted to this proximal aglycone binding site. Accommodation of 3'-linked L-arabinofuranoside decorations is observed in the -2 subsite and could, most likely, be tolerated when bound to xylosides in -3 and +4. A notable feature of the binding mode of decorated substrates is the way in which the subsite specificities are tailored both to prevent the formation of "dead-end" reaction products and to facilitate synergy with the xylan degradation-accessory enzymes such as alpha-glucuronidase. The data described in this report and in the accompanying paper ( Fujimoto, Z., Kaneko, S., Kuno, A., Kobayashi, H., Kusakabe, I., and Mizuno, H. ( 2004) J. Biol. Chem. 279, 9606 - 9614) indicate that the complementarity in the binding of decorated substrates between the glycone and aglycone regions appears to be a conserved feature of GH10 xylanases.	Newcastle Univ, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England; Univ Tecn Lisboa, CIISA Fac Med Vet, P-1300477 Lisbon, Portugal	Newcastle University - UK; University of York - UK; Universidade de Lisboa	Gilbert, HJ (corresponding author), Newcastle Univ, Sch Cell & Mol Biosci, Agr Bldg, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	H.J.Gilbert@Newcastle.ac.uk	Davies, Gideon J/A-9042-2011	Davies, Gideon J/0000-0002-7343-776X; Fontes, Carlos/0000-0002-1219-9753; Ferreira, Luis/0000-0002-3543-9166; Taylor, Edward/0000-0003-4024-0976; Turkenburg, Johan/0000-0001-6992-6838				Andrews SR, 2000, J BIOL CHEM, V275, P23027, DOI 10.1074/jbc.M000128200; ATKINS EDT, 1992, PROGR BIOTECHNOL, V7, P39; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beylot MH, 2001, BIOCHEM J, V358, P607, DOI 10.1042/0264-6021:3580607; Biely P, 1997, J BIOTECHNOL, V57, P151, DOI 10.1016/S0168-1656(97)00096-5; BIELY P, 1981, EUR J BIOCHEM, V119, P559, DOI 10.1111/j.1432-1033.1981.tb05644.x; BRETT CT, 1996, TOPICS PLANT FUNCTIO, V1; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Charnock SJ, 1998, J BIOL CHEM, V273, P32187, DOI 10.1074/jbc.273.48.32187; Charnock SJ, 1997, J BIOL CHEM, V272, P2942, DOI 10.1074/jbc.272.5.2942; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; Ducros V, 2000, J BIOL CHEM, V275, P23020, DOI 10.1074/jbc.275.30.23020; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fontes CMGA, 2000, MICROBIOL-SGM, V146, P1959, DOI 10.1099/00221287-146-8-1959; Fujimoto Z, 2004, J BIOL CHEM, V279, P9606, DOI 10.1074/jbc.M312293200; HARRIS GW, 1994, STRUCTURE, V2, P1107, DOI 10.1016/S0969-2126(94)00112-X; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lo Leggio L, 1999, PROTEINS, V36, P295; Lo Leggio L, 2000, PROTEINS, V41, P362, DOI 10.1002/1097-0134(20001115)41:3<362::AID-PROT80>3.0.CO;2-N; MATSUI I, 1991, J BIOCHEM-TOKYO, V109, P566, DOI 10.1093/oxfordjournals.jbchem.a123420; Nagy T, 2003, J BIOL CHEM, V278, P20286, DOI 10.1074/jbc.M302205200; Nagy T, 2002, J BACTERIOL, V184, P4925, DOI 10.1128/JB.184.17.4925-4929.2002; Notenboom V, 1998, NAT STRUCT BIOL, V5, P812, DOI 10.1038/1852; Nurizzo D, 2002, STRUCTURE, V10, P547, DOI 10.1016/S0969-2126(02)00742-6; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Schmidt A, 1999, BIOCHEMISTRY-US, V38, P2403, DOI 10.1021/bi982108l; Sidhu G, 1999, BIOCHEMISTRY-US, V38, P5346, DOI 10.1021/bi982946f; SOMOGYI M, 1952, J BIOL CHEM, V195, P19; SUGANUMA T, 1978, J BIOCHEM-TOKYO, V84, P293, DOI 10.1093/oxfordjournals.jbchem.a132130; White A, 1996, NAT STRUCT BIOL, V3, P149, DOI 10.1038/nsb0296-149; Xie HF, 2001, BIOCHEMISTRY-US, V40, P5700, DOI 10.1021/bi010034z	35	143	146	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9597	9605		10.1074/jbc.M312278200	http://dx.doi.org/10.1074/jbc.M312278200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14668328	hybrid			2022-12-25	WOS:000189265900127
J	Cheng, X; Kinosaki, M; Takami, M; Choi, Y; Zhang, HT; Murali, R				Cheng, X; Kinosaki, M; Takami, M; Choi, Y; Zhang, HT; Murali, R			Disabling of receptor activator of nuclear factor-kappa B (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; OSTEOCLAST DIFFERENTIATION FACTOR; N-TERMINAL KINASE; TNF-RECEPTOR; CRYSTAL-STRUCTURE; T-CELLS; FAMILY-MEMBER; LIGAND RANKL; POSTMENOPAUSAL WOMEN; MULTIPLE-MYELOMA	The tumor necrosis factor family ligand, tumor necrosis factor-related activation-induced cytokine ( TRANCE), and its receptors, receptor activator of nuclear factor-kappaB ( RANK) and osteoprotegerin (OPG), are known to be regulators of development and activation of osteoclasts in bone remodeling. Sustained osteoclast activation that occurs through TRANCE-RANK causes osteopenic disorders such as osteoporosis and contributes to osteolytic metastases. Here, we report a rationally designed small molecule mimic of osteoprotegerin to inhibit osteoclast formation in vitro and limit bone loss in an animal model of osteoporosis. One of the mimetics, OP3-4, significantly inhibited osteoclast formation in vitro (IC50 = 10 muM) and effectively inhibited total bone loss in ovariectomized mice at a dosage of 2 mg/kg/day. Unlike soluble OPG receptors, which preclude TRANCE binding to RANK, OP3-4 shows the ability to modulate RANK-TRANCE signaling pathways and alters the biological functions of the RANK-TRANCE receptor complex by facilitating a defective receptor complex. These features suggest that OPG-derived small molecules can be used as a probe to understand complex biological functions of RANK-TRANCE-OPG receptors and also can be used as a platform to develop more useful therapeutic agents for inflammation and bone disease.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Abramson Family Canc Res Inst Canc Res, Philadelphia, PA 19104 USA	University of Pennsylvania	Murali, R (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Abramson Family Canc Res Inst Canc Res, 252 John Morgan Bldg, Philadelphia, PA 19104 USA.	murali@xray.med.upenn.edu		Zhang, Hongtao/0000-0001-9173-0049; Murali, Ramachandran/0000-0002-8384-2793; Takami, Masamichi/0000-0002-4506-3975				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Andersson N, 2001, J ENDOCRINOL, V170, P529, DOI 10.1677/joe.0.1700529; Arron JR, 2001, J BIOL CHEM, V276, P30011, DOI 10.1074/jbc.M100414200; Atkins GJ, 2001, BONE, V28, P370, DOI 10.1016/S8756-3282(01)00404-5; Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Bekker PJ, 2001, J BONE MINER RES, V16, P348, DOI 10.1359/jbmr.2001.16.2.348; Bell Norman H., 2001, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V1, P93, DOI 10.2174/1568008013341622; Berezov A, 2001, J MED CHEM, V44, P2565, DOI 10.1021/jm000527m; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Bodmer JL, 2002, TRENDS BIOCHEM SCI, V27, P19, DOI 10.1016/S0968-0004(01)01995-8; Body JJ, 2003, CANCER-AM CANCER SOC, V97, P887, DOI 10.1002/cncr.11138; BRUCCOLERI RE, 1988, NATURE, V335, P564, DOI 10.1038/335564a0; Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527; Cha SS, 2000, J BIOL CHEM, V275, P31171, DOI 10.1074/jbc.M004414200; Choi Y, 2001, EUR J IMMUNOL, V31, P2179, DOI 10.1002/1521-4141(200107)31:7<2179::AID-IMMU2179>3.0.CO;2-X; Croucher PI, 2001, BLOOD, V98, P3534, DOI 10.1182/blood.V98.13.3534; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; Eghbali-Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Green EA, 2002, IMMUNITY, V16, P183, DOI 10.1016/S1074-7613(02)00279-0; Hofbauer LC, 2001, J MOL MED, V79, P243, DOI 10.1007/s001090100226; Holen I, 2002, CANCER RES, V62, P1619; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Idriss HT, 2000, MICROSC RES TECHNIQ, V50, P184, DOI 10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H; Ito S, 2002, J BIOL CHEM, V277, P6631, DOI 10.1074/jbc.M106525200; Jimi E, 1999, J IMMUNOL, V163, P434; Jones DH, 2002, ANN RHEUM DIS, V61, P32, DOI 10.1136/ard.61.suppl_2.ii32; Josien R, 2000, J EXP MED, V191, P495, DOI 10.1084/jem.191.3.495; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050; Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Lam J, 2001, J CLIN INVEST, V108, P971, DOI 10.1172/JCI13890; Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756-3282(01)00657-3; Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200; Lee YJ, 2001, J IMMUNOL, V167, P82, DOI 10.4049/jimmunol.167.1.82; Lee ZH, 2000, MOL PHARMACOL, V58, P1536, DOI 10.1124/mol.58.6.1536; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Martin TJ, 2001, TRENDS ENDOCRIN MET, V12, P2, DOI 10.1016/S1043-2760(00)00351-9; Michigami T, 2001, CANCER RES, V61, P1637; Min H, 2000, J EXP MED, V192, P463, DOI 10.1084/jem.192.4.463; Mori H, 2002, HISTOCHEM CELL BIOL, V117, P283, DOI 10.1007/s00418-001-0376-9; Muhlenbeck F, 2000, J BIOL CHEM, V275, P32208, DOI 10.1074/jbc.M000482200; Murali R, 1998, IMMUNOL RES, V17, P163, DOI 10.1007/BF02786441; MURALI R, 2000, CYTOKINE INHIBITORS, P133; Naismith JH, 1998, TRENDS BIOCHEM SCI, V23, P74, DOI 10.1016/S0968-0004(97)01164-X; Naismith JH, 1996, J INFLAMM, V47, P1; NAISMITH JH, 1995, J BIOL CHEM, V270, P13303, DOI 10.1074/jbc.270.22.13303; Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788; Natoli G, 1998, BIOCHEM PHARMACOL, V56, P915, DOI 10.1016/S0006-2952(98)00154-3; Park BW, 2000, NAT BIOTECHNOL, V18, P194, DOI 10.1038/72651; Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002-9440(10)63016-7; RAMACHANDRAN GN, 1968, BIOPOLYMERS, V6, P1255, DOI 10.1002/bip.1968.360060903; SALI A, 1990, J MOL BIOL, V212, P403, DOI 10.1016/0022-2836(90)90134-8; Sato M, 1997, ENDOCRINOLOGY, V138, P4330, DOI 10.1210/en.138.10.4330; Schoppet M, 2002, ARTERIOSCL THROM VAS, V22, P549, DOI 10.1161/01.ATV.0000012303.37971.DA; Shiotani A, 2002, ANAT REC, V268, P137, DOI 10.1002/ar.10121; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Srivastava S, 2001, J BIOL CHEM, V276, P8836, DOI 10.1074/jbc.M010764200; STUBER E, 1995, IMMUNITY, V2, P507, DOI 10.1016/1074-7613(95)90031-4; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Takami M, 2002, J IMMUNOL, V169, P1516, DOI 10.4049/jimmunol.169.3.1516; Takasaki W, 1997, NAT BIOTECHNOL, V15, P1266, DOI 10.1038/nbt1197-1266; Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753; Walsh MC, 2003, CYTOKINE GROWTH F R, V14, P251, DOI 10.1016/S1359-6101(03)00027-3; Wang RX, 2002, EUR J IMMUNOL, V32, P1090, DOI 10.1002/1521-4141(200204)32:4<1090::AID-IMMU1090>3.0.CO;2-P; Weitzmann MN, 2001, J BONE MINER RES, V16, P328, DOI 10.1359/jbmr.2001.16.2.328; Wong BR, 1999, J LEUKOCYTE BIOL, V65, P715, DOI 10.1002/jlb.65.6.715; ZHANG KYJ, 1994, PROTEIN SCI, V3, P687	73	72	78	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8269	8277		10.1074/jbc.M309690200	http://dx.doi.org/10.1074/jbc.M309690200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14679212	hybrid			2022-12-25	WOS:000189103300109
J	Di Leva, F; Ferrante, MI; Demarchi, F; Caravelli, A; Matarazzo, MR; Giacca, M; D'Urso, M; D'Esposito, M; Franze, A				Di Leva, F; Ferrante, MI; Demarchi, F; Caravelli, A; Matarazzo, MR; Giacca, M; D'Urso, M; D'Esposito, M; Franze, A			Human synaptobrevin-like 1 gene basal transcription is regulated through the interaction of selenocysteine tRNA gene transcription activating factor-zinc finger 143 factors with evolutionary conserved cis-elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMALDEHYDE CROSS-LINKING; MOLECULAR-CLONING; MEMBRANE-PROTEIN; POLYMERASE-III; STAF; PROMOTER; METHYLATION; REGION; ZNF76; SYBL1	The synaptobrevin-like 1 (SYBL1) gene is ubiquitously expressed and codes for an unusual member of the v-SNAREs molecules implicated in cellular exocytosis. This X-linked gene has the peculiarity of also being present on the Y chromosome in a transcriptional inactive status. Moreover, although ubiquitous, the function of SYBL1 is prominent in specific tissues, such as brain. As a first insight into the molecular mechanisms controlling SYBL1 expression, in this report we describe the extent and role of SYBL1 upstream regions and characterize the binding of trans-acting factors. In vivo foot-printing experiments identify three protected regions. Band shift and transient reporter gene assays indicate a strong role of two of these evolutionary conserved regions in regulating SYBL1 transcription. Because one site is the classical CAAT box, we characterized the binding to the other site of the mammalian homologues of the selenocysteine tRNA gene transcription activating factor (Staf) family, zinc-finger transcription factors, and their role in regulating SYBL1 expression. The results reported here clarify that a Staf-zinc finger family factor, together with the CAAT factor, is the major nuclear protein bound to the SYBL1 promoter region and is responsible for its regulation in HeLa cells, thus identifying the basic control of SYBL1 transcription. In vivo binding of Staf proteins to the SYBL1 promoter is confirmed by chromatin immunoprecipitation assays. Our results identify a fourth mRNA promoter stimulated by a member of the Staf-zinc finger family, the function of which on mRNA polymerase II promoters is still very poorly understood.	CNR, Inst Genet & Biophys A Buzzati Traverso, I-80131 Naples, Italy; Univ Naples Federico II, Dept Neurosci & Behav Sci, Inst Audiol, I-80131 Naples, Italy; Int Ctr Genet Engn & Biotechnol, I-30142 Trieste, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); University of Naples Federico II; International Center for Genetic Engineering & Biotechnology (ICGEB)	Franze, A (corresponding author), CNR, Inst Genet & Biophys A Buzzati Traverso, Via P Castellino 111, I-80131 Naples, Italy.	franze@iigb.na.cnr.it	Giacca, Mauro/J-9287-2016; Franzè, Annamaria/V-3837-2019; D'Esposito, Maurizio/AAY-6376-2020; Franze', Annamaria/H-2539-2012	Giacca, Mauro/0000-0003-2927-7225; Franzè, Annamaria/0000-0002-4392-9739; Demarchi, Francesca/0000-0003-1565-3162; Ferrante, Maria Immacolata/0000-0002-8102-8018; DI LEVA, Francesca/0000-0002-6167-0679	Telethon [GGP02308] Funding Source: Medline	Telethon(Fondazione Telethon)		Adachi K, 1998, J BIOL CHEM, V273, P8598, DOI 10.1074/jbc.273.15.8598; DEsposito M, 1996, NAT GENET, V13, P227, DOI 10.1038/ng0696-227; Filippini F, 2001, TRENDS BIOCHEM SCI, V26, P407, DOI 10.1016/S0968-0004(01)01861-8; Fournier C, 2002, EMBO J, V21, P6560, DOI 10.1093/emboj/cdf655; Galli T, 1998, MOL BIOL CELL, V9, P1437, DOI 10.1091/mbc.9.6.1437; Hansen RS, 2000, HUM MOL GENET, V9, P2575, DOI 10.1093/hmg/9.18.2575; Huber R, 1999, P NATL ACAD SCI USA, V96, P616, DOI 10.1073/pnas.96.2.616; Kagoshima H, 1996, J BIOL CHEM, V271, P33074, DOI 10.1074/jbc.271.51.33074; Kubota H, 2000, J BIOL CHEM, V275, P28641, DOI 10.1074/jbc.M005009200; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Mach CM, 2002, J BIOL CHEM, V277, P4853, DOI 10.1074/jbc.M108308200; MAJELLO B, 1995, ONCOGENE, V10, P1841; Martinez-Arca S, 2000, J CELL BIOL, V149, P889, DOI 10.1083/jcb.149.4.889; Martinez-Arca S, 2003, P NATL ACAD SCI USA, V100, P9011, DOI 10.1073/pnas.1431910100; Matarazzo MR, 1999, GENE, V240, P233, DOI 10.1016/S0378-1119(99)00375-3; Matarazzo MR, 2002, HUM MOL GENET, V11, P3191, DOI 10.1093/hmg/11.25.3191; MUELLER PR, 1992, CURRENT PROTOCOLS MO; Myslinski E, 1998, J BIOL CHEM, V273, P21998, DOI 10.1074/jbc.273.34.21998; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; RAGOUSSIS J, 1992, GENOMICS, V14, P673, DOI 10.1016/S0888-7543(05)80167-3; Rincon JC, 1998, NUCLEIC ACIDS RES, V26, P4846, DOI 10.1093/nar/26.21.4846; Saur D, 2002, J BIOL CHEM, V277, P25798, DOI 10.1074/jbc.M109802200; Schaub M, 1997, EMBO J, V16, P173, DOI 10.1093/emboj/16.1.173; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; Schuster C, 1998, MOL CELL BIOL, V18, P2650, DOI 10.1128/MCB.18.5.2650; SCHUSTER C, 1995, EMBO J, V14, P3777, DOI 10.1002/j.1460-2075.1995.tb00047.x; TOMMERUP N, 1995, GENOMICS, V27, P259, DOI 10.1006/geno.1995.1040; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5	28	9	9	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7734	7739		10.1074/jbc.M308140200	http://dx.doi.org/10.1074/jbc.M308140200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14672948	hybrid			2022-12-25	WOS:000189103300046
J	Olzmann, JA; Brown, K; Wilkinson, KD; Rees, HD; Huai, Q; Ke, HM; Levey, AI; Li, L; Chin, LS				Olzmann, JA; Brown, K; Wilkinson, KD; Rees, HD; Huai, Q; Ke, HM; Levey, AI; Li, L; Chin, LS			Familial Parkinson's disease-associated L166P mutation disrupts DJ-1 protein folding and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; INTRACELLULAR PROTEASE; PYROCOCCUS-FURIOSUS; ANDROGEN RECEPTOR; 2 PARTS; GENE; UBIQUITIN; DEGRADATION; FERTILITY	Mutations in DJ-1, a protein of unknown function, were recently identified as the cause for an autosomal recessive, early onset form of familial Parkinson's disease. Here we report that DJ-1 is a dimeric protein that exhibits protease activity but no chaperone activity. The protease activity was abolished by mutation of Cys-106 to Ala, suggesting that DJ-1 functions as a cysteine protease. Our studies revealed that the Parkinson's disease-linked L166P mutation impaired the intrinsic folding propensity of DJ-1 protein, resulting in a spontaneously unfolded structure that was incapable of forming a homodimer with itself or a heterodimer with wild-type DJ-1. Correlating with the disruption of DJ-1 structure, the L166P mutation abolished the catalytic function of DJ-1. Furthermore, as a result of protein misfolding, the L166P mutant DJ-1 was selectively polyubiquitinated and rapidly degraded by the proteasome. Together these findings provide insights into the molecular mechanism by which loss-of-function mutations in DJ-1 lead to Parkinson's disease.	Emory Univ, Sch Med, Dept Pharmacol, Ctr Neurodegenerat Dis, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Biochem, Ctr Neurodegenerat Dis, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Neurol, Ctr Neurodegenerat Dis, Atlanta, GA 30322 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	Emory University; Emory University; Emory University; University of North Carolina; University of North Carolina Chapel Hill	Li, L (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, Ctr Neurodegenerat Dis, 1510 Clifton Rd, Atlanta, GA 30322 USA.	lianli@pharm.emory.edu	Levey, Allan/F-2104-2011	Levey, Allan/0000-0002-3153-502X; Chin, Lih-Shen/0000-0002-0817-0368; Olzmann, James/0000-0001-7751-8316; Li, Lian/0000-0003-4700-1134	NIA NIH HHS [AG021489] Funding Source: Medline; NIEHS NIH HHS [ES012068] Funding Source: Medline; NINDS NIH HHS [F31 NS054597-01, F31 NS054597, F31 NS054597-02, NS047199] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U54ES012068] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047199, F31NS054597] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021489] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Batra R, 2001, NAT STRUCT BIOL, V8, P810, DOI 10.1038/nsb0901-810; BLUMENTALS II, 1990, APPL ENVIRON MICROB, V56, P1992, DOI 10.1128/AEM.56.7.1992-1998.1990; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Buchner J, 1998, METHOD ENZYMOL, V290, P323, DOI 10.1016/S0076-6879(98)90029-5; Chin LS, 2002, J BIOL CHEM, V277, P35071, DOI 10.1074/jbc.M203300200; Chin LS, 2000, J BIOL CHEM, V275, P1191, DOI 10.1074/jbc.275.2.1191; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; DARKE PL, 1994, J BIOL CHEM, V269, P18708; Dawson TM, 2003, J CLIN INVEST, V111, P145, DOI 10.1172/JCI200317575; Du XL, 2000, P NATL ACAD SCI USA, V97, P14079, DOI 10.1073/pnas.260503597; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; Giasson BI, 2003, CELL, V114, P1, DOI 10.1016/S0092-8674(03)00509-9; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gwinn-Hardy K, 2002, MOVEMENT DISORD, V17, P645, DOI 10.1002/mds.10173; Hague S, 2003, ANN NEUROL, V54, P271, DOI 10.1002/ana.10663; Halio SB, 1996, J BACTERIOL, V178, P2605, DOI 10.1128/jb.178.9.2605-2612.1996; Hod Y, 1999, J CELL BIOCHEM, V72, P435, DOI 10.1002/(SICI)1097-4644(19990301)72:3<435::AID-JCB12>3.3.CO;2-8; Honbou K, 2003, J BIOL CHEM, V278, P31380, DOI 10.1074/jbc.M305878200; Huai Q, 2003, FEBS LETT, V549, P171, DOI 10.1016/S0014-5793(03)00764-6; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Jones LJ, 1997, ANAL BIOCHEM, V251, P144, DOI 10.1006/abio.1997.2259; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Klinefelter GR, 2002, J ANDROL, V23, P48, DOI 10.1002/jand.2002.23.1.48; Klinefelter GR, 1997, J ANDROL, V18, P139; Lang AE, 1998, NEW ENGL J MED, V339, P1130, DOI 10.1056/NEJM199810153391607; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Le Naour F, 2001, CLIN CANCER RES, V7, P3328; Lee SJ, 2003, J BIOL CHEM, V278, P44552, DOI 10.1074/jbc.M304517200; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; LI L, 1990, BIOCHEMISTRY-US, V29, P5428, DOI 10.1021/bi00475a003; Li YK, 2001, J BIOL CHEM, V276, P40824, DOI 10.1074/jbc.M106141200; Macedo MG, 2003, HUM MOL GENET, V12, P2807, DOI 10.1093/hmg/ddg304; McClellan AJ, 2001, NAT CELL BIOL, V3, pE51, DOI 10.1038/35055162; McGrath WJ, 2001, BIOCHEMISTRY-US, V40, P13237, DOI 10.1021/bi0111653; McNaught KS, 2003, ANN NEUROL, V53, pS73, DOI 10.1002/ana.10512; Miller DW, 2003, J BIOL CHEM, V278, P36588, DOI 10.1074/jbc.M304272200; Mitsumoto A, 2001, FREE RADICAL RES, V35, P301, DOI 10.1080/10715760100300831; Mizote T, 1999, MICROBIOL-UK, V145, P495, DOI 10.1099/13500872-145-2-495; Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132; Niki T, 2003, MOL CANCER RES, V1, P247; Sastry MSR, 2002, J BIOL CHEM, V277, P46026, DOI 10.1074/jbc.M205800200; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Takahashi K, 2001, J BIOL CHEM, V276, P37556, DOI 10.1074/jbc.M101730200; Tao X, 2003, J BIOL CHEM, V278, P31372, DOI 10.1074/jbc.M304221200; Tsai YC, 2003, J BIOL CHEM, V278, P22044, DOI 10.1074/jbc.M212235200; Wagenfeld A, 1998, BIOCHEM BIOPH RES CO, V251, P545, DOI 10.1006/bbrc.1998.9512; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; Welch JE, 1998, J ANDROL, V19, P385; Wheeler TC, 2002, J BIOL CHEM, V277, P10273, DOI 10.1074/jbc.M107857200; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Wilson MA, 2003, P NATL ACAD SCI USA, V100, P9256, DOI 10.1073/pnas.1133288100	53	218	225	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8506	8515		10.1074/jbc.M311017200	http://dx.doi.org/10.1074/jbc.M311017200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14665635	Green Published, hybrid			2022-12-25	WOS:000189103300134
J	Goel, R; Phillips-Mason, PJ; Gardner, A; Raben, DM; Baldassare, JJ				Goel, R; Phillips-Mason, PJ; Gardner, A; Raben, DM; Baldassare, JJ			alpha-thrombin-mediated phosphatidylinositol 3-kinase activation through release of G beta gamma dimers from G alpha q and G alpha(i2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; 1321N1 ASTROCYTOMA-CELLS; PERTUSSIS-TOXIN; SIGNALING PATHWAYS; ENDOTHELIAL-CELLS; PHOSPHOLIPASE-C; GENE-EXPRESSION; DNA-SYNTHESIS; LIPID RAFTS; SUBUNITS	Chinese hamster embryonic fibroblasts (IIC9 cells) express the Galpha subunits Galpha(s), Galpha(i2), Galpha(i3), Galpha(o), Galpha(q/11), and Galpha(13). Consistent with reports in other cell types, alpha-thrombin stimulates a subset of the expressed G proteins in IIC9 cells, namely G(i2), G(i3), and G(q) as measured by an in vitro membrane [S-35]guanosine 5'-O-(3-thio)triphosphate binding assay. Using specific Ga peptides, which block coupling of G-protein receptors to selective G proteins, as well as dominant negative xanthine nucleotide-binding Ga mutants, we show that activation of the phosphatidylinositol 3-kinase/Akt pathway is dependent on G(q) and G(i2). To examine the role of the two G proteins, we examined the events upstream of PI 3-kinase. The activation of the PI 3-kinase/Akt pathway by alpha-thrombin in IIC9 cells is blocked by the expression of dominant negative Ras and beta-arrestin1 (Phillips-Mason, P. J., Raben, D. M., and Baldassare, J. J. (2000) J. BioL Chem. 275, 18046-18053, and Goel, R., Phillips-Mason, P. J., Raben, D. M., and Baldassare, J. J. (2002) J. BioL Chem. 277, 18640-18648), indicating a role for Ras and beta-arrestin1. Interestingly, inhibition of G(i2) and G(q) activation blocks Ras activation and beta-arrestin1 membrane translocation, respectively. Furthermore, expression of the Gbetagamma sequestrant, alpha-transducin, inhibits both Ras activation and membrane translocation of beta-arrestin1, suggesting that Gbetagamma dimers from Galpha(i2) and Galpha(q) activate different effectors to coordinately regulate the PI 3-kinase/Akt pathway.	St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Saint Louis University; Johns Hopkins University	Baldassare, JJ (corresponding author), St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, 1402 S Grand Blvd, St Louis, MO 63104 USA.	baldasjj@slu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059251] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM59251] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albert PR, 2002, CELL SIGNAL, V14, P407, DOI 10.1016/S0898-6568(01)00259-5; ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; BAFFY G, 1994, J BIOL CHEM, V269, P8483; Barr AJ, 1997, J BIOL CHEM, V272, P2223; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Brock C, 2003, J CELL BIOL, V160, P89, DOI 10.1083/jcb.200210115; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; Cheng J, 1997, J BIOL CHEM, V272, P17312, DOI 10.1074/jbc.272.28.17312; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; Dhanasekaran N, 1998, BIOL SIGNAL RECEPT, V7, P109; Dobrowsky RT, 2000, CELL SIGNAL, V12, P81, DOI 10.1016/S0898-6568(99)00072-8; Fields TA, 1997, BIOCHEM J, V321, P561, DOI 10.1042/bj3210561; Gardner A, 2002, CELL SIGNAL, V14, P499, DOI 10.1016/S0898-6568(01)00279-0; GARDNER AJ, 1998, THESIS ST LOUIS U ST; Gilchrist A, 1999, J BIOL CHEM, V274, P6610, DOI 10.1074/jbc.274.10.6610; Gilchrist A, 2001, J BIOL CHEM, V276, P25672, DOI 10.1074/jbc.M100914200; Goel R, 2002, ANN NY ACAD SCI, V973, P138, DOI 10.1111/j.1749-6632.2002.tb04622.x; Goel R, 2002, J BIOL CHEM, V277, P18640, DOI 10.1074/jbc.M108995200; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Heximer SP, 1999, J BIOL CHEM, V274, P34253, DOI 10.1074/jbc.274.48.34253; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; Kanthou C, 1996, CELL SIGNAL, V8, P59, DOI 10.1016/0898-6568(95)02018-7; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Lents NH, 2002, J BIOL CHEM, V277, P47469, DOI 10.1074/jbc.M207425200; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Ogino Y, 1996, EUR J PHARMACOL, V316, P105, DOI 10.1016/S0014-2999(96)00653-X; Phillips-Mason PJ, 2000, J BIOL CHEM, V275, P18046, DOI 10.1074/jbc.M909194199; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Post GR, 1996, MOL BIOL CELL, V7, P1679, DOI 10.1091/mbc.7.11.1679; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Rahman A, 2002, CIRC RES, V91, P398, DOI 10.1161/01.RES.0000033520.95242.A2; Scott JK, 2001, EMBO J, V20, P767, DOI 10.1093/emboj/20.4.767; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Taylor SJ, 2001, METHOD ENZYMOL, V333, P333; Vanhauwe JF, 2002, J BIOL CHEM, V277, P34143, DOI 10.1074/jbc.M204477200; Verrall S, 1997, J BIOL CHEM, V272, P6898, DOI 10.1074/jbc.272.11.6898; Weber JD, 1997, J BIOL CHEM, V272, P17320, DOI 10.1074/jbc.272.28.17320; Windh RT, 2002, METHOD ENZYMOL, V344, P3; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; Yu B, 2000, J BIOL CHEM, V275, P71, DOI 10.1074/jbc.275.1.71; Zhang SY, 1996, J BIOL CHEM, V271, P33575, DOI 10.1074/jbc.271.52.33575	46	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6701	6710		10.1074/jbc.M308753200	http://dx.doi.org/10.1074/jbc.M308753200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14668344	hybrid			2022-12-25	WOS:000188969200062
J	Ueda, R; Iizuka, Y; Yoshida, K; Kawase, T; Kawakami, Y; Toda, M				Ueda, R; Iizuka, Y; Yoshida, K; Kawase, T; Kawakami, Y; Toda, M			Identification of a human glioma antigen, SOX6, recognized by patients' sera	ONCOGENE			English	Article						glioma; tumor antigen; CT antigen; SOX6; SEREX; IgG response	IMMUNE-RESPONSES; NERVOUS-SYSTEM; BRAIN-TUMORS; GENE SOX6; PROTEIN; TESTIS; SRY; LYMPHOCYTES; EXPRESSION; MOUSE	To identify tumor antigens for glioma, a human testis cDNA library was screened by serological identification of antigens by recombinant expression cloning with sera from glioma patients. In this screening, the most frequently isolated antigen was SOX6, an Sry-related high-mobility group (HMG) box-containing gene. SOX6 is a transcriptional factor that is specifically expressed in the developing central nervous system and in the early stages of chondrogenesis in mouse embryos. IgG antibodies against SOX6 were detected in sera from 12 of 36 glioma patients (33.3%), 0 of 14 patients with other brain disease (0%), and one of 54 other cancer patients (1.9%). In sera from 37 healthy individuals, no IgG responses against SOX6 were detected, except in an elderly female. Furthermore, Western blot and ELISA analyses with sera from glioma patients revealed that the DNA-binding domain, the HMG box of SOX6, might be a dominant epitope of IgGs against SOX6. RT-PCR and Northern blot analysis revealed that the SOX6 gene was more highly expressed in glioma tissues than in normal adult tissues, except testis. Western blot analysis with an anti-SOX6 antibody demonstrated that the SOX6 protein was expressed in glioma tissues, but not in normal adult brain tissue. Immunohistochemical analysis with the anti-SOX6 antibody showed that all the glioma tissues analysed expressed SOX6 in tumor cells, but only a few SOX6-positive cells were detected in non-neoplastic tissues from the cerebral cortex. In summary, these results indicate that the developmentally regulated transcription factor SOX6 is aberrantly expressed in glioma and specifically recognized by IgGs from glioma patients' sera.	Keio Univ, Sch Med, Dept Neurosurg, Neuroimmunol Res Grp,Shinjuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Inst Adv Med Res, Div Cellular Signaling,Shinjuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Neuroimmunol Res Grp, Shinjuku Ku, Tokyo 1608582, Japan	Keio University; Keio University; Keio University	Toda, M (corresponding author), Keio Univ, Sch Med, Dept Neurosurg, Neuroimmunol Res Grp,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	todam@sc.itc.keio.ac.jp	nakamura, asuka/S-7235-2016; Toda, Masahiro/L-2268-2013; Kawakami, Yutaka/E-7429-2013; Yoshida, Kazunari/L-2255-2013	Kawakami, Yutaka/0000-0003-4836-2855; 				Almqvist PM, 2002, J HISTOCHEM CYTOCHEM, V50, P147, DOI 10.1177/002215540205000203; Brass N, 1997, HUM MOL GENET, V6, P33, DOI 10.1093/hmg/6.1.33; BRICHARD V, 1993, J EXP MED, V178, P489, DOI 10.1084/jem.178.2.489; CATTORETTI G, 1992, J PATHOL, V168, P357, DOI 10.1002/path.1711680404; Chen YT, 1997, P NATL ACAD SCI USA, V94, P1914, DOI 10.1073/pnas.94.5.1914; Cohen-Barak G, 2001, GENE, V265, P157, DOI 10.1016/S0378-1119(01)00346-8; CONNOR F, 1995, NUCLEIC ACIDS RES, V23, P3365, DOI 10.1093/nar/23.17.3365; Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327; Fischer U, 2001, CLIN EXP IMMUNOL, V126, P206, DOI 10.1046/j.1365-2249.2001.01635.x; Hagiwara N, 2000, P NATL ACAD SCI USA, V97, P4180, DOI 10.1073/pnas.97.8.4180; Kamachi Y, 1998, DEVELOPMENT, V125, P2521; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Narahara M, 2002, BIOL PHARM BULL, V25, P705, DOI 10.1248/bpb.25.705; Pevny LH, 1997, CURR OPIN GENET DEV, V7, P338, DOI 10.1016/S0959-437X(97)80147-5; Pingault V, 1998, NAT GENET, V18, P171, DOI 10.1038/ng0298-171; PRADOS MD, 1992, INT J RADIAT ONCOL, V23, P3, DOI 10.1016/0360-3016(92)90537-R; ROBBINS PF, 1994, CANCER RES, V54, P3124; Sahin U, 2000, CLIN CANCER RES, V6, P3916; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; Scanlan MJ, 1998, INT J CANCER, V76, P652, DOI 10.1002/(SICI)1097-0215(19980529)76:5<652::AID-IJC7>3.3.CO;2-9; Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0; Southard-Smith EM, 1998, NAT GENET, V18, P60, DOI 10.1038/ng0198-60; Stockert E, 1998, J EXP MED, V187, P1349, DOI 10.1084/jem.187.8.1349; Struss AK, 2001, ONCOGENE, V20, P4107, DOI 10.1038/sj.onc.1204552; TAKAHASHI K, 1995, CANCER RES, V55, P3478; Toda M, 2001, GLIA, V34, P1, DOI 10.1002/glia.1034; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0; Xia Y, 2000, CANCER RES, V60, P6303; Yamashita A, 2000, FEBS LETT, V481, P147, DOI 10.1016/S0014-5793(00)01987-6	33	51	56	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1420	1427		10.1038/sj.onc.1207252	http://dx.doi.org/10.1038/sj.onc.1207252			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14691456	Green Submitted			2022-12-25	WOS:000189035800009
J	Wong, SK; Li, WH; Moore, MJ; Choe, H; Farzan, M				Wong, SK; Li, WH; Moore, MJ; Choe, H; Farzan, M			A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE RESPIRATORY SYNDROME; SPIKE GLYCOPROTEIN; RECEPTOR; VIRUS; IDENTIFICATION; EXPRESSION; DOMAIN; ENTRY; SITE	The coronavirus spike (S) protein mediates infection of receptor-expressing host cells and is a critical target for antiviral neutralizing antibodies. Angiotensin-converting enzyme 2 (ACE2) is a functional receptor for the coronavirus (severe acute respiratory syndrome (SARS)-CoV) that causes SARS. Here we demonstrate that a 193-amino acid fragment of the S protein (residues 318-510) bound ACE2 more efficiently than did the full S1 domain (residues 12-672). Smaller S protein fragments, expressing residues 327-510 or 318-490, did not detectably bind ACE2. A point mutation at aspartic acid 454 abolished association of the full S1 domain and of the 193-residue fragment with ACE2. The 193-residue fragment blocked S protein-mediated infection with an IC50 of less than 10 nM, whereas the IC50 of the S1 domain was similar to50 nM. These data identify an independently folded receptor-binding domain of the SARS-CoV S protein.	Harvard Univ, Brigham & Womens Hosp, Sch Med,Partners AIDS Res Ctr, Dept Med Microbiol & Mol Genet, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Pulm Div,Perlmutter Lab, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Farzan, M (corresponding author), Partners AIDS Res Ctr, 65 Landsdowne St, Cambridge, MA 02139 USA.	farzan@mbcrr.harvard.edu		Li, Wenhui/0000-0003-1305-7404; Farzan, Michael/0000-0002-2990-5319				Bannert N, 2000, J VIROL, V74, P10984, DOI 10.1128/JVI.74.23.10984-10993.2000; Bonavia A, 2003, J VIROL, V77, P2530, DOI 10.1128/JVI.77.4.2530-2538.2003; Breslin JJ, 2003, J VIROL, V77, P4435, DOI 10.1128/JVI.77.7.4435-4438.2003; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; DVEKSLER GS, 1993, J VIROL, V67, P1; DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a; Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757; Jackwood MW, 2001, AVIAN DIS, V45, P366, DOI 10.2307/1592976; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; KUBO H, 1994, J VIROL, V68, P5403, DOI 10.1128/JVI.68.9.5403-5410.1994; Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Sturman L S, 1984, Adv Exp Med Biol, V173, P25; YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0	18	513	576	2	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3197	3201		10.1074/jbc.C300520200	http://dx.doi.org/10.1074/jbc.C300520200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14670965	hybrid, Green Published			2022-12-25	WOS:000188379600009
J	Tepper, AWJW; Bubacco, L; Canters, GW				Tepper, AWJW; Bubacco, L; Canters, GW			Stopped-flow fluorescence studies of inhibitor binding to tyrosinase from Streptomyces antibioticus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATECHOL OXIDASE; ACTIVE-SITE; SPECTROSCOPIC PROPERTIES; MUSHROOM TYROSINASE; CRYSTAL-STRUCTURE; FUNCTIONAL UNIT; EPIDERMIS TYROSINASE; MAGNETIC-PROPERTIES; NATIVE HEMOCYANIN; STRUCTURAL BASIS	Tyrosinase (Ty) is a type 3 copper protein involved in the rate-limiting step of melanin synthesis. It is shown that the endogenous Trp fluorescence of tyrosinase from Streptomyces antibioticus is remarkably sensitive to the redox state. The fluorescence emission intensity of the [(Cu(I) Cu(I)] reduced species is more than twice that of the oxygen-bound [Cu(II)-O-2(2-)- Cu(II)] form. The emission intensity of the oxidized [Cu(II)-OH--Cu(II)] protein (Ty(met)) appears to be dependent on an acid-base equilibrium with a pK(a) value of 4.5 +/- 0.1. The binding of fluoride was studied under pseudo first-order conditions using stopped-flow fluorescence spectroscopy. The kinetic parameters k(on), K-d, and the fraction of fluorescence emission quenched upon fluoride binding show a similar pH dependence as above with an average pKa value of 4.62 +/- 0.05. Both observations are related to the dissociation of Cu-2-bridging hydroxide at low pH. It is further shown that Ty is rapidly inactivated at low pH and that halide protects the enzyme from this inactivation. All results support the hypothesis that halide displaces hydroxide as the Cu-2-bridging ligand in Ty(met). The relevance of the experimental findings for the catalytic cycle is discussed. The data are consistent with the data obtained from other techniques, validating the use of fluorescence quenching as a sensitive and effective tool in studying ligand binding and substrate conversion.	Leiden Univ, Gorlaeus Labs, Leiden Inst Chem, NL-2333 CC Leiden, Netherlands; Univ Padua, Dept Biol, I-30121 Padua, Italy	Leiden University; Leiden University - Excl LUMC; University of Padua	Canters, GW (corresponding author), Leiden Univ, Einsteinweg 55,POB 9502, NL-2300 RA Leiden, Netherlands.	canters@chem.leidenuniv.nl	Bubacco, Luigi/B-5602-2012	Bubacco, Luigi/0000-0001-7927-9208				Ali SA, 1999, COMP BIOCHEM PHYS A, V122, P65; Amudha P, 1999, POLYHEDRON, V18, P1355, DOI 10.1016/S0277-5387(98)00401-X; Belle C, 2002, INORG CHEM, V41, P479, DOI 10.1021/ic010534g; BELTRAMINI M, 1982, BIOCHEM J, V205, P173, DOI 10.1042/bj2050173; Bubacco L, 1999, FEBS LETT, V442, P215, DOI 10.1016/S0014-5793(98)01662-7; Bubacco L, 2000, J MOL CATAL B-ENZYM, V8, P27, DOI 10.1016/S1381-1177(99)00064-8; Bubacco L, 2003, J BIOL CHEM, V278, P7381, DOI 10.1074/jbc.M206394200; CABANES J, 1984, BIOCHIM BIOPHYS ACTA, V790, P101, DOI 10.1016/0167-4838(84)90212-7; Cuff ME, 1998, J MOL BIOL, V278, P855, DOI 10.1006/jmbi.1998.1647; Dean J. A., 1999, LANGES HDB CHEM; Decker H, 2000, ANGEW CHEM INT EDIT, V39, P1591, DOI 10.1002/(SICI)1521-3773(20000502)39:9<1591::AID-ANIE1591>3.0.CO;2-H; Decker H, 2000, TRENDS BIOCHEM SCI, V25, P392, DOI 10.1016/S0968-0004(00)01602-9; Dolashka P, 1996, BIOCHEM J, V315, P139, DOI 10.1042/bj3150139; Dolashka-Angelova P, 1999, SPECTROCHIM ACTA A, V55, P2927, DOI 10.1016/S1386-1425(99)00172-9; Dolashka-Angelova P, 2000, INT J BIOCHEM CELL B, V32, P529, DOI 10.1016/S1357-2725(99)00151-X; Dolashka-Angelova P, 2000, SPECTROCHIM ACTA A, V56, P1985, DOI 10.1016/S1386-1425(99)00273-5; Eicken C, 1998, FEBS LETT, V436, P293, DOI 10.1016/S0014-5793(98)01113-2; Eicken C, 1999, CURR OPIN STRUC BIOL, V9, P677, DOI 10.1016/S0959-440X(99)00029-9; Espin JC, 1999, J AGR FOOD CHEM, V47, P2638, DOI 10.1021/jf981055b; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; HASHIGUCHI H, 1977, MOL PHARMACOL, V13, P362; HAZES B, 1993, PROTEIN SCI, V2, P597; HEALEY DF, 1981, ARCH BIOCHEM BIOPHYS, V211, P86, DOI 10.1016/0003-9861(81)90432-X; Hristova R, 1997, SPECTROCHIM ACTA A, V53, P471, DOI 10.1016/S1386-1425(96)01837-9; Hristova R, 2000, OXID COMMUN, V23, P145; Idakieva K, 1995, COMP BIOCHEM PHYS B, V112, P599, DOI 10.1016/0305-0491(95)00102-6; IOZUMI K, 1993, J INVEST DERMATOL, V100, P806, DOI 10.1111/1523-1747.ep12476630; IWATA M, 1990, J INVEST DERMATOL, V95, P9, DOI 10.1111/1523-1747.ep12872677; JACKMAN MP, 1991, BIOCHEM J, V274, P707, DOI 10.1042/bj2740707; Jimenez M, 2001, J AGR FOOD CHEM, V49, P4060, DOI 10.1021/jf010194h; Klabunde T, 1998, NAT STRUCT BIOL, V5, P1084, DOI 10.1038/4193; Kubo I, 1999, J AGR FOOD CHEM, V47, P4121, DOI 10.1021/jf990201q; Lakowicz J.R., 1999, PRINCIPLES FLUORESCE, P242; LEBODIA L, 1993, PROTEIN-STRUCT FUNCT, V16, P219; LERCH K, 1972, EUR J BIOCHEM, V31, P427, DOI 10.1111/j.1432-1033.1972.tb02549.x; Lippitz M, 2002, P NATL ACAD SCI USA, V99, P2772, DOI 10.1073/pnas.052662999; MADDALUNO JF, 1988, EXPERIENTIA, V44, P885, DOI 10.1007/BF01941189; MAGNUS KA, 1994, PROTEINS, V19, P302, DOI 10.1002/prot.340190405; MARTINEZ JH, 1985, BIOCHEM INT, V11, P729; MARTINEZ JH, 1986, COMP BIOCHEM PHYS B, V83, P633, DOI 10.1016/0305-0491(86)90309-3; Meier B, 1998, BIOCHEM J, V331, P403, DOI 10.1042/bj3310403; MENON S, 1990, ARCH BIOCHEM BIOPHYS, V280, P27, DOI 10.1016/0003-9861(90)90513-X; Monzani E, 1998, INORG CHEM, V37, P553, DOI 10.1021/ic970996n; NAEYAERT JM, 1991, BRIT J DERMATOL, V125, P297, DOI 10.1111/j.1365-2133.1991.tb14161.x; Neri F, 1997, BIOCHEMISTRY-US, V36, P8947, DOI 10.1021/bi970248+; No JK, 1999, LIFE SCI, V65, pPL241, DOI 10.1016/S0024-3205(99)00492-0; Oetting WS, 2000, PIGM CELL RES, V13, P320, DOI 10.1034/j.1600-0749.2000.130503.x; OETTING WS, 1994, J INVEST DERMATOL, V103, pS131, DOI 10.1111/1523-1747.ep12399447; PENAFIEL R, 1984, BIOCHIM BIOPHYS ACTA, V788, P327, DOI 10.1016/0167-4838(84)90045-1; Pervanova K, 2000, SPECTROCHIM ACTA A, V56, P615, DOI 10.1016/S1386-1425(99)00261-9; Rodriguez-Lopez JN, 2000, BIOCHEMISTRY-US, V39, P10497, DOI 10.1021/bi000539+; Salvato B, 1998, BIOCHEMISTRY-US, V37, P14065, DOI 10.1021/bi980879j; SANCHEZFERRER A, 1995, BBA-PROTEIN STRUCT M, V1247, P1; Schutz J, 2001, BBA-PROTEIN STRUCT M, V1546, P325, DOI 10.1016/S0167-4838(01)00152-2; Seo SY, 2003, J AGR FOOD CHEM, V51, P2837, DOI 10.1021/jf020826f; SHAKLAI N, 1978, BIOCHEMISTRY-US, V17, P4438, DOI 10.1021/bi00614a013; Solomon EI, 1996, CHEM REV, V96, P2563, DOI 10.1021/cr950046o; Stoeva S, 1995, SPECTROCHIM ACTA A, V51, P1965, DOI 10.1016/0584-8539(95)01538-6; Tepper AWJW, 2002, J BIOL CHEM, V277, P30436, DOI 10.1074/jbc.M202461200; Todd MJ, 2000, BIOCHEMISTRY-US, V39, P5389, DOI 10.1021/bi992287m; Torelli S, 2000, INORG CHEM, V39, P3526, DOI 10.1021/ic991450z; van Gastel M, 2000, FEBS LETT, V474, P228, DOI 10.1016/S0014-5793(00)01609-4; VanGelder CWG, 1997, PHYTOCHEMISTRY, V45, P1309, DOI 10.1016/S0031-9422(97)00186-6; WILCOX DE, 1985, J AM CHEM SOC, V107, P4015, DOI 10.1021/ja00299a043; Xu F, 1997, J BIOL CHEM, V272, P924, DOI 10.1074/jbc.272.2.924	66	23	23	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13425	13434		10.1074/jbc.M309367200	http://dx.doi.org/10.1074/jbc.M309367200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14699163	hybrid			2022-12-25	WOS:000220478500020
J	Montano, MM; Deng, HY; Liu, M; Sun, XY; Singal, R				Montano, MM; Deng, HY; Liu, M; Sun, XY; Singal, R			Transcriptional regulation by the estrogen receptor of antioxidative stress enzymes and its functional implications	ONCOGENE			English	Article						estrogen receptor; antiestrogens; glutathione-S-transferase; gamma-glutamylcysteine synthetase	GLUTATHIONE-S-TRANSFERASE; GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; QUINONE REDUCTASE GENE; BREAST-CANCER CELLS; HUMAN PROSTATE-CANCER; SUBUNIT GENE; P1 GENE; TELOMERASE ACTIVITY; DRUG-RESISTANCE; EXPRESSION	We previously reported that antiestrogen-liganded estrogen receptor beta (ERbeta) transcriptionally activates the major detoxifying enzyme quinone reductase (QR)(NAD(P) H:-quinone oxidoreductase). Our studies also indicate that upregulation of QR, either by overexpression or induction by tamoxifen, can protect breast cells against oxidative DNA damage caused by estrogen metabolites. We now report on the upregulation of glutathione S-transferases Pi (GST-Pi) and gamma-glutamylcysteine synthetase heavy subunit (GCSh) expression by antiestrogens. Studies indicate the regulation of GST-Pi and GCSh transcriptional activity by ER. While ER regulation is mediated by an electrophile response element (EpRE), we identified mechanistic differences in the involvement of other transcription factors. Regardless of these differences, ERbeta-mediated regulation of GST-Pi and GCSh point towards an important role for ERbeta in cellular protection against oxidative stress. A protective role is supported by our observation of inhibition of estrogen-induced DNA damage upon upregulation of GST-Pi and GCSh expression.	Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44102 USA; Univ Miami, Dept Med, Miami, FL 33136 USA	Case Western Reserve University; University of Miami	Montano, MM (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, HG Wood Bldg W307,2109 Adelbert Rd, Cleveland, OH 44106 USA.	mxm126@po.cwru.edu			NCI NIH HHS [CA80959] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bianco NR, 2003, MOL ENDOCRINOL, V17, P1344, DOI 10.1210/me.2002-0382; Bianco NR, 2002, ONCOGENE, V21, P5233, DOI 10.1038/sj.onc.1205645; CHA YN, 1982, CANCER RES, V42, P2609; Dahl EL, 2001, TOXICOL SCI, V61, P265, DOI 10.1093/toxsci/61.2.265; Dhakshinamoorthy S, 2000, CURR TOP CELL REGUL, V36, P201; Esteller M, 1998, CANCER RES, V58, P4515; Gamcsik MP, 2002, BIOCHEM PHARMACOL, V63, P843, DOI 10.1016/S0006-2952(01)00931-5; Griffith OW, 1999, ADV ENZYMOL RAMB, V73, P209, DOI 10.1002/9780470123195.ch7; Hellriegel ET, 1996, BIOCHEM PHARMACOL, V52, P1561, DOI 10.1016/S0006-2952(96)00560-6; Jaiswal AK, 2000, FREE RADICAL BIO MED, V29, P254, DOI 10.1016/S0891-5849(00)00306-3; Jhaveri MS, 1998, GENE, V210, P1, DOI 10.1016/S0378-1119(98)00021-3; Jhaveri MS, 1998, BBA-GENE STRUCT EXPR, V1396, P179, DOI 10.1016/S0167-4781(97)00187-5; Kyo S, 1999, CANCER RES, V59, P5917; Liu RM, 1998, AM J PHYSIOL-LUNG C, V275, pL861, DOI 10.1152/ajplung.1998.275.5.L861; Matsumoto M, 2000, BIOCHEM J, V349, P225, DOI 10.1042/0264-6021:3490225; Maugard CM, 2001, INT J CANCER, V91, P334, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1057>3.0.CO;2-H; Misiti S, 2000, MOL CELL BIOL, V20, P3764, DOI 10.1128/MCB.20.11.3764-3771.2000; Mitrunen K, 2001, CANCER EPIDEM BIOMAR, V10, P229; Mizutani K, 2000, J HYPERTENS, V18, P1833, DOI 10.1097/00004872-200018120-00018; MOFFAT GJ, 1994, J BIOL CHEM, V269, P16397; Moffat GJ, 1996, J BIOL CHEM, V271, P20740, DOI 10.1074/jbc.271.34.20740; Moinova HR, 1998, J BIOL CHEM, V273, P14683, DOI 10.1074/jbc.273.24.14683; Montano MM, 2000, J BIOL CHEM, V275, P34306, DOI 10.1074/jbc.M003880200; Montano MM, 1997, P NATL ACAD SCI USA, V94, P2581, DOI 10.1073/pnas.94.6.2581; Montano MM, 1998, J BIOL CHEM, V273, P25443, DOI 10.1074/jbc.273.39.25443; MORROW CS, 1990, GENE, V88, P215, DOI 10.1016/0378-1119(90)90034-O; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; Nanni S, 2002, J CLIN INVEST, V110, P219, DOI 10.1172/JCI200215552; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; PRESTERA T, 1993, ADV ENZYME REGUL, V33, P281; Rahman I, 1999, AM J PHYSIOL-LUNG C, V277, pL1067, DOI 10.1152/ajplung.1999.277.6.L1067; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059; Singal R, 2001, CANCER RES, V61, P4820; STRANGE RC, 2001, MUTAT RES, V82, P21; TALALAY P, 1989, ADV ENZYME REGUL, V28, P237; TEW KD, 1994, CANCER RES, V54, P4313; Walsh AC, 2001, TOXICOL SCI, V61, P218, DOI 10.1093/toxsci/61.2.218; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Wilkinson J, 1998, BIOCHEM BIOPH RES CO, V253, P855, DOI 10.1006/bbrc.1998.9804; XIA CL, 1993, BIOCHEM J, V292, P845, DOI 10.1042/bj2920845; Yoshida T, 2000, CARCINOGENESIS, V21, P2193, DOI 10.1093/carcin/21.12.2193; Zhang Y, 2003, J STEROID BIOCHEM, V85, P401, DOI 10.1016/S0960-0760(03)00230-9	44	58	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2442	2453		10.1038/sj.onc.1207358	http://dx.doi.org/10.1038/sj.onc.1207358			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14676828				2022-12-25	WOS:000220558000002
J	Singh, SK; Yang, K; Karthikeyan, S; Huynh, T; Zhang, XJ; Phillips, MA; Zhang, H				Singh, SK; Yang, K; Karthikeyan, S; Huynh, T; Zhang, XJ; Phillips, MA; Zhang, H			The thrH gene product of Pseudomonas aeruginosa is a dual activity enzyme with a novel phosphoserine : homoserine phosphotransferase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; PHOSPHATASE; KINASE; DEHALOGENASE; ORGANIZATION; ASPARTATE; CATALYSIS; PROTEINS; ANALOG	The thrH gene product of Pseudomonas aeruginosa has been shown to complement both homoserine kinase ( thrB gene product) and phosphoserine phosphatase (serB gene product) activities in vivo. Sequence comparison has revealed that ThrH is related to phosphoserine phosphatases (PSP, EC 3.1.3.3) and belongs to the L-2-haloacid dehalogenase-like protein superfamily. We have solved the crystal structures of ThrH in the apoform and in complex with a bound product phosphate. The structure confirms an overall fold similar to that of PSP. Most of the catalytic residues of PSP are also conserved in ThrH, suggesting that similar catalytic mechanisms are used by both enzymes. Spectrophotometry-based in vitro assays show that ThrH is indeed a phosphoserine phosphatase with a K-m of 0.207 mM and k(cat) of 13.4 min(-1), comparable with those of other PSPs. More interestingly, using high pressure liquid chromatography-based assays, we have demonstrated that ThrH is able to further transfer the phosphoryl group to homoserine using phosphoserine as the phosphoryl group donor, indicating that ThrH has a novel phosphoserine: homoserine phosphotransferase activity.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Zhang, H (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA.	zhang@chop.swmed.edu	Karthikeyan, Subramanian/F-8808-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063689] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 63689] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Cheek S, 2002, J MOL BIOL, V320, P855, DOI 10.1016/S0022-2836(02)00538-7; Cho H, 2001, P NATL ACAD SCI USA, V98, P8525, DOI 10.1073/pnas.131213698; CLEPET C, 1992, MOL MICROBIOL, V6, P3109, DOI 10.1111/j.1365-2958.1992.tb01768.x; Collet JF, 1999, J BIOL CHEM, V274, P33985, DOI 10.1074/jbc.274.48.33985; Collet JF, 1998, J BIOL CHEM, V273, P14107, DOI 10.1074/jbc.273.23.14107; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Daugherty M, 2001, J BACTERIOL, V183, P292, DOI 10.1128/JB.183.1.292-300.2001; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Huo XW, 1996, ARCH BIOCHEM BIOPHYS, V330, P373, DOI 10.1006/abbi.1996.0264; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim HY, 2002, J BIOL CHEM, V277, P46651, DOI 10.1074/jbc.M204866200; Krishna SS, 2001, BIOCHEMISTRY-US, V40, P10810, DOI 10.1021/bi010851z; Lahiri SD, 2003, SCIENCE, V299, P2067, DOI 10.1126/science.1082710; Lahiri SD, 2002, BIOCHEMISTRY-US, V41, P8351, DOI 10.1021/bi0202373; Marchenko GN, 1999, MICROBIOL-UK, V145, P3273, DOI 10.1099/00221287-145-11-3273; Morais MC, 2000, BIOCHEMISTRY-US, V39, P10385, DOI 10.1021/bi001171j; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nicholls A., 1992, GRASP GRAPHICAL REPR; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parsons JF, 2002, PROTEINS, V46, P393, DOI 10.1002/prot.10057; Patte J. C., 1996, ESCHERICHIA COLI SAL, V1, P528; Patte JC, 1999, MICROBIOL-SGM, V145, P845, DOI 10.1099/13500872-145-4-845; Peeraer Y, 2003, ACTA CRYSTALLOGR D, V59, P971, DOI 10.1107/S0907444903005407; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Ridder IS, 1997, J BIOL CHEM, V272, P33015, DOI 10.1074/jbc.272.52.33015; ROBICHON-SZULMAJSTER H., 1966, GENETICS, V53, P609; STAUFFER GV, 1996, ESCHERICHIA COLI SAL, V1, P509; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Wang WR, 2001, STRUCTURE, V9, P65, DOI 10.1016/S0969-2126(00)00558-X; Wang WR, 2002, J MOL BIOL, V319, P421, DOI 10.1016/S0022-2836(02)00324-8; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; Zhou T, 2000, STRUCTURE, V8, P1247, DOI 10.1016/S0969-2126(00)00533-5	37	16	17	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13166	13173		10.1074/jbc.M311393200	http://dx.doi.org/10.1074/jbc.M311393200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14699121	hybrid			2022-12-25	WOS:000220334900138
J	Arndt, PG; Suzuki, N; Avdi, NJ; Malcolm, KC; Worthen, GS				Arndt, PG; Suzuki, N; Avdi, NJ; Malcolm, KC; Worthen, GS			Lipopolysaccharide-induced c-Jun NH2-terminal kinase activation in human neutrophils - Role of phosphatidylinositol 3-kinase and Syk-mediated pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; KAPPA-B ACTIVATION; TUMOR-NECROSIS-FACTOR; MONOCYTE CHEMOATTRACTANT PROTEIN-1; GROWTH-FACTOR; BACTERIAL LIPOPOLYSACCHARIDE; SELECTIVE ACTIVATION; SIGNAL-TRANSDUCTION; ADAPTER MOLECULE; FACTOR-RECEPTOR	Polymorphonuclear leukocytes (neutrophils) respond to lipopolysaccharide (LPS) through the up-regulation of several pro-inflammatory mediators. We have recently shown that LPS-stimulated neutrophils express monocyte chemoattractant protein 1 (MCP-1), an AP-1-dependent gene, suggesting that LPS activates the c-Jun N-terminal kinase (JNK) pathway in neutrophils. Previously, we have shown the activation of p38 MAPK, but not JNK, in suspended neutrophils stimulated with LPS but have recently shown activation of JNK by TNF-alpha in an adherent neutrophil system. We show here that exposure to LPS activates JNK in non-suspended neutrophils and that LPS-induced MCP-1 expression, but not tumor necrosis factor-alpha (TNF-alpha) or interleukin-8 (IL-8), is dependent on JNK activation. In addition, LPS stimulation of non-suspended neutrophils activates Syk and phosphatidylinositol 3-kinase (PI3K). Inhibition of Syk with piceatannol or PI3K with wortmannin inhibited LPS-induced JNK activation and decreased MCP-1 expression after exposure to LPS, suggesting that both Syk and PI3K reside in a signaling pathway leading to LPS-induced JNK activation in neutrophils. This Syk- and PI3K-dependent pathway leading to JNK activation after LPS exposure in non-suspended neutrophils is specific for JNK, because inhibition of neither Syk nor PI3K decreased p38 activation after LPS stimulation. Furthermore we show that PI3K inhibition decreased LPS-induced Syk activation suggesting that PI3K resides upstream of Syk in this pathway. Finally, we show that Syk associates with Toll-like receptor 4 (TLR4) upon LPS stimulation further implicating Syk in the LPS-induced signaling pathway in neutrophils. Overall our data suggests that LPS induces JNK activation only in non-suspended neutrophils, which proceeds through Syk- and PI3K-dependent pathways, and that JNK activation is important for LPS-induced MCP-1 expression but not for TNF-alpha or IL-8 expression.	Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Div Cell Biol, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Med, Div Pulm & Crit Care Med, Denver, CO 80206 USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Arndt, PG (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, 1400 Jackson St,D403, Denver, CO 80206 USA.	Patrick.Arndt@UCHSC.edu						Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Assefa Z, 1999, BIOCHEM BIOPH RES CO, V261, P641, DOI 10.1006/bbrc.1999.1090; Avdi NJ, 2001, J BIOL CHEM, V276, P2189, DOI 10.1074/jbc.M007527200; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bisotto S, 2001, BIOCHEM J, V360, P77, DOI 10.1042/0264-6021:3600077; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Cesaris P. D., 1999, J BIOL CHEM, V274, P28978; Chae P, 2002, INFECT IMMUN, V70, P3164, DOI 10.1128/IAI.70.6.3164-3169.2002; Cooney DS, 2001, J IMMUNOL, V167, P844, DOI 10.4049/jimmunol.167.2.844; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crowley MT, 1997, J EXP MED, V186, P1027, DOI 10.1084/jem.186.7.1027; Deacon K, 1999, J BIOL CHEM, V274, P16604, DOI 10.1074/jbc.274.23.16604; DJEU JY, 1990, BLOOD, V76, P1405; Fernandez R, 1998, J IMMUNOL, V160, P5154; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; GANZ T, 1987, INFECT IMMUN, V55, P568, DOI 10.1128/IAI.55.3.568-571.1987; Go YM, 2001, J APPL PHYSIOL, V91, P1574, DOI 10.1152/jappl.2001.91.4.1574; Go YM, 1998, AM J PHYSIOL-HEART C, V275, pH1898, DOI 10.1152/ajpheart.1998.275.5.H1898; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; GUTHRIE LA, 1984, J EXP MED, V160, P1656, DOI 10.1084/jem.160.6.1656; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Inanami O, 1999, ANTIOXID REDOX SIGN, V1, P113, DOI 10.1089/ars.1999.1.1-113; Ishizuka T, 1999, J IMMUNOL, V162, P2087; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; Jefferies CA, 2000, J BIOL CHEM, V275, P3114, DOI 10.1074/jbc.275.5.3114; Jefferies CA, 2003, J BIOL CHEM, V278, P26258, DOI 10.1074/jbc.M301484200; Kang JL, 2001, AM J RESP CRIT CARE, V164, P2206, DOI 10.1164/ajrccm.164.12.2104017; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Klein JB, 2001, CELL SIGNAL, V13, P335, DOI 10.1016/S0898-6568(01)00151-6; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Laprise P, 2002, J BIOL CHEM, V277, P8226, DOI 10.1074/jbc.M110235200; Lawler S, 1998, CURR BIOL, V8, P1387, DOI 10.1016/S0960-9822(98)00019-0; LEVY O, 1995, J IMMUNOL, V154, P5403; LLOYD AR, 1992, IMMUNOL TODAY, V13, P169, DOI 10.1016/0167-5699(92)90121-M; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; LORD PCW, 1991, J CLIN INVEST, V87, P1312, DOI 10.1172/JCI115134; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; Malcolm KC, 2003, AM J PHYSIOL-LUNG C, V284, pL663, DOI 10.1152/ajplung.00094.2002; MILLER EJ, 1992, AM REV RESPIR DIS, V146, P427, DOI 10.1164/ajrccm/146.2.427; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Naccache PH, 2000, J BIOL CHEM, V275, P23636, DOI 10.1074/jbc.M001780200; Nahas N, 1996, BIOCHEM J, V318, P247, DOI 10.1042/bj3180247; Nakayama K, 2001, J IMMUNOL, V167, P1145, DOI 10.4049/jimmunol.167.3.1145; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; Nick JA, 1996, J IMMUNOL, V156, P4867; Nick JA, 1999, J CLIN INVEST, V103, P851, DOI 10.1172/JCI5257; Pfeiffer A, 2001, EUR J IMMUNOL, V31, P3153, DOI 10.1002/1521-4141(200111)31:11<3153::AID-IMMU3153>3.0.CO;2-0; Procyk KJ, 2000, BLOOD, V96, P2592; Raeder EMB, 1999, J IMMUNOL, V163, P6785; Rhee SH, 2000, J BIOL CHEM, V275, P34035, DOI 10.1074/jbc.M007386200; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; Sanghera JS, 1996, J IMMUNOL, V156, P4457; SHYY YJ, 1990, BIOCHEM BIOPH RES CO, V169, P346, DOI 10.1016/0006-291X(90)90338-N; Somwar R, 2001, J BIOL CHEM, V276, P46079, DOI 10.1074/jbc.M109093200; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEINBERG KP, 1994, AM J RESP CRIT CARE, V150, P113, DOI 10.1164/ajrccm.150.1.8025736; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STRIETER RM, 1992, AM J PATHOL, V141, P397; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Triantafilou M, 2002, J CELL SCI, V115, P2603; Vines CM, 2001, IMMUNITY, V15, P507, DOI 10.1016/S1074-7613(01)00221-7; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamauchi J, 2000, J BIOL CHEM, V275, P7633, DOI 10.1074/jbc.275.11.7633; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yoshimura A, 1999, J IMMUNOL, V163, P1; Yoshizumi M, 2001, MOL PHARMACOL, V60, P656; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	79	119	125	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10883	10891		10.1074/jbc.M309901200	http://dx.doi.org/10.1074/jbc.M309901200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699155	hybrid			2022-12-25	WOS:000220157600009
J	Dulhunty, AF; Curtis, SM; Watson, S; Cengia, L; Casarotto, MG				Dulhunty, AF; Curtis, SM; Watson, S; Cengia, L; Casarotto, MG			Multiple actions of imperatoxin a on ryanodine receptors - Interactions with the II-III loop "A" fragment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; MUSCLE DIHYDROPYRIDINE RECEPTOR; SKELETAL-MUSCLE; CA2+ RELEASE; SARCOPLASMIC-RETICULUM; SUBCONDUCTANCE STATES; CYTOPLASMIC LOOP; SCORPION TOXIN; CARDIAC-MUSCLE; ACTIVATION	Imperatoxin A is a high affinity activator of ryanodine receptors. The toxin contains a positively charged surface structure similar to that of the A fragment of skeletal dihydropyridine receptors ( peptide A), suggesting that the toxin and peptide could bind to a common site on the ryanodine receptor. However, the question of a common binding site has not been resolved, and the concentration dependence of the actions of the toxin has not been fully explored. We characterize two novel high affinity actions of the toxin on the transient gating of cardiac and skeletal channels, in addition to the well documented lower affinity induction of prolonged substates. Transient activity was ( a) enhanced with 0.2 - 10 nM toxin and ( b) depressed by > 50 nM toxin. The toxin at greater than or equal to1 nM enhanced Ca2+ release from SR in a manner consistent with two independent activation processes. The effects of the toxin on transient activity, as well as the toxin-induced substate, were independent of cytoplasmic Ca2+ or Mg2+ concentrations or the presence of adenine nucleotide and were seen in diisothiocyanostilbene-2', 2'-disulfonic acid-modified channels. Peptide A activated skeletal and cardiac channels with 100 nM cytoplasmic Ca2+ and competed with Imperatoxin A in the high affinity enhancement of transient channel activity and Ca2+ release from SR. In contrast to transient activity, prolonged substate openings induced by the toxin were not altered in the presence of peptide A. The results suggest that Imperatoxin A has three independent actions on ryanodine receptor channels and competes with peptide A for at least one action.	Australian Natl Univ, John Curtin Sch Med Res, Div Mol Biosci, Canberra, ACT 2601, Australia; Australian Natl Univ, Res Sch Chem, Canberra, ACT, Australia; Australian Natl Univ, Biotron Ltd, Canberra, ACT 2601, Australia	Australian National University; John Curtin School of Medical Research; Australian National University; Australian National University	Dulhunty, AF (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Mol Biosci, Canberra, ACT 2601, Australia.	angela.dulhunty@anu.edu.au	Casarotto, Marco/D-8704-2011; Dulhunty, Angela/AAO-5421-2020	Dulhunty, Angela/0000-0001-9493-4944; Casarotto, Marco/0000-0002-0571-7671				Ahern CA, 2001, BIOPHYS J, V81, P3294, DOI 10.1016/S0006-3495(01)75963-2; Casarotto MG, 2000, J BIOL CHEM, V275, P11631, DOI 10.1074/jbc.275.16.11631; Casarotto MG, 2001, BIOPHYS J, V80, P2715, DOI 10.1016/S0006-3495(01)76240-6; Chen L, 2003, J BIOL CHEM, V278, P16095, DOI 10.1074/jbc.M209501200; Dulhunty AF, 2002, PROG BIOPHYS MOL BIO, V79, P45, DOI 10.1016/S0079-6107(02)00013-5; Dulhunty AF, 1999, BIOPHYS J, V77, P189, DOI 10.1016/S0006-3495(99)76881-5; ELHAYEK R, 1995, J BIOL CHEM, V270, P22116, DOI 10.1074/jbc.270.38.22116; Fajloun Z, 2000, FEBS LETT, V469, P179, DOI 10.1016/S0014-5793(00)01239-4; Franzini-Armstrong C, 1998, ANN NY ACAD SCI, V853, P20, DOI 10.1111/j.1749-6632.1998.tb08253.x; Gallant EM, 2001, BIOPHYS J, V80, P1769, DOI 10.1016/S0006-3495(01)76147-4; Green D, 2003, BIOCHEM J, V370, P517, DOI 10.1042/BJ20021488; Gurrola GB, 1999, J BIOL CHEM, V274, P7879, DOI 10.1074/jbc.274.12.7879; Haarmann CS, 2003, BIOCHEM J, V372, P305, DOI 10.1042/BJ20021763; Hill AP, 2002, BIOPHYS J, V82, P3037, DOI 10.1016/S0006-3495(02)75644-0; Hirata Y, 1999, BBA-MOL CELL RES, V1451, P132, DOI 10.1016/S0167-4889(99)00082-8; Klinger M, 2001, BIOCHEM J, V355, P827, DOI 10.1042/bj3550827; Lamb GD, 2000, AM J PHYSIOL-CELL PH, V279, pC891, DOI 10.1152/ajpcell.2000.279.4.C891; LAVER DR, 1995, J MEMBRANE BIOL, V147, P7; Leong P, 1998, J BIOL CHEM, V273, P7791, DOI 10.1074/jbc.273.14.7791; Li YX, 2001, J PHYSIOL-LONDON, V537, P17, DOI 10.1111/j.1469-7793.2001.0017k.x; LU XY, 1994, J BIOL CHEM, V269, P6511; MINUM EW, 1993, STAT REASONING PSYCH, P475; Mosbah A, 2000, PROTEINS, V40, P436, DOI 10.1002/1097-0134(20000815)40:3&lt;436::AID-PROT90&gt;3.0.CO;2-9; O'Neill ER, 2003, BIOPHYS J, V84, P1674, DOI 10.1016/S0006-3495(03)74976-5; O'Reilly FM, 2002, BIOPHYS J, V82, P145, DOI 10.1016/S0006-3495(02)75381-2; Oba T, 1996, AM J PHYSIOL-CELL PH, V271, pC819, DOI 10.1152/ajpcell.1996.271.3.C819; Proenza C, 2000, J BIOL CHEM, V275, P29935, DOI 10.1074/jbc.C000464200; Proenza C, 2002, J BIOL CHEM, V277, P6530, DOI 10.1074/jbc.M106471200; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; Samso M, 1999, J CELL BIOL, V146, P493, DOI 10.1083/jcb.146.2.493; SERYSHEVA II, 1995, NAT STRUCT BIOL, V2, P18, DOI 10.1038/nsb0195-18; Sharma MR, 1998, J BIOL CHEM, V273, P18429, DOI 10.1074/jbc.273.29.18429; Stange M, 2001, BIOPHYS J, V81, P1419, DOI 10.1016/S0006-3495(01)75797-9; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; Tripathy A, 1998, J GEN PHYSIOL, V111, P679, DOI 10.1085/jgp.111.5.679; Wilkens CM, 2001, P NATL ACAD SCI USA, V98, P5892, DOI 10.1073/pnas.101618098; Zhu XS, 1999, FEBS LETT, V450, P221, DOI 10.1016/S0014-5793(99)00496-2	37	33	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11853	11862		10.1074/jbc.M310466200	http://dx.doi.org/10.1074/jbc.M310466200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699105	hybrid			2022-12-25	WOS:000220157600122
J	Murai-Takebe, R; Noguchi, T; Ogura, T; Mikami, T; Yanagi, K; Inagaki, K; Ohnishi, H; Matozaki, T; Kasuga, M				Murai-Takebe, R; Noguchi, T; Ogura, T; Mikami, T; Yanagi, K; Inagaki, K; Ohnishi, H; Matozaki, T; Kasuga, M			Ubiquitination-mediated regulation of biosynthesis of the adhesion receptor SHPS-1 in response to endoplasmic reticulum stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED-PROTEIN RESPONSE; ER-ASSOCIATED DEGRADATION; F-BOX; TRANSMEMBRANE GLYCOPROTEIN; QUALITY-CONTROL; SIRP-ALPHA; GROWTH; LIGAND; CELLS; CD47	Misfolding of proteins during endoplasmic reticulum (ER) stress results in the formation of cytotoxic aggregates. The ER-associated degradation pathway counteracts such aggregation through the elimination of misfolded proteins by the ubiquitin-proteasome system. We now show that SHP substrate-1 (SHPS-1), a transmembrane glycoprotein that regulates cytoskeletal reorganization and cell-cell communication, is a physiological substrate for the Skp1-Cullin1-NFB42-Rbx1 (SCFNFB42) E3 ubiquitin ligase, a proposed mediator of ER-associated degradation. SCFNFB42 mediated the polyubiquitination of immature SHPS-1 and its degradation by the proteasome. Ectopic expression of NFB42 both suppressed the formation of aggresome-like structures and the phosphorylation of the translational regulator eIF2alpha induced by overproduction of SHPS-1 as well as increased the amount of mature SHPS-1 at the cell surface. An NFB42 mutant lacking the F box domain had no such effects. Our results suggest that SCFNFB42 regulates SHPS-1 biosynthesis in response to ER stress.	Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet & Digest & Kidney Dis,Chuo Ku, Kobe, Hyogo 6500017, Japan; Sumitomo Chem Co Ltd, Environm Hlth Sci Lab, Takarazuka, Hyogo 6658555, Japan; Gunma Univ, Inst Mol & Cellular Regulat, Biosignal Res Ctr, Maebashi, Gumma 3718512, Japan	Kobe University; Sumitomo Chem Co Ltd; Gunma University	Noguchi, T (corresponding author), Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet & Digest & Kidney Dis,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	noguchi@med.kobe-u.ac.jp						Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Cant CA, 2001, CELL MOL LIFE SCI, V58, P117, DOI 10.1007/PL00000771; CHUANG W, 1990, DEV BIOL, V137, P219, DOI 10.1016/0012-1606(90)90249-I; Comu S, 1997, J NEUROSCI, V17, P8702; Craig KL, 1999, PROG BIOPHYS MOL BIO, V72, P299, DOI 10.1016/S0079-6107(99)00010-3; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; Erhardt JA, 1998, J BIOL CHEM, V273, P35222, DOI 10.1074/jbc.273.52.35222; Friedlander R, 2000, NAT CELL BIOL, V2, P379, DOI 10.1038/35017001; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Graves TK, 2001, J CELL SCI, V114, P3685; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Han X, 2000, J BIOL CHEM, V275, P37984, DOI 10.1074/jbc.M002334200; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Inagaki K, 2000, EMBO J, V19, P6721, DOI 10.1093/emboj/19.24.6721; Jiang PH, 1999, J BIOL CHEM, V274, P559, DOI 10.1074/jbc.274.2.559; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Liu Y, 2002, J BIOL CHEM, V277, P10028, DOI 10.1074/jbc.M109720200; Machida K, 2000, ONCOGENE, V19, P1710, DOI 10.1038/sj.onc.1203497; Mi ZP, 2000, J COMP NEUROL, V416, P335; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Oshima K, 2002, FEBS LETT, V519, P1, DOI 10.1016/S0014-5793(02)02703-5; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; PROSTKO CR, 1993, MOL CELL BIOCHEM, V128, P255, DOI 10.1007/BF01076776; Saginario C, 1998, MOL CELL BIOL, V18, P6213, DOI 10.1128/MCB.18.11.6213; Sano S, 1997, FEBS LETT, V411, P327, DOI 10.1016/S0014-5793(97)00724-2; Seiffert M, 2001, BLOOD, V97, P2741, DOI 10.1182/blood.V97.9.2741; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; SHIBUYA N, 1988, J BIOL CHEM, V263, P728; Takada T, 1998, J BIOL CHEM, V273, P9234, DOI 10.1074/jbc.273.15.9234; Timms JF, 1999, CURR BIOL, V9, P927, DOI 10.1016/S0960-9822(99)80401-1; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; van den Nieuwenhof IM, 2001, J CELL SCI, V114, P1321; WONG WL, 1993, BIOCHEM J, V289, P71, DOI 10.1042/bj2890071; Yamao T, 2002, J BIOL CHEM, V277, P39833, DOI 10.1074/jbc.M203287200; Yamao T, 1997, BIOCHEM BIOPH RES CO, V231, P61, DOI 10.1006/bbrc.1996.6047; Yoshida Y, 2002, NATURE, V418, P438, DOI 10.1038/nature00890	44	14	16	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11616	11625		10.1074/jbc.M311463200	http://dx.doi.org/10.1074/jbc.M311463200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701835	hybrid			2022-12-25	WOS:000220157600095
J	Araki, R; Takahashi, H; Fukumura, R; Sun, FY; Umeda, N; Sujino, M; Inouye, SIT; Saito, T; Abe, M				Araki, R; Takahashi, H; Fukumura, R; Sun, FY; Umeda, N; Sujino, M; Inouye, SIT; Saito, T; Abe, M			Restricted expression and photic induction of a novel mouse regulatory factor X4 transcript in the suprachiasmatic nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II DEFICIENCY; PROMOTER BINDING-PROTEIN; DNA-BINDING; CIRCADIAN CLOCK; GENE-EXPRESSION; MESSENGER-RNAS; RFX FAMILY; LIGHT; DROSOPHILA; SYSTEM	The regulatory factor X (RFX) family of transcription factors is characterized by a unique and highly conserved 76-amino acid residue DNA-binding domain. Mammals have five RFX genes, but the physiological functions of their products are unknown, with the exception of RFX5. Here a mouse RFX4 transcript was identified that encodes a peptide of 735 amino acids, including the DNA-binding domain. Its expression was localized in the suprachiasmatic nucleus, the central pacemaker site of the circadian clock. Also, light exposure was found to induce its gene expression in a subjective night-specific manner. Polyclonal antibodies were prepared, and an 80-kDa band was detected in the suprachiasmatic nucleus by Western hybridization. A histochemical study showed a localization of the products in the nucleus. This is the first report on mouse RFX4, which contains the RFX DNA-binding motif. Our investigation may provide clues to the physiological function of RFX4.	Natl Inst Radiol Sci, Transcriptome Res Ctr, Inage Ku, Chiba 2638555, Japan; Japan Soc Promot Sci, Kawaguchi, Saitama 3320012, Japan; Yamaguchi Univ, Dept Phys Informat & Biol, Yamaguchi 7538512, Japan	National Institutes for Quantum Science & Technology; Japan Society for the Promotion of Science; Yamaguchi University	Abe, M (corresponding author), Natl Inst Radiol Sci, Transcriptome Res Ctr, Inage Ku, Anagawa 4-9-1, Chiba 2638555, Japan.	abemasum@nirs.go.jp		Abe, Masumi/0000-0003-1550-2006; Takahashi, Hirokazu/0000-0002-9425-6546				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Baqui MMA, 2000, ENDOCRINOLOGY, V141, P4309, DOI 10.1210/en.141.11.4309; Blackshear PJ, 2003, DEVELOPMENT, V130, P4539, DOI 10.1242/dev.00661; Cermakian N, 2002, CURR OPIN NEUROBIOL, V12, P359, DOI 10.1016/S0959-4388(02)00347-1; DOTZLAW H, 1992, MOL ENDOCRINOL, V6, P773, DOI 10.1210/me.6.5.773; Doyle J, 1996, GENOMICS, V35, P227, DOI 10.1006/geno.1996.0343; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Durand B, 2000, GENE, V246, P285, DOI 10.1016/S0378-1119(00)00093-7; Durand B, 1997, EMBO J, V16, P1045, DOI 10.1093/emboj/16.5.1045; Emery P, 1996, NUCLEIC ACIDS RES, V24, P803, DOI 10.1093/nar/24.5.803; FLOREZ JC, 1995, ANN MED, V27, P481, DOI 10.3109/07853899709002457; Gajiwala KS, 2000, NATURE, V403, P916, DOI 10.1038/35002634; Gau D, 2002, NEURON, V34, P245, DOI 10.1016/S0896-6273(02)00656-6; Gillette MU, 1997, CURR OPIN NEUROBIOL, V7, P797, DOI 10.1016/S0959-4388(97)80138-9; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; Guido ME, 1996, BRAIN RES, V739, P132, DOI 10.1016/S0006-8993(96)00816-5; Honrado GI, 1996, J COMP PHYSIOL A, V178, P563; INOUYE ST, 1979, P NATL ACAD SCI USA, V76, P5962, DOI 10.1073/pnas.76.11.5962; Karsai A, 2002, BIOTECHNIQUES, V32, P790, DOI 10.2144/02324st05; Kawai J, 2001, NATURE, V409, P685, DOI 10.1038/35055500; Kilduff TS, 1998, J BIOL RHYTHM, V13, P347, DOI 10.1177/074873098129000174; Klein D.C., 1991, SUPRACHIASMATIC NUCL; KORNHAUSER JM, 1990, NEURON, V5, P127, DOI 10.1016/0896-6273(90)90303-W; Kornhauser JM, 1996, BEHAV GENET, V26, P221, DOI 10.1007/BF02359382; Masternak K, 1998, NAT GENET, V20, P273, DOI 10.1038/3081; Morotami-Yano K, 2002, J BIOL CHEM, V277, P836, DOI 10.1074/jbc.M108638200; Morris ME, 1998, SCIENCE, V279, P1544, DOI 10.1126/science.279.5356.1544; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; REITH W, 1994, MOL CELL BIOL, V14, P1230, DOI 10.1128/MCB.14.2.1230; REITH W, 1988, CELL, V53, P897, DOI 10.1016/S0092-8674(88)90389-3; REITH W, 1990, GENE DEV, V4, P1528, DOI 10.1101/gad.4.9.1528; REITH W, 1989, P NATL ACAD SCI USA, V86, P4200, DOI 10.1073/pnas.86.11.4200; Romijn HJ, 1996, J COMP NEUROL, V372, P1; RUSAK B, 1992, MOL BRAIN RES, V14, P124, DOI 10.1016/0169-328X(92)90019-8; Schmitt EK, 2000, J BIOL CHEM, V275, P9348, DOI 10.1074/jbc.275.13.9348; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Stehle JH, 1996, NEUROSCI LETT, V217, P169, DOI 10.1016/0304-3940(96)13103-7; STEIMLE V, 1995, GENE DEV, V9, P1021, DOI 10.1101/gad.9.9.1021; Swoboda P, 2000, MOL CELL, V5, P411, DOI 10.1016/S1097-2765(00)80436-0; Takahashi J S, 1991, Curr Opin Neurobiol, V1, P556, DOI 10.1016/S0959-4388(05)80028-5; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Ueda HR, 2002, NATURE, V418, P534, DOI 10.1038/nature00906; Vandaele C, 2001, MECH DEVELOP, V103, P159, DOI 10.1016/S0925-4773(01)00340-9; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Wiechmann AF, 2002, J PINEAL RES, V33, P178, DOI 10.1034/j.1600-079X.2002.02935.x; Wisor JP, 1997, J COMP NEUROL, V378, P229; WU SY, 1995, MOL CELL BIOL, V15, P1479; ZHOU SB, 1993, J BIOL CHEM, V268, P12655	49	21	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10237	10242		10.1074/jbc.M312761200	http://dx.doi.org/10.1074/jbc.M312761200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701801	hybrid			2022-12-25	WOS:000220050400071
J	Kitzing, K; Auweter, S; Amrhein, N; Macheroux, P				Kitzing, K; Auweter, S; Amrhein, N; Macheroux, P			Mechanism of chorismate synthase - Role of the two invariant histidine residues in the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANALOGS PROVIDE EVIDENCE; NEUROSPORA-CRASSA; FLAVIN; SUBSTRATE; BINDING; INTERMEDIATE; PHOSPHATE; FMN	Chorismate synthase catalyzes the last step in the common shikimate pathway leading to aromatic compounds such as the aromatic amino acids. The reaction consists of the 1,4-anti-elimination of the 3-phosphate group and the C-(6proR) hydrogen from 5-enolpyruvylshikimate 3-phosphate to yield chorismate. Although this reaction does not involve a net redox change, the enzyme has an absolute requirement for reduced flavin mononucleotide, which is not consumed during the reaction. Two invariant histidine residues are found in the active site of the enzyme: His(17) and His(106). Using site-directed mutagenesis, both histidines were replaced by alanine, reducing the activity 10- and 20-fold in the H106A and H17A mutant protein, respectively. Based on the characterization of the two single mutant proteins, it is proposed that His106 serves to protonate the monoanionic reduced FMN, whereas His(17) protonates the leaving phosphate group of the substrate. An enzymatic reaction mechanism in keeping with the experimental results is presented.	Swiss Fed Inst Technol, Inst Plant Sci, Dept Agr & Food Sci, CH-8092 Zurich, Switzerland; Swiss Fed Inst Technol, Inst Plant Sci, Dept Biol, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Macheroux, P (corresponding author), Graz Tech Univ, Inst Biochem, Petersgasse 12-II, A-8010 Graz, Austria.	peter.macheroux@tugraz.at	Macheroux, Peter/AAB-5157-2019	Macheroux, Peter/0000-0002-0242-454X				Bornemann S, 1996, BIOCHEMISTRY-US, V35, P9907, DOI 10.1021/bi952958q; Bornemann S, 2000, BIOORG CHEM, V28, P191, DOI 10.1006/bioo.2000.1174; Bornemann S, 1996, BIOCHEM SOC T, V24, P84, DOI 10.1042/bst0240084; Dmitrenko O, 2001, ORG LETT, V3, P4137, DOI 10.1021/ol0167964; DRAPER RD, 1968, ARCH BIOCHEM BIOPHYS, V125, P802, DOI 10.1016/0003-9861(68)90517-1; DUDLEY KH, 1964, HELV CHIM ACTA, V47, P1354, DOI 10.1002/hlca.19640470531; Fitzpatrick TB, 2001, J BIOL CHEM, V276, P18052, DOI 10.1074/jbc.M100867200; FLOSS HG, 1972, J BIOL CHEM, V247, P736; HALL LH, 1987, INT J QUANTUM CHEM, V31, P217, DOI 10.1002/qua.560310204; HENSTRAND JM, 1995, J BIOL CHEM, V270, P20447, DOI 10.1074/jbc.270.35.20447; Kitzing K, 2001, J BIOL CHEM, V276, P42658, DOI 10.1074/jbc.M107249200; Knaggs AR, 2001, NAT PROD REP, V18, P334, DOI 10.1039/b001717p; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Macheroux P, 1996, BIOCHEMISTRY-US, V35, P1643, DOI 10.1021/bi951705u; Macheroux P, 1999, PLANTA, V207, P325, DOI 10.1007/s004250050489; Macheroux P, 1998, BIOCHEM J, V335, P319, DOI 10.1042/bj3350319; Macheroux P, 1996, J BIOL CHEM, V271, P25850, DOI 10.1074/jbc.271.42.25850; MACHEROUX P, 1997, FLAVINS FLAVOPROTEIN, P113; Maclean J, 2003, STRUCTURE, V11, P1499, DOI 10.1016/j.str.2003.11.005; Maniatis T., 1982, MOL CLONING LAB MANU; Massey V., 1991, FLAVINS FLAVOPROTEIN, P581; Miles E W, 1977, Methods Enzymol, V47, P431; MORELL H, 1967, J BIOL CHEM, V242, P82; Osborne A, 2000, J BIOL CHEM, V275, P35825, DOI 10.1074/jbc.M005796200; RAMJEE MN, 1991, J AM CHEM SOC, V113, P8566, DOI 10.1021/ja00022a078; WELCH GR, 1974, ARCH BIOCHEM BIOPHYS, V165, P505, DOI 10.1016/0003-9861(74)90276-8	26	26	29	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9451	9461		10.1074/jbc.M312471200	http://dx.doi.org/10.1074/jbc.M312471200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14668332	hybrid			2022-12-25	WOS:000189265900111
J	Xin, HW; Yoon, HG; Singh, PB; Wong, JM; Qin, J				Xin, HW; Yoon, HG; Singh, PB; Wong, JM; Qin, J			Components of a pathway maintaining histone modification and heterochromatin protein 1 binding at the pericentric heterochromatin in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CANCER-CELLS; DNA METHYLATION; H3 METHYLTRANSFERASE; LYSINE-9 METHYLATION; NEUROSPORA-CRASSA; COMPLEX; HP1; DNMT1; HYPOMETHYLATION; ARABIDOPSIS	Heterochromatin is a higher order chromatin structure that is important for transcriptional silencing, chromosome segregation, and genome stability. The establishment and maintenance of heterochromatin is regulated not only by genetic elements but also by epigenetic elements that include histone tail modification ( e. g. acetylation and methylation) and DNA methylation. Here we show that the p33ING1-Sin3-HDAC complex as well as DNA methyltransferase 1 (DNMT1) and DNMT1-associated protein 1 (DMAP1) are components of a pathway required for maintaining proper histone modification and heterochromatin protein 1 binding at the pericentric heterochromatin. p33ING1 and DMAP1 interact physically and co-localize to heterochromatin in the late S phase, and both are required for heterochromatin protein 1 binding to heterochromatin. Although the p33ING1-Sin3-HDAC and DMAP1-DNMT1 complexes are recruited independently to pericentric heterochromatin regions, they are both required for deacetylation of histones and methylation of histone H3 at lysine 9. These data support a cooperative model for histone deacetylation, methylation, and DNA methylation in maintaining pericentric heterochromatin structure throughout cell divisions.	Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Roslin Inst Edinburgh, Div Gene Express & Dev, Nucl Reprogramming Lab, Roslin EH25 9PS, Midlothian, Scotland	Baylor College of Medicine; Baylor College of Medicine; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute	Qin, J (corresponding author), Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA.	jqin@bcm.tmc.edu	Singh, Prim/G-1088-2014	Singh, Prim/0000-0002-9571-0974; Xin, Huawei/0000-0003-4017-6572; Wong, Jiemin/0000-0002-5311-842X				Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572; Cowell IG, 2002, CHROMOSOMA, V111, P22, DOI 10.1007/s00412-002-0182-8; David G, 2003, GENE DEV, V17, P2396, DOI 10.1101/gad.1109403; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Festenstein R, 2003, SCIENCE, V299, P719, DOI 10.1126/science.1078694; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Gendrel AV, 2002, SCIENCE, V297, P1871, DOI 10.1126/science.1074950; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Li JW, 2002, GENE DEV, V16, P687, DOI 10.1101/gad.962502; Maison C, 2002, NAT GENET, V30, P329, DOI 10.1038/ng843; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Skowyra D, 2001, J BIOL CHEM, V276, P8734, DOI 10.1074/jbc.M007664200; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Soppe WJJ, 2002, EMBO J, V21, P6549, DOI 10.1093/emboj/cdf657; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Tamaru H, 2003, NAT GENET, V34, P75, DOI 10.1038/ng1143; Wang Y, 2000, GENE DEV, V14, P927; WAYE JS, 1985, NUCLEIC ACIDS RES, V13, P2731, DOI 10.1093/nar/13.8.2731	26	46	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9539	9546		10.1074/jbc.M311587200	http://dx.doi.org/10.1074/jbc.M311587200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14665632	hybrid			2022-12-25	WOS:000189265900121
J	Zhao, HR; Bernardo, MM; Osenkowski, P; Sohail, A; Pei, DQ; Nagase, H; Kashiwagi, M; Soloway, PD; DeClerck, YA; Fridman, R				Zhao, HR; Bernardo, MM; Osenkowski, P; Sohail, A; Pei, DQ; Nagase, H; Kashiwagi, M; Soloway, PD; DeClerck, YA; Fridman, R			Differential inhibition of membrane type 3 (MT3)-matrix metalloproteinase (MMP) and MT1-MMP by tissue inhibitor of metalloproteinase (TIMP)-2 and TIMP-3 regulates pro-MMP-2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-MATRIX METALLOPROTEINASE; HIGH-AFFINITY BINDING; C-TERMINAL DOMAIN; GELATINASE-A; CELL-SURFACE; PROGELATINASE-A; 1-MATRIX METALLOPROTEINASE; PERICELLULAR PROTEOLYSIS; EFFICIENT ACTIVATION; EXPRESSION SYSTEM	The membrane type (MT)-matrix metalloproteinases (MMPs) constitute a subgroup of membrane-anchored MMPs that are major mediators of pericellular proteolysis and physiological activators of pro-MMP-2. The MT-MMPs also exhibit differential inhibition by members of the tissue inhibitor of metalloproteinase ( TIMP) family. Here we investigated the processing, catalytic activity, and TIMP inhibition of MT3-MMP (MMP-16). Inhibitor profile and mutant enzyme studies indicated that MT3-MMP is regulated on the cell surface by autocatalytic processing and ectodomain shedding. Inhibition kinetic studies showed that TIMP-3 is a high affinity inhibitor of MT3-MMP when compared with MT1-MMP (K-i = 0.008 nM for MT3-MMP versus K-i = 0.16 nM for MT1-MMP). In contrast, TIMP-2 is a better inhibitor of MT1-MMP. MT3-MMP requires TIMP-2 to accomplish full pro-MMP-2 activation and this process is enhanced in marimastat-pretreated cells, consistent with regulation of active enzyme turnover by synthetic MMP inhibitors. TIMP-3 also enhances the activation of pro-MMP-2 by MT3-MMP but not by MT1-MMP. TIMP-4, in contrast, cannot support pro-MMP-2 activation with either enzyme. Affinity chromatography experiments demonstrated that pro-MMP-2 can assemble trimolecular complexes with a catalytic domain of MT3-MMP and TIMP-2 or TIMP-3 suggesting that pro-MMP-2 activation by MT3-MMP involves ternary complex formation on the cell surface. These results demonstrate that TIMP-3 is a major regulator of MT3-MMP activity and further underscores the unique interactions of TIMPs with MT-MMPs in the control of pericellular proteolysis.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; Univ London Imperial Coll Sci Technol & Med, Div Rheumatol, Kennedy Inst, London W6 8LH, England; Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; Univ So Calif, Childrens Hosp Los Angeles, Div Hematol Oncol, Los Angeles, CA 90027 USA; Univ So Calif, Childrens Hosp Los Angeles, Dept Pediat, Los Angeles, CA 90027 USA	Wayne State University; University of Minnesota System; University of Minnesota Twin Cities; Imperial College London; University of Oxford; Cornell University; Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles; University of Southern California	Fridman, R (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, 540 E Canfield Ave, Detroit, MI 48201 USA.	rfridman@med.wayne.edu	Soloway, Paul/T-8243-2019	DeClerck, Yves/0000-0002-3688-0113; Sohail, Anjum/0000-0001-5567-9645; Soloway, Paul/0000-0003-1967-0437	NATIONAL CANCER INSTITUTE [R01CA100475, R01CA061986] Funding Source: NIH RePORTER; NCI NIH HHS [CA100475, CA61986] Funding Source: Medline; NIAMS NIH HHS [AR39198] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; AnandApte B, 1996, BIOCHEM CELL BIOL, V74, P853, DOI 10.1139/o96-090; APTE SS, 1994, GENOMICS, V19, P86, DOI 10.1006/geno.1994.1016; APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; Aznavoorian S, 2001, CANCER RES, V61, P6264; Bernardo MM, 2003, BIOCHEM J, V374, P739, DOI 10.1042/BJ20030557; Bernardo MM, 2002, J BIOL CHEM, V277, P11201, DOI 10.1074/jbc.M111021200; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; Bigg HF, 2001, CANCER RES, V61, P3610; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Butler GS, 1997, EUR J BIOCHEM, V244, P653, DOI 10.1111/j.1432-1033.1997.t01-1-00653.x; Butler GS, 1999, J BIOL CHEM, V274, P10846, DOI 10.1074/jbc.274.16.10846; Daja MM, 2003, PROSTATE CANCER P D, V6, P15, DOI 10.1038/sj.pcan.4500609; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Fridman R, 2003, CURR TOP DEV BIOL, V54, P75, DOI 10.1016/S0070-2153(03)54005-4; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hernandez-Barrantes S, 2002, SEMIN CANCER BIOL, V12, P131, DOI 10.1006/scbi.2001.0421; Hernandez-Barrantes S, 2001, BIOCHEM BIOPH RES CO, V281, P126, DOI 10.1006/bbrc.2001.4323; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2002, J EXP MED, V195, P295, DOI 10.1084/jem.20010815; Iida J, 2001, J BIOL CHEM, V276, P18786, DOI 10.1074/jbc.M010053200; Jiang AX, 2003, J BIOL CHEM, V278, P38765, DOI 10.1074/jbc.M306618200; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Jo Y, 2000, BIOCHEM J, V345, P511, DOI 10.1042/bj3450511; Jung JC, 2002, DEV DYNAM, V223, P402, DOI 10.1002/dvdy.10069; Kai HST, 2002, J BIOL CHEM, V277, P48696, DOI 10.1074/jbc.M209177200; Kang TB, 2000, FASEB J, V14, P2559, DOI 10.1096/fj.00-0269com; Kang TB, 2002, CANCER RES, V62, P675; Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200; Kitagawa Y, 1999, J UROLOGY, V162, P905, DOI 10.1097/00005392-199909010-00088; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; KNIGHT CG, 1995, METHOD ENZYMOL, V248, P18; Ko YC, 1997, BIOCHEM BIOPH RES CO, V236, P100, DOI 10.1006/bbrc.1997.6859; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Maquoi E, 2000, J BIOL CHEM, V275, P11368, DOI 10.1074/jbc.275.15.11368; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Morgunova E, 2002, P NATL ACAD SCI USA, V99, P7414, DOI 10.1073/pnas.102185399; Morrison CJ, 2001, J BIOL CHEM, V276, P47402, DOI 10.1074/jbc.M108643200; Murphy G, 2003, BIOCHEM SOC SYMP, V70, P65, DOI 10.1042/bss0700065; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; Nakada M, 1999, AM J PATHOL, V154, P417, DOI 10.1016/S0002-9440(10)65288-1; Nuttall RK, 2003, MOL CANCER RES, V1, P333; Ohnishi Y, 2001, EUR J DERMATOL, V11, P420; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; Olson MW, 1998, J BIOL CHEM, V273, P10672, DOI 10.1074/jbc.273.17.10672; Olson MW, 2000, J BIOL CHEM, V275, P2661, DOI 10.1074/jbc.275.4.2661; Overall CM, 1999, J BIOL CHEM, V274, P4421, DOI 10.1074/jbc.274.7.4421; Overall CM, 2002, MOL BIOTECHNOL, V22, P51, DOI 10.1385/MB:22:1:051; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Seidah NG, 2002, ESSAYS BIOCHEM, V38, P79, DOI 10.1042/bse0380079; Seiki M, 2003, CANCER METAST REV, V22, P129, DOI 10.1023/A:1023087113214; Shimada T, 1999, EUR J BIOCHEM, V262, P907, DOI 10.1046/j.1432-1327.1999.00459.x; Shofuda K, 1997, J BIOL CHEM, V272, P9749; Shofuda K, 2001, FASEB J, V15, P2010, DOI 10.1096/fj.00-0871fje; Shofuda KI, 2001, ANN NY ACAD SCI, V947, P337; Stanton H, 1998, J CELL SCI, V111, P2789; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Toth M, 2002, J BIOL CHEM, V277, P26340, DOI 10.1074/jbc.M200655200; Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200; Toth M, 2003, BIOCHEM BIOPH RES CO, V308, P386, DOI 10.1016/S0006-291X(03)01405-0; Toth M, 1997, CANCER RES, V57, P3159; Troeberg L, 2002, BIOCHEMISTRY-US, V41, P15025, DOI 10.1021/bi026454l; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; URIA JA, 1994, CANCER RES, V54, P2091; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; Worley JR, 2003, BIOCHEM J, V372, P799, DOI 10.1042/BJ20021573; Yoshiyama Y, 1998, ACTA NEUROPATHOL, V96, P347, DOI 10.1007/s004010050904; Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200; Zucker S, 2003, CURR TOP DEV BIOL, V54, P1, DOI 10.1016/S0070-2153(03)54004-2	77	119	127	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8592	8601		10.1074/jbc.M308708200	http://dx.doi.org/10.1074/jbc.M308708200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14681236	hybrid			2022-12-25	WOS:000189265900010
J	Boukaba, A; Georgieva, EI; Myers, FA; Thorne, AW; Lopez-Rodas, G; Crane-Robinson, C; Franco, L				Boukaba, A; Georgieva, EI; Myers, FA; Thorne, AW; Lopez-Rodas, G; Crane-Robinson, C; Franco, L			A short-range gradient of histone H3 acetylation and Tup1p redistribution at the promoter of the Saccharomyces cerevisiae SUC2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNF1 PROTEIN-KINASE; DNASE-I SENSITIVITY; CHROMATIN-STRUCTURE; GLUCOSE REPRESSION; SWI-SNF; NUCLEOSOME ACETYLATION; INVERTASE SYNTHESIS; YEAST; COMPLEX; TRANSCRIPTION	Chromatin immunoprecipitation assays are used to map H3 and H4 acetylation over the promoter nucleosomes and the coding region of the Saccharomyces cerevisiae SUC2 gene, under repressed and derepressed conditions, using wild type and mutant strains. In wild type cells, a high level of H3 acetylation at the distal end of the promoter drops sharply toward the proximal nucleosome that covers the TATA box, a gradient that become even steeper on derepression. In contrast, substantial H4 acetylation shows no such gradient and extends into the coding region. Overall levels of both H3 and H4 acetylation rise on derepression. Mutation of GCN5 or SNF2 lead to substantially reduced SUC2 expression; in gnc5 there is no reduction in basal H3 acetylation, but large reductions occur on derepression. SNF2 mutation has little effect on H3 acetylation, so SAGA and SWI/SNF recruitment seem to be independent events. H4 acetylation is little affected by either GCN5 or SNF2 mutation. In a double snf2/gcn5 mutant (very low SUC2 expression), H3 acetylation is at the minimal level, but H4 acetylation remains largely unaffected. Transcription is thus linked to H3 but not H4 acetylation. Chromatin immunoprecipitation assays show that Tup1p is evenly distributed over the four promoter nucleosomes in repressed wild type cells but redistributes upstream on derepression, a movement probably linked to its conversion from a repressor to an activator.	Univ Valencia, Dept Biochem & Mol Biol, E-46100 Burjassot, Valencia, Spain; Bulgarian Acad Sci, Inst Genet, BU-1113 Sofia, Bulgaria; Univ Portsmouth, Fac Sci, Inst Biomed & Biomol Sci, Biophys Labs, Portsmouth PO1 2DT, Hants, England	University of Valencia; Bulgarian Academy of Sciences; University of Portsmouth	Franco, L (corresponding author), Univ Valencia, Dept Biochem & Mol Biol, Dr Moliner 50, E-46100 Burjassot, Valencia, Spain.	luis.franco@uv.es	Georgieva, Elena/O-1674-2019; , thorne/AAC-4984-2020; LOPEZ-RODAS, GERARDO/I-1349-2015	, thorne/0000-0002-8670-2358; Myers, Fiona/0000-0001-5568-1817; Franco, Luis/0000-0001-9610-6448; LOPEZ-RODAS, GERARDO/0000-0001-8367-653X				Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Biggar SR, 1999, EMBO J, V18, P2254, DOI 10.1093/emboj/18.8.2254; Bone JR, 2001, J BIOL CHEM, V276, P1808, DOI 10.1074/jbc.M008668200; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Bu Y, 1998, NUCLEIC ACIDS RES, V26, P1002, DOI 10.1093/nar/26.4.1002; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; CARLSON M, 1984, GENETICS, V107, P19; CARLSON M, 1981, GENETICS, V98, P25; CELENZA JL, 1984, MOL CELL BIOL, V4, P49, DOI 10.1128/MCB.4.1.49; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; Davie JK, 2003, J BIOL CHEM, V278, P50158, DOI 10.1074/jbc.M309753200; Davie JK, 2002, MOL CELL BIOL, V22, P693, DOI 10.1128/MCB.22.3.693-703.2002; Deckert J, 2001, MOL CELL BIOL, V21, P2726, DOI 10.1128/MCB.21.8.2726-2735.2001; DeVit MJ, 1997, MOL BIOL CELL, V8, P1603, DOI 10.1091/mbc.8.8.1603; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Forsberg EC, 2001, BIOESSAYS, V23, P820, DOI 10.1002/bies.1117; Gavin IM, 1997, EMBO J, V16, P6263, DOI 10.1093/emboj/16.20.6263; Goldstein A, 1975, Methods Enzymol, V42, P504; Grant PA, 1999, J BIOL CHEM, V274, P5895, DOI 10.1074/jbc.274.9.5895; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; IGUAL JC, 1992, MOL MICROBIOL, V6, P1867, DOI 10.1111/j.1365-2958.1992.tb01359.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Iyer V, 1996, P NATL ACAD SCI USA, V93, P5208, DOI 10.1073/pnas.93.11.5208; Jiang R, 1997, MOL CELL BIOL, V17, P2099, DOI 10.1128/MCB.17.4.2099; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Lutfiyya LL, 1998, GENETICS, V150, P1377; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; MATALLANA E, 1992, MOL GEN GENET, V231, P395, DOI 10.1007/BF00292708; Myers FA, 2001, J BIOL CHEM, V276, P20197, DOI 10.1074/jbc.M009472200; NEHLIN JO, 1992, NUCLEIC ACIDS RES, V20, P5271, DOI 10.1093/nar/20.20.5271; NEIGEBORN L, 1984, GENETICS, V108, P845; NEIGEBORN L, 1987, GENETICS, V115, P247; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Papamichos-Chronakis M, 2002, MOL CELL, V9, P1297, DOI 10.1016/S1097-2765(02)00545-2; PEREZORTIN JE, 1986, MOL GEN GENET, V205, P422, DOI 10.1007/BF00338077; PEREZORTIN JE, 1987, NUCLEIC ACIDS RES, V15, P6937; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Proft M, 2002, MOL CELL, V9, P1307, DOI 10.1016/S1097-2765(02)00557-9; Recht J, 1999, EMBO J, V18, P229, DOI 10.1093/emboj/18.1.229; Redd MJ, 1997, J BIOL CHEM, V272, P11193; Roberts SM, 1997, GENETICS, V147, P451; Salgado APC, 2002, FEBS LETT, V532, P324, DOI 10.1016/S0014-5793(02)03695-5; Sterner DE, 1999, MOL CELL BIOL, V19, P86; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; Torres L, 2000, FASEB J, V14, P95, DOI 10.1096/fasebj.14.1.95; Treitel MA, 1998, MOL CELL BIOL, V18, P6273, DOI 10.1128/MCB.18.11.6273; TREITEL MA, 1995, P NATL ACAD SCI USA, V92, P3132, DOI 10.1073/pnas.92.8.3132; Varanasi US, 1996, MOL CELL BIOL, V16, P6707; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Watson AD, 2000, GENE DEV, V14, P2737, DOI 10.1101/gad.829100; WILLIAMS FE, 1990, MOL CELL BIOL, V10, P6500, DOI 10.1128/MCB.10.12.6500; Wilson WA, 1996, CURR BIOL, V6, P1426, DOI 10.1016/S0960-9822(96)00747-6; Wu L, 1997, NUCLEIC ACIDS RES, V25, P4230, DOI 10.1093/nar/25.21.4230	55	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7678	7684		10.1074/jbc.M310849200	http://dx.doi.org/10.1074/jbc.M310849200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14670975	hybrid			2022-12-25	WOS:000189103300039
J	Dairou, J; Atmane, N; Rodrigues-Lima, F; Dupret, JM				Dairou, J; Atmane, N; Rodrigues-Lima, F; Dupret, JM			Peroxynitrite irreversibly inactivates the human xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 (NAT1) in human breast cancer cells - A cellular and mechanistic study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLTRANSFERASE; NITRIC-OXIDE; ACTIVE-SITE; REVERSIBLE INACTIVATION; COLORECTAL-CARCINOMA; CATALYTIC MECHANISM; MOLECULAR-GENETICS; CREATINE-KINASE; INHIBITION; NITRATION	Arylamine N-acetyltransferases (NATs) play an important role in the detoxification and metabolic activation of a variety of aromatic xenobiotics, including numerous carcinogens. Both of the human isoforms, NAT1 and NAT2, display interindividual variations, and associations between NAT genotypes and cancer risk have been established. Contrary to NAT2, NAT1 has a ubiquitous tissue distribution and has been shown to be expressed in cancer cells. Given that the activity of NAT1 depends on a reactive cysteine that can be a target for oxidants, we studied whether peroxynitrite, a highly reactive nitrogen species involved in human carcinogenesis, could inhibit the activity of endogenous NAT1 in MCF7 breast cancer cells. We show here that exposure of MCF7 cells to physiological concentrations of peroxynitrite and to a peroxynitrite generator (3-morpholinosydnonimine N-ethylcarbamide, or SIN1) leads to the irreversible inactivation of NAT1 in cells. Further kinetic and mechanistic analyses using recombinant NAT1 showed that the enzyme is rapidly (k(inact) = 5 x 10(4) M-1.s(-1)) and irreversibly inactivated by peroxynitrite. This inactivation is due to oxidative modification of the catalytic cysteine. We conclude that the reducing cellular environment of MCF7 cells does not sufficiently protect NAT1 from peroxynitrite-dependent inactivation and that only high concentrations of reduced glutathione could significantly protect NAT1. Thus, cellular generation of peroxynitrite may contribute to carcinogenesis and tumor progression by weakening key cellular defense enzymes such as NAT1.	Univ Paris 06, CNRS, Unite Mixte Rech 7000, F-75013 Paris, France; Univ Paris 07, Unite Format & Rech Biochim, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite	Rodrigues-Lima, F (corresponding author), Univ Paris 06, CNRS, Unite Mixte Rech 7000, F-75013 Paris, France.	rlima@ext.jussieu.fr; jmdupret@infobiogen.fr						Adam PJ, 2003, MOL CANCER RES, V1, P826; ANDRES HH, 1988, J BIOL CHEM, V263, P7521; Atmane N, 2003, J BIOL CHEM, V278, P35086, DOI 10.1074/jbc.M303813200; BADAWI AF, 1995, CANCER RES, V55, P5230; BLUM M, 1990, DNA CELL BIOL, V9, P193, DOI 10.1089/dna.1990.9.193; Boelsterli, 2003, MECH TOXICOLOGY MOL; Butcher N. J., 2002, Pharmacogenomics Journal, V2, P30, DOI 10.1038/sj.tpj.6500053; Butcher NJ, 2000, MOL PHARMACOL, V57, P468, DOI 10.1124/mol.57.3.468; Butcher NJ, 2000, BIOCHEM PHARMACOL, V60, P1829, DOI 10.1016/S0006-2952(00)00501-3; Caselli A, 1998, J BIOL CHEM, V273, P32554, DOI 10.1074/jbc.273.49.32554; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Daiber A, 2000, EUR J BIOCHEM, V267, P6729, DOI 10.1046/j.1432-1033.2000.01768.x; Dairou J, 2003, BIOCHEM BIOPH RES CO, V307, P1059, DOI 10.1016/S0006-291X(03)01311-1; DEGUCHI T, 1992, J BIOL CHEM, V267, P18140; Delgoda R, 2003, BBA-GEN SUBJECTS, V1620, P8, DOI 10.1016/S0304-4165(02)00500-7; DUPRET JM, 1992, J BIOL CHEM, V267, P7381; Filomeni G, 2002, BIOCHEM PHARMACOL, V64, P1057, DOI 10.1016/S0006-2952(02)01176-0; Giles NM, 2003, BIOCHEM BIOPH RES CO, V300, P1, DOI 10.1016/S0006-291X(02)02770-5; GRANT DM, 1991, MOL PHARMACOL, V39, P184; Groves JT, 1999, CURR OPIN CHEM BIOL, V3, P226, DOI 10.1016/S1367-5931(99)80036-2; Hein DW, 2002, MUTAT RES-FUND MOL M, V506, P65, DOI 10.1016/S0027-5107(02)00153-7; Hein DW, 2000, CANCER EPIDEM BIOMAR, V9, P29; Hein DW, 2000, DRUG METAB DISPOS, V28, P1425; Hosker BS, 2001, DIABETOLOGIA, V44, pA144; Ignarro LJ, 1999, BIOSCIENCE REP, V19, P51, DOI 10.1023/A:1020150124721; ILETT KF, 1994, BIOCHEM PHARMACOL, V47, P914, DOI 10.1016/0006-2952(94)90493-6; Josephs M, 2002, FEBS LETT, V531, P329, DOI 10.1016/S0014-5793(02)03551-2; Kondo S, 2002, CANCER LETT, V179, P87, DOI 10.1016/S0304-3835(01)00859-X; Konorev EA, 1998, FEBS LETT, V427, P171, DOI 10.1016/S0014-5793(98)00413-X; Kuhn DM, 1999, J BIOL CHEM, V274, P29726, DOI 10.1074/jbc.274.42.29726; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Lin HL, 2003, CHEM RES TOXICOL, V16, P129, DOI 10.1021/tx020040b; Liu LM, 1999, CELL DEATH DIFFER, V6, P937, DOI 10.1038/sj.cdd.4400578; Maeda H, 1998, BIOCHEMISTRY-MOSCOW+, V63, P854; Matas N, 1997, CYTOGENET CELL GENET, V77, P290, DOI 10.1159/000134601; Meisel P, 2002, PHARMACOGENOMICS, V3, P349, DOI 10.1517/14622416.3.3.349; Mihm MJ, 2002, BIOCHIMIE, V84, P1013, DOI 10.1016/S0300-9084(02)00005-6; Mohr S, 1997, BIOCHEM BIOPH RES CO, V238, P387, DOI 10.1006/bbrc.1997.7304; Mushtaq A, 2002, J BIOL CHEM, V277, P12175, DOI 10.1074/jbc.M104365200; Payne CM, 1999, ANTIOXID REDOX SIGN, V1, P449, DOI 10.1089/ars.1999.1.4-449; Percival MD, 1999, BIOCHEMISTRY-US, V38, P13574, DOI 10.1021/bi991028u; Pompeo F, 2002, PHARMACOGENOMICS, V3, P19, DOI 10.1517/14622416.3.1.19; RADI R, 1991, J BIOL CHEM, V266, P4244; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; Rodrigues-Lima F, 2003, J HISTOCHEM CYTOCHEM, V51, P789, DOI 10.1177/002215540305100610; Rodrigues-Lima F., 2002, Pharmacogenomics Journal, V2, P152, DOI 10.1038/sj.tpj.6500114; Rodrigues-Lima F, 2002, BIOCHEM BIOPH RES CO, V291, P116, DOI 10.1006/bbrc.2002.6414; Rodrigues-Lima F, 2001, BIOCHEM J, V356, P327, DOI 10.1042/0264-6021:3560327; Samoszuk M, 2002, BREAST CANCER RES TR, V74, P271, DOI 10.1023/A:1016328526866; Sandy J, 2002, J MOL BIOL, V318, P1071, DOI 10.1016/S0022-2836(02)00141-9; Sim E, 2000, HUM MOL GENET, V9, P2435, DOI 10.1093/hmg/9.16.2435; Sinclair JC, 2000, NAT STRUCT BIOL, V7, P560; Sinclair JC, 1998, PROTEIN EXPRES PURIF, V12, P371, DOI 10.1006/prep.1997.0856; Singh RJ, 1999, ARCH BIOCHEM BIOPHYS, V361, P331, DOI 10.1006/abbi.1998.1007; Slaviero KA, 2003, LANCET ONCOL, V4, P224, DOI 10.1016/S1470-2045(03)01034-9; Stachowiak O, 1998, J BIOL CHEM, V273, P16694, DOI 10.1074/jbc.273.27.16694; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Szaleczky E, 2000, J CLIN GASTROENTEROL, V30, P47, DOI 10.1097/00004836-200001000-00008; Takakura K, 1999, ARCH BIOCHEM BIOPHYS, V369, P197, DOI 10.1006/abbi.1999.1374; Wong PSY, 2001, ARCH BIOCHEM BIOPHYS, V394, P216, DOI 10.1006/abbi.2001.2532; Wu YL, 1998, FEBS LETT, V440, P111, DOI 10.1016/S0014-5793(98)01415-X	61	59	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7708	7714		10.1074/jbc.M311469200	http://dx.doi.org/10.1074/jbc.M311469200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14672957	hybrid			2022-12-25	WOS:000189103300043
J	Loo, TW; Bartlett, MC; Clarke, DM				Loo, TW; Bartlett, MC; Clarke, DM			Disulfide cross-linking analysis shows that transmembrane segments 5 and 8 of human P-glycoprotein are close together on the cytoplasmic side of the membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED ATPASE ACTIVITY; DRUG-BINDING SITE; CYSTEINE-SCANNING MUTAGENESIS; MULTIDRUG-RESISTANCE; ESCHERICHIA-COLI; FUNCTIONAL CONSEQUENCES; COVALENT MODIFICATION; MUTATIONAL ANALYSIS; PERIPLASMIC LOOPS; LACTOSE PERMEASE	Human P-glycoprotein (P-gp) transports a wide variety of structurally diverse compounds out of the cell. Knowledge about the packing of the transmembrane (TM) segments is essential for understanding the mechanism of drug recognition and transport. We used cysteine-scanning mutagenesis and disulfide cross-linking analysis to determine which TM segment in the COOH half of P-gp was close to TMs 5 and 6 since these segments in the NH2 half are important for drug binding. An active Cys-less P-gp mutant cDNA was used to generate 240 double cysteine mutants that contained 1 cysteine in TMs 5 or 6 and another in TMs 7 or 8. The mutants were subjected to oxidative cross-linking analysis. No disulfide cross-linking was observed in the 140 TM6/TM7 or TM6/TM8 mutants. By contrast, cross-linking was detected in several P-gp TM5/TM8 mutants. At 4degreesC, when thermal motion is low, P-gp mutants N296C(TM5)/G774C(TM8), I299C(TM5)/F770C(TM8), I299C(TM5)/G774C(TM8), and G300C(TM5)/F770C(TM8) showed extensive cross-linking with oxidant. These mutants retained drug-stimulated ATPase activity, but their activities were inhibited after treatment with oxidant. Similarly, disulfide cross-linking was inhibited by vanadate trapping of nucleotide. These results indicate that significant conformational changes must occur between TMs 5 and 8 during ATP hydrolysis. We revised the rotational symmetry model for TM packing based on our results and by comparison to the crystal structure of MsbA (Chang, G. (2003) J. Mol. Biol. 330, 419-430) such that TM5 is adjacent to TM8, TM2 is adjacent to TM11, and TMs 1 and 7 are next to TMs 6 and 12, respectively.	Univ Toronto, Dept Med, Canadian Inst Hlth Res, Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	Institute for Work & Health; University of Toronto; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, Canadian Inst Hlth Res, Grp Membrane Biol, Rm 7342,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	david.clarke@utoronto.ca	Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188	NCI NIH HHS [CA80900] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambudkar SV, 1997, J BIOL CHEM, V272, P21160, DOI 10.1074/jbc.272.34.21160; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; Doerrler WT, 2001, J BIOL CHEM, V276, P11461, DOI 10.1074/jbc.C100091200; GOODNO CC, 1982, METHOD ENZYMOL, V85, P116; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hrycyna CA, 2001, SEMIN CELL DEV BIOL, V12, P247, DOI 10.1006/scdb.2000.0250; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; KATZ BA, 1986, J BIOL CHEM, V261, P5480; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 2003, J BIOL CHEM, V278, P39706, DOI 10.1074/jbc.M308559200; Loo TW, 2003, J BIOL CHEM, V278, P1575, DOI 10.1074/jbc.M211307200; Loo TW, 2003, J BIOL CHEM, V278, P13603, DOI 10.1074/jbc.C300073200; Loo TW, 2000, J BIOL CHEM, V275, P19435, DOI 10.1074/jbc.C000222200; Loo TW, 1996, J BIOL CHEM, V271, P27488, DOI 10.1074/jbc.271.44.27488; Loo TW, 1999, BIOCHEM CELL BIOL, V77, P11, DOI 10.1139/bcb-77-1-11; Loo TW, 2003, J BIOL CHEM, V278, P50136, DOI 10.1074/jbc.M310448200; Loo TW, 2003, J BIOL CHEM, V278, P20449, DOI 10.1074/jbc.C300154200; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; Loo TW, 1999, J BIOL CHEM, V274, P24759, DOI 10.1074/jbc.274.35.24759; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; LOO TW, 1993, J BIOL CHEM, V268, P3143; Loo TW, 1996, J BIOL CHEM, V271, P27482, DOI 10.1074/jbc.271.44.27482; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Loo TW, 2002, J BIOL CHEM, V277, P27585, DOI 10.1074/jbc.C200330200; Loo TW, 2002, J BIOL CHEM, V277, P44332, DOI 10.1074/jbc.M208433200; Loo TW, 2002, J BIOL CHEM, V277, P41303, DOI 10.1074/jbc.C200484200; Loo TW, 1998, J BIOL CHEM, V273, P14671, DOI 10.1074/jbc.273.24.14671; Loo TW, 1998, J BIOL CHEM, V273, P32373, DOI 10.1074/jbc.273.49.32373; Loo TW, 2002, P NATL ACAD SCI USA, V99, P3511, DOI 10.1073/pnas.022049799; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; Loo TW, 2001, J BIOL CHEM, V276, P31800, DOI 10.1074/jbc.M103498200; LOO TW, 1994, BIOCHEMISTRY-US, V33, P14049, DOI 10.1021/bi00251a013; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; Loo TW, 2001, J BIOL CHEM, V276, P14972, DOI 10.1074/jbc.M100407200; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; Loo TW, 2000, J BIOL CHEM, V275, P39272, DOI 10.1074/jbc.M007741200; Loo TW, 1996, J BIOL CHEM, V271, P15414, DOI 10.1074/jbc.271.26.15414; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; LOO TW, 1993, J BIOL CHEM, V268, P19965; Loo TW, 1998, METHOD ENZYMOL, V292, P480; Omote H, 2002, J BIOL CHEM, V277, P45688, DOI 10.1074/jbc.M206479200; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Sun JZ, 1999, BIOCHEMISTRY-US, V38, P3100, DOI 10.1021/bi982360t; Sun JZ, 1998, BIOCHEMISTRY-US, V37, P8020, DOI 10.1021/bi973192s; Thomas Hilary, 2003, Cancer Control, V10, P159; Urbatsch IL, 2003, J BIOL CHEM, V278, P23171, DOI 10.1074/jbc.M301957200; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	62	71	75	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7692	7697		10.1074/jbc.M311825200	http://dx.doi.org/10.1074/jbc.M311825200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14670948	hybrid			2022-12-25	WOS:000189103300041
J	Mattera, R; Ritter, B; Sidhu, SS; McPherson, PS; Bonifacino, JS				Mattera, R; Ritter, B; Sidhu, SS; McPherson, PS; Bonifacino, JS			Definition of the consensus motif recognized by gamma-adaptin ear domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCESSORY PROTEIN RECRUITMENT; STRUCTURAL EXPLANATION; APPENDAGE DOMAIN; PHAGE DISPLAY; BINDING; INTERACTS; IDENTIFICATION; SPECIFICITY; EXPRESSION; COMPLEX	The heterotetrameric adaptor complex 1 (AP-1) and the monomeric Golgi-localized, gamma ear-containing, Arf-binding (GGA) proteins are components of clathrin coats associated with the trans-Golgi network and endosomes. The carboxyl-terminal ear domains (or gamma-adaptin ear (GAE) domains) of two gamma-adaptin subunit isoforms of AP-1 and of the GGAs are structurally similar and bind to a common set of accessory proteins. In this study, we have systematically defined a core tetrapeptide motif PsiG(P/D/E)(Psi/L/M) (where Psi is an aromatic residue), which is responsible for the interactions of accessory proteins with GAE domains. The definition of this motif has allowed us to identify novel GAE-binding partners named NECAP and aftiphilin, which also contain clathrin-binding motifs. These findings shed light on the mechanism of accessory protein recruitment to trans-Golgi network and endosomal clathrin coats.	NICHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); McGill University; Roche Holding; Genentech	Bonifacino, JS (corresponding author), NICHD, Cell Biol & Metab Branch, NIH, Bldg 18T,Rm 101, Bethesda, MD 20892 USA.	juan@helix.nih.gov		Ritter, Brigitte/0000-0002-0094-0460; Bonifacino, Juan S./0000-0002-5673-6370	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001607] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001607] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aguilar RC, 2001, J BIOL CHEM, V276, P13145, DOI 10.1074/jbc.M010591200; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Brett TJ, 2002, STRUCTURE, V10, P797, DOI 10.1016/S0969-2126(02)00784-0; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Collins BM, 2003, NAT STRUCT BIOL, V10, P607, DOI 10.1038/nsb955; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; Deshayes K, 2002, CHEM BIOL, V9, P495, DOI 10.1016/S1074-5521(02)00129-1; Duncan MC, 2003, TRENDS CELL BIOL, V13, P211, DOI 10.1016/S0962-8924(03)00076-X; Duncan MC, 2003, NAT CELL BIOL, V5, P77, DOI 10.1038/ncb901; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; Hirst J, 2003, MOL BIOL CELL, V14, P625, DOI 10.1091/mbc.E02-09-0552; Kalthoff C, 2002, MOL BIOL CELL, V13, P4060, DOI 10.1091/mbc.E02-03-0171; Kent HM, 2002, STRUCTURE, V10, P1139, DOI 10.1016/S0969-2126(02)00801-8; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Kirchhausen T, 2002, CELL, V109, P413, DOI 10.1016/S0092-8674(02)00751-1; Lewin DA, 1998, FEBS LETT, V435, P263, DOI 10.1016/S0014-5793(98)01083-7; Lui WWY, 2003, MOL BIOL CELL, V14, P2385, DOI 10.1091/mbc.e02-11-0735; Mattera R, 2003, EMBO J, V22, P78, DOI 10.1093/emboj/cdg015; Miller GJ, 2003, NAT STRUCT BIOL, V10, P599, DOI 10.1038/nsb953; Mills IG, 2003, J CELL BIOL, V160, P213, DOI 10.1083/jcb.200208023; Nogi T, 2002, NAT STRUCT BIOL, V9, P527, DOI 10.1038/nsb808; Ohno H, 1998, J BIOL CHEM, V273, P25915, DOI 10.1074/jbc.273.40.25915; Owen DJ, 2000, EMBO J, V19, P4216, DOI 10.1093/emboj/19.16.4216; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Owen DJ, 2001, TRAFFIC, V2, P105, DOI 10.1034/j.1600-0854.2001.020205.x; Page LJ, 1999, J CELL BIOL, V146, P993, DOI 10.1083/jcb.146.5.993; Ritter B, 2003, EMBO REP, V4, P1089, DOI 10.1038/sj.embor.7400004; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; Sidhu SS, 2000, METHOD ENZYMOL, V328, P333, DOI 10.1016/S0076-6879(00)28406-1; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Takatsu H, 2000, BIOCHEM BIOPH RES CO, V271, P719, DOI 10.1006/bbrc.2000.2700; Traub LM, 1999, P NATL ACAD SCI USA, V96, P8907, DOI 10.1073/pnas.96.16.8907; Wasiak S, 2002, J CELL BIOL, V158, P855, DOI 10.1083/jcb.200205078; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	36	51	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8018	8028		10.1074/jbc.M311873200	http://dx.doi.org/10.1074/jbc.M311873200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14665628	hybrid			2022-12-25	WOS:000189103300080
J	Baek, SJ; Kim, JS; Nixon, JB; DiAugustine, RP; Eling, TE				Baek, SJ; Kim, JS; Nixon, JB; DiAugustine, RP; Eling, TE			Expression of NAG-1, a transforming growth factor-beta superfamily member, by troglitazone requires the early growth response gene EGR-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; SMOOTH-MUSCLE-CELLS; VASCULAR ENDOTHELIAL-CELLS; BREAST-CANCER CELLS; PPAR-GAMMA; TRANSCRIPTION FACTOR; INDUCE APOPTOSIS; CYCLE ARREST; SIGNALING PATHWAY; CARCINOMA CELLS	Troglitazone (TGZ) and 15-deoxy-Delta(12,14) -prostaglandin J(2) (PGJ(2)) are peroxisome proliferator-activated receptor-gamma (PPARgamma) ligands that have been shown to possess pro-apoptotic activity in human colon cancer. Although these compounds bind to PPARgamma transcription factors as agonists, emerging evidence suggests that TGZ acts independently of PPARgamma in many functions, including apoptosis. We previously reported that TGZ induces an early growth response transcription factor (EGR-1) by the ERK phosphorylation pathway rather than by the PPARgamma pathway (Baek, S. J., Wilson, L. C., Hsi, L. C., and Eling, T. E. (2003) J. Biol. Chem. 278, 5845-5853). In this report, we show that the expression of the antitumorigenic and/or pro-apoptotic gene NAG-1 (nonsteroidal anti-inflammatory drug-Activated gene-1) is induced by TGZ and correlates with EGR-1 induction. In cotransfection and gel shift assays, we show that EGR-1-binding sites are located within region -73 to -51 of the NAG-1 promoter and have an important role in the transactivation of TGZ-induced NAG-1 expression. In contrast, PGJ(2) induced NAG-1 protein expression, but PJG(2) may not affect the same region that TGZ does in the NAG-1 promoter. The effect of PGJ(2) is probably PPARgamma-dependent because a PPARgamma antagonist inhibited the PGJ(2)-induced expression of NAG-1. TGZ-induced NAG-1 expression was not inhibited by the PPARgamma antagonist. The fact that TGZ-induced NAG-1 expression was accompanied by the biosynthesis of EGR-1 also suggests that EGR-1 plays a pivotal role in TGZ-induced NAG-1 expression. Our results suggest that EGR-1 induction is a unique property of TGZ, but is independent of PPARgamma activation. The up-regulation of NAG-1 may provide a novel explanation for the antitumorigenic property of TGZ.	NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ Tennessee, Coll Vet Med, Dept Pathobiol, Knoxville, TN 37996 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture	Eling, TE (corresponding author), NIEHS, Mol Carcinogenesis Lab, NIH, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	Eling@niehs.nih.gov		Baek, Seung/0000-0001-7866-7778	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES010016, ZIAES010016, Z01ES048005] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Andrew SD, 2002, GENE, V298, P9, DOI 10.1016/S0378-1119(02)00919-8; Bae MA, 2003, TOXICOL LETT, V139, P67, DOI 10.1016/S0378-4274(02)00468-X; Baek SJ, 2003, J BIOL CHEM, V278, P5845, DOI 10.1074/jbc.M208394200; Baek SJ, 2002, J PHARMACOL EXP THER, V301, P1126, DOI 10.1124/jpet.301.3.1126; Baek SJ, 2002, CARCINOGENESIS, V23, P425, DOI 10.1093/carcin/23.3.425; Baek SJ, 2001, J BIOL CHEM, V276, P33384, DOI 10.1074/jbc.M101814200; Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Calogero A, 2001, CLIN CANCER RES, V7, P2788; Chang TH, 2000, CANCER RES, V60, P1129; Chung SH, 2002, JPN J CANCER RES, V93, P1358, DOI 10.1111/j.1349-7006.2002.tb01245.x; Davies SS, 2001, J BIOL CHEM, V276, P16015, DOI 10.1074/jbc.M100878200; Davis W, 2003, NUCLEIC ACIDS RES, V31, P1097, DOI 10.1093/nar/gkg192; Eligini S, 2002, THROMB HAEMOSTASIS, V88, P524; Elstner E, 2002, BREAST CANCER RES TR, V74, P155, DOI 10.1023/A:1016114026769; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Fajas L, 1998, FEBS LETT, V438, P55, DOI 10.1016/S0014-5793(98)01273-3; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Hattori Y, 1999, HYPERTENSION, V33, P943, DOI 10.1161/01.HYP.33.4.943; Heaney AP, 2002, NAT MED, V8, P1281, DOI 10.1038/nm784; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; HUANG RP, 1994, BIOCHEM BIOPH RES CO, V200, P1271, DOI 10.1006/bbrc.1994.1588; Huang RP, 1998, CELL DEATH DIFFER, V5, P96, DOI 10.1038/sj.cdd.4400322; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; HUANG RP, 1995, CANCER RES, V55, P5054; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Kim KS, 2002, GASTROENTEROLOGY, V122, P1388, DOI 10.1053/gast.2002.32972; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kubota T, 1998, CANCER RES, V58, P3344; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Liu CT, 2000, J BIOL CHEM, V275, P20315, DOI 10.1074/jbc.M909046199; Liu CT, 1998, CANCER GENE THER, V5, P3; Liu T, 2003, CANCER RES, V63, P5034; Masamune A, 2002, PANCREAS, V24, P130, DOI 10.1097/00006676-200203000-00003; MUTHUKKUMAR S, 1995, MOL CELL BIOL, V15, P6262; Muthukkumar S, 1997, J BIOL CHEM, V272, P27987, DOI 10.1074/jbc.272.44.27987; Nair P, 1997, J BIOL CHEM, V272, P20131, DOI 10.1074/jbc.272.32.20131; Nencioni A, 2002, EXP HEMATOL, V30, P1020, DOI 10.1016/S0301-472X(02)00877-9; Newman D, 2003, MOL PHARMACOL, V63, P557, DOI 10.1124/mol.63.3.557; Nikitakis NG, 2002, BRIT J CANCER, V87, P1396, DOI 10.1038/sj.bjc.6600618; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; Okura T, 2000, EUR J PHARMACOL, V407, P227, DOI 10.1016/S0014-2999(00)00758-5; Raychowdhury R, 2002, MOL ENDOCRINOL, V16, P2802, DOI 10.1210/me.2001-0292; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; Swirnoff AH, 1998, MOL CELL BIOL, V18, P512, DOI 10.1128/MCB.18.1.512; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Wakino S, 2001, J BIOL CHEM, V276, P47650, DOI 10.1074/jbc.M108719200; Wang MH, 1999, DIABETES, V48, P254, DOI 10.2337/diabetes.48.2.254; Wilson LC, 2003, INT J CANCER, V105, P747, DOI 10.1002/ijc.11173; Yang WL, 2001, CARCINOGENESIS, V22, P1379, DOI 10.1093/carcin/22.9.1379; Yin F, 2001, BIOCHEM BIOPH RES CO, V286, P916, DOI 10.1006/bbrc.2001.5491; Yoshizawa K, 2002, CANCER-AM CANCER SOC, V95, P2243, DOI 10.1002/cncr.10906; Zhang JF, 2002, BIOCHEM BIOPH RES CO, V298, P128, DOI 10.1016/S0006-291X(02)02401-4; Zhang XH, 2003, AM J PHYSIOL-RENAL, V284, pF1216, DOI 10.1152/ajprenal.00426.2002	61	121	126	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6883	6892		10.1074/jbc.M305295200	http://dx.doi.org/10.1074/jbc.M305295200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14662774	hybrid			2022-12-25	WOS:000188969200083
J	Kumar, R; Angelini, S; Hemminki, K				Kumar, R; Angelini, S; Hemminki, K			Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9	ONCOGENE			English	Article						BRAF; N-ras; melanoma; mutation; FAL; SSCP	MALIGNANT-MELANOMA; TUMOR PROGRESSION; CDKN2A MUTATIONS; B-RAF; GENE; FREQUENCY; CANCER; HETEROZYGOSITY; PATHWAYS; COMMON	We searched and report mutations in the BRAF and N-ras genes in 22 out of 35 (63 percent) primary sporadic melanomas. In three melanomas, mutations were concomitantly present in both genes. In all, 10 out of 12 mutations in the BRAF gene involved the 'hot spot' codon 600 (In all communications on mutations in the BRAF gene, the nucleotide and codon numbers have been based on the NCBI gene bank nucleotide sequence NM_004333. However, according to NCBI gene bank sequence with accession number NT_007914, there is a discrepancy of one codon (three nucleotides) in exon 1 in the sequence with accession number NM_004333. The sequence analysis of exon 1 of the BRAF gene in our laboratory has shown that the sequence derived from NT_007914 is correct (Kumar et al., 2003). Due to the correctness of the latter, sequence numbering of codons and nucleotides after exon 1 are changed by +1 and +3, respectively.), one tandem CT1789-90TC base change represented a novel mutation and another mutation caused a G466R amino-acid change within the glycine-rich loop in the kinase domain. Mutations in the N-ras gene in 11 melanomas were at codon 61 whereas two melanomas carried mutations in codon 12 including a tandem mutation GG>AA. We observed an inverse association between BRAF/N-ras mutations and the frequency of loss of heterozygosity (LOH) on chromosome 9 at 10 different loci. Melanomas with BRAF/N-ras mutations showed a statistically significant decreased frequency of LOH on chromosome 9 compared with cases without mutations (mean fractional allelic loss (FAL) = 0.29 +/- 0.23 vs 0.72 +/- 0.33; t-test, P = 0.0001). Difference in the FAL value between tumours with and without BRAF/N-ras mutations on 33 loci on five other chromosomes was not statistically significant (mean FAL 0.17 +/- 0.19 vs 0.25 +/- 0.22; t-test, P = 0.24). Melanoma cases with BRAF/N-ras mutations were also associated with lower age at diagnosis than cases without mutations (mean age 80.38 +/- 7.24 vs 65.77 +/- 19.79 years; t-test, P = 0.02). Our data suggest that the occurrence of BRAF/N-ras mutations compensate the requirement for the allelic loss at chromosome 9, which is one of the key events in melanoma.	German Canc Res Ctr, Div Mol Genet Epidemiol, D-69210 Heidelberg, Germany; Karolinska Inst, Novum, Ctr Nutr & Toxicol, Dept Biosci, S-14157 Huddinge, Sweden	Helmholtz Association; German Cancer Research Center (DKFZ); Karolinska Institutet	Kumar, R (corresponding author), German Canc Res Ctr, Div Mol Genet Epidemiol, Neuenheimer Feld 580 TP3, D-69210 Heidelberg, Germany.	kumar@cnt.ki.se	Kumar, Rajiv/H-6431-2019; angelini, Sabrina/AAB-5220-2022; ravegnini, gloria/K-1330-2016	Kumar, Rajiv/0000-0002-6093-0395; ravegnini, gloria/0000-0002-7774-402X; Angelini, Sabrina/0000-0002-1609-0421				Bishop DT, 2002, J NATL CANCER I, V94, P894, DOI 10.1093/jnci/94.12.894; Bolshakov S, 2003, CLIN CANCER RES, V9, P228; Brose MS, 2002, CANCER RES, V62, P6997; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Castellano M, 1999, MELANOMA RES, V9, P421, DOI 10.1097/00008390-199910000-00001; Chin L, 1998, GENE DEV, V12, P3467, DOI 10.1101/gad.12.22.3467; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Demunter A, 2001, J INVEST DERMATOL, V117, P1483, DOI 10.1046/j.0022-202x.2001.01601.x; Eskandarpour M, 2003, J NATL CANCER I, V95, P790, DOI 10.1093/jnci/95.11.790; Funk JO, 1998, J CUTAN PATHOL, V25, P291, DOI 10.1111/j.1600-0560.1998.tb01748.x; Gilchrest BA, 1999, NEW ENGL J MED, V340, P1341, DOI 10.1056/NEJM199904293401707; Halaban R, 2000, PIGM CELL RES, V13, P4, DOI 10.1034/j.1600-0749.2000.130103.x; Hemminki K, 2001, MELANOMA RES, V11, P133, DOI 10.1097/00008390-200104000-00007; Hingorani SR, 2003, CURR OPIN GENET DEV, V13, P6, DOI 10.1016/S0959-437X(02)00017-5; Jiveskog S, 1998, J INVEST DERMATOL, V111, P757, DOI 10.1046/j.1523-1747.1998.00376.x; Kumar R, 1999, MELANOMA RES, V9, P138, DOI 10.1097/00008390-199904000-00005; Kumar R, 1998, GENE CHROMOSOME CANC, V23, P273, DOI 10.1002/(SICI)1098-2264(199811)23:3<273::AID-GCC11>3.0.CO;2-N; Kumar R, 1998, INT J CANCER, V75, P193, DOI 10.1002/(SICI)1097-0215(19980119)75:2<193::AID-IJC5>3.3.CO;2-5; Kumar R, 2001, INT J CANCER, V95, P388, DOI 10.1002/1097-0215(20011120)95:6<388::AID-IJC1069>3.0.CO;2-6; KUMAR R, 2003, IN PRESS CLIN CANC R; Laud K, 2003, CANCER RES, V63, P3061; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Naoki K, 2002, CANCER RES, V62, P7001; Omholt K, 2002, CLIN CANCER RES, V8, P3468; Pollock PM, 2001, CANCER RES, V61, P1154; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Pollock PM, 2002, CANCER CELL, V2, P5, DOI 10.1016/S1535-6108(02)00089-2; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Saida T, 2001, J DERMATOL SCI, V26, P1, DOI 10.1016/S0923-1811(01)00085-8; Satyamoorthy K, 2003, CANCER RES, V63, P756; Sharpless NE, 2003, ONCOGENE, V22, P3092, DOI 10.1038/sj.onc.1206461; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Smeds J, 2000, MUTAGENESIS, V15, P257, DOI 10.1093/mutage/15.3.257; vanElsas A, 1997, MELANOMA RES, V7, pS107; Walker GJ, 2002, J INVEST DERMATOL, V119, P783, DOI 10.1046/j.1523-1747.2002.00217.x; Whiteman DC, 2001, CANCER CAUSE CONTROL, V12, P69, DOI 10.1023/A:1008980919928; Yang FC, 2001, SEMIN CANCER BIOL, V11, P261, DOI 10.1006/scbi.2000.0376; Yuen ST, 2002, CANCER RES, V62, P6451; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429	42	75	75	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2003	22	58					9217	9224		10.1038/sj.onc.1206909	http://dx.doi.org/10.1038/sj.onc.1206909			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755JU	14681681				2022-12-25	WOS:000187400400003
J	Gupta, S; Hastak, K; Afaq, F; Ahmad, N; Mukhtar, H				Gupta, S; Hastak, K; Afaq, F; Ahmad, N; Mukhtar, H			Essential role of caspases in epigallocatechin-3-gallate-mediated inhibition of nuclear factor kappaB and induction of apoptosis	ONCOGENE			English	Article						green tea; epigallocatechin-3-gallate; caspases; apoptosis; nuclear factor-kappa B	TEA CONSTITUENT (-)-EPIGALLOCATECHIN-3-GALLATE; PROSTATE CARCINOMA-CELLS; EPIGALLOCATECHIN GALLATE; CANCER-THERAPY; CYCLE ARREST; DEATH; PROTEASE; GROWTH; PATHWAYS; ACTIVATION	Green tea constituent (-) epigallocatechin-3-gallate (EGCG) has shown remarkable cancer-preventive and some cancer-therapeutic effects. This is partially because of its ability to induce apoptosis in cancer cells without affecting normal cells. Previous studies from our laboratory have shown the involvement of NF-kappaB pathway in EGCG-mediated cell-cycle deregulation and apoptosis of human epidermoid carcinoma A431 cells. Here we show the essential role of caspases in EGCG-mediated inhibition of NF-kappaB and its subsequent apoptosis. Treatment of A431 cells with EGCG (10-40 mug/ml) resulted in dose-dependent inhibition of NF-kappaB/p65, induction of DNA breaks, cleavage of poly(ADP-ribose) polymerase (PARP) and morphological changes consistent with apoptosis. EGCG treatment of cells also resulted in significant activation of caspases, as shown by the dose- and time-dependent increase in DEVDase activity, and protein expression of caspase-3, -8 and -9. EGCG-mediated caspase activation induces proteolytic cleavage of NF-kappaB/p65 subunit, leading to the loss of transactivation domains, and driving the cells towards apoptosis. EGCG-mediated induction of apoptosis was significantly blocked by the caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone (Z-VAD-FMK), and moderately blocked by the specific caspase-3 inhibitor Z-DEVD-FMK. Further, pretreatment of cells with Z-VAD-FMK was found to suppress the cleavage of NF-kappaB/p65 subunit, thereby increasing nuclear translocation, DNA binding and transcriptional activity, thus protecting the cells from EGCG-induced apoptosis. Taken together, these studies for the first time demonstrate that EGCG-mediated activation of caspases is critical, at least in part, for inhibition of NF-kappaB and subsequent apoptosis.	Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Madison, WI 53706 USA; Case Western Reserve Univ, Dept Urol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Environm Hlth Sci, Cleveland, OH 44106 USA	University of Wisconsin System; University of Wisconsin Madison; Case Western Reserve University; Case Western Reserve University	Mukhtar, H (corresponding author), Univ Wisconsin, Med Sci Ctr, Dept Dermatol, 1300 Univ Ave, Madison, WI 53706 USA.	hmukhtar@wisc.edu		Gupta, Sanjay/0000-0002-9492-3249	NCI NIH HHS [R01 CA 78809] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078809] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 2000, BIOCHEM PHARMACOL, V60, P1033, DOI 10.1016/S0006-2952(00)00393-2; Ahmad N, 2000, ARCH BIOCHEM BIOPHYS, V376, P338, DOI 10.1006/abbi.2000.1742; Ahmad N, 1997, JNCI-J NATL CANCER I, V89, P1881, DOI 10.1093/jnci/89.24.1881; Bours V, 2000, BIOCHEM PHARMACOL, V60, P1085, DOI 10.1016/S0006-2952(00)00391-9; Chen ZP, 1998, CANCER LETT, V129, P173, DOI 10.1016/S0304-3835(98)00108-6; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chung JH, 2003, FASEB J, V17, P1913, DOI 10.1096/fj.02-0914fje; Chung LY, 2001, LIFE SCI, V68, P1207, DOI 10.1016/S0024-3205(00)01020-1; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Clement MV, 1998, BLOOD, V92, P996; Ferreira CG, 2002, CLIN CANCER RES, V8, P2024; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Grutter MG, 2000, CURR OPIN STRUC BIOL, V10, P649, DOI 10.1016/S0959-440X(00)00146-9; Gupta S, 2000, TOXICOL APPL PHARM, V164, P82, DOI 10.1006/taap.1999.8885; Gupta S, 2003, ARCH BIOCHEM BIOPHYS, V410, P177, DOI 10.1016/S0003-9861(02)00668-9; Hastak K, 2003, ONCOGENE, V22, P4851, DOI 10.1038/sj.onc.1206708; Hayakawa S, 2001, BIOCHEM BIOPH RES CO, V285, P1102, DOI 10.1006/bbrc.2001.5293; Islam S, 2000, BIOCHEM BIOPH RES CO, V270, P793, DOI 10.1006/bbrc.2000.2536; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Joyce D, 2001, CYTOKINE GROWTH F R, V12, P73, DOI 10.1016/S1359-6101(00)00018-6; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kim PKM, 2001, DRUG RESIST UPDATE, V4, P293, DOI 10.1054/drup.2001.0223; Kong ANT, 2001, MUTAT RES-FUND MOL M, V480, P231, DOI 10.1016/S0027-5107(01)00182-8; Kuo PL, 2003, J BIOMED SCI, V10, P219, DOI 10.1159/000068711; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Masuda M, 2001, CLIN CANCER RES, V7, P4220; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Ravi R, 1998, CANCER RES, V58, P882; Schwartz SA, 1999, SURG ONCOL, V8, P143, DOI 10.1016/S0960-7404(00)00012-8; Singh AK, 2002, ARCH BIOCHEM BIOPHYS, V401, P29, DOI 10.1016/S0003-9861(02)00013-9; Stennicke HR, 2000, BBA-PROTEIN STRUCT M, V1477, P299, DOI 10.1016/S0167-4838(99)00281-2; Surh YJ, 2001, MUTAT RES-FUND MOL M, V480, P243, DOI 10.1016/S0027-5107(01)00183-X; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yang GY, 1998, CARCINOGENESIS, V19, P611, DOI 10.1093/carcin/19.4.611; Yu R, 1998, CANCER RES, V58, P402; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0	41	168	182	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2507	2522		10.1038/sj.onc.1207353	http://dx.doi.org/10.1038/sj.onc.1207353			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14676829				2022-12-25	WOS:000220558000008
J	Marani, M; Hancock, D; Lopes, R; Tenev, T; Downward, J; Lemoine, NR				Marani, M; Hancock, D; Lopes, R; Tenev, T; Downward, J; Lemoine, NR			Role of Bim in the survival pathway induced by Raf in epithelial cells	ONCOGENE			English	Article						Bim; anoikis; phosphorylation; EGF receptor	GROWTH-FACTOR RECEPTOR; BCL-2 FAMILY; PROTEIN BIM; PROAPOPTOTIC ACTIVITY; DEPENDENT PATHWAY; SIGNALING PATHWAY; BH3-ONLY PROTEIN; KINASE PATHWAY; MOTOR COMPLEX; ACTIVATION	Selective and sustained activation of the Raf/MAP kinase pathway in MCF-10A DeltaRaf-ER cells, a spontaneously immortalized human mammary epithelial cell line, was previously shown to protect these cells from suspension-induced cell death, a critical feature of the Ras-transformed phenotype. Although autocrine signalling through the EGF receptor is crucial for the protection induced by Raf in these cells, we report here the existence of an additional, more direct survival mechanism, linking Raf activation to the inhibition of a proapoptotic member of the Bcl-2 family, Bim. While detachment from the matrix results in transcriptional induction of two variants of this BH3-only protein, BimEL and BimL, activation of the Raf/ERK signalling both prevents Bim upregulation specifically and leads to phosphorylation and degradation of the BimEL isoform. This represents an important route to protect epithelial cells from the proapoptotic effect of Bim.	Hammersmith Hosp, Imperial Coll London, Canc Res UK Mol Oncol Unit, London W12 0NN, England; Canc Res UK London Res Inst, Signal Transduct Lab, London WC2A 3PX, England; Inst Canc Res, Chester Beatty Labs, Breakthrough Toby Robins Breast Canc Res Ctr, London SW3 6JB, England	Cancer Research UK; Imperial College London; Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Lemoine, NR (corresponding author), Hammersmith Hosp, Imperial Coll London, Canc Res UK Mol Oncol Unit, DuCane Rd, London W12 0NN, England.	nick.lemoine@cancer.org.uk	Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729; Tenev, Tencho/0000-0001-8762-1069				Biswas SC, 2002, J BIOL CHEM, V277, P49511, DOI 10.1074/jbc.M208086200; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; BOS JL, 1989, CANCER RES, V49, P4682; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gilmore AP, 2002, J BIOL CHEM, V277, P27643, DOI 10.1074/jbc.M108863200; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1432, DOI 10.1210/me.12.9.1432; Jost M, 2001, J BIOL CHEM, V276, P6320, DOI 10.1074/jbc.M008210200; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; LEI K, 2003, P NATL ACAD SCI USA, V18, P18; Leu CM, 2000, ONCOGENE, V19, P1665, DOI 10.1038/sj.onc.1203452; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Liu YZ, 1999, NUCLEIC ACIDS RES, V27, P2086, DOI 10.1093/nar/27.10.2086; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Marshansky V, 2001, J IMMUNOL, V166, P3130, DOI 10.4049/jimmunol.166.5.3130; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Miyashita MUT, 2001, FEBS LETT, V509, P135, DOI 10.1016/S0014-5793(01)03145-3; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Streuli CH, 1999, J MAMMARY GLAND BIOL, V4, P183, DOI 10.1023/A:1018729308878; Weston CR, 2003, ONCOGENE, V22, P1281, DOI 10.1038/sj.onc.1206261	36	93	98	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2431	2441		10.1038/sj.onc.1207364	http://dx.doi.org/10.1038/sj.onc.1207364			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14676826				2022-12-25	WOS:000220558000001
J	Miyazaki, K; Fujita, T; Ozaki, T; Kato, C; Kurose, Y; Sakamoto, M; Kato, S; Goto, T; Itoyama, Y; Aoki, M; Nakagawara, A				Miyazaki, K; Fujita, T; Ozaki, T; Kato, C; Kurose, Y; Sakamoto, M; Kato, S; Goto, T; Itoyama, Y; Aoki, M; Nakagawara, A			NEDL1, a novel ubiquitin-protein isopeptide ligase for dishevelled-1, targets mutant superoxide dismutase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; INTRACYTOPLASMIC HYALINE INCLUSIONS; POSTERIOR COLUMN INVOLVEMENT; SOD1 GENE-MUTATIONS; ENDOPLASMIC-RETICULUM; UNFOLDED PROTEIN; GOLGI-APPARATUS; SPINAL-CORD; DISEASE; ALS	Approximately 20% of familial amyotrophic lateral sclerosis (FALS) arises from germ-line mutations in the superoxide dismutase-1 (SOD1) gene. However, the molecular mechanisms underlying the process have been elusive. Here, we show that a neuronal homologous to E6AP carboxyl terminus (HECT)-type ubiquitin-protein isopeptide ligase (NEDL1) physically binds translocon-associated protein-delta and also binds and ubiquitinates mutant (but not wild-type) SOD1 proportionately to the disease severity caused by that particular mutant. Immunohistochemically, NEDL1 is present in the central region of the Lewy body-like hyaline inclusions in the spinal cord ventral horn motor neurons of both FALS patients and mutant SOD1 transgenic mice. Two-hybrid screening for the physiological targets of NEDL1 has identified Dishevelled-1, one of the key transducers in the Wnt signaling pathway. Mutant SOD1 also interacted with Dishevelled-1 in the presence of NEDL1 and caused its dysfunction. Thus, our results suggest that an adverse interaction among misfolded SOD1, NEDL1, translocon-associated protein-delta, and Dishevelled-1 forms a ubiquitinated protein complex that is included in potentially cytotoxic protein aggregates and that mutually affects their functions, leading to motor neuron death in FALS.	Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; Tottori Univ, Fac Med, Inst Neurol Sci, Div Neuropathol, Yonago, Tottori 6838504, Japan; Hisamitsu Pharmaceut Co Inc, Tokyo 100622, Japan; Tohoku Univ, Sch Med, Dept Neurol, Sendai, Miyagi 9808574, Japan	Chiba Cancer Center; Tottori University; Hisamitsu Pharmaceutical Co Ltd; Tohoku University	Nakagawara, A (corresponding author), Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-ccri.chuo.chiba.jp						Andersen PM, 1996, BRAIN, V119, P1153, DOI 10.1093/brain/119.4.1153; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; BROCHELT DR, 1994, P NATL ACAD SCI USA, V16, P8292; Brown RH, 2001, SEMIN NEUROL, V21, P131; Cleveland DW, 2000, NAT MED, V6, P1320, DOI 10.1038/82122; Cluskey S, 2001, J CLIN PATHOL-MOL PA, V54, P386; Cudkowicz ME, 1997, ANN NEUROL, V41, P210, DOI 10.1002/ana.410410212; De Ferrari GV, 2000, BRAIN RES REV, V33, P1, DOI 10.1016/S0165-0173(00)00021-7; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Fons RD, 2003, J CELL BIOL, V160, P529, DOI 10.1083/jcb.200210095; Fujita Y, 2000, J NEUROL SCI, V174, P137, DOI 10.1016/S0022-510X(00)00265-3; HARTMANN E, 1993, EUR J BIOCHEM, V214, P375, DOI 10.1111/j.1432-1033.1993.tb17933.x; Harvey KF, 1999, TRENDS CELL BIOL, V9, P166, DOI 10.1016/S0962-8924(99)01541-X; Hoffman EK, 1996, J NEUROL SCI, V139, P15, DOI 10.1016/S0022-510X(96)00031-7; Julien JP, 2000, J NEUROL SCI, V180, P7, DOI 10.1016/S0022-510X(00)00422-6; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; Kato M, 2001, NEUROSCI LETT, V312, P165, DOI 10.1016/S0304-3940(01)02212-1; Kato S, 1996, J NEUROPATH EXP NEUR, V55, P1089, DOI 10.1097/00005072-199655100-00009; Kato S, 1997, AM J PATHOL, V151, P611; Kato S, 2000, AMYOTROPH LATERAL SC, V1, P163, DOI 10.1080/14660820050515160; Kaytor MD, 2002, CURR OPIN NEUROBIOL, V12, P275, DOI 10.1016/S0959-4388(02)00320-3; Keller JN, 2000, NEUROSCIENCE, V98, P149, DOI 10.1016/S0306-4522(00)00067-1; Krylova O, 2000, J CELL BIOL, V151, P83, DOI 10.1083/jcb.151.1.83; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Kunst CB, 1997, NAT GENET, V15, P91, DOI 10.1038/ng0197-91; Luo ZG, 2002, NEURON, V35, P489, DOI 10.1016/S0896-6273(02)00783-3; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Mourelatos Z, 1996, P NATL ACAD SCI USA, V93, P5472, DOI 10.1073/pnas.93.11.5472; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Nagai M, 2001, J NEUROSCI, V21, P9246, DOI 10.1523/JNEUROSCI.21-23-09246.2001; Nakagawara A, 1998, MED PEDIATR ONCOL, V31, P113, DOI 10.1002/(SICI)1096-911X(199808)31:2<113::AID-MPO14>3.0.CO;2-O; Niwa J, 2002, J BIOL CHEM, V277, P36793, DOI 10.1074/jbc.M206559200; OGASAWARA M, 1993, NAT GENET, V5, P323, DOI 10.1038/ng1293-323; Okado-Matsumoto A, 2002, P NATL ACAD SCI USA, V99, P9010, DOI 10.1073/pnas.132260399; Orrell RW, 2001, NEUROLOGY, V57, P9, DOI 10.1212/WNL.57.1.9; Orrell RW, 2000, NEUROMUSCULAR DISORD, V10, P63, DOI 10.1016/S0960-8966(99)00071-1; Ratovitski T, 1999, HUM MOL GENET, V8, P1451, DOI 10.1093/hmg/8.8.1451; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Shibata N, 1996, J NEUROPATH EXP NEUR, V55, P481, DOI 10.1097/00005072-199604000-00011; SUSSMAN DJ, 1994, DEV BIOL, V166, P73, DOI 10.1006/dbio.1994.1297; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Tsang M, 1996, DEV DYNAM, V207, P253, DOI 10.1002/(SICI)1097-0177(199611)207:3<253::AID-AJA2>3.0.CO;2-G; VERSTEEG R, 1995, EUR J CANCER, V31A, P538, DOI 10.1016/0959-8049(95)00037-J; Wharton KA, 2003, DEV BIOL, V253, P1, DOI 10.1006/dbio.2002.0869; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59	46	133	145	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11327	11335		10.1074/jbc.M312389200	http://dx.doi.org/10.1074/jbc.M312389200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14684739	hybrid			2022-12-25	WOS:000220157600061
J	Sugimoto, Y; Nakato, T; Kita, A; Takahashi, Y; Hatae, N; Tabata, H; Tanaka, S; Ichikawa, A				Sugimoto, Y; Nakato, T; Kita, A; Takahashi, Y; Hatae, N; Tabata, H; Tanaka, S; Ichikawa, A			A cluster of aromatic amino acids in the i2 loop plays a key role for G(s) coupling in prostaglandin EP2 and EP3 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING PROPERTIES; G-BETA-GAMMA; CARBOXYLIC-ACID; ARGININE RESIDUE; 2 ISOFORMS; FUNCTIONAL INTERACTION; MOLECULAR-MECHANISMS; DOMAINS DETERMINE; TERMINAL DOMAINS; G-PROTEINS	To assess the structural requirements for G(s) coupling by prostaglandin E receptors (EPs), the G(s)-coupled EP2 and G(i)-coupled EP3beta receptors were used to generate hybrid receptors. Interchanging of the whole i2 loop and its N-terminal half (i2N) had no effect on the binding of both receptors expressed in HEK293 cells. Agonist-induced cAMP formation was observed in wild type EP2 but not in the i2 loop- or i2N-substituted EP2. Wild type EP3beta left cAMP levels unaffected, whereas i2 loop- and i2N-substituted EP3 gained agonist-induced adenylyl cyclase stimulation. In EP2, the ability to stimulate cAMP formation was lost by mutation of Tyr(143) into Ala but retained by mutations into Phe, Trp, and Leu. Consistent with this observation, substitution of the equivalent His(140) enabled EP3beta to stimulate cAMP formation with the rank order of Phe > Tyr > Trp > Leu. The point mutation of His140 into Phe was effective in another EP3 variant in which its C-terminal tail is different or lacking. Simultaneous mutation of the adjacent Trp(141) to Ala but not at the following Tyr(142) weakened the acquired ability to stimulate cAMP levels in the EP3 mutant. Mutation of EP2 at adjacent Phe(144) to Ala but not at Tyr(145) reduced the efficiency of agonist-induced cAMP formation. In Chinese hamster ovary cells stably expressing G(s)-acquired EP3 mutant, an agonist-dependent cAMP formation was observed, and pertussis toxin markedly augmented cAMP formation. These results suggest that a cluster of hydrophobic aromatic amino acids in the i2 loop plays a key role for G(s) coupling.	Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Ichikawa, A (corresponding author), Mukogawa Womens Univ, Sch Pharmaceut Sci, 11-68 Kyuban Chou, Nishinomiya, Hyogo 6638179, Japan.	aichikaw@mwu.mukogawa-u.ac.jp	Tanaka, Satoshi/H-6800-2019; Sugimoto, Yukihiko/AAV-6470-2021; TANAKA, Satoshi/B-1624-2011	Tanaka, Satoshi/0000-0002-3468-7694; Sugimoto, Yukihiko/0000-0001-6973-932X; TANAKA, Satoshi/0000-0002-3468-7694				ARORA KK, 1995, J BIOL CHEM, V270, P22820, DOI 10.1074/jbc.270.39.22820; Bahia DS, 1998, BIOCHEMISTRY-US, V37, P11555, DOI 10.1021/bi980284o; Chang CS, 1997, PROSTAGLANDINS, V54, P437, DOI 10.1016/S0090-6980(97)00064-6; Chang CS, 1997, BIOCHEM J, V322, P597, DOI 10.1042/bj3220597; Coleman RA, 1990, COMPREHENSIVE MED CH, P643; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Erlenbach I, 2001, J BIOL CHEM, V276, P29382, DOI 10.1074/jbc.M103203200; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hasegawa H, 1996, J BIOL CHEM, V271, P1857, DOI 10.1074/jbc.271.4.1857; Hatae N, 2002, BIOCHEM BIOPH RES CO, V290, P162, DOI 10.1006/bbrc.2001.6169; Hizaki H, 1997, FEBS LETT, V414, P323, DOI 10.1016/S0014-5793(97)01020-X; Ichikawa A, 1997, ADV EXP MED BIOL, V433, P239; IRIE A, 1993, EUR J BIOCHEM, V217, P313, DOI 10.1111/j.1432-1033.1993.tb18248.x; KATSUYAMA M, 1995, FEBS LETT, V372, P151, DOI 10.1016/0014-5793(95)00966-D; Kobayashi T, 2000, J BIOL CHEM, V275, P24294, DOI 10.1074/jbc.M002437200; Kostenis E, 1997, J BIOL CHEM, V272, P23675, DOI 10.1074/jbc.272.38.23675; Kostenis E, 1997, BIOCHEMISTRY-US, V36, P1487, DOI 10.1021/bi962554d; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Liu J, 1996, J BIOL CHEM, V271, P8772, DOI 10.1074/jbc.271.15.8772; Liu S, 2002, J BIOL CHEM, V277, P25707, DOI 10.1074/jbc.M201015200; MILLIGAN G, 1994, METHOD ENZYMOL, V237, P268; MORO O, 1993, J BIOL CHEM, V268, P22273; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Negishi M, 1996, FEBS LETT, V386, P165, DOI 10.1016/0014-5793(96)00354-7; NEGISHI M, 1995, J LIPID MEDIAT CELL, V12, P379, DOI 10.1016/0929-7855(95)00024-K; NEGISHI M, 1995, J BIOL CHEM, V270, P16122, DOI 10.1074/jbc.270.27.16122; NEGISHI M, 1995, BBA-LIPID LIPID MET, V1259, P109, DOI 10.1016/0005-2760(95)00146-4; NEGISHI M, 1993, J BIOL CHEM, V268, P9517; NEGISHI M, 1995, BIOCHEM BIOPH RES CO, V212, P279, DOI 10.1006/bbrc.1995.1967; Nishigaki N, 1996, MOL PHARMACOL, V50, P1031; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; REGAN JW, 1994, MOL PHARMACOL, V46, P213; Satoh S, 1999, BIOCHEM BIOPH RES CO, V255, P164, DOI 10.1006/bbrc.1998.0161; Smit MJ, 1996, J BIOL CHEM, V271, P7574, DOI 10.1074/jbc.271.13.7574; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501	39	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11016	11026		10.1074/jbc.M307404200	http://dx.doi.org/10.1074/jbc.M307404200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699136	hybrid			2022-12-25	WOS:000220157600024
J	Baba, SW; Belogrudov, GI; Lee, JC; Lee, PT; Strahan, J; Shepherd, JN; Clarke, CF				Baba, SW; Belogrudov, GI; Lee, JC; Lee, PT; Strahan, J; Shepherd, JN; Clarke, CF			Yeast Coq5 C-methyltransferase is required for stability of other polypeptides involved in coenzyme Q biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; UBIQUINONE BIOSYNTHESIS; GENE ENCODES; PROTEIN; STEPS; IDENTIFICATION; MITOCHONDRIA; MEMBRANE; STRAINS; DISEASE	Coenzyme Q (Q) functions in the electron transport chain of both prokaryotes and eukaryotes. The biosynthesis of Q requires a number of steps involving at least eight Coq polypeptides. Coq5p is required for the C-methyltransferase step in Q biosynthesis. In this study we demonstrate that Coq5p is peripherally associated with the inner mitochondrial membrane on the matrix side. Phenotypic characterization of a collection of coq5 mutant yeast strains indicates that while each of the coq5 mutant strains are rescued by the Saccharomyces cerevisiae COQ5 gene, only the coq5-2 and coq5-5 mutants are rescued by expression of Escherichia coli ubiE, a homolog of COQ5. The coq5-2 and coq5-5 mutants contain mutations within or adjacent to conserved methyltransferase motifs that would be expected to disrupt the catalysis of C-methylation. The steady state levels of the Coq5-2 and Coq5-5 mutant polypeptides are not decreased relative to wild type Coq5p. Two other polypeptides required for Q biosynthesis, Coq3p and Coq4p, are detected in the wild type parent and in the coq5-2 and coq5-5 mutants, but are not detected in the coq5-null mutant, or in the coq5-4 or coq5-3 mutants. The effect of the coq5-4 mutation is similar to a null, since it results in a stop codon at position 93. However, the coq5-3 mutation (G304D) is located just four amino acids away from the C terminus. While C-methyltransferase activity is detectable in mitochondria isolated from this mutant, the steady state level of Coq5p is dramatically decreased. These studies show that at least two functions can be attributed to Coq5p; first, it is required to catalyze the C-methyltransferase step in Q biosynthesis and second, it is involved in stabilizing the Coq3 and Coq4 polypeptides required for Q biosynthesis.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Gonzaga Univ, Dept Chem, Spokane, WA 99258 USA	University of California System; University of California Los Angeles; Gonzaga University	Clarke, CF (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 607 Charles E Young Dr E, Los Angeles, CA 90095 USA.	cathy@mbi.ucla.edu		Lee, Justine C./0000-0002-8943-0837	NIGMS NIH HHS [GM45952] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barkovich RJ, 1997, J BIOL CHEM, V272, P9182; BELOGRUDOV G, 1994, BIOCHEMISTRY-US, V33, P4571, DOI 10.1021/bi00181a018; Burke D., 2000, METHODS YEAST GENETI, P171; Chanfreau G, 1998, EMBO J, V17, P3726, DOI 10.1093/emboj/17.13.3726; CLARKE CF, 1991, J BIOL CHEM, V266, P16636; Crane FL, 2001, J AM COLL NUTR, V20, P591, DOI 10.1080/07315724.2001.10719063; Culbertson MR, 2003, CURR OPIN GENET DEV, V13, P207, DOI 10.1016/S0959-437X(03)00014-5; Dibrov E, 1997, J BIOL CHEM, V272, P9175; Dutton P.L., 2001, COENZYME Q OXIDATION, P65; Ernster L., 1993, CLIN INVESTIGATOR, V71, P60; Ferrante RJ, 2002, J NEUROSCI, V22, P1592, DOI 10.1523/JNEUROSCI.22-05-01592.2002; GIBSON F, 1973, Biochemical Society Transactions, V1, P317; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Hagerman RA, 2002, BBA-GENE STRUCT EXPR, V1578, P51, DOI 10.1016/S0167-4781(02)00496-7; Hsu AY, 2000, BBA-MOL CELL BIOL L, V1484, P287, DOI 10.1016/S1388-1981(00)00019-6; Hsu AY, 1996, BIOCHEMISTRY-US, V35, P9797, DOI 10.1021/bi9602932; JONASSEN T, 2001, COENZYME Q MOL MECH, P185; KAGAN VE, 1996, HDB ANTIOXIDANTS, P157; Katz JE, 2003, MOL CELL PROTEOMICS, V2, P525, DOI 10.1074/mcp.M300037-MCP200; Koch M, 2003, EUR J BIOCHEM, V270, P84, DOI 10.1046/j.1432-1033.2003.03364.x; Larsen PL, 2002, SCIENCE, V295, P120, DOI 10.1126/science.1064653; Lee PT, 1997, J BACTERIOL, V179, P1748, DOI 10.1128/jb.179.5.1748-1754.1997; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; Meganathan R, 2001, FEMS MICROBIOL LETT, V203, P131, DOI 10.1016/S0378-1097(01)00330-5; PAYNE GS, 1987, MOL CELL BIOL, V7, P3888, DOI 10.1128/MCB.7.11.3888; Poon WW, 1999, J BIOL CHEM, V274, P21665, DOI 10.1074/jbc.274.31.21665; Poon WW, 1997, MOL ASPECTS MED, V18, pS121; Santos-Ocana C, 1998, J BIOL CHEM, V273, P8099, DOI 10.1074/jbc.273.14.8099; Schubert HL, 2003, TRENDS BIOCHEM SCI, V28, P329, DOI 10.1016/S0968-0004(03)00090-2; Shults CW, 2002, ARCH NEUROL-CHICAGO, V59, P1541, DOI 10.1001/archneur.59.10.1541; SIKORSKI RS, 1989, GENETICS, V122, P19; Stenmark P, 2001, J BIOL CHEM, V276, P33297, DOI 10.1074/jbc.C100346200; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627; YOUNG IG, 1971, J BACTERIOL, V105, P769, DOI 10.1128/JB.105.3.769-778.1971	37	51	54	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10052	10059		10.1074/jbc.M313712200	http://dx.doi.org/10.1074/jbc.M313712200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701817	hybrid			2022-12-25	WOS:000220050400049
J	Chen, CH; Paing, MM; Trejo, J				Chen, CH; Paing, MM; Trejo, J			Termination of protease-activated receptor-1 signaling by beta-arrestins is independent of receptor phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTANCE-P RECEPTOR; THROMBIN-RECEPTOR; COUPLED RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; ADRENERGIC-RECEPTOR; PLATELET ACTIVATION; INTERNALIZATION; TRAFFICKING; DESENSITIZATION; ENDOCYTOSIS	Protease-activated receptor 1 (PAR1), a G protein-coupled receptor (GPCR) for thrombin, is the prototypic member of a family of protease-activated receptors. PAR1 is irreversibly proteolytically activated; thus, the magnitude and duration of thrombin cellular responses are determined primarily by mechanisms responsible for termination of receptor signaling. Both phosphorylation and beta-arrestins contribute to rapid desensitization of PAR1 signaling. However, the relative contribution of each of these pathways to the termination of PAR1 signaling is not known. Co-expression of PAR1 with beta-arrestin 1 (betaarr1) in COS-7 cells resulted in a marked inhibition of PAR1 signaling, whereas beta-arrestin 2 (betaarr2) was essentially inactive. Strikingly, signaling by a PAR1 cytoplasmic tail mutant defective in agonist-induced phosphorylation was also attenuated more effectively by betaarr1 compared with betaarr2. In contrast, both beta-arrestin isoforms were equally effective at desensitizing the substance P receptor, a classic reversibly activated GPCR. PAR1 coimmunoprecipitated betaarr1 in an agonist-dependent manner, whereas betaarr2 association was virtually undetectable. Remarkably, betaarr1 also interacted with phosphorylation defective PAR1 mutant, whereas betaarr2 did not. Moreover, constitutively active beta-arrestin mutants, betaarr1 R169E and betaarr2 R170E, that bind to activated receptor independent of phosphorylation failed to enhance either wild type or mutant PAR1 desensitization compared with normal versions of these proteins. In contrast, beta-arrestin mutants displayed enhanced activity at desensitizing the serotonin 5-hydroxytryptamine(2A) receptor. Taken together, these results suggest that, in addition to PAR1 cytoplasmic tail phosphorylation itself, beta-arrestin binding independent of phosphorylation promotes desensitization of PAR1 signaling. These findings reveal a new level of complexity in the regulation of protease-activated GPCR signaling.	Univ N Carolina, Sch Med, Dept Pharmacol, Cardiovasc Biol Ctr,Lineberger Comprehens Canc Ct, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Trejo, J (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, Cardiovasc Biol Ctr,Lineberger Comprehens Canc Ct, 1106 Mary Ellen Jones Bldg, Chapel Hill, NC 27599 USA.	joann_trejo@med.unc.edu		TREJO, JOANN/0000-0003-4405-6228	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073328, K01HL067697] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67697, HL073328] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barak LS, 1999, J BIOL CHEM, V274, P7565, DOI 10.1074/jbc.274.11.7565; Celver J, 2002, J BIOL CHEM, V277, P9043, DOI 10.1074/jbc.M107400200; CHEN J, 1994, J BIOL CHEM, V269, P16041; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; COUGHLIN SR, 1994, TRENDS CARDIOVAS MED, V4, P77, DOI 10.1016/1050-1738(94)90013-2; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Gray JA, 2003, MOL PHARMACOL, V63, P961, DOI 10.1124/mol.63.5.961; Hammes SR, 1999, BIOCHEMISTRY-US, V38, P2486, DOI 10.1021/bi982527i; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; ISHII K, 1994, J BIOL CHEM, V269, P1125; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Kohout TA, 2003, MOL PHARMACOL, V63, P9, DOI 10.1124/mol.63.1.9; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; McConalogue K, 1999, J BIOL CHEM, V274, P16257, DOI 10.1074/jbc.274.23.16257; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Mukherjee S, 2002, J BIOL CHEM, V277, P17916, DOI 10.1074/jbc.M110479200; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; O'Brien PJ, 2001, ONCOGENE, V20, P1570, DOI 10.1038/sj.onc.1204194; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Paing MM, 2002, J BIOL CHEM, V277, P1292, DOI 10.1074/jbc.M109160200; Schmidlin F, 2002, P NATL ACAD SCI USA, V99, P3324, DOI 10.1073/pnas.052161299; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Tiruppathi C, 2000, P NATL ACAD SCI USA, V97, P7440, DOI 10.1073/pnas.97.13.7440; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; Trejo J, 1998, P NATL ACAD SCI USA, V95, P13698, DOI 10.1073/pnas.95.23.13698; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999	34	58	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10020	10031		10.1074/jbc.M310590200	http://dx.doi.org/10.1074/jbc.M310590200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699102	Green Published, hybrid			2022-12-25	WOS:000220050400046
J	Goldman, EH; Chen, L; Fu, H				Goldman, EH; Chen, L; Fu, H			Activation of apoptosis signal-regulating kinase 1 by reactive oxygen species through dephosphorylation at serine 967 and 14-3-3 dissociation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CELL-DEATH; PROTEIN-KINASE; MOLECULAR-CLONING; OXIDATIVE STRESS; ASK1; PHOSPHORYLATION; SURVIVAL; BAD; PHOSPHATASE; THIOREDOXIN	Oxidative stress has been indicated in a variety of pathological processes such as atherosclerosis, diabetes, and neurodegenerative diseases. Understanding how intracellular signaling pathways respond to oxidative insults such as hydrogen peroxide (H2O2) would have significant therapeutic implications. Recent genetic studies have placed apoptosis signal-regulating kinase 1 (ASK1) in a pivotal position in transmitting H2O2-initiated signals. How ASK1 is activated by H2O2, though, remains a subject of intense investigation. Here we report a mechanism by which H2O2 induces ASK1 activation through dynamic control of its phosphorylation at serine 967. We found that treatment of COS7 cells with H2O2 triggers dephosphorylation of Ser-967 through an okadaic acid-sensitive phosphatase, resulting in dissociation of the ASK1.14-3-3 complex with concomitant increase of ASK1 catalytic activity and ASK1-mediated activation of JNK and p38 pathways.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Mol & Syst Pharmacol, Atlanta, GA 30322 USA; Cell Signaling Technol, Beverly, MA 01915 USA	Emory University; Emory University	Fu, H (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 1510 Clifton Rd, Atlanta, GA 30322 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053165, R01GM053165, R01GM060033] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53165, GM60033] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; Cho SG, 2001, J BIOL CHEM, V276, P12749, DOI 10.1074/jbc.M005561200; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Geleziunas R, 2001, NATURE, V410, P834, DOI 10.1038/35071111; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Hirotani S, 2002, CIRCULATION, V105, P509, DOI 10.1161/hc0402.102863; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Liu YM, 2002, CIRC RES, V90, P1259, DOI 10.1161/01.RES.0000022160.64355.62; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Masters SC, 2001, MOL PHARMACOL, V60, P1325, DOI 10.1124/mol.60.6.1325; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Park HS, 2002, MOL CELL BIOL, V22, P7721, DOI 10.1128/MCB.22.22.7721-7730.2002; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Takeda K, 2003, CELL STRUCT FUNCT, V28, P23; Tobiume K, 1997, BIOCHEM BIOPH RES CO, V239, P905, DOI 10.1006/bbrc.1997.7580; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Xing HM, 2000, EMBO J, V19, P349, DOI 10.1093/emboj/19.3.349; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Zama T, 2002, J BIOL CHEM, V277, P23919, DOI 10.1074/jbc.M200838200; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhang R, 2003, J CLIN INVEST, V111, P1933, DOI 10.1172/JCI200317790; Zou XH, 2001, MOL CELL BIOL, V21, P4818, DOI 10.1128/MCB.21.14.4818-4828.2001	41	173	188	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10442	10449		10.1074/jbc.M311129200	http://dx.doi.org/10.1074/jbc.M311129200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688258	hybrid			2022-12-25	WOS:000220050400095
J	Testa, A; Lotti, F; Cairns, L; Grande, A; Ottolenghi, S; Ferrari, G; Ronchi, A				Testa, A; Lotti, F; Cairns, L; Grande, A; Ottolenghi, S; Ferrari, G; Ronchi, A			Deletion of a negatively acting sequence in a chimeric GATA-1 enhancer-long terminal repeat greatly increases retrovirally mediated erythroid expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; HEMATOPOIETIC STEM-CELLS; GLOBIN MESSENGER-RNA; GENE-TRANSFER; VECTORS; PROMOTER; UPSTREAM; METHYLATION; ELEMENT; MICE	The locus control region of the beta-globin gene cluster has been used previously to direct erythroid expression of globin genes from retroviral vectors for the purpose of gene therapy. Short erythroid regulatory elements represent a potentially valuable alternative to the locus control region. Among them, the GATA-1 enhancer HS2 was used to replace the retroviral enhancer within the 3'-long terminal repeat (LTR) of the retroviral vector SFCM, converting it into an erythroid-specific regulatory element. In this work, we have functionally studied an additional GATA-1 enhancer, HS1. HS1 participates in the transcriptional autoregulation of GATA-1 through an essential GATA-binding site that is footprinted in vivo. In this work we identified within HS1 a new in vivo footprinted region, and we showed that this sequence indeed binds a nuclear protein in vitro. Addition of HS1 to HS2 within the LTR of SFCM significantly improves the expression of a reporter gene. The deletion of the newly identified footprinted sequence in the retroviral construct further increases expression up to a level almost equal to that of the wild type retroviral LTR, without loss of erythroid specificity, suggesting that this sequence may act as a negative regulatory element. An improved vector backbone, MDeltaN, allows even better expression from the new GATA cassette. These results suggest that substantial improvement of overall expression can be achieved by the combination of multiple changes in both regulatory elements and vectors.	Univ Milan Bicocca, Dipartimento Biotecnol & Biosci, I-20126 Milan, Italy; Univ Modena & Reggio Emilia, Dipartimento Sci Biomed, I-41100 Modena, Italy; Hosp San Raffaele, Telethon Inst Gene Therapy, I-20132 Milan, Italy	University of Milano-Bicocca; Universita di Modena e Reggio Emilia; Fondazione Telethon; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Ronchi, A (corresponding author), Univ Milan Bicocca, Dipartimento Biotecnol & Biosci, Piazza Sci 2, I-20126 Milan, Italy.	antonella.ronchi@unimib.it	Grande, Alexis/D-5816-2015; Ferrari, Giuliana/AAB-5546-2019; Lotti, Francesco/AAC-3186-2019	Grande, Alexis/0000-0003-3319-1707; Ferrari, Giuliana/0000-0003-0790-3133; RONCHI, ANTONELLA ELLENA/0000-0002-3905-1038	Telethon [TGT06S01, TGT03E01] Funding Source: Medline	Telethon(Fondazione Telethon)		BECKER PB, 1993, METHOD ENZYMOL, V218, P568; Cairns L, 2003, J CELL PHYSIOL, V195, P38, DOI 10.1002/jcp.10241; CAIRNS LA, 1994, EMBO J, V13, P4577, DOI 10.1002/j.1460-2075.1994.tb06779.x; CHALLITA PM, 1994, P NATL ACAD SCI USA, V91, P2567, DOI 10.1073/pnas.91.7.2567; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Grande A, 1999, BLOOD, V93, P3276, DOI 10.1182/blood.V93.10.3276.410k08_3276_3285; HANNON R, 1991, P NATL ACAD SCI USA, V88, P3004, DOI 10.1073/pnas.88.8.3004; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Krall WJ, 1996, GENE THER, V3, P37; Lorincz MC, 2000, MOL CELL BIOL, V20, P842, DOI 10.1128/MCB.20.3.842-850.2000; Lotti F, 2002, J VIROL, V76, P3996, DOI 10.1128/JVI.76.8.3996-4007.2002; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; May C, 2000, NATURE, V406, P82, DOI 10.1038/35017565; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P6781, DOI 10.1073/pnas.94.13.6781; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P7976, DOI 10.1073/pnas.94.15.7976; Moreau-Gaudry F, 2001, BLOOD, V98, P2664, DOI 10.1182/blood.V98.9.2664; NICOLIS S, 1991, NUCLEIC ACIDS RES, V19, P5285, DOI 10.1093/nar/19.19.5285; Nishimura S, 2000, MOL CELL BIOL, V20, P713, DOI 10.1128/MCB.20.2.713-723.2000; Onodera K, 1997, P NATL ACAD SCI USA, V94, P4487, DOI 10.1073/pnas.94.9.4487; Pawliuk R, 2001, SCIENCE, V294, P2368, DOI 10.1126/science.1065806; PEVNY L, 1995, DEVELOPMENT, V121, P163; Phillips K, 1996, NAT MED, V2, P1154, DOI 10.1038/nm1096-1154; Pikaart MI, 1998, GENE DEV, V12, P2852, DOI 10.1101/gad.12.18.2852; QUIVY JP, 1993, NUCLEIC ACIDS RES, V21, P2779, DOI 10.1093/nar/21.11.2779; RONCHI A, 1989, NUCLEIC ACIDS RES, V17, P10231, DOI 10.1093/nar/17.24.10231; Ronchi Antonella, 1997, Genes and Function, V1, P245; Russell D, 2001, BLOOD, V98, P2595, DOI 10.1182/blood.V98.9.2595a; Sabatino DE, 2000, P NATL ACAD SCI USA, V97, P13294, DOI 10.1073/pnas.230453097; Sanyal A, 1999, HUM GENE THER, V10, P2859, DOI 10.1089/10430349950016582; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; Takahashi S, 1997, J BIOL CHEM, V272, P12611, DOI 10.1074/jbc.272.19.12611; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; Verzeletti S, 1998, HUM GENE THER, V9, P2243, DOI 10.1089/hum.1998.9.15-2243; Vyas P, 1999, DEVELOPMENT, V126, P2799; WEISS MJ, 1995, P NATL ACAD SCI USA, V92, P9623, DOI 10.1073/pnas.92.21.9623; Yamamoto M, 1997, GENES CELLS, V2, P107, DOI 10.1046/j.1365-2443.1997.1080305.x	38	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10523	10531		10.1074/jbc.M313638200	http://dx.doi.org/10.1074/jbc.M313638200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701820	hybrid			2022-12-25	WOS:000220050400105
J	Yuasa, K; Fukumoto, S; Kamasaki, Y; Yamada, A; Fukumoto, E; Kanaoka, K; Saito, K; Harada, H; Arikawa-Hirasawa, E; Miyagoe-Suzuki, Y; Takeda, S; Okamoto, K; Kato, Y; Fujiwara, T				Yuasa, K; Fukumoto, S; Kamasaki, Y; Yamada, A; Fukumoto, E; Kanaoka, K; Saito, K; Harada, H; Arikawa-Hirasawa, E; Miyagoe-Suzuki, Y; Takeda, S; Okamoto, K; Kato, Y; Fujiwara, T			Laminin alpha 2 is essential for odontoblast differentiation regulating dentin sialoprotein expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL MUSCULAR-DYSTROPHY; LINKED AMELOGENESIS IMPERFECTA; TOOTH DEVELOPMENT; TARGETED DISRUPTION; MUTANT MICE; IN-VIVO; GENE; MEROSIN; MOUSE; BINDING	Laminin alpha2 is subunit of laminin-2 (alpha2beta1gamma1), which is a major component of the muscle basement membrane. Although the laminin alpha2 chain is expressed in the early stage of dental mesenchyme development and localized in the tooth germ basement membrane, its expression pattern in the late stage of tooth germ development and molecular roles are not clearly understood. We analyzed the role of laminin alpha2 in tooth development by using targeted mice with a disrupted lama2 gene. Laminin alpha2 is expressed in dental mesenchymal cells, especially in odontoblasts and during the maturation stage of ameloblasts, but not in the pre-secretory or secretory stages of ameloblasts. Lama2 mutant mice have thin dentin and a widely opened dentinal tube, as compared with wildtype and heterozygote mice, which is similar to the phenotype of dentinogenesis imperfecta. During dentin formation, the expression of dentin sialoprotein, a marker of odontoblast differentiation, was found to be decreased in odontoblasts from mutant mice. Furthermore, in primary cultures of dental mesenchymal cells, dentin matrix protein, and dentin sialophosphoprotein, mRNA expression was increased in laminin-2 coated dishes but not in those coated with other matrices, fibronectin, or type I collagen. Our results suggest that laminin alpha2 is essential for odontoblast differentiation and regulates the expression of dentin matrix proteins.	Nagasaki Univ, Grad Sch Biomed Sci, Dept Dev & Reconstruct Med, Div Pediat Dent, Nagasaki 8528588, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Publ Hlth, Div Oral Hlth Serv Res, Nagasaki 8528588, Japan; Osaka Univ, Grad Sch Dent, Dept Oral Anat & Dev Biol, Suita, Osaka 5650871, Japan; Juntendo Univ, Sch Med, Dept Neurol, Bunkyo Ku, Tokyo 1138421, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mol Therapy, Tokyo 1878502, Japan	Nagasaki University; Nagasaki University; Osaka University; Juntendo University; National Center for Neurology & Psychiatry - Japan	Fukumoto, S (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Dept Dev & Reconstruct Med, Div Pediat Dent, 1-7-1 Sakamoto, Nagasaki 8528588, Japan.	satoshi@dh.nagasaki-u.ac.jp	Saito, Kan/AAG-3507-2020; Saito, Kan/AFS-5564-2022	Saito, Kan/0000-0002-2151-6204; Saito, Kan/0000-0002-2151-6204; Fukumoto, Satoshi/0000-0002-5046-6891				Begue-Kirn C, 1998, EUR J ORAL SCI, V106, P963, DOI 10.1046/j.0909-8836.1998.eos106510.x; Boskey AL, 1997, CALCIFIED TISSUE INT, V61, P298, DOI 10.1007/s002239900339; BROWN JC, 1994, J CELL SCI, V107, P329; Cerny R, 1996, J BONE MINER RES, V11, P883; Collier PM, 1997, ARCH ORAL BIOL, V42, P235, DOI 10.1016/S0003-9969(96)00099-4; Deutsch, 1998, CONNECT TISSUE RES, V39, P141; Diekwisch TGH, 1997, J HISTOCHEM CYTOCHEM, V45, P859, DOI 10.1177/002215549704500610; DSOUZA RN, 1992, J HISTOCHEM CYTOCHEM, V40, P359, DOI 10.1177/40.3.1552175; DSouza RN, 1997, J BONE MINER RES, V12, P2040, DOI 10.1359/jbmr.1997.12.12.2040; Feng JQ, 1998, J BIOL CHEM, V273, P9457, DOI 10.1074/jbc.273.16.9457; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; Fong C D, 1996, Adv Dent Res, V10, P195; Fukumoto E, 2003, J DENT RES, V82, P17, DOI 10.1177/154405910308200105; Gibson CW, 2001, J BIOL CHEM, V276, P31871, DOI 10.1074/jbc.M104624200; Hoshi K, 1999, J BONE MINER RES, V14, P273, DOI 10.1359/jbmr.1999.14.2.273; Kawano S, 2002, CONNECT TISSUE RES, V43, P409, DOI 10.1080/03008200290000637; Krebsbach PH, 1996, J BIOL CHEM, V271, P4431; KUKITA A, 1992, CALCIFIED TISSUE INT, V51, P393, DOI 10.1007/BF00316886; LAGERSTROM M, 1991, GENOMICS, V10, P971, DOI 10.1016/0888-7543(91)90187-J; Lee SK, 1996, INT J DEV BIOL, V40, P1141; LENCH NJ, 1995, HUM MUTAT, V5, P251, DOI 10.1002/humu.1380050310; LESOT H, 1981, DEV BIOL, V82, P371, DOI 10.1016/0012-1606(81)90460-7; LUMSDEN AGS, 1988, DEVELOPMENT, V103, P155; MacDougall M, 1997, J BIOL CHEM, V272, P835, DOI 10.1074/jbc.272.2.835; MacDougall M, 1997, GENOMICS, V41, P115, DOI 10.1006/geno.1997.4643; Miyagoe Y, 1997, FEBS LETT, V415, P33, DOI 10.1016/S0014-5793(97)01007-7; Miyagoe-Suzuki Y, 2000, MICROSC RES TECHNIQ, V48, P181, DOI 10.1002/(SICI)1097-0029(20000201/15)48:3/4<181::AID-JEMT6>3.0.CO;2-Q; Nguyen BP, 2000, J BIOL CHEM, V275, P31896, DOI 10.1074/jbc.M006379200; Pall EA, 1996, J BIOL CHEM, V271, P3817; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; Ruch J V, 1987, Revis Biol Celular, V14, P1; Ryan MC, 1999, J CELL BIOL, V145, P1309, DOI 10.1083/jcb.145.6.1309; Salmivirta K, 1998, ANN NY ACAD SCI, V857, P279, DOI 10.1111/j.1749-6632.1998.tb10132.x; Salmivirta K, 1997, DEV DYNAM, V210, P206, DOI 10.1002/(SICI)1097-0177(199711)210:3<206::AID-AJA2>3.3.CO;2-S; SCHULER F, 1995, J CELL SCI, V108, P3795; Sewry CA, 1998, NEUROPATH APPL NEURO, V24, P66; SHORER Z, 1995, J CHILD NEUROL, V10, P472, DOI 10.1177/088307389501000610; SIMMER JP, 1994, CALCIFIED TISSUE INT, V54, P312, DOI 10.1007/BF00295956; Smith CE, 1998, CONNECT TISSUE RES, V39, P75, DOI 10.3109/03008209809023914; Sreenath T, 2003, J BIOL CHEM, V278, P24874, DOI 10.1074/jbc.M303908200; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; THESLEFF I, 1981, DIFFERENTIATION, V18, P75, DOI 10.1111/j.1432-0436.1981.tb01107.x; THESLEFF I, 1981, DEV BIOL, V81, P182, DOI 10.1016/0012-1606(81)90361-4; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; TOME FMS, 1994, CR ACAD SCI III-VIE, V317, P351; Vachon PH, 1996, J CELL BIOL, V134, P1483, DOI 10.1083/jcb.134.6.1483; Xiao SX, 2001, NAT GENET, V27, P201, DOI 10.1038/84848; XU H, 1994, P NATL ACAD SCI USA, V91, P5572, DOI 10.1073/pnas.91.12.5572; YAMADA H, 1994, FEBS LETT, V352, P49, DOI 10.1016/0014-5793(94)00917-1; YURCHENCO PD, 1994, CURR OPIN CELL BIOL, V6, P674, DOI 10.1016/0955-0674(94)90093-0; Zhang XH, 2001, NAT GENET, V27, P151, DOI 10.1038/84765	52	55	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10286	10292		10.1074/jbc.M310013200	http://dx.doi.org/10.1074/jbc.M310013200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14681233	hybrid			2022-12-25	WOS:000220050400077
J	Brdlik, CM; Crews, CM				Brdlik, CM; Crews, CM			A single amino acid residue defines the difference in ovalicin sensitivity between type I and II methionine aminopeptidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOGENESIS INHIBITOR TNP-470; ESCHERICHIA-COLI; PHASE-I; FUMAGILLIN; YEAST; GENE; EXPRESSION; AGM-1470; ANALOGS	TNP-470, the first anti-angiogenic small molecule to enter clinical trials, targets methionine aminopeptidase-2 (MetAP-2), a metalloprotease that cleaves the N-terminal methionine of proteins. Previously, biochemical binding, in vivo yeast studies, and structural studies of human methionine aminopeptidase-2 bound to TNP-470 and its analogs fumagillin and ovalicin revealed that these compounds exhibit specificity for MetAP-2 over its family member MetAP-1. To further elucidate the nature of this specificity, we developed a yeast-based screen for human MetAP-2 mutations that confer ovalicin resistance. Of the three resistant alleles, A362T appeared in the majority of clones and was found to be the most resistant to the ovalicin class of inhibitors. Alignment of human MetAP-2 with human MetAP-1, which is naturally ovalicin-resistant, revealed that the analogous residue in MetAP-1 is also a threonine. Mutation of this residue to alanine resulted in an ovalicin-sensitive MetAP-1 allele, demonstrating that an alanine at this position is critical for inhibition by ovalicin. These results provide a molecular explanation for the specificity exhibited by this class of anti-angiogenic agents for MetAP-2 over MetAP-1 and may prove useful in the development of additional MetAP-2-specific therapeutic agents.	Yale Univ, Dept Genet, New Haven, CT 06520 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Yale Univ, Dept Pharmacol, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA	Yale University; Yale University; Yale University; Yale University	Crews, CM (corresponding author), 219 Prospect St, New Haven, CT 06520 USA.	craig.crews@yale.edu	Crews, Craig M./ABH-9346-2020	Crews, Craig M./0000-0002-8456-2005	NATIONAL CANCER INSTITUTE [R01CA083049] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA83049, R01 CA083049-05S1, R01 CA083049] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARFIN SM, 1995, P NATL ACAD SCI USA, V92, P7714, DOI 10.1073/pnas.92.17.7714; Baldwin JE, 2002, TETRAHEDRON, V58, P5441, DOI 10.1016/S0040-4020(02)00514-8; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; CHANG SYP, 1989, J BACTERIOL, V171, P4071, DOI 10.1128/jb.171.7.4071-4072.1989; CHANG YH, 1992, J BIOL CHEM, V267, P8007; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; Dezube BJ, 1998, J CLIN ONCOL, V16, P1444, DOI 10.1200/JCO.1998.16.4.1444; Dummitt B, 2002, PROTEIN PEPTIDE LETT, V9, P295, DOI 10.2174/0929866023408607; FINK G, 1991, METHODS ENZYMOL GUID, V194, P322; Griffith EC, 1998, P NATL ACAD SCI USA, V95, P15183, DOI 10.1073/pnas.95.26.15183; Griffith EC, 1997, CHEM BIOL, V4, P461, DOI 10.1016/S1074-5521(97)90198-8; Han CK, 2000, BIOORG MED CHEM LETT, V10, P39, DOI 10.1016/S0960-894X(99)00577-6; HIETER P, 1985, CELL, V42, P913, DOI 10.1016/0092-8674(85)90287-9; HIETER P, 1985, CELL, V40, P381, DOI 10.1016/0092-8674(85)90152-7; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; Kruger EA, 2000, EXPERT OPIN INV DRUG, V9, P1383, DOI 10.1517/13543784.9.6.1383; Kudelka AP, 1997, CLIN CANCER RES, V3, P1501; KUSAKA M, 1991, BIOCHEM BIOPH RES CO, V174, P1070, DOI 10.1016/0006-291X(91)91529-L; Kwon JY, 2000, J ANTIBIOT, V53, P799, DOI 10.7164/antibiotics.53.799; Li X, 1995, P NATL ACAD SCI USA, V92, P12357, DOI 10.1073/pnas.92.26.12357; Liu SP, 1998, SCIENCE, V282, P1324, DOI 10.1126/science.282.5392.1324; Lowther WT, 1998, P NATL ACAD SCI USA, V95, P12153, DOI 10.1073/pnas.95.21.12153; Lowther WT, 2000, BBA-PROTEIN STRUCT M, V1477, P157, DOI 10.1016/S0167-4838(99)00271-X; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; OREILLY MS, 1995, J PEDIATR SURG, V30, P325, DOI 10.1016/0022-3468(95)90583-9; PEACOCK DJ, 1995, CELL IMMUNOL, V160, P178, DOI 10.1016/0008-8749(95)80025-E; RODERICK SL, 1993, BIOCHEMISTRY-US, V32, P3907, DOI 10.1021/bi00066a009; Rohan RM, 2000, FASEB J, V14, P871, DOI 10.1096/fasebj.14.7.871; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Shusterman S, 2001, CLIN CANCER RES, V7, P977; Sin N, 1997, P NATL ACAD SCI USA, V94, P6099, DOI 10.1073/pnas.94.12.6099; Son KH, 2002, BIOORGAN MED CHEM, V10, P185, DOI 10.1016/S0968-0896(01)00268-1; Stadler WM, 1999, J CLIN ONCOL, V17, P2541, DOI 10.1200/JCO.1999.17.8.2541; Wang JY, 2003, BIOCHEMISTRY-US, V42, P5035, DOI 10.1021/bi020670c; Weisman R, 2001, J BIOL CHEM, V276, P24736, DOI 10.1074/jbc.M102090200	37	19	19	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9475	9480		10.1074/jbc.M307246200	http://dx.doi.org/10.1074/jbc.M307246200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676204	Green Accepted, hybrid			2022-12-25	WOS:000189265900113
J	Kumar, AP; Piedrafita, FJ; Reynolds, WF				Kumar, AP; Piedrafita, FJ; Reynolds, WF			Peroxisome proliferator-activated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the -463GA promoter polymorphism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; HUMAN ATHEROSCLEROTIC LESIONS; ASSOCIATION IMPLICATES MYELOPEROXIDASE; HYPOCHLORITE-MODIFIED PROTEINS; MONOCYTE-DERIVED MACROPHAGES; ACUTE CORONARY SYNDROMES; LOW-DENSITY-LIPOPROTEIN; ACID RESPONSE ELEMENT; ALZHEIMERS-DISEASE; PPAR-GAMMA	A functional myeloperoxidase (MPO) promoter polymorphism, - 463GA, has been associated with incidence or severity of inflammatory diseases, including atherosclerosis and Alzheimer's disease, and some cancers. The polymorphism is within an Alu element encoding four hexamer repeats recognized by nuclear receptors (AluRRE). Here we show that peroxisome proliferator-activated receptor gamma (PPARgamma) agonists strongly regulate MPO gene expression through the AluRRE. Opposite effects were observed in granulocyte/macrophage colony-stimulating factor ( GMCSF)- versus macrophage colony-stimulating factor (MCSF)-derived macrophages (Mphi): Expression was markedly up-regulated ( mean 26-fold) in MCSF-Mphi and down-regulated (34-fold) in GMCSF-Mphi. This was observed with rosiglitazone and three other PPARgamma ligands of the thiazolidinedione class, as well as the natural prostaglandin metabolite 15-deoxy-Delta(12,14) prostaglandin J(2). The selective PPARgamma antagonist, GW9662, blocked both the positive and negative effects on MPO expression. Gel retardation assays showed PPARgamma bound hexamers 3/4, and estrogen receptor-alpha bound hexamers 1/2, with -463A in hexamer 1 enhancing binding. Estrogen blocked PPARgamma effects on MPO expression, especially for the A allele. Charcoal filtration of fetal calf serum eliminated the block of PPARgamma, whereas replenishing the medium with 17beta-estradiol reinstated the block. These findings suggest a model in which estrogen receptor binds the AluRRE, preventing PPARgamma binding to the adjacent site. The positive and negative regulation by PPARgamma ligands, and the block by estrogen, was also observed in transgenic mice expressing the G and A alleles. The mouse MPO gene, which lacks the primate-specific AluRRE, was unresponsive to PPARgamma ligands, suggesting the human MPO transgenes will enhance the utility of mouse models for diseases involving MPO, such as atherosclerosis and Alzheimer's.	Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA		Reynolds, WF (corresponding author), Sidney Kimmel Canc Ctr, 10835 Altman Row, San Diego, CA 92121 USA.	wreynolds@skcc.org			NIA NIH HHS [R01 AG17879] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG017879] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akagawa KS, 2002, INT J HEMATOL, V76, P27, DOI 10.1007/BF02982715; AKIYAMA H, 1994, BRAIN RES, V639, P171, DOI 10.1016/0006-8993(94)91779-5; Baldus S, 2003, CIRCULATION, V108, P1440, DOI 10.1161/01.CIR.0000090690.67322.51; Brennan ML, 2001, J CLIN INVEST, V107, P419, DOI 10.1172/JCI8797; Brennan ML, 2001, J NEUROIMMUNOL, V112, P97, DOI 10.1016/S0165-5728(00)00392-1; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Chumakov AM, 2000, INT J ONCOL, V16, P401; CLINTON SK, 1992, AM J PATHOL, V140, P301; Crawford FC, 2001, EXP NEUROL, V167, P456, DOI 10.1006/exnr.2000.7560; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; Davies SS, 2001, J BIOL CHEM, V276, P16015, DOI 10.1074/jbc.M100878200; Du YS, 1997, P NATL ACAD SCI USA, V94, P11657, DOI 10.1073/pnas.94.21.11657; Ediger TR, 2002, MOL ENDOCRINOL, V16, P1828, DOI 10.1210/me.2001-0290; Eiserich JP, 2002, SCIENCE, V296, P2391, DOI 10.1126/science.1106830; Fontaine C, 2003, J BIOL CHEM, V278, P37672, DOI 10.1074/jbc.M304664200; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Heinecke JW, 2002, TOXICOLOGY, V177, P11, DOI 10.1016/S0300-483X(02)00192-0; Hoy A, 2001, EUR J HUM GENET, V9, P780, DOI 10.1038/sj.ejhg.5200702; Keler T, 2000, J IMMUNOL, V164, P5746, DOI 10.4049/jimmunol.164.11.5746; Klebanoff SJ, 1999, P ASSOC AM PHYSICIAN, V111, P383, DOI 10.1111/paa.1999.111.5.383; KLEBANOFF SJ, 1970, SCIENCE, V169, P1095, DOI 10.1126/science.169.3950.1095; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Koeffler HP, 2003, CLIN CANCER RES, V9, P1; Komuro I, 2001, J BIOL CHEM, V276, P24360, DOI 10.1074/jbc.M102081200; Kutter D, 2000, ACTA HAEMATOL-BASEL, V104, P10, DOI 10.1159/000041062; Leesnitzer LM, 2002, BIOCHEMISTRY-US, V41, P6640, DOI 10.1021/bi0159581; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Leininger-Muller B, 2003, NEUROSCI LETT, V349, P95, DOI 10.1016/S0304-3940(03)00795-X; Li M, 2000, MOL CELL BIOL, V20, P4699, DOI 10.1128/MCB.20.13.4699-4707.2000; London SJ, 1997, CANCER RES, V57, P5001; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Makela R, 2003, J CLIN ENDOCR METAB, V88, P3823, DOI 10.1210/jc.2002-021771; Makela R, 2003, LAB INVEST, V83, P919, DOI 10.1097/01.LAB.0000077981.49367.46; Malle E, 2000, EUR J BIOCHEM, V267, P4495, DOI 10.1046/j.1432-1327.2000.01498.x; Marx N, 1998, AM J PATHOL, V153, P17, DOI 10.1016/S0002-9440(10)65540-X; Meisel P, 2002, GENES IMMUN, V3, P102, DOI 10.1038/sj.gene.6363840; Moore KJ, 2001, NAT MED, V7, P41, DOI 10.1038/83328; Murphy GM, 2000, AM J PATHOL, V157, P895, DOI 10.1016/S0002-9440(10)64603-2; Nagra RM, 1997, J NEUROIMMUNOL, V78, P97, DOI 10.1016/S0165-5728(97)00089-1; NAUSEEF WM, 1988, EUR J HAEMATOL, V40, P97; Nauseef WM, 2001, J CLIN INVEST, V107, P401, DOI 10.1172/JCI11713; Nauseef WM, 2001, INT J HEMATOL, V74, P125, DOI 10.1007/BF02981994; Nikpoor B, 2001, AM HEART J, V142, P336, DOI 10.1067/mhj.2001.116769; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; Pecoits R, 2003, KIDNEY INT, V63, pS172, DOI 10.1046/j.1523-1755.63.s84.32.x; Piedrafita FJ, 1996, J BIOL CHEM, V271, P14412, DOI 10.1074/jbc.271.24.14412; Plenz G, 1999, ATHEROSCLEROSIS, V144, P25, DOI 10.1016/S0021-9150(99)00035-0; Podrez EA, 2000, J CLIN INVEST, V105, P1095, DOI 10.1172/JCI8574; Reynolds W, 2002, GENES IMMUN, V3, P345, DOI 10.1038/sj.gene.6363880; Reynolds WF, 2000, NEUROLOGY, V55, P1284, DOI 10.1212/WNL.55.9.1284; Reynolds WF, 1999, EXP NEUROL, V155, P31, DOI 10.1006/exnr.1998.6977; Reynolds WF, 1997, BLOOD, V90, P2730, DOI 10.1182/blood.V90.7.2730.2730_2730_2737; Reynolds WF, 2002, CLIN IMMUNOL, V103, P154, DOI 10.1006/clim.2002.5206; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Schabath MB, 2002, LUNG CANCER-J IASLC, V37, P35, DOI 10.1016/S0169-5002(02)00034-X; Shi YH, 2002, P NATL ACAD SCI USA, V99, P2613, DOI 10.1073/pnas.052707099; Shibata T, 2002, J BIOL CHEM, V277, P10459, DOI 10.1074/jbc.M110314200; Spiegelman B M, 1997, Eur J Med Res, V2, P457; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9; Tarkowski E, 2001, ACTA NEUROL SCAND, V103, P166, DOI 10.1034/j.1600-0404.2001.103003166.x; VANSANT G, 1995, P NATL ACAD SCI USA, V92, P8229, DOI 10.1073/pnas.92.18.8229; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a; YOUNG DA, 1990, J IMMUNOL, V145, P607; Zhang ZL, 2001, JAMA-J AM MED ASSOC, V286, P2136, DOI 10.1001/jama.286.17.2136	71	84	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8300	8315		10.1074/jbc.M311625200	http://dx.doi.org/10.1074/jbc.M311625200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14668325	hybrid			2022-12-25	WOS:000189103300112
J	Lionneton, F; Lelievre, E; Baillat, D; Stehelin, D; Soncin, F				Lionneton, F; Lelievre, E; Baillat, D; Stehelin, D; Soncin, F			Characterization and functional analysis of the p42Ets-1 variant of the mouse Ets-1 transcription factor	ONCOGENE			English	Article						Ets-1; endothelium; VE-cadherin; gene promoter	DNA-BINDING MOTIF; CHICK-EMBRYO; MURINE ETS-1; PROTEIN INTERACTIONS; ENDOTHELIAL-CELLS; GENE-EXPRESSION; C-ETS-1; PROMOTER; DOMAIN; PHOSPHORYLATION	We have identified the mouse exon VII splice variant of the Ets-1 transcription factor. The variant is expressed in all cell lines which express ets-1, at lower levels, it is also expressed in the mouse embryo in vivo. The corresponding protein, p42Ets-1, is a transcription factor as it is able to bind to specific DNA sequences and to transactivate a bona. de ETS reporter vector. A comparison of optimal DNA-binding sites shows that p42Ets-1 binds to more various DNA sequences than p51Ets-1; p42Ets-1 recognizes the same optimal consensus sequence as p51Ets-1, but also many variations of it, mainly at base -1, which is located just prior to the GGAA/T core sequence. The binding differences were quantified by surface plasmon resonance analyses and the protein region responsible for the differences in DNA sequence recognition located in the Val(280)-Glu(302) fragment, which is encoded by exon VII. The specific DNA-binding properties of each isoform translates into clear differences in activity, p42Ets-1 transactivates the natural VE-cadherin gene promoter through both ETS-binding site (EBS)2 and EBS4 whereas p51Ets-1 is mainly active on EBS4. Altogether, our data suggest that p42Ets-1 acts as a distinct transcription factor from p51Ets-1.	Inst Biol Lille, CNRS, UMR 8526, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS)	Soncin, F (corresponding author), Inst Biol Lille, CNRS, UMR 8526, 1 Rue Calmette, F-59021 Lille, France.		SONCIN, Fabrice/A-1475-2009	SONCIN, Fabrice/0000-0001-6312-0673; Lelievre, Etienne/0000-0003-0452-1578				Anderson MK, 1999, DEVELOPMENT, V126, P3131; Baillat D, 2002, J BIOL CHEM, V277, P29386, DOI 10.1074/jbc.M200088200; Barton K, 1998, IMMUNITY, V9, P555, DOI 10.1016/S1074-7613(00)80638-X; BELLACOSA A, 1994, J VIROL, V68, P2320, DOI 10.1128/JVI.68.4.2320-2330.1994; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Bradford AP, 1996, J BIOL CHEM, V271, P24639, DOI 10.1074/jbc.271.40.24639; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; Calmels TPG, 1995, BIOL CELL, V84, P53, DOI 10.1016/0248-4900(96)81318-9; Castellano R, 2002, J BIOL CHEM, V277, P42841, DOI 10.1074/jbc.M207689200; Cowley DO, 2000, GENE DEV, V14, P366; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; FISHER RJ, 1994, PROTEIN SCI, V3, P257; FISHER RJ, 1991, ONCOGENE, V6, P2249; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; Garvie CW, 2002, J BIOL CHEM, V277, P45529, DOI 10.1074/jbc.M206327200; Garvie CW, 2001, MOL CELL, V8, P1267, DOI 10.1016/S1097-2765(01)00410-5; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, V1, P29; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; Gory S, 1998, J BIOL CHEM, V273, P6750, DOI 10.1074/jbc.273.12.6750; GREVIN D, 1993, INT J DEV BIOL, V37, P519; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HOWARD PW, 1995, J BIOL CHEM, V270, P20930, DOI 10.1074/jbc.270.36.20930; Huang CC, 1997, ONCOGENE, V15, P851, DOI 10.1038/sj.onc.1201408; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; JORCYK CL, 1991, ONCOGENE, V6, P523; KOIZUMI S, 1990, ONCOGENE, V5, P675; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; Lelievre E, 2002, J BIOL CHEM, V277, P25143, DOI 10.1074/jbc.M201628200; Lelievre E, 2001, INT J BIOCHEM CELL B, V33, P391, DOI 10.1016/S1357-2725(01)00025-5; Lelievre E, 2000, ONCOGENE, V19, P2438, DOI 10.1038/sj.onc.1203563; Li RH, 1999, P NATL ACAD SCI USA, V96, P3876, DOI 10.1073/pnas.96.7.3876; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; Lionneton F, 2001, PROTEIN EXPRES PURIF, V21, P492, DOI 10.1006/prep.2001.1405; Liu H, 2002, MOL BIOL CELL, V13, P4497, DOI 10.1091/mbc.E02-03-0149; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; Mo Y, 2000, NAT STRUCT BIOL, V7, P292; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; PARDANAUD L, 1993, CELL ADHES COMMUN, V1, P151, DOI 10.3109/15419069309095691; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; QUEVA C, 1993, ONCOGENE, V8, P2511; RABAULT B, 1994, J BIOL CHEM, V269, P28143; RAYGALLET D, 1995, ONCOGENE, V11, P303; Skalicky JJ, 1996, PROTEIN SCI, V5, P296; VANDENBUNDER B, 1989, DEVELOPMENT, V107, P265; VANDENBUNDER B, 1994, INVAS METAST, V14, P198; Werner MH, 1997, J BIOMOL NMR, V10, P317, DOI 10.1023/A:1018399711996; WERNERT N, 1994, CANCER RES, V54, P5683; WERNERT N, 1992, AM J PATHOL, V140, P119; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218	53	13	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2003	22	57					9156	9164		10.1038/sj.onc.1207241	http://dx.doi.org/10.1038/sj.onc.1207241			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	752FJ	14668797				2022-12-25	WOS:000187149100006
J	McLeod, SJ; Shum, AJ; Lee, RL; Takei, F; Gold, MR				McLeod, SJ; Shum, AJ; Lee, RL; Takei, F; Gold, MR			The Rap GTPases regulate integrin-mediated adhesion, cell spreading, actin polymerization, and Pyk2 tyrosine phosphorylation in B lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN-RECEPTOR; T-CELL; RAP1-INDUCED ADHESION; ACTIVATION; KINASE; CHEMOKINE; LFA-1; MORPHOLOGY; EXPRESSION; MIGRATION	Integrin-mediated adhesion plays an important role in B cell development and activation. Signaling initiated by antigens, chemokines, or phorbol esters can rapidly convert integrins to an activated adhesion-competent state. The binding of integrins to their ligands can then induce actin-dependent cell spreading, which can facilitate cell-cell adhesion or cell migration on extracellular matrices. The signaling pathways involved in integrin activation and post-adhesion events in B cells are not completely understood. We have previously shown that anti-Ig antibodies, the chemokine stromal cell-derived factor-1 (SDF-1; CXCL12), and phorbol esters activate the Rap1 and Rap2 GTPases in B cells and that Rap activation is essential for SDF-1-induced B cell migration (McLeod, S. J., Li, A. H. Y., Lee, R. L., Burgess, A. E., and Gold, M. R. ( 2002) J. Immunol. 169, 1365 - 1371; Christian, S. L., Lee, R. L., McLeod, S. J., Burgess, A. E., Li, A. H. Y., Dang-Lawson, M., Lin, K. B. L., and Gold, M. R. (2003) J. Biol. Chem. 278, 41756 - 41767). We show here that preventing Rap activation by expressing Rap-specific GTPase-activating protein II (RapGAPII) significantly decreased lymphocyte function-associated antigen-1- and alpha(4) integrin-dependent binding of murine B cell lines to purified adhesion molecules and to other cells. Conversely, augmenting Rap activation by expressing a constitutively active form of Rap2 enhanced B cell adhesion, showing for the first time that Rap2 can promote integrin activation. We also show that blocking Rap activation inhibited anti-Ig-induced cell spreading and phorbol ester-induced actin polymerization as well as anti-Ig- and SDF-1-induced phosphorylation of Pyk2, a tyrosine kinase involved in morphological changes and chemokine-induced B cell migration. Thus, the Rap GTPases regulate integrin-mediated B cell adhesion as well as processes that control B cell morphology and migration.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada	University of British Columbia; British Columbia Cancer Agency	Gold, MR (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.	mgold@interchange.ubc.ca	Gold, Michael/AAF-2081-2021	Gold, Michael/0000-0003-1222-3191; Takei, Fumio/0000-0002-3620-5046				Abraham RT, 2002, NAT IMMUNOL, V3, P212, DOI 10.1038/ni0302-212; Arai A, 2001, J BIOL CHEM, V276, P10453, DOI 10.1074/jbc.M004627200; Arroyo AG, 1996, CELL, V85, P997, DOI 10.1016/S0092-8674(00)81301-X; Asha H, 1999, EMBO J, V18, P605, DOI 10.1093/emboj/18.3.605; Astier A, 1997, J BIOL CHEM, V272, P228; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Berlin-Rufenach C, 1999, J EXP MED, V189, P1467, DOI 10.1084/jem.189.9.1467; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; Christian SL, 2003, J BIOL CHEM, V278, P41756, DOI 10.1074/jbc.M303180200; Constantin G, 2000, IMMUNITY, V13, P759, DOI 10.1016/S1074-7613(00)00074-1; CORRADI MP, 1987, J IMMUNOL, V138, P2075; Croker BA, 2002, J IMMUNOL, V168, P3376, DOI 10.4049/jimmunol.168.7.3376; DANG LH, 1991, J IMMUNOL, V146, P3273; Doucey MA, 2003, J BIOL CHEM, V278, P26983, DOI 10.1074/jbc.M302709200; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; FREUNDLICH B, 1983, J IMMUNOL METHODS, V62, P31, DOI 10.1016/0022-1759(83)90107-2; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Gismondi A, 2003, J IMMUNOL, V170, P3065, DOI 10.4049/jimmunol.170.6.3065; Guinamard R, 2000, NAT IMMUNOL, V1, P31, DOI 10.1038/76882; Harris ES, 2000, J BIOL CHEM, V275, P23409, DOI 10.1074/jbc.R000004200; Heo WD, 2003, CELL, V113, P315; Ingham RJ, 2001, J BIOL CHEM, V276, P12257, DOI 10.1074/jbc.M010590200; Katagiri K, 2002, MOL CELL BIOL, V22, P1001, DOI 10.1128/MCB.22.4.1001-1015.2002; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Katagiri T, 2000, J BIOL CHEM, V275, P19645, DOI 10.1074/jbc.M909828199; Kellermann SA, 2002, IMMUNOL REV, V186, P172, DOI 10.1034/j.1600-065X.2002.18615.x; KOOPMAN G, 1991, J EXP MED, V173, P1297, DOI 10.1084/jem.173.6.1297; KOOPMAN G, 1994, J IMMUNOL, V152, P3760; Krebs Danielle L., 1999, Methods in Cell Science, V21, P57, DOI 10.1023/A:1009843325770; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; Lakkakorpi PT, 2003, J BIOL CHEM, V278, P11502, DOI 10.1074/jbc.M206579200; Laudanna C, 2002, IMMUNOL REV, V186, P37, DOI 10.1034/j.1600-065X.2002.18604.x; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; LEMOINE FM, 1990, BLOOD, V76, P2311; LEMOINE FM, 1988, EXP HEMATOL, V16, P718; Leuker CE, 2001, J EXP MED, V193, P755, DOI 10.1084/jem.193.6.755; Li X, 1999, J BIOL CHEM, V274, P8917, DOI 10.1074/jbc.274.13.8917; Litvak V, 2000, J BIOL CHEM, V275, P32736, DOI 10.1074/jbc.M004200200; Lo CG, 2003, J EXP MED, V197, P353, DOI 10.1084/jem.20021569; Lyons PD, 2001, J BIOL CHEM, V276, P24422, DOI 10.1074/jbc.M011080200; McLeod SJ, 1998, J BIOL CHEM, V273, P29218, DOI 10.1074/jbc.273.44.29218; McLeod SJ, 2002, J IMMUNOL, V169, P1365, DOI 10.4049/jimmunol.169.3.1365; MELAMED I, 1991, J IMMUNOL, V147, P1139; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; Montoya MC, 2002, IMMUNOL REV, V186, P68, DOI 10.1034/j.1600-065X.2002.18607.x; Okigaki M, 2003, P NATL ACAD SCI USA, V100, P10740, DOI 10.1073/pnas.1834348100; Oostendorp RAJ, 1997, LEUKEMIA LYMPHOMA, V24, P423, DOI 10.3109/10428199709055581; Owen JD, 1999, MOL CELL BIOL, V19, P4806; PATARROYO M, 1983, CELL IMMUNOL, V81, P373, DOI 10.1016/0008-8749(83)90244-7; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; POSTIGO AA, 1991, EUR J IMMUNOL, V21, P2437, DOI 10.1002/eji.1830211021; REBSTEIN PJ, 1993, DEV GENET, V14, P347, DOI 10.1002/dvg.1020140504; Rebstein PJ, 1997, EXP CELL RES, V231, P276, DOI 10.1006/excr.1996.3466; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Rose DM, 2002, IMMUNOL REV, V186, P118, DOI 10.1034/j.1600-065X.2002.18611.x; Rott LS, 2000, J LEUKOCYTE BIOL, V68, P807; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SANCHEZMADRID F, 1983, J EXP MED, V158, P586, DOI 10.1084/jem.158.2.586; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; Shimonaka M, 2003, J CELL BIOL, V161, P417, DOI 10.1083/jcb.200301133; Stephens L, 2002, CURR OPIN CELL BIOL, V14, P203, DOI 10.1016/S0955-0674(02)00311-3; Suga K, 2001, FEBS LETT, V489, P249, DOI 10.1016/S0014-5793(00)02222-5; Tohyama Y, 2003, MOL BIOL CELL, V14, P2570, DOI 10.1091/mbc.E02-09-0615; Vicente-Manzanares M, 1998, EUR J IMMUNOL, V28, P2197, DOI 10.1002/(SICI)1521-4141(199807)28:07<2197::AID-IMMU2197>3.0.CO;2-F; WELDER CA, 1993, J IMMUNOL, V150, P2203	70	112	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12009	12019		10.1074/jbc.M313098200	http://dx.doi.org/10.1074/jbc.M313098200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14701796	hybrid			2022-12-25	WOS:000220334900003
J	Charrasse, S; Comunale, F; Gilbert, E; Delattre, O; Gauthier-Rouviere, C				Charrasse, S; Comunale, F; Gilbert, E; Delattre, O; Gauthier-Rouviere, C			Variation in cadherins and catenins expression is linked to both proliferation and transformation of Rhabdomyosarcoma	ONCOGENE			English	Article						rhabdomyosarcoma; cadherins; catenins; transformation	GROWTH-FACTOR-II; SERUM RESPONSE FACTOR; MOUSE C2C12 MYOBLASTS; RHO-FAMILY GTPASES; N-CADHERIN; CELL-ADHESION; MYOGENIC DIFFERENTIATION; TERMINAL DIFFERENTIATION; BREAST-CANCER; PEDIATRIC RHABDOMYOSARCOMA	Cadherins are a family of transmembrane glycoproteins that mediate Ca2+-dependent homophilic cell-cell adhesion and play a crucial role in cell differentiation. E-cadherin-mediated cell-cell adhesion is lost during the development of most epithelial cancers. This study examines cadherin-dependent adhesion in cell lines derived from rhabdomyosarcoma (RMS), a highly malignant soft-tissue tumor committed to the myogenic lineage, but arrested prior to terminal differentiation. We analysed the expression of cadherins and associated catenins at the mRNA and protein levels as well as their localization in nine RMS-derived cell lines relative to normal myoblasts. We show a decrease in the expression of cadherins and catenins in all RMS-derived cell lines compared to control cells. This decrease in the expression of N- and M-cadherin was confirmed in RMS biopsies. In contrast, R-cadherin is found expressed in RMS, whereas it is normally absent in normal myoblasts. We show that a decrease of R-cadherin expression using RNA interference inhibits cell proliferation of the RD cell line. In addition to their diminished expression, cadherins and catenins do not localize to intercellular contacts in embryonal RMS (ERMS), whereas specific persistent localization is seen in alveolar RMS (ARMS)-derived cell lines. Thus, RMS exhibit defects in the expression of molecules of the cadherin family. Defects in the localization of these adhesion molecules at the sites of cell-cell contact are specifically observed in the ERMS subtype. In addition, our data suggest that R-cadherin is a specific diagnostic marker for RMS and is also an important factor of RMS cell proliferation.	CNRS, UPR 1086, CRBM, F-34293 Montpellier, France; Inst Curie, INSERM,U509, Sect Rech, Lab Pathol Mol Canc, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Gauthier-Rouviere, C (corresponding author), CNRS, UPR 1086, CRBM, 1919 Route Mende, F-34293 Montpellier, France.	gauthier@crbm.cnrs-mop.fr		GAUTHIER-ROUVIERE, Cecile/0000-0002-8364-3882; delattre, olivier/0000-0002-8730-2276; Comunale, Franck/0000-0001-8838-2151				Barr FG, 1999, CANCER RES, V59, p1711S; BesnardGuerin C, 1996, HUM GENET, V97, P163, DOI 10.1007/BF02265259; Bouche M, 2000, FASEB J, V14, P1147, DOI 10.1096/fasebj.14.9.1147; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carnac G, 1998, MOL BIOL CELL, V9, P1891, DOI 10.1091/mbc.9.7.1891; Chalmers IJ, 2001, CANCER GENET CYTOGEN, V126, P39, DOI 10.1016/S0165-4608(00)00376-9; CHARDIN P, 1985, INT J CANCER, V35, P647, DOI 10.1002/ijc.2910350513; Charrasse S, 2002, J CELL BIOL, V158, P953, DOI 10.1083/jcb.200202034; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; DEGIOVANNI C, 1995, BRIT J CANCER, V72, P1224, DOI 10.1038/bjc.1995.490; DUBAND JL, 1987, J CELL BIOL, V104, P1361, DOI 10.1083/jcb.104.5.1361; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; Eusebi V, 2000, AM J SURG PATHOL, V24, P223, DOI 10.1097/00000478-200002000-00008; Ferracini R, 1996, ONCOGENE, V12, P1697; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; GARSON JA, 1986, LANCET, V1, P1496; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; GauthierRouviere C, 1996, MOL BIOL CELL, V7, P719, DOI 10.1091/mbc.7.5.719; GeorgeWeinstein M, 1997, DEV BIOL, V185, P14, DOI 10.1006/dbio.1997.8542; Goichberg P, 1998, MOL BIOL CELL, V9, P3119, DOI 10.1091/mbc.9.11.3119; Hajra KM, 2002, CANCER RES, V62, P1613; Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083; HATTA K, 1987, DEV BIOL, V120, P215, DOI 10.1016/0012-1606(87)90119-9; KALEBIC T, 1994, CANCER RES, V54, P5531; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KIMURA Y, 1995, DEV BIOL, V169, P347, DOI 10.1006/dbio.1995.1149; Knudsen KA, 1990, CURR OPIN CELL BIOL, V2, P902, DOI 10.1016/0955-0674(90)90090-2; Ko K, 2000, AM J PHYSIOL-CELL PH, V279, pC147, DOI 10.1152/ajpcell.2000.279.1.C147; Kumar S, 2000, MODERN PATHOL, V13, P988, DOI 10.1038/modpathol.3880179; Linask KK, 1998, DEV BIOL, V202, P85, DOI 10.1006/dbio.1998.9025; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Marucci G., 2000, Pathologica (Genoa), V92, P198; Meriane M, 2002, ONCOGENE, V21, P2901, DOI 10.1038/sj.onc.1205396; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; MINNITI CP, 1994, AM J CLIN PATHOL, V101, P198, DOI 10.1093/ajcp/101.2.198; Nojima D, 2001, MOL CARCINOGEN, V32, P19, DOI 10.1002/mc.1060; Nollet F, 1999, Mol Cell Biol Res Commun, V2, P77, DOI 10.1006/mcbr.1999.0155; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Ostrovsky O, 2002, J BIOL CHEM, V277, P40043, DOI 10.1074/jbc.M205494200; Pinkerton R, 1998, B CANCER, V85, P1015; Pohar-Marinsek Z, 2002, ANAL QUANT CYTOL, V24, P212; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Proulx AA, 1997, CELL GROWTH DIFFER, V8, P533; Prowse DM, 1997, CELL BIOL INT, V21, P833, DOI 10.1006/cbir.1997.0202; Puri PL, 2000, GENE DEV, V14, P574; Ribeiro LA, 2002, MOL CARCINOGEN, V34, P187, DOI 10.1002/mc.10064; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Rosenberg P, 1997, DEV BIOL, V187, P55, DOI 10.1006/dbio.1997.8602; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; Sharp R, 2002, NAT MED, V8, P1276, DOI 10.1038/nm787; SOLER AP, 1993, EXP CELL RES, V208, P84, DOI 10.1006/excr.1993.1225; STRATTON MR, 1989, CANCER RES, V49, P6324; Suzuki H, 1996, GENE CHROMOSOME CANC, V17, P225, DOI 10.1002/(SICI)1098-2264(199612)17:4<225::AID-GCC4>3.0.CO;2-5; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; VANDROMME M, 1992, J CELL BIOL, V118, P1489, DOI 10.1083/jcb.118.6.1489; Visser M, 1997, ONCOGENE, V15, P1309, DOI 10.1038/sj.onc.1201302; WANG NP, 1995, AM J PATHOL, V147, P1799; WEXLER LH, 1994, CA-CANCER J CLIN, V44, P211, DOI 10.3322/canjclin.44.4.211; ZESCHNIGK M, 1995, J CELL SCI, V108, P2973; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344; Zhang LJ, 1996, CANCER RES, V56, P1367	64	26	26	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2420	2430		10.1038/sj.onc.1207382	http://dx.doi.org/10.1038/sj.onc.1207382			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14691446				2022-12-25	WOS:000220427700016
J	Lewis, MD; Roberts, BJ				Lewis, MD; Roberts, BJ			Role of the C-terminal alpha-helical domain of the von Hippel-Lindau protein in its E3 ubiquitin ligase activity	ONCOGENE			English	Article						VHL; HIF; ubiquitin; cancer	TUMOR-SUPPRESSOR PROTEIN; HYPOXIA-INDUCIBLE FACTOR-1; TRANSCRIPTIONAL ACTIVITY; PROLYL HYDROXYLATION/; REGULATE HIF; DISEASE; MUTATIONS; VHL; GENE; HYDROXYPROLINE	In the present study, the role of the C-terminal alpha-helical domain (amino acid (aa) 195-208) of the von Hippel Lindau (VHL) tumour suppressor was investigated. Deletions of the VHL C-terminus up to the naturally occurring 195-Gln-Term resulted in hypoxia-inducible factor (HIF)-1alpha downregulation in renal cell carcinoma (RCC)4 cells during normoxia, suggesting that this domain is not an absolute requirement for the ubiquitination of HIF-1alpha. However, detailed investigation of the ubiquitin protein isopeptide ligase ubiquitin ligase properties of VHL revealed C-terminal deletions to cause a significant impairment of HIF-1alpha ubiquitination, which is shown to be due to a loss in high-affinity binding to the target substrate. When VHL regulation of both HIF-1alpha N- and C-terminal oxygen-dependent degradation domains (HIF-ODDD) was investigated, it was found that only ubiquitination of the C-terminal HIF-ODDD was affected by the deletion of the VHL C-terminus. When RCC4 cells expressing C-terminal truncations of VHL were exposed to graded hypoxia, differences in the induction of HIF-1alpha were observed in comparison with full-length VHL, with a shift in the maximal induction of HIF-1alpha to a higher oxygen tension. These changes were accompanied by increased glucose transporter 1 expression, p300 CH1 domain binding and HIF-mediated reporter activity. We have thus defined a role for the C-terminal alpha-helical domain of VHL in the regulation of HIF-1alpha.	Univ S Australia, Sch Pharmaceut Mol & Biomed Sci, Adelaide, SA 5000, Australia	University of South Australia	Roberts, BJ (corresponding author), Univ S Australia, Sch Pharmaceut Mol & Biomed Sci, Reid Bldg,Frome Rd, Adelaide, SA 5000, Australia.	Ben.Roberts@unisa.edu.au	Lewis, Martin/A-8489-2008; Lewis, Martin/A-3881-2010	Lewis, Martin/0000-0002-3332-3776				Clifford SC, 2001, ADV CANCER RES, V82, P85, DOI 10.1016/S0065-230X(01)82003-0; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Ohh M, 1999, MOL MED TODAY, V5, P257, DOI 10.1016/S1357-4310(99)01481-1; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Roberts BJ, 1999, J BIOL CHEM, V274, P36351, DOI 10.1074/jbc.274.51.36351; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; WHALEY JM, 1994, AM J HUM GENET, V55, P1092; Zbar B, 1996, HUM MUTAT, V8, P348, DOI 10.1002/(SICI)1098-1004(1996)8:4<348::AID-HUMU8>3.0.CO;2-3	23	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2315	2323		10.1038/sj.onc.1207384	http://dx.doi.org/10.1038/sj.onc.1207384			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14691445				2022-12-25	WOS:000220427700005
J	Hong, M; Luo, SZ; Baumeister, P; Huang, JM; Gogia, RK; Li, MQ; Lee, AS				Hong, M; Luo, SZ; Baumeister, P; Huang, JM; Gogia, RK; Li, MQ; Lee, AS			Underglycosylation of ATF6 as a novel sensing mechanism for activation of the unfolded protein response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETICULUM STRESS-RESPONSE; CHAIN BINDING-PROTEIN; ENDOPLASMIC-RETICULUM; ER STRESS; TRANSCRIPTION FACTOR-6; NF-Y; ELEMENT; GLYCOSYLATION; PROMOTER; KINASE	ATF6 is a key transcriptional activator of the unfolded protein response (UPR), which allows mammalian cells to maintain cellular homeostasis when they are subjected to a variety of environmental and physiological stresses that target the endoplasmic reticulum (ER). ATF6, a 90-kDa ER transmembrane protein, contains three evolutionarily conserved N-linked glycosylation sites within its carboxyl luminal domain. Although it is well established that p90ATF6 activation requires transit from the ER to the Golgi, where it is cleaved by the S1P/S2P protease system to generate a nuclear form p60ATF6 that acts as a transcriptional activator, the functional significance of p90ATF6 N-linked glycosylation is unknown. Here we show that ER Ca2+ depletion stress, a triggering mechanism for the UPR, induces the formation of ATF6(f), which represents de novo partial glycosylation of newly synthesized p90ATF6. By mutating a single amino acid within the N-linked glycosylation site closest to the carboxyl terminus of p90ATF6, we recreated ATF6(f). This mutation sharply reduces p90ATF6 association with calreticulin, a major Ca2+-binding chaperone for N-glycoprotein. We further determined that ATF6(f) exhibits a faster rate of constitutive transport to the Golgi, resulting in a higher level of p60ATF6 in the nucleus and stronger transactivating activity in the absence of ER stress. Additional analysis of p90ATF6 mutants targeting single or multiple N-glycosylation sites also showed higher constitutive transactivating activity than wild type ATF6. Because accumulation of underglycosylated proteins in the ER is a potent inducer for the UPR, these studies uncover a novel mechanism whereby the glycosylation status of p90ATF6 can serve as a sensor for ER homeostasis, resulting in ATF6 activation to trigger the UPR.	Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, USC Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Lee, AS (corresponding author), Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, 1441 Eastlake Ave, Los Angeles, CA 90089 USA.	amylee@hsc.usc.edu		Lee, Amy/0000-0002-0378-5443	NCI NIH HHS [CA27607] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA027607, R01CA027607] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; CAO XJ, 1995, J BIOL CHEM, V270, P494, DOI 10.1074/jbc.270.1.494; Chen X, 2002, J BIOL CHEM, V277, P13045, DOI 10.1074/jbc.M110636200; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; FEIGE JJ, 1987, J CELL PHYSIOL, V133, P461, DOI 10.1002/jcp.1041330306; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; Harris MR, 1998, J IMMUNOL, V160, P5404; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Haze K, 2001, BIOCHEM J, V355, P19, DOI 10.1042/0264-6021:3550019; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; Luo S, 2002, BIOCHEM J, V366, P787, DOI 10.1042/BJ20011802; Luo SZ, 2003, J BIOL CHEM, V278, P37375, DOI 10.1074/jbc.M303619200; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Meunier L, 2002, MOL BIOL CELL, V13, P4456, DOI 10.1091/mbc.E02-05-0311; Michalak M, 2002, CELL CALCIUM, V32, P269, DOI 10.1016/S0143416002001884; Mintz PJ, 2003, NAT BIOTECHNOL, V21, P57, DOI 10.1038/nbt774; Nilsson I, 2000, J BIOL CHEM, V275, P17338, DOI 10.1074/jbc.M002317200; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; Parker R, 2001, MOL CELL BIOL, V21, P3220, DOI 10.1128/MCB.21.9.3220-3233.2001; Ramakrishnan M, 1997, J CELL PHYSIOL, V170, P115, DOI 10.1002/(SICI)1097-4652(199702)170:2<115::AID-JCP3>3.3.CO;2-J; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Reddy RK, 2002, CANCER RES, V62, P7207; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Thuerauf DJ, 2001, J BIOL CHEM, V276, P48309, DOI 10.1074/jbc.M107146200; Wang Y, 2000, J BIOL CHEM, V275, P27013; Werstuck GH, 2001, J CLIN INVEST, V107, P1263, DOI 10.1172/JCI11596; Wormald MR, 1999, STRUCTURE, V7, pR155, DOI 10.1016/S0969-2126(99)80095-1; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Zhou YH, 1998, J NATL CANCER I, V90, P381, DOI 10.1093/jnci/90.5.381; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957	40	121	124	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11354	11363		10.1074/jbc.M309804200	http://dx.doi.org/10.1074/jbc.M309804200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699159	hybrid			2022-12-25	WOS:000220157600064
J	Roisin-Bouffay, C; Luciani, MF; Klein, G; Levraud, JP; Adam, M; Golstein, P				Roisin-Bouffay, C; Luciani, MF; Klein, G; Levraud, JP; Adam, M; Golstein, P			Developmental cell death in Dictyostelium does not require paracaspase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS; DIFFERENTIATION; FAMILIES; ORIGIN	Apoptotic cell death often requires caspases. Caspases are part of a family of related molecules including also paracaspases and metacaspases. Are molecules of this family generally involved in cell death? More specifically, do non-apoptotic caspase-independent types of cell death require paracaspases or metacaspases? Dictyostelium discoideum lends itself well to answering these questions because 1) it undergoes non-apoptotic developmental cell death of a vacuolar autophagic type and 2) it bears neither caspase nor metacaspase genes and apparently only one paracaspase gene. This only paracaspase gene can be inactivated by homologous recombination. Paracaspase-null clones were thus obtained in each of four distinct Dictyostelium strains. These clones were tested in two systems, developmental stalk cell death in vivo and vacuolar autophagic cell death in a monolayer system mimicking developmental cell death. Compared with parent cells, all of the paracaspase-null cells showed unaltered cell death in both test systems. In addition, paracaspase inactivation led to no alteration in development or interaction with a range of bacteria. Thus, in Dictyostelium, vacuolar programmed cell death in development and in a monolayer model in vitro would seem not to require paracaspase. To our knowledge, this is the first instance of developmental programmed cell death shown to be independent of any caspase, paracaspase or metacaspase. These results have implications as to the relationship in evolution between cell death and the caspase family.	Univ Mediterranie, Ctr Immunol Marseille Luminy, CNRS, INSERM, F-13288 Marseille 9, France; Comm Energie Atom Grenobel, Lab Biochim & Biophys Syst Integres, F-38054 Grenoble 9, France; Inst Pasteur, Unite Postulante Macrophages & Dev Immun, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; CEA; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Golstein, P (corresponding author), Univ Mediterranie, Ctr Immunol Marseille Luminy, CNRS, INSERM, Parc Sci Liminy,Case 906, F-13288 Marseille 9, France.	golstein@ciml.univ-mrs.fr	Golstein, Pierre/A-4954-2014	Golstein, Pierre/0000-0003-1750-3483				Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Aravind L, 2002, PROTEINS, V46, P355, DOI 10.1002/prot.10060; Baldauf SL, 2000, SCIENCE, V290, P972, DOI 10.1126/science.290.5493.972; CORNILLON S, 1994, J CELL SCI, V107, P2691; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; Eichinger L, 2003, EMBO J, V22, P1941, DOI 10.1093/emboj/cdg214; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; FONG D, 1978, J BACTERIOL, V134, P521, DOI 10.1128/JB.134.2.521-527.1978; Golstein P, 2003, NAT REV MOL CELL BIO, V4, P798, DOI 10.1038/nrm1224; HADWIGER JA, 1992, GENE DEV, V6, P38, DOI 10.1101/gad.6.1.38; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; KAY RR, 1987, METHOD CELL BIOL, V28, P433; Koonin EV, 2002, CELL DEATH DIFFER, V9, P394, DOI 10.1038/sj.cdd.4400991; Lamkanfi M, 2002, CELL DEATH DIFFER, V9, P358, DOI 10.1038/sj.cdd.4400989; Levraud JP, 2003, J CELL BIOL, V160, P1105, DOI 10.1083/jcb.200212104; Levraud JP, 2001, METHOD CELL BIOL, V66, P469; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Olie RA, 1998, CURR BIOL, V8, P955, DOI 10.1016/S0960-9822(98)70395-1; Puta F, 1998, FOLIA BIOL-PRAGUE, V44, P185; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; WHITTINGHAM WF, 1960, P NATL ACAD SCI USA, V46, P642, DOI 10.1073/pnas.46.5.642; Yuan J, 2003, NEURON, V40, P401, DOI 10.1016/S0896-6273(03)00601-9	28	62	65	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11489	11494		10.1074/jbc.M312741200	http://dx.doi.org/10.1074/jbc.M312741200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14681218	hybrid			2022-12-25	WOS:000220157600080
J	Bao, XF; Nishimura, S; Mikami, T; Yamada, S; Itoh, N; Sugahara, K				Bao, XF; Nishimura, S; Mikami, T; Yamada, S; Itoh, N; Sugahara, K			Chondroitin sulfate/dermatan sulfate hybrid chains from embryonic pig brain, which contain a higher proportion of L-iduronic acid than those from adult pig brain, exhibit neuritogenic and growth factor binding activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LINKAGE REGION; DERMATAN SULFATE; NEURITE OUTGROWTH; ZETA/RPTP-BETA; HEPARAN-SULFATE; FACTOR MIDKINE; HIGH-AFFINITY; RAT-BRAIN; PROTEOGLYCANS; SPECIFICITIES	We have shown that over-sulfated chondroitin sulfate/ dermatan sulfate (CS/DS) chains from various marine organisms exhibit growth factor binding activities and neurite outgrowth-promoting activities in embryonic mouse hippocampal neurons in vitro. In this study we demonstrated that CS/DS hybrid chains purified from embryonic pig brain displayed marked neuritogenic activity and growth factor binding activities toward fibroblast growth factor 2 (FGF2), FGF10, FGF18, pleiotrophin, and midkine, all of which exhibit neuroregulatory activities in the brain. In contrast, the CS/DS preparation from adult pig brain showed considerably less activity to bind these growth factors and no neuritogenic activity. Structural analysis indicated that the average size of the CS/DS chains was similar ( 40 kDa) between these two preparations, but the disaccharide compositions differed considerably, with a significant proportion of L-iduronic acid (IdoUA)-containing disaccharides ( 8 similar to 9%) in the CS/DS chains from embryos but not in those from adults (< 1%). Interestingly, both neurite out-growth-promoting activity and growth factor binding activities of the CS/DS chains from embryos were abolished by digestion not only with chondroitinase ABC but also with chondroitinase B, suggesting that the IdoUA-containing motifs are essential for these activities. These findings imply that the temporal expression of CS/DS hybrid structures containing both GlcUA and IdoUA and binding activities toward various growth factors play important roles in neurogenesis in the early stages of the development of the brain.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biochem Genet, Kyoto 6068501, Japan	Kobe Pharmaceutical University; Kyoto University	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, 4-19-1 Motoyamakita Machi, Kobe, Hyogo 6588558, Japan.	k-sugar@kobepharma-u.ac.jp						Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; BAO X, 2003, SEIKAGAKU, V75, P908; Bechard D, 2001, J BIOL CHEM, V276, P48341, DOI 10.1074/jbc.M108395200; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; CASU B, 1988, TRENDS BIOCHEM SCI, V13, P747; Clement AM, 1999, NEUROSCI LETT, V269, P125, DOI 10.1016/S0304-3940(99)00432-2; Clement AM, 1998, J BIOL CHEM, V273, P28444, DOI 10.1074/jbc.273.43.28444; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Esko JD, 1996, CURR OPIN STRUC BIOL, V6, P663, DOI 10.1016/S0959-440X(96)80034-0; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; FernaudEspinosa I, 1996, J NEUROBIOL, V30, P410, DOI 10.1002/(SICI)1097-4695(199607)30:3<410::AID-NEU9>3.0.CO;2-7; HERNDON ME, 1990, NEURON, V4, P949, DOI 10.1016/0896-6273(90)90148-9; Hikino M, 2003, J BIOL CHEM, V278, P43744, DOI 10.1074/jbc.M308169200; Hu MCT, 1998, MOL CELL BIOL, V18, P6063, DOI 10.1128/MCB.18.10.6063; ICHIJO H, 2003, CONNECT TISSUE, V35, P11; Kappler J, 1998, BRAIN RES, V793, P328, DOI 10.1016/S0006-8993(98)00260-1; Kinoshita A, 1997, J BIOL CHEM, V272, P19656, DOI 10.1074/jbc.272.32.19656; Kinoshita A, 1999, ANAL BIOCHEM, V269, P367, DOI 10.1006/abio.1999.4027; Kitagawa H, 1997, J BIOL CHEM, V272, P31377, DOI 10.1074/jbc.272.50.31377; LAFONT F, 1992, DEVELOPMENT, V114, P17; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; Maeda N, 2003, J BIOL CHEM, V278, P35805, DOI 10.1074/jbc.M305530200; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; MARGOLIS RK, 1993, EXPERIENTIA, V49, P429, DOI 10.1007/BF01923587; Mikami T, 2003, J BIOL CHEM, V278, P36115, DOI 10.1074/jbc.M306044200; Moon LDF, 2001, NAT NEUROSCI, V4, P465, DOI 10.1038/87415; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; Mulloy B, 2000, GLYCOBIOLOGY, V10, P1147, DOI 10.1093/glycob/10.11.1147; Muramatsu T, 2001, TRENDS GLYCOSCI GLYC, V13, P563, DOI 10.4052/tigg.13.563; Nadanaka S, 1998, J BIOL CHEM, V273, P3296, DOI 10.1074/jbc.273.6.3296; OHYA T, 1970, BIOCHIM BIOPHYS ACTA, V198, P607, DOI 10.1016/0005-2744(70)90139-7; OOHIRA A, 1988, J BIOL CHEM, V263, P10240; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; SAITO H, 1968, J BIOL CHEM, V243, P1536; Silbert JE, 2002, IUBMB LIFE, V54, P177, DOI 10.1080/15216540214923; Snow DM, 2003, EXP NEUROL, V182, P310, DOI 10.1016/S0014-4886(03)00034-7; SUGAHARA K, 1995, J BIOL CHEM, V270, P7204, DOI 10.1074/jbc.270.13.7204; SUGAHARA K, 1994, CARBOHYD RES, V255, P145, DOI 10.1016/S0008-6215(00)90976-5; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; SUGAHARA K, 1989, BIOCHEM BIOPH RES CO, V162, P189, DOI 10.1016/0006-291X(89)91980-3; SUGAHARA K, 1992, J BIOL CHEM, V267, P1528; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; Sugahara K, 2000, TRENDS GLYCOSCI GLYC, V12, P321, DOI 10.4052/tigg.12.321; SUGAHARA K, 2002, ANAL TECHNIQUES EVAL, P79; Sugiyama E, 1997, GLYCOBIOLOGY, V7, P719, DOI 10.1093/glycob/7.5.719; Tanaka M, 2003, J NEUROSCI, V23, P2804, DOI 10.1523/jneurosci.23-07-02804.2003; Tiedemann K, 2001, ARCH BIOCHEM BIOPHYS, V391, P65, DOI 10.1006/abbi.2001.2376; Trowbridge JM, 2002, J BIOL CHEM, V277, P42815, DOI 10.1074/jbc.M204959200; Trowbridge JM, 2002, GLYCOBIOLOGY, V12, p117R, DOI 10.1093/glycob/cwf066; Ueoka C, 2000, J BIOL CHEM, V275, P37407, DOI 10.1074/jbc.M002538200; Yamada S, 2002, J BIOL CHEM, V277, P31877, DOI 10.1074/jbc.M205078200; Yoshida K., 1993, DERMATAN SULFATE PRO, P55; Zou K, 2000, EUR J BIOCHEM, V267, P4046, DOI 10.1046/j.1432-1327.2000.01440.x; Zou P, 2003, GLYCOBIOLOGY, V13, P35, DOI 10.1093/glycob/cwg001	58	98	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9765	9776		10.1074/jbc.M310877200	http://dx.doi.org/10.1074/jbc.M310877200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699094	hybrid			2022-12-25	WOS:000220050400015
J	Chabes, AL; Bjorklund, S; Thelander, L				Chabes, AL; Bjorklund, S; Thelander, L			S phase-specific transcription of the mouse ribonucleotide reductase R2 gene requires both a proximal repressive E2F-binding site and an upstream promoter activating region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CELL-CYCLE; DNA-DAMAGE; SUBUNIT GENE; IN-VITRO; R1 GENE; NF-Y; PROTEIN; E2F; EXPRESSION	Ribonucleotide reductase is essential for supplying a balanced pool of the four deoxyribonucleotides required for DNA synthesis and repair. The active enzyme consists of two non-identical subunits called proteins R1 and R2. There are multiple levels of regulation of ribonucleotide reductase activity, which is highest during the S and G(2) phases of an unperturbed cell cycle in mammalian cells. Previous reports in the literature have indicated that the S phase-specific transcription of the mammalian R2 gene is regulated by a transcriptional block, is dependent on the transcription factor E2F1, or is simply regulated by proteins that bind to promoter CCAAT boxes plus the TATA box. Here, we demonstrate that the S phase-specific transcription of the mouse R2 gene is dependent on an upstream promoter activating region (located at nucleotides (nt) - 672 to - 527 from the transcription start site) and one proximal promoter repressive element ( located at nt - 112 to - 107) that binds E2F4. Binding to the E2F site is modulated by binding of nuclear factor-Y to an adjacent CCAAT element ( nt - 79 to - 75). The upstream activating region is crucial for overall R2 promoter activity. Mutation of the E2F-binding site leads to premature promoter activation in G(1) and increases overall promoter activity but only when the upstream activating region is present and intact. Therefore, E2F-dependent repression is essential for cell cycle-specific R2 transcription.	Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden	Umea University	Thelander, L (corresponding author), Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden.	Lars.Thelander@medchem.umu.se	Bjørklund, Geir/B-7319-2014	Bjørklund, Geir/0000-0003-2632-3935				BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; BRISSENDEN JE, 1988, EXP CELL RES, V174, P302, DOI 10.1016/0014-4827(88)90165-6; Chabes A, 2000, J BIOL CHEM, V275, P17747, DOI 10.1074/jbc.M000799200; Chabes A, 2003, CELL, V112, P391, DOI 10.1016/S0092-8674(03)00075-8; Chabes AL, 2003, P NATL ACAD SCI USA, V100, P3925, DOI 10.1073/pnas.0330774100; Chaboute ME, 2000, PLANT CELL, V12, P1987, DOI 10.1105/tpc.12.10.1987; Costanzo M, 2003, MOL CELL BIOL, V23, P5064, DOI 10.1128/MCB.23.14.5064-5077.2003; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; FILATOV D, 1995, J BIOL CHEM, V270, P25239, DOI 10.1074/jbc.270.42.25239; Guittet O, 2001, J BIOL CHEM, V276, P40647, DOI 10.1074/jbc.M106088200; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; JOHANSSON E, 1995, J BIOL CHEM, V270, P30162, DOI 10.1074/jbc.270.50.30162; Johansson E, 1998, J BIOL CHEM, V273, P29816, DOI 10.1074/jbc.273.45.29816; KOCH C, 1993, SCIENCE, V261, P1551, DOI 10.1126/science.8372350; Kotova I, 2003, EUR J BIOCHEM, V270, P1791, DOI 10.1046/j.1432-1033.2003.03541.x; Kotova I, 2001, EUR J BIOCHEM, V268, P4527, DOI 10.1046/j.1432-1327.2001.02378.x; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; Park JB, 2000, BIOCHEM BIOPH RES CO, V267, P651, DOI 10.1006/bbrc.1999.1980; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PAVLOFF N, 1992, J DNA SEQUENCING MAP, V2, P227; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Romier C, 2003, J BIOL CHEM, V278, P1336, DOI 10.1074/jbc.M209635200; Saitoh S, 2002, CELL, V109, P563, DOI 10.1016/S0092-8674(02)00753-5; Siddiqui H, 2003, MOL CELL BIOL, V23, P7719, DOI 10.1128/MCB.23.21.7719-7731.2003; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; YANG-FENG T L, 1987, Genomics, V1, P77, DOI 10.1016/0888-7543(87)90108-X; Zhao XL, 2001, EMBO J, V20, P3544, DOI 10.1093/emboj/20.13.3544; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666; Zhou B, 2001, CYTOGENET CELL GENET, V95, P52, DOI 10.1159/000057017	36	73	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10796	10807		10.1074/jbc.M312482200	http://dx.doi.org/10.1074/jbc.M312482200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688249	hybrid			2022-12-25	WOS:000220050400135
J	Ruchira; Hink, MA; Bosgraaf, L; van Haastert, PJM; Visser, AJWG				Ruchira; Hink, MA; Bosgraaf, L; van Haastert, PJM; Visser, AJWG			Pleckstrin homology domain diffusion in Dictyostelium cytoplasm studied using fluorescence correlation spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-DYNAMICS; FUSION PROTEINS; BINDING; CELLS; LEVEL	The translocation of pleckstrin homology (PH) domain-containing proteins from the cytoplasm to the plasma membrane plays an important role in the chemotaxis mechanism of Dictyostelium cells. The diffusion of three PH domain-green fluorescent protein (GFP) fusions (PH2-GFP, PH10-GFP, and PH-CRAC (cytosolic regulator of adenylyl cyclase)-GFP) in the cytoplasm of vegetative and chemotaxing Dictyostelium cells has been studied using fluorescence correlation spectroscopy to gain a better understanding of the functioning of the domains and to assess the effect of initiation of chemotaxis on these domains in the cell. PH2-GFP was homogeneously distributed in vegetative as well as chemotaxing cells, whereas PH10-GFP and PH-CRAC-GFP showed translocation to the leading edge of the chemotaxing cell. The diffusion characteristics of PH2-GFP and PH-CRAC-GFP were very similar; however, PH10-GFP exhibited slower diffusion. Photon counting histogram statistics show that this slow diffusion was not due to aggregation. Diffusion of the three PH domains was affected to similar extents by intracellular heterogeneities in vegetative as well as chemotaxing cells. From the diffusion of free cytoplasmic GFP, it was calculated that the viscosity in chemotaxing cells was 1.7 times lower than in vegetative cells. In chemotaxing cells, PH2-GFP showed increased mobility, whereas the mobilities of PH10-GFP and PH-CRAC-GFP remained unchanged.	Univ Wageningen & Res Ctr, Biochem Lab, Microspect Ctr, NL-6703 HA Wageningen, Netherlands; Univ Groningen, Dept Biochem, NL-9747 AG Groningen, Netherlands	Wageningen University & Research; University of Groningen	Ruchira (corresponding author), Univ Wageningen & Res Ctr, Biochem Lab, Microspect Ctr, Dreijenlaan 3, NL-6703 HA Wageningen, Netherlands.	ru.ruchira@wur.nl	Engel, Ruchira/A-5394-2010	Engel, Ruchira/0000-0002-0630-5767				Bottomley MJ, 1998, BBA-MOL CELL BIOL L, V1436, P165, DOI 10.1016/S0005-2760(98)00141-6; Brock R, 2001, SPRINGER SERIES CHEM, V65, P132; Brock R, 1999, P NATL ACAD SCI USA, V96, P10123, DOI 10.1073/pnas.96.18.10123; Chen Y, 1999, BIOPHYS J, V77, P553, DOI 10.1016/S0006-3495(99)76912-2; Chen Y, 2002, BIOPHYS J, V82, P133, DOI 10.1016/S0006-3495(02)75380-0; Dittrich P, 2001, BIOL CHEM, V382, P491, DOI 10.1515/BC.2001.061; Eid JS, 2000, REV SCI INSTRUM, V71, P361, DOI 10.1063/1.1150208; Firtel RA, 2000, BIOESSAYS, V22, P603, DOI 10.1002/1521-1878(200007)22:7<603::AID-BIES3>3.0.CO;2-#; Hess ST, 2002, BIOCHEMISTRY-US, V41, P697, DOI 10.1021/bi0118512; Hink MA, 2003, METHOD ENZYMOL, V361, P93; Hink MA, 1999, LANGMUIR, V15, P992, DOI 10.1021/la980949n; Hirata M, 1998, JPN J PHARMACOL, V76, P255, DOI 10.1254/jjp.76.255; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; LUBYPHELPS K, 1986, J CELL BIOL, V102, P2015, DOI 10.1083/jcb.102.6.2015; Meseth U, 1999, BIOPHYS J, V76, P1619, DOI 10.1016/S0006-3495(99)77321-2; Muller JD, 2000, BIOPHYS J, V78, P474, DOI 10.1016/S0006-3495(00)76610-0; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Potma EO, 2001, BIOPHYS J, V81, P2010, DOI 10.1016/S0006-3495(01)75851-1; Schwille P, 1999, BIOPHYS J, V77, P2251, DOI 10.1016/S0006-3495(99)77065-7; Varnai P, 2002, J BIOL CHEM, V277, P27412, DOI 10.1074/jbc.M109672200; Wachsmuth M, 2000, J MOL BIOL, V298, P677, DOI 10.1006/jmbi.2000.3692	22	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10013	10019		10.1074/jbc.M310039200	http://dx.doi.org/10.1074/jbc.M310039200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699152	hybrid, Green Published			2022-12-25	WOS:000220050400045
J	Sunters, A; Thomas, DP; Yeudall, WA; Grigoriadis, AE				Sunters, A; Thomas, DP; Yeudall, WA; Grigoriadis, AE			Accelerated cell cycle progression in osteoblasts overexpressing the c-fos proto-oncogene - Induction of cyclin A and enhanced CDK2 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING TRANSCRIPTION FACTOR-2; INDUCED OSTEOSARCOMA FORMATION; S-PHASE; NEGATIVE REGULATORS; PROTEIN EXPRESSION; TRANSGENIC MICE; GENE-EXPRESSION; BONE-FORMATION; UP-REGULATION; JUN	Transgenic mice overexpressing the c-Fos oncoprotein develop osteosarcomas that are associated with deregulated expression of cell cycle genes. Here we have generated osteoblast cell lines expressing c-fos under the control of a tetracycline-regulatable promoter to investigate the role of c-Fos in osteoblast cell cycle control in vitro. Three stable subclones, AT9.2, AT9.3, and AT9.7, derived from MC3T3-E1 mouse osteoblasts, expressed high levels of exogenous c-fos mRNA and protein in the absence of tetracycline. Functional contribution of ectopic c-Fos to AP-1 complexes was confirmed by electromobility shift assays and transactivation of AP-1 reporter constructs. Induction of exogenous c-Fos in quiescent AT9.2 cells caused accelerated S-phase entry following serum stimulation, resulting in enhanced growth rate. Ectopic c-Fos resulted in increased expression of cyclins A and E protein levels, and premature activation of cyclin A-, cyclin E-, and cyclin-dependent kinase (CDK) 2-associated kinase activities, although cyclin D levels and CDK4 activity were not affected significantly in these cell lines. The enhanced CDK2 kinase activity was associated with a rapid, concomitant dissociation of p27 from CDK2-containing complexes. Deregulated cyclin A expression and CDK2 activity was also observed in primary mouse osteoblasts overexpressing c-Fos, but not in fibroblasts, and c-Fos transgenic tumor-derived osteosarcoma cells constitutively expressed high levels of cyclin A protein. These data suggest that overexpression of c-Fos in osteoblasts results in accelerated S phase entry as a result of deregulated cyclin A/E-CDK2 activity. This represents a novel role for c-Fos in osteoblast growth control and may provide c-Fos-overexpressing osteoblasts with a growth advantage during tumorigenesis.	Univ London Kings Coll, Guys Hosp, Dept Craniofacial Dev, London SE1 9RT, England; Univ London Kings Coll, Guys Hosp, Dept Orthodont, London SE1 9RT, England; Virginia Commonwealth Univ, Philips Inst Oral & Craniofacial Mol Biol, Richmond, VA 23298 USA	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Virginia Commonwealth University	Grigoriadis, AE (corresponding author), Univ London Kings Coll, Guys Hosp, Dept Craniofacial Dev, Guys Tower,Floor 28,London Bridge, London SE1 9RT, England.	agrigori@hgmp.mrc.ac.uk						ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Allan K, 2000, ARCH PATHOL LAB MED, V124, P216; Andrecht S, 2002, J BIOL CHEM, V277, P35961, DOI 10.1074/jbc.M202847200; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; BALSALOBRE A, 1995, ONCOGENE, V11, P455; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Beier F, 2000, J BIOL CHEM, V275, P12948, DOI 10.1074/jbc.275.17.12948; Beier F, 1999, P NATL ACAD SCI USA, V96, P1433, DOI 10.1073/pnas.96.4.1433; Bellows CG, 1998, BONE, V23, P119, DOI 10.1016/S8756-3282(98)00084-2; Benassi MS, 1999, INT J CANCER, V84, P489, DOI 10.1002/(SICI)1097-0215(19991022)84:5<489::AID-IJC7>3.0.CO;2-D; BRECHOT C, 1993, CURR OPIN GENET DEV, V3, P11, DOI 10.1016/S0959-437X(05)80335-1; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; Clark W, 2000, MOL CELL BIOL, V20, P2529, DOI 10.1128/MCB.20.7.2529-2542.2000; Crowe David L., 2000, Molecular Cell Biology Research Communications, V3, P243, DOI 10.1006/mcbr.2000.0221; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; Drissi H, 1999, CANCER RES, V59, P3705; FIELD SJ, 1992, P NATL ACAD SCI USA, V89, P9306, DOI 10.1073/pnas.89.19.9306; Fleischmann A, 2000, GENE DEV, V14, P2695, DOI 10.1101/gad.187900; Gamberi G, 1998, ONCOLOGY-BASEL, V55, P556, DOI 10.1159/000011912; GRIGORIADIS AE, 1995, TRENDS GENET, V11, P436, DOI 10.1016/S0168-9525(00)89142-8; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Handa K, 1999, INT J CANCER, V84, P225, DOI 10.1002/(SICI)1097-0215(19990621)84:3<225::AID-IJC5>3.0.CO;2-A; HOYLAND J, 1994, J BONE MINER RES, V9, P1191; Huuhtanen RL, 1999, CANCER RES, V59, P2885; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 2001, J ENDOCRINOL, V169, P447, DOI 10.1677/joe.0.1690447; Kobayashi K, 1997, J IMMUNOL, V158, P2050; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Longhi A, 2001, ONCOL REP, V8, P131; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; Nielsen GP, 1998, AM J PATHOL, V153, P159, DOI 10.1016/S0002-9440(10)65556-3; OCONNOR PM, 1991, CANCER RES, V51, P6550; Onishi T, 1997, ENDOCRINOLOGY, V138, P1995, DOI 10.1210/en.138.5.1995; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Pompetti F, 1996, J CELL BIOCHEM, V63, P37; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Smith E, 2000, J BIOL CHEM, V275, P19992, DOI 10.1074/jbc.M001758200; SMITH E, 1995, CANCER RES, V55, P5019; Sunters A, 1998, DEV GENET, V22, P386, DOI 10.1002/(SICI)1520-6408(1998)22:4<386::AID-DVG8>3.0.CO;2-2; Sylvester AM, 1998, J CLIN INVEST, V101, P940, DOI 10.1172/JCI1630; TATE SS, 1990, FASEB J, V4, P227, DOI 10.1096/fasebj.4.2.2298343; Thomas DP, 2000, J CELL SCI, V113, P439; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; WANG ZQ, 1995, CANCER RES, V55, P6244; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x; Wei G, 1999, INT J CANCER, V80, P199, DOI 10.1002/(SICI)1097-0215(19990118)80:2<199::AID-IJC7>3.0.CO;2-4; WIMMEL A, 1994, ONCOGENE, V9, P995; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x	72	58	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9882	9891		10.1074/jbc.M310184200	http://dx.doi.org/10.1074/jbc.M310184200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699150	hybrid			2022-12-25	WOS:000220050400028
J	Zsembery, A; Fortenberry, JA; Liang, LH; Bebok, Z; Tucker, TA; Boyce, AT; Braunstein, GM; Welty, E; Bell, PD; Sorscher, EJ; Clancy, JP; Schwiebert, EM				Zsembery, A; Fortenberry, JA; Liang, LH; Bebok, Z; Tucker, TA; Boyce, AT; Braunstein, GM; Welty, E; Bell, PD; Sorscher, EJ; Clancy, JP; Schwiebert, EM			Extracellular zinc and ATP restore chloride secretion across cystic fibrosis airway epithelia by triggering calcium entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR CHANNELS; CYTOSOLIC CA2+; SURFACE LIQUID; COMMON COLD; RELEASE; TRANSPORT; MEMBRANE; CONDUCTANCE; VOLUME; DESENSITIZATION	Cystic fibrosis (CF) is caused by defective cyclic AMP-dependent cystic fibrosis transmembrane conductance regulator Cl- channels. Thus, CF epithelia fail to transport Cl- and water. A postulated therapeutic avenue in CF is activation of alternative Ca2+- dependent Cl- channels. We hypothesized that stimulation of Ca2+ entry from the extracellular space could trigger a sustained Ca2+ signal to activate Ca2+-dependent Cl- channels. Cytosolic [Ca2+](i) was measured in non-polarized human CF (IB3-1) and non-CF (16HBE14o(-)) airway epithelial cells. Primary human CF and non-CF airway epithelial monolayers as well as Calu-3 monolayers were used to assess anion secretion. In vivo nasal potential difference measurements were performed in non-CF and two different CF mouse (DeltaF508 homozygous and bitransgenic gut-corrected but lung-null) models. Zinc and ATP induced a sustained, reversible, and reproducible increase in cytosolic Ca2+ in CF and non-CF cells with chemistry and pharmacology most consistent with activation of P2X purinergic receptor channels. P2X purinergic receptor channel-mediated Ca2+ entry stimulated sustained Cl- and HCO3- secretion in CF and non-CF epithelial monolayers. In non-CF mice, zinc and ATP induced a significant Cl- secretory response similar to the effects of agonists that increase intracellular cAMP levels. More importantly, in both CF mouse models, Cl- permeability of nasal epithelia was restored in a sustained manner by zinc and ATP. These effects were reversible and reacquirable upon removal and readdition of agonists. Our data suggest that activation of P2X calcium entry channels may have profound therapeutic benefit for CF that is independent of cystic fibrosis transmembrane conductance regulator genotype.	Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Gregory Fleming James Cyst Fibrosis Res Ctr, Birmingham, AL 35294 USA; Hungarian Acad Sci, H-1089 Budapest, Hungary; Semmelweis Univ, Nephrol Res Grp, H-1089 Budapest, Hungary	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Hungarian Academy of Sciences; Semmelweis University	Zsembery, A (corresponding author), Univ Alabama Birmingham, Dept Physiol & Biophys, MCLM 740,1918 Univ Blvd, Birmingham, AL 35294 USA.	zsembery@physiology.uab.edu; eschwiebert@physiology.uab.edu		Tucker, Torry/0000-0002-0823-3234; Sorscher, Eric J./0000-0001-9341-3354	NHLBI NIH HHS [R01 HL63934] Funding Source: Medline; NIDDK NIH HHS [DK 54367, DK62397] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054367] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnon A, 2000, AM J PHYSIOL-CELL PH, V278, pC163, DOI 10.1152/ajpcell.2000.278.1.C163; Balzer M, 1999, CARDIOVASC RES, V42, P543, DOI 10.1016/S0008-6363(99)00025-5; Baricordi OR, 1996, BLOOD, V87, P682, DOI 10.1182/blood.V87.2.682.bloodjournal872682; Brady KG, 2001, AM J PHYSIOL-LUNG C, V281, pL1173, DOI 10.1152/ajplung.2001.281.5.L1173; Braunstein GM, 2001, J BIOL CHEM, V276, P6621, DOI 10.1074/jbc.M005893200; Brewer GJ, 1999, J LAB CLIN MED, V134, P322, DOI 10.1016/S0022-2143(99)90213-5; Camello C, 1999, J PHYSIOL-LONDON, V516, P399, DOI 10.1111/j.1469-7793.1999.0399v.x; Clarke LL, 1999, AM J PHYSIOL-CELL PH, V276, pC777, DOI 10.1152/ajpcell.1999.276.4.C777; CLARKE LL, 1992, AM J PHYSIOL, V263, pC348, DOI 10.1152/ajpcell.1992.263.2.C348; Colvin RA, 1998, NEUROREPORT, V9, P3091, DOI 10.1097/00001756-199809140-00032; Cuthbert AW, 2003, J PHYSIOL-LONDON, V551, P79, DOI 10.1113/jphysiol.2003.046482; Davies PA, 2003, J BIOL CHEM, V278, P712, DOI 10.1074/jbc.M208814200; Davis PB, 1996, AM J RESP CRIT CARE, V154, P1229, DOI 10.1164/ajrccm.154.5.8912731; Devor DC, 1999, J GEN PHYSIOL, V113, P743, DOI 10.1085/jgp.113.5.743; ESCHENBACHER WL, 1991, AM REV RESPIR DIS, V143, P341, DOI 10.1164/ajrccm/143.2.341; FERRARI D, 1994, AM J PHYSIOL-CELL PH, V267, pC886, DOI 10.1152/ajpcell.1994.267.4.C886; Fischer H, 2002, AM J PHYSIOL-CELL PH, V282, pC736, DOI 10.1152/ajpcell.00369.2001; Fuller CM, 2000, NEWS PHYSIOL SCI, V15, P165; Gabriel SE, 2000, J BIOL CHEM, V275, P35028, DOI 10.1074/jbc.M004953200; Giovannucci DR, 2002, J PHYSIOL-LONDON, V540, P469, DOI 10.1113/jphysiol.2001.013453; GRUENERT DC, 1988, P NATL ACAD SCI USA, V85, P5951, DOI 10.1073/pnas.85.16.5951; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guyot A, 2002, J PHYSIOL-LONDON, V545, P199, DOI 10.1113/jphysiol.2002.030148; Haidl P, 2000, EUR RESPIR J, V16, P1102, DOI 10.1034/j.1399-3003.2000.16f14.x; Hershfinkel M, 2001, P NATL ACAD SCI USA, V98, P11749, DOI 10.1073/pnas.201193398; Hogstrand C, 1999, TOXICOLOGY, V133, P139, DOI 10.1016/S0300-483X(99)00020-7; Jan CR, 1999, N-S ARCH PHARMACOL, V360, P249, DOI 10.1007/s002109900055; Kellerman D, 2002, ADV DRUG DELIVER REV, V54, P1463, DOI 10.1016/S0169-409X(02)00154-0; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; Krebs NF, 2000, PEDIATR RES, V48, P256, DOI 10.1203/00006450-200008000-00022; Kunzelmann K, 2001, CLIN EXP PHARMACOL P, V28, P857, DOI 10.1046/j.1440-1681.2001.03541.x; Lansley AB, 1999, BIOPHYS J, V77, P629, DOI 10.1016/S0006-3495(99)76919-5; Ma WY, 1999, NATURE, V400, P894, DOI 10.1038/23743; McNulty TJ, 1999, BIOCHEM J, V339, P555, DOI 10.1042/0264-6021:3390555; Mossad SB, 1996, ANN INTERN MED, V125, P81, DOI 10.7326/0003-4819-125-2-199607150-00001; Mossad SB, 2003, QJM-INT J MED, V96, P35, DOI 10.1093/qjmed/hcg004; Negulyaev YA, 2000, NEUROSCI LETT, V279, P165, DOI 10.1016/S0304-3940(99)00976-3; Nilius B, 2001, BRIT J PHARMACOL, V134, P453, DOI 10.1038/sj.bjp.0704272; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Novick SG, 1997, MED HYPOTHESES, V49, P347, DOI 10.1016/S0306-9877(97)90201-2; Ostrom RS, 2000, J BIOL CHEM, V275, P11735, DOI 10.1074/jbc.275.16.11735; Otero M, 2000, MOL CELL BIOCHEM, V205, P115, DOI 10.1023/A:1007018001735; Rychkov G, 2001, HEPATOLOGY, V33, P938, DOI 10.1053/jhep.2001.23051; Tarran R, 2002, J GEN PHYSIOL, V120, P407, DOI 10.1085/jgp.20028599; Taylor AL, 1999, J CLIN INVEST, V104, P875, DOI 10.1172/JCI7270; Torres GE, 1999, J BIOL CHEM, V274, P6653, DOI 10.1074/jbc.274.10.6653; Truong-Tran AQ, 2001, IMMUNOL CELL BIOL, V79, P170, DOI 10.1046/j.1440-1711.2001.00986.x; Tucker TA, 2003, AM J PHYSIOL-CELL PH, V284, pC791, DOI 10.1152/ajpcell.00435.2002; Uehara A, 2002, CELL CALCIUM, V31, P89, DOI 10.1054/ceca.2001.0257; Vennekens R, 2001, PFLUG ARCH EUR J PHY, V442, P237, DOI 10.1007/s004240100517; Wang K, 2002, AM J HUM GENET, V71, P66, DOI 10.1086/341125; Widdicombe JH, 2002, AM J RESP CRIT CARE, V165, P1566, DOI 10.1164/ajrccm.165.11.165111; WILEY JS, 1989, BLOOD, V73, P1316; ZEIHER BG, 1995, J CLIN INVEST, V96, P2051, DOI 10.1172/JCI118253; ZEITLIN PL, 1991, AM J RESP CELL MOL, V4, P313, DOI 10.1165/ajrcmb/4.4.313; Zeitlin PL, 1999, J CLIN INVEST, V103, P447, DOI 10.1172/JCI6346; Zitt C, 2002, PROG NEUROBIOL, V66, P243, DOI 10.1016/S0301-0082(02)00002-3; Zsembery A, 2003, J BIOL CHEM, V278, P13398, DOI 10.1074/jbc.M212277200	58	70	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10720	10729		10.1074/jbc.M313391200	http://dx.doi.org/10.1074/jbc.M313391200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701827	hybrid			2022-12-25	WOS:000220050400127
J	Hershko, T; Ginsberg, D				Hershko, T; Ginsberg, D			Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; FAMILY-MEMBER; E2F-1-INDUCED APOPTOSIS; NEURONAL APOPTOSIS; GENE-EXPRESSION; RELATIVE BIM; CANCER-CELLS; CPG ISLAND; S PHASE; P53	The E2F1 transcription factor is a critical downstream target of the tumor suppressor pRB. The retinoblastoma (RB) pathway is often inactivated in human tumors, resulting in deregulated E2F activity that can induce both proliferation and apoptosis. Bcl-2 homology 3 (BH3)-only proteins are pro-apoptotic members of the Bcl-2 protein family that trigger apoptosis in response to diverse stimuli. We show here that E2F1 up-regulates the expression of the pro-apoptotic BH3-only proteins PUMA, Noxa, Bim, and Hrk/DP5 through a direct transcriptional mechanism. Expression of the E7 protein of HPV16, which disrupts RB/E2F complexes, also up-regulates the expression of these four BH3-only proteins, implicating endogenous E2F in this phenomenon. Indeed, endogenous E2F1 binds the promoters of these four genes. Furthermore, inhibition of E2F1-induced expression of either Noxa or PUMA results in a significant reduction in E2F1-induced apoptosis, indicating that increased Noxa and PUMA levels mediate this E2F1-induced apoptosis. Importantly, inhibition of E2F activity abolishes DNA damage-induced elevation of PUMA levels, implicating E2F in the physiological regulation of PUMA expression. These data provide a novel direct link between E2F and the apoptotic machinery and may explain the increased sensitivity of cells with a defective RB/E2F pathway to chemotherapy.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Ginsberg, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	doron.ginsberg@weizmann.ac.il		ginsberg, doron/0000-0002-1257-4920				Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Berkovich E, 2003, ONCOGENE, V22, P161, DOI 10.1038/sj.onc.1206144; Berkovich E, 2003, CELL CYCLE, V2, P127, DOI 10.4161/cc.2.2.293; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Croxton R, 2002, ONCOGENE, V21, P1359, DOI 10.1038/sj.onc.1205157; DeGregori J, 2002, BBA-REV CANCER, V1602, P131, DOI 10.1016/S0304-419X(02)00051-3; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Dong YB, 1999, CANCER, V86, P2021, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2021::AID-CNCR20>3.0.CO;2-1; Eischen CM, 2001, ONCOGENE, V20, P6983, DOI 10.1038/sj.onc.1204892; Furukawa Y, 2002, J BIOL CHEM, V277, P39760, DOI 10.1074/jbc.M200805200; Ginsberg D, 2002, FEBS LETT, V529, P122, DOI 10.1016/S0014-5793(02)03270-2; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; Gomez-Manzano C, 2001, CANCER RES, V61, P6693; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Imaizumi K, 1999, J BIOL CHEM, V274, P7975, DOI 10.1074/jbc.274.12.7975; Imaizumi K, 1997, J BIOL CHEM, V272, P18842, DOI 10.1074/jbc.272.30.18842; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Phillips AC, 2001, APOPTOSIS, V6, P173, DOI 10.1023/A:1011332625740; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Stanelle J, 2002, NUCLEIC ACIDS RES, V30, P1859, DOI 10.1093/nar/30.8.1859; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Wu CL, 1996, MOL CELL BIOL, V16, P3698; Yang HL, 2000, CLIN CANCER RES, V6, P1579; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	38	266	280	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8627	8634		10.1074/jbc.M312866200	http://dx.doi.org/10.1074/jbc.M312866200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14684737	hybrid			2022-12-25	WOS:000189265900014
J	Schoch, GA; Yano, JK; Wester, MR; Griffin, KJ; Stout, CD; Johnson, EF				Schoch, GA; Yano, JK; Wester, MR; Griffin, KJ; Stout, CD; Johnson, EF			Structure of human microsomal cytochrome P4502C8 - Evidence for a peripheral fatty acid binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGSTROM RESOLUTION; METABOLISM; EXPRESSION; PURIFICATION; REDUCTASE; PROGRAM; ENZYMES; CYP2C8	A 2.7-Angstrom molecular structure of human microsomal cytochrome P450 2C8 (CYP2C8) was determined by x-ray crystallography. The membrane protein was modified for crystallization by replacement of the hydrophobic N-terminal transmembrane domain with a short hydrophilic sequence before residue 28. The structure of the native sequence is complete from residue 28 to the beginning of a C-terminal histidine tag used for purification. CYP2C8 is one of the principal hepatic drug-metabolizing enzymes that oxidizes therapeutic drugs such as taxol and cerivastatin and endobiotics such as retinoic acid and arachidonic acid. Consistent with the relatively large size of its preferred substrates, the active site volume is twice that observed for the structure of CYP2C5. The extended active site cavity is bounded by the beta1 sheet and helix F' that have not previously been implicated in substrate recognition by mammalian P450s. CYP2C8 crystallized as a symmetric dimer formed by the interaction of helices F, F', G', and G. Two molecules of palmitic acid are bound in the dimer interface. The dimer is observed in solution, and mass spectrometry confirmed the association of palmitic acid with the enzyme. This novel finding identifies a peripheral binding site in P450s that may contribute to drug-drug interactions in P450 metabolism.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Stout, CD (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd,MB8, La Jolla, CA 92037 USA.	dave@scripps.edu; johnson@scripps.edu		Yano, Jason/0000-0002-9774-2611	NCRR NIH HHS [M01 RR00883] Funding Source: Medline; NIGMS NIH HHS [GM31001, GM59229] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031001, R01GM059229] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALSTON K, 1991, J BIOL CHEM, V266, P735; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baldwin SJ, 1999, BRIT J CLIN PHARMACO, V48, P424; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cosme J, 2000, J BIOL CHEM, V275, P2545, DOI 10.1074/jbc.275.4.2545; Cresteil T, 2002, DRUG METAB DISPOS, V30, P438, DOI 10.1124/dmd.30.4.438; Jefcoate C R, 1978, Methods Enzymol, V52, P258; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Klose TS, 1999, J BIOCHEM MOL TOXIC, V13, P289, DOI 10.1002/(SICI)1099-0461(1999)13:6<289::AID-JBT1>3.0.CO;2-N; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee DS, 2003, J BIOL CHEM, V278, P9761, DOI 10.1074/jbc.M211575200; LESLIE AGW, 1996, DATA COLLECTION STRA; Li XQ, 2002, J PHARMACOL EXP THER, V300, P399, DOI 10.1124/jpet.300.2.399; Marill J, 2000, MOL PHARMACOL, V58, P1341, DOI 10.1124/mol.58.6.1341; MATSUURA S, 1978, J CELL BIOL, V78, P503, DOI 10.1083/jcb.78.2.503; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Nishimura M, 2003, YAKUGAKU ZASSHI, V123, P369; OHTA Y, 1994, J BIOL CHEM, V269, P15597; Ohyama K, 2000, DRUG METAB DISPOS, V28, P1303; OMURA T, 1964, J BIOL CHEM, V239, P2379; Prueksaritanont T, 2002, DRUG METAB DISPOS, V30, P1280, DOI 10.1124/dmd.30.11.1280; RAHMAN A, 1994, CANCER RES, V54, P5543; RICHARDSON TH, 1995, ARCH BIOCHEM BIOPHYS, V323, P87, DOI 10.1006/abbi.1995.0013; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; Scott EE, 2003, P NATL ACAD SCI USA, V100, P13196, DOI 10.1073/pnas.2133986100; Szczesna-Skorupa E, 2003, J BIOL CHEM, V278, P31269, DOI 10.1074/jbc.M301489200; Tracy TS, 1999, BRIT J CLIN PHARMACO, V47, P545, DOI 10.1046/j.1365-2125.1999.00923.x; vonWachenfeldt C, 1997, ARCH BIOCHEM BIOPHYS, V339, P107, DOI 10.1006/abbi.1996.9859; Wang JS, 2002, DRUG METAB DISPOS, V30, P1352, DOI 10.1124/dmd.30.12.1352; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Wester MR, 2003, BIOCHEMISTRY-US, V42, P9335, DOI 10.1021/bi034556l; Wester MR, 2003, BIOCHEMISTRY-US, V42, P6370, DOI 10.1021/bi0273922; Wester MR, 2002, METHOD ENZYMOL, V357, P73; Williams D, 2002, CLIN PHARMACOKINET, V41, P343, DOI 10.2165/00003088-200241050-00003; Williams PA, 2000, MOL CELL, V5, P121, DOI 10.1016/S1097-2765(00)80408-6; YAMADA M, 1995, BIOCHEMISTRY-US, V34, P10113, DOI 10.1021/bi00032a003; Yamazaki H, 1999, DRUG METAB DISPOS, V27, P1260; Yano JK, 2000, J BIOL CHEM, V275, P31086, DOI 10.1074/jbc.M004281200; ZELDIN DC, 1995, ARCH BIOCHEM BIOPHYS, V322, P76, DOI 10.1006/abbi.1995.1438; Zhao X, 2003, CURR DRUG METAB, V4, P73, DOI 10.2174/1389200033336892	43	341	351	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9497	9503		10.1074/jbc.M312516200	http://dx.doi.org/10.1074/jbc.M312516200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676196	hybrid			2022-12-25	WOS:000189265900116
J	Tanaka, Y; Kobayashi, H; Suzuki, M; Kanayama, N; Terao, T				Tanaka, Y; Kobayashi, H; Suzuki, M; Kanayama, N; Terao, T			Transforming growth factor-beta 1-dependent urokinase up-regulation and promotion of invasion are involved in Src-MAPK-dependent signaling in human ovarian cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PLASMINOGEN-ACTIVATOR; FACTOR-I; PHOSPHATIDYLINOSITOL-3 KINASE; PHOSPHOINOSITIDE 3-KINASE; RECEPTOR EXPRESSION; PROTEASE INHIBITOR; TGF-BETA; BIKUNIN; AKT	Urokinase-type plasminogen activator (uPA) has been implicated in tumor cell invasion and metastasis. We reported previously that transforming growth factor (TGF)-beta1 induces a dose- and time-dependent up-regulation of uPA mRNA and protein in highly invasive human ovarian cancer cell line HRA, leading to invasion. To further elucidate the mechanism of the invasive effect of TGF-beta1, we investigated which signaling pathway transduced by TGF-beta1 is responsible for this effect. Here, we show that 1) nontoxic concentrations of TGF-beta1 activated Src kinase; 2) TGF-beta1 rapidly phosphorylates ERK1/2 and Akt, but not p38; 3) pharmacological Src inhibitor PP2 or antisense ( AS) c-Src oligodeoxynucleotide (ODN) treatment reduced TGF-beta1-induced phosphorylation of ERK1/2 and Akt by 85 - 90% compared with controls; 4) pharmacological inhibition of MAPK by PD98059 abrogated TGF-beta1-mediated Akt stimulation, whereas TGF-beta1-induced ERK1/2 stimulation was not inhibited by PI3K inhibitor LY294002 or AS-PI3K ODN transfection; 5) up-regulation of uPA mRNA in response to TGF-beta1 was almost totally blocked by PP2 and PD98059 and partially (similar to55%) by LY294002; 6) TGF-beta1-induced uPA mRNA up-regulation was inhibited by treatment with AS ODNs to c-Src or PI3K by 90 or 60%, respectively, compared with control ODN treatment; and 7) blockade of the release of the transcription factor NF-kappaB by pyrrolidinedithiocarbamate reduced the TGF-beta1-induced activation of the uPA gene by similar to 65%. In addition, curcumin, a blocker of the transcriptional factor AP-1, partially (35%) canceled this effect. Taken together, these data support a role for TGF-beta1 activation of two distinct pathways ( Src-MAPK- PI3K-NF-kappaB-dependent and Src-MAPK-AP-1-dependent) for TGF-beta1-dependent uPA up-regulation and promotion of invasion.	Hamamatsu Univ Sch Med, Dept Obstet & Gynecol, Shizuoka 4313192, Japan	Hamamatsu University School of Medicine	Kobayashi, H (corresponding author), Hamamatsu Univ Sch Med, Dept Obstet & Gynecol, Handayama 1-20-1, Shizuoka 4313192, Japan.	hirokoba@hama-med.ac.jp						BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DEL PL, 1997, SCIENCE, V278, P687; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Dunn SE, 2001, CANCER RES, V61, P1367; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; Fukuda K, 1998, ONCOGENE, V16, P3349, DOI 10.1038/sj.onc.1201896; Han SH, 1998, J PHARMACOL EXP THER, V287, P1105; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Hirashima Y, 2003, J BIOL CHEM, V278, P26793, DOI 10.1074/jbc.M212187200; Iglesias M, 2000, ONCOGENE, V19, P4134, DOI 10.1038/sj.onc.1203764; Ivanov VN, 2002, J BIOL CHEM, V277, P4932, DOI 10.1074/jbc.M108233200; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kim JT, 2002, J BIOL CHEM, V277, P31938, DOI 10.1074/jbc.M201178200; Kobayashi H, 1998, EUR J BIOCHEM, V253, P817, DOI 10.1046/j.1432-1327.1998.2530817.x; Kobayashi H, 2003, J BIOL CHEM, V278, P7790, DOI 10.1074/jbc.M210407200; Kobayashi H, 2002, EUR J BIOCHEM, V269, P3945, DOI 10.1046/j.1432-1033.2002.03068.x; Kobayashi H, 2001, J BIOL CHEM, V276, P2015, DOI 10.1074/jbc.M007650200; Krasilnikov MA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P59; Li RH, 2001, J BIOL CHEM, V276, P28767, DOI 10.1074/jbc.M100158200; Liu Q, 1998, J IMMUNOL, V160, P1393; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; Mehra A, 2002, BIOCHEM CELL BIOL, V80, P605, DOI 10.1139/O02-161; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Morel JCM, 2002, J BIOL CHEM, V277, P34679, DOI 10.1074/jbc.M206337200; Mori T, 2000, J NEURO-ONCOL, V46, P115, DOI 10.1023/A:1006339717748; Muehlenweg B, 2001, EXPERT OPIN BIOL TH, V1, P683; Ozes ON, 1999, NATURE, V401, P82; Rak J, 1995, CANCER METAST REV, V14, P263, DOI 10.1007/BF00690598; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shimamura H, 2003, J AM SOC NEPHROL, V14, P1427, DOI 10.1097/01.ASN.0000066140.99610.32; Shin EY, 2002, J CANCER RES CLIN, V128, P596, DOI 10.1007/s00432-002-0388-4; Suzuki M, 2003, INT J CANCER, V104, P289, DOI 10.1002/ijc.10950; Suzuki M, 2003, J BIOL CHEM, V278, P14640, DOI 10.1074/jbc.M300239200; Suzuki M, 2002, J BIOL CHEM, V277, P8022, DOI 10.1074/jbc.M108545200; Tanno S, 2001, CANCER RES, V61, P589; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Xi SC, 2003, J BIOL CHEM, V278, P31574, DOI 10.1074/jbc.M303499200; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	46	64	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8567	8576		10.1074/jbc.M309131200	http://dx.doi.org/10.1074/jbc.M309131200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676209	hybrid			2022-12-25	WOS:000189265900007
J	Znaidi, S; Pelletier, B; Mukai, Y; Labbe, S				Znaidi, S; Pelletier, B; Mukai, Y; Labbe, S			The Schizosaccharomyces pombe corepressor Tup11 interacts with the iron-responsive transcription factor Fep1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; TRANSPORTER GENE-EXPRESSION; NEURAL SPECIFICITY GENE; FISSION YEAST; DNA-BINDING; SIDEROPHORE BIOSYNTHESIS; USTILAGO-MAYDIS; NEUROSPORA-CRASSA; GATA FACTOR; CAENORHABDITIS-ELEGANS	The Schizosaccharomyces pombe fep1(+) gene encodes a GATA transcription factor that represses the expression of iron transport genes in response to elevated iron concentrations. This transcriptional response is altered only in strains harboring a combined deletion of both tup11(+) and tup12(+) genes. This suggests that Tup11 is capable of negatively regulating iron transport gene expression in the absence of Tup12 and vice versa. The tup11(+)- and tup12(+)-encoded proteins resemble the Saccharomyces cerevisiae Tup1 corepressor. Using yeast two-hybrid analysis we show that Tup11 and Fep1 physically interact with each other. The C-terminal region from amino acids 242 to 564 of Fep1 is required for interaction with Tup11. Within this region, a minimal domain encompassing amino acids 405 - 541 was sufficient for Tup11-Fep1 association. Deletion mapping analysis revealed that the WD40-repeat sequence motifs of Tup11 are necessary for its interaction with Fep1. Analysis of Tup11 mutants with single amino acid substitutions in the WD40 repeats suggested that the Fep1 transcription factor interacts with a putative flat upper surface on the predicted beta-propeller structure of this motif. Further analysis by in vivo coimmunoprecipitation showed that Tup11 and Fep1 are physically associated. In vitro pull-down experiments further verified a direct interaction between the Fep1 C terminus and the Tup11 C-terminal WD40 repeat domain. Taken together, these results describe the first example of a physical interaction between a corepressor and an iron-sensing factor controlling the expression of iron uptake genes.	Univ Sherbrooke, Fac Med, Dept Biochim, Sherbrooke, PQ J1H 5N4, Canada; Osaka Univ, Dept Biotechnol, Suita, Osaka 5650871, Japan	University of Sherbrooke; Osaka University	Labbe, S (corresponding author), Univ Sherbrooke, Fac Med, Dept Biochim, 3001 12E Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.	Simon.Labbe@USherbrooke.ca	Znaidi, Sadri/W-6952-2019	Znaidi, Sadri/0000-0001-9238-2218; Mukai, Yukio/0000-0003-1265-0839; Labbe, Simon/0000-0002-4947-523X				ALFA C, 1993, EXPT FISSION YEASTS; An ZQ, 1997, P NATL ACAD SCI USA, V94, P5882, DOI 10.1073/pnas.94.11.5882; An ZQ, 1997, EMBO J, V16, P1742, DOI 10.1093/emboj/16.7.1742; Askwith C, 1997, J BIOL CHEM, V272, P401; BALASUBRAMANIAN B, 1993, MOL CELL BIOL, V13, P6071, DOI 10.1128/MCB.13.10.6071; Beaudoin J, 2003, J BIOL CHEM, V278, P14565, DOI 10.1074/jbc.M300861200; Beaudoin J, 2001, J BIOL CHEM, V276, P15472, DOI 10.1074/jbc.M011256200; Bezanilla M, 1997, MOL BIOL CELL, V8, P2693, DOI 10.1091/mbc.8.12.2693; Boukhalfa H, 2002, BIOMETALS, V15, P325, DOI 10.1023/A:1020218608266; Chen DR, 2003, MOL BIOL CELL, V14, P214, DOI 10.1091/mbc.E02-08-0499; Dancis A, 1998, J PEDIATR-US, V132, pS24, DOI 10.1016/S0022-3476(98)70524-4; Davie JK, 2002, MOL CELL BIOL, V22, P693, DOI 10.1128/MCB.22.3.693-703.2002; Deckert J, 2001, MOL CELL BIOL, V21, P2726, DOI 10.1128/MCB.21.8.2726-2735.2001; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; Fashena SJ, 2000, METHOD ENZYMOL, V328, P14, DOI 10.1016/S0076-6879(00)28387-0; Gilbreth M, 1998, P NATL ACAD SCI USA, V95, P14781, DOI 10.1073/pnas.95.25.14781; Greenall A, 2002, MOL BIOL CELL, V13, P2977, DOI 10.1091/mbc.01-12-0568; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Haas H, 1997, GENE, V184, P33, DOI 10.1016/S0378-1119(96)00570-7; Haas H, 1999, J BIOL CHEM, V274, P4613, DOI 10.1074/jbc.274.8.4613; Haas H, 2003, APPL MICROBIOL BIOT, V62, P316, DOI 10.1007/s00253-003-1335-2; Harrison KA, 2002, BIOCHEMISTRY-US, V41, P15288, DOI 10.1021/bi0204995; Henikoff S, 2003, NATURE, V423, P814, DOI 10.1038/423814a; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Janoo RTK, 2001, GENETICS, V157, P1205; JOHNSON AD, 1995, CURR OPIN GENET DEV, V5, P552, DOI 10.1016/0959-437X(95)80022-0; Kaplan J, 2002, CELL, V111, P603, DOI 10.1016/S0092-8674(02)01164-9; Kaplan J, 2002, SEMIN HEMATOL, V39, P219, DOI 10.1053/shem.2002.35631; KELLERMANN OK, 1982, METHOD ENZYMOL, V90, P459; Knight SAB, 2002, MICROBIOL-SGM, V148, P29, DOI 10.1099/00221287-148-1-29; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; Komachi K, 1997, MOL CELL BIOL, V17, P6023, DOI 10.1128/MCB.17.10.6023; Kowalski K, 2002, J BIOL CHEM, V277, P35720, DOI 10.1074/jbc.M204663200; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Labbe S, 1999, J BIOL CHEM, V274, P36252, DOI 10.1074/jbc.274.51.36252; Lesuisse E, 2001, MICROBIOL-UK, V147, P289, DOI 10.1099/00221287-147-2-289; Lesuisse E, 2002, YEAST, V19, P329, DOI 10.1002/yea.840; Mackay JP, 1998, J BIOL CHEM, V273, P30560, DOI 10.1074/jbc.273.46.30560; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; Mazmanian SK, 2003, SCIENCE, V299, P906, DOI 10.1126/science.1081147; MILLER DM, 1993, GENETICS, V135, P741; Miller JH., 1972, EXPT MOL GENETICS; Mukai Y, 1999, MOL CELL BIOL, V19, P8461; Mukai Y, 2003, J BIOL CHEM, V278, P18895, DOI 10.1074/jbc.M302155200; Oberegger H, 2002, BIOCHEM SOC T, V30, P781, DOI 10.1042/bst0300781; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; Ostling J, 1996, MOL CELL BIOL, V16, P753; Papamichos-Chronakis M, 2000, J BIOL CHEM, V275, P8397, DOI 10.1074/jbc.275.12.8397; Papamichos-Chronakis M, 2002, MOL CELL, V9, P1297, DOI 10.1016/S1097-2765(02)00545-2; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Pelletier B, 2003, NUCLEIC ACIDS RES, V31, P4332, DOI 10.1093/nar/gkg647; Pelletier B, 2002, J BIOL CHEM, V277, P22950, DOI 10.1074/jbc.M202682200; Pflugrad A, 1997, DEVELOPMENT, V124, P1699; Philpott CC, 2002, BIOCHEM SOC T, V30, P698, DOI 10.1042/bst0300698; Pickles LM, 2002, STRUCTURE, V10, P751, DOI 10.1016/S0969-2126(02)00768-2; Proft M, 2002, MOL CELL, V9, P1307, DOI 10.1016/S1097-2765(02)00557-9; Proft M, 2001, EMBO J, V20, P1123, DOI 10.1093/emboj/20.5.1123; ROMAN DG, 1993, MOL CELL BIOL, V13, P4342, DOI 10.1128/MCB.13.7.4342; Rutherford JC, 2003, J BIOL CHEM, V278, P27636, DOI 10.1074/jbc.M300076200; Scazzocchio C, 2000, CURR OPIN MICROBIOL, V3, P126, DOI 10.1016/S1369-5274(00)00063-1; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Smith RL, 2000, TRENDS BIOCHEM SCI, V25, P325, DOI 10.1016/S0968-0004(00)01592-9; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Sprague ER, 2000, EMBO J, V19, P3016, DOI 10.1093/emboj/19.12.3016; Steele MR, 2001, CELL SIGNAL, V13, P507, DOI 10.1016/S0898-6568(01)00167-X; Tasto JJ, 2001, YEAST, V18, P657, DOI 10.1002/yea.713; Touati D, 2000, ARCH BIOCHEM BIOPHYS, V373, P1, DOI 10.1006/abbi.1999.1518; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Varanasi US, 1996, MOL CELL BIOL, V16, P6707; VOISARD C, 1993, MOL CELL BIOL, V13, P7091, DOI 10.1128/MCB.13.11.7091; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VOJTEK AB, 1997, YEAST 2 HYBRID SYSTE, P29; Wessling-Resnick M, 1999, CRIT REV BIOCHEM MOL, V34, P285, DOI 10.1080/10409239991209318; WHYATT DJ, 1993, EMBO J, V12, P4993, DOI 10.1002/j.1460-2075.1993.tb06193.x; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307; Winnier AR, 1999, GENE DEV, V13, P2774, DOI 10.1101/gad.13.21.2774; Zhou LW, 1999, BIOCHEMISTRY-US, V38, P4335, DOI 10.1021/bi982543f; Zhou LW, 1998, MOL GEN GENET, V259, P532, DOI 10.1007/s004380050845	83	43	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9462	9474		10.1074/jbc.M312787200	http://dx.doi.org/10.1074/jbc.M312787200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14668334	hybrid			2022-12-25	WOS:000189265900112
J	Kang, DC; Gopalkrishnan, RV; Lin, L; Randolph, A; Valerie, K; Pestka, S; Fisher, PB				Kang, DC; Gopalkrishnan, RV; Lin, L; Randolph, A; Valerie, K; Pestka, S; Fisher, PB			Expression analysis and genomic characterization of human melanoma differentiation associated gene-5, mda-5: a novel type I interferon-responsive apoptosis-inducing gene	ONCOGENE			English	Article						helicard; CARD; RNA helicase; terminal differentiation	HUMAN POLYNUCLEOTIDE PHOSPHORYLASE; TRANS-RETINOIC ACID; TERMINAL DIFFERENTIATION; PROTEIN FAMILY; ALPHA-INTERFERON; GAMMA-INTERFERON; GROWTH ARREST; CANCER CELLS; HYBRIDIZATION; IDENTIFICATION	Melanoma differentiation associated gene-5 (mda-5) was identified by subtraction hybridization as a novel upregulated gene in HO-1 human melanoma cells induced to terminally differentiate by treatment with IFN-beta + MEZ. Considering its unique structure, consisting of a caspase recruitment domain (CARD) and an RNA helicase domain, it was hypothesized that mda-5 contributes to apoptosis occurring during terminal differentiation. We have currently examined the expression pattern of mda-5 in normal tissues, during induction of terminal differentiation and after treatment with type I IFNs. In addition, we have defined its genomic structure and chromosomal location. IFN-beta, a type I IFN, induces mda-5 expression in a biphasic and dose-dependent manner. Based on its temporal kinetics of induction and lack of requirement for prior protein synthesis mda-5 is an early type I IFN-responsive gene. The level of mda-5 mRNA is in low abundance in normal tissues, whereas expression is induced in a spectrum of normal and cancer cells by IFN-beta. Expression of mda-5 by means of a replication incompetent adenovirus, Ad. mda-5, induces apoptosis in HO-1 cells as confirmed by morphologic, biochemical and molecular assays. Additionally, the combination of Ad.mda-5+MEZ further augments apoptosis as observed in Ad. null or uninfected HO-1 cells induced to terminally differentiate by treatment with IFN-beta+MEZ. The mda-5 gene is located on human chromosome 2q24 and consists of 16 exons, without pseudogenes, and is conserved in the mouse genome. Present data documents that mda-5 is a novel type I IFN-inducible gene, which may contribute to apoptosis induction during terminal differentiation and during IFN treatment. The conserved genomic and protein structure of mda-5 in human and mouse will permit analysis of the evolution and developmental aspects of this gene.	Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA; Columbia Univ Coll Phys & Surg, Dept Neurosurg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Urol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	Columbia University; Virginia Commonwealth University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Columbia University; Columbia University	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, BB-1501,630 W 168th St, New York, NY 10032 USA.	pbf1@columbia.edu	Valerie, Kristoffer/AAL-8299-2021		NATIONAL CANCER INSTITUTE [R01CA098712, R01CA035675, R01CA097318] Funding Source: NIH RePORTER; NCI NIH HHS [CA35675, CA97318, CA98712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akesson E, 2002, GENES IMMUN, V3, P279, DOI 10.1038/sj.gene.6363866; Barber GN, 2001, CELL DEATH DIFFER, V8, P113, DOI 10.1038/sj.cdd.4400823; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Bouchier-Hayes L, 2002, EMBO REP, V3, P616, DOI 10.1093/embo-reports/kvf139; Chien G, 2001, CANCER GENET CYTOGEN, V126, P63, DOI 10.1016/S0165-4608(00)00392-7; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; de Veer MJ, 2001, J LEUKOCYTE BIOL, V69, P912; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Du Plessis L, 1999, CANCER RES, V59, P1877; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; FISHER PB, 1985, PHARMACOL THERAPEUT, V27, P143, DOI 10.1016/0163-7258(85)90067-1; Fisher PB, 2003, CANCER BIOL THER, V2, pS23; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; Friesen H J, 1981, Methods Enzymol, V78, P430; Fusenig N E, 1995, Recent Results Cancer Res, V139, P1; Garattini Enrico, 2001, Current Opinion in Pharmacology, V1, P358, DOI 10.1016/S1471-4892(01)00062-5; Gopalkrishnan RV, 2000, ONCOGENE, V19, P4405, DOI 10.1038/sj.onc.1203767; Gopalkrishnan RV, 1998, J BIOL CHEM, V273, P10972, DOI 10.1074/jbc.273.18.10972; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Holmes Matthew, 2003, Methods Mol Biol, V234, P1; Huang F, 1999, GENE, V236, P125, DOI 10.1016/S0378-1119(99)00244-9; Huang F, 1999, ONCOGENE, V18, P3546, DOI 10.1038/sj.onc.1202715; Jackson DP, 2003, MELANOMA RES, V13, P219, DOI 10.1097/00008390-200306000-00001; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; Jankowsky E, 2000, NUCLEIC ACIDS RES, V28, P333, DOI 10.1093/nar/28.1.333; Jia SF, 1999, J INTERF CYTOK RES, V19, P617, DOI 10.1089/107999099313758; JIANG H, 1994, MOL CELL DIFFER, V2, P22139; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P41; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; Jiang HP, 2000, P NATL ACAD SCI USA, V97, P12684, DOI 10.1073/pnas.220431297; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; JIANG HP, 1995, ONCOGENE, V10, P1855; Kang DC, 2001, GENE, V267, P233, DOI 10.1016/S0378-1119(01)00384-5; Kang DC, 2002, P NATL ACAD SCI USA, V99, P637, DOI 10.1073/pnas.022637199; Kovacsovics M, 2002, CURR BIOL, V12, P838, DOI 10.1016/S0960-9822(02)00842-4; Kumon K, 2001, JPN J CANCER RES, V92, P854, DOI 10.1111/j.1349-7006.2001.tb01172.x; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; Leszczyniecka M, 2003, GENE, V316, P143, DOI 10.1016/S0378-1119(03)00752-2; Leszczyniecka M, 2002, P NATL ACAD SCI USA, V99, P16636, DOI 10.1073/pnas.252643699; Leszczyniecka M, 2001, PHARMACOL THERAPEUT, V90, P105, DOI 10.1016/S0163-7258(01)00132-2; Levy DE, 2002, J INTERF CYTOK RES, V22, P87, DOI 10.1089/107999002753452692; Lin JJ, 1998, GENE, V207, P105, DOI 10.1016/S0378-1119(97)00562-3; Lindner DJ, 2000, BBA-MOL CELL RES, V1496, P196, DOI 10.1016/S0167-4889(00)00021-5; Lotem J, 2002, ONCOGENE, V21, P3284, DOI 10.1038/sj.onc.1205319; Lovat PE, 1997, EUR J CANCER, V33, P2075, DOI 10.1016/S0959-8049(97)00242-6; Luking A, 1998, CRIT REV BIOCHEM MOL, V33, P259, DOI 10.1080/10409239891204233; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; PACKER RJ, 1991, NEUROL CLIN, V9, P405, DOI 10.1016/S0733-8619(18)30293-7; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Peng Zhihai, 2002, Zhonghua Wai Ke Za Zhi, V40, P776; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Pestka S, 2000, BIOPOLYMERS, V55, P254, DOI 10.1002/1097-0282(2000)55:4<254::AID-BIP1001>3.0.CO;2-1; PESTKA S, 1997, SEMIN ONCOL, V24; Petersen OW, 1998, ADV CANCER RES, V75, P135, DOI 10.1016/S0065-230X(08)60741-1; Raffray M, 1997, PHARMACOL THERAPEUT, V75, P153, DOI 10.1016/S0163-7258(97)00037-5; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Sangfelt O, 2001, MED ONCOL, V18, P3, DOI 10.1385/MO:18:1:3; Saunders LR, 2003, FASEB J, V17, P961, DOI 10.1096/fj.02-0958rev; Scott RE, 1997, PHARMACOL THERAPEUT, V73, P51, DOI 10.1016/S0163-7258(96)00120-9; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Su ZZ, 2001, P NATL ACAD SCI USA, V98, P10332, DOI 10.1073/pnas.171315198; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Tanabe T, 2000, J NEURO-ONCOL, V48, P225, DOI 10.1023/A:1006476408190; Tapper J, 1998, CANCER RES, V58, P2715; Toida M, 2001, CANCER GENET CYTOGEN, V127, P34, DOI 10.1016/S0165-4608(00)00410-6; Wang Q, 1998, GENE, V222, P83, DOI 10.1016/S0378-1119(98)00476-4; Wang Z Y, 2000, Lancet Oncol, V1, P101, DOI 10.1016/S1470-2045(00)00017-6; Will CL, 2002, EMBO J, V21, P4978, DOI 10.1093/emboj/cdf480; Yeatman TJ, 1996, CLIN EXP METASTAS, V14, P246; Zhang JW, 2000, J BIOSCIENCES, V25, P275, DOI 10.1007/BF02703936; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355	74	142	152	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1789	1800		10.1038/sj.onc.1207300	http://dx.doi.org/10.1038/sj.onc.1207300			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	14676839				2022-12-25	WOS:000220029300014
J	Broderick, KE; Kean, L; Dow, JAT; Pyne, NJ; Davies, SA				Broderick, KE; Kean, L; Dow, JAT; Pyne, NJ; Davies, SA			Ectopic expression of bovine type 5 phosphodiesterase confers a renal phenotype in Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; HUMAN CGMP-BINDING; NITRIC-OXIDE; MALPIGHIAN TUBULES; EPITHELIAL FUNCTION; SIGNALING PATHWAY; FLUID SECRETION; MELANOGASTER; PDE5; GENE	cGMP signaling regulates epithelial fluid transport by Drosophila Malpighian (renal) tubules. In order to directly evaluate the importance of cGMP-degrading phosphodiesterases (PDEs) in epithelial transport, bovine PDE5 (a bona fide cGMP-PDE), was ectopically expressed in vivo. Transgenic UAS-PDE5 Drosophila were generated, and PDE5 expression was driven in specified tubule cells in vivo by cell-specific GAL4 drivers. Targeted expression was verified by PCR and Western blotting. Immunolocalization of PDE5 in tubule confirmed specificity of expression and demonstrated localization to the apical plasma membrane. GAL4/UAS-PDE5 tubules exhibit increased cG-PDE activity and reduced basal cGMP levels compared with control lines. We show that wild-type and control tubules are sensitive to the PDE5-specific inhibitor sildenafil and that GAL4/UAS-PDE5 tubules display enhanced sensitivity to sildenafil, compared with controls. cGMP content in GAL4/UAS-PDE5 tubules is restored to control levels by treatment with sildenafil. Thus bovine PDE5 retains cGMP-degrading activity and inhibitor sensitivity when expressed in Drosophila. Expression of PDE5 in tubule principal cells results in an epithelial phenotype, reducing rates of basal and cGMP-/Cardioaccelatory peptide(2b)(CAP(2b))-stimulated fluid transport. Furthermore, inhibition of PDE5 activity by sildenafil restores basal and cGMP-stimulated fluid transport rates to control levels. However, corticotrophin releasing factor-like-stimulated transport, which is activated by cAMP signaling, was unaffected, confirming that only cGMP-stimulated signaling events in tubule are compromised by overexpression of PDE5. Successful ectopic expression of a vertebrate cG-PDE in Drosophila has shown that cG-PDE has a critical role in tubule function in vivo and that cG-PDE function is conserved across evolution. The transgene also provides a generic tool for the analysis of cGMP signaling in Drosophila.	Univ Glasgow, Inst Biomed & Life Sci, Div Mol Genet, Glasgow G11 6NU, Lanark, Scotland; Univ Strathclyde, Strathclyde Inst Biomed Sci, Dept Physiol & Pharmacol, Glasgow G4 0NR, Lanark, Scotland	University of Glasgow; University of Strathclyde	Davies, SA (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Mol Genet, Glasgow G11 6NU, Lanark, Scotland.	s.a.davies@bio.gla.ac.uk	Dow, Julian/M-2371-2019	Dow, Julian/0000-0002-9595-5146; Pyne, Nigel/0000-0002-5657-4578				Bouley R, 2000, J CLIN INVEST, V106, P1115, DOI 10.1172/JCI9594; BRAND AH, 1993, DEVELOPMENT, V118, P401; Broderick KE, 2003, AM J PHYSIOL-CELL PH, V285, pC1207, DOI 10.1152/ajpcell.00123.2003; Cabrero P, 2002, J EXP BIOL, V205, P3799; Corbin JD, 2000, EUR J BIOCHEM, V267, P2760, DOI 10.1046/j.1432-1327.2000.01297.x; Corbin JD, 1999, J BIOL CHEM, V274, P13729, DOI 10.1074/jbc.274.20.13729; Corbin JD, 2002, INT J CLIN PRACT, V56, P453; Davies SA, 1995, AM J PHYSIOL-REG I, V269, pR1321, DOI 10.1152/ajpregu.1995.269.6.R1321; Davies SA, 1997, AM J PHYSIOL-REG I, V273, pR823, DOI 10.1152/ajpregu.1997.273.2.R823; Davies SA, 2000, INSECT BIOCHEM MOLEC, V30, P1123, DOI 10.1016/S0965-1748(00)00118-1; Dousa TP, 1999, KIDNEY INT, V55, P29, DOI 10.1046/j.1523-1755.1999.00233.x; Dow JAT, 2003, PHYSIOL REV, V83, P687, DOI 10.1152/physrev.00035.2002; Dow JAT, 1999, J BIOENERG BIOMEMBR, V31, P75, DOI 10.1023/A:1005400731289; Dow JAT, 2001, ADV INSECT PHYSIOL, V28, P1, DOI 10.1016/S0065-2806(01)28008-4; DOW JAT, 1994, AM J PHYSIOL, V266, pR1716, DOI 10.1152/ajpregu.1994.266.5.R1716; DOW JAT, 1994, J EXP BIOL, V197, P421; Kean L, 2002, AM J PHYSIOL-REG I, V282, pR1297, DOI 10.1152/ajpregu.00584.2001; KERR M, 2000, COMP BIOCH PHYSL, V126, P77; Kurjak M, 2001, J PHYSIOL-LONDON, V534, P827, DOI 10.1111/j.1469-7793.2001.00827.x; Lee EYW, 1996, AM J PHYSIOL-RENAL, V271, pF3, DOI 10.1152/ajprenal.1996.271.1.F3; Loughney K, 1998, GENE, V216, P139, DOI 10.1016/S0378-1119(98)00303-5; MacPherson MR, 2001, AM J PHYSIOL-CELL PH, V280, pC394, DOI 10.1152/ajpcell.2001.280.2.C394; Mullershausen F, 2003, J CELL BIOL, V160, P719, DOI 10.1083/jcb.200211041; Murthy KS, 2001, BIOCHEM J, V360, P199, DOI 10.1042/0264-6021:3600199; Pollock VP, 2003, J EXP BIOL, V206, P901, DOI 10.1242/jeb.00189; PYNE NJ, 1993, AGENT ACTION SUPPL, V43, P35; Radford JC, 2002, J BIOL CHEM, V277, P38810, DOI 10.1074/jbc.M203694200; Riegel JA, 1998, J EXP BIOL, V201, P3411; Rosay P, 1997, J CELL SCI, V110, P1683; Sokolowski MB, 2002, NATURE, V419, P893, DOI 10.1038/419893a; SOZEN HA, 1997, P NATL ACAD SCI USA, V94, P5207; Stacey P, 1998, BIOCHEM BIOPH RES CO, V247, P249, DOI 10.1006/bbrc.1998.8769; Sung BJ, 2003, NATURE, V425, P98, DOI 10.1038/nature01914; Terhzaz S, 1999, J EXP BIOL, V202, P3667; Turko IV, 1999, MOL PHARMACOL, V56, P124, DOI 10.1124/mol.56.1.124; Turko IV, 1998, BIOCHEM J, V329, P505; Vaandrager AB, 1996, MOL CELL BIOCHEM, V157, P23, DOI 10.1007/BF00227877; Welch WJ, 2002, CURR OPIN NEPHROL HY, V11, P109, DOI 10.1097/00041552-200201000-00016	38	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8159	8168		10.1074/jbc.M304679200	http://dx.doi.org/10.1074/jbc.M304679200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14662775	hybrid			2022-12-25	WOS:000189103300097
J	Xu, BE; Stippec, S; Lenertz, L; Lee, BH; Zhang, W; Lee, YK; Cobb, MH				Xu, BE; Stippec, S; Lenertz, L; Lee, BH; Zhang, W; Lee, YK; Cobb, MH			WNK1 activates ERK5 by an MEKK2/3-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; TYROSINE KINASES; IDENTIFICATION; PATHWAYS; GENE; MEK5; PHOSPHORYLATION; NEUROTROPHINS	WNK1 belongs to a unique protein kinase family that lacks the catalytic lysine in its normal position. Mutations in human WNK1 and WNK4 have been implicated in causing a familial form of hypertension. Here we report that overexpression of WNK1 led to increased activity of cotransfected ERK5 in HEK293 cells. ERK5 activation was blocked by the MEK5 inhibitor U0126 and expression of a dominant negative MEK5 mutant. Expression of dominant negative mutants of MEKK2 and MEKK3 also blocked activation of ERK5 by WNK1. Moreover, both MEKK2 and MEKK3 coimmunoprecipitated with endogenous WNK1 from cell lysates. WNK1 phosphorylated both MEKK2 and - 3 in vitro, and MEKK3 was activated by WNK1 in 293 cells. Finally, ERK5 activation by epidermal growth factor was attenuated by suppression of WNK1 expression using small interfering RNA. Taken together, these results place WNK1 in the ERK5 MAP kinase pathway upstream of MEKK2/3.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	mcobb@mednet.swmed.edu		Cobb, Melanie/0000-0003-0833-5473; Lee, Byung-Hoon/0000-0002-7101-0471	NIGMS NIH HHS [GM53032] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; Cameron SJ, 2004, J BIOL CHEM, V279, P1506, DOI 10.1074/jbc.M308755200; Cavanaugh JE, 2001, J NEUROSCI, V21, P434, DOI 10.1523/JNEUROSCI.21-02-00434.2001; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Chen Z, 2003, J BIOL CHEM, V278, P22278, DOI 10.1074/jbc.M301173200; Chen Z, 2001, J BIOL CHEM, V276, P16070, DOI 10.1074/jbc.M100681200; Diaz-Meco MT, 2001, MOL CELL BIOL, V21, P1218, DOI 10.1128/MCB.21.4.1218-1227.2001; Dong F, 2001, J BIOL CHEM, V276, P10811, DOI 10.1074/jbc.M008748200; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; English JM, 1999, J BIOL CHEM, V274, P31588, DOI 10.1074/jbc.274.44.31588; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Karihaloo A, 2001, J BIOL CHEM, V276, P9166, DOI 10.1074/jbc.M009963200; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kostich M, 2002, GENOME BIOL, V3; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Morrison DK, 2000, J CELL BIOL, V150, pF57, DOI 10.1083/jcb.150.2.F57; Murakami-Kojima M, 2002, PLANT CELL PHYSIOL, V43, P675, DOI 10.1093/pcp/pcf084; Nakamichi N, 2002, BIOSCI BIOTECH BIOCH, V66, P2429, DOI 10.1271/bbb.66.2429; Pearson GW, 2002, J BIOL CHEM, V277, P48094, DOI 10.1074/jbc.M208535200; Sun WY, 2001, J BIOL CHEM, V276, P5093, DOI 10.1074/jbc.M003719200; Verissimo F, 2001, ONCOGENE, V20, P5562, DOI 10.1038/sj.onc.1204726; Watson FL, 2001, NAT NEUROSCI, V4, P981, DOI 10.1038/nn720; Wilson FH, 2001, SCIENCE, V293, P1107, DOI 10.1126/science.1062844; Wilson FH, 2003, P NATL ACAD SCI USA, V100, P680, DOI 10.1073/pnas.242735399; Xu BE, 2002, J BIOL CHEM, V277, P48456, DOI 10.1074/jbc.M207917200; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; Yan C, 2001, J BIOL CHEM, V276, P10870, DOI 10.1074/jbc.M009286200; Yang CL, 2003, J CLIN INVEST, V111, P1039, DOI 10.1172/JCI200317443; Zambrowicz BP, 2003, P NATL ACAD SCI USA, V100, P14109, DOI 10.1073/pnas.2336103100; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	36	118	121	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7826	7831		10.1074/jbc.M313465200	http://dx.doi.org/10.1074/jbc.M313465200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14681216	hybrid			2022-12-25	WOS:000189103300058
J	Baroli, I; Gutman, BL; Ledford, HK; Shin, JW; Chin, BL; Havaux, M; Niyogi, KK				Baroli, I; Gutman, BL; Ledford, HK; Shin, JW; Chin, BL; Havaux, M; Niyogi, KK			Photo-oxidative stress in a xanthophyll-deficient mutant of Chlamydomonas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLET OXYGEN; PHOTOPROTECTION; GENE; ACCUMULATION; CAROTENOIDS; REINHARDTII; PLANTS	When there is an imbalance between the light energy absorbed by a photosynthetic organism and that which can be utilized in photosynthesis, photo-oxidative stress can damage pigments, proteins, lipids, and nucleic acids. In this work we compared the wild type and a xanthophyll-deficient mutant of Chlamydomonas reinhardtii in their response to high amounts of light. Wildtype Chlamydomonas cells were able to acclimate to high amounts of light following transfer from low light conditions. In contrast, the npq1 lor1 double mutant, which lacks protective xanthophylls (zeaxanthin and lutein) in the chloroplast, progressively lost viability and photosynthetic capacity along with destruction of thylakoid membrane protein-pigment complexes and accumulation of reactive oxygen species and membrane lipid peroxides. Loss of viability was partially rescued by lowered oxygen tension, suggesting that the high sensitivity of the mutant to light stress is caused by the production of reactive oxygen species in the chloroplast. Cell death was not prevented by the addition of an organic carbon source to the growth medium, demonstrating that the photo-oxidative damage can target other essential chloroplast processes besides photosynthesis. From the differential sensitivity of the mutant to exogenously added pro-oxidants, we infer that the reactive oxygen species produced during light stress in npq1 lor1 may be singlet oxygen and/or superoxide but not hydrogen peroxide. The bleaching phenotype of npq1 lor1 was not due to enhanced photodamage to photosystem II but rather to a less localized phenomenon of accumulation of photo-oxidation products in chloroplast membranes.	Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; Univ Mediterranee, CEA 1000,CEA 163, CNRS,Lab Ecophysiol Photosynth,UMR, Dept Ecophysiol Vegetale & Microbiol,Cdarache, F-13108 St Paul Les Durance, France	University of California System; University of California Berkeley; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Niyogi, KK (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA.	niyogi@nature.berkeley.edu		Baroli, Irene/0000-0001-9014-0821	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007127, R01GM058799] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32-GM07127, GM58799] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baroli I, 2003, PLANT CELL, V15, P992, DOI 10.1105/tpc.010405; Baroli I, 2000, PHILOS T R SOC B, V355, P1385, DOI 10.1098/rstb.2000.0700; CADENAS E, 1984, PHOTOCHEM PHOTOBIOL, V40, P823, DOI 10.1111/j.1751-1097.1984.tb04657.x; CHUNAEV AS, 1991, PHOTOSYNTHETICA, V25, P291; DEMMIGADAMS B, 1990, BIOCHIM BIOPHYS ACTA, V1020, P1, DOI 10.1016/0005-2728(90)90088-L; Ducruet JM, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P4353; Elrad D, 2002, PLANT CELL, V14, P1801, DOI 10.1105/tpc.002154; Frank H. A., 1993, CAROTENOIDS PHOTOSYN, P252, DOI [10.1007/978-94-011-2124-8_8, DOI 10.1007/978-94-011-2124-8_8]; Gruszecki WI, 1999, ADV PHOTOSYNTH, V8, P363; Harris E., 1989, CHLAMYDOMONAS SOURCE, P575; Havaux M, 1999, P NATL ACAD SCI USA, V96, P8762, DOI 10.1073/pnas.96.15.8762; Havaux M, 2003, TRENDS PLANT SCI, V8, P409, DOI 10.1016/S1360-1385(03)00185-7; Havaux M, 1998, TRENDS PLANT SCI, V3, P147, DOI 10.1016/S1360-1385(98)01200-X; Hideg E, 1998, BIOCHEMISTRY-US, V37, P11405, DOI 10.1021/bi972890+; Leisinger U, 2001, PLANT MOL BIOL, V46, P395, DOI 10.1023/A:1010601424452; MACPHERSON AN, 1993, BIOCHIM BIOPHYS ACTA, V1143, P301, DOI 10.1016/0005-2728(93)90201-P; Muller P, 2001, PLANT PHYSIOL, V125, P1558, DOI 10.1104/pp.125.4.1558; Muller-Moule P, 2003, PLANT PHYSIOL, V133, P748, DOI 10.1104/pp.103.026252; Niyogi KK, 1997, P NATL ACAD SCI USA, V94, P14162, DOI 10.1073/pnas.94.25.14162; Niyogi KK, 2001, PHOTOSYNTH RES, V67, P139, DOI 10.1023/A:1010661102365; Niyogi KK, 1997, PLANT CELL, V9, P1369, DOI 10.2307/3870388; OELMULLER R, 1989, PHOTOCHEM PHOTOBIOL, V49, P229, DOI 10.1111/j.1751-1097.1989.tb04101.x; Pogson BJ, 1998, P NATL ACAD SCI USA, V95, P13324, DOI 10.1073/pnas.95.22.13324; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Ryter SW, 1998, FREE RADICAL BIO MED, V24, P1520, DOI 10.1016/S0891-5849(97)00461-9; SCHMIDT GW, 1977, P NATL ACAD SCI USA, V74, P610, DOI 10.1073/pnas.74.2.610; TELFER A, 1994, J BIOL CHEM, V269, P13244; Vavilin DV, 1998, PHOTOCHEM PHOTOBIOL, V68, P191, DOI 10.1111/j.1751-1097.1998.tb02488.x; WEBB MR, 1995, PLANT PHYSIOL, V107, P885, DOI 10.1104/pp.107.3.885	29	96	96	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6337	6344		10.1074/jbc.M312919200	http://dx.doi.org/10.1074/jbc.M312919200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14665619	hybrid			2022-12-25	WOS:000188969200018
J	Pendino, F; Dudognon, C; Delhommeau, F; Sahraoui, T; Flexor, M; Bennaceur-Griscelli, A; Lanotte, M; Segal-Bendirdjian, E				Pendino, F; Dudognon, C; Delhommeau, F; Sahraoui, T; Flexor, M; Bennaceur-Griscelli, A; Lanotte, M; Segal-Bendirdjian, E			Retinoic acid receptor alpha and retinoid-X receptor-specific agonists synergistically target telomerase expression and induce tumor cell death	ONCOGENE			English	Article						telomerase; hTERT; retinoids; RAR; RXR; nuclear receptors	ACUTE PROMYELOCYTIC LEUKEMIA; CATALYTIC SUBUNIT GENE; SELECTIVE RETINOIDS; CANCER-THERAPY; RNA COMPONENT; IDENTIFICATION; MATURATION; RESISTANCE; LINE; NB4	Retinoids modulate growth and differentiation of cancer cells through activation of gene transcription via the nuclear retinoic-acid receptors (RAR) and retinoid-X receptors (RXR). Their use in differentiation therapy of acute promyelocytic leukemia (APL) represents a model concept for reprogramming cancer cells. However, they also regulate antiproliferative genes whose functions do not mechanistically concur to this program. Recently, we have shown that, independently of maturation, a long-term all-trans retinoic acid (ATRA) treatment of the maturation-resistant APL cell line (NB4-LR1) represses telomerase (hTERT), leading to telomere shortening and death. Using retinoid-receptor-specific agonists, we demonstrate herein that cross-talk between RARalpha and RXR dual-liganded to their respective agonists resulted in strong synergistic downregulation of hTERT and subsequent cell death. Importantly, unlike ATRA, this synergy was obtained at very low agonist concentrations and occurred in other ATRA maturation-resistant APL cells. These findings provide the first demonstration that dual-liganded RXR and RARalpha signaling should allow efficient targeting of telomerase in differentiation-resistant tumor cells. Such a combination therapy might hold promise in clinic to avoid side effects of ATRA whose administration can indiscriminately activate all RARs. Given the tissue-specific expression of RARs, a tissue-selective therapy targeting telomerase in tumor cells by synthetic agonists can be envisioned.	Hop St Louis, INSERM, U496, Inst Hematol, F-75475 Paris 10, France; Inst Gustave Roussy, INSERM, U362, F-94800 Villejuif, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy	Segal-Bendirdjian, E (corresponding author), Hop St Louis, INSERM, U496, Inst Hematol, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.	esegal@jupiter.chu-stlouis.fr	PENDINO, Frederic/G-6630-2017	bennaceur griscelli, annelise/0000-0002-3557-4499; Delhommeau, Francois/0000-0002-4915-0734; Segal-Bendirdjian, Evelyne/0000-0001-9813-4880				AMOS B, 1990, METHOD ENZYMOL, V190, P217; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; Chou WC, 2001, J CLIN INVEST, V108, P1541, DOI 10.1172/JCI14064; DE LUCA LM, 1991, FASEB J, V5, P2924; DELESCLUSE C, 1991, MOL PHARMACOL, V40, P556; Duprez E, 2000, LEUKEMIA, V14, P255, DOI 10.1038/sj.leu.2401683; DUPREZ E, 1992, LEUKEMIA, V6, P1281; Fenaux P, 2001, SEMIN HEMATOL, V38, P13, DOI 10.1053/shem.2001.20862; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Gallagher RE, 2002, LEUKEMIA, V16, P1940, DOI 10.1038/sj.leu.2402719; Germain P, 2002, NATURE, V415, P187, DOI 10.1038/415187a; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GUDAS LJ, 1994, J BIOL CHEM, V269, P15399; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Helder MN, 2002, CANCER INVEST, V20, P82, DOI 10.1081/CNV-120000370; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LANOTTE M, 1991, BLOOD, V77, P1080; LEHMANN JM, 1991, CANCER RES, V51, P4804; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mergny JL, 2002, NUCLEIC ACIDS RES, V30, P839, DOI 10.1093/nar/30.4.839; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Miller VA, 1997, J CLIN ONCOL, V15, P790, DOI 10.1200/JCO.1997.15.2.790; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Pendino F, 2002, LEUKEMIA, V16, P826, DOI 10.1038/sj.leu.2402470; Pendino F, 2001, P NATL ACAD SCI USA, V98, P6662, DOI 10.1073/pnas.111464998; ROY DY, 1995, MOL CELL BIOL, V15, P6481; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; Sun SY, 2000, CLIN CANCER RES, V6, P1563; URBACH J, 1994, BIOCHEM J, V299, P459, DOI 10.1042/bj2990459; Van heusden J, 1998, BRIT J CANCER, V77, P26, DOI 10.1038/bjc.1998.5; Weinberg RA, 1998, NATURE, V396, P23, DOI 10.1038/23825; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Xu D, 1996, LEUKEMIA, V10, P1354; Xu DW, 2000, BLOOD, V96, P4313, DOI 10.1182/blood.V96.13.4313.h8004313_4313_4318; Zusi FC, 2002, DRUG DISCOV TODAY, V7, P1165, DOI 10.1016/S1359-6446(02)02526-6	40	32	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2003	22	57					9142	9150		10.1038/sj.onc.1207093	http://dx.doi.org/10.1038/sj.onc.1207093			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	752FJ	14668795				2022-12-25	WOS:000187149100004
J	Watamoto, K; Towatari, M; Ozawa, Y; Miyata, Y; Okamoto, M; Abe, A; Naoe, T; Saito, H				Watamoto, K; Towatari, M; Ozawa, Y; Miyata, Y; Okamoto, M; Abe, A; Naoe, T; Saito, H			Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation	ONCOGENE			English	Article						GATA-1; HDAC; differentiation; MEL	TRANSCRIPTION FACTOR GATA-1; HISTONE ACETYLTRANSFERASE ACTIVITY; ERYTHROID-DIFFERENTIATION; ERYTHROLEUKEMIC CELLS; HEMATOPOIETIC-CELLS; NUCLEOSOMAL DNA; SOMATIC HYBRIDS; FINGER PROTEIN; STEM-CELLS; IN-VITRO	The transcription factor GATA-1 plays a significant role in erythroid differentiation and association with CBP stimulates its activity by acetylation. It is possible that histone deacetylases (HDACs) repress the activity of GATA-1. In the present study, we investigated whether class I and class II HDACs interact with GATA-1 to regulate its function and indeed, GATA-1 is directly associated with HDAC3, HDAC4 and HDAC5. The expression pro. ling and our previous observation that GATA-2 interacts with members of the HDAC family prompted us to investigate further the biological relevance of the interaction between GATA-1 and HDAC5. Coexpression of HDAC5 suppressed the transcriptional potential of GATA-1. Our results demonstrated that GATA-1 and HDAC5 colocalized to the nucleus of murine erythroleukemia (MEL) cells. Furthermore, a portion of HDAC5 moved to the cytoplasm concomitant with MEL cell erythroid differentiation, which was induced by treatment with N,N'-hexamethylenebisacetamide. These observations support the suggestion that control of the HDAC5 nucleocytoplasmic distribution might be associated with MEL cell differentiation, possibly through regulated GATA-1 transactivation.	Nagoya Univ, Dept Mol Med, Grad Sch Med, Nagoya, Aichi 4668550, Japan; Natl Nagoya Hosp, Nagoya, Aichi 4600001, Japan	Nagoya University	Towatari, M (corresponding author), Nagoya Univ, Dept Mol Med, Grad Sch Med, Nagoya, Aichi 4668550, Japan.		Naoe, Tomoki/I-1888-2012					Bertos NR, 2001, BIOCHEM CELL BIOL, V79, P243, DOI 10.1139/bcb-79-3-243; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CONSCIENCE JF, 1977, EXP CELL RES, V105, P401, DOI 10.1016/0014-4827(77)90137-9; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Crispino JD, 1999, MOL CELL, V3, P219, DOI 10.1016/S1097-2765(00)80312-3; CROTTA S, 1990, NUCLEIC ACIDS RES, V18, P6863, DOI 10.1093/nar/18.23.6863; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; GEORGE KM, 1994, DEVELOPMENT, V120, P2673; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; HEBERLEIN C, 1992, MOL CELL BIOL, V12, P1815, DOI 10.1128/MCB.12.4.1815; HONG L, 1993, J BIOL CHEM, V268, P305; Hu E, 2000, J BIOL CHEM, V275, P15254, DOI 10.1074/jbc.M908988199; Ikonomi P, 2000, EXP HEMATOL, V28, P1423, DOI 10.1016/S0301-472X(00)00553-1; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LEONARD MW, 1993, DEVELOPMENT, V119, P519; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ORKIN SH, 1992, BLOOD, V80, P575; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; Ozawa Y, 2001, BLOOD, V98, P2116, DOI 10.1182/blood.V98.7.2116; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Shore D, 2000, P NATL ACAD SCI USA, V97, P14030, DOI 10.1073/pnas.011506198; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Takahashi T, 2000, ONCOGENE, V19, P134, DOI 10.1038/sj.onc.1203228; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; TOWATARI M, 1995, J BIOL CHEM, V270, P4101, DOI 10.1074/jbc.270.8.4101; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Tsuzuki S, 2000, MOL CELL BIOL, V20, P6276, DOI 10.1128/MCB.20.17.6276-6286.2000; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693; Wang AH, 1999, MOL CELL BIOL, V19, P7816; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YOMOGIDA K, 1994, DEVELOPMENT, V120, P1759; Zhang P, 2000, BLOOD, V96, P2641; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	59	68	68	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2003	22	57					9176	9184		10.1038/sj.onc.1206902	http://dx.doi.org/10.1038/sj.onc.1206902			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	752FJ	14668799				2022-12-25	WOS:000187149100008
J	Moon, EJ; Jeong, CH; Jeong, JW; Kim, KR; Yu, DY; Murakami, S; Kim, CW; Kim, KW				Moon, EJ; Jeong, CH; Jeong, JW; Kim, KR; Yu, DY; Murakami, S; Kim, CW; Kim, KW			Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor-1 alpha	FASEB JOURNAL			English	Article						hepatocellular carcinoma; pVHL; HBx-transgenic mice; ubiquitination; hypoxia	UBIQUITIN-PROTEASOME PATHWAY; FACTOR 1-ALPHA; HEPATOCELLULAR-CARCINOMA; TRANSGENIC MICE; HBX PROTEIN; HIF-ALPHA; FACTOR-I; TRANSCRIPTION; GENE; TRANSACTIVATION	Hepatitis B virus X protein (HBx) is closely involved in the development of hepatocellular carcinoma, a highly vascularized solid tumor. Here we show that HBx increases the transcriptional activity and protein level of hypoxia-inducible factor-1alpha (HIF-1alpha) under both normoxic and hypoxic conditions, and it also stimulates angiogenesis. HBx directly interacted with the bHLH/PAS domain of HIF-1alpha but not with the von Hippel-Lindau protein (pVHL). HBx decreased the binding of pVHL to HIF-1alpha and prevented ubiquitin-dependent degradation of HIF-1alpha. In HBx-transgenic mice, HIF-1alpha and vascular endothelial growth factor were strongly detected in the dysplastic lesion, where HBx was also more highly expressed than in the non-neoplastic region of the liver. An immunohistochemical study showed that microvessels are more abundant in the dysplastic lesion than in the non-neoplastic region. Our data suggest that HBx stabilizes HIF-1alpha and leads to angiogenesis during hepatocarcinogenesis.	Seoul Natl Univ, Coll Pharm, Res Inst Pharmaceut Sci, Seoul 151742, South Korea; Pusan Natl Univ, Dept Mol Biol, Pusan 609735, South Korea; Korea Res Inst Biosci & Biotechnol, Taejon 305333, South Korea; Kanazawa Univ, Canc Res Inst, Dept Mol Biol, Div Mol Oncol, Kanazawa, Ishikawa 920, Japan; Seoul Natl Univ, Coll Med, Dept Pathol, Ctr Canc Res, Seoul 110799, South Korea	Seoul National University (SNU); Pusan National University; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Kanazawa University; Seoul National University (SNU)	Kim, KW (corresponding author), Seoul Natl Univ, Coll Pharm, Res Inst Pharmaceut Sci, Seoul 151742, South Korea.	qwonkim@plaza.snu.ac.kr	Kim, Kyu Won/AAJ-7213-2020; Kim, Chul-Woo/F-7008-2011					BREEDIS C, 1954, AM J PATHOL, V30, P969; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Choi BH, 1998, DNA CELL BIOL, V17, P951, DOI 10.1089/dna.1998.17.951; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Haviv I, 1998, MOL CELL BIOL, V18, P1562, DOI 10.1128/MCB.18.3.1562; Haviv I, 1996, EMBO J, V15, P3413, DOI 10.1002/j.1460-2075.1996.tb00707.x; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; LAU JYN, 1993, LANCET, V342, P1335; Lee SW, 2000, BIOCHEM BIOPH RES CO, V268, P456, DOI 10.1006/bbrc.2000.2093; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; Lin Y, 1997, J BIOL CHEM, V272, P7132, DOI 10.1074/jbc.272.11.7132; Liver Cancer Study Group of Japan, 1992, GEN RUL CLIN PATH ST; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; MURAKAMI S, 1994, J BIOL CHEM, V269, P15118; Murakami S, 2001, J GASTROENTEROL, V36, P651, DOI 10.1007/s005350170027; Nomura T, 1999, BBA-MOL BASIS DIS, V1453, P330, DOI 10.1016/S0925-4439(99)00004-6; Ohno H, 1997, J MED VIROL, V52, P413, DOI 10.1002/(SICI)1096-9071(199708)52:4<413::AID-JMV12>3.0.CO;2-H; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; UEDA K, 1992, HUM PATHOL, V23, P619, DOI 10.1016/0046-8177(92)90316-U; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANLESS IR, 1995, HEPATOLOGY, V22, P983, DOI 10.1002/hep.1840220341; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; Zhong H, 1999, CANCER RES, V59, P5830	36	139	142	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					382	+		10.1096/fj.03-0153fje	http://dx.doi.org/10.1096/fj.03-0153fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14688211				2022-12-25	WOS:000188067500017
J	Mozzicato, S; Joshi, BV; Jacobson, KA; Liang, BT				Mozzicato, S; Joshi, BV; Jacobson, KA; Liang, BT			Role of direct RhoA-phospholipase D interaction in mediating adenosine-induced protection from cardiac ischemia	FASEB JOURNAL			English	Article						receptor; monomeric G protein; heart cell; myocyte; A(3) agonist	A(3) RECEPTORS; SIMULATED ISCHEMIA; A(1); ACTIVATION; MYOCYTES; GENE; CARDIOMYOCYTES; INJURY; KINASE; HEART	Activation of adenosine A(1) or A(3) receptors protects heart cells from ischemia-induced injury. The A(3) receptor signals via RhoA and phospholipase D (PLD) to induce cardioprotection. The objective of the study was to investigate how RhoA activates PLD to achieve the anti-ischemic effect of adenosine A(3) receptors. In an established cardiac myocyte model of preconditioning using the cultured chick embryo heart cells, overexpression of the RhoA-noninteracting PLD1 mutant I870R selectively blocked the A(3) agonist (Cl-IBMECA, 10 nM)-induced cardioprotection. 1870R caused a significantly higher percentage of cardiac cells killed in A(3) agonist-treated than in A(1) agonist (CCPA, 10 nM)-treated myocytes (ANOVA and posttest comparison, P<0.01). Consistent with its inhibitory effect on the PLD activity, I870R attenuated the Cl-IBMECA-mediated PLD activation. Cl-IBMECA caused a 41 +/- 15% increase in PLD activity in mock-transfected myocytes (P<0.01, paired t test) while having only a slight stimulatory effect on the PLD activity in I870R-transfected cells. To further test the anti-ischemic role of a direct RhoA-PLD1 interaction, atrial cardiac myocytes were rendered null for native adenosine receptors by treatment with irreversible A(1) antagonist m-DITC-XAC and were selectively transfected with the human adenosine A(1) or A(3) receptor cDNA individually or they were cotransfected with cDNAs encoding either receptor plus I870R. 1870R preferentially inhibited the human A(3) receptor-mediated protection from ischemia. The RhoA-noninteracting PLD1 mutant caused a significantly higher percentage of cardiac cells killed in myocytes cotransfected with the human A(3) receptor than in those cells expressing the human A(1) receptor (ANOVA and posttest comparison, P<0.01). The present data provided the first demonstration of a novel physiological role for the direct RhoA-PLD1 interaction, that of potent protection from cardiac ischemia. The study further supported the concept that a divergent signaling mechanism mediates the anti-ischemic effect of adenosine A(1) and A(3) receptors.	Univ Connecticut, Ctr Hlth, Dept Cardiol, Farmington, CT 06030 USA; NIDDK, Mol Recognit Sect, NIH, Bethesda, MD 20892 USA	University of Connecticut; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Liang, BT (corresponding author), Univ Connecticut, Ctr Hlth, Dept Cardiol, 263 Farmington Ave, Farmington, CT 06030 USA.	bliang@uchc.edu	Jacobson, Kenneth Alan/A-1530-2009	Jacobson, Kenneth Alan/0000-0001-8104-1493	Intramural NIH HHS [Z01 DK031117-20] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031117] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbracchio MP, 1997, BIOCHEM BIOPH RES CO, V241, P297, DOI 10.1006/bbrc.1997.7705; ARMSTRONG S, 1994, CARDIOVASC RES, V28, P1049, DOI 10.1093/cvr/28.7.1049; Auchampach JA, 1997, CIRC RES, V80, P800; Bartlett RJ, 2000, NAT BIOTECHNOL, V18, P615, DOI 10.1038/76448; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Carr CS, 1997, CARDIOVASC RES, V36, P52, DOI 10.1016/S0008-6363(97)00160-0; Du GW, 2000, MOL BIOL CELL, V11, P4359, DOI 10.1091/mbc.11.12.4359; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; GC, 1990, CIRCULATION, V82, P609; Goetzl EJ, 2000, J BIOL CHEM, V275, P14573, DOI 10.1074/jbc.275.19.14573; GROVER GJ, 1992, CIRCULATION, V86, P1310, DOI 10.1161/01.CIR.86.4.1310; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Jacobson KA, 2000, J BIOL CHEM, V275, P30272, DOI 10.1074/jbc.M001520200; Lee JE, 2001, FASEB J, V15, P1886, DOI 10.1096/fj.01-0212com; Liang BT, 1996, NUCLEIC ACIDS RES, V24, P1382, DOI 10.1093/nar/24.7.1382; Liang BT, 1998, P NATL ACAD SCI USA, V95, P6995, DOI 10.1073/pnas.95.12.6995; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Parsons M, 2000, FASEB J, V14, P1423, DOI 10.1096/fj.14.10.1423; Safran N, 2001, MOL CELL BIOCHEM, V217, P143, DOI 10.1023/A:1007209321969; Shaikh N, 2001, INORG REACT MECH, V3, P117; Stambaugh K, 1997, AM J PHYSIOL-HEART C, V273, pH501; STILES GL, 1988, MOL PHARMACOL, V34, P724; Strickler J, 1996, J CLIN INVEST, V98, P1773, DOI 10.1172/JCI118976; Taylor JM, 2000, J BIOL CHEM, V275, P19250, DOI 10.1074/jbc.M909099199; Tracey WR, 1997, CARDIOVASC RES, V33, P410, DOI 10.1016/S0008-6363(96)00240-4; Wang JX, 1997, EUR J PHARMACOL, V320, P241, DOI 10.1016/S0014-2999(96)00901-6; XU H, 1992, NUCLEIC ACIDS RES, V20, P6425, DOI 10.1093/nar/20.23.6425; Yamazaki M, 1999, J BIOL CHEM, V274, P6035, DOI 10.1074/jbc.274.10.6035	29	41	42	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					406	+		10.1096/fj.03-0592fje	http://dx.doi.org/10.1096/fj.03-0592fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14688204				2022-12-25	WOS:000188067500010
J	Guizouarn, H; Gabillat, N; Borgese, F				Guizouarn, H; Gabillat, N; Borgese, F			Evidence for up-regulation of the endogenous Na-K-2Cl co-transporter by molecular interactions with the anion exchanger tAE1 expressed in Xenopus oocyte	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CELL-VOLUME REGULATION; RED-CELL; TROUT ERYTHROCYTES; CHLORIDE CHANNELS; NA+/H+ EXCHANGE; TRANSPORT; CFTR; BAND-3; INHIBITION	Expression of trout anion exchanger 1 (tAE1) in Xenopus oocyte led to the stimulation of a Na+- and Cl--dependent Rb influx. Functional features and pharmacological data strongly suggest that this Rb influx is mediated by the endogenous Na-K-2Cl (NKCC) co-transporter. The functional relationship between expression of tAE1 and activation of the NKCC co-transporter was investigated. Indeed, it was shown previously that tAE1 expressed in Xenopus oocyte induces a strong anion conductance which is correlated with an increased taurine permeability. Measurements of intracellular ion contents ruled out the involvement of any modification of known electrochemical parameters in NKCC co-transporter activation by tAE1. Furthermore, using chimera of tAE1 made with AE1 from other species unable to exhibit anion conductance led to the conclusion that there was no correlation between tAE1 anion conductance and NKCC co-transporter stimulation. Therefore, a possible molecular interaction between tAE1 and the NKCC co-transporter was investigated. Our results clearly show that NKCC activation is dependent upon the C-terminal part of tAE1. Chimeric constructions where tAE1 C-terminal part was substituted by the corresponding part of mouse AE1 abolished co-transporter activation. Moreover, steric encumbrance on the C-terminal end of tAE1 with a specific antibody or with a protein fusion also prevented the co-transporter activation. These data suggest a new role for some anion exchangers in controlling other transporter activity by molecular interactions.	Univ Nice Sophia Antipolis, CNRS, UMR 6078, Lab Physiol Membranes Cellulaires, F-06230 Villefranche Sur Mer, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Guizouarn, H (corresponding author), Univ Nice Sophia Antipolis, CNRS, UMR 6078, Lab Physiol Membranes Cellulaires, Chemin Lazaret, F-06230 Villefranche Sur Mer, France.	guizouarn@obs-vlfr.fr		BORGESE, Franck/0000-0001-7718-2111; Guizouarn, Helene/0000-0002-8757-6672				Alper SL, 2002, J NEPHROL, V15, pS41; BORGESE F, 1991, BIOCHIM BIOPHYS ACTA, V1066, P252, DOI 10.1016/0005-2736(91)90194-D; Briel M, 1998, J PHYSIOL-LONDON, V508, P825, DOI 10.1111/j.1469-7793.1998.825bp.x; Casey JR, 1998, BIOCHEM CELL BIOL, V76, P709, DOI 10.1139/bcb-76-5-709; CHETRITE G, 1985, J MOL BIOL, V185, P639, DOI 10.1016/0022-2836(85)90076-2; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FIEVET B, 1995, EMBO J, V14, P5158, DOI 10.1002/j.1460-2075.1995.tb00200.x; Fievet B, 1998, P NATL ACAD SCI USA, V95, P10996, DOI 10.1073/pnas.95.18.10996; Fujinaga J, 1999, J BIOL CHEM, V274, P6626, DOI 10.1074/jbc.274.10.6626; GARCIAROMEU F, 1991, J PHYSIOL-LONDON, V440, P547, DOI 10.1113/jphysiol.1991.sp018724; Gillen CM, 1999, AM J PHYSIOL-CELL PH, V276, pC328, DOI 10.1152/ajpcell.1999.276.2.C328; Guizouarn H, 1999, AM J PHYSIOL-CELL PH, V276, pC210, DOI 10.1152/ajpcell.1999.276.1.C210; Guizouarn H, 2003, J MEMBRANE BIOL, V193, P109, DOI 10.1007/s00232-002-2012-6; Guizouarn H, 2001, J PHYSIOL-LONDON, V535, P497, DOI 10.1111/j.1469-7793.2001.t01-1-00497.x; Guizouarn H, 2000, J PHYSIOL-LONDON, V523, P147, DOI 10.1111/j.1469-7793.2000.t01-1-00147.x; Jay DG, 1996, CELL, V86, P853, DOI 10.1016/S0092-8674(00)80160-9; Kunzelmann K, 1997, FEBS LETT, V400, P341, DOI 10.1016/S0014-5793(96)01414-7; Lamprecht G, 2002, BIOCHEMISTRY-US, V41, P12336, DOI 10.1021/bi0259103; Lee M G, 2001, JOP, V2, P203; Liedtke CM, 2002, AM J PHYSIOL-LUNG C, V282, pL1151, DOI 10.1152/ajplung.00143.2001; LOW PS, 1993, J BIOL CHEM, V268, P14627; McNicholas CM, 1996, P NATL ACAD SCI USA, V93, P8083, DOI 10.1073/pnas.93.15.8083; MOTAIS R, 1987, J GEN PHYSIOL, V90, P197, DOI 10.1085/jgp.90.2.197; Palfrey HC, 1994, CELLULAR MOL PHYSL C, P201; RABE A, 1995, PFLUG ARCH EUR J PHY, V429, P659, DOI 10.1007/BF00373986; REIK LM, 1987, J IMMUNOL METHODS, V100, P123, DOI 10.1016/0022-1759(87)90180-3; ROBERTSON MA, 1994, AM J PHYSIOL, V267, pC146, DOI 10.1152/ajpcell.1994.267.1.C146; Russell JM, 2000, PHYSIOL REV, V80, P211, DOI 10.1152/physrev.2000.80.1.211; Schreiber R, 1997, PFLUG ARCH EUR J PHY, V434, P841, DOI 10.1007/s004240050473; Schreiber R, 1999, P NATL ACAD SCI USA, V96, P5310, DOI 10.1073/pnas.96.9.5310; Schreiber R, 2000, FEBS LETT, V475, P291, DOI 10.1016/S0014-5793(00)01689-6; Schultz BD, 1996, AM J PHYSIOL-LUNG C, V271, pL192, DOI 10.1152/ajplung.1996.271.2.L192; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SHETLAR RE, 1990, BIOCHIM BIOPHYS ACTA, V1023, P184, DOI 10.1016/0005-2736(90)90412-H; SHIGERU BHK, 2002, EMBO J, V21, P5662; Shumaker H, 1999, AM J PHYSIOL-CELL PH, V277, pC1100, DOI 10.1152/ajpcell.1999.277.6.C1100; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; SUVITAYAVAT W, 1994, AM J PHYSIOL, V266, pC284, DOI 10.1152/ajpcell.1994.266.1.C284; Vince JW, 1998, J BIOL CHEM, V273, P28430, DOI 10.1074/jbc.273.43.28430; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020	40	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11513	11520		10.1074/jbc.M311920200	http://dx.doi.org/10.1074/jbc.M311920200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699110	hybrid			2022-12-25	WOS:000220157600083
J	Cluzel, C; Lethias, C; Garrone, R; Exposito, JY				Cluzel, C; Lethias, C; Garrone, R; Exposito, JY			Distinct maturations of N-propeptide domains in fibrillar procollagen molecules involved in the formation of heterotypic fibrils in adult sea urchin collagenous tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL PROPEPTIDE; STRONGYLOCENTROTUS-PURPURATUS; ASTHENOSOMA-IJIMAI; I PROCOLLAGEN; 2-ALPHA CHAIN; XIV COLLAGEN; V COLLAGEN; PROTEINASE; EXPRESSION; IDENTIFICATION	We have characterized the primary structure of a new sea urchin fibrillar collagen, the 5alpha chain, including nine repeats of the sea urchin fibrillar module in its N-propeptide. By Western blot and immunofluorescence analyses, we have shown that 5alpha is co-localized in adult collagenous ligaments with the 2alpha fibrillar collagen chain and fibrosurfin, two other extracellular matrix proteins possessing sea urchin fibrillar modules. At the ultrastructural level, the 5alpha N-propeptide is detected at the surface of fibrils, suggesting the retention of this domain in mature collagen molecules. Biochemical characterization of pepsinized collagen molecules extracted from the test tissue ( the endoskeleton) together with a matrix-assisted laser desorption ionization time-of-flight analysis allowed us to determine that 5alpha is a quantitatively minor fibrillar collagen chain in comparison with the 1alpha and 2alpha chains. Moreover, 5alpha forms heterotrimeric molecules with two 1alpha chains. Hence, as in vertebrates, sea urchin collagen fibrils are made up of quantitatively major and minor fibrillar molecules undergoing distinct maturation of their N-propeptide regions and participating in the formation of heterotypic fibrils.	Univ Lyon 1, Inst Federatif Rech Biosci Lyon Gerland 128, CNRS,Unite Mixte Rech 5086, Inst Biol & Chim Prot, F-69367 Lyon 07, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Exposito, JY (corresponding author), Univ Lyon 1, Inst Federatif Rech Biosci Lyon Gerland 128, CNRS,Unite Mixte Rech 5086, Inst Biol & Chim Prot, 7 Passage Vercors, F-69367 Lyon 07, France.	jy.exposito@ibcp.fr		Cluzel, Caroline/0000-0001-8946-3439; Exposito, Jean-Yves/0000-0002-4926-4942				BERGER J, 1985, BIOCHEMISTRY-US, V24, P600, DOI 10.1021/bi00324a009; Boot-Handford RP, 2003, BIOESSAYS, V25, P142, DOI 10.1002/bies.10230; Boot-Handford RP, 2003, J BIOL CHEM, V278, P31067, DOI 10.1074/jbc.M212889200; BURKE RD, 1989, COMP BIOCHEM PHYS B, V94, P41, DOI 10.1016/0305-0491(89)90007-2; Cluzel C, 2000, MATRIX BIOL, V19, P545, DOI 10.1016/S0945-053X(00)00109-8; Cluzel C, 2001, J BIOL CHEM, V276, P18108, DOI 10.1074/jbc.M009597200; COLIGE A, 1995, J BIOL CHEM, V270, P16724, DOI 10.1074/jbc.270.28.16724; CORTAY JC, 1994, J BIOL CHEM, V269, P14885; DALESSIO M, 1989, P NATL ACAD SCI USA, V86, P9303, DOI 10.1073/pnas.86.23.9303; DALESSIO M, 1990, J BIOL CHEM, V265, P7050; Ellers O, 1996, P ROY SOC B-BIOL SCI, V263, P39, DOI 10.1098/rspb.1996.0007; EXPOSITO JY, 1992, J BIOL CHEM, V267, P17404; EXPOSITO JY, 1992, J BIOL CHEM, V267, P15559; EXPOSITO JY, 1995, EUR J BIOCHEM, V234, P59, DOI 10.1111/j.1432-1033.1995.059_c.x; Exposito JY, 2002, ANAT RECORD, V268, P302, DOI 10.1002/ar.10162; HOJIMA Y, 1994, J BIOL CHEM, V269, P11381; Johnson AS, 2002, P ROY SOC B-BIOL SCI, V269, P215, DOI 10.1098/rspb.2001.1881; KLEMAN JP, 1992, EUR J BIOCHEM, V210, P329, DOI 10.1111/j.1432-1033.1992.tb17425.x; Koch M, 2003, J BIOL CHEM, V278, P43236, DOI 10.1074/jbc.M302112200; LEAHY PS, 1986, METHOD CELL BIOL, V27, P1, DOI 10.1016/S0091-679X(08)60339-8; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; Lethias C, 1997, EUR J BIOCHEM, V245, P434, DOI 10.1111/j.1432-1033.1997.t01-2-00434.x; LETHIAS C, 1993, J INVEST DERMATOL, V101, P92, DOI 10.1111/1523-1747.ep12360433; Miller EJ, 1984, EXTRACELLULAR MATRIX, P41; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; NIYIBIZI C, 1989, FEBS LETT, V242, P314, DOI 10.1016/0014-5793(89)80492-2; Omura Y, 1996, COMP BIOCHEM PHYS B, V115, P63, DOI 10.1016/0305-0491(96)00085-5; Pace JM, 2003, MATRIX BIOL, V22, P3, DOI 10.1016/S0945-053X(03)00007-6; Prockop DJ, 1998, MATRIX BIOL, V16, P399, DOI 10.1016/S0945-053X(98)90013-0; PUCCIMINAFRA I, 1978, J SUBMICR CYTOL PATH, V10, P53; SHIMIZU K, 1990, BIOCHIM BIOPHYS ACTA, V1038, P39, DOI 10.1016/0167-4838(90)90007-3; TOMITA M, 1994, BBA-GENE STRUCT EXPR, V1217, P131, DOI 10.1016/0167-4781(94)90026-4; TROTTER JA, 1994, COMP BIOCHEM PHYS B, V107, P125, DOI 10.1016/0305-0491(94)90234-8; TUDERMAN L, 1978, BIOCHEMISTRY-US, V17, P2948, DOI 10.1021/bi00608a002; Wang WM, 2003, J BIOL CHEM, V278, P19549, DOI 10.1074/jbc.M300767200; Wilkie IC, 2002, J EXP BIOL, V205, P159; Wilkins MR, 1997, ELECTROPHORESIS, V18, P403, DOI 10.1002/elps.1150180314	37	14	14	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9811	9817		10.1074/jbc.M311803200	http://dx.doi.org/10.1074/jbc.M311803200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14665629	hybrid			2022-12-25	WOS:000220050400020
J	Kim, JY; Han, WS; Namkung, W; Lee, JH; Kim, KH; Shin, HW; Kim, E; Lee, MG				Kim, JY; Han, WS; Namkung, W; Lee, JH; Kim, KH; Shin, HW; Kim, E; Lee, MG			Inhibitory regulation of cystic fibrosis transmembrane conductance regulator anion-transporting activities by Shank2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY PROTEINS; DEPENDENT HCO3-TRANSPORT; CFTR CHLORIDE CHANNELS; MOLECULAR-MECHANISM; CL-/HCO3-EXCHANGE; PANCREATIC DUCT; FAMILY; CELLS; PDZ; ASSOCIATION	Accumulating evidence suggests that protein-protein interactions play an important role in transepithelial ion transport. In the present study, we report on the biochemical and functional association between cystic fibrosis transmembrane conductance regulator (CFTR) and a PDZ domain-containing protein Shank2. Exploratory reverse transcription-PCR screening revealed mRNAs for several members of PDZ domain-containing proteins in epithelial cells. Shank2, one of these scaffolding proteins, showed a strong interaction with CFTR by yeast two-hybrid assays. Shank2-CFTR interaction was verified by co-immunoprecipitation experiments in mammalian cells. Notably, this interaction was abolished by mutations in the PDZ domain of Shank2. Protein phosphorylation, HCO3- transport and Cl- current by CFTR were measured in NIH 3T3 cells with heterologous expression of Shank2. Of interest, expression of Shank2 suppressed cAMP-induced phosphorylation and activation of CFTR. Importantly, loss of Shank2 by stable transfection of antisense-hShank2 plasmid strongly increased CFTR currents in colonic T84 cells, in which CFTR and Shank2 were natively expressed. Our results indicate that Shank2 negatively regulates CFTR and that this may play a significant role in maintaining epithelial homeostasis under normal and diseased conditions such as those presented by secretory diarrhea.	Yonsei Univ, Coll Med, Dept Pharmacol, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul 120752, South Korea; Korea Adv Inst Sci & Technol, Creat Res Ctr Synaptogenesis, Taejon 305701, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST)	Lee, MG (corresponding author), Yonsei Univ, Coll Med, Dept Pharmacol, 134 Sinchon Dong, Seoul 120752, South Korea.	mlee@yumc.yonsei.ac.kr	Kim, Eunjoon/C-1566-2011; Lee, Min Goo/D-5635-2012; Lee, Min Goo/AAS-4636-2020; Kim, Joo Young/X-7562-2019	Lee, Min Goo/0000-0001-7436-012X; Lee, Min Goo/0000-0001-7436-012X; Kim, Joo Young/0000-0003-2623-1491				Ahn W, 2001, J BIOL CHEM, V276, P17236, DOI 10.1074/jbc.M011763200; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; Boeckers TM, 2002, J NEUROCHEM, V81, P903, DOI 10.1046/j.1471-4159.2002.00931.x; Choi JY, 2001, NATURE, V410, P94, DOI 10.1038/35065099; Cormet-Boyaka E, 2002, P NATL ACAD SCI USA, V99, P12477, DOI 10.1073/pnas.192203899; Dahan D, 2001, PFLUG ARCH EUR J PHY, V443, pS92, DOI 10.1007/s004240100652; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; GABRIEL SE, 1994, SCIENCE, V266, P107, DOI 10.1126/science.7524148; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Ko SBH, 2002, EMBO J, V21, P5662, DOI 10.1093/emboj/cdf580; Kunzelmann K, 2002, PHYSIOL REV, V82, P245, DOI 10.1152/physrev.00026.2001; Kunzelmann K, 2001, NEWS PHYSIOL SCI, V16, P167; Lee M G, 2001, JOP, V2, P203; Lee MG, 1999, J BIOL CHEM, V274, P3414, DOI 10.1074/jbc.274.6.3414; Lee MG, 1999, J BIOL CHEM, V274, P14670, DOI 10.1074/jbc.274.21.14670; Lim S, 1999, J BIOL CHEM, V274, P29510, DOI 10.1074/jbc.274.41.29510; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; Mok H, 2002, J NEUROSCI, V22, P5253; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; Namkung W, 2003, J BIOL CHEM, V278, P200, DOI 10.1074/jbc.M207199200; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; Park E, 2003, J BIOL CHEM, V278, P19220, DOI 10.1074/jbc.M301052200; Park M, 2002, J BIOL CHEM, V277, P50503, DOI 10.1074/jbc.M201862200; Quinton PM, 2001, NAT MED, V7, P292, DOI 10.1038/85429; QUINTON PM, 1999, PHYSIOL REV, V79, P3; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; Sheng M, 2000, J CELL SCI, V113, P1851; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9	32	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10389	10396		10.1074/jbc.M312871200	http://dx.doi.org/10.1074/jbc.M312871200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14679199	hybrid, Green Published			2022-12-25	WOS:000220050400089
J	Sharma, S; Sommers, JA; Wu, L; Bohr, VA; Hickson, ID; Brosh, RM				Sharma, S; Sommers, JA; Wu, L; Bohr, VA; Hickson, ID; Brosh, RM			Stimulation of flap endonuclease-1 by the Bloom's syndrome protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME GENE-PRODUCT; OKAZAKI FRAGMENT MATURATION; WERNERS-SYNDROME GENES; DNA-REPLICATION; BIOCHEMICAL-CHARACTERIZATION; MUTATION AVOIDANCE; MISMATCH REPAIR; RECQ HELICASES; BLM HELICASE; IN-VIVO	Bloom's syndrome (BS) is a rare autosomal recessive genetic disorder associated with genomic instability and an elevated risk of cancer. Cellular features of BS include an accumulation of abnormal replication intermediates and increased sister chromatid exchange. Although it has been suggested that the underlying defect responsible for hyper-recombination in BS cells is a temporal delay in the maturation of DNA replication intermediates, the precise role of the BS gene product, BLM, in DNA metabolism remains elusive. We report here a novel interaction of the BLM protein with the human 5'-flap endonuclease/5'-3' exonuclease (FEN-1), a genome stability factor involved in Okazaki fragment processing and DNA repair. BLM protein stimulates both the endonucleolytic and exonucleolytic cleavage activity of FEN-1 and this functional interaction is independent of BLM catalytic activity. BLM and FEN-1 are associated with each other in human nuclei as shown by their reciprocal co-immunoprecipitation from HeLa nuclear extracts. The BLM-FEN-1 physical interaction is mediated through a region of the BLM C-terminal domain that shares homology with the FEN-1 interaction domain of the Werner syndrome protein, a RecQ helicase family member homologous to BLM. This study provides the first evidence for a direct interaction of BLM with a human nucleolytic enzyme. We suggest that functional interactions between RecQ helicases and Rad2 family nucleases serve to process DNA substrates that are intermediates in DNA replication and repair.	NIA, Lab Mol Gerontol, NIH, DHHS, Baltimore, MD 21224 USA; Univ Oxford, Weatherall Inst Mol Med, Canc Res UK Labs, John Radcliffe Hosp, Oxford OX3 9DS, England; Univ Hyderabad, Sch Life Sci, Dept Biochem, Hyderabad 500046, Andhra Pradesh, India	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Cancer Research UK; University of Oxford; University of Hyderabad	Brosh, RM (corresponding author), NIA, Lab Mol Gerontol, NIH, DHHS, Baltimore, MD 21224 USA.	BroshR@grc.nia.gov	Sharma, Sudha/AAV-6152-2021; Hickson, Ian/AAJ-7548-2020; Bohr, Vilhelm/AAP-5931-2020	Sharma, Sudha/0000-0003-2765-2482; Hickson, Ian/0000-0002-0583-566X	NATIONAL INSTITUTE ON AGING [Z01AG000726, ZIAAG000741, ZIAAG000726, Z01AG000741] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ayyagari R, 2003, J BIOL CHEM, V278, P1618, DOI 10.1074/jbc.M209801200; Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 2002, J BIOL CHEM, V277, P23236, DOI 10.1074/jbc.M111446200; Brosh RM, 2002, BIOCHEMISTRY-US, V41, P12204, DOI 10.1021/bi026031j; Brosh RM, 2001, EMBO J, V20, P5791; Brosh RM, 2001, J BIOL CHEM, V276, P3024, DOI 10.1074/jbc.M006784200; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; CHAGANTI RS, 1974, P NATL ACAD SCI USA, V71, P4508, DOI 10.1073/pnas.71.11.4508; CHENG RZ, 1990, MUTAT RES, V237, P259, DOI 10.1016/0921-8734(90)90008-F; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GERMAN J, 2000, MOL METABOLIC BASIS, P733; GIANNELLI F, 1977, NATURE, V265, P466, DOI 10.1038/265466a0; GRODEN J, 1992, HUM GENET, V90, P360; Henneke G, 2003, TRENDS BIOCHEM SCI, V28, P384, DOI 10.1016/S0968-0004(03)00138-5; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Imamura O, 2003, P NATL ACAD SCI USA, V100, P8193, DOI 10.1073/pnas.1431624100; Janscak P, 2003, J MOL BIOL, V330, P29, DOI 10.1016/S0022-2836(03)00534-5; Johnson FB, 2000, CANCER RES, V60, P1162; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 1999, CURR BIOL, V9, P597, DOI 10.1016/S0960-9822(99)80264-4; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Kucherlapati M, 2002, P NATL ACAD SCI USA, V99, P9924, DOI 10.1073/pnas.152321699; Langland G, 2001, J BIOL CHEM, V276, P30031, DOI 10.1074/jbc.M009664200; Lee BI, 1999, J BIOL CHEM, V274, P37763, DOI 10.1074/jbc.274.53.37763; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Lindor NM, 2000, AM J MED GENET, V90, P223, DOI 10.1002/(SICI)1096-8628(20000131)90:3<223::AID-AJMG7>3.0.CO;2-Z; LONN U, 1990, CANCER RES, V50, P3141; Meetei AR, 2003, MOL CELL BIOL, V23, P3417, DOI 10.1128/MCB.23.10.3417-3426.2003; Myung K, 2001, NATURE, V411, P1073, DOI 10.1038/35082608; Nakayama H, 2002, ONCOGENE, V21, P9008, DOI 10.1038/sj.onc.1205959; NAKAYAMA K, 1985, MOL GEN GENET, V200, P266, DOI 10.1007/BF00425434; Neff NF, 1999, MOL BIOL CELL, V10, P665, DOI 10.1091/mbc.10.3.665; Negritto MC, 2001, MOL CELL BIOL, V21, P2349, DOI 10.1128/MCB.21.7.2349-2358.2001; Onoda F, 2000, MUTAT RES-DNA REPAIR, V459, P203, DOI 10.1016/S0921-8777(99)00071-3; Onoda F, 2001, MOL GEN GENET, V264, P702, DOI 10.1007/s004380000358; Opresko PL, 2002, J BIOL CHEM, V277, P41110, DOI 10.1074/jbc.M205396200; Pedrazzi G, 2001, NUCLEIC ACIDS RES, V29, P4378, DOI 10.1093/nar/29.21.4378; Qiu JZ, 1999, J BIOL CHEM, V274, P17893, DOI 10.1074/jbc.274.25.17893; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Sharma S, 2003, J BIOL CHEM, V278, P23487, DOI 10.1074/jbc.M212798200; Sharma S, 2004, MOL BIOL CELL, V15, P734, DOI 10.1091/mbc.E03-08-0567; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Sun XM, 2003, DNA REPAIR, V2, P925, DOI 10.1016/S1568-7864(03)00093-4; Tishkoff DX, 1998, CANCER RES, V58, P5027; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Tran PT, 2002, DNA REPAIR, V1, P895, DOI 10.1016/S1568-7864(02)00114-3; van Brabant AJ, 2000, BIOCHEMISTRY-US, V39, P14617, DOI 10.1021/bi0018640; von Kobbe C, 2002, J BIOL CHEM, V277, P22035, DOI 10.1074/jbc.M200914200; Wang Y, 2000, GENE DEV, V14, P927; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Wu L, 2002, NUCLEIC ACIDS RES, V30, P4823, DOI 10.1093/nar/gkf611; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; Yang Q, 2002, J BIOL CHEM, V277, P31980, DOI 10.1074/jbc.M204111200; Yankiwski V, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-11; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	66	82	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9847	9856		10.1074/jbc.M309898200	http://dx.doi.org/10.1074/jbc.M309898200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688284	hybrid			2022-12-25	WOS:000220050400024
J	Tzeng, TY; Liu, HC; Yang, CH				Tzeng, TY; Liu, HC; Yang, CH			The C-terminal sequence of LMADS1 is essential for the formation of homodimers for B function proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MADS-BOX GENES; FLORAL ORGAN IDENTITY; HOMEOTIC GENE; FLOWER DEVELOPMENT; MOLECULAR EVOLUTION; MULTIGENE FAMILY; ARABIDOPSIS; APETALA3; EXPRESSION; PISTILLATA	LMADS1, a lily ( Lilium longiflorum) AP3 orthologue, contains the complete consensus sequence of the paleoAP3 ( YGSHDLRLA) and PI-derived (YEFRVQPSQPNLH) motifs in the C-terminal region of the protein. Interestingly, through yeast two-hybrid analysis, LMADS1 was found to be capable of forming homodimers. These results indicated that LMADS1 represents an ancestral form of the B function protein, which retains the ability to form homodimers in regulating petal and stamen development in lily. To explore the involvement of the conserved motifs in the C-terminal region of LMADS1 in forming homodimers, truncated forms of LMADS1 were generated, and their ability to form homodimers was analyzed using yeast two-hybrid and electrophoretic mobility shift assay. The ability of LMADS1 to form homodimers decreased once the C-terminal paleoAP3 motif was deleted. When both paleoAP3 and PI-derived motifs were deleted, the ability of LMADS1 to form homodimers was completely abolished. This result indicated that although the paleoAP3 motif promotes the formation of LMADS1 homodimers, the PI-derived motif is essential. Deletion analysis indicated that two amino acids, RV, of the 5 final amino acids, YEFRV, in the PI-derived motif are essential for the formation of homodimers. Further, point mutation analysis indicated that amino acid Val was absolutely necessary, whereas residue Arg played a less important role in the formation of homodimers. Furthermore, Arabidopsis AP3 was able to form homodimers once its C-terminal region was replaced by that of LMADS1. This result indicated that the C-terminal region of LMADS1 is responsible and essential for homodimer formation of the ancestral form of the B function protein.	Natl Chung Hsing Univ, Grad Inst Biotechnol, Taichung 40227, Taiwan	National Chung Hsing University	Yang, CH (corresponding author), Natl Chung Hsing Univ, Grad Inst Biotechnol, Taichung 40227, Taiwan.	chyang@dragon.nchu.edu.tw		Tzeng, Tsai-Yu/0000-0001-7334-6270				ANGENENT GC, 1992, PLANT CELL, V4, P983, DOI 10.1105/tpc.4.8.983; ANGENENT GC, 1995, PLANT CELL, V7, P505; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; CHUNG YY, 1995, PLANT SCI, V109, P45, DOI 10.1016/0168-9452(95)04153-L; DOYLE JJ, 1994, SYST BIOL, V43, P307; Egea-Cortines M, 1999, EMBO J, V18, P5370, DOI 10.1093/emboj/18.19.5370; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOTO K, 1994, GENE DEV, V8, P1548, DOI 10.1101/gad.8.13.1548; Hill TA, 1998, DEVELOPMENT, V125, P1711; Hsu HF, 2002, PLANT CELL PHYSIOL, V43, P1198, DOI 10.1093/pcp/pcf143; HUANG H, 1993, NUCLEIC ACIDS RES, V21, P4769, DOI 10.1093/nar/21.20.4769; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; JACK T, 1994, CELL, V76, P703, DOI 10.1016/0092-8674(94)90509-6; Kramer EM, 1998, GENETICS, V149, P765; Kyozuka J, 2000, PLANT CELL PHYSIOL, V41, P710, DOI 10.1093/pcp/41.6.710; McGonigle B, 1996, GENE DEV, V10, P1812, DOI 10.1101/gad.10.14.1812; Miller J.H., 1992, SHORT COURSE BACTERI, P74; Moon YH, 1999, PLANT MOL BIOL, V40, P167, DOI 10.1023/A:1026429922616; Mouradov A, 1999, DEV GENET, V25, P245, DOI 10.1002/(SICI)1520-6408(1999)25:3&lt;245::AID-DVG7&gt;3.0.CO;2-N; Munster T, 2001, GENE, V262, P1, DOI 10.1016/S0378-1119(00)00556-4; Purugganan MD, 1997, J MOL EVOL, V45, P392, DOI 10.1007/PL00006244; PURUGGANAN MD, 1995, GENETICS, V140, P345; Riechmann JL, 1996, P NATL ACAD SCI USA, V93, P4793, DOI 10.1073/pnas.93.10.4793; Riechmann JL, 1997, BIOL CHEM, V378, P1079; ROUNSLEY SD, 1995, PLANT CELL, V7, P1259, DOI 10.1105/tpc.7.8.1259; SCHWARZSOMMER Z, 1992, EMBO J, V11, P251, DOI 10.1002/j.1460-2075.1992.tb05048.x; Sheppard LA, 2000, PLANT PHYSIOL, V124, P627, DOI 10.1104/pp.124.2.627; SHIRAISHI H, 1993, PLANT J, V4, P385, DOI 10.1046/j.1365-313X.1993.04020385.x; Sundstrom J, 1999, DEV GENET, V25, P253, DOI 10.1002/(SICI)1520-6408(1999)25:3&lt;253::AID-DVG8&gt;3.0.CO;2-P; Theissen G, 2000, PLANT MOL BIOL, V42, P115, DOI 10.1023/A:1006332105728; THEISSEN G, 1995, CURR OPIN GENET DEV, V5, P628, DOI 10.1016/0959-437X(95)80032-8; Theissen G, 1996, J MOL EVOL, V43, P484, DOI 10.1007/PL00006110; Tilly JJ, 1998, DEVELOPMENT, V125, P1647; TROBNER W, 1992, EMBO J, V11, P4693, DOI 10.1002/j.1460-2075.1992.tb05574.x; Tzeng TY, 2001, PLANT CELL PHYSIOL, V42, P1156, DOI 10.1093/pcp/pce151; Vandenbussche M, 2003, NUCLEIC ACIDS RES, V31, P4401, DOI 10.1093/nar/gkg642; VANDERKROL AR, 1993, GENE DEV, V7, P1214, DOI 10.1101/gad.7.7a.1214; Winter KU, 1999, P NATL ACAD SCI USA, V96, P7342, DOI 10.1073/pnas.96.13.7342; Winter KU, 2002, MOL BIOL EVOL, V19, P587, DOI 10.1093/oxfordjournals.molbev.a004118; Yu DY, 1999, PLANT J, V17, P51, DOI 10.1046/j.1365-313X.1999.00351.x	40	40	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10747	10755		10.1074/jbc.M311646200	http://dx.doi.org/10.1074/jbc.M311646200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14676188	hybrid			2022-12-25	WOS:000220050400130
J	Fraser, CS; Lee, JY; Mayeur, GL; Bushell, M; Doudna, JA; Hershey, JWB				Fraser, CS; Lee, JY; Mayeur, GL; Bushell, M; Doudna, JA; Hershey, JWB			The j-subunit of human translation initiation factor eIF3 is required for the stable binding of eIF3 and its subcomplexes to 40 S ribosomal subunits in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN PROTEIN-SYNTHESIS; MESSENGER-RNA; FACTOR 4G; COMPLEX; YEAST; INTERACTS; PURIFICATION; PRT1; HOMOLOG; ASSOCIATION	Eukaryotic initiation factor 3 (eIF3) is a 12-subunit protein complex that plays a central role in binding of initiator methionyl-tRNA and mRNA to the 40 S ribosomal subunit to form the 40 S initiation complex. The molecular mechanisms by which eIF3 exerts these functions are poorly understood. To learn more about the structure and function of eIF3 we have expressed and purified individual human eIF3 subunits or complexes of eIF3 subunits using baculovirus-infected Sf9 cells. The results indicate that the subunits of human eIF3 that have homologs in Saccharomyces cerevisiae form subcomplexes that reflect the subunit interactions seen in the yeast eIF3 core complex. In addition, we have used an in vitro 40 S ribosomal subunit binding assay to investigate subunit requirements for efficient association of the eIF3 subcomplexes to the 40 S ribosomal subunit. eIF3j alone binds to the 40 S ribosomal subunit, and its presence is required for stable 40 S binding of an eIF3bgi subcomplex. Furthermore, purified eIF3 lacking eIF3j binds 40 S ribosomal subunits weakly, but binds tightly when eIF3j is added. Cleavage of a 16-residue C-terminal peptide from eIF3j by caspase-3 significantly reduces the affinity of eIF3j for the 40 S ribosomal subunit, and the cleaved form provides substantially less stabilization of purified eIF3-40S complexes. These results indicate that eIF3j, and especially its C terminus, play an important role in the recruitment of eIF3 to the 40 S ribosomal subunit.	Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA	University of California System; University of California Davis	Hershey, JWB (corresponding author), Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA.	jwhershey@ucdavis.edu	Fraser, Christopher/H-9186-2013		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022135] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-22135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Algire MA, 2002, RNA, V8, P382, DOI 10.1017/S1355838202029527; Asano K, 1998, J BIOL CHEM, V273, P18573, DOI 10.1074/jbc.273.29.18573; Asano K, 1997, J BIOL CHEM, V272, P1101, DOI 10.1074/jbc.272.2.1101; Bandyopadhyay A, 1999, NUCLEIC ACIDS RES, V27, P1331, DOI 10.1093/nar/27.5.1331; BENNE R, 1976, P NATL ACAD SCI USA, V73, P3005, DOI 10.1073/pnas.73.9.3005; Block KL, 1998, J BIOL CHEM, V273, P31901, DOI 10.1074/jbc.273.48.31901; Browning KS, 2001, TRENDS BIOCHEM SCI, V26, P284, DOI 10.1016/S0968-0004(01)01825-4; BROWNLUEDI ML, 1982, BIOCHEMISTRY-US, V21, P4202, DOI 10.1021/bi00261a002; Bushell M, 2000, EUR J BIOCHEM, V267, P1083, DOI 10.1046/j.1432-1327.2000.01101.x; Chaudhuri J, 1997, J BIOL CHEM, V272, P30975, DOI 10.1074/jbc.272.49.30975; Chaudhuri J, 1999, J BIOL CHEM, V274, P17975, DOI 10.1074/jbc.274.25.17975; Clemens MJ, 1998, ONCOGENE, V17, P2921, DOI 10.1038/sj.onc.1202227; DANAIE P, 1995, J BIOL CHEM, V270, P4288, DOI 10.1074/jbc.270.9.4288; Das S, 2000, MOL CELL BIOL, V20, P3942, DOI 10.1128/MCB.20.11.3942-3950.2000; FALVEY AK, 1970, J MOL BIOL, V53, P1, DOI 10.1016/0022-2836(70)90042-2; Fletcher CM, 1999, EMBO J, V18, P2631, DOI 10.1093/emboj/18.9.2631; GOSS DJ, 1988, BIOCHEMISTRY-US, V27, P1489, DOI 10.1021/bi00405a014; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Korneeva NL, 2000, J BIOL CHEM, V275, P41369, DOI 10.1074/jbc.M007525200; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Lin L, 2001, J CELL BIOCHEM, V80, P483, DOI 10.1002/1097-4644(20010315)80:4<483::AID-JCB1002>3.0.CO;2-B; Marissen WE, 1998, MOL CELL BIOL, V18, P7565, DOI 10.1128/MCB.18.12.7565; Methot N, 1996, MOL CELL BIOL, V16, P5328; Methot N, 1997, J BIOL CHEM, V272, P1110, DOI 10.1074/jbc.272.2.1110; Morris-Desbois C, 2001, J BIOL CHEM, V276, P45988, DOI 10.1074/jbc.M104966200; NARANDA T, 1994, J BIOL CHEM, V269, P32286; Palecek J, 2001, BIOCHEM BIOPH RES CO, V282, P1244, DOI 10.1006/bbrc.2001.4721; Phan L, 1998, MOL CELL BIOL, V18, P4935, DOI 10.1128/MCB.18.8.4935; Phan L, 2001, EMBO J, V20, P2954, DOI 10.1093/emboj/20.11.2954; Pincheira R, 2001, EUR J CELL BIOL, V80, P410, DOI 10.1078/0171-9335-00176; SAFER B, 1976, P NATL ACAD SCI USA, V73, P2584, DOI 10.1073/pnas.73.8.2584; SCHREIER MH, 1977, J MOL BIOL, V116, P727, DOI 10.1016/0022-2836(77)90268-6; Tee AR, 2002, MOL CELL BIOL, V22, P1674, DOI 10.1128/MCB.22.6.1674-1683.2002; THOMPSON HA, 1977, BIOCHEMISTRY-US, V16, P2221, DOI 10.1021/bi00629a028; TRACHSEL H, 1979, BIOCHIM BIOPHYS ACTA, V565, P305, DOI 10.1016/0005-2787(79)90207-7; Valasek L, 2002, EMBO J, V21, P5886, DOI 10.1093/emboj/cdf563; Valasek L, 2001, J BIOL CHEM, V276, P43351, DOI 10.1074/jbc.M106887200; Valasek L, 2001, EMBO J, V20, P891, DOI 10.1093/emboj/20.4.891; Valasek L, 1999, J BIOL CHEM, V274, P27567, DOI 10.1074/jbc.274.39.27567	40	97	113	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8946	8956		10.1074/jbc.M312745200	http://dx.doi.org/10.1074/jbc.M312745200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14688252	hybrid			2022-12-25	WOS:000189265900053
J	Hosfield, DJ; Zhang, YM; Dougan, DR; Broun, A; Tari, LW; Swanson, RV; Finn, J				Hosfield, DJ; Zhang, YM; Dougan, DR; Broun, A; Tari, LW; Swanson, RV; Finn, J			Structural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYL DIPHOSPHATE SYNTHASE; NITROGEN-CONTAINING BISPHOSPHONATES; PYROPHOSPHATE SYNTHASE; ESCHERICHIA-COLI; IN-VITRO; OSTEOPOROSIS; PURIFICATION; ALENDRONATE; SYNTHETASE; PROTEINS	Farnesyl pyrophosphate synthetase (FPPS) synthesizes farnesyl pyrophosphate through successive condensations of isopentyl pyrophosphate with dimethylallyl pyrophosphate and geranyl pyrophosphate. Nitrogen-containing bisphosphonate drugs used to treat osteoclast-mediated bone resorption and tumor-induced hypercalcemia are potent inhibitors of the enzyme. Here we present crystal structures of substrate and bisphosphonate complexes of FPPS. The structures reveal how enzyme conformational changes organize conserved active site residues to exploit metal-induced ionization and substrate positioning for catalysis. The structures further demonstrate how nitrogen-containing bisphosphonates mimic a carbocation intermediate to inhibit the enzyme. Together, these FPPS complexes provide a structural template for the design of novel inhibitors that may prove useful for the treatment of osteoporosis and other clinical indications including cancer.	Syrrx Inc, Dept Struct Chem, San Diego, CA 92121 USA; Tril Pharmaceut, San Diego, CA 92121 USA		Hosfield, DJ (corresponding author), Syrrx Inc, Dept Struct Chem, 10410 Sci Ctr Dr, San Diego, CA 92121 USA.			Swanson, Ronald/0000-0002-6486-2676				Bartl R, 2002, DEUT MED WOCHENSCHR, V127, P638; Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502; CORNFORTH JW, 1966, J BIOL CHEM, V241, P3970; DING VDH, 1991, BIOCHEM J, V275, P61, DOI 10.1042/bj2750061; Green JR, 2003, CANCER, V97, P840, DOI 10.1002/cncr.11128; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Holstein SA, 2003, BIOCHEMISTRY-US, V42, P4384, DOI 10.1021/bi027227m; Hosfield D, 2003, J STRUCT BIOL, V142, P207, DOI 10.1016/S1047-8477(03)00051-0; Keller RK, 1999, BIOCHEM BIOPH RES CO, V266, P560, DOI 10.1006/bbrc.1999.1849; KOYAMA T, 1993, J BIOCHEM-TOKYO, V113, P355, DOI 10.1093/oxfordjournals.jbchem.a124051; LAFORTELLE E, 1997, METHOD ENZYMOL, V276, P472; Leyes AE, 1999, ORG LETT, V1, P1071, DOI 10.1021/ol990876e; Martin MB, 1999, BIOCHEM BIOPH RES CO, V263, P754, DOI 10.1006/bbrc.1999.1404; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Montalvetti A, 2003, J BIOL CHEM, V278, P17075, DOI 10.1074/jbc.M210467200; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; NISHINO T, 1972, J AM CHEM SOC, V94, P6849, DOI 10.1021/ja00774a045; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Phan RM, 2000, ORG LETT, V2, P2287, DOI 10.1021/ol006055n; POULTER CD, 1978, J BIOL CHEM, V253, P7227; Riccardi A, 2003, TUMORI J, V89, P223, DOI 10.1177/030089160308900301; Rodan GA, 2003, J BONE JOINT SURG AM, V85A, P8, DOI 10.2106/00004623-200300003-00003; Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640; Spurgeon SL, 1981, BIOSYNTHESIS ISOPREN, P1; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018; van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499; van Beek E, 1999, BIOCHEM BIOPH RES CO, V255, P491, DOI 10.1006/bbrc.1999.0224; Vicent D, 2000, MOL CELL BIOL, V20, P2158, DOI 10.1128/MCB.20.6.2158-2166.2000; Waldman A, 2003, DRUGS, V63, P139, DOI 10.2165/00003495-200363020-00002; Watts NB, 2003, CLIN GERIATR MED, V19, P395, DOI 10.1016/S0749-0690(02)00069-1; Werbovetz Karl A, 2002, Expert Opin Ther Targets, V6, P407, DOI 10.1517/14728222.6.4.407	32	226	234	1	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8526	8529		10.1074/jbc.C300511200	http://dx.doi.org/10.1074/jbc.C300511200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14672944	hybrid			2022-12-25	WOS:000189265900002
J	Maclean, KN; Kraus, E; Kraus, JP				Maclean, KN; Kraus, E; Kraus, JP			The dominant role of Sp1 in regulating the cystathionine beta-synthase-1a and -1b promoters facilitates potential tissue-specific regulation by Kruppel-like factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SYNTHASE GENE; THYMIDINE KINASE PROMOTER; DNA-BINDING ACTIVITY; TRANSCRIPTION FACTORS; SACCHAROMYCES-CEREVISIAE; CELL-PROLIFERATION; ALZHEIMERS-DISEASE; NF-Y; EXPRESSION; ACTIVATION	Cystathionine beta-synthase (CBS) catalyzes the condensation of serine with homocysteine to form cystathionine and occupies a crucial regulatory position between the methionine cycle and transsulfuration. The human cystathionine beta-synthase gene promoters - 1a and - 1b are expressed in a limited number of tissues and are coordinately regulated with proliferation through a redox-sensitive mechanism. Site-directed mutagenesis, DNase I footprinting and deletion analysis of 5276 bp of 5' proximal - 1b flanking sequence revealed that this region does not confer tissue-specific expression and that 210 bp of proximal sequence is sufficient for maximal promoter activity. As little as 32 bp of the - 1b proximal promoter region is capable of driving transcription in HepG2 cells, and this activity is entirely dependent upon the presence of a single overlapping Sp1/Egr1 binding site. Co-transfection studies in Drosophila SL2 cells indicated that both promoters are transactivated by Sp1 and Sp3 but only the - 1b promoter is subject to a site-specific synergistic regulatory interaction between Sp1 and Sp3. Sp1-deficient fibroblasts expressing both Sp3 and NF-Y were negative for CBS activity. Transfection of these cells with a mammalian Sp1 expression construct induced high levels of CBS activity indicating that Sp1 has a critical and indispensable role in the regulation of cystathionine beta-synthase. Sp1 binding to both CBS promoters is sensitive to proliferation status and is negatively regulated by Kruppel-like factors in co-transfection experiments suggesting a possible mechanism for the tissue specific regulation of cystathionine beta-synthase.	Univ Colorado, Sch Med, Dept Pediat, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Maclean, KN (corresponding author), Univ Colorado, Sch Med, Dept Pediat, C-233, Denver, CO 80262 USA.	ken.maclean@uchsc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065217] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL65217] Funding Source: Medline; NICHD NIH HHS [P01 HD0805] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Bao LM, 1998, ARCH BIOCHEM BIOPHYS, V350, P95, DOI 10.1006/abbi.1997.0486; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRIDOVICHKEIL JL, 1993, CELL GROWTH DIFFER, V4, P679; FRIDOVICHKEIL JL, 1991, CELL GROWTH DIFFER, V2, P67; Gaboli M, 2001, GENE DEV, V15, P1625, DOI 10.1101/gad.902301; Ge YB, 2003, BLOOD, V101, P1551, DOI 10.1182/blood-2002-07-2337; Ge YB, 2001, BIOCHEM J, V357, P97, DOI 10.1042/0264-6021:3570097; Ge YB, 2001, J BIOL CHEM, V276, P43570, DOI 10.1074/jbc.M104930200; Georgopoulos K, 1997, ANNU REV IMMUNOL, V15, P155, DOI 10.1146/annurev.immunol.15.1.155; GOLDSTEIN JL, 1972, J CLIN INVEST, V51, P1034, DOI 10.1172/JCI106863; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hromas R, 1996, LEUKEMIA, V10, P1049; IKEDA K, 1993, GENE, V136, P341; Janosik M, 2001, AM J HUM GENET, V68, P1506, DOI 10.1086/320597; Kaczynski J, 2001, J BIOL CHEM, V276, P36749, DOI 10.1074/jbc.M105831200; Karsunky H, 2002, NAT GENET, V30, P295, DOI 10.1038/ng831; KRAUS JP, 1987, METHOD ENZYMOL, V143, P388; Kraus JP, 1998, GENOMICS, V52, P312, DOI 10.1006/geno.1998.5437; Kruman II, 2002, J NEUROSCI, V22, P1752, DOI 10.1523/JNEUROSCI.22-05-01752.2002; Kumar AP, 1998, BIOCHEM BIOPH RES CO, V252, P517, DOI 10.1006/bbrc.1998.9676; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; Maclean KN, 2002, J CELL PHYSIOL, V192, P81, DOI 10.1002/jcp.10118; Maclean KN, 2000, J INORG BIOCHEM, V81, P161, DOI 10.1016/S0162-0134(00)00100-8; Maclean KN, 2002, HUM MUTAT, V19, P641, DOI 10.1002/humu.10089; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; MILLS JL, 1995, LANCET, V345, P149, DOI 10.1016/S0140-6736(95)90165-5; Mudd S., 2001, METABOLIC MOL BASES, P2007; MUDD SH, 1965, J BIOL CHEM, V240, P4382; Nagavarapu U, 2001, J BIOL CHEM, V276, P16749, DOI 10.1074/jbc.M009712200; Noti JD, 1997, J BIOL CHEM, V272, P24038, DOI 10.1074/jbc.272.38.24038; O'Leary KA, 2000, ARCH BIOCHEM BIOPHYS, V379, P97, DOI 10.1006/abbi.2000.1862; PANI L, 1992, MOL CELL BIOL, V12, P552, DOI 10.1128/MCB.12.2.552; Ping DS, 2000, J BIOL CHEM, V275, P1708, DOI 10.1074/jbc.275.3.1708; Quere I, 1999, BIOCHEM BIOPH RES CO, V254, P127, DOI 10.1006/bbrc.1998.9079; Schafer D, 1996, FEBS LETT, V391, P35, DOI 10.1016/0014-5793(96)00701-6; Selhub J, 1997, HAEMATOLOGICA, V82, P129; Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SKOVBY F, 1984, HUM GENET, V65, P291, DOI 10.1007/BF00286520; SMITH GJ, 1984, PATHOLOGY, V16, P401, DOI 10.3109/00313028409084730; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Terraz C, 2001, J BIOL CHEM, V276, P37011, DOI 10.1074/jbc.M104185200; WADE DP, 1994, J BIOL CHEM, V269, P19757; Wieczorek E, 2000, J BIOL CHEM, V275, P12879, DOI 10.1074/jbc.275.17.12879; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281; WU SE, 1983, BIOCHEMISTRY-US, V22, P2828, DOI 10.1021/bi00281a009; Yoon JH, 1999, BIOCHEM J, V344, P367, DOI 10.1042/0264-6021:3440367; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	55	26	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8558	8566		10.1074/jbc.M310211200	http://dx.doi.org/10.1074/jbc.M310211200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14670973	hybrid			2022-12-25	WOS:000189265900006
J	Vogel, CFA; Sciullo, E; Park, S; Liedtke, C; Trautwein, C; Matsumura, F				Vogel, CFA; Sciullo, E; Park, S; Liedtke, C; Trautwein, C; Matsumura, F			Dioxin increases C/EBP beta transcription by activating cAMP/protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN-BETA; KAPPA-B INTERACTIONS; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; ADIPOCYTE DIFFERENTIATION; HYDROCARBON RECEPTOR; STRESS-RESPONSE; C-JUN; GENE; EXPRESSION; PROMOTER	The environmental pollutant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD = dioxin) has been shown to increase the expression of C/EBPbeta. The modulated expression of C/EBPbeta has been suggested to be associated with toxic responses of TCDD such as wasting syndrome, diabetes, and inhibition of adipocyte differentiation. This study focused on the regulatory mechanism of TCDD-mediated transcriptional activation of C/EBPbeta. Elevated C/EBPbeta mRNA and protein levels in mouse embryonic fibroblasts (C(3)H(10)T1/2) and in mouse hepatoma cells (Hepa1c1c7) were correlated with increased binding affinity of the C/EBPbeta protein. Transfection studies with different deletion constructs of the CCAAT/enhancer-binding protein promoter indicated that a small region located 60-120 bp upstream of the start site of transcription is required for activation of the C/EBPbeta gene by TCDD in both cell lines tested. Further analysis using mutation constructs of the C/EBPbeta promoter demonstrated that activation of the C/EBPbeta promoter is mediated through incomplete cAMP-response element-binding protein (CREB) sites located close to the TATA box of the C/EBPbeta gene. The protein kinase A (PKA) inhibitor H89 completely blocks the TCDD-dependent effect on C/EBPbeta promoter activity, indicating that TCDD activates CREB binding via a cAMP/PKA pathway, which is supported by the increased cAMP level and PKA activity observed after TCDD treatment. Gel shift analyses demonstrated that CREB itself binds to the putative CREB motif that mediates the TCDD-dependent effect on C/EBPbeta gene transcription. Cotransfection experiments with CREB and PKA expression plasmids further supported our conclusions that the TCDD-dependent effect on C/EBPbeta transcription is mediated via PKA-dependent CREB activation.	Univ Calif Davis, Dept Environm Toxicol, Davis, CA 95616 USA; Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, D-30625 Hannover, Lower Saxony, Germany	University of California System; University of California Davis; Hannover Medical School	Matsumura, F (corresponding author), Univ Calif Davis, Dept Environm Toxicol, 1 Shields Ave, Davis, CA 95616 USA.	fmatsumura@ucdavis.edu	Liedtke, Christian/DTV-1874-2022	Liedtke, Christian/0000-0003-4681-7887	NIEHS NIH HHS [P0-1-ES5707, R0-ES05233] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bolger GB, 2003, J BIOL CHEM, V278, P33351, DOI 10.1074/jbc.M303269200; BOMBICK DW, 1988, P NATL ACAD SCI USA, V85, P4128, DOI 10.1073/pnas.85.12.4128; Carver LA, 1997, J BIOL CHEM, V272, P11452; CHANG CJ, 1995, DNA CELL BIOL, V14, P529, DOI 10.1089/dna.1995.14.529; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dunlap DY, 2002, TOXICOLOGY, V172, P125, DOI 10.1016/S0300-483X(02)00006-9; Enan E, 1996, REPROD TOXICOL, V10, P191, DOI 10.1016/0890-6238(96)00021-4; Foka P, 2001, BIOCHEM BIOPH RES CO, V285, P430, DOI 10.1006/bbrc.2001.5203; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Jaspers I, 1997, AM J PHYSIOL-LUNG C, V272, pL504, DOI 10.1152/ajplung.1997.272.3.L504; Jurado LA, 2002, J BIOL CHEM, V277, P27606, DOI 10.1074/jbc.M201429200; Kazlauskas A, 1999, J BIOL CHEM, V274, P13519, DOI 10.1074/jbc.274.19.13519; Kim DW, 2000, ONCOGENE, V19, P5498, DOI 10.1038/sj.onc.1203945; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LaPres JJ, 2000, J BIOL CHEM, V275, P6153, DOI 10.1074/jbc.275.9.6153; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Lenny N, 1997, MOL BIOL REP, V24, P157, DOI 10.1023/A:1006859700409; Lin WC, 2002, DNA CELL BIOL, V21, P551, DOI 10.1089/104454902320308924; Liu PCC, 2002, J BIOCHEM MOL TOXIC, V16, P70, DOI 10.1002/jbt.10020; Liu PCC, 1996, MOL PHARMACOL, V49, P989; LIU PCC, 1998, BIOCHEM PHARMACOL, V23, P123; Ma Q, 1997, J BIOL CHEM, V272, P8878; Matsumura F, 2003, BIOCHEM PHARMACOL, V66, P527, DOI 10.1016/S0006-2952(03)00157-6; MATSUMURA F, 1984, ARCH ENVIRON CON TOX, V13, P509, DOI 10.1007/BF01056330; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Meyer BK, 1999, BIOCHEMISTRY-US, V38, P8907, DOI 10.1021/bi982223w; Mink S, 1999, BBA-GENE STRUCT EXPR, V1447, P175, DOI 10.1016/S0167-4781(99)00168-2; Nebert DW, 2000, BIOCHEM PHARMACOL, V59, P65, DOI 10.1016/S0006-2952(99)00310-X; Niehof M, 2001, J BIOL CHEM, V276, P9016, DOI 10.1074/jbc.M009284200; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; PARK EA, 1993, J BIOL CHEM, V268, P613; PHILLIPS M, 1995, J CELL SCI, V108, P395; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Reddy ST, 2000, J BIOL CHEM, V275, P3107, DOI 10.1074/jbc.275.5.3107; Roesler WJ, 2001, ANNU REV NUTR, V21, P141, DOI 10.1146/annurev.nutr.21.1.141; Savouret JF, 2001, J BIOL CHEM, V276, P3054, DOI 10.1074/jbc.M005988200; Simeonova PP, 1997, J IMMUNOL, V159, P3921; STAHL BU, 1993, TOXICOLOGY, V79, P81, DOI 10.1016/0300-483X(93)90207-9; Tian Y, 1999, J BIOL CHEM, V274, P510, DOI 10.1074/jbc.274.1.510; Tian YN, 2002, CHEM-BIOL INTERACT, V141, P97, DOI 10.1016/S0009-2797(02)00068-6; Vogel C, 2000, CARCINOGENESIS, V21, P2267, DOI 10.1093/carcin/21.12.2267; Vogel CFA, 2003, BIOCHEM PHARMACOL, V66, P1231, DOI 10.1016/S0006-2952(03)00404-0; Welm AL, 1999, MOL CELL BIOL, V19, P1695; Yan SF, 1997, J BIOL CHEM, V272, P4287, DOI 10.1074/jbc.272.7.4287; YAN SF, 1995, J BIOL CHEM, V270, P11463, DOI 10.1074/jbc.270.19.11463; Yang YM, 2002, BBA-GENE STRUCT EXPR, V1577, P102, DOI 10.1016/S0167-4781(02)00401-3; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	50	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8886	8894		10.1074/jbc.M310190200	http://dx.doi.org/10.1074/jbc.M310190200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14684744	hybrid			2022-12-25	WOS:000189265900046
J	Conant, K; St Hillaire, C; Nagase, H; Visse, R; Gary, D; Haughey, N; Anderson, C; Turchan, J; Nath, A				Conant, K; St Hillaire, C; Nagase, H; Visse, R; Gary, D; Haughey, N; Anderson, C; Turchan, J; Nath, A			Matrix metalloproteinase 1 interacts with neuronal integrins and stimulates dephosphorylation of Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; MATRIX METALLOPROTEINASES; CELL-ADHESION; SIGNALING PATHWAY; GELATINASE-A; INDUCTION; ACID; LOCALIZATION; ACTIVATION; RECEPTORS	Several studies have demonstrated that matrix metalloproteinases (MMPs) are cytotoxic. The responsible mechanisms, however, are not well understood. MMPs may promote cytotoxicity through their ability to disrupt or degrade matrix proteins that support cell survival, and MMPs may also cleave substrates to generate molecules that stimulate cell death. In addition, MMPs may themselves act on cell surface receptors that affect cell survival. Among such receptors is the alpha(2)beta(1) integrin, a complex that has previously been linked to leukocyte death. In the present study we show that human neurons express alpha(2)beta(1) and that pro-MMP-1 interacts with this integrin complex. We also show that stimulation of neuronal cultures with MMP-1 is associated with a rapid reduction in the phosphorylation of Akt, a kinase that can influence caspase activity and cell survival. Moreover, MMP-1-associated dephosphorylation of Akt is inhibited by a blocking antibody to the alpha(2) integrin, but not by batimastat, an inhibitor of MMP-1 enzymatic activity. Such dephosphorylation is also stimulated by a catalytic mutant of pro-MMP-1. Additional studies show that MMP-1 causes neuronal death, which is significantly diminished by both a general caspase inhibitor and anti-(2) but not by batimastat. Together, these results suggest that MMP-1 can stimulate dephosphorylation of Akt and neuronal death through a non-proteolytic mechanism that involves changes in integrin signaling.	Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neuropathol, Baltimore, MD 21287 USA; Univ London Imperial Coll Sci Technol & Med, Kennedy Inst Rheumatol, Dept Matrix Biol, London W6 8LH, England	Johns Hopkins University; Johns Hopkins University; Imperial College London; University of Oxford	Conant, K (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurol, Pathol Bldg,Rm 625,600 N Wolfe St, Baltimore, MD 21287 USA.	kconant@mail.jhmi.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH063722] Funding Source: NIH RePORTER; NIMH NIH HHS [MH63722] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Arencibia I, 2002, EUR J IMMUNOL, V32, P1129, DOI 10.1002/1521-4141(200204)32:4<1129::AID-IMMU1129>3.0.CO;2-G; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Chen HJ, 2003, AM J PHYSIOL-HEART C, V284, pH1612, DOI 10.1152/ajpheart.00992.2002; Chen ZL, 2003, MOL BIOL CELL, V14, P2665, DOI 10.1091/mbc.E02-12-0832; Chung L, 2000, J BIOL CHEM, V275, P29610, DOI 10.1074/jbc.M004039200; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Conant K, 2002, J NEUROCHEM, V82, P885, DOI 10.1046/j.1471-4159.2002.01038.x; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P6684, DOI 10.1021/bi00187a039; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dumin JA, 2001, J BIOL CHEM, V276, P29368, DOI 10.1074/jbc.M104179200; Fernandez-Patron C, 1999, CIRC RES, V85, P906; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; GOTTSCHALL PE, 1995, J NEUROCHEM, V64, P1513; Grisaru D, 1999, EUR J BIOCHEM, V264, P672, DOI 10.1046/j.1432-1327.1999.00693.x; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Hashimoto M, 2002, J BIOL CHEM, V277, P32985, DOI 10.1074/jbc.M202803200; Huang XC, 1996, ADV EXP MED BIOL, V396, P209; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Johnston JB, 2001, ANN NEUROL, V49, P230, DOI 10.1002/1531-8249(20010201)49:2<230::AID-ANA43>3.0.CO;2-O; Kim HE, 2000, J CLIN INVEST, V106, P857, DOI 10.1172/JCI8040; MAGNUSON DSK, 1995, ANN NEUROL, V37, P373, DOI 10.1002/ana.410370314; Manna PP, 2003, J IMMUNOL, V170, P3544, DOI 10.4049/jimmunol.170.7.3544; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; McFarlane S, 2003, NEURON, V37, P559, DOI 10.1016/S0896-6273(03)00089-8; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; Milner R, 2002, J NEUROSCI RES, V69, P286, DOI 10.1002/jnr.10321; Murphy-Ullrich JE, 2001, J CLIN INVEST, V107, P785, DOI 10.1172/JCI12609; Nath D, 2000, J CELL SCI, V113, P2319; Pankov R, 2003, J BIOL CHEM, V278, P18671, DOI 10.1074/jbc.M300879200; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108; Schonbeck U, 1998, J IMMUNOL, V161, P3340; SPURLINO JC, 1994, PROTEINS, V19, P98, DOI 10.1002/prot.340190203; Stepanova VV, 2002, BIOCHEMISTRY-MOSCOW+, V67, P109, DOI 10.1023/A:1013912500373; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; Stricker TP, 2001, J BIOL CHEM, V276, P29375, DOI 10.1074/jbc.M102217200; Takada T, 2002, J BIOL CHEM, V277, P34359, DOI 10.1074/jbc.M206541200; Ueda H, 2001, J BIOL CHEM, V276, P6846, DOI 10.1074/jbc.M007541200; Van den Steen PE, 2000, BLOOD, V96, P2673, DOI 10.1182/blood.V96.8.2673.h8002673_2673_2681; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Vos CMP, 2000, EXP NEUROL, V163, P324, DOI 10.1006/exnr.2000.7388; Woessner J.F., 2000, PROTEIN PROFILE SER; Yong VW, 1998, TRENDS NEUROSCI, V21, P75; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zhang KY, 2003, NAT NEUROSCI, V6, P1064, DOI 10.1038/nn1127; Zigrino P, 2002, J BIOL CHEM, V277, P40528, DOI 10.1074/jbc.M202049200	50	52	56	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8056	8062		10.1074/jbc.M307051200	http://dx.doi.org/10.1074/jbc.M307051200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14679206	hybrid			2022-12-25	WOS:000189103300084
J	Mouillet, JF; Sonnenberg-Hirche, C; Yan, XM; Sadovsky, Y				Mouillet, JF; Sonnenberg-Hirche, C; Yan, XM; Sadovsky, Y			p300 regulates the synergy of steroidogenic factor-1 and early growth response-1 in activating luteinizing hormone-beta subunit gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GONADOTROPIN-RELEASING-HORMONE; NUCLEAR-RECEPTOR; TRANSCRIPTIONAL COACTIVATOR; TRANSGENIC MICE; NGFI-A; HISTONE ACETYLTRANSFERASE; MOLECULAR-CLONING; DISCRETE STAGES; BINDING-SITES; GNRH RECEPTOR	Tight regulation of luteinizing hormone-beta subunit (LHbeta) expression is critical for differentiation and maturation of mammalian sexual organs and reproductive function. Two transcription factors, steroidogenic factor-1 (SF-1) and early growth response-1 (Egr-1), play a central role in activating LHbeta promoter, and the synergy between these two factors is essential in mediating gonadotropin-releasing hormone stimulation of LHbeta promoter. Here we demonstrate that the transcriptional co-activator p300 regulates this synergy. Overexpression of p300 results in strong stimulation of LHbeta promoter but only in the presence of both SF-1 and Egr-1, and not in the presence of other Egr proteins. Mutation of the binding sites for either SF-1 or Egr-1 completely abolishes the synergy between these two factors, as well as the influence of p300. Importantly, LHbeta promoter is precipitated using p300 antibodies in a chromatin immunoprecipitation assay with LbetaT2 gonadotropes, and this effect is enhanced by gonadotropin-releasing hormone. The influence of p300 on LHbeta promoter is potentiated by steroid receptor co-activator, as well as by E1A proteins, and attenuated by Smad nuclear interacting protein 1. Taken together, these results suggest that p300 is recruited to LHbeta promoter where it coordinates the functional synergy between SF-1 and Egr-1.	Washington Univ, Sch Med, Dept Obstet & Gynecol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Sadovsky, Y (corresponding author), Washington Univ, Sch Med, Dept Obstet & Gynecol, 4566 Scott Ave,Campus Box 8064, St Louis, MO 63110 USA.	sadovskyy@wustl.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037571] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD37571] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alarid ET, 1996, DEVELOPMENT, V122, P3319; Alarid ET, 1998, MOL CELL ENDOCRINOL, V140, P25; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Crawford PA, 1997, MOL ENDOCRINOL, V11, P1626, DOI 10.1210/me.11.11.1626; Crawford PA, 1998, MOL CELL BIOL, V18, P2949, DOI 10.1128/MCB.18.5.2949; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; Demarest SJ, 2002, NATURE, V415, P549, DOI 10.1038/415549a; Dorn C, 1999, J BIOL CHEM, V274, P13870, DOI 10.1074/jbc.274.20.13870; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FOLKERS GE, 1995, MOL CELL BIOL, V15, P5868; GHARIB SD, 1990, ENDOCR REV, V11, P177, DOI 10.1210/edrv-11-1-177; Goodman RH, 2000, GENE DEV, V14, P1553; Halvorson LM, 1996, J BIOL CHEM, V271, P6645, DOI 10.1074/jbc.271.12.6645; Halvorson LM, 1998, J BIOL CHEM, V273, P14712, DOI 10.1074/jbc.273.24.14712; Hammer GD, 1999, FRONT NEUROENDOCRIN, V20, P199, DOI 10.1006/frne.1999.0182; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; Ito M, 1998, MOL ENDOCRINOL, V12, P290, DOI 10.1210/me.12.2.290; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; Kaiser UB, 2000, MOL ENDOCRINOL, V14, P1235, DOI 10.1210/me.14.8.1235; Kakita T, 1999, J BIOL CHEM, V274, P34096, DOI 10.1074/jbc.274.48.34096; KERI RA, 1994, MOL ENDOCRINOL, V8, P1807, DOI 10.1210/me.8.12.1807; Kim RH, 2001, J BIOL CHEM, V276, P46297, DOI 10.1074/jbc.M103819200; Kim RH, 2000, GENE DEV, V14, P1605; Kraus S, 2001, ARCH MED RES, V32, P499, DOI 10.1016/S0188-4409(01)00331-9; Lee KC, 2003, MOL ENDOCRINOL, V17, P908, DOI 10.1210/me.2002-0308; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Li JW, 2000, MOL CELL BIOL, V20, P2031, DOI 10.1128/MCB.20.6.2031-2042.2000; Liu Z, 2001, P NATL ACAD SCI USA, V98, P12426, DOI 10.1073/pnas.231474798; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MAGES HW, 1993, INT IMMUNOL, V5, P63, DOI 10.1093/intimm/5.1.63; Meijer OC, 2000, ENDOCRINOLOGY, V141, P2192, DOI 10.1210/en.141.6.2192; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Monte D, 1998, J BIOL CHEM, V273, P4585, DOI 10.1074/jbc.273.8.4585; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; MULLER HJ, 1991, P NATL ACAD SCI USA, V88, P10079, DOI 10.1073/pnas.88.22.10079; Ou QL, 2001, MOL ENDOCRINOL, V15, P69, DOI 10.1210/me.15.1.69; PATWARDHAN S, 1991, ONCOGENE, V6, P917; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Quirk CC, 2001, MOL ENDOCRINOL, V15, P734, DOI 10.1210/me.15.5.734; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; SADOVSKY Y, 1995, P NATL ACAD SCI USA, V92, P10939, DOI 10.1073/pnas.92.24.10939; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Sheppard HM, 2001, MOL CELL BIOL, V21, P39, DOI 10.1128/MCB.21.1.39-50.2001; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Silverman ES, 1998, BIOCHEM J, V336, P183, DOI 10.1042/bj3360183; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; SUGGS SV, 1990, NUCLEIC ACIDS RES, V18, P4283, DOI 10.1093/nar/18.14.4283; SVENSSON C, 1984, EMBO J, V3, P789, DOI 10.1002/j.1460-2075.1984.tb01886.x; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Themmen APN, 2000, ENDOCR REV, V21, P551, DOI 10.1210/er.21.5.551; Thomas P, 1996, ENDOCRINOLOGY, V137, P2979, DOI 10.1210/en.137.7.2979; Topilko P, 1998, MOL ENDOCRINOL, V12, P107, DOI 10.1210/mend.12.1.0049; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Tremblay JJ, 1999, EMBO J, V18, P3431, DOI 10.1093/emboj/18.12.3431; Tremblay JJ, 1999, MOL CELL BIOL, V19, P2567; TSUTSUMI M, 1992, MOL ENDOCRINOL, V6, P1163, DOI 10.1210/me.6.7.1163; Turgeon JL, 1996, MOL ENDOCRINOL, V10, P439, DOI 10.1210/me.10.4.439; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wahlstrom GM, 1999, MOL ENDOCRINOL, V13, P1119, DOI 10.1210/me.13.7.1119; Weck J, 2000, MOL ENDOCRINOL, V14, P472, DOI 10.1210/me.14.4.472; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; Wolfe MW, 1999, MOL ENDOCRINOL, V13, P752, DOI 10.1210/me.13.5.752; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zhao LP, 2001, DEVELOPMENT, V128, P147	79	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7832	7839		10.1074/jbc.M312574200	http://dx.doi.org/10.1074/jbc.M312574200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14681221	hybrid			2022-12-25	WOS:000189103300059
J	Park, HS; Yu, JW; Cho, JH; Kim, MS; Huh, SH; Ryoo, K; Choi, EJ				Park, HS; Yu, JW; Cho, JH; Kim, MS; Huh, SH; Ryoo, K; Choi, EJ			Inhibition of apoptosis signal-regulating kinase 1 by nitric oxide through a thiol redox mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; S-NITROSYLATION; PC12 CELLS; INTERFERON-GAMMA; 1 ASK1; SYNTHASE; CALCIUM; DIFFERENTIATION; SURVIVAL	Nitric oxide is an endogenous thiol-reactive molecule that modulates the functions of many regulatory proteins by a thiol-redox mechanism. NO has now been shown to inhibit the activation of apoptosis signal-regulating kinase 1 (ASK1) in murine fibrosarcoma L929 cells through such a mechanism. Exposure of L929 cells to interferon-gamma resulted in the endogenous production of NO and in inhibition of the activation of ASK1 by hydrogen peroxide. The interferon-gamma-induced inhibition of ASK1 activity was blocked by N-G-nitro-L-arginine, an inhibitor of NO synthase. Furthermore, the NO donor S-nitro-N-acetyl-DL-penicillamine (SNAP) inhibited ASK1 activity in vitro, and this inhibition was reversed by thiol-reducing agents such as dithiothreitol and beta-mercaptoethanol. SNAP did not inhibit the kinase activities of MKK3, MKK6, or p38 in vitro. The inhibition of ASK1 by interferon-gamma was not changed by 1H-(1,2,4) oxadiazolo[4,3-alpha] quinoxalin-1-one, an inhibitor of guanylyl cyclase nor was it mimicked by 8-bromo-cyclic GMP. Site-directed mutagenesis revealed that replacement of cysteine 869 of ASK1 by serine rendered this protein resistant to the inhibitory effects both of interferon-gamma in intact cells and of SNAP in vitro. Coimmunoprecipitation data showed that NO production inhibited a binding of ASK1, but not ASK1(C869S), to MKK3 or MKK6. Moreover, interferon-gamma induced the S-nitrosylation of endogenous ASK1 in L929 cells. Together, these results suggest that NO mediates the interferon-gamma-induced inhibition of ASK1 in L929 cells through a thiol-redox mechanism.	Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea; Korea Univ, Natl Creat Res Initiat Ctr Cell Death, Seoul 136701, South Korea	Korea University; Korea University	Choi, EJ (corresponding author), Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea.	ejchoi@korea.ac.kr	Cho, Jun-Ho/AAF-2210-2019	Cho, Jun-Ho/0000-0002-8756-8824; Yu, Je-Wook/0000-0001-5943-4071				Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; CHESROWN SE, 1994, BIOCHEM BIOPH RES CO, V200, P126, DOI 10.1006/bbrc.1994.1424; Cho SG, 2001, J BIOL CHEM, V276, P12749, DOI 10.1074/jbc.M005561200; Choi YB, 2000, NAT NEUROSCI, V3, P15, DOI 10.1038/71090; DelaTorre A, 1997, BIOCHEM BIOPH RES CO, V238, P703, DOI 10.1006/bbrc.1997.7279; DUHE RJ, 1994, J BIOL CHEM, V269, P7290; FEINSTEIN DL, 1994, ANN NY ACAD SCI, V738, P325; GALEA E, 1994, J NEUROSCI RES, V37, P406, DOI 10.1002/jnr.490370313; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; HEWETT SJ, 1993, NEUROSCI LETT, V164, P229, DOI 10.1016/0304-3940(93)90898-U; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; IGNARRO LJ, 1991, BIOCHEM PHARMACOL, V41, P485, DOI 10.1016/0006-2952(91)90618-F; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kim H, 1997, BIOCHEMISTRY-US, V36, P13677, DOI 10.1021/bi970837f; Ko YG, 2001, J BIOL CHEM, V276, P6030, DOI 10.1074/jbc.M006189200; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; Park HS, 2000, P NATL ACAD SCI USA, V97, P14382, DOI 10.1073/pnas.97.26.14382; Park HS, 2000, J BIOL CHEM, V275, P2527, DOI 10.1074/jbc.275.4.2527; Park HS, 2001, EMBO J, V20, P446, DOI 10.1093/emboj/20.3.446; PHELPS DC, 1981, BIOCHEMISTRY-US, V20, P453, DOI 10.1021/bi00506a001; POPESCU LM, 1985, EUR J PHARMACOL, V107, P393, DOI 10.1016/0014-2999(85)90269-9; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sayama K, 2001, J BIOL CHEM, V276, P999, DOI 10.1074/jbc.M003425200; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Takeda K, 2000, J BIOL CHEM, V275, P9805, DOI 10.1074/jbc.275.13.9805; Teng KK, 1999, J BIOL CHEM, V274, P37315, DOI 10.1074/jbc.274.52.37315; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Wang DM, 1998, J BIOL CHEM, V273, P33027, DOI 10.1074/jbc.273.49.33027; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511	46	87	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7584	7590		10.1074/jbc.M304183200	http://dx.doi.org/10.1074/jbc.M304183200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14668338	hybrid			2022-12-25	WOS:000189103300027
J	Rescalli, E; Saini, S; Bartocci, C; Rychlewski, L; de Lorenzo, V; Bertoni, G				Rescalli, E; Saini, S; Bartocci, C; Rychlewski, L; de Lorenzo, V; Bertoni, G			Novel physiological modulation of the Pu promoter of TOL plasmid - Negative regulatory role of the TurA protein of Pseudomonas putida in the response to suboptimal growth temperatures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATOR; H-NS; EFFECTOR CONTROL; RNA-POLYMERASE; B-LINKER; INTEGRATION; SIGMA(54); DNA; GENE; BINDING	From crude protein extracts of Pseudomonas putida KT2440, we identified a small protein, TurA, able to bind to DNA fragments bearing the entire Pu promoter sequence of the TOL plasmid. The knock-out inactivation of the turA gene resulted in enhanced transcription initiation from the Pu promoter, initially suggesting a negative regulatory role of TurA on Pu expression. Ectopic expression of TurA both in P. putida and in Escherichia coli reporter strains and transcription in vitro of the Pu promoter in the presence of purified TurA confirmed the TurA repressor role on Pu activity. turA gene inactivation did not significantly alter two well characterized physiological regulations of the Pu expression in routine conditions of cultivation, exponential silencing, and carbon-mediated repression, respectively. However, the growth at suboptimal temperatures resulted in a TurA-dependent increase of Pu repression. These results strongly suggest that a physiological significance of the negative role of TurA on Pu activity could be limitation of the expression of the toluene-degrading enzymes at suboptimal growth temperatures. Therefore, the identification of TurA as Pu-binding protein revealed a novel physiological modulation of Pu promoter that is different from those strictly nutritional described previously.	Univ Milan, Dipartimento Sci Biomol & Biotecnol, I-20133 Milan, Italy; BioInfoBank Inst, PL-60744 Poznan, Poland; CSIC, Ctr Nacl Biotecnol, Dept Microbial Biotechnol, E-28049 Madrid, Spain	University of Milan; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Bertoni, G (corresponding author), Univ Milan, Dipartimento Sci Biomol & Biotecnol, Via Celoria 26, I-20133 Milan, Italy.	giovanni.bertoni@unimi.it	BERTONI, GIOVANNI/J-3437-2012	BERTONI, GIOVANNI/0000-0001-5761-9494; de Lorenzo, Victor/0000-0002-6041-2731				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Atlung T, 1997, MOL MICROBIOL, V24, P7, DOI 10.1046/j.1365-2958.1997.3151679.x; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Bertin P, 2001, BIOCHIMIE, V83, P235, DOI 10.1016/S0300-9084(01)01247-0; Bertoni G, 1998, EMBO J, V17, P5120, DOI 10.1093/emboj/17.17.5120; Buck M, 2000, J BACTERIOL, V182, P4129, DOI 10.1128/JB.182.15.4129-4136.2000; Carmona M, 1999, J BIOL CHEM, V274, P33790, DOI 10.1074/jbc.274.47.33790; Cases I, 1998, CURR OPIN MICROBIOL, V1, P303, DOI 10.1016/S1369-5274(98)80034-9; Cases I, 1999, J BIOL CHEM, V274, P15562, DOI 10.1074/jbc.274.22.15562; Cases I, 1996, MOL MICROBIOL, V19, P7, DOI 10.1046/j.1365-2958.1996.345873.x; Cases I, 2000, J BACTERIOL, V182, P956, DOI 10.1128/JB.182.4.956-960.2000; Cases I, 2001, EMBO J, V20, P1, DOI 10.1093/emboj/20.1.1; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DELORENZO V, 1991, EMBO J, V10, P1159, DOI 10.1002/j.1460-2075.1991.tb08056.x; DELORENZO V, 1993, GENE, V123, P17, DOI 10.1016/0378-1119(93)90533-9; DELORENZO V, 1994, METHOD ENZYMOL, V235, P386; Diggle SP, 2002, J BACTERIOL, V184, P2576, DOI 10.1128/JB.184.10.2576-2586.2002; Falconi M, 1998, EMBO J, V17, P7033, DOI 10.1093/emboj/17.23.7033; FERNANDEZ S, 1995, MOL MICROBIOL, V16, P205, DOI 10.1111/j.1365-2958.1995.tb02293.x; Garmendia J, 2000, MOL MICROBIOL, V38, P401, DOI 10.1046/j.1365-2958.2000.02139.x; GARMENDIA J, 2001, THESIS U AUTONOMA MA; Geiselmann J, 1997, BIOL CHEM, V378, P599; Ginalski K, 2003, NUCLEIC ACIDS RES, V31, P3804, DOI 10.1093/nar/gkg504; HERRERO M, 1990, J BACTERIOL, V172, P6557, DOI 10.1128/jb.172.11.6557-6567.1990; HOLTEL A, 1994, J BACTERIOL, V176, P1773, DOI 10.1128/jb.176.6.1773-1776.1994; Hommais F, 2001, MOL MICROBIOL, V40, P20, DOI 10.1046/j.1365-2958.2001.02358.x; KANIGA K, 1991, GENE, V109, P137, DOI 10.1016/0378-1119(91)90599-7; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Macchi R, 2003, J BIOL CHEM, V278, P27695, DOI 10.1074/jbc.M303031200; MORITA M, 1979, EUR J BIOCHEM, V97, P435, DOI 10.1111/j.1432-1033.1979.tb13131.x; Nelson KE, 2002, ENVIRON MICROBIOL, V4, P799, DOI 10.1046/j.1462-2920.2002.00366.x; O'Neill E, 1999, J BIOL CHEM, V274, P32425, DOI 10.1074/jbc.274.45.32425; O'Neill E, 1998, MOL MICROBIOL, V28, P131, DOI 10.1046/j.1365-2958.1998.00780.x; O'Neill E, 2001, EMBO J, V20, P819, DOI 10.1093/emboj/20.4.819; PEREZMARTIN J, 1994, J BIOL CHEM, V269, P22657; PerezMartin J, 1996, CELL, V86, P331, DOI 10.1016/S0092-8674(00)80104-X; PerezMartin J, 1996, J MOL BIOL, V258, P575, DOI 10.1006/jmbi.1996.0270; PEREZMARTIN J, 1995, P NATL ACAD SCI USA, V92, P7277, DOI 10.1073/pnas.92.16.7277; Peterson JD, 2001, NUCLEIC ACIDS RES, V29, P123, DOI 10.1093/nar/29.1.123; Ramos JL, 1997, ANNU REV MICROBIOL, V51, P341, DOI 10.1146/annurev.micro.51.1.341; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; Rosenthal RS, 1998, PROTEIN SCI, V7, P178, DOI 10.1002/pro.5560070118; SAMBROOK J, 2000, MOL CLONING LAB MANU; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SPASSKY A, 1984, NUCLEIC ACIDS RES, V12, P5321, DOI 10.1093/nar/12.13.5321; SPURIO R, 1992, MOL GEN GENET, V231, P201, DOI 10.1007/BF00279792; Studholme DJ, 2003, J BACTERIOL, V185, P1757, DOI 10.1128/JB.185.6.1757-1767.2003; Sze CC, 2002, J BACTERIOL, V184, P760, DOI 10.1128/JB.184.3.760-770.2002; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Valls M, 2002, J BIOL CHEM, V277, P2169, DOI 10.1074/jbc.M108162200; VANDERMEER JR, 1992, MICROBIOL REV, V56, P677, DOI 10.1128/MMBR.56.4.677-694.1992; Wikstrom P, 2001, J MOL BIOL, V314, P971, DOI 10.1006/jmbi.2000.5212; Xu H, 2001, CURR OPIN MICROBIOL, V4, P138, DOI 10.1016/S1369-5274(00)00179-X; Zhang X, 2002, MOL MICROBIOL, V45, P895, DOI 10.1046/j.1365-2958.2002.03065.x	57	38	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7777	7784		10.1074/jbc.M310580200	http://dx.doi.org/10.1074/jbc.M310580200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14672954	hybrid			2022-12-25	WOS:000189103300051
J	Huang, HJ; Zegarro-Moro, OL; Benson, D; Tindall, DJ				Huang, HJ; Zegarro-Moro, OL; Benson, D; Tindall, DJ			Androgens repress Bcl-2 expression via activation of the retinoblastoma (RB) protein in prostate cancer cells	ONCOGENE			English	Article						androgen receptor; Bcl-2; RB; transcription regulation; prostate cancer	HAMMERHEAD RIBOZYME; CYCLE PROGRESSION; TUMOR-MODEL; S-PHASE; GENE; APOPTOSIS; PROMOTER; RECEPTOR; OLIGODEOXYNUCLEOTIDES; INDEPENDENCE	The oncogene Bcl- 2 is upregulated frequently in prostate tumors following androgen ablation therapy, and Bcl- 2 overexpression may contribute to the androgen- refractory relapse of the disease. However, the molecular mechanism underlying androgenic regulation of Bcl- 2 in prostate cancer cells is understood poorly. In this study, we demonstrated that no androgen response element ( ARE) was identified in the androgen- regulated region of the P1 promoter of Bcl- 2 gene, whereas, we provided evidence that the androgenic effect is mediated by E2F1 protein through a putative E2F- binding site in the promoter. We further demonstrated that retinoblastoma ( RB) protein plays a critical role in androgen regulation of Bcl- 2. The phosphorylation levels of RB at serine residues 780 and 795 were decreased in LNCaP cells treated with androgens. Ectopic expression of a constitutively active form of RB inhibited expression of Bcl- 2. Knockdown of endogenous RB protein by an Rb small inference RNA ( siRNA) induced an increase in Bcl- 2 levels. Most importantly, the effect of androgens on Bcl- 2 was abolished completely by specific inhibition of RB function with a mutated E1A. Finally, androgen treatment of LNCaP cells upregulated specifically levels of the cyclin-dependent kinase inhibitors ( CDKIs) p15INK4B and p27KIP1. Ectopic expression of p15INK4B and/ or p27KIP1 inhibited Bcl- 2 expression. Knockdown of endogenous p15INK4B or p27KIP1 protein with a pool of siRNAs diminished androgen- induced downregulation of Bcl- 2 expression. Therefore, our data indicate that androgens suppress Bcl- 2 expression through negatively modulating activities of the E2F site in the Bcl- 2 promoter by activating the CDKI- RB axis.	Mayo Clin & Mayo Fdn, Dept Urol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Tindall, DJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Urol, 200 1st St SW, Rochester, MN 55905 USA.	tindall.donald@mayo.edu			NATIONAL CANCER INSTITUTE [P50CA091956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060920] Funding Source: NIH RePORTER; NCI NIH HHS [CA91956] Funding Source: Medline; NIDDK NIH HHS [DK60920] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agus DB, 1999, J NATL CANCER I, V91, P1869, DOI 10.1093/jnci/91.21.1869; Bruckheimer EM, 2003, J UROLOGY, V169, P1553, DOI 10.1097/01.ju.0000055140.91204.c7; Butler R, 2000, CELL GROWTH DIFFER, V11, P49; Cheema SK, 2003, J BIOL CHEM, V278, P19995, DOI 10.1074/jbc.M205865200; Chi KN, 2001, CLIN CANCER RES, V7, P3920; COLOMBEL M, 1993, AM J PATHOL, V143, P390; Cordon-Cardo C, 1998, JNCI-J NATL CANCER I, V90, P1284, DOI 10.1093/jnci/90.17.1284; Decary S, 2002, MOL CELL BIOL, V22, P7877, DOI 10.1128/MCB.22.22.7877-7888.2002; Denmeade SR, 1996, PROSTATE, V28, P251; Dorai T, 1997, PROSTATE, V32, P246, DOI 10.1002/(SICI)1097-0045(19970901)32:4<246::AID-PROS4>3.0.CO;2-H; Dorai T, 1997, ANTICANCER RES, V17, P3307; Fernandez A, 2001, J NATL CANCER I, V93, P208, DOI 10.1093/jnci/93.3.208; Gleave M, 1999, CLIN CANCER RES, V5, P2891; Gleave M, 1999, PROSTATE CANCER P D, V2, pS15, DOI 10.1038/sj.pcan.4500341; Gleave ME, 1999, UROLOGY, V54, P36, DOI 10.1016/S0090-4295(99)00453-7; Gomez-Manzano C, 2001, CANCER RES, V61, P6693; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Haldar S, 1997, CANCER RES, V57, P229; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; Huang H, 2002, CRIT REV EUKAR GENE, V12, P193, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i3.30; Huang H, 2001, J BIOL CHEM, V276, P38830, DOI 10.1074/jbc.M103632200; Huang HJ, 1999, CANCER RES, V59, P2981; Huggins C, 1941, CANCER RES, V1, P293; ISAACS JT, 1984, PROSTATE, V5, P545, DOI 10.1002/pros.2990050510; Jiang Z, 2002, J CELL BIOL, V156, P185, DOI 10.1083/jcb.200106084; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Kimura K, 2001, CANCER RES, V61, P5611; Krajewska M, 1996, AM J PATHOL, V148, P1567; KYPRIANOU N, 1990, CANCER RES, V50, P3748; Lapointe J, 1999, ENDOCRINOLOGY, V140, P416, DOI 10.1210/en.140.1.416; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Liu SL, 2000, ONCOGENE, V19, P3352, DOI 10.1038/sj.onc.1203675; Lu LF, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-22; Masiello D, 2002, J BIOL CHEM, V277, P26321, DOI 10.1074/jbc.M203310200; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; McDonnell TJ, 1997, J UROLOGY, V157, P569, DOI 10.1016/S0022-5347(01)65204-2; Miyake H, 1999, CANCER RES, V59, P4030; MIYASHITA T, 1994, CANCER RES, V54, P3131; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; RAFFO AJ, 1995, CANCER RES, V55, P4438; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Swinnen JV, 1997, P NATL ACAD SCI USA, V94, P12975, DOI 10.1073/pnas.94.24.12975; Tsihlias J, 2000, ONCOGENE, V19, P670, DOI 10.1038/sj.onc.1203369; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; WESTIN P, 1995, AM J PATHOL, V146, P1368; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Yang RM, 1998, J UROLOGY, V159, P941, DOI 10.1016/S0022-5347(01)63776-5; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008	53	42	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2161	2176		10.1038/sj.onc.1207326	http://dx.doi.org/10.1038/sj.onc.1207326			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14676836				2022-12-25	WOS:000220280900006
J	Boesen, T; Mohammad, SS; Pavitt, GD; Andersen, GR				Boesen, T; Mohammad, SS; Pavitt, GD; Andersen, GR			Structure of the catalytic fragment of translation initiation factor 2B and identification of a critically important catalytic residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; FACTOR 5 EIF5; CRYSTAL-STRUCTURE; EPSILON-SUBUNIT; BETA-SUBUNIT; ACTIVATION; GTPASE; COMPLEX; BINDING; RAS	Eukaryotic initiation factor (eIF) 2B catalyzes the nucleotide activation of eIF2 to its active GTP-bound state. The exchange activity has been mapped to the C terminus of the eIF2Bepsilon subunit. We have determined the crystal structure of residues 544 - 704 from yeast eIF2Bepsilon at 2.3-Angstrom resolution, and this fragment is an all-helical protein built around the conserved aromatic acidic ( AA) boxes also found in eIF4G and eIF5. The eight helices are organized in a manner similar to HEAT repeats. The molecule is highly asymmetric with respect to surface charge and conservation. One area in the N terminus is proposed to be directly involved in catalysis. In agreement with this hypothesis, mutation of glutamate 569 is shown to be lethal. An acidic belt and a second area in the C terminus containing residues from the AA boxes are important for binding to eIF2. Two mutations causing the fatal human genetic disease leukoencephalopathy with vanishing white matter are buried and appear to disrupt the structural integrity of the catalytic domain rather than interfering directly with catalysis or binding of eIF2.	Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark; Univ Manchester, Inst Sci & Technol, Manchester M60 1QD, Lancs, England	Aarhus University; University of Manchester	Andersen, GR (corresponding author), Aarhus Univ, Dept Mol Biol, Gustav Wieds Vej 10C, DK-8000 Aarhus C, Denmark.	grand@imsb.au.dk	Pavitt, Graham D/A-1363-2010	Pavitt, Graham D/0000-0002-8593-2418; Boesen, Thomas/0000-0002-5633-6844; Andersen, Gregers Rom/0000-0001-6292-3319	NIGMS NIH HHS [GM62789-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062789] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen GR, 2000, MOL CELL, V6, P1261, DOI 10.1016/S1097-2765(00)00122-2; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; Andrade MA, 2001, J MOL BIOL, V309, P1, DOI 10.1006/jmbi.2001.4624; Asano K, 1999, EMBO J, V18, P1673, DOI 10.1093/emboj/18.6.1673; Beraud-Dufour S, 1998, EMBO J, V17, P3651, DOI 10.1093/emboj/17.13.3651; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUSHMAN JL, 1993, MOL CELL BIOL, V13, P1920, DOI 10.1128/MCB.13.3.1920; CHAKRABARTI A, 1991, J BIOL CHEM, V266, P14039; Das S, 2000, MOL CELL BIOL, V20, P3942, DOI 10.1128/MCB.20.11.3942-3950.2000; Das S, 1997, J BIOL CHEM, V272, P31712, DOI 10.1074/jbc.272.50.31712; Das S, 2001, J BIOL CHEM, V276, P6720, DOI 10.1074/jbc.M008863200; DEVER TE, 1995, MOL CELL BIOL, V15, P6351; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Erickson FL, 1996, EMBO J, V15, P6311, DOI 10.1002/j.1460-2075.1996.tb01021.x; Erickson FL, 2001, GENETICS, V158, P123; Fabian JR, 1997, J BIOL CHEM, V272, P12359, DOI 10.1074/jbc.272.19.12359; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Gomez E, 2002, EMBO J, V21, P5292, DOI 10.1093/emboj/cdf515; Gomez E, 2000, MOL CELL BIOL, V20, P3965, DOI 10.1128/MCB.20.11.3965-3976.2000; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Leegwater PAJ, 2001, NAT GENET, V29, P383, DOI 10.1038/ng764; LESLIE AGW, 1992, NEWSLETTER PROTEIN C, V26; Marcotrigiano J, 2001, MOL CELL, V7, P193, DOI 10.1016/S1097-2765(01)00167-8; Margarit SM, 2003, CELL, V112, P685, DOI 10.1016/S0092-8674(03)00149-1; Mazza C, 2001, MOL CELL, V8, P383, DOI 10.1016/S1097-2765(01)00299-4; Paulin FEM, 2001, CURR BIOL, V11, P55, DOI 10.1016/S0960-9822(00)00025-7; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; van der Knaap MS, 2002, ANN NEUROL, V51, P264, DOI 10.1002/ana.10112; Wang XM, 2001, EMBO J, V20, P4349, DOI 10.1093/emboj/20.16.4349; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Williams DD, 2001, J BIOL CHEM, V276, P3733, DOI 10.1074/jbc.M008041200; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Yang WM, 1996, MOL CELL BIOL, V16, P6603	43	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10584	10592		10.1074/jbc.M311055200	http://dx.doi.org/10.1074/jbc.M311055200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14681227	hybrid			2022-12-25	WOS:000220050400112
J	Brown, CO; Chi, X; Garcia-Gras, E; Shirai, M; Feng, XH; Schwartz, RJ				Brown, CO; Chi, X; Garcia-Gras, E; Shirai, M; Feng, XH; Schwartz, RJ			The cardiac determination factor, Nkx2-5, is activated by mutual cofactors GATA-4 and Smad1/4 via a novel upstream enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEINS; TUMOR-SUPPRESSOR SMAD4/DPC4; DNA-BINDING TARGETS; GROWTH-FACTOR-BETA; TGF-BETA; CARDIOMYOCYTE DIFFERENTIATION; TRANSCRIPTION FACTORS; GENE-EXPRESSION; MESODERM INDUCTION; MOUSE EMBRYO	The mammalian homologue of Drosophila tinman, Nkx2-5, plays an early role in regulating cardiac genes and morphogenesis. Bone morphogenetic proteins (BMPs), members of the transforming growth factor (TGF)-beta family of signaling molecules, are involved in numerous developmental processes. BMP signaling is crucial in the regulation of Nkx2-5 expression and specification of the cardiac lineage. Constitutively active BMP type I receptor or the downstream pathway components and DNA-binding transcription factors, Smad1/4 directly activated Nkx2-5 gene transcription. We identified and characterized a novel upstream Nkx2-5 enhancer, composed of clustered repeats of Smad and GATA DNA binding sites. This composite Nkx2-5 enhancer was a direct target of BMP signaling via cooperative interactions between the downstream transducers Smad1/4 and GATA-4. In mammalian two hybrid assays, Smad factors recruited the hybrid gene GATA4-VP16 to strongly drive transcription of a reporter gene containing multimerized Smad binding sites These cofactors interacted through the second zinc finger and adjacent basic domain of GATA-4 and the N-terminal domain of Smads. Smad4 and GATA4 were also found to bind in vivo with the Nkx2-5 composite enhancer, as revealed by chromatin immunoprecipitation analysis of differentiated P19 cells. Finally, transgenic mice containing the Smad/GATA composite enhancer recapitulated early murine Nkx2-5 cardiac expression and deletion of this enhancer within a 10-kb transgene pBS-Nkx2-5 LacZ significantly reduced expression in the cardiac crescent. Thus, integration of GATA transcription factors with BMP signaling, through co-association with Smads factors, may initiate early Nkx2-5 expression; suggesting a vital role for the combination of these factors in the specification of cardiac progenitors.	Baylor Coll Med, Dept Med, Ctr Cardiovasc Dev, Houston, TX 77030 USA; Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Schwartz, RJ (corresponding author), 1 Baylor Plaza, Houston, TX 77030 USA.	schwartz@bcm.tmc.edu		Garcia Gras, Eduardo/0000-0002-6930-0111	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049953] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL49953] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blokzijl A, 2002, CURR BIOL, V12, P35, DOI 10.1016/S0960-9822(01)00623-6; Chang DF, 2003, DEV CELL, V4, P107, DOI 10.1016/S1534-5807(02)00396-9; Chang H, 2002, ENDOCR REV, V23, P787, DOI 10.1210/er.2002-0003; Chang H, 1999, DEVELOPMENT, V126, P1631; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; Chen CY, 1996, MOL CELL BIOL, V16, P6372; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; Ehrman LA, 1999, DEV BIOL, V207, P163, DOI 10.1006/dbio.1998.9167; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; Jamali M, 2001, FEBS LETT, V509, P126, DOI 10.1016/S0014-5793(01)03151-9; Johnson K, 1999, J BIOL CHEM, V274, P20709, DOI 10.1074/jbc.274.29.20709; Johnson KD, 2002, METHODS, V26, P27, DOI 10.1016/S1046-2023(02)00005-1; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Ladd AN, 1998, DEV BIOL, V204, P407, DOI 10.1006/dbio.1998.9094; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Liberatore CM, 2002, DEV BIOL, V244, P243, DOI 10.1006/dbio.2002.0604; Lien CL, 1999, DEVELOPMENT, V126, P75; Lien CL, 2002, DEV BIOL, V244, P257, DOI 10.1006/dbio.2002.0603; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Monzen K, 1999, MOL CELL BIOL, V19, P7096; Monzen K, 2001, J CELL BIOL, V153, P687, DOI 10.1083/jcb.153.4.687; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; Ramchandran R, 2000, AM J HEMATOL, V65, P14, DOI 10.1002/1096-8652(200009)65:1<14::AID-AJH3>3.0.CO;2-F; Reecy JM, 1999, DEVELOPMENT, V126, P839; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; Schneider MD, 2003, CYTOKINE GROWTH F R, V14, P1, DOI 10.1016/S1359-6101(02)00053-9; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; Schwartz RJ, 1999, DEVELOPMENT, V126, P4187; Searcy RD, 1998, DEVELOPMENT, V125, P4461; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Skerjanc IS, 1999, TRENDS CARDIOVAS MED, V9, P139, DOI 10.1016/S1050-1738(99)00017-1; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Walters MJ, 2001, MECH DEVELOP, V100, P263, DOI 10.1016/S0925-4773(00)00535-9; Weinstein M, 1998, P NATL ACAD SCI USA, V95, P9378, DOI 10.1073/pnas.95.16.9378; Xu X, 1998, GENE DEV, V12, P2354, DOI 10.1101/gad.12.15.2354; Yang X, 1998, P NATL ACAD SCI USA, V95, P3667, DOI 10.1073/pnas.95.7.3667; Yatskievych TA, 1997, DEVELOPMENT, V124, P2561; Zhang HB, 1996, DEVELOPMENT, V122, P2977	50	124	132	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10659	10669		10.1074/jbc.M301648200	http://dx.doi.org/10.1074/jbc.M301648200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14662776	hybrid			2022-12-25	WOS:000220050400120
J	Chu, X; Tong, Q; Cheung, JY; Wozney, J; Conrad, K; Mazack, V; Zhang, WY; Stahl, R; Barber, DL; Miller, BA				Chu, X; Tong, Q; Cheung, JY; Wozney, J; Conrad, K; Mazack, V; Zhang, WY; Stahl, R; Barber, DL; Miller, BA			Interaction of TRPC2 and TRPC6 in erythropoietin modulation of calcium influx	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR-FREE CALCIUM; CAPACITATIVE CA2+ ENTRY; PHENYLHYDRAZINE-TREATED MICE; MURINE ERYTHROLEUKEMIA-CELLS; HUMAN ERYTHROID PRECURSORS; CENTRAL-NERVOUS-SYSTEM; HUMAN ERYTHROBLASTS; CATION CHANNEL; RECEPTOR; DIFFERENTIATION	Erythropoietin (Epo) modulates calcium influx through voltage-independent calcium-permeable channel(s). Here, we characterized the expression of transient receptor potential channels (TRPCs) in primary erythroid cells and examined their regulation. Erythroblasts were isolated from the spleens of phenylhydrazine-treated mice, and Epo stimulation resulted in a significant and dose-dependent increase in [Ca](i). Among the classical TRPC channels, expression of three N-terminal splice variants of TRPC2 (clones 14, 17, and alpha) and of TRPC6 were demonstrated in these erythroblasts by both reverse transcriptase-PCR and Western blotting. Confocal microscopy confirmed localization to the plasma membrane. To determine the function of individual TRPC channels in erythropoietin modulation of calcium influx, digital video imaging was used to measure calcium influx through these TRPCs in a Chinese hamster ovary (CHO) cell model. Single CHO-S cells, expressing transfected Epo-R, were identified by detection of green fluorescent protein. Cells that express transfected TRPCs were identified by detection of blue fluorescent protein. [Ca](i) was monitored with Fura Red. Epo stimulation of CHO-S cells transfected with single TRPC2 isoforms (clone 14, 17, or alpha) and Epo-R resulted in a significant increase in [ Ca] i. This was not observed in cells transfected with Epo-R and TRPC6. In addition, coexpression of TRPC6 with TRPC2 and Epo-R inhibited the increase in [Ca](i) observed after Epo stimulation. Immunoprecipitation experiments demonstrated that TRPC2 associates with TRPC6, indicating that these TRPCs can form multimeric channels. These data demonstrate that specific TRPCs are expressed in primary erythroid cells and that two of these channels, TRPC2 and TRPC6, can interact to modulate calcium influx stimulated by erythropoietin.	Geisinger Med Clin, Henry Hood Res Program, Sigfried & Janet Weis Ctr Res, Danville, PA 17822 USA; Geisinger Med Clin, Dept Med, Danville, PA 17822 USA; Geisinger Med Clin, Dept Pediat, Danville, PA 17822 USA; Ontario Canc Inst, Div Cellular & Mol Biol, Toronto, ON M5S 2M9, Canada	Geisinger Medical Center; Geisinger Medical Center; Geisinger Medical Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Miller, BA (corresponding author), Geisinger Med Clin, Henry Hood Res Program, Sigfried & Janet Weis Ctr Res, 100 N Acad Dr, Danville, PA 17822 USA.	bamiller1@geisinger.edu		Barber, Dwayne/0000-0001-5528-8150	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046778, R56DK046778] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 58672] Funding Source: Medline; NIDDK NIH HHS [DK 46778] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akimoto T, 2001, NEPHROL DIAL TRANSPL, V16, P491, DOI 10.1093/ndt/16.3.491; Balzer M, 1999, CARDIOVASC RES, V42, P543, DOI 10.1016/S0008-6363(99)00025-5; Barber DL, 2001, BLOOD, V97, P2230, DOI 10.1182/blood.V97.8.2230; BILLESTRUP N, 1995, P NATL ACAD SCI USA, V92, P2725, DOI 10.1073/pnas.92.7.2725; Birnbaumer L, 2000, RECENT PROG HORM RES, V55, P127; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Buess M, 1999, ONCOGENE, V18, P1487, DOI 10.1038/sj.onc.1202445; Cerami A, 2001, SEMIN ONCOL, V28, P66, DOI 10.1053/sonc.2001.25401; Cheung JY, 1997, BLOOD, V89, P92, DOI 10.1182/blood.V89.1.92.92_92_100; CHEUNG JY, 1992, J CLIN INVEST, V90, P1850, DOI 10.1172/JCI116061; Chu X, 2002, J BIOL CHEM, V277, P34375, DOI 10.1074/jbc.M205541200; Dame C, 2001, BIOL NEONATE, V79, P228; Duncan LM, 1998, CANCER RES, V58, P1515; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GILLO B, 1993, BLOOD, V81, P783; Goel M, 2002, J BIOL CHEM, V277, P48303, DOI 10.1074/jbc.M207882200; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Heiner I, 2003, BIOCHEM J, V371, P1045, DOI 10.1042/BJ20021975; HENSOLD JO, 1991, BLOOD, V77, P1362; Hodges VM, 1999, BRIT J HAEMATOL, V106, P325, DOI 10.1046/j.1365-2141.1999.01535.x; Hoenderop JGJ, 2003, EMBO J, V22, P776, DOI 10.1093/emboj/cdg080; Hofmann T, 2000, BIOCHEM J, V351, P115, DOI 10.1042/0264-6021:3510115; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Hunter JJ, 1998, GENOMICS, V54, P116, DOI 10.1006/geno.1998.5549; Jungnickel MK, 2001, NAT CELL BIOL, V3, P499, DOI 10.1038/35074570; Kina T, 2000, BRIT J HAEMATOL, V109, P280, DOI 10.1046/j.1365-2141.2000.02037.x; Koshimura K, 1999, J NEUROCHEM, V72, P2565, DOI 10.1046/j.1471-4159.1999.0722565.x; KRYSTAL G, 1983, EXP HEMATOL, V11, P649; KUREBAYASHI N, 1993, BIOPHYS J, V64, P1934, DOI 10.1016/S0006-3495(93)81564-9; LEVENSON R, 1980, P NATL ACAD SCI-BIOL, V77, P5948, DOI 10.1073/pnas.77.10.5948; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; Liman ER, 1999, P NATL ACAD SCI USA, V96, P5791, DOI 10.1073/pnas.96.10.5791; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; MASUDA S, 1993, J BIOL CHEM, V268, P11208; MILLER BA, 1989, BLOOD, V73, P1188; Miller BA, 1999, J BIOL CHEM, V274, P20465, DOI 10.1074/jbc.274.29.20465; MILLER BA, 1988, J CLIN INVEST, V82, P309, DOI 10.1172/JCI113588; Miller CP, 2002, BLOOD, V99, P898, DOI 10.1182/blood.V99.3.898; MISITI J, 1979, J CLIN INVEST, V64, P1573, DOI 10.1172/JCI109618; MLADENOVIC J, 1988, J LAB CLIN MED, V112, P23; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 2001, Sci STKE, V2001, pre1, DOI 10.1126/stke.2001.90.re1; Ni ZM, 1998, HYPERTENSION, V32, P724, DOI 10.1161/01.HYP.32.4.724; Ogilvie M, 2000, J BIOL CHEM, V275, P39754, DOI 10.1074/jbc.M004999200; SAWYER ST, 1984, J BIOL CHEM, V259, P2769; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; Wu YM, 1997, AM J PHYSIOL-HEART C, V273, pH2161, DOI 10.1152/ajpheart.1997.273.5.H2161; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Xu XZS, 2001, P NATL ACAD SCI USA, V98, P10692, DOI 10.1073/pnas.191360198; Xu XZS, 2000, NEURON, V26, P647, DOI 10.1016/S0896-6273(00)81201-5; Yildirim E, 2003, P NATL ACAD SCI USA, V100, P2220, DOI 10.1073/pnas.0438036100; Yu Y, 2003, AM J PHYSIOL-CELL PH, V284, pC316, DOI 10.1152/ajpcell.00125.2002; Zhang L, 2001, J BIOL CHEM, V276, P13331, DOI 10.1074/jbc.M008914200; Zhang MY, 1998, BLOOD, V92, P1225, DOI 10.1182/blood.V92.4.1225.416k20_1225_1234; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7	57	55	59	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10514	10522		10.1074/jbc.M308478200	http://dx.doi.org/10.1074/jbc.M308478200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699131	hybrid			2022-12-25	WOS:000220050400104
J	Luo, BH; Takagi, J; Springer, TA				Luo, BH; Takagi, J; Springer, TA			Locking the beta(3) integrin I-like domain into high and low affinity conformations with disulfides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; A-DOMAIN; EXTRACELLULAR SEGMENT; SUBUNIT; PROTEIN; LIGAND; ACTIVATION; COMPLEX; ALPHA(5)BETA(1); ALPHA-L-BETA-2	Although integrin alpha subunit I domains exist in multiple conformations, it is controversial whether integrin beta subunit I-like domains undergo structurally analogous movements of the alpha7-helix that are linked to affinity for ligand. Disulfide bonds were introduced into the beta(3) integrin I-like domain to lock its beta6-alpha7 loop and alpha7-helix in two distinct conformations. Soluble ligand binding, ligand mimetic mAb binding and cell adhesion studies showed that disulfide-bonded receptor alpha(IIbbeta3)(T329C/A347C) was locked in a low affinity state, and dithiothreitol treatment restored the capability of being activated to high affinity binding; by contrast, disulfide-bonded alpha(IIb)beta3(V332C/M335C) was locked in a high affinity state. The results suggest that activation of the beta subunit I-like domain is analogous to that of the alpha subunit I domain, i.e. that axial movement in the C-terminal direction of the alpha7-helix is linked to rearrangement of the I-like domain metal ion-dependent adhesion site into a high affinity conformation.	Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School	Springer, TA (corresponding author), Harvard Univ, Sch Med, CBR Inst Biomed Res, 200 Longwood Ave, Boston, MA 02115 USA.	springeroffice@cbr.med.harvard.edu			NHLBI NIH HHS [HL48675] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; EIRIN MT, 1986, BIOCHEM J, V240, P147, DOI 10.1042/bj2400147; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Huang CC, 1997, P NATL ACAD SCI USA, V94, P3162, DOI 10.1073/pnas.94.7.3162; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; KALOMIRIS EL, 1985, BIOCHEMISTRY-US, V24, P5430, DOI 10.1021/bi00341a022; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2387, DOI 10.1073/pnas.041606398; Lu CF, 1997, J IMMUNOL, V159, P268; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; Luo BH, 2003, P NATL ACAD SCI USA, V100, P2403, DOI 10.1073/pnas.0438060100; Mould AP, 2003, J BIOL CHEM, V278, P51622, DOI 10.1074/jbc.M306655200; Mould AP, 2003, J BIOL CHEM, V278, P17028, DOI 10.1074/jbc.M213139200; Mould AP, 2002, J BIOL CHEM, V277, P19800, DOI 10.1074/jbc.M201571200; Puzon-McLaughlin W, 2000, J BIOL CHEM, V275, P7795, DOI 10.1074/jbc.275.11.7795; Shimaoka M, 2001, P NATL ACAD SCI USA, V98, P6009, DOI 10.1073/pnas.101130498; Shimaoka M, 2002, P NATL ACAD SCI USA, V99, P16737, DOI 10.1073/pnas.252633099; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2003, EMBO J, V22, P4607, DOI 10.1093/emboj/cdg445; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yan BX, 2000, J BIOL CHEM, V275, P39964, DOI 10.1074/jbc.M007041200	29	79	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10215	10221		10.1074/jbc.M312732200	http://dx.doi.org/10.1074/jbc.M312732200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14681220	hybrid, Green Published			2022-12-25	WOS:000220050400068
J	Mahabeleshwar, GH; Das, R; Kundu, GC				Mahabeleshwar, GH; Das, R; Kundu, GC			Tyrosine kinase, p56(lck)-induced cell motility, and urokinase-type plasminogen activator secretion involve activation of epidermal growth factor receptor/extracellular signal regulated kinase pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-MEDIATED SECRETION; BREAST-CANCER CELLS; KAPPA-B; PROTEIN-KINASE; PROMATRIX METALLOPROTEINASE-2; MATRIX-METALLOPROTEINASE; DEPENDENT MECHANISM; T-CELLS; PHOSPHORYLATION; MIGRATION	We have recently reported that tyrosine kinase, p56(lck) regulates cell motility and nuclear factor kappaB-mediated secretion of urokinase-type plasminogen activator (uPA) through tyrosine phosphorylation of IkappaBalpha following hypoxia/reoxygenation (Mahabeleshwar, G. H., and Kundu, G. C. ( 2003) J. Biol. Chem. 278, 52598 - 52612). However, the role of hypoxia/reoxygenation (H/R) on ERK1/2-mediated uPA secretion and cell motility and the involvement of p56(lck) and EGF receptor in these processes in breast cancer cells is not well defined. We provide here evidence that H/R induces Lck kinase activity and Lck-dependent tyrosine phosphorylation of EGF receptor in highly invasive (MDA-MB-231) and low invasive (MCF-7) breast cancer cells. H/R also stimulates MEK-1 and ERK1/2 phosphorylations, and H/R-induced phosphorylations were suppressed by the dominant negative form of Lck (DN Lck, K273R) as well as pharmacological inhibitors of EGF receptor and Lck indicating that EGF receptors and Lck are involved in these processes. Transfection of these cells with wild type Lck or Lck F505 (Y505F) but not with Lck F394 (Y394F) induced phosphorylations of EGF receptor followed by MEK-1 and ERK1/2, suggesting that Lck is upstream of EGF receptor and Tyr-394 of Lck is crucial for these processes. H/R also induced uPA secretion and cell motility in these cells. DN Lck and inhibitors of Lck, EGF receptor, and MEK-1 suppressed H/R-induced uPA secretion and cell motility. To our knowledge, this is the first report that p56lck in presence of H/R regulates MEK-1-dependent ERK1/2 phosphorylation and uPA secretion through tyrosine phosphorylation of EGF receptor, and it further demonstrates that all of these signaling molecules ultimately control the motility of breast cancer cells.	NCCS, Pune 411007, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Kundu, GC (corresponding author), NCCS, NCCS Complex, Pune 411007, Maharashtra, India.	gopalkundu@hotmail.com	Kundu, Gopal C./ABA-9897-2020					ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; Bevan P, 2001, J CELL SCI, V114, P1429; BOULET I, 1987, BIOCHEM BIOPH RES CO, V149, P56, DOI 10.1016/0006-291X(87)91604-4; Das R, 2003, J BIOL CHEM, V278, P28593, DOI 10.1074/jbc.M303445200; DECESARE D, 1995, ONCOGENE, V11, P365; DONATO NJ, 1989, J BIOL CHEM, V264, P20474; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; FUJII K, 1995, EXP CELL RES, V216, P261, DOI 10.1006/excr.1995.1032; GUPTA S, 1994, J BIOL CHEM, V269, P17349; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; Hashimoto Y, 2000, J BIOL CHEM, V275, P34541, DOI 10.1074/jbc.M005332200; Hensley K, 2002, ARCH BIOCHEM BIOPHYS, V397, P377, DOI 10.1006/abbi.2001.2630; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; Karin M, 1996, PHILOS T ROY SOC B, V351, P127, DOI 10.1098/rstb.1996.0008; KOSTER A, 1991, ANTICANCER RES, V11, P193; LAURA M, 2002, J BIOL CHEM, V277, P9405; Mahabeleshwar GH, 2003, J BIOL CHEM, V278, P6209, DOI 10.1074/jbc.M208905200; Mahabeleshwar GH, 2003, J BIOL CHEM, V278, P52598, DOI 10.1074/jbc.M308941200; Maheshwari G, 2001, J CELL BIOL, V155, P1123, DOI 10.1083/jcb.200109060; Mariotti A, 2001, J CELL BIOL, V155, P447, DOI 10.1083/jcb.200105017; MURPHY G, 1994, ANN NY ACAD SCI, V732, P31, DOI 10.1111/j.1749-6632.1994.tb24722.x; NAKAMURA K, 1993, ONCOGENE, V8, P3133; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Philip S, 2001, J BIOL CHEM, V276, P44926, DOI 10.1074/jbc.M103334200; Philip S, 2003, J BIOL CHEM, V278, P14487, DOI 10.1074/jbc.M207309200; Price JT, 1999, CANCER RES, V59, P5475; RADINSKY R, 1995, CLIN CANCER RES, V1, P19; Yousefi S, 2003, CLIN EXP IMMUNOL, V133, P78, DOI 10.1046/j.1365-2249.2003.02187.x	31	24	26	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9733	9742		10.1074/jbc.M311400200	http://dx.doi.org/10.1074/jbc.M311400200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699120	hybrid			2022-12-25	WOS:000220050400011
J	Mansy, SS; Wu, SP; Cowan, JA				Mansy, SS; Wu, SP; Cowan, JA			Iron-sulfur cluster biosynthesis - Biochemical characterization of the conformational dynamics of Thermotoga maritima IscU and the relevance for cellular cluster assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLTEN-GLOBULE STATE; ESCHERICHIA-COLI; ALPHA-LACTALBUMIN; STRUCTURAL-CHARACTERIZATION; 2FE-2S CLUSTER; SERUM-ALBUMIN; BINDING SITE; PROTEIN; STABILITY; INTERMEDIATE	Important for the understanding of the functional properties of the iron-sulfur scaffold IscU is knowledge of the structure and dynamics of this protein class. Structural characterization of Thermotoga maritima IscU by CD (Mansy, S. S., Wu, G., Surerus, K. K., and Cowan, J. A. (2002) J. Biol. Chem. 277, 21397-21404) and high resolution NMR (Bertini, I., Cowan, J. A., Del Bianco, C., Luchinat, C., and Mansy, S. S. (2003) J. Mol. Biol. 331, 907-924) yielded data indicating a high degree of secondary structure. However, the latter also revealed IscU to exist in a dynamic equilibrium between two or more distinct conformations, possibly existing in a molten globule state. Herein, we further characterize the molten globule characteristics of T. maritima IscU by near-ultraviolet circular dichroism, 1-anilino-8-naphthalenesulfonic acid binding, free energy of unfolding, hydrodynamic radius measurements, and limited tryptic digestion. The data suggest unusual dynamic behavior that is not fully consistent with typical protein states such as fully folded, fully unfolded, or molten globule. For instance, the existence of a stable tertiary fold is supported by near-UV CD spectra and hydrodynamic radius measurements, whereas other data are less clearly interpretable and may be viewed as consistent with either a molten globule or fully folded state. However, all of the data are consistent with our previous hypothesis of a protein sampling multiple discrete tertiary conformations in which these structural transitions occur on a "slow" time scale. To describe such proteins, we introduce the term multiple discrete conformers.	Ohio State Univ, Evans Lab Chem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Cowan, JA (corresponding author), Ohio State Univ, Evans Lab Chem, 100 W 18th Ave, Columbus, OH 43210 USA.	cowan@chemistry.ohio-state.edu	Mansy, Sheref/E-6266-2010	Mansy, Sheref/0000-0003-2382-198X				Agar JN, 2000, J BIOL INORG CHEM, V5, P167, DOI 10.1007/s007750050361; Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; AHMAD F, 1992, BIOCHEM J, V287, P481, DOI 10.1042/bj2870481; BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; Bertini I, 2003, J MOL BIOL, V331, P907, DOI 10.1016/S0022-2836(03)00768-X; Betton JM, 1996, J BIOL CHEM, V271, P8046, DOI 10.1074/jbc.271.14.8046; BUROVA TV, 1995, PROTEIN SCI, V4, P909; Cavagnero S, 2001, BIOCHEMISTRY-US, V40, P14459, DOI 10.1021/bi011500n; CHAFFOTTE A, 1991, BIOCHEMISTRY-US, V30, P8067, DOI 10.1021/bi00246a027; Dams T, 1999, BIOCHEMISTRY-US, V38, P9169, DOI 10.1021/bi990635e; de la Torre JG, 2000, BIOPHYS J, V78, P719, DOI 10.1016/S0006-3495(00)76630-6; de Laureto PP, 2002, PROTEIN SCI, V11, P2932, DOI 10.1110/ps.0205802; Del Vecchio P, 2002, BIOCHEMISTRY-US, V41, P1364, DOI 10.1021/bi011146t; DELAURETO PP, 1995, BIOCHEMISTRY-US, V34, P12596, DOI 10.1021/bi00039a015; EISENBERG D, 1979, PHYSICAL CHEM, P718; EWBANK JJ, 1993, BIOCHEMISTRY-US, V32, P3694, DOI 10.1021/bi00065a023; Felitsky DJ, 2003, BIOCHEMISTRY-US, V42, P2202, DOI 10.1021/bi0270992; Fernandez-Recio J, 1999, J MOL BIOL, V290, P319, DOI 10.1006/jmbi.1999.2863; FINK AL, 1994, BIOCHEMISTRY-US, V33, P12504, DOI 10.1021/bi00207a018; Foster MW, 2000, J AM CHEM SOC, V122, P6805, DOI 10.1021/ja000800+; Genzor CG, 1996, PROTEIN SCI, V5, P1376, DOI 10.1002/pro.5560050716; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; HURLEY JK, 1995, PROTEIN SCI, V4, P58; Hwang DM, 1996, J MOL EVOL, V43, P536, DOI 10.1007/PL00006114; Jensen LT, 2000, MOL CELL BIOL, V20, P3918, DOI 10.1128/MCB.20.11.3918-3927.2000; Kaiser JT, 2000, J MOL BIOL, V297, P451, DOI 10.1006/jmbi.2000.3581; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Krebs C, 2001, BIOCHEMISTRY-US, V40, P14069, DOI 10.1021/bi015656z; Kusmierczyk AR, 2000, J BIOL CHEM, V275, P33504, DOI 10.1074/jbc.M006256200; KUWAJIMA K, 1977, J MOL BIOL, V114, P241, DOI 10.1016/0022-2836(77)90208-X; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P43; Mansy SS, 2002, J BIOL CHEM, V277, P21397, DOI 10.1074/jbc.M201439200; MARMORINO JL, 1995, BIOCHEMISTRY-US, V34, P3140, DOI 10.1021/bi00010a002; Matthews JM, 2000, BIOCHEMISTRY-US, V39, P1942, DOI 10.1021/bi991973i; Matulis D, 1998, BIOPHYS J, V74, P422, DOI 10.1016/S0006-3495(98)77799-9; McElroy C, 2002, J MOL BIOL, V323, P463, DOI 10.1016/S0022-2836(02)00940-3; MONTONO C, 1999, BIOCHEMISTRY-US, V38, P1332; Muzammil S, 2000, PROTEINS, V40, P29, DOI 10.1002/(SICI)1097-0134(20000701)40:1<29::AID-PROT50>3.0.CO;2-P; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Nuth M, 2002, J AM CHEM SOC, V124, P8774, DOI 10.1021/ja0264596; Ogasahara K, 1998, BIOCHEMISTRY-US, V37, P17537, DOI 10.1021/bi9814585; OHGUSHI M, 1983, FEBS LETT, V164, P21, DOI 10.1016/0014-5793(83)80010-6; Ollagnier-de-Choudens S, 2001, J BIOL CHEM, V276, P22604, DOI 10.1074/jbc.M102902200; PACE CN, 1988, J BIOL CHEM, V263, P11820; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; Reddy GB, 2000, J BIOL CHEM, V275, P4565, DOI 10.1074/jbc.275.7.4565; REYNOLDS JA, 1970, J BIOL CHEM, V245, P5161; SCHECHTER AN, 1968, J MOL BIOL, V35, P567, DOI 10.1016/S0022-2836(68)80015-4; SCHELLMAN JA, 1987, BIOPOLYMERS, V26, P549, DOI 10.1002/bip.360260408; Schurmann G, 2001, MOL BIOL CELL, V12, P1765, DOI 10.1091/mbc.12.6.1765; Schwartz CJ, 2001, P NATL ACAD SCI USA, V98, P14895, DOI 10.1073/pnas.251550898; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SIRANGELO I, 1994, FEBS LETT, V338, P11, DOI 10.1016/0014-5793(94)80107-X; SPUERGIN P, 1995, EUR J BIOCHEM, V231, P405, DOI 10.1111/j.1432-1033.1995.tb20713.x; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; TAKASE K, 1974, BIOCHIM BIOPHYS ACTA, V371, P352, DOI 10.1016/0005-2795(74)90031-2; TANFORD C, 1964, J AM CHEM SOC, V86, P2050, DOI 10.1021/ja01064a028; TANFORD C, 1967, J AM CHEM SOC, V89, P729, DOI 10.1021/ja00980a001; Tchorzewski M, 2003, BIOCHEMISTRY-US, V42, P3399, DOI 10.1021/bi0206006; TURNER DC, 1968, BIOCHEMISTRY-US, V7, P3381, DOI 10.1021/bi00850a011; Wang CQ, 1998, BIOCHEMISTRY-US, V37, P8457, DOI 10.1021/bi9723010; WEBER G, 1964, J BIOL CHEM, V239, P1415; Wittung-Stafshede P, 1998, BBA-PROTEIN STRUCT M, V1382, P324, DOI 10.1016/S0167-4838(97)00176-3; Wittung-Stafshede P, 2000, J INORG BIOCHEM, V78, P35, DOI 10.1016/S0162-0134(99)00202-0; Wu G, 2002, BIOCHEMISTRY-US, V41, P5024, DOI 10.1021/bi016073s; Wu G, 2002, J BIOL INORG CHEM, V7, P526, DOI 10.1007/s00775-001-0330-2; Wu SP, 2002, BIOCHEMISTRY-US, V41, P8876, DOI 10.1021/bi0256781; XIE D, 1991, BIOCHEMISTRY-US, V30, P10673, DOI 10.1021/bi00108a010; Yao J, 2001, BIOCHEMISTRY-US, V40, P3561, DOI 10.1021/bi002776i; Yoon T, 2003, J AM CHEM SOC, V125, P6078, DOI 10.1021/ja027967i; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	73	33	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10469	10475		10.1074/jbc.M312051200	http://dx.doi.org/10.1074/jbc.M312051200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688265	hybrid			2022-12-25	WOS:000220050400098
J	Prasad, S; Cantwell, AM; Bush, LA; Shih, P; Xu, H; Di Cera, E				Prasad, S; Cantwell, AM; Bush, LA; Shih, P; Xu, H; Di Cera, E			Residue Asp-189 controls both substrate binding and the monovalent cation specificity of thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE; CONVERTING TRYPSIN; CHYMOTRYPSIN; ACTIVATION; SITE; HIRUDIN; ENZYME; RECOGNITION; EVOLUTION; LYASE	Residue Asp-189 plays an important dual role in thrombin: it defines the primary specificity for Arg side chains and participates indirectly in the coordination of Na+. The former role is shared by other proteases with trypsin-like specificity, whereas the latter is unique to Na+-activated proteases in blood coagulation and the complement system. Replacement of Asp-189 with Ala, Asn, Glu, and Ser drastically reduces the specificity toward substrates carrying Arg or Lys at P1, whereas it has little or no effect toward the hydrolysis of substrates carrying Phe at P1. These findings confirm the important role of Asp-189 in substrate recognition by trypsin-like proteases. The substitutions also affect significantly and unexpectedly the monovalent cation specificity of the enzyme. The Ala and Asn mutations abrogate monovalent cation binding, whereas the Ser and Glu mutations change the monovalent cation preference from Na+ to the smaller cation Li+ or to the larger cation Rb+, respectively. The observation that a single amino acid substitution can alter the monovalent cation specificity of thrombin from Na+ (Asp-189) to Li+ (Ser-189) or Rb+ (Glu-189) is unprecedented in the realm of monovalent cation-activated enzymes.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Di Cera, E (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.	enrico@biochem.wustl.edu			NHLBI NIH HHS [HL73813, HL58141, HL49413] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL049413, R01HL073813, R01HL049413, R01HL058141] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AYALA YH, 1994, J MOL BIOL, V235, P733, DOI 10.1006/jmbi.1994.1024; Ayala YM, 2001, PROTEINS, V45, P107, DOI 10.1002/prot.1130; BRAUN PJ, 1988, BIOCHEMISTRY-US, V27, P6517, DOI 10.1021/bi00417a048; Chuang YJ, 2001, BIOCHEMISTRY-US, V40, P6670, DOI 10.1021/bi002933d; Dang QD, 1996, P NATL ACAD SCI USA, V93, P10653, DOI 10.1073/pnas.93.20.10653; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; Di Cera E, 2003, CHEST, V124, p11S, DOI 10.1378/chest.124.3_suppl.11S; DiCera E, 1996, BIOPHYS J, V70, P174, DOI 10.1016/S0006-3495(96)79558-9; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; GRAF L, 1988, P NATL ACAD SCI USA, V85, P4961, DOI 10.1073/pnas.85.14.4961; Guinto ER, 1999, P NATL ACAD SCI USA, V96, P1852, DOI 10.1073/pnas.96.5.1852; HEDSTROM L, 1994, BIOCHEMISTRY-US, V33, P8764, DOI 10.1021/bi00195a018; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; Hedstrom L, 2002, CHEM REV, V102, P4501, DOI 10.1021/cr000033x; Jing H, 1999, EMBO J, V18, P804, DOI 10.1093/emboj/18.4.804; Krem MM, 2003, BIOPHYS CHEM, V100, P315, DOI 10.1016/S0301-4622(02)00289-2; Krem MM, 2002, TRENDS BIOCHEM SCI, V27, P67, DOI 10.1016/S0968-0004(01)02007-2; Krem MM, 2001, EMBO J, V20, P3036, DOI 10.1093/emboj/20.12.3036; Olson ST, 2002, TRENDS CARDIOVAS MED, V12, P331, DOI 10.1016/S1050-1738(02)00183-4; PERONA JJ, 1995, BIOCHEMISTRY-US, V34, P1489, DOI 10.1021/bi00005a004; Phillips RS, 1998, EUR J BIOCHEM, V255, P508, DOI 10.1046/j.1432-1327.1998.2550508.x; Pineda AO, 2002, J BIOL CHEM, V277, P40177, DOI 10.1074/jbc.C200465200; Prasad S, 2003, P NATL ACAD SCI USA, V100, P13785, DOI 10.1073/pnas.2333109100; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; Sundararaju B, 2000, BIOCHEMISTRY-US, V39, P8546, DOI 10.1021/bi000063u; Szabo E, 2003, J MOL BIOL, V331, P1121, DOI 10.1016/S0022-2836(03)00849-0; Szabo E, 1999, EUR J BIOCHEM, V263, P20, DOI 10.1046/j.1432-1327.1999.00452.x; Venekei I, 1996, FEBS LETT, V379, P143, DOI 10.1016/0014-5793(95)01484-5; Vindigni A, 1996, BIOCHEMISTRY-US, V35, P4417, DOI 10.1021/bi952834d; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008	32	43	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10103	10108		10.1074/jbc.M312614200	http://dx.doi.org/10.1074/jbc.M312614200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14679197	hybrid			2022-12-25	WOS:000220050400055
J	Rosnet, O; Blanco-Betancourt, C; Grivel, K; Richter, K; Schiff, C				Rosnet, O; Blanco-Betancourt, C; Grivel, K; Richter, K; Schiff, C			Binding of free immunoglobulin light chains to VpreB3 inhibits their maturation and secretion in chicken B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED-PROTEIN RESPONSE; FREE KAPPA-LIGHT; ENDOPLASMIC-RETICULUM; PRE-B; QUALITY-CONTROL; CEREBROSPINAL-FLUID; MULTIPLE-MYELOMA; GENE CONVERSION; BONE-MARROW; MAST-CELLS	The VpreB3 gene product was first characterized as an immunoglobulin (Ig) mu heavy chain-binding protein in mouse precursor B (pre-B) cells. Although its function is unknown, it has been proposed to participate in the assembly and transport of the pre-B cell receptor. We have identified a VpreB3 orthologous gene in chicken that is located close to the immunoglobulin light chain (LC) gene cluster and specifically expressed in the bursa of Fabricius. By overexpressing VpreB3 in the DT40 IgM(+) immature chicken B cell line, we have characterized VpreB3 as an endoplasmic reticulum-resident glycoprotein that binds preferentially to free IgLC. However, binding to IgHC is observed in IgLC-deficient DT40 cells. Interaction of VpreB3 with free IgLC is partly covalent and induces retention of free IgLC in the endoplasmic reticulum, preventing their secretion without affecting IgM surface expression. Our results demonstrate that this evolutionarily conserved molecule may play a role in the regulation of the maturation and secretion of free IgLC in B cells. We discuss possible implications in the regulation of the immune response.	Univ Mediterranee, INSERM, CNRS, Ctr Immunol Marseille Luminy, F-13288 Marseille 09, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Rosnet, O (corresponding author), Univ Mediterranee, INSERM, CNRS, Ctr Immunol Marseille Luminy, Campus Luminy,Case 906, F-13288 Marseille 09, France.	rosnet@ciml.univ-mrs.fr; schiff@ciml.univ-mrs.fr	Rosnet, Olivier/G-3536-2013	Rosnet, Olivier/0000-0002-3020-910X				Benoist C, 2002, NATURE, V420, P875, DOI 10.1038/nature01324; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; Brouns GS, 1996, J BIOL CHEM, V271, P19272, DOI 10.1074/jbc.271.32.19272; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; Cariappa A, 2002, CURR OPIN IMMUNOL, V14, P241, DOI 10.1016/S0952-7915(02)00328-X; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; FAGNART OC, 1988, J NEUROIMMUNOL, V19, P119, DOI 10.1016/0165-5728(88)90041-0; Fang T, 2001, J IMMUNOL, V167, P3846, DOI 10.4049/jimmunol.167.7.3846; Gauthier L, 2002, P NATL ACAD SCI USA, V99, P13014, DOI 10.1073/pnas.202323999; Hardy RR, 2000, IMMUNOL REV, V175, P23, DOI 10.1111/j.1600-065X.2000.imr017517.x; Hayakawa K, 1999, SCIENCE, V285, P113, DOI 10.1126/science.285.5424.113; Hertz M, 1998, CURR OPIN IMMUNOL, V10, P208, DOI 10.1016/S0952-7915(98)80250-1; Hoffmann R, 2002, GENOME RES, V12, P98, DOI 10.1101/gr.201501; KALOFF CR, 1995, IMMUNITY, V2, P629, DOI 10.1016/1074-7613(95)90007-1; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; KNITTLER MR, 1995, P NATL ACAD SCI USA, V92, P1764, DOI 10.1073/pnas.92.5.1764; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; LAMERS KJB, 1995, J NEUROIMMUNOL, V62, P19, DOI 10.1016/0165-5728(95)00086-H; Lassoued K, 1996, J EXP MED, V183, P421, DOI 10.1084/jem.183.2.421; Leitzgen K, 1997, J BIOL CHEM, V272, P3117, DOI 10.1074/jbc.272.5.3117; LENNY N, 1991, J BIOL CHEM, V266, P20532; Litman GF, 1999, ANNU REV IMMUNOL, V17, P109, DOI 10.1146/annurev.immunol.17.1.109; Martensson IL, 2002, SEMIN IMMUNOL, V14, P335, DOI 10.1016/S1044-5323(02)00066-0; Masteller E L, 1997, Int Rev Immunol, V15, P185, DOI 10.3109/08830189709068176; Mazumder B, 2003, TRENDS BIOCHEM SCI, V28, P91, DOI 10.1016/S0968-0004(03)00002-1; Meffre E, 2002, P NATL ACAD SCI USA, V99, P11334, DOI 10.1073/pnas.172369999; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Niiro H, 2002, NAT REV IMMUNOL, V2, P945, DOI 10.1038/nri955; OHNISHI K, 1994, J BIOL CHEM, V269, P28347; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; Reddy PS, 1998, BIOESSAYS, V20, P546, DOI 10.1002/(SICI)1521-1878(199807)20:7<546::AID-BIES5>3.0.CO;2-I; Redegeld FA, 2003, TRENDS IMMUNOL, V24, P181, DOI 10.1016/S1471-4906(03)00059-0; Redegeld FA, 2002, NAT MED, V8, P694, DOI 10.1038/nm722; REYNAUD CA, 1994, ADV IMMUNOL, V57, P353, DOI 10.1016/S0065-2776(08)60676-8; Rolink AG, 2000, J EXP MED, V191, P23, DOI 10.1084/jem.191.1.23; Rosnet O, 1999, CYTOGENET CELL GENET, V87, P205, DOI 10.1159/000015468; Sampath P, 2003, MOL CELL BIOL, V23, P1509, DOI 10.1128/MCB.23.5.1509-1519.2003; Shaffer AL, 2001, IMMUNITY, V15, P375, DOI 10.1016/S1074-7613(01)00194-7; SHIRASAWA T, 1993, EMBO J, V12, P1827, DOI 10.1002/j.1460-2075.1993.tb05831.x; SINCLAIR D, 1986, BRIT J HAEMATOL, V62, P689, DOI 10.1111/j.1365-2141.1986.tb04092.x; Skowronek MH, 1998, P NATL ACAD SCI USA, V95, P1574, DOI 10.1073/pnas.95.4.1574; SOLLING K, 1982, SCAND J HAEMATOL, V28, P309; THOMPSON CB, 1987, CELL, V48, P369, DOI 10.1016/0092-8674(87)90188-7	47	22	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10228	10236		10.1074/jbc.M312169-A200	http://dx.doi.org/10.1074/jbc.M312169-A200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14670953	hybrid			2022-12-25	WOS:000220050400070
J	Viegas, LR; Vicent, GP; Baranao, JL; Beato, M; Pecci, A				Viegas, LR; Vicent, GP; Baranao, JL; Beato, M; Pecci, A			Steroid hormones induce bcl-X gene expression through direct activation of distal promoter P4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; GLUCOCORTICOID RECEPTOR; IN-VIVO; APOPTOSIS; BINDING; PROTEINS; LINE; RNA; DEXAMETHASONE; EXTRACTION	Bcl-X exists in at least five different isoforms with complex effects on programmed cell death. Glucocorticoids and progestins control bcl-X expression and influence the ratio between bcl-X-L ( antiapoptotic isoform) and bcl-X-S (proapoptotic isoform) in different tissues. The 5'-UTR region of the mouse bcl-X gene contains at least five different promoters, which exhibit a tissue-specific pattern of promoter usage. Several mRNAs with different 5'-leading exons can be generated upon promoter activation. Here we explore the potential of the various bcl-X gene promoters to be regulated by glucocorticoids or progestins. We found that the region located immediately upstream of promoter 4 (P4) contains two hormone response element (HRE)-like sequences at positions - 3040 ( HRE I) and - 3001 ( HRE II) relative to the translation initiation codon. These HRE-like sequences confer hormone responsiveness to a core promoter and bind glucocorticoid or progesterone receptors in vitro. Point mutations of both HREs that prevent steroid receptor binding also eliminate hormonal inducibility. In cells treated with glucocorticoids, the hormone receptor is recruited to the P4 region containing the HREs. Analysis of the products of the endogenous bcl-X in epithelial mammary cells showed that only transcripts originating from P4 increased upon hormone treatment. This observation correlates with the induction of the bcl-X-L mRNA, suggesting that P4 is one of the bcl-X promoters responsible for the generation of this antiapoptotic isoform.	Ctr Regulacio Genom, E-08003 Barcelona, Spain; Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol, RA-1428 Buenos Aires, DF, Argentina; Consejo Nacl Invest Cient & Tecn, RA-1428 Buenos Aires, DF, Argentina	Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	Beato, M (corresponding author), Ctr Regulacio Genom, Passeig Maritim 37-49, E-08003 Barcelona, Spain.	miguel.beato@crg.es	Beato, Miguel/B-5564-2015; Vicent, Guillermo P./K-5432-2015	Beato, Miguel/0000-0002-2878-2222; Vicent, Guillermo P./0000-0002-0554-2226				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bottenstein J, 1979, Methods Enzymol, V58, P94; CHALEPAKIS G, 1990, DNA CELL BIOL, V9, P355, DOI 10.1089/dna.1990.9.355; Chang TC, 1997, FEBS LETT, V415, P11, DOI 10.1016/S0014-5793(97)01083-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Di Croce L, 1999, MOL CELL, V4, P45, DOI 10.1016/S1097-2765(00)80186-0; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; FANG W, 1994, J IMMUNOL, V153, P4388; Gascoyne DM, 2003, J BIOL CHEM, V278, P18022, DOI 10.1074/jbc.M301812200; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; Heermeier K, 1996, MECH DEVELOP, V56, P197, DOI 10.1016/0925-4773(96)88032-4; KASTNER P, 1990, J BIOL CHEM, V265, P12163; KEYDAR I, 1979, EUR J CANCER, V15, P659, DOI 10.1016/0014-2964(79)90139-7; KRAJEWSKI S, 1994, AM J PATHOL, V145, P515; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; Pecci A, 1997, J BIOL CHEM, V272, P11791, DOI 10.1074/jbc.272.18.11791; Pecci A, 2001, J BIOL CHEM, V276, P21062, DOI 10.1074/jbc.M008665200; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; SCHEIDEREIT C, 1983, NATURE, V304, P749, DOI 10.1038/304749a0; Schorr K, 2000, CANCER RES, V60, P5950; Shiraiwa N, 1996, J BIOL CHEM, V271, P13258, DOI 10.1074/jbc.271.22.13258; Strutt H, 1999, METH MOL B, V119, P455; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; Vicent GP, 2002, EXP CELL RES, V276, P142, DOI 10.1006/excr.2002.5532; Walton KD, 2001, MECH DEVELOP, V109, P281, DOI 10.1016/S0925-4773(01)00549-4; Yamamoto M, 1998, HEPATOLOGY, V27, P959, DOI 10.1002/hep.510270410; Yang XF, 1997, IMMUNITY, V7, P629, DOI 10.1016/S1074-7613(00)80384-2; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	30	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9831	9839		10.1074/jbc.M312402200	http://dx.doi.org/10.1074/jbc.M312402200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14679196	hybrid			2022-12-25	WOS:000220050400022
J	Chen, XY; Huang, LM; Kung, HJ; Ann, DK; Shih, HM				Chen, XY; Huang, LM; Kung, HJ; Ann, DK; Shih, HM			The role of tyrosine kinase Etk/Bmx in EGF-induced apoptosis of MDA-MB-468 breast cancer cells	ONCOGENE			English	Article						Etk kinase; EGF-induced apoptosis; Statl activation	EPIDERMAL-GROWTH-FACTOR; FACTOR RECEPTOR GENE; FOCAL ADHESION KINASE; X-LINKED AGAMMAGLOBULINEMIA; TEC FAMILY; PHOSPHATIDYLINOSITOL 3'-KINASE; MEDIATED APOPTOSIS; SIGNALING PATHWAY; FACTOR-ALPHA; PH-DOMAIN	Etk/Bmx, a member of the Tec family of tyrosine kinases, mediates various signaling pathways and confers several cellular functions. In the present study, we have explored the functional role of Etk in mediating EGF-induced apoptosis, using MDA-MB-468 cell line as a model. We first demonstrated that EGF treatment induces Etk tyrosine phosphorylation in both HeLa and MDA-MB468 cells. Overexpression of Etk by recombinant adenovirus in MDA-MB-468 cells potentiates the extent of EGF-induced cell apoptosis. The observed Etk-enhanced MDA-MB-468 cell apoptosis is associated with the Stat1 activation, as demonstrated by electrophoresis mobility shift assays and reporter gene assays. By contrast, a kinase domain deletion mutant EtkDeltaK, functioning as a dominant-negative mutant, ameliorates EGF- induced Stat1 activation and apoptosis in MDA-MB-468 cells. To explore whether the activated Etk alone is sufficient for inducing apoptosis, a conditionally activated Etk (DeltaEtk-ER), a chimeric fusion protein of PH domain-truncated Etk and ligand-binding domain of estrogen receptor, was introduced into MDA-MB-468 cells. Upon beta-estradiol ligand activation, the DeltaEtk-ER could stimulate Stat1 activity and confer cell apoptosis independent of EGF treatment. Taken together, our findings indicate that Etk is a downstream signaling molecule of EGF receptor and suggest that Etk activation is essential for transducing the EGF- induced apoptotic signaling.	Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 11529, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA; Univ So Calif, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA	National Health Research Institutes - Taiwan; National Defense Medical Center; University of California System; University of California Davis; University of Southern California	Shih, HM (corresponding author), Natl Hlth Res Inst, Div Mol & Genom Med, 128,Sec2,Yen Chiu Yuan RD, Taipei 11529, Taiwan.	shihh@nhri.org.tw	Shih, Hsiu-Ming/S-7023-2018; Kung, Hsing-Jien/C-7651-2013		NCI NIH HHS [CA39207] Funding Source: Medline; NIDCR NIH HHS [R01 DE10742, DE14183] Funding Source: Medline; PHS HHS [91574] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA039207, R01CA039207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014183] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Anderson JS, 1996, P NATL ACAD SCI USA, V93, P10966, DOI 10.1073/pnas.93.20.10966; ARMSTRONG DK, 1994, CANCER RES, V54, P5280; August A, 2002, INT J BIOCHEM CELL B, V34, P1184, DOI 10.1016/S1357-2725(02)00068-7; Bagheri-Yarmand R, 2001, J BIOL CHEM, V276, P29403, DOI 10.1074/jbc.M103129200; Berclaz G, 2001, INT J ONCOL, V19, P1155; Bromberg JF, 1998, CELL GROWTH DIFFER, V9, P505; Bunnell SC, 2000, J BIOL CHEM, V275, P2219, DOI 10.1074/jbc.275.3.2219; Chau CH, 2002, ONCOGENE, V21, P8817, DOI 10.1038/sj.onc.1206032; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; COSTA S, 1988, LANCET, V2, P1258; Czar MJ, 2001, BIOCHEM SOC T, V29, P863, DOI 10.1042/BST0290863; DEPALAZZO IEG, 1993, CANCER RES, V53, P3217; DERYNCK R, 1987, CANCER RES, V47, P707; Ekman N, 2000, ONCOGENE, V19, P4151, DOI 10.1038/sj.onc.1203763; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; Gulli LF, 1996, CELL GROWTH DIFFER, V7, P173; Hognason T, 2001, FEBS LETT, V491, P9, DOI 10.1016/S0014-5793(01)02166-4; Hsueh RC, 2000, ADV IMMUNOL, V75, P283, DOI 10.1016/S0065-2776(00)75007-3; Ibrahim SO, 1997, ANTICANCER RES, V17, P4539; Islam TC, 2000, J GENE MED, V2, P204; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Jui HY, 2000, J BIOL CHEM, V275, P41124, DOI 10.1074/jbc.M007772200; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; KIKUCHI A, 1990, BRIT J DERMATOL, V123, P49, DOI 10.1111/j.1365-2133.1990.tb01823.x; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Lewis CM, 2001, CURR OPIN IMMUNOL, V13, P317, DOI 10.1016/S0952-7915(00)00221-1; Lu ZM, 2001, MOL CELL BIOL, V21, P4016, DOI 10.1128/MCB.21.12.4016-4031.2001; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MANO H, 1995, BLOOD, V85, P343; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MERLINO GT, 1985, J CLIN INVEST, V75, P1077, DOI 10.1172/JCI111770; Miller AT, 2002, CURR OPIN IMMUNOL, V14, P331, DOI 10.1016/S0952-7915(02)00345-X; Misra UK, 1998, CELL SIGNAL, V10, P441, DOI 10.1016/S0898-6568(97)00171-X; Pan S, 2002, MOL CELL BIOL, V22, P7512, DOI 10.1128/MCB.22.21.7512-7523.2002; Price JT, 1999, CANCER RES, V59, P5475; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Qiu Y, 2000, ONCOGENE, V19, P5651, DOI 10.1038/sj.onc.1203958; Rajantie I, 2001, MOL CELL BIOL, V21, P4647, DOI 10.1128/MCB.21.14.4647-4655.2001; Ramsauer K, 2002, P NATL ACAD SCI USA, V99, P12859, DOI 10.1073/pnas.192264999; RO J, 1988, CANCER RES, V48, P161; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; SAINSBURY JRC, 1988, BRIT J CANCER, V58, P458, DOI 10.1038/bjc.1988.240; Satterthwaite AB, 1998, SEMIN IMMUNOL, V10, P309, DOI 10.1006/smim.1998.0123; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Smith CIE, 2001, BIOESSAYS, V23, P436, DOI 10.1002/bies.1062; Stephanou A, 2002, FASEB J, V16, P1841, DOI 10.1096/fj.02-0150fje; Stephanou A, 2001, J BIOL CHEM, V276, P28340, DOI 10.1074/jbc.M101177200; Suhardja A, 2003, MICROSC RES TECHNIQ, V60, P70, DOI 10.1002/jemt.10245; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; Thomas T, 1999, J CELL PHYSIOL, V179, P257, DOI 10.1002/(SICI)1097-4652(199906)179:3<257::AID-JCP3>3.0.CO;2-4; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; Tsang DK, 1999, INT J ONCOL, V15, P519; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; Vignais ML, 1999, MOL CELL BIOL, V19, P3727; Vihinen M, 2000, FRONT BIOSCI-LANDMRK, V5, pD917, DOI 10.2741/vihinen; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Wen X, 1999, J BIOL CHEM, V274, P38204, DOI 10.1074/jbc.274.53.38204; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Wu YM, 2001, J BIOL CHEM, V276, P17672, DOI 10.1074/jbc.M010964200; XU YH, 1984, P NATL ACAD SCI-BIOL, V81, P7308, DOI 10.1073/pnas.81.23.7308; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687; Yart A, 2001, J BIOL CHEM, V276, P8856, DOI 10.1074/jbc.M006966200	67	32	36	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1854	1862		10.1038/sj.onc.1207308	http://dx.doi.org/10.1038/sj.onc.1207308			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14676838				2022-12-25	WOS:000220129500007
J	Crane, A; Aguilar-Bryan, L				Crane, A; Aguilar-Bryan, L			Assembly, maturation, and turnover of K-ATP channel subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA; AFFINITY SULFONYLUREA RECEPTOR; TRANSMEMBRANE CONDUCTANCE REGULATOR; ENDOPLASMIC-RETICULUM; POTASSIUM CHANNEL; INSULIN-SECRETION; CONGENITAL HYPERINSULINISM; FAMILIAL HYPERINSULINISM; SURFACE EXPRESSION; CYSTIC-FIBROSIS	ATP-sensitive K+, or K-ATP, channels are comprised of K(IR)6.x and sulfonylurea receptor (SUR) subunits that assemble as octamers, (K-IR/SUR)(4). The assembly pathway is unknown. Pulse-labeling studies show that when K(IR)6.2 is expressed individually, its turnover is biphasic; similar to60% is lost with t(1/2) similar to 36 min. The remainder converts to a long-lived species (t(1/2) similar to 26 h) with an estimated half-time of 1.2 h. Expressed alone, SUR1 has a long half-life, similar to25.5 h. When K(IR)6.2 and SUR1 are co-expressed, they associate rapidly and the fast degradation of KIR6.2 is eliminated. Based on changes in the glycosylation state of SUR1, the half-time for the maturation of K-ATP channels, including completion of assembly, transit to the Golgi, and glycosylation, is similar to 2.2 h. Estimation of the turnover rates of mature, fully glycosylated SUR1 associated with K(IR)6.2 and of K(IR)6.2 associated with Myc-tagged SUR1 gave similar values for the half-life of K-ATP channels, a mean value of similar to 7.3 h. K-ATP channel subunits in INS-1 beta-cells displayed qualitatively similar kinetics. The results imply the octameric channels are stable. Two mutations, K(IR)6.2 W91R and SUR1 DeltaF1388, identified in patients with the severe form of familial hyperinsulinism, profoundly alter the rate of KIR6.2 and SUR1 turnover, respectively. Both mutant subunits associate with their respective partners but dissociate freely and degrade rapidly. The data support models of channel formation in which K(IR)6.2-SUR1 heteromers assemble functional channels and are inconsistent with models where SUR1 can only assemble with K(IR)6.2 tetramers.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Aguilar-Bryan, L (corresponding author), Baylor Coll Med, Dept Med, Houston, TX 77030 USA.	lbryan@bcm.tmc.edu			NIDDK NIH HHS [DK57671] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057671] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Babenko AP, 1999, FEBS LETT, V445, P131, DOI 10.1016/S0014-5793(99)00102-7; BRYAN J, 2000, DIABETES MELLITUS, P61; Cabral CM, 2002, MOL BIOL CELL, V13, P2639, DOI 10.1091/mbc.E02-02-0068; Cartier EA, 2001, P NATL ACAD SCI USA, V98, P2882, DOI 10.1073/pnas.051499698; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Conti LR, 2002, J BIOL CHEM, V277, P25416, DOI 10.1074/jbc.M203109200; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Drain P, 1998, P NATL ACAD SCI USA, V95, P13953, DOI 10.1073/pnas.95.23.13953; Dunne MJ, 1997, NEW ENGL J MED, V336, P703, DOI 10.1056/NEJM199703063361005; Fournet JC, 2003, HORM RES, V59, P30, DOI 10.1159/000067842; Glaser B, 2000, SEMIN PERINATOL, V24, P150, DOI 10.1053/sp.2000.6365; Glaser B, 2000, CHANNELOPATHIES - COMMON MECHANISMS IN AURA, ARRHYTHMIA AND ALKALOSIS, P299, DOI 10.1016/B978-044450489-0/50014-8; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; HRESKO RC, 1994, J BIOL CHEM, V269, P32110; Huopio H, 2003, LANCET, V361, P301, DOI 10.1016/S0140-6736(03)12325-2; Huopio H, 2000, J CLIN INVEST, V106, P897, DOI 10.1172/JCI9804; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; Khanna R, 2001, J BIOL CHEM, V276, P34028, DOI 10.1074/jbc.M105248200; KOPITO RR, 1999, PHYSIOL REV, V79, P167; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lippincott-Schwartz J, 2000, ANNU REV CELL DEV BI, V16, P557, DOI 10.1146/annurev.cellbio.16.1.557; LOO TW, 1994, J BIOL CHEM, V269, P28683; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Nagaya N, 1997, J BIOL CHEM, V272, P3022, DOI 10.1074/jbc.272.5.3022; Nelson DA, 1996, BIOCHEMISTRY-US, V35, P14793, DOI 10.1021/bi960777y; Nestorowicz A, 1996, HUM MOL GENET, V5, P1813, DOI 10.1093/hmg/5.11.1813; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Nufer O, 2003, CURR BIOL, V13, pR391, DOI 10.1016/S0960-9822(03)00318-X; O'Kelly I, 2002, CELL, V111, P577, DOI 10.1016/S0092-8674(02)01040-1; Partridge CJ, 2001, J BIOL CHEM, V276, P35947, DOI 10.1074/jbc.M104762200; Reimann F, 2003, DIABETOLOGIA, V46, P241, DOI 10.1007/s00125-002-1014-3; Riordan JR, 1999, AM J HUM GENET, V64, P1499, DOI 10.1086/302429; SCHWANSTECHER M, 1994, J BIOL CHEM, V269, P17768; Schwappach B, 2000, NEURON, V26, P155, DOI 10.1016/S0896-6273(00)81146-0; Seghers V, 2000, J BIOL CHEM, V275, P9270, DOI 10.1074/jbc.275.13.9270; Sharma N, 1999, J BIOL CHEM, V274, P20628, DOI 10.1074/jbc.274.29.20628; Shi G, 1999, J MEMBRANE BIOL, V168, P265, DOI 10.1007/s002329900515; Shyng SL, 1998, DIABETES, V47, P1145, DOI 10.2337/diabetes.47.7.1145; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Taschenberger G, 2002, J BIOL CHEM, V277, P17139, DOI 10.1074/jbc.M200363200; Thornton PS, 2003, DIABETES, V52, P2403, DOI 10.2337/diabetes.52.9.2403; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Varki A, 1998, TRENDS CELL BIOL, V8, P34, DOI 10.1016/S0962-8924(97)01198-7; WARD CL, 1994, J BIOL CHEM, V269, P25710; YOSHIMURA A, 1989, BIOCHIM BIOPHYS ACTA, V992, P307, DOI 10.1016/0304-4165(89)90089-5; Yuan HB, 2003, CURR BIOL, V13, P638, DOI 10.1016/S0960-9822(03)00208-2; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	51	58	60	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9080	9090		10.1074/jbc.M311079200	http://dx.doi.org/10.1074/jbc.M311079200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14699091	hybrid			2022-12-25	WOS:000189265900069
J	Gustafson, WC; Ray, S; Jamieson, L; Thompson, EA; Brasier, AR; Fields, AP				Gustafson, WC; Ray, S; Jamieson, L; Thompson, EA; Brasier, AR; Fields, AP			Bcr-Abl regulates protein kinase C iota (PKC iota) transcription via an Elk1 site in the PKC iota promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; COLON CARCINOGENESIS; BETA-II; PHILADELPHIA-CHROMOSOME; K562 CELLS; MEDIATED TRANSFORMATION; INDUCE APOPTOSIS; ACTIVATION; BCR/ABL; RAS	The protein kinase C (PKC) family of serine/threonine kinases plays an important role in numerous cancer signaling pathways, including those downstream of the bcr-abl oncogene. We demonstrated previously that atypical PKCiota is required for Bcr-Abl-mediated resistance of human K562 chronic myelogenous leukemia (CML) cells to Taxol-induced apoptosis. Here, we report that the pattern of PKC isozyme expression characteristic of CML cells is regulated by Bcr-Abl. When Bcr-Abl was expressed in Bcr-Abl-negative HL-60 promyelocytic leukemia cells, expression of the PKCbetaI, PKCbetaII, and PKCiota genes was induced, whereas expression of the PKCdelta gene was reduced to levels similar to those found in CML cells. Given the importance of PKCiota in Bcr-Abl-mediated transformation, we characterized the mechanism by which Bcr-Abl regulates PKCiota expression. A 1200-bp PKC iota promoter construct isolated from genomic DNA was highly active in Bcr-Abl-positive K562 cells and was activated when Bcr-Abl-negative cells were transfected with Bcr-Abl. Bcr-Abl-mediated induction of the PKCiota promoter was dependent upon MEK1/2 activity, but not phosphatidylinositol 3-kinase or p38 MAPK activity. Mutational analysis of the PKCiota promoter revealed a region between 97 and 114 bp upstream of the transcriptional start site that is responsible for Bcr-Abl-mediated regulation. Mutation of a consensus Elk1-binding site within this region abolished Bcr-Abl-mediated regulation. We conclude that Bcr-Abl regulates PKCiota expression through the MEK-dependent activation of an Elk1 element within the proximal PKCiota promoter. Our results indicate that Bcr-Abl-mediated transformation involves transcriptional activation of the PKCiota gene, which in turn is required for Bcr-Abl-mediated chemoresistance.	Mayo Clin, Ctr Comprehens Canc, Jacksonville, FL 32224 USA; Univ Texas, Med Branch, Dept Internal Med, Galveston, TX 77555 USA	Mayo Clinic; University of Texas System; University of Texas Medical Branch Galveston	Fields, AP (corresponding author), Mayo Clin, Ctr Comprehens Canc, Griffin Canc Res Bldg,Rm 312,4500 San Pablo Rd, Jacksonville, FL 32224 USA.	fields.alan@mayo.edu	Ray, Sutapa/D-3272-2012	Ray, Sutapa/0000-0003-4234-2124; Brasier, Allan/0000-0002-5012-4090				Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Che W, 2001, CIRCULATION, V104, P1399, DOI 10.1161/hc3701.095581; Clark JH, 2002, BIOCHEMISTRY-US, V41, P11847, DOI 10.1021/bi025600k; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; Cortez D, 1996, ONCOGENE, V13, P2589; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Desai DS, 1999, BIOCHEM BIOPH RES CO, V263, P28, DOI 10.1006/bbrc.1999.1307; Druker BJ, 2003, MOL CANCER THER, V2, P225; Fields Alan P, 2003, Methods Mol Biol, V233, P519; Gokmen-Polar Y, 2001, CANCER RES, V61, P1375; GOSS VL, 1994, J BIOL CHEM, V269, P19074; GOTOH A, 1994, LEUKEMIA, V8, P115; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; Kang CD, 2000, LEUKEMIA RES, V24, P527, DOI 10.1016/S0145-2126(00)00010-2; Keeshan K, 2001, LEUKEMIA, V15, P1823, DOI 10.1038/sj.leu.2402309; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; Kirchner D, 2003, EXP HEMATOL, V31, P504, DOI 10.1016/S0301-472X(03)00069-9; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Lu Y, 2001, ONCOGENE, V20, P4777, DOI 10.1038/sj.onc.1204607; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MANDANAS RA, 1993, BLOOD, V82, P1838; Morgan MA, 2001, BLOOD, V97, P1823, DOI 10.1182/blood.V97.6.1823; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; Murray NR, 2002, J CELL BIOL, V157, P915, DOI 10.1083/jcb.200201127; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; Murray NR, 1999, J CELL BIOL, V145, P699, DOI 10.1083/jcb.145.4.699; OBEID LM, 1992, J BIOL CHEM, V267, P20804; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Perrotti D, 2000, MOL CELL BIOL, V20, P6159, DOI 10.1128/MCB.20.16.6159-6169.2000; Quan TH, 1999, J BIOL CHEM, V274, P28566, DOI 10.1074/jbc.274.40.28566; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SAKAI N, 1994, EXP CELL RES, V215, P131, DOI 10.1006/excr.1994.1324; Shuai K, 1996, ONCOGENE, V13, P247; SKORSKI T, 1994, J EXP MED, V179, P1855, DOI 10.1084/jem.179.6.1855; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Sonoyama J, 2002, J BIOL CHEM, V277, P8076, DOI 10.1074/jbc.M111501200; TAKANAGA H, 1995, FEBS LETT, V368, P276, DOI 10.1016/0014-5793(95)00665-V; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; Yu CR, 2002, CANCER RES, V62, P188; Yu WS, 2003, J BIOL CHEM, V278, P11167, DOI 10.1074/jbc.M211424200	47	38	40	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9400	9408		10.1074/jbc.M312840200	http://dx.doi.org/10.1074/jbc.M312840200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14670960	hybrid			2022-12-25	WOS:000189265900105
J	Silvie, O; Franetich, JF; Charrin, S; Mueller, MS; Siau, A; Bodescot, M; Rubinstein, E; Hannoun, L; Charoenvit, Y; Kocken, CH; Thomas, AW; van Gemert, GJ; Sauerwein, RW; Blackman, MJ; Anders, RF; Pluschke, G; Mazier, D				Silvie, O; Franetich, JF; Charrin, S; Mueller, MS; Siau, A; Bodescot, M; Rubinstein, E; Hannoun, L; Charoenvit, Y; Kocken, CH; Thomas, AW; van Gemert, GJ; Sauerwein, RW; Blackman, MJ; Anders, RF; Pluschke, G; Mazier, D			A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL EPITOPES; APICOMPLEXAN PARASITES; GLIDING MOTILITY; CIRCUMSPOROZOITE PROTEIN; MONOCLONAL-ANTIBODIES; ERYTHROCYTE INVASION; MICRONEMAL PROTEINS; ANONYMOUS PROTEIN; HOST-CELLS; SURFACE	Plasmodium sporozoites are transmitted through the bite of infected mosquitoes and invade hepatocytes as a first and obligatory step of the parasite life cycle in man. Hepatocyte invasion involves proteins secreted from parasite vesicles called micronemes, the most characterized being the thrombospondin-related adhesive protein ( TRAP). Here we investigated the expression and function of another microneme protein recently identified in Plasmodium falciparum sporozoites, apical membrane antigen 1 (AMA-1). P. falciparum AMA-1 is expressed in sporozoites and is lost after invasion of hepatocytes, and anti-AMA-1 antibodies inhibit sporozoite invasion, suggesting that the protein is involved during invasion of hepatocytes. As observed with TRAP, AMA-1 is initially mostly sequestered within the sporozoite. Upon microneme exocytosis, AMA-1 and TRAP relocate to the sporozoite surface, where they are proteolytically cleaved, resulting in the shedding of soluble fragments. A subset of serine protease inhibitors blocks the processing and shedding of both AMA-1 and TRAP and inhibits sporozoite infectivity, suggesting that interfering with sporozoite proteolytic processing may constitute a valuable strategy to prevent hepatocyte infection.	Univ Paris 06, CHU Pitie Salpetriere, INSERM, U511, F-75013 Paris, France; Univ Paris 11, Hop Paul Brousse, Inst Andre Lwoff, INSERM,U268, F-94807 Villejuif, France; Swiss Trop Inst, CH-4002 Basel, Switzerland; Hop La Pitie Salpetriere, Serv chirurg Digest Hepatobiliopancreat & Transpl, F-75013 Paris, France; USN, Med Res Ctr, Malaria Program, Silver Spring, MD 20910 USA; Biomed Primate Res Ctr, Dept Parasitol, NL-2280 GH Rijswijk, Netherlands; Univ Med Ctr St Radboud, Dept Med Microbiol, NL-6500 HB Nijmegen, Netherlands; Natl Inst Med Res, Div Parasitol, London NW7 1AA, England; La Trobe Univ, Dept Biochem, Bundoora, Vic 3086, Australia; La Trobe Univ, Cooperat Res Ctr Vaccine Technol, Bundoora, Vic 3086, Australia	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; University of Basel; Swiss Tropical & Public Health Institute; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; United States Department of Defense; United States Navy; Radboud University Nijmegen; MRC National Institute for Medical Research; La Trobe University; La Trobe University	Silvie, O (corresponding author), Univ Paris 06, INSERM, U511, 91 Blvd Hop, F-75013 Paris, France.	silvie@ext.jussieu.fr	CHARRIN, Stephanie/B-2892-2019; Franetich, Jean-François/GZA-9674-2022; Sauerwein, Robert/C-8519-2013; Rubinstein, Eric/B-4650-2019; Silvie, Olivier/AAF-5437-2021; Silvie, Olivier/K-7290-2017	Rubinstein, Eric/0000-0001-7623-9665; Silvie, Olivier/0000-0002-0525-6940; Silvie, Olivier/0000-0002-0525-6940; Charrin, Stephanie/0000-0002-4942-3990; Anders, Robin/0000-0002-0693-4547; Kocken, Clemens/0000-0002-4784-1734				Bannister LH, 2003, J CELL SCI, V116, P3825, DOI 10.1242/jcs.00665; Bergman LW, 2003, J CELL SCI, V116, P39, DOI 10.1242/jcs.00194; Bhanot P, 2003, MOL BIOCHEM PARASIT, V126, P263, DOI 10.1016/S0166-6851(02)00295-5; Carruthers VB, 1999, CELL MICROBIOL, V1, P225, DOI 10.1046/j.1462-5822.1999.00023.x; Charoenvit Y, 1997, INFECT IMMUN, V65, P3430, DOI 10.1128/IAI.65.8.3430-3437.1997; Coley AM, 2001, PROTEIN ENG, V14, P691, DOI 10.1093/protein/14.9.691; CREWTHER PE, 1990, EXP PARASITOL, V70, P193, DOI 10.1016/0014-4894(90)90100-Q; DRUILHE P, 1986, INFECT IMMUN, V53, P393, DOI 10.1128/IAI.53.2.393-397.1986; Fichera ME, 1997, NATURE, V390, P407, DOI 10.1038/37132; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; Gantt S, 2000, INFECT IMMUN, V68, P3667, DOI 10.1128/IAI.68.6.3667-3673.2000; GUGUENGUILLOUZO C, 1982, CELL BIOL INT REP, V6, P625, DOI 10.1016/0309-1651(82)90187-4; Healer J, 2002, INFECT IMMUN, V70, P5751, DOI 10.1128/IAI.70.10.5751-5758.2002; Hodder AN, 2001, INFECT IMMUN, V69, P3286, DOI 10.1128/IAI.69.5.3286-3294.2001; Howell SA, 2003, J BIOL CHEM, V278, P23890, DOI 10.1074/jbc.M302160200; Howell SA, 2001, J BIOL CHEM, V276, P31311, DOI 10.1074/jbc.M103076200; ISOM HC, 1985, P NATL ACAD SCI USA, V82, P3252, DOI 10.1073/pnas.82.10.3252; Kappe S, 1999, J CELL BIOL, V147, P937, DOI 10.1083/jcb.147.5.937; Kappe SHI, 2003, TRENDS PARASITOL, V19, P135, DOI 10.1016/S1471-4922(03)00007-2; Kocken CHM, 2002, INFECT IMMUN, V70, P4471, DOI 10.1128/IAI.70.8.4471-4476.2002; Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485; MAZIER D, 1985, SCIENCE, V227, P440, DOI 10.1126/science.3880923; MEIS JFGM, 1985, CELL BIOL INT REP, V9, P976, DOI 10.1016/0309-1651(85)90062-1; Menard R, 2001, CELL MICROBIOL, V3, P63, DOI 10.1046/j.1462-5822.2001.00097.x; Menard R, 2000, MICROBES INFECT, V2, P633, DOI 10.1016/S1286-4579(00)00362-2; Mota MM, 2002, NAT MED, V8, P1318, DOI 10.1038/nm785; Mueller MS, 2003, INFECT IMMUN, V71, P4749, DOI 10.1128/IAI.71.8.4749-4758.2003; NARUM DL, 1994, MOL BIOCHEM PARASIT, V67, P59, DOI 10.1016/0166-6851(94)90096-5; Opitz C, 2002, EMBO J, V21, P1577, DOI 10.1093/emboj/21.7.1577; PONNUDURAI T, 1982, T ROY SOC TROP MED H, V76, P242, DOI 10.1016/0035-9203(82)90289-9; STEWART MJ, 1991, J PROTOZOOL, V38, P411, DOI 10.1111/j.1550-7408.1991.tb01379.x; STUBER D, 1990, EUR J IMMUNOL, V20, P819, DOI 10.1002/eji.1830200416; Sultan AA, 1997, CELL, V90, P511, DOI 10.1016/S0092-8674(00)80511-5; Triglia T, 2000, MOL MICROBIOL, V38, P706, DOI 10.1046/j.1365-2958.2000.02175.x	34	239	249	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9490	9496		10.1074/jbc.M311331200	http://dx.doi.org/10.1074/jbc.M311331200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676185	Green Published, hybrid			2022-12-25	WOS:000189265900115
J	Grundstrom, S; Anderson, P; Scheipers, P; Sundstedt, A				Grundstrom, S; Anderson, P; Scheipers, P; Sundstedt, A			Bcl-3 and NF kappa B p50-p50 homodimers act as transcriptional repressors in tolerant CD4(+) T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANDIDATE PROTOONCOGENE BCL-3; STAPHYLOCOCCAL ENTEROTOXIN-A; NECROSIS-FACTOR-ALPHA; IN-VIVO; P50 HOMODIMERS; NUCLEAR TRANSLOCATION; ONCOPROTEIN BCL-3; GENE-EXPRESSION; LYMPHOCYTE-PROLIFERATION; NF-KAPPA-B1 P50	The transcriptional events that control T cell tolerance are still poorly understood. To investigate why tolerant T cells fail to produce interleukin (IL)-2, we analyzed the regulation of NFkappaB-mediated transcription in CD4(+) T cells after tolerance induction in vivo. We demonstrate that a predominance of p50-p50 homodimers binding to the IL-2 promoter kappaB site in tolerant T cells correlated with repression of NFkappaB-driven transcription. Impaired translocation of the p65 subunit in tolerant T cells was a result from reduced activation of IkappaB kinase and poor phosphorylation and degradation of cytosolic IkappaBs. Moreover, tolerant T cells expressed high amounts of the p50 protein. However, the increased expression of p50 could not be explained by activation-induced de novo synthesis of the precursor p105, which was constitutively expressed in tolerant T cells. We also demonstrate the exclusive induction of the IkappaB protein B cell lymphoma 3 (Bcl-3) in tolerant T cells as well as its specific binding to the NFkappaB site. These results suggest that the cellular ratio of NFkappaB dimers, and thus the repression of NFkappaB activity and IL-2 production, are regulated at several levels in tolerant CD4(+) T cells in vivo.	Act Biotech Res Ctr, S-22363 Lund, Sweden; Lund Univ, Dept Cell & Mol Biol, Biomed Ctr I12, Sect Tumor Immunol, S-22184 Lund, Sweden; Lund Univ, Biomed Ctr I13, Immunol Sect, S-22184 Lund, Sweden	Lund University; Lund University	Grundstrom, S (corresponding author), Huddinge Univ Hosp, Ctr Infect Dis, F59, SE-14186 Stockholm, Sweden.	susanna.grundstrom@medhs.ki.se	Brighenti, Susanna/AAA-2255-2022	Brighenti, Susanna/0000-0001-8540-153X; Anderson, Per/0000-0002-0958-7990				BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; Bohuslav J, 1998, J CLIN INVEST, V102, P1645, DOI 10.1172/JCI3877; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Brasier AR, 2001, J BIOL CHEM, V276, P32080, DOI 10.1074/jbc.M102949200; Bundy DL, 1997, J BIOL CHEM, V272, P33132, DOI 10.1074/jbc.272.52.33132; Caamano JH, 1996, MOL CELL BIOL, V16, P1342; Ciechanover A, 2001, BIOCHIMIE, V83, P341, DOI 10.1016/S0300-9084(01)01239-1; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; DOHLSTEN M, 1993, IMMUNOLOGY, V79, P520; FRANZOSO G, 1993, EMBO J, V12, P3893, DOI 10.1002/j.1460-2075.1993.tb06067.x; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Grundstrom S, 2000, J IMMUNOL, V164, P1175, DOI 10.4049/jimmunol.164.3.1175; Han YQ, 1997, J BIOL CHEM, V272, P9825; Healy JI, 1997, IMMUNITY, V6, P419, DOI 10.1016/S1074-7613(00)80285-X; HEDLUND G, 1991, J IMMUNOL, V147, P4082; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Heissmeyer V, 2001, MOL CELL BIOL, V21, P1024, DOI 10.1128/MCB.21.4.1024-1035.2001; Hour TC, 2000, EUR J CELL BIOL, V79, P121, DOI 10.1078/S0171-9335(04)70014-X; Kalli K, 1998, MOL CELL BIOL, V18, P3140, DOI 10.1128/MCB.18.6.3140; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kastenbauer S, 1999, INFECT IMMUN, V67, P1553; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Kurland JF, 2001, J BIOL CHEM, V276, P45380, DOI 10.1074/jbc.M108294200; Lechler R, 2001, IMMUNOLOGY, V103, P262, DOI 10.1046/j.1365-2567.2001.01250.x; Lin L, 2000, EMBO J, V19, P4712, DOI 10.1093/emboj/19.17.4712; Liou HC, 1999, INT IMMUNOL, V11, P361, DOI 10.1093/intimm/11.3.361; Miller C, 1999, J EXP MED, V190, P53, DOI 10.1084/jem.190.1.53; Mondino A, 1996, J IMMUNOL, V157, P2048; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; Noel C, 2001, INT IMMUNOL, V13, P431, DOI 10.1093/intimm/13.4.431; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; Pape KA, 1998, CIBA F SYMP, V215, P103; PIMENTELMUINOS FX, 1995, EUR J IMMUNOL, V25, P179, DOI 10.1002/eji.1830250130; PLAKSIN D, 1993, J EXP MED, V177, P1651, DOI 10.1084/jem.177.6.1651; RELLAHAN BL, 1990, J EXP MED, V172, P1091, DOI 10.1084/jem.172.4.1091; Richard M, 1999, BLOOD, V93, P4318, DOI 10.1182/blood.V93.12.4318.412k09_4318_4327; ROSENFELD MG, 1983, NATURE, V304, P129, DOI 10.1038/304129a0; Rothenberg EV, 1996, P NATL ACAD SCI USA, V93, P9358, DOI 10.1073/pnas.93.18.9358; Salmeron A, 2001, J BIOL CHEM, V276, P22215, DOI 10.1074/jbc.M101754200; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SUNDSTEDT A, 1994, IMMUNOLOGY, V82, P117; Sundstedt A, 1996, P NATL ACAD SCI USA, V93, P979, DOI 10.1073/pnas.93.3.979; Sundstedt A, 1998, J IMMUNOL, V161, P5930; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Udalova IA, 2000, MOL CELL BIOL, V20, P9113, DOI 10.1128/MCB.20.24.9113-9119.2000; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; Wedel A, 1999, BIOL CHEM, V380, P1193, DOI 10.1515/BC.1999.151; ZIEGLERHEITBROCK HWL, 1994, J BIOL CHEM, V269, P17001	56	73	78	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8460	8468		10.1074/jbc.M312398200	http://dx.doi.org/10.1074/jbc.M312398200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14668329	hybrid			2022-12-25	WOS:000189103300129
J	Veljkovic, E; Stasiuk, S; Skelly, PJ; Shoemaker, CB; Verrey, F				Veljkovic, E; Stasiuk, S; Skelly, PJ; Shoemaker, CB; Verrey, F			Functional characterization of Caenorhabditis elegans heteromeric amino acid transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4F2 HEAVY-CHAIN; SUBSTRATE SELECTIVITY; GENE-EXPRESSION; SYSTEM L; IDENTIFICATION; CLONING; EXCHANGERS; CYSTINURIA; KIDNEY	Mammalian heteromeric amino acid transporters (HATs) are composed of a multi-transmembrane spanning catalytic protein covalently associated with a type II glycoprotein (e.g. 4F2hc, rBAT) through a disulfide bond. Caenorhabditis elegans has nine genes encoding close homologues of the HAT catalytic proteins. Three of these genes (designated AAT-1 to AAT-3) have a much higher degree of similarity to the mammalian homologues than the other six, including the presence of a cysteine residue at the position known to form a disulfide bridge to the glycoprotein partner in mammalian HATs. C. elegans also has two genes encoding homologues of the heteromeric amino acid transporter type II glycoprotein subunits (designated ATG-1 and ATG-2). Both ATG, and/or AAT-1, -2, -3 proteins were expressed in Xenopus oocytes and tested for amino acid transport function. This screen revealed that AAT-1 and AAT-3 facilitate amino acid transport when expressed together with ATG-2 but not with ATG-1 or the mammalian type II glycoproteins 4F2hc and rBAT. AAT-1 and AAT-3 covalently bind to both C. elegans ATG glycoproteins, but only the pairs with ATG-2 traffic to the oocyte surface. Both of these functional, surface-expressed C. elegans HATs transport most neutral amino acids and display the highest transport rate for L-Ala and L-Ser (apparent Km 100 muM range). Similar to their mammalian counterparts, the C. elegans HATs function as (near) obligatory amino acid exchangers. Taken together, this study demonstrates that the heteromeric structure and the amino acid exchange function of HATs have been conserved throughout the evolution of nematodes to mammals.	Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; AgRes, Anim Hlth, Upper Hutt, New Zealand; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA	University of Zurich; AgResearch - New Zealand; Harvard University; Harvard T.H. Chan School of Public Health	Verrey, F (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	verrey@access.unizh.ch		Verrey, Francois/0000-0003-3250-9824				Bauch C, 2002, AM J PHYSIOL-RENAL, V283, pF181, DOI 10.1152/ajprenal.00212.2001; Chillaron J, 2001, AM J PHYSIOL-RENAL, V281, pF995, DOI 10.1152/ajprenal.2001.281.6.F995; Fukasawa Y, 2000, J BIOL CHEM, V275, P9690, DOI 10.1074/jbc.275.13.9690; Harlow E., 1988, ANTIBODIES LAB MANUA; Hill AA, 2000, SCIENCE, V290, P809, DOI 10.1126/science.290.5492.809; Jiang M, 2001, P NATL ACAD SCI USA, V98, P218, DOI 10.1073/pnas.011520898; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; Meier C, 2002, EMBO J, V21, P580, DOI 10.1093/emboj/21.4.580; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Pfeiffer R, 1999, MOL BIOL CELL, V10, P4135, DOI 10.1091/mbc.10.12.4135; Pfeiffer R, 1998, FEBS LETT, V439, P157, DOI 10.1016/S0014-5793(98)01359-3; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; Puoti A, 1997, P NATL ACAD SCI USA, V94, P5949, DOI 10.1073/pnas.94.11.5949; Rajan DP, 1999, J BIOL CHEM, V274, P29005, DOI 10.1074/jbc.274.41.29005; Rossier G, 1999, J BIOL CHEM, V274, P34948, DOI 10.1074/jbc.274.49.34948; Segawa H, 1999, J BIOL CHEM, V274, P19745, DOI 10.1074/jbc.274.28.19745; Verrey F, 2003, PFLUG ARCH EUR J PHY, V445, P529, DOI 10.1007/S00424-002-0973-Z; Verrey F, 1999, J MEMBRANE BIOL, V172, P181, DOI 10.1007/s002329900595; Wagner CA, 2001, AM J PHYSIOL-CELL PH, V281, pC1077, DOI 10.1152/ajpcell.2001.281.4.C1077; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596	22	21	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7655	7662		10.1074/jbc.M309528200	http://dx.doi.org/10.1074/jbc.M309528200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14668347	hybrid			2022-12-25	WOS:000189103300036
J	Luoh, SW; Venkatesan, N; Tripathi, R				Luoh, SW; Venkatesan, N; Tripathi, R			Overexpression of the amplified Pip4k2 beta gene from 17q11-12 in breast cancer cells confers proliferation advantage	ONCOGENE			English	Article						tumor biology; breast cancer; gene amplification; gene expression; HER-2/Neu	IN-SITU HYBRIDIZATION; PHOSPHATIDYLINOSITOL PHOSPHATE KINASES; GROWTH-FACTOR RECEPTOR; HER-2/NEU GENE; N-MYC; INOSITIDE PHOSPHORYLATION; AMPLIFICATION STATUS; 11Q13 AMPLIFICATION; PUTATIVE ONCOGENE; PROGNOSTIC-FACTOR	Gene amplification is common in solid tumors and is associated with adverse prognosis, disease progression, and development of drug resistance. A small segment from chromosome 17q11-12 containing the HER-2/Neu gene is amplified in about 25% of breast cancer. HER-2/Neu amplification is associated with adverse prognosis and may predict response to chemotherapy and hormonal manipulation. Moreover, HER-2/Neu amplification may select patients for anti-HER-2/Neu-based therapy with Herceptin. We and others recently described a common sequence element from the HER-2/Neu region that was amplified in breast cancer cells. In addition, most, if not all, of the amplified genes from this region display overexpression. This raises the intriguing possibility that genes immediately adjacent to HER-2/Neu may influence the biological behavior of breast cancer carrying HER-2/ Neu amplification and serve as rational targets for therapy. By extracting sequence information from public databases, we have constructed a contig in bacterial artificial chromosomes (BACs) that extends from HER-2/ Neu to a phosphotidylinositol phosphate kinase (PIPK), Pip4k2beta from 17q11 - 12. Although a role of PI-3-kinase and AKT in cancer biology has been previously described, PIPK has not been previously implicated. We show that Pip4k2b, initially known as Pip5k2beta, is amplified in a subset of breast cancer cell lines and primary breast cancer samples that carry HER-2/ Neu amplification. Out of eight breast cancer cell lines with HER-2/ Neu amplification, three have concomitant amplification of the Pip4k2beta gene - UACC-812, BT-474 and ZR-75-30. Similarly, two out of four primary breast tumors with HER-2/ Neu amplification carry Pip4k2b gene amplification. Intriguingly, one tumor displays an increase in the gene copy number of Pip4k2b that is significantly more than that of HER-2/ Neu. Moreover, dual color FISH reveals that amplified Pip4k2b gene may exist in a distinct structure from that of HER-2/ Neu in ZR-75-30 cell line. These studies suggest that Pip4k2b may reside on an amplification maximum distinct from that of HER-2/Neu and serve as an independent target for amplification and selective retention. Pip4k2beta amplification is associated with overexpression at the RNA and protein level in breast cancer cell lines. Stable expression of Pip4k2b in breast cancer cell lines with and without HER-2/Neu amplification increases cell proliferation and anchorage-independent growth. The above observations implicate Pip4k2b in the development and/or progression of breast cancer. Our study suggests that Pip4k2b may be a distinct target for gene amplification and selective retention from 17q11-12.	Univ Calif Los Angeles, Med Ctr, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA; Cincinnati Vet Affairs Med Ctr, Cincinnati, OH 45220 USA; Univ Cincinnati, Coll Med, Dept Med, Div Hematol & Oncol, Cincinnati, OH 45267 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; University System of Ohio; University of Cincinnati	Luoh, SW (corresponding author), Oregon Hlth Sci Univ, Portland VA Med Ctr, RAD 47,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.							AMLER LC, 1989, MOL CELL BIOL, V9, P4903, DOI 10.1128/MCB.9.11.4903; Anderson RA, 1999, J BIOL CHEM, V274, P9907, DOI 10.1074/jbc.274.15.9907; Arneson LS, 1999, J BIOL CHEM, V274, P17794, DOI 10.1074/jbc.274.25.17794; Barlund M, 2000, CANCER RES, V60, P5340; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Brien TP, 2000, HUM PATHOL, V31, P35, DOI 10.1016/S0046-8177(00)80195-1; Bringuier PP, 1996, ONCOGENE, V12, P1747; Castellino AM, 1997, J BIOL CHEM, V272, P5861, DOI 10.1074/jbc.272.9.5861; CHAZIN VR, 1992, ONCOGENE, V7, P1859; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Homma K, 1998, J BIOL CHEM, V273, P15779, DOI 10.1074/jbc.273.25.15779; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; Ishikawa T, 1997, AM J PATHOL, V151, P761; Kauraniemi P, 2001, CANCER RES, V61, P8235; Kunz J, 2000, MOL CELL, V5, P1, DOI 10.1016/S1097-2765(00)80398-6; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P439; Luoh SW, 2002, CANCER GENET CYTOGEN, V136, P43, DOI 10.1016/S0165-4608(01)00657-4; Massion PP, 2002, CANCER RES, V62, P3636; McEwen RK, 1999, J BIOL CHEM, V274, P33905, DOI 10.1074/jbc.274.48.33905; Mejillano M, 2001, J BIOL CHEM, V276, P1865, DOI 10.1074/jbc.M007271200; Monni O, 2001, P NATL ACAD SCI USA, V98, P5711, DOI 10.1073/pnas.091582298; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; Nakajima M, 1999, CANCER, V85, P1894; Nessling M, 1998, GENE CHROMOSOME CANC, V23, P307, DOI 10.1002/(SICI)1098-2264(199812)23:4<307::AID-GCC5>3.0.CO;2-#; Paik SM, 1998, JNCI-J NATL CANCER I, V90, P1361, DOI 10.1093/jnci/90.18.1361; Pauletti G, 2000, J CLIN ONCOL, V18, P3651, DOI 10.1200/JCO.2000.18.21.3651; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; PRESS MF, 1994, CANCER RES, V54, P5675; PRESS MF, 1993, CANCER RES, V53, P4960; PROCTOR AJ, 1991, ONCOGENE, V6, P789; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Rao VD, 1998, CELL, V94, P829, DOI 10.1016/S0092-8674(00)81741-9; RAVDIN PM, 1995, GENE, V159, P19, DOI 10.1016/0378-1119(94)00866-Q; ROELOFS H, 1993, GENE CHROMOSOME CANC, V7, P74, DOI 10.1002/gcc.2870070203; Rolitsky CD, 1999, INT J GYNECOL PATHOL, V18, P138, DOI 10.1097/00004347-199904000-00007; Ross JS, 1999, SEMIN CANCER BIOL, V9, P125, DOI 10.1006/scbi.1998.0083; Ross JS, 1997, HUM PATHOL, V28, P827, DOI 10.1016/S0046-8177(97)90157-X; Rozenvayn N, 2001, J BIOL CHEM, V276, P22410, DOI 10.1074/jbc.M008184200; Rubie H, 1997, J CLIN ONCOL, V15, P1171, DOI 10.1200/JCO.1997.15.3.1171; Savelyeva L, 2001, CANCER LETT, V167, P115, DOI 10.1016/S0304-3835(01)00472-4; Sbrissa D, 1999, J BIOL CHEM, V274, P21589, DOI 10.1074/jbc.274.31.21589; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SZEPETOWSKI P, 1992, ONCOGENE, V7, P751; SZEPETOWSKI P, 1993, GENOMICS, V16, P745, DOI 10.1006/geno.1993.1257; THEILLET C, 1990, ONCOGENE, V5, P147; Thor AD, 1998, JNCI-J NATL CANCER I, V90, P1346, DOI 10.1093/jnci/90.18.1346; Tolias KF, 1998, J BIOL CHEM, V273, P18040, DOI 10.1074/jbc.273.29.18040; Walch AK, 2000, MODERN PATHOL, V13, P814, DOI 10.1038/modpathol.3880143; Wu GJ, 2000, CANCER RES, V60, P5371; Wu GJ, 2001, CANCER RES, V61, P4951; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756	67	38	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	2004	23	7					1354	1363		10.1038/sj.onc.1207251	http://dx.doi.org/10.1038/sj.onc.1207251			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14691457				2022-12-25	WOS:000189035800003
J	Liu, SL; Sugimoto, Y; Sorio, C; Tecchio, C; Lin, YC				Liu, SL; Sugimoto, Y; Sorio, C; Tecchio, C; Lin, YC			Function analysis of estrogenically regulated protein tyrosine phosphatase gamma (PTP gamma) in human breast cancer cell line MCF-7	ONCOGENE			English	Article						human breast; human breast cancer; protein tyrosine phosphatase gamma; overexpression; antisense; soft agar assay	EXPRESSION; GENE; CLONING; REGION; BRAIN; DOMAIN; CDNA; LUNG	Protein tyrosine phosphatase gamma (PTPgamma) is a member of the receptor-like family of tyrosine phosphatases and has been implicated as a tumor suppressor gene in kidney and lung cancers. Based on our previous findings, we hypothesize that PTPgamma is a potential estrogen-regulated tumor suppressor gene in human breast cancer. To examine the effects of PTPgamma on growth of MCF-7 human breast cancer cells and compare the estrogenic responses of human breast cells with different PTPgamma expression levels, we established several stably transfected MCF-7 cell lines expressing different levels of PTPgamma, which were confirmed by RT-PCR and immunostaining. In our work, we used the antisense construct to breakdown endogenous PTPgamma level in MCF-7 cells. The results from doubling time assay suggested that PTPgamma is capable of inhibiting MCF-7 breast cancer cell growth. We further demonstrated that PTPgamma is able to inhibit anchorage-independent growth of breast cancer cells in soft agar and reduce the estrogenic responses of MCF-7 cell proliferation to estradiol-17beta (E-2) and zeranol (Z, a nonsteroidal growth promoter with estrogenic activity). Our data suggest that PTPgamma may function as an important modulator in regulating the process of tumorigenesis in human breast.	Ohio State Univ, Coll Vet Med, Lab Reprod & Mol Endocrinol, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Univ Verona, Dipartimento Patol, I-37134 Verona, Italy	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Verona	Lin, YC (corresponding author), Ohio State Univ, Coll Vet Med, Lab Reprod & Mol Endocrinol, 1900 Coffey Rd, Columbus, OH 43210 USA.	lin.15@osu.edu	Sorio, Claudio/F-2764-2018; Liu, Suling/N-2796-2013; tecchio, cristina/GRX-9586-2022; liu, suling/AAF-5249-2019; Sugimoto, Yasuro/AAR-1423-2021; Sugimoto, Yasuro/B-4004-2012	Sorio, Claudio/0000-0003-2739-4014; Liu, Suling/0000-0002-0475-0242; liu, suling/0000-0002-0475-0242; Sugimoto, Yasuro/0000-0002-5094-4347	NCI NIH HHS [CA 95915, CA 94718] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA095915, R21CA094718] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNEA G, 1993, MOL CELL BIOL, V13, P1497, DOI 10.1128/MCB.13.3.1497; GAITS F, 1995, BIOCHEM J, V311, P97, DOI 10.1042/bj3110097; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; Krop IE, 2001, P NATL ACAD SCI USA, V98, P9796, DOI 10.1073/pnas.171138398; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; Kulp SK, 2000, BIOL REPROD, V62, P181; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LAFORGIA S, 1993, CANCER RES, V53, P3118; LEVY JB, 1993, J BIOL CHEM, V268, P10573; LIN YC, 1994, P AM ASS CANC RES 85, V35, pA607; Liu SL, 2002, BREAST CANCER RES TR, V71, P21, DOI 10.1023/A:1013343718942; LUBINSKI J, 1994, CANCER RES, V54, P3710; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; Poliseno L, 2002, CANCER CHEMOTH PHARM, V50, P127, DOI 10.1007/s00280-002-0467-x; SHOCK LP, 1995, MOL BRAIN RES, V28, P110, DOI 10.1016/0169-328X(94)00190-P; Sorio C, 1997, BLOOD, V90, P49; SORIO C, 1995, CANCER RES, V55, P4855; TSUKAMOTO T, 1992, CANCER RES, V52, P3506; van Niekerk CC, 1999, CANCER LETT, V137, P61, DOI 10.1016/S0304-3835(98)00344-9; Zheng J, 2000, ANTICANCER RES, V20, P11	23	34	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1256	1262		10.1038/sj.onc.1207235	http://dx.doi.org/10.1038/sj.onc.1207235			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14676845				2022-12-25	WOS:000188892200010
J	Guelen, L; Paterson, H; Gaken, J; Meyers, M; Farzaneh, F; Tavassoli, M				Guelen, L; Paterson, H; Gaken, J; Meyers, M; Farzaneh, F; Tavassoli, M			TAT-apoptin is efficiently delivered and induces apoptosis in cancer cells	ONCOGENE			English	Article						apoptin; CAV; apoptosis; TAT-PTD; protein delivery; death effector	CHICKEN ANEMIA VIRUS; PROTEIN TRANSDUCTION; TUMOR-CELLS; MAMMALIAN-CELLS; INDUCTION; INDIVIDUALS; ACTIVATION; CASPASE-3; CYCLE; DNA	Apoptin has been described to induce apoptosis in various human cancer cell lines, but not in normal cells, thus making it an interesting candidate for the development of novel therapeutic strategies. Apoptin was generated and cloned into several mammalian expression vectors. Transfection or microinjection of apoptin cDNA resulted in its expression, initially in the cytoplasm with a filamentous pattern. Subsequently, apoptin entered the nucleus and efficiently induced apoptosis in several cancer cell lines. Nuclear localization was shown to be required for induction of apoptosis. Apoptin expression level was found to be an important determinant of the efficiency of induction of apoptosis. Surprisingly, expression of apoptin or GFP-apoptin cDNA induced apoptosis in some normal cells. When fused to the HIV-TAT protein transduction domain and delivered as a protein, TAT-apoptin was transduced efficiently (>90%) into normal and tumour cells. However, TAT-apoptin remained in the cytoplasm and did not kill normal 6689 and 1BR3 fibroblasts. In contrast TAT-apoptin migrated from the cytoplasm to the nucleus of Saos-2 and HSC-3 cancer cells resulting in apoptosis after 24 h. This study shows that apoptin is a powerful apoptosis-inducing protein with a potential for cancer therapy.	Guys Kings & St Thomas Sch Med & Dent, Rayne Inst, Dept Oral Med & Pathol, Head & Neck Oncol Grp, London, England; Inst Canc Res, Chester Beatty Labs, CRC, Ctr Cell & Mol Biol, London SW3 6JB, England; Guys Kings & St Thomas Sch Med & Dent, Rayne Inst, Dept Mol Med, London, England	University of London; King's College London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; King's College London	Tavassoli, M (corresponding author), GKT Sch Med & Dent, Head & Neck Oncol Grp, Rayne Inst, 123 Coldharbour Lane, London SE5 9NU, England.	mahvash.tavassoli@kcl.ac.uk	Farzaneh, Farzin/B-4902-2009	Farzaneh, Farzin/0000-0002-9275-2415				Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; Danen-van Oorschot AAAM, 2000, J VIROL, V74, P7072, DOI 10.1128/JVI.74.15.7072-7078.2000; Danen-van Oorschot AAAM, 2003, J BIOL CHEM, V278, P27729, DOI 10.1074/jbc.M303114200; DanenVanOorschot AAAM, 1997, P NATL ACAD SCI USA, V94, P5843; Flinterman M, 2003, ONCOGENE, V22, P1965, DOI 10.1038/sj.onc.1206190; Ford KG, 2001, GENE THER, V8, P1, DOI 10.1038/sj.gt.3301383; Gius DR, 1999, CANCER RES, V59, P2577; HOLME TC, 1990, EUR J SURG ONCOL, V16, P161; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; MEEHAN BM, 1992, ARCH VIROL, V124, P301, DOI 10.1007/BF01309811; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; NOTEBORN MHM, 1994, J VIROL, V68, P346, DOI 10.1128/JVI.68.1.346-351.1994; NOTEBORN MHM, 1991, J VIROL, V65, P3131, DOI 10.1128/JVI.65.6.3131-3139.1991; Noteborn MHM, 1998, MUTAT RES-FUND MOL M, V400, P447, DOI 10.1016/S0027-5107(98)00016-5; Oorschot AAAMD, 1999, LEUKEMIA, V13, pS75, DOI 10.1038/sj.leu.2401291; Rohn JL, 2002, J BIOL CHEM, V277, P50820, DOI 10.1074/jbc.M208557200; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Vocero-Akbani AM, 1999, NAT MED, V5, P29, DOI 10.1038/4710; Weber CH, 2001, TRENDS BIOCHEM SCI, V26, P475, DOI 10.1016/S0968-0004(01)01905-3; Zhang YH, 1999, CANCER RES, V59, P3010; Zhuang SM, 1995, CARCINOGENESIS, V16, P2939, DOI 10.1093/carcin/16.12.2939; ZHUANG SM, 1995, LEUKEMIA, V9, pS118; ZHUANG SM, 1995, CANCER RES, V55, P486	28	120	150	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1153	1165		10.1038/sj.onc.1207224	http://dx.doi.org/10.1038/sj.onc.1207224			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14691460				2022-12-25	WOS:000188749900014
J	Jin, XS; Foley, KM; Geiger, JH				Jin, XS; Foley, KM; Geiger, JH			The structure of the 1L-myo-inositol-1-phosphate synthase-NAD(+)-2deoxy-D-glucitol 6-(E)-vinylhomophosphonate complex demands a revision of the enzyme mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOINOSITOL 1-PHOSPHATE SYNTHASE; MYO-INOSITOL-1-PHOSPHATE SYNTHASE; L-MYO-INOSITOL-1-PHOSPHATE SYNTHASE; INOSITOL-1-PHOSPHATE SYNTHASE; DEHYDROQUINATE SYNTHASE; ARABIDOPSIS-THALIANA; CRYSTAL-STRUCTURE; BOVINE TESTIS; INOSITOL; GLUCOSE	1L-myo-inositol 1-phosphate (MIP) synthase catalyzes the conversion of D-glucose 6-phosphate to 1L-myo-inositol 1-phosphate, the first and rate-limiting step in the biosynthesis of all inositol-containing compounds. It involves an oxidation, enolization, intramolecular aldol cyclization, and reduction. Here we present the structure of MIP synthase in complex with NAD(+) and a high-affinity inhibitor, 2-deoxy-D-glucitol 6-(E)-vinylhomophosphonate. This structure reveals interactions between the enzyme active site residues and the inhibitor that are significantly different from that proposed for 2-deoxy-D-glucitol 6- phosphate in the previously published structure of MIP synthase-NAD(+)-2-deoxy-D-glucitol 6- phosphate. There are several other conformational changes in NAD(+) and the enzyme active site as well. Based on the new structural data, we propose a new and completely different mechanism for MIP synthase.	Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA	Michigan State University	Geiger, JH (corresponding author), Michigan State Univ, Dept Chem, 320 Chem, E Lansing, MI 48824 USA.		ID, IMCACAT/D-5867-2014	Jin, Xiangshu/0000-0002-6551-8850; Geiger, James/0000-0002-9443-4488				ABUABIED M, 1994, PLANT PHYSIOL, V106, P1689, DOI 10.1104/pp.106.4.1689; ADHIKARI J, 1983, FEBS LETT, V163, P46, DOI 10.1016/0014-5793(83)81159-4; ADHIKARI J, 1988, INDIAN J BIOCHEM BIO, V25, P408; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ARGANOFF BW, 1991, INOSITOL PHOSPHATES, P20; BARNETT J E G, 1973, Biochemical Society Transactions, V1, P1267; BARNETT JEG, 1968, BIOCHEM J, V108, P125, DOI 10.1042/bj1080125; BELMAKER RG, 1995, DEPRESSION MANIA NEU; Belmaker RH, 1996, ANNU REV MED, V47, P47; BENDER SL, 1989, BIOCHEMISTRY-US, V28, P7560, DOI 10.1021/bi00445a010; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carpenter EP, 1998, NATURE, V394, P299, DOI 10.1038/28431; Chen LJ, 2000, BIOCHEMISTRY-US, V39, P12415, DOI 10.1021/bi001517q; DEANJOHNSON M, 1989, J BIOL CHEM, V264, P1274; EXTON JH, 1986, ADV CYCLIC NUCL PROT, V20, P211; FREY PA, 1987, PYRIDINE NUCLEOTID B, P461; HASEGAWA R, 1981, P NATL ACAD SCI-BIOL, V78, P4863, DOI 10.1073/pnas.78.8.4863; Ishitani M, 1996, PLANT J, V9, P537, DOI 10.1046/j.1365-313X.1996.09040537.x; Jin XS, 2003, ACTA CRYSTALLOGR D, V59, P1154, DOI 10.1107/S0907444903008205; JOHNSON MD, 1995, PLANT PHYSIOL, V107, P613, DOI 10.1104/pp.107.2.613; JOHNSON MD, 1994, PLANT PHYSIOL, V105, P1023, DOI 10.1104/pp.105.3.1023; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LOEWUS FA, 1962, BIOCHEM BIOPH RES CO, V7, P204, DOI 10.1016/0006-291X(62)90175-4; LOEWUS MW, 1977, J BIOL CHEM, V252, P7221; LOEWUS MW, 1980, J BIOL CHEM, V255, P1710; LOEWUS MW, 1980, CARBOHYD RES, V82, P333, DOI 10.1016/S0008-6215(00)85707-9; Lohia A, 1999, MOL BIOCHEM PARASIT, V98, P67, DOI 10.1016/S0166-6851(98)00147-9; Majumder AL, 1997, BBA-LIPID LIPID MET, V1348, P245, DOI 10.1016/S0005-2760(97)00122-7; MAUCK LA, 1980, BIOCHEMISTRY-US, V19, P3623, DOI 10.1021/bi00556a031; MIGAUD ME, 1995, J AM CHEM SOC, V117, P5154, DOI 10.1021/ja00123a019; Norman RA, 2002, STRUCTURE, V10, P393, DOI 10.1016/S0969-2126(02)00718-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park D, 2000, BBA-GENE STRUCT EXPR, V1494, P277, DOI 10.1016/S0167-4781(00)00085-3; POTTER BVL, 1995, ANGEW CHEM INT EDIT, V34, P1933, DOI 10.1002/anie.199519331; SHERMAN WR, 1969, J BIOL CHEM, V244, P5703; SMART CC, 1993, PLANT J, V4, P279, DOI 10.1046/j.1365-313X.1993.04020279.x; Stein AJ, 2002, J BIOL CHEM, V277, P9484, DOI 10.1074/jbc.M109371200; Stein AJ, 2000, ACTA CRYSTALLOGR D, V56, P348, DOI 10.1107/S0907444999016777; Tian F, 1999, J AM CHEM SOC, V121, P5795, DOI 10.1021/ja9900196; Vaden DL, 2001, J BIOL CHEM, V276, P15466, DOI 10.1074/jbc.M004179200; WANG X, 1995, PLANT PHYSIOL, V110, P336; Williams RSB, 2002, NATURE, V417, P292, DOI 10.1038/417292a; WONG YHH, 1982, METHOD ENZYMOL, V90, P309	45	22	23	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13889	13895		10.1074/jbc.M308986200	http://dx.doi.org/10.1074/jbc.M308986200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14684747	hybrid			2022-12-25	WOS:000220478500075
J	Balbis, A; Baquiran, G; Dumas, V; Posner, BI				Balbis, A; Baquiran, G; Dumas, V; Posner, BI			Effect of inhibiting vacuolar acidification on insulin signaling in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; DEPENDENT DIABETES-MELLITUS; PROTEIN-KINASE-B; RECEPTOR KINASE; RAT HEPATOCYTES; PHOSPHATIDYLINOSITOL 3-KINASE; INTERNALIZED INSULIN; GLYCOGEN-SYNTHASE; TRANSDUCTION PATHWAYS; ENDOSOMAL PROTEOLYSIS	Previous studies have shown that the endosomal apparatus plays an important role in insulin signaling. Inhibition of endosomal acidification leads to a decrease in insulin-insulin receptor kinase (IRK) dissociation and insulin degradation. Thus, vacuolar pH could function as a modulator of insulin signaling in endosomes. In the present study we show that in primary hepatocytes pretreated with bafilomycin, there is an inhibition of vacuolar acidification. Incubation of these cells with insulin was followed by an augmentation of IRK activity but an inhibition of phosphatidylinositol 3-kinase/Akt activity and a decrease in insulin-induced DNA and glycogen synthesis. Bafilomycin treatment inhibited IRK recycling to the plasma membrane without affecting IRK internalization. Impaired IRK recycling correlated with a decrease in insulin signaling. We suggest that inhibiting vacuolar acidification sequesters activated IRKs in an intracellular compartment(s) where signaling is inhibited. This implies that endosomal receptor trafficking plays a role in regulating signal transduction.	McGill Univ, Fac Med, Polypeptide Hormone Lab, Montreal, PQ H3A 2B2, Canada	McGill University	Posner, BI (corresponding author), McGill Univ, Fac Med, Polypeptide Hormone Lab, 3640 Univ St,Ste W315, Montreal, PQ H3A 2B2, Canada.	barry.posner@staff.mcgill.ca	Posner, Barry/B-6733-2008					Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; AUTHIER F, 1994, J BIOL CHEM, V269, P3010; Authier F, 2002, J BIOL CHEM, V277, P9437, DOI 10.1074/jbc.M110188200; Band CJ, 1999, ENDOCRINOLOGY, V140, P5626, DOI 10.1210/en.140.12.5626; Band CJ, 1997, J BIOL CHEM, V272, P138; Bevan AP, 1997, J BIOL CHEM, V272, P26833, DOI 10.1074/jbc.272.43.26833; BEVAN AP, 1995, J BIOL CHEM, V270, P10784, DOI 10.1074/jbc.270.18.10784; BURGESS JW, 1992, J BIOL CHEM, V267, P10077; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; Contreres JO, 1998, J BIOL CHEM, V273, P22007, DOI 10.1074/jbc.273.34.22007; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DESBUQUOIS B, 1992, DIABETES METAB, V18, P104; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; DOHERTY JJ, 1990, J CELL BIOL, V110, P35, DOI 10.1083/jcb.110.1.35; Drake PG, 1998, MOL CELL BIOCHEM, V182, P79, DOI 10.1023/A:1006808100755; Drose S, 1997, J EXP BIOL, V200, P1; DUNN WA, 1986, J CELL BIOL, V102, P24, DOI 10.1083/jcb.102.1.24; FAURE R, 1992, J BIOL CHEM, V267, P11215; HAMEL FG, 1988, J BIOL CHEM, V263, P6703; Hribal ML, 2001, MOL PHARMACOL, V59, P322, DOI 10.1124/mol.59.2.322; JOHNSON LS, 1993, MOL BIOL CELL, V4, P1251, DOI 10.1091/mbc.4.12.1251; KHAN MN, 1989, J BIOL CHEM, V264, P12931; Lavoie L, 1999, J BIOL CHEM, V274, P28279, DOI 10.1074/jbc.274.40.28279; LEVY JR, 1987, ENDOCRINOLOGY, V121, P2075, DOI 10.1210/endo-121-6-2075; LEVYTOLEDANO R, 1993, ENDOCRINOLOGY, V133, P1803, DOI 10.1210/en.133.4.1803; MANABE T, 1993, J CELL PHYSIOL, V157, P445, DOI 10.1002/jcp.1041570303; MARSHALL S, 1985, J BIOL CHEM, V260, P4136; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Mounier C, 2001, MOL CELL ENDOCRINOL, V173, P15, DOI 10.1016/S0303-7207(00)00439-1; Navab R, 2001, J BIOL CHEM, V276, P13644, DOI 10.1074/jbc.M100019200; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; Posner Barry I, 2003, Curr Opin Investig Drugs, V4, P430; POSNER BI, 1982, J BIOL CHEM, V257, P5789; POWRIE JK, 1993, METABOLISM, V42, P415, DOI 10.1016/0026-0495(93)90096-7; POWRIE JK, 1991, AM J PHYSIOL, V260, pE897, DOI 10.1152/ajpendo.1991.260.6.E897; ROMANEK R, 1993, BIOCHEM J, V296, P321, DOI 10.1042/bj2960321; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; Rother KI, 1998, J BIOL CHEM, V273, P17491, DOI 10.1074/jbc.273.28.17491; Saurin AJ, 1996, BIOCHEM J, V313, P65, DOI 10.1042/bj3130065; Sesti G, 1996, DIABETOLOGIA, V39, P289; SMITH GD, 1987, BRIT MED J, V294, P465, DOI 10.1136/bmj.294.6570.465; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; UEDA M, 1985, J BIOL CHEM, V260, P3941; Urso B, 1999, J BIOL CHEM, V274, P30864, DOI 10.1074/jbc.274.43.30864; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; Wang Y, 2002, MOL CELL BIOL, V22, P7279, DOI 10.1128/MCB.22.20.7279-7290.2002	47	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12777	12785		10.1074/jbc.M311493200	http://dx.doi.org/10.1074/jbc.M311493200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14688247	hybrid			2022-12-25	WOS:000220334900092
J	Bharadwaj, R; Qi, W; Yu, HT				Bharadwaj, R; Qi, W; Yu, HT			Identification of two novel components of the human NDC80 kinetochore complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; SPINDLE CHECKPOINT; CHROMOSOME SEGREGATION; MICROTUBULE ATTACHMENT; MAMMALIAN-CELLS; BUDDING YEAST; MAD2; MITOSIS; CENTROMERE; TENSION	Proper kinetochore function is essential for the accurate segregation of chromosomes during mitosis. Kinetochores provide the attachment sites for spindle microtubules and are required for the alignment of chromosomes at the metaphase plate ( chromosome congression). Components of the conserved NDC80 complex are required for chromosome congression, and their disruption results in mitotic arrest accompanied by multiple spindle aberrations. To better understand the function of the NDC80 complex, we have identified two novel subunits of the human NDC80 complex, termed human SPC25 ( hSPC25) and human SPC24 ( hSPC24), using an immunoaffinity approach. hSPC25 interacted with HEC1 ( human homolog of yeast Ndc80) throughout the cell cycle and localized to kinetochores during mitosis. RNA interference- mediated depletion of hSPC25 in HeLa cells caused aberrant mitosis, followed by cell death, a phenotype similar to that of cells depleted of HEC1. Loss of hSPC25 also caused multiple spindle aberrations, including elongated, multipolar, and fractured spindles. In the absence of hSPC25, MAD1 and HEC1 failed to localize to kinetochores during mitosis, whereas the kinetochore localization of BUB1 and BUBR1 was largely unaffected. Interestingly, the kinetochore localization of MAD1 in cells with a compromised NDC80 function was restored upon microtubule depolymerization. Thus, hSPC25 is an essential kinetochore component that plays a significant role in proper execution of mitotic events.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yu, HT (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	hongtao.yu@utsouthwestern.edu		Qi, Wei/0000-0003-0813-5316; Yu, Hongtao/0000-0002-8861-049X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061542] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 61542] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Campbell MS, 2001, J CELL SCI, V114, P953; Cheeseman IM, 2002, J CELL BIOL, V157, P199, DOI 10.1083/jcb.200201052; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; Chen RH, 1998, J CELL BIOL, V143, P283, DOI 10.1083/jcb.143.2.283; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; DeLuca JG, 2002, J CELL BIOL, V159, P549, DOI 10.1083/jcb.200208159; DeLuca JG, 2003, CURR BIOL, V13, P2103, DOI 10.1016/j.cub.2003.10.056; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; Gorbsky GJ, 2001, CURR BIOL, V11, pR1001, DOI 10.1016/S0960-9822(01)00609-1; Goshima G, 2003, J CELL BIOL, V160, P25, DOI 10.1083/jcb.200210005; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hori T, 2003, J CELL SCI, V116, P3347, DOI 10.1242/jcs.00645; Howell BJ, 2000, J CELL BIOL, V150, P1233, DOI 10.1083/jcb.150.6.1233; Hunt PA, 2002, SCIENCE, V296, P2181, DOI 10.1126/science.1071907; Jablonski SA, 1998, CHROMOSOMA, V107, P386, DOI 10.1007/s004120050322; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kallio MJ, 2002, J CELL BIOL, V158, P841, DOI 10.1083/jcb.200201135; Luo XL, 2002, MOL CELL, V9, P59, DOI 10.1016/S1097-2765(01)00435-X; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; McCleland ML, 2003, GENE DEV, V17, P101, DOI 10.1101/gad.1040903; Millband DN, 2002, TRENDS CELL BIOL, V12, P205, DOI 10.1016/S0962-8924(02)02276-6; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Nasmyth K, 2002, SCIENCE, V297, P559, DOI 10.1126/science.1074757; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Pinsky BA, 2003, DEV CELL, V5, P735, DOI 10.1016/S1534-5807(03)00322-8; Shannon KB, 2002, MOL BIOL CELL, V13, P3706, DOI 10.1091/mbc.E02-03-0137; Skoufias DA, 2001, P NATL ACAD SCI USA, V98, P4492, DOI 10.1073/pnas.081076898; Taylor SS, 2001, J CELL SCI, V114, P4385; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1; Waters JC, 1998, J CELL BIOL, V141, P1181, DOI 10.1083/jcb.141.5.1181; Westermann S, 2003, J CELL BIOL, V163, P215, DOI 10.1083/jcb.200305100; Wigge PA, 2001, J CELL BIOL, V152, P349, DOI 10.1083/jcb.152.2.349; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4; Zhou J, 2002, J BIOL CHEM, V277, P17200, DOI 10.1074/jbc.M110369200	39	93	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13076	13085		10.1074/jbc.M310224200	http://dx.doi.org/10.1074/jbc.M310224200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14699129	hybrid			2022-12-25	WOS:000220334900128
J	Pajvani, UB; Hawkins, M; Combs, TP; Rajala, MW; Doebber, T; Berger, JP; Wagner, JA; Wu, M; Knopps, A; Xiang, AH; Utzschneider, KM; Kahn, SE; Olefsky, JM; Buchanan, TA; Scherer, PE				Pajvani, UB; Hawkins, M; Combs, TP; Rajala, MW; Doebber, T; Berger, JP; Wagner, JA; Wu, M; Knopps, A; Xiang, AH; Utzschneider, KM; Kahn, SE; Olefsky, JM; Buchanan, TA; Scherer, PE			Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; GLUCOSE-PRODUCTION; DIABETES-MELLITUS; PROTEIN ACRP30; RESISTANCE; AGONISTS; OBESITY; TROGLITAZONE; ASSOCIATION; INDUCTION	Adiponectin is an adipocyte-specific secretory protein that circulates in serum as a hexamer of relatively low molecular weight (LMW) and a larger multimeric structure of high molecular weight (HMW). Serum levels of the protein correlate with systemic insulin sensitivity. The full-length protein affects hepatic gluconeogenesis through improved insulin sensitivity, and a proteolytic fragment of adiponectin stimulates beta oxidation in muscle. Here, we show that the ratio, and not the absolute amounts, between these two oligomeric forms ( HMW to LMW) is critical in determining insulin sensitivity. We define a new index, SA, that can be calculated as the ratio of HMW/(HMW + LMW). db/db mice, despite similar total adiponectin levels, display decreased SA values compared with wild type littermates, as do type II diabetic patients compared with insulin-sensitive individuals. Furthermore, SA improves with peroxisome proliferator-activated receptor-gamma agonist treatment ( thiazolidinedione; TZD) in mice and humans. We demonstrate that changes in SA in a number of type 2 diabetic cohorts serve as a quantitative indicator of improvements in insulin sensitivity obtained during TZD treatment, whereas changes in total serum adiponectin levels do not correlate well at the individual level. Acute alterations in S-A (DeltaS(A)) are strongly correlated with improvements in hepatic insulin sensitivity and are less relevant as an indicator of improved muscle insulin sensitivity in response to TZD treatment, further underscoring the conclusions from previous clamp studies that suggested that the liver is the primary site of action for the full-length protein. These observations suggest that the HMW adiponectin complex is the active form of this protein, which we directly demonstrate in vivo by its ability to depress serum glucose levels in a dose-dependent manner.	Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Ctr Diabet Res & Training, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Div Endocrinol, Bronx, NY 10461 USA; Merck Res Labs, Rahway, NJ 07065 USA; SGS Biopharma, B-12060 Antwerp, Belgium; Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90033 USA; Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA; Univ Washington, Seattle, WA 98108 USA; Univ Calif San Diego, Dept Endocrinol & Metab, La Jolla, CA 92093 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Merck & Company; University of Southern California; University of Southern California; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of California System; University of California San Diego	Scherer, PE (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	scherer@aecom.yu.edu	Scherer, Philipp E/K-7819-2012	Scherer, Philipp E/0000-0003-0680-3392; Utzschneider, Kristina/0000-0002-4924-196X; Kahn, Steven/0000-0001-7307-9002	NIDDK NIH HHS [2R01 DK 46374, DK 02654, DK 17047] Funding Source: Medline; NIGMS NIH HHS [T32 GM 07288] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK002654, R01DK046374, P30DK017047] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams AD, 2003, BIOORG MED CHEM LETT, V13, P3185, DOI 10.1016/S0960-894X(03)00702-9; Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Azen SP, 1998, CONTROL CLIN TRIALS, V19, P217, DOI 10.1016/S0197-2456(97)00151-7; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; BERGMAN RN, 1987, J CLIN INVEST, V79, P790, DOI 10.1172/JCI112886; Chao L, 2000, J CLIN INVEST, V106, P1221, DOI 10.1172/JCI11245; Cnop M, 2003, DIABETOLOGIA, V46, P459, DOI 10.1007/s00125-003-1074-z; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; Combs TP, 2002, ENDOCRINOLOGY, V143, P998, DOI 10.1210/endo.143.3.8662; Day C, 1999, DIABETIC MED, V16, P179, DOI 10.1046/j.1464-5491.1999.00023.x; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Hevener AL, 2003, NAT MED, V9, P1491, DOI 10.1038/nm956; Hogg PJ, 2003, TRENDS BIOCHEM SCI, V28, P210, DOI 10.1016/S0968-0004(03)00057-4; Kim JK, 2003, DIABETES, V52, P1311, DOI 10.2337/diabetes.52.6.1311; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Maeda N, 2001, DIABETES, V50, P2094, DOI 10.2337/diabetes.50.9.2094; Olefsky JM, 2000, J CLIN INVEST, V106, P467, DOI 10.1172/JCI10843; Pajvani UB, 2003, J BIOL CHEM, V278, P9073, DOI 10.1074/jbc.M207198200; Prigeon RL, 1998, J CLIN ENDOCR METAB, V83, P819, DOI 10.1210/jc.83.3.819; Rajala MW, 2003, J CLIN INVEST, V111, P225, DOI 10.1172/JCI200316521; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; VAAG A, 1995, DIABETOLOGIA, V38, P326, DOI 10.1007/s001250050289; VASSEUR F, 2002, CURR DIAB REP, V3, P151; Waki H, 2003, J BIOL CHEM, V278, P40352, DOI 10.1074/jbc.M300365200; Weyer C, 2001, J CLIN ENDOCR METAB, V86, P1930, DOI 10.1210/jc.86.5.1930; Yu JG, 2002, DIABETES, V51, P2968, DOI 10.2337/diabetes.51.10.2968; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	29	939	981	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12152	12162		10.1074/jbc.M311113200	http://dx.doi.org/10.1074/jbc.M311113200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14699128	hybrid			2022-12-25	WOS:000220334900021
J	Bayless, KJ; Davis, GE				Bayless, KJ; Davis, GE			Microtubule depolymerization rapidly collapses capillary tube networks in vitro and angiogenic vessels in vivo through the small GTPase Rho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL MORPHOGENESIS; CASPASE-MEDIATED ACTIVATION; FOCAL ADHESIONS; LUMEN FORMATION; STRESS FIBERS; APOPTOSIS; INHIBITION; MEMBRANE; PROTEINS; PHOSPHORYLATION	Maintenance of endothelial cell tube integrity is dependent on an intact cytoskeleton. We present data indicating that rapid collapse of endothelial tubular networks in vitro occurs in a dose-dependent manner after administration of microtubule-depolymerizing reagents but not after actin depolymerization. Pretreatment of endothelial cell networks with C3 exoenzyme or recombinant adenoviruses expressing dominant negative RhoA resulted in complete blockade of tube collapse, indicating a role for RhoA in these events. Microtubule depolymerization also resulted in activation of RhoA, whereas increased expression of constitutively active RhoA induced cell rounding and apoptosis of endothelial cells. Furthermore, following treatment with the chemotherapeutic agent vinblastine, rapid capillary tube network collapse occurred followed by endothelial cell apoptosis. Vinblastine, but not control agents, induced cleavage of procaspase-3, procaspase-9, and procaspase-8, along with the known caspase targets p21-activated kinase-2 and gelsolin, indicating that tube collapse caused a defined apoptotic response. Using a model of vascular endothelial growth factor-stimulated angiogenesis in vivo, vinblastine treatment also resulted in collapse and apoptosis of angiogenic blood vessels. Apoptotic endothelial cells stained strongly for cleaved caspase-3, and terminal dUTP nick-end labeling staining revealed fragmented nuclei in vinblastine-treated but not control angiogenic areas. Together, these findings indicate that microtubule-depolymerizing agents directly induce endothelial network collapse in vitro and in vivo leading to endothelial cell apoptosis in a manner dependent on the small GTPase, RhoA. In addition, these findings reveal a novel function for microtubule disrupting chemotherapeutic agents, namely their ability to rapidly collapse newly formed angiogenic vessels, which may contribute to their effectiveness in limiting angiogenesis and tumor growth.	Texas A&M Univ, Hlth Sci Ctr, Dept Pathol & Lab Med, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Davis, GE (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Dept Pathol & Lab Med, 255 Reynolds Med Bldg, College Stn, TX 77843 USA.	gedavis@tamu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL069603, R01HL059373] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 59373, F32 HL69603] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abal M, 2003, CURR CANCER DRUG TAR, V3, P193, DOI 10.2174/1568009033481967; Aznar S, 2001, CANCER LETT, V165, P1, DOI 10.1016/S0304-3835(01)00412-8; Bayless KJ, 2000, AM J PATHOL, V156, P1673, DOI 10.1016/S0002-9440(10)65038-9; Bayless KJ, 2002, J CELL SCI, V115, P1123; Bell SE, 2001, J CELL SCI, V114, P2755; Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960-9822(02)70714-8; BORNSTEIN MB, 1958, LAB INVEST, V7, P134; Browder T, 2000, CANCER RES, V60, P1878; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Davis GE, 2000, IN VITRO CELL DEV-AN, V36, P513; Davis GE, 1996, EXP CELL RES, V224, P39, DOI 10.1006/excr.1996.0109; Davis GE, 2002, ANAT RECORD, V268, P252, DOI 10.1002/ar.10159; DAVIS GE, 1995, EXP CELL RES, V216, P113, DOI 10.1006/excr.1995.1015; Eikesdal HP, 2001, INT J RADIAT ONCOL, V51, P535, DOI 10.1016/S0360-3016(01)01693-5; Enomoto T, 1996, CELL STRUCT FUNCT, V21, P317, DOI 10.1247/csf.21.317; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; Flusberg DA, 2001, MOL BIOL CELL, V12, P3087, DOI 10.1091/mbc.12.10.3087; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hippenstiel S, 2002, AM J PHYSIOL-LUNG C, V283, pL830, DOI 10.1152/ajplung.00467.2001; Hotchkiss KA, 2002, MOL CANCER THER, V1, P1191; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Jordan MA, 1998, METHOD ENZYMOL, V298, P252, DOI 10.1016/S0076-6879(98)98024-7; Kamada S, 1998, P NATL ACAD SCI USA, V95, P8532, DOI 10.1073/pnas.95.15.8532; Kerbel RS, 2000, EUR J CANCER, V36, P1248, DOI 10.1016/S0959-8049(00)00092-7; Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li XW, 2002, J BIOL CHEM, V277, P15309, DOI 10.1074/jbc.M201253200; Liu BP, 1998, CELL ADHES COMMUN, V5, P249, DOI 10.3109/15419069809040295; Maddox AS, 2003, J CELL BIOL, V160, P255, DOI 10.1083/jcb.200207130; MAXWELL SA, 1991, CELL GROWTH DIFFER, V2, P115; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; OCONNOLLY JO, 2002, MOL BIOL CELL, V13, P2474; Pathan N, 2001, NEOPLASIA, V3, P550, DOI 10.1038/sj.neo.7900213; Platts SH, 2002, J VASC RES, V39, P173, DOI 10.1159/000057765; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ribatti D, 1999, HISTOCHEM CELL BIOL, V112, P447, DOI 10.1007/s004180050427; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Salazar R, 1999, EXP CELL RES, V249, P22, DOI 10.1006/excr.1999.4460; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Senger DR, 1996, AM J PATHOL, V149, P1; Vacca A, 1999, BLOOD, V94, P4143, DOI 10.1182/blood.V94.12.4143.424k26_4143_4155; Zhang QH, 1997, MOL BIOL CELL, V8, P1415, DOI 10.1091/mbc.8.8.1415	46	95	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11686	11695		10.1074/jbc.M308373200	http://dx.doi.org/10.1074/jbc.M308373200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699132	hybrid			2022-12-25	WOS:000220157600104
J	Tsitsigiannis, DI; Zarnowski, R; Keller, NP				Tsitsigiannis, DI; Zarnowski, R; Keller, NP			The lipid body protein, PpoA, coordinates sexual and asexual sporulation in Aspergillus nidulans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNGUS GAEUMANNOMYCES-GRAMINIS; LINOLEATE DIOL SYNTHASE; FATTY-ACID-COMPOSITION; ESSENTIAL REGULATOR; COP9 SIGNALOSOME; GENE; BODIES; IDENTIFICATION; EXPRESSION; DIOXYGENASE	The coexistence of sexual and asexual reproductive cycles within the same individual is a striking phenomenon in numerous fungi. In the fungus Aspergillus nidulans (teleomorph: Emericella nidulans) endogenous oxylipins, called psi factor, serve as hormone-like signals that modulate the timing and balance between sexual and asexual spore development. Here, we report the identification of A. nidulans ppoA, encoding a putative fatty acid dioxygenase, involved in the biosynthesis of the linoleic acid derived oxylipin psiBalpha. PpoA is required for balancing anamorph and teleomorph development. Deletion of ppoA significantly reduced the level of psiBalpha and increased the ratio of asexual to sexual spore numbers 4-fold. In contrast, forced expression of ppoA resulted in elevated levels of psiBalpha and decreased the ratio of asexual to sexual spore numbers 6-fold. ppoA expression is mediated by two developmental regulators, VeA and the COP9 signalosome, such that ppoA transcript levels are correlated with the initiation of asexual and sexual fruiting body formation. PpoA localizes in lipid bodies in these tissues. These data support an important role for oxylipins in integrating mitotic and meiotic spore development.	Univ Wisconsin, Dept Plant Pathol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Keller, NP (corresponding author), Univ Wisconsin, Dept Plant Pathol, Madison, WI 53706 USA.	npk@plantpath.wisc.edu	Tsitsigiannis, Dimitrios/F-1009-2017; Zarnowski, Robert/A-2786-2009; Keller, Nancy P./ABC-5911-2021	Tsitsigiannis, Dimitrios/0000-0003-2006-6106; Zarnowski, Robert/0000-0001-6343-1500; 				Abell BM, 1997, PLANT CELL, V9, P1481, DOI 10.1105/tpc.9.8.1481; Adams TH, 1998, MICROBIOL MOL BIOL R, V62, P35, DOI 10.1128/MMBR.62.1.35-54.1998; Athenstaedt K, 1999, J BACTERIOL, V181, P6441, DOI 10.1128/JB.181.20.6441-6448.1999; BENNETT JW, 1992, ASPERGILLUS BIOL IND, V23, P35; BOWERS WS, 1986, SCIENCE, V232, P105, DOI 10.1126/science.232.4746.105; Braus GH, 2002, MYCOLOGY S, V15, P215; Brown DA, 2001, CURR BIOL, V11, pR446, DOI 10.1016/S0960-9822(01)00257-3; BROWSE J, 1986, ANAL BIOCHEM, V152, P141, DOI 10.1016/0003-2697(86)90132-6; Busch S, 2003, MOL MICROBIOL, V49, P717, DOI 10.1046/j.1365-2958.2003.03612.x; BUTNICK NZ, 1984, J BACTERIOL, V160, P533, DOI 10.1128/JB.160.2.533-540.1984; Calvo AM, 2002, MICROBIOL MOL BIOL R, V66, P447, DOI 10.1128/MMBR.66.3.447-459.2002; Calvo AM, 2001, J BIOL CHEM, V276, P25766, DOI 10.1074/jbc.M100732200; Calvo AM, 1999, APPL ENVIRON MICROB, V65, P3668; Carvalho MDF, 2002, GENET MOL BIOL, V25, P485, DOI 10.1590/S1415-47572002000400019; Champe S, 1981, FUNGAL SPORE MORPHOG, P255; CHAMPE SP, 1989, J BACTERIOL, V171, P3982, DOI 10.1128/jb.171.7.3982-3988.1989; CHAMPE SP, 1987, J GEN MICROBIOL, V133, P1383; Chen JCF, 2001, PLANT CELL PHYSIOL, V42, P1245, DOI 10.1093/pcp/pce160; Deng XW, 2000, TRENDS GENET, V16, P202, DOI 10.1016/S0168-9525(00)01982-X; EVANS JL, 1986, CAN J MICROBIOL, V32, P179, DOI 10.1139/m86-035; Fox SR, 2000, LIPIDS, V35, P23, DOI 10.1007/s11745-000-0490-5; Ghanevati M, 2002, EUR J BIOCHEM, V269, P3531, DOI 10.1046/j.1432-1033.2002.03039.x; GREENSPAN P, 1985, J CELL BIOL, V100, P965, DOI 10.1083/jcb.100.3.965; HAMBERG M, 1994, ARCH BIOCHEM BIOPHYS, V309, P77, DOI 10.1006/abbi.1994.1087; Han KH, 2001, MOL MICROBIOL, V41, P299, DOI 10.1046/j.1365-2958.2001.02472.x; Hause B, 2000, PLANTA, V210, P708, DOI 10.1007/s004250050671; Herman R.P., 1999, EICOSANOIDS RELATED, DOI [10.1515/9781400873111-008, DOI 10.1515/9781400873111-008]; Hornsten L, 1999, J BIOL CHEM, V274, P28219, DOI 10.1074/jbc.274.40.28219; Huber SMFE, 2002, MOL GENET GENOMICS, V267, P757, DOI 10.1007/s00438-002-0717-y; Kamisaka Y, 1999, BBA-MOL CELL BIOL L, V1438, P185, DOI 10.1016/S1388-1981(99)00050-5; Kim HS, 2002, FUNGAL GENET BIOL, V37, P72, DOI 10.1016/S1087-1845(02)00029-4; Lee SB, 1990, PCR PROTOCOLS GUIDE, P282, DOI DOI 10.1016/B978-0-12-372180-8.50038-X; MAZUR P, 1990, TETRAHEDRON LETT, V31, P3837, DOI 10.1016/S0040-4039(00)97482-3; MAZUR P, 1991, J CHEM SOC CHEM COMM, P1486, DOI 10.1039/c39910001486; MILLER BL, 1985, MOL CELL BIOL, V5, P1714, DOI 10.1128/MCB.5.7.1714; Murphy DJ, 2001, PROG LIPID RES, V40, P325, DOI 10.1016/S0163-7827(01)00013-3; PONTECORVO G, 1953, ADV GENET, V5, P141, DOI 10.1016/S0065-2660(08)60408-3; PUNT PJ, 1991, J BIOTECHNOL, V17, P19, DOI 10.1016/0168-1656(91)90024-P; SAMBROOK J, 2001, MOL CLON LAB MANUAL; Sienko M, 1999, CURR GENET, V35, P638, DOI 10.1007/s002940050463; Su C, 1998, J BIOL CHEM, V273, P20744, DOI 10.1074/jbc.273.33.20744; Su C, 1996, J BIOL CHEM, V271, P14112, DOI 10.1074/jbc.271.24.14112; Ting JTL, 1997, J BIOL CHEM, V272, P3699, DOI 10.1074/jbc.272.6.3699; Weller PF, 1999, INT ARCH ALLERGY IMM, V118, P450, DOI 10.1159/000024161; YAGER LN, 1992, ASPERGILLUS BIOL IND, P19; Yu JH, 1996, CURR GENET, V29, P549, DOI 10.1007/s002940050084; Zarnowski R, 2000, PHYTOCHEMISTRY, V55, P975, DOI 10.1016/S0031-9422(00)00219-3; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	48	144	157	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11344	11353		10.1074/jbc.M310840200	http://dx.doi.org/10.1074/jbc.M310840200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699095	hybrid			2022-12-25	WOS:000220157600063
J	Abbas, T; White, D; Hui, L; Yoshida, K; Foster, DA; Bargonetti, J				Abbas, T; White, D; Hui, L; Yoshida, K; Foster, DA; Bargonetti, J			Inhibition of human p53 basal transcription by down-regulation of protein kinase C delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; TUMOR PROMOTION; PHORBOL ESTER; CELLS; EXPRESSION; ACTIVATION; GENE; APOPTOSIS; 12-O-TETRADECANOYLPHORBOL-13-ACETATE; PHOSPHORYLATION	In response to DNA damage, signal transduction pathways are activated that result in the increase of p53 protein levels, leading to either growth arrest or apoptosis. Protein kinase C (PKC) delta has been implicated as a tumor suppressor that is down-regulated by tumor-promoting phorbol esters in both mouse skin and cell culture models. We report here that the tumor-promoting phorbol ester 12-O-tetradecanoylphorbol-13-acetate prevents DNA damage-induced up-regulation of p53 by down-regulating PKC delta. Regulation of p53 in response to stress most commonly occurs by preventing ubiquitination and degradation of the p53 protein. Surprisingly, suppression of p53 expression by inhibition of PKC delta was caused by the inhibition of p53 synthesis, not increased degradation of p53 protein. Inhibiting PKC delta blocked both basal transcription of the human p53 gene and initiation of transcription from the human p53 promoter. Therefore, the tumor-suppressing effects of PKC delta are mediated at least in part through activating p53 transcription.	CUNY Hunter Coll, Inst Biomolec Struct & Funct, New York, NY 10021 USA; CUNY Hunter Coll, Dept Biol Sci, Grad Sch, New York, NY 10021 USA; Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Genet, Tokyo 1138510, Japan	City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System; Hunter College (CUNY); Tokyo Medical & Dental University (TMDU)	Bargonetti, J (corresponding author), CUNY Hunter Coll, Inst Biomolec Struct & Funct, 695 Pk Ave, New York, NY 10021 USA.	bargonetti@genectr.hunter.cuny.edu		Bargonetti, Jill/0000-0003-2692-0991	NATIONAL CANCER INSTITUTE [R29CA046677, R01CA046677] Funding Source: NIH RePORTER; NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RR-03037] Funding Source: Medline; NIGMS NIH HHS [GM60754] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbas T, 2002, J BIOL CHEM, V277, P40513, DOI 10.1074/jbc.M205495200; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Basu A, 2001, CELL DEATH DIFFER, V8, P899, DOI 10.1038/sj.cdd.4400885; Chernov MV, 2001, J BIOL CHEM, V276, P31819, DOI 10.1074/jbc.M103170200; Clamp A, 2002, ANTI-CANCER DRUG, V13, P673, DOI 10.1097/00001813-200208000-00001; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Durland-Busbice S, 2002, LEUKEMIA, V16, P2165, DOI 10.1038/sj.leu.2402647; FOURNIER A, 1987, NATURE, V330, P767, DOI 10.1038/330767a0; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; Ghosh JC, 1999, J RADIAT RES, V40, P23, DOI 10.1269/jrr.40.23; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; HANSEN LA, 1990, CANCER RES, V50, P5740; Heit I, 2001, ONCOGENE, V20, P5143, DOI 10.1038/sj.onc.1204657; Hornia A, 1999, MOL CELL BIOL, V19, P7672; KASTAN MB, 1991, CANCER RES, V51, P4279; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; LAW JC, 1993, LEUKEMIA RES, V17, P1045, DOI 10.1016/0145-2126(93)90161-D; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; MAGNELLI L, 1995, BIOCHEM BIOPH RES CO, V215, P641, DOI 10.1006/bbrc.1995.2512; Magnelli L, 1998, BIOCHEM BIOPH RES CO, V249, P222, DOI 10.1006/bbrc.1998.9039; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Niwa K, 2002, FREE RADICAL RES, V36, P1147, DOI 10.1080/1071576021000016409; Oren M, 2002, BIOCHEM PHARMACOL, V64, P865, DOI 10.1016/S0006-2952(02)01149-8; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; RAMET M, 1995, CARCINOGENESIS, V16, P2117, DOI 10.1093/carcin/16.9.2117; Reddig PJ, 1999, CANCER RES, V59, P5710; Reisman D, 1998, SEMIN CANCER BIOL, V8, P317, DOI 10.1006/scbi.1998.0094; Ren J, 2002, J BIOL CHEM, V277, P33758, DOI 10.1074/jbc.M110667200; ROCKWELL S, 1995, ONCOL RES, V7, P39; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SKOUV J, 1994, CELL GROWTH DIFFER, V5, P329; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; Su F, 2002, GENE DEV, V16, P46, DOI 10.1101/gad.942902; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yoshida K, 2002, J BIOL CHEM, V277, P48372, DOI 10.1074/jbc.M205485200; Zhong MH, 2002, ONCOGENE, V21, P1071, DOI 10.1038/sj/onc/1205165	45	52	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9970	9977		10.1074/jbc.M306979200	http://dx.doi.org/10.1074/jbc.M306979200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699137	hybrid			2022-12-25	WOS:000220050400040
J	Bao, XY; Chen, YY; Reuss, L; Altenberg, GA				Bao, XY; Chen, YY; Reuss, L; Altenberg, GA			Functional expression in Xenopus Oocytes of gap-junctional hemichannels formed by a cysteine-less connexin 43	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; INTRACELLULAR CALCIUM; CHANNELS; MEMBRANE; CELLS; PHOSPHORYLATION; IDENTIFICATION; ASTROCYTES; PORE	Gap-junctional channels are formed by two connexons or gap-junctional hemichannels in series, with each connexon conformed by six connexin molecules. As with other membrane proteins, structural information on connexons can potentially be obtained with techniques that take advantage of the highly specific thiol chemistry by positioning Cys residues at locations of interest, ideally in an otherwise Cys-less protein. It has been shown that conserved Cys residues located in the extracellular loops of connexins are essential for the docking of connexons from adjacent cells, preventing the formation of functional gap-junctional channels. Here we engineered a Cys-less version of connexin 43 (Cx43) and assessed its function using a Xenopus oocyte expression system. The Cys-less protein was expressed at the plasma membrane and did not form gap-junctional channels but formed hemichannels that behave similarly to those formed by Cx43 in terms of permeation to carboxyfluorescein. The carboxyfluorescein permeability of Cys-less hemichannels was increased by protein kinase C inhibition, like the wild-type Cx43 hemichannels. We generated a protein with a single Cys in a position ( residue 34) thought to face the channel pore and show that thiol modification of the Cys abolishes the carboxyfluorescein permeability. We conclude that Cys-less Cx43 forms regulated functional hemichannels, and therefore Cys-less Cx43 is a useful tool for future structural studies.	Univ Texas, Med Branch, Sealy Ctr Struct Biol, Membrane Prot Lab, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Physiol & Biophys, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Altenberg, GA (corresponding author), Univ Texas, Med Branch, Sealy Ctr Struct Biol, Membrane Prot Lab, Galveston, TX 77555 USA.	galtenbe@utmb.edu		Altenberg, Guillermo/0000-0002-8932-740X				BAO X, 2004, IN PRESS AM J PHYSL; Becker DL, 1998, CELL BIOL INT, V22, P527, DOI 10.1006/cbir.1998.0295; BERTHOUD VM, 1992, EUR J CELL BIOL, V57, P40; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; Bruzzone S, 2001, J BIOL CHEM, V276, P48300, DOI 10.1074/jbc.M107308200; Bukauskas FF, 2001, BIOPHYS J, V81, P137, DOI 10.1016/S0006-3495(01)75687-1; Button B, 2001, J GEN PHYSIOL, V117, P457, DOI 10.1085/jgp.117.5.457; DAHL G, 1992, BIOPHYS J, V62, P172, DOI 10.1016/S0006-3495(92)81803-9; DAHL G, 1991, EUR J BIOCHEM, V197, P141, DOI 10.1111/j.1432-1033.1991.tb15892.x; DEVRIES SH, 1992, J PHYSIOL-LONDON, V445, P201, DOI 10.1113/jphysiol.1992.sp018920; DUPONT E, 1989, J MEMBRANE BIOL, V108, P247, DOI 10.1007/BF01871739; Ebihara L, 1996, BIOPHYS J, V71, P742, DOI 10.1016/S0006-3495(96)79273-1; Foote CI, 1998, J CELL BIOL, V140, P1187, DOI 10.1083/jcb.140.5.1187; Franco L, 2001, J BIOL CHEM, V276, P21642, DOI 10.1074/jbc.M010536200; GOODENOUGH DA, 1975, AM J CLIN PATHOL, V63, P636; Harris AL, 2001, Q REV BIOPHYS, V34, P325, DOI 10.1017/S0033583501003705; John SA, 1999, J BIOL CHEM, V274, P236, DOI 10.1074/jbc.274.1.236; JOHN SA, 1991, BIOCHEM BIOPH RES CO, V178, P1312, DOI 10.1016/0006-291X(91)91037-D; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; Li HY, 1996, J CELL BIOL, V134, P1019, DOI 10.1083/jcb.134.4.1019; LITTLE TL, 1995, AM J PHYSIOL-HEART C, V268, pH729, DOI 10.1152/ajpheart.1995.268.2.H729; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; Moreno AP, 2002, CIRC RES, V90, P450, DOI 10.1161/hh0402.105667; PEPPER MS, 1992, AM J PHYSIOL, V262, pC1246, DOI 10.1152/ajpcell.1992.262.5.C1246; Plotkin LI, 2002, J BIOL CHEM, V277, P8648, DOI 10.1074/jbc.M108625200; RAHMAN S, 1991, J CELL SCI, V100, P567; Revilla A, 1999, BIOPHYS J, V77, P1374, DOI 10.1016/S0006-3495(99)76986-9; SAINIO K, 1992, DEVELOPMENT, V115, P827; Skerrett IM, 2001, CELL COMMUN ADHES, V8, P179, DOI 10.3109/15419060109080720; Skerrett IM, 2002, J CELL BIOL, V159, P349, DOI 10.1083/jcb.200207060; SPRAY DC, 1981, J GEN PHYSIOL, V77, P77, DOI 10.1085/jgp.77.1.77; Stout CE, 2002, J BIOL CHEM, V277, P10482, DOI 10.1074/jbc.M109902200; Toyofuku T, 1998, J BIOL CHEM, V273, P1519, DOI 10.1074/jbc.273.3.1519; Unger VM, 1999, SCIENCE, V283, P1176, DOI 10.1126/science.283.5405.1176; Unger VM, 1997, NAT STRUCT BIOL, V4, P39, DOI 10.1038/nsb0197-39; UNWIN PNT, 1980, NATURE, V283, P545, DOI 10.1038/283545a0; Vanoye CG, 1999, AM J PHYSIOL-CELL PH, V276, pC279, DOI 10.1152/ajpcell.1999.276.1.C279; Venance L, 1998, J PHYSIOL-LONDON, V510, P429, DOI 10.1111/j.1469-7793.1998.429bk.x; Vergara L, 2003, J MEMBRANE BIOL, V196, P173, DOI 10.1007/s00232-003-0636-9; Zhou XW, 1997, BIOPHYS J, V72, P1946, DOI 10.1016/S0006-3495(97)78840-4	40	43	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9689	9692		10.1074/jbc.M311438200	http://dx.doi.org/10.1074/jbc.M311438200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14676187	hybrid			2022-12-25	WOS:000220050400005
J	Jindou, S; Soda, A; Karita, S; Kajino, T; Beguin, P; Wu, JHD; Inagaki, M; Kimura, T; Sakka, K; Ohmiya, K				Jindou, S; Soda, A; Karita, S; Kajino, T; Beguin, P; Wu, JHD; Inagaki, M; Kimura, T; Sakka, K; Ohmiya, K			Cohesin-dockerin Interactions within and between Clostridium josui and Clostridium thermocellum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATING PROTEIN CIPA; SCAFFOLDING PROTEIN; NUCLEOTIDE-SEQUENCES; CELLULOSOME; CELLULOLYTICUM; ENDOGLUCANASE; COMPONENT; DOMAINS; PURIFICATION; EXPRESSION	The cellulosome components are assembled into the cellulosome complex by the interaction between one of the repeated cohesin domains of a scaffolding protein and the dockerin domain of an enzyme component. We prepared five recombinant cohesin polypeptides of the Clostridium thermocellum scaffolding protein CipA, two dockerin polypeptides of C. thermocellum Xyn11A and Xyn10C, four cohesin polypeptides of Clostridium josui CipA, and two dockerin polypeptides of C. josui Aga27A and Cel8A, and qualitatively and quantitatively examined the cohesin-dockerin interactions within C. thermocellum and C. josui, respectively, and the species specificity of the cohesin-dockerin interactions between these two bacteria. Surface plasmon resonance (SPR) analysis indicated that there was a certain selectivity, with a maximal 34-fold difference in the K-D values, in the cohesin-dockerin interactions within a combination of C. josui, although this was not detected by qualitative analysis. Affinity blotting analysis suggested that there was at least one exception to the species specificity in the cohesin-dockerin interactions, although species specificity was generally conserved among the cohesin and dockerin polypeptides from C. thermocellum and C. josui, i.e. the dockerin polypeptides of C. thermocellum Xyn11A exceptionally bound to the cohesin polypeptides from C. josui CipA. SPR analysis confirmed this exceptional binding. We discuss the relationship between the species specificity of the cohesin-dockerin binding and the conserved amino acid residues in the dockerin domains.	Mie Univ, Fac Bioresources, Tsu, Mie 5148507, Japan; Toyota Cent Res & Dev Labs Inc, Special Res Lab 2, Aichi 4801192, Japan; Inst Pasteur, Dept Biotechnol, F-75724 Paris 15, France; Univ Rochester, Dept Chem Engn, Rochester, NY 14627 USA	Mie University; Toyota Central R&D Labs Inc; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Rochester	Sakka, K (corresponding author), Mie Univ, Fac Bioresources, 1515 Kamihamacho, Tsu, Mie 5148507, Japan.	sakka@bio.mie-u.ac.jp		Beguin, Pierre/0000-0002-5372-6281				Ahsan MM, 1996, J BACTERIOL, V178, P5732, DOI 10.1128/jb.178.19.5732-5740.1996; Beguin P, 1996, PROTEIN SCI, V5, P1192; Ciruela A, 1998, FEBS LETT, V422, P221, DOI 10.1016/S0014-5793(97)01590-1; DOI RH, 1994, CRIT REV MICROBIOL, V20, P87, DOI 10.3109/10408419409113548; Fierobe HP, 1999, BIOCHEMISTRY-US, V38, P12822, DOI 10.1021/bi9911740; FUJINO T, 1993, J FERMENT BIOENG, V76, P243, DOI 10.1016/0922-338X(93)90188-E; GarciaCampayo V, 1997, J BIOTECHNOL, V57, P39, DOI 10.1016/S0168-1656(97)00086-2; GERNGROSS UT, 1993, MOL MICROBIOL, V8, P325, DOI 10.1111/j.1365-2958.1993.tb01576.x; Hayashi H, 1997, J BACTERIOL, V179, P4246, DOI 10.1128/jb.179.13.4246-4253.1997; Hayashi H, 1999, APPL MICROBIOL BIOT, V51, P348, DOI 10.1007/s002530051401; Jindou S, 2002, J BACTERIOL, V184, P600, DOI 10.1128/JB.184.2.600-604.2002; Kakiuchi M, 1998, J BACTERIOL, V180, P4303, DOI 10.1128/JB.180.16.4303-4308.1998; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamed R, 1983, BIOTECHNOL BIOENG S, V13, P163; Lytle B, 1996, J BACTERIOL, V178, P1200, DOI 10.1128/jb.178.4.1200-1203.1996; Mechaly A, 2000, PROTEINS, V39, P170, DOI 10.1002/(SICI)1097-0134(20000501)39:2<170::AID-PROT7>3.0.CO;2-H; MORAG E, 1992, Enzyme and Microbial Technology, V14, P289, DOI 10.1016/0141-0229(92)90153-F; Ohara H, 2000, BIOSCI BIOTECH BIOCH, V64, P254, DOI 10.1271/bbb.64.254; Pages S, 1999, J BACTERIOL, V181, P1801; Pages S, 1997, PROTEINS, V29, P517, DOI 10.1002/(SICI)1097-0134(199712)29:4<517::AID-PROT11>3.3.CO;2-I; Pages S, 1996, J BACTERIOL, V178, P2279, DOI 10.1128/jb.178.8.2279-2286.1996; SAKKA K, 1994, GENETICS BIOCH ECOLO, P32; SHOSEYOV O, 1992, P NATL ACAD SCI USA, V89, P3483, DOI 10.1073/pnas.89.8.3483; Steenbakkers PJM, 2001, J BACTERIOL, V183, P5325, DOI 10.1128/JB.183.18.5325-5333.2001; SUKHUMAVASI J, 1988, INT J SYST BACTERIOL, V38, P179, DOI 10.1099/00207713-38-2-179; YARON S, 1995, FEBS LETT, V360, P121, DOI 10.1016/0014-5793(95)00074-J	26	48	52	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9867	9874		10.1074/jbc.M308673200	http://dx.doi.org/10.1074/jbc.M308673200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688277	hybrid			2022-12-25	WOS:000220050400026
J	Morgan, GW; Goulding, D; Field, MC				Morgan, GW; Goulding, D; Field, MC			The single dynamin-like protein of Trypanosoma brucei regulates mitochondrial division and is not required for endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; DEVELOPMENTAL REGULATION; PATHOGENIC TRYPANOSOMES; ENDOPLASMIC-RETICULUM; CHLOROPLAST DIVISION; MOLECULAR-CLONING; CELL-CYCLE; GTPASE; MORPHOLOGY; MEMBRANE	Members of the evolutionarily conserved dynamin-related GTPase family mediate numerous cellular membrane remodeling events. Dynamin family functions include the scission of clathrin-coated pits from the plasma membrane, mitochondrial fission, and chloroplast division. Here we report that the divergent eukaryote Trypanosoma brucei possesses a single dynamin family gene, which we have designated TbDLP. Furthermore, a single dynamin family gene is also found in the Leishmania major and Trypanosoma vivax genomes, indicating that this is a conserved feature among the kinetoplastida. TbDLP is most homologous to the DMN/DRP family of dynamin-like proteins. Indirect immunofluorescence microscopy reveals that TbDLP is distributed in punctate structures within the cell that partially co-localize with the mitochondrion when labeled with MitoTracker. To define TbDLP function, we have used RNA interference to silence the TbDLP gene. Reduction of TbDLP protein levels causes a profound alteration in mitochondrial morphology without affecting the structure of other membrane-bound compartments, including the endocytic and exocytic apparatus. The mitochondrial profiles present in wild type trypanosomes fuse and collapse in the mutant cells, and by electron microscopy the mitochondria are found to contain an accumulation of constriction sites. These findings demonstrate TbDLP functions in division of the mitochondrial membrane. Most significantly, as TbDLP is the sole member of the dynamin family in this organism, scission of clathrin-coated pits involved in protein trafficking through the highly active endocytic system in trypanosomes must function in the absence of dynamin. The evolutionary implications of these findings are discussed.	Univ London Imperial Coll Sci Technol & Med, Wellcome Trust Labs Mol Parasitol, London SW7 2AY, England	Imperial College London	Field, MC (corresponding author), Univ London Imperial Coll Sci Technol & Med, Wellcome Trust Labs Mol Parasitol, Exhibit Rd, London SW7 2AY, England.	mfield@ic.ac.uk	Field, Mark/AAD-6455-2021	Field, Mark/0000-0002-4866-2885				Allen CL, 2003, EMBO J, V22, P4991, DOI 10.1093/emboj/cdg481; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BANGS JD, 1993, J CELL SCI, V105, P1101; Beech PL, 2000, SCIENCE, V287, P1276, DOI 10.1126/science.287.5456.1276; Berridge MJ, 2002, CELL CALCIUM, V32, P235, DOI 10.1016/S0143416002001823; Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014; BRICKMAN MJ, 1995, J CELL SCI, V108, P3611; CHEN JH, 1995, CELL, V80, P61, DOI 10.1016/0092-8674(95)90451-4; Danino D, 2001, CURR OPIN CELL BIOL, V13, P454, DOI 10.1016/S0955-0674(00)00236-2; Erickson HP, 2000, J CELL BIOL, V148, P1103, DOI 10.1083/jcb.148.6.1103; Field H, 1997, J BIOL CHEM, V272, P10498, DOI 10.1074/jbc.272.16.10498; Field H, 2000, MOL BIOCHEM PARASIT, V106, P21, DOI 10.1016/S0166-6851(99)00192-9; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; Grunfelder CG, 2003, MOL BIOL CELL, V14, P2029, DOI 10.1091/mbc.E02-10-0640; Harlow E., 1988, ANTIBODIES LAB MANUA; HECKER H, 1980, PATHOL RES PRACT, V166, P203; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Hoepfner D, 2001, J CELL BIOL, V155, P979, DOI 10.1083/jcb.200107028; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; LaCount DJ, 2000, MOL BIOCHEM PARASIT, V111, P67, DOI 10.1016/S0166-6851(00)00300-5; Lang BF, 1999, ANNU REV GENET, V33, P351, DOI 10.1146/annurev.genet.33.1.351; Legesse-Miller A, 2003, MOL BIOL CELL, V14, P1953, DOI 10.1091/mbc.E02-10-0657; Matthews KR, 1999, PARASITOL TODAY, V15, P76, DOI 10.1016/S0169-4758(98)01381-7; MICHELS PAM, 1986, EMBO J, V5, P1049, DOI 10.1002/j.1460-2075.1986.tb04321.x; Miyagishima S, 2003, PLANT CELL, V15, P655, DOI 10.1105/tpc.009373; Morgan GW, 2002, TRENDS PARASITOL, V18, P540, DOI 10.1016/S1471-4922(02)02392-9; Morgan GW, 2001, J CELL SCI, V114, P2605; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Nishida K, 2003, P NATL ACAD SCI USA, V100, P2146, DOI 10.1073/pnas.0436886100; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; Ogbadoyi EO, 2003, MOL BIOL CELL, V14, P1769, DOI 10.1091/mbc.E02-08-0525; Osteryoung KW, 1998, PLANT CELL, V10, P1991, DOI 10.1105/tpc.10.12.1991; Otsuga D, 1998, J CELL BIOL, V143, P333, DOI 10.1083/jcb.143.2.333; Pitts KR, 1999, MOL BIOL CELL, V10, P4403, DOI 10.1091/mbc.10.12.4403; PRIEST JW, 1994, J BIOENERG BIOMEMBR, V26, P179, DOI 10.1007/BF00763067; Redmond S, 2003, MOL BIOCHEM PARASIT, V128, P115, DOI 10.1016/S0166-6851(03)00045-8; ROBINSON DR, 1991, NATURE, V352, P731, DOI 10.1038/352731a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Sogin ML, 1998, INT J PARASITOL, V28, P11, DOI 10.1016/S0020-7519(97)00181-1; Song BD, 2003, BIOCHEMISTRY-US, V42, P1369, DOI 10.1021/bi027062h; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Swofford D., 1998, PAUP VERSION 4 0; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; van der Bliek AM, 1999, TRENDS CELL BIOL, V9, P96, DOI 10.1016/S0962-8924(98)01490-1; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VATER CA, 1992, J CELL BIOL, V119, P773, DOI 10.1083/jcb.119.4.773; VICKERMAN K, 1965, NATURE, V208, P762, DOI 10.1038/208762a0; VICKERMAN K, 1985, BRIT MED BULL, V41, P105, DOI 10.1093/oxfordjournals.bmb.a072036; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310; Wienke DC, 1999, MOL BIOL CELL, V10, P225, DOI 10.1091/mbc.10.1.225; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; Wong ED, 2000, J CELL BIOL, V151, P341, DOI 10.1083/jcb.151.2.341	55	66	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10692	10701		10.1074/jbc.M312178200	http://dx.doi.org/10.1074/jbc.M312178200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14670954	hybrid			2022-12-25	WOS:000220050400124
J	Bisognano, C; Kelley, WL; Estoppey, T; Francois, P; Schrenzel, J; Li, DM; Lew, DP; Hooper, DC; Cheung, AL; Vaudaux, P				Bisognano, C; Kelley, WL; Estoppey, T; Francois, P; Schrenzel, J; Li, DM; Lew, DP; Hooper, DC; Cheung, AL; Vaudaux, P			A RecA-LexA-dependent pathway mediates ciprofloxacin-induced fibronectin binding in Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBINHIBITORY CONCENTRATIONS; ESCHERICHIA-COLI; DNA-DAMAGE; INCREASED EXPRESSION; BACILLUS-SUBTILIS; EPITHELIAL-CELLS; VIRULENCE GENES; SOS RESPONSE; MURINE MODEL; PROTEINS	Subinhibitory concentrations of ciprofloxacin (CPX) raise the fibronectin-mediated attachment of fluoroquinolone-resistant Staphylococcus aureus by selectively inducing fnbB coding for one of two fibronectin-binding proteins: FnBPB. To identify candidate regulatory pathway(s) linking drug exposure to up-regulation of fnbB, we disrupted the global response regulators agr, sarA, and recA in the highly quinolone-resistant strain RA1. Whereas agr and sarA mutants of RA1 exposed to CPX still displayed increased adhesion to fibronectin, the CPX-triggered response was abolished in the uvs-568 recA mutant, but was restored following complementation with wild type recA. Steady-state levels of recA and fnbB, but not fnbA, mRNA were co-coordinately increased >3-fold in CPX-exposed strain RA1. Electrophoretic mobility shift assays revealed specific binding of purified S. aureus SOS-repressor LexA to recA and fnbB, but not to fnbA or rpoB promoters. DNase I footprint analysis showed LexA binding overlapping the core promoter elements in fnbB. We conclude that activation of recA and derepression of lexA-regulated genes by CPX may represent a response to drug-induced damage that results in a novel induction of a virulence factor leading to increased bacterial tissue adherence.	Univ Hosp, Div Infect Dis, CH-1211 Geneva 14, Switzerland; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02114 USA; Dartmouth Coll, Sch Med, Dept Microbiol, Hanover, NH 03755 USA	University of Geneva; Harvard University; Harvard Medical School; Massachusetts General Hospital; Dartmouth College	Kelley, WL (corresponding author), Univ Hosp, Div Infect Dis, CH-1211 Geneva 14, Switzerland.	william.kelley@hcuge.ch	Schrenzel, Jacques/AAC-5685-2021; francois, patrice/AAL-5583-2020; Schrenzel, Jacques/P-8525-2017	Schrenzel, Jacques/0000-0001-5464-7764; Schrenzel, Jacques/0000-0001-5464-7764; francois, patrice/0000-0002-0540-750X	NIAID NIH HHS [AI47441, AI23988] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047441, R37AI023988, R01AI023988] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson DG, 1998, CELL, V95, P975, DOI 10.1016/S0092-8674(00)81721-3; BAYLES KW, 1994, GENE, V147, P13, DOI 10.1016/0378-1119(94)90033-7; Bischoff M, 2001, J BACTERIOL, V183, P5171, DOI 10.1128/JB.183.17.5171-5179.2001; Bisognano C, 1997, ANTIMICROB AGENTS CH, V41, P906, DOI 10.1128/AAC.41.5.906; Bisognano C, 2000, ANTIMICROB AGENTS CH, V44, P1428, DOI 10.1128/AAC.44.6.1428-1437.2000; BLEDOV I, 2003, SCIENCE, V300, P1404; BUTCHER WG, 1994, CHEMOTHERAPY, V40, P114, DOI 10.1159/000239182; CHEUNG AL, 1994, ANAL BIOCHEM, V222, P511, DOI 10.1006/abio.1994.1528; Courcelle J, 2001, GENETICS, V158, P41; Dziewanowska K, 2000, INFECT IMMUN, V68, P6321, DOI 10.1128/IAI.68.11.6321-6328.2000; Dziewanowska K, 1999, INFECT IMMUN, V67, P4673, DOI 10.1128/IAI.67.9.4673-4678.1999; Fernandez de Henestrosa AR, 2000, MOL MICROBIOL, V35, P1560, DOI 10.1046/j.1365-2958.2000.01826.x; Fournier B, 2000, ANTIMICROB AGENTS CH, V44, P2160, DOI 10.1128/AAC.44.8.2160-2165.2000; Gertz S, 2000, J BACTERIOL, V182, P6983, DOI 10.1128/JB.182.24.6983-6991.2000; GREENE C, 1995, MOL MICROBIOL, V17, P1143, DOI 10.1111/j.1365-2958.1995.mmi_17061143.x; Hooper DC, 2002, LANCET INFECT DIS, V2, P530, DOI 10.1016/S1473-3099(02)00369-9; HOWARD BMA, 1993, J PHARM PHARMACOL, V45, P658, DOI 10.1111/j.2042-7158.1993.tb05673.x; Karlsson A, 2001, INFECT IMMUN, V69, P4742, DOI 10.1128/IAI.69.8.4742-4748.2001; KERNODLE DS, 1995, J INFECT DIS, V172, P410, DOI 10.1093/infdis/172.2.410; KIM B, 1992, SCIENCE, V255, P203, DOI 10.1126/science.1553548; Kullik I, 1998, J BACTERIOL, V180, P4814, DOI 10.1128/JB.180.18.4814-4820.1998; Kuroda M, 2001, LANCET, V357, P1225, DOI 10.1016/S0140-6736(00)04403-2; LEE CY, 1991, GENE, V103, P101, DOI 10.1016/0378-1119(91)90399-V; LEE JC, 1995, METHOD MOL BIOL, V47, P209, DOI DOI 10.1385/0-89603-310-4:209; LI D, 2003, CLIN MICRO INF S1, V9, P89; LITTLE JW, 1994, METHOD ENZYMOL, V244, P273; LOVETT CM, 1988, J BACTERIOL, V170, P1467, DOI 10.1128/jb.170.4.1467-1474.1988; Manna AC, 1998, J BACTERIOL, V180, P3828, DOI 10.1128/JB.180.15.3828-3836.1998; Mei JM, 1997, MOL MICROBIOL, V26, P399, DOI 10.1046/j.1365-2958.1997.5911966.x; Menzies BE, 2003, CURR OPIN INFECT DIS, V16, P225, DOI 10.1097/00001432-200306000-00007; Novick RP, 2003, MOL MICROBIOL, V48, P1429, DOI 10.1046/j.1365-2958.2003.03526.x; Ohlsen K, 1998, ANTIMICROB AGENTS CH, V42, P2817, DOI 10.1128/AAC.42.11.2817; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; PHILLIPS I, 1987, J ANTIMICROB CHEMOTH, V20, P631, DOI 10.1093/jac/20.5.631; PITTET D, 1995, ARCH INTERN MED, V155, P1177, DOI 10.1001/archinte.155.11.1177; POWER EGM, 1992, J MED MICROBIOL, V36, P78, DOI 10.1099/00222615-36-2-78; PROCTOR RA, 1983, J ANTIMICROB CHEMOTH, V12, P85, DOI 10.1093/jac/12.suppl_C.85; PROCTOR RA, 1983, ANTIMICROB AGENTS CH, V24, P823, DOI 10.1128/AAC.24.5.823; Sinha B, 1999, CELL MICROBIOL, V1, P101, DOI 10.1046/j.1462-5822.1999.00011.x; Sinha B, 2000, INFECT IMMUN, V68, P6871, DOI 10.1128/IAI.68.12.6871-6878.2000; STAHL ML, 1983, J BACTERIOL, V154, P406, DOI 10.1128/JB.154.1.406-412.1983; Sutton MD, 2000, ANNU REV GENET, V34, P479, DOI 10.1146/annurev.genet.34.1.479; VANBOGELEN RA, 1987, J BACTERIOL, V169, P26, DOI 10.1128/jb.169.1.26-32.1987; Vaudaux P, 2002, INFECT IMMUN, V70, P5428, DOI 10.1128/IAI.70.10.5428-5437.2002; Vaudaux P., 2000, INFECT ASS INDWELLIN, P1; Vaudaux PE, 1998, ANTIMICROB AGENTS CH, V42, P564, DOI 10.1128/AAC.42.3.564; WALKER GC, 1987, ESCHERICHIA COLI SAL, V2, P1346; Winterling KW, 1998, J BACTERIOL, V180, P2201, DOI 10.1128/JB.180.8.2201-2211.1998; Wolz C, 2000, MOL MICROBIOL, V36, P230, DOI 10.1046/j.1365-2958.2000.01853.x; Yeiser B, 2002, P NATL ACAD SCI USA, V99, P8737, DOI 10.1073/pnas.092269199	50	64	66	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9064	9071		10.1074/jbc.M309836200	http://dx.doi.org/10.1074/jbc.M309836200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14699158	hybrid			2022-12-25	WOS:000189265900067
J	Hankamer, BD; Elderkin, SL; Buck, M; Nield, J				Hankamer, BD; Elderkin, SL; Buck, M; Nield, J			Organization of the AAA(+) adaptor protein PspA is an oligomeric ring	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PHAGE-SHOCK; CRYOELECTRON MICROSCOPY; YERSINIA-ENTEROCOLITICA; TRANSCRIPTION; GENE; RECONSTRUCTION; EXPRESSION; BIOGENESIS; SYSTEM	The 25.3 kDa "adaptor" protein, PspA (dphage shock protein A), is found in the cytoplasm and in association with the inner membrane of certain bacteria. PspA plays critical roles in negatively regulating the phage shock response and maintaining membrane integrity, especially during the export of proteins such as virulence factors. Homologues of PspA function exist for thylakoid biogenesis. Here we report the first three-dimensional reconstruction of a PspA assembly from Escherichia coli, visualized by electron microscopy and single particle analysis to a resolution of 30 Angstrom. The assembly forms a 9-fold rotationally symmetric ring with an outer diameter of 200 Angstrom, an inner diameter of 95 Angstrom, and a height of similar to85 Angstrom. The molecular mass of the complex was calculated to be 1023 kDa by size exclusion chromatography, suggesting that each of the nine domains is likely to be composed of four PspA subunits. The functional implications of this PspA structure are discussed in terms of its interaction with the protein export machinery of the bacterial cell and its AAA(+) protein partner, PspF.	Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia	Imperial College London; University of Queensland	Nield, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England.	j.nield@imperial.ac.uk	Nield, Jon/C-5892-2013; Hankamer, Ben D/C-9688-2015	Nield, Jon/0000-0001-9983-0239; Hankamer, Ben D/0000-0001-9284-4929				Adams H, 2003, J BACTERIOL, V185, P1174, DOI 10.1128/JB.185.4.1174-1180.2003; Beuron F, 2003, J MOL BIOL, V327, P619, DOI 10.1016/S0022-2836(03)00178-5; Bordes P, 2003, P NATL ACAD SCI USA, V100, P2278, DOI 10.1073/pnas.0537525100; Darwin AJ, 1999, MOL MICROBIOL, V32, P51, DOI 10.1046/j.1365-2958.1999.01324.x; Darwin AJ, 2001, MOL MICROBIOL, V39, P429, DOI 10.1046/j.1365-2958.2001.02235.x; Dougan DA, 2002, FEBS LETT, V529, P6, DOI 10.1016/S0014-5793(02)03179-4; Dworkin J, 2000, J BACTERIOL, V182, P311, DOI 10.1128/JB.182.2.311-319.2000; Elderkin S, 2002, J MOL BIOL, V320, P23, DOI 10.1016/S0022-2836(02)00404-7; Eriksson S, 2003, MOL MICROBIOL, V47, P103, DOI 10.1046/j.1365-2958.2003.03313.x; Hardie KR, 1996, EMBO J, V15, P978, DOI 10.1002/j.1460-2075.1996.tb00434.x; Jones SE, 2003, J BACTERIOL, V185, P6707, DOI 10.1128/JB.185.22.6707-6711.2003; JONES TA, 1993, O VERSION 5 9 MANUAL; Jovanovic G, 1999, J MOL BIOL, V285, P469, DOI 10.1006/jmbi.1998.2263; KLEEREBEZEM M, 1993, MOL MICROBIOL, V7, P947, DOI 10.1111/j.1365-2958.1993.tb01186.x; Kleerebezem M, 1996, EMBO J, V15, P162, DOI 10.1002/j.1460-2075.1996.tb00344.x; Koster M, 2000, INT J MED MICROBIOL, V290, P325; Kroll D, 2001, P NATL ACAD SCI USA, V98, P4238, DOI 10.1073/pnas.061500998; Model P, 1997, MOL MICROBIOL, V24, P255, DOI 10.1046/j.1365-2958.1997.3481712.x; Opalka N, 2003, J MOL BIOL, V325, P461, DOI 10.1016/S0022-2836(02)01246-9; Ruprecht J, 2001, PROG BIOPHYS MOL BIO, V75, P121, DOI 10.1016/S0079-6107(01)00004-9; van der Laan M, 2003, P NATL ACAD SCI USA, V100, P5801, DOI 10.1073/pnas.0636761100; van Heel M, 2000, Q REV BIOPHYS, V33, P307, DOI 10.1017/S0033583500003644; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P111, DOI 10.1016/0304-3991(87)90078-7; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; Westphal S, 2001, P NATL ACAD SCI USA, V98, P4243, DOI 10.1073/pnas.061501198; Zhang X, 2002, MOL MICROBIOL, V45, P895, DOI 10.1046/j.1365-2958.2002.03065.x; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X	27	66	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8862	8866		10.1074/jbc.M307889200	http://dx.doi.org/10.1074/jbc.M307889200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14688274	hybrid			2022-12-25	WOS:000189265900042
J	Housden, NG; Harrison, S; Housden, HR; Thomas, KA; Beckingham, JA; Roberts, SE; Bottomley, SP; Graille, M; Stura, E; Gore, MG				Housden, NG; Harrison, S; Housden, HR; Thomas, KA; Beckingham, JA; Roberts, SE; Bottomley, SP; Graille, M; Stura, E; Gore, MG			Observation and characterization of the interaction between a single immunoglobulin binding domain of protein L and two equivalents of human kappa light chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTOSTREPTOCOCCUS-MAGNUS; SITE; IGG	Detailed stopped-flow studies in combination with site-directed mutagenesis, isothermal titration calorimetry data and x-ray crystallographic knowledge have revealed that the biphasic pre-equilibrium fluorescence changes reported for a single Ig-binding domain of protein L from Peptostreptococcus magnus binding to kappa light chain are due to the binding of the kappa light chain at two separate sites on the protein L molecule. Elimination of binding site 2 through the mutation A66W has allowed the K-d for kappa light chain binding at site 1 to be measured by stopped-flow fluorescence and isothermal titration calorimetry techniques, giving values of 48.0 +/- 8.0 nM and 37.5 +/- 7.3 nM respectively. Conversely, a double mutation Y53F/L57H eliminates binding at site 1 and has allowed the Kd for binding at site 2 to be determined. Stopped-flow fluorimetry suggests this to be 3.4 +/- 0.8 muM in good agreement with the value of 4.6 +/- 0.8 muM determined by isothermal titration calorimetry. The mutation Y53F reduces the affinity of site 1 to approximately that of site 2.	Univ Southampton, Sch Biol Sci, Dept Biochem, Div Biochem & Mol Biol, Southampton SO16 7PX, Hants, England; Ctr Etud Saclay, DIEP, CEA, F-91191 Gif Sur Yvette, France	University of Southampton; CEA; UDICE-French Research Universities; Universite Paris Saclay	Gore, MG (corresponding author), Univ Southampton, Sch Biol Sci, Dept Biochem, Div Biochem & Mol Biol, Bassett Crescent E, Southampton SO16 7PX, Hants, England.	M.G.Gore@soton.ac.uk	Stura, Enrico A./A-2793-2010; GRAILLE, Marc/D-3242-2014	Stura, Enrico A./0000-0001-6718-2118; GRAILLE, Marc/0000-0002-7853-5852; Housden, Nicholas/0000-0002-4706-8278				Beckingham JA, 2001, BIOCHEM J, V353, P395, DOI 10.1042/0264-6021:3530395; Beckingham JA, 1999, BIOCHEM J, V340, P193, DOI 10.1042/0264-6021:3400193; Bottomley SP, 1995, BIOSEPARATION, V5, P359; Enokizono J, 1997, J MOL BIOL, V270, P8, DOI 10.1006/jmbi.1997.1090; Gore M. G., 2000, SPECTROPHOTOMETRY SP; Graille M, 2002, J BIOL CHEM, V277, P47500, DOI 10.1074/jbc.M206105200; Graille M, 2001, STRUCTURE, V9, P679, DOI 10.1016/S0969-2126(01)00630-X; Hiromi K., 1979, KINETICS FAST ENZYME; KASTERN W, 1990, INFECT IMMUN, V58, P1217, DOI 10.1128/IAI.58.5.1217-1222.1990; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; MCPHERSON SG, 2000, PCR; PATELLA V, 1990, J IMMUNOL, V145, P3054; Stura EA, 2002, ACTA CRYSTALLOGR D, V58, P1744, DOI 10.1107/S0907444902012805; WIKSTROM M, 1994, BIOCHEMISTRY-US, V33, P14011, DOI 10.1021/bi00251a008; Wikstrom M, 1996, EUR J BIOCHEM, V235, P543, DOI 10.1111/j.1432-1033.1996.00543.x; WIKSTROM M, 1995, J MOL BIOL, V250, P128, DOI 10.1006/jmbi.1995.0364; WILSON MT, 2000, SPECTROPHOTOMETRY SP	18	17	22	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9370	9378		10.1074/jbc.M312938200	http://dx.doi.org/10.1074/jbc.M312938200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14668335	hybrid, Green Published, Green Accepted			2022-12-25	WOS:000189265900101
J	Martin, D; Rojo, AI; Salinas, M; Diaz, R; Gallardo, G; Alam, J; de Galarreta, CMR; Cuadrado, A				Martin, D; Rojo, AI; Salinas, M; Diaz, R; Gallardo, G; Alam, J; de Galarreta, CMR; Cuadrado, A			Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; OXIDATIVE STRESS; GENE-EXPRESSION; NF-E2-RELATED FACTOR-2; EPITHELIAL-CELLS; PRIMARY CULTURES; SODIUM ARSENITE; DNA-DAMAGE; INDUCTION; ACTIVATION	The phosphatidylinositol 3-kinase (PI3K)/Akt pathway elicits a survival signal against multiple apoptotic insults. In addition, phase II enzymes such as heme oxygenase-1 (HO-1) protect cells against diverse toxins and oxidative stress. In this work, we describe a link between these defense systems at the level of transcriptional regulation of the antioxidant enzyme HO-1. The herb-derived phenol carnosol induced HO-1 expression at both mRNA and protein levels. Luciferase reporter assays indicated that carnosol targeted the mouse ho1 promoter at two enhancer regions comprising the antioxidant response elements (AREs). Moreover, carnosol increased the nuclear levels of Nrf2, a transcription factor governing AREs. Electrophoretic mobility shift assays and luciferase reporter assays with a dominant-negative Nrf2 mutant indicated that carnosol increased the binding of Nrf2 to ARE and induced Nrf2-dependent activation of the ho1 promoter. While investigating the signaling pathways responsible for HO-1 induction, we observed that carnosol activated the ERK, p38, and JNK pathways as well as the survival pathway driven by PI3K. Inhibition of PI3K reduced the increase in Nrf2 protein levels and activation of the ho1 promoter. Expression of active PI3K-CAAX ( where A is aliphatic amino acid) was sufficient to activate AREs. The use of dominant-negative mutants of protein kinase Czeta and Akt1, two kinases downstream from PI3K, demonstrated a requirement for active Akt1, but not protein kinase Czeta. Moreover, the long-term antioxidant effect of carnosol was partially blocked by PI3K or HO-1 inhibitors, further demonstrating that carnosol attenuates oxidative stress through a pathway that involves PI3K and HO-1.	Univ Autonoma Madrid, Fac Med, Dept Bioquim, E-28029 Madrid, Spain; Univ Autonoma Madrid, Fac Med, Inst Invest Biomed, E-28029 Madrid, Spain; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Univ Palmas Gran Canaria, Fac Med, Dept Bioquim, Gran Canaria 35016, Spain	Autonomous University of Madrid; Autonomous University of Madrid; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Universidad de Las Palmas de Gran Canaria	Cuadrado, A (corresponding author), Univ Autonoma Madrid, Fac Med, Dept Bioquim, Arzobispo Morcillo 4, E-28029 Madrid, Spain.	antonio.cuadrado@uam.es	campos, german gallardo/Z-5267-2019; Alam, Jawed/F-2596-2010; Rojo, Ana I/AAA-5203-2019	campos, german gallardo/0000-0002-1516-1750; Alam, Jawed/0000-0001-6520-482X; Rojo, Ana I/0000-0002-0312-5867; Martin Izquierdo, Daniel/0000-0002-8880-9087; Cuadrado, Antonio/0000-0002-3444-9012; Cuadrado, Antonio/0000-0002-4039-7140				Alam J, 2000, J BIOL CHEM, V275, P27694; Alam J, 2003, AM J PHYSIOL-RENAL, V284, pF743, DOI 10.1152/ajprenal.00376.2002; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Balogun E, 2003, BIOCHEM J, V371, P887, DOI 10.1042/BJ20021619; Bauer M, 2002, ANTIOXID REDOX SIGN, V4, P749, DOI 10.1089/152308602760598891; Chen J, 2003, J NEUROCHEM, V85, P1247, DOI 10.1046/j.1471-4159.2003.01776.x; Chen K, 2000, CELL MOL BIOL, V46, P609; Chen K, 2000, J NEUROCHEM, V75, P304, DOI 10.1046/j.1471-4159.2000.0750304.x; Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev; Dinkova-Kostova AT, 2002, MINI-REV MED CHEM, V2, P595, DOI 10.2174/1389557023405558; Dinkova-Kostova AT, 2001, P NATL ACAD SCI USA, V98, P3404, DOI 10.1073/pnas.051632198; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; Elbirt KK, 1999, P ASSOC AM PHYSICIAN, V111, P438, DOI 10.1111/paa.1999.111.5.438; Gong PF, 2002, ARCH BIOCHEM BIOPHYS, V405, P265, DOI 10.1016/S0003-9861(02)00404-6; Hayes JD, 2001, CANCER LETT, V174, P103, DOI 10.1016/S0304-3835(01)00695-4; Hill-Kapturczak N, 2001, AM J PHYSIOL-RENAL, V281, pF851, DOI 10.1152/ajprenal.0140.2001; Hill-Kapturczak N, 2000, J BIOL CHEM, V275, P40904, DOI 10.1074/jbc.M006621200; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Immenschuh S, 1998, BIOCHEM J, V334, P141, DOI 10.1042/bj3340141; Iqbal M, 2003, PHARMACOL TOXICOL, V92, P33, DOI 10.1034/j.1600-0773.2003.920106.x; Ischiropoulos H, 1999, METHOD ENZYMOL, V301, P367; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kiemer AK, 2003, ENDOCRINOLOGY, V144, P802, DOI 10.1210/en.2002-220610; Kietzmann T, 2003, J BIOL CHEM, V278, P17927, DOI 10.1074/jbc.M203929200; Klein JA, 2003, J CLIN INVEST, V111, P785, DOI 10.1172/JCI200318182; Lee JM, 2001, J BIOL CHEM, V276, P20011, DOI 10.1074/jbc.M100734200; Lim GP, 2001, J NEUROSCI, V21, P8370, DOI 10.1523/JNEUROSCI.21-21-08370.2001; Liu HL, 2003, J NEUROCHEM, V86, P1553, DOI 10.1046/j.1471-4159.2003.01978.x; Lo AH, 2002, CARCINOGENESIS, V23, P983, DOI 10.1093/carcin/23.6.983; Maeshima H, 1996, NUCLEIC ACIDS RES, V24, P2959, DOI 10.1093/nar/24.15.2959; Maines MD, 2003, TOXICOL SCI, V71, P9, DOI 10.1093/toxsci/71.1.9; Maines MD, 2000, CELL MOL BIOL, V46, P573; Martin D, 2001, J NEUROCHEM, V78, P1000, DOI 10.1046/j.1471-4159.2001.00472.x; Masuya Y, 1998, J BIOCHEM-TOKYO, V124, P628; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Mazza F, 2003, EXP BIOL MED, V228, P576, DOI 10.1177/15353702-0322805-31; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Numazawa S, 2003, AM J PHYSIOL-CELL PH, V285, pC334, DOI 10.1152/ajpcell.00043.2003; Oguro T, 1998, J PHARMACOL EXP THER, V287, P773; Ohlmann A, 2003, EXP BIOL MED, V228, P584, DOI 10.1177/15353702-0322805-51; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; RIZZARDINI M, 1993, BIOCHEM J, V290, P343, DOI 10.1042/bj2900343; Ryter SW, 2002, ANTIOXID REDOX SIGN, V4, P625, DOI 10.1089/15230860260220120; Saikawa Y, 2000, Hum Mutat, V16, P178, DOI 10.1002/1098-1004(200008)16:2<178::AID-HUMU16>3.0.CO;2-X; Salinas M, 2003, J BIOL CHEM, V278, P13898, DOI 10.1074/jbc.M209164200; Scapagnini G, 2002, MOL PHARMACOL, V61, P554, DOI 10.1124/mol.61.3.554; Shan Y, 2000, ARCH BIOCHEM BIOPHYS, V380, P219, DOI 10.1006/abbi.2000.1921; Stewart D, 2003, J BIOL CHEM, V278, P2396, DOI 10.1074/jbc.M209195200; Terry CM, 1999, AM J PHYSIOL-HEART C, V276, pH1493, DOI 10.1152/ajpheart.1999.276.5.H1493; Zeng HH, 2001, ACTA PHARMACOL SIN, V22, P1094	54	592	607	0	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8919	8929		10.1074/jbc.M309660200	http://dx.doi.org/10.1074/jbc.M309660200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14688281	hybrid			2022-12-25	WOS:000189265900050
J	Watanabe, I; Zhu, J; Recio-Pinto, E; Thornhill, WB				Watanabe, I; Zhu, J; Recio-Pinto, E; Thornhill, WB			Glycosylation affects the protein stability and cell surface expression of Kv1.4 but not Kv1.1 potassium channels - A pore region determinant dictates the effect of glycosylation on trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CHANNELS; DIVERSITY	Kv1.1 and Kv1.4 potassium channels are plasma membrane glycoproteins involved in action potential repolarization. We have shown previously that glycosylation affects the gating function of Kv1.1 (Watanabe, I., Wang, H. G., Sutachan, J. J., Zhu, J., Recio-Pinto, E. & Thornhill, W. B. (2003) J. Physiol. (Lond.) 550, 51-66) and that a pore region determinant of Kv1.1 and Kv1.4 affects their cell surface trafficking negatively or positively, respectively (Zhu, J., Watanabe, I., Gomez, B. & Thornhill, W. B. (2001) J. Biol. Chem. 276, 39419-39427). Here we investigated the role of N-glycosylation of Kv1.1 and Kv1.4 on their protein stability, cellular localization pattern, and trafficking to the cell surface. We found that preventing N-glycosylation of Kv1.4 decreased its protein stability, induced its high partial intracellular retention, and decreased its cell surface protein levels, whereas it had little or no effect on these parameters for Kv1.1. Exchanging a trafficking pore region determinant between Kv1.1 and Kv1.4 reversed these effects of glycosylation on these chimeric channels. Thus it appeared that the Kv1.4 pore region determinant and the sugar tree attached to the S1-S2 linker showed some type of dependence in promoting proper trafficking of the protein to the cell surface, and this dependence can be transferred to chimeric Kv1.1 proteins that contain the Kv1.4 pore. Understanding the different trafficking programs of Kv1 channels, and whether they are altered by glycosylation, will highlight the different posttranslational mechanisms available to cells to modify their cell surface ion channel levels and possibly their signaling characteristics.	Fordham Univ, Dept Biol Sci, Bronx, NY 10458 USA; NYU, Sch Med, Dept Anesthesiol, New York, NY 10016 USA	Fordham University; New York University	Thornhill, WB (corresponding author), Fordham Univ, Dept Biol Sci, Bronx, NY 10458 USA.	thornhill@fordham.edu			NINDS NIH HHS [NS29633] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029633] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Carchon H, 1999, BBA-MOL BASIS DIS, V1455, P155, DOI 10.1016/S0925-4439(99)00073-3; Coetzee WA, 1999, ANN NY ACAD SCI, V868, P233, DOI 10.1111/j.1749-6632.1999.tb11293.x; Coleman SK, 1999, J NEUROCHEM, V73, P849, DOI 10.1046/j.1471-4159.1999.0730849.x; Hille B., 2001, IONIC CHANNELS EXCIT, P814; IVANINA T, 1994, BIOCHEMISTRY-US, V33, P8786, DOI 10.1021/bi00195a021; Jaeken J, 1991, Acta Paediatr Scand Suppl, V375, P1; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Jugloff DGM, 2000, J BIOL CHEM, V275, P1357, DOI 10.1074/jbc.275.2.1357; Khanna R, 2001, J BIOL CHEM, V276, P34028, DOI 10.1074/jbc.M105248200; LENNARZ W, 1983, METHOD ENZYMOL, V98, P91; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; Tamarappoo BK, 1999, J BIOL CHEM, V274, P34825, DOI 10.1074/jbc.274.49.34825; Thornhill WB, 1996, J BIOL CHEM, V271, P19093, DOI 10.1074/jbc.271.32.19093; Watanabe I, 2003, J PHYSIOL-LONDON, V550, P51, DOI 10.1113/jphysiol.2003.040337; Zhu J, 2003, BIOCHEM J, V375, P761, DOI 10.1042/BJ20030885; Zhu J, 2003, J BIOL CHEM, V278, P25558, DOI 10.1074/jbc.M207984200; Zhu J, 2001, J BIOL CHEM, V276, P39419, DOI 10.1074/jbc.M107399200	17	90	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8879	8885		10.1074/jbc.M309802200	http://dx.doi.org/10.1074/jbc.M309802200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14688283	hybrid			2022-12-25	WOS:000189265900045
J	Daroui, P; Desai, SD; Li, TK; Liu, AA; Liu, LF				Daroui, P; Desai, SD; Li, TK; Liu, AA; Liu, LF			Hydrogen peroxide induces topoisomerase I-mediated DNA damage and cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENT COMPLEXES; YEAST-CELLS; IONIZING-RADIATION; RADICAL GENERATION; INDUCED APOPTOSIS; OXIDATIVE STRESS; FENTON REACTION; CAMPTOTHECIN; REPAIR; SACCHAROMYCES	Reactive oxygen species modify DNA, generating various DNA lesions including modified bases such as 8-oxoguanine (8-oxoG). These base-modified DNA lesions have been shown to trap DNA topoisomerase I (TOP1) into covalent cleavage complexes. In this study, we have investigated the role of TOP1 in hydrogen peroxide toxicity. We showed that ectopic expression of TOP1 in Saccharomyces cerevisiae conferred sensitivity to hydrogen peroxide, and this sensitivity was dependent on RAD9 checkpoint function. Moreover, in the mammalian cell culture system, hydrogen peroxide-induced growth inhibition and apoptosis were shown to be partly TOP1-dependent as evidenced by a specific increase in resistance to hydrogen peroxide in TOP1-deficient P388/ CPT45 murine leukemia cells as compared with their TOP1-proficient parental cell line P388. In addition, hydrogen peroxide was shown to induce TOP1-DNA cross-links. These results support a model in which hydrogen peroxide promotes the trapping of TOP1 on oxidative DNA lesions to form TOP1-DNA cleavage complexes that contribute to hydrogen peroxide toxicity.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Liu, LF (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Lane, Piscataway, NJ 08854 USA.	lliu@umdnj.edu		LI, TSAI-KUN/0000-0003-0393-2340; Daroui, Parima/0000-0002-9669-9383; Liu, Leroy/0000-0001-9396-763X	NCI NIH HHS [CA077433, CA39662] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039662, R01CA077433] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BJORNSTI MA, 1989, CANCER RES, V49, P6318; BRILL SJ, 1988, CELL, V54, P403, DOI 10.1016/0092-8674(88)90203-6; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; Buda F, 2003, CHEM-EUR J, V9, P3436, DOI 10.1002/chem.200204444; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; CARMICHAEL J, 1987, CANCER RES, V47, P936; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Chatgilialoglu C, 2001, EXP GERONTOL, V36, P1459, DOI 10.1016/S0531-5565(01)00132-2; Desai SD, 2003, MOL CELL BIOL, V23, P2341, DOI 10.1128/MCB.23.7.2341-2350.2003; Dizdaroglu M, 2002, FREE RADICAL BIO MED, V32, P1102, DOI 10.1016/S0891-5849(02)00826-2; ENG WK, 1990, MOL PHARMACOL, V38, P471; Epe B, 2002, BIOL CHEM, V383, P467, DOI 10.1515/BC.2002.049; Flattery-O'Brien JA, 1998, J BIOL CHEM, V273, P8564, DOI 10.1074/jbc.273.15.8564; GOTO T, 1985, P NATL ACAD SCI USA, V82, P7178, DOI 10.1073/pnas.82.21.7178; HALLIWELL B, 1992, FEBS LETT, V307, P108, DOI 10.1016/0014-5793(92)80911-Y; Halliwell B, 2000, FEBS LETT, V486, P10, DOI 10.1016/S0014-5793(00)02197-9; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; IMLAY JA, 1988, SCIENCE, V240, P640, DOI 10.1126/science.2834821; JENNER P, 1994, LANCET, V344, P796, DOI 10.1016/S0140-6736(94)92347-7; KAUH EA, 1995, P NATL ACAD SCI USA, V92, P6299, DOI 10.1073/pnas.92.14.6299; Khelifa T, 1999, BIOCHEM PHARMACOL, V58, P1247, DOI 10.1016/S0006-2952(99)00213-0; KNAB AM, 1993, J BIOL CHEM, V268, P22322; Lelli JL, 1998, FREE RADICAL BIO MED, V25, P694, DOI 10.1016/S0891-5849(98)00107-5; Leroy C, 2001, EMBO J, V20, P2896, DOI 10.1093/emboj/20.11.2896; Lesher DTT, 2002, P NATL ACAD SCI USA, V99, P12102, DOI 10.1073/pnas.192282699; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; Li TK, 1999, GENE DEV, V13, P1553, DOI 10.1101/gad.13.12.1553; Li TK, 2003, CANCER RES, V63, P8400; Liu CY, 2002, P NATL ACAD SCI USA, V99, P14970, DOI 10.1073/pnas.182557199; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Loft S, 1996, J MOL MED, V74, P297, DOI 10.1007/BF00207507; MATTERN MR, 1993, ONCOL RES, V5, P467; MATTERN MR, 1991, CANCER RES, V51, P5813; Meng LH, 2003, CURR TOP MED CHEM, V3, P305; Nanavaty UB, 2002, EXP LUNG RES, V28, P591, DOI 10.1080/01902140260426715; Nitiss JL, 2001, J BIOL CHEM, V276, P26708, DOI 10.1074/jbc.M102674200; PARK EM, 1992, P NATL ACAD SCI USA, V89, P3375, DOI 10.1073/pnas.89.8.3375; Pouliot JJ, 1999, SCIENCE, V286, P552, DOI 10.1126/science.286.5439.552; Pouliot JJ, 2001, GENES CELLS, V6, P677, DOI 10.1046/j.1365-2443.2001.00452.x; Pourquier P, 2000, P NATL ACAD SCI USA, V97, P1885, DOI 10.1073/pnas.97.4.1885; Pourquier P, 1997, J BIOL CHEM, V272, P26441, DOI 10.1074/jbc.272.42.26441; Pourquier P, 1999, J BIOL CHEM, V274, P8516, DOI 10.1074/jbc.274.13.8516; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; Ramirez R, 2003, J BIOL CHEM, V278, P836, DOI 10.1074/jbc.M206818200; Ren JG, 2001, FEBS LETT, V488, P123, DOI 10.1016/S0014-5793(00)02377-2; ROCA J, 1992, NUCLEIC ACIDS RES, V20, P4671, DOI 10.1093/nar/20.17.4671; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; Sekiguchi M, 2002, ONCOGENE, V21, P8895, DOI 10.1038/sj.onc.1206023; SHERO JH, 1986, SCIENCE, V231, P737, DOI 10.1126/science.3003910; SUBRAMANIAN D, 1995, CANCER RES, V55, P2097; Toh GWL, 2003, BIOCHEM SOC T, V31, P242, DOI 10.1042/bst0310242; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; WOESSNER RD, 1992, ONCOL RES, V4, P481; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; WOOD ML, 1992, NUCLEIC ACIDS RES, V20, P6023, DOI 10.1093/nar/20.22.6023	56	108	113	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14587	14594		10.1074/jbc.M311370200	http://dx.doi.org/10.1074/jbc.M311370200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14688260	hybrid			2022-12-25	WOS:000220594700016
J	Tagawa, H; Karnan, S; Kasugai, Y; Tuzuki, S; Suzuki, R; Hosokawa, Y; Seto, M				Tagawa, H; Karnan, S; Kasugai, Y; Tuzuki, S; Suzuki, R; Hosokawa, Y; Seto, M			MASL1, a candidate oncogene found in amplification at 8p23.1, is translocated in immunoblastic B-cell lymphoma cell line OCI-LY8	ONCOGENE			English	Article						MASL1; lymphoma; oncogene; 8p23; translocation; amplification	NON-HODGKIN-LYMPHOMA; CHROMOSOME 8P; FREQUENT LOSS; CYCLIN D1; CANCER; GENE; LYMPHOMA/LEUKEMIA; CARCINOMA; SEQUENCES; PRAD1	Genetic amplification at chromosome 8p23.1 has been reported in some solid tumors. Translocation of 8p23.1 has also been reported in hematological malignancies and head and neck squamous cell cancer. In an attempt to clarify whether this translocation is implicated in lymphomagenesis, we performed FISH analysis of the immunoblastic B-cell lymphoma cell line OCI-LY8, which has chromosome translocation at 8p23.1, with various BAC clones. We found split signals on BAC, RP11-18L2 where the MASL1 gene is located. This translocation was found to produce a chimeric transcript of MASL1 exon 1 with a cryptic exon from the genome region at 14q21. Our study indicates that MASL1 is not only a target gene for genomic amplification but also for chromosomal translocation. Since tumorigenic activity of the MASL1 has not been proven, its in vitro transforming activity was studied and in vivo nude mice assay were performed. Although no in vitro transforming activity was detected by focus formation, the in vivo tumorigenesis assay with nude mice showed that both MASL1 and chimeric MASL1 possess tumorigenic activity. This suggests that MASL1 is an important oncogene not only for solid tumors but also for hematologic malignancies.	Aichi Canc Ctr, Res Inst, Div Mol Med, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center	Seto, M (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Med, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	mseto@aichi-cc.jp		Kasugai, Yumiko/0000-0003-4764-4455; Suzuki, Ritsuro/0000-0002-5974-7614				Chaganti SR, 1998, GENE CHROMOSOME CANC, V23, P328, DOI 10.1002/(SICI)1098-2264(199812)23:4<328::AID-GCC8>3.0.CO;2-M; CHANG H, 1992, J CLIN INVEST, V89, P1014, DOI 10.1172/JCI115642; EMI M, 1992, CANCER RES, V52, P5368; Gilhuis HJ, 2000, CLIN NEUROL NEUROSUR, V102, P203, DOI 10.1016/S0303-8467(00)00112-8; Jin YS, 2001, CANCER GENET CYTOGEN, V130, P111, DOI 10.1016/S0165-4608(01)00476-9; KNOWLES MA, 1993, ONCOGENE, V8, P1357; KOMATSU H, 1994, BLOOD, V84, P1226; Martinez-Climent JA, 2001, BLOOD, V98, P3479, DOI 10.1182/blood.V98.12.3479; MATSUYAMA H, 1994, ONCOGENE, V9, P3071; Mehra S, 2002, GENE CHROMOSOME CANC, V33, P225, DOI 10.1002/gcc.10025; Nupponen NN, 2000, MICROSC RES TECHNIQ, V51, P456, DOI 10.1002/1097-0029(20001201)51:5<456::AID-JEMT8>3.0.CO;2-H; PYKETT MJ, 1994, CANCER GENET CYTOGEN, V76, P23, DOI 10.1016/0165-4608(94)90064-7; Sakabe T, 1999, CANCER RES, V59, P511; Sakakura C, 1999, GENE CHROMOSOME CANC, V24, P299, DOI 10.1002/(SICI)1098-2264(199904)24:4<299::AID-GCC2>3.0.CO;2-U; SETO M, 1992, ONCOGENE, V7, P1401; SIN C, 1979, P NATL ACAD SCI USA, V76, P5714; Stock C, 2000, GENE CHROMOSOME CANC, V28, P329, DOI 10.1002/1098-2264(200007)28:3<329::AID-GCC11>3.0.CO;2-F; Sunwoo JB, 1996, GENE CHROMOSOME CANC, V16, P164, DOI 10.1002/(SICI)1098-2264(199607)16:3<164::AID-GCC2>3.0.CO;2-X; Tagawa H, 2002, GENE CHROMOSOME CANC, V34, P175, DOI 10.1002/gcc.10057; Tanner MM, 1998, AM J PATHOL, V153, P191, DOI 10.1016/S0002-9440(10)65560-5; TWEEDDALE ME, 1987, BLOOD, V69, P1307; Wong N, 2000, HUM PATHOL, V31, P771, DOI 10.1053/hupa.2000.7625	22	30	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2576	2581		10.1038/sj.onc.1207352	http://dx.doi.org/10.1038/sj.onc.1207352			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14691450				2022-12-25	WOS:000220558000016
J	Gardner, AF; Joyce, CM; Jack, WE				Gardner, AF; Joyce, CM; Jack, WE			Comparative kinetics of nucleotide analog incorporation by vent DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I KLENOW FRAGMENT; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; SUGAR RECOGNITION; ARCHAEON; ALPHA; IDENTIFICATION; REPLICATION; MECHANISM; FAMILY	Comparative kinetic and structural analyses of a variety of polymerases have revealed both common and divergent elements of nucleotide discrimination. Although the parameters for dNTP incorporation by the hyperthermophilic archaeal Family B Vent DNA polymerase are similar to those previously derived for Family A and B DNA polymerases, parameters for analog incorporation reveal alternative strategies for discrimination by this enzyme. Discrimination against ribonucleotides was characterized by a decrease in the affinity of NTP binding and a lower rate of phosphoryl transfer, whereas discrimination against ddNTPs was almost exclusively due to a slower rate of phosphodiester bond formation. Unlike Family A DNA polymerases, incorporation of 9-[(2-hydroxyethoxy) methyl] X triphosphates (where X is adenine, cytosine, guanine, or thymine; acyNTPs) by Vent DNA polymerase was enhanced over ddNTPs via a 50-fold increase in phosphoryl transfer rate. Furthermore, a mutant with increased propensity for nucleotide analog incorporation (Vent(A488L) DNA polymerase) had unaltered dNTP incorporation while displaying enhanced nucleotide analog binding affinity and rates of phosphoryl transfer. Based on kinetic data and available structural information from other DNA polymerases, we propose active site models for dNTP, ddNTP, and acyNTP selection by hyperthermophilic archaeal DNA polymerases to rationalize structural and functional differences between polymerases.	New England Biolabs Inc, Beverly, MA 01915 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University	Jack, WE (corresponding author), New England Biolabs Inc, 32 Tozer Rd, Beverly, MA 01915 USA.	jack@neb.com			NIGMS NIH HHS [GM-28550] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028550] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arezi B, 2002, J MOL BIOL, V322, P719, DOI 10.1016/S0022-2836(02)00843-4; Astatke M, 1998, J MOL BIOL, V278, P147, DOI 10.1006/jmbi.1998.1672; Astatke M, 1998, P NATL ACAD SCI USA, V95, P3402, DOI 10.1073/pnas.95.7.3402; Bankier A T, 1993, Methods Mol Biol, V23, P83; Benkovic SJ, 1995, METHOD ENZYMOL, V262, P257; Bonnin A, 1999, J MOL BIOL, V290, P241, DOI 10.1006/jmbi.1999.2900; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; Brandis JW, 1996, BIOCHEMISTRY-US, V35, P2189, DOI 10.1021/bi951682j; Brandis JW, 1999, NUCLEIC ACIDS RES, V27, P1912, DOI 10.1093/nar/27.8.1912; Cann IKO, 1998, P NATL ACAD SCI USA, V95, P14250, DOI 10.1073/pnas.95.24.14250; Chen XN, 1999, GENOME RES, V9, P492; DAHLBERG ME, 1991, BIOCHEMISTRY-US, V30, P4835, DOI 10.1021/bi00234a002; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; DONG Q, 1993, J BIOL CHEM, V268, P24163; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Evans SJ, 2000, NUCLEIC ACIDS RES, V28, P1059, DOI 10.1093/nar/28.5.1059; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; Filee J, 2002, J MOL EVOL, V54, P763, DOI 10.1007/s00239-001-0078-x; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Freeman S, 1996, MOL BIOTECHNOL, V5, P125, DOI 10.1007/BF02789061; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; Gardner AF, 1999, NUCLEIC ACIDS RES, V27, P2545, DOI 10.1093/nar/27.12.2545; Gardner AF, 2002, NUCLEIC ACIDS RES, V30, P605, DOI 10.1093/nar/30.2.605; GILLIN FD, 1975, BIOCHEM BIOPH RES CO, V64, P457, DOI 10.1016/0006-291X(75)90343-5; Hashimoto H, 2001, J MOL BIOL, V306, P469, DOI 10.1006/jmbi.2000.4403; Hopfner KP, 1999, P NATL ACAD SCI USA, V96, P3600, DOI 10.1073/pnas.96.7.3600; ILSLEY DD, 1999, FASEB J, V13, pA144; JOHNSON KA, 1995, METHOD ENZYMOL, V249, P38; Johnson SJ, 2003, P NATL ACAD SCI USA, V100, P3895, DOI 10.1073/pnas.0630532100; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KONG HM, 1993, J BIOL CHEM, V268, P1965; Minnick DT, 2002, P NATL ACAD SCI USA, V99, P1194, DOI 10.1073/pnas.032457899; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; Perler FB, 1996, ADV PROTEIN CHEM, V48, P377; PETERSON MG, 1988, NUCLEIC ACIDS RES, V16, P10915, DOI 10.1093/nar/16.22.10915; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; PROBER JM, 1987, SCIENCE, V238, P336, DOI 10.1126/science.2443975; REID R, 1988, J BIOL CHEM, V263, P3898; Rodriguez AC, 2000, J MOL BIOL, V299, P447, DOI 10.1006/jmbi.2000.3728; SEARS LE, 1992, BIOTECHNIQUES, V13, P626; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; TRAINOR GL, 1996, Patent No. 5558991; Truniger V, 1999, J MOL BIOL, V286, P57, DOI 10.1006/jmbi.1998.2477; Yang GW, 2002, BIOCHEMISTRY-US, V41, P10256, DOI 10.1021/bi0202171; Yang GW, 2002, BIOCHEMISTRY-US, V41, P2526, DOI 10.1021/bi0119924; Zhao YX, 1999, STRUCTURE, V7, P1189, DOI 10.1016/S0969-2126(00)80053-2; [No title captured]	50	30	60	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11834	11842		10.1074/jbc.M308286200	http://dx.doi.org/10.1074/jbc.M308286200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699133	hybrid			2022-12-25	WOS:000220157600120
J	Bosc, LVG; Wilkerson, MK; Bradley, KN; Eckman, DM; Hill-Eubanks, DC; Nelson, MT				Bosc, LVG; Wilkerson, MK; Bradley, KN; Eckman, DM; Hill-Eubanks, DC; Nelson, MT			Intraluminal pressure is a stimulus for NFATc3 nuclear accumulation - Role of calcium, endothelium-derived nitric oxide, and cGMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; ACTIVATED T-CELLS; CEREBRAL-ARTERIES; TRANSCRIPTIONAL PATHWAY; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; CALCINEURIN; CA2+; HYPERTROPHY; CHANNELS	The transcription factor NFAT ( nuclear factor of activated T-cells) is implicated in cardiac hypertrophy and vasculogenesis. NFAT activation, reflecting dephosphorylation by the calcium-dependent phosphatase, calcineurin, and subsequent nuclear localization, is generally thought to require a sustained increase in intracellular calcium. However, in smooth muscle we have found that elevation of calcium by membrane depolarization fails to induce an increase in nuclear localization of the NFATc3 isoform. Here, we demonstrate that physiological intravascular pressure ( 100 mm Hg) induces an increase in NFATc3 nuclear localization in mouse cerebral arteries. Pressure-induced NFATc3 nuclear accumulation is abrogated by endothelial denudation and by nitric-oxide synthase, cGMP-dependent kinase (PKG), and voltage-dependent calcium channels inhibition. We further show that exogenous nitric oxide, in combination with an elevation in calcium, is an effective stimulus for NFATc3 nuclear accumulation. c-Jun terminal kinase 2 (JNK) activity, which has been shown to regulate NFATc3 nuclear export, is also reduced by pressure, an effect that is prevented by pretreatment with a PKG inhibitor. Consistent with this, pressure-induced NFATc3 nuclear accumulation is independent of PKG in arteries from JNK2(-/-) mice. Collectively, our results indicate that both activation of the NO/PKG pathway and elevation of smooth muscle calcium are required for NFATc3 nuclear accumulation and that PKG inhibits JNK2 to decrease NFAT nuclear export. Our findings suggest that at physiological intravascular pressures NFATc3 is localized to the nucleus in smooth muscle cells of intact arteries and indicate a novel and unexpected role for nitric oxide/PKG in NFAT activation.	Univ Vermont, Dept Pharmacol, Coll Med, Burlington, VT 05405 USA; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	University of Vermont; University of Glasgow	Nelson, MT (corresponding author), Univ Vermont, Dept Pharmacol, Coll Med, 89 Beaumont Ave, Burlington, VT 05405 USA.	mark.nelson@uvm.edu		Nelson, Mark/0000-0002-6608-8784; Gonzalez Bosc, Laura/0000-0001-7505-4909	NHLBI NIH HHS [HL63722, HL07647-12, HL44455, HL07944] Funding Source: Medline; NIDDK NIH HHS [DDK53832] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007944, R01HL044455, R01HL063722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK053832, R01DK053832] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bang L, 1999, SCAND CARDIOVASC J, V33, P71; Boerth NJ, 1997, J VASC RES, V34, P245, DOI 10.1159/000159231; Bolz SS, 2003, CIRCULATION, V107, P3081, DOI 10.1161/01.CIR.0000074202.19612.8C; BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909; Casteel DE, 2002, J BIOL CHEM, V277, P32003, DOI 10.1074/jbc.M112332200; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Ciani E, 2002, J NEUROCHEM, V82, P1282, DOI 10.1046/j.1471-4159.2002.01080.x; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Delling U, 2000, MOL CELL BIOL, V20, P6600, DOI 10.1128/MCB.20.17.6600-6611.2000; Doughty JM, 1998, PFLUG ARCH EUR J PHY, V436, P220, DOI 10.1007/s004240050625; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FARACI FM, 1990, CIRC RES, V66, P8, DOI 10.1161/01.RES.66.1.8; Feil R, 2003, CIRC RES, V93, P907, DOI 10.1161/01.RES.0000100390.68771.CC; Fiedler B, 2002, P NATL ACAD SCI USA, V99, P11363, DOI 10.1073/pnas.162100799; Gomez MF, 2003, J BIOL CHEM, V278, P46847, DOI 10.1074/jbc.M304765200; Gomez MF, 2002, J BIOL CHEM, V277, P37756, DOI 10.1074/jbc.M203596200; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gudi T, 2002, J BIOL CHEM, V277, P37382, DOI 10.1074/jbc.M204491200; Gudi T, 2000, ONCOGENE, V19, P6324, DOI 10.1038/sj.onc.1204007; HARDER DR, 1984, CIRC RES, V55, P197, DOI 10.1161/01.RES.55.2.197; Hill-Eubanks DC, 2003, TRENDS CARDIOVAS MED, V13, P56, DOI 10.1016/S1050-1738(02)00212-8; HO AM, 1994, J BIOL CHEM, V269, P28181; Ho IC, 1998, P NATL ACAD SCI USA, V95, P15537, DOI 10.1073/pnas.95.26.15537; Hofmann F, 2000, J CELL SCI, V113, P1671; Horsley V, 2001, J CELL BIOL, V153, P329, DOI 10.1083/jcb.153.2.329; Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200; Jacob A, 2002, AM J PHYSIOL-CELL PH, V283, pC704, DOI 10.1152/ajpcell.00110.2002; Keef KD, 2001, AM J PHYSIOL-CELL PH, V281, pC1743; Knot HJ, 1998, J PHYSIOL-LONDON, V508, P199, DOI 10.1111/j.1469-7793.1998.199br.x; Koller A, 2003, BIOCHEM BIOPH RES CO, V300, P155, DOI 10.1016/S0006-291X(02)02799-7; Lehen'kyi V V, 2002, Cardiovasc Toxicol, V2, P151, DOI 10.1385/CT:2:2:151; Lincoln TM, 1998, ACTA PHYSIOL SCAND, V164, P507, DOI 10.1111/j.1365-201X.1998.tb10700.x; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; MEININGER GA, 1992, AM J PHYSIOL, V263, pH647, DOI 10.1152/ajpheart.1992.263.3.H647; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MONCADA S, 1991, PHARMACOL REV, V43, P109; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; Ohkawa Y, 2003, BIOCHEM BIOPH RES CO, V301, P78, DOI 10.1016/S0006-291X(02)02965-0; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; Porter VA, 1998, AM J PHYSIOL-CELL PH, V274, pC1346; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; ROBERTSON BE, 1993, AM J PHYSIOL, V265, pC299; Rubart M, 1996, J GEN PHYSIOL, V107, P459, DOI 10.1085/jgp.107.4.459; Ruiz-Velasco V, 1998, CIRC RES, V82, P557, DOI 10.1161/01.RES.82.5.557; Sausbier M, 2000, CIRC RES, V87, P825, DOI 10.1161/01.RES.87.9.825; Sauzeau V, 2003, J BIOL CHEM, V278, P9472, DOI 10.1074/jbc.M212776200; Schlossmann J, 2003, ANN MED, V35, P21, DOI 10.1080/07853890310004093; Sharma GD, 2002, MOL CELL BIOCHEM, V233, P165, DOI 10.1023/A:1015882302796; Stevenson AS, 2001, J BIOL CHEM, V276, P15018, DOI 10.1074/jbc.M011684200; Sun D, 2001, AM J PHYSIOL-HEART C, V280, pH714, DOI 10.1152/ajpheart.2001.280.2.H714; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; van Rooij E, 2002, J BIOL CHEM, V277, P48617, DOI 10.1074/jbc.M206532200; Wada H, 2002, J CELL BIOL, V156, P983, DOI 10.1083/jcb.200106057; Wilkins BJ, 2002, MOL CELL BIOL, V22, P7603, DOI 10.1128/MCB.22.21.7603-7613.2002; Yamahara K, 2003, P NATL ACAD SCI USA, V100, P3404, DOI 10.1073/pnas.0538059100; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8	62	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10702	10709		10.1074/jbc.M312920200	http://dx.doi.org/10.1074/jbc.M312920200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688253	hybrid			2022-12-25	WOS:000220050400125
J	Schnepp, RW; Mao, H; Sykes, SM; Zong, WX; Silva, A; La, P; Hua, XX				Schnepp, RW; Mao, H; Sykes, SM; Zong, WX; Silva, A; La, P; Hua, XX			Menin induces apoptosis in murine embryonic fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE ENDOCRINE NEOPLASIA; TYPE-1 GENE-PRODUCT; CHROMOSOME-ABNORMALITIES; CHILDHOOD NEUROBLASTOMAS; EXPRESSION; GROWTH; PROTEINS; CASPASE-8; ORTHOLOG; BAX	Multiple endocrine neoplasia type I (MEN1) is a hereditary tumor syndrome characterized by multiple endocrine and occasionally non-endocrine tumors. The tumor suppressor gene Men1, which is frequently mutated in MEN1 patients, encodes the nuclear protein menin. Although many tumor suppressor genes are involved in the regulation of apoptosis, it is unclear whether menin facilitates apoptosis. Here we show that ectopic overexpression of menin via adenoviruses induces apoptosis in murine embryonic fibroblasts. The induction of apoptosis depends on Bax and Bak, two proapoptotic proteins. Moreover, loss of menin expression compromises apoptosis induced by UV irradiation and tumor necrosis factor-alpha (TNF-alpha), whereas complementation of meninnull cells with menin restores sensitivity to UV- and TNF-alpha-induced apoptosis. Interestingly, loss of menin reduces the expression of procaspase 8, a critical protease that is essential for apoptosis induced by death-related receptors, whereas complementation of the meninnull cells up-regulates the expression of procaspase 8. Furthermore, complementation of menin-null cells with menin increases the activation of caspase 8 in response to TNF-alpha treatment. These results suggest a proapoptotic function for menin that may be important in suppressing the development of MEN1.	Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Hua, XX (corresponding author), Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.	huax@mail.med.upenn.edu			NCI NIH HHS [K01 CA078592-06, K01CA78592] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA078592] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal SK, 1999, CELL, V96, P143, DOI 10.1016/S0092-8674(00)80967-8; Chandrasekharappa SC, 2003, J INTERN MED, V253, P606, DOI 10.1046/j.1365-2796.2003.01165.x; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Crabtree JS, 2001, P NATL ACAD SCI USA, V98, P1118, DOI 10.1073/pnas.98.3.1118; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Guru SC, 2001, GENE, V263, P31, DOI 10.1016/S0378-1119(00)00562-X; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Ikeo Y, 2000, LAB INVEST, V80, P797, DOI 10.1038/labinvest.3780084; Itakura Y, 2000, BIOMED PHARMACOTHER, V54, p187S, DOI 10.1016/S0753-3322(00)80041-4; Jin SH, 2003, CANCER RES, V63, P4204; Kaji H, 1999, CANCER RES, V59, P5097; Kaji H, 2001, P NATL ACAD SCI USA, V98, P3837, DOI 10.1073/pnas.061358098; Khodaei S, 1999, BIOCHEM BIOPH RES CO, V264, P404, DOI 10.1006/bbrc.1999.1529; Kim YS, 1999, ONCOGENE, V18, P5936, DOI 10.1038/sj.onc.1203005; La P, 2003, ONCOGENE, V22, P198, DOI 10.1038/sj.onc.1206100; Lemmens IH, 2001, BIOCHEM BIOPH RES CO, V286, P426, DOI 10.1006/bbrc.2001.5405; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Manickam P, 2000, MAMM GENOME, V11, P448, DOI 10.1007/s003350010085; Marx SJ, 1999, RECENT PROG HORM RES, V54, P397; Namihira H, 2002, J MOL ENDOCRINOL, V29, P297, DOI 10.1677/jme.0.0290297; Nord B, 2000, INT J CANCER, V87, P463, DOI 10.1002/1097-0215(20000815)87:4<463::AID-IJC1>3.0.CO;2-8; Pannett AAJ, 1999, ENDOCR-RELAT CANCER, V6, P449, DOI 10.1677/erc.0.0060449; Poisson A, 2003, CANCER LETT, V189, P1, DOI 10.1016/S0304-3835(02)00509-8; Saito Y, 2003, GENE THER, V10, P1961, DOI 10.1038/sj.gt.3302100; Salmena L, 2003, GENE DEV, V17, P883, DOI 10.1101/gad.1063703; Sayo Y, 2002, ENDOCRINOLOGY, V143, P2437, DOI 10.1210/en.143.6.2437; SCAPPATICCI S, 1992, CANCER GENET CYTOGEN, V63, P17, DOI 10.1016/0165-4608(92)90057-F; SCAPPATICCI S, 1991, CANCER GENET CYTOGEN, V52, P85, DOI 10.1016/0165-4608(91)90057-2; Schussheim DH, 2001, TRENDS ENDOCRIN MET, V12, P173, DOI 10.1016/S1043-2760(00)00372-6; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stewart C, 1998, ONCOGENE, V17, P2485, DOI 10.1038/sj.onc.1202164; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Teitz T, 2001, J MOL MED, V79, P428, DOI 10.1007/s001090100233; Thakker RV, 2000, ENDOCRIN METAB CLIN, V29, P541, DOI 10.1016/S0889-8529(05)70150-X; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; van Kesteren RE, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-16-j0004.2001; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Wautot V, 2000, INT J CANCER, V85, P877, DOI 10.1002/(SICI)1097-0215(20000315)85:6<877::AID-IJC23>3.0.CO;2-F; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	51	66	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10685	10691		10.1074/jbc.M308073200	http://dx.doi.org/10.1074/jbc.M308073200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688275	Green Accepted, hybrid			2022-12-25	WOS:000220050400123
J	Walczak, R; Joseph, SB; Laffitte, BA; Castrillo, A; Pei, LM; Tontonoz, P				Walczak, R; Joseph, SB; Laffitte, BA; Castrillo, A; Pei, LM; Tontonoz, P			Transcription of the vascular endothelial growth factor gene in macrophages is regulated by liver X receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR-1; SMOOTH-MUSCLE-CELLS; FACTOR EXPRESSION; ACTIVATED RECEPTOR; LXR-ALPHA; MURINE MACROPHAGES; LIPID-METABOLISM; ANGIOGENESIS; ATHEROSCLEROSIS; MICE	Macrophages are an important source of angiogenic activity in wound healing, cancer, and chronic inflammation. Vascular endothelial growth factor ( VEGF), a cytokine produced by macrophages, is a primary inducer of angiogenesis and neovascularization in these contexts. VEGF expression by macrophages is known to be stimulated by low oxygen tension as well as by inflammatory signals. In this study, we provide evidence that Vegfa gene expression is also regulated by activation of liver X receptors (LXRs). VEGF mRNA was induced in response to synthetic LXR agonists in murine and human primary macrophages as well as in murine adipose tissue in vivo. The effects of LXR ligands on VEGF expression were independent of hypoxia-inducible factor HIF-1alpha activation and did not require the previously characterized hypoxia response element in the VEGF promoter. Rather, LXR/retinoid X receptor heterodimers bound directly to a conserved hormone response element (LXRE) in the promoter of the murine and human Vegfa genes. Both LXRalpha and LXRbeta transactivated the VEGF promoter in transient transfection assays. Finally, we show that induction of VEGF expression by inflammatory stimuli was independent of LXRs, because these effects were preserved in LXR null macrophages. These observations identify VEGF as an LXR target gene and point to a previously unrecognized role for LXRs in vascular biology.	Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Tontonoz, P (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, Box 951662, Los Angeles, CA 90095 USA.	ptontonoz@mednet.ucla.edu		Joseph, Sean/0000-0002-2602-8517	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066088] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-66088] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bamba H, 2000, BIOCHEM BIOPH RES CO, V273, P485, DOI 10.1006/bbrc.2000.2969; BENAV P, 1995, FEBS LETT, V372, P83, DOI 10.1016/0014-5793(95)00956-A; BOEHM MF, 1995, J MED CHEM, V38, P3146, DOI 10.1021/jm00016a018; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; Broxmeyer HE, 1995, INT J HEMATOL, V62, P203; Castrillo A, 2003, J BIOL CHEM, V278, P10443, DOI 10.1074/jbc.M213071200; Celletti FL, 2001, NAT MED, V7, P425, DOI 10.1038/86490; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; CLAFFEY KP, 1992, J BIOL CHEM, V267, P16317; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; Fehrenbach H, 1999, ANAT REC, V254, P61; Flamme I, 1997, J CELL PHYSIOL, V173, P206, DOI 10.1002/(SICI)1097-4652(199711)173:2<206::AID-JCP22>3.0.CO;2-C; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; Gerber HP, 1999, DEVELOPMENT, V126, P1149; Gerber HP, 2002, NATURE, V417, P954, DOI 10.1038/nature00821; Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005; Inoue M, 2001, ARTERIOSCL THROM VAS, V21, P560, DOI 10.1161/01.ATV.21.4.560; Itaya H, 2001, THROMB HAEMOSTASIS, V85, P171, DOI 10.1055/s-0037-1612921; Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299; Jozkowicz A, 2000, ACTA BIOCHIM POL, V47, P1147, DOI 10.18388/abp.2000_3967; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kiriakidis S, 2003, J CELL SCI, V116, P665, DOI 10.1242/jcs.00286; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Leibovich SJ, 2002, AM J PATHOL, V160, P2231, DOI 10.1016/S0002-9440(10)61170-4; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Moulton KS, 2003, P NATL ACAD SCI USA, V100, P4736, DOI 10.1073/pnas.0730843100; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Phillips G D, 1994, In Vivo, V8, P961; Pinhal-Enfield G, 2003, AM J PATHOL, V163, P711, DOI 10.1016/S0002-9440(10)63698-X; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2002, NAT MED, V8, P1243, DOI 10.1038/nm1102-1243; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Tangirala RK, 2002, P NATL ACAD SCI USA, V99, P11896, DOI 10.1073/pnas.182199799; Tontonoz P, 2003, MOL ENDOCRINOL, V17, P985, DOI 10.1210/me.2003-0061; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Xiong M, 1998, AM J PATHOL, V153, P587, DOI 10.1016/S0002-9440(10)65601-5	49	52	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9905	9911		10.1074/jbc.M310587200	http://dx.doi.org/10.1074/jbc.M310587200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699103	hybrid			2022-12-25	WOS:000220050400031
J	Gutierrez-Cirlos, EB; Merbitz-Zahradnik, T; Trumpower, BL				Gutierrez-Cirlos, EB; Merbitz-Zahradnik, T; Trumpower, BL			Inhibition of the yeast cytochrome bc(1) complex by ilicicolin H, a novel inhibitor that acts at the Qn site of the bc(1) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEADY-STATE KINETICS; UBIQUINOL OXIDATION; ELECTRON-TRANSFER; C OXIDOREDUCTASE; MECHANISM; ANTIMYCIN; MITOCHONDRIA; ANALOGS; Q(O)	Ilicicolin H is an antibiotic isolated from the "imperfect" fungus Cylindrocladium iliciola strain MFC-870. Ilicicolin inhibits mitochondrial respiration by inhibiting the cytochrome bc(1) complex. In order to identify the site of ilicicolin action within the bc(1) complex we have characterized the effects of ilicicolin on the cytochrome bc(1) complex of Saccharomyces cerevisiae. Ilicicolin inhibits ubiquinol-cytochrome c reductase activity of the yeast bc(1) complex with an IC50 of 3-5 nM, while 200 - 250 nM ilicicolin was required to obtain comparable inhibition of the bovine bc(1) complex. Ilicicolin blocks oxidation-reduction of cytochrome b through center N of the bc(1) complex and promotes oxidant-induced reduction of cytochrome b but has no effect on oxidation of ubiquinol through center P. These results indicate that ilicicolin binds to the Qn site of the bc(1) complex. Ilicicolin induces a blue shift in the absorption spectrum of ferro-cytochrome b, and titration of the spectral shift indicates binding of one inhibitor molecule per Qn site. The effects of ilicicolin on electron transfer reactions in the bc(1) complex are similar to those of antimycin, another inhibitor that binds to the Qn site of the bc(1) complex. However, because the two inhibitors have different effects on the absorption spectrum of cytochrome b, they differ in their mode of binding to the Qn site.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Trumpower, BL (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, 7200 Vail, Hanover, NH 03755 USA.	Trumpower@Dartmouth.edu	Gutierrez Cirlos, Emma Berta/D-4463-2011; Gutiérrez, Emma/AAG-5191-2021	Gutierrez Cirlos, Emma Berta/0000-0002-6672-1711	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020379, R01GM020379] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 20379] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERDEN JA, 1972, BIOCHIM BIOPHYS ACTA, V256, P199, DOI 10.1016/0005-2728(72)90053-9; BOWYER JR, 1980, FEBS LETT, V115, P171, DOI 10.1016/0014-5793(80)81160-4; Brasseur G, 1996, BBA-BIOENERGETICS, V1275, P61, DOI 10.1016/0005-2728(96)00051-5; CAVAZZONI M, 1993, ARCH BIOCHEM BIOPHYS, V303, P246, DOI 10.1006/abbi.1993.1279; ESPOSTI MD, 1986, EUR J BIOCHEM, V160, P547, DOI 10.1111/j.1432-1033.1986.tb10073.x; Gutierrez-Cirlos EB, 2002, J BIOL CHEM, V277, P1195, DOI 10.1074/jbc.M109097200; HAYAKAWA S, 1971, J ANTIBIOT, V24, P653, DOI 10.7164/antibiotics.24.653; HOWELL N, 1993, BIOCHEMISTRY-US, V32, P11162, DOI 10.1021/bi00092a028; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; KAMENSKY Y, 1985, FEBS LETT, V181, P95, DOI 10.1016/0014-5793(85)81120-0; Kim H, 1999, J AM CHEM SOC, V121, P4902, DOI 10.1021/ja990190h; KUBOTA T, 1992, J BIOCHEM-TOKYO, V111, P91, DOI 10.1093/oxfordjournals.jbchem.a123725; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; Margoliash E, 1967, METHOD ENZYMOL, V10, P339; MATSUMOTO M, 1976, TETRAHEDRON LETT, P3827; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; Palsdottir H, 2003, J BIOL CHEM, V278, P31303, DOI 10.1074/jbc.M302195200; SLATER EC, 1973, BIOCHIM BIOPHYS ACTA, V301, P129, DOI 10.1016/0304-4173(73)90002-5; Snyder C, 1998, BBA-BIOENERGETICS, V1365, P125, DOI 10.1016/S0005-2728(98)00052-8; Snyder CH, 1999, J BIOL CHEM, V274, P31209, DOI 10.1074/jbc.274.44.31209; Snyder CH, 2000, J BIOL CHEM, V275, P13535, DOI 10.1074/jbc.275.18.13535; TANABE M, 1983, TETRAHEDRON, V39, P3569, DOI 10.1016/S0040-4020(01)88667-1; TOKUTAKE N, 1993, BIOCHIM BIOPHYS ACTA, V1142, P262, DOI 10.1016/0005-2728(93)90154-8; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	26	48	50	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8708	8714		10.1074/jbc.M311805200	http://dx.doi.org/10.1074/jbc.M311805200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14670947	hybrid			2022-12-25	WOS:000189265900023
J	Javelle, A; Severi, E; Thornton, J; Merrick, M				Javelle, A; Severi, E; Thornton, J; Merrick, M			Ammonium sensing in Escherichia coli - Role of the ammonium transporter AmtB and AmtB-GlnK complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PROTEIN; GLUTAMINE-SYNTHETASE; MOLECULAR CHARACTERIZATION; GENE-EXPRESSION; REVEALS; PII; VECTORS; HOMOLOG; OPERON; FAMILY	The Amt proteins are high affinity ammonium transporters that are conserved in all domains of life. In bacteria and archaea the Amt structural genes ( amtB) are invariably linked to glnK, which encodes a member of the P-II signal transduction protein family, proteins that regulate many facets of nitrogen metabolism. We have now shown that Escherichia coli AmtB is inactivated by formation of a membrane-bound complex with GlnK. Complex formation is reversible and occurs within seconds in response to micromolar changes in the extracellular ammonium concentration. Regulation is mediated by the uridylylation/deuridylylation of GlnK in direct response to fluctuations in the intracellular glutamine pool. Furthermore under physiological conditions AmtB activity is required for GlnK deuridylylation. Hence the transporter is an integral part of the signal transduction cascade, and AmtB can be formally considered to act as an ammonium sensor. This system provides an exquisitely sensitive mechanism to control ammonium flux into the cell, and the conservation of glnK linkage to amtB suggests that this regulatory mechanism may occur throughout prokaryotes.	John Innes Ctr Plant Sci Res, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Merrick, M (corresponding author), John Innes Ctr Plant Sci Res, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England.	mike.merrick@bbsrc.ac.uk						Arcondeguy T, 2001, MICROBIOL MOL BIOL R, V65, P80, DOI 10.1128/MMBR.65.1.80-105.2001; Atkinson MR, 1998, MOL MICROBIOL, V29, P431, DOI 10.1046/j.1365-2958.1998.00932.x; Atkinson MR, 1999, MOL MICROBIOL, V32, P301, DOI 10.1046/j.1365-2958.1999.01349.x; Atkinson MR, 2002, J BACTERIOL, V184, P5364, DOI 10.1128/JB.184.19.5364-5375.2002; Avent ND, 1996, J BIOL CHEM, V271, P14233, DOI 10.1074/jbc.271.24.14233; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; Blakey D, 2002, BIOCHEM J, V364, P527, DOI 10.1042/BJ20011761; Blauwkamp TA, 2003, MOL MICROBIOL, V48, P1017, DOI 10.1046/j.1365-2958.2003.03479.x; Blauwkamp TA, 2002, MOL MICROBIOL, V46, P203, DOI 10.1046/j.1365-2958.2002.03153.x; Coutts G, 2002, EMBO J, V21, P536, DOI 10.1093/emboj/21.4.536; Forchhammer K, 1999, MOL MICROBIOL, V33, P338, DOI 10.1046/j.1365-2958.1999.01477.x; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Ikeda TP, 1996, J MOL BIOL, V259, P589, DOI 10.1006/jmbi.1996.0342; Jack R, 1999, J BACTERIOL, V181, P1156, DOI 10.1128/JB.181.4.1156-1162.1999; Javelle A, 2003, TRENDS MICROBIOL, V11, P53, DOI 10.1016/S0966-842X(02)00012-4; Javelle A, 2003, MOL MICROBIOL, V47, P411, DOI 10.1046/j.1365-2958.2003.03303.x; Javelle A, 2001, FEBS LETT, V505, P393, DOI 10.1016/S0014-5793(01)02802-2; JAYAKUMAR A, 1986, J BACTERIOL, V166, P281, DOI 10.1128/jb.166.1.281-284.1986; Jiang P, 1998, BIOCHEMISTRY-US, V37, P12782, DOI 10.1021/bi980667m; KLEINER D, 1985, FEMS MICROBIOL LETT, V32, P87, DOI 10.1016/0378-1097(85)90059-X; LIAW SH, 1995, PROTEIN SCI, V4, P2358, DOI 10.1002/pro.5560041114; Little R, 2002, J BIOL CHEM, V277, P15472, DOI 10.1074/jbc.M112262200; Lorenz MC, 1998, EMBO J, V17, P1236, DOI 10.1093/emboj/17.5.1236; Ludewig U, 2003, J BIOL CHEM, V278, P45603, DOI 10.1074/jbc.M307424200; Maharjan RP, 2003, ANAL BIOCHEM, V313, P145; Maheswaran M, 2003, MICROBIOL-SGM, V149, P2163, DOI 10.1099/mic.0.26449-0; Marini AM, 2000, MOL MICROBIOL, V38, P552, DOI 10.1046/j.1365-2958.2000.02151.x; Marini AM, 1997, TRENDS BIOCHEM SCI, V22, P460, DOI 10.1016/S0968-0004(97)01132-8; Marini AM, 2000, NAT GENET, V26, P341, DOI 10.1038/81656; Monahan BJ, 2002, FUNGAL GENET BIOL, V36, P35, DOI 10.1016/S1087-1845(02)00004-X; Plumbridge J, 2002, CURR OPIN MICROBIOL, V5, P187, DOI 10.1016/S1369-5274(02)00296-5; Reyes-Ramirez F, 2001, J BACTERIOL, V183, P3076, DOI 10.1128/JB.183.10.3076-3082.2001; SCHUTT H, 1972, EUR J BIOCHEM, V26, P68, DOI 10.1111/j.1432-1033.1972.tb01740.x; Smith DG, 2003, MOL MICROBIOL, V50, P259, DOI 10.1046/j.1365-2958.2003.03680.x; Thomas G, 2000, TRENDS GENET, V16, P11, DOI 10.1016/S0168-9525(99)01887-9; Thomas GH, 2000, MOL MICROBIOL, V37, P331, DOI 10.1046/j.1365-2958.2000.01994.x; VANDOMMELEN A, 2001, AUST J PLANT PHYSL, V28, P959; vanHeeswijk WC, 1996, MOL MICROBIOL, V21, P133, DOI 10.1046/j.1365-2958.1996.6281349.x; WANG MY, 1993, PLANT PHYSIOL, V103, P1259, DOI 10.1104/pp.103.4.1463; Westhoff CM, 2002, J BIOL CHEM, V277, P12499, DOI 10.1074/jbc.C200060200; Xu YB, 1998, J MOL BIOL, V282, P149, DOI 10.1006/jmbi.1998.1979; Yakunin AF, 2002, J BACTERIOL, V184, P4081, DOI 10.1128/JB.184.15.4081-4088.2002; Zhang YP, 2001, J BACTERIOL, V183, P6159, DOI 10.1128/JB.183.21.6159-6168.2001	43	171	178	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8530	8538		10.1074/jbc.M312399200	http://dx.doi.org/10.1074/jbc.M312399200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14668330	hybrid			2022-12-25	WOS:000189265900003
J	Lee, JS; Hmama, Z; Mui, A; Reiner, NE				Lee, JS; Hmama, Z; Mui, A; Reiner, NE			Stable gene silencing in human monocytic cell lines using lentiviral-delivered small interference RNA - Silencing of the p110 alpha isoform of phosphoinositide 3-kinase reveals differential regulation of adherence induced by 1 alpha,25-dihydroxycholecalciferol and bacterial lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; KINASE-C-ZETA; PHOSPHATIDYLINOSITOL 3-KINASE; MAMMALIAN-CELLS; ADENOASSOCIATED VIRUS; PROTEIN-KINASE; THP-1 CELLS; IN-VIVO; B-CELL; EMBRYONIC LETHALITY	Studying mononuclear phagocyte cell biology through genetic manipulation by non-viral transfection methods has been challenging due to the dual problems of low transfection efficiency and the difficulty in obtaining stable transfection. To overcome this problem, we developed a system for mediating RNA interference in monocytic cells. The p110alpha isoform of phosphoinositide 3-kinases (PI3Ks) was silenced using a lentiviral vector expressing short hairpin RNA (shRNA). This resulted in the generation of stable THP-1 and U-937 monocytic cell lines deficient in p110alpha. Notably, p110alpha was silenced without affecting levels of either the other class I-A PI3K catalytic subunits p110beta and p110delta, or the p85alpha regulatory subunit. The role of p110alpha in mediating cell adherence was examined. Monocyte adherence induced in response to either lipopolysaccharide (LPS) or 1alpha, 25-dihydroxycholecalciferol (D-3) was blocked by the PI3K inhibitor LY294002. However, although adherence induced in response to D3 was sensitive to silencing of p110alpha, LPS-induced adherence was not. Expression of the monocyte differentiation marker CD11b was also induced by D-3 in a PI3K-dependent manner and gene silencing using shRNA showed that p110alpha was also required for this effect. Taken together, these findings demonstrate that LPS and D-3 use distinct isoforms of class IA PI3K to induce functional responses and that lentiviral-mediated delivery of shRNA is a powerful approach to study monocyte biology.	Univ British Columbia, Fac Med, Dept Med, Div Infect Dis, Vancouver, BC V5Z 3J5, Canada; Univ British Columbia, Fac Med, Dept Surg, Vancouver, BC V5Z 3J5, Canada; Univ British Columbia, Fac Med, Dept Microbiol & Immunol, Vancouver, BC V5Z 3J5, Canada; Univ British Columbia, Fac Sci, Vancouver, BC V5Z 3J5, Canada; Vancouver Coastal Hlth Res Inst, Vancouver, BC V5Z 3J5, Canada	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; Vancouver Coastal Health Research Institute	Reiner, NE (corresponding author), Univ British Columbia, Fac Med, Dept Med, Div Infect Dis, Rm 452D,2733 Heather St, Vancouver, BC V5Z 3J5, Canada.	ethan@interchange.ubc.ca						Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Bambacioni F, 2001, HAEMATOLOGICA, V86, P1095; Beeton CA, 2000, BIOCHEM J, V350, P353, DOI 10.1042/0264-6021:3500353; Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; Bi L, 2002, MAMM GENOME, V13, P169, DOI 10.1007/s00335-001-2123-x; Blomer U, 1997, J VIROL, V71, P6641; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Buchschacher GL, 2000, BLOOD, V95, P2499; Burke B, 2002, J LEUKOCYTE BIOL, V72, P417; Clayton E, 2002, J EXP MED, V196, P753, DOI 10.1084/jem.20020805; Dey BR, 1998, GENE, V209, P175, DOI 10.1016/S0378-1119(98)00045-6; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; Ehlers MRW, 2000, MICROBES INFECT, V2, P289, DOI 10.1016/S1286-4579(00)00299-9; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Far RKK, 2003, NUCLEIC ACIDS RES, V31, P4417, DOI 10.1093/nar/gkg649; Farach-Carson MC, 2003, CURR DRUG TARGETS, V4, P67, DOI 10.2174/1389450033347118; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Follenzi Antonia, 2002, Methods Mol Med, V69, P259; Foukas LC, 2003, ARCH BIOCHEM BIOPHYS, V414, P13, DOI 10.1016/S0003-9861(03)00177-2; Fratti RA, 2001, J CELL BIOL, V154, P631, DOI 10.1083/jcb.200106049; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Fukao T, 2002, NAT IMMUNOL, V3, P295, DOI 10.1038/ni768; Funaki M, 1999, J BIOL CHEM, V274, P22019, DOI 10.1074/jbc.274.31.22019; Garcia-Garcia E, 2002, J LEUKOCYTE BIOL, V72, P107; Hamada K, 1998, BIOCHEM BIOPH RES CO, V244, P745, DOI 10.1006/bbrc.1998.8328; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; HerreraVelit P, 1997, J BIOL CHEM, V272, P16445, DOI 10.1074/jbc.272.26.16445; Hewison M, 2001, Rev Endocr Metab Disord, V2, P217, DOI 10.1023/A:1010015013211; HICKSTEIN DD, 1987, J BIOL CHEM, V262, P5576; Hmama Z, 1999, J BIOL CHEM, V274, P1050, DOI 10.1074/jbc.274.2.1050; Hmama Z, 1999, J EXP MED, V190, P1583, DOI 10.1084/jem.190.11.1583; Hohjoh H, 2002, FEBS LETT, V521, P195, DOI 10.1016/S0014-5793(02)02860-0; Introna M, 1998, BRIT J HAEMATOL, V103, P449, DOI 10.1046/j.1365-2141.1998.01020.x; Itou T, 1998, INT J HEMATOL, V67, P27; Janssen JWG, 1998, ONCOGENE, V16, P1767, DOI 10.1038/sj.onc.1201695; Jimenez C, 2002, J BIOL CHEM, V277, P41556, DOI 10.1074/jbc.M205893200; JOCKUSCH BM, 1991, J CELL SCI, P41; Jou ST, 2002, MOL CELL BIOL, V22, P8580, DOI 10.1128/MCB.22.24.8580-8591.2002; Kafri T, 1997, NAT GENET, V17, P314, DOI 10.1038/ng1197-314; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; Kusumawati A, 1999, ANAL BIOCHEM, V269, P219, DOI 10.1006/abio.1999.4024; LEIBBRANDT MEI, 1994, CELL GROWTH DIFFER, V5, P17; Liao HS, 1997, J LIPID RES, V38, P1433; Liu Y, 2000, J INTERF CYTOK RES, V20, P21, DOI 10.1089/107999000312702; Lu-Kuo JM, 2000, J BIOL CHEM, V275, P6022, DOI 10.1074/jbc.275.8.6022; Mauvais-Jarvis F, 2002, J CLIN INVEST, V109, P141, DOI 10.1172/JCI200213305; McGilvray ID, 1998, J SURG RES, V80, P272, DOI 10.1006/jsre.1998.5319; MILLER LJ, 1986, J IMMUNOL, V137, P2891; Miyoshi H, 1997, P NATL ACAD SCI USA, V94, P10319, DOI 10.1073/pnas.94.19.10319; Monick MM, 2000, J IMMUNOL, V165, P4632, DOI 10.4049/jimmunol.165.8.4632; Mountain A, 2000, TRENDS BIOTECHNOL, V18, P119, DOI 10.1016/S0167-7799(99)01416-X; MURAO S, 1983, CANCER RES, V43, P4989; Nakajima H, 1996, LEUKEMIA RES, V20, P665, DOI 10.1016/0145-2126(96)00020-3; Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Norman AW, 2002, MOL CELL ENDOCRINOL, V197, P1, DOI 10.1016/S0303-7207(02)00273-3; Norman AW, 2002, STEROIDS, V67, P457, DOI 10.1016/S0039-128X(01)00167-2; Okkenhaug K, 2002, SCIENCE, V297, P1031; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paddison PJ, 2002, CANCER CELL, V2, P17, DOI 10.1016/S1535-6108(02)00092-2; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Pinette KV, 2003, MINI-REV MED CHEM, V3, P193, DOI 10.2174/1389557033488204; POHLMAN TH, 1986, J IMMUNOL, V136, P4548; POLLA BS, 1986, J CLIN INVEST, V77, P1332, DOI 10.1172/JCI112438; Ponnazhagan S, 2001, J VIROL, V75, P9493, DOI 10.1128/JVI.75.19.9493-9501.2001; Schwende H, 1996, J LEUKOCYTE BIOL, V59, P555, DOI 10.1002/jlb.59.4.555; SHATTOCK RJ, 1993, J VIROL, V67, P3569, DOI 10.1128/JVI.67.6.3569-3575.1993; Shepherd PR, 1997, J BIOL CHEM, V272, P19000, DOI 10.1074/jbc.272.30.19000; Shi Y, 2003, TRENDS GENET, V19, P9, DOI 10.1016/S0168-9525(02)00005-7; Siddhanta U, 1998, J CELL BIOL, V143, P1647, DOI 10.1083/jcb.143.6.1647; SMEDLY LA, 1986, J CLIN INVEST, V77, P1233, DOI 10.1172/JCI112426; Stripecke R, 2000, BLOOD, V96, P1317, DOI 10.1182/blood.V96.4.1317; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; Tiscornia G, 2003, P NATL ACAD SCI USA, V100, P1844, DOI 10.1073/pnas.0437912100; Ueki K, 2002, MOL CELL BIOL, V22, P965, DOI 10.1128/MCB.22.3.965-977.2002; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Vieira OV, 2001, J CELL BIOL, V155, P19, DOI 10.1083/jcb.200107069; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wagner RS, 1996, SHOCK, V5, P41, DOI 10.1097/00024382-199601000-00009; Wymann MP, 2003, TRENDS PHARMACOL SCI, V24, P366, DOI 10.1016/S0165-6147(03)00163-9; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739	85	36	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9379	9388		10.1074/jbc.M310638200	http://dx.doi.org/10.1074/jbc.M310638200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14672955	hybrid			2022-12-25	WOS:000189265900102
J	Morais, MC; Zhang, GF; Zhang, WH; Olsen, DB; Dunaway-Mariano, D; Allen, KN				Morais, MC; Zhang, GF; Zhang, WH; Olsen, DB; Dunaway-Mariano, D; Allen, KN			X-ray crystallographic and site-directed mutagenesis analysis of the mechanism of Schiff-base formation in phosphonoacetaldehyde hydrolase catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-PHOSPHORUS BOND; ACTIVE-SITE; ACETOACETATE DECARBOXYLASE; MOLECULAR REPLACEMENT; SEQUENCE-ANALYSIS; CRYSTAL-STRUCTURE; CLEAVING ENZYME; CLEAVAGE; SUBSTRATE; MODELS	Phosphonoacetaldehyde hydrolase ( phosphonatase) catalyzes the hydrolytic P-C bond cleavage of phosphonoacetaldehyde (Pald) to form orthophosphate and acetaldehyde. The reaction proceeds via a Schiff-base intermediate formed between Lys-53 and the Pald carbonyl. The x-ray crystal structures of the wild-type phosphonatase complexed with Mg(II) alone or with Mg( II) plus vinylsulfonate ( a phosphonoethylenamine analog) were determined to 2.8 and 2.4 Angstrom, respectively. These structures were used to determine the identity and positions of active site residues surrounding the Lys-53 ammonium group and the Pald carbonyl. These include Cys-22, His-56, Tyr-128, and Met-49. Site-directed mutagenesis was then employed to determine whether or not these groups participate in catalysis. Based on rate contributions, Tyr-128 and Cys-22 were eliminated as potential catalytic groups. The Lys-53 epsilon-amino group, positioned for reaction with the Pald carbonyl, forms a hydrogen bond with water 120. Water 120 is also within hydrogen bond distance of an imidazole nitrogen of His-56 and the sulfur atom of Met-49. Kinetic constants for mutants indicated that His-56 (1000-fold reduction in k(cat)/K-m upon Ala substitution) and Met-49 (17,000-fold reduction in k(cat)/K-m upon Leu substitution) function in catalysis of Schiff-base formation. Based on these results, it is proposed that a network of hydrogen bonds among Lys-53, water 120, His-56, and Met-49 facilitate proton transfer from Lys-53 to the carbinolamine intermediate. Comparison of the vinylsulfonate complex versus unliganded structures indicated that association of the cap and core domains is essential for the positioning of the Lys-53 for attack at the Pald carbonyl and that substrate binding at the core domain stabilizes cap domain binding.	Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA; Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA	University of New Mexico; Boston University	Dunaway-Mariano, D (corresponding author), Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA.	dd39@unm.edu; allen@med-xtal.bu.edu	Allen, Karen N./J-7045-2019	Allen, Karen N./0000-0001-7296-0551; olsen, david/0000-0001-5521-0206	NIGMS NIH HHS [GM61099] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061099] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allard J, 2001, P NATL ACAD SCI USA, V98, P3679, DOI 10.1073/pnas.071380898; ALLEN KN, 1998, COMPREHENSIVE BIOL C, P135; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker AS, 1998, BIOCHEMISTRY-US, V37, P9305, DOI 10.1021/bi972677d; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Choi KH, 1999, BIOCHEMISTRY-US, V38, P12655, DOI 10.1021/bi9828371; Choi KH, 2001, BIOCHEMISTRY-US, V40, P13868, DOI 10.1021/bi0114877; GUTHRIE JP, 1967, FED PROC, V26, P562; GUTHRIE JP, 1972, J AM CHEM SOC, V94, P7024, DOI 10.1021/ja00775a027; Heine A, 2001, SCIENCE, V294, P369, DOI 10.1126/science.1063601; Highbarger LA, 1996, BIOCHEMISTRY-US, V35, P41, DOI 10.1021/bi9518306; ISBELL AF, 1969, J ORG CHEM, V34, P755, DOI 10.1021/jo01255a067; JENCKS WP, 1969, CATALYSIS CHEM ENZYM, P121; Jia J, 1997, PROTEIN SCI, V6, P119; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KOKESH FC, 1971, J AM CHEM SOC, V93, P7270, DOI 10.1021/ja00755a025; Kononova SV, 2002, BIOCHEMISTRY-MOSCOW+, V67, P184, DOI 10.1023/A:1014409929875; LANAUZE JM, 1970, BIOCHIM BIOPHYS ACTA, V212, P332, DOI 10.1016/0005-2744(70)90214-7; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MATTHEWS BW, 1985, METHOD ENZYMOL, V114, P176; Maurady A, 2002, J BIOL CHEM, V277, P9474, DOI 10.1074/jbc.M107600200; MCMULLAN G, 1994, J BACTERIOL, V176, P320, DOI 10.1128/JB.176.2.320-324.1994; Morais MC, 2000, ACTA CRYSTALLOGR D, V56, P206, DOI 10.1107/S0907444999015899; Morais MC, 2000, BIOCHEMISTRY-US, V39, P10385, DOI 10.1021/bi001171j; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; OLEARY MH, 1972, J AM CHEM SOC, V94, P626, DOI 10.1021/ja00757a051; OLSEN DB, 1992, ARCH BIOCHEM BIOPHYS, V296, P144, DOI 10.1016/0003-9861(92)90556-C; OLSEN DB, 1988, BIOCHEMISTRY-US, V27, P2229, DOI 10.1021/bi00406a063; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; ROSSMANN MG, 1990, ACTA CRYSTALLOGR A, V46, P73, DOI 10.1107/S0108767389009815; SCHMIDT DE, 1971, BIOCHEMISTRY-US, V10, P1249; Ternan NG, 1998, BIOCHEM BIOPH RES CO, V248, P378, DOI 10.1006/bbrc.1998.8962; VOET D, 1990, BIOCHEMISTRY-US, P62; WACKETT LP, 1987, J BACTERIOL, V169, P710, DOI 10.1128/jb.169.2.710-717.1987; Zhang GF, 2002, BIOCHEMISTRY-US, V41, P13370, DOI 10.1021/bi026388n	37	28	30	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9353	9361		10.1074/jbc.M312345200	http://dx.doi.org/10.1074/jbc.M312345200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14670958	hybrid			2022-12-25	WOS:000189265900099
J	Schaaf, G; Ludewig, U; Erenoglu, BE; Mori, S; Kitahara, T; von Wiren, N				Schaaf, G; Ludewig, U; Erenoglu, BE; Mori, S; Kitahara, T; von Wiren, N			ZmYS1 functions as a proton-coupled symporter for phytosiderophore- and nicotianamine-chelated metals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOPEPTIDE TRANSPORTER; IRON-PHYTOSIDEROPHORES; CALCAREOUS SOIL; H+-COTRANSPORTS; MUGINEIC ACID; PLANT; MAIZE; AFFINITY; ENCODES; ROOTS	Among higher plants graminaceous species have the unique ability to efficiently acquire iron from alkaline soils with low iron solubility by secreting phytosiderophores, which are hexadentate metal chelators with high affinity for Fe(III). Iron(III)-phytosiderophores are subsequently taken up by roots via YS1 transporters, that belong to the OPT oligopeptide transporter family. Despite its physiological importance at alkaline pH, uptake of Fe-phytosiderophores into roots of wild-type maize plants was greater at acidic pH and sensitive to the proton uncoupler CCCP. To access the mechanism of Fe-phytosiderophore acquisition, ZmYS1 was expressed in an iron uptake-defective yeast mutant and in Xenopus oocytes, where ZmYS1-dependent Fe-phytosiderophore transport was stimulated at acidic pH and sensitive to CCCP. Electrophysiological analysis in oocytes demonstrated that Fe-phytosiderophore transport depends on proton cotransport and on the membrane potential, which allows ZmYS1-mediated transport even at alkaline pH. We further investigated substrate specificity and observed that ZmYS1 complemented the growth defect of the zinc uptake-defective yeast mutant zap1 and transported various phytosiderophore-bound metals into oocytes, including zinc, copper, nickel, and, at a lower rate, also manganese and cadmium. Unexpectedly, ZmYS1 also transported Ni(II), Fe( II), and Fe( III) complexes with nicotianamine, a structural analog of phytosiderophores, which has been shown to act as an intracellular metal chelator in all higher plants. Our results show that ZmYS1 encodes a proton-coupled broad-range metal-phytosiderophore transporter that additionally transports Fe- and Ni-nicotianamine. These biochemical properties indicate a novel role of YS1 transporters for heavy metal homeostasis in plants.	Univ Hohenheim, Inst Pflanzenernahrung, D-70593 Stuttgart, Germany; Univ Tubingen, ZMBP Pflanzenphysiol, D-72076 Tubingen, Germany; Univ Tokyo, Lab Plant Mol Physiol, Bunkyo Ku, Tokyo 1138657, Japan; Univ Tokyo, Organ Chem Lab, Bunkyo Ku, Tokyo 1138657, Japan	University Hohenheim; Eberhard Karls University of Tubingen; University of Tokyo; University of Tokyo	von Wiren, N (corresponding author), Univ Hohenheim, Inst Pflanzenernahrung, D-70593 Stuttgart, Germany.	vonwiren@uni-hohenheim.de	Schaaf, Gabriel/F-1956-2014	Schaaf, Gabriel/0000-0001-9022-4515; von Wiren, Nicolaus/0000-0002-4966-425X				Braun V, 1999, TRENDS BIOCHEM SCI, V24, P104, DOI 10.1016/S0968-0004(99)01359-6; Chrispeels MJ, 1999, PLANT CELL, V11, P661, DOI 10.1105/tpc.11.4.661; Connolly EL, 2002, PLANT CELL, V14, P1347, DOI 10.1105/tpc.001263; Curie C, 2001, NATURE, V409, P346, DOI 10.1038/35053080; Eide D, 1996, P NATL ACAD SCI USA, V93, P5624, DOI 10.1073/pnas.93.11.5624; EIDE D, 1992, J GEN MICROBIOL, V138, P347, DOI 10.1099/00221287-138-2-347; Fischer WN, 2002, PLANT J, V29, P717, DOI 10.1046/j.1365-313X.2002.01248.x; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Hauser M, 2000, J BIOL CHEM, V275, P3037, DOI 10.1074/jbc.275.5.3037; Ling HQ, 1999, P NATL ACAD SCI USA, V96, P7098, DOI 10.1073/pnas.96.12.7098; Liu LH, 2003, PLANT CELL, V15, P790, DOI 10.1105/tpc.007120; Lubkowitz MA, 1998, MOL MICROBIOL, V28, P729, DOI 10.1046/j.1365-2958.1998.00827.x; Ludewig U, 2002, J BIOL CHEM, V277, P13548, DOI 10.1074/jbc.M200739200; MA JF, 1993, PHYTOCHEMISTRY, V34, P599, DOI 10.1016/0031-9422(93)85323-J; Marschner H., 1995, MINERAL NUTR HIGHER, V2nd ed.; Miyakoshi K, 2001, TETRAHEDRON, V57, P3355, DOI 10.1016/S0040-4020(01)00215-0; Mizuno D, 2003, PLANT PHYSIOL, V132, P1989, DOI 10.1104/pp.102.019869; NEILANDS JB, 1995, J BIOL CHEM, V270, P26723, DOI 10.1074/jbc.270.45.26723; Pich A, 2001, PLANTA, V213, P967, DOI 10.1007/s004250100573; RENTSCH D, 1995, FEBS LETT, V370, P264, DOI 10.1016/0014-5793(95)00853-2; ROMHELD V, 1986, PLANT PHYSIOL, V80, P175, DOI 10.1104/pp.80.1.175; Romheld V, 2000, J PLANT NUTR, V23, P1857, DOI 10.1080/01904160009382148; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmidt W, 2003, TRENDS PLANT SCI, V8, P188, DOI 10.1016/S1360-1385(03)00048-7; SHI WM, 1988, SOIL SCI PLANT NUTR, V34, P585, DOI 10.1080/00380768.1988.10416473; SHOJIMA S, 1990, PLANT PHYSIOL, V93, P1497, DOI 10.1104/pp.93.4.1497; Spizzo T, 1997, MOL GEN GENET, V256, P547; SUGIURA Y, 1984, STRUCT BOND, V58, P107, DOI 10.1007/BFb0111313; Takahashi M, 2003, PLANT CELL, V15, P1263, DOI 10.1105/tpc.010256; Takahashi M, 2001, NAT BIOTECHNOL, V19, P466, DOI 10.1038/88143; THIBAUD JB, 1988, PLANT PHYSIOL, V88, P1469, DOI 10.1104/pp.88.4.1469; Thomine S, 2000, P NATL ACAD SCI USA, V97, P4991, DOI 10.1073/pnas.97.9.4991; Tolay I, 2001, J EXP BOT, V52, P1093, DOI 10.1093/jexbot/52.358.1093; TOULON V, 1989, PLANTA, V179, P235, DOI 10.1007/BF00393694; TREEBY M, 1989, PLANT SOIL, V114, P217, DOI 10.1007/BF02220801; Vacchina V, 2003, ANAL CHEM, V75, P2740, DOI 10.1021/ac020704m; Vert G, 2002, PLANT CELL, V14, P1223, DOI 10.1105/tpc.001388; von Wiren N, 2000, PLANT PHYSIOL, V124, P1149, DOI 10.1104/pp.124.3.1149; von Wiren N, 1999, PLANT PHYSIOL, V119, P1107, DOI 10.1104/pp.119.3.1107; VONWIREN N, 1994, PLANT PHYSIOL, V106, P71, DOI 10.1104/pp.106.1.71; VONWIREN N, 1995, PHYSIOL PLANTARUM, V93, P611, DOI 10.1111/j.1399-3054.1995.tb05107.x; vonWiren N, 1996, PLANT PHYSIOL, V111, P1119, DOI 10.1104/pp.111.4.1119; WALTER A, 1995, J PLANT NUTR, V18, P1577, DOI 10.1080/01904169509365005; Yen MR, 2001, MICROBIOL-SGM, V147, P2881, DOI 10.1099/00221287-147-11-2881; ZHANG FS, 1991, SOIL SCI PLANT NUTR, V37, P671, DOI 10.1080/00380768.1991.10416935; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044	47	260	286	3	69	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9091	9096		10.1074/jbc.M311799200	http://dx.doi.org/10.1074/jbc.M311799200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14699112	hybrid			2022-12-25	WOS:000189265900070
J	Kim, H; Kwak, NJ; Lee, JY; Choi, BH; Lim, Y; Ko, YJ; Kim, YH; Huh, PW; Lee, KH; Rha, HK; Wang, YP				Kim, H; Kwak, NJ; Lee, JY; Choi, BH; Lim, Y; Ko, YJ; Kim, YH; Huh, PW; Lee, KH; Rha, HK; Wang, YP			Merlin neutralizes the inhibitory effect of Mdm2 on p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR; NEUROFIBROMATOSIS TYPE-2; GENE-PRODUCT; CELL-GROWTH; C-ABL; ONCOPROTEIN MDM2; FEEDBACK LOOP; EXPRESSION; PROMOTES; MUTATION	The stability of p53 tumor suppressor is regulated by Mdm2 via the ubiquitination and proteasome-mediated proteolysis pathway. The c-Abl and PTEN tumor suppressors are known to stabilize p53 by blocking the Mdm2-mediated p53 degradation. This study investigated the correlation between p53 and merlin, a neurofibromatosis 2 ( NF2)-related tumor suppressor, in association with the Mdm2 function. The results showed that merlin increased the p53 stability by inhibiting the Mdm2-mediated degradation of p53, which accompanied the increase in the p53-dependent transcriptional activity. The stabilization of p53 by merlin appeared to be accomplished through Mdm2 degradation, and the N-terminal region of merlin was responsible for this novel activity. This study also showed that overexpression of merlin-induced apoptosis of cells depending preferentially on p53 in response to the serum starvation or a chemotherapeutic agent. These results suggest that merlin could be a positive regulator of p53 in terms of tumor suppressor activity, and provide the promising therapeutic means for treating tumors with non-functional merlin or Mdm2 overexpression.	Catholic Univ Korea, Neurosci Genome Res Ctr, Seoul 137701, South Korea; Catholic Univ Korea, Dept Occupat & Environm Med, Seoul 137701, South Korea; Catholic Univ Korea, Dept Pharmacol, Seoul 137701, South Korea; Catholic Univ Korea, Dept Thorac & Cardiovasc Surg, Seoul 137701, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Lee, KH (corresponding author), Catholic Univ Korea, Neurosci Genome Res Ctr, 505 Banpo Dong, Seoul 137701, South Korea.	Lkh@catholic.ac.kr	Lee, Joo-Yong/AAE-3388-2019	Lee, Joo-Yong/0000-0003-1049-6006				Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Giovannini M, 2000, GENE DEV, V14, P1617; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Han JS, 2000, BIOCHEM BIOPH RES CO, V272, P525, DOI 10.1006/bbrc.2000.2801; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Ikeda K, 1999, J NEUROSURG, V91, P85, DOI 10.3171/jns.1999.91.1.0085; Kim H, 2002, MOL CELLS, V14, P108; Kim JY, 2002, BIOCHEM BIOPH RES CO, V296, P1295, DOI 10.1016/S0006-291X(02)02077-6; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lee H, 1998, J BIOL CHEM, V273, P19786, DOI 10.1074/jbc.273.31.19786; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Schulze KMM, 2002, HUM MOL GENET, V11, P69, DOI 10.1093/hmg/11.1.69; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; SHORT MP, 1994, NEUROFIBROMATOSES PA, P414; Sionov RV, 2001, MOL CELL BIOL, V21, P5869; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Sun CX, 2002, J CELL SCI, V115, P3991, DOI 10.1242/jcs.00094; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; TIKOO A, 1994, J BIOL CHEM, V269, P23387; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; VAN MEIR EG, 1994, CANCER RES, V54, P649; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	39	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7812	7818		10.1074/jbc.M305526200	http://dx.doi.org/10.1074/jbc.M305526200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14679203	Green Published, hybrid			2022-12-25	WOS:000189103300056
J	Nebohacova, M; Maslov, DA; Falick, AM; Simpson, L				Nebohacova, M; Maslov, DA; Falick, AM; Simpson, L			The effect of RNA interference down-regulation of RNA editing 3 '-terminal uridylyl transferase (TUTase) 1 on mitochondrial de novo protein synthesis and stability of respiratory complexes in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; LEISHMANIA-TARENTOLAE; MESSENGER-RNA; KINETOPLASTID MITOCHONDRIA; TRANSLATION PRODUCTS; ALTERNATIVE OXIDASE; GUIDE RNAS; YEAST; IDENTIFICATION; COMPONENTS	Inhibition of RNA editing by down-regulation of expression of the mitochondrial RNA editing TUTase 1 by RNA interference had profound effects on kinetoplast biogenesis in Trypanosoma brucei procyclic cells. De novo synthesis of the apocytochrome b and cytochrome oxidase subunit I proteins was no longer detectable after 3 days of RNAi. The effect on protein synthesis correlated with a decline in the levels of the assembled mitochondrial respiratory complexes III and IV, and also cyanide-sensitive oxygen uptake. The steady-state levels of nuclear-encoded subunits of complexes III and IV were also significantly decreased. Because the levels of the corresponding mRNAs were not affected, the observed effect was likely due to an increased turnover of these imported mitochondrial proteins. This induced protein degradation was selective for components of complexes III and IV, because little effect was observed on components of the F-1 . F-0-ATPase complex and on several other mitochondrial proteins.	Univ Calif Los Angeles, Howard Hughes Med Inst, MacDonald Res Labs 6780, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA; Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Mass Spectrometry Lab, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Riverside; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Simpson, L (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, MacDonald Res Labs 6780, 675 Charles Young Dr S, Los Angeles, CA 90095 USA.	simpson@kdna.ucla.edu	Nebohacova, Martina/I-3937-2014		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009102, R37AI009102] Funding Source: NIH RePORTER; NIAID NIH HHS [AI09102] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alfonzo JD, 1997, NUCLEIC ACIDS RES, V25, P3751, DOI 10.1093/nar/25.19.3751; Aphasizhev R, 2003, P NATL ACAD SCI USA, V100, P10617, DOI 10.1073/pnas.1833120100; Aphasizhev R, 2003, RNA, V9, P62, DOI 10.1261/rna.2134303; Aphasizhev R, 2003, EMBO J, V22, P913, DOI 10.1093/emboj/cdg083; Aphasizhev R, 2002, CELL, V108, P637, DOI 10.1016/S0092-8674(02)00647-5; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BENNE R, 1983, NUCLEIC ACIDS RES, V11, P6925, DOI 10.1093/nar/11.20.6925; BHAT GJ, 1990, CELL, V61, P885, DOI 10.1016/0092-8674(90)90199-O; Bienvenut WV, 2002, PROTEOMICS, V2, P868, DOI 10.1002/1615-9861(200207)2:7<868::AID-PROT868>3.0.CO;2-D; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1990, CELL, V62, P391, DOI 10.1016/0092-8674(90)90375-O; BRALY P, 1974, J PROTOZOOL, V21, P782, DOI 10.1111/j.1550-7408.1974.tb03752.x; Bringaud F, 1995, MOL BIOCHEM PARASIT, V74, P119, DOI 10.1016/0166-6851(95)02486-7; BRINGAUD F, 1995, MOL BIOCHEM PARASIT, V71, P65, DOI 10.1016/0166-6851(95)00023-T; Brown BSV, 2001, MOL BIOCHEM PARASIT, V113, P289, DOI 10.1016/S0166-6851(01)00233-X; BRUN R, 1979, ACTA TROP, V36, P289; Chaudhuri M, 1998, MOL BIOCHEM PARASIT, V95, P53, DOI 10.1016/S0166-6851(98)00091-7; Chaudhuri M, 1996, MOL BIOCHEM PARASIT, V83, P125, DOI 10.1016/S0166-6851(96)02754-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; de Jong L, 2000, FEBS LETT, V483, P62, DOI 10.1016/S0014-5793(00)02086-X; Estevez AM, 1999, GENE, V240, P247, DOI 10.1016/S0378-1119(99)00437-0; Estevez AM, 1999, MOL BIOCHEM PARASIT, V103, P251, DOI 10.1016/S0166-6851(99)00139-5; Fox TD, 1996, EXPERIENTIA, V52, P1130, DOI 10.1007/BF01952112; Glerum DM, 1997, J BIOL CHEM, V272, P19088, DOI 10.1074/jbc.272.30.19088; Glerum DM, 1997, FEBS LETT, V412, P410, DOI 10.1016/S0014-5793(97)00799-0; Grivell LA, 1999, FEBS LETT, V452, P57, DOI 10.1016/S0014-5793(99)00532-3; HAYASHI J, 1990, BIOCHEM BIOPH RES CO, V167, P216, DOI 10.1016/0006-291X(90)91753-F; Horvath A, 2000, J BIOL CHEM, V275, P17160, DOI 10.1074/jbc.M907246199; Horvath A, 2000, SCIENCE, V287, P1639, DOI 10.1126/science.287.5458.1639; Horvath A, 2002, J BIOL CHEM, V277, P7222, DOI 10.1074/jbc.M109715200; Horvath A, 2000, EXP PARASITOL, V96, P160, DOI 10.1006/expr.2000.4564; Kable ML, 1996, SCIENCE, V273, P1189, DOI 10.1126/science.273.5279.1189; Kable ML, 1997, TRENDS BIOCHEM SCI, V22, P162, DOI 10.1016/S0968-0004(97)01041-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARRES CAM, 1977, BIOCHIM BIOPHYS ACTA, V462, P531, DOI 10.1016/0005-2728(77)90099-8; MASLOV DA, 1992, CELL, V70, P459, DOI 10.1016/0092-8674(92)90170-H; Maslov DA, 2002, MOL BIOCHEM PARASIT, V125, P113, DOI 10.1016/S0166-6851(02)00235-9; Panigrahi AK, 2003, J AM SOC MASS SPECTR, V14, P728, DOI 10.1016/S1044-0305(03)00126-0; Panigrahi AK, 2003, RNA, V9, P484, DOI 10.1261/rna.2194603; PRIEST JW, 1993, BIOCHIM BIOPHYS ACTA, V1144, P229, DOI 10.1016/0005-2728(93)90178-I; Sanchirico ME, 1998, EMBO J, V17, P5796, DOI 10.1093/emboj/17.19.5796; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Schnaufer A, 2003, MOL CELL, V12, P307, DOI 10.1016/S1097-2765(03)00286-7; Simpson L, 2003, RNA, V9, P265, DOI 10.1261/rna.2178403; Simpson L, 1998, NUCLEIC ACIDS RES, V26, P170, DOI 10.1093/nar/26.1.170; Stuart K, 2002, MOL MICROBIOL, V45, P591, DOI 10.1046/j.1365-2958.2002.03028.x; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; Tielens AGM, 1998, PARASITOL TODAY, V14, P265, DOI 10.1016/S0169-4758(98)01263-0	49	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7819	7825		10.1074/jbc.M311360200	http://dx.doi.org/10.1074/jbc.M311360200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14681226	hybrid			2022-12-25	WOS:000189103300057
J	Dou, SX; Wang, PY; Xu, HQ; Xi, XG				Dou, SX; Wang, PY; Xu, HQ; Xi, XG			The DNA binding properties of the Escherichia coli RecQ helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; WERNER-SYNDROME PROTEIN; SYNDROME GENE-PRODUCT; NUCLEIC-ACID INTERACTIONS; TOPOISOMERASE-III-ALPHA; FLUORESCENCE ANISOTROPY; EQUILIBRIUM BINDING; REP HELICASE; ILLEGITIMATE RECOMBINATION; REPLICATION CHECKPOINT	The RecQ helicase family is highly conserved from bacteria to men and plays a conserved role in the preservation of genome integrity. Its deficiency in human cells leads to a marked genomic instability that is associated with premature aging and cancer. To determine the thermodynamic parameters for the interaction of Escherichia coli RecQ helicase with DNA, equilibrium binding studies have been performed using the thermodynamic rigorous fluorescence titration technique. Steady-state fluorescence anisotropy measurements of fluorescein-labeled oligonucleotides revealed that RecQ helicase bound to DNA with an apparent binding stoichiometry of 1 protein monomer/10 nucleotides. This stoichiometry was not altered in the presence of AMPPNP (adenosine 5'-(beta,gamma-imido) triphosphate) or ADP. Analyses of RecQ helicase interactions with oligonucleotides of different lengths over a wide range of pH, NaCl, and nucleic acid concentrations indicate that the RecQ helicase has a single strong DNA binding site with an association constant at 25 degreesC of K = 6.7 +/- 0.95 x 10(6) M-1 and a cooperativity parameter of omega = 25.5 +/- 1.2. Both single-stranded DNA and double-stranded DNA bind competitively to the same site. The intrinsic affinities are salt-dependent, and the formation of DNA-helicase complex is accompanied by a net release of 3-4 ions. Allosteric effects of nucleotide cofactors on RecQ binding to DNA were observed only for single-stranded DNA in the presence of 1.5 mm AMPPNP, whereas both AMPPNP and ADP had no detectable effect on double-stranded DNA binding over a large range of nucleotide cofactor concentrations.	Ecole Normale Super, CNRS, UMR 8113, Lab Biotechnol & Pharmacol Genet Appl, F-94235 Cachan, France; Chinese Acad Sci, Inst Phys, Lab Soft Matter Phys, Beijing 100080, Peoples R China	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; Chinese Academy of Sciences; Institute of Physics, CAS	Xi, XG (corresponding author), Ecole Normale Super, CNRS, UMR 8113, Lab Biotechnol & Pharmacol Genet Appl, 61 Ave President Wilson, F-94235 Cachan, France.	xi@lbpa.ens-cachan.fr	王, 鹏业/A-9811-2012; Xi, Xu Guang/AAK-4511-2020; Dou, Shi Xue/D-5179-2012	Dou, Shi Xue/0000-0003-3824-7693; Wang, Peng-Ye/0000-0002-9765-0610; Dou, Shuo-Xing/0000-0002-7201-2081				Bernstein DA, 2003, EMBO J, V22, P4910, DOI 10.1093/emboj/cdg500; Bird LE, 1998, NUCLEIC ACIDS RES, V26, P2686, DOI 10.1093/nar/26.11.2686; Brosh RM, 2001, EMBO J, V20, P5791; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Brosh RM, 2001, J BIOL CHEM, V276, P35093, DOI 10.1074/jbc.M103332200; Bujalowski W, 2000, BIOCHEMISTRY-US, V39, P2106, DOI 10.1021/bi992413m; BUJALOWSKI W, 1987, BIOCHEMISTRY-US, V26, P3099, DOI 10.1021/bi00385a023; BUJALOWSKI W, 1987, J MOL BIOL, V195, P897, DOI 10.1016/0022-2836(87)90493-1; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; EPSTEIN MA, 1978, PROG EXP TUMOR RES, V21, P72; Frei C, 2000, J CELL SCI, V113, P2641; Frei C, 2000, GENE DEV, V14, P81; Freire R, 2001, NUCLEIC ACIDS RES, V29, P3172, DOI 10.1093/nar/29.15.3172; Gourves AS, 2000, J BIOL CHEM, V275, P10864, DOI 10.1074/jbc.275.15.10864; Hanada K, 2000, P NATL ACAD SCI USA, V97, P5989, DOI 10.1073/pnas.100101297; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Harmon FG, 2001, J BIOL CHEM, V276, P232, DOI 10.1074/jbc.M006555200; HEYDUK T, 1993, NATURE, V364, P548, DOI 10.1038/364548a0; HINGORANI MM, 1993, BIOCHEMISTRY-US, V32, P12478, DOI 10.1021/bi00097a028; Jezewska MJ, 1996, J BIOL CHEM, V271, P4261; Jezewska MJ, 2000, BIOCHEMISTRY-US, V39, P10454, DOI 10.1021/bi001113y; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; KOPELMAN M, 1976, BIOCHIM BIOPHYS ACTA, V439, P449, DOI 10.1016/0005-2795(76)90082-9; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; LAHUE EE, 1990, J BACTERIOL, V172, P1385, DOI 10.1128/jb.172.3.1385-1391.1990; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Lohman TM, 1998, CELL, V93, P9, DOI 10.1016/S0092-8674(00)81139-3; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; LOHMAN TM, 1991, METHOD ENZYMOL, V208, P258; Mechanic LE, 1999, J BIOL CHEM, V274, P12488, DOI 10.1074/jbc.274.18.12488; Morris PD, 2001, J BIOL CHEM, V276, P19691, DOI 10.1074/jbc.M010928200; Namsaraev EA, 1998, J BIOL CHEM, V273, P6177, DOI 10.1074/jbc.273.11.6177; Ozers MS, 1997, J BIOL CHEM, V272, P30405, DOI 10.1074/jbc.272.48.30405; PERRINO FW, 1990, MUTAT RES, V236, P289, DOI 10.1016/0921-8777(90)90012-T; Preugschat F, 2000, BIOCHEMISTRY-US, V39, P5174, DOI 10.1021/bi9923860; Sevenich FW, 1998, NUCLEIC ACIDS RES, V26, P1373, DOI 10.1093/nar/26.6.1373; Szekely AM, 2000, P NATL ACAD SCI USA, V97, P11365, DOI 10.1073/pnas.97.21.11365; Tougu K, 1996, J BIOL CHEM, V271, P21398, DOI 10.1074/jbc.271.35.21398; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; Wu L, 2002, NUCLEIC ACIDS RES, V30, P4823, DOI 10.1093/nar/gkf611; Wu X, 2001, NUCLEIC ACIDS RES, V29, P1765, DOI 10.1093/nar/29.8.1765; Xu H, 2001, BIOCHEMISTRY-US, V40, P7651, DOI 10.1021/bi010116n; Xu HQ, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng070; Xu HQ, 2003, J BIOL CHEM, V278, P34925, DOI 10.1074/jbc.M303581200; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	52	50	65	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6354	6363		10.1074/jbc.M311272200	http://dx.doi.org/10.1074/jbc.M311272200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14665634	hybrid			2022-12-25	WOS:000188969200020
J	Lannon, CL; Martin, MJ; Tognon, CE; Jin, W; Kim, SJ; Sorensen, PHB				Lannon, CL; Martin, MJ; Tognon, CE; Jin, W; Kim, SJ; Sorensen, PHB			A highly conserved NTRK3 C-terminal sequence in the ETV6-NTRK3 oncoprotein binds the phosphotyrosine binding domain of insulin receptor substrate-1 - An essential interaction for transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION; GENE FUSION; CONGENITAL FIBROSARCOMA; PROSTATE-CANCER; NEUROTROPHIN RECEPTORS; IRS-1 PHOSPHORYLATION; MESOBLASTIC NEPHROMA; MYELOGENOUS LEUKEMIA	Receptor tyrosine kinases are integral components of cellular signaling pathways and are frequently deregulated in malignancies. The NTRK family of neurotrophin receptors mediate neuronal cell survival and differentiation, but altered NTRK signaling has also been implicated in oncogenesis. The ETV6-NTRK3 (EN) gene fusion occurs in human pediatric spindle cell sarcomas and secretory breast carcinoma, and encodes the oligomerization domain of the ETV6 transcription factor fused to the protein-tyrosine kinase domain of NTRK3. The EN protein functions as a constitutively active protein-tyrosine kinase with potent transforming activity in multiple cell lineages, and EN constitutively activates both the Ras-MAPK and phosphatidylinositol 3-kinase-Akt pathways. EN transformation is associated with constitutive tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1). Further, IRS-1 functions as the adaptor protein linking EN to downstream signaling pathways. However, the exact nature of the EN-IRS-1 interaction remains unknown. We now demonstrate that EN specifically binds the phosphotyrosine binding domain of IRS-1 via an interaction at the C terminus of EN. An EN mutant lacking the C-terminal 19 amino acids does not bind IRS-1 and lacks transforming ability. Moreover, expression of an IRS-1 polypeptide containing the phosphotyrosine binding domain acts in a dominant negative manner to inhibit EN transformation, and overexpression of IRS-1 potentiates EN transforming activity. These findings indicate that EN-IRS-1 complex formation through the NTRK3 C terminus is essential for EN transformation.	British Columbia Res Inst Childrens & Womens Hlth, Dept Pathol, Vancouver, BC V5Z 4H4, Canada; British Columbia Res Inst Childrens & Womens Hlth, Dept Pediat, Vancouver, BC V5Z 4H4, Canada; Univ British Columbia, Vancouver, BC V5Z 4H4, Canada; NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA	University of British Columbia; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Sorensen, PHB (corresponding author), British Columbia Res Inst Childrens & Womens Hlth, Dept Pathol, Rm 3082,950 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	psor@interchange.ubc.ca		, Matthew/0000-0002-8948-961X	NATIONAL CANCER INSTITUTE [Z01BC005617] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; BONGARZONE I, 1989, ONCOGENE, V4, P1457; Chang Q, 2002, CANCER RES, V62, P6035; Eguchi M, 1999, BLOOD, V93, P1355, DOI 10.1182/blood.V93.4.1355; Giovannone B, 2000, DIABETES-METAB RES, V16, P434, DOI 10.1002/1520-7560(2000)9999:9999<::AID-DMRR159>3.0.CO;2-8; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GUITON M, 1995, J BIOL CHEM, V270, P20384, DOI 10.1074/jbc.270.35.20384; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Hallberg B, 1998, ONCOGENE, V17, P691, DOI 10.1038/sj.onc.1201980; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; Hisaoka M, 2002, J PATHOL, V197, P661, DOI 10.1002/path.1138; Ito T, 1996, MOL CELL BIOL, V16, P943; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Knezevich SR, 1998, CANCER RES, V58, P5046; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Lassak A, 2002, J BIOL CHEM, V277, P17231, DOI 10.1074/jbc.M110885200; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Liu Q, 2000, EMBO J, V19, P1827, DOI 10.1093/emboj/19.8.1827; Melck D, 2000, ENDOCRINOLOGY, V141, P118, DOI 10.1210/en.141.1.118; Meshinchi S, 2003, BLOOD, V102, P1474, DOI 10.1182/blood-2003-01-0137; Miknyoczki SJ, 1999, INT J CANCER, V81, P417, DOI 10.1002/(SICI)1097-0215(19990505)81:3<417::AID-IJC16>3.0.CO;2-6; Miranda C, 2001, J CELL PHYSIOL, V186, P35; Morrison KB, 2002, ONCOGENE, V21, P5684, DOI 10.1038/sj.onc.1205669; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; NALDINI L, 1986, MOL CELL BIOL, V6, P1803, DOI 10.1128/MCB.6.5.1803; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; Pahlman S, 1996, MOL MED TODAY, V2, P432, DOI 10.1016/1357-4310(96)84847-7; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; REINACH FC, 1986, NATURE, V322, P648, DOI 10.1038/322648a0; Reiss K, 2000, ONCOGENE, V19, P2687, DOI 10.1038/sj.onc.1203587; Reuther GW, 2000, MOL CELL BIOL, V20, P8655, DOI 10.1128/MCB.20.23.8655-8666.2000; Rubin BP, 1998, AM J PATHOL, V153, P1451, DOI 10.1016/S0002-9440(10)65732-X; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Tanaka S, 1996, J BIOL CHEM, V271, P14610, DOI 10.1074/jbc.271.24.14610; Tanaka S, 1996, CANCER RES, V56, P3391; Tognon C, 2001, CANCER RES, V61, P8909; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0; Traina F, 2003, FEBS LETT, V535, P17, DOI 10.1016/S0014-5793(02)03845-0; Wai DH, 2000, ONCOGENE, V19, P906, DOI 10.1038/sj.onc.1203396; Walch ET, 1999, CLIN EXP METASTAS, V17, P307, DOI 10.1023/A:1006652605568; Weeraratna AT, 2000, PROSTATE, V45, P140, DOI 10.1002/1097-0045(20001001)45:2<140::AID-PROS8>3.0.CO;2-#; Weng LP, 2001, HUM MOL GENET, V10, P605, DOI 10.1093/hmg/10.6.605; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; WHITE MF, 1997, DIABETOLOGIA, V40, P2; Yan KS, 2002, FEBS LETT, V513, P67, DOI 10.1016/S0014-5793(01)03305-1; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300	52	52	53	5	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6225	6234		10.1074/jbc.M307388200	http://dx.doi.org/10.1074/jbc.M307388200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14668342	hybrid			2022-12-25	WOS:000188969200006
J	Zou, Y; Jung, KJ; Kim, JW; Yu, BP; Chung, HY				Zou, Y; Jung, KJ; Kim, JW; Yu, BP; Chung, HY			Alteration of soluble adhesion molecules during aging and their modulation by calorie restriction	FASEB JOURNAL			English	Article						vascular aging; inflammation; oxidative stress; endothelial cells; reactive oxygen/nitrogen species	OXIDATIVE STRESS; DIETARY RESTRICTION; INFLAMMATION HYPOTHESIS; XANTHINE-OXIDASE; HEART-DISEASE; LUNG-CELLS; AGE; PLASMA; INHALATION; ENDOTOXIN	To investigate the status of soluble adhesion molecules (sAMs) during aging, the present study determined protein levels of several major sAMs in serum samples obtained from rats at different ages. These sAMs include E-selection, P-selection, vascular cell adhesion molecule 1 (VCAM-1), and intercellular adhesion molecule 1 (ICAM-1) Fischer 344 rats, ages 6, 12, 18, and 24 months, fed ad libitum (AL) and calorie restricted (CR) diets were used in this study. Analysis by Western blotting showed that the levels of all sAMs studied increased during aging in AL rats, but were effectively blunted in the CR rats. Total reactive oxygen species/reactive nitrogen species (ROS/RNS) levels were measured by fluorescent probe 2',7'-dichlorofluorescin diacetate. Increased ROS/RNS levels were found to coincide with increase levels of superoxide-generating xanthine oxidase in serum during aging, but were found suppressed by CR. Increases in sAMs levels were duplicated in another experiment in which young (13-month-old) and old (31-month-old) rats were injected with proinflammatory lipopolysaccharide. These findings suggest that the altered expressions of sAMs may be due to increased oxidative stress with advanced age and that these increases were prevented by CR through its antioxidative action.	Pusan Natl Univ, Coll Pharm, Dept Pharm, Pusan 609735, South Korea; Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA	Pusan National University; University of Texas System; University of Texas Health San Antonio	Chung, HY (corresponding author), Pusan Natl Univ, Coll Pharm, Dept Pharm, 30 Jangjeon Dong, Pusan 609735, South Korea.	hyjung@pusan.ac.kr	zou, yani/F-6361-2011					BERTRAND HA, 1999, METHODS AGING RES, P271; Brown AA, 2001, AM J CLIN NUTR, V73, P673; Calingasan NY, 2000, BRAIN RES, V885, P62, DOI 10.1016/S0006-8993(00)02933-4; CATHCART R, 1984, METHOD ENZYMOL, V105, P352; Chung H Y, 1999, J Nutr Health Aging, V3, P19; Chung HY, 1997, AGE, V20, P127, DOI 10.1007/s11357-997-0012-2; Chung HY, 2002, MICROSC RES TECHNIQ, V59, P264, DOI 10.1002/jemt.10203; Chung HY, 2001, ANN NY ACAD SCI, V928, P327; DEROCHEMONTEIXGALVE B, 1991, INFECT IMMUN, V59, P3646, DOI 10.1128/IAI.59.10.3646-3650.1991; Droge W, 2002, EXP GERONTOL, V37, P1333, DOI 10.1016/S0531-5565(02)00175-4; Espinosa-Heidmann DG, 2002, INVEST OPHTH VIS SCI, V43, P1567; Galis ZS, 2002, CIRC RES, V90, P251, DOI 10.1161/res.90.3.251; Guo ZM, 2002, MECH AGEING DEV, V123, P1121, DOI 10.1016/S0047-6374(02)00008-8; HABIB A, 1993, J BIOL CHEM, V268, P32448; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Hawes E M, 1993, Am J Cardiovasc Pathol, V4, P326; Heinz A, 2003, PSYCHOPHARMACOLOGY, V165, P111, DOI 10.1007/s00213-002-1244-6; HSIEH V, 1994, INT ARCH ALLERGY IMM, V104, P42, DOI 10.1159/000236707; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARTIGUEMATTEI C, 1990, J CHROMATOGR-BIOMED, V529, P93, DOI 10.1016/S0378-4347(00)83810-4; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Lowe JB, 1997, J CLIN INVEST, V100, pS47; Lyons PD, 1998, GLIA, V22, P103, DOI 10.1002/(SICI)1098-1136(199802)22:2<103::AID-GLIA1>3.0.CO;2-8; Marin J, 1999, EXP GERONTOL, V34, P503, DOI 10.1016/S0531-5565(99)00029-7; Miles EA, 2001, CLIN SCI, V100, P91, DOI 10.1042/CS20000198; Morisaki N, 1997, ATHEROSCLEROSIS, V131, P43, DOI 10.1016/S0021-9150(97)06083-8; Mukherjee P, 2002, BRIT J CANCER, V86, P1615, DOI 10.1038/sj.bjc.6600298; Nash MC, 1996, CLIN EXP IMMUNOL, V103, P167, DOI 10.1046/j.1365-2249.1996.925616.x; Nielsen VG, 1996, AM J RESP CRIT CARE, V154, P1364, DOI 10.1164/ajrccm.154.5.8912749; Pu FR, 2002, BIOMATERIALS, V23, P4705, DOI 10.1016/S0142-9612(02)00219-3; Purschwitz K, 2001, Z GERONTOL GERIATR, V34, P476, DOI 10.1007/s003910170022; Radi ZA, 2001, J VET INTERN MED, V15, P516, DOI 10.1892/0891-6640(2001)015&lt;0516:CAMLTA&gt;2.3.CO;2; Ridker PM, 1998, LANCET, V351, P88, DOI 10.1016/S0140-6736(97)09032-6; SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4; Yu BP, 2001, DIABETES RES CLIN PR, V54, pS73, DOI 10.1016/S0168-8227(01)00338-2; Yu BP, 1996, FREE RADICAL BIO MED, V21, P651, DOI 10.1016/0891-5849(96)00162-1; YU BP, 1985, J GERONTOL, V40, P657, DOI 10.1093/geronj/40.6.657; Zaremba Jaroslaw, 2002, Folia Morphol (Warsz), V61, P1	38	88	90	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					320	+		10.1096/fj.03-0849fje	http://dx.doi.org/10.1096/fj.03-0849fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14688195				2022-12-25	WOS:000188067500001
J	Hausmann, S; Erdjument-Bromage, H; Shuman, S				Hausmann, S; Erdjument-Bromage, H; Shuman, S			Schizosaccharomyces pombe carboxyl-terminal domain (CTD) phosphatase Fcp1 - Distributive mechanism, minimal CTD substrate, and active site mapping	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; T4 POLYNUCLEOTIDE KINASE; PHOSPHOSERINE PHOSPHATASE; SACCHAROMYCES-CEREVISIAE; PROTEIN PHOSPHATASE; TRANSCRIPTION ELONGATION; MUTATIONAL ANALYSIS; CAPPING ENZYME; REPAIR ENZYME; PHOSPHORYLATION	Schizosaccharomyces pombe Fcp1 is an essential protein serine phosphatase that preferentially dephosphorylates Ser(2) of the RNA polymerase II C-terminal domain (CTD) heptad repeat (YSPTSPS7)-S-1-P-2-T-3-S-4-P-5-S-6. Here we show that: (i) Fcp1 acts distributively during the hydrolysis of substrates containing tandem Ser(2)-PO4 heptads; (ii) the minimal optimal CTD substrate for Fcp1 is a single heptad of phasing (SPSYSPT4)-P-5-S-6-Y-7-S-1-P-2-T-3; and (iii) single alanine mutations of flanking residues Tyr(1) or Pro(3) result in 6-fold decrements in CTD phosphatase activity. Fcp1 belongs to the DXDX(T/V) family of phosphotransferases that act via an acyl-phosphoenzyme intermediate. An alanine scan of 11 conserved positions of S. pombe Fcp1 identifies Thr(174), Tyr(237), Thr(243), and Tyr(249) as important for phosphatase activity. Structure-activity relationships at these positions were determined by introducing conservative substitutions. Our results, together with previous mutational studies, highlight a constellation of 11 amino acids that are conserved in all Fcp1 orthologs and likely comprise the active site.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org		Erdjument-Bromage, Hediye/0000-0003-0224-3594	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052470] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA08748] Funding Source: Medline; NIGMS NIH HHS [GM52470] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allegrin S, 2001, J BIOL CHEM, V276, P33526, DOI 10.1074/jbc.M104088200; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; Archambault J, 1998, J BIOL CHEM, V273, P27593, DOI 10.1074/jbc.273.42.27593; Archambault J, 1997, P NATL ACAD SCI USA, V94, P14300, DOI 10.1073/pnas.94.26.14300; Bentley D, 2002, CURR OPIN CELL BIOL, V14, P336, DOI 10.1016/S0955-0674(02)00333-2; Chambers RS, 1996, J BIOL CHEM, V271, P24498, DOI 10.1074/jbc.271.40.24498; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Cho H, 2001, P NATL ACAD SCI USA, V98, P8525, DOI 10.1073/pnas.131213698; Cho H, 1999, GENE DEV, V13, P1540, DOI 10.1101/gad.13.12.1540; Collet JF, 1999, J BIOL CHEM, V274, P33985, DOI 10.1074/jbc.274.48.33985; Collet JF, 1998, J BIOL CHEM, V273, P14107, DOI 10.1074/jbc.273.23.14107; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; Fabrega C, 2003, MOL CELL, V11, P1549, DOI 10.1016/S1097-2765(03)00187-4; Friedl EM, 2003, P NATL ACAD SCI USA, V100, P2328, DOI 10.1073/pnas.2628049100; Galburt EA, 2002, STRUCTURE, V10, P1249, DOI 10.1016/S0969-2126(02)00835-3; Hausmann S, 2002, J BIOL CHEM, V277, P21213, DOI 10.1074/jbc.M202056200; Hausmann S, 2003, J BIOL CHEM, V278, P13627, DOI 10.1074/jbc.M213191200; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; Karagiannis J, 2001, J CELL SCI, V114, P2929; Kimura M, 2002, MOL CELL BIOL, V22, P1577, DOI 10.1128/MCB.22.5.1577-1588.2002; Kobor MS, 2000, MOL CELL BIOL, V20, P7438, DOI 10.1128/MCB.20.20.7438-7449.2000; Kobor MS, 1999, MOL CELL, V4, P55, DOI 10.1016/S1097-2765(00)80187-2; Kobor MS, 2002, BBA-GENE STRUCT EXPR, V1577, P261, DOI 10.1016/S0167-4781(02)00457-8; Koiwa H, 2002, P NATL ACAD SCI USA, V99, P10893, DOI 10.1073/pnas.112276199; Lahiri SD, 2003, SCIENCE, V299, P2067, DOI 10.1126/science.1082710; Lin PS, 2002, J BIOL CHEM, V277, P45949, DOI 10.1074/jbc.M208588200; Lin PS, 2002, PROG NUCLEIC ACID RE, V72, P333, DOI 10.1016/S0079-6603(02)72074-6; Palancade B, 2003, EUR J BIOCHEM, V270, P3859, DOI 10.1046/j.1432-1033.2003.03794.x; Palancade B, 2002, J BIOL CHEM, V277, P36061, DOI 10.1074/jbc.M205192200; Palancade B, 2001, MOL CELL BIOL, V21, P6359, DOI 10.1128/MCB.21.19.6359-6368.2001; Pei Y, 2001, J BIOL CHEM, V276, P28075, DOI 10.1074/jbc.M102170200; Pei Y, 2001, NUCLEIC ACIDS RES, V29, P387, DOI 10.1093/nar/29.2.387; Prelich G, 2002, EUKARYOT CELL, V1, P153, DOI 10.1128/EC.1.2.153-162.2002; Takagi T, 2002, EUKARYOT CELL, V1, P448, DOI 10.1128/EC.1.3.448-457.2002; Thaller MC, 1998, PROTEIN SCI, V7, P1647, DOI 10.1002/pro.5560070722; Varon R, 2003, NAT GENET, V35, P185, DOI 10.1038/ng1243; Wang LK, 2002, NUCLEIC ACIDS RES, V30, P1073, DOI 10.1093/nar/30.4.1073; Wang LK, 2002, EMBO J, V21, P3873, DOI 10.1093/emboj/cdf397; Wang LK, 2001, J BIOL CHEM, V276, P26868, DOI 10.1074/jbc.M103663200; Wang WR, 2002, J MOL BIOL, V319, P421, DOI 10.1016/S0022-2836(02)00324-8; Washington K, 2002, J BIOL CHEM, V277, P40442, DOI 10.1074/jbc.M205687200; Xu YX, 2003, GENE DEV, V17, P2765, DOI 10.1101/gad.1135503; Yeo M, 2003, J BIOL CHEM, V278, P26078, DOI 10.1074/jbc.M301791200; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753	46	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10892	10900		10.1074/jbc.M312513200	http://dx.doi.org/10.1074/jbc.M312513200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701811	hybrid			2022-12-25	WOS:000220157600010
J	Li, QM; Sudhof, TC				Li, QM; Sudhof, TC			Cleavage of amyloid-beta precursor protein and amyloid-beta precursor-like protein by BACE 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; CELL-SURFACE PROTEINS; ALZHEIMERS-DISEASE; GAMMA-SECRETASE; INTRACELLULAR DOMAIN; TERMINAL FRAGMENT; ASPARTYL PROTEASE; FE65 PROTEIN; APP GENE; FAMILY	Site-specific proteolysis of the amyloid-beta precursor protein (APP) by BACE 1 and gamma-secretase, a central event in Alzheimer disease, releases a large secreted extracellular fragment ( called APPS), peptides of 40 - 43 residues derived from extracellular and transmembrane sequences (Abeta), and a short intracellular fragment ( APP intracellular domain) that may function as a transcriptional activator in a complex with the adaptor protein Fe65 and the nuclear protein Tip60. APP is closely related to APP-like protein (APLP) 1 and APLP2, but only APP is known to be cleaved by BACE 1 and to be involved in Alzheimer disease. We now demonstrate that similar to APP, APLP1 and APLP2 are also cleaved by BACE 1 but not by ADAM 9, another APP protease, and also transactivate nuclear Tip60 in a complex with Fe65. Paradoxically, although BACE 1 cleavage appears to be specific for APP and APLPs, their cleavage sequences exhibit no homology, and a short sequence ( 7 amino acids) from APP that when placed close to the membrane converts a membrane protein that is normally not cleaved by BACE 1 into a BACE 1 substrate. Our data demonstrate that APLPs and APP are processed similarly to act via the same nuclear target, suggesting that BACE 1 cleavage regulates a common function of APP and APLPs in neurons.	Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75390 USA.	Thomas.Sudhof@UTSouthwestern.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH069585] Funding Source: NIH RePORTER; NIMH NIH HHS [R01-MH69585-01] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Bayer TA, 1999, MOL PSYCHIATR, V4, P524, DOI 10.1038/sj.mp.4000552; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356; Biederer T, 2002, J NEUROSCI, V22, P7340; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; Duilio A, 1998, BIOCHEM J, V330, P513, DOI 10.1042/bj3300513; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Fortini ME, 2001, CURR OPIN CELL BIOL, V13, P627, DOI 10.1016/S0955-0674(00)00261-1; Gao YH, 2001, P NATL ACAD SCI USA, V98, P14979, DOI 10.1073/pnas.261463298; Gruninger-Leitch F, 2002, J BIOL CHEM, V277, P4687, DOI 10.1074/jbc.M109266200; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Heber S, 2000, J NEUROSCI, V20, P7951; Hotoda N, 2002, BIOCHEM BIOPH RES CO, V293, P800, DOI 10.1016/S0006-291X(02)00302-9; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; Kitazume S, 2003, J BIOL CHEM, V278, P14865, DOI 10.1074/jbc.M206262200; KOO EH, 1994, J BIOL CHEM, V269, P17386; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leissring MA, 2002, P NATL ACAD SCI USA, V99, P4697, DOI 10.1073/pnas.072033799; Lichtenthaler SF, 2003, J BIOL CHEM, V278, P48713, DOI 10.1074/jbc.M303861200; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; McLoughlin DM, 1996, FEBS LETT, V397, P197; Moechars D, 1996, EMBO J, V15, P1265, DOI 10.1002/j.1460-2075.1996.tb00468.x; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; PANGALOS MN, 1995, J NEUROCHEM, V65, P762; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Sandbrink R, 1996, ANN NY ACAD SCI, V777, P281, DOI 10.1111/j.1749-6632.1996.tb34433.x; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; SCHAEGGER H, 1978, ANAL BIOCHEM, V166, P368; Scheinfeld MH, 2002, J BIOL CHEM, V277, P44195, DOI 10.1074/jbc.M208110200; Scholefield Z, 2003, J CELL BIOL, V163, P97, DOI 10.1083/jcb.200303059; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Sisodia SS, 1996, ANN NY ACAD SCI, V777, P77, DOI 10.1111/j.1749-6632.1996.tb34404.x; SPRECHER CA, 1993, BIOCHEMISTRY-US, V32, P4481, DOI 10.1021/bi00068a002; Steiner H, 2001, J MOL NEUROSCI, V17, P193, DOI 10.1385/JMN:17:2:193; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1994, J BIOL CHEM, V269, P11987; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walsh DM, 2003, BIOCHEMISTRY-US, V42, P6664, DOI 10.1021/bi027375c; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; Wolfe MS, 2001, J BIOL CHEM, V276, P5413, DOI 10.1074/jbc.R000026200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200	58	190	191	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10542	10550		10.1074/jbc.M310001200	http://dx.doi.org/10.1074/jbc.M310001200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699153	hybrid			2022-12-25	WOS:000220050400107
J	Cook, JG; Chasse, DAD; Nevins, JR				Cook, JG; Chasse, DAD; Nevins, JR			The regulated association of Cdt1 with minichromosome maintenance proteins and Cdc6 in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; EUKARYOTIC DNA-REPLICATION; NUCLEOTIDE-BINDING SITE; LICENSING FACTOR CDT1; S-PHASE; SACCHAROMYCES-CEREVISIAE; NUCLEAR-LOCALIZATION; FISSION YEAST; BUDDING YEAST; MCM-PROTEINS	Chromosomal DNA replication requires the recruitment of the six-subunit minichromosome maintenance (Mcm) complex to chromatin through the action of Cdc6 and Cdt1. Although considerable work has described the functions of Cdc6 and Cdt1 in yeast and biochemical systems, evidence that their mammalian counterparts are subject to distinct regulation suggests the need to further explore the molecular relationships involving Cdc6 and Cdt1. Here we demonstrate that Cdc6 and Cdt1 are mutually dependent on one another for loading Mcm complexes onto chromatin in mammalian cells. The association of Cdt1 with Mcm2 is regulated by cell growth. Mcm2 prepared from quiescent cells associates very weakly with Cdt1, whereas Mcm2 from serum-stimulated cells associates with Cdt1 much more efficiently. Cdc6, which normally accumulates as cells progress from quiescence into G(1), is capable of inducing the binding of Mcm2 to Cdt1 when ectopically expressed in quiescent cells. We further show that Cdc6 physically associates with Cdt1 via its N-terminal noncatalytic domain, a region we had previously shown to be essential for Cdc6 function. Cdt1 activity is inhibited by the geminin protein, and we provide evidence that the mechanism of this inhibition involves blocking the binding of Cdt1 to both Mcm2 and Cdc6. These results identify novel molecular functions for both Cdc6 and geminin in controlling the association of Cdt1 with other components of the replication apparatus and indicate that the association of Cdt1 with the Mcm complex is controlled as cells exit and reenter the cell cycle.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Mol Genet & Microbiol, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute	Nevins, JR (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Mol Genet & Microbiol, Box 3054, Durham, NC 27710 USA.	jnevins@duke.edu		Cook, Jeanette/0000-0003-0849-7405	NCI NIH HHS [1 K01 CA094907-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA094907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Bastians H, 1999, MOL BIOL CELL, V10, P3927, DOI 10.1091/mbc.10.11.3927; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Berger C, 1999, CYTOGENET CELL GENET, V86, P307, DOI 10.1159/000015324; Blow JJ, 2001, EMBO J, V20, P3293, DOI 10.1093/emboj/20.13.3293; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Cook JG, 2002, P NATL ACAD SCI USA, V99, P1347, DOI 10.1073/pnas.032677499; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DELMOLINO LM, 2001, J BIOL CHEM, V9, P9; Devault A, 2002, CURR BIOL, V12, P689, DOI 10.1016/S0960-9822(02)00768-6; Diffley JFX, 2002, J CELL SCI, V115, P869; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Gopalakrishnan V, 2001, P NATL ACAD SCI USA, V98, P13114, DOI 10.1073/pnas.221467598; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Herbig U, 1999, MOL BIOL CELL, V10, P2631, DOI 10.1091/mbc.10.8.2631; Higa LAA, 2003, NAT CELL BIOL, V5, P1008, DOI 10.1038/ncb1061; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; Labib K, 1999, NAT CELL BIOL, V1, P415, DOI 10.1038/15649; Li CJ, 2002, MOL CELL BIOL, V22, P105, DOI 10.1128/MCB.22.1.105-116.2002; Li XH, 2003, J BIOL CHEM, V278, P30854, DOI 10.1074/jbc.C300251200; Luo KQ, 2003, BIOCHEM BIOPH RES CO, V306, P851, DOI 10.1016/S0006-291X(03)01082-9; Madine MA, 2000, J STRUCT BIOL, V129, P198, DOI 10.1006/jsbi.2000.4218; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; Mihaylov IS, 2002, MOL CELL BIOL, V22, P1868, DOI 10.1128/MCB.22.6.1868-1880.2002; MUSAHL C, 1995, EUR J BIOCHEM, V230, P1096, DOI 10.1111/j.1432-1033.1995.tb20660.x; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nevins JR, 1997, METHOD ENZYMOL, V283, P205; Nishitani H, 2002, GENES CELLS, V7, P523, DOI 10.1046/j.1365-2443.2002.00544.x; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; Pelizon C, 2000, GENE DEV, V14, P2526, DOI 10.1101/gad.176300; Pelizon C, 2003, TRENDS CELL BIOL, V13, P110, DOI 10.1016/S0962-8924(03)00024-2; Perkins G, 1998, MOL CELL, V2, P23, DOI 10.1016/S1097-2765(00)80110-0; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Quinn LM, 2001, GENE DEV, V15, P2741, DOI 10.1101/gad.916201; Rialland M, 2002, J CELL SCI, V115, P1435; Ritzi M, 2000, GENE, V245, P13, DOI 10.1016/S0378-1119(00)00020-2; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; SCHULTE D, 1995, J CELL SCI, V108, P1381; Shreeram S, 2002, ONCOGENE, V21, P6624, DOI 10.1038/sj.onc.1205910; Stoeber K, 1998, EMBO J, V17, P7219, DOI 10.1093/emboj/17.24.7219; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Takisawa H, 2000, CURR OPIN CELL BIOL, V12, P690, DOI 10.1016/S0955-0674(00)00153-8; Tanaka S, 2002, NAT CELL BIOL, V4, P198, DOI 10.1038/ncb757; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Tatsumi Y, 2003, J BIOL CHEM, V278, P41528, DOI 10.1074/jbc.M307534200; TODOROV IT, 1994, J CELL SCI, V107, P253; Tsuruga H, 1997, BIOCHEM BIOPH RES CO, V236, P118, DOI 10.1006/bbrc.1997.6865; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Wang B, 1999, J BIOL CHEM, V274, P8291, DOI 10.1074/jbc.274.12.8291; Weinreich M, 1999, P NATL ACAD SCI USA, V96, P441, DOI 10.1073/pnas.96.2.441; Whittaker AJ, 2000, GENE DEV, V14, P1765; Williams RS, 1997, P NATL ACAD SCI USA, V94, P142, DOI 10.1073/pnas.94.1.142; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; Yanagi K, 2002, J BIOL CHEM, V277, P40871, DOI 10.1074/jbc.M206202200; Yanow SK, 2001, EMBO J, V20, P4648, DOI 10.1093/emboj/20.17.4648	66	83	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9625	9633		10.1074/jbc.M311933200	http://dx.doi.org/10.1074/jbc.M311933200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14672932	hybrid			2022-12-25	WOS:000189265900130
J	Fujimoto, Z; Kaneko, S; Kuno, A; Kobayashi, H; Kusakabe, I; Mizuno, H				Fujimoto, Z; Kaneko, S; Kuno, A; Kobayashi, H; Kusakabe, I; Mizuno, H			Crystal structures of decorated xylooligosaccharides bound to a family 10 xylanase from Streptomyces olivaceoviridis E-86	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F/10 XYLANASE; BINDING DOMAIN; BETA-XYLANASE; MODULE; CEX; SPECIFICITY; SEQUENCE; CLASSIFICATION; ASSOCIATION; MECHANISMS	The family 10 xylanase from Streptomyces olivaceoviridis E-86 (SoXyn10A) consists of a GH10 catalytic domain, which is joined by a Gly/Pro-rich linker to a family 13 carbohydrate-binding module (CBM13) that interacts with xylan. To understand how GH10 xylanases and CBM13 recognize decorated xylans, the crystal structure of SoXyn10A was determined in complex with alpha-L-arabinofuranosyl- and 4-O-methyl-alpha-D-glucuronosyl-xylooligosaccharides. The bound sugars were observed in the subsites of the catalytic cleft and also in subdomains alpha and gamma of CBM13. The data reveal that the binding mode of the oligosaccharides in the active site of the catalytic domain is entirely consistent with the substrate specificity and, in conjunction with the accompanying paper (Pell, G., Taylor, E. J., Gloster, T. M., Turkenburg, J. P., Fontes, C. M. G. A., Ferreira, L. M. A., Nagy, T., Clark, S. J., Davies, G. J., and Gilbert, H. J. ( 2004) J. Biol. Chem. 279, 9597 - 9605), demonstrate that the accommodation of the side chains in decorated xylans is conserved in GH10 xylanases of SoXyn10A against arabinoglucuronoxylan. CBM13 was shown to bind xylose or xylooligosaccharides reversibly by using nonsymmetric sugars as the ligands. The independent multiple sites in CBM13 may increase the probability of substrate binding.	Natl Inst Agrobiol Sci, Dept Biochem, Tsukuba, Ibaraki 3058602, Japan; Natl Food Res Inst, Biol Funct Div, Tsukuba, Ibaraki 3058642, Japan; Yamagata Univ, Dept Mat & Biol Chem, Yamagata 9908560, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan	National Institute of Agrobiological Sciences - Japan; National Agriculture & Food Research Organization - Japan; National Food Research Institute - Japan; Yamagata University; University of Tsukuba	Fujimoto, Z (corresponding author), Natl Inst Agrobiol Sci, Dept Biochem, 2-1-2 Kannondai, Tsukuba, Ibaraki 3058602, Japan.	zui@affrc.go.jp	Kuno, Atsushi/M-2151-2018	Kuno, Atsushi/0000-0002-6147-6171; Fujimoto, Zui/0000-0002-3551-6854				Birsan C, 1998, BIOCHEM SOC T, V26, P156, DOI 10.1042/bst0260156; Boraston AB, 2003, STRUCTURE, V11, P665, DOI 10.1016/S0969-2126(03)00100-X; Boraston AB, 2000, BIOCHEM J, V350, P933, DOI 10.1042/0264-6021:3500933; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; DEREWENDA U, 1994, J BIOL CHEM, V269, P20811; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Fujimoto Z, 1997, J BIOCHEM-TOKYO, V121, P826; Fujimoto Z, 2000, J MOL BIOL, V300, P575, DOI 10.1006/jmbi.2000.3877; Fujimoto Z, 2002, J MOL BIOL, V316, P65, DOI 10.1006/jmbi.2001.5338; Gilbert HJ, 2002, ROY SOC CH, P89, DOI 10.1039/9781847550323-00089; HARRIS GW, 1994, STRUCTURE, V2, P1107, DOI 10.1016/S0969-2126(94)00112-X; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Kaneko S, 1999, FEBS LETT, V460, P61, DOI 10.1016/S0014-5793(99)01318-6; Kaneko S, 2000, PROTEIN ENG, V13, P873, DOI 10.1093/protein/13.12.873; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuno A, 2000, FEBS LETT, V482, P231, DOI 10.1016/S0014-5793(00)02067-6; Kuno A, 1999, FEBS LETT, V450, P299, DOI 10.1016/S0014-5793(99)00498-6; Kuno A, 1998, J FERMENT BIOENG, V86, P434, DOI 10.1016/S0922-338X(98)80147-5; KUSAKABE I, 1983, AGR BIOL CHEM TOKYO, V47, P2713, DOI 10.1080/00021369.1983.10866038; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MURZIN AG, 1992, J MOL BIOL, V223, P531, DOI 10.1016/0022-2836(92)90668-A; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Notenboom V, 2002, BIOCHEMISTRY-US, V41, P4246, DOI 10.1021/bi015865j; Notenboom V, 1998, NAT STRUCT BIOL, V5, P812, DOI 10.1038/1852; Pell G, 2004, J BIOL CHEM, V279, P9597, DOI 10.1074/jbc.M312278200; Rossmann MG, 1999, ACTA CRYSTALLOGR D, V55, P1631, DOI 10.1107/S0907444999008379; RUTENBER E, 1987, NATURE, V326, P624, DOI 10.1038/326624a0; Scharpf M, 2002, BIOCHEMISTRY-US, V41, P4255, DOI 10.1021/bi015866b; Schmidt A, 1999, BIOCHEMISTRY-US, V38, P2403, DOI 10.1021/bi982108l; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WHITE A, 1994, BIOCHEMISTRY-US, V33, P12546, DOI 10.1021/bi00208a003; Yoshida S, 1998, J WOOD SCI, V44, P457, DOI 10.1007/BF00833410; YOSHIDA S, 1994, BIOSCI BIOTECH BIOCH, V58, P2068, DOI 10.1271/bbb.58.2068; YOSHIDA S, 1990, AGR BIOL CHEM TOKYO, V54, P449, DOI 10.1080/00021369.1990.10869948	38	67	68	2	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9606	9614		10.1074/jbc.M312293200	http://dx.doi.org/10.1074/jbc.M312293200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14670957	hybrid			2022-12-25	WOS:000189265900128
J	Gillian, AL; Svaren, J				Gillian, AL; Svaren, J			The Ddx20/DP103 dead box protein represses transcriptional activation by Egr2/Krox-20	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY GROWTH-RESPONSE-2 GENE; TOOTH-DISEASE TYPE-1; NGFI-A EGR-1; DEVELOPING HINDBRAIN; INHERITED NEUROPATHIES; SEGMENTAL EXPRESSION; MISSENSE MUTATION; NAB PROTEINS; RNA HELICASE; KROX-20	The early growth response 2 (Egr2/Krox- 20) transcription factor is essential for myelination of the peripheral nervous system and segmentation of the vertebrate hindbrain. To probe the mechanism by which Egr2 is regulated, we used a yeast two-hybrid assay and identified an RNA helicase, Ddx20 (DP103/Gemin3), as an Egr2-interacting protein. Mammalian two-hybrid assays indicated that Ddx20 can interact with Egr1, Egr3, and Egr4, in addition to Egr2, making it the only known cofactor that interacts with all four Egr family members. Using several Egr2 target promoters, we found that Ddx20 repressed Egr2-mediated transcriptional activation with significant promoter specificity. In addition, Ddx20 repressed Egr2-mediated activation of the endogenous insulin-like growth factor 2 (IGF2) gene. Interestingly, the C-terminal segment of Ddx20, which lacks the DEAD box helicase domain, was sufficient for its robust and specific repression. We also examined possible interactions between Ddx20 and Nab proteins, the only other known corepressors of the Egr family, and found that these two corepressors act independently. Finally, transcriptional repression assays performed in the presence of a histone deacetylase inhibitor ( trichostatin A) indicate that although repression of certain promoters by Ddx20 requires histone deacetylase activity, another repression mechanism must also be involved. Because Egr2 is critical for hindbrain development and peripheral nerve myelination, modulation of Egr2 by Ddx20 may play an important role in maintaining the correct expression level of Egr2 target genes.	Univ Wisconsin, Sch Vet Med, Dept Comparat Biosci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Svaren, J (corresponding author), Univ Wisconsin, Sch Vet Med, Dept Comparat Biosci, 2015 Linden Dr, Madison, WI 53706 USA.	jpsvaren@wisc.edu	Svaren, John/A-1605-2010	Svaren, John/0000-0003-2963-7921	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD041590] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007654] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL007654] Funding Source: Medline; NICHD NIH HHS [HD41590] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bae SK, 1999, CANCER RES, V59, P5989; Bellone E, 1999, Hum Mutat, V14, P353, DOI 10.1002/(SICI)1098-1004(199910)14:4<353::AID-HUMU17>3.3.CO;2-W; Biesiada E, 1996, J BIOL CHEM, V271, P18576, DOI 10.1074/jbc.271.31.18576; Boerkoel CF, 2001, NEUROGENETICS, V3, P153, DOI 10.1007/s100480100107; Campbell L, 2000, HUM MOL GENET, V9, P1093, DOI 10.1093/hmg/9.7.1093; Charroux B, 1999, J CELL BIOL, V147, P1181, DOI 10.1083/jcb.147.6.1181; CROSBY SD, 1992, P NATL ACAD SCI USA, V89, P4739, DOI 10.1073/pnas.89.10.4739; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V20; Giudicelli F, 2001, GENE DEV, V15, P567, DOI 10.1101/gad.189801; Grundhoff AT, 1999, J BIOL CHEM, V274, P19136, DOI 10.1074/jbc.274.27.19136; James P, 1996, GENETICS, V144, P1425; Klappacher GW, 2002, CELL, V109, P169, DOI 10.1016/S0092-8674(02)00714-6; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; Levi G, 1996, DEVELOPMENT, V122, P113; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Mechta-Grigoriou F, 2000, DEVELOPMENT, V127, P119; Mellitzer G, 1999, NATURE, V400, P77, DOI 10.1038/21907; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Nagarajan R, 2001, NEURON, V30, P355, DOI 10.1016/S0896-6273(01)00282-3; Nonchev S, 1996, DEVELOPMENT, V122, P543; Numakura C, 2003, J NEUROL SCI, V210, P61, DOI 10.1016/S0022-510X(03)00028-5; O'Donovan KJ, 1999, TRENDS NEUROSCI, V22, P167, DOI 10.1016/S0166-2236(98)01343-5; Ou QL, 2001, MOL ENDOCRINOL, V15, P69, DOI 10.1210/me.15.1.69; Pareyson D, 2000, NEUROLOGY, V54, P1696, DOI 10.1212/WNL.54.8.1696; Rajendran RR, 2003, J BIOL CHEM, V278, P4628, DOI 10.1074/jbc.M210066200; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; Schenone A, 1999, CURR OPIN NEUROL, V12, P603, DOI 10.1097/00019052-199910000-00015; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; Seitanidou T, 1997, MECH DEVELOP, V65, P31, DOI 10.1016/S0925-4773(97)00051-8; Sevetson BR, 2000, J BIOL CHEM, V275, P9749, DOI 10.1074/jbc.275.13.9749; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; Svaren J, 2000, J BIOL CHEM, V275, P38524, DOI 10.1074/jbc.M005220200; Svaren J, 1996, MOL CELL BIOL, V16, P3545; Svaren J, 1998, EMBO J, V17, P6010, DOI 10.1093/emboj/17.20.6010; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; Swirnoff AH, 1998, MOL CELL BIOL, V18, P512, DOI 10.1128/MCB.18.1.512; Theil T, 1998, DEVELOPMENT, V125, P443; Timmerman V, 1999, NEUROLOGY, V52, P1827, DOI 10.1212/WNL.52.9.1827; TOPILKO P, 1994, NATURE, V371, P796, DOI 10.1038/371796a0; VESQUE C, 1992, NUCLEIC ACIDS RES, V20, P2485, DOI 10.1093/nar/20.10.2485; Wang D, 1997, ONCOGENE, V14, P2291, DOI 10.1038/sj.onc.1201069; Warner LE, 1999, HUM MOL GENET, V8, P1245, DOI 10.1093/hmg/8.7.1245; Warner LE, 1999, ANNU REV MED, V50, P263, DOI 10.1146/annurev.med.50.1.263; Warner LE, 1998, NAT GENET, V18, P382, DOI 10.1038/ng0498-382; WILSON TE, 1992, J BIOL CHEM, V267, P3718; Yan XM, 2003, MOL CELL BIOL, V23, P414, DOI 10.1128/MCB.23.1.414-423.2003; Yoshihara T, 2001, J NEUROL SCI, V184, P149, DOI 10.1016/S0022-510X(00)00504-9	50	48	54	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9056	9063		10.1074/jbc.M309308200	http://dx.doi.org/10.1074/jbc.M309308200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14699164	hybrid			2022-12-25	WOS:000189265900066
J	Kahlig, KM; Javitch, JA; Galli, A				Kahlig, KM; Javitch, JA; Galli, A			Amphetamine regulation of dopamine transport - Combined measurements of transporter currents and transporter imaging support the endocytosis of an active carrier	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PARKINSONISM-INDUCING NEUROTOXIN; GREEN FLUORESCENT PROTEIN; XENOPUS-LAEVIS OOCYTES; PLASMA-MEMBRANE; MEDIATED INTERNALIZATION; SURFACE EXPRESSION; MICE LACKING; CELL-LINES; COCAINE	Dopaminergic neurotransmission is fine-tuned by the rate of removal of dopamine (DA) from the extracellular space via the Na+/ Cl--dependent DA transporter (DAT). DAT is a target of psychostimulants such as amphetamine ( AMPH) and cocaine. Previously, we reported that AMPH redistributes the human DAT away from the cell surface. This process was associated with a reduction in transport capacity. This loss of transport capacity may result either from a modification of the function of DAT that is independent of its cell surface redistribution and/or from a reduction in the number of active transporters at the plasma membrane that results from DAT trafficking. To discriminate between these possibilities, we stably transfected HEK-293 cells with a yellow fluorescent protein (YFP)tagged human DAT (hDAT cells). In hDAT cells, acute exposure to AMPH induced a time-dependent loss of hDAT activity. By coupling confocal imaging with patch-clamp whole-cell recordings, we have demonstrated for the first time that the loss of AMPH-induced hDAT activity temporally parallels the accumulation of intracellular hDAT. In addition, presteady-state current analysis revealed a cocaine-sensitive, voltage-dependent capacitance current that correlated with the level of transporter membrane expression and in turn served to monitor the AMPH-induced trafficking of hDAT. We found that the decrease in hDAT cell surface expression induced by AMPH was not paralleled by changes in the ability of the single transporter to carry charges. Quasi-stationary noise analysis of the AMPH-induced hDAT currents revealed that the unitary transporter current remained unaltered during the loss of hDAT membrane expression. Taken together, these data strongly suggest that the AMPH-induced reduction of hDAT transport capacity results from the removal of active hDAT from the plasma membrane.	Vanderbilt Univ, Ctr Mol Neurosci, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Columbia Univ Coll Phys & Surg, Ctr Mol Recognit, Dept Psychiat, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Ctr Mol Recognit, Dept Pharmacol, New York, NY 10032 USA	Vanderbilt University; Columbia University; Columbia University	Galli, A (corresponding author), Vanderbilt Univ, Ctr Mol Neurosci, Dept Physiol & Mol Biophys, 465 21st Ave S, Nashville, TN 37232 USA.	Aurelio.Galli@vanderbilt.edu		Javitch, Jonathan/0000-0001-7395-2967	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA014684, R01DA013975, R01DA011495] Funding Source: NIH RePORTER; NIDA NIH HHS [DA11495, DA14684, DA13975] Funding Source: Medline; NIMH NIH HHS [MH57324] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Apparsundaram S, 1998, J PHARMACOL EXP THER, V287, P744; BLAKELY RD, 1994, J EXP BIOL, V196, P263; Carneiro AM, 2002, J NEUROSCI, V22, P7045; Carvelli L, 2002, J NEUROCHEM, V81, P859, DOI 10.1046/j.1471-4159.2002.00892.x; Choe ES, 2002, NEUROPSYCHOPHARMACOL, V27, P565; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Daws LC, 2002, BIOCHEM BIOPH RES CO, V290, P1545, DOI 10.1006/bbrc.2002.6384; Derbez AE, 2002, J PHARMACOL EXP THER, V301, P306, DOI 10.1124/jpet.301.1.306; Doolen S, 2001, J PHARMACOL EXP THER, V296, P931; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; GALLI A, 1995, J EXP BIOL, V198, P2197; Galli A, 1996, P NATL ACAD SCI USA, V93, P8671, DOI 10.1073/pnas.93.16.8671; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J; Granas C, 2003, J BIOL CHEM, V278, P4990, DOI 10.1074/jbc.M205058200; Gulley JM, 2002, J NEUROCHEM, V83, P400, DOI 10.1046/j.1471-4159.2002.01133.x; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; Howell LL, 2001, J PHARMACOL EXP THER, V298, P1; Ingram SL, 2002, NAT NEUROSCI, V5, P971, DOI 10.1038/nn920; Inoue M, 2003, NATURE, V422, P629, DOI 10.1038/nature01533; IVERSEN LL, 1971, BRIT J PHARMACOL, V41, P571, DOI 10.1111/j.1476-5381.1971.tb07066.x; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; Jones SR, 1998, J NEUROSCI, V18, P1979; Kantor L, 1998, J PHARMACOL EXP THER, V284, P592; Khoshbouei H, 2003, J BIOL CHEM, V278, P12070, DOI 10.1074/jbc.M212815200; Klamo EM, 1996, J BIOL CHEM, V271, P14937, DOI 10.1074/jbc.271.25.14937; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; Lippincott-Schwartz J, 1999, METHOD CELL BIOL, V58, P261; Little KY, 2002, MOL PHARMACOL, V61, P436, DOI 10.1124/mol.61.2.436; Loder MK, 2003, J BIOL CHEM, V278, P22168, DOI 10.1074/jbc.M301845200; Mackenzie B, 1996, J BIOL CHEM, V271, P32678, DOI 10.1074/jbc.271.51.32678; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; Mager S, 1998, METHOD ENZYMOL, V296, P551; Mayfield RD, 2001, MOL PHARMACOL, V59, P113, DOI 10.1124/mol.59.1.113; Melikian HE, 1999, J NEUROSCI, V19, P7699; Page G, 2001, J NEUROCHEM, V76, P1282, DOI 10.1046/j.1471-4159.2001.00179.x; PIFL C, 1993, J NEUROSCI, V13, P4246, DOI 10.1523/jneurosci.13-10-04246.1993; Piston DW, 1999, METHOD CELL BIOL, V58, P31; Rees S, 1996, BIOTECHNIQUES, V20, P102; Robbins AK, 1998, BIOTECHNIQUES, V25, P240, DOI 10.2144/98252st04; Saunders C, 2000, P NATL ACAD SCI USA, V97, P6850, DOI 10.1073/pnas.110035297; Sonders MS, 1997, J NEUROSCI, V17, P960; Sorkina T, 2003, J BIOL CHEM, V278, P28274, DOI 10.1074/jbc.M210652200; SULZER D, 1993, J NEUROCHEM, V60, P527, DOI 10.1111/j.1471-4159.1993.tb03181.x; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; Whistler JL, 1999, J BIOL CHEM, V274, P24575, DOI 10.1074/jbc.274.35.24575; ZAMPIGHI GA, 1995, J MEMBRANE BIOL, V148, P65; Zhu SJ, 1997, J PHARMACOL EXP THER, V282, P1358	52	76	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8966	8975		10.1074/jbc.M303976200	http://dx.doi.org/10.1074/jbc.M303976200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14699142	hybrid			2022-12-25	WOS:000189265900055
J	Milakovic, T; Tucholski, J; McCoy, E; Johnson, GVW				Milakovic, T; Tucholski, J; McCoy, E; Johnson, GVW			Intracellular localization and activity state of tissue transglutaminase differentially impacts cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING ENZYMES; RETINOBLASTOMA PROTEIN; NUCLEAR-LOCALIZATION; IN-SITU; APOPTOSIS; CYCLE; CALCIUM; PHOSPHORYLATION; IDENTIFICATION; EXPRESSION	Tissue transglutaminase (tTG) is a unique member of the transglutaminase family as it is both a transamidating enzyme and a GTPase. In the cell tTG is mostly cytosolic, however it is also found in the nucleus and associated with the plasma membrane. tTG can be proapoptotic, however anti-apoptotic activities of the enzyme have also been reported. To determine how the intracellular localization and transamidating activity of tTG modulates its effects on apoptosis, HEK293 cells were transiently transfected with tTG or [C277S] tTG ( which lacks transamidating activity) constructs that were targeted to different intracellular compartments. Apoptosis was induced by thapsigargin treatment, which results in increased intracellular calcium concentrations. Cytosolic tTG was pro-apoptotic, while nuclear localization of [C277S] tTG attenuated apoptosis. Membrane-targeted tTG had neither pro- nor anti-apoptotic functions. This finding indicates for the first time that intracellular localization is an important determinant of the effect of tTG on apoptosis. Previous studies have suggested that tTG may modulate retinoblastoma (Rb) protein, an important suppressor of apoptosis. tTG interacted with Rb and after induction of apoptosis, the interaction of nuclear-targeted [ C277S] tTG with Rb was increased significantly concomitant with an attenuation of apoptosis. In contrast, the interaction of nuclear-targeted tTG with Rb was significantly decreased and apoptosis was not attenuated. These data suggest that tTG protects cells against apoptosis in response to stimuli that do not result in increased transamidating activity by translocating to the nucleus, and that complexing with Rb may be an important aspect of the protective effects of tTG.	Univ Alabama Birmingham, Dept Psychiat, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Johnson, GVW (corresponding author), Univ Alabama Birmingham, Dept Psychiat, 1720 7th Ave S,SC1061, Birmingham, AL 35294 USA.	gvwj@uab.edu	Johnson, Gail V.W./K-4723-2012	Johnson, Gail V.W./0000-0003-3464-0404	NATIONAL INSTITUTE ON AGING [R01AG012396] Funding Source: NIH RePORTER; NIA NIH HHS [AG12396] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; An B, 1996, CANCER RES, V56, P438; Antonyak MA, 2001, J BIOL CHEM, V276, P33582, DOI 10.1074/jbc.M105318200; Boehm JE, 2002, J BIOL CHEM, V277, P20127, DOI 10.1074/jbc.C200147200; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chau BN, 2002, NAT CELL BIOL, V4, P757, DOI 10.1038/ncb853; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Claudio P, 2002, GENOME BIOL, V3; DASCALU A, 1995, J PHYSIOL-LONDON, V486, P97, DOI 10.1113/jphysiol.1995.sp020793; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Fattman CL, 2001, ONCOGENE, V20, P2918, DOI 10.1038/sj.onc.1204414; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FISCHERFANTUZZI L, 1988, MOL CELL BIOL, V8, P5495, DOI 10.1128/MCB.8.12.5495; FURUYA Y, 1994, CANCER RES, V54, P6167; GREENBERG CS, 1987, BLOOD, V70, P702; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Griffin M, 2002, BIOCHEM J, V368, P377, DOI 10.1042/BJ20021234; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; Hettasch JM, 1996, LAB INVEST, V75, P637; IWAKI T, 1994, AM J PATHOL, V145, P776; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; Johnson GVW, 1997, BRAIN RES, V751, P323, DOI 10.1016/S0006-8993(96)01431-X; JONES KT, 1994, EXP CELL RES, V210, P71, DOI 10.1006/excr.1994.1011; Karpuj MV, 1999, P NATL ACAD SCI USA, V96, P7388, DOI 10.1073/pnas.96.13.7388; Kim JH, 2001, ANN NY ACAD SCI, V928, P65; Lesort M, 1999, J NEUROCHEM, V73, P2018; Lesort M, 2000, PROG NEUROBIOL, V61, P439, DOI 10.1016/S0301-0082(99)00052-0; Lesort M, 1998, J BIOL CHEM, V273, P11991, DOI 10.1074/jbc.273.20.11991; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Maas T, 2000, J BIOL CHEM, V275, P15733, DOI 10.1074/jbc.M000389200; MACCIONI RB, 1986, MOL CELL BIOCHEM, V69, P161; Marchenko SM, 2000, EXP PHYSIOL, V85, P151, DOI 10.1017/S0958067000019436; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Nath R, 1997, BIOCHEM MOL BIOL INT, V43, P197; Oliverio S, 1999, J BIOL CHEM, V274, P34123, DOI 10.1074/jbc.274.48.34123; Oliverio S, 1997, MOL CELL BIOL, V17, P6040, DOI 10.1128/MCB.17.10.6040; Peng XJ, 1999, FEBS LETT, V446, P35, DOI 10.1016/S0014-5793(99)00018-6; PIACENTINI M, 1991, CELL TISSUE RES, V263, P227, DOI 10.1007/BF00318764; Piredda L, 1999, FASEB J, V13, P355, DOI 10.1096/fasebj.13.2.355; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; SINGH US, 1995, BIOCHEMISTRY-US, V34, P15863, DOI 10.1021/bi00048a032; SLIFE CW, 1985, ARCH BIOCHEM BIOPHYS, V241, P329, DOI 10.1016/0003-9861(85)90554-5; Stevens C, 2003, ARCH BIOCHEM BIOPHYS, V412, P157, DOI 10.1016/S0003-9861(03)00054-7; TAKEUCHI Y, 1992, FEBS LETT, V307, P177, DOI 10.1016/0014-5793(92)80762-6; Tan XQ, 1997, J BIOL CHEM, V272, P9613; TOESCU EC, 1994, PFLUG ARCH EUR J PHY, V427, P325, DOI 10.1007/BF00374541; Tong JF, 1999, BIOCHEM J, V343, P39, DOI 10.1042/0264-6021:3430039; Tucholski J, 1999, J NEUROCHEM, V73, P1871; Tucholski J, 2002, J NEUROCHEM, V81, P780, DOI 10.1046/j.1471-4159.2002.00859.x; Tucholski J, 2001, NEUROSCIENCE, V102, P481, DOI 10.1016/S0306-4522(00)00482-6; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; YEE AS, 1998, FRONT BIOSCI, V3, P532; Yen A, 1997, EUR J CELL BIOL, V72, P159; Zarkowska T, 1997, ONCOGENE, V14, P249, DOI 10.1038/sj.onc.1200824; Zhang JW, 1998, J BIOL CHEM, V273, P2288, DOI 10.1074/jbc.273.4.2288; Zhang RL, 2003, GLIA, V42, P194, DOI 10.1002/glia.10222	63	94	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8715	8722		10.1074/jbc.M308479200	http://dx.doi.org/10.1074/jbc.M308479200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14670969	hybrid			2022-12-25	WOS:000189265900024
J	Reilly, KB; Srinivasan, S; Hatley, ME; Patricia, MK; Lannigan, J; Bolick, DT; Vandenhoff, G; Pei, H; Natarajan, R; Nadler, JL; Hedrick, CC				Reilly, KB; Srinivasan, S; Hatley, ME; Patricia, MK; Lannigan, J; Bolick, DT; Vandenhoff, G; Pei, H; Natarajan, R; Nadler, JL; Hedrick, CC			12/15-lipoxygenase activity mediates inflammatory monocyte/endothelial interactions and atherosclerosis in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MONOCYTE ADHESION; GENE DISRUPTION; INBRED STRAINS; MESSENGER-RNA; 15-LIPOXYGENASE; EXPRESSION; OXIDATION; ACID; LDL	We have shown that the 12/15-lipoxygenase (12/15-LO) product 12S-hydroxyeicosatetraenoic acid increases monocyte adhesion to human endothelial cells (EC) in vitro. Recent studies have implicated 12/15-LO in mediating atherosclerosis in mice. We generated transgenic mice on a C57BL/6J (B6) background that modestly overexpressed the murine 12/15-LO gene ( designated LOTG). LOTG mice had 2.5-fold elevations in levels of 12S-hydroxyeicosatetraenoic acid and a 2-fold increase in expression of 12/15-LO protein in vivo. These mice developed spontaneous aortic fatty streak lesions on a chow diet. Thus, we examined effects of 12/15-LO expression on early events leading to atherosclerosis in these mice. We found that, under basal unstimulated conditions, LOTG EC bound more monocytes than B6 control EC ( 18 +/- 2 versus 7 +/- 1 monocytes/field, respectively; p < 0.0001). Inhibition of 12/15-LO activity in LOTG EC using a 12/15-LO ribozyme completely blocked monocyte adhesion in LOTG mice. Thus, 12/15-LO activity is required for monocyte/EC adhesion in the vessel wall. Expression of ICAM-1 in aortic endothelia of LOTG mice was increased severalfold. VCAM-1 expression was not changed. In a series of blocking studies, antibodies to alpha(4) and beta(2) integrins in WEHI monocytes blocked monocyte adhesion to both LOTG and B6 control EC. Inhibition of ICAM-1, VCAM-1, and connecting segment-1 fibronectin in EC significantly reduced adhesion of WEHI monocytes to LOTG EC. In summary, these data indicate that EC from LOTG mice are "pre-activated" to bind monocytes. Monocyte adhesion in LOTG mice is mediated through beta(2) integrin and ICAM-1 interactions as well as through VLA-4 and connecting segment-1 fibronectin/ VCAM-1 interactions. Thus, 12/15-LO mediates monocyte/ EC interactions in the vessel wall in atherogenesis at least in part through molecular regulation of expression of endothelial adhesion molecules.	Univ Virginia, Cardiovasc Res Ctr, Div Endocrinol & Metab, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; City Hope Natl Med Ctr, Beckman Res Inst, Dept Diabet, Duarte, CA 91010 USA	University of Virginia; University of Virginia; City of Hope; Beckman Research Institute of City of Hope	Hedrick, CC (corresponding author), Univ Virginia, Cardiovasc Res Ctr, Div Endocrinol & Metab, MR5 Rm G123,POB 801394,415 Lane Rd, Charlottesville, VA 22908 USA.	cch6n@virginia.edu	Hedrick, Catherine/D-1106-2012; Bolick, David/A-3467-2017	Lannigan, Joanne/0000-0002-3981-8681	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL055798, R01HL071141] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039721] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL071141-01, P01 HL55798-08] Funding Source: Medline; NIDDK NIH HHS [DK39721] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENZ DJ, 1995, J BIOL CHEM, V270, P5191, DOI 10.1074/jbc.270.10.5191; Bleich D, 1999, J CLIN INVEST, V103, P1431, DOI 10.1172/JCI5241; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; Chavis C, 1999, ANAL BIOCHEM, V271, P105, DOI 10.1006/abio.1999.4113; CHEN XS, 1994, J BIOL CHEM, V269, P13979; CHO H, 1991, J MED CHEM, V34, P1503, DOI 10.1021/jm00108a039; Cyrus T, 1999, J CLIN INVEST, V103, P1597, DOI 10.1172/JCI5897; Daugherty Alan, 2003, Methods Mol Biol, V209, P293; FOLCIK VA, 1995, J CLIN INVEST, V96, P504, DOI 10.1172/JCI118062; Funk CD, 2002, PROSTAG OTH LIPID M, V68-9, P303, DOI 10.1016/S0090-6980(02)00036-9; Funk CD, 2001, TRENDS CARDIOVAS MED, V11, P116; Funk CD, 1996, BBA-LIPID LIPID MET, V1304, P65, DOI 10.1016/S0005-2760(96)00107-5; George J, 2001, CIRCULATION, V104, P1646, DOI 10.1161/hc3901.095772; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; Harats D, 2000, ARTERIOSCL THROM VAS, V20, P2100, DOI 10.1161/01.ATV.20.9.2100; Hatley ME, 2003, J BIOL CHEM, V278, P25369, DOI 10.1074/jbc.M301175200; Hedrick CC, 2001, J LIPID RES, V42, P563; Honda HM, 1999, ARTERIOSCL THROM VAS, V19, P680, DOI 10.1161/01.ATV.19.3.680; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Huo YQ, 2001, J CLIN INVEST, V108, P1307, DOI 10.1172/JCI12877; Huo YQ, 2000, CIRC RES, V87, P153, DOI 10.1161/01.RES.87.2.153; ISHIDA BY, 1989, ATHEROSCLEROSIS MOUS, P189; Johnson EN, 1999, ADV EXP MED BIOL, V447, P63; Kuhn H, 1999, ADV EXP MED BIOL, V447, P5; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maier KG, 2000, AM J PHYSIOL-HEART C, V279, pH863, DOI 10.1152/ajpheart.2000.279.2.H863; McEvoy LM, 1997, J EXP MED, V185, P2069, DOI 10.1084/jem.185.12.2069; MCNALLY AK, 1990, J IMMUNOL, V145, P254; PAIGEN B, 1985, ATHEROSCLEROSIS, V57, P65, DOI 10.1016/0021-9150(85)90138-8; PAIGEN B, 1990, ARTERIOSCLEROSIS, V10, P316, DOI 10.1161/01.ATV.10.2.316; Patricia MK, 2001, CIRC RES, V88, P659, DOI 10.1161/hh0701.088838; Patricia MK, 1999, ARTERIOSCL THROM VAS, V19, P2615, DOI 10.1161/01.ATV.19.11.2615; Sigari F, 1997, ARTERIOSCL THROM VAS, V17, P3639, DOI 10.1161/01.ATV.17.12.3639; SPECTOR AA, 1988, PROG LIPID RES, V27, P271, DOI 10.1016/0163-7827(88)90009-4; Srinivasan S, 2003, CIRC RES, V92, P371, DOI 10.1161/01.RES.0000061714.74668.5C; Sun DX, 1996, J BIOL CHEM, V271, P24055, DOI 10.1074/jbc.271.39.24055; TSAO PS, 1994, CIRCULATION, V89, P2176, DOI 10.1161/01.CIR.89.5.2176; WALENGA RW, 1988, PEDIATR RES, V24, P563, DOI 10.1203/00006450-198811000-00005; WALENGA RW, 1987, PROSTAGLANDINS, V34, P733, DOI 10.1016/0090-6980(87)90296-6; WANG LX, 1990, J LIPID RES, V31, P2265; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111; YLAHERTTUALA S, 1990, P NATL ACAD SCI USA, V87, P6959, DOI 10.1073/pnas.87.18.6959; YLAHERTTUALA S, 1995, J CLIN INVEST, V95, P2692, DOI 10.1172/JCI117971; Yoshimoto T, 2002, PROSTAG OTH LIPID M, V68-9, P245, DOI 10.1016/S0163-7827(97)00002-7; Zhao L, 2002, J BIOL CHEM, V277, P35350, DOI 10.1074/jbc.M205738200; Zink MH, 2001, AM J PHYSIOL-HEART C, V280, pH693, DOI 10.1152/ajpheart.2001.280.2.H693	47	113	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9440	9450		10.1074/jbc.M303857200	http://dx.doi.org/10.1074/jbc.M303857200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676201	hybrid			2022-12-25	WOS:000189265900110
J	Velasco-Loyden, G; Arribas, J; Lopez-Casillas, F				Velasco-Loyden, G; Arribas, J; Lopez-Casillas, F			The shedding of betaglycan is regulated by pervanadate and mediated by membrane type matrix metalloprotease-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR-BETA; AMYLOID PRECURSOR PROTEIN; RECOMBINANT SOLUBLE BETAGLYCAN; TGF-BETA; CONVERTING-ENZYME; LIGAND-BINDING; III RECEPTOR; TYROSINE PHOSPHORYLATION; ENDOTHELIAL-CELLS	Betaglycan is a membrane-anchored proteoglycan that binds transforming growth factor-beta (TGF-beta) via its core protein. A soluble form of betaglycan can be released by proteolytic cleavage ( also known as shedding) of the membrane-bound form, yielding soluble betaglycan. The mechanism leading to the generation of soluble betaglycan is poorly understood. Because the membrane and soluble forms of betaglycan have opposite effects regulating the availability of TGF-beta, it is important to characterize the shedding of betaglycan further. Here we present evidence showing that in certain cell types, pervanadate, a general tyrosine phosphatase inhibitor, induces the release of the previously described fragment that encompasses almost the entire extracellular domain of betaglycan (sBG-120). In addition, treatment with pervanadate unveils the existence of a novel 90-kDa fragment (sBG-90). Noticeably, the cleavage that generates sBG-90 is mediated by a tissue inhibitor of metalloprotease-2-sensitive protease. Overexpression of all membrane type matrix metalloproteases (MT-MMPs) described to date indicates that MT1-MMP and MT3-MMP are endowed with ability to generate sBG-90. Furthermore, the patterns of expression of different MT-MMPs in the cell lines used in this study suggest that MT1-MMP is the protease involved in the shedding of sBG-90. Overexpression of MT1-MMP in COS-1 cells, which do not express detectable levels of this metalloprotease, confirms the feasibility of this hypothesis. Unexpectedly, during the course of these experiments, we observed that MT2-MMP decreases the levels of MT1-MMP and betaglycan. Finally, binding competition experiments indicate that, similar to the wild type membrane betaglycan, sBG-90 binds the TGF-beta2 isoform with greater affinity than TGF-beta1, suggesting that once released, it could affect the cellular availability of TGF-beta.	Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Biol Celular, Mexico City 04510, DF, Mexico; Hosp Univ Vall Hebron, Med Oncol Serv, Lab Rec Oncol, Barcelona 08035, Spain	Universidad Nacional Autonoma de Mexico; Hospital Universitari Vall d'Hebron	Lopez-Casillas, F (corresponding author), Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Biol Celular, Apartado Postal 70-246, Mexico City 04510, DF, Mexico.	fcasilla@ifc.unam.mx	Arribas, Joaquin/M-4482-2014	Arribas, Joaquin/0000-0002-0504-0664				Amour A, 2002, FEBS LETT, V524, P154, DOI 10.1016/S0014-5793(02)03047-8; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; Arribas J, 1997, J BIOL CHEM, V272, P17160, DOI 10.1074/jbc.272.27.17160; Arribas J, 2002, CHEM REV, V102, P4627, DOI 10.1021/cr010202t; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Bandyopadhyay A, 2002, CANCER RES, V62, P4690; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Bjorn SF, 2000, PLACENTA, V21, P170, DOI 10.1053/plac.1999.0447; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobe GC, 2001, J BIOL CHEM, V276, P24627, DOI 10.1074/jbc.M100188200; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Borroto A, 2003, J BIOL CHEM, V278, P25933, DOI 10.1074/jbc.M301673200; Brown CB, 1999, SCIENCE, V283, P2080, DOI 10.1126/science.283.5410.2080; Butler GS, 1997, EUR J BIOCHEM, V244, P653, DOI 10.1111/j.1432-1033.1997.t01-1-00653.x; Chapman SC, 2002, MOL CELL ENDOCRINOL, V196, P79, DOI 10.1016/S0303-7207(02)00227-7; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; Codony-Servat J, 1999, CANCER RES, V59, P1196; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Eickelberg O, 2002, J BIOL CHEM, V277, P823, DOI 10.1074/jbc.M105110200; Endo K, 2003, J BIOL CHEM, V278, P40764, DOI 10.1074/jbc.M306736200; English WR, 2000, J BIOL CHEM, V275, P14046, DOI 10.1074/jbc.275.19.14046; English WR, 2001, FEBS LETT, V491, P137, DOI 10.1016/S0014-5793(01)02150-0; Esparza-Lopez J, 2001, J BIOL CHEM, V276, P14588, DOI 10.1074/jbc.M008866200; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Gray PC, 2002, MOL CELL ENDOCRINOL, V188, P253, DOI 10.1016/S0303-7207(02)00037-0; Haro H, 2000, J CLIN INVEST, V105, P143, DOI 10.1172/JCI7091; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINGSTON RE, 1990, CURRENT PROTOCOLS MO; Lewis KA, 2000, NATURE, V404, P411, DOI 10.1038/35006129; Llano E, 1999, CANCER RES, V59, P2570; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Lunn CA, 1997, FEBS LETT, V400, P333, DOI 10.1016/S0014-5793(96)01410-X; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Merlos-Suarez A, 1998, J BIOL CHEM, V273, P24955, DOI 10.1074/jbc.273.38.24955; Merlos-Suarez A, 2001, J BIOL CHEM, V276, P48510, DOI 10.1074/jbc.M103488200; Nakada M, 1999, AM J PATHOL, V154, P417, DOI 10.1016/S0002-9440(10)65288-1; Pepin MC, 1995, FEBS LETT, V377, P368, DOI 10.1016/0014-5793(95)01378-4; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Reiland J, 1996, BIOCHEM J, V319, P39, DOI 10.1042/bj3190039; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANKAR S, 1995, J BIOL CHEM, V270, P13567, DOI 10.1074/jbc.270.22.13567; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schlondorff J, 2001, J BIOL CHEM, V276, P14665, DOI 10.1074/jbc.M010741200; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; Shofuda K, 1997, J BIOL CHEM, V272, P9749; SLACK BE, 1995, J BIOL CHEM, V270, P8337, DOI 10.1074/jbc.270.14.8337; Stenvers KL, 2003, MOL CELL BIOL, V23, P4371, DOI 10.1128/MCB.23.12.4371-4385.2003; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Urena JM, 1999, J CELL SCI, V112, P773; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; Velasco G, 2000, CANCER RES, V60, P877; Vilchis-Landeros MM, 2001, BIOCHEM J, V355, P215, DOI 10.1042/0264-6021:3550215; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; Wiater E, 2003, J BIOL CHEM, V278, P7934, DOI 10.1074/jbc.M209710200; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zucker S, 2003, CURR TOP DEV BIOL, V54, P1, DOI 10.1016/S0070-2153(03)54004-2	72	95	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7721	7733		10.1074/jbc.M306499200	http://dx.doi.org/10.1074/jbc.M306499200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14672946	hybrid			2022-12-25	WOS:000189103300045
J	Mamidipudi, V; Lin, CR; Seibenhener, ML; Wooten, MW				Mamidipudi, V; Lin, CR; Seibenhener, ML; Wooten, MW			Regulation of interleukin receptor-associated kinase (IRAK) phosphorylation and signaling by iota protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATION; PKC; ZETA; IDENTIFICATION; FAMILY; CELLS	We have previously shown that the activity of the interleukin-1 (IL-1) receptor-associated kinase (IRAK) is required for nerve growth factor (NGF)-induced activation of NF-kappaB and cell survival ((2002) J. Biol. Chem. 277, 28010-28018). Herein we demonstrate that NGF induces co-association of IRAK with atypical protein kinase C iota (PKC) and that the iota PKC.IRAK complex is recruited to the p75 neurotrophin receptor. Recruitment of IRAK to the receptor was dependent upon the activity of the iota PKC. Moreover, transfection of kinase-dead iota PKC blocked both NGF- and IL-1-induced IRAK activation and the activity of NF-kappaB. Hence, iota PKC lies upstream of IRAK in the kappaB pathway. Examining the primary structure of IRAK, we identified three putative PKC phosphorylation sites; iota PKC selectively phosphorylated peptide 1 (R (T) under bar AS) within the death domain domain at Thr(66), which is highly conserved among all IRAK family members. Mutation of Thr(66) to Ala impaired the autokinase activity of IRAK and reduced its association with iota PKC but not TRAM resulting in impaired NGF- as well as IL-1-induced NF-kappaB activation. These findings provide insight into the underlying mechanism whereby IRAK regulates the kappaB pathway and reveal that IRAK is a substrate of iota PKC.	Auburn Univ, Dept Biol Sci, Program Cell & Mol Biosci, Auburn, AL 36849 USA; Stanford Univ, Dept Med, Stanford, CA 94305 USA	Auburn University System; Auburn University; Stanford University	Wooten, MW (corresponding author), Auburn Univ, Dept Biol Sci, Program Cell & Mol Biosci, 331 Funchess Hall, Auburn, AL 36849 USA.	wootemw@auburn.edu			NINDS NIH HHS [NS-33661] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033661] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Chapline C, 1998, J BIOL CHEM, V273, P19482, DOI 10.1074/jbc.273.31.19482; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; Hu J, 2002, J IMMUNOL, V168, P3910, DOI 10.4049/jimmunol.168.8.3910; Knop J, 1999, FEBS LETT, V448, P81, DOI 10.1016/S0014-5793(99)00322-1; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Li XX, 1999, MOL CELL BIOL, V19, P4643; Li XX, 2001, P NATL ACAD SCI USA, V98, P4461, DOI 10.1073/pnas.071054198; Mamidipudi V, 2002, J BIOL CHEM, V277, P28010, DOI 10.1074/jbc.M109730200; Martin MU, 2002, BBA-MOL CELL RES, V1592, P265, DOI 10.1016/S0167-4889(02)00320-8; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Qian YC, 2001, J BIOL CHEM, V276, P41661, DOI 10.1074/jbc.M102262200; Ross K, 2002, J BIOL CHEM, V277, P37414, DOI 10.1074/jbc.M205160200; Vig E, 1999, J BIOL CHEM, V274, P13077, DOI 10.1074/jbc.274.19.13077; Wooten MW, 1999, CELL DEATH DIFFER, V6, P753, DOI 10.1038/sj.cdd.4400548	16	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4161	4165		10.1074/jbc.C300431200	http://dx.doi.org/10.1074/jbc.C300431200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14684752	hybrid			2022-12-25	WOS:000188554300031
J	Dazy, S; Damiola, F; Parisey, N; Beug, H; Gandrillon, O				Dazy, S; Damiola, F; Parisey, N; Beug, H; Gandrillon, O			The MEK-1/ERKs signalling pathway is differentially involved in the self-renewal of early and late avian erythroid progenitor cells	ONCOGENE			English	Article						MEK-1; self-renewal; TGF-alpha; erythropoiesis	P38 MAP KINASE; V-ERBA; STEM-CELLS; GLUCOCORTICOID-RECEPTOR; TYROSINE KINASE; C-KIT; APOPTOSIS; ACTIVATION; GROWTH; PROLIFERATION	Making decisions between self-renewal and differentiation is a central ability of stem cells. Elucidation of molecular networks governing this decision is therefore of prime importance. A model of choice to explore this question is represented by chicken erythroid progenitors, in which self-renewal versus differentiation as well as progenitor maturation are regulated by external factor combinations. We used this system to study whether similar or different signalling pathways were involved in the self-renewal of early, immature or more mature erythroid progenitors. We show that a transforming growth factor (TGF)-alpha-activated Ras/MEK-1/ERK1/2 pathway is strictly required for immature self-renewing cells but becomes fully dispensable when those cells are induced to differentiate. Consequently, pharmacological inhibition of this pathway led to spontaneous differentiation, only dependent on the presence of survival signals. Conversely, ectopic expression of a constitutive form of MEK-1 stimulates renewal and arrests differentiation process. Finally, we demonstrate that the ERK/MAPK signalling pathway is required in early but not in late primary erythroid progenitors, which can be turned into each other by different growth factor combinations specifically driving their renewal. To the best of our knowledge, this is the first description of a central role of ERK/MAPK signalling in regulating progenitor plasticity in the same cell type under different environmental conditions.	Univ Lyon 1, Ctr Genet Mol & Cellulaire, Lab Signalisat & Ident Cellulaires, CNRS,UMR 5534, F-69622 Villeurbanne, France; Inst Mol Pathol, A-1030 Vienna, Austria	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Gandrillon, O (corresponding author), Univ Lyon 1, Ctr Genet Mol & Cellulaire, Lab Signalisat & Ident Cellulaires, CNRS,UMR 5534, Bat Gregoire Mendel,16 Rue Dubois, F-69622 Villeurbanne, France.	Gandrillon@cgmc.univ-lyon1.fr		Parisey, Nicolas/0000-0003-2439-3809; Damiola, Francesca/0000-0002-0238-1252				Bartunek P, 1996, CYTOKINE, V8, P14, DOI 10.1006/cyto.1996.0003; Bauer A, 1998, EMBO J, V17, P4291, DOI 10.1093/emboj/17.15.4291; Bauer A, 1999, GENE DEV, V13, P2996, DOI 10.1101/gad.13.22.2996; BAUER A, 2001, HEMATOPOIESIS DEV AP, P368; Bogdan S, 2001, CURR BIOL, V11, pR292, DOI 10.1016/S0960-9822(01)00167-1; Bourgin C, 2000, FEBS LETT, V480, P113, DOI 10.1016/S0014-5793(00)01906-2; BRUNET A, 1994, ONCOGENE, V9, P3379; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHOW SC, 1995, FEBS LETT, V364, P134, DOI 10.1016/0014-5793(95)00370-O; Dolznig H, 2002, CURR BIOL, V12, P1076, DOI 10.1016/S0960-9822(02)00930-2; Dolznig H, 2001, FASEB J, V15, P1442, DOI 10.1096/fj.00-0705fje; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; Gandrillon O, 1999, EMBO J, V18, P2764, DOI 10.1093/emboj/18.10.2764; GANDRILLON O, 1994, ONCOGENE, V9, P749; Gandrillon O, 1998, ONCOGENE, V16, P563, DOI 10.1038/sj.onc.1201550; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; Heinrich R, 2002, MOL CELL, V9, P957, DOI 10.1016/S1097-2765(02)00528-2; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOWENZ E, 1987, MODERN TRENDS HUMA 7, V31, P199; LACOSTEELEAUME AS, 1994, EXP CELL RES, V213, P198, DOI 10.1006/excr.1994.1191; Lesault I, 2002, EMBO J, V21, P694, DOI 10.1093/emboj/21.4.694; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matsuzaki T, 2000, ONCOGENE, V19, P1500, DOI 10.1038/sj.onc.1203461; Nagata Y, 1998, BLOOD, V92, P1859, DOI 10.1182/blood.V92.6.1859.418k37_1859_1869; Nishigaki K, 2000, J VIROL, V74, P3037, DOI 10.1128/JVI.74.7.3037-3045.2000; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Quang CT, 1997, EMBO J, V16, P5639, DOI 10.1093/emboj/16.18.5639; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; SAMARUT J, 1982, CELL, V28, P921, DOI 10.1016/0092-8674(82)90071-X; Schoeberl B, 2002, NAT BIOTECHNOL, V20, P370, DOI 10.1038/nbt0402-370; Somervaille TCP, 2001, BLOOD, V98, P1374, DOI 10.1182/blood.V98.5.1374; STEINLEIN P, 1994, GROWTH FACTORS, V10, P1, DOI 10.3109/08977199409019599; STEINLEIN P, 1995, CURR BIOL, V5, P191, DOI 10.1016/S0960-9822(95)00040-6; Tamir A, 2000, CELL GROWTH DIFFER, V11, P269; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Verfaillie CM, 2002, TRENDS CELL BIOL, V12, P502, DOI 10.1016/S0962-8924(02)02386-3; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; von Lindern M, 2001, ONCOGENE, V20, P3651, DOI 10.1038/sj.onc.1204494; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X; Wessely O, 1999, BIOL CHEM, V380, P187, DOI 10.1515/BC.1999.027; Wessely O, 1997, EMBO J, V16, P267, DOI 10.1093/emboj/16.2.267; Witt O, 2000, BLOOD, V95, P2391, DOI 10.1182/blood.V95.7.2391.007k21_2391_2396; Zochodne B, 2000, ONCOGENE, V19, P2296, DOI 10.1038/sj.onc.1203590	52	23	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2003	22	58					9205	9216		10.1038/sj.onc.1207049	http://dx.doi.org/10.1038/sj.onc.1207049			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755JU	14681680				2022-12-25	WOS:000187400400002
J	Galkin, A; Kulakova, L; Sarikaya, E; Lim, K; Howard, A; Herzberg, O				Galkin, A; Kulakova, L; Sarikaya, E; Lim, K; Howard, A; Herzberg, O			Structural insight into arginine degradation by arginine deiminase, an antibacterial and parasite drug target	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA; CRYSTAL-STRUCTURE; AMIDINOTRANSFERASE; PROTEIN; ENZYME; IDENTIFICATION; BIOSYNTHESIS; EXPRESSION; SOFTWARE; CLONING	L-Arginine deiminase (ADI) catalyzes the irreversible hydrolysis of arginine to citrulline and ammonia. ADI is involved in the first step of the most widespread anaerobic route of arginine degradation. ADI, missing in high eukaryotes, is a potential antimicrobial and antiparasitic drug target. We have determined the crystal structure of ADI from Pseudomonas aeruginosa by the multi-wavelength anomalous diffraction method at 2.45 Angstrom resolution. The structure exhibits similarity to other arginine-modifying or substituted arginine-modifying enzymes such as dimethylarginine dimethylaminohydrolase (DDAH), arginine: glycine amidinotransferase, and arginine: inosamine-phosphate amidinotransferase, despite the lack of significant amino acid sequence homology to these enzymes. The similarity spans a core domain comprising five betabetaalphabeta motifs arranged in a circle around a 5-fold pseudosymmetry axis. ADI contains an additional alpha-helical domain of novel topology inserted between the first and the second betabetaalphabeta modules. A catalytic triad, Cys-His-Glu/Asp ( arranged in a different manner from that of the thiol proteases), seen in the other arginine-modifying enzymes is also conserved in ADI, as well as many other residues involved in substrate binding. Based on this conservation pattern and the assumption that the substrate binding mode is similar to that of DDAH, an ADI catalytic mechanism is proposed. The main players are Cys-406, which mounts the nucleophilic attack on the carbon atom of the guanidinium group of arginine, and His-278, which serves as a general base.	Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; Argonne Natl Lab, Adv Photon Source, Argonne, IL 60439 USA; IIT, Chicago, IL 60616 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); United States Department of Energy (DOE); Argonne National Laboratory; Illinois Institute of Technology	Herzberg, O (corresponding author), Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, 9600 Gudelsky Dr, Rockville, MD 20850 USA.	osnat@carb.umbi.umd.edu	ID, IMCACAT/D-5867-2014	Herzberg, Osnat/0000-0003-2823-7627	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM057890] Funding Source: NIH RePORTER; NIGMS NIH HHS [P01 GM57890] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUR H, 1989, EUR J BIOCHEM, V179, P53, DOI 10.1111/j.1432-1033.1989.tb14520.x; Beloussow K, 2002, CANCER LETT, V183, P155, DOI 10.1016/S0304-3835(01)00793-5; Biagini GA, 2003, MOL BIOCHEM PARASIT, V128, P11, DOI 10.1016/S0166-6851(03)00025-2; Bode W, 2000, BBA-PROTEIN STRUCT M, V1477, P241, DOI 10.1016/S0167-4838(99)00276-9; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DeLano WL, 2002, PYMOL USERS MANUAL; Eckmann L, 2000, J IMMUNOL, V164, P1478, DOI 10.4049/jimmunol.164.3.1478; Fritsche E, 1998, BIOCHEMISTRY-US, V37, P17664, DOI 10.1021/bi981949p; Fritsche E, 1999, J BIOL CHEM, V274, P3026, DOI 10.1074/jbc.274.5.3026; GAMPER M, 1991, J BACTERIOL, V173, P4742, DOI 10.1128/jb.173.15.4742-4750.1991; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Humm A, 1997, EMBO J, V16, P3373, DOI 10.1093/emboj/16.12.3373; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P941, DOI 10.1107/S0907444999001031; Knodler LA, 1998, J BIOL CHEM, V273, P4470, DOI 10.1074/jbc.273.8.4470; Krissinel E., 2003, P 5 INT C MOL STRUCT, P88; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leiper JM, 1999, BIOCHEM J, V343, P209, DOI 10.1042/0264-6021:3430209; Lu CD, 1999, J BACTERIOL, V181, P2459, DOI 10.1128/JB.181.8.2459-2464.1999; LUTHI E, 1986, J GEN MICROBIOL, V132, P2667; Murray-Rust J, 2001, NAT STRUCT BIOL, V8, P679, DOI 10.1038/90387; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Oudjama Y, 2002, ACTA CRYSTALLOGR D, V58, P2150, DOI 10.1107/S0907444902015743; Palm JED, 2003, J INFECT DIS, V187, P1849, DOI 10.1086/375356; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Shirai H, 2001, TRENDS BIOCHEM SCI, V26, P465, DOI 10.1016/S0968-0004(01)01906-5; Smith RS, 2003, CURR OPIN MICROBIOL, V6, P56, DOI 10.1016/S1369-5274(03)00008-0; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; Wheatley Denys N., 2002, Pathology and Oncology Research, V8, P18; Ye S, 2001, CURR OPIN STRUC BIOL, V11, P740, DOI 10.1016/S0959-440X(01)00275-5; Zuniga M, 2002, MOL PHYLOGENET EVOL, V25, P429, DOI 10.1016/S1055-7903(02)00277-4	30	67	71	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14001	14008		10.1074/jbc.M313410200	http://dx.doi.org/10.1074/jbc.M313410200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14701825	hybrid			2022-12-25	WOS:000220478500088
J	Stedman, C; Robertson, G; Coulter, S; Liddle, C				Stedman, C; Robertson, G; Coulter, S; Liddle, C			Feed-forward regulation of bile acid detoxification by CYP3A4 - Studies in humanized transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREGNANE-X-RECEPTOR; CONSTITUTIVE-ANDROSTANE RECEPTOR; ORPHAN NUCLEAR RECEPTOR; HUMAN LIVER-MICROSOMES; LITHOCHOLIC ACID; BILIARY OBSTRUCTION; DUCT LIGATION; RAT-LIVER; METABOLISM; CHOLESTASIS	Bile acids are potentially toxic end products of cholesterol metabolism and their concentrations must be tightly regulated. Homeostasis is maintained by both feed-forward regulation and feedback regulation. We used humanized transgenic mice incorporating 13 kb of the 5' regulatory flanking sequence of CYP3A4 linked to a lacZ reporter gene to explore the in vivo relationship between bile acids and physiological adaptive CYP3A gene regulation in acute cholestasis after bile duct ligation (BDL). Male transgenic mice were subjected to BDL or sham surgery prior to sacrifice on days 3, 6, and 10, and others were injected with intraperitoneal lithocholic acid (LCA) or vehicle alone. BDL resulted in marked hepatic activation of the CYP3A4/lacZ transgene in pericentral hepatocytes, with an 80-fold increase in transgene activation by day 10. Individual bile acids were quantified by liquid chromatography/mass spectrometry. Serum 6beta-hydroxylated bile acids were increased following BDL, confirming the physiological relevance of endogenous Cyp3a induction to bile acid detoxification. Although concentrations of conjugated primary bile acids increased after BDL, there was no increase in LCA, a putative PXR ligand, indicating that this cannot be the only endogenous bile acid mediating this protective response. Moreover, in LCA-treated animals, 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside staining showed hepatic activation of the CYP3A4 transgene only on the liver capsular surface, and minimal parenchymal induction, despite significant liver injury. This study demonstrates that CYP3A up-regulation is a significant in vivo adaptive response to cholestasis. However, this up-regulation is not dependent on increases in circulating LCA and the role of other bile acids as regulatory molecules requires further exploration.	Univ Sydney, Dept Clin Pharmacol, Mol Pharmacol Lab, Westmead, NSW 2145, Australia; Univ Sydney, Dept Med, Mol Pharmacol Lab, Westmead, NSW 2145, Australia; Westmead Hosp, Westmead Millennium Inst, Storr Liver Unit, Westmead, NSW 2145, Australia; Westmead Hosp, Inst Clin Pathol & Med Res, Westmead, NSW 2145, Australia	University of Sydney; University of Sydney; University of Sydney; Westmead Institute for Medical Research; University of Sydney	Liddle, C (corresponding author), Westmead Hosp, Dept Clin Pharmacol, Darcy Rd, Westmead, NSW 2145, Australia.	chris_liddle@wmi.usyd.edu.au						Araya Z, 1999, BBA-MOL CELL BIOL L, V1438, P47, DOI 10.1016/S1388-1981(99)00031-1; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; BORNHEIM LM, 1990, MOL PHARMACOL, V38, P319; BREMMELGAARD A, 1980, SCAND J GASTROENTERO, V15, P593, DOI 10.3109/00365528009182221; CHANG TKH, 1993, BIOCHEM J, V291, P429, DOI 10.1042/bj2910429; Chiang JYL, 2002, ENDOCR REV, V23, P443, DOI 10.1210/er.2000-0035; DANIELSS.H, 1968, BIOCHEMISTRY-US, V7, P346, DOI 10.1021/bi00841a044; DANIELSSON H, 1973, STEROIDS, V22, P567, DOI 10.1016/0039-128X(73)90013-5; DUELAND S, 1991, BIOCHEM J, V280, P373, DOI 10.1042/bj2800373; Eyssen HJ, 1999, APPL ENVIRON MICROB, V65, P3158; FOSTER R, 1988, J BIOL CHEM, V263, P11528; Furster C, 1999, BBA-MOL CELL BIOL L, V1437, P46, DOI 10.1016/S0005-2760(98)00175-1; Gascon-Barre M, 2003, HEPATOLOGY, V37, P1034, DOI 10.1053/jhep.2003.50176; GEORGE J, 1995, HEPATOLOGY, V21, P120, DOI 10.1002/hep.1840210121; GREIM H, 1972, GASTROENTEROLOGY, V63, P846; GUSTAFSSON J, 1978, J LIPID RES, V19, P237; Hofmann Alan F., 1994, P677; Honda A, 2001, J BIOL CHEM, V276, P34579, DOI 10.1074/jbc.M103025200; KINUGASA T, 1981, J LIPID RES, V22, P201; Kitada H, 2003, J BIOL CHEM, V278, P17838, DOI 10.1074/jbc.M210634200; LAMBIOTTE M, 1988, EUR J BIOCHEM, V175, P595, DOI 10.1111/j.1432-1033.1988.tb14233.x; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; Maglich JM, 2002, MOL PHARMACOL, V62, P638, DOI 10.1124/mol.62.3.638; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Moore LB, 2002, MOL ENDOCRINOL, V16, P977, DOI 10.1210/me.16.5.977; Naito T, 1996, J SURG RES, V65, P70, DOI 10.1006/jsre.1996.0345; Ourlin JC, 2003, MOL ENDOCRINOL, V17, P1693, DOI 10.1210/me.2002-0383; PALMER RH, 1972, ARCH INTERN MED, V130, P606, DOI 10.1001/archinte.130.4.606; Paolini M, 2000, J INVEST MED, V48, P49; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Purucker E, 2001, BBA-GEN SUBJECTS, V1526, P44, DOI 10.1016/S0304-4165(01)00096-4; RADOMINSKA A, 1993, SEMIN LIVER DIS, V13, P219, DOI 10.1055/s-2007-1007351; Robertson GR, 2003, MOL PHARMACOL, V64, P42, DOI 10.1124/mol.64.1.42; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Schuetz EG, 1998, MOL PHARMACOL, V54, P1113, DOI 10.1124/mol.54.6.1113; Schuetz EG, 2001, J BIOL CHEM, V276, P39411, DOI 10.1074/jbc.M106340200; Setchell KDR, 1997, GASTROENTEROLOGY, V112, P226, DOI 10.1016/S0016-5085(97)70239-7; SETCHELL KDR, 1995, BIOCHEMISTRY-US, V34, P4169, DOI 10.1021/bi00013a004; Sonoda J, 2002, P NATL ACAD SCI USA, V99, P13801, DOI 10.1073/pnas.212494599; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; SUMMERFIELD JA, 1976, BIOCHEM J, V154, P507, DOI 10.1042/bj1540507; TAKITA M, 1988, J BIOCHEM-TOKYO, V103, P778, DOI 10.1093/oxfordjournals.jbchem.a122346; TEIXEIRA J, 1991, J BIOL CHEM, V266, P21030; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398	45	75	78	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11336	11343		10.1074/jbc.M310258200	http://dx.doi.org/10.1074/jbc.M310258200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14681232	hybrid			2022-12-25	WOS:000220157600062
J	Chrestensen, CA; Schroeder, MJ; Shabanowitz, J; Hunt, DF; Pelo, JW; Worthington, MT; Sturgill, TW				Chrestensen, CA; Schroeder, MJ; Shabanowitz, J; Hunt, DF; Pelo, JW; Worthington, MT; Sturgill, TW			MAPKAP kinase 2 phosphorylates tristetraprolin on in vivo sites including Ser(178), a site required for 14-3-3 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MESSENGER-RNA STABILITY; ZINC-FINGER PROTEINS; AU-RICH ELEMENTS; ACTIVATED PROTEIN-KINASE-2; TNF-ALPHA; NUCLEAR EXPORT; P38; IDENTIFICATION; SUBSTRATE	MAPKAP kinase 2 (MK2) is required for tumor necrosis factor synthesis. Tristetraprolin (TTP) binds to the 3'-untranslated region of tumor necrosis factor mRNA and regulates its fate. We identified in vitro and in vivo phosphorylation sites in TTP using nanoflow high pressure liquid chromatography microelectrospray ionization tandem mass spectrometry and novel methods for direct digestion of TTP bound to affinity matrices (GSH-beads or anti-Myc linked to magnetic beads). MK2Delta3B, activated in Escherichia coli by p38alpha, phosphorylates TTP in vitro at major sites Ser(52) and Ser(178) (> 10-fold in abundance) as well as at several minor sites that were detected after enriching for phosphopeptides with immobilized metal affinity chromatography. MK2 phosphorylation of TTP creates a functional 14-3-3 binding site. In cells, TTP was phosphorylated at Ser(52), Ser(178), Thr(250), and Ser(316) and at SP sites in a cluster (Ser(80)/ Ser(82)/Ser(85)). Anisomycin treatment of NIH 3T3 cells increased phosphorylation of Ser(52) and Ser(178). Overexpression of MK2 sufficed to increase phosphorylation of Ser(52) and Ser(178) but not Ser(80)/Ser(82)/ Ser(85) or Thr(250). Thus, Ser(52) and Ser(178) are putative MK2 sites in vivo. Identified phosphosite(s) may be biologic switches controlling mRNA stability and translation.	Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Chem, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Digest Hlth Ctr Excellence, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia	Sturgill, TW (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Box 800735, Charlottesville, VA 22908 USA.	tws7w@virginia.edu	Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060720, T32DK007320] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537, R01GM062890] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32-DK07320, DK60720] Funding Source: Medline; NIGMS NIH HHS [GM37537, GM62890] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amann BT, 2003, BIOCHEMISTRY-US, V42, P217, DOI 10.1021/bi026988m; Baseggio L, 2002, EUR CYTOKINE NETW, V13, P92; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460-2075.1995.tb00280.x; Blackshear PJ, 2002, BIOCHEM SOC T, V30, P945, DOI 10.1042/BST0300945; Bollig F, 2003, BIOCHEM BIOPH RES CO, V301, P665, DOI 10.1016/S0006-291X(03)00015-9; BOSWORTH HB, 2002, J PALLIATIVE MED, V5, P829; Brooks SA, 2002, ARTHRITIS RHEUM, V46, P1362, DOI 10.1002/art.10235; Cano E, 1996, ONCOGENE, V12, P805; Cao HP, 2003, ARCH BIOCHEM BIOPHYS, V412, P106, DOI 10.1016/S0003-9861(03)00012-2; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Cheng TJ, 2003, J CELL BIOCHEM, V89, P589, DOI 10.1002/jcb.10511; Chrestensen CA, 2002, J BIOL CHEM, V277, P27733, DOI 10.1074/jbc.M202663200; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; ENGEL K, 1995, J BIOL CHEM, V270, P27213, DOI 10.1074/jbc.270.45.27213; Fairhurst AM, 2003, ARTHRITIS RES THER, V5, pR214, DOI 10.1186/ar778; Ficarro SB, 2002, NAT BIOTECHNOL, V20, P301, DOI 10.1038/nbt0302-301; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; Johnson BA, 2000, ONCOGENE, V19, P1657, DOI 10.1038/sj.onc.1203474; Johnson BA, 2002, J BIOL CHEM, V277, P18029, DOI 10.1074/jbc.M110465200; Johnson BA, 2002, ONCOGENE, V21, P4237, DOI 10.1038/sj.onc.1205526; Kedersha N, 2002, BIOCHEM SOC T, V30, P963, DOI 10.1042/BST0300963; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Kotlyarov A, 2002, BIOCHEM SOC T, V30, P959, DOI 10.1042/BST0300959; Kotlyarov A, 2002, MOL CELL BIOL, V22, P4827, DOI 10.1128/MCB.22.13.4827-4835.2002; Lai WS, 2003, MOL CELL BIOL, V23, P3798, DOI 10.1128/MCB.23.11.3798-3812.2003; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Li Y, 2003, J BIOL CHEM, V278, P13663, DOI 10.1074/jbc.M300862200; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; Meng WY, 2002, J BIOL CHEM, V277, P37401, DOI 10.1074/jbc.C200418200; Murata T, 2000, BIOCHEM BIOPH RES CO, V274, P526, DOI 10.1006/bbrc.2000.3182; Murata T, 2002, BIOCHEM BIOPH RES CO, V293, P1242, DOI 10.1016/S0006-291X(02)00363-7; Neininger A, 2002, J BIOL CHEM, V277, P3065, DOI 10.1074/jbc.C100685200; Phillips RS, 2002, J BIOL CHEM, V277, P11606, DOI 10.1074/jbc.M111457200; Poteet-Smith CE, 1999, J BIOL CHEM, V274, P22135, DOI 10.1074/jbc.274.32.22135; Powell DW, 2003, MOL CELL BIOL, V23, P5376, DOI 10.1128/MCB.23.15.5376-5387.2003; Rousseau S, 2002, EMBO J, V21, P6505, DOI 10.1093/emboj/cdf639; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shi Y, 2002, BIOL CHEM, V383, P1519, DOI 10.1515/BC.2002.173; Singh S, 2003, J BIOL CHEM, V278, P36410, DOI 10.1074/jbc.M306428200; Stoecklin G, 2000, MOL CELL BIOL, V20, P3753, DOI 10.1128/MCB.20.11.3753-3763.2000; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; TAYLOR GA, 1995, J BIOL CHEM, V270, P13341, DOI 10.1074/jbc.270.22.13341; Taylor GA, 1996, MOL ENDOCRINOL, V10, P140, DOI 10.1210/me.10.2.140; Terpe K, 2003, APPL MICROBIOL BIOT, V60, P523, DOI 10.1007/s00253-002-1158-6; Wilkie GS, 2003, TRENDS BIOCHEM SCI, V28, P182, DOI 10.1016/S0968-0004(03)00051-3; Worthington MT, 1996, P NATL ACAD SCI USA, V93, P13754, DOI 10.1073/pnas.93.24.13754; Worthington MT, 2002, J BIOL CHEM, V277, P48558, DOI 10.1074/jbc.M206505200; Zhu W, 2001, AM J PHYSIOL-LUNG C, V281, pL499, DOI 10.1152/ajplung.2001.281.2.L499	54	219	231	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10176	10184		10.1074/jbc.M310486200	http://dx.doi.org/10.1074/jbc.M310486200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688255	hybrid			2022-12-25	WOS:000220050400064
J	Lee, JH; Jeong, SM; Lee, BH; Noh, HS; Kim, BK; Kim, JI; Rhim, H; Kim, HC; Kim, KM; Nah, SY				Lee, JH; Jeong, SM; Lee, BH; Noh, HS; Kim, BK; Kim, JI; Rhim, H; Kim, HC; Kim, KM; Nah, SY			Prevention of ginsenoside-induced desensitization of Ca2+-activated Cl- current by microinjection of inositol hexakisphosphate in Xenopus laevis oocytes - Involvement of GRK2 AND beta-arrestin I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTANCE-P RECEPTOR; PROTEIN-KINASE-C; NEUROTRANSMITTER RESPONSES; PHOSPHOLIPASE-C; PHORBOL ESTER; CHANNEL; ROLES; PENTAKISPHOSPHATE; PHOSPHORYLATION; INHIBITION	We demonstrated that ginsenosides, the active ingredient of Panax ginseng, enhance endogenous Ca2+-activated Cl- currents via Galpha(q/11)-phospholipase C-beta3 pathway in Xenopus laevis oocytes. Moreover, prolonged treatment of ginsenosides induced Cl- channel desensitization. However, the molecular mechanisms involved in ginsenoside-induced Cl- channel desensitization have not yet been determined precisely. To provide answers to these questions, we investigated the changes in ginsenoside-induced Cl- channel desensitization after intraoocyte injection of inositol hexakisphosphate (InsP(6)), which is known to bind beta-arrestins and interfere with beta-arrestin- induced receptor down-regulation, and cRNAs coding beta-arrestin I/II and G-protein receptor kinase 2 (GRK2), which is known to phosphorylate G protein-coupled receptors and attenuate agonist stimulations. When control oocytes were stimulated with ginsenosides, the second, third, and fourth responses to ginsenosides were 69.6 +/- 4.1, 9.2 +/- 2.3, and 2.6 +/- 2.2% of the first responses, respectively. Preintraoocyte injection of InsP(6) before ginsenoside treatment restored ginsenoside effect to initial response levels in a concentration, time-, and structurally specific manner, in that inositol hexasulfate had no effect. The EC50 was 13.9 +/- 8.7 muM. Injection of cRNA coding beta-arrestin I but not beta-arrestin II blocked InsP(6) effect on prevention of ginsenoside-induced Cl- channel desensitization. Injection of cRNA coding GRK2 abolished ginsenoside effect enhancing Cl- current. However, the GRK2-caused loss of ginsenoside effect on Cl- current was prevented by coinjection of GRK2 with GRK2-K220R, a dominant-negative mutant of GRK. These results indicate that ginsenoside-induced Cl- channel desensitization is mediated via activation of GRK2 and beta-arrestin I.	Konkuk Univ, Coll Vet Med, Res Lab Study Ginseng Signal Transduct, Seoul 143701, South Korea; Konkuk Univ, Coll Med, Seoul 143701, South Korea; Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Korean Inst Sci & Technol, Biomed Res Ctr, Seoul 136791, South Korea; Kangwon Natl Univ, Coll Pharm, Chunchon 200701, South Korea; Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea	Konkuk University; Konkuk University; Konkuk University Medical Center; Gwangju Institute of Science & Technology (GIST); Korea Institute of Science & Technology (KIST); Kangwon National University; Chonnam National University	Nah, SY (corresponding author), Konkuk Univ, Coll Vet Med, Res Lab Study Ginseng Signal Transduct, Seoul 143701, South Korea.	synah@konkuk.ac.kr		Lee, Junho/0000-0003-0913-8578				Appleyard SM, 1999, J BIOL CHEM, V274, P23802, DOI 10.1074/jbc.274.34.23802; Aragay AM, 1999, J BIOL CHEM, V274, P4807, DOI 10.1074/jbc.274.8.4807; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; Choi S, 2003, EUR J PHARMACOL, V468, P83, DOI 10.1016/S0014-2999(03)01666-2; Choi S, 2001, J BIOL CHEM, V276, P48797, DOI 10.1074/jbc.M104346200; Choi S, 2001, BRIT J PHARMACOL, V132, P641, DOI 10.1038/sj.bjp.0703856; CYR CR, 1993, J BIOL CHEM, V268, P26071; DASCAL N, 1986, MOL BRAIN RES, V1, P201, DOI 10.1016/0169-328X(86)90026-4; Ferguson SSG, 1998, SEMIN CELL DEV BIOL, V9, P119, DOI 10.1006/scdb.1997.0216; Hanley NRS, 2002, J PHARMACOL EXP THER, V300, P468, DOI 10.1124/jpet.300.2.468; HESLOP JP, 1985, J EXP BIOL, V119, P395; Hill JJ, 2001, J BIOL CHEM, V276, P5505, DOI 10.1074/jbc.M008213200; ITO I, 1988, J CELL PHYSIOL, V134, P155, DOI 10.1002/jcp.1041340120; KATO K, 1988, J NEUROCHEM, V50, P766, DOI 10.1111/j.1471-4159.1988.tb02980.x; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LEEBLUNDBERG LMF, 1985, P NATL ACAD SCI USA, V82, P5651, DOI 10.1073/pnas.82.17.5651; LUPUMEIRI M, 1989, PFLUG ARCH EUR J PHY, V413, P498, DOI 10.1007/BF00594180; McConalogue K, 1998, MOL BIOL CELL, V9, P2305, DOI 10.1091/mbc.9.8.2305; MORAN O, 1989, MOL BRAIN RES, V5, P193, DOI 10.1016/0169-328X(89)90035-1; NAH SY, 1994, J ETHNOPHARMACOL, V42, P45, DOI 10.1016/0378-8741(94)90022-1; NAH SY, 1995, P NATL ACAD SCI USA, V92, P8739, DOI 10.1073/pnas.92.19.8739; Nah SY, 1997, KOREAN J GINSENG SCI, V21, P1; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; ORELLANA S, 1987, J BIOL CHEM, V262, P1638; PALCZEWSKI K, 1991, FEBS LETT, V295, P195, DOI 10.1016/0014-5793(91)81416-6; PALCZEWSKI K, 1992, NEURON, V8, P117, DOI 10.1016/0896-6273(92)90113-R; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; SASAKAWA N, 1994, MOL PHARMACOL, V46, P380; SHEARS SB, 1989, BIOCHEM J, V260, P313, DOI 10.1042/bj2600313; SINGER D, 1990, PFLUG ARCH EUR J PHY, V416, P7, DOI 10.1007/BF00370215; SZWERGOLD BS, 1987, BIOCHEM BIOPH RES CO, V149, P874, DOI 10.1016/0006-291X(87)90489-X; Tyler Varro E., 1995, Journal of Pharmacy Technology, V11, P214	32	22	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9912	9921		10.1074/jbc.M310824200	http://dx.doi.org/10.1074/jbc.M310824200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699097	hybrid			2022-12-25	WOS:000220050400032
J	Medeiros, LA; Khan, T; El Khoury, JB; Pham, CLL; Hatters, DM; Howlett, GJ; Lopez, R; O'Brien, KD; Moore, KJ				Medeiros, LA; Khan, T; El Khoury, JB; Pham, CLL; Hatters, DM; Howlett, GJ; Lopez, R; O'Brien, KD; Moore, KJ			Fibrillar amyloid protein present in atheroma activates CD36 signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCAVENGER RECEPTOR CD36; APOLIPOPROTEIN-C-II; ALZHEIMERS-DISEASE; ATHEROSCLEROTIC PLAQUES; A-I; DENSITY; MACROPHAGES; MECHANISMS; DEPOSITS	The self-association of proteins to form amyloid fibrils has been implicated in the pathogenesis of a number of diseases including Alzheimer's, Parkinson's, and Creutzfeldt-Jakob diseases. We recently reported that the myeloid scavenger receptor CD36 initiates a signaling cascade upon binding to fibrillar beta-amyloid that stimulates recruitment of microglia in the brain and production of inflammatory mediators. This receptor plays a key role in the pathogenesis of atherosclerosis, prompting us to evaluate whether fibrillar proteins were present in atherosclerotic lesions that could initiate signaling via CD36. We show that apolipoprotein C-II, a component of very low and high density lipoproteins, readily forms amyloid fibrils that initiate macrophage inflammatory responses including reactive oxygen production and tumor necrosis factor alpha expression. Using macrophages derived from wild type and Cd36(-/-) mice to distinguish CD36-specific events, we show that fibrillar apolipoprotein C-II activates a signaling cascade downstream of this receptor that includes Lyn and p44/42 MAPKs. Interruption of this signaling pathway through targeted deletion of Cd36 or blocking of p44/42 MAPK activation inhibits macrophage tumor necrosis factor alpha gene expression. Finally, we demonstrate that apolipoprotein C-II in human atheroma co-localizes to regions positive for markers of amyloid and macrophage accumulation. Together, these data characterize a CD36-dependent signaling cascade initiated by fibrillar amyloid species that may promote atherogenesis.	Harvard Univ, Sch Med, Lipid Metab Unit, Massachusetts Gen Hosp, Boston, MA 02114 USA; Harvard Univ, Sch Med, Div Rheumatol Allergy & Immunol, Massachusetts Gen Hosp, Boston, MA 02114 USA; Univ Washington, Div Cardiol, Seattle, WA 98195 USA; Univ Melbourne, Russell Grimwade Sch Biochem & Mol Biol, Melbourne, Vic 3010, Australia	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Washington; University of Washington Seattle; University of Melbourne	Moore, KJ (corresponding author), Harvard Univ, Sch Med, Lipid Metab Unit, Massachusetts Gen Hosp, Boston, MA 02114 USA.	kmoore@molbio.mgh.harvard.edu	O'Brien, Kevin Douglas/HDO-1461-2022; O'Brien, Kevin/CAH-4638-2022; Moore, Kathryn/ABE-6416-2020	O'Brien, Kevin Douglas/0000-0002-2293-9196; O'Brien, Kevin/0000-0002-2293-9196; Moore, Kathryn/0000-0003-2505-2547; Hatters, Danny/0000-0002-9965-2847	NIA NIH HHS [R01AG/HL20255] Funding Source: Medline; NINDS NIH HHS [NS41330-3] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS041330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020255] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bamberger ME, 2003, J NEUROSCI, V23, P2665; Bergstrom J, 2001, BIOCHEM BIOPH RES CO, V285, P903, DOI 10.1006/bbrc.2001.5260; Clarke R, 2002, CARDIOVASC DRUG THER, V16, P411, DOI 10.1023/A:1022134418372; COETZEE GA, 1986, J BIOL CHEM, V261, P9644; Coraci IS, 2002, AM J PATHOL, V160, P101, DOI 10.1016/S0002-9440(10)64354-4; De Meyer GRY, 2002, CIRC RES, V90, P1197, DOI 10.1161/01.RES.0000020017.84398.61; Dichtl Wolfgang, 2000, Molecular Cell Biology Research Communications, V4, P50, DOI 10.1006/mcbr.2000.0256; El Khoury JB, 2003, J EXP MED, V197, P1657, DOI 10.1084/jem.20021546; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; GOWN AM, 1986, AM J PATHOL, V125, P191; Hatters DM, 2002, J BIOL CHEM, V277, P7824, DOI 10.1074/jbc.M110429200; Hatters DM, 2003, BIOPHYS J, V85, P3979, DOI 10.1016/S0006-3495(03)74812-7; Hatters DM, 2000, BIOCHEMISTRY-US, V39, P8276, DOI 10.1021/bi000002w; HAVEL RJ, 1973, BIOCHEMISTRY-US, V12, P1828, DOI 10.1021/bi00733a026; HIGUCHI K, 1991, BIOCHEM J, V279, P427, DOI 10.1042/bj2790427; JACKSON RL, 1986, METHOD ENZYMOL, V128, P288; Janciauskiene S, 2001, ATHEROSCLEROSIS, V158, P41, DOI 10.1016/S0021-9150(00)00767-X; Kunjathoor VV, 2002, J BIOL CHEM, V277, P49982, DOI 10.1074/jbc.M209649200; Lin CY, 1999, J LIPID RES, V40, P1618; Mak PA, 2002, J BIOL CHEM, V277, P31900, DOI 10.1074/jbc.M202993200; Marsche G, 2003, J BIOL CHEM, V278, P47562, DOI 10.1074/jbc.M308428200; Moore KJ, 2001, NAT MED, V7, P41, DOI 10.1038/83328; Moore KJ, 2002, J BIOL CHEM, V277, P47373, DOI 10.1074/jbc.M208788200; Mucchiano GI, 2001, J PATHOL, V193, P270, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH753>3.0.CO;2-S; Mucchiano GI, 2001, AM J CLIN PATHOL, V115, P298; O'Brien KD, 1998, CIRCULATION, V98, P519, DOI 10.1161/01.CIR.98.6.519; O'Nuallain B, 2002, P NATL ACAD SCI USA, V99, P1485, DOI 10.1073/pnas.022662599; PEPYS MB, 1994, P NATL ACAD SCI USA, V91, P5602, DOI 10.1073/pnas.91.12.5602; Pham CLL, 2002, BIOCHEMISTRY-US, V41, P14313, DOI 10.1021/bi026070v; Podrez EA, 2000, J CLIN INVEST, V105, P1095, DOI 10.1172/JCI8574; Podrez EA, 2002, J BIOL CHEM, V277, P38517, DOI 10.1074/jbc.M205924200; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Steinberg D, 2002, CIRCULATION, V105, P2107, DOI 10.1161/01.CIR.0000014762.06201.06; Tedgui A, 2002, CIRC RES, V90, P1145, DOI 10.1161/01.RES.0000023048.87638.92; Wang CS, 1996, BBA-LIPID LIPID MET, V1302, P224, DOI 10.1016/0005-2760(96)00065-3; WEINBERG RB, 1985, J BIOL CHEM, V260, P4914; WESTERMARK P, 1995, AM J PATHOL, V147, P1186; WISNIEWSKI T, 1995, LANCET, V345, P956, DOI 10.1016/S0140-6736(95)90701-7; WISNIEWSKI T, 1995, AM J PATHOL, V147, P238	42	118	120	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10643	10648		10.1074/jbc.M311735200	http://dx.doi.org/10.1074/jbc.M311735200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699114	hybrid			2022-12-25	WOS:000220050400118
J	Scheijen, B; Bronk, M; van der Meer, T; De Jong, D; Bernards, R				Scheijen, B; Bronk, M; van der Meer, T; De Jong, D; Bernards, R			High incidence of thymic epithelial tumors in E2F2 transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PHASE ENTRY; CELLULAR PROLIFERATION; TRANSCRIPTION FACTORS; IN-VIVO; DEREGULATED EXPRESSION; NEGATIVE SELECTION; DNA-REPLICATION; MOUSE MODEL; APOPTOSIS; CELLS	In virtually all human tumors, genetic and epigenetic alterations have been found which affect the INK4/-CYCLIN D/RB pathway, which regulates cell cycle entry and exit in normal cells. E2F transcription factors are important downstream components of this pathway, which act by controlling the expression of genes involved in DNA replication and cell cycle progression. To determine whether E2F2 deregulation promotes proliferation and tumorigenesis in vivo, we generated E2F2 transgenic mice, in which the Emu and murine pim1 promoter ( pp) direct high expression of E2F2 in thymic epithelial cells. Emu-pp-E2F2 mice start to develop cytokeratin- and ER-TR4-positive cortical thymomas from the age of 20 weeks, and within 1 year, nearly all mice succumb to gross thymic epithelial tumors. General thymic morphology is largely maintained, but T cell development is perturbed in thymomas, with proportionately less CD4(+) CD8(+) double-positive thymocytes. In the first 3 months, E2F2 transgenic thymi exhibit only mild epithelial hyperplasia, and thereafter thymomas arise stochastically, probably following additional mutations. Interestingly, Emu-pp-E2F1 mice do not display cortical thymomas. These data argue that E2F2 promotes unscheduled cell division and oncogenic transformation of thymic epithelial cells.	Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	R.Bernards@nki.nl	Scheijen, Blanca/E-3523-2016	Scheijen, Blanca/0000-0001-8029-9230; Bernards, Rene/0000-0001-8677-3423				ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262; Allen JD, 1997, ONCOGENE, V15, P1133, DOI 10.1038/sj.onc.1201288; Bargou RC, 1996, J EXP MED, V183, P1205, DOI 10.1084/jem.183.3.1205; Baudino TA, 2003, MOL CELL, V11, P905, DOI 10.1016/S1097-2765(03)00102-3; Bennett AR, 2002, IMMUNITY, V16, P803, DOI 10.1016/S1074-7613(02)00321-7; BOYD RL, 1993, IMMUNOL TODAY, V14, P445, DOI 10.1016/0167-5699(93)90248-J; Carraresi L, 2001, ONCOGENE, V20, P8148, DOI 10.1038/sj.onc.1205007; Chen Q, 2000, INVEST OPHTH VIS SCI, V41, P4223; Cloud JE, 2002, MOL CELL BIOL, V22, P2663, DOI 10.1128/MCB.22.8.2663-2672.2002; Conner EA, 2000, ONCOGENE, V19, P5054, DOI 10.1038/sj.onc.1203885; Dagnino L, 1997, MECH DEVELOP, V66, P13, DOI 10.1016/S0925-4773(97)00083-X; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DeGregori J, 2002, BBA-REV CANCER, V1602, P131, DOI 10.1016/S0304-419X(02)00051-3; delaLuna S, 1996, J CELL SCI, V109, P2443; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dong YB, 2002, CANCER RES, V62, P1776; Elliott MJ, 2002, TUMOR BIOL, V23, P76, DOI 10.1159/000059708; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Fueyo J, 1998, NAT MED, V4, P685, DOI 10.1038/nm0698-685; Garcia I, 2000, CELL GROWTH DIFFER, V11, P91; Gill J, 2002, NAT IMMUNOL, V3, P635, DOI 10.1038/ni812; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Humbert PO, 2000, GENE DEV, V14, P690; Hunt KK, 1997, CANCER RES, V57, P4722; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; IZON DJ, 1994, INT IMMUNOL, V6, P31, DOI 10.1093/intimm/6.1.31; Klug DB, 1998, P NATL ACAD SCI USA, V95, P11822, DOI 10.1073/pnas.95.20.11822; Lee SS, 1998, VIRCHOWS ARCH, V432, P33, DOI 10.1007/s004280050131; Li FX, 2003, MOL CELL BIOL, V23, P3607, DOI 10.1128/MCB.23.10.3607-3622.2003; Lomazzi M, 2002, NAT GENET, V31, P190, DOI 10.1038/ng891; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; MULLER H, 2000, BIOCHIM BIOPHYS ACTA, V1470, P1; Murga M, 2001, IMMUNITY, V15, P959, DOI 10.1016/S1074-7613(01)00254-0; ORMONDROYD E, 1995, ONCOGENE, V11, P1437; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; Rampalli AM, 1998, ONCOGENE, V16, P399, DOI 10.1038/sj.onc.1201546; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Rheinwald JG, 2002, MOL CELL BIOL, V22, P5157, DOI 10.1128/MCB.22.14.5157-5172.2002; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; Rodriguez-Puebla ML, 2000, AM J PATHOL, V157, P1039, DOI 10.1016/S0002-9440(10)64616-0; Rogers KT, 1996, P NATL ACAD SCI USA, V93, P7594, DOI 10.1073/pnas.93.15.7594; Rounbehler RJ, 2002, CANCER RES, V62, P3276; RUTHER U, 1988, CELL, V53, P847, DOI 10.1016/S0092-8674(88)90289-9; Scheijen B, 2003, MOL CELL BIOL, V23, P3656, DOI 10.1128/MCB.23.10.3656-3668.2003; Slack JMW, 2000, SCIENCE, V287, P1431, DOI 10.1126/science.287.5457.1431; Smith DS, 2000, CELL GROWTH DIFFER, V11, P625; SPANOPOULOU E, 1989, NATURE, V342, P185, DOI 10.1038/342185a0; VANVLIET E, 1984, EUR J IMMUNOL, V14, P524, DOI 10.1002/eji.1830140608; Wikonkal NM, 2003, NAT CELL BIOL, V5, P655, DOI 10.1038/ncb1001; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Zhu JW, 1999, CELL GROWTH DIFFER, V10, P829; Zhu JW, 2001, MOL CELL BIOL, V21, P8547, DOI 10.1128/MCB.21.24.8547-8564.2001	61	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10476	10483		10.1074/jbc.M313682200	http://dx.doi.org/10.1074/jbc.M313682200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14684733	hybrid, Green Published			2022-12-25	WOS:000220050400099
J	Gate, L; Majumdar, RS; Lunk, A; Tew, KD				Gate, L; Majumdar, RS; Lunk, A; Tew, KD			Increased myeloproliferation in glutathione S-transferase pi-deficient mice is associated with a deregulation of JNK and janus kinase/STAT pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; TYROSINE-PHOSPHATASE SHP-1; RAS-DEPENDENT ACTIVATION; C-JUN; CONSTITUTIVE ACTIVATION; CELL-LINES; P53 PHOSPHORYLATION; JAK/STAT PATHWAY; PROLIFERATION	It has been shown that glutathione S-transferase pi (GSTpi) interacts with and suppresses the activity of c-Jun NH2-terminal kinase (JNK). GST-deficient mice (GSTpi(-/-)) have higher levels of circulating white blood cells, with similar proportions of lymphocytes, monocytes, and granulocytes. Interestingly, a selective expansion of splenic B lymphocytes was observed in GSTpi(-/-) animals but no change in T lymphocytes or natural killer cells. A peptidomimetic inhibitor of GSTpi that disrupts the interaction between GSTpi and JNK mimics in wild type mice the increased myeloproliferation observed in GSTpi(-/-) animals. Until now, the molecular basis for this effect has not been defined. In an in vitro hematopoiesis assay, interleukin-3, granulocyte colony-stimulating factor, and granulocyte/ macrophage colony-stimulating factor were more effective at stimulating proliferation of hematopoietic cells in GSTpi(-/-) mice than in wild type. The JNK inhibitor SP600125 which caused little inhibition of cytokine-induced myeloproliferation in wild type mice, decreased the number of colonies in GSTpi(-/-) animals. A more sustained phosphorylation of the STAT family of proteins was also observed in GSTpi(-/-) bone marrow-derived mast cells exposed to interleukin-3. This was associated with an increased proliferation and a down-regulation of expression of negative regulators of the Janus kinase-STAT pathway SHP, Src homology 2 domain-containing tyrosine phosphatase-1 and -2. The increased activation of JNK and STATs in GSTpi-deficient mice provides a viable mechanism for the increased myeloproliferation in these animals. These data also confirm the important role that GSTpi plays in the regulation of cell signaling pathways in a myeloproliferative setting.	Fox Chase Canc Ctr, Dept Pharmacol, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Tew, KD (corresponding author), Fox Chase Canc Ctr, Dept Pharmacol, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	KD_Tew@fccc.edu			NATIONAL CANCER INSTITUTE [P30CA006927, R01CA085660] Funding Source: NIH RePORTER; NCI NIH HHS [CA85660, CA06927] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Baumann MA, 2001, AM J HEMATOL, V68, P99, DOI 10.1002/ajh.1160; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Chai SK, 1997, J IMMUNOL, V159, P4720; Davis W, 2001, J PHARMACOL EXP THER, V296, P1; Dong Zigang, 2003, Mol Interv, V3, P306, DOI 10.1124/mi.3.6.306; Foltz IN, 1997, BLOOD, V89, P3092, DOI 10.1182/blood.V89.9.3092; Gamero AM, 2001, J BIOL CHEM, V276, P13547, DOI 10.1074/jbc.M007948200; Gate Laurent, 2001, Expert Opin Ther Targets, V5, P477; Hochedlinger K, 2002, ONCOGENE, V21, P2441, DOI 10.1038/sj.onc.1205348; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Kauvar LM, 1998, CHEM-BIOL INTERACT, V112, P225, DOI 10.1016/S0009-2797(97)00163-4; Keller G, 1999, EXP HEMATOL, V27, P777, DOI 10.1016/S0301-472X(99)00024-7; Kirito K, 2002, INT J HEMATOL, V75, P51, DOI 10.1007/BF02981979; Kishi H, 2001, J BIOL CHEM, V276, P39115, DOI 10.1074/jbc.M105134200; Kita A, 2003, BIOCHEM BIOPH RES CO, V302, P805, DOI 10.1016/S0006-291X(03)00264-X; Kwon YW, 2002, J BIOL CHEM, V277, P1837, DOI 10.1074/jbc.M105033200; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; Larsen L, 2002, APMIS, V110, P833, DOI 10.1034/j.1600-0463.2002.1101201.x; Miranda MB, 2002, LEUKEMIA, V16, P683, DOI 10.1038/sj.leu.2402400; Morgan AS, 1996, CANCER CHEMOTH PHARM, V37, P363, DOI 10.1007/s002800050398; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Paling NRD, 2002, BIOCHEM J, V368, P885, DOI 10.1042/BJ20021054; Rane SG, 2002, ONCOGENE, V21, P3334, DOI 10.1038/sj.onc.1205398; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; Ruscoe JE, 2001, J PHARMACOL EXP THER, V298, P339; Schwabe RF, 2003, HEPATOLOGY, V37, P824, DOI 10.1053/jhep.2003.50135; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shuai K, 1996, ONCOGENE, V13, P247; Spiekermann K, 2002, EXP HEMATOL, V30, P262, DOI 10.1016/S0301-472X(01)00787-1; Srinivasa SP, 2002, LEUKEMIA, V16, P244, DOI 10.1038/sj.leu.2402367; Su YR, 2002, J LIPID RES, V43, P2180, DOI 10.1194/jlr.D200020-JLR200; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; TEW KD, 1994, CANCER RES, V54, P4313; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Townsend Danyelle, 2003, Am J Pharmacogenomics, V3, P157, DOI 10.2165/00129785-200303030-00002; Wang T, 2001, J BIOL CHEM, V276, P20999, DOI 10.1074/jbc.M101355200; Ward AC, 2000, BLOOD, V95, P19; WeberNordt RM, 1996, BLOOD, V88, P809; Wheadon H, 2002, CELL SIGNAL, V14, P219, DOI 10.1016/S0898-6568(01)00241-8; Wu CY, 2003, GENE, V306, P1, DOI 10.1016/S0378-1119(03)00400-1; Yang YM, 2003, CLIN CANCER RES, V9, P391; Yin ZM, 2000, CANCER RES, V60, P4053; Yu CL, 2000, J BIOL CHEM, V275, P599, DOI 10.1074/jbc.275.1.599	48	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8608	8616		10.1074/jbc.M308613200	http://dx.doi.org/10.1074/jbc.M308613200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14684749	hybrid			2022-12-25	WOS:000189265900012
J	Gauthier, NC; Ricci, V; Gounon, P; Doye, A; Tauc, M; Poujeol, P; Boquet, P				Gauthier, NC; Ricci, V; Gounon, P; Doye, A; Tauc, M; Poujeol, P; Boquet, P			Glycosylphosphatidylinositol-anchored proteins and actin cytoskeleton modulate chloride transport by channels formed by the Helicobacter pylori vacuolating cytotoxin VacA in HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-SELECTIVE CHANNELS; TOXIN VACA; PLASMA-MEMBRANE; LIPID-BILAYERS; RAFTS; INTERNALIZATION; ACCUMULATION; ENDOCYTOSIS; INHIBITION; ENDOSOMES	The vacuolating cytotoxin VacA is an important virulence factor of Helicobacter pylori. Removing glycosylphosphatidylinositol-anchored proteins (GPI-Ps) from the cell surface by phosphatidylinositol-phospholipase C or disrupting the cell actin cytoskeleton by cytochalasin D reduced VacA-induced vacuolation of cells (Ricci V., Galmiche, A., Doye, A., Necchi, V., Solcia, E., and Boquet, P. ( 2000) Mol. Biol. Cell 11, 3897 - 3909). Using the fluorescent dye 6-methoxy-N-ethylquinolinium chloride, an indicator for cytosolic chloride, we have investigated the role of either GPI-Ps or actin cytoskeleton in the activity of the selective anionic channel formed by VacA at the plasma membrane level. Removal of GPI-Ps from HeLa cell surfaces did not impair VacA localization into lipid rafts but strongly reduced VacA channel-mediated cell influx and efflux of chloride. Disruption of the actin cytoskeleton of HeLa cells by cytochalasin D did not affect VacA localization in lipid rafts but blocked VacA cell internalization and inhibited cell vacuolation while increasing the overall chloride transport by the toxin channel at the cell surface. Specific enlargement of Rab7-positive compartments induced by VacA could be mimicked by the weak base chloroquine alone, and the vacuolating activities of either chloroquine alone or VacA were blocked with the same potency by the anion channel blocker 5-nitro-2-(3-phenylpropylamino)- benzoic acid shown to inhibit VacA channel activity ( Tombola, F., Oregna, F., Brutsche, S., Szabo`, I., Del Giudice, G., Rappuoli, R., Montecucco, C., Papini, E., and Zoratti, M. ( 1999) FEBS Lett. 460, 221 - 225). We suggest that formation of functional VacA channels at the cell surface required GPI-Ps and that endocytosis of these channels by an actin-dependent process increases the chloride content of late endosomes that accumulate weak bases, provoking their enlargement by osmotic swelling.	Fac Med, INSERM, U452, F-06107 Nice, France; Univ Pavia, Dept Expt Med, Human Physiol Sect, I-27100 Pavia, Italy; Univ Nice, Ctr Commun Microscopie Appl, F-06108 Nice, France; Fac Sci, CNRS, UMR 6548, F-06108 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Pavia; UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS)	Boquet, P (corresponding author), Fac Med, INSERM, U452, IFR 50,28 Ave Valombrose, F-06107 Nice, France.	boquet@unice.fr	Tauc, Michel/F-1530-2013	Tauc, Michel/0000-0002-8383-9818				Adrian M, 2002, J MOL BIOL, V318, P121, DOI 10.1016/S0022-2836(02)00047-5; Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; BIWERSI J, 1991, BIOCHEMISTRY-US, V30, P7879, DOI 10.1021/bi00246a001; Boquet P, 2003, TRENDS MICROBIOL, V11, P410, DOI 10.1016/S0966-842X(03)00211-7; Cover TL, 1996, MOL MICROBIOL, V20, P241, DOI 10.1111/j.1365-2958.1996.tb02612.x; COVER TL, 1992, J BIOL CHEM, V267, P10570; Cover TL, 1997, J CELL BIOL, V138, P759, DOI 10.1083/jcb.138.4.759; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; Czajkowsky DM, 1999, P NATL ACAD SCI USA, V96, P2001, DOI 10.1073/pnas.96.5.2001; DAVITZ MA, 1986, J EXP MED, V163, P1150, DOI 10.1084/jem.163.5.1150; deBernard M, 1997, MOL MICROBIOL, V26, P665, DOI 10.1046/j.1365-2958.1997.5881952.x; DEBERNARD M, 1995, J BIOL CHEM, V270, P23937, DOI 10.1074/jbc.270.41.23937; Deckert M, 1996, J CELL BIOL, V133, P791, DOI 10.1083/jcb.133.4.791; Fivaz M, 2001, CURR TOP MICROBIOL, V257, P35; Fujiwara T, 2002, J CELL BIOL, V157, P1071, DOI 10.1083/jcb.200202050; Garner JA, 1996, INFECT IMMUN, V64, P4197, DOI 10.1128/IAI.64.10.4197-4203.1996; Gebert B, 2003, SCIENCE, V301, P1099, DOI 10.1126/science.1086871; GOGELEIN H, 1989, PFLUG ARCH EUR J PHY, V413, P287, DOI 10.1007/BF00583543; Hotchin NA, 2000, J BIOL CHEM, V275, P14009, DOI 10.1074/jbc.C000153200; Iwamoto H, 1999, FEBS LETT, V450, P101, DOI 10.1016/S0014-5793(99)00474-3; Kuo CH, 2003, BIOCHEM BIOPH RES CO, V303, P640, DOI 10.1016/S0006-291X(03)00380-2; Lupetti P, 1996, J CELL BIOL, V133, P801, DOI 10.1083/jcb.133.4.801; Mcclain MS, 2003, J BIOL CHEM, V278, P12101, DOI 10.1074/jbc.M212595200; Morbiato L, 2001, FEBS LETT, V508, P479, DOI 10.1016/S0014-5793(01)03133-7; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; OHKUMA S, 1981, J CELL BIOL, V90, P656, DOI 10.1083/jcb.90.3.656; Papini E, 2001, TOXICON, V39, P1757, DOI 10.1016/S0041-0101(01)00162-3; PAPINI E, 1994, P NATL ACAD SCI USA, V91, P9720, DOI 10.1073/pnas.91.21.9720; Patel HK, 2002, INFECT IMMUN, V70, P4112, DOI 10.1128/IAI.70.8.4112-4123.2002; Peterson JR, 2002, CHEM BIOL, V9, P1275, DOI 10.1016/S1074-5521(02)00284-3; Ricci V, 2000, MOL BIOL CELL, V11, P3897, DOI 10.1091/mbc.11.11.3897; Ricci V, 1997, J PATHOL, V183, P453; Salama NR, 2001, INFECT IMMUN, V69, P730, DOI 10.1128/IAI.69.2.730-736.2001; Schraw W, 2002, J BIOL CHEM, V277, P34642, DOI 10.1074/jbc.M203466200; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sonawane ND, 2003, J CELL BIOL, V160, P1129, DOI 10.1083/jcb.200211098; Sonawane ND, 2002, J BIOL CHEM, V277, P5506, DOI 10.1074/jbc.M110818200; Szabo I, 1999, EMBO J, V18, P5517, DOI 10.1093/emboj/18.20.5517; Tombola F, 1999, FEBS LETT, V460, P221, DOI 10.1016/S0014-5793(99)01348-4; Tombola F, 1999, BIOPHYS J, V76, P1401, DOI 10.1016/S0006-3495(99)77301-7; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Vinion-Dubiel AD, 1999, J BIOL CHEM, V274, P37736, DOI 10.1074/jbc.274.53.37736; Willhite DC, 2002, INFECT IMMUN, V70, P3824, DOI 10.1128/IAI.70.7.3824-3832.2002; Ye D, 1999, J BIOL CHEM, V274, P9277, DOI 10.1074/jbc.274.14.9277	44	34	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9481	9489		10.1074/jbc.M312040200	http://dx.doi.org/10.1074/jbc.M312040200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676190	hybrid			2022-12-25	WOS:000189265900114
J	He, F; Mao, ML; Wensel, TG				He, F; Mao, ML; Wensel, TG			Enhancement of phototransduction G protein-effector interactions by phosphoinositides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; LIGHT-MEDIATED BREAKDOWN; CGMP PHOSPHODIESTERASE; PHOSPHOLIPASE-C; RETINAL RODS; IN-VIVO; BOVINE; ADAPTATION; PHOTORECEPTOR; MEMBRANES	Light responses in photoreceptor cells are mediated by the action of the G protein transducin (G(t)) on the effector enzyme cGMP phosphodiesterase (PDE6) at the surface of disk membranes. The enzymatic components needed for phosphoinositide-based signaling are known to be present in rod cells, but it has remained uncertain what role phosphoinositides play in vertebrate phototransduction. Reconstitution of PDE6 and activated G(alphat), on the surface of large unilamellar vesicles containing D-myo-phosphatidylinositol-4,5-bisphosphate (PI(4,5) P-2), stimulated PDE activity nearly 4-fold above the level observed with membranes containing no phosphoinositides, whereas G protein-independent activation by trypsin was unaffected by the presence of phosphoinositides. PDE activity was similarly stimulated by D-myo-phosphatidylinositol-3,4-bisphosphate and D-myophosphatidylinositol-4- phosphate ( PI( 4) P), but much less by D-myo-phosphatidylinositol-5-phosphate (PI(5) P-2) or D-myo-phosphatidylinositol-3,5-bisphosphate. Incubation of rod outer segment membranes with phosphoinositide-specific phospholipase C decreased G protein-stimulated activation of endogenous PDE6, but not trypsin-stimulated PDE activity. Binding experiments using phosphoinositide-containing vesicles revealed patterns of PDE6 binding and PDE6-enhanced G(alphat)-GTPgammaS binding, consistent with the activation profile PI(4,5) P-2 > PI(4) P > PI(5) P similar to control vesicles. These results suggest that enhancement of effector-G protein interactions represents a possible mechanism for modulation of phototransduction gain by changes in phosphoinositide levels, perhaps occurring in response to long-term changes in illumination or other environmental cues.	Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA	Baylor College of Medicine	Wensel, TG (corresponding author), Baylor Coll Med, Dept Biochem & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	twensel@bcm.tmc.edu		Wensel, Theodore/0000-0003-3518-9352	NEI NIH HHS [EY07001] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Calvert PD, 2002, J GEN PHYSIOL, V119, P129, DOI 10.1085/jgp.119.2.129; CHOE HG, 1990, EXP EYE RES, V51, P167, DOI 10.1016/0014-4835(90)90069-7; DAS ND, 1986, CELL STRUCT FUNCT, V11, P53, DOI 10.1247/csf.11.53; DAS ND, 1987, CELL STRUCT FUNCT, V12, P471, DOI 10.1247/csf.12.471; GHALAYINI A, 1984, BIOCHEM BIOPH RES CO, V124, P503, DOI 10.1016/0006-291X(84)91582-1; Ghalayini AJ, 1998, J NEUROCHEM, V70, P171; GHALAYINI AJ, 1991, J NEUROCHEM, V57, P1405, DOI 10.1111/j.1471-4159.1991.tb08307.x; GHALAYINI AJ, 1992, J BIOL CHEM, V267, P17977; GHALAYINI AJ, 1995, CURR EYE RES, V14, P1025, DOI 10.3109/02713689508998525; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HAYASHI F, 1985, BIOCHEM BIOPH RES CO, V128, P954, DOI 10.1016/0006-291X(85)90139-1; He F, 2000, J BIOL CHEM, V275, P20572, DOI 10.1074/jbc.M000440200; Hessel E, 2003, J BIOL CHEM, V278, P22853, DOI 10.1074/jbc.M302747200; Hurley JB, 2002, J GEN PHYSIOL, V119, P125, DOI 10.1085/jgp.119.2.125; Jindrova H, 1998, PHYSIOL RES, V47, P285; Kennedy MJ, 2001, NEURON, V31, P87, DOI 10.1016/S0896-6273(01)00340-3; MALINSKI JA, 1992, BIOCHEMISTRY-US, V31, P9502, DOI 10.1021/bi00154a024; Melia TJ, 2000, J BIOL CHEM, V275, P3535, DOI 10.1074/jbc.275.5.3535; MILLAR FA, 1988, BIOCHIM BIOPHYS ACTA, V970, P205, DOI 10.1016/0167-4889(88)90180-2; Nasuhoglu C, 2002, ANAL BIOCHEM, V301, P243, DOI 10.1006/abio.2001.5489; Nikonov S, 2000, J GEN PHYSIOL, V116, P795, DOI 10.1085/jgp.116.6.795; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; Peng YW, 1997, P NATL ACAD SCI USA, V94, P1995, DOI 10.1073/pnas.94.5.1995; Pugh EN, 1999, CURR OPIN NEUROBIOL, V9, P410, DOI 10.1016/S0959-4388(99)80062-2; SRIVASTAVA D, 1995, BIOCHEM J, V308, P653, DOI 10.1042/bj3080653; Tcheudji JFK, 2001, J MOL BIOL, V310, P781, DOI 10.1006/jmbi.2001.4813; Womack KB, 2000, J NEUROSCI, V20, P2792	29	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8986	8990		10.1074/jbc.M311488200	http://dx.doi.org/10.1074/jbc.M311488200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14699118	hybrid			2022-12-25	WOS:000189265900057
J	Leach, MR; Williams, DB				Leach, MR; Williams, DB			Lectin-deficient calnexin is capable of binding class I histocompatibility molecules in vivo and preventing their degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE MHC ANTIGENS; TCR-ALPHA PROTEINS; MISFOLDED GLYCOPROTEINS; QUALITY-CONTROL; LINKED OLIGOSACCHARIDE; CALRETICULIN FUNCTIONS; MONOCLONAL-ANTIBODIES; CHAPERONE; COMPLEX; ASSOCIATION	Calnexin is a membrane-bound lectin of the endoplasmic reticulum (ER) that binds transiently to newly synthesized glycoproteins. By interacting with oligosaccharides of the form Glc(1)Man(9)GlcNAc(2), calnexin enhances the folding of glycoprotein substrates, retains misfolded variants in the ER, and in some cases participates in their degradation. Calnexin has also been shown to bind polypeptides in vivo that do not possess a glycan of this form and to function in vitro as a molecular chaperone for nonglycosylated proteins. To test the relative importance of the lectin site compared with the polypeptide-binding site, we have generated six calnexin mutants defective in oligosaccharide binding using site-directed mutagenesis. Expressed as glutathione S-transferase fusions, these mutants were still capable of binding ERp57, a thiol oxidoreductase, and preventing the aggregation of a nonglycosylated substrate, citrate synthase. They were, however, unable to bind Glc(1) Man(9)GlcNAc(2) oligosaccharide and were compromised in preventing the aggregation of the monoglucosylated substrate jack bean alpha-mannosidase. Two of these mutants were then engineered into full-length calnexin for heterologous expression in Drosophila cells along with the murine class I histocompatibility molecules K-b and D-b as model glycoproteins. In this system, lectin site-defective calnexin was able to replace wild type calnexin in forming a complex with K-b and D-b heavy chains and preventing their degradation. Thus, at least for class I molecules, the lectin site of calnexin is dispensable for some of its chaperone functions.	Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto	Williams, DB (corresponding author), Univ Toronto, Dept Biochem, Med Sci Bldg, Toronto, ON M5S 1A8, Canada.	david.williams@utoronto.ca						Adar R, 1996, EUR J BIOCHEM, V239, P668, DOI 10.1111/j.1432-1033.1996.0668u.x; ARUNACHALAM B, 1995, J BIOL CHEM, V270, P2784, DOI 10.1074/jbc.270.6.2784; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Chang W, 1997, J BIOL CHEM, V272, P28925, DOI 10.1074/jbc.272.46.28925; Chillaron J, 2000, BIOL CHEM, V381, P1155, DOI 10.1515/BC.2000.143; Christodoulou S, 1997, GENE, V191, P143, DOI 10.1016/S0378-1119(97)00025-5; Danilczyk UG, 2000, J BIOL CHEM, V275, P13089, DOI 10.1074/jbc.275.17.13089; Danilczyk UG, 2001, J BIOL CHEM, V276, P25532, DOI 10.1074/jbc.M100270200; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; Frickel EM, 2002, P NATL ACAD SCI USA, V99, P1954, DOI 10.1073/pnas.042699099; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HAPEL AJ, 1981, CELL, V25, P179, DOI 10.1016/0092-8674(81)90242-7; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; Ihara Y, 1999, MOL CELL, V4, P331, DOI 10.1016/S1097-2765(00)80335-4; Ikawa M, 1997, NATURE, V387, P607, DOI 10.1038/42484; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; Jannatipour M, 1998, BIOCHEMISTRY-US, V37, P17253, DOI 10.1021/bi981785c; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; Labriola C, 1999, MOL BIOL CELL, V10, P1381, DOI 10.1091/mbc.10.5.1381; Leach MR, 2002, J BIOL CHEM, V277, P29686, DOI 10.1074/jbc.M202405200; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; MACHOLD RP, 1995, J EXP MED, V181, P1111, DOI 10.1084/jem.181.3.1111; Mancino L, 2002, P NATL ACAD SCI USA, V99, P5931, DOI 10.1073/pnas.092031799; MIRKOV TE, 1993, GLYCOBIOLOGY, V3, P581, DOI 10.1093/glycob/3.6.581; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; Molinari M, 2002, J CELL BIOL, V158, P247, DOI 10.1083/jcb.200204122; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; ORA A, 1995, J BIOL CHEM, V270, P26060, DOI 10.1074/jbc.270.44.26060; OSAWA T, 1987, ANNU REV BIOCHEM, V56, P21, DOI 10.1146/annurev.biochem.56.1.21; Otteken A, 1996, J BIOL CHEM, V271, P97, DOI 10.1074/jbc.271.1.97; OZATO K, 1981, J IMMUNOL, V126, P317; OZATO K, 1980, J IMMUNOL, V125, P2473; PARKER CG, 1995, EMBO J, V14, P1294, DOI 10.1002/j.1460-2075.1995.tb07115.x; Parodi AJ, 2000, BIOCHEM J, V348, P1, DOI 10.1042/0264-6021:3480001; Patil AR, 2000, J BIOL CHEM, V275, P24348, DOI 10.1074/jbc.M003102200; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; Popov M, 1999, J BIOL CHEM, V274, P17635, DOI 10.1074/jbc.274.25.17635; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; RAJAGOPALAN S, 1994, J EXP MED, V180, P407, DOI 10.1084/jem.180.1.407; Rodan AR, 1996, EMBO J, V15, P6921, DOI 10.1002/j.1460-2075.1996.tb01084.x; RUNGE KW, 1986, J BIOL CHEM, V261, P5582; Saito Y, 1999, EMBO J, V18, P6718, DOI 10.1093/emboj/18.23.6718; Schrag JD, 2001, MOL CELL, V8, P633, DOI 10.1016/S1097-2765(01)00318-5; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; Smith M J, 1992, DNA Seq, V3, P247, DOI 10.3109/10425179209034025; SMITH MH, 1986, MOL IMMUNOL, V23, P1077, DOI 10.1016/0161-5890(86)90006-4; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; Stronge VS, 2001, J BIOL CHEM, V276, P39779, DOI 10.1074/jbc.M107091200; Swanton E, 2003, EMBO J, V22, P2948, DOI 10.1093/emboj/cdg300; Toyofuku K, 1999, J BIOCHEM, V125, P82, DOI 10.1093/oxfordjournals.jbchem.a022272; Trombetta ES, 2000, J CELL BIOL, V148, P1123, DOI 10.1083/jcb.148.6.1123; VANEIJSDEN RR, 1994, GLYCOCONJUGATE J, V11, P375, DOI 10.1007/BF00731212; vanLeeuwen JEM, 1996, J BIOL CHEM, V271, P9660, DOI 10.1074/jbc.271.16.9660; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; Wang J, 2000, BIOCHEMISTRY-US, V39, P8993, DOI 10.1021/bi000027v; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; Wilson CM, 2000, J BIOL CHEM, V275, P21224, DOI 10.1074/jbc.M000567200; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009; Zhang Q, 1998, J IMMUNOL, V160, P831; Zhu KY, 1996, FEBS LETT, V390, P271, DOI 10.1016/0014-5793(96)00671-0	67	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9072	9079		10.1074/jbc.M310788200	http://dx.doi.org/10.1074/jbc.M310788200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14699098	hybrid			2022-12-25	WOS:000189265900068
J	Wang, X; Ma, DW; Keski-Oja, J; Pei, DQ				Wang, X; Ma, DW; Keski-Oja, J; Pei, DQ			Co-recycling of MT1-MMP and MT3-MMP through the trans-Golgi network - Identification of DKV582 as a recycling signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 MATRIX-METALLOPROTEINASE; CELL-SURFACE; MDCK CELLS; MT-MMPS; ACTIVATION; PROGELATINASE; MEMBRANE-TYPE-1; LOCALIZATION; PROTEOLYSIS; CARCINOMAS	Members of the membrane-type matrix metalloproteinases (MT-MMPs) have been implicated in a wide range of physiological and pathological processes from normal development to tumor growth. Tethered on plasma membrane, these enzymes are potentially regulated by the trafficking machinery of the cells. Here we demonstrate that both MT1-MMP and MT3-MMP are internalized, transported to the trans-Golgi network through early endosomes, and recycled back to cell surface in 60 min in a manner distinct from the one employed by transferrin receptor. Interestingly, co-expressed MT1-MMP and MT3-MMP are localized and routed in the same vesicles throughout the trafficking process. We further demonstrated that the carboxyl-terminal sequence DKV582 of MT1-MMP is required for its recycling, thus defining a novel recycling motif. These results suggest that MT-MMPs may coordinate their proteolytic activities through the cellular trafficking machinery.	Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; Chinese Acad Sci, Shanghai Inst Organ Chem, Shanghai 200032, Peoples R China; Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland; Univ Helsinki, Haartman Inst, Dept Virol, FIN-00014 Helsinki, Finland; Univ Helsinki Hosp, FIN-00014 Helsinki, Finland	University of Minnesota System; University of Minnesota Twin Cities; Chinese Academy of Sciences; Shanghai Institute of Organic Chemistry, CAS; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Pei, DQ (corresponding author), 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	peixx003@umn.edu	Wang, Xing/G-2917-2015		NCI NIH HHS [CA76308] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA076308, R01CA076308] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; HUNZIKER W, 1990, EMBO J, V9, P3515, DOI 10.1002/j.1460-2075.1990.tb07560.x; Jiang AX, 2003, J BIOL CHEM, V278, P38765, DOI 10.1074/jbc.M306618200; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Jou TS, 2000, MOL BIOL CELL, V11, P287, DOI 10.1091/mbc.11.1.287; Kang TB, 2000, FASEB J, V14, P2559, DOI 10.1096/fj.00-0269com; Kang TB, 2002, CANCER RES, V62, P675; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Koblinski JE, 2000, CLIN CHIM ACTA, V291, P113, DOI 10.1016/S0009-8981(99)00224-7; Lehti K, 2002, J BIOL CHEM, V277, P8440, DOI 10.1074/jbc.M109128200; Llano E, 1999, CANCER RES, V59, P2570; Muller L, 2003, J BIOL CHEM, V278, P545, DOI 10.1074/jbc.M208949200; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; Pei DQ, 1999, CELL RES, V9, P291, DOI 10.1038/sj.cr.7290028; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1997, THROMB HAEMOSTASIS, V78, P497; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; Ueno H, 1997, CANCER RES, V57, P2055; Urena JM, 1999, J CELL SCI, V112, P773; Velasco G, 2000, CANCER RES, V60, P877; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WU W, 2004, IN PRESS BIOORG MED; Yang HB, 2002, J BIOL CHEM, V277, P30219, DOI 10.1074/jbc.M111933200; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	34	85	87	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9331	9336		10.1074/jbc.M312369200	http://dx.doi.org/10.1074/jbc.M312369200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14665622	hybrid			2022-12-25	WOS:000189265900096
J	Wu, XY; Suetsugu, S; Cooper, LA; Takenawa, T; Guan, JL				Wu, XY; Suetsugu, S; Cooper, LA; Takenawa, T; Guan, JL			Focal adhesion kinase regulation of N-WASP subcellular localization and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; GTPASE-ACTIVATING PROTEIN; PROMOTED CELL-MIGRATION; SRC FAMILY KINASES; TYROSINE PHOSPHORYLATION; ARP2/3 COMPLEX; STRESS FIBERS; PHOSPHATIDYLINOSITOL 3-KINASE; ACTIN-FILAMENTS; GROWTH-FACTOR	N-WASP is a member of the WASP family of proteins that regulate actin cytoskeleton remodeling. FAK is a cytoplasmic tyrosine kinase implicated in integrin signaling during cell migration. Here we identify a direct interaction between N-WASP and FAK and show that N-WASP is phosphorylated by FAK at a conserved tyrosine residue, Tyr(256). We found that phosphorylation of Tyr(256) affected N-WASP nuclear localization, suggesting that phosphorylation of N-WASP by FAK may regulate its activity in vivo by altering its subcellular localization. We also showed that the nuclear localization of N-WASP is dependent on its being in the open conformation either after its activation by Cdc42 or the truncation of the C-terminal VCA domain. Phosphorylation of Tyr(256) of N-WASP could reduce its interaction with nuclear importin NPI-1, which might be responsible for its decreased nuclear localization. Lastly, we show that phosphorylation of Tyr(256) plays an important role in promoting cell migration. Together, these results suggest a novel regulatory mechanism of N-WASP by tyrosine phosphorylation and subcellular localization and its potential role in the regulation of cell migration.	Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA; Univ Tokyo, Dept Biochem, Tokyo 1088639, Japan	Cornell University; University of Tokyo	Guan, JL (corresponding author), Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA.	jg19@cornell.edu	Suetsugu, Shiro/ABB-6033-2020; Suetsugu, Shiro/B-3300-2010; Suetsugu, Shiro/AAF-4427-2019	Suetsugu, Shiro/0000-0002-4612-0628; Suetsugu, Shiro/0000-0002-4612-0628				Abbi S, 2002, MOL BIOL CELL, V13, P3178, DOI 10.1091/mbc.E02-05-0295; Baba Y, 1999, BLOOD, V93, P2003, DOI 10.1182/blood.V93.6.2003.406k13_2003_2012; Bear JE, 2001, CURR OPIN CELL BIOL, V13, P158, DOI 10.1016/S0955-0674(00)00193-9; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Christopher RA, 2000, INT J MOL MED, V5, P575; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Cooper LA, 2003, MOL CELL BIOL, V23, P8030, DOI 10.1128/MCB.23.22.8030-8041.2003; Cory GOC, 2002, J BIOL CHEM, V277, P45115, DOI 10.1074/jbc.M203346200; DeMali KA, 2002, J CELL BIOL, V159, P881, DOI 10.1083/jcb.200206043; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Guinamard R, 1998, FEBS LETT, V434, P431, DOI 10.1016/S0014-5793(98)01016-3; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han DC, 2000, J BIOL CHEM, V275, P28911, DOI 10.1074/jbc.M001997200; Han DC, 2002, J BIOL CHEM, V277, P45655, DOI 10.1074/jbc.M203165200; Han DC, 2001, ONCOGENE, V20, P346, DOI 10.1038/sj.onc.1204068; Hauck CR, 2002, IUBMB LIFE, V53, P115, DOI 10.1080/15216540211470; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; Ren XD, 2000, J CELL SCI, V113, P3673; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ren XR, 2001, J CELL BIOL, V152, P971, DOI 10.1083/jcb.152.5.971; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Ridley AJ, 2001, J CELL SCI, V114, P2713; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Sturge J, 2002, J CELL SCI, V115, P699; Suetsugu S, 2002, DEV CELL, V3, P645, DOI 10.1016/S1534-5807(02)00324-6; Takenawa T, 2001, J CELL SCI, V114, P1801; Taylor JM, 1998, J BIOL CHEM, V273, P8063, DOI 10.1074/jbc.273.14.8063; Torres E, 2003, MOL CELL, V11, P1215, DOI 10.1016/S1097-2765(03)00139-4; Vetterkind S, 2002, J BIOL CHEM, V277, P87, DOI 10.1074/jbc.M104555200; Welch MD, 1999, TRENDS CELL BIOL, V9, P423, DOI 10.1016/S0962-8924(99)01651-7; Westphal RS, 2000, EMBO J, V19, P4589, DOI 10.1093/emboj/19.17.4589; Withers BE, 1996, PROTEIN EXPRES PURIF, V7, P12, DOI 10.1006/prep.1996.0002; Yamaguchi H, 2002, CANCER RES, V62, P2503; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997; Zhao JH, 2003, MOL CELL, V11, P1503, DOI 10.1016/S1097-2765(03)00179-5	54	50	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9565	9576		10.1074/jbc.M310739200	http://dx.doi.org/10.1074/jbc.M310739200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676198	hybrid			2022-12-25	WOS:000189265900124
J	Reyes-Moreno, C; Girouard, J; Lapointe, R; Darveau, A; Mourad, W				Reyes-Moreno, C; Girouard, J; Lapointe, R; Darveau, A; Mourad, W			CD40/CD40 homodimers are required for CD40-induced phosphatidylinositol 3-kinase-dependent expression of B7.2 by human B lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTHRITIDIS-DERIVED MITOGEN; GERMINAL CENTER FORMATION; NF-KAPPA-B; CD40 LIGAND; CYTOKINE SECRETION; CELL DEVELOPMENT; PROTEIN-KINASE; FACTORS TRAFS; ACTIVATION; RECEPTOR	Preformed CD40/CD40 homodimers were initially observed on human Burkitt lymphoma cell lines, normal B cells, and transitional bladder carcinoma cell lines. However, the nature and the biological relevance of these homodimers have not yet been investigated. In the present study, we demonstrated that Epstein-Barr virus-transformed B cells and CD40-transfected HEK 293 cells constitutively expressed disulfide-linked CD40/ CD40 homodimers at low levels. Oligomerization of CD40 leads to a rapid and significant increase in the disulfide-linked CD40/ CD40 homodimer formation, a response that could be prevented using a thiol-alkylating agent. Formation of CD40/ CD40 homodimers was found to be absolutely required for CD40-mediated activation of phosphatidylinositol 3-kinase, which, in turn regulated B7.2 expression. In contrast, CD40 monomers provided the minimal signal emerging from CD40, activating p38 MAP kinase and inducing homotypic B cell adhesion. CD40/ CD40 homodimer formation was totally independent of TRAF1/2/3/5 associations with the threonine at position 254 in the cytoplasmic tail of the CD40 molecules. This finding may be vital to better understanding the molecular mechanisms that govern cell signaling triggered by CD40/ CD154 interactions.	CHU Laval, CRRI, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Dept Biochem & Microbiol, Quebec City, PQ G1V 4G2, Canada; Ctr Hosp Univ Montreal, Ctr Rech, Montreal, PQ H2W 1T8, Canada	Laval University; Laval University; Universite de Montreal	Mourad, W (corresponding author), CHU Laval, CRRI, 2705 Blvd Laurier,T-121, Quebec City, PQ G1V 4G2, Canada.	walid.mourad@crchul.ulaval.ca		Mourad, Walid/0000-0002-1859-9387				ALDACCAK R, 1995, EUR J IMMUNOL, V25, P2539, DOI 10.1002/eji.1830250920; Arron JR, 2001, J BIOL CHEM, V276, P30011, DOI 10.1074/jbc.M100414200; Baccam M, 1999, EUR J IMMUNOL, V29, P3855, DOI 10.1002/(SICI)1521-4141(199912)29:12<3855::AID-IMMU3855>3.0.CO;2-S; Baker MP, 1998, BLOOD, V92, P2830, DOI 10.1182/blood.V92.8.2830.420k10_2830_2843; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Borriello F, 1997, IMMUNITY, V6, P303, DOI 10.1016/S1074-7613(00)80333-7; BRAESCHANDERSEN S, 1989, J IMMUNOL, V142, P562; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Clayton E, 2002, J EXP MED, V196, P753, DOI 10.1084/jem.20020805; Dallman C, 2003, APOPTOSIS, V8, P45, DOI 10.1023/A:1021696902187; Ding JY, 2000, J BIOL CHEM, V275, P30873, DOI 10.1074/jbc.M004813200; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; Etongue-Mayer P, 2002, EUR J IMMUNOL, V32, P50, DOI 10.1002/1521-4141(200201)32:1<50::AID-IMMU50>3.0.CO;2-A; Evans DE, 2000, J IMMUNOL, V164, P688, DOI 10.4049/jimmunol.164.2.688; Fanslow W C, 1994, Semin Immunol, V6, P267, DOI 10.1006/smim.1994.1035; FARIS M, 1994, J EXP MED, V179, P1923, DOI 10.1084/jem.179.6.1923; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Grammer A C, 2000, Adv Immunol, V76, P61; Grammer AC, 1998, J IMMUNOL, V161, P1183; GRAZIOLI L, 1994, J BIOL CHEM, V269, P22304; Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2; Haswell LE, 2001, EUR J IMMUNOL, V31, P3094, DOI 10.1002/1521-4141(2001010)31:10<3094::AID-IMMU3094>3.0.CO;2-F; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Jalukar SV, 2000, J IMMUNOL, V164, P623, DOI 10.4049/jimmunol.164.2.623; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; Langlois MA, 2000, EUR J IMMUNOL, V30, P1748, DOI 10.1002/1521-4141(200006)30:6<1748::AID-IMMU1748>3.0.CO;2-J; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LEVINE BL, 1995, INT IMMUNOL, V7, P891, DOI 10.1093/intimm/7.6.891; Li YY, 1996, J IMMUNOL, V157, P1440; Lutgens E, 1999, NAT MED, V5, P1313, DOI 10.1038/15271; Mauri C, 2000, NAT MED, V6, P673, DOI 10.1038/76251; Morris AE, 1999, J BIOL CHEM, V274, P418, DOI 10.1074/jbc.274.1.418; Pound JD, 1999, INT IMMUNOL, V11, P11, DOI 10.1093/intimm/11.1.11; Pullen SS, 1999, BIOCHEMISTRY-US, V38, P10168, DOI 10.1021/bi9909905; Pullen SS, 1999, J BIOL CHEM, V274, P14246, DOI 10.1074/jbc.274.20.14246; REN CL, 1994, J EXP MED, V179, P673, DOI 10.1084/jem.179.2.673; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; Schonbeck U, 2001, CELL MOL LIFE SCI, V58, P4, DOI 10.1007/PL00000776; Sutherland CL, 1996, J IMMUNOL, V157, P3381; Tamada K, 2002, J CLIN INVEST, V109, P549, DOI 10.1172/JCI200213604; Town T, 2001, NEUROCHEM INT, V39, P371, DOI 10.1016/S0197-0186(01)00044-4; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6	48	39	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7799	7806		10.1074/jbc.M313168200	http://dx.doi.org/10.1074/jbc.M313168200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14676197	hybrid			2022-12-25	WOS:000189103300054
J	Sozio, MS; Mathis, MA; Young, JA; Walchli, S; Pitcher, LA; Wrage, PC; Bartok, B; Campbell, A; Watts, JD; Aebersold, R; van Huijsduijnen, RH; van Oers, NSC				Sozio, MS; Mathis, MA; Young, JA; Walchli, S; Pitcher, LA; Wrage, PC; Bartok, B; Campbell, A; Watts, JD; Aebersold, R; van Huijsduijnen, RH; van Oers, NSC			PTPH1 is a predominant protein-tyrosine phosphatase capable of interacting with and dephosphorylating the T cell receptor zeta subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR; TCR-ZETA; SIGNAL-TRANSDUCTION; STRUCTURAL BASIS; MOLECULAR-BASIS; MOTH-EATEN; KINASE; CD45; SUBSTRATE; COMPLEX	Protein-tyrosine phosphatases (PTPases) play key roles in regulating tyrosine phosphorylation levels in cells, yet the identity of their substrates remains limited. We report here on the identification of PTPases capable of dephosphorylating the phosphorylated immune tyrosine-based activation motifs present in the T cell receptor zeta subunit. To characterize these PTPases, we purified enzyme activities directed against the phosphorylated T cell receptor zeta subunit by a combination of anion and cation chromatography procedures. A novel ELISA-based PTPase assay was developed to rapidly screen protein fractions for enzyme activity following the various chromatography steps. We present data that SHP-1 and PTPH1 are present in highly enriched protein fractions that exhibit PTPase activities toward a tyrosine-phosphorylated TCR zeta substrate (specific activity ranging from 0.23 to 40 pmol/min/mug). We also used a protein-tyrosine phosphatase substrate-trapping library comprising the catalytic domains of 47 distinct protein-tyrosine phosphatases, representing almost all the tyrosine phosphatases identified in the human genome. PTPH1 was the predominant phosphatase capable of complexing phospho-zeta. Subsequent transfection assays indicated that SHP-1 and PTPH1 are the two principal PTPases capable of regulating the phosphorylation state of the TCR zeta ITAMs, with PTPH1 directly dephosphorylating zeta. This is the first reported demonstration that PTPH1 is a candidate PTPase capable of interacting with and dephosphorylating TCR zeta.	Univ Texas, SW Med Ctr, Ctr Immunol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75390 USA; Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland; Inst Syst Biol, Seattle, WA 98103 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Institute for Systems Biology (ISB)	van Oers, NSC (corresponding author), NA7-201,6000 Harry Hines Blvd, Dallas, TX 75390 USA.	nicolai.vanoers@utsouthwestern.edu	Van+Oers, Nicolai/ABA-2437-2021; Hooft van Huijsduijnen, Rob/B-3653-2009	Walchli, Sebastien/0000-0001-5869-1746; Hooft van Huijsduijnen, Rob/0000-0002-2261-9424; van Oers, Nicolai/0000-0002-6545-8405	NIAID NIH HHS [AI42953] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042953] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AFFOLTER M, 1994, ANAL BIOCHEM, V223, P74, DOI 10.1006/abio.1994.1549; Alexander DR, 2000, SEMIN IMMUNOL, V12, P349, DOI 10.1006/smim.2000.0218; Brockdorff J, 1999, EUR J IMMUNOL, V29, P2539, DOI 10.1002/(SICI)1521-4141(199908)29:08<2539::AID-IMMU2539>3.0.CO;2-M; Calvo CR, 1997, J EXP MED, V186, P1645, DOI 10.1084/jem.186.10.1645; Chu DH, 1996, EMBO J, V15, P6251, DOI 10.1002/j.1460-2075.1996.tb01015.x; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; Cloutier JF, 1999, J EXP MED, V189, P111, DOI 10.1084/jem.189.1.111; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Frearson JA, 1998, J EXP MED, V187, P1417, DOI 10.1084/jem.187.9.1417; FURUKAWA T, 1994, P NATL ACAD SCI USA, V91, P10928, DOI 10.1073/pnas.91.23.10928; Futterer K, 1998, J MOL BIOL, V281, P523, DOI 10.1006/jmbi.1998.1964; Gjorloff-Wingren A, 1999, EUR J IMMUNOL, V29, P3845, DOI 10.1002/(SICI)1521-4141(199912)29:12<3845::AID-IMMU3845>3.0.CO;2-U; Gjorloff-Wingren A, 2000, EUR J IMMUNOL, V30, P2412, DOI 10.1002/1521-4141(2000)30:8<2412::AID-IMMU2412>3.0.CO;2-J; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Guntermann C, 2002, J IMMUNOL, V168, P4420, DOI 10.4049/jimmunol.168.9.4420; Han SL, 2000, EUR J IMMUNOL, V30, P1318, DOI 10.1002/(SICI)1521-4141(200005)30:5<1318::AID-IMMU1318>3.0.CO;2-G; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; Hippen KL, 1997, IMMUNITY, V7, P49, DOI 10.1016/S1074-7613(00)80509-9; Huyer G, 1999, CURR BIOL, V9, pR129, DOI 10.1016/S0960-9822(99)80080-3; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lee KM, 1998, SCIENCE, V282, P2263, DOI 10.1126/science.282.5397.2263; Lorenz U, 1996, P NATL ACAD SCI USA, V93, P9624, DOI 10.1073/pnas.93.18.9624; Love PE, 2000, IMMUNITY, V12, P591, DOI 10.1016/S1074-7613(00)80210-1; MORGAN DO, 1991, METHOD ENZYMOL, V200, P645; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; Neel BG, 1997, CURR OPIN IMMUNOL, V9, P405, DOI 10.1016/S0952-7915(97)80088-X; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; Pani G, 1996, J EXP MED, V184, P839, DOI 10.1084/jem.184.3.839; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; Pitcher LA, 2003, TRENDS IMMUNOL, V24, P554, DOI 10.1016/j.it.2003.08.003; Pitcher LA, 2003, IMMUNOL REV, V191, P47, DOI 10.1034/j.1600-065X.2003.00003.x; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; Stone JD, 1997, J IMMUNOL, V158, P5773; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; van Oers NSC, 2000, NAT IMMUNOL, V1, P322, DOI 10.1038/79774; Van Vactor D, 1998, CURR OPIN GENET DEV, V8, P112, DOI 10.1016/S0959-437X(98)80070-1; VANOERS NSC, 1995, J EXP MED, V182, P1585, DOI 10.1084/jem.182.5.1585; Veillette A, 2002, ANNU REV IMMUNOL, V20, P669, DOI 10.1146/annurev.immunol.20.081501.130710; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Walchli S, 2000, J BIOL CHEM, V275, P9792, DOI 10.1074/jbc.275.13.9792; WATTS JD, 1992, J BIOL CHEM, V267, P901; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Weissenhorn W, 1996, EUR J BIOCHEM, V238, P440, DOI 10.1111/j.1432-1033.1996.0440z.x; Yang J, 2000, J BIOL CHEM, V275, P4066, DOI 10.1074/jbc.275.6.4066; Zhang SH, 1999, J BIOL CHEM, V274, P17806, DOI 10.1074/jbc.274.25.17806; ZHANG SH, 1995, J BIOL CHEM, V270, P20067, DOI 10.1074/jbc.270.34.20067	52	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7760	7769		10.1074/jbc.M309994200	http://dx.doi.org/10.1074/jbc.M309994200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14672952	hybrid			2022-12-25	WOS:000189103300049
J	Tang, CR; Vaughan, AM; Oram, JF				Tang, CR; Vaughan, AM; Oram, JF			Janus kinase 2 modulates the apolipoprotein interactions with ABCA1 required for removing cellular cholesterol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASSETTE TRANSPORTER A1; HIGH-DENSITY-LIPOPROTEIN; APOA-I; SIGNALING PATHWAYS; PEST SEQUENCE; EFFLUX; BINDING; PHOSPHORYLATION; DEGRADATION; MACROPHAGES	ATP-binding cassette transporter A1 (ABCA1) mediates transport of cellular cholesterol and phospholipids to high density lipoprotein (HDL) apolipoproteins, such as apoA-I. ABCA1 mutations can cause a severe HDL deficiency and atherosclerosis. Here we show that the protein-tyrosine kinase (TK) Janus kinase 2 (JAK2) modulates the apolipoprotein interactions with ABCA1 required for removing cellular lipids. The protein kinase A (PKA) inhibitor H89, the TK inhibitor genistein, and the JAK2 inhibitor AG490 suppressed apoA-I-mediated cholesterol and phospholipid efflux from ABCA1-expressing cells without altering the membrane ABCA1 content. Whereas PKA inhibition had no effect on apoA-I binding to cells or to ABCA1, TK and JAK2 inhibition greatly reduced these activities. Conversely, PKA but not JAK2 inhibition significantly reduced the intrinsic cholesterol translocase activity of ABCA1. Mutant cells lacking JAK2 had a severely impaired apoA-I-mediated cholesterol and phospholipid efflux and apoA-I binding despite normal ABCA1 protein levels and near normal cholesterol translocase activity. Thus, although PKA modulates ABCA1 lipid transport activity, JAK2 appears to selectively modulate apolipoprotein interactions with ABCA1. TK-mediated phosphorylation of ABCA1 was undetectable, implicating the involvement of another JAK2-targeted protein. Acute incubation of ABCA1-expressing cells with apoA-I had no effect on ABCA1 phosphorylation but stimulated JAK2 autophosphorylation. These results suggest that the interaction of apolipoproteins with ABCA1-expressing cells activates JAK2, which in turn activates a process that enhances apolipoprotein interactions with ABCA1 and lipid removal from cells.	Univ Washington, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Oram, JF (corresponding author), Univ Washington, Dept Med, Box 356424, Seattle, WA 98195 USA.	joram@u.washington.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055362] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL186, HL55362] Funding Source: Medline; NIDDK NIH HHS [DK02456] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aiello RJ, 2003, ARTERIOSCL THROM VAS, V23, P972, DOI 10.1161/01.ATV.0000054661.21499.FB; Arakawa R, 2002, J BIOL CHEM, V277, P22426, DOI 10.1074/jbc.M202996200; ASSMANN G, 1995, METABOLIC MOL BASES, P2053; Burfoot MS, 1997, J BIOL CHEM, V272, P24183, DOI 10.1074/jbc.272.39.24183; Carvalheira JBC, 2003, BIOL CHEM, V384, P151, DOI 10.1515/BC.2003.016; Clee SM, 2000, J CLIN INVEST, V106, P1263, DOI 10.1172/JCI10727; Costet P, 2000, J BIOL CHEM, V275, P28240; Feng B, 2002, J BIOL CHEM, V277, P43271, DOI 10.1074/jbc.M207532200; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; Fitzgerald ML, 2002, J BIOL CHEM, V277, P33178, DOI 10.1074/jbc.M204996200; Garver WS, 1997, ARTERIOSCL THROM VAS, V17, P2698, DOI 10.1161/01.ATV.17.11.2698; Gual P, 1998, ENDOCRINOLOGY, V139, P884, DOI 10.1210/en.139.3.884; Haidar B, 2002, J LIPID RES, V43, P2087, DOI 10.1194/jlr.M200235-JLR200; Joyce C, 2003, ARTERIOSCL THROM VAS, V23, P965, DOI 10.1161/01.ATV.0000055194.85073.FF; Kerr IM, 2003, FEBS LETT, V546, P1, DOI 10.1016/S0014-5793(03)00411-3; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Martinez LO, 2003, J BIOL CHEM, V278, P37368, DOI 10.1074/jbc.M307161200; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 2003, ARTERIOSCL THROM VAS, V23, P720, DOI 10.1161/01.ATV.0000054662.44688.9A; Rane SG, 2000, ONCOGENE, V19, P5662, DOI 10.1038/sj.onc.1203925; Saad MJA, 1996, J BIOL CHEM, V271, P22100, DOI 10.1074/jbc.271.36.22100; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; See RH, 2002, J BIOL CHEM, V277, P41835, DOI 10.1074/jbc.M204923200; SERFATYLACROSNIERE C, 1994, ATHEROSCLEROSIS, V107, P85, DOI 10.1016/0021-9150(94)90144-9; Singaraja RR, 2003, ARTERIOSCL THROM VAS, V23, P1322, DOI 10.1161/01.ATV.0000078520.89539.77; Vaughan AM, 2003, J LIPID RES, V44, P1373, DOI 10.1194/jlr.M300078-JLR200; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2003, ARTERIOSCL THROM VAS, V23, P1178, DOI 10.1161/01.ATV.0000075912.83860.26; Wang N, 2003, J CLIN INVEST, V111, P99, DOI 10.1172/JCI200316808; Wang YT, 2002, J BIOL CHEM, V277, P5692, DOI 10.1074/jbc.M109977200; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; Wellington CL, 2003, J LIPID RES, V44, P1470, DOI 10.1194/jlr.M300110-JLR200; Yamauchi Y, 2003, J BIOL CHEM, V278, P47890, DOI 10.1074/jbc.M306258200	33	96	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7622	7628		10.1074/jbc.M312571200	http://dx.doi.org/10.1074/jbc.M312571200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14668333	hybrid			2022-12-25	WOS:000189103300032
J	Zhao, XB; Girotto, S; Yu, SW; Magliozzo, RS				Zhao, XB; Girotto, S; Yu, SW; Magliozzo, RS			Evidence for radical formation at Tyr-353 in Mycobacterium tuberculosis catalase-peroxidase (KatG)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H SYNTHASE-1 AND-2; NITRIC-OXIDE; ISONIAZID ACTIVATION; TYROSYL RADICALS; PHOTOSYSTEM-II; RIBONUCLEOTIDE REDUCTASE; DRUG-RESISTANCE; PURIFICATION; IDENTIFICATION; CATALYSIS	Mycobacterium tuberculosis KatG is a heme-containing catalase-peroxidase responsible for activation, through its peroxidase cycle, of the front line antituberculosis antibiotic isoniazid (isonicotinic acid hydrazide). Formation of Compound I (oxyferryl heme-porphyrin pi-cation radical), the classical peroxidase intermediate generated when the resting enzyme turns over with alkyl peroxides, is rapidly followed by production of a protein-centered tyrosyl radical in this enzyme. In our efforts to identify the residue at which this radical is formed, nitric oxide was used as a radical scavenging reagent. Quenching of the tyrosyl radical generated in the presence of NO was shown using electron paramagnetic resonance spectroscopy, and formation of nitrotyrosine was confirmed by proteolytic digestion followed by high performance liquid chromatography analysis of the NO-treated enzyme. These results are consistent with formation of nitrosyltyrosine by addition of NO to tyrosyl radical and oxidation of this intermediate to nitrotyrosine. Two predominant nitrotyrosine-containing peptides were identified that were purified and sequenced by Edman degradation. Both peptides were derived from the same M. tuberculosis KatG sequence spanning residues 346-356 with the amino acid sequence SPAGAWQYTAK, and both peptides contained nitrotyrosine at residue 353. Some modification of Trp-351 most probably into nitrosotryptophan was also found in one of the two peptides. Control experiments using denatured KatG or carried out in the absence of peroxide did not produce nitrotyrosine. In the mutant enzyme KatG(Y353F), which was constructed using site-directed mutagenesis, a tyrosyl radical was also formed upon turnover with peroxide but in poor yield compared with wild-type KatG. Residue Tyr-353 is unique to M. tuberculosis KatG and may play a special role in the function of this enzyme.	CUNY Brooklyn Coll, Dept Chem, Brooklyn, NY 11210 USA; CUNY, Grad Ctr, Dept Chem, New York, NY 10016 USA; CUNY, Grad Ctr, Dept Biochem, New York, NY 10016 USA	City University of New York (CUNY) System; Brooklyn College (CUNY); City University of New York (CUNY) System; City University of New York (CUNY) System	Magliozzo, RS (corresponding author), CUNY Brooklyn Coll, Dept Chem, 2900 Bedford Ave, Brooklyn, NY 11210 USA.	rmaglioz@brooklyn.cuny.edu	Girotto, Stefania/F-5997-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043582] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-43582] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARRY BA, 1990, J BIOL CHEM, V265, P20139; Carpena X, 2003, J MOL BIOL, V327, P475, DOI 10.1016/S0022-2836(03)00122-0; Chouchane S, 2000, BIOCHEMISTRY-US, V39, P9975, DOI 10.1021/bi0005815; Chouchane S, 2002, J BIOL CHEM, V277, P42633, DOI 10.1074/jbc.M207916200; DUNFORD HB, 1999, HEME PEROXIDASES, P141; EISERICH JP, 1995, BIOCHEM J, V310, P745, DOI 10.1042/bj3100745; Goodwin DC, 1998, J BIOL CHEM, V273, P8903, DOI 10.1074/jbc.273.15.8903; Gunther MR, 1997, J BIOL CHEM, V272, P17086, DOI 10.1074/jbc.272.27.17086; Gunther MR, 2000, FREE RADICAL BIO MED, V28, P709, DOI 10.1016/S0891-5849(00)00164-7; Herold S, 2002, BIOCHEMISTRY-US, V41, P13460, DOI 10.1021/bi026046h; Ivancich A, 2001, BIOCHEMISTRY-US, V40, P6860, DOI 10.1021/bi002826j; Ivancich A, 1997, BIOCHEMISTRY-US, V36, P9356, DOI 10.1021/bi970886s; Johnsson K, 1997, J BIOL CHEM, V272, P2834, DOI 10.1074/jbc.272.5.2834; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; Kirsch M, 2003, J BIOL CHEM, V278, P11931, DOI 10.1074/jbc.M300237200; Langella E, 2002, J AM CHEM SOC, V124, P11531, DOI 10.1021/ja020465k; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; LEPOIVRE M, 1994, J BIOL CHEM, V269, P21891; LOEWEN PC, 1990, BIOCHEM CELL BIOL, V68, P1037, DOI 10.1139/o90-153; MARCINKEVICIENE JA, 1995, J BIOL CHEM, V270, P22290, DOI 10.1074/jbc.270.38.22290; Musser JM, 1996, J INFECT DIS, V173, P196, DOI 10.1093/infdis/173.1.196; Nagy JM, 1997, J BIOL CHEM, V272, P31265, DOI 10.1074/jbc.272.50.31265; PACKER L, 1996, METHOD ENZYMOL, V269, P185; PETROULEAS V, 1990, BIOCHIM BIOPHYS ACTA, V1015, P131, DOI 10.1016/0005-2728(90)90224-R; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Szalai VA, 1996, BIOCHEMISTRY-US, V35, P15080, DOI 10.1021/bi961117w; Tsai AL, 2000, PROSTAG OTH LIPID M, V62, P231, DOI 10.1016/S0090-6980(00)00083-6; Tsai AL, 1999, J BIOL CHEM, V274, P21695, DOI 10.1074/jbc.274.31.21695; Wei CJ, 2003, ANTIMICROB AGENTS CH, V47, P670, DOI 10.1128/AAC.47.2.670-675.2003; Yamada Y, 2002, NAT STRUCT BIOL, V9, P691, DOI 10.1038/nsb834; Yu SW, 2003, J BIOL CHEM, V278, P44121, DOI 10.1074/jbc.M304757200; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0; ZHANG Y, 1994, J ANTIMICROB CHEMOTH, V34, P313, DOI 10.1093/jac/34.3.313	34	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7606	7612		10.1074/jbc.M311884200	http://dx.doi.org/10.1074/jbc.M311884200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14665627	hybrid			2022-12-25	WOS:000189103300030
J	Higami, Y; Pugh, TD; Page, GP; Allison, DB; Prolla, TA; Weindruch, R				Higami, Y; Pugh, TD; Page, GP; Allison, DB; Prolla, TA; Weindruch, R			Adipose tissue energy metabolism: altered gene expression profile of mice subjected to long-term caloric restriction	FASEB JOURNAL			English	Article						white adipose tissue; oligonucleotide microarrays; aging	INSULIN-RECEPTOR SUBSTRATE-1; VISCERAL FAT; ADIPOCYTE DIFFERENTIATION; TRANSCRIPTIONAL PROFILES; 3T3-L1 PREADIPOCYTES; DIETARY RESTRICTION; UNCOUPLING PROTEINS; LEPTIN RESISTANCE; BROWN ADIPOCYTES; ANTIAGING ACTION	We investigated the influences of short-term and lifespan-prolonging long-term caloric restriction (LCR) on gene expression in white adipose tissue (WAT). Over 11,000 genes were examined using high-density oligonucleotide microarrays in four groups of 10- to 11-month-old male C57B16 mice that were either fasted for 18 h before death (F), subjected to short-term caloric restriction for 23 days (SCR), or LCR for 9 months and compared with nonfasted control (CO) mice. Only a few transcripts of F and SCR were differentially expressed compared with CO mice. In contrast, 345 transcripts of 6,266 genes found to be expressed in WAT were altered significantly by LCR. The expression of several genes encoding proteins involved in energy metabolism was increased by LCR. Further, many of the shifts in gene expression after LCR are known to occur during adipocyte differentiation. Selected LCR-associated alterations of gene expression were supported by quantitative reverse transcriptase-polymerase chain reaction, histology, and histochemical examinations. Our data provide new insights on the metabolic state associated with aging retardation by LCR.	Vet Adm Hosp, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA; Univ Wisconsin, Dept Med, Madison, WI USA; Univ Wisconsin, Wisconsin Reg Primate Res Ctr, Madison, WI 53715 USA; Univ Alabama, Dept Biostat, Sect Stat Genet, Birmingham, AL 35249 USA; Univ Alabama, Clin Nutr Res Ctr, Birmingham, AL 35249 USA; Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; Univ Wisconsin, Dept Med Genet, Madison, WI 53706 USA	Geriatric Research Education & Clinical Center; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Weindruch, R (corresponding author), Vet Adm Hosp, Ctr Geriatr Res Educ & Clin, 2500 Overlook Terrace, Madison, WI 53705 USA.	rhweindr@wisc.edu		Higami, Yoshikazu/0000-0003-1381-0777; Allison, David/0000-0003-3566-9399; Page, Grier/0000-0003-2582-3786				Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Ailhaud G, 2002, CURR OPIN CLIN NUTR, V5, P385, DOI 10.1097/00075197-200207000-00006; Barzilai N, 1998, J CLIN INVEST, V101, P1353, DOI 10.1172/JCI485; Barzilai N, 1999, DIABETES, V48, P94, DOI 10.2337/diabetes.48.1.94; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Berwick DC, 2002, J BIOL CHEM, V277, P33895, DOI 10.1074/jbc.M204681200; Bodnar JS, 2002, NAT GENET, V30, P110, DOI 10.1038/ng811; Cao SX, 2001, P NATL ACAD SCI USA, V98, P10630, DOI 10.1073/pnas.191313598; Chendrasekhar A, 1996, J TRAUMA, V40, P963, DOI 10.1097/00005373-199606000-00016; Clouthier DE, 1997, J CLIN INVEST, V100, P2697, DOI 10.1172/JCI119815; Collins S, 2001, EXP BIOL MED, V226, P982, DOI 10.1177/153537020122601104; COUSIN B, 1992, J CELL SCI, V103, P931; Davidson RT, 2002, AM J PHYSIOL-ENDOC M, V282, pE270, DOI 10.1152/ajpendo.00232.2001; Dean DJ, 2000, ACTA PHYSIOL SCAND, V169, P133, DOI 10.1046/j.1365-201x.2000.00723.x; Du H, 2001, J LIPID RES, V42, P489; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; ENZI G, 1986, AM J CLIN NUTR, V44, P739, DOI 10.1093/ajcn/44.6.739; Fernandez-Galaz C, 2002, DIABETOLOGIA, V45, P997, DOI 10.1007/s00125-002-0851-4; FRAZE E, 1987, J AM GERIATR SOC, V35, P224, DOI 10.1111/j.1532-5415.1987.tb02313.x; Gabriely I, 2002, DIABETES, V51, P2951, DOI 10.2337/diabetes.51.10.2951; Himms-Hagen J, 2000, AM J PHYSIOL-CELL PH, V279, pC670, DOI 10.1152/ajpcell.2000.279.3.C670; HOLLIDAY R, 1989, BIOESSAYS, V10, P125, DOI 10.1002/bies.950100408; Jessen BA, 2002, GENE, V299, P95, DOI 10.1016/S0378-1119(02)01017-X; Jimenez M, 2003, EUR J BIOCHEM, V270, P699, DOI 10.1046/j.1432-1033.2003.03422.x; Kerner J, 2000, BBA-MOL CELL BIOL L, V1486, P1, DOI 10.1016/S1388-1981(00)00044-5; Kirschner LS, 1999, THYROID, V9, P143, DOI 10.1089/thy.1999.9.143; Kratchmarova I, 2002, MOL CELL PROTEOMICS, V1, P213, DOI 10.1074/mcp.M200006-MCP200; Le Roith D, 2001, DIABETES CARE, V24, P588, DOI 10.2337/diacare.24.3.588; Lee CK, 2002, P NATL ACAD SCI USA, V99, P14988, DOI 10.1073/pnas.232308999; Londos C, 1999, ANN NY ACAD SCI, V892, P155, DOI 10.1111/j.1749-6632.1999.tb07794.x; Ma XH, 2002, J GERONTOL A-BIOL, V57, pB225, DOI 10.1093/gerona/57.6.B225; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; Masoro EJ, 1996, J GERONTOL A-BIOL, V51, pB387, DOI 10.1093/gerona/51A.6.B387; Matsuzaka T, 2002, J LIPID RES, V43, P911; Mora S, 2002, DIABETES-METAB RES, V18, P345, DOI 10.1002/dmrr.321; Mori M, 1999, FEBS LETT, V458, P17, DOI 10.1016/S0014-5793(99)01111-4; Nadler ST, 2000, P NATL ACAD SCI USA, V97, P11371, DOI 10.1073/pnas.97.21.11371; Nam S Y, 2000, Obes Rev, V1, P73, DOI 10.1046/j.1467-789x.2000.00015.x; Nonogaki K, 2000, DIABETOLOGIA, V43, P533, DOI 10.1007/s001250051341; NOVIKOFF AB, 1980, J CELL BIOL, V87, P180, DOI 10.1083/jcb.87.1.180; OLSEN SR, 1991, MOL ENDOCRINOL, V5, P1246, DOI 10.1210/mend-5-9-1246; Pugh TD, 1999, NEUROBIOL AGING, V20, P157, DOI 10.1016/S0197-4580(99)00043-3; Ramsay RR, 2000, BIOCHEM SOC T, V28, P182, DOI 10.1042/bst0280182; Rashid Mitchell N, 2003, Prev Cardiol, V6, P42, DOI 10.1111/j.1520-037X.2003.01358.x; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Relaix F, 1998, NAT GENET, V18, P287, DOI 10.1038/ng0398-287; Rosen ED, 2000, GENE DEV, V14, P1293; Ross SE, 2002, MOL CELL BIOL, V22, P5989, DOI 10.1128/MCB.22.16.5989-5999.2002; Salway J.G., 2017, METABOLISM GLANCE; SELIGMAN AM, 1968, J CELL BIOL, V38, P1, DOI 10.1083/jcb.38.1.1; Shimokawa I, 1999, AGING-CLIN EXP RES, V11, P380, DOI 10.1007/BF03339816; Shimokawa I, 2001, MECH AGEING DEV, V122, P1511, DOI 10.1016/S0047-6374(01)00284-6; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Soukas A, 2001, J BIOL CHEM, V276, P34167, DOI 10.1074/jbc.M104421200; Soukas A, 2000, GENE DEV, V14, P963; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; SPINDLER SR, 1991, J GERONTOL, V46, pB233, DOI 10.1093/geronj/46.6.B233; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Strosberg AD, 1996, TRENDS PHARMACOL SCI, V17, P373, DOI 10.1016/S0165-6147(96)80011-3; Sykiotis GP, 2001, MOL ENDOCRINOL, V15, P1864, DOI 10.1210/me.15.11.1864; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; THAJCHAYAPONG P, 1976, HORM METAB RES, V8, P190, DOI 10.1055/s-0028-1093658; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; Wang ZQ, 1997, EXP GERONTOL, V32, P671, DOI 10.1016/S0531-5565(97)00054-5; Wang ZW, 2001, FASEB J, V15, P108, DOI 10.1096/fj.00-0310com; Weindruch R., 1988, RETARDATION AGING DI; Wonsey DR, 2002, P NATL ACAD SCI USA, V99, P6649, DOI 10.1073/pnas.102523299; YU BP, 1994, MODULATION AGING PRO; Zhu JH, 1999, P NATL ACAD SCI USA, V96, P14911, DOI 10.1073/pnas.96.26.14911	69	130	137	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					415	+		10.1096/fj.03-0678fje	http://dx.doi.org/10.1096/fj.03-0678fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14688200				2022-12-25	WOS:000188067500006
J	Sengupta, TK; Bandyopadhyay, S; Fernandes, DJ; Spicer, EK				Sengupta, TK; Bandyopadhyay, S; Fernandes, DJ; Spicer, EK			Identification of nucleolin as an AU-rich element binding protein involved in bcl-2 mRNA stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HELA CYTOPLASMIC EXTRACTS; HUMAN CANCER-CELLS; OKADAIC ACID; RIBOSOMAL-RNA; 3'-UNTRANSLATED REGION; DOWN-REGULATION; LEUKEMIA-CELLS; APOPTOSIS; DESTABILIZATION	bcl-2 mRNA contains an AU-rich element (ARE) that functions in regulating bcl-2 stability. Our earlier studies indicated that taxol- or okadaic acid-induced bcl-2 mRNA destabilization in HL-60 cells is associated with decreased binding of trans-acting factors to the ARE. To identify factors that play a role in the regulation of bcl-2 mRNA stability, bcl-2 ARE-binding proteins were purified from HL-60 cells. Three polypeptides of 100, 70, and 32 kDa were isolated from a bcl-2 ARE affinity matrix. Matrix-assisted laser desorption ionization mass spectroscopy analysis identified these proteins as full-length nucleolin and proteolytic fragments of nucleolin. RNA gel shifts assays indicated that recombinant nucleolin ( residues 284-707) binds specifically to bcl-2 ARE RNA. In addition, recombinant nucleolin decreases the rate of decay of mRNA in HL-60 cell extracts in an ARE-dependent manner. Taxol or okadaic acid treatment of HL-60 cells results in proteolysis of nucleolin in a similar time frame as drug-induced bcl-2 mRNA down-regulation. These findings suggest that nucleolin functions as a bcl-2-stabilizing factor and that taxol and okadaic acid treatment induces apoptosis in HL-60 cells through a process that involves down-regulation of nucleolin and destabilization of bcl-2 mRNA.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pharmaceut Sci, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Spicer, EK (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, POB 250509, Charleston, SC 29425 USA.	spicer@musc.edu	Sengupta, Tapas K/P-7126-2014		NATIONAL CANCER INSTITUTE [R01CA087553] Funding Source: NIH RePORTER; NCI NIH HHS [CA 87553] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allain FHT, 2000, EMBO J, V19, P6870, DOI 10.1093/emboj/19.24.6870; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bandyopadhyay S, 2003, BIOCHEM PHARMACOL, V66, P1151, DOI 10.1016/S0006-2952(03)00453-2; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BUGLER B, 1987, J BIOL CHEM, V262, P10922; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Ceman S, 1999, MOL CELL BIOL, V19, P7925; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Chen CY, 2000, GENE DEV, V14, P1236; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Dehlin E, 2000, EMBO J, V19, P1079, DOI 10.1093/emboj/19.5.1079; DERENZINI M, 1995, LAB INVEST, V73, P497; Donnini M, 2001, BIOCHEM BIOPH RES CO, V287, P1063, DOI 10.1006/bbrc.2001.5700; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Ford LP, 1999, METHODS, V17, P21, DOI 10.1006/meth.1998.0703; Gao G, 2000, MOL PHARMACOL, V58, P1001, DOI 10.1124/mol.58.5.1001; Gao M, 2001, EMBO J, V20, P1134, DOI 10.1093/emboj/20.5.1134; Ginisty H, 1999, J CELL SCI, V112, P761; Ginisty H, 1998, EMBO J, V17, P1476, DOI 10.1093/emboj/17.5.1476; GLUICK TC, 1994, J MOL BIOL, V241, P246, DOI 10.1006/jmbi.1994.1493; GORDON G, 1987, NATURE, V329, P489; GUY GR, 1992, J BIOL CHEM, V267, P1846; Hanakahi LA, 1997, P NATL ACAD SCI USA, V94, P3605, DOI 10.1073/pnas.94.8.3605; Harris N L, 2001, Hematology Am Soc Hematol Educ Program, P194, DOI 10.1182/asheducation-2001.1.194; Huang Y, 1999, ONCOGENE, V18, P3431, DOI 10.1038/sj.onc.1202685; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lapucci A, 2002, J BIOL CHEM, V277, P16139, DOI 10.1074/jbc.M201377200; Liu Y., 1996, Cellular Pharmacology, V3, P405; Malter JS, 2001, J NEUROSCI RES, V66, P311, DOI 10.1002/jnr.10021; Mi YC, 2003, J BIOL CHEM, V278, P8572, DOI 10.1074/jbc.M207637200; Morimoto H, 2002, J HISTOCHEM CYTOCHEM, V50, P1187, DOI 10.1177/002215540205000905; Mukherjee D, 2002, EMBO J, V21, P165, DOI 10.1093/emboj/21.1.165; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Raghavan A, 2001, J BIOL CHEM, V276, P47958, DOI 10.1074/jbc.M109511200; Reed J C, 1997, Adv Pharmacol, V41, P501, DOI 10.1016/S1054-3589(08)61070-4; Riordan FA, 1998, FEBS LETT, V435, P195, DOI 10.1016/S0014-5793(98)01070-9; Schiavone N, 2000, FASEB J, V14, P174, DOI 10.1096/fasebj.14.1.174; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SCHNEIDER HR, 1989, EUR J BIOCHEM, V180, P449, DOI 10.1111/j.1432-1033.1989.tb14667.x; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; Skalweit A, 2003, CIRC RES, V92, P419, DOI 10.1161/01.RES.0000059300.67152.4E; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; STEUBE KG, 1995, LEUKEMIA, V9, P1841; Tholanikunnel BG, 1999, BIOCHEMISTRY-US, V38, P15564, DOI 10.1021/bi9913348; Westmark CJ, 2001, J BIOL CHEM, V276, P1119, DOI 10.1074/jbc.M009435200; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; Yang C, 2002, NUCLEIC ACIDS RES, V30, P2251, DOI 10.1093/nar/30.10.2251; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24007; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; Zhou GS, 1997, J BIOL CHEM, V272, P31130, DOI 10.1074/jbc.272.49.31130	55	136	141	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10855	10863		10.1074/jbc.M309111200	http://dx.doi.org/10.1074/jbc.M309111200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14679209	hybrid			2022-12-25	WOS:000220157600006
J	Uchiki, T; Dice, LT; Hettich, RL; Dealwis, C				Uchiki, T; Dice, LT; Hettich, RL; Dealwis, C			Identification of phosphorylation sites on the yeast ribonucleotide reductase inhibitor Sml1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZATION MASS-SPECTROMETRY; DNA-DAMAGE; SACCHAROMYCES-CEREVISIAE; PROTEIN-PHOSPHORYLATION; CHECKPOINT PATHWAYS; GLYCOGEN-SYNTHASE; CDK INHIBITOR; BUDDING YEAST; CELL-CYCLE; KINASE	Sml1 is a small protein in Saccharomyces cerevisiae which inhibits the activity of ribonucleotide reductase (RNR). RNR catalyzes the rate-limiting step of de novo dNTP synthesis. Sml1 is a downstream effector of the Mec1/Rad53 cell cycle checkpoint pathway. The phosphorylation by Dun1 kinase during S phase or in response to DNA damage leads to diminished levels of Sml1. Removal of Sml1 increases the population of active RNR, which raises cellular dNTP levels. In this study using mass spectrometry and site-directed mutagenesis, we have identified the region of Sml1 phosphorylation to be between residues 52 and 64 containing the sequence GSSAS-ASASSLEM. This is the first identification of a phosphorylation sequence of a Dun1 biological substrate. This sequence is quite different from the consensus Dun1 phosphorylation sequence reported previously from peptide library studies. The specific phosphoserines were identified to be Ser(56), Ser(58), and Ser(60) by chemical modification of these residues to S-ethylcysteines followed by collision activated dissociation. To investigate further Sml1 phosphorylation, we constructed the single mutants S56A, S58A, S60A, and the triple mutant S56A/S58A/S60A and compared their degrees of phosphorylation with that of wild type Sml1. We observed a 90% decrease in the relative phosphorylation of S60A compared with that of wild type, a 25% decrease in S58A, and little or no decrease in the S56A mutant. There was no observed phosphate incorporation in the triple mutant, suggesting that Ser(56), Ser(58), and Ser(60) in Sml1 are the sites of phosphorylation. Further mutagenesis studies reveal that Dun1 kinase requires an acidic residue at the +3 position, and there is cooperativity between the phosphorylation sites. These results show that Dun1 has a unique phosphorylation motif.	Oak Ridge Natl Lab, Div Chem Sci, Organ & Biol Mass Spectrometry Grp, Oak Ridge, TN 37831 USA; Univ Tennessee, Genome Sci & Technol Grad Sch, Knoxville, TN 37996 USA; Univ Tennessee, Dept Biochem & Cellular & Mol Biol, Knoxville, TN 37996 USA	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Knoxville	Hettich, RL (corresponding author), Oak Ridge Natl Lab, Div Chem Sci, Organ & Biol Mass Spectrometry Grp, POB 2008, Oak Ridge, TN 37831 USA.	hettichrl@ornl.gov	Hettich, Robert L/N-1458-2016	Hettich, Robert L/0000-0001-7708-786X	NCI NIH HHS [1R01CA100827-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100827] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adamczyk M, 2001, RAPID COMMUN MASS SP, V15, P1481, DOI 10.1002/rcm.394; Bashkirov VI, 2003, MOL CELL BIOL, V23, P1441, DOI 10.1128/MCB.23.4.1441-1452.2003; Bashkirov VI, 2000, MOL CELL BIOL, V20, P4393, DOI 10.1128/MCB.20.12.4393-4404.2000; Benito J, 1998, EMBO J, V17, P482, DOI 10.1093/emboj/17.2.482; Chabes A, 1999, J BIOL CHEM, V274, P36679, DOI 10.1074/jbc.274.51.36679; Cleverley KE, 1998, BIOCHEMISTRY-US, V37, P3917, DOI 10.1021/bi9724523; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; FLOTOW H, 1989, J BIOL CHEM, V264, P9126; Fraczkiewicz R, 1998, J COMPUT CHEM, V19, P319, DOI 10.1002/(SICI)1096-987X(199802)19:3<319::AID-JCC6>3.0.CO;2-W; Gardner R, 1999, EMBO J, V18, P3173, DOI 10.1093/emboj/18.11.3173; GAUTHIER JW, 1991, ANAL CHIM ACTA, V246, P211, DOI 10.1016/S0003-2670(00)80678-9; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Horn DM, 2000, J AM SOC MASS SPECTR, V11, P320, DOI 10.1016/S1044-0305(99)00157-9; Huang MX, 1997, MOL CELL BIOL, V17, P6105, DOI 10.1128/MCB.17.10.6105; Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3; Lapko VN, 1997, BIOCHEMISTRY-US, V36, P10595, DOI 10.1021/bi970708z; MEYER HE, 1991, METHOD ENZYMOL, V201, P169; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Oda Y, 2001, NAT BIOTECHNOL, V19, P379, DOI 10.1038/86783; Pati D, 1997, MOL CELL BIOL, V17, P3037, DOI 10.1128/MCB.17.6.3037; Posewitz MC, 1999, ANAL CHEM, V71, P2883, DOI 10.1021/ac981409y; Resing KA, 1997, METHOD ENZYMOL, V283, P29; Sanchez Y, 1997, METHOD ENZYMOL, V283, P398; Stensballe A, 2000, RAPID COMMUN MASS SP, V14, P1793, DOI 10.1002/1097-0231(20001015)14:19<1793::AID-RCM95>3.0.CO;2-Q; THOMAS BJ, 1989, GENETICS, V123, P725; Uchiki T, 2002, ANAL BIOCHEM, V301, P35, DOI 10.1006/abio.2001.5492; UCHIKI T, 2002, 50 ASMS C MASS SPECT; Vacratsis PO, 2002, BIOCHEMISTRY-US, V41, P5613, DOI 10.1021/bi016075c; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; WATTS JD, 1994, J BIOL CHEM, V269, P29520; Zhang XL, 1998, ANAL CHEM, V70, P2050, DOI 10.1021/ac971207m; Zhao XL, 2001, EMBO J, V20, P3544, DOI 10.1093/emboj/20.13.3544; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4; Zhao XL, 2002, P NATL ACAD SCI USA, V99, P3746, DOI 10.1073/pnas.062502299; Zhao XL, 2000, MOL CELL BIOL, V20, P9076, DOI 10.1128/MCB.20.23.9076-9083.2000; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G	38	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11293	11303		10.1074/jbc.M309751200	http://dx.doi.org/10.1074/jbc.M309751200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14684746	hybrid			2022-12-25	WOS:000220157600057
J	Fernandez, D; Ghanta, A; Kauffman, GW; Sanguinetti, MC				Fernandez, D; Ghanta, A; Kauffman, GW; Sanguinetti, MC			Physicochemical features of the hERG channel drug binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QT INTERVAL PROLONGATION; K+ CHANNEL; POTASSIUM CHANNEL; CARDIAC-ARRHYTHMIA; BLOCK; INHIBITION; RECTIFIER; MUTATIONS; AFFINITY; PORE	Blockade of hERG K+ channels in the heart is an unintentional side effect of many drugs and can induce cardiac arrhythmia and sudden death. It has become common practice in the past few years to screen compounds for hERG channel activity early during the drug discovery process. Understanding the molecular basis of drug binding to hERG is crucial for the rational design of medications devoid of this activity. We previously identified 2 aromatic residues, Tyr-652 and Phe-656, located in the S6 domain of hERG, as critical sites of interaction with structurally diverse drugs. Here, Tyr-652 and Phe-656 were systematically mutated to different residues to determine how the physicochemical properties of the amino acid side group affected channel block by cisapride, terfenadine, and MK-499. The potency for block by all three drugs was well correlated with measures of hydrophobicity, especially the two-dimensional approximation of the van der Waals hydrophobic surface area of the side chain of residue 656. For residue 652, an aromatic side group was essential for high affinity block, suggesting the importance of a cation-pi interaction between Tyr-652 and the basic tertiary nitrogen of these drugs. hERG also lacks a Pro-Val-Pro motif common to the S6 domain of most other voltage-gated K+ channels. Introduction of Pro-Val-Pro into hERG reduced sensitivity to drugs but also altered channel gating. Together, these findings assign specific residues to receptor fields predicted by pharmacophore models of hERG channel blockers and provide a refined molecular understanding of the drug binding site.	Univ Utah, Nora Eccles Harrison Cardiovasc Res & Training In, Salt Lake City, UT 84112 USA; Univ Utah, Dept Physiol, Salt Lake City, UT 84112 USA; Pfizer Global R&D, Groton, CT 06340 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Pfizer	Sanguinetti, MC (corresponding author), Univ Utah, Nora Eccles Harrison Cardiovasc Res & Training In, 95 N 2000 E, Salt Lake City, UT 84112 USA.	michael.sanguinetti@hmbg.utah.edu	Sanguinetti, Michael/AAN-2615-2020		NHLBI NIH HHS [HL55236] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055236] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cavalli A, 2002, J MED CHEM, V45, P3844, DOI 10.1021/jm0208875; Chen J, 2002, P NATL ACAD SCI USA, V99, P12461, DOI 10.1073/pnas.192367299; del Camino D, 2000, NATURE, V403, P321, DOI 10.1038/35002099; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Ekins S, 2002, J PHARMACOL EXP THER, V301, P427, DOI 10.1124/jpet.301.2.427; Fermini B, 2003, NAT REV DRUG DISCOV, V2, P439, DOI 10.1038/nrd1108; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; JURS PC, 1979, COMPUTER ASSISTED DR, P103; Kamiya K, 2001, MOL PHARMACOL, V60, P244, DOI 10.1124/mol.60.2.244; Karplus PA, 1997, PROTEIN SCI, V6, P1302; Keating MT, 2001, CELL, V104, P569, DOI 10.1016/S0092-8674(01)00243-4; Lees-Miller JP, 2000, MOL PHARMACOL, V57, P367; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; Milnes JT, 2003, BRIT J PHARMACOL, V139, P887, DOI 10.1038/sj.bjp.0705335; Mitcheson JS, 2000, J GEN PHYSIOL, V115, P229, DOI 10.1085/jgp.115.3.229; Mitcheson JS, 2000, P NATL ACAD SCI USA, V97, P12329, DOI 10.1073/pnas.210244497; Mitcheson JS, 2003, BRIT J PHARMACOL, V139, P883, DOI 10.1038/sj.bjp.0705336; Mohler PJ, 2003, NATURE, V421, P634, DOI 10.1038/nature01335; Pearlstein R, 2003, J MED CHEM, V46, P2017, DOI 10.1021/jm0205651; Pearlstein RA, 2003, BIOORG MED CHEM LETT, V13, P1829, DOI 10.1016/S0960-894X(03)00196-3; Potet F, 2001, J PHARMACOL EXP THER, V299, P1007; RADZICKA A, 1988, BIOCHEMISTRY-US, V27, P1664, DOI 10.1021/bi00405a042; Redfern WS, 2003, CARDIOVASC RES, V58, P32, DOI 10.1016/S0008-6363(02)00846-5; Roy ML, 1996, CIRCULATION, V94, P817, DOI 10.1161/01.CIR.94.4.817; Sanchez-Chapula JA, 2003, MOL PHARMACOL, V63, P1051, DOI 10.1124/mol.63.5.1051; Sanchez-Chapula JA, 2002, J BIOL CHEM, V277, P23587, DOI 10.1074/jbc.M200448200; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1999, J PHYSIOL-LONDON, V514, P667, DOI 10.1111/j.1469-7793.1999.667ad.x; Spector PS, 1996, CIRC RES, V78, P499, DOI 10.1161/01.RES.78.3.499; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; STUPER AJ, 1976, J CHEM INF COMP SCI, V16, P99, DOI 10.1021/ci60006a014; SUTTER JM, 1995, J CHEM INF COMP SCI, V35, P77, DOI 10.1021/ci00023a011; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Wildman SA, 1999, J CHEM INF COMP SCI, V39, P868, DOI 10.1021/ci990307l	34	240	249	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10120	10127		10.1074/jbc.M310683200	http://dx.doi.org/10.1074/jbc.M310683200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699101	hybrid			2022-12-25	WOS:000220050400057
J	Reinehr, R; Gorg, B; Hongen, A; Haussinger, D				Reinehr, R; Gorg, B; Hongen, A; Haussinger, D			CD95-tyrosine nitration inhibits hyperosmotic and CD95 ligand-induced CD95 activation in rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SUPPRESSES; TYROSINE PHOSPHORYLATION; INDUCED APOPTOSIS; S-NITROSYLATION; MITOCHONDRIAL RESPIRATION; PROTEIN-KINASE; IN-VIVO; PEROXYNITRITE; CELLS; DEATH	Epidermal growth factor receptor-dependent CD95-tyrosine phosphorylation was recently identified as an early step in apoptosis induction via the CD95 system (Reinehr, R., Schliess, F., and Haussinger, D. (2003) FASEB J. 17, 731-733). The effect of peroxynitrite (ONOO-) on modulation of the hyperosmotic and CD95 ligand (CD95L)-induced CD95 activation process was studied. Pretreatment of hepatocytes with ONOO- inhibited CD95L- and hyperosmolarity-induced CD95 membrane trafficking and formation of the death-inducing signaling complex, but not epidermal growth factor receptor activation and its association with CD95. Under these conditions, however, no tyrosine phosphorylation of CD95 occurred; instead, CD95 was tyrosine-nitrated. When ONOO- was added after induction of CD95-tyrosine phosphorylation by CD95L or hyperosmolarity, tyrosine nitration of CD95 was largely prevented and death-inducing signaling complex formation occurred. CD95-tyrosine nitration abolished the hyperosmotic sensitization of hepatocytes toward CD95L- induced apoptosis. Additionally, in CD95-yellow fluorescent protein-transfected Huh7-hepatoma cells, ONOO- induced CD95 Tyr nitration and prevented CD95L- induced Tyr phosphorylation and apoptosis. Tyrosine-nitrated CD95 was also found in rat livers derived from an in vivo model of endotoxinemia. The data suggest that CD95-tyrosine nitration prevents CD95 activation by inhibiting CD95-tyrosine phosphorylation. Apparently, CD95-tyrosine phosphorylation and nitration are mutually exclusive. The data identify critical tyrosine residues of CD95 as another target of the anti-apoptotic action of NO.	Univ Dusseldorf, Clin Gastroenterol Hepatol & Infectiol, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Haussinger, D (corresponding author), Univ Klinikum Dusseldorf, Klin Gastroenterol Hepatol & Infektiol, Moorenstr 5, D-40225 Dusseldorf, Germany.	haeussin@uni-duesseldorf.de	Reinehr, Roland/G-6118-2016	Gorg, Boris/0000-0002-4630-9420				BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; BOLANOS JP, 1994, J NEUROCHEM, V63, P910; Brito C, 1999, J IMMUNOL, V162, P3356; Brown GC, 1999, BBA-BIOENERGETICS, V1411, P351, DOI 10.1016/S0005-2728(99)00025-0; Castaneda F, 2001, J CANCER RES CLIN, V127, P418, DOI 10.1007/s004320000227; Crow JP, 1997, J NEUROCHEM, V69, P1945; Faubion WA, 1999, HEPATOLOGY, V29, P1, DOI 10.1002/hep.510290101; Faubion WA, 1999, J CLIN INVEST, V103, P137, DOI 10.1172/JCI4765; Fu YX, 2001, J BIOL CHEM, V276, P43004, DOI 10.1074/jbc.M106946200; Fumarola C, 2001, CELL DEATH DIFFER, V8, P1004, DOI 10.1038/sj.cdd.4400902; Gaut JP, 2002, J CLIN INVEST, V109, P1311, DOI 10.1172/JCI200215021; Goldstein S, 2000, J BIOL CHEM, V275, P3031, DOI 10.1074/jbc.275.5.3031; Gorg B, 2003, HEPATOLOGY, V37, P334, DOI 10.1053/jhep.2003.50061; GRANGER DL, 1980, J CLIN INVEST, V65, P357, DOI 10.1172/JCI109679; Hurst JK, 2002, J CLIN INVEST, V109, P1287, DOI 10.1172/JCI200215816; Kim YM, 2000, HEPATOLOGY, V32, P770, DOI 10.1053/jhep.2000.18291; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kim YM, 1999, J NEUROSCI, V19, P6740, DOI 10.1523/JNEUROSCI.19-16-06740.1999; Kiroycheva M, 2000, J AM SOC NEPHROL, V11, P1026, DOI 10.1681/ASN.V1161026; Klotz LO, 2002, FREE RADICAL BIO MED, V33, P737, DOI 10.1016/S0891-5849(02)00892-4; Klotz LO, 2000, BIOCHEM J, V352, P219, DOI 10.1042/0264-6021:3520219; Kong SK, 1996, P NATL ACAD SCI USA, V93, P3377, DOI 10.1073/pnas.93.8.3377; Kurz AK, 2000, BIOCHEM J, V350, P207, DOI 10.1042/0264-6021:3500207; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Lala PK, 2001, LANCET ONCOL, V2, P149, DOI 10.1016/S1470-2045(00)00256-4; Lang F, 2000, CELL PHYSIOL BIOCHEM, V10, P417, DOI 10.1159/000016367; Li JR, 1999, J BIOL CHEM, V274, P17325, DOI 10.1074/jbc.274.24.17325; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; LIU SF, 1993, BIOCHEM BIOPH RES CO, V196, P1208, DOI 10.1006/bbrc.1993.2380; Mallozzi C, 2001, FEBS LETT, V503, P189, DOI 10.1016/S0014-5793(01)02726-0; Miyoshi H, 1999, GASTROENTEROLOGY, V117, P669, DOI 10.1016/S0016-5085(99)70461-0; NAKABAYASHI H, 1984, JPN J CANCER RES, V75, P151; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Park HS, 2000, P NATL ACAD SCI USA, V97, P14382, DOI 10.1073/pnas.97.26.14382; Ramezanian MS, 1996, METHOD ENZYMOL, V269, P195; Reinehr R, 2003, FASEB J, V17, P731, DOI 10.1096/fj.02-0915fje; Reinehr R, 2003, GASTROENTEROLOGY, V125, P839, DOI 10.1016/S0016-5085(03)01055-2; Reinehr R, 2002, HEPATOLOGY, V36, P602, DOI 10.1053/jhep.2002.35447; Saeki M, 1999, NEUROSCI RES, V33, P325, DOI 10.1016/S0168-0102(99)00019-X; Schliess F, 2002, FASEB J, V16, P739, DOI 10.1096/fj.01-0862fje; Schroeter H, 2003, BIOCHEM J, V372, P359, DOI 10.1042/BJ20030201; Seki Shuichi, 1999, Medical Electron Microscopy, V32, P199; Tzeng E, 1997, SURGERY, V122, P255, DOI 10.1016/S0039-6060(97)90016-7; Wang YN, 2002, ANN NY ACAD SCI, V962, P415, DOI 10.1111/j.1749-6632.2002.tb04085.x; Yoon JH, 2002, J HEPATOL, V37, P400, DOI 10.1016/S0168-8278(02)00209-X; Zamora R, 2001, J BIOL CHEM, V276, P46887, DOI 10.1074/jbc.M101865200; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	49	56	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10364	10373		10.1074/jbc.M311997200	http://dx.doi.org/10.1074/jbc.M311997200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14679192	hybrid			2022-12-25	WOS:000220050400086
J	Sawada, H; Kohno, R; Kihara, T; Izumi, Y; Sakka, N; Ibi, M; Nakanishi, M; Nakamizo, T; Yamakawa, K; Shibasaki, H; Yamamoto, N; Akaike, A; Inden, M; Kitamura, Y; Taniguchi, T; Shimohama, S				Sawada, H; Kohno, R; Kihara, T; Izumi, Y; Sakka, N; Ibi, M; Nakanishi, M; Nakamizo, T; Yamakawa, K; Shibasaki, H; Yamamoto, N; Akaike, A; Inden, M; Kitamura, Y; Taniguchi, T; Shimohama, S			Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein inclusions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL COMPLEX-I; PARKINSONS-DISEASE; LEWY BODIES; CELL-DEATH; SIGNALING PATHWAY; SUBSTANTIA-NIGRA; PROTEIN; DEGRADATION; APOPTOSIS; KINASE	Parkinson's disease is characterized by dopaminergic neuronal death and the presence of Lewy bodies. alpha-Synuclein is a major component of Lewy bodies, but the process of its accumulation and its relationship to dopaminergic neuronal death has not been resolved. Although the pathogenesis has not been clarified, mitochondrial complex I is suppressed, and caspase-3 is activated in the affected midbrain. Here we report that a combination of 1-methyl-4-phenylpyridinium ion (MPP+) or rotenone and proteasome inhibition causes the appearance of alpha-synuclein-positive inclusion bodies. Unexpectedly, however, proteasome inhibition blocked MPP+- or rotenone-induced dopaminergic neuronal death. MPP+ elevated proteasome activity, dephosphorylated mitogen-activating protein kinase ( MAPK), and activated caspase-3. Proteasome inhibition reversed the MAPK dephosphorylation and blocked caspase-3 activation; the neuroprotection was blocked by a p42 and p44 MAPK kinase inhibitor. Thus, the proteasome plays an important role in both inclusion body formation and dopaminergic neuronal death but these processes form opposite sides on the proteasome regulation in this model.	Grad Sch Med, Dept Neurol, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Pharmaceut Univ, Dept Neurobiol, Yamashina Ku, Kyoto 6078412, Japan	Kyoto University; Kyoto Pharmaceutical University	Shimohama, S (corresponding author), Grad Sch Med, Dept Neurol, Sakyo Ku, 54 Shogoin Kawaharacho, Kyoto 6068507, Japan.	i53367@sakura.kudpc.kyoto-u.ac.jp	Nakamizo, Tomoki/AAM-8615-2021	Nakamizo, Tomoki/0000-0002-8377-1235; Inden, Masatoshi/0000-0002-7480-4920; Ibi, Masakazu/0000-0003-1414-100X; Sawada, Hideyuki/0000-0002-5909-3366				Bennett MC, 1999, J BIOL CHEM, V274, P33855, DOI 10.1074/jbc.274.48.33855; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.3.CO;2-S; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; Canu N, 2000, J NEUROSCI, V20, P589, DOI 10.1523/JNEUROSCI.20-02-00589.2000; Drexler HCA, 2000, FASEB J, V14, P65, DOI 10.1096/fasebj.14.1.65; Farrer M, 2001, ANN NEUROL, V50, P293, DOI 10.1002/ana.1132; Ferrer I, 2001, J NEURAL TRANSM, V108, P1383, DOI 10.1007/s007020100015; Furukawa Y, 2002, ANN NEUROL, V51, P779, DOI 10.1002/ana.10207; Grimm LM, 1996, EMBO J, V15, P3835, DOI 10.1002/j.1460-2075.1996.tb00757.x; Hartmann A, 2000, P NATL ACAD SCI USA, V97, P2875, DOI 10.1073/pnas.040556597; Hashimoto K, 2000, J NEUROCHEM, V74, P92, DOI 10.1046/j.1471-4159.2000.0740092.x; HATTORI N, 1991, ANN NEUROL, V30, P563, DOI 10.1002/ana.410300409; Hoglinger GU, 2003, J NEUROCHEM, V86, P1297, DOI 10.1046/j.1471-4159.2003.01952.x; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; Manenti S, 2002, BIOCHEM BIOPH RES CO, V294, P976, DOI 10.1016/S0006-291X(02)00594-6; McNaught KS, 2002, NEUROREPORT, V13, P1437, DOI 10.1097/00001756-200208070-00018; McNaught KS, 2002, J NEUROCHEM, V81, P301, DOI 10.1046/j.1471-4159.2002.00821.x; McNaught KSP, 2001, NEUROSCI LETT, V297, P191, DOI 10.1016/S0304-3940(00)01701-8; MIZUNO Y, 1987, J NEUROCHEM, V48, P1787, DOI 10.1111/j.1471-4159.1987.tb05737.x; Mori H, 1998, NEUROLOGY, V51, P890, DOI 10.1212/WNL.51.3.890; Naoi M, 1997, J NEURAL TRANSM-SUPP, P89; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Przedborski S, 2001, CLIN NEUROSCI RES, V1, P407, DOI 10.1016/S1566-2772(01)00019-6; Qiu JH, 2000, J NEUROSCI, V20, P259, DOI 10.1523/JNEUROSCI.20-01-00259.2000; RAMSAY RR, 1986, BIOCHEM BIOPH RES CO, V134, P743, DOI 10.1016/S0006-291X(86)80483-1; Rideout HJ, 2001, J NEUROCHEM, V78, P899, DOI 10.1046/j.1471-4159.2001.00474.x; Sadoul R, 1996, EMBO J, V15, P3845, DOI 10.1002/j.1460-2075.1996.tb00758.x; Sawada H, 2000, FASEB J, V14, P1202, DOI 10.1096/fasebj.14.9.1202; Sawada H, 1996, J NEUROSCI RES, V43, P503, DOI 10.1002/(SICI)1097-4547(19960215)43:4<503::AID-JNR12>3.0.CO;2-2; Schapira AHV, 1998, ANN NEUROL, V44, pS89, DOI 10.1002/ana.410440714; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; Schulte TW, 1997, BIOCHEM BIOPH RES CO, V239, P655, DOI 10.1006/bbrc.1997.7527; Sherer TB, 2003, EXP NEUROL, V179, P9, DOI 10.1006/exnr.2002.8072; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Stadheim TA, 2001, CANCER RES, V61, P1533; Takeda A, 1998, AM J PATHOL, V152, P367; Tatton NA, 2000, EXP NEUROL, V166, P29, DOI 10.1006/exnr.2000.7489; Tortosa A, 1997, NEUROSCI LETT, V238, P78, DOI 10.1016/S0304-3940(97)00837-9; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; van de Warrenburg BPC, 2001, NEUROLOGY, V56, P555, DOI 10.1212/WNL.56.4.555; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Xue LZ, 2000, J BIOL CHEM, V275, P8817, DOI 10.1074/jbc.275.12.8817; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797; Zhu JH, 2002, AM J PATHOL, V161, P2087, DOI 10.1016/S0002-9440(10)64487-2	52	97	102	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10710	10719		10.1074/jbc.M308434200	http://dx.doi.org/10.1074/jbc.M308434200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14672949	hybrid			2022-12-25	WOS:000220050400126
J	Ai, WD; Liu, Y; Langlois, M; Wang, TC				Ai, WD; Liu, Y; Langlois, M; Wang, TC			Kruppel-like factor 4 (KLF4) represses histidine decarboxylase gene expression through an upstream Sp1 site and downstream gastrin responsive elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KRUPPEL-LIKE FACTOR; PHORBOL 12-MYRISTATE 13-ACETATE; ZINC-FINGER PROTEIN; HUMAN KERATIN 4; PROMOTER ACTIVITY; TRANSCRIPTION FACTORS; CANCER CELLS; EPITHELIAL-CELLS; CPG METHYLATION; GUT	Histidine decarboxylase (HDC) is the enzyme that catalyzes the conversion of histidine to histamine, a bioamine that plays an important role in allergic responses, inflammation, neurotransmission, and gastric acid secretion. Previously, we demonstrated that gastrin activates HDC promoter activity in a gastric cancer (AGS-E) cell line through three overlapping downstream promoter elements. In the current study, we used the yeast one-hybrid strategy to identify nuclear factors that bind to these three elements. Among eight positives from the one-hybrid screen, we identified Kruppel-like factor 4 (KLF4) (previously known as gut-enriched Kruppel-like factor ( GKLF)) as one factor that binds to the gastrin responsive elements in the HDC promoter. Electrophoretic mobility shift assays confirmed that KLF4 is able to bind all three gastrin responsive elements. In addition, transient cotransfection experiments showed that overexpression of KLF4 dose dependently and specifically inhibited HDC promoter activity. Regulation of HDC transcription by KLF4 was confirmed by changes in the endogenous HDC messenger RNA by KLF4 small interfering RNA and KLF4 overexpression. We further showed that KLF4 inhibits HDC promoter activity by competing with Sp1 at the upstream GC box and also independently by binding the three downstream gastrin responsive elements. Taken together, these results indicate that KLF4 can act to repress HDC gene expression by Sp1-dependent and - independent mechanisms.	Univ Massachusetts, Sch Med, Div Gastroenterol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Wang, TC (corresponding author), Univ Massachusetts, Sch Med, Div Gastroenterol, Lazare Res Bldg,Rm 208,364 Plantat St, Worcester, MA 01605 USA.	timothy.wang@umassmed.edu	Li, Yapeng/N-1042-2017	Li, Yapeng/0000-0002-5042-6881	NIDDK NIH HHS [R01 DK-48077] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048077] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adam PJ, 2000, J BIOL CHEM, V275, P37798, DOI 10.1074/jbc.M006323200; Ai WD, 1999, J VIROL, V73, P4220, DOI 10.1128/JVI.73.5.4220-4229.1999; Barocelli E, 2003, PHARMACOL RES, V47, P299, DOI 10.1016/S1043-6618(03)00009-4; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Brembeck FH, 2000, J BIOL CHEM, V275, P28230; Chen ZY, 2002, J BIOL CHEM, V277, P46831, DOI 10.1074/jbc.M204816200; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fleming JV, 2003, J BIOL CHEM, V278, P686, DOI 10.1074/jbc.M210718200; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Geiman DE, 2000, NUCLEIC ACIDS RES, V28, P1106, DOI 10.1093/nar/28.5.1106; Gelfaned EW, 2002, AM J MED, V113, p2S; Gerhard M, 2001, ENDOCRINOLOGY, V142, P3663, DOI 10.1210/en.142.8.3663; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GIGLIONI B, 1989, BIOCHEM BIOPH RES CO, V164, P149, DOI 10.1016/0006-291X(89)91695-1; Higaki Y, 2002, NUCLEIC ACIDS RES, V30, P2270, DOI 10.1093/nar/30.11.2270; Hirasawa N, 2001, EUR J PHARMACOL, V418, P23, DOI 10.1016/S0014-2999(01)00931-1; Hocker M, 1997, J BIOL CHEM, V272, P27015, DOI 10.1074/jbc.272.43.27015; Hocker M, 1998, J BIOL CHEM, V273, P23046, DOI 10.1074/jbc.273.36.23046; Hocker M, 1996, AM J PHYSIOL-GASTR L, V270, pG619, DOI 10.1152/ajpgi.1996.270.4.G619; Hocker M, 1996, YALE J BIOL MED, V69, P21; Hocker M, 1998, J BIOL CHEM, V273, P34000, DOI 10.1074/jbc.273.51.34000; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; Jaubert J, 2003, DEVELOPMENT, V130, P2767, DOI 10.1242/dev.00477; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Katz JP, 2002, DEVELOPMENT, V129, P2619; KATZ JP, 2003, ABSTR DIGESTIVE DIS, pA147; Krikun G, 2000, MOL ENDOCRINOL, V14, P393, DOI 10.1210/me.14.3.393; Kuramasu A, 1998, J BIOL CHEM, V273, P31607, DOI 10.1074/jbc.273.47.31607; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; MCLAUGHLIN JT, 2004, AM J PHYSIOL, V268, pG51; Medina MA, 1999, BIOCHEM PHARMACOL, V57, P1341, DOI 10.1016/S0006-2952(99)00005-2; Miller KA, 2001, J BIOL CHEM, V276, P42863, DOI 10.1074/jbc.M108130200; OHGOH M, 1993, BIOCHEM BIOPH RES CO, V196, P1113, DOI 10.1006/bbrc.1993.2366; Okano J, 2000, FEBS LETT, V473, P95, DOI 10.1016/S0014-5793(00)01468-X; Pacilio M, 2001, BIOCHEM BIOPH RES CO, V285, P1095, DOI 10.1006/bbrc.2001.5296; RANGACHARI PK, 1992, AM J PHYSIOL, V262, pG1, DOI 10.1152/ajpgi.1992.262.1.G1; Raychowdhury R, 1999, J BIOL CHEM, V274, P20961, DOI 10.1074/jbc.274.30.20961; Raychowdhury R, 2002, BIOCHEM BIOPH RES CO, V297, P1089, DOI 10.1016/S0006-291X(02)02345-8; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1998, NUCLEIC ACIDS RES, V26, P796, DOI 10.1093/nar/26.3.796; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SINCLAIR NF, 2004, IN PRESS AM J PHYSL; Suzuki H, 1996, J BIOL CHEM, V271, P18981, DOI 10.1074/jbc.271.31.18981; Suzuki-Ishigaki S, 2000, NUCLEIC ACIDS RES, V28, P2627, DOI 10.1093/nar/28.14.2627; Wessler S, 2002, FASEB J, V16, P417, DOI 10.1096/fj.01-0766fje; Wessler S, 2000, J BIOL CHEM, V275, P3629, DOI 10.1074/jbc.275.5.3629; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917; Zhang ZS, 1996, J BIOL CHEM, V271, P14188, DOI 10.1074/jbc.271.24.14188	54	55	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8684	8693		10.1074/jbc.M308278200	http://dx.doi.org/10.1074/jbc.M308278200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14670968	hybrid			2022-12-25	WOS:000189265900020
J	Antoniou, AN; Ford, S; Taurog, JD; Butcher, GW; Powis, SJ				Antoniou, AN; Ford, S; Taurog, JD; Butcher, GW; Powis, SJ			Formation of HLA-B27 homodimers and their relationship to assembly kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I MOLECULES; UNFOLDED PROTEIN RESPONSE; CD4(+) T-LYMPHOCYTES; ANKYLOSING-SPONDYLITIS; ENDOPLASMIC-RETICULUM; CELL-SURFACE; INFLAMMATORY DISEASE; MONOCLONAL-ANTIBODY; HEAVY-CHAINS; ANTIGEN PRESENTATION	The human HLA-B27 class I molecule exhibits a strong association with the inflammatory arthritic disorder ankylosing spondylitis and other related arthropathies. Major histocompatibility complex class I heavy chains normally associate with beta(2)-microglobulin and peptide in the endoplasmic reticulum before transit to the cell surface. However, an unusual characteristic of HLA-B27 is its ability to form heavy chain homodimers through an unpaired cysteine at position 67 in the peptide groove. Homodimers have previously been detected within the ER and at the cell surface, but their mechanism of formation and role in disease remain undefined. Here we demonstrate, in the rat C58 thymoma cell line and in human HeLa cells transfected with HLA-B27, that homodimer formation involves not only cysteine at position 67 but also the conserved structural cysteine at position 164. We also show that homodimer formation can be induced in the non-disease- associated HLA class I allele HLA-A2 by slowing its assembly rate by incubation of cells at 26degreesC, suggesting that homodimer formation in the endoplasmic reticulum may occur as a result of the slower folding kinetics of HLA-B27. Finally, we report an association between unfolded HLA-B27 molecules and immunoglobulin-binding protein at the cell surface.	Univ Dundee, Sch Life Sci, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland; Univ Texas, SW Med Ctr, Harold C Simmons Arthrit Res Ctr, Dallas, TX 75390 USA; Babraham Inst, Mol Immunol Programme, Cambridge CB2 4AT, England	University of Dundee; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Powis, SJ (corresponding author), Univ Dundee, Sch Life Sci, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland.	s.j.powis@dundee.ac.uk		Powis, Simon/0000-0003-4218-2984; Antoniou, Antony/0000-0002-6536-7781				Allen RL, 1999, IMMUNOGENETICS, V50, P220, DOI 10.1007/s002510050596; Allen RL, 2001, J IMMUNOL, V167, P5543, DOI 10.4049/jimmunol.167.10.5543; Allen RL, 1999, J IMMUNOL, V162, P5045; Alvarez I, 2001, J BIOL CHEM, V276, P48740, DOI 10.1074/jbc.M108882200; Antoniou AN, 2003, ANTIOXID REDOX SIGN, V5, P375, DOI 10.1089/152308603768295104; Antoniou AN, 2003, CURR OPIN IMMUNOL, V15, P75, DOI 10.1016/S0952-7915(02)00010-9; Antoniou AN, 2002, EMBO J, V21, P2655, DOI 10.1093/emboj/21.11.2655; Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; Aridor M, 2000, TRAFFIC, V1, P836, DOI 10.1034/j.1600-0854.2000.011104.x; BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; Bird LA, 2003, EUR J IMMUNOL, V33, P748, DOI 10.1002/eji.200323678; Bowness P, 2002, RHEUMATOLOGY, V41, P857, DOI 10.1093/rheumatology/41.8.857; Boyle LH, 2003, RHEUMATOLOGY, V42, P404, DOI 10.1093/rheumatology/keg097; Boyle LH, 2001, J IMMUNOL, V167, P2619, DOI 10.4049/jimmunol.167.5.2619; Boyson JE, 2002, P NATL ACAD SCI USA, V99, P16180, DOI 10.1073/pnas.212643199; BREWERTON DA, 1973, LANCET, V1, P904; Cauli A, 2002, RHEUMATOLOGY, V41, P1375, DOI 10.1093/rheumatology/41.12.1375; Colbert RA, 2000, MOL MED TODAY, V6, P224, DOI 10.1016/S1357-4310(00)01699-3; Dangoria NS, 2002, J BIOL CHEM, V277, P23459, DOI 10.1074/jbc.M110336200; de Castro JAL, 1998, CURR OPIN IMMUNOL, V10, P59, DOI 10.1016/S0952-7915(98)80033-2; Dick TP, 2002, METHOD ENZYMOL, V348, P49, DOI 10.1016/S0076-6879(02)48625-9; Dick TP, 2002, IMMUNITY, V16, P87, DOI 10.1016/S1074-7613(02)00263-7; Duftner C, 2003, ARTHRITIS RES THER, V5, pR292, DOI 10.1186/ar793; Elliott JG, 1997, J BIOL CHEM, V272, P13849, DOI 10.1074/jbc.272.21.13849; ELLIS SA, 1982, HUM IMMUNOL, V5, P49, DOI 10.1016/0198-8859(82)90030-1; ELZAATARI FAK, 1990, J IMMUNOL, V144, P1512; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gu J, 2002, J RHEUMATOL, V29, P2159; HAAS IG, 1991, CURR TOP MICROBIOL, V167, P71; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hellman R, 1999, J CELL BIOL, V144, P21, DOI 10.1083/jcb.144.1.21; Hendershot L, 1996, P NATL ACAD SCI USA, V93, P5269, DOI 10.1073/pnas.93.11.5269; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; KHARE SD, 1995, J EXP MED, V182, P1153, DOI 10.1084/jem.182.4.1153; Kingsbury DJ, 2000, ARTHRITIS RHEUM, V43, P2290, DOI 10.1002/1529-0131(200010)43:10<2290::AID-ANR17>3.0.CO;2-6; Kollnberger S, 2002, ARTHRITIS RHEUM, V46, P2972, DOI 10.1002/art.10605; Kostyu DD, 1997, HUM IMMUNOL, V57, P1, DOI 10.1016/S0198-8859(97)00175-4; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Malik P, 2002, J IMMUNOL, V169, P4379, DOI 10.4049/jimmunol.169.8.4379; Mear JP, 1999, J IMMUNOL, V163, P6665; NOSSNER E, 1995, J EXP MED, V181, P327, DOI 10.1084/jem.181.1.327; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; PARHAM P, 1981, HUM IMMUNOL, V3, P277, DOI 10.1016/0198-8859(81)90065-3; Peh CA, 1998, IMMUNITY, V8, P531, DOI 10.1016/S1074-7613(00)80558-0; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; Powis SJ, 1997, EUR J IMMUNOL, V27, P2744, DOI 10.1002/eji.1830271040; Ramos M, 2002, TISSUE ANTIGENS, V60, P191, DOI 10.1034/j.1399-0039.2002.600301.x; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; SCHLOSSTEIN L, 1973, NEW ENGL J MED, V288, P704, DOI 10.1056/NEJM197304052881403; SIMONS JF, 1995, J CELL BIOL, V130, P41, DOI 10.1083/jcb.130.1.41; STAM NJ, 1986, J IMMUNOL, V137, P2299; TAUROG JD, 1993, J IMMUNOL, V150, P4168; Taurog JD, 1999, IMMUNOL REV, V169, P209; Uchanska-Ziegler B, 2003, TRENDS IMMUNOL, V24, P73, DOI 10.1016/S1471-4906(02)00028-5; WEINREICH S, 1995, HUM IMMUNOL, V42, P103, DOI 10.1016/0198-8859(94)00034-N; WHELAN MA, 1993, EUR J IMMUNOL, V23, P3278, DOI 10.1002/eji.1830231233; Wiest DL, 1997, P NATL ACAD SCI USA, V94, P1884, DOI 10.1073/pnas.94.5.1884; Williams AP, 2002, IMMUNITY, V16, P509, DOI 10.1016/S1074-7613(02)00304-7; YAMAGUCHI A, 1995, ARTHRITIS RHEUM-US, V38, P1672, DOI 10.1002/art.1780381120; Yamamoto K, 2001, EMBO J, V20, P3082, DOI 10.1093/emboj/20.12.3082; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009; Zhang Q, 1998, J IMMUNOL, V160, P831; ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944	68	82	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8895	8902		10.1074/jbc.M311757200	http://dx.doi.org/10.1074/jbc.M311757200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14684742	hybrid			2022-12-25	WOS:000189265900047
J	Jewett, TJ; Sibley, LD				Jewett, TJ; Sibley, LD			The toxoplasma proteins MIC2 and M2AP form a hexameric complex necessary for intracellular survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; HOST-CELLS; APICOMPLEXAN PARASITES; MICRONEME PROTEINS; MOLECULAR CHARACTERIZATION; GONDII; INVASION; SECRETION; CLEAVAGE; THROMBOSPONDIN	Toxoplasma gondii parasites gain entry into host cells through a process that depends on apically stored adhesins that are strategically released during invasion. One of these adhesins, microneme protein 2 (MIC2), is a type one transmembrane protein that binds to an accessory protein known as MIC2-associated protein (M2AP). Together the MIC2 . M2AP complex participates in host cell attachment and invasion. The short cytoplasmic C-domain of MIC2 is implicated in protein trafficking and mediating an association with the parasite cytoskeleton. To define the role of the cytoplasmic domain of MIC2, proteins lacking the C-domain were expressed in transgenic T. gondii. Surprisingly, protein trafficking and secretion were not affected. We hypothesized that mutant mic2 lacking the C-domain might be escorted to the micronemes by association with endogenous wild-type MIC2 possessing functional transmembrane and cytoplasmic domains. To investigate this interaction, native blue gels and gel filtration were employed to identify a stable macromolecular MIC2 . M2AP complex of similar to 450 kDa. Our findings reveal that MIC2 and M2AP proteins form stable hexamers consisting of three alphabeta dimers. Resolution of this complex has implications for how MIC2 . M2AP associates with host cell receptors and the cytoskeleton to facilitate parasite motility and invasion.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Sibley, LD (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.	sibley@borcim.wustl.edu	Sibley, L. David/C-4616-2008		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034036] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI034036, AI34036] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Brossier F, 2003, J BIOL CHEM, V278, P6229, DOI 10.1074/jbc.M209837200; Brydges SD, 2000, MOL BIOCHEM PARASIT, V111, P51, DOI 10.1016/S0166-6851(00)00296-6; Buscaglia CA, 2003, MOL BIOL CELL, V14, P4947, DOI 10.1091/mbc.E03-06-0355; Carruthers VB, 1999, CELL MICROBIOL, V1, P225, DOI 10.1046/j.1462-5822.1999.00023.x; Carruthers VB, 1999, BIOCHEM J, V342, P379, DOI 10.1042/0264-6021:3420379; Carruthers VB, 2000, J BIOL CHEM, V275, P14346, DOI 10.1074/jbc.275.19.14346; Carruthers VB, 1999, MOL MICROBIOL, V31, P421, DOI 10.1046/j.1365-2958.1999.01174.x; Carruthers VB, 1997, EUR J CELL BIOL, V73, P114; Carruthers VB, 2000, INFECT IMMUN, V68, P4005, DOI 10.1128/IAI.68.7.4005-4011.2000; Cerede O, 2002, EMBO J, V21, P2526, DOI 10.1093/emboj/21.11.2526; Di Cristina M, 2000, MOL CELL BIOL, V20, P7332, DOI 10.1128/MCB.20.19.7332-7341.2000; Donald RGK, 1998, MOL BIOCHEM PARASIT, V91, P295, DOI 10.1016/S0166-6851(97)00210-7; HARPER JM, 2004, IN PRESS MOL BIOCH P; Huynh MH, 2003, EMBO J, V22, P2082, DOI 10.1093/emboj/cdg217; Jewett TJ, 2003, MOL CELL, V11, P885, DOI 10.1016/S1097-2765(03)00113-8; Kappe S, 1999, J CELL BIOL, V147, P937, DOI 10.1083/jcb.147.5.937; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Meissner M, 2002, J CELL SCI, V115, P563; Morrissette NS, 2002, MICROBIOL MOL BIOL R, V66, P21, DOI 10.1128/MMBR.66.1.21-38.2002; Opitz C, 2002, EMBO J, V21, P1577, DOI 10.1093/emboj/21.7.1577; Rabenau KE, 2001, MOL MICROBIOL, V41, P537, DOI 10.1046/j.1365-2958.2001.02513.x; Reiss M, 2001, J CELL BIOL, V152, P563, DOI 10.1083/jcb.152.3.563; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Soldati D, 2001, INT J PARASITOL, V31, P1293, DOI 10.1016/S0020-7519(01)00257-0; Urban S, 2003, MOL CELL, V11, P1425, DOI 10.1016/S1097-2765(03)00181-3; Wan KL, 1997, MOL BIOCHEM PARASIT, V84, P203, DOI 10.1016/S0166-6851(96)02796-X	28	41	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9362	9369		10.1074/jbc.M312590200	http://dx.doi.org/10.1074/jbc.M312590200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14670959	hybrid			2022-12-25	WOS:000189265900100
J	Lozupone, F; Lugini, L; Matarrese, P; Luciani, F; Federici, C; Iessi, E; Margutti, P; Stassi, G; Malorni, W; Fais, S				Lozupone, F; Lugini, L; Matarrese, P; Luciani, F; Federici, C; Iessi, E; Margutti, P; Stassi, G; Malorni, W; Fais, S			Identification and relevance of the CD95-binding domain in the N-terminal region of ezrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; FERM DOMAIN; PLASMA-MEMBRANE; ACTIN-BINDING; TYROSINE PHOSPHORYLATION; T-LYMPHOCYTES; ERM PROTEINS; EPITHELIAL-CELLS; MOESIN; CYTOSKELETON	The CD95 (Fas/APO-1) linkage to the actin cytoskeleton through ezrin is an essential requirement for susceptibility to the CD95-mediated apoptosis in CD4+ T cells. We have previously shown that moesin was not involved in the binding to CD95. Here we further support the specificity of the ezrin/CD95 binding, showing that radixin did not bind CD95. The ezrin region specifically and directly involved in the binding to CD95 was located in the middle lobe of the ezrin FERM domain, between amino acids 149 and 168. In this region, ezrin, radixin, and moesin show 60-65% identity, as compared with the 86% identity in the whole FERM domain. Transfection of two different human cell lines with a green fluorescent protein-tagged ezrin mutated in the CD95-binding epitope, induced a marked inhibition of CD95-mediated apoptosis. In these cells, the mutated ezrin did not co-localize or co-immunoprecipitate with CD95. Further analysis showed that the mutated ezrin, while unable to bind CD95, was fully able to bind actin, thus preventing the actin linkage to CD95. Altogether, our results support the specificity of ezrin in the association to CD95 and the importance of the ezrin-to-CD95 linkage in CD95-mediated apoptosis. Moreover, this study suggests that a major role of ezrin is to connect CD95 to actin, thus allowing the CD95 polarization on the cells and the occurrence of the following multiple cascades of the CD95 pathway.	Ist Super Sanita, Immunol Lab, Tumor Immunol Sect, I-00161 Rome, Italy; Ist Super Sanita, Lab Ultrastruct, I-00161 Rome, Italy; Univ Palermo, Dept Surg & Oncol Sci, Lab Cellular & Mol Pathophysiol, I-90127 Palermo, Italy	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); University of Palermo	Fais, S (corresponding author), Ist Super Sanita, Immunol Lab, Tumor Immunol Sect, Viale Regina Elena 299, I-00161 Rome, Italy.	fais@iss.it	Lugini, Luana/J-8672-2016; Malorni, Walter/G-5874-2016; Federici, Cristina/O-4676-2016; Iessi, Elisabetta/O-2460-2017; Fais, Stefano/J-8638-2016; Stassi, Giorgio/AAC-1175-2022; Lozupone, Francesco/H-2998-2016; Matarrese, Paola/A-4369-2014	Lugini, Luana/0000-0002-8778-2601; Federici, Cristina/0000-0001-6366-0231; Iessi, Elisabetta/0000-0001-7221-9173; Fais, Stefano/0000-0001-9060-2766; Lozupone, Francesco/0000-0002-4959-9400; Luciani, Francesca/0000-0002-1362-2808; malorni, walter/0000-0002-1223-7000				Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Ausbel FM, 1994, CURRENT PROTOCOLS MO; Barret C, 2000, J CELL BIOL, V151, P1067, DOI 10.1083/jcb.151.5.1067; BERRYMAN M, 1993, J CELL SCI, V105, P1025; BRETSCHER A, 1983, J CELL BIOL, V97, P425, DOI 10.1083/jcb.97.2.425; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Bretscher A, 1997, J CELL SCI, V110, P3011; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; del Pozo MA, 1998, CELL ADHES COMMUN, V6, P125, DOI 10.3109/15419069809004468; Edwards SD, 2001, BIOCHEMISTRY-US, V40, P7061, DOI 10.1021/bi010419h; Fais S, 2000, HISTOL HISTOPATHOL, V15, P539, DOI 10.14670/HH-15.539; Fais S, 2003, J LEUKOCYTE BIOL, V73, P556, DOI 10.1189/jlb.1102568; FRANCK Z, 1993, J CELL SCI, V105, P219; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; Gautreau A, 2002, CURR OPIN CELL BIOL, V14, P104, DOI 10.1016/S0955-0674(01)00300-3; Gautreau A, 2000, J CELL BIOL, V150, P193, DOI 10.1083/jcb.150.1.193; Giammarioli AM, 2001, FEBS LETT, V506, P45, DOI 10.1016/S0014-5793(01)02776-4; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Jiang WG, 1995, BIOCHEM BIOPH RES CO, V217, P1062, DOI 10.1006/bbrc.1995.2877; Kondo T, 1997, J CELL BIOL, V139, P749, DOI 10.1083/jcb.139.3.749; KRIEG J, 1992, J BIOL CHEM, V267, P19258; Kulms D, 2002, CELL DEATH DIFFER, V9, P598, DOI 10.1038/sj.cdd.4401002; Kurashima K, 1999, J BIOL CHEM, V274, P29843, DOI 10.1074/jbc.274.42.29843; Louvet-Vallee S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248-4900(00)01078-9; Luciani F, 2002, BLOOD, V99, P641, DOI 10.1182/blood.V99.2.641; Parlato S, 2000, EMBO J, V19, P5123, DOI 10.1093/emboj/19.19.5123; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Perez OD, 2002, IMMUNITY, V16, P51, DOI 10.1016/S1074-7613(02)00266-2; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; Ramoni C, 2002, EUR J IMMUNOL, V32, P3059, DOI 10.1002/1521-4141(200211)32:11<3059::AID-IMMU3059>3.0.CO;2-3; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Roy C, 1997, J BIOL CHEM, V272, P20088, DOI 10.1074/jbc.272.32.20088; Serrador JM, 1997, J CELL BIOL, V138, P1409, DOI 10.1083/jcb.138.6.1409; Serrador JM, 1998, BLOOD, V91, P4632, DOI 10.1182/blood.V91.12.4632.412k17_4632_4644; Smith WJ, 2003, J BIOL CHEM, V278, P4949, DOI 10.1074/jbc.M210601200; Smith WJ, 2002, ACTA CRYSTALLOGR D, V58, P1359, DOI [10.1107/S0907444902010004, 10.1107/S0907444902009162]; TAKEUCHI K, 1994, J CELL SCI, V107, P1921; THUILLIER L, 1994, CELL IMMUNOL, V156, P322, DOI 10.1006/cimm.1994.1178; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; Turunen O, 1998, BBA-PROTEIN STRUCT M, V1387, P1, DOI 10.1016/S0167-4838(98)00103-4; Vicente-Manzanares M, 2000, Dev Immunol, V7, P51, DOI 10.1155/2000/70801; Wang GQ, 2001, J BIOL CHEM, V276, P3610, DOI 10.1074/jbc.M006222200; Yao XB, 1996, J BIOL CHEM, V271, P7224, DOI 10.1074/jbc.271.12.7224; YONEMURA S, 1993, J CELL BIOL, V120, P437, DOI 10.1083/jcb.120.2.437	49	56	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9199	9207		10.1074/jbc.M305561200	http://dx.doi.org/10.1074/jbc.M305561200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676203	hybrid			2022-12-25	WOS:000189265900081
J	Ng, CP; Lee, HC; Ho, CW; Arooz, T; Siu, WY; Lau, A; Poon, RYC				Ng, CP; Lee, HC; Ho, CW; Arooz, T; Siu, WY; Lau, A; Poon, RYC			Differential mode of regulation of the checkpoint kinases CHK1 and CHK2 by their regulatory domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; CELL-CYCLE; PROTEIN-KINASE; TUMOR-SUPPRESSOR; PHOSPHORYLATION; ATR; ACTIVATION; CLASPIN; PATHWAY; BINDING	CHK1 and CHK2 are key mediators that link the machineries that monitor DNA integrity to components of the cell cycle engine. Despite the similarity and potential redundancy in their functions, CHK1 and CHK2 are unrelated protein kinases, each having a distinctive regulatory domain. Here we compare how the regulatory domains of human CHK1 and CHK2 modulate the respective kinase activities. Recombinant CHK1 has only low basal activity when expressed in cultured cells. Surprisingly, disruption of the C-terminal regulatory domain activates CHK1 even in the absence of stress. Unlike the full-length protein, C-terminally truncated CHK1 displays autophosphorylation, phosphorylates CDC25C on Ser(216), and delays cell cycle progression. Intriguingly, enzymatic activity decreases when the entire regulatory domain is removed, suggesting that the regulatory domain contains both inhibitory and stimulatory elements. Conversely, the kinase domain suppresses Ser(345) phosphorylation, a major ATM/ATR phosphorylation site in the regulatory domain. In marked contrast, CHK2 expressed in either mammalian cells or in bacteria is already active as a kinase against itself and CDC25C and can delay cell cycle progression. Unlike CHK1, disruption of the regulatory domain of CHK2 abolishes its kinase activity. Moreover, the regulatory domain of CHK2, but not that of CHK1, can oligomerize. Finally, CHK1 but not CHK2 is phosphorylated during the spindle assembly checkpoint, which correlates with the inhibition of the kinase. The mitotic phosphorylation of CHK1 requires the regulatory domain, does not involve Ser(345), and is independent on ATM. Collectively, these data reveal the very different mode of regulation between CHK1 and CHK2.	Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Poon, RYC (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Hong Kong, Peoples R China.	bcrandy@ust.hk		Poon, Randy/0000-0001-5571-6231				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ahn J, 2002, J BIOL CHEM, V277, P48418, DOI 10.1074/jbc.M208321200; Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Ahn JY, 2000, CANCER RES, V60, P5934; Arooz T, 2000, BIOCHEMISTRY-US, V39, P9494, DOI 10.1021/bi0009643; Ausubel FM, 1991, CURRENT PROTOCOLS MO; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Chow JPH, 2003, MOL BIOL CELL, V14, P3989, DOI 10.1091/mbc.E03-03-0168; Chow JPH, 2003, J BIOL CHEM, V278, P40815, DOI 10.1074/jbc.M306683200; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Fung TK, 2002, J BIOL CHEM, V277, P35140, DOI 10.1074/jbc.M205503200; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gatei M, 2003, J BIOL CHEM, V278, P14806, DOI 10.1074/jbc.M210862200; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; Jeong SY, 2003, J BIOL CHEM, V278, P46782, DOI 10.1074/jbc.M304551200; Jiang W, 1998, BIOTECHNIQUES, V24, P349; KEYOMARSI K, 1991, CANCER RES, V51, P3602; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai A, 2003, NAT CELL BIOL, V5, P161, DOI 10.1038/ncb921; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lee J, 2001, MOL BIOL CELL, V12, P551, DOI 10.1091/mbc.12.3.551; Li JJ, 2002, MOL CELL, V9, P1045, DOI 10.1016/S1097-2765(02)00527-0; Liu QH, 2000, GENE DEV, V14, P1448; Lopez-Girona A, 2001, P NATL ACAD SCI USA, V98, P11289, DOI 10.1073/pnas.191557598; Lopez-Girona A, 2001, CURR BIOL, V11, P50, DOI 10.1016/S0960-9822(00)00026-9; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Millband DN, 2002, TRENDS CELL BIOL, V12, P205, DOI 10.1016/S0962-8924(02)02276-6; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Schwarz JK, 2003, MOL CANCER RES, V1, P598; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Siu WY, 1999, EXP CELL RES, V250, P131, DOI 10.1006/excr.1999.4551; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Takai H, 2000, GENE DEV, V14, P1439; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Wang JYJ, 2000, NATURE, V405, P404, DOI 10.1038/35013171; Wang X, 2003, J BIOL CHEM, V278, P30869, DOI 10.1074/jbc.M301876200; Weiss RS, 2002, CURR BIOL, V12, P73, DOI 10.1016/S0960-9822(01)00626-1; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Yam CH, 1999, MOL CELL BIOL, V19, P635; Yam CH, 2000, J BIOL CHEM, V275, P3158, DOI 10.1074/jbc.275.5.3158; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	58	48	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8808	8819		10.1074/jbc.M312215200	http://dx.doi.org/10.1074/jbc.M312215200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14681223	hybrid			2022-12-25	WOS:000189265900036
J	Rodriguez, M; Li, SSC; Harper, JW; Zhou, SY				Rodriguez, M; Li, SSC; Harper, JW; Zhou, SY			An oriented peptide array library (OPAL) strategy to study protein-protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOEPITOPE ANTIBODY; COMBINATORIAL LIBRARIES; SUBSTRATE-SPECIFICITY; MONOCLONAL-ANTIBODIES; IDENTIFYING LIGANDS; RECEPTOR LIGANDS; MITOTIC CELLS; DOMAINS; BINDING; KINASE	One of the major questions in signal transduction is how the specificities of protein-protein interactions determine the assembly of distinct signaling complexes in response to stimuli. Several peptide library methods have been developed and widely used to study protein-protein interactions. These approaches primarily rely on peptide or DNA sequencing to identify the peptide or consensus motif for binding and may prove too costly or difficult to accommodate high throughput applications. We report here an oriented peptide array library (OPAL) approach that should facilitate high throughput proteomic analysis of protein-protein interactions. OPAL integrates the principles of both the oriented peptide libraries and array technologies. Hundreds of pools of oriented peptide libraries are synthesized as amino acid scan arrays. We demonstrate that these arrays can be used to map the specificities of a variety of interactions, including antibodies, protein domains such Src homology 2 domains, and protein kinases.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Western Ontario, Fac Med & Dent, Dept Biochem, London, ON N6A 5C1, Canada	Baylor College of Medicine; Western University (University of Western Ontario)	Zhou, SY (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA.	songyang@bcm.tmc.edu		Harper, Jeffrey/0000-0002-6944-7236	NCI NIH HHS [CA84208] Funding Source: Medline; NIA NIH HHS [R01 AG011085, AG11085] Funding Source: Medline; NIGMS NIH HHS [GM569209] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084208] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CABILLY S, 1998, METHODS MOL BIOL COM, V87, P87; CAMPBELL MS, 1995, J CELL BIOL, V129, P1195, DOI 10.1083/jcb.129.5.1195; CULL MG, 1992, P NATL ACAD SCI USA, V89, P1865, DOI 10.1073/pnas.89.5.1865; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; CYERT MS, 1988, DEV BIOL, V129, P209, DOI 10.1016/0012-1606(88)90175-3; Daum JR, 1998, J BIOL CHEM, V273, P30622, DOI 10.1074/jbc.273.46.30622; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; DOOLEY CT, 1993, LIFE SCI, V52, P1509, DOI 10.1016/0024-3205(93)90113-H; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Frank R, 2002, J IMMUNOL METHODS, V267, P13, DOI 10.1016/S0022-1759(02)00137-0; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GEYSEN HM, 1986, MOL IMMUNOL, V23, P709, DOI 10.1016/0161-5890(86)90081-7; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; Han DC, 2001, ONCOGENE, V20, P6315, DOI 10.1038/sj.onc.1204775; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; KEMP BE, 1977, J BIOL CHEM, V252, P4888; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; MAEJI NJ, 1990, J IMMUNOL METHODS, V134, P23; Mah AS, 2001, P NATL ACAD SCI USA, V98, P7325, DOI 10.1073/pnas.141098998; MATTHEAKIS LC, 1994, P NATL ACAD SCI USA, V91, P9022, DOI 10.1073/pnas.91.19.9022; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Nollau P, 2001, P NATL ACAD SCI USA, V98, P13531, DOI 10.1073/pnas.241215998; OOI J, 1995, ONCOGENE, V10, P1621; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Tegge WJ, 1998, METH MOL B, V87, P99; Thommes K, 1999, BIOCHEM J, V341, P211, DOI 10.1042/0264-6021:3410211; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; Zhou SY, 1999, PROG BIOPHYS MOL BIO, V71, P359, DOI 10.1016/S0079-6107(98)00045-5	37	74	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8802	8807		10.1074/jbc.M311886200	http://dx.doi.org/10.1074/jbc.M311886200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14679191	hybrid			2022-12-25	WOS:000189265900035
J	Kessler, N; Schuhmann, H; Morneweg, S; Linne, U; Marahiel, MA				Kessler, N; Schuhmann, H; Morneweg, S; Linne, U; Marahiel, MA			The linear pentadecapeptide gramicidin is assembled by four multimodular nonribosomal peptide synthetases that comprise 16 modules with 56 catalytic domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATION DOMAINS; BIOCHEMICAL-CHARACTERIZATION; MOLECULAR CHARACTERIZATION; EPIMERIZATION DOMAIN; BIOSYNTHESIS OPERON; ENZYME; CONDENSATION; PROTEIN; ACID; PHENYLALANINE	Linear gramicidin is a membrane channel forming pentadecapeptide that is produced via the nonribosomal pathway. It consists of 15 hydrophobic amino acids with alternating L- and D-configuration forming a beta-helix-like structure. It has an N-formylated valine and a C-terminal ethanolamine. Here we report cloning and sequencing of the entire biosynthetic gene cluster as well as initial biochemical analysis of a new reductase domain. The biosynthetic gene cluster was identified on two nonoverlapping fosmids and a 13-kilobase pair (kbp) interbridge fragment covering a region of 74 kbp. Four very large open reading frames, lgrA, lgrB, lgrC, and lgrD with 6.8, 15.5, 23.3, and 15.3 kbp, were identified and shown to encode nonribosomal peptide synthetases with two, four, six, and four modules, respectively. Within the 16 modules identified, seven epimerization domains in alternating positions were detected as well as a putative formylation domain fused to the first module LgrA and a putative reductase domain attached to the C-terminal module of LgrD. Analysis of the substrate specificity by phylogenetic studies using the residues of the substrate-binding pockets of all 16 adenylation domains revealed a good agreement of the substrate amino acids predicted with the sequence of linear gramicidin. Additional biochemical analysis of the three adenylation domains of modules 1, 2, and 3 confirmed the colinearity of this nonribosomal peptide synthetase assembly line. Module 16 was predicted to activate glycine, which would then, being the C-terminal residue of the peptide chain, be reduced by the adjacent reductase domain to give ethanolamine, thereby releasing the final product N-formyl-pentadecapeptide-ethanolamine. However, initial biochemical analysis of this reductase showed only a one-step reduction yielding the corresponding aldehyde in vitro.	Univ Marburg, FB Chem, D-35032 Marburg, Germany	Philipps University Marburg	Marahiel, MA (corresponding author), Univ Marburg, FB Chem, Hans Meerwein Str, D-35032 Marburg, Germany.	marahiel@chemie.uni-marburg.de						AKASHI K, 1977, J BIOCHEM-TOKYO, V81, P269, DOI 10.1093/oxfordjournals.jbchem.a131446; AKERS HA, 1977, BIOCHEMISTRY-US, V16, P5722, DOI 10.1021/bi00645a012; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Challis GL, 2000, CHEM BIOL, V7, P211, DOI 10.1016/S1074-5521(00)00091-0; Clugston SL, 2003, BIOCHEMISTRY-US, V42, P12095, DOI 10.1021/bi035090+; Conti E, 1997, EMBO J, V16, P4174, DOI 10.1093/emboj/16.14.4174; DIECKMANN R, 1995, FEBS LETT, V357, P212, DOI 10.1016/0014-5793(94)01342-X; Doekel S, 2000, CHEM BIOL, V7, P373, DOI 10.1016/S1074-5521(00)00118-6; Gaitatzis N, 2001, P NATL ACAD SCI USA, V98, P11136, DOI 10.1073/pnas.201167098; HAESE A, 1993, MOL MICROBIOL, V7, P905, DOI 10.1111/j.1365-2958.1993.tb01181.x; Hotchkiss RD, 1940, J BIOL CHEM, V132, P791; Keating TA, 2002, NAT STRUCT BIOL, V9, P522, DOI 10.1038/nsb810; Konz D, 1997, CHEM BIOL, V4, P927, DOI 10.1016/S1074-5521(97)90301-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Linne U, 2003, BIOCHEMISTRY-US, V42, P5114, DOI 10.1021/bi034223o; Linne U, 2001, BIOCHEMISTRY-US, V40, P15824, DOI 10.1021/bi011595t; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; Mootz HD, 1997, J BACTERIOL, V179, P6843, DOI 10.1128/jb.179.21.6843-6850.1997; Mootz HD, 2000, P NATL ACAD SCI USA, V97, P5848, DOI 10.1073/pnas.100075897; Mootz HD, 2002, CHEMBIOCHEM, V3, P490, DOI 10.1002/1439-7633(20020603)3:6<490::AID-CBIC490>3.0.CO;2-N; Pospiech A, 1996, MICROBIOL-UK, V142, P741, DOI 10.1099/00221287-142-4-741; Rouhiainen L, 2000, MOL MICROBIOL, V37, P156, DOI 10.1046/j.1365-2958.2000.01982.x; SAGISAKA S, 1959, NATURE, V184, P1709, DOI 10.1038/1841709b0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARGES R, 1965, J AM CHEM SOC, V87, P2011, DOI 10.1021/ja01087a027; Schmitt E, 1996, EMBO J, V15, P4749, DOI 10.1002/j.1460-2075.1996.tb00852.x; Schwarzer D, 2002, P NATL ACAD SCI USA, V99, P14083, DOI 10.1073/pnas.212382199; Sieber SA, 2003, J AM CHEM SOC, V125, P10862, DOI 10.1021/ja0361852; Silakowski B, 2000, EUR J BIOCHEM, V267, P6476, DOI 10.1046/j.1432-1327.2000.01740.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STACHELHAUS T, 1995, J BIOL CHEM, V270, P6163, DOI 10.1074/jbc.270.11.6163; Stachelhaus T, 1998, J BIOL CHEM, V273, P22773, DOI 10.1074/jbc.273.35.22773; Stachelhaus T, 2000, BIOCHEMISTRY-US, V39, P5775, DOI 10.1021/bi9929002; Stachelhaus T, 1999, CHEM BIOL, V6, P493, DOI 10.1016/S1074-5521(99)80082-9; STACHELHAUS T, 1995, FEMS MICROBIOL LETT, V125, P3, DOI 10.1016/0378-1097(94)00459-5; STEIN T, 1995, BIOCHEMISTRY-US, V34, P4633, DOI 10.1021/bi00014a017; Wallace BA, 1998, J STRUCT BIOL, V121, P123, DOI 10.1006/jsbi.1997.3948; Weber T, 2001, STRUCTURE, V9, pR3, DOI 10.1016/S0969-2126(00)00560-8; WEINSTEIN S, 1980, J MOL BIOL, V143, P1, DOI 10.1016/0022-2836(80)90121-7	39	76	86	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7413	7419		10.1074/jbc.M309658200	http://dx.doi.org/10.1074/jbc.M309658200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14670971	hybrid			2022-12-25	WOS:000189103300007
J	Ko, JE; Kim, CW; Kim, DR				Ko, JE; Kim, CW; Kim, DR			Amino acid residues in RAG1 responsible for the interaction with RAG2 during the V(D)J recombination process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SYNAPTIC COMPLEX; ACTIVE-SITE; IN-VITRO; CLEAVAGE; GENES; DNA; INITIATION; DEFINITION; BINDING	The V(D) J recombinase, a complex of RAG1 and RAG2, carries out a gene rearrangement process that is required for the achievement of diverse antigen receptor repertoires during the early developmental stage of lymphocytes. It recognizes a specific site spanning the coding DNA region of antigen receptor genes and produces double-stranded DNA breaks at the board between coding and signal sequences. Two broken DNA ends are joined by a double-stranded break repair system. Both RAG (recombination activation gene) 1 and RAG2 proteins are absolutely required for this process although the catalytic residues of V(D) J recombinase are exclusively located at RAG1 according to recent mutational analyses. In this study we identified some acidic amino acid residues in RAG1 responsible for the interaction with RAG2. Mutation on these residues caused a decrease of cleavage activity in vitro and failure of RAG-RSS DNA synaptic complex formation. This result is complementary to previous reports in which positively charged amino acids in RAG2 play an important role in RAG1 binding.	Gyeongsang Natl Univ, Dept Biochem, Jinju 660751, South Korea; Gyeongsang Natl Univ, Coll Med, RINS, Jinju 660751, South Korea; Gyeongsang Natl Univ, Gyeongsang Inst Hlth Sci, Jinju 660751, South Korea	Gyeongsang National University; Gyeongsang National University; Gyeongsang National University	Kim, DR (corresponding author), Gyeongsang Natl Univ, Dept Biochem, 92 Chilam Dong, Jinju 660751, South Korea.	drkim@gsnu.ac.kr						Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; Aidinis V, 2000, J IMMUNOL, V164, P5826, DOI 10.4049/jimmunol.164.11.5826; Akamatsu Y, 1998, MOL CELL BIOL, V18, P4670, DOI 10.1128/MCB.18.8.4670; Bailin T, 1999, MOL CELL BIOL, V19, P4664; Besmer E, 1998, MOL CELL, V2, P817, DOI 10.1016/S1097-2765(00)80296-8; Eastman QM, 1996, NATURE, V380, P85, DOI 10.1038/380085a0; EPPLEN JT, 1987, HUM GENET, V75, P300, DOI 10.1007/BF00284099; Fugmann SD, 2000, MOL CELL, V5, P97, DOI 10.1016/S1097-2765(00)80406-2; FUMANN S, 2001, MOL CELL, V8, P889; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; Hiom K, 1997, CELL, V88, P65, DOI 10.1016/S0092-8674(00)81859-0; Hiom K, 1998, MOL CELL, V1, P1011, DOI 10.1016/S1097-2765(00)80101-X; Kim DD, 2000, MOL CELLS, V10, P367; Kim DR, 1998, MOL CELL BIOL, V18, P4679, DOI 10.1128/MCB.18.8.4679; Kim DR, 1999, GENE DEV, V13, P3070, DOI 10.1101/gad.13.23.3070; Landree MA, 1999, GENE DEV, V13, P3059, DOI 10.1101/gad.13.23.3059; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000; McMahan CJ, 1997, J IMMUNOL, V158, P2202; Mo XM, 1999, J BIOL CHEM, V274, P7025, DOI 10.1074/jbc.274.11.7025; Mundy CL, 2002, MOL CELL BIOL, V22, P69, DOI 10.1128/MCB.22.1.69-77.2002; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; QUI J, 2001, MOL CELL, V7, P77; SADOFSKY MJ, 1994, NUCLEIC ACIDS RES, V22, P1805, DOI 10.1093/nar/22.10.1805; SADOFSKY MJ, 1993, NUCLEIC ACIDS RES, V21, P5644, DOI 10.1093/nar/21.24.5644; SAKANO H, 1979, NATURE, V280, P288, DOI 10.1038/280288a0; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; Swanson PC, 1999, MOL CELL BIOL, V19, P3674; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8	33	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7715	7720		10.1074/jbc.M311471200	http://dx.doi.org/10.1074/jbc.M311471200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14670978	hybrid			2022-12-25	WOS:000189103300044
J	Liu, J; Liao, ZJ; Camden, J; Griffin, KD; Garrad, RC; Santiago-Perez, LI; Gonzalez, FA; Seye, CI; Weisman, GA; Erb, L				Liu, J; Liao, ZJ; Camden, J; Griffin, KD; Garrad, RC; Santiago-Perez, LI; Gonzalez, FA; Seye, CI; Weisman, GA; Erb, L			Src homology 3 binding sites in the P2Y(2) nucleotide receptor interact with Src and regulate activities of Src, proline-rich tyrosine kinase 2, and growth factor receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; EGF RECEPTOR; C-SRC; BETA(2)-ADRENERGIC RECEPTOR; MEDIATED ACTIVATION; EXTRACELLULAR ATP; BETA; ADHESION; INTEGRIN; PYK2	Many G protein-coupled receptors activate growth factor receptors, although the mechanisms controlling this transactivation are unclear. We have identified two pro-line-rich, SH3 binding sites (PXXP) in the carboxyl-terminal tail of the human P2Y(2) nucleotide receptor that directly associate with the tyrosine kinase Src in protein binding assays. Furthermore, Src co-precipitated with the P2Y(2) receptor in 1321N1 astrocytoma cells stimulated with the P2Y(2) receptor agonist UTP. A mutant P2Y(2) receptor lacking the PXXP motifs was found to stimulate calcium mobilization and serine/threonine phosphorylation of the Erk1/2 mitogen-activated protein kinases, like the wild-type receptor, but was defective in its ability to stimulate tyrosine phosphorylation of Src and Src-dependent tyrosine phosphorylation of the proline-rich tyrosine kinase 2, epidermal growth factor receptor (EGFR), and platelet-derived growth factor receptor. Dual immunofluorescence labeling of the P2Y(2) receptor and the EGFR indicated that UTP caused an increase in the co-localization of these receptors in the plasma membrane that was prevented by the Src inhibitor PP2. Together, these data suggest that agonist-induced binding of Src to the SH3 binding sites in the P2Y(2) receptor facilitates Src activation, which recruits the EGFR into a protein complex with the P2Y(2) receptor and allows Src to efficiently phosphorylate the EGFR.	Univ Missouri, Dept Biochem, Columbia, MO 65212 USA; SW Missouri State Univ, Dept Biomed Sci, Springfield, MO 65804 USA; Univ Puerto Rico, Dept Chem, Rio Piedras, PR 00931 USA	University of Missouri System; University of Missouri Columbia; Missouri State University; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; University of Puerto Rico Rio Piedras	Erb, L (corresponding author), Univ Missouri, Dept Biochem, M743 Med Sci Bldg, Columbia, MO 65212 USA.	erbl@missouri.edu		Erb, Laurie/0000-0001-6372-3378	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015565] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG018357] Funding Source: NIH RePORTER; NCRR NIH HHS [RR15565] Funding Source: Medline; NIA NIH HHS [AG18357] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahn JS, 2000, AM J PHYSIOL-CELL PH, V279, pC286, DOI 10.1152/ajpcell.2000.279.2.C286; Andreev J, 2001, J BIOL CHEM, V276, P20130, DOI 10.1074/jbc.M102307200; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Borges E, 2000, J BIOL CHEM, V275, P39867, DOI 10.1074/jbc.M007040200; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Du QS, 2001, J CELL SCI, V114, P2977; ERB L, 1995, J BIOL CHEM, V270, P4185, DOI 10.1074/jbc.270.9.4185; Erb L, 2001, J CELL BIOL, V153, P491, DOI 10.1083/jcb.153.3.491; GREEN SA, 1994, J BIOL CHEM, V269, P26215; Honda S, 2001, J NEUROSCI, V21, P1975, DOI 10.1523/JNEUROSCI.21-06-01975.2001; Kranenburg O, 1997, EMBO J, V16, P3097, DOI 10.1093/emboj/16.11.3097; LUSTIG KD, 1992, BIOCHIM BIOPHYS ACTA, V1134, P61, DOI 10.1016/0167-4889(92)90028-A; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Ma YC, 2002, TRENDS CARDIOVAS MED, V12, P46, DOI 10.1016/S1050-1738(01)00138-4; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Oldenhof J, 1998, BIOCHEMISTRY-US, V37, P15726, DOI 10.1021/bi981634+; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Satterwhite CM, 1999, AM J PHYSIOL-HEART C, V276, pH1091, DOI 10.1152/ajpheart.1999.276.3.H1091; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Seye CI, 2002, CIRCULATION, V106, P2720, DOI 10.1161/01.CIR.0000038111.00518.35; Shah BH, 2002, MOL PHARMACOL, V61, P343, DOI 10.1124/mol.61.2.343; Soltoff SP, 1998, J BIOL CHEM, V273, P2653, DOI 10.1074/jbc.273.5.2653; Soltoff SP, 1998, J BIOL CHEM, V273, P23110, DOI 10.1074/jbc.273.36.23110; Tang YT, 1999, P NATL ACAD SCI USA, V96, P12559, DOI 10.1073/pnas.96.22.12559; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zhong HY, 1999, BIOCHEM J, V344, P889, DOI 10.1042/0264-6021:3440889	35	129	139	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8212	8218		10.1074/jbc.M312230200	http://dx.doi.org/10.1074/jbc.M312230200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14670955	hybrid			2022-12-25	WOS:000189103300103
J	Fu, XY; Kao, JLF; Bergt, C; Kassim, SY; Huq, NP; d'Avignon, A; Parks, WC; Mecham, RP; Heinecke, JW				Fu, XY; Kao, JLF; Bergt, C; Kassim, SY; Huq, NP; d'Avignon, A; Parks, WC; Mecham, RP; Heinecke, JW			Oxidative cross-linking of tryptophan to glycine restrains matrix metalloproteinase activity - Specific structural motifs control protein oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HYPOCHLOROUS ACID; MYELOPEROXIDASE; ACTIVATION; COLLAGENASE; MECHANISM; CYSTEINE; PATHWAY	Matrix metalloproteinases (MMPs) function in homeostatic and repair processes, but unregulated catalysis by these extracellular proteinases leads to the pathological destruction of tissue proteins. An important mechanism for controlling enzyme activity might involve hypochlorous acid (HOCl), a potent oxidant produced by the myeloperoxidase system of phagocytes. We have shown that inactivation of MMP-7 (matrilysin) by HOCl coincides with the formation of a novel oxidation product, WG-4, through modification of adjacent tryptophan and glycine residues and loss of 4 atomic mass units. Here, we use mass spectrometry, UV/visible spectroscopy, hydrogen-deuterium exchange, and NMR spectroscopy to investigate the formation and structure of WG-4. For the initial step, HOCl chlorinates the indole ring of tryptophan. The resulting 3-chloroindolenine generates a previously unknown cyclic indole-amide species, in which tryptophan cross-links to the main chain nitrogen of the adjacent glycine residue to form an aromatic six-membered ring. WG-4 kinks and stiffens the peptide backbone, which may hinder the interaction of substrate with the catalytic pocket of MMP-7. Our observations indicate that specific structural motifs are important for controlling protein modification by oxidants and suggest that pericellular oxidant production by phagocytes might limit MMP activity during inflammation.	Univ Washington, Dept Med, Seattle, WA 98195 USA; Washington Univ, Dept Chem, St Louis, MO 63110 USA; Washington Univ, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	University of Washington; University of Washington Seattle; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Heinecke, JW (corresponding author), Univ Washington, Dept Med, Box 356426, Seattle, WA 98195 USA.	heineeke@u.washington.edu	Parks, William C./AAH-6786-2021	Huq Saifee, Nabiha/0000-0003-1646-9201	NHLBI NIH HHS [HL64344] Funding Source: Medline; NIA NIH HHS [AG021191] Funding Source: Medline; NIDDK NIH HHS [P30 DK35816] Funding Source: Medline; NIEHS NIH HHS [P30 ES07033] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064344] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK035816] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021191] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Carr AC, 2000, BIOCHEM J, V346, P491, DOI 10.1042/0264-6021:3460491; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; DEROSA M, 1978, J ORG CHEM, V43, P2639, DOI 10.1021/jo00407a017; Fu XY, 2003, J BIOL CHEM, V278, P28403, DOI 10.1074/jbc.M304739200; Fu XY, 2002, BIOCHEMISTRY-US, V41, P1293, DOI 10.1021/bi015777z; Fu XY, 2001, J BIOL CHEM, V276, P41279, DOI 10.1074/jbc.M106958200; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Henderson JP, 2003, J BIOL CHEM, V278, P23522, DOI 10.1074/jbc.M303928200; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; Kang DK, 2003, J BIOL CHEM, V278, P14857, DOI 10.1074/jbc.M300616200; KATRITZKY AR, 1984, COMPREHENSIVE HETERO, V4, P214; Kettle AJ, 2000, REDOX REP, V5, P179, DOI 10.1179/135100000101535726; KLEBANOFF SJ, 1978, NEUTROPHIL FUNCTIONA; Libby P, 2001, CIRCULATION, V104, P365, DOI 10.1161/01.CIR.104.3.365; MICHAELIS J, 1992, ARCH BIOCHEM BIOPHYS, V292, P555, DOI 10.1016/0003-9861(92)90030-Z; PEPPIN GJ, 1986, P NATL ACAD SCI USA, V83, P4322, DOI 10.1073/pnas.83.12.4322; Rajagopalan S, 1996, J CLIN INVEST, V98, P2572, DOI 10.1172/JCI119076; Razmiafshari M, 2001, TOXICOL APPL PHARM, V172, P1, DOI 10.1006/taap.2001.9132; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; SANDERS JKM, 1993, MODERN NMR SPECTROSC; Shapiro SD, 2002, BIOCHEM SOC T, V30, P98, DOI 10.1042/BST0300098; van Montfort RLM, 2003, NATURE, V423, P773, DOI 10.1038/nature01681; VISSERS MCM, 1991, ARCH BIOCHEM BIOPHYS, V285, P53, DOI 10.1016/0003-9861(91)90327-F; WEISS SJ, 1985, SCIENCE, V227, P747, DOI 10.1126/science.2982211; Winterbourn CC, 2000, CURR OPIN HEMATOL, V7, P53, DOI 10.1097/00062752-200001000-00010; Woessner J.F., 2000, PROTEIN PROFILE SER; Zhang H, 2003, J BIOL CHEM, V278, P24078, DOI 10.1074/jbc.M302051200	29	80	80	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6209	6212		10.1074/jbc.C300506200	http://dx.doi.org/10.1074/jbc.C300506200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14670964	hybrid			2022-12-25	WOS:000188969200002
J	McMullen, M; Keller, R; Sussman, M; Pumiglia, K				McMullen, M; Keller, R; Sussman, M; Pumiglia, K			Vascular endothelial growth factor-mediated activation of p38 is dependent upon Src and RAFTK/Pyk2	ONCOGENE			English	Article						p38; VEGF; migration; RAFTK/Pyk2; Src	FOCAL ADHESION KINASE; PROTEIN-KINASE; TYROSINE KINASE; TRANSCRIPTION FACTOR; DIFFERENTIAL REGULATION; CELL-MIGRATION; NITRIC-OXIDE; VEGF; ANGIOGENESIS; CALCIUM	Vascular endothelial growth factor ( VEGF) induces activation of p38 mitogen-activated protein kinase ( MAPK) in primary endothelial cells and may be critical for VEGF-induced angiogenesis. We investigated the molecular basis for p38 activation in response to VEGF. The expression of a C-terminal splice variant of FAK, FRNK, had no affect on VEGF-induced activation of p38; however, expression of a dominant-negative RAFTK/ Pyk2 mutant led to a decrease in the activation of p38, but had no affect on extracellular signal-regulated kinase (ERK). Since calcium regulates RAFTK/ Pyk2, we investigated its role in p38 activity. Preincubation with EGTA suppressed p38 activation, while calcium ionophore induced p38 activity. Inhibition of phospholipase C ( PLC) resulted in complete inhibition of ERK, while having no affect on p38 activity. These data suggested a bifurcation in the regulation of MAPKs that occurs at the level of PLC and RAFTK/ Pyk2 activation. Src family kinases interact with RAFTK/ Pyk2. Inhibition of Src by either pharmacological or genetic means decreased p38 activity. Finally, we found that both Src and RAFTK/ Pyk2 were essential for endothelial cell migration. These data identified a novel regulatory network involving extracellular calcium, RAFTK/ Pyk2, Src and p38. This signaling network appears to be critical for VEGF-induced endothelial cell migration.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; Albany Med Coll, Ctr Cardiovasc Sci, Albany, NY 12208 USA; Cincinnati Childrens Hosp, Div Cardiol, Cincinnati, OH USA	Albany Medical College; Albany Medical College; Cincinnati Children's Hospital Medical Center	Pumiglia, K (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, Mail Code 165,47 New Scotland Ave, Albany, NY 12208 USA.	pumiglk@mail.amc.edu	; Sussman, Mark/H-2284-2014	Pumiglia, Kevin/0000-0003-4655-0334; Sussman, Mark/0000-0002-0104-4799	NATIONAL CANCER INSTITUTE [R01CA081419] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007194] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA081419, R01-CA-81419] Funding Source: Medline; NHLBI NIH HHS [T32-HL-07194] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Avraham HK, 2003, J BIOL CHEM, V278, P36661, DOI 10.1074/jbc.M301253200; Bi WZ, 1999, DEV BIOL, V211, P255, DOI 10.1006/dbio.1999.9307; Blanquet PR, 2003, NEUROSCIENCE, V118, P477, DOI 10.1016/S0306-4522(02)00963-6; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CRISCUOLO GR, 1989, J NEUROSURG, V71, P884, DOI 10.3171/jns.1989.71.6.0884; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Faehling M, 2002, FASEB J, V16, P1805, DOI 10.1096/fj.01-0938fje; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Garnier-Raveaud S, 2001, GROWTH FACTORS, V19, P35, DOI 10.3109/08977190109001074; Giroux S, 1999, CURR BIOL, V9, P369, DOI 10.1016/S0960-9822(99)80164-X; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hudmon A, 2002, ANNU REV BIOCHEM, V71, P473, DOI 10.1146/annurev.biochem.71.110601.135410; Huser J, 1997, AM J PHYSIOL-CELL PH, V273, pC1775, DOI 10.1152/ajpcell.1997.273.5.C1775; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Ishii Y, 2001, LEUKEMIA RES, V25, P813, DOI 10.1016/S0145-2126(01)00026-1; Issbrucker K, 2002, FASEB J, V16, P262, DOI 10.1096/fj.02-0329fje; Jiang TY, 2003, J BIOL CHEM, V278, P15789, DOI 10.1074/jbc.M212525200; Kalmes A, 1999, FEBS LETT, V444, P71, DOI 10.1016/S0014-5793(99)00034-4; Karkkainen MJ, 2000, ONCOGENE, V19, P5598, DOI 10.1038/sj.onc.1203855; Kawasaki K, 2003, MOL CELL BIOL, V23, P5726, DOI 10.1128/MCB.23.16.5726-5737.2003; Keogh RJ, 2002, BIOCHEM BIOPH RES CO, V294, P1001, DOI 10.1016/S0006-291X(02)00568-5; Kumar S, 1999, J BIOL CHEM, V274, P30657, DOI 10.1074/jbc.274.43.30657; Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58; Lian JP, 1999, J IMMUNOL, V163, P4527; Lin Q, 1998, DEVELOPMENT, V125, P4565; Liu F, 2001, AM J RESP CELL MOL, V24, P711, DOI 10.1165/ajrcmb.24.6.4323; McShan GD, 2002, INT J ONCOL, V21, P197; Meadows KN, 2001, J BIOL CHEM, V276, P49289, DOI 10.1074/jbc.M108069200; Mudgett JS, 2000, P NATL ACAD SCI USA, V97, P10454, DOI 10.1073/pnas.180316397; Nagashima KI, 2002, MOL BIOL CELL, V13, P4231, DOI 10.1091/mbc.E02-04-0181; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Paul R, 2001, NAT MED, V7, P222, DOI 10.1038/84675; Pocock TM, 2000, AM J PHYSIOL-HEART C, V279, pH1625, DOI 10.1152/ajpheart.2000.279.4.H1625; Pocock TM, 2001, J PHYSIOL-LONDON, V534, P479, DOI 10.1111/j.1469-7793.2001.00479.x; Rikitake Y, 2001, AM J PHYSIOL-HEART C, V281, pH266, DOI 10.1152/ajpheart.2001.281.1.H266; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Sarkar S, 2002, LEUKEMIA LYMPHOMA, V43, P1663, DOI 10.1080/1042819021000003009; Seymour LW, 1996, LAB INVEST, V75, P427; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Sorokin A, 2001, J BIOL CHEM, V276, P21521, DOI 10.1074/jbc.M008869200; Suarez S, 2001, J CELL SCI, V114, P1229; Toutenhoofd SL, 2000, CELL CALCIUM, V28, P83, DOI 10.1054/ceca.2000.0136; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yang JH, 2000, NAT GENET, V24, P309, DOI 10.1038/73550; Zahalka MA, 2003, FASEB J, V17, P955, DOI 10.1096/fj.02-0960fje; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	59	59	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1275	1282		10.1038/sj.onc.1207243	http://dx.doi.org/10.1038/sj.onc.1207243			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14676843				2022-12-25	WOS:000188892200012
J	Gillgrass, A; Cardiff, RD; Sharan, N; Kannan, S; Muller, WJ				Gillgrass, A; Cardiff, RD; Sharan, N; Kannan, S; Muller, WJ			Epidermal growth factor receptor-dependent activation of Gab1 is involved in ErbB-2-mediated mammary tumor progression	ONCOGENE			English	Article						epidermal growth factor receptor; Gab-1; waved-2; ErbB-2; transgenic	HUMAN-BREAST-CANCER; TRANSGENIC MICE; TYROSINE KINASE; PROTO-ONCOGENE; NEU ONCOGENE; TGF-ALPHA; INDUCTION; OVEREXPRESSION; AMPLIFICATION; TUMORIGENESIS	Activation of the epidermal growth factor receptor (EGFR) family is thought to play an important role in mammary tumorigenesis and metastasis. The potent transforming activity of the EGFR family is due to their ability to heterodimerize with each other in response to a number of mitogenic ligands. The formation of EGFR and ErbB-2 heterodimers has been recently implicated as an important factor in the induction of sporadic human breast cancers. To directly assess whether the catalytic activity of EGFR is required for ErbB-2 induction of mammary tumors, we have interbred transgenic mice expressing ErbB-2 oncogene under the transcriptional control of the mouse mammary tumor virus (MMTV) promoter/enhancer to a naturally occurring mouse mutant carrying a catalytically impaired EGFR (waved-2 mice). Although the female transgenic mice possessing mutant EGFR developed mammary tumors, the tumors occurred only after a delayed latency period, and were fewer in number. The impaired tumor phenotype was further correlated with debilitated phosphorylation of the Gab1 multisubstrate adapter. These observations provide evidence that efficient ErbB-2-induced mammary tumor progression requires EGFR-dependent activation of Gab1.	McMaster Univ, MOBIX, Hamilton, ON L8S 4K1, Canada; Univ Calif Davis, Davis, CA 95616 USA; McGill Univ, Dept Med, Mol Oncol Grp, Montreal, PQ, Canada; McGill Univ, Dept Biochem, Montreal, PQ, Canada	McMaster University; University of California System; University of California Davis; McGill University; McGill University	Muller, WJ (corresponding author), McGill Univ, Royal Victoria Hosp, Dept Biochem, 687 Pne Ave W,Rm H-5-21, Montreal, PQ H3A 1A1, Canada.							Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; FOWLER KJ, 1995, P NATL ACAD SCI USA, V92, P1465, DOI 10.1073/pnas.92.5.1465; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Lenferink AEG, 2000, P NATL ACAD SCI USA, V97, P9609, DOI 10.1073/pnas.160564197; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Rowse GJ, 1998, CANCER RES, V58, P2675; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; Tzahar E, 1996, MOL CELL BIOL, V16, P5276	22	23	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2003	22	57					9151	9155		10.1038/sj.onc.1206983	http://dx.doi.org/10.1038/sj.onc.1206983			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	752FJ	14668796				2022-12-25	WOS:000187149100005
J	Kelicen, P; Tindberg, N				Kelicen, P; Tindberg, N			Lipopolysaccharide induces CYP2E1 in astrocytes through MAP kinase kinase-3 and C/EBP beta and -delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED-PROTEIN-KINASE; CCAAT/ENHANCER-BINDING-PROTEIN; INDUCIBLE CYTOCHROME-P-450 IIE1; DOWN-REGULATION; INFLAMMATORY CYTOKINES; GENE-EXPRESSION; RAT-LIVER; IN-VIVO; C-JUN; ETHANOL	Cytochrome P450 2E1 (CYP2E1) is highly inducible in a subset of astrocytes in vivo following ischemic or mechanical injury and in vitro by lipopolysaccharide (LPS) or interleukin-1beta. We have studied the mechanism of induction, and found that transcriptional activation of CYP2E1 occurred within 3 h, and CYP2E1 dependent catalytic activity was induced more than 4-fold within 5 h. The induction was sensitive to several tyrosine kinase inhibitors, and was further modulated by inhibitors of p38 MAP kinase. MAP kinase kinase-3 (MKK3) was phosphorylated in response to LPS, and expression of constitutively active MKK3, but not the MAP kinase kinases MEKK1 or MKK1, activated CYP2E1. Transcriptional activation was mediated through a C/EBPbeta and -delta binding element situated at -486/-474, and appeared to involve activation of prebound factors as well as recruitment of newly synthesized C/EBPbeta and -delta. It is thus suggested that LPS induces MKK3 activation in astrocytes, which in turn stimulates a C/EBPbeta and -delta binding element to mediate transcriptional activation of CYP2E1.	Karolinska Inst, Inst Environm Med, Div Mol Toxicol, S-17177 Stockholm, Sweden	Karolinska Institutet	Tindberg, N (corresponding author), Karolinska Inst, Inst Environm Med, Div Mol Toxicol, S-17177 Stockholm, Sweden.	nictin@ki.se						ABDELRAZZAK Z, 1993, MOL PHARMACOL, V44, P707; Bae MA, 2001, MOL PHARMACOL, V60, P847; Baldassare JJ, 1999, J IMMUNOL, V162, P5367; Bhat NR, 2002, J BIOL CHEM, V277, P29584, DOI 10.1074/jbc.M204994200; Bondoc FY, 1999, BIOCHEM PHARMACOL, V58, P461, DOI 10.1016/S0006-2952(99)00111-2; Cardinaux JR, 2000, GLIA, V29, P91, DOI 10.1002/(SICI)1098-1136(20000101)29:1<91::AID-GLIA9>3.0.CO;2-I; CASAZZA JP, 1984, J BIOL CHEM, V259, P231; Cassel TN, 2000, AM J RESP CELL MOL, V22, P469, DOI 10.1165/ajrcmb.22.4.3916; CHEN JQ, 1995, J BIOL CHEM, V270, P25233, DOI 10.1074/jbc.270.42.25233; Chen Q, 1997, J BIOL CHEM, V272, P14532, DOI 10.1074/jbc.272.23.14532; Cuenda A, 2000, INT J BIOCHEM CELL B, V32, P581, DOI 10.1016/S1357-2725(00)00003-0; Cui X, 2003, BBA-GEN SUBJECTS, V1619, P325, DOI 10.1016/S0304-4165(02)00491-9; Davis MA, 1999, TOXICOL APPL PHARM, V161, P59, DOI 10.1006/taap.1999.8765; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; EKSTROM G, 1989, BIOCHEM PHARMACOL, V38, P1313, DOI 10.1016/0006-2952(89)90338-9; Eyers PA, 1999, FEBS LETT, V451, P191, DOI 10.1016/S0014-5793(99)00552-9; Frevel MAE, 2003, MOL CELL BIOL, V23, P425, DOI 10.1128/MCB.23.2.425-436.2003; Hakkola J, 2003, J PHARMACOL EXP THER, V304, P1048, DOI 10.1124/jpet.102.041582; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HAN JH, 1993, J BIOL CHEM, V268, P25009; HANSSON T, 1990, NEUROSCIENCE, V34, P451, DOI 10.1016/0306-4522(90)90154-V; Harris VK, 2001, ONCOGENE, V20, P1730, DOI 10.1038/sj.onc.1204249; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hu HM, 2000, J BIOL CHEM, V275, P16373, DOI 10.1074/jbc.M910269199; Hu Y, 1999, BIOCHEM BIOPH RES CO, V263, P286, DOI 10.1006/bbrc.1999.1362; JOHANSSON I, 1986, FEBS LETT, V196, P59, DOI 10.1016/0014-5793(86)80214-9; Jover R, 2002, FASEB J, V16, P1799, DOI 10.1096/fj.02-0195fje; Keesler GA, 1998, PROTEIN EXPRES PURIF, V14, P221, DOI 10.1006/prep.1998.0947; Kietzmann T, 2003, J BIOL CHEM, V278, P17927, DOI 10.1074/jbc.M203929200; Lim S, 2002, J BIOL CHEM, V277, P25040, DOI 10.1074/jbc.M203257200; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; MONTOLIU C, 1995, J NEUROCHEM, V65, P2561; MORGAN ET, 1994, BBA-GENE STRUCT EXPR, V1219, P475, DOI 10.1016/0167-4781(94)90074-4; MORGAN ET, 1993, BIOCHEM PHARMACOL, V45, P415, DOI 10.1016/0006-2952(93)90078-B; Nord M, 1998, DNA CELL BIOL, V17, P481, DOI 10.1089/dna.1998.17.481; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; POPE RM, 1994, J CLIN INVEST, V94, P1449, DOI 10.1172/JCI117482; Sewer MB, 1996, DRUG METAB DISPOS, V24, P401; Simi A, 2000, J CEREBR BLOOD F MET, V20, P1077, DOI 10.1097/00004647-200007000-00007; Simi A, 2002, J NEUROCHEM, V83, P727, DOI 10.1046/j.1471-4159.2002.01178.x; Tindberg N, 1996, MOL PHARMACOL, V50, P1065; TINDBERG N, 1989, BIOCHEMISTRY-US, V28, P4499, DOI 10.1021/bi00436a056; Tindberg N, 2003, J NEUROCHEM, V86, P888, DOI 10.1046/j.1471-4159.2003.01897.x; Tindberg N, 1996, J NEUROCHEM, V67, P2066, DOI 10.1046/j.1471-4159.1996.67052066.x; Tindberg N, 2000, NEUROCHEM RES, V25, P527, DOI 10.1023/A:1007520311457; UMENO M, 1988, J BIOL CHEM, V263, P4956; Wang H, 2001, BRIT J PHARMACOL, V133, P713, DOI 10.1038/sj.bjp.0704102; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WARNER M, 1994, P NATL ACAD SCI USA, V91, P1019, DOI 10.1073/pnas.91.3.1019; Yano S, 1996, J BIOL CHEM, V271, P23520, DOI 10.1074/jbc.271.38.23520	53	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15734	15742		10.1074/jbc.M311850200	http://dx.doi.org/10.1074/jbc.M311850200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14670949	hybrid			2022-12-25	WOS:000220747900007
J	Cox, KH; Kulkarni, A; Tate, JJ; Cooper, TG				Cox, KH; Kulkarni, A; Tate, JJ; Cooper, TG			Gln3 phosphorylation and intracellular localization in nutrient limitation and starvation differ from those generated by rapamycin inhibition of tor1/2 in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGEN CATABOLITE REPRESSION; RETROGRADE GENE-EXPRESSION; NUCLEAR-LOCALIZATION; SIGNALING PATHWAYS; PROTEINS; TARGET; TAP42	The ability of the cell to sense environmental conditions and alter gene expression in response to them is critical to its survival. In Saccharomyces cerevisiae, the Tor1/2 serine/threonine kinases are global regulators situated at the top of a signal cascade reported to receive and transmit nutritional signals associated with the nitrogen supply of the cell. At the other end of that cascade is Gln3, one of two transcriptional activators responsible for most nitrogen catabolic gene expression. When nitrogen is in excess, Tor1/2 are active, and Gln3 is phosphorylated and localizes to the cytoplasm. If Tor1/2 are inhibited by rapamycin or mutation, Gln3 becomes dephosphorylated, accumulates in the nucleus, and mediates nitrogen catabolite repression (NCR)-sensitive transcription. The observations that Gln3 also accumulates in the nuclei of cells provided with poor nitrogen sources or during nitrogen starvation has led to the conclusion that Tor1/2 control intracellular Gln3 localization and NCR-sensitive transcription by regulating Gln3 phosphorylation/dephosphorylation. To test this model, we compared Gln3 phosphorylation states and intracellular localizations under a variety of physiological conditions known to elicit different levels of NCR-sensitive transcription. Our data indicate that: (i) observable Gln3 phosphorylation levels do not correlate in a consistent way with the quality or quantity of the nitrogen source provided, the intracellular localization of Gln3, or the capacity to support NCR-sensitive transcription. (ii) Gln3-Myc(13) is hyperphosphorylated during nitrogen and carbon starvation, but this uniform response does not correlate with Gln3 intracellular localization. (iii) Gln3-Myc(13) dephosphorylation and nuclear localization correlate with one another at early but not late times after rapamycin treatment. These data suggest that rapamycin treatment and growth with poor nitrogen sources bring about nuclear accumulation of Gln3 but likely do so by different mechanisms or by a common mechanism involving molecules other than Gln3 and/or other than the levels of Gln3-Myc(13) phosphorylation thus far detected by others and ourselves.	Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Cooper, TG (corresponding author), Univ Tennessee, Dept Mol Sci, 858 Madison Ave,Rm 501, Memphis, TN 38163 USA.	tcooper@utmem.edu		Cooper, Terrance G./0000-0002-7651-9963	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035642] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35642, R01 GM035642] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1991, CURRENT PROTOCOLS MO; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bertram PG, 2002, MOL CELL BIOL, V22, P1246, DOI 10.1128/MCB.22.4.1246-1252.2002; Bertram PG, 2000, J BIOL CHEM, V275, P35727, DOI 10.1074/jbc.M004235200; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Carvalho J, 2001, J BIOL CHEM, V276, P25359, DOI 10.1074/jbc.M103050200; Cooper T., 1982, MOL BIOL YEAST SACCH, P39, DOI DOI 10.1101/087969180.11B.39; Cooper TG, 2002, FEMS MICROBIOL REV, V26, P223, DOI 10.1111/j.1574-6976.2002.tb00612.x; Cooper TG, 1996, MYCOTA, V3, P139; COOPER TG, 2004, IN PRESS CURR GEN; Cox KH, 2002, J BIOL CHEM, V277, P37559, DOI 10.1074/jbc.M204879200; Cox KH, 2000, J BIOL CHEM, V275, P17611, DOI 10.1074/jbc.M001648200; Crespo JL, 2002, MICROBIOL MOL BIOL R, V66, P579, DOI 10.1128/MMBR.66.4.579-591.2002; Cyert MS, 2001, J BIOL CHEM, V276, P20805, DOI 10.1074/jbc.R100012200; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Jacinto E, 2001, MOL CELL, V8, P1017, DOI 10.1016/S1097-2765(01)00386-0; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Shamji AF, 2000, CURR BIOL, V10, P1574, DOI 10.1016/S0960-9822(00)00866-6; Tate JJ, 2002, J BIOL CHEM, V277, P20477, DOI 10.1074/jbc.M200962200; Tate JJ, 2003, J BIOL CHEM, V278, P36924, DOI 10.1074/jbc.M301829200	26	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10270	10278		10.1074/jbc.M312023200	http://dx.doi.org/10.1074/jbc.M312023200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14679193	Green Accepted, hybrid			2022-12-25	WOS:000220050400075
J	Robalino, J; Joshi, B; Fahrenkrug, SC; Jagus, R				Robalino, J; Joshi, B; Fahrenkrug, SC; Jagus, R			Two zebrafish eIF4E family members are differentially expressed and functionally divergent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATION INITIATION-FACTOR; CAP-BINDING-PROTEIN; FACTOR 4G EIF4G; RNA 5' CAP; FACTOR 4E; CAENORHABDITIS-ELEGANS; DEPENDENT TRANSLATION; FACTOR EIF-4E; PHOSPHORYLATION; YEAST	Eukaryotic translation initiation factor 4E (eIF4E) is an essential component of the translational machinery that binds m(7)GTP and mediates the recruitment of capped mRNAs by the small ribosomal subunit. Recently, a number of proteins with homology to eIF4E have been reported in plants, invertebrates, and mammals. Together with the prototypical translation factor, these constitute a new family of structurally related proteins. To distinguish the prototypical translation factor eIF4E from other family members, it has been termed eIF4E-1 (Keiper, B. D., Lamphear, B. J., Deshpande, A. M., Jankowska-Anyszka, M., Aamodt, E. J., Blumenthal, T., and Rhoads, R. E. ( 2000) J. Biol. Chem. 275, 10590 - 10596). We describe the characterization of two eIF4E family members in the zebrafish Danio rerio. Based on their relative identities with human eIF4E-1, these zebrafish proteins are termed eIF4E-1A (82%) and eIF4E-1B (66%). eIF4E-1B, originally termed eIF4E( L), has been reported previously as the zebrafish eIF4E-1 counterpart (Fahrenkrug, S. C., Dahlquist, M. O., Clark, K., and Hackett, P. B. ( 1999) Differentiation 65, 191 - 201; Fahrenkrug, S. C., Joshi, B., Hackett, P. B., and Jagus, R. ( 2000) Differentiation 66, 15 - 22). Sequence comparisons suggest that the two genes probably evolved from a duplication event that occurred during vertebrate evolution. eIF4E-1A is expressed ubiquitously in zebrafish, whereas expression of eIF4E-1B is restricted to early embryonic development and to gonads and muscle of the tissues investigated. The ability of these two zebrafish proteins to bind m7GTP, eIF4G, and 4E-BP, as well as to complement yeast conditionally deficient in functional eIF4E, show that eIF4E-1A is a functional equivalent of human eIF4E-1. Surprisingly, although eIF4E-1B possesses all known residues thought to be required for interaction with the cap structure, eIF4G, and 4E-BPs, it fails to interact with any of these components, suggesting that this protein serves a role other than that assigned to eIF4E.	Univ Maryland, Ctr Marine Biotechnol, Columbus Ctr, Baltimore, MD 21202 USA; Escuela Super Polit Litoral, Guayaquil, Ecuador; Greenebaum Canc Ctr, Program Oncol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; Escuela Superior Politecnica del Litoral; University System of Maryland; University of Maryland Baltimore	Jagus, R (corresponding author), Univ Maryland, Ctr Marine Biotechnol, Columbus Ctr, 701 E Pratt St,Suite 236, Baltimore, MD 21202 USA.	jagus@umbi.umd.edu		Fahrenkrug, Scott/0000-0002-7176-6551				ABRAMSON RD, 1987, J BIOL CHEM, V262, P3826; ALTMANN M, 1989, J BIOL CHEM, V264, P12145; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; Dostie J, 2000, EMBO J, V19, P3142, DOI 10.1093/emboj/19.12.3142; Fahrenkrug SC, 1999, DIFFERENTIATION, V65, P191, DOI 10.1046/j.1432-0436.1999.6540191.x; Fahrenkrug SC, 2000, DIFFERENTIATION, V66, P15, DOI 10.1046/j.1432-0436.2000.066001015.x; FAHRENKRUG SC, 1997, THESIS U MINNESOTA M; Fletcher CM, 1998, BIOCHEMISTRY-US, V37, P9, DOI 10.1021/bi972494r; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FLYNN A, 1995, J BIOL CHEM, V270, P21684, DOI 10.1074/jbc.270.37.21684; Furuichi Y, 2000, ADV VIRUS RES, V55, P135, DOI 10.1016/S0065-3527(00)55003-9; Gao MX, 1998, J BIOL CHEM, V273, P4622, DOI 10.1074/jbc.273.8.4622; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hentze MW, 1997, SCIENCE, V275, P500, DOI 10.1126/science.275.5299.500; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; JAGUS R, 1993, DEV GENET, V14, P412, DOI 10.1002/dvg.1020140603; JAGUS R, 1998, CURRENT PROTOCOLS CE; Jankowska-Anyszka M, 1998, J BIOL CHEM, V273, P10538, DOI 10.1074/jbc.273.17.10538; Joshi B, 2002, BIOTECHNIQUES, V33, P392, DOI 10.2144/02332rr06; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; Keiper BD, 2000, J BIOL CHEM, V275, P10590, DOI 10.1074/jbc.275.14.10590; Keiper BD, 1999, INT J BIOCHEM CELL B, V31, P37, DOI 10.1016/S1357-2725(98)00130-7; Lachance PED, 2002, MOL CELL BIOL, V22, P1656, DOI 10.1128/MCB.22.6.1656-1663.2002; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Lilie H, 1998, CURR OPIN BIOTECH, V9, P497, DOI 10.1016/S0958-1669(98)80035-9; LIOU RF, 1990, MOL CELL BIOL, V10, P1764, DOI 10.1128/MCB.10.4.1764; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2194, DOI 10.1021/bi9724319; MAKKINJE A, 1995, J BIOL CHEM, V270, P14824, DOI 10.1074/jbc.270.24.14824; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997-717; McKendrick L, 1999, INT J BIOCHEM CELL B, V31, P31, DOI 10.1016/S1357-2725(98)00129-0; McKendrick L, 2001, EUR J BIOCHEM, V268, P5375, DOI 10.1046/j.0014-2956.2001.02478.x; Miyoshi H, 2002, EMBO J, V21, P4680, DOI 10.1093/emboj/cdf473; Morino S, 1996, EUR J BIOCHEM, V239, P597, DOI 10.1111/j.1432-1033.1996.0597u.x; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Ptushkina M, 1998, EMBO J, V17, P4798, DOI 10.1093/emboj/17.16.4798; Ptushkina M, 2001, NUCLEIC ACIDS RES, V29, P4561, DOI 10.1093/nar/29.22.4561; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Pyronnet S, 2000, BIOCHEM PHARMACOL, V60, P1237, DOI 10.1016/S0006-2952(00)00429-9; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; Raught B, 1999, INT J BIOCHEM CELL B, V31, P43, DOI 10.1016/S1357-2725(98)00131-9; Rom E, 1998, J BIOL CHEM, V273, P13104, DOI 10.1074/jbc.273.21.13104; Rudolph R, 1997, PROTEIN FUNCTION PRA, P57; Ruud KA, 1998, J BIOL CHEM, V273, P10325, DOI 10.1074/jbc.273.17.10325; Savinova O, 1997, METHODS, V11, P419, DOI 10.1006/meth.1996.0438; Scheper GC, 2002, J BIOL CHEM, V277, P3303, DOI 10.1074/jbc.M103607200; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SONENBERG N, 1978, P NATL ACAD SCI USA, V75, P4843, DOI 10.1073/pnas.75.10.4843; SONENBERG N, 1979, P NATL ACAD SCI USA, V76, P4345, DOI 10.1073/pnas.76.9.4345; Stebbins-Boaz B, 1999, MOL CELL, V4, P1017, DOI 10.1016/S1097-2765(00)80230-0; Stolarski R, 1996, BBA-PROTEIN STRUCT M, V1293, P97, DOI 10.1016/0167-4838(95)00232-4; STUDIER FW, 1990, METHOD ENZYMOL, V185, P49; UEDA H, 1991, BIOCHIM BIOPHYS ACTA, V1075, P181, DOI 10.1016/0304-4165(91)90249-G; Vasilescu S, 1996, J BIOL CHEM, V271, P7030, DOI 10.1074/jbc.271.12.7030; Wakiyama M, 2001, BIOSCI BIOTECH BIOCH, V65, P232, DOI 10.1271/bbb.65.232; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; WESTERFIELD M, 1995, ZEBRAFISH BOOK	65	39	43	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10532	10541		10.1074/jbc.M313688200	http://dx.doi.org/10.1074/jbc.M313688200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701818				2022-12-25	WOS:000220050400106
J	Day, RM; Thiel, G; Lum, J; Chevere, RD; Yang, YZ; Stevens, J; Sibert, L; Fanburg, BL				Day, RM; Thiel, G; Lum, J; Chevere, RD; Yang, YZ; Stevens, J; Sibert, L; Fanburg, BL			Hepatocyte growth factor regulates angiotensin converting enzyme expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; MESSENGER-RNA EXPRESSION; ACTIVATED PROTEIN-KINASE; FACTOR SCATTER FACTOR; GENE-EXPRESSION; ENHANCED EXPRESSION; LIVER-REGENERATION; ENDOTHELIAL-CELLS; LAVAGE FLUID; LUNG INJURY	Hepatocyte growth factor (HGF) is a mitogen, morphogen, and motogen that functions in tissue healing and acts as an anti-fibrotic factor. The mechanism for this is not well understood. Recent studies implicate somatic angiotensin-converting enzyme (ACE) in fibrosis. We examined the effects of HGF on ACE expression in bovine pulmonary artery endothelial cells (BPAEC). Short term treatment of BPAEC with HGF transiently increased both ACE mRNA (3 h) and activity (24 h), as determined by ACE protease assays and reverse transcription-PCR. Incubation of BPAEC with HGF for longer periods suppressed ACE mRNA (6 h) and activity (72 h). In contrast, phorbol ester (PMA) treatment produced sustained increase in ACE mRNA and activity. We examined the short term molecular effects of HGF on ACE using PMA for comparison. HGF and PMA increased transcription from a luciferase reporter with the core ACE promoter, which contains a composite binding site for SP1/3 and Egr-1. Immunocytochemistry and electrophoretic mobility shift assay showed that both HGF and PMA increased Egr-1 binding. HGF also increased SP3 binding, as measured by EMSA. However, HGF and PMA increased the cellular activity of only Egr-1, not SP3, as measured by luciferase reporter assays. Deletion of the Egr-1 site in the reporter construct completely abrogated HGF-induced transcription but only similar to50% of PMA-induced activity. Expression of dominant negative Egr-1 and SP3 blocked up-regulation of the ACE promoter by HGF but only reduced up-regulation by PMA. These results show that HGF transiently increases gene transcription of ACE via activation of Egr-1, whereas PMA regulation involves Egr-1 and additional factor(s).	Tufts Univ New England Med Ctr, Tupper Res Inst, Div Pulm & Crit Care, Boston, MA 02111 USA; Univ Saarland, Med Ctr, Dept Med Biochem & Mol Biol, D-6642 Homburg, Germany	Tufts Medical Center; Saarland University	Day, RM (corresponding author), Georgetown Univ, Sch Med, Dept Pharmacol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.	reginamday@hotmail.com			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073929, R01HL042376, R01HL014456] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-42376, R01 HL073929-01A1, R01 HL073929, R01 HL-14456] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adamson IYR, 1999, AM J PATHOL, V155, P949, DOI 10.1016/S0002-9440(10)65194-2; Ali SM, 1998, PHARMACOLOGY, V57, P20, DOI 10.1159/000028222; ASCHOFF JM, 1994, ANAL BIOCHEM, V219, P218, DOI 10.1006/abio.1994.1260; BARRETOCHAVES M, 2001, AM J PHYSIOL-REG I, V280, P25; Border WA, 1998, HYPERTENSION, V31, P181, DOI 10.1161/01.HYP.31.1.181; CALDWELL PRB, 1976, SCIENCE, V191, P1050, DOI 10.1126/science.175444; Campbell SE, 1997, J MOL CELL CARDIOL, V29, P1947, DOI 10.1006/jmcc.1997.0435; Cibelli G, 1996, EUR J BIOCHEM, V237, P311, DOI 10.1111/j.1432-1033.1996.0311n.x; CORVOL P, 1995, J HYPERTENS, V13, pS3, DOI 10.1097/00004872-199509003-00002; Cui MZ, 1999, J BIOL CHEM, V274, P32795, DOI 10.1074/jbc.274.46.32795; DASARATHY Y, 1992, AM J PHYSIOL, V263, pL645, DOI 10.1152/ajplung.1992.263.6.L645; Day RM, 2001, AM J RESP CELL MOL, V25, P613, DOI 10.1165/ajrcmb.25.5.4521; DELVECCHIO PJ, 1981, J CELL PHYSIOL, V108, P337, DOI 10.1002/jcp.1041080307; Dohi M, 2000, AM J RESP CRIT CARE, V162, P2302, DOI 10.1164/ajrccm.162.6.9908097; FISHEL RS, 1995, J CLIN INVEST, V95, P377, DOI 10.1172/JCI117666; FRIEDLAND J, 1976, AM J CLIN PATHOL, V66, P416; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; HAMANOUE M, 1992, HEPATOLOGY, V16, P1485, DOI 10.1002/hep.1840160626; HIRSCH AT, 1991, CIRC RES, V69, P475, DOI 10.1161/01.RES.69.2.475; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOOPER NM, 1991, INT J BIOCHEM, V23, P641, DOI 10.1016/0020-711X(91)90032-I; Huang RP, 1997, J CELL BIOCHEM, V66, P489, DOI 10.1002/(SICI)1097-4644(19970915)66:4<489::AID-JCB8>3.0.CO;2-H; IGAWA T, 1993, AM J PHYSIOL, V265, pF61, DOI 10.1152/ajprenal.1993.265.1.F61; KATO H, 1991, J HYPERTENS, V9, P17; Kawai-Kowase K, 1999, CIRC RES, V85, P787, DOI 10.1161/01.RES.85.9.787; KAWAIDA K, 1994, P NATL ACAD SCI USA, V91, P4357, DOI 10.1073/pnas.91.10.4357; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Kitta K, 2001, FREE RADICAL BIO MED, V31, P902, DOI 10.1016/S0891-5849(01)00663-3; LANZILLO JJ, 1994, PCR METH APPL, V4, P167; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAEDA J, 1995, AM J RESP CRIT CARE, V152, P1587, DOI 10.1164/ajrccm.152.5.7582299; Marshall RP, 2000, AM J RESP CRIT CARE, V161, P1999, DOI 10.1164/ajrccm.161.6.9907004; MATSUDA Y, 1995, J BIOCHEM-TOKYO, V118, P643, DOI 10.1093/oxfordjournals.jbchem.a124958; Matsuda Y, 1997, HEPATOLOGY, V26, P81; Matsumoto K, 1993, EXS, V65, P225; McKay S, 1998, AM J RESP CELL MOL, V18, P823, DOI 10.1165/ajrcmb.18.6.2924; Minc E, 1999, J BIOL CHEM, V274, P503, DOI 10.1074/jbc.274.1.503; OKABE T, 1987, BIOCHEM BIOPH RES CO, V145, P1211, DOI 10.1016/0006-291X(87)91566-X; Okada K, 1998, AM J RESP CRIT CARE, V158, P939, DOI 10.1164/ajrccm.158.3.9710007; Ono K, 1997, CIRCULATION, V95, P2552, DOI 10.1161/01.CIR.95.11.2552; ROSEN EM, 1985, J CELL PHYSIOL, V122, P30, DOI 10.1002/jcp.1041220106; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Sacco G, 2001, EUR J PHARMACOL, V414, P71, DOI 10.1016/S0014-2999(01)00782-8; Saijonmaa O, 2001, AM J PHYSIOL-HEART C, V280, pH885, DOI 10.1152/ajpheart.2001.280.2.H885; Schaper W, 1997, CIRCULATION, V95, P2471, DOI 10.1161/01.CIR.95.11.2471; SCHUNKERT H, 1990, J CLIN INVEST, V86, P1913, DOI 10.1172/JCI114924; Srivastava S, 1998, J CLIN INVEST, V102, P1850, DOI 10.1172/JCI4561; Sun YO, 1998, J MOL CELL CARDIOL, V30, P1559, DOI 10.1006/jmcc.1998.0721; Tahara M, 1999, J CLIN INVEST, V103, P313, DOI 10.1172/JCI4433; Taipale J, 1996, J BIOL CHEM, V271, P4342; TESTUT P, 1993, BIOCHEM J, V293, P843, DOI 10.1042/bj2930843; Thiel G, 2000, BBA-GENE STRUCT EXPR, V1493, P289, DOI 10.1016/S0167-4781(00)00207-4; Tsuzuki N, 2001, NEUROL RES, V23, P417, DOI 10.1179/016164101101198659; Uehara Y, 2000, GENESIS, V27, P99, DOI 10.1002/1526-968X(200007)27:3<99::AID-GENE20>3.0.CO;2-Y; Ueno S, 1996, CANCER CHEMOTH PHARM, V38, P233, DOI 10.1007/s002800050476; Uhal BD, 1998, AM J PHYSIOL-LUNG C, V275, pL1013, DOI 10.1152/ajplung.1998.275.5.L1013; Venkatesan N, 1997, LIFE SCI, V61, pPL51; Verghese GM, 1998, AM J RESP CRIT CARE, V158, P386, DOI 10.1164/ajrccm.158.2.9711111; Villard E, 1998, J BIOL CHEM, V273, P25191, DOI 10.1074/jbc.273.39.25191; Wang RQ, 2000, AM J PHYSIOL-LUNG C, V279, pL143, DOI 10.1152/ajplung.2000.279.1.L143; Wang RQ, 1999, AM J PHYSIOL-LUNG C, V277, pL1245, DOI 10.1152/ajplung.1999.277.6.L1245; Wung BS, 1999, CIRC RES, V84, P804; Yaekashiwa M, 1997, AM J RESP CRIT CARE, V156, P1937, DOI 10.1164/ajrccm.156.6.9611057; Yamada T, 2000, AM J RESP CRIT CARE, V162, P707, DOI 10.1164/ajrccm.162.2.9908064; Yamazaki H, 1997, EUR RESPIR J, V10, P2539, DOI 10.1183/09031936.97.10112539; YANAGITA K, 1993, J BIOL CHEM, V268, P21212; Yasuda H, 1996, HEPATOLOGY, V24, P636, DOI 10.1002/hep.510240328; Yasuda S, 1999, HYPERTENSION, V33, P1374, DOI 10.1161/01.HYP.33.6.1374; Zhang F, 2003, J BIOL CHEM, V278, P44246, DOI 10.1074/jbc.M305564200; Zhuo JL, 1998, J HYPERTENS, V16, P2027, DOI 10.1097/00004872-199816121-00026; Zulueta JJ, 2002, AM J RESP CELL MOL, V26, P22, DOI 10.1165/ajrcmb.26.1.4510	72	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8792	8801		10.1074/jbc.M311140200	http://dx.doi.org/10.1074/jbc.M311140200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14679188	hybrid, Green Accepted			2022-12-25	WOS:000189265900034
J	Oyedotun, KS; Lemire, BD				Oyedotun, KS; Lemire, BD			The quaternary structure of the Saccharomyces cerevisiae succinate dehydrogenase - Homology modeling, cofactor docking, and molecular dynamics simulation studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI FUMARATE REDUCTASE; QUINONE-BINDING-SITES; PARTICLE MESH EWALD; ESCHERICHIA-COLI; UBIQUINONE OXIDOREDUCTASE; AUTOMATED DOCKING; COMPLEX-II; RESPIRATORY COMPLEX; ELECTRON-TRANSFER; FLEXIBLE LIGANDS	Succinate dehydrogenases and fumarate reductases are complex mitochondrial or bacterial respiratory chain proteins with remarkably similar structures and functions. Succinate dehydrogenase oxidizes succinate and reduces ubiquinone using a flavin adenine dinucleotide cofactor and iron-sulfur clusters to transport electrons. A model of the quaternary structure of the tetrameric Saccharomyces cerevisiae succinate dehydrogenase was constructed based on the crystal structures of the Escherichia coli succinate dehydrogenase, the E. coli fumarate reductase, and the Wolinella succinogenes fumarate reductase. One FAD and three iron-sulfur clusters were docked into the Sdh1p and Sdh2p catalytic dimer. One b-type heme and two ubiquinone or inhibitor analog molecules were docked into the Sdh3p and Sdh4p membrane dimer. The model is consistent with numerous experimental observations. The calculated free energies of inhibitor binding are in excellent agreement with the experimentally determined inhibitory constants. Functionally important residues identified by mutagenesis of the SDH3 and SDH4 genes are located near the two proposed quinone-binding sites, which are separated by the heme. The proximal quinone-binding site, located nearest the catalytic dimer, has a considerably more polar environment than the distal site. Alternative low energy conformations of the membrane subunits were explored in a molecular dynamics simulation of the dimer embedded in a phospholipid bilayer. The simulation offers insight into why Sdh4p Cys-78 may be serving as the second axial ligand for the heme instead of a histidine residue. We discuss the possible roles of heme and of the two quinone-binding sites in electron transport.	Univ Alberta, Dept Biochem, Canadian Inst Hlth Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada	University of Alberta	Lemire, BD (corresponding author), Univ Alberta, Dept Biochem, Canadian Inst Hlth Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada.	bernard.lemire@ualberta.ca						Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; Bamford VA, 2002, EMBO J, V21, P5599, DOI 10.1093/emboj/cdf566; Barak A, 1998, FUTURE GENER COMP SY, V13, P361, DOI 10.1016/S0167-739X(97)00037-X; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144; Cecchini G, 2002, BBA-BIOENERGETICS, V1553, P140, DOI 10.1016/S0005-2728(01)00238-9; COLE ST, 1985, BIOCHIM BIOPHYS ACTA, V811, P381, DOI 10.1016/0304-4173(85)90008-4; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753; Gasteiger J., 1990, TETRAHEDRON COMPUT M, V3, P537, DOI DOI 10.1016/0898-5529(90)90156-3; Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6; GOODSELL DS, 1990, PROTEINS, V8, P195, DOI 10.1002/prot.340080302; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guo J, 2003, J BIOL CHEM, V278, P47629, DOI 10.1074/jbc.M306312200; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; Hagerhall C, 1996, FEBS LETT, V389, P25, DOI 10.1016/0014-5793(96)00529-7; Hederstedt L, 1999, SCIENCE, V284, P1941, DOI 10.1126/science.284.5422.1941; HEDERSTEDT L, 1992, MOL MECHANISMS BIOEN, P163; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; Iverson TM, 2000, CURR OPIN STRUC BIOL, V10, P448, DOI 10.1016/S0959-440X(00)00113-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; Lancaster CRD, 1999, NATURE, V402, P377, DOI 10.1038/46483; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lemire BD, 2002, BBA-BIOENERGETICS, V1553, P102, DOI 10.1016/S0005-2728(01)00229-8; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; Melo F, 1997, J MOL BIOL, V267, P207, DOI 10.1006/jmbi.1996.0868; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Morris GM, 1996, J COMPUT AID MOL DES, V10, P293, DOI 10.1007/BF00124499; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Oyedotun KS, 1999, FEBS LETT, V442, P203, DOI 10.1016/S0014-5793(98)01657-3; Oyedotun KS, 1999, BBA-BIOENERGETICS, V1411, P170, DOI 10.1016/S0005-2728(99)00040-7; Oyedotun KS, 2001, J BIOL CHEM, V276, P16936, DOI 10.1074/jbc.M100184200; Oyedotun KS, 1999, J BIOL CHEM, V274, P23956, DOI 10.1074/jbc.274.34.23956; Oyedotun KS, 1997, J BIOL CHEM, V272, P31382, DOI 10.1074/jbc.272.50.31382; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Rustin P, 2002, BBA-BIOENERGETICS, V1553, P117, DOI 10.1016/S0005-2728(01)00228-6; SAITOH I, 1992, EUR J BIOCHEM, V209, P73, DOI 10.1111/j.1432-1033.1992.tb17262.x; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schwede T, 2000, RES MICROBIOL, V151, P107, DOI 10.1016/S0923-2508(00)00121-2; Senoo-Matsuda N, 2001, J BIOL CHEM, V276, P41553, DOI 10.1074/jbc.M104718200; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; SIPPL MJ, 1990, J MOL BIOL, V213, P859, DOI 10.1016/S0022-2836(05)80269-4; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tieleman DP, 1996, J CHEM PHYS, V105, P4871, DOI 10.1063/1.472323; WESTENBERG DJ, 1993, J BIOL CHEM, V268, P815; WESTENBERG DJ, 1990, J BIOL CHEM, V265, P19560; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605; Yankovskaya V, 1996, J BIOL CHEM, V271, P21020, DOI 10.1074/jbc.271.35.21020	56	164	180	4	64	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9424	9431		10.1074/jbc.M311876200	http://dx.doi.org/10.1074/jbc.M311876200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14672929	hybrid			2022-12-25	WOS:000189265900108
J	Sato, Y; Sagami, I; Shimizu, T				Sato, Y; Sagami, I; Shimizu, T			Identification of caveolin-1-interacting sites in neuronal nitric-oxide synthase - Molecular mechanism for inhibition of NO formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER; SCAFFOLDING DOMAIN; SKELETAL-MUSCLE; CALMODULIN; CAVEOLIN; BINDING; FLAVIN; ACTIVATION; ROLES; EXPRESSION	Caveolin is known to down-regulate both neuronal (nNOS) and endothelial nitric-oxide synthase (eNOS). In the present study, direct interactions of recombinant caveolin-1 with both the oxygenase and reductase domains of nNOS were demonstrated using in vitro binding assays. To elucidate the mechanism of nNOS regulation by caveolin, we examined the effects of a caveolin-1 scaffolding domain peptide (CaV1p1; residues (82-101)) on the catalytic activities of wild-type and mutant nNOSs. CaV1p1 inhibited NO formation activity and NADPH oxidation of wild-type nNOS in a dose-dependent manner with an IC50 value of 1.8 muM. Mutations of Phe(584) and Trp(587) within a caveolin binding consensus motif of the oxygenase domain did not result in the loss of CaV1p1 inhibition, indicating that an alternate region of nNOS mediates inhibition by caveolin. The addition of CaV1p1 also inhibited more than 90% of the cytochrome c reductase activity in the isolated reductase domain with or without the calmodulin (CaM) binding site, whereas CaV1p1 inhibited ferricyanide reductase activity by only 50%. These results suggest that there are significant differences in the mechanism of inhibition by caveolin for nNOS as compared with those previously reported for eNOS. Further analysis of the interaction through the use of several reductase domain deletion mutants revealed that the FMN domain was essential for successful interaction between caveolin-1 and nNOS reductase. We also examined the effects of CaV1p1 on an autoinhibitory domain deletion mutant (Delta40) and a C-terminal truncation mutant (DeltaC33), both of which are able to form NO in the absence of CaM, unlike the wild-type enzyme. Interestingly, CaV1p1 inhibited CaM-dependent, but not CaM-independent, NO formation activities of both Delta40 and DeltaC33, suggesting that CaV1p1 inhibits interdomain electron transfer induced by CaM from the reductase domain to the oxygenase domain.	Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan	Tohoku University	Sagami, I (corresponding author), Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, 2-1-1 Katahira, Sendai, Miyagi 9808577, Japan.	ikuko@tagen.tohoku.ac.jp		Shimizu, Toru/0000-0002-3950-5554				Adak S, 2001, J BIOL CHEM, V276, P1244, DOI 10.1074/jbc.M006857200; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Bucci M, 2000, NAT MED, V6, P1362, DOI 10.1038/82176; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; Chen PF, 2000, J BIOL CHEM, V275, P13155, DOI 10.1074/jbc.275.17.13155; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Daff S, 1999, J BIOL CHEM, V274, P30589, DOI 10.1074/jbc.274.43.30589; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Feron O, 1998, BIOCHEMISTRY-US, V37, P193, DOI 10.1021/bi972307p; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Ghosh S, 1998, J BIOL CHEM, V273, P22267, DOI 10.1074/jbc.273.35.22267; Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200; Ignarro LJ, 2000, NITRIC OXIDE BIOL PA; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; Li HY, 2001, BIOCHEMISTRY-US, V40, P5399, DOI 10.1021/bi002658v; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; Ludwig ML, 1999, STRUCTURE, V7, pR73, DOI 10.1016/S0969-2126(99)80047-1; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Masters B.S., 2000, NITRIC OXIDE BIOL PA, P91; Matsuda H, 1999, BBA-GEN SUBJECTS, V1473, P345, DOI 10.1016/S0304-4165(99)00193-2; Mayer B, 2000, NITRIC OXIDE; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; Montgomery HJ, 2000, J BIOL CHEM, V275, P5052, DOI 10.1074/jbc.275.7.5052; NATHAN C, 1994, J BIOL CHEM, V269, P13725; Nedvetsky PI, 2002, P NATL ACAD SCI USA, V99, P16510, DOI 10.1073/pnas.262701999; Nishida CR, 1999, J BIOL CHEM, V274, P14692, DOI 10.1074/jbc.274.21.14692; Nishida CR, 2001, J BIOL CHEM, V276, P20116, DOI 10.1074/jbc.M101548200; Repetto S, 1999, BIOCHEM BIOPH RES CO, V261, P547, DOI 10.1006/bbrc.1999.1055; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Rozhkova EA, 2002, J BIOL CHEM, V277, P16888, DOI 10.1074/jbc.M200642200; Sagami I, 1998, J BIOL CHEM, V273, P2105, DOI 10.1074/jbc.273.4.2105; Sagami I, 2001, J BIOL CHEM, V276, P30036, DOI 10.1074/jbc.M104123200; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; SESSA WC, 1992, J BIOL CHEM, V267, P15274; Shimanuki T, 1999, J BIOL CHEM, V274, P26956, DOI 10.1074/jbc.274.38.26956; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Song Y, 2001, BIOCHEM J, V355, P357, DOI 10.1042/0264-6021:3550357; Stuehr DJ, 2000, HANDB EXP PHARMACOL, V143, P33; Sunada Y, 2001, HUM MOL GENET, V10, P173, DOI 10.1093/hmg/10.3.173; Venema VJ, 1997, J BIOL CHEM, V272, P28187, DOI 10.1074/jbc.272.45.28187	46	65	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8827	8836		10.1074/jbc.M310327200	http://dx.doi.org/10.1074/jbc.M310327200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14681230	hybrid			2022-12-25	WOS:000189265900038
J	Woo, CW; Lucarelli, E; Thiele, CJ				Woo, CW; Lucarelli, E; Thiele, CJ			NGF activation of TrkA decreases N-myc expression via MAPK path leading to a decrease in neuroblastoma cell number	ONCOGENE			English	Article						NGF; TrkA; N-myc; MAPK; neuroblastoma; cell cycle; p27; E2F	NERVE GROWTH-FACTOR; RETINOIC ACID; FACTOR RECEPTOR; NEURONAL DIFFERENTIATION; CYCLE ARREST; PC12 CELLS; FACTOR I; INDUCTION; PROTEINS; RAP1	In neuroblastoma (NB), expression of the TrkA receptor is correlated with good prognosis while N-myc amplification is correlated with poor prognosis. Decreased N-myc levels are key to controlling growth and inducing differentiation in NB cells. In this report, we detail mechanisms by which nerve growth factor (NGF) decreases N-myc levels in TrkA-transfected NB cells and its effect on NB cell proliferation. NGF induced a decrease in N-myc mRNA within 1 h of treatment that occurred in the presence of cycloheximide. The stability of N-myc mRNA was not affected by NGF, indicating a transcriptional control of N-myc mRNA by NGF. NGF but not brain-derived neurotrophic factor (BDNF) decreased N-myc levels demonstrating that p75 alone was not involved. The NGF-induced decrease in N-myc expression was blocked by the Trk tyrosine kinase (TK) antagonist K252a indicating that signals transduced by Trk TK downstream targets were involved. Pharmacologic inhibitors implicated the mitogen-activated protein kinase (MAPK) path. This was supported by the finding that expression of a constitutively activated component of the MAPK path, MAPK kinase (MEK), decreased N-myc levels. Alterations in the level of N-myc are known to alter NB cell cycle progression by affecting the levels of E2Fs and p27(kip1). Consistent with these findings, NGF decreased NB cell number and decreased cyclin E-dependent kinase activity via an increase in p27(kip1). Thus, our results indicate that the MAP kinase is selectively involved in the NGF-induced N-myc downregulation through a transcriptional mechanism. Furthermore, NGF affects the time required for 15N TrkA cells to complete a replication cycle by decreasing N-myc, E2Fs, cyclin E kinase activity and increasing p27(kip1) binding to cyclin E kinase.	NCI, Cell & Mol Biol Sect, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Thiele, CJ (corresponding author), NCI, Cell & Mol Biol Sect, Pediat Oncol Branch, NIH, Bldg 10 Rm 13N240,10 Ctr MSC-1928, Bethesda, MD 20892 USA.	thielec@mail.nih.gov	Lucarelli, Enrico/AAF-1612-2021; Enrico, Lucarelli/G-3588-2015	Lucarelli, Enrico/0000-0002-6681-6374; Enrico, Lucarelli/0000-0002-6681-6374				Adams MR, 2000, MOL CELL BIOL, V20, P3633, DOI 10.1128/MCB.20.10.3633-3639.2000; Amati B., 2001, BIOCHIM BIOPHYS ACTA, V1471, P135; AZAR CG, 1990, CELL GROWTH DIFFER, V1, P421; Beier R, 2000, EMBO J, V19, P5813, DOI 10.1093/emboj/19.21.5813; Berns K, 2000, ONCOGENE, V19, P4822, DOI 10.1038/sj.onc.1203879; Billon N, 1996, ONCOGENE, V13, P2047; Bogenmann E, 1998, ONCOGENE, V17, P2367, DOI 10.1038/sj.onc.1202160; BORRELLO MG, 1993, INT J CANCER, V54, P540, DOI 10.1002/ijc.2910540404; Bulseco DA, 2001, J CELL BIOCHEM, V81, P193, DOI 10.1002/1097-4644(20010401)81:1<193::AID-JCB1035>3.0.CO;2-B; Chambery D, 1999, CANCER RES, V59, P2898; CICCARONE V, 1989, CANCER RES, V49, P219; Dechant G, 2001, CELL TISSUE RES, V305, P229, DOI 10.1007/s004410100378; Decker SJ, 1995, J BIOL CHEM, V270, P30841, DOI 10.1074/jbc.270.52.30841; DOBASHI Y, 1995, J BIOL CHEM, V270, P23031, DOI 10.1074/jbc.270.39.23031; Fan LJ, 2001, CANCER RES, V61, P1073; HARTMAN DS, 1994, J NEUROCHEM, V63, P1261; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Kihara-Negishi F, 2001, ONCOGENE, V20, P6039, DOI 10.1038/sj.onc.1204756; Kim BS, 1998, J BIOL CHEM, V273, P34543, DOI 10.1074/jbc.273.51.34543; KNUDSON AG, 1980, NEW ENGL J MED, V302, P1254, DOI 10.1056/NEJM198005293022210; KOGNER P, 1993, CANCER RES, V53, P2044; LAVENIUS E, 1995, CELL GROWTH DIFFER, V6, P727; LUCARELLI E, 1995, J BIOL CHEM, V270, P24725, DOI 10.1074/jbc.270.42.24725; Lutz W, 1996, ONCOGENE, V13, P803; MacNicol MC, 1999, J BIOL CHEM, V274, P13193, DOI 10.1074/jbc.274.19.13193; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MATSUMOTO K, 1995, CANCER RES, V55, P1798; Matsuo T, 1998, ONCOGENE, V16, P3337, DOI 10.1038/sj.onc.1201830; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; Misawa A, 2003, INT J CANCER, V104, P233, DOI 10.1002/ijc.10914; Misawa A, 2000, CANCER RES, V60, P64; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Nakamura M, 2003, CELL DEATH DIFFER, V10, P230, DOI 10.1038/sj.cdd.4401125; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; Persengiev SP, 1999, MOL CELL BIOL, V19, P6048; Persengiev SP, 2001, ONCOGENE, V20, P5124, DOI 10.1038/sj.onc.1204663; POLUHA W, 1995, ONCOGENE, V10, P185; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; REYNOLDS CP, 1986, J NATL CANCER I, V76, P375; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; Strieder V, 2003, J BIOL CHEM, V278, P2983, DOI 10.1074/jbc.M207596200; Strieder V, 2002, CANCER LETT, V180, P107, DOI 10.1016/S0304-3835(02)00020-4; SUZUKI T, 1993, J NATL CANCER I, V85, P377, DOI 10.1093/jnci/85.5.377; THIELE CJ, 1988, ONCOGENE, V3, P281; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; vanGrunsven LA, 1996, ONCOGENE, V12, P1347; Veenstra TD, 1997, BIOCHEM BIOPH RES CO, V235, P15, DOI 10.1006/bbrc.1997.6718; WADA RK, 1992, ONCOGENE, V7, P711; Wittrock J, 2002, ANTICANCER RES, V22, P4205; Wu CB, 2001, J NEUROSCI, V21, P5406, DOI 10.1523/JNEUROSCI.21-15-05406.2001; Yang SH, 2002, MOL CELL BIOL, V22, P5036, DOI 10.1128/MCB.22.14.5036-5046.2002; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhang XH, 1999, ANTICANCER RES, V19, P1641	59	25	30	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1522	1530		10.1038/sj.onc.1207267	http://dx.doi.org/10.1038/sj.onc.1207267			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14691455				2022-12-25	WOS:000189219500005
J	Eberle, J; Fecker, LF; Hossini, AM; Wieder, T; Daniel, PT; Orfanos, CE; Geilen, CC				Eberle, J; Fecker, LF; Hossini, AM; Wieder, T; Daniel, PT; Orfanos, CE; Geilen, CC			CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants	ONCOGENE			English	Article						CD95L/FasL; melanoma; transfection; apoptosis	CERAMIDE-MEDIATED APOPTOSIS; DRUG-INDUCED APOPTOSIS; FAS-LIGAND; SURFACE-ANTIGENS; TUMOR-REGRESSION; MONOCLONAL-ANTIBODY; DEATH RECEPTORS; GENE-EXPRESSION; CANCER CELLS; IN-VIVO	The significance of CD95/Fas ligand expression by melanoma cells has remained a controversial matter in recent years. On the other hand, CD95 activation may represent a powerful tool for eliminating tumor cells. Here, we demonstrate expression of CD95 in 15/17 human melanoma cell lines analysed, but complete lack of CD95 ligand (CD95L). Overexpression of CD95 in a tetracycline-inducible expression system enhanced melanoma cell sensitivity to CD95 ligation but was unable to trigger apoptosis by itself. In clear contrast, all melanoma cells tested responded with increased apoptosis to conditional expression of CD95L (2-10-fold), both after transient and after stable transfection. Activation of caspase-8, Bid cleavage, cytochrome c release and caspase-3 activation followed after CD95L induction indicating a functional CD95-signaling cascade. CD95L was also able to enhance the proapoptotic effect of chemotherapeutics applied in parallel. Nude mouse experiments revealed that tumorigenicity was lost when melanoma xenografts were triggered to express CD95L. In addition, further progression of pre-existing melanomas was inhibited and even regression was seen after induction of CD95L expression. Due to these data, transfection of CD95L proofs as a highly efficient tool against melanoma cells in vitro and in vivo, and targeted expression of CD95L may thus represent a suitable strategy for melanoma therapy.	Charite Univ Med Berlin, Dept Dermatol, D-14195 Berlin, Germany; Humboldt Univ, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin	Eberle, J (corresponding author), Charite Univ Med Berlin, Dept Dermatol, Campus Benjamin Franklin,Fabeckstr 60-62, D-14195 Berlin, Germany.			Eberle, Jurgen/0000-0001-8533-1519				Ambar BB, 1999, HUM GENE THER, V10, P1641, DOI 10.1089/10430349950017644; Andreola G, 2002, J EXP MED, V195, P1303, DOI 10.1084/jem.20011624; Aragane Y, 2000, J INVEST DERMATOL, V115, P1008, DOI 10.1046/j.1523-1747.2000.00164.x; Arai H, 1997, P NATL ACAD SCI USA, V94, P13862, DOI 10.1073/pnas.94.25.13862; BEAN MA, 1975, CANCER RES, V35, P2902; Behrens CK, 2001, J IMMUNOL, V166, P3240, DOI 10.4049/jimmunol.166.5.3240; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; BRUGGEN J, 1981, CANCER IMMUNOL IMMUN, V10, P121; Bullani RR, 2002, MELANOMA RES, V12, P263, DOI 10.1097/00008390-200206000-00010; CAREY TE, 1976, P NATL ACAD SCI USA, V73, P3278, DOI 10.1073/pnas.73.9.3278; Chappell DB, 1999, CANCER RES, V59, P59; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CONEY LR, 1994, INT J CANCER, V58, P562, DOI 10.1002/ijc.2910580419; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; DHEIN J, 1992, J IMMUNOL, V149, P3166; EBERLE J, 1995, ARCH DERMATOL RES, V287, P421, DOI 10.1007/BF00373422; Eberle J, 2002, BRIT J CANCER, V86, P1957, DOI 10.1038/sj.bjc.6600351; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gross A, 2001, IUBMB LIFE, V52, P231, DOI 10.1080/15216540152846046; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Hedlund TE, 1999, CELL DEATH DIFFER, V6, P175, DOI 10.1038/sj.cdd.4400477; Helmbach H, 2001, INT J CANCER, V93, P617, DOI 10.1002/ijc.1378; Ivanov VN, 2003, ONCOGENE, V22, P3152, DOI 10.1038/sj.onc.1206456; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; LOCKSHIN A, 1985, CANCER RES, V45, P345; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; MARIANI SM, 1995, EUR J IMMUNOL, V25, P2303, DOI 10.1002/eji.1830250828; Muschen M, 2000, J MOL MED-JMM, V78, P312, DOI 10.1007/s001090000112; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; OEHM A, 1992, J BIOL CHEM, V267, P10709; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Okamoto S, 1999, J SURG RES, V84, P77, DOI 10.1006/jsre.1999.5613; Park BJ, 1999, HUM GENE THER, V10, P889, DOI 10.1089/10430349950018292; Pruschy M, 2001, INT J RADIAT ONCOL, V49, P561, DOI 10.1016/S0360-3016(00)01480-2; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Raisova M, 2000, FEBS LETT, V473, P27, DOI 10.1016/S0014-5793(00)01491-5; Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x; Redondo P, 2002, BRIT J DERMATOL, V147, P80, DOI 10.1046/j.1365-2133.2002.04745.x; Seino KI, 1997, NAT MED, V3, P165, DOI 10.1038/nm0297-165; Shinoura N, 2000, CANCER GENE THER, V7, P732, DOI 10.1038/sj.cgt.7700160; Sieg S, 1999, CELL IMMUNOL, V195, P89, DOI 10.1006/cimm.1999.1530; Strater J, 2001, CELL DEATH DIFFER, V8, P273, DOI 10.1038/sj.cdd.4400813; Suda T, 1997, J EXP MED, V186, P2045, DOI 10.1084/jem.186.12.2045; Timmer T, 2002, J PATHOL, V196, P125, DOI 10.1002/path.1028; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wieder T, 1998, J BIOL CHEM, V273, P11025, DOI 10.1074/jbc.273.18.11025; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378	54	55	58	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2003	22	57					9131	9141		10.1038/sj.onc.1207228	http://dx.doi.org/10.1038/sj.onc.1207228			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	752FJ	14668794				2022-12-25	WOS:000187149100003
J	Pranada, AL; Metz, S; Herrmann, A; Heinrich, PC; Muller-Newen, G				Pranada, AL; Metz, S; Herrmann, A; Heinrich, PC; Muller-Newen, G			Real time analysis of STAT3 nucleocytoplasmic shuttling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STUDYING PROTEIN DYNAMICS; LIVING CELLS; TARGETED DISRUPTION; SIGNAL TRANSDUCER; NUCLEAR IMPORT; ACTIVATION; PHOSPHORYLATION; RECEPTOR; COMPLEX; BINDING	The transcription factor STAT3 is most important for the signal transduction of interleukin-6 and related cytokines. Upon stimulation cytoplasmic STAT3 is phosphorylated at tyrosine 705, translocates into the nucleus, and induces target genes. Notably, STAT proteins are also detectable in the nuclei of unstimulated cells. In this report we introduce a new method for the real time analysis of STAT3 nucleocytoplasmic shuttling in living cells which is based on the recently established fluorescence localization after photobleaching (FLAP) approach. STAT3 was C-terminally fused with the cyan (CFP) and yellow (YFP) variants of the green fluorescent protein. In the resulting STAT3-CFP-YFP (STAT3-CY) fusion protein the YFP can be selectively bleached using the 514-nm laser of a confocal microscope. This setting allows studies on the dynamics of STAT3 nucleocytoplasmic transport by monitoring the subcellular distribution of fluorescently labeled and selectively bleached STAT3-CY. By this means we demonstrate that STAT3-CY shuttles continuously between the cytosol and the nucleus in unstimulated cells. This constitutive shuttling does not depend on the phosphorylation of tyrosine 705 because a STAT3(Y705F)-CY mutant shuttles to the same extent as STAT3-CY. Experiments with deletion mutants reveal that the N-terminal moiety of STAT3 is essential for shuttling. Further studies suggest that a decrease in STAT3 nuclear export contributes to the nuclear accumulation of STAT3 in response to cytokine stimulation. The new approach presented in this study is generally applicable to any protein of interest for analyzing nucleocytoplasmic transport mechanisms in real time.	Rhein Westfal TH Aachen Klinikum, Inst Biochem, D-52057 Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital	Muller-Newen, G (corresponding author), Rhein Westfal TH Aachen Klinikum, Inst Biochem, Pauwelsstr 30, D-52057 Aachen, Germany.	mueller-newen@rwth-aachen.de						ANDUS T, 1987, FEBS LETT, V221, P18, DOI 10.1016/0014-5793(87)80344-7; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Behrmann I, 1997, J BIOL CHEM, V272, P5269, DOI 10.1074/jbc.272.8.5269; Bhattacharya S, 2003, J CLIN INVEST, V111, P553, DOI 10.1172/JCI200315372; Braunstein J, 2003, J BIOL CHEM, V278, P34133, DOI 10.1074/jbc.M304531200; Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Dunn GA, 2002, J MICROSC-OXFORD, V205, P109, DOI 10.1046/j.0022-2720.2001.001007.x; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; Haan S, 2000, BIOCHEM J, V345, P417, DOI 10.1042/0264-6021:3450417; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Herrington J, 1999, J BIOL CHEM, V274, P5138, DOI 10.1074/jbc.274.8.5138; Herrmann A, 2004, J CELL SCI, V117, P339, DOI 10.1242/jcs.00833; Kretzschmar AK, 2004, BIOCHEM J, V377, P289, DOI 10.1042/BJ20030708; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Lillemeier BF, 2001, EMBO J, V20, P2508, DOI 10.1093/emboj/20.10.2508; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; Ma J, 2003, J BIOL CHEM, V278, P29252, DOI 10.1074/jbc.M304196200; MCBRIDE K, 2003, SCI STKE; Meyer T, 2002, EMBO J, V21, P344, DOI 10.1093/emboj/21.3.344; Meyer T, 2002, EXP CELL RES, V272, P45, DOI 10.1006/excr.2001.5405; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Ndubuisi MI, 1999, J BIOL CHEM, V274, P25499, DOI 10.1074/jbc.274.36.25499; Novak U, 1998, BIOCHEM BIOPH RES CO, V247, P558, DOI 10.1006/bbrc.1998.8829; Robb L, 1998, NAT MED, V4, P303, DOI 10.1038/nm0398-303; Schindler CW, 2002, J CLIN INVEST, V109, P1133, DOI 10.1172/JCI200215644; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Stancato LF, 1996, J BIOL CHEM, V271, P4134; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407; Zeng R, 2002, J IMMUNOL, V168, P4567, DOI 10.4049/jimmunol.168.9.4567; Zhang T, 2002, J BIOL CHEM, V277, P17556, DOI 10.1074/jbc.M105525200; Zicha D, 2003, SCIENCE, V300, P142, DOI 10.1126/science.1082026	38	118	122	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15114	15123		10.1074/jbc.M312530200	http://dx.doi.org/10.1074/jbc.M312530200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14701810	hybrid			2022-12-25	WOS:000220594700077
J	Lee, YL; Lee, KF; Xu, JS; He, QY; Chiu, JF; Lee, WM; Luk, JM; Yeung, WSB				Lee, YL; Lee, KF; Xu, JS; He, QY; Chiu, JF; Lee, WM; Luk, JM; Yeung, WSB			The embryotrophic activity of oviductal cell-derived complement C3b and iC3b, a novel function of complement protein in reproduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE COFACTOR PROTEIN; DECAY-ACCELERATING FACTOR; HUMAN FALLOPIAN-TUBE; MOUSE EMBRYO; MENSTRUAL-CYCLE; ESTROUS-CYCLE; COMPONENT C3; IN-VITRO; EXPRESSION; ENDOMETRIUM	The oviduct-derived embryotrophic factor, ETF-3, enhances the development of trophectoderm and the hatching process of treated embryos. Monoclonal anti-ETF-3 antibody that abolishes the embryotrophic activity of ETF-3 recognized a 115-kDa protein from the conditioned medium of immortalized human oviductal cells. Mass spectrometry analysis showed that the protein was complement C3. Western blot analysis using an antibody against C3 confirmed the cross-reactivities between anti-C3 antibody with ETF-3 and anti-ETF-3 antibody with C3 and its derivatives, C3b and iC3b. Both derivatives, but not C3, were embryotrophic. iC3b was most efficient in enhancing the development of blastocysts with larger size and higher hatching rate, consistent with the previous reported embryotrophic activity of ETF-3. Embryos treated with iC3b contained iC3b immunoreactivity. The oviductal epithelium produced C3 as evidenced by the presence of C3 immunoreactivity and mRNA in the human oviduct and cultured oviductal cells. Cyclical changes in the expression of C3 immunoreactivity and mRNA were also found in the mouse oviduct with the highest expression at the estrus stage. Molecules involving in the conversion of C3b to iC3b and binding of iC3b were present in the human oviduct (factor I) and mouse preimplantation embryo (Crry and CR3), respectively. In conclusion, the present data showed that the oviduct produced C3/C3b, which was converted to iC3b to stimulate embryo development.	Univ Hong Kong, Dept Obstet & Gynaecol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Chem, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Zool, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong	Yeung, WSB (corresponding author), Univ Hong Kong, Dept Obstet & Gynaecol, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	wsbyeung@hkucc.hku.hk	Lee, Will M/D-2357-2009; Luk, John/A-4085-2008; He, Qing-Yu/H-7078-2014; Lee, Yin Lau/C-4639-2009; Lee, Calvin Kai Fai/C-4328-2009	Luk, John/0000-0002-6323-7940; He, Qing-Yu/0000-0003-0503-9492; Lee, Yin Lau/0000-0003-0559-4381; Lee, Calvin Kai Fai/0000-0001-5957-439X				ANDERSON DJ, 1993, P NATL ACAD SCI USA, V90, P10051, DOI 10.1073/pnas.90.21.10051; Bloor DJ, 2002, MOL HUM REPROD, V8, P237, DOI 10.1093/molehr/8.3.237; BONGSO A, 1989, HUM REPROD, V4, P706, DOI 10.1093/oxfordjournals.humrep.a136971; Buhi WC, 2003, THERIOGENOLOGY, V60, P225, DOI 10.1016/S0093-691X(03)00027-X; BUHI WC, 1992, J EXP ZOOL, V262, P426, DOI 10.1002/jez.1402620409; Buhi WC, 2000, CELLS TISSUES ORGANS, V166, P165, DOI 10.1159/000016731; Caucheteux SM, 2003, IMMUNITY, V18, P169, DOI 10.1016/S1074-7613(03)00028-1; CHATOT CL, 1989, J REPROD FERTIL, V86, P679, DOI 10.1530/jrf.0.0860679; Gardner DK, 1998, HUM REPROD, V13, P3434, DOI 10.1093/humrep/13.12.3434; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; HASTY LA, 1994, AM J OBSTET GYNECOL, V170, P168; He QY, 2003, J CELL BIOCHEM, V89, P868, DOI 10.1002/jcb.10576; He QY, 2003, PROTEOMICS, V3, P666, DOI 10.1002/pmic.200300394; Hogan B., 1994, MANIPULATING MOUSE E, P19; JENSEN TS, 1995, AM J REPROD IMMUNOL, V34, P1; KIM YU, 1995, J EXP MED, V181, P151, DOI 10.1084/jem.181.1.151; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; Lee YL, 2003, BIOL REPROD, V68, P375, DOI 10.1095/biolreprod.102.007336; Lee YL, 2001, MOL REPROD DEV, V59, P400, DOI 10.1002/mrd.1046; Li SH, 2002, BIOL REPROD, V66, P322, DOI 10.1095/biolreprod66.2.322; LIU LPS, 1995, HUM REPROD, V10, P2781, DOI 10.1093/oxfordjournals.humrep.a135791; Liu LPS, 1998, HUM REPROD, V13, P1613, DOI 10.1093/humrep/13.6.1613; Llanos RJ, 2000, COMP BIOCHEM PHYS A, V127, P29, DOI 10.1016/S1095-6433(00)00228-2; LUBLIN DM, 1989, ANNU REV IMMUNOL, V7, P35, DOI 10.1146/annurev.immunol.7.1.35; LUK JMC, 1990, J IMMUNOL METHODS, V129, P243, DOI 10.1016/0022-1759(90)90445-2; Molina H, 2002, CELL MOL LIFE SCI, V59, P220, DOI 10.1007/s00018-002-8418-6; MORLEY BJ, 2000, COMPLEMENT FACTSBOOK, P88; PUY LA, 1993, J REPROD FERTIL, V99, P385, DOI 10.1530/jrf.0.0990385; RIOTSONIS K, 1998, J IMMUNOL, V161, P6819; SATO T, 1993, ENDOCRINOLOGY, V133, P397, DOI 10.1210/en.133.1.397; Schlaf G, 1999, IMMUNOLOGY, V98, P464, DOI 10.1046/j.1365-2567.1999.00886.x; SERVIS C, 1989, J IMMUNOL, V142, P2207; SEYA T, 1989, BIOCHEM J, V264, P581, DOI 10.1042/bj2640581; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Sjoblom C, 1999, HUM REPROD, V14, P3069, DOI 10.1093/humrep/14.12.3069; SUTHERLAND AE, 1993, DEVELOPMENT, V119, P1175; Tao XJ, 1997, FERTIL STERIL, V68, P460, DOI 10.1016/S0015-0282(97)00254-9; TAUBER PF, 1985, AM J OBSTET GYNECOL, V151, P1115, DOI 10.1016/0002-9378(85)90394-1; Taylor CT, 1996, MOL HUM REPROD, V2, P52, DOI 10.1093/molehr/2.1.52; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490; Xu JS, 2001, BIOL REPROD, V65, P1481, DOI 10.1095/biolreprod65.5.1481; Yeung W.S.B., 2002, REPROD MED REV, V10, P21, DOI [10.1017/S0962279902000121, DOI 10.1017/S0962279902000121]; YEUNG WSB, 1992, HUM REPROD, V7, P1144, DOI 10.1093/oxfordjournals.humrep.a137810; ZHAO Y, 1994, J CLIN ENDOCR METAB, V79, P662, DOI 10.1210/jc.79.2.662	44	63	64	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12763	12768		10.1074/jbc.M311160200	http://dx.doi.org/10.1074/jbc.M311160200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14699127	hybrid, Green Submitted			2022-12-25	WOS:000220334900090
J	Mehta, A; Shaha, C				Mehta, A; Shaha, C			Apoptotic death in Leishmania donovani promastigotes in response to respiratory chain inhibition - Complex II inhibition results in increased pentamidine cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; ROTENONE-INDUCED APOPTOSIS; PARASITE LEISHMANIA; ELECTRON-TRANSPORT; OXIDATIVE STRESS; SH-SY5Y CELLS; HL-60 CELLS; ANTIMYCIN-A; MITOCHONDRIA; ACTIVATION	The biochemical changes consequent to respiratory chain inhibition and their relationship to cell death in Leishmania spp. remain elusive. Inhibitors of respiratory chain complexes I, II, and III were able to induce apoptotic death of the bloodstream form of Leishmania donovani. Complex I inhibition resulted in mitochondrial hyperpolarization that was preceded by increased superoxide production. Limitation of electron transport by thenoyltrifluoroacetone and antimycin A, inhibitors of complexes II and III, respectively, resulted in dissipation of mitochondrial membrane potential that was sensitive to cyclosporin A, a blocker of mitochondrial permeability transition pore. Further studies conducted with thenoyltrifluoroacetone showed maximal generation of hydrogen peroxide with a moderate elevation of superoxide levels. Complex III inhibition provoked superoxide generation only. Interference with complex II but not complexes I and III increased intracellular Ca2+. A tight link between Ca2+ and reactive oxygen species was demonstrated by antioxidant-induced diminution of the Ca2+ increase. However, chelation of extracellular Ca2+ could not abrogate the early increase of reactive oxygen species, providing evidence that Ca2+ elevation was downstream to reactive oxygen species generation. Ca2+ influx occurred through nonselective cation and L-type channels and Na+/Ca2+ exchanger-like pathways. Antioxidants such as glutathione and Ca2+ channel blockers reduced apoptotic death. This study provides a new possibility that concurrent inhibition of respiratory chain complex II with pentamidine administration increases cytotoxicity of the drug. This increased cytotoxicity was connected to a 4-fold elevation in intracellular Ca2+ that was pooled only from intracellular sources. Therefore, inhibition of complexes I, II, and III leads to apoptosis and complex II inhibition in parallel with pentamidine administration-enhanced drug efficacy.	Natl Inst Immunol, New Delhi 110067, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Shaha, C (corresponding author), Natl Inst Immunol, Aruna Asaf Ali Marg, New Delhi 110067, India.	cshaha@nii.res.in	Mehta, Ashish/A-5537-2011	Mehta, Ashish/0000-0002-0187-4477				Armstrong JS, 2001, BIOCHEM BIOPH RES CO, V289, P973, DOI 10.1006/bbrc.2001.6054; Arnoult D, 2002, CELL DEATH DIFFER, V9, P65, DOI 10.1038/sj.cdd.4400951; Barbu A, 2002, MOL CELL ENDOCRINOL, V190, P75, DOI 10.1016/S0303-7207(02)00009-6; Basselin M, 1997, PARASITOL RES, V83, P413, DOI 10.1007/s004360050274; Bermudez R, 1997, MOL BIOCHEM PARASIT, V90, P43, DOI 10.1016/S0166-6851(97)00131-X; Bray PG, 2003, TRENDS PARASITOL, V19, P232, DOI 10.1016/S1471-4922(03)00069-2; Brill LB, 2003, EXP NEUROL, V181, P25, DOI 10.1016/S0014-4886(02)00045-6; CHANG KP, 1976, SCIENCE, V193, P678, DOI 10.1126/science.948742; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; Chinopoulos C, 2000, J NEUROSCI, V20, P2094; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CROFT SL, 1982, ANN TROP MED PARASIT, V76, P37, DOI 10.1080/00034983.1982.11687502; Das M, 2001, J CELL SCI, V114, P2461; Datta G, 2000, INDIAN J MED RES, V112, P15; de Graaf AO, 2002, BBA-BIOENERGETICS, V1554, P57, DOI 10.1016/S0005-2728(02)00213-X; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; Dvorakova K, 2001, BLOOD, V97, P3544, DOI 10.1182/blood.V97.11.3544; FAIRLAMB AH, 1985, SCIENCE, V227, P1485, DOI 10.1126/science.3883489; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Isenberg JS, 2000, TOXICOL SCI, V53, P340, DOI 10.1093/toxsci/53.2.340; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kalbacova M, 2003, CYTOM PART A, V52A, P110, DOI 10.1002/cyto.a.10031; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Kelso GF, 2002, ANN NY ACAD SCI, V959, P263, DOI 10.1111/j.1749-6632.2002.tb02098.x; King MA, 2002, CYTOMETRY, V49, P106, DOI 10.1002/cyto.10156; Kitamura Y, 2002, NEUROSCI LETT, V333, P25, DOI 10.1016/S0304-3940(02)00964-3; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Lee N, 2002, CELL DEATH DIFFER, V9, P53, DOI 10.1038/sj.cdd.4400952; Lemasters JJ, 1999, AM J PHYSIOL-GASTR L, V276, pG1, DOI 10.1152/ajpgi.1999.276.1.G1; Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200; Ly JD, 2003, APOPTOSIS, V8, P115, DOI 10.1023/A:1022945107762; Martinou JC, 1999, NATURE, V399, P411, DOI 10.1038/20804; Matsunaga T, 1996, LEUKEMIA LYMPHOMA, V20, P487, DOI 10.3109/10428199609052434; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; Mukherjee SB, 2002, J BIOL CHEM, V277, P24717, DOI 10.1074/jbc.M201961200; MUTURINJOGU R, 1980, MOL BIOCHEM PARASIT, V1, P13, DOI 10.1016/0166-6851(80)90038-9; Opuni K, 2000, J BIOL CHEM, V275, P21549, DOI 10.1074/jbc.M003158200; Pastore A, 2003, CLIN CHIM ACTA, V333, P19, DOI 10.1016/S0009-8981(03)00200-6; Pei W, 2003, FASEB J, V17, P520, DOI 10.1096/fj.02-0653fje; Pelicano H, 2003, J BIOL CHEM, V278, P37832, DOI 10.1074/jbc.M301546200; Schlegel RA, 2001, CELL DEATH DIFFER, V8, P551, DOI 10.1038/sj.cdd.4400817; Sereno D, 2001, ANTIMICROB AGENTS CH, V45, P2064, DOI 10.1128/AAC.45.7.2064-2069.2001; Skulachev VP, 1996, FEBS LETT, V397, P7, DOI 10.1016/0014-5793(96)00989-1; Staniek K, 2002, FREE RADICAL RES, V36, P381, DOI 10.1080/10715760290021225; STEWART BW, 1994, JNCI-J NATL CANCER I, V86, P1286, DOI 10.1093/jnci/86.17.1286; Sudhandiran G, 2003, J BIOL CHEM, V278, P25120, DOI 10.1074/jbc.M301975200; Szalai G, 2000, J BIOL CHEM, V275, P15305, DOI 10.1074/jbc.275.20.15305; Yuhki K, 2001, J CARDIOVASC PHARM, V38, P850, DOI 10.1097/00005344-200112000-00006; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zangger H, 2002, CELL DEATH DIFFER, V9, P1126, DOI 10.1038/sj.cdd.4401071	52	157	161	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11798	11813		10.1074/jbc.M309341200	http://dx.doi.org/10.1074/jbc.M309341200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14679210	hybrid			2022-12-25	WOS:000220157600117
J	Qin, HJ; Percival-Smith, A; Li, CJ; Jia, CYH; Gloor, G; Li, SSC				Qin, HJ; Percival-Smith, A; Li, CJ; Jia, CYH; Gloor, G; Li, SSC			A novel transmembrane protein recruits numb to the plasma membrane during asymmetric cell division	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; FATE DETERMINANT NUMB; DROSOPHILA-MELANOGASTER; NOTCH RECEPTOR; DAUGHTER CELL; PTB DOMAIN; LOCALIZATION; POLARITY; COMPLEX; PROSPERO	Numb, an evolutionarily conserved cell fate-determining factor, plays a pivotal role in the development of Drosophila and vertebrate nervous systems. Despite lacking a transmembrane segment, Numb is associated with the cell membrane during the asymmetric cell division of Drosophila neural precursor cells and is selectively partitioned to one of the two progeny cells from a binary cell division. Numb contains an N-terminal phosphotyrosine-binding (PTB) domain that is essential for both the asymmetric localization and the fate specification function of Numb. We report here the isolation and characterization of a novel PTB domain-binding protein, NIP (Numb-interacting protein). NIP is a multipass transmembrane protein that contains two PTB domain-binding, NXXF motifs required for the interaction with Numb. In dividing Drosophila neuroblasts, NIP is colocalized to the cell membrane with Numb in a basal cortical crescent. Expression of NIP in Cos-7 cells recruited Numb from the cytosol to the plasma membrane. This recruitment of Numb to membrane by NIP was dependent on the presence of at least one NXXF site. In Drosophila Schneider 2 cells, NIP and Numb were colocalized at the plasma membrane. Inhibition of NIP expression by RNA interference released Numb to the cytosol. These results suggest that a direct protein-protein interaction between NIP and Numb is necessary and sufficient for the recruitment of Numb to the plasma membrane. Recruitment of Numb to a basal cortical crescent in a dividing neuroblast is essential for Numb to function as an intrinsic cell fate determinant.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Biol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Li, SSC (corresponding author), Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada.	sli@uwo.ca	Gloor, Greg B/D-1671-2013	Gloor, Gregory/0000-0001-5803-3380				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Betschinger J, 2003, NATURE, V422, P326, DOI 10.1038/nature01486; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Chien CT, 1998, MOL CELL BIOL, V18, P598, DOI 10.1128/MCB.18.1.598; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Dho SE, 1998, J BIOL CHEM, V273, P9179, DOI 10.1074/jbc.273.15.9179; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; Frank R, 2002, J IMMUNOL METHODS, V267, P13, DOI 10.1016/S0022-1759(02)00137-0; Frise E, 1996, P NATL ACAD SCI USA, V93, P11925, DOI 10.1073/pnas.93.21.11925; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; HIRATA J, 1995, NATURE, V377, P627, DOI 10.1038/377627a0; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; IkeshimaKataoka H, 1997, NATURE, V390, P625, DOI 10.1038/37641; Jan YN, 2001, NAT REV NEUROSCI, V2, P772, DOI 10.1038/35097516; Jan YN, 1998, NATURE, V392, P775, DOI 10.1038/33854; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; Kilpartick GJ, 1999, TRENDS PHARMACOL SCI, V20, P294, DOI 10.1016/S0165-6147(99)01355-3; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Knoblich JA, 2001, NAT REV MOL CELL BIO, V2, P11, DOI 10.1038/35048085; Knoblich JA, 1997, P NATL ACAD SCI USA, V94, P13005, DOI 10.1073/pnas.94.24.13005; KNOBLICH JA, 1994, CELL, V76, P477; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; Li CJ, 2003, J BIOL CHEM, V278, P3852, DOI 10.1074/jbc.M206649200; Li SC, 1998, NAT STRUCT BIOL, V5, P1075, DOI 10.1038/4185; Li SC, 1997, P NATL ACAD SCI USA, V94, P7204, DOI 10.1073/pnas.94.14.7204; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Lu BW, 1998, CELL, V95, P225, DOI 10.1016/S0092-8674(00)81753-5; Lu BW, 1998, CURR OPIN GENET DEV, V8, P392, DOI 10.1016/S0959-437X(98)80108-1; McGill MA, 2003, J BIOL CHEM, V278, P23196, DOI 10.1074/jbc.M302827200; Nie J, 2002, EMBO J, V21, P93, DOI 10.1093/emboj/21.1.93; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Petronczki M, 2001, NAT CELL BIOL, V3, P43, DOI 10.1038/35050550; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Qin HJ, 2001, J PATHOL, V195, P604, DOI 10.1002/path.994; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Schaefer M, 2001, EXP CELL RES, V271, P66, DOI 10.1006/excr.2001.5371; Schober M, 1999, NATURE, V402, P548, DOI 10.1038/990135; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Shen CP, 1997, CELL, V90, P449, DOI 10.1016/S0092-8674(00)80505-X; Spana EP, 1996, NEURON, V17, P21, DOI 10.1016/S0896-6273(00)80277-9; SPANA EP, 1995, DEVELOPMENT, V121, P3489; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; Wakamatsu Y, 2000, DEVELOPMENT, V127, P2811; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; Wodarz A, 2000, J CELL BIOL, V150, P1361, DOI 10.1083/jcb.150.6.1361; Yaich L, 1998, J BIOL CHEM, V273, P10381, DOI 10.1074/jbc.273.17.10381; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5; Zhong WM, 1996, NEURON, V17, P43, DOI 10.1016/S0896-6273(00)80279-2; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; Zwahlen C, 2000, EMBO J, V19, P1505, DOI 10.1093/emboj/19.7.1505	58	29	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11304	11312		10.1074/jbc.M311733200	http://dx.doi.org/10.1074/jbc.M311733200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14670962	hybrid			2022-12-25	WOS:000220157600058
J	Stone, SJ; Myers, HM; Watkins, SM; Brown, BE; Feingold, KR; Elias, PM; Farese, RV				Stone, SJ; Myers, HM; Watkins, SM; Brown, BE; Feingold, KR; Elias, PM; Farese, RV			Lipopenia and skin barrier abnormalities in DGAT2-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COA-DIACYLGLYCEROL ACYLTRANSFERASE-1; FATTY-ACID DEFICIENCY; WHITE ADIPOSE-TISSUE; MONOACYLGLYCEROL ACYLTRANSFERASE; PERMEABILITY BARRIER; EMBRYONIC LETHALITY; LEPTIN SENSITIVITY; OBESITY RESISTANCE; APOLIPOPROTEIN-B; STRATUM-CORNEUM	synthesis of triglycerides is catalyzed by two known acyl-CoA:diacylglycerol acyltransferase (DGAT) enzymes. Although they catalyze the same biochemical reaction, these enzymes share no sequence homology, and their relative functions are poorly understood. Gene knockout studies in mice have revealed that DGAT1 contributes to triglyceride synthesis in tissues and plays an important role in regulating energy metabolism but is not essential for life. Here we show that DGAT2 plays a fundamental role in mammalian triglyceride synthesis and is required for survival. DGAT2-deficient (Dgat2(-/-)) mice are lipopenic and die soon after birth, apparently from profound reductions in substrates for energy metabolism and from impaired permeability barrier function in the skin. DGAT1 was unable to compensate for the absence of DGAT2, supporting the hypothesis that the two enzymes play fundamentally different roles in mammalian triglyceride metabolism.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Vet Affairs Med Ctr, Dept Med, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, Dept Dermatol, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, Med Serv, San Francisco, CA 94121 USA; Lip Technol, W Sacramento, CA 95691 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA)	Farese, RV (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA.	bfarese@gladstone.ucsf.edu			NIDDK NIH HHS [DK56084, R01 DK056084] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056084, R56DK056084] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brindley D. N, 1991, BIOCH LIPIDS LIPOPRO, P171; Burr GO, 1929, J BIOL CHEM, V82, P345; Cao JS, 2003, J BIOL CHEM, V278, P25657, DOI 10.1074/jbc.M302835200; Cao JS, 2003, J BIOL CHEM, V278, P13860, DOI 10.1074/jbc.M300139200; Cartlidge P, 2000, Semin Neonatol, V5, P273, DOI 10.1053/siny.2000.0013; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; Chen HC, 2003, J CLIN INVEST, V111, P1715, DOI [10.1172/JCI15859, 10.1172/JCI200315859]; Chen HC, 2002, DIABETES, V51, P3189, DOI 10.2337/diabetes.51.11.3189; Chen HC, 2002, J CLIN INVEST, V109, P175, DOI 10.1172/JCI0213880; Chen HC, 2002, J CLIN INVEST, V109, P1049, DOI [10.1172/JCI200214672, 10.1172/JCI0214672]; Chen HC, 2002, ENDOCRINOLOGY, V143, P2893, DOI 10.1210/en.143.8.2893; Cheng D, 2003, J BIOL CHEM, V278, P13611, DOI 10.1074/jbc.C300042200; ELIAS PM, 1980, J INVEST DERMATOL, V74, P230, DOI 10.1111/1523-1747.ep12541775; ELIAS PM, 1978, LAB INVEST, V39, P574; Farese RV, 1996, J LIPID RES, V37, P347; FARESE RV, 1995, P NATL ACAD SCI USA, V92, P1774, DOI 10.1073/pnas.92.5.1774; FOLCH J, 1957, J BIOL CHEM, V226, P497; GRUBAUER G, 1989, J LIPID RES, V30, P323; GUNSTONE FD, 1994, LIPID HDB, P646; HOLLERAN WM, 1991, J CLIN INVEST, V88, P1338, DOI 10.1172/JCI115439; Holt RIG, 2002, TRENDS ENDOCRIN MET, V13, P392, DOI 10.1016/S1043-2760(02)00697-5; HOU SYE, 1991, J INVEST DERMATOL, V96, P215, DOI 10.1111/1523-1747.ep12461361; Kuramoto N, 2002, J CLIN INVEST, V109, P243, DOI 10.1172/JCI200213563; Lockwood JF, 2003, AM J PHYSIOL-ENDOC M, V285, pE927, DOI 10.1152/ajpendo.00179.2003; MADISON KC, 1987, J INVEST DERMATOL, V88, P714, DOI 10.1111/1523-1747.ep12470386; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Oelkers P, 2002, J BIOL CHEM, V277, P8877, DOI 10.1074/jbc.M111646200; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; Sandager L, 2002, J BIOL CHEM, V277, P6478, DOI 10.1074/jbc.M109109200; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; SNYDER F, 1959, BIOCHIM BIOPHYS ACTA, V34, P244; Sorger D, 2002, J BACTERIOL, V184, P519, DOI 10.1128/JB.184.2.519-524.2002; Unger RH, 2001, DIABETES, V50, pS118, DOI 10.2337/diabetes.50.2007.S118; Unger RH, 2002, BBA-MOL CELL BIOL L, V1585, P202, DOI 10.1016/S1388-1981(02)00342-6; Wakimoto K, 2003, BIOCHEM BIOPH RES CO, V310, P296, DOI 10.1016/j.bbrc.2003.09.015; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Watkins SM, 2001, LIPIDS, V36, P247, DOI 10.1007/s11745-001-0714-8; WERTZ PW, 1990, J LIPID RES, V31, P1839; Yen CLE, 2003, J BIOL CHEM, V278, P18532, DOI 10.1074/jbc.M301633200; Yen CLE, 2002, P NATL ACAD SCI USA, V99, P8512, DOI 10.1073/pnas.132274899; Zhang Q, 2003, J BIOL CHEM, V278, P47145, DOI 10.1074/jbc.M306998200	46	442	486	3	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11767	11776		10.1074/jbc.M311000200	http://dx.doi.org/10.1074/jbc.M311000200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14668353	hybrid			2022-12-25	WOS:000220157600114
J	Lu, T; Sathe, SS; Swiatkowski, SM; Hampole, CV; Stark, GR				Lu, T; Sathe, SS; Swiatkowski, SM; Hampole, CV; Stark, GR			Secretion of cytokines and growth factors as a general cause of constitutive NF kappa B activation in cancer	ONCOGENE			English	Article						TGF beta 2; FGF5; microarrays; mutant 293 cells; ELISA	FACTOR-C EXPRESSION; TUMOR-NECROSIS-FACTOR; LYMPH-NODE METASTASIS; RECEPTOR ACTIVATOR; FACTOR-BETA; AUTOCRINE PRODUCTION; PANCREATIC-CANCER; LIGAND RANKL; II-RECEPTOR; KINASE	The constitutive activation of nuclear factor kappaB ( NFkappaB) helps a variety of tumors to resist apoptosis and desensitizes them to chemotherapy, but the causes are still largely unknown. W e have analysed this phenomenon in eight mutant cell lines derived from human 293 cells, selected for NFkappaB- dependent expression of a marker gene, and also in seven tumor- derived cell lines. Conditioned media from all of these cells stimulated the activation of NFkappaB ( up to 30- fold) in indicator cells carrying an NFkappaB- responsive reporter. Therefore, secretion of extracellular factors as the cause of constitutive activation seems to be general. The mRNAs encoding several different cytokines and growth factors were greatly overexpressed in the tumor and mutant cells. The pattern of overexpression was distinct in each cell line, indicating that the phenomenon is complex. Two secreted factors whose roles in the constitutive activation of NFkappaB are not well defined were investigated further as pure proteins: transforming growth factor beta2 ( TGFbeta2) and fibroblast growth factor 5 ( FGF5) were both highly expressed in some mutant clones and tumor cell lines, each activated NFkappaB alone, and the combination was synergistic. Our data indicate that a group of different factors, expressed at abnormally high levels, can contribute singly and synergistically to the constitutive activation of NFkappaB in all of the mutant and tumor cell lines we studied. Since several NFkappaB target genes encode secreted proteins that induce NFkappaB, autocrine loops are likely to be ubiquitously important in the constitutive activation of NFkappaB in cancer. We provide the first evidence of the general, complex, and synergistic activation of NFkappaB in tumor and mutant cell lines through the action of secreted factors and suggest that the same explanation is likely for the constitutive activation of NFkappaB in cancers.	Cleveland Clin Fdn, Lerner Res Inst NB21, Dept Mol Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Stark, GR (corresponding author), Cleveland Clin Fdn, Lerner Res Inst NB21, Dept Mol Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	starkg@ccf.org		Swiatkowski, Shannon/0000-0003-4110-268X				Alitalo K, 2002, CANCER CELL, V1, P219, DOI 10.1016/S1535-6108(02)00051-X; Arlt A, 2002, CANCER RES, V62, P910; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Bhat-Nakshatri P, 2002, ONCOGENE, V21, P2066, DOI 10.1038/sj.onc.1205243; BRACH MA, 1991, PATHOBIOLOGY, V59, P284, DOI 10.1159/000163664; Brown JM, 2001, UROLOGY, V57, P611, DOI 10.1016/S0090-4295(00)01122-5; Byrd VM, 1999, J IMMUNOL, V162, P5853; Chen TP, 1999, INT J CANCER, V82, P43; Chen TP, 1998, CANCER RES, V58, P4805; Clauss M, 2000, SEMIN THROMB HEMOST, V26, P561, DOI 10.1055/s-2000-13213; Coussens LM, 2001, J EXP MED, V193, pF23, DOI 10.1084/jem.193.6.F23; Coward WR, 2002, J IMMUNOL, V169, P5287, DOI 10.4049/jimmunol.169.9.5287; Deng JO, 2002, CANCER CELL, V2, P323, DOI 10.1016/S1535-6108(02)00154-X; Furudoi A, 2002, ONCOLOGY-BASEL, V62, P157, DOI 10.1159/000048262; Furuta K, 1999, INT J CANCER, V81, P851, DOI 10.1002/(SICI)1097-0215(19990611)81:6<851::AID-IJC2>3.0.CO;2-D; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Held-Feindt J, 2002, INT J CANCER, V98, P352, DOI 10.1002/ijc.10207; Hermouet S, 2000, LEUKEMIA LYMPHOMA, V38, P39, DOI 10.3109/10428190009060317; Hishima T, 2000, AM J SURG PATHOL, V24, P742, DOI 10.1097/00000478-200005000-00014; Iacopetta BJ, 1999, J PATHOL, V187, P428, DOI 10.1002/(SICI)1096-9896(199903)187:4<428::AID-PATH264>3.0.CO;2-A; KACINSKI BM, 1995, ANN MED, V27, P79, DOI 10.3109/07853899509031941; Karkkainen MJ, 2000, ONCOGENE, V19, P5598, DOI 10.1038/sj.onc.1203855; Karkkainen MJ, 2002, NAT CELL BIOL, V4, pE2, DOI 10.1038/ncb0102-e2; Kascinski Barry, 2002, Cancer Treat Res, V107, P285; Klomp HJ, 2002, CLIN CANCER RES, V8, P823; Kornmann M, 1997, ONCOGENE, V15, P1417, DOI 10.1038/sj.onc.1201307; Koubek K, 1999, EUR J HAEMATOL, V63, P1; Li JM, 1998, MOL CELL BIOL, V18, P110, DOI 10.1128/MCB.18.1.110; LU TB, UNPUB; Mattila MMT, 2002, INT J CANCER, V98, P946, DOI 10.1002/ijc.10283; McDermott RS, 2002, EUR CYTOKINE NETW, V13, P121; Mentlein R, 2002, J NEUROCHEM, V83, P747, DOI 10.1046/j.1471-4159.2002.01179.x; Michigami T, 2001, CANCER RES, V61, P1637; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992-1000.2002; O'Neill LAJ, 2002, MOL CELL, V10, P969, DOI 10.1016/S1097-2765(02)00754-2; OCONNELL MA, 1995, J BIOL CHEM, V270, P7399, DOI 10.1074/jbc.270.13.7399; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Romieu-Mourez R, 2002, CANCER RES, V62, P6770; Roux S, 2002, AM J CLIN PATHOL, V117, P210; Sapi E, 1999, P SOC EXP BIOL MED, V220, P1, DOI 10.1046/j.1525-1373.1999.d01-1.x; SATHE SS, UNPUB; Schiemann WP, 1999, BLOOD, V94, P2854, DOI 10.1182/blood.V94.8.2854.420k07_2854_2861; Sezer O, 2002, BLOOD, V99, P4646, DOI 10.1182/blood-2002-01-0148; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Takahashi A, 2002, ONCOLOGY-BASEL, V62, P121, DOI 10.1159/000048257; Ueda M, 2002, INT J CANCER, V98, P335, DOI 10.1002/ijc.10193; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wolf JS, 2001, CLIN CANCER RES, V7, P1812; Xing LP, 2002, J BONE MINER RES, V17, P1200, DOI 10.1359/jbmr.2002.17.7.1200; Yamamoto H, 1998, J IMMUNOL, V161, P4753; Yonemura Y, 1999, CLIN CANCER RES, V5, P1823; Zhang N, 1999, J BIOL CHEM, V274, P12959, DOI 10.1074/jbc.274.19.12959	56	63	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2138	2145		10.1038/sj.onc.1207332	http://dx.doi.org/10.1038/sj.onc.1207332			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14676835				2022-12-25	WOS:000220280900003
J	Cui, DY; Brown, CR; Chiang, HL				Cui, DY; Brown, CR; Chiang, HL			The type 1 phosphatase Reg1p-Glc7p is required for the glucoseinduced degradation of fructose-1,6-bisphosphatase in the vacuole	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; CARBON CATABOLITE REPRESSION; CELL-CYCLE PROGRESSION; SNF1 PROTEIN-KINASE; MEMBRANE-FUSION; GENETIC INTERACTIONS; REGULATORY SUBUNITS; DEFICIENT MUTANTS; PEPTIDE SEQUENCES; CATALYTIC SUBUNIT	Protein phosphatases play an important role in vesicular trafficking and membrane fusion processes. The type 1 phosphatase Glc7p and its regulatory subunit Reg1p were identified as required components in the glucose-induced targeting of the key gluconeogenic enzyme fructose-1,6-bisphosphatase (FBPase) to the vacuole for degradation. The interaction of Reg1p with Glc7p was important for the transport of FBPase from intermediate vacuole import and degradation (Vid) vesicles to vacuoles. The glc7-T152K mutant strain exhibited a reduced Reg1p binding along with defects in FBPase degradation and Vid vesicle trafficking to the vacuole. In this mutant, Vid vesicles were the most defective components, whereas the vacuole was also defective. Shp1p and Glc8p regulate Glc7p phosphatase activity and are required for FBPase degradation. In the Deltashp1 and Deltaglc8 strains, Reg1p-Glc7p interaction was not affected, suggesting that phosphatase activity is also necessary for FBPase degradation. Similar to those seen in the glc7-T152K mutant, the Deltashp1 and Deltaglc8 mutants exhibited severely defective Vid vesicles, but partially defective vacuoles. Taken together, our results suggest that Reg1p-Glc7p interaction and Glc7p phosphatase activity play a required role in the Vid vesicle to vacuole-trafficking step along the FBPase degradation pathway.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Brown, CR (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, 500 Univ Dr, Hershey, PA 17033 USA.	crb13@psu.edu			NIGMS NIH HHS [R01GM59480] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059480] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarraberes FA, 2001, BBA-BIOMEMBRANES, V1513, P1, DOI 10.1016/S0304-4157(01)00005-3; Baker SH, 1997, GENETICS, V145, P615; Brown CR, 2001, J BIOL CHEM, V276, P48017, DOI 10.1074/jbc.M109222200; Brown CR, 2003, J BIOL CHEM, V278, P25688, DOI 10.1074/jbc.M210549200; Brown CR, 2002, J CELL SCI, V115, P655; Brown CR, 2000, J CELL BIOL, V150, P65, DOI 10.1083/jcb.150.1.65; CANNON JF, 1994, GENETICS, V136, P485; Cheng C, 1997, YEAST, V13, P1; CHIANG HL, 1988, J BIOL CHEM, V263, P6797; CHIANG HL, 1991, NATURE, V350, P313, DOI 10.1038/350313a0; Chiang MC, 1998, J CELL BIOL, V140, P1347, DOI 10.1083/jcb.140.6.1347; Cullen PJ, 2002, EUKARYOT CELL, V1, P884, DOI 10.1128/EC.1.6.884-894.2002; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; Dombek KM, 1999, MOL CELL BIOL, V19, P6029; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; ENTIAN KD, 1980, MOL GEN GENET, V177, P345, DOI 10.1007/BF00267449; FENG ZH, 1991, J BIOL CHEM, V266, P23796; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; Frederick DL, 1996, MOL CELL BIOL, V16, P2922; GANCEDO C, 1971, J BACTERIOL, V107, P401, DOI 10.1128/JB.107.2.401-405.1971; Gurunathan S, 2002, MOL BIOL CELL, V13, P1594, DOI 10.1091/mbc.01-11-0541; Hammerle M, 1998, J BIOL CHEM, V273, P25000, DOI 10.1074/jbc.273.39.25000; HISAMOTO N, 1994, MOL CELL BIOL, V14, P3158, DOI 10.1128/MCB.14.5.3158; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hoffman M, 1996, GENETICS, V143, P1555; HOLZER H, 1989, RBC-CELL BIOL REV, V21, P305; Horak J, 2002, J BIOL CHEM, V277, P8248, DOI 10.1074/jbc.M107255200; Huang DQ, 1996, GENETICS, V143, P119; Huang PH, 1997, J CELL BIOL, V136, P803, DOI 10.1083/jcb.136.4.803; Jiang H, 2000, MOL GEN GENET, V263, P411, DOI 10.1007/s004380051185; Jiang Y, 1998, EMBO J, V17, P6942, DOI 10.1093/emboj/17.23.6942; Kholodenko BN, 2002, TRENDS CELL BIOL, V12, P173, DOI 10.1016/S0962-8924(02)02251-1; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Kozubowski L, 2003, MOL BIOL CELL, V14, P26, DOI 10.1091/mbc.E02-06-0373; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MATSUMOTO K, 1983, J BACTERIOL, V153, P1405, DOI 10.1128/JB.153.3.1405-1414.1983; NEIGEBORN L, 1987, GENETICS, V115, P247; Nigavekar SS, 2002, ARCH BIOCHEM BIOPHYS, V404, P71, DOI 10.1016/S0003-9861(02)00231-X; Ozcan S, 1999, MICROBIOL MOL BIOL R, V63, P554; Peters C, 1999, SCIENCE, V285, P1084, DOI 10.1126/science.285.5430.1084; Sanz P, 2000, MOL CELL BIOL, V20, P1321, DOI 10.1128/MCB.20.4.1321-1328.2000; SCHORK SM, 1994, FEBS LETT, V349, P270, DOI 10.1016/0014-5793(94)00668-7; Shieh HL, 1998, J BIOL CHEM, V273, P3381, DOI 10.1074/jbc.273.6.3381; Shieh HL, 2001, J BIOL CHEM, V276, P10398, DOI 10.1074/jbc.M001767200; Stark MJR, 1996, YEAST, V12, P1647, DOI 10.1002/(SICI)1097-0061(199612)12:16<1647::AID-YEA71>3.0.CO;2-Q; STUART JS, 1994, MOL CELL BIOL, V14, P896, DOI 10.1128/MCB.14.2.896; Suzuki K, 2002, DEV CELL, V3, P815, DOI 10.1016/S1534-5807(02)00359-3; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; Tu JL, 1996, MOL CELL BIOL, V16, P4199; TU JL, 1994, MOL CELL BIOL, V14, P6789, DOI 10.1128/MCB.14.10.6789; TU JL, 1995, EMBO J, V14, P5939, DOI 10.1002/j.1460-2075.1995.tb00282.x; Wang CW, 2003, MOL MED, V9, P65, DOI 10.1007/BF03402040; WEK RC, 1992, MOL CELL BIOL, V12, P5700, DOI 10.1128/MCB.12.12.5700; Wickner W, 2002, EMBO J, V21, P1241, DOI 10.1093/emboj/21.6.1241; Wickner W, 2000, ANNU REV BIOCHEM, V69, P247, DOI 10.1146/annurev.biochem.69.1.247; Wu XL, 2001, BIOCHEMISTRY-US, V40, P7410, DOI 10.1021/bi002796k; ZHANG SR, 1995, MOL CELL BIOL, V15, P2037	58	18	19	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9713	9724		10.1074/jbc.M310793200	http://dx.doi.org/10.1074/jbc.M310793200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14684743	hybrid			2022-12-25	WOS:000220050400009
J	Prentice, E; Jerome, WG; Yoshimori, T; Mizushima, N; Denison, MR				Prentice, E; Jerome, WG; Yoshimori, T; Mizushima, N; Denison, MR			Coronavirus replication complex formation utilizes components of cellular autophagy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE HEPATITIS-VIRUS; ACUTE RESPIRATORY SYNDROME; 3C-LIKE PROTEINASE ACTIVITY; DOUBLE-MEMBRANE VESICLES; EMBRYONIC STEM-CELLS; MURINE CORONAVIRUS; ENDOPLASMIC-RETICULUM; POLIOVIRUS INFECTION; VIRAL-RNA; IN-VITRO	The coronavirus mouse hepatitis virus (MHV) performs RNA replication on double membrane vesicles (DMVs) in the cytoplasm of the host cell. However, the mechanism by which these DMVs form has not been determined. Using genetic, biochemical, and cell imaging approaches, the role of autophagy in DMV formation and MHV replication was investigated. The results demonstrated that replication complexes co-localize with the autophagy proteins, microtubule-associated protein light-chain 3 and Apg12. MHV infection induces autophagy by a mechanism that is resistant to 3-methyladenine inhibition. MHV replication is impaired in autophagy knockout, APG5-/-, embryonic stem cell lines, but wild-type levels of MHV replication are restored by expression of Apg5 in the APG5-/- cells. In MHV-infected APG5-/- cells, DMVs were not detected; rather, the rough endoplasmic reticulum was dramatically swollen. The results of this study suggest that autophagy is required for formation of double membrane-bound MHV replication complexes and that DMV formation significantly enhances the efficiency of replication. Furthermore, the rough endoplasmic reticulum is implicated as the possible source of membranes for replication complexes.	Vanderbilt Univ, Med Ctr, Dept Microbiol & Immunol, Nashville, TN 37221 USA; Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37221 USA; Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37221 USA; Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37221 USA; Vanderbilt Univ, Med Ctr, Elizabeth B Lamb Ctr Pediat Res, Nashville, TN 37221 USA; Natl Inst Genet, Dept Cell Genet, Mishima, Shizuoka 4118540, Japan; Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan; Japan Sci & Technol Corp, Precursory Res Embryon Sci & Technol, Unit Proc & Combines Circuit, Kawaguchi 3320012, Japan; Japan Sci & Technol Corp, Core Res Evolutionary Sci & Technol Program, Kawaguchi 3320012, Japan	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Denison, MR (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pediat, D6217 MCN, Nashville, TN 37232 USA.	mark.denison@vanderbilt.edu	Denison, Mark R/O-7258-2018; Mizushima, Noboru/C-3635-2009	Denison, Mark R/0000-0003-2655-0900; Mizushima, Noboru/0000-0002-6258-6444	NCI NIH HHS [CA68485] Funding Source: Medline; NHLBI NIH HHS [5 T32HL07751] Funding Source: Medline; NIAID NIH HHS [AI50083] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007751] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020593, P60DK020593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bi WZ, 1998, J NEUROVIROL, V4, P594, DOI 10.3109/13550289809114226; Bost AG, 2000, J VIROL, V74, P3379, DOI 10.1128/JVI.74.7.3379-3387.2000; Bost AG, 2001, VIROLOGY, V285, P21, DOI 10.1006/viro.2001.0932; Denison MR, 1999, J VIROL, V73, P6862, DOI 10.1128/JVI.73.8.6862-6871.1999; Denison MR, 2001, ADV EXP MED BIOL, V494, P655; DONG SH, 1994, VIROLOGY, V204, P541, DOI 10.1006/viro.1994.1567; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Gosert R, 2002, J VIROL, V76, P3697, DOI 10.1128/JVI.76.8.3697-3708.2002; Hegyi A, 2002, J GEN VIROL, V83, P595, DOI 10.1099/0022-1317-83-3-595; Hegyi A, 2002, J GEN VIROL, V83, P581, DOI 10.1099/0022-1317-83-3-581; HIRANO N, 1984, JPN J VET SCI, V46, P757; HIRANO N, 1974, ARCH GES VIRUSFORSCH, V44, P298, DOI 10.1007/BF01240618; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; Kuma A, 2002, J BIOL CHEM, V277, P18619, DOI 10.1074/jbc.M111889200; Kyuwa S, 1997, EXP ANIM TOKYO, V46, P311, DOI 10.1538/expanim.46.311; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Lu XT, 1998, J VIROL, V72, P2265, DOI 10.1128/JVI.72.3.2265-2271.1998; Lu XT, 1996, VIROLOGY, V222, P375, DOI 10.1006/viro.1996.0434; Lu YQ, 1997, VIROLOGY, V230, P335, DOI 10.1006/viro.1997.8479; LU YQ, 1995, J VIROL, V69, P3554, DOI 10.1128/JVI.69.6.3554-3559.1995; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Okumura A, 1996, J VIROL, V70, P4146, DOI 10.1128/JVI.70.6.4146-4149.1996; Pedersen KW, 1999, J VIROL, V73, P2016, DOI 10.1128/JVI.73.3.2016-2026.1999; Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634; Reggiori F, 2002, EUKARYOT CELL, V1, P11, DOI 10.1128/EC.01.1.11-21.2002; Schlegel A, 1996, J VIROL, V70, P6576, DOI 10.1128/JVI.70.10.6576-6588.1996; Shi ST, 1999, J VIROL, V73, P5957, DOI 10.1128/JVI.73.7.5957-5969.1999; Sims AC, 2000, J VIROL, V74, P5647, DOI 10.1128/JVI.74.12.5647-5654.2000; Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9; Suhy DA, 2000, J VIROL, V74, P8953, DOI 10.1128/JVI.74.19.8953-8965.2000; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299	34	334	359	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10136	10141		10.1074/jbc.M306124200	http://dx.doi.org/10.1074/jbc.M306124200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699140	Green Published, hybrid			2022-12-25	WOS:000220050400059
J	Roll-Mecak, A; Alone, P; Cao, CN; Dever, TE; Burley, SK				Roll-Mecak, A; Alone, P; Cao, CN; Dever, TE; Burley, SK			X-ray structure of translation initiation factor eIF2 gamma - Implications for tRNA and eIF2 alpha binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; EF-TU; ANOMALOUS DIFFRACTION; BETA-SUBUNIT; GCN4; COMPLEX; INSIGHTS; REVEALS; GAMMA; YEAST	The x-ray structure of the gamma-subunit of the heterotrimeric translation initiation factor eIF2 has been determined to 2.4-Angstrom resolution. eIF2 is a GTPase that delivers the initiator Met-tRNA to the P site on the small ribosomal subunit during a rate-limiting initiation step in translation. The structure of eIF2gamma closely resembles that of EF1A . GTP, consisting of an N-terminal G domain followed by two beta-barrels arranged in a closed configuration with domain II packed against the G domain in the vicinity of the Switch regions. The G domain of eIF2gamma has an unusual zinc ribbon motif, not previously found in other GTPases. Structure-based site-directed mutagenesis was used to identify two adjacent features on the surface of eIF2gamma that bind the alpha-subunit and Met-tRNA(i)(Met), respectively. These structural, biochemical, and genetic results provide new insights into eIF2 ternary complex assembly.	Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Rockefeller Univ, Labs Mol Biophys, New York, NY 10021 USA; NICHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA	Howard Hughes Medical Institute; Rockefeller University; Rockefeller University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Burley, SK (corresponding author), Struct GenomiX Inc, 10505 Roselle St, San Diego, CA 92121 USA.	stephen_burley@stromix.com	Dever, Thomas/GSE-0966-2022	Roll-Mecak, Antonina/0000-0003-2621-7307; Burley, Stephen K./0000-0002-2487-9713; Dever, Thomas/0000-0001-7120-9678	NIGMS NIH HHS [GM61262] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001010] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061262] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen GR, 2000, J MOL BIOL, V297, P421, DOI 10.1006/jmbi.2000.3564; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Das S, 1997, J BIOL CHEM, V272, P31712, DOI 10.1074/jbc.272.50.31712; DEVER TE, 1995, MOL CELL BIOL, V15, P6351; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DORRIS DR, 1995, EMBO J, V14, P2239, DOI 10.1002/j.1460-2075.1995.tb07218.x; Erickson FL, 1997, MOL GEN GENET, V253, P711; Erickson FL, 1996, EMBO J, V15, P6311, DOI 10.1002/j.1460-2075.1996.tb01021.x; Erickson FL, 2001, GENETICS, V158, P123; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; HARASHIMA S, 1986, MOL CELL BIOL, V6, P3990, DOI 10.1128/MCB.6.11.3990; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; Krishna SS, 2003, NUCLEIC ACIDS RES, V31, P532, DOI 10.1093/nar/gkg161; Kyrpides NC, 1998, P NATL ACAD SCI USA, V95, P3726, DOI 10.1073/pnas.95.7.3726; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laurino JP, 1999, MOL CELL BIOL, V19, P173; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nika J, 2001, J BIOL CHEM, V276, P1051, DOI 10.1074/jbc.M007398200; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rice LM, 2000, ACTA CRYSTALLOGR D, V56, P1413, DOI 10.1107/S0907444900010039; Roll-Mecak A, 2001, TRENDS BIOCHEM SCI, V26, P705, DOI 10.1016/S0968-0004(01)02024-2; Roll-Mecak A, 2000, CELL, V103, P781, DOI 10.1016/S0092-8674(00)00181-1; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; Schmitt E, 2002, EMBO J, V21, P1821, DOI 10.1093/emboj/21.7.1821; Sherman F., 1974, METHODS YEAST GENETI; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Spurio R, 2000, J BIOL CHEM, V275, P2447, DOI 10.1074/jbc.275.4.2447; TRACHSEL H, 1996, TRANSLATIONAL CONTRO, P113; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504	35	65	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10634	10642		10.1074/jbc.M310418200	http://dx.doi.org/10.1074/jbc.M310418200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688270	hybrid			2022-12-25	WOS:000220050400117
J	Soskine, M; Adam, Y; Schuldiner, S				Soskine, M; Adam, Y; Schuldiner, S			Direct evidence for substrate-induced proton release in detergent-solubilized EmrE, a multidrug transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMMON BINDING-SITE; ESCHERICHIA-COLI; ANTIPORTER; OLIGOMER; REVEALS; H+	A novel approach to study coupling of substrate and ion fluxes is presented. EmrE is an H+-coupled multidrug transporter from Escherichia coli. Detergent-solubilized EmrE binds substrate with high affinity in a pH-dependent mode. Here we show, for the first time in an ion-coupled transporter, substrate-induced release of protons in a detergent-solubilized preparation. The direct measurements allow for an important quantitation of the phenomenon. Thus, stoichiometry of the release in the wild type and a mutant with a single carboxyl at position 14 is very similar and about 0.8 protons/monomer. The findings demonstrate that the only residue involved in proton release is a highly conserved membrane-embedded glutamate (Glu-14) and that all the Glu-14 residues in the EmrE functional oligomer participate in proton release. Furthermore, from the pH dependence of the release we determined the pK of Glu-14 as 8.5 and for an aspartate replacement at the same position as 6.7. The high pK of the carboxyl at position 14 is essential for coupling of fluxes of protons and substrates.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Schuldiner, S (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel.	Shimon.Schuldiner@huji.ac.il	Adam, Yoav/AAU-4570-2020; Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237; Soskine, Misha/0000-0002-2198-9466	NINDS NIH HHS [NS16708] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016708, R56NS016708] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; Gutman N, 2003, J BIOL CHEM, V278, P16082, DOI 10.1074/jbc.M213120200; HUMPHREYS CJ, 1991, BIOCHEM SOC T, V19, P95, DOI 10.1042/bst0190095; Koteiche HA, 2003, BIOCHEMISTRY-US, V42, P6099, DOI 10.1021/bi0342867; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; Muth TR, 2000, EMBO J, V19, P234, DOI 10.1093/emboj/19.2.234; Ninio S, 2003, J BIOL CHEM, V278, P12000, DOI 10.1074/jbc.M213119200; Ninio S, 2001, J BIOL CHEM, V276, P48250, DOI 10.1074/jbc.M108231200; Rotem D, 2001, J BIOL CHEM, V276, P48243, DOI 10.1074/jbc.M108229200; Sahin-Toth M, 2000, P NATL ACAD SCI USA, V97, P10729, DOI 10.1073/pnas.200351797; Schuldiner S, 2001, J MOL MICROB BIOTECH, V3, P155; Schuldiner S, 2001, NEWS PHYSIOL SCI, V16, P130; Soskine M, 2002, P NATL ACAD SCI USA, V99, P12043, DOI 10.1073/pnas.192392899; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Tate CG, 2003, J MOL BIOL, V332, P229, DOI 10.1016/S0022-2836(03)00895-7; Yerushalmi H, 2000, BIOCHEMISTRY-US, V39, P14711, DOI 10.1021/bi001892i; Yerushalmi H, 2000, FEBS LETT, V476, P93, DOI 10.1016/S0014-5793(00)01677-X; Yerushalmi H, 2000, J BIOL CHEM, V275, P5264, DOI 10.1074/jbc.275.8.5264; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856; Yerushalmi H, 2001, J BIOL CHEM, V276, P12744, DOI 10.1074/jbc.M010979200; Yerushalmi H, 1996, J BIOL CHEM, V271, P31044, DOI 10.1074/jbc.271.49.31044	21	54	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9951	9955		10.1074/jbc.M312853200	http://dx.doi.org/10.1074/jbc.M312853200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701800	hybrid			2022-12-25	WOS:000220050400037
J	Yano, M; Terada, K; Mori, M				Yano, M; Terada, K; Mori, M			Mitochondrial import receptors Tom20 and Tom22 have chaperone-like activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; PREPROTEIN TRANSLOCASE; OUTER-MEMBRANE; TRIGGER FACTOR; FUNCTIONAL-ANALYSIS; TOM70; IDENTIFICATION; RECOGNITION; PRECURSOR; BINDING	Mitochondrial preproteins are synthesized in the cytosol with N-terminal signal sequences (presequences) or internal targeting signals. Generally, preproteins with presequences are initially recognized by Tom20 ( translocase of the outer membrane) and, subsequently, by Tom22, whereas hydrophobic preproteins with internal targeting signals are first recognized by Tom70. Recent studies suggest that Tom70 associates with molecular chaperones, thereby maintaining their substrate preproteins in an import-competent state. However, such a function has not been reported for other Tom component(s). Here, we investigated a role for Tom20 in preventing substrate preproteins from aggregating. In vitro binding assays showed that Tom20 binds to guanidinium chloride unfolded substrate proteins regardless of the presence or absence of presequences. This suggests that Tom20 functions as a receptor not only for presequences but also for mature portions exposed in unfolded preproteins. Aggregation suppression assays on citrate synthase showed that the cytosolic domain of Tom20 has a chaperone-like activity to prevent this protein from aggregating. This activity was inhibited by a presequence peptide, suggesting that the binding site of Tom20 for presequence is identical or close to the active site for the chaperone-like activity. The cytosolic domain of Tom22 also showed a similar activity for citrate synthase, whereas Tom70 did not. These results suggest that the cytosolic domains of Tom20 and Tom22 function to maintain their substrate preproteins unfolded and prevent them from aggregating on the mitochondrial surface.	Kumamoto Univ, Grad Sch Med Sci, Dept Mol Genet, Kumamoto 8608556, Japan	Kumamoto University	Yano, M (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Mol Genet, Honjo 1-1-1, Kumamoto 8608556, Japan.	myano@gpo.kumamoto-u.ac.jp; masa@gpo.kumamoto-u.ac.jp						Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; Alvarez-Dolado M, 1999, J NEUROCHEM, V73, P2240, DOI 10.1046/j.1471-4159.1999.0732240.x; Brix J, 2000, J MOL BIOL, V303, P479, DOI 10.1006/jmbi.2000.4120; Brix J, 1999, J BIOL CHEM, V274, P16522, DOI 10.1074/jbc.274.23.16522; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; GOPING IS, 1995, FEBS LETT, V373, P45; Hanson B, 1996, EUR J BIOCHEM, V235, P750, DOI 10.1111/j.1432-1033.1996.t01-1-00750.x; Herrmann JM, 2000, CURR OPIN MICROBIOL, V3, P210, DOI 10.1016/S1369-5274(00)00077-1; Johnston AJ, 2002, J BIOL CHEM, V277, P42197, DOI 10.1074/jbc.M205613200; Komiya T, 1997, EMBO J, V16, P4267, DOI 10.1093/emboj/16.14.4267; Lill R, 1996, TRENDS CELL BIOL, V6, P56, DOI 10.1016/0962-8924(96)81015-4; LILL R, 1988, CELL, V54, P1013, DOI 10.1016/0092-8674(88)90116-X; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; Maier R, 2001, J MOL BIOL, V314, P1181, DOI 10.1006/jmbi.2000.5192; Mori M, 1998, BBA-MOL CELL RES, V1403, P12, DOI 10.1016/S0167-4889(98)00021-4; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Neupert W, 2002, NAT REV MOL CELL BIO, V3, P555, DOI 10.1038/nrm878; Obita T, 2003, J MOL BIOL, V328, P495, DOI 10.1016/S0022-2836(03)00288-2; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Pirkl F, 2001, J BIOL CHEM, V276, P37034, DOI 10.1074/jbc.M102595200; Saeki K, 2000, J BIOL CHEM, V275, P31996, DOI 10.1074/jbc.M004794200; Schleiff E, 1999, J CELL BIOL, V145, P973, DOI 10.1083/jcb.145.5.973; SEKI N, 1995, FEBS LETT, V375, P307, DOI 10.1016/0014-5793(95)01229-8; Suzuki H, 2002, J CELL SCI, V115, P1895; Suzuki H, 2000, J BIOL CHEM, V275, P37930, DOI 10.1074/jbc.M006558200; Terada K, 2000, J BIOL CHEM, V275, P24728, DOI 10.1074/jbc.M002021200; TERADA K, 1995, MOL CELL BIOL, V15, P3708; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; Wright G, 2001, EXP CELL RES, V263, P107, DOI 10.1006/excr.2000.5096; Yano M, 2003, J CELL BIOL, V163, P45, DOI 10.1083/jcb.200305051; Yano M, 2000, MOL CELL BIOL, V20, P7205, DOI 10.1128/MCB.20.19.7205-7213.2000; Yano M, 1998, J BIOL CHEM, V273, P26844, DOI 10.1074/jbc.273.41.26844; Yano M, 1997, J BIOL CHEM, V272, P8459, DOI 10.1074/jbc.272.13.8459; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3	34	28	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10808	10813		10.1074/jbc.M311710200	http://dx.doi.org/10.1074/jbc.M311710200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699115	hybrid			2022-12-25	WOS:000220050400136
J	Larrayoz, IM; Casado, FJ; Pastor-Anglada, M; Lostao, MP				Larrayoz, IM; Casado, FJ; Pastor-Anglada, M; Lostao, MP			Electrophysiological characterization of the human Na+/nucleoside cotransporter 1 (hCNT1) and role of adenosine on hCNT1 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ GLUCOSE COTRANSPORTER; NUCLEOSIDE TRANSPORTER; ELECTROGENIC PROPERTIES; PYRIMIDINE; KINETICS; CURRENTS; PURINE; SGLT1; IDENTIFICATION; SELECTIVITY	We previously reported that the human Na+/nucleoside transporter pyrimidine-preferring 1 (hCNT1) is electrogenic and transports gemcitabine and 5'-deoxy-5- fluorouridine, a precursor of the active drug 5-fluorouracil. Nevertheless, a complete electrophysiological characterization of the basic properties of hCNT1-mediated translocation has not been performed yet, and the exact role of adenosine in hCNT1 function has not been addressed either. In the present work we have used the two-electrode voltage clamp technique to investigate hCNT1 transport mechanism and study the kinetic properties of adenosine as an inhibitor of hCNT1. We show that hCNT1 exhibits presteady-state currents that disappear upon the addition of adenosine or uridine. Adenosine, a purine nucleoside described as a substrate of the pyrimidine-preferring transporters, is not a substrate of hCNT1 but a high affinity blocker able to inhibit uridine-induced inward currents, the Na+-leak currents, and the presteady-state currents, with a K-i of 6.5 muM. The kinetic parameters for uridine, gemcitabine, and 5'-deoxy-5-fluorouridine were studied as a function of membrane potential; at -50 mV, K-0.5 was 37, 18, and 245 muM, respectively, and remained voltage-independent. I-max for gemcitabine was voltage-independent and accounts for similar to40% that for uridine at -50 mV. Maximal current for 5'-DFUR was voltage-dependent and was similar to150% that for uridine at all membrane potentials. K-0.5(Na+) for Na+ was voltage-independent at hyperpolarized membrane potentials (1.2 mM at - 50 mV), whereas I-max(Na+) was voltage-dependent, increasing 2-fold from -50 to -150 mV. Direct measurements of H-3-nucleoside or Na-22 fluxes with the charge-associated revealed a ratio of two positive inward charges per nucleoside and one Na+ per positive inward charge, suggesting a stoichiometry of two Na+/nucleoside.	Univ Navarra, Dept Fisiol & Nutr, E-31080 Pamplona, Spain; Univ Barcelona, Fac Biol, Dept Bioquim & Biol Mol, E-08071 Barcelona, Spain	University of Navarra; University of Barcelona	Lostao, MP (corresponding author), Univ Navarra, Dept Fisiol & Nutr, C Irunlarrea S-N, E-31080 Pamplona, Spain.	plostao@unav.es	Lostao, M. Pilar/AAW-4238-2021; Lostao, M. Pilar/ABH-4714-2020; Larrayoz, Ignacio M/I-5613-2012	Lostao, M. Pilar/0000-0002-7319-3451; Lostao, M. Pilar/0000-0002-7319-3451; Larrayoz, Ignacio M/0000-0003-1629-152X; Casado Merediz, Francisco Javier/0000-0003-0192-841X				Baldwin SA, 1999, MOL MED TODAY, V5, P216, DOI 10.1016/S1357-4310(99)01459-8; BIRNIR B, 1991, PFLUG ARCH EUR J PHY, V418, P79, DOI 10.1007/BF00370455; Casado FJ, 2002, J PHYSIOL BIOCHEM, V58, P207, DOI 10.1007/BF03179858; Diez-Sampedro A, 2000, J MEMBRANE BIOL, V176, P111, DOI 10.1007/s002320001081; Diez-Sampedro A, 2001, AM J PHYSIOL-RENAL, V280, pF278, DOI 10.1152/ajprenal.2001.280.2.F278; Dresser MJ, 2000, DRUG METAB DISPOS, V28, P1135; Fang X, 1996, BIOCHEM J, V317, P457, DOI 10.1042/bj3170457; Forlani G, 2001, BBA-MOL CELL RES, V1538, P172, DOI 10.1016/S0167-4889(00)00144-0; Gerstin KM, 2002, AM J PHYSIOL-RENAL, V283, pF344, DOI 10.1152/ajprenal.00274.2001; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Hazama A, 1997, J MEMBRANE BIOL, V155, P175, DOI 10.1007/s002329900169; Hirayama BA, 2001, BRIT J PHARMACOL, V134, P484, DOI 10.1038/sj.bjp.0704274; Klamo EM, 1996, J BIOL CHEM, V271, P14937, DOI 10.1074/jbc.271.25.14937; Loewen SK, 1999, J BIOL CHEM, V274, P24475, DOI 10.1074/jbc.274.35.24475; Loewen SK, 2003, YEAST, V20, P661, DOI 10.1002/yea.1000; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; Loo DDF, 2000, J BIOL CHEM, V275, P37414, DOI 10.1074/jbc.M007241200; LOSTAO MP, 1994, J MEMBRANE BIOL, V142, P161; Lostao MP, 2000, FEBS LETT, V481, P137, DOI 10.1016/S0014-5793(00)01983-9; Mackenzie B, 2003, J BIOL CHEM, V278, P23720, DOI 10.1074/jbc.M212718200; Mackenzie B, 1998, J MEMBRANE BIOL, V162, P101, DOI 10.1007/s002329900347; Mackey JR, 1999, JNCI-J NATL CANCER I, V91, P1876, DOI 10.1093/jnci/91.21.1876; Mata JF, 2001, MOL PHARMACOL, V59, P1542, DOI 10.1124/mol.59.6.1542; PARENT L, 1992, J MEMBRANE BIOL, V125, P63; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; Pastor-Anglada M, 1998, TRENDS PHARMACOL SCI, V19, P424, DOI 10.1016/S0165-6147(98)01253-X; Ritzel MWL, 1997, AM J PHYSIOL-CELL PH, V272, pC707, DOI 10.1152/ajpcell.1997.272.2.C707; Ritzel MWL, 2001, J BIOL CHEM, V276, P2914, DOI 10.1074/jbc.M007746200; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; Weiss JN, 1997, FASEB J, V11, P835, DOI 10.1096/fasebj.11.11.9285481; Yao SY, 2002, AM J PHYSIOL-CELL PH, V283, pC155, DOI 10.1152/ajpcell.00587.2001; Yao SYM, 1996, MOL PHARMACOL, V50, P1529	32	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8999	9007		10.1074/jbc.M311940200	http://dx.doi.org/10.1074/jbc.M311940200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14701834	Green Published, hybrid			2022-12-25	WOS:000189265900059
J	Oyedotun, KS; Yau, PF; Lemire, BD				Oyedotun, KS; Yau, PF; Lemire, BD			Identification of the heme axial ligands in the cytochrome b(562) of the Saccharomyces cerevisiae succinate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS SUCCINATE; COMPLEX-II SUCCINATE; MEMBRANE-INTEGRAL DOMAIN; QUINONE-BINDING-SITES; FUMARATE REDUCTASE; UBIQUINONE OXIDOREDUCTASE; WOLINELLA-SUCCINOGENES; ESCHERICHIA-COLI; PROTON; BIOENERGETICS	Succinate dehydrogenase (SDH) plays a key role in energy generation by coupling the oxidation of succinate to the reduction of ubiquinone in the mitochondrial electron transport chain. The Saccharomyces cerevisiae SDH is composed of a catalytic dimer of the Sdh1p and Sdh2p subunits containing flavin adenine dinucleotide (FAD) and iron-sulfur clusters and a heme b-containing membrane-anchoring domain comprised of the Sdh3p and Sdh4p subunits. We systematically mutated all the histidine and cysteine residues in Sdh3p and Sdh4p to identify the residues involved in axial heme ligation. The mutants were characterized for growth on a non-fermentable carbon source, for enzyme assembly, for succinate-dependent quinone reduction, for heme b content, and for heme spectral properties. Mutation of Sdh3p His-46 or His-113 leads to a marked reduction in the catalytic efficiency of the enzyme for quinone reduction, suggesting that these residues form part of a quinone-binding site. We identified Sdh3p His-106 and Sdh4p Cys-78 as the most probable axial ligands for cytochrome b(562). Replacement of His-106 or Cys-78 with an alanine residue leads to a marked reduction in cytochrome b(562) content and to altered heme spectral characteristics that are consistent with a direct perturbation of heme b environment. This is the first identification of a cysteine residue serving as an axial ligand for heme b in the SDH family of enzymes. Loss of cytochrome b(562) has no effect on enzyme assembly and quinone reduction; the role of the heme in enzyme structure and function is discussed.	Univ Alberta, Dept Biochem, Canadian Inst Hlth Res Grp Membrane Prot Res, Edmonton, AB T6G 2H7, Canada	University of Alberta	Lemire, BD (corresponding author), Univ Alberta, Dept Biochem, Canadian Inst Hlth Res Grp Membrane Prot Res, Edmonton, AB T6G 2H7, Canada.	bernard.lemire@ualberta.ca						Ackrell BAC, 2000, FEBS LETT, V466, P1, DOI 10.1016/S0014-5793(99)01749-4; Ackrell BAC, 2002, MOL ASPECTS MED, V23, P369, DOI 10.1016/S0098-2997(02)00012-2; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Baysal BE, 2002, J MED GENET, V39, P178, DOI 10.1136/jmg.39.3.178; Baysal BE, 2001, J MOL MED, V79, P495, DOI 10.1007/s001090100267; BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144; Cecchini G, 2003, ANNU REV BIOCHEM, V72, P77, DOI 10.1146/annurev.biochem.72.121801.161700; Cecchini G, 2003, FEBS LETT, V545, P31, DOI 10.1016/S0014-5793(03)00390-9; Cecchini G, 2002, BBA-BIOENERGETICS, V1553, P140, DOI 10.1016/S0005-2728(01)00238-9; COLE ST, 1985, BIOCHIM BIOPHYS ACTA, V811, P381, DOI 10.1016/0304-4173(85)90008-4; CROUSE BR, 1995, FEBS LETT, V367, P1, DOI 10.1016/0014-5793(95)00522-B; Fisher N, 2000, J MOL BIOL, V296, P1153, DOI 10.1006/jmbi.2000.3509; FRIDEN H, 1990, BIOCHIM BIOPHYS ACTA, V1041, P207, DOI 10.1016/0167-4838(90)90067-P; HAGERHALL C, 1995, BIOCHEMISTRY-US, V34, P11080; HAGERHALL C, 1992, BIOCHEMISTRY-US, V31, P7411, DOI 10.1021/bi00147a028; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; Hagerhall C, 1996, FEBS LETT, V389, P25, DOI 10.1016/0014-5793(96)00529-7; Hederstedt L, 1998, BIOCHEM SOC T, V26, P408, DOI 10.1042/bst0260408; Hederstedt L, 1999, SCIENCE, V284, P1941, DOI 10.1126/science.284.5422.1941; Hederstedt L, 2002, BBA-BIOENERGETICS, V1553, P74, DOI 10.1016/S0005-2728(01)00231-6; HEDERSTEDT L, 1992, MOL MECHANISMS BIOEN, P163; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; KITA K, 1989, J BIOL CHEM, V264, P2672; Kroger A, 2002, BBA-BIOENERGETICS, V1553, P23, DOI 10.1016/S0005-2728(01)00234-1; Lancaster CRD, 1999, NATURE, V402, P377, DOI 10.1038/46483; Lancaster CRD, 2002, BBA-BIOMEMBRANES, V1565, P215, DOI 10.1016/S0005-2736(02)00571-0; Lemire BD, 2002, BBA-BIOENERGETICS, V1553, P102, DOI 10.1016/S0005-2728(01)00229-8; Maklashina E, 2001, J BIOL CHEM, V276, P18968, DOI 10.1074/jbc.M011270200; Messner KR, 2002, J BIOL CHEM, V277, P42563, DOI 10.1074/jbc.M204958200; Nakamura K, 1996, J BIOL CHEM, V271, P521, DOI 10.1074/jbc.271.1.521; Ohnishi T, 2000, STRUCTURE, V8, pR23, DOI 10.1016/S0969-2126(00)00098-8; Oyedotun KS, 2004, J BIOL CHEM, V279, P9424, DOI 10.1074/jbc.M311876200; Oyedotun KS, 1999, FEBS LETT, V442, P203, DOI 10.1016/S0014-5793(98)01657-3; Oyedotun KS, 2001, J BIOL CHEM, V276, P16936, DOI 10.1074/jbc.M100184200; Oyedotun KS, 1999, J BIOL CHEM, V274, P23956, DOI 10.1074/jbc.274.34.23956; Oyedotun KS, 1997, J BIOL CHEM, V272, P31382, DOI 10.1074/jbc.272.50.31382; Rich P, 1999, BIOCHEM SOC T, V27, P561, DOI 10.1042/bst0270561; Rustin P, 2002, BBA-BIOENERGETICS, V1553, P117, DOI 10.1016/S0005-2728(01)00228-6; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Schnorpfeil M, 2001, EUR J BIOCHEM, V268, P3069, DOI 10.1046/j.1432-1327.2001.02202.x; Vibat CRT, 1998, BIOCHEMISTRY-US, V37, P4148, DOI 10.1021/bi9716635; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605; YU L, 1987, J BIOL CHEM, V262, P1137	44	21	24	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9432	9439		10.1074/jbc.M311877200	http://dx.doi.org/10.1074/jbc.M311877200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14672930	hybrid			2022-12-25	WOS:000189265900109
J	Perron, K; Caille, O; Rossier, C; van Delden, C; Dumas, JL; Kohler, T				Perron, K; Caille, O; Rossier, C; van Delden, C; Dumas, JL; Kohler, T			CzcR-CzcS, a two-component system involved in heavy metal and carbapenem resistance in Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCALIGENES-EUTROPHUS CH34; MULTIPLE ANTIBIOTIC-RESISTANCE; MULTIDRUG EFFLUX SYSTEM; GRAM-NEGATIVE BACTERIA; BASIC-AMINO-ACIDS; MEXE-MEXF-OPRN; OUTER-MEMBRANE; HISTIDINE KINASE; ESCHERICHIA-COLI; ZINC	Pseudomonas aeruginosa is an environmental bacterium involved in mineralization of organic matter. It is also an opportunistic pathogen able to cause serious infections in immunocompromised hosts. As such, it is exposed to xenobiotics including solvents, heavy metals, and antimicrobials. We studied the response of P. aeruginosa upon exposure to heavy metals or antibiotics to investigate whether common regulatory mechanisms govern resistance to both types of compounds. We showed that sublethal zinc concentrations induced resistance to zinc, cadmium, and cobalt, while lethal zinc concentrations selected mutants constitutively resistant to these heavy metals. Both zinc-induced and stable zinc-resistant strains were also resistant to the carbapenem antibiotic imipenem. On the other hand, only 20% of clones selected on imipenem were also resistant to zinc. Heavy metal resistance in the mutants could be correlated by quantitative real time PCR with increased expression of the heavy metal efflux pump CzcCBA and its cognate two-component regulator genes czcR-czcS. Western blot analysis revealed reduced expression of the basic amino acid and carbapenem-specific OprD porin in all imipenem-resistant mutants. Sequencing of the czcR-czcS DNA region in eight independent zinc- and imipenem-resistant mutants revealed the presence of the same V194L mutation in the CzcS sensor protein. Overexpression in a susceptible wild type strain of the mutated CzsS protein, but not of the wild type form, resulted in decreased oprD and increased czcC expression. We further show that zinc is released from latex urinary catheters into urine in amounts sufficient to induce carbapenem resistance in P. aeruginosa, possibly compromising treatment of urinary tract infections by this class of antibiotics.	Univ Geneva, Ctr Med Univ, Dept Genet & Microbiol, CH-1211 Geneva 4, Switzerland; Univ Geneva, Ctr Med Univ, Dept Bot & Plant Biol Sci 3, Lab Bacteriol & Microbial Ecol, CH-1211 Geneva 4, Switzerland	University of Geneva; University of Geneva	Kohler, T (corresponding author), Univ Geneva, Ctr Med Univ, Dept Genet & Microbiol, CH-1211 Geneva 4, Switzerland.	Thilo.Kohler@medecine.unige.ch	Perron, Karl/AAC-3128-2022; Köhler, Thilo/AAN-9498-2021	Perron, Karl/0000-0002-3259-4638				ANDERSEN J, 1990, BIOCHEMISTRY-US, V29, P9249, DOI 10.1021/bi00491a020; Baxter IA, 1997, J ANTIMICROB CHEMOTH, V39, P838, DOI 10.1093/jac/39.6.838; Conejo MC, 2003, ANTIMICROB AGENTS CH, V47, P2313, DOI 10.1128/AAC.47.7.2313-2315.2003; COOPER GL, 1993, J CLIN MICROBIOL, V31, P2366, DOI 10.1128/JCM.31.9.2366-2370.1993; Daly JS, 1997, J CLIN MICROBIOL, V35, P1027, DOI 10.1128/JCM.35.4.1027-1029.1997; DEHAAN KEC, 1990, BURNS, V16, P393, DOI 10.1016/0305-4179(90)90016-P; Delihas N, 2001, J MOL BIOL, V313, P1, DOI 10.1006/jmbi.2001.5029; DEVICENTE A, 1990, J APPL BACTERIOL, V68, P625, DOI 10.1111/j.1365-2672.1990.tb05228.x; Dutta R, 2000, J BIOL CHEM, V275, P38645, DOI 10.1074/jbc.M005872200; Epp SF, 2001, ANTIMICROB AGENTS CH, V45, P1780, DOI 10.1128/AAC.45.6.1780-1787.2001; ESTERLING L, 1994, MOL MICROBIOL, V12, P639, DOI 10.1111/j.1365-2958.1994.tb01051.x; Filali BK, 2000, CURR MICROBIOL, V41, P151, DOI 10.1007/s0028400; FUKUDA H, 1990, ANTIMICROB AGENTS CH, V34, P1757, DOI 10.1128/AAC.34.9.1757; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; HANSON RS, 1981, MANUAL METHODS GENER, P328; Hassan MET, 1999, GENE, V238, P417, DOI 10.1016/S0378-1119(99)00349-2; Hoang TT, 1998, GENE, V212, P77, DOI 10.1016/S0378-1119(98)00130-9; Hsing WH, 1998, J BACTERIOL, V180, P4538, DOI 10.1128/JB.180.17.4538-4546.1998; Kohler T, 1999, J BACTERIOL, V181, P6300; Kohler T, 1997, MOL MICROBIOL, V23, P345, DOI 10.1046/j.1365-2958.1997.2281594.x; LI XZ, 1995, ANTIMICROB AGENTS CH, V39, P1948, DOI 10.1128/AAC.39.9.1948; LIESEGANG H, 1993, J BACTERIOL, V175, P767, DOI 10.1128/JB.175.3.767-778.1993; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARQUES AM, 1979, J APPL BACTERIOL, V47, P347, DOI 10.1111/j.1365-2672.1979.tb01765.x; Martinez-Martinez L, 1999, ANTIMICROB AGENTS CH, V43, P397, DOI 10.1128/AAC.43.2.397; Maseda H, 2000, FEMS MICROBIOL LETT, V192, P107, DOI 10.1016/S0378-1097(00)00419-5; MASUDA N, 1992, ANTIMICROB AGENTS CH, V36, P1847, DOI 10.1128/AAC.36.9.1847; Mergeay M, 2003, FEMS MICROBIOL REV, V27, P385, DOI 10.1016/S0168-6445(03)00045-7; MERGEAY M, 1978, CR SOC BIOL, V172, P575; MERGEAY M, 1985, J BACTERIOL, V162, P328, DOI 10.1128/JB.162.1.328-334.1985; NIES D, 1987, J BACTERIOL, V169, P4865, DOI 10.1128/jb.169.10.4865-4868.1987; NIES DH, 1992, J BACTERIOL, V174, P8102, DOI 10.1128/JB.174.24.8102-8110.1992; NIES DH, 1989, J BACTERIOL, V171, P896, DOI 10.1128/jb.171.2.896-900.1989; Nikaido H, 1996, J BACTERIOL, V178, P5853, DOI 10.1128/jb.178.20.5853-5859.1996; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Ochs MM, 1999, ANTIMICROB AGENTS CH, V43, P1085, DOI 10.1128/AAC.43.5.1085; Park H, 1998, P NATL ACAD SCI USA, V95, P6728, DOI 10.1073/pnas.95.12.6728; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; POOLE K, 1993, J BACTERIOL, V175, P7363, DOI 10.1128/JB.175.22.7363-7372.1993; RAMOSAIRES J, 1999, ANTIMICROB AGENTS CH, V43, P2624; Rensing C, 1997, J BACTERIOL, V179, P6871, DOI 10.1128/jb.179.22.6871-6879.1997; Rosenfeld M, 2003, CURR OPIN PULM MED, V9, P492, DOI 10.1097/00063198-200311000-00008; SAIER MH, 1994, MOL MICROBIOL, V11, P841, DOI DOI 10.1111/J.1365-2958.1994.TB00362.X; Sambrook J, 2001, MOL CLONING LAB MANU; SCHMIDT T, 1994, J BACTERIOL, V176, P7045, DOI 10.1128/JB.176.22.7045-7054.1994; SMITH AW, 1989, NUCLEIC ACIDS RES, V17, P10509, DOI 10.1093/nar/17.24.10509; Stover CK, 2000, NATURE, V406, P959, DOI 10.1038/35023079; TALJA M, 1993, ANN CHIR GYNAECOL FE, V82, P74; Tanaka T, 1997, MICROBIOL IMMUNOL, V41, P697, DOI 10.1111/j.1348-0421.1997.tb01913.x; TRIAS J, 1990, J BIOL CHEM, V265, P15680; TRIAS J, 1990, ANTIMICROB AGENTS CH, V34, P52, DOI 10.1128/AAC.34.1.52; Wang CL, 1997, APPL ENVIRON MICROB, V63, P4075, DOI 10.1128/AEM.63.10.4075-4078.1997; YONEYAMA H, 1993, ANTIMICROB AGENTS CH, V37, P2385, DOI 10.1128/AAC.37.11.2385; Yoshida T, 2002, MOL MICROBIOL, V46, P1283, DOI 10.1046/j.1365-2958.2002.03240.x; Zhu Y, 2000, P NATL ACAD SCI USA, V97, P7808, DOI 10.1073/pnas.97.14.7808; Zhu Y, 2003, J BIOL CHEM, V278, P22812, DOI 10.1074/jbc.M300916200; Ziha-Zarifi I, 1999, ANTIMICROB AGENTS CH, V43, P287, DOI 10.1128/AAC.43.2.287	57	197	220	7	55	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8761	8768		10.1074/jbc.M312080200	http://dx.doi.org/10.1074/jbc.M312080200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14679195	hybrid			2022-12-25	WOS:000189265900030
J	Caplan, JF; Filipenko, NR; Fitzpatrick, SL; Waisman, DM				Caplan, JF; Filipenko, NR; Fitzpatrick, SL; Waisman, DM			Regulation of annexin A2 by reversible glutathionylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II TETRAMER; PHOSPHOLIPID-BINDING; MEMBRANE INTERACTIONS; S-GLUTATHIOLATION; QUICK-FREEZE; PROTEINS; ACTIN; IDENTIFICATION; AGGREGATION; CELL	The annexin A2-S100A10 heterotetramer (AIIt) is a multifunctional Ca2+-dependent, phospholipid-binding, and F-actin-binding phosphoprotein composed of two annexin A2 subunits and two S100A10 subunits. It was reported previously that oxidative stress from exogenous hydrogen peroxide or generated in response to tumor necrosis factor-alpha results in the glutathionylation of Cys(8) of annexin A2. In this study, we demonstrate that AIIt is an oxidatively labile protein whose level of activity is regulated by the redox status of its sulfhydryl groups. Oxidation of AIIt by diamide resulted in a time- and concentration-dependent loss of the ability of AIIt to interact with phospholipid liposomes and F-actin. The inhibitory effect of diamide on the activity of AIIt was partially reversed by dithiothreitol. In addition, incubation of AIIt with diamide and GSH resulted in the glutathionylation of AIIt in vitro. Mass spectrometry established the incorporation of 2 mol of GSH/mol of annexin A2 subunit at Cys(8) and Cys(132). Glutathionylation potentiated the inhibitory effects of diamide on the activity of AIIt. Furthermore, AIIt could be deglutathionylated by glutaredoxin (thiol transferase). Thus, we show for the first time that AIIt can undergo functional reactivation by glutaredoxin, therefore establishing that AIIt is regulated by reversible glutathionylation.	Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Oncol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	Waisman, DM (corresponding author), Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Canc Biol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	waisman@ucalgary.ca		Waisman, David/0000-0002-5097-9662				BABIZHAYEV MA, 1990, MECH AGEING DEV, V56, P199, DOI 10.1016/0047-6374(90)90082-Q; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; BLACKWOOD RA, 1990, BIOCHEM J, V266, P195, DOI 10.1042/bj2660195; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burger A, 1996, J MOL BIOL, V257, P839, DOI 10.1006/jmbi.1996.0205; Choi KS, 2003, MOL B INT U, P218; Choi KS, 2001, J BIOL CHEM, V276, P25212, DOI 10.1074/jbc.M101426200; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; Davis DA, 1996, BIOCHEMISTRY-US, V35, P2482, DOI 10.1021/bi951525k; Donato R., 1999, Cell Calcium, V26, P85, DOI 10.1054/ceca.1999.0079; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; Filipenko NR, 2003, MOL B INT U, P127; Filipenko NR, 2001, J BIOL CHEM, V276, P5310, DOI 10.1074/jbc.M009710200; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; GLENNEY JR, 1987, J CELL BIOL, V104, P503, DOI 10.1083/jcb.104.3.503; Hajjar KA, 1998, J INVEST MED, V46, P364; Hayes JD, 1999, FREE RADICAL RES, V31, P273, DOI 10.1080/10715769900300851; HITT AL, 1994, CURR OPIN CELL BIOL, V6, P120, DOI 10.1016/0955-0674(94)90125-2; HUBAISHY I, 1995, BIOCHEMISTRY-US, V34, P14527, DOI 10.1021/bi00044a031; IKEBUCHI NW, 1990, J BIOL CHEM, V265, P3392; JOHNSTONE SA, 1992, J BIOL CHEM, V267, P25976; Kang HM, 1997, BIOCHEMISTRY-US, V36, P2041, DOI 10.1021/bi962569b; Kassam G, 1997, J BIOL CHEM, V272, P15093, DOI 10.1074/jbc.272.24.15093; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; KOSOWER EM, 1972, BIOCHIM BIOPHYS ACTA, V264, P39, DOI 10.1016/0304-4165(72)90114-6; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; Kwon M, 2002, J BIOL CHEM, V277, P10903, DOI 10.1074/jbc.M111219200; LIU L, 1995, BBA-LIPID LIPID MET, V1259, P166, DOI 10.1016/0005-2760(95)00159-A; Liu L, 2002, EUR J BIOCHEM, V269, P4277, DOI 10.1046/j.1432-1033.2002.03118.x; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Moss SE, 1997, TRENDS CELL BIOL, V7, P87, DOI 10.1016/S0962-8924(96)10049-0; NAKATA T, 1990, J CELL BIOL, V110, P13, DOI 10.1083/jcb.110.1.13; Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561; Okamoto T, 2001, J BIOL CHEM, V276, P29596, DOI 10.1074/jbc.M102417200; Palmieri SJ, 2000, CELL MOTIL CYTOSKEL, V46, P285, DOI 10.1002/1097-0169(200008)46:4<285::AID-CM6>3.0.CO;2-N; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Rowan WH, 2002, BIOCHEMISTRY-US, V41, P1409, DOI 10.1021/bi0119767; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Seaton BA, 1998, BIOMETALS, V11, P399, DOI 10.1023/A:1009205925714; SENDA T, 1994, CELL TISSUE RES, V277, P51; Seres T, 1996, J IMMUNOL, V156, P1973; Singh TK, 2000, ARCH BIOCHEM BIOPHYS, V381, P235, DOI 10.1006/abbi.2000.1994; Smith CV, 1996, TOXICOL APPL PHARM, V140, P1, DOI 10.1006/taap.1996.0191; Sullivan DM, 2000, BIOCHEMISTRY-US, V39, P11121, DOI 10.1021/bi0007674; SWAIRJO MA, 1994, ANNU REV BIOPH BIOM, V23, P193, DOI 10.1146/annurev.bb.23.060194.001205; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; Yin HL, 1999, J BIOL CHEM, V274, P32529, DOI 10.1074/jbc.274.46.32529; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	52	73	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7740	7750		10.1074/jbc.M313049200	http://dx.doi.org/10.1074/jbc.M313049200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14668336	hybrid			2022-12-25	WOS:000189103300047
J	Nguyen, TM; Lieberherr, M; Fritsch, J; Guillozo, H; Alvarez, ML; Fitouri, Z; Jehan, F; Garabedian, M				Nguyen, TM; Lieberherr, M; Fritsch, J; Guillozo, H; Alvarez, ML; Fitouri, Z; Jehan, F; Garabedian, M			The rapid effects of 1,25-dihydroxyvitamin D-3 require the vitamin D receptor and influence 24-hydroxylase activity - Studies in human skin fibroblasts bearing vitamin D receptor mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; D-RESISTANT RICKETS; BINDING DOMAIN; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; MOUSE OSTEOBLASTS; MEMBRANE-RECEPTOR; HORMONE RECEPTOR; CYP24 PROMOTER; CALCIUM; CELLS	If both rapid and genomic pathways may co-exist in the same cell, the involvement of the nuclear vitamin D receptor (VDR) in the rapid effects of 1,25-dihydroxyvitamin D-3 (1,25-(OH)(2)D-3) remains unclear. We therefore studied rapid and long term effects of 1,25-(OH)(2)D-3 in cultured skin fibroblasts from three patients with severe vitamin D-resistant rickets and one age-matched control. Patients bear homozygous missense VDR mutations that abolished either VDR binding to DNA (patient 1, mutation K45E) or its stable ligand binding (patients 2 and 3, mutation W286R). In patient 1 cells, 1,25-(OH)(2)D-3 (1 pM-10 nM) had no effect on either intracellular calcium or 24-hydroxylase (enzyme activity and mRNA expression). In contrast, cells bearing the W286R mutation had calcium responses to 1,25-(OH)(2)D-3 (profile and magnitude) and 24-hydroxylase responses to low (1 pM-100 pM) 1,25-(OH)(2)D-3 concentrations (activity, CYP24, and ferredoxin mRNAs) similar to those of controls. The blocker of Ca2+ channels, verapamil, impeded both rapid (calcium) and long term (24-hydroxylase activity, CYP24, and ferredoxin mRNAs) responses in patient and control fibroblasts. The MEK 1/2 kinase inhibitor PD98059 also blocked the CYP24 mRNA response. Taken together, these results suggest that 1,25-(OH)(2)D-3 rapid effects require the presence of VDR and control, in part, the first step of 1,25-(OH)(2)D-3 catabolism via increased mRNA expression of the CYP24 and ferredoxin genes in the 24-hydroxylase complex.	Hop St Vincent de Paul, CNRS, UPR 1524, UMR 8104, F-75014 Paris, France; INRA, Lab Nutr & Secur Alimentaire, F-78352 Jouy En Josas, France; Hop Enfants, Serv Pediat, Tunis 1007, Tunisia	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Universite de Tunis-El-Manar; Hopital d'Enfants	Nguyen, TM (corresponding author), Hop St Vincent de Paul, CNRS, UPR 1524, UMR 8104, 82 Ave Denfert Rechereau, F-75014 Paris, France.	cnrs.svp@wanadoo.fr	Jehan, Frederic/P-1568-2014	Jehan, Frederic/0000-0003-1271-6594				BARAN DT, 1994, P SOC EXP BIOL MED, V207, P175, DOI 10.3181/00379727-207-43803; Baran DT, 2000, J CELL BIOCHEM, V78, P34, DOI 10.1002/(SICI)1097-4644(20000701)78:1<34::AID-JCB4>3.3.CO;2-Q; Barsony J, 1997, J BIOL CHEM, V272, P5774, DOI 10.1074/jbc.272.9.5774; BARSONY J, 1992, J BIOL CHEM, V267, P457; BENO DWA, 1995, J BIOL CHEM, V270, P3642, DOI 10.1074/jbc.270.8.3642; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; BOURDEAU A, 1990, ENDOCRINOLOGY, V127, P2739; CAFFREY JM, 1989, J BIOL CHEM, V264, P20265; CHEN KS, 1993, P NATL ACAD SCI USA, V90, P4543, DOI 10.1073/pnas.90.10.4543; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Christakos S, 2003, J CELL BIOCHEM, V88, P238, DOI 10.1002/jcb.10349; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; DEBOLAND AR, 1990, BIOCHEM BIOPH RES CO, V166, P217, DOI 10.1016/0006-291X(90)91933-J; Dwivedi PP, 2002, J BIOL CHEM, V277, P29643, DOI 10.1074/jbc.M204561200; Erben RG, 2002, MOL ENDOCRINOL, V16, P1524, DOI 10.1210/me.16.7.1524; Farach-Carson MC, 2003, CURR DRUG TARGETS, V4, P67, DOI 10.2174/1389450033347118; Gniadecki R, 1996, J INVEST DERMATOL, V106, P1212, DOI 10.1111/1523-1747.ep12348498; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Henry HL, 2001, STEROIDS, V66, P391, DOI 10.1016/S0039-128X(00)00158-6; HEWISON M, 1993, CLIN ENDOCRINOL, V39, P663, DOI 10.1111/j.1365-2265.1993.tb02424.x; Kerry DM, 1996, J BIOL CHEM, V271, P29715, DOI 10.1074/jbc.271.47.29715; Kim YS, 1996, ENDOCRINOLOGY, V137, P3649, DOI 10.1210/en.137.9.3649; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; Le Mellay V, 1999, J CELL BIOCHEM, V75, P138, DOI 10.1002/(SICI)1097-4644(19991001)75:1<138::AID-JCB14>3.0.CO;2-I; LeMellay V, 1997, J BIOL CHEM, V272, P11902, DOI 10.1074/jbc.272.18.11902; LIEBERHERR M, 1989, J BIOL CHEM, V264, P20403; LIEBERHERR M, 1987, J BIOL CHEM, V262, P13168; Mailhot G, 2000, ENDOCRINOLOGY, V141, P891, DOI 10.1210/en.141.3.891; Malloy PJ, 1999, ENDOCR REV, V20, P156, DOI 10.1210/er.20.2.156; MASSHEIMER V, 1994, CELL SIGNAL, V6, P299, DOI 10.1016/0898-6568(94)90034-5; Naor Z, 2000, TRENDS ENDOCRIN MET, V11, P91, DOI 10.1016/S1043-2760(99)00232-5; Nemere I, 1998, J BONE MINER RES, V13, P1353, DOI 10.1359/jbmr.1998.13.9.1353; NEMERE I, 1984, ENDOCRINOLOGY, V115, P1476, DOI 10.1210/endo-115-4-1476; Nguyen TM, 2002, J BONE MINER RES, V17, P1728, DOI 10.1359/jbmr.2002.17.9.1728; NISHIMURA A, 1994, ENDOCRINOLOGY, V134, P1794, DOI 10.1210/en.134.4.1794; Norman AW, 2002, MOL CELL ENDOCRINOL, V197, P1, DOI 10.1016/S0303-7207(02)00273-3; Norman AW, 1998, J BONE MINER RES, V13, P1360, DOI 10.1359/jbmr.1998.13.9.1360; OHYAMA Y, 1993, BIOCHEMISTRY-US, V32, P76, DOI 10.1021/bi00052a011; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Prufer K, 2002, MOL ENDOCRINOL, V16, P1738, DOI 10.1210/me.2001-0345; RASMUSSEN H, 1982, FED PROC, V41, P72; RUT AR, 1994, CLIN ENDOCRINOL, V41, P581, DOI 10.1111/j.1365-2265.1994.tb01822.x; Schwartz Z, 2001, CALCIFIED TISSUE INT, V69, P365, DOI 10.1007/s00223-001-1009-y; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Song XD, 1998, ENDOCRINOLOGY, V139, P457, DOI 10.1210/en.139.2.457; Wali R, 2001, J BONE MINER RES, V16, pS229; WHEELER DG, 1995, NUCLEIC ACIDS RES, V23, P3268, DOI 10.1093/nar/23.16.3268	48	46	48	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7591	7597		10.1074/jbc.M309517200	http://dx.doi.org/10.1074/jbc.M309517200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14665637	hybrid			2022-12-25	WOS:000189103300028
J	Wu, YI; Munshi, HG; Sen, R; Snipas, SJ; Salvesen, GS; Fridman, R; Stack, MS				Wu, YI; Munshi, HG; Sen, R; Snipas, SJ; Salvesen, GS; Fridman, R; Stack, MS			Glycosylation broadens the substrate profile of membrane type 1 matrix metalloproteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE; TISSUE INHIBITOR; I COLLAGEN; MEDIATED ENDOCYTOSIS; CATALYTIC DOMAIN; PROGELATINASE-A; CARCINOMA-CELLS; TUMOR INVASION; ACTIVE ENZYME; GROWTH-FACTOR	Membrane type 1 matrix metalloproteinase (MT1-MMP) is a collagenolytic enzyme that has been implicated in normal development and in pathological processes such as cancer metastasis. The activity of MT1-MMP is regulated extensively at the post-translational level, and the current data support the hypothesis that MT1-MMP activity is modulated by glycosylation. Enzymatic deglycosylation, site-directed mutagenesis, and lectin precipitation assays were used to demonstrate that MT1-MMP contains O-linked complex carbohydrates on the Thr(291), Thr(299), Thr(300), and/or Ser(301) residues in the proline-rich linker region. MT1-MMP glycoforms were detected in human cancer cell lines, suggesting that MT1-MMP activity may be regulated by differential glycosylation in vivo. Although the autolytic processing and interstitial collagenase activity of MT1-MMP were not impaired in glycosylation-deficient mutants, cell surface MT1-MMP-catalyzed activation of pro-matrix metalloproteinase-2 ( proMMP-2) required proper glycosylation of MT1-MMP. The inability of carbohydrate-free MT1-MMP to activate proMMP-2 was not a result of defective MT1-MMP zymogen activation, aberrant protein stability, or inability of the mature enzyme to oligomerize. Rather, our data support a mechanism whereby glycosylation affects the recruitment of tissue inhibitor of metalloproteinases-2 (TIMP-2) to the cell surface, resulting in defective formation of the MT1-MMP/ TIMP-2/proMMP-2 trimeric activation complex. These data provide evidence for an additional mechanism for post-translational control of MT1-MMP activity and suggest that glycosylation of MT1-MMP may regulate its substrate targeting.	Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Burnham Inst, Program Apoptosis & Cell Death Res, La Jolla, CA 92037 USA; Wayne State Univ, Dept Pathol, Detroit, MI 48202 USA	Northwestern University; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Sanford Burnham Prebys Medical Discovery Institute; Wayne State University	Stack, MS (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave,Tarry 8-715, Chicago, IL 60611 USA.	mss130@northwestern.edu	yi, wu/GLR-2824-2022		NCI NIH HHS [K08CA94877, R01CA85870] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085870, K08CA094877] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschuler Y, 2000, MOL BIOL CELL, V11, P819, DOI 10.1091/mbc.11.3.819; ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Ellerbroek SM, 2001, J BIOL CHEM, V276, P24833, DOI 10.1074/jbc.M005631200; English WR, 2000, J BIOL CHEM, V275, P14046, DOI 10.1074/jbc.275.19.14046; English WR, 2001, J BIOL CHEM, V276, P42018, DOI 10.1074/jbc.M107783200; Galvez BG, 2002, J CELL BIOL, V159, P509, DOI 10.1083/jcb.200205026; Hansen JE, 1997, NUCLEIC ACIDS RES, V25, P278, DOI 10.1093/nar/25.1.278; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; HUET G, 1995, J CELL SCI, V108, P1275; Huet G, 1998, J CELL BIOL, V141, P1311, DOI 10.1083/jcb.141.6.1311; Ihrke G, 2001, EMBO J, V20, P6256, DOI 10.1093/emboj/20.22.6256; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Kojima S, 2000, FEBS LETT, V480, P142, DOI 10.1016/S0014-5793(00)01919-0; Koo HM, 2002, MOL CELLS, V13, P118; KUAN SF, 1989, J BIOL CHEM, V264, P19271; Lehti K, 2002, J BIOL CHEM, V277, P8440, DOI 10.1074/jbc.M109128200; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; Maquoi E, 2000, J BIOL CHEM, V275, P11368, DOI 10.1074/jbc.275.15.11368; Maquoi E, 1998, FEBS LETT, V424, P262, DOI 10.1016/S0014-5793(98)00187-2; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Munshi HG, 2002, J BIOL CHEM, V277, P41480, DOI 10.1074/jbc.M207695200; Munshi HG, 2002, METHOD CELL BIOL, V69, P195, DOI 10.1016/S0091-679X(02)69013-2; Murphy G, 1999, APMIS, V107, P38, DOI 10.1111/j.1699-0463.1999.tb01524.x; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Noe V, 2001, J CELL SCI, V114, P111; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; Overall CM, 1999, J BIOL CHEM, V274, P4421, DOI 10.1074/jbc.274.7.4421; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Preece G, 1996, J BIOL CHEM, V271, P11634, DOI 10.1074/jbc.271.20.11634; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Rozanov DV, 2003, J BIOL CHEM, V278, P8257, DOI 10.1074/jbc.M213246200; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Seiki M, 2002, CURR OPIN CELL BIOL, V14, P624, DOI 10.1016/S0955-0674(02)00363-0; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Tam EM, 2002, J BIOL CHEM, V277, P39005, DOI 10.1074/jbc.M206874200; Toth M, 2002, J BIOL CHEM, V277, P26340, DOI 10.1074/jbc.M200655200; Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200; Tsukada H, 2002, J BIOL CHEM, V277, P27378, DOI 10.1074/jbc.M201367200; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; Van den Steen PE, 2001, BBA-GEN SUBJECTS, V1528, P61, DOI 10.1016/S0304-4165(01)00190-8; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; Yu Q, 2000, GENE DEV, V14, P163; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	68	71	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8278	8289		10.1074/jbc.M311870200	http://dx.doi.org/10.1074/jbc.M311870200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14670950	hybrid			2022-12-25	WOS:000189103300110
J	Omori, K; Naruishi, K; Nishimura, F; Yamada-Naruishi, H; Takashiba, S				Omori, K; Naruishi, K; Nishimura, F; Yamada-Naruishi, H; Takashiba, S			High glucose enhances interleukin-6-induced vascular endothelial growth factor 165 expression via activation of Gp130-mediated p44/42 MAPK-CCAAT/enhancer binding protein signaling in gingival fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; GENE-EXPRESSION; DIABETIC COMPLICATIONS; 3T3-L1 PREADIPOCYTES; VEGF; RECEPTOR; ADIPOGENESIS; ANGIOGENESIS; MIGRATION; MELLITUS	Diabetic patients are susceptible to severe inflammatory periodontitis manifesting as swollen gingiva with bleeding, but the underlying mechanism is not well understood. Our purpose was to determine the effect of a high glucose (HG) condition on the interleukin-6/soluble interleukin-6 receptor (IL-6/sIL-6R)-induced activation of signaling and vascular endothelial growth factor (VEGF) expression in human gingival fibroblasts (HGFs). In this study, HGFs were cultured for at least two passages under a normal glucose (NG; 5.5 mm) condition or high glucose (25 mm) condition. Importantly, the HG condition significantly induced expression of gp130 mRNA in HGFs compared with levels in control cells. Consistent with the expression of its mRNA, the HG condition also increased the expression of gp130 protein, and phosphorylation of the tyrosine residue by gp130 was enhanced significantly by IL-6/sIL-6R stimulation. Furthermore, the HG condition enhanced the IL-6/sIL-6R-induced phosphorylation of p44/42 MAPK and led to subsequent activation of CCAAT/enhancer binding protein in nuclei. In contrast, there was no significant difference in phosphorylation of JNK between the HG and NG condition. Interestingly, HGFs increased IL-6/sIL-6R,induced VEGF165 mRNA expression and VEGF165 secretion under the HG condition compared with levels under the NG condition. In contrast, the induction of VEGF165 secretion was partially inhibited by PD98059 (selective p44/42 MAPK inhibitor) under the HG condition. In addition, the VEGF165 secretion was completely inhibited by the combination of PD98059 and SP600125 (JNK inhibitor). Our findings suggest that the HG condition indirectly increases VEGF expression via activation of gp130-mediated p44/42 MAPK-CCAAT/enhancer binding protein signaling in HGFs. Thus, elevated VEGF secretion in HGFs under the HG condition may play a role in the development of the severe periodontitis observed in diabetic patients.	Okayama Univ, Grad Sch Med & Dent, Dept Pathophysiol Periodontal Sci, Okayama 7008525, Japan	Okayama University	Takashiba, S (corresponding author), Okayama Univ, Grad Sch Med & Dent, Dept Pathophysiol Periodontal Sci, 2-5-1 Shikata Cho, Okayama 7008525, Japan.	stakashi@cc.okayama-u.ae.jp	Omori, Kazuhiro/AAX-5268-2020; Takashiba, Shogo/C-9830-2010	Takashiba, Shogo/0000-0002-4712-6829				Akira S, 1997, ADV IMMUNOL, V65, P1, DOI 10.1016/S0065-2776(08)60740-3; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Benjamin LE, 2001, AM J PATHOL, V158, P1181, DOI 10.1016/S0002-9440(10)64066-7; Bickel M, 2001, J CLIN PERIODONTOL, V28, P840, DOI 10.1034/j.1600-051x.2001.028009840.x; Cameron NE, 2001, DIABETOLOGIA, V44, P1973, DOI 10.1007/s001250100001; Cho YH, 2003, MOL PHARMACOL, V63, P512, DOI 10.1124/mol.63.3.512; Funamoto M, 2000, J BIOL CHEM, V275, P10561, DOI 10.1074/jbc.275.14.10561; Funatsu H, 2001, RETINA-J RET VIT DIS, V21, P469, DOI 10.1097/00006982-200110000-00009; GHOSH D, 1991, TRENDS BIOCHEM SCI, V16, P445, DOI 10.1016/0968-0004(91)90173-S; GUILLOT JL, 1995, J PERIODONTOL, V66, P667, DOI 10.1902/jop.1995.66.8.667; Hamm JK, 2001, J BIOL CHEM, V276, P18464, DOI 10.1074/jbc.M100797200; Hoshi S, 2002, BIOCHEM BIOPH RES CO, V290, P177, DOI 10.1006/bbrc.2001.6138; Iacopino A M, 2001, Ann Periodontol, V6, P125, DOI 10.1902/annals.2001.6.1.125; Isner JM, 2001, CIRC RES, V89, P389, DOI 10.1161/hh1701.096259; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Lee TH, 2002, J BIOL CHEM, V277, P10445, DOI 10.1074/jbc.M107348200; LOPESVIRELLA MF, 1996, DIABETES S3, V45, P40; Mandl-Weber S, 2002, KIDNEY INT, V61, P570, DOI 10.1046/j.1523-1755.2002.00143.x; Naruishi K, 2003, TRANSPLANTATION, V76, P1380, DOI 10.1097/01.TP.0000085661.52980.95; Naruishi K, 1999, J PERIODONTAL RES, V34, P296, DOI 10.1111/j.1600-0765.1999.tb02257.x; Naruishi K, 2001, J DENT RES, V80, P1421, DOI 10.1177/00220345010800050701; Natarajan R, 1997, AM J PHYSIOL-HEART C, V273, pH2224, DOI 10.1152/ajpheart.1997.273.5.H2224; Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026; Persson RE, 2003, J CLIN PERIODONTOL, V30, P207, DOI 10.1034/j.1600-051X.2003.00237.x; Prusty D, 2002, J BIOL CHEM, V277, P46226, DOI 10.1074/jbc.M207776200; Ritz E, 1999, NEW ENGL J MED, V341, P1127, DOI 10.1056/NEJM199910073411506; Rogus JJ, 2002, DIABETES, V51, P1655, DOI 10.2337/diabetes.51.6.1655; Soskolne W A, 2001, Ann Periodontol, V6, P91, DOI 10.1902/annals.2001.6.1.91; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; Unlu F, 2003, J PERIODONTOL, V74, P181, DOI 10.1902/jop.2003.74.2.181; Wei D, 2002, INT IMMUNOPHARMACOL, V2, P1163, DOI 10.1016/S1567-5769(02)00082-6; Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5; Zeng HY, 2001, J BIOL CHEM, V276, P32714, DOI 10.1074/jbc.M103130200	35	35	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6643	6649		10.1074/jbc.M311688200	http://dx.doi.org/10.1074/jbc.M311688200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14676217	Green Submitted, hybrid			2022-12-25	WOS:000188969200054
J	Poch, E; Carbonell, P; Franco, S; Diez-Juan, A; Blasco, MA; Andres, V				Poch, Enric; Carbonell, Paz; Franco, Sonia; Diez-Juan, Antonio; Blasco, Maria A.; Andres, Vicente			Short telomeres protect from diet-induced atherosclerosis in apolipoprotein E-null mice	FASEB JOURNAL			English	Article									[Poch, Enric; Carbonell, Paz; Diez-Juan, Antonio; Andres, Vicente] CSIC, Inst Biomed Valencia, Dept Mol & Cellular Pathol & Therapy, Lab Vasc Biol, Valencia 46010, Spain; [Franco, Sonia; Blasco, Maria A.] CSIC, Ctr Nacl Biotecnol, Dept Oncol & Immunol, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Andres, V (corresponding author), CSIC, Inst Biomed Valencia, Dept Mol & Cellular Pathol & Therapy, Lab Vasc Biol, Valencia 46010, Spain.	vandres@ibv.csic.es	Diez Juan, Antonio/D-3695-2018; Blasco, Maria A./M-1694-2014; Andres, Vicente/I-6440-2014; Diez-Juan, Antonio/H-5464-2015	Blasco, Maria A./0000-0002-4211-233X; Andres, Vicente/0000-0002-0125-7209; Diez-Juan, Antonio/0000-0002-0166-1869					0	66	68	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					418	420		10.1096/fj.03-0710fje	http://dx.doi.org/10.1096/fj.03-0710fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V38YG	14688198	Green Submitted			2022-12-25	WOS:000209378100001
J	Amir, RE; Haecker, H; Karin, M; Ciechanover, A				Amir, RE; Haecker, H; Karin, M; Ciechanover, A			Mechanism of processing of the NF-kappa B2 p100 precursor: identification of the specific polyubiquitin chain-anchoring lysine residue and analysis of the role of NEDD8-modification on the SCF beta-TrCP ubiquitin ligase	ONCOGENE			English	Article						ubiquitin; processing; NF-kappa B2; p100; p52; NEDD8	NF-KAPPA-B; NEDD8; PROTEIN; E3; PHOSPHORYLATION; DEGRADATION; ACTIVATION; PATHWAY; SYSTEM; ALPHA	Processing of the NF-kappaB2 precursor p100 to the mature p52 subunit is regulated via a unique pathway. NF-kappaB-inducing kinase (NIK) induces IkappaB kinase alpha (IKKalpha)-mediated phosphorylation of specific serine residues in the C-terminal domain of p100, leading to recruitment of the SCFbeta-TrCP ubiquitin ligase. We identified a single lysine residue, K855, that serves as the ubiquitin-anchoring residue required for signal-induced processing of p100. In a reconstituted system containing purified components, p100-K855R could not be ubiquitinated. In a crude extract and cells, only residual, signal-independent ubiquitination and processing were retained. Importantly, K855 is located in a site homologous to K22 that serves as an ubiquitination site in IkappaBalpha. This suggests a common recognition mechanism for the two molecules. In contrast, p105, the p100 homologue, lacks a similar Lys residue. We also demonstrate that the NEDD8 pathway is essential for the SCFbeta-TrCP activity. In a reconstituted system, efficient ubiquitination of p100 required all three components of the pathway - E1, the UBC12 E2 and NEDD8. Experiments in reconstituted systems and in cells demonstrated that SCFbeta-TrCP, which contains a mutant Cul-1 that cannot be NEDDylated, cannot stimulate ubiquitination and processing. Similarly, dominant negative UBC12 inhibits, in a reversible manner, both ubiquitination and processing of p100.	Technion Israel Inst Technol, Fac Med, Dept Biochem, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel; Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; University of California System; University of California San Diego	Ciechanover, A (corresponding author), Technion Israel Inst Technol, Fac Med, Dept Biochem, POB 9649, IL-31096 Haifa, Israel.	c_tzachy@netvision.net.il	Haecker, Hans/F-6826-2013; Ciechanover, Aaron J/C-9166-2017	Haecker, Hans/0000-0001-5971-0451; 				Amir RE, 2002, J BIOL CHEM, V277, P23253, DOI 10.1074/jbc.M200967200; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Ben-Neriah Y, 2002, NAT IMMUNOL, V3, P20, DOI 10.1038/ni0102-20; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200; Gong LM, 2000, J BIOL CHEM, V275, P14212, DOI 10.1074/jbc.275.19.14212; Gong LM, 1999, J BIOL CHEM, V274, P12036, DOI 10.1074/jbc.274.17.12036; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Kamitani T, 2001, J BIOL CHEM, V276, P46655, DOI 10.1074/jbc.M108636200; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Morimoto M, 2000, BIOCHEM BIOPH RES CO, V270, P1093, DOI 10.1006/bbrc.2000.2576; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Neri A, 1996, LEUKEMIA LYMPHOMA, V23, P43, DOI 10.3109/10428199609054800; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; Osaka F, 1998, GENE DEV, V12, P2263, DOI 10.1101/gad.12.15.2263; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; Wu K, 2002, J BIOL CHEM, V277, P516, DOI 10.1074/jbc.M108008200; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3	29	84	88	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2540	2547		10.1038/sj.onc.1207366	http://dx.doi.org/10.1038/sj.onc.1207366			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14676825				2022-12-25	WOS:000220558000011
J	Dominguez, F; Moreno, J; Cejudo, FJ				Dominguez, F; Moreno, J; Cejudo, FJ			A gibberellin-induced nuclease is localized in the nucleus of wheat aleurone cells undergoing programmed cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARLEY ALEURONE; GENE-EXPRESSION; MAIZE ENDOSPERM; DNA FRAGMENTATION; APOPTOSIS; DEGRADATION; GERMINATION; MECHANISMS; CARBOXYPEPTIDASE; DIFFERENTIATION	The aleurone layer of cereal grains undergoes a gibberellin-regulated process of programmed cell death (PCD) following germination. We have applied a combination of ultrastructural and biochemical approaches to analyze aleurone PCD in intact wheat grains. The terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay revealed that PCD was initiated in aleurone cells proximal to the embryo and then extended to distal cells. DNA fragmentation and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling analysis revealed PCD of aleurone cells in maize grains, although the process was delayed as compared with wheat. Aleurone cells undergoing PCD showed a rapid vacuolation with high lytic activity in the cytoplasm, whereas the nucleus, which adopted an irregular shape, appeared essentially intact and showed symptoms of degradation at the end of the process. A nuclease activity was identified localized in the nucleus of aleurone cells undergoing PCD, just prior to the appearance of DNA laddering. This nuclease was induced by gibberellic acid treatment and was not detected when gibberellin synthesis was inhibited or in gibberellic acid-insensitive mutants. This nuclease was activated by Ca2+ and Mg2+, strongly inhibited by Zn2+, and showed optimum activity at neutral pH, resembling nucleases involved in apoptosis of animal cells.	Ctr Invest Cient Isla de la Cartuja, Inst Bioquim Vegetal & Fotosintesis, Seville 41092, Spain; Univ Seville, Fac Biol, Dept Biol Celular, E-41012 Seville, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-JA-USE - Centro de Investigaciones Cientificas Isla de La Cartuja (CICIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF); University of Sevilla	Cejudo, FJ (corresponding author), Ctr Invest Cient Isla de la Cartuja, Inst Bioquim Vegetal & Fotosintesis, Avda Amer Vespucio S-N, Seville 41092, Spain.	fjcejudo@us.es	Cejudo, Francisco Javier/M-2749-2014	Cejudo, Francisco Javier/0000-0002-3936-5491				ALNEMRI ES, 1989, J BIOL CHEM, V264, P4104; Appleford NEJ, 1997, PHYSIOL PLANTARUM, V100, P534, DOI 10.1034/j.1399-3054.1997.1000315.x; BAULCOMBE DC, 1987, J BIOL CHEM, V262, P13726; Becraft PW, 2000, DEVELOPMENT, V127, P4039; Bethke PC, 1996, PLANT PHYSIOL, V110, P521, DOI 10.1104/pp.110.2.521; Bethke PC, 1999, PLANT CELL, V11, P1033, DOI 10.1105/tpc.11.6.1033; Bethke PC, 1997, J EXP BOT, V48, P1337, DOI 10.1093/jxb/48.7.1337; Bethke PC, 1998, ANN BOT-LONDON, V82, P399, DOI 10.1006/anbo.1998.0702; Buckner B, 1998, TRENDS PLANT SCI, V3, P218, DOI 10.1016/S1360-1385(98)01254-0; Buckner B, 2000, PHYSIOL PLANTARUM, V108, P231, DOI 10.1034/j.1399-3054.2000.108003231.x; CEJUDO FJ, 1992, PLANT J, V2, P937; Counis MF, 2000, BIOCHEM CELL BIOL, V78, P405, DOI 10.1139/bcb-78-4-405; del Pozo O, 1998, CURR BIOL, V8, P1129, DOI 10.1016/S0960-9822(98)70469-5; Dominguez F, 2002, PLANTA, V215, P727, DOI 10.1007/s00425-002-0809-2; Dominguez F, 1999, PLANT PHYSIOL, V119, P81, DOI 10.1104/pp.119.1.81; Dominguez F, 1998, PLANT J, V15, P569, DOI 10.1046/j.1365-313X.1998.00233.x; Dominguez F, 2001, PLANTA, V213, P352, DOI 10.1007/s004250000517; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fath A, 1999, PLANT J, V20, P305, DOI 10.1046/j.1365-313X.1999.t01-2-00605.x; Fath A, 2000, PLANT MOL BIOL, V44, P255, DOI 10.1023/A:1026584207243; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; FLINTHAM JE, 1983, THEOR APPL GENET, V66, P249, DOI 10.1007/BF00251155; Gonzalez MC, 1998, PLANT PHYSIOL, V116, P1249, DOI 10.1104/pp.116.4.1249; Greenberg JT, 1996, P NATL ACAD SCI USA, V93, P12094, DOI 10.1073/pnas.93.22.12094; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Ito J, 2002, PLANT CELL, V14, P3201, DOI 10.1105/tpc.006411; Jones AM, 1996, TRENDS PLANT SCI, V1, P114, DOI 10.1016/S1360-1385(96)90005-9; Jones AM, 2001, PLANT PHYSIOL, V125, P94, DOI 10.1104/pp.125.1.94; KALINSKI A, 1986, J BIOL CHEM, V261, P1393; KERR JFR, 1995, METHOD CELL BIOL, V46, P1; Korthout HAAJ, 2000, FEBS LETT, V475, P139, DOI 10.1016/S0014-5793(00)01643-4; Kuo AL, 1996, PLANT CELL, V8, P259, DOI 10.1105/tpc.8.2.259; Kuriyama H, 2002, CURR OPIN PLANT BIOL, V5, P568, DOI 10.1016/S1369-5266(02)00305-9; Lam E, 1999, CURR OPIN PLANT BIOL, V2, P502, DOI 10.1016/S1369-5266(99)00026-6; Martins LM, 1997, TRENDS CELL BIOL, V7, P111; Marty F, 1999, PLANT CELL, V11, P587, DOI 10.1105/tpc.11.4.587; MITTLER R, 1995, PLANT CELL, V7, P29, DOI 10.1105/tpc.7.1.29; MORRISON IN, 1978, PLANTA, V140, P19, DOI 10.1007/BF00389375; NORSTOG K, 1974, BOT GAZ, V135, P97, DOI 10.1086/336736; Obara K, 2001, PLANT PHYSIOL, V125, P615, DOI 10.1104/pp.125.2.615; Orzaez D, 1997, PLANT J, V11, P137, DOI 10.1046/j.1365-313X.1997.11010137.x; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; Pennell RI, 1997, PLANT CELL, V9, P1157, DOI 10.1105/tpc.9.7.1157; Rademacher W, 2000, ANNU REV PLANT PHYS, V51, P501, DOI 10.1146/annurev.arplant.51.1.501; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; Skadsen RW, 1998, PHYSIOL PLANTARUM, V104, P486, DOI 10.1034/j.1399-3054.1998.1040326.x; Sugiyama M, 2000, PLANT MOL BIOL, V44, P387, DOI 10.1023/A:1026504911786; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; Swanson SJ, 1998, PLANT CELL, V10, P685, DOI 10.1105/tpc.10.5.685; TILLY JL, 1993, J CELL PHYSIOL, V154, P519, DOI 10.1002/jcp.1041540310; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; WANG HL, 1994, PROTOPLASMA, V182, P39, DOI 10.1007/BF01403687; Wang M, 1998, J EXP BOT, V49, P1293, DOI 10.1093/jexbot/49.325.1293; Wang M, 1996, PLANT MOL BIOL, V32, P1125, DOI 10.1007/BF00041396; Woltering EJ, 2002, PLANT PHYSIOL, V130, P1764, DOI 10.1104/pp.006338; Young TE, 1997, PLANT PHYSIOL, V115, P737, DOI 10.1104/pp.115.2.737; Young TE, 2000, PLANT MOL BIOL, V42, P397, DOI 10.1023/A:1006333103342; Young TE, 1999, PLANT MOL BIOL, V39, P915, DOI 10.1023/A:1006134027834; Zamzami N, 1999, NATURE, V401, P127, DOI 10.1038/43591	60	62	67	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11530	11536		10.1074/jbc.M308082200	http://dx.doi.org/10.1074/jbc.M308082200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699134	Green Published, hybrid			2022-12-25	WOS:000220157600085
J	Lambert, O; Cavusoglu, N; Gallay, J; Vincent, M; Rigaud, JL; Henry, JP; Ayala-Sanmartin, J				Lambert, O; Cavusoglu, N; Gallay, J; Vincent, M; Rigaud, JL; Henry, JP; Ayala-Sanmartin, J			Novel organization and properties of annexin 2-membrane complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIME-RESOLVED FLUORESCENCE; TRYPTOPHAN RESIDUE TRP-59; SITE-DIRECTED MUTAGENESIS; HEART APOCYTOCHROME-C; PHOSPHOLIPID-BINDING; CRYSTAL-STRUCTURE; MEMBRANE-BINDING; VESICLE AGGREGATION; CALPACTIN-I; MOLECULAR CHARACTERIZATION	Annexin 2 belongs to the annexin family of proteins that bind to phospholipid membranes in a Ca2+-dependent manner. Here we show that, under mild acidic conditions, annexin 2 binds to and aggregates membranes containing anionic phospholipids, a fact that questions the mechanism of its interaction with membranes via Ca2+ bridges only. The H+ sensitivity of annexin 2-mediated aggregation is modulated by lipid composition (i.e. cholesterol content). Cryo-electron microscopy of aggregated liposomes revealed that both the monomeric and the tetrameric forms of the protein form bridges between the liposomes at acidic pH. Monomeric annexin 2 induced two different organizations of the membrane junctions. The first resembled that obtained at pH 7 in the presence of Ca2+. For the tetramer, the arrangement was different. These bridges seemed more flexible than the Ca2+-mediated junctions allowing the invagination of membranes. Time-resolved fluorescence analysis at mild acidic pH and the measurement of Stokes radius revealed that the protein undergoes conformational changes similar to those induced by Ca2+. Labeling with the lipophilic probe 3-(trifluoromethyl)-3-(m-[I-125]iodophenyl)diazirine indicated that the protein has access to the hydrophobic part of the membrane at both acidic pH in the absence of Ca2+ and at neutral pH in the presence of Ca2+. Models for the membrane interactions of annexin 2 at neutral pH in the presence of Ca2+ and at acidic pH are discussed.	CHU St Antoine, INSERM, U538, F-75012 Paris, France; CNRS, Inst Biol Physicochim, UPR 1929, Unite Biol Cellulaire & Mol Secret, F-75005 Paris, France; CNRS, Inst Curie, F-75005 Paris, France; Univ Paris 11, CNRS, Lab Utilisat Rayonnement Electromagnet, F-91898 Orsay, France; Hop St Antoine, INSERM, U592, Lab Physiopathol Cellulaire & Mol Retine, F-75012 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Ayala-Sanmartin, J (corresponding author), CHU St Antoine, INSERM, U538, 27 Rue Chaligny, F-75012 Paris, France.	jayala@chusa.jussieu.fr		Lambert, Olivier/0000-0002-5651-8082; Cavusoglu, Nukhet/0000-0001-9350-5312				Ayala-Sanmartin J, 2001, BIOCHEM BIOPH RES CO, V283, P72, DOI 10.1006/bbrc.2001.4748; Ayala-Sanmartin J, 2001, BBA-BIOMEMBRANES, V1510, P18, DOI 10.1016/S0005-2736(00)00262-5; Ayala-Sanmartin J, 2000, BIOCHEMISTRY-US, V39, P15179, DOI 10.1021/bi000501x; Ayala-Sanmartin J, 2000, BIOCHEMISTRY-US, V39, P15190, DOI 10.1021/bi000764r; BECKER T, 1990, EMBO J, V9, P4207, DOI 10.1002/j.1460-2075.1990.tb07868.x; Bitto E, 2000, BIOCHEMISTRY-US, V39, P13469, DOI 10.1021/bi001275u; BLACKWOOD RA, 1990, BIOCHEM J, V266, P195, DOI 10.1042/bj2660195; Brazill DT, 2000, J BIOL CHEM, V275, P19231, DOI 10.1074/jbc.M000900200; BROCHON JC, 1994, METHOD ENZYMOL, V240, P262; Burger A, 1996, J MOL BIOL, V257, P839, DOI 10.1006/jmbi.1996.0205; Campos B, 1998, BIOCHEMISTRY-US, V37, P8004, DOI 10.1021/bi973142n; CONCHA NO, 1993, SCIENCE, V261, P1321, DOI 10.1126/science.8362244; Corsico B, 2001, J BIOL CHEM, V276, P16978, DOI 10.1074/jbc.M011533200; CREUTZ CE, 1981, J CELL BIOL, V91, P247, DOI 10.1083/jcb.91.1.247; Davletov B, 1998, J BIOL CHEM, V273, P19093, DOI 10.1074/jbc.273.30.19093; DELAFUENTE M, 1995, BIOCHEMISTRY-US, V34, P10393, DOI 10.1021/bi00033a010; DESJARDINS M, 1994, J BIOL CHEM, V269, P32194; DRUST DS, 1991, J NEUROCHEM, V56, P469, DOI 10.1111/j.1471-4159.1991.tb08174.x; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; ERNST JD, 1991, J BIOL CHEM, V266, P6670; Faigle W, 1998, J CELL BIOL, V141, P1121, DOI 10.1083/jcb.141.5.1121; Faure AV, 2002, EXP CELL RES, V276, P79, DOI 10.1006/excr.2002.5512; GENGE BR, 1991, J BIOL CHEM, V266, P10678; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; GERKE V, 1985, J BIOL CHEM, V260, P1688; GLENNEY JR, 1987, J CELL BIOL, V104, P503, DOI 10.1083/jcb.104.3.503; Golczak Marcin, 2001, FASEB Journal, V15, P1083; Goldmann WH, 1999, EUR J BIOCHEM, V261, P155, DOI 10.1046/j.1432-1327.1999.00259.x; HOEKSTRA D, 1993, BIOCHEMISTRY-US, V32, P14194, DOI 10.1021/bi00214a019; Isas JM, 2000, BIOCHEMISTRY-US, V39, P3015, DOI 10.1021/bi9922401; Johnson JE, 1997, BBA-BIOMEMBRANES, V1324, P273, DOI 10.1016/S0005-2736(96)00233-7; JOHNSSON N, 1988, EMBO J, V7, P2435, DOI 10.1002/j.1460-2075.1988.tb03089.x; JONES PG, 1994, BIOCHEMISTRY-US, V33, P13751, DOI 10.1021/bi00250a028; Jost M, 1997, J CELL SCI, V110, P221; Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639; Kohler G, 1997, BIOCHEMISTRY-US, V36, P8189, DOI 10.1021/bi9703960; Lambert O, 1997, J MOL BIOL, V272, P42, DOI 10.1006/jmbi.1997.1183; Langen R, 1998, P NATL ACAD SCI USA, V95, P14060, DOI 10.1073/pnas.95.24.14060; Lee KH, 1999, FEBS LETT, V442, P143, DOI 10.1016/S0014-5793(98)01643-3; Liu L, 1999, CELL SIGNAL, V11, P317, DOI 10.1016/S0898-6568(98)00047-3; MEERS P, 1990, BIOCHEMISTRY-US, V29, P3325, DOI 10.1021/bi00465a025; Montaville P, 2002, J BIOL CHEM, V277, P24684, DOI 10.1074/jbc.M109595200; Oling F, 2000, J MOL BIOL, V304, P561, DOI 10.1006/jmbi.2000.4183; Otto JC, 1996, J BIOL CHEM, V271, P9906, DOI 10.1074/jbc.271.17.9906; PIGAULT C, 1990, BIOCHIM BIOPHYS ACTA, V1037, P106, DOI 10.1016/0167-4838(90)90108-R; POWELL MA, 1987, BIOCHEM J, V247, P321, DOI 10.1042/bj2470321; Ramirez MA, 2000, J MEMBRANE BIOL, V177, P149, DOI 10.1007/s002320001108; Rety S, 1999, NAT STRUCT BIOL, V6, P89; Rosengarth A, 1998, FEBS LETT, V438, P279, DOI 10.1016/S0014-5793(98)01318-0; Rosengarth A, 1999, J MOL BIOL, V288, P1013, DOI 10.1006/jmbi.1999.2732; SETOYOUNG D, 1992, BIOCHIM BIOPHYS ACTA, V1102, P213, DOI 10.1016/0167-4838(92)90512-C; SOPKOVA J, 1994, BIOCHEMISTRY-US, V33, P4490, DOI 10.1021/bi00181a008; SOPKOVA J, 1993, J MOL BIOL, V234, P816, DOI 10.1006/jmbi.1993.1627; Sopkova J, 1998, BIOCHEMISTRY-US, V37, P11962, DOI 10.1021/bi980773o; Souza MM, 2000, MOL CELL BIOCHEM, V210, P173, DOI 10.1023/A:1007154412805; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968; Thery C, 1999, J CELL BIOL, V147, P599, DOI 10.1083/jcb.147.3.599; THIEL C, 1991, J BIOL CHEM, V266, P14732; VINCENT M, 1995, J PHYS CHEM-US, V99, P14931, DOI 10.1021/j100041a006; VINCENT M, 1988, BIOCHEMISTRY-US, V27, P8752, DOI 10.1021/bi00424a010; VINCENT M, 1991, EUR BIOPHYS J, V20, P183, DOI 10.1007/BF01561141; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592	63	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10872	10882		10.1074/jbc.M313657200	http://dx.doi.org/10.1074/jbc.M313657200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701819	hybrid			2022-12-25	WOS:000220157600008
J	Leu, TH; Yeh, HH; Huang, CC; Chuang, YC; Su, SL; Maa, MC				Leu, TH; Yeh, HH; Huang, CC; Chuang, YC; Su, SL; Maa, MC			Participation of p97(Eps8) in Src-mediated transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; HISTONE DEACETYLASE INHIBITOR; TYROSINE KINASE SUBSTRATE; TRICHOSTATIN-A; MORPHOLOGICAL REVERSION; WAF1/CIP1 GENE; EPS8; EXPRESSION; CELLS; PHOSPHORYLATION	Histone acetylase and histone deacetylase are two crucial enzymes that determine the structure of chromatin, regulating gene expression. In this study, we observed that trichostatin A (TSA), a specific histone deacetylase inhibitor, could effectively inhibit the growth of v-Src-transformed (IV5) cells and abrogate their ability to form colonies in soft agar. Further analysis demonstrated that, although TSA reduced the expression of Eps8 in a dose- and time-dependent manner, both the protein expression and kinase activity of v-Src remained constant, and the abundance and phosphotyrosine levels of Src substrates, including cortactin, focal adhesion kinase, p130(Cas), paxillin, and Shc, were not altered. Notably, removal of TSA from the medium restored not only the expression of Eps8, but also cellular growth. Northern and reverse transcription-PCR analyses revealed the significant reduction of eps8 transcripts in TSA-treated IV5 cells relative to control cells. When active Src-expressing chicken embryonic cells were forced to overexpress p97(Eps8), they became resistant to TSA-mediated anti-proliferation. Furthermore, using small interference RNA of eps8, we demonstrated the requirement for Eps8 in IV5 cell proliferation. Thus, our results highlight a critical role for p97(Eps8) in TSA-exerted growth inhibition of v-Src-transformed cells.	Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan; Chung Shan Med Univ, Inst Biochem, Taichung 402, Taiwan	National Cheng Kung University; Chung Shan Medical University	Maa, MC (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan.	mc1331@csmc.edu.tw	Hsu, Kuei-Sen/AAV-8386-2021					Aalfs JD, 2000, TRENDS BIOCHEM SCI, V25, P548, DOI 10.1016/S0968-0004(00)01689-3; ARTS J, 1995, BIOCHEM J, V310, P171, DOI 10.1042/bj3100171; Biesova Z, 1997, ONCOGENE, V14, P233, DOI 10.1038/sj.onc.1200822; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FUTAMURA M, 1995, ONCOGENE, V10, P1119; Gallo R, 1997, ONCOGENE, V15, P1929, DOI 10.1038/sj.onc.1201344; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; KARLSSON T, 1995, ONCOGENE, V10, P1475; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Kim Y, 2003, ONCOGENE, V22, P826, DOI 10.1038/sj.onc.1206068; Kostyniuk CL, 2002, ONCOGENE, V21, P6340, DOI 10.1038/sj.onc.1205787; Kwon HJ, 1998, P NATL ACAD SCI USA, V95, P3356, DOI 10.1073/pnas.95.7.3356; Lanzetti L, 2000, NATURE, V408, P374, DOI 10.1038/35042605; Leu TH, 2002, ONCOGENE, V21, P6992, DOI 10.1038/sj.onc.1205904; Luo RX, 1999, J NATL CANCER I, V91, P1288, DOI 10.1093/jnci/91.15.1288; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1992, ONCOGENE, V7, P2429; Maa MC, 1998, BIOCHEM BIOPH RES CO, V251, P344, DOI 10.1006/bbrc.1998.9464; Maa MC, 1999, BBA-MOL CELL RES, V1450, P341, DOI 10.1016/S0167-4889(99)00069-5; Maa MC, 2001, ONCOGENE, V20, P106, DOI 10.1038/sj.onc.1204069; Mariadason JM, 2000, CANCER RES, V60, P4561; Matoskova B, 1996, ONCOGENE, V12, P2679; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; MIYASHITA T, 1994, FEBS LETT, V353, P225, DOI 10.1016/0014-5793(94)01034-X; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Rombouts K, 2002, J HEPATOL, V37, P788, DOI 10.1016/S0168-8278(02)00275-1; Rombouts K, 2002, EXP CELL RES, V278, P184, DOI 10.1006/excr.2002.5577; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; SUGITA K, 1992, CANCER RES, V52, P168; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; TSUJI N, 1976, J ANTIBIOT, V29, P1, DOI 10.7164/antibiotics.29.1; Vigushin DM, 2001, CLIN CANCER RES, V7, P971; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; WONG WT, 1994, ONCOGENE, V9, P3057; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	42	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9875	9881		10.1074/jbc.M309884200	http://dx.doi.org/10.1074/jbc.M309884200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699156	hybrid			2022-12-25	WOS:000220050400027
J	Xiong, HB; Zhu, C; Li, FL; Hegazi, R; He, KL; Babyatsky, M; Bauer, AJ; Plevy, SE				Xiong, HB; Zhu, C; Li, FL; Hegazi, R; He, KL; Babyatsky, M; Bauer, AJ; Plevy, SE			Inhibition of interleukin-12 p40 transcription and NF-kappa B activation by nitric oxide in murine macrophages and dendritic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; BLOOD MONONUCLEAR-CELLS; IFN-GAMMA PRODUCTION; MOUSE BONE-MARROW; MICE LACKING; T-CELLS; IL-12; GENE; EXPRESSION; MECHANISMS	Nitric oxide ( NO), an important effector molecule of the innate immune system, can also regulate adaptive immunity. In this study, the molecular effects of NO on the toll-like receptor signaling pathway were determined using interleukin-12 (IL-12) as an immunologically relevant target gene. The principal conclusion of these experiments is that NO inhibits IL-1 receptor-associated kinase ( IRAK) activity and attenuates the molecular interaction between tumor necrosis factor receptor-associated factor-6 and IRAK. As a consequence, the NO donor S-nitroso-N-acetylpenicillamine ( SNAP) inhibits lipopolysaccharide (LPS)-induced IL-12 p40 mRNA expression, protein production, and promoter activity in murine macrophages, dendritic cells, and the murine macrophage cell line RAW 264.7. Splenocytes from inducible nitric-oxide synthase-deficient mice demonstrate markedly increased IL-12 p40 protein and mRNA expression compared with wild type splenocytes. The inhibitory action of NO on IL-12 p40 is independent of the cytokine IL-10. The effects of NO can be directly attributed to inhibition of NF-kappaB activation through IRAK-dependent pathways. Accordingly, SNAP strongly reduces LPS-induced NF-kappaB DNA binding to the p40 promoter and inhibits LPS-induced IkappaB phosphorylation. Similarly, NO attenuates IL-1beta-induced NF-kappaB activation. These experiments provide another example of how an innate immune molecule may have a profound effect on adaptive immunity.	Univ Pittsburgh, Sch Med, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15261 USA; Mt Sinai Sch Med, Immunobiol Ctr, New York, NY 10029 USA; Mt Sinai Sch Med, Div Gastroenterol, New York, NY 10029 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Plevy, SE (corresponding author), Univ Pittsburgh, Sch Med, Div Gastroenterol Hepatol & Nutr, Scaife Hall,Rm S566,3550 Terrace St, Pittsburgh, PA 15261 USA.	sep1@pitt.edu	Hegazi, Refaat A./AAR-4026-2021; Hegazi, Refaat/ABG-4179-2020					Aste-Amezaga M, 1998, J IMMUNOL, V160, P5936; Bogdan C, 1998, J EXP MED, V187, P1361, DOI 10.1084/jem.187.9.1361; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; Fenyk-Melody JE, 1998, J IMMUNOL, V160, P2940; GUBLER U, 1991, P NATL ACAD SCI USA, V88, P4143, DOI 10.1073/pnas.88.10.4143; Huang FP, 1998, EUR J IMMUNOL, V28, P4062, DOI 10.1002/(SICI)1521-4141(199812)28:12<4062::AID-IMMU4062>3.0.CO;2-K; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Kwak HJ, 2001, MOL CELLS, V12, P178; La EH, 2001, J IMMUNOL, V166, P6149, DOI 10.4049/jimmunol.166.10.6149; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; LANDER HM, 1993, J IMMUNOL, V150, P1509; Liu JJ, 2003, J IMMUNOL, V170, P4489, DOI 10.4049/jimmunol.170.9.4489; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; MacLean A, 1998, J GEN VIROL, V79, P825, DOI 10.1099/0022-1317-79-4-825; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; MONCADA S, 1991, PHARMACOL REV, V43, P109; MURPHY TL, 1995, MOL CELL BIOL, V15, P5258; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; Nazarenko I, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e37; Niedbala W, 2002, P NATL ACAD SCI USA, V99, P16186, DOI 10.1073/pnas.252464599; PENG HB, 1995, J BIOL CHEM, V270, P17050, DOI 10.1074/jbc.270.28.17050; Plevy SE, 1997, MOL CELL BIOL, V17, P4572, DOI 10.1128/MCB.17.8.4572; Sanjabi S, 2000, P NATL ACAD SCI USA, V97, P12705, DOI 10.1073/pnas.230436397; SCHOENHAUT DS, 1992, J IMMUNOL, V148, P3433; Seder RA, 1996, J IMMUNOL, V157, P2745; Swantek JL, 2000, J IMMUNOL, V164, P4301, DOI 10.4049/jimmunol.164.8.4301; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; WOLF SF, 1991, J IMMUNOL, V146, P3074; Xiong HB, 1996, CELL IMMUNOL, V172, P118, DOI 10.1006/cimm.1996.0222; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Zhu C, 2001, J BIOL CHEM, V276, P18519, DOI 10.1074/jbc.M100440200	36	86	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10776	10783		10.1074/jbc.M313416200	http://dx.doi.org/10.1074/jbc.M313416200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14679201	hybrid			2022-12-25	WOS:000220050400133
J	Filipenko, NR; MacLeod, TJ; Yoon, CS; Waisman, DM				Filipenko, NR; MacLeod, TJ; Yoon, CS; Waisman, DM			Annexin A2 is a novel RNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT EXOCYTOSIS; ROUS-SARCOMA-VIRUS; C-MYC ONCOGENE; CALPACTIN-I; HEAVY-CHAIN; LIGHT-CHAIN; PHOSPHOLIPID-BINDING; ENHANCED EXPRESSION; CELLULAR SUBSTRATE; KINASE SUBSTRATE	Annexin A2 (ANXA2) is a Ca2+-binding protein that is up-regulated in virally transformed cell lines and in human tumors. Here, we show that ANXA2 binds directly to both ribonucleotide homopolymers and human c-myc RNA. ANXA2 was shown to bind specifically to poly( G) with high affinity (K-d = 60 nM) and not to poly( A), poly( C), or poly( U). The binding of ANXA2 to poly( G) required Ca2+ (A(50%) = 10 muM). The presence of RNA in the immunoprecipitates of ANXA2 isolated from HeLa cells established that ANXA2 formed a ribonucleoprotein complex in vivo. Sucrose gradient analysis showed that ANXA2 associates with ribonucleoprotein complexes and not with polyribosomes. Reverse transcriptase-PCR identified c-myc mRNA as a component of the ribonucleoprotein complex formed by ANXA2 in vivo, and binding studies confirmed a direct interaction between ANXA2 and c-myc mRNA. Transfection of LNCaP cells with the ANXA2 gene resulted in the up-regulation of c-Myc protein. These findings identify ANXA2 as a Ca2+-dependent RNA-binding protein that interacts with the mRNA of the nuclear oncogene, c-myc.	Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Oncol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	Waisman, DM (corresponding author), Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Canc Biol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	waisman@ucalgary.ca		Waisman, David/0000-0002-5097-9662	NCI NIH HHS [R01CA 78639] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078639] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI SM, 1989, NATURE, V340, P313, DOI 10.1038/340313a0; ALI SM, 1990, CELL SIGNAL, V2, P265, DOI 10.1016/0898-6568(90)90054-E; ARANY I, 1994, SURG ONCOL, V3, P153, DOI 10.1016/0960-7404(94)90044-2; ARRIGO AP, 1983, EMBO J, V2, P309, DOI 10.1002/j.1460-2075.1983.tb01424.x; Ayala-Sanmartin J, 2000, BIOCHEMISTRY-US, V39, P15190, DOI 10.1021/bi000764r; Babiychuk EB, 2000, J CELL BIOL, V150, P1113, DOI 10.1083/jcb.150.5.1113; Babiychuk EB, 2002, FASEB J, V16, DOI 10.1096/fj.02-0070com; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; BOYKO V, 1994, FEBS LETT, V345, P139, DOI 10.1016/0014-5793(94)00419-6; Brown V, 1998, J BIOL CHEM, V273, P15521, DOI 10.1074/jbc.273.25.15521; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1991, MOL CELL BIOL, V11, P3419, DOI 10.1128/MCB.11.7.3419; Burger A, 1996, J MOL BIOL, V257, P839, DOI 10.1006/jmbi.1996.0205; BURGOYNE RD, 1988, NATURE, V331, P20, DOI 10.1038/331020a0; Chetcuti A, 2001, CANCER RES, V61, P6331; CHU E, 1995, MOL CELL BIOL, V15, P179, DOI 10.1128/MCB.15.1.179; COURTNEIDGE S, 1983, MOL CELL BIOL, V3, P340, DOI 10.1128/MCB.3.3.340; Doyle GAR, 1998, NUCLEIC ACIDS RES, V26, P5036, DOI 10.1093/nar/26.22.5036; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Eberhard DA, 2001, J CELL SCI, V114, P3155; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; Emoto K, 2001, ANTICANCER RES, V21, P1339; ERIKSON E, 1980, CELL, V21, P829, DOI 10.1016/0092-8674(80)90446-8; ERIKSON E, 1984, MOL CELL BIOL, V4, P77, DOI 10.1128/MCB.4.1.77; Filipenko NR, 2003, MOL B INT U, P127; FROHLICH M, 1990, MOL CELL BIOL, V10, P3216, DOI 10.1128/MCB.10.6.3216; GERKE V, 1985, EMBO J, V4, P2917, DOI 10.1002/j.1460-2075.1985.tb04023.x; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; GLENNEY JR, 1985, P NATL ACAD SCI USA, V82, P7884, DOI 10.1073/pnas.82.23.7884; HARDER T, 1993, J CELL BIOL, V123, P1119, DOI 10.1083/jcb.123.5.1119; Herms JW, 1999, SURG NEUROL, V51, P536, DOI 10.1016/S0090-3019(98)00028-7; JINDAL HK, 1991, J BIOL CHEM, V266, P5169; KEITH G, 1983, BIOCHIMIE, V65, P367, DOI 10.1016/S0300-9084(83)80159-X; Kenmochi N, 1998, GENOME RES, V8, P509, DOI 10.1101/gr.8.5.509; KEUTZER JC, 1990, EXP CELL RES, V188, P153, DOI 10.1016/0014-4827(90)90291-H; KHANNA NC, 1990, BIOCHEMISTRY-US, V29, P4852, DOI 10.1021/bi00472a015; KRISHNA P, 1990, P NATL ACAD SCI USA, V87, P1292, DOI 10.1073/pnas.87.4.1292; KROWCZYNSKA AM, 1989, NUCLEIC ACIDS RES, V17, P6408, DOI 10.1093/nar/17.15.6408; LENS D, 1994, LEUKEMIA, V8, P2102; Menell JS, 1999, NEW ENGL J MED, V340, P994, DOI 10.1056/NEJM199904013401303; Okuse K, 2002, NATURE, V417, P653, DOI 10.1038/nature00781; OZAKI T, 1993, ONCOGENE, V8, P1707; POWELL MA, 1987, BIOCHEM J, V247, P321, DOI 10.1042/bj2470321; RADKE K, 1979, P NATL ACAD SCI USA, V76, P5212, DOI 10.1073/pnas.76.10.5212; REEVES SA, 1992, CANCER RES, V52, P6871; SALEHI Z, 1990, J IMMUNOL, V145, P276; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; Schleger C, 2002, MODERN PATHOL, V15, P462, DOI 10.1038/modpathol.3880547; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; Vedeler A, 2000, BIOCHEM J, V348, P565, DOI 10.1042/0264-6021:3480565; VISHWANATHA JK, 1993, CARCINOGENESIS, V14, P2575, DOI 10.1093/carcin/14.12.2575; VISHWANATHA JK, 1992, J CELL SCI, V101, P25; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; WANG MY, 1992, NUCLEIC ACIDS RES, V20, P3519, DOI 10.1093/nar/20.13.3519; West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990; Zalfa F, 2003, CELL, V112, P317, DOI 10.1016/S0092-8674(03)00079-5; Zeuschner D, 2001, EUR J CELL BIOL, V80, P499, DOI 10.1078/0171-9335-00184; ZINN AR, 1994, MOL CELL BIOL, V14, P2485, DOI 10.1128/MCB.14.4.2485; ZOKAS L, 1987, J CELL BIOL, V105, P2111, DOI 10.1083/jcb.105.5.2111	60	108	121	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8723	8731		10.1074/jbc.M311951200	http://dx.doi.org/10.1074/jbc.M311951200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14672933	hybrid			2022-12-25	WOS:000189265900025
J	Hegazy, UM; Mannervik, B; Stenberg, G				Hegazy, UM; Mannervik, B; Stenberg, G			Functional role of the lock and key motif at the subunit interface of glutathione transferase P1-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; HELIX-COIL TRANSITION; INDUCED-FIT MECHANISM; S-TRANSFERASES; CLASS-PI; 3-DIMENSIONAL STRUCTURE; CATALYTIC MECHANISM; SULFHYDRYL-GROUP; ENTHALPY CHANGE; HUMAN PLACENTA	The glutathione transferases (GSTs) represent a superfamily of dimeric proteins. Each subunit has an active site, but there is no evidence for the existence of catalytically active monomers. The lock and key motif is responsible for a highly conserved hydrophobic interaction in the subunit interface of pi, mu, and alpha class glutathione transferases. The key residue, which is either Phe or Tyr (Tyr(50) in human GSTP1-1) in one subunit, is wedged into a hydrophobic pocket of the other subunit. To study how an essentially inactive subunit influences the activity of the neighboring subunit, we have generated the heterodimer composed of subunits from the fully active human wild-type GSTP1-1 and the nearly inactive mutant Y50A obtained by mutation of the key residue Tyr(50) to Ala. Although the key residue is located far from the catalytic center, the k(cat) value of mutant Y50A decreased about 1300-fold in comparison with the wild-type enzyme. The decrease of the kcat value of the heterodimer by about 27-fold rather than the expected 2-fold in comparison with the wild-type enzyme indicates that the two active sites of the dimeric enzyme work synergistically. Further evidence for cooperativity was found in the nonhyperbolic GSH saturation curves. A network of hydrogen-bonded water molecules, found in crystal structures of GSTP1-1, connects the two active sites and the main chain carbonyl group of Tyr50, thereby offering a mechanism for communication between the two active sites. It is concluded that a subunit becomes catalytically competent by positioning the key residue of one subunit into the lock pocket of the other subunit, thereby stabilizing the loop following the helix alpha2, which interacts directly with GSH.	Uppsala Univ, Ctr Biomed, Dept Biochem, SE-75123 Uppsala, Sweden	Uppsala University	Stenberg, G (corresponding author), Uppsala Univ, Ctr Biomed, Dept Biochem, Box 576, SE-75123 Uppsala, Sweden.	gun.stenberg@biokem.uu.se	Hegazy, Usama/E-4066-2010; Hegazy, Usama/H-3568-2019	Hegazy, Usama/0000-0002-3611-0792				Abdalla AM, 2002, PROTEIN ENG, V15, P827, DOI 10.1093/protein/15.10.827; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; BARDSLEY WG, 1995, COMPUT CHEM, V19, P75, DOI 10.1016/0097-8485(95)00007-F; Board PG, 1997, BIOCHEM J, V328, P929; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; BOYER TD, 1989, HEPATOLOGY, V9, P486, DOI 10.1002/hep.1840090324; BUETLER TM, 1992, J ENVIRON SCI HEAL C, V10, P181; Caccuri AM, 1999, J BIOL CHEM, V274, P19276, DOI 10.1074/jbc.274.27.19276; CHOU PY, 1971, BIOPOLYMERS, V10, P657, DOI 10.1002/bip.360100406; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; GARCIASAEZ I, 1994, J MOL BIOL, V237, P298, DOI 10.1006/jmbi.1994.1232; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HAYES JD, 1988, GLUTATHIONE CONJUGAT, P316; Hitchens TK, 2001, BIOCHEMISTRY-US, V40, P11660, DOI 10.1021/bi010909+; Hornby JAT, 2002, BIOCHEMISTRY-US, V41, P14238, DOI 10.1021/bi020548d; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; KOLM RH, 1995, PROTEIN EXPRES PURIF, V6, P265, DOI 10.1006/prep.1995.1034; Lo Bello M, 1998, J MOL BIOL, V284, P1717; LOBELLO M, 1993, BIOCHEM BIOPH RES CO, V194, P804, DOI 10.1006/bbrc.1993.1893; LOBELLO M, 1990, FEBS LETT, V263, P389, DOI 10.1016/0014-5793(90)81421-J; LOBELLO M, 1995, J BIOL CHEM, V270, P1249; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1992, BIOCHEM J, V282, P305, DOI 10.1042/bj2820305; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Mannervik B., 1978, CONJUGATION REACTION, P101; MEYER DJ, 1995, BIOCHEM J, V311, P739, DOI 10.1042/bj3110739; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; Oakley AJ, 1998, BIOCHEMISTRY-US, V37, P9912, DOI 10.1021/bi980323w; Oakley AJ, 1997, J MOL BIOL, V274, P84, DOI 10.1006/jmbi.1997.1364; Pemble SE, 1996, BIOCHEM J, V319, P749, DOI 10.1042/bj3190749; Pickett C.B., 1989, ANNU REV BIOCHEM, V58, P734; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; RIALDI G, 1966, J AM CHEM SOC, V88, P5719, DOI 10.1021/ja00976a007; RICCI G, 1991, J BIOL CHEM, V266, P21409; RICCI G, 1995, J BIOL CHEM, V270, P1243, DOI 10.1074/jbc.270.3.1243; Ricci G, 1996, J BIOL CHEM, V271, P16187, DOI 10.1074/jbc.271.27.16187; Rossjohn J, 1998, STRUCT FOLD DES, V6, P721, DOI 10.1016/S0969-2126(98)00074-4; Sayed Y, 2000, FEBS LETT, V465, P169, DOI 10.1016/S0014-5793(99)01747-0; SCHOLTZ JM, 1991, P NATL ACAD SCI USA, V88, P2854, DOI 10.1073/pnas.88.7.2854; SHEN H, 1991, ARCH BIOCHEM BIOPHYS, V286, P178, DOI 10.1016/0003-9861(91)90025-E; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; Stella L, 1999, PROTEINS, V37, P1; Stenberg G, 2000, BIOCHEM BIOPH RES CO, V271, P59, DOI 10.1006/bbrc.2000.2579; TAHIR MK, 1985, FEBS LETT, V181, P249; TAHIR MK, 1986, J BIOL CHEM, V261, P1048; TAMAI K, 1990, BIOCHEM BIOPH RES CO, V167, P331, DOI 10.1016/0006-291X(90)91769-O; Vargo MA, 2001, BIOCHEMISTRY-US, V40, P8624; WAXMAN DJ, 1990, CANCER RES, V50, P6449; WILCE MCJ, 1994, BBA-PROTEIN STRUCT M, V1205, P1, DOI 10.1016/0167-4838(94)90086-8	51	43	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9586	9596		10.1074/jbc.M312320200	http://dx.doi.org/10.1074/jbc.M312320200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676193	hybrid			2022-12-25	WOS:000189265900126
J	Padmanabhan, B; Kuzuhara, T; Adachi, N; Horikoshi, M				Padmanabhan, B; Kuzuhara, T; Adachi, N; Horikoshi, M			The crystal structure of CCG1/TAF(II)250-interacting factor B (CIB)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE ACTIVITY; TRANSCRIPTION FACTOR ATF; TATA-BINDING PROTEIN; ALPHA/BETA-HYDROLASE; HUMAN TAF(II)250; DNA-BINDING; INITIATION; NUCLEOSOME; ACETYLATION; PROMOTER	The general transcription initiation factor TFIID and its interactors play critical roles in regulating the transcription from both naked and chromatin DNA. We have isolated a novel TFIID interactor that we denoted as CCG1/TAF(II)250-interacting factor B (CIB). We show here that CIB activates transcription. To further understand the function of this protein, we determined its crystal structure at 2.2-Angstrom resolution. The tertiary structure of CIB reveals an alpha/beta-hydrolase fold that resembles structures in the prokaryotic alpha/beta-hydrolase family proteins. It is not similar in structure or primary sequence to any eukaryotic transcription or chromatin factors that have been reported to date. CIB possesses a conserved catalytic triad that is found in other alpha/beta-hydrolases, and our in vitro studies confirmed that it bears hydrolase activity. However, CIB differs from other alpha/beta-hydrolases in that it lacks a binding site excursion, which facilitates the substrate selectivity of the other alpha/beta-hydrolases. Further functional characterization of CIB based on its tertiary structure and through biochemical studies may provide novel insights into the mechanisms that regulate eukaryotic transcription.	Japan Sci & Technol Corp, Exploratory Res Adv Technol, Horikoshi Gene Selector Project, Tsukuba, Ibaraki 3002635, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Dev Biol Lab, Bunkyo Ku, Tokyo 1130032, Japan	Japan Science & Technology Agency (JST); University of Tokyo	Horikoshi, M (corresponding author), Japan Sci & Technol Corp, Exploratory Res Adv Technol, Horikoshi Gene Selector Project, 5-9-6 Tokodai, Tsukuba, Ibaraki 3002635, Japan.	horikosh@iam.u-tokyo.ac.jp		Kuzuhara, Takashi/0000-0003-0565-6060				Adachi N, 2002, J BIOL CHEM, V277, P35688, DOI 10.1074/jbc.M204640200; Akey CW, 2003, CURR OPIN STRUC BIOL, V13, P6, DOI 10.1016/S0959-440X(03)00002-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bando M, 1997, J BIOCHEM-TOKYO, V121, P591; Birck C, 1998, CELL, V94, P239, DOI 10.1016/S0092-8674(00)81423-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; Chimura T, 2002, P NATL ACAD SCI USA, V99, P9334, DOI 10.1073/pnas.142627899; CRAIK CS, 1987, SCIENCE, V237, P909, DOI 10.1126/science.3303334; CYGLER M, 1994, J AM CHEM SOC, V116, P3180, DOI 10.1021/ja00087a002; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HECHT HJ, 1994, NAT STRUCT BIOL, V1, P532, DOI 10.1038/nsb0894-532; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; Hochheimer A, 2003, GENE DEV, V17, P1309, DOI 10.1101/gad.1099903; Hofmann B, 1998, J MOL BIOL, V279, P889, DOI 10.1006/jmbi.1998.1802; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kanaya S, 1998, BIOCHEM J, V332, P75, DOI 10.1042/bj3320075; Kim KK, 1997, STRUCTURE, V5, P1571, DOI 10.1016/S0969-2126(97)00306-7; Kimura A, 2002, NAT GENET, V32, P370, DOI 10.1038/ng993; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Marmorstein R, 2001, STRUCTURE, V9, P1127, DOI 10.1016/S0969-2126(01)00690-6; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Moshkin YM, 2002, GENE DEV, V16, P2621, DOI 10.1101/gad.231202; Munakata T, 2000, GENES CELLS, V5, P221, DOI 10.1046/j.1365-2443.2000.00319.x; Nandhagopal N, 1997, P JPN ACAD B-PHYS, V73, P154, DOI 10.2183/pjab.73.154; Nardini M, 1999, J BIOL CHEM, V274, P14579, DOI 10.1074/jbc.274.21.14579; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Padmanabhan B, 2000, ACTA CRYSTALLOGR D, V56, P1479, DOI 10.1107/S0907444900010957; Padmanabhan B, 2001, J CRYST GROWTH, V232, P326, DOI 10.1016/S0022-0248(01)01073-9; Pham AD, 2000, SCIENCE, V289, P2357, DOI 10.1126/science.289.5488.2357; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; Rossmann MG, 1999, ACTA CRYSTALLOGR D, V55, P1631, DOI 10.1107/S0907444999008379; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SEKIGUCHI T, 1988, EMBO J, V7, P1683, DOI 10.1002/j.1460-2075.1988.tb02996.x; Selleck W, 2001, NAT STRUCT BIOL, V8, P695, DOI 10.1038/90408; Siegert JL, 1999, MOL CELL BIOL, V19, P846; Sutton A, 2003, J BIOL CHEM, V278, P16887, DOI 10.1074/jbc.M210709200; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; TAKADA R, 1992, P NATL ACAD SCI USA, V89, P11809, DOI 10.1073/pnas.89.24.11809; Tan S, 2001, NAT STRUCT BIOL, V8, P8, DOI 10.1038/83098; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tyler JK, 1999, NATURE, V402, P555, DOI 10.1038/990147; Umehara T, 2003, J BIOL CHEM, V278, P35660, DOI 10.1074/jbc.M303549200; Umehara T, 2002, GENES CELLS, V7, P59, DOI 10.1046/j.1356-9597.2001.00493.x; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; Veenstra GJC, 2001, TRENDS BIOCHEM SCI, V26, P665, DOI 10.1016/S0968-0004(01)01970-3; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; Woychik NA, 2002, CELL, V108, P453, DOI 10.1016/S0092-8674(02)00646-3; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; Yamaki M, 2001, GENES CELLS, V6, P1043, DOI 10.1046/j.1365-2443.2001.00487.x; Yamamoto T, 1998, GENES CELLS, V3, P347, DOI 10.1046/j.1365-2443.1998.00195.x; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yeates TO, 2002, CELL, V111, P5, DOI 10.1016/S0092-8674(02)01010-3; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	75	16	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9615	9624		10.1074/jbc.M312165200	http://dx.doi.org/10.1074/jbc.M312165200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14672934	hybrid			2022-12-25	WOS:000189265900129
J	Perez-Ortiz, JM; Tranque, P; Vaquero, CF; Domingo, B; Molina, F; Calvo, S; Jordan, J; Cena, V; Llopis, J				Perez-Ortiz, JM; Tranque, P; Vaquero, CF; Domingo, B; Molina, F; Calvo, S; Jordan, J; Cena, V; Llopis, J			Glitazones differentially regulate primary astrocyte and glioma cell survival - Involvement of reactive oxygen species and peroxisome proliferator-activated receptor-gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); OXIDATIVE STRESS; CYCLE ARREST; METABOLISM; APOPTOSIS; AGONISTS; KINASE; INHIBIT; GROWTH	The glitazones or thiazolidinediones are ligands of the peroxisome proliferator-activated receptor gamma (PPARgamma). The glitazones are used in the treatment of diabetes, regulate adipogenesis, inflammation, cell proliferation, and induce apoptosis in several cancer cell types. High grade astrocytomas are rapidly growing tumors derived from astrocytes, for which new treatments are needed. We determined the effects of two glitazones, ciglitazone and the therapeutic rosiglitazone, on the survival of serum-deprived primary rat astrocytes and glioma cell lines C6 and U251, which were assessed by the methylthiazolyl tetrazolium assay and lactate dehydrogenase release. Rosiglitazone ( 5 - 20 muM) decreased survival of glioma cells without affecting primary astrocytes, whereas ciglitazone at 20 muM was toxic for both cell types. Ciglitazone at 10 muM was cytoprotective for primary astrocytes but toxic to glioma cells. Cell death induced by ciglitazone, but not rosiglitazone, presented apoptotic features ( Hoechst staining and externalization of phosphatidylserine). Two mechanisms to explain cytotoxicity were investigated: activation of PPARgamma and production of reactive oxygen species (ROS). PPARgamma does not seem to be the main mechanism involved, because the order of efficacy for cytotoxicity, ciglitazone > rosiglitazone, was inverse of their reported affinities for activating PPARgamma. In addition, GW9662, an inhibitor of PPARgamma, only slightly attenuated cytotoxicity. However, the rapid increase in ROS production and the marked reduction of cell death with the antioxidants ebselen and N-acetylcysteine, indicate that ROS have a key role in glitazone cytotoxicity. Ciglitazone caused a dose-dependent and rapid loss ( in minutes) of mitochondrial membrane potential in glioma cells. Therefore, mitochondria are a likely source of ROS and early targets of glitazone cytotoxicity. Our results highlight the potential of rosiglitazone and related compounds for the treatment of astrogliomas.	Univ Castilla La Mancha, Fac Med, Physiol Unit, Albacete 02006, Spain; Univ Castilla La Mancha, Ctr Reg Invest Biomed, Albacete 02006, Spain	Universidad de Castilla-La Mancha; Universidad de Castilla-La Mancha	Tranque, P (corresponding author), Univ Castilla La Mancha, Fac Med, Physiol Unit, Ave Almansa S-N, Albacete 02006, Spain.	pedro.tranque@uclm.es	Cena, Valentin/L-1751-2017; Llopis, Juan/I-2622-2012; PÉREZ-ORTIZ, JOSÉ M./R-5379-2019	Cena, Valentin/0000-0001-8928-3681; Llopis, Juan/0000-0002-9460-0642; PÉREZ-ORTIZ, JOSÉ M./0000-0002-3588-6273; Tranque Gomez, Pedro Antonio/0000-0003-1072-7337; jordan, joaquin/0000-0002-6809-3384; Fernandez Vaquero, Cecilia/0000-0002-7415-9060; Domingo, Beatriz/0000-0001-9430-4803				ALTMAN FP, 1976, HISTOCHEM J, V8, P471, DOI 10.1007/BF01003837; Bae MA, 2003, TOXICOL LETT, V139, P67, DOI 10.1016/S0378-4274(02)00468-X; BASS DA, 1983, J IMMUNOL, V130, P1910; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Chattopadhyay N, 2000, J NEUROSCI RES, V61, P67, DOI 10.1002/1097-4547(20000701)61:1<67::AID-JNR8>3.0.CO;2-7; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; Colca JR, 2004, AM J PHYSIOL-ENDOC M, V286, pE252, DOI 10.1152/ajpendo.00424.2003; Dello Russo C, 2003, J BIOL CHEM, V278, P5828, DOI 10.1074/jbc.M208132200; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gale EAM, 2001, LANCET, V357, P1870, DOI 10.1016/S0140-6736(00)04960-6; Gupta RA, 2003, J BIOL CHEM, V278, P7431, DOI 10.1074/jbc.M208076200; Han D, 2003, J BIOL CHEM, V278, P5557, DOI 10.1074/jbc.M210269200; INOUE I, 2004, AM J PHYSIOL, V286, pE252; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kielian T, 2003, J NEUROSCI RES, V71, P315, DOI 10.1002/jnr.10501; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; Leesnitzer LM, 2002, BIOCHEMISTRY-US, V41, P6640, DOI 10.1021/bi0159581; Lennon AM, 2002, J BIOL CHEM, V277, P29681, DOI 10.1074/jbc.M201517200; LOEW LM, 1993, BIOPHYS J, V65, P2396, DOI 10.1016/S0006-3495(93)81318-3; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MEISTER A, 1995, METHOD ENZYMOL, V251, P3, DOI 10.1016/0076-6879(95)51106-7; Moore KJ, 2001, NAT MED, V7, P41, DOI 10.1038/83328; Mossner R, 2002, J INVEST DERMATOL, V119, P576, DOI 10.1046/j.1523-1747.2002.01861.x; Narayanan PK, 2003, CYTOM PART A, V52A, P28, DOI 10.1002/cyto.a.10011; Park EJ, 2003, J BIOL CHEM, V278, P14747, DOI 10.1074/jbc.M210819200; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; SHRIEVE DC, 1988, J BIOL CHEM, V263, P14107; Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006.abs; Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145; Takeda K, 2001, J BIOL CHEM, V276, P48950, DOI 10.1074/jbc.M108722200; Teruel T, 2003, J BIOL CHEM, V278, P263, DOI 10.1074/jbc.M207200200; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; TWENTYMAN PR, 1987, BRIT J CANCER, V56, P279, DOI 10.1038/bjc.1987.190; Ueda S, 2002, ANTIOXID REDOX SIGN, V4, P405, DOI 10.1089/15230860260196209; Wang YL, 2002, J BIOL CHEM, V277, P31781, DOI 10.1074/jbc.M204279200; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; Wilmer WA, 2001, BIOCHEM BIOPH RES CO, V281, P57, DOI 10.1006/bbrc.2001.4301; Yoshizawa K, 2002, CANCER-AM CANCER SOC, V95, P2243, DOI 10.1002/cncr.10906; YOUNG PR, 1994, BBA-GEN SUBJECTS, V1201, P461, DOI 10.1016/0304-4165(94)90077-9; Zander T, 2002, J NEUROCHEM, V81, P1052, DOI 10.1046/j.1471-4159.2002.00899.x	47	113	115	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8976	8985		10.1074/jbc.M308518200	http://dx.doi.org/10.1074/jbc.M308518200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14699130	hybrid			2022-12-25	WOS:000189265900056
J	Tsukahara, F; Maru, Y				Tsukahara, F; Maru, Y			Identification of novel nuclear export and nuclear localization-related signals in human heat shock cognate protein 70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-BINDING DOMAIN; NUCLEOCYTOPLASMIC TRANSPORT; SACCHAROMYCES-CEREVISIAE; KARYOPHILIC PROTEINS; SUBSTRATE-BINDING; HUMAN HSP70; HSC70; RECEPTOR; IMPORT; ATPASE	Heat shock cognate protein 70 (Hsc70) serves nuclear transport of several proteins as a molecular chaperone. We have recently identified a novel variant of human Hsc70, heat shock cognate protein 54 (Hsc54), that lacks amino acid residues 464-616 in the protein binding and variable domains of Hsc70. In the present study, we examined nucleocytoplasmic localization of Hsc70 and Hsc54 by using green fluorescent protein (GFP) fusions. GFP-Hsc70 is localized in both the cytoplasm and the nucleus at 37degreesC and accumulated into the nucleolus/nucleus after heat shock, whereas GFP-Hsc54 always remained exclusively in the cytoplasm under these conditions. Mutation studies indicated that 20 amino acid residues of nuclear localization-related signals, which are missing in Hsc54 but are retained in Hsc70, are required for proper nuclear localization of Hsc70. We further found that Hsc54 contains a functional leucine-rich nuclear export signal (NES, (LDVTPLSL401)-L-394) which is differently situated from the previously proposed NES in Saccharomyces cerevisiae Ssb1p. The cytoplasmic localization of Hsc54 was impaired by a mutation in NES as well as by a nuclear export inhibitor, leptomycin B, suggesting that Hsc54 is actively exported from the nucleus to the cytoplasm through a CRM1-dependent mechanism. In contrast, the nucleocytoplasmic localization of Hsc70 was not affected by the same mutation of NES or leptomycin B. These results suggest that the nuclear localization-related signal could functionally mask NES leading to prolonged retention of Hsc70 in the nucleus. An additional mechanism for unmasking the NES may regulate nucleocytoplasmic trafficking of Hsc70.	Tokyo Womens Med Univ, Sch Med, Dept Pharmacol, Shinjuku Ku, Tokyo 1628666, Japan	Tokyo Women's Medical University	Tsukahara, F (corresponding author), Tokyo Womens Med Univ, Sch Med, Dept Pharmacol, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.	fuji@research.twmu.ac.jp						ABE T, 1995, BIOCHEM BIOPH RES CO, V206, P548, DOI 10.1006/bbrc.1995.1078; Akakura S, 2001, J BIOL CHEM, V276, P14649, DOI 10.1074/jbc.M100200200; BHATTACHARYYA T, 1995, J BIOL CHEM, V270, P1705, DOI 10.1074/jbc.270.4.1705; DANG CV, 1989, J BIOL CHEM, V264, P18019; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; Eberhart DE, 1996, HUM MOL GENET, V5, P1083, DOI 10.1093/hmg/5.8.1083; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Fujihara SM, 1999, EMBO J, V18, P411, DOI 10.1093/emboj/18.2.411; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Hu SM, 1996, ARCH BIOCHEM BIOPHYS, V332, P163, DOI 10.1006/abbi.1996.0328; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; Lamian V, 1996, EXP CELL RES, V228, P84, DOI 10.1006/excr.1996.0302; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MILARSKI KL, 1989, J CELL BIOL, V109, P1947, DOI 10.1083/jcb.109.5.1947; MORSHAUSER RC, 1995, BIOCHEMISTRY-US, V34, P6261, DOI 10.1021/bi00019a001; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; NUNES SL, 1995, BIOCHEM BIOPH RES CO, V213, P1, DOI 10.1006/bbrc.1995.2090; OKUNO Y, 1993, EXP CELL RES, V206, P134, DOI 10.1006/excr.1993.1129; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; Shulga N, 1999, J BIOL CHEM, V274, P16501, DOI 10.1074/jbc.274.23.16501; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; TSAI MY, 1994, J BIOL CHEM, V269, P5958; Tsukahara F, 2000, MOL PHARMACOL, V58, P1257, DOI 10.1124/mol.58.6.1257; WANG TF, 1993, J BIOL CHEM, V268, P26049; WELCH WJ, 1988, J CELL BIOL, V106, P1117, DOI 10.1083/jcb.106.4.1117; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; YANG J, 1994, MOL CELL BIOL, V14, P5088, DOI 10.1128/MCB.14.8.5088; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	38	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8867	8872		10.1074/jbc.M308848200	http://dx.doi.org/10.1074/jbc.M308848200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14684748	hybrid			2022-12-25	WOS:000189265900043
J	Ren, Y; Meng, SS; Mei, L; Zhao, ZJ; Jove, R; Wu, J				Ren, Y; Meng, SS; Mei, L; Zhao, ZJ; Jove, R; Wu, J			Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PROTEIN-KINASE; PHOSPHATASE SHP-2; C-SRC; FACTOR RECEPTOR; EPITHELIAL MORPHOGENESIS; LYSOPHOSPHATIDIC ACID; SIGNALING PATHWAY; FAMILY KINASES; CELL MOTILITY	Epidermal growth factor (EGF) induces paxillin tyrosine dephosphorylation and Src activation, but the signaling pathways that mediate these responses were largely undefined. We found that Gab1, a docking protein for the SHP2 protein-tyrosine phosphatase in EGF-stimulated cells, was associated with paxillin. SHP2 dephosphorylated paxillin and caused dissociation of Csk, a negative regulator of Src, from paxillin but had no effect on paxillin-Src association. A lower level of Src Tyr-530 phosphorylation was detected in paxillin-associated Src in EGF-stimulated cells. Expression of an SHP2 binding defective mutant of Gab1 (Gab1FF) or a catalytically inactive mutant of SHP2 (SHP2DN) prevented paxillin tyrosine dephosphorylation and Src activation induced by EGF. Importantly, Gab1FF blocked paxillin-SHP2 complex formation, Src Tyr-530 dephosphorylation, Erk activation, and cell migration induced by EGF. Inhibition of Src tyrosine kinase activity abrogated EGF-stimulated Erk activation and cell migration. Together, these results reveal that Gab1 recruits SHP2 to dephosphorylate paxillin, leading to dissociation of Csk from the paxillin-Src complex and Src activation and that Src is an SHP2 effector involved in EGF-stimulated Erk activation and cell migration.	H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ Alabama, Dept Neurobiol, Civitan Int Res Ctr, Birmingham, AL 35294 USA; Univ Alabama, Dept Pathol, Civitan Int Res Ctr, Birmingham, AL 35294 USA; Univ Alabama, Dept Phys Med & Rehabil, Civitan Int Res Ctr, Birmingham, AL 35294 USA; Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Dept Med, Div Hematol Oncol, Nashville, TN 37232 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Vanderbilt University	Wu, J (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, MRC 3-E,12902 Magnolia Dr, Tampa, FL 33612 USA.	wu@moffitt.usf.edu	Wu, Jie/R-2404-2019; Mei, Lin/G-8755-2012	Wu, Jie/0000-0002-2864-1606; 	NCI NIH HHS [R01 CA077467, CA77467] Funding Source: Medline; NINDS NIH HHS [NS44521, NS45710] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA077467, R29CA077467, R01CA077467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044521, R01NS045710] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; Belsches-Jablonski AP, 2001, ONCOGENE, V20, P1465, DOI 10.1038/sj.onc.1204205; Boyer B, 1997, EMBO J, V16, P5904, DOI 10.1093/emboj/16.19.5904; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; Cai T, 2002, J CELL BIOL, V159, P103, DOI 10.1083/jcb.200205017; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; Cunnick JM, 2002, J BIOL CHEM, V277, P9498, DOI 10.1074/jbc.M110547200; Cunnick JM, 2001, J BIOL CHEM, V276, P24380, DOI 10.1074/jbc.M010275200; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Davidson D, 2003, MOL CELL BIOL, V23, P2017, DOI 10.1128/MCB.23.6.2017-2028.2003; Dorsey JF, 2002, BLOOD, V99, P1388, DOI 10.1182/blood.V99.4.1388; Dorsey JF, 2002, LEUKEMIA, V16, P1589, DOI 10.1038/sj.leu.2402678; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Guvakova MA, 1999, EXP CELL RES, V251, P244, DOI 10.1006/excr.1999.4566; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Inagaki K, 2000, ONCOGENE, V19, P75, DOI 10.1038/sj.onc.1203204; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Ishibe S, 2003, MOL CELL, V12, P1275, DOI 10.1016/S1097-2765(03)00406-4; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Kim H, 1999, EXP CELL RES, V253, P78, DOI 10.1006/excr.1999.4706; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Krueger JS, 2001, ONCOGENE, V20, P4209, DOI 10.1038/sj.onc.1204541; Lotz M, 2003, J SURG RES, V109, P123, DOI 10.1016/S0022-4804(02)00100-2; Lu ZM, 2001, MOL CELL BIOL, V21, P4016, DOI 10.1128/MCB.21.12.4016-4031.2001; Manes S, 1999, MOL CELL BIOL, V19, P3125; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; MEI L, 1994, J BIOL CHEM, V269, P12254; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Olayioye MA, 2001, EXP CELL RES, V267, P81, DOI 10.1006/excr.2001.5242; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Ouwens DM, 1996, BIOCHEM J, V318, P609, DOI 10.1042/bj3180609; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Ren Y, 2003, ANTICANCER RES, V23, P3231; Rosario M, 2003, TRENDS CELL BIOL, V13, P328, DOI 10.1016/S0962-8924(03)00104-1; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SATO KI, 1995, BIOCHEM BIOPH RES CO, V210, P844, DOI 10.1006/bbrc.1995.1735; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Tsubouchi A, 2002, J CELL BIOL, V159, P673, DOI 10.1083/jcb.200202117; Turner CE, 2000, J CELL SCI, V113, P4139; Vadlamudi RK, 2002, J CELL PHYSIOL, V190, P189, DOI 10.1002/JCP.10054; WENG ZG, 1993, J BIOL CHEM, V268, P14956; Yart A, 2001, J BIOL CHEM, V276, P8856, DOI 10.1074/jbc.M006966200; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zeng Q, 1998, ANAL BIOCHEM, V259, P187, DOI 10.1006/abio.1998.2645; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765	55	136	139	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8497	8505		10.1074/jbc.M312575200	http://dx.doi.org/10.1074/jbc.M312575200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14665621	hybrid			2022-12-25	WOS:000189103300133
J	Wang, N; Kudryavtseva, E; Ch'en, IL; McCormick, J; Sugihara, TM; Ruiz, R; Andersen, B				Wang, N; Kudryavtseva, E; Ch'en, IL; McCormick, J; Sugihara, TM; Ruiz, R; Andersen, B			Expression of an engrailed-LMO4 fusion protein in mammary epithelial cells inhibits mammary gland development in mice	ONCOGENE			English	Article						LMO4; mammary gland development; heregulin; engrailed fusion protein	LIM DOMAIN GENE; TRANSGENIC MICE; LOBULOALVEOLAR DEVELOPMENT; TRANSCRIPTION FACTORS; HOMEODOMAIN PROTEINS; BREAST-CANCER; GROWTH-FACTOR; LMO PROTEINS; DIFFERENTIATION; BINDING	LIM domain factors and associated cofactors are important developmental regulators in pattern formation and organogenesis. In addition, overexpression of two LIM-only factors (LMOs) causes acute lymphocytic leukemia. The more recently discovered LMO factor LMO4 is highly expressed in proliferating epithelial cells, and frequently overexpressed in breast carcinoma. Here we show that while LMO4 is expressed throughout mammary gland development, it is dramatically upregulated in mammary epithelial cells during midpregnancy. The LMO coactivator Clim2/Ldb1/NLI showed a similar expression pattern, consistent with the idea that LMO4 and Clim2 act as a complex in mammary epithelial cells. In MCF-7 cells, LMO4 transcripts were upregulated by heregulin, an activator of ErbB receptors that are known to be important in mammary gland development and breast cancer. To test the hypothesis that LMO4 plays roles in mammary gland development, we created an engrailed-LMO4 fusion protein. This fusion protein maintains the ability to interact with Clim2, but acts as a dominant repressor of both basal and activated transcription when recruited to a DNA-regulatory region. When the engrailed-LMO4 fusion protein was expressed under control of the MMTV promoter in transgenic mice, both ductular development in virgin mice and alveolar development in pregnant mice were inhibited. These results suggest that LMO4 plays a role in promoting mammary gland development.	Univ Calif Irvine, Dept Med, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biol Chem, Div Endocrinol & Metab, Irvine, CA 92697 USA; Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California San Diego	Andersen, B (corresponding author), Univ Calif Irvine, Dept Med, Sprague Hall,Room 206, Irvine, CA 92697 USA.	bogi@uci.edu			NIAMS NIH HHS [AR02080] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR002080] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; Agulnick AD, 1996, NATURE, V384, P270, DOI 10.1038/384270a0; Andersen B, 1997, GENE DEV, V11, P1873, DOI 10.1101/gad.11.14.1873; Bach I, 1999, NAT GENET, V22, P394, DOI 10.1038/11970; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Bach I, 1997, GENE DEV, V11, P1370, DOI 10.1101/gad.11.11.1370; Bao JX, 2000, DEVELOPMENT, V127, P425; Brisken C, 1999, DEV BIOL, V210, P96, DOI 10.1006/dbio.1999.9271; Chen CB, 2002, DEVELOPMENT, V129, P2401; Dasen JS, 1999, CELL, V97, P587, DOI 10.1016/S0092-8674(00)80770-9; Eceles SA, 2001, J MAMMARY GLAND BIOL, V6, P393, DOI 10.1023/A:1014730829872; Grutz G, 1998, ONCOGENE, V17, P2799, DOI 10.1038/sj.onc.1202502; Gruvberger S, 2001, CANCER RES, V61, P5979; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; Herblot S, 2000, NAT IMMUNOL, V1, P138, DOI 10.1038/77819; Hollemann T, 1998, DEVELOPMENT, V125, P2425; Jones FE, 1999, ONCOGENE, V18, P3481, DOI 10.1038/sj.onc.1202698; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; Kenny DA, 1998, P NATL ACAD SCI USA, V95, P11257, DOI 10.1073/pnas.95.19.11257; Kitsberg DI, 1996, ONCOGENE, V13, P2507; Krane IM, 1996, ONCOGENE, V12, P1781; Kudoh T, 2001, P NATL ACAD SCI USA, V98, P7852, DOI 10.1073/pnas.141224098; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Li L, 2002, ONCOGENE, V21, P4900, DOI 10.1038/sj.onc.1205634; Liu C, 2002, AM J PHYSIOL-LUNG C, V283, pL468, DOI 10.1152/ajplung.00044.2002; Mead PE, 2001, DEVELOPMENT, V128, P2301; Montross WT, 2000, J CELL SCI, V113, P1759; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Ono Y, 1998, MOL CELL BIOL, V18, P6939, DOI 10.1128/MCB.18.12.6939; Osada H., 1997, Leukemia (Basingstoke), V11, P307; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; Rabbitts TH, 1999, CANCER RES, V59, p1794S; Racevskis J, 1999, BBA-GENE STRUCT EXPR, V1445, P148, DOI 10.1016/S0167-4781(99)00037-8; Rudland PS, 1998, BIOCHEM SOC SYMP, P1; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Stern DF, 2003, EXP CELL RES, V284, P89, DOI 10.1016/S0014-4827(02)00103-9; Sugihara TM, 2001, J BIOL CHEM, V276, P33036, DOI 10.1074/jbc.M103000200; Sugihara TM, 1998, P NATL ACAD SCI USA, V95, P15418, DOI 10.1073/pnas.95.26.15418; Sum EYM, 2002, J BIOL CHEM, V277, P7849, DOI 10.1074/jbc.M110603200; Sykes TG, 1998, DEVELOPMENT, V125, P4595; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; Visvader JE, 1997, P NATL ACAD SCI USA, V94, P13707, DOI 10.1073/pnas.94.25.13707; Visvader JE, 2001, P NATL ACAD SCI USA, V98, P14452, DOI 10.1073/pnas.251547698; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; Zeng CY, 1998, P NATL ACAD SCI USA, V95, P10637, DOI 10.1073/pnas.95.18.10637	52	33	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1507	1513		10.1038/sj.onc.1207288	http://dx.doi.org/10.1038/sj.onc.1207288			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14676840				2022-12-25	WOS:000189219500003
J	Kimura, A; Kinjyo, I; Matsumura, Y; Mori, H; Mashima, R; Harada, M; Chien, KR; Yasukawa, H; Yoshimura, A				Kimura, A; Kinjyo, I; Matsumura, Y; Mori, H; Mashima, R; Harada, M; Chien, KR; Yasukawa, H; Yoshimura, A			SOCS3 is a physiological negative regulator for granulopoiesis and granulocyte colony-stimulating factor receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-CSF RECEPTOR; NEUTROPHIL CHEMOTAXIS; CYTOKINE SIGNALING-3; STAT3 ACTIVATION; WHOLE-BLOOD; MICE; MACROPHAGES; MUTATION; BINDING; GENE	The suppressor of cytokine signaling-3 (SOCS3/CIS3) has been shown to be an important negative regulator of cytokines, especially cytokines that activate STAT3. To examine the role of SOCS3 in neutrophils and the granulocyte colony-stimulating factor (G-CSF) signaling in vivo, we compared neutrophils from two types of conditional knockout mice, LysM-Cre:SOCS3(fl/fl) mice and Tie2-Cre:SOCS3(fl/fl) mice, in which the Socs3 gene had been deleted in mature neutrophils and hematopoietic stem cells, respectively. The size of the G-CSF-dependent colonies from Tie2-Cre:SOCS3(fl/fl) mouse bone marrow was much larger than that of colonies from control wild-type mice, while the size of interleukin-3-dependent colonies was similar. Moreover, LysM-Cre:SOCS3(fl/fl) mice had more neutrophils than SOCS3(fl/fl) mice, suggesting that SOCS3 is a negative regulator of G-CSF signaling in neutrophils. Consistent with this notion, G-CSF-induced STAT3 as well as mitogen-activated protein kinase activation was much stronger and prolonged in SOCS3-deficient mature neutrophils than in wildtype neutrophils. The preventive effect of G-CSF on apoptosis was more prominent in SOCS3-deficient mature neutrophils than in control neutrophils. These data indicate that SOCS3 negatively regulates granulopoiesis and G-CSF signaling in neutrophils and may contribute to neutrophilia or neutropenia.	Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med, Dept Internal Med, Higashi Ku, Fukuoka 8128582, Japan; Univ Calif San Diego, Inst Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Kurume Univ, Cardiovasc Res Inst, Kurume, Fukuoka 8300011, Japan; Kurume Univ, Dept Internal Med 3, Kurume, Fukuoka 8300011, Japan	Kyushu University; Kyushu University; University of California System; University of California San Diego; University of California System; University of California San Diego; Kurume University; Kurume University	Yoshimura, A (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yakihiko@bioreg.kyushu-u.ac.jp	MORI, HIROYUKI/D-3343-2013; Yoshimura, Akihiko/K-5515-2013	Kinjyo, Ichiko/0000-0001-7051-3790; Kimura, Akiko/0000-0001-8136-5009				Basu S, 2000, BLOOD, V95, P3725; BELLAVITE P, 1983, EUR J CLIN INVEST, V13, P363; Cassatella MA, 1999, BLOOD, V94, P2880, DOI 10.1182/blood.V94.8.2880.420k31_2880_2889; Cavallaro A, 2003, PHYSIOL RES, V52, P555; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Constien R, 2001, GENESIS, V30, P36, DOI 10.1002/gene.1030; Hermans MHA, 2003, BLOOD, V101, P2584, DOI 10.1182/blood-2002-07-2062; Hermans MHA, 1999, J EXP MED, V189, P683, DOI 10.1084/jem.189.4.683; Hermans MHA, 1998, BLOOD, V92, P32, DOI 10.1182/blood.V92.1.32.413k42_32_39; Hong F, 2002, J CLIN INVEST, V110, P1503, DOI 10.1172/JCI200215841; Hortner M, 2002, J IMMUNOL, V169, P1219, DOI 10.4049/jimmunol.169.3.1219; Kisanuki YY, 2001, DEV BIOL, V230, P230, DOI 10.1006/dbio.2000.0106; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Lee CK, 2002, IMMUNITY, V17, P63, DOI 10.1016/S1074-7613(02)00336-9; LIESCHKE GJ, 1994, BLOOD, V84, P1737; Ludwig A, 1997, BLOOD, V90, P4588; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; McLemore ML, 1998, J CLIN INVEST, V102, P483, DOI 10.1172/JCI3216; MIER JW, 1990, BLOOD, V76, P1933; NICHOLSON SE, 1995, BLOOD, V86, P3698, DOI 10.1182/blood.V86.10.3698.bloodjournal86103698; Roberts AW, 2001, P NATL ACAD SCI USA, V98, P9324, DOI 10.1073/pnas.161271798; Rodriguez ME, 2001, J IMMUNOL METHODS, V252, P33, DOI 10.1016/S0022-1759(01)00329-5; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; Sasaki A, 2003, J BIOL CHEM, V278, P2432, DOI 10.1074/jbc.C200608200; SCHRODER JM, 1987, J IMMUNOL, V139, P3474; Shimoda K, 1997, BLOOD, V90, P597, DOI 10.1182/blood.V90.2.597.597_597_604; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Takahashi Y, 2003, EMBO J, V22, P372, DOI 10.1093/emboj/cdg057; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Tian SS, 1996, BLOOD, V88, P4435, DOI 10.1182/blood.V88.12.4435.bloodjournal88124435; TIAN SS, 1994, BLOOD, V84, P1760; Tonko-Geymayer S, 2002, MOL ENDOCRINOL, V16, P1680, DOI 10.1210/me.16.7.1680; Ward AC, 1998, BBA-MOL CELL RES, V1448, P70, DOI 10.1016/S0167-4889(98)00120-7; Ward AC, 1999, BLOOD, V93, P113, DOI 10.1182/blood.V93.1.113.401k33_113_124; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938	37	93	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6905	6910		10.1074/jbc.C300496200	http://dx.doi.org/10.1074/jbc.C300496200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14699146	hybrid			2022-12-25	WOS:000188969200085
J	Regl, G; Kasper, M; Schnidar, H; Eichberger, T; Neill, GW; Ikram, MS; Quinn, AG; Philpott, MP; Frischauf, AM; Aberger, F				Regl, G; Kasper, M; Schnidar, H; Eichberger, T; Neill, GW; Ikram, MS; Quinn, AG; Philpott, MP; Frischauf, AM; Aberger, F			The zinc-finger transcription factor GLI2 antagonizes contact inhibition and differentiation of human epidermal cells	ONCOGENE			English	Article						hedgehog signalling; GLI proteins; keratinocytes; basal cell carcinoma; epidermal differentiation; cell cycle	SONIC HEDGEHOG; KERATINOCYTE DIFFERENTIATION; GENE-EXPRESSION; CYCLE PROGRESSION; UP-REGULATION; TARGET GENES; FLOOR PLATE; BASAL; PROLIFERATION; CARCINOMA	In stratified epidermis, activation of the Hh/Gli signal transduction pathway has been implicated in the control of cell proliferation and tumorigenesis. The zinc-finger transcription factor Gli2 has been identified as critical mediator of the Hh signal at the distal end of the pathway, but the molecular mechanisms by which Gli2 regulates cell proliferation or induces epidermal malignancies such as basal cell carcinoma are still unclear. Here, we provide evidence for a role of human GLI2 in antagonizing contact inhibition and epidermal differentiation. We show by gene expression pro. ling that activation of the GLI2 oncogene in human keratinocytes activates the transcription of a number of genes involved in cell cycle progression such as E2F1, CCND1, CDC2 and CDC45L, while it represses genes associated with epidermal differentiation. Analysis of the proliferative effect of GLI2 revealed that GLI2 is able to induce G1-S phase progression in contact-inhibited keratinocytes. Detailed time-course experiments identified E2F1 as early transcriptional target of GLI2. Further, we show that GLI2 expression in human keratinocytes results in a marked downregulation of epidermal differentiation markers. The data suggest a role for GLI2 in Hh-induced epidermal neoplasia by opposing epithelial cell cycle arrest signals and epidermal differentiation.	Salzburg Univ, Inst Genet, A-5020 Salzburg, Austria; Univ London, Barts & London Queen Mary Sch Med & Dent, Ctr Cutaneaous Res, London WC1E 7HU, England; AstraZeneca R&D Charnwood, Expt Med, Loughborough, Leics, England	Salzburg University; University of London; Queen Mary University London; AstraZeneca	Aberger, F (corresponding author), Salzburg Univ, Inst Genet, Hellbrunner Str 34, A-5020 Salzburg, Austria.	fritz.aberger@sbg.ac.at	Kasper, Maria/Q-6318-2016; Schnidar, Harald/C-7049-2009; Neill, Graham/C-9008-2012; Aberger, Fritz/B-6357-2012	Aberger, Fritz/0000-0003-2009-6305; Philpott, Michael/0000-0002-1255-4612; Kasper, Maria/0000-0002-6117-2717				Aberger F, 2001, GENOMICS, V77, P50, DOI 10.1006/geno.2001.6623; Arata Y, 2000, J BIOL CHEM, V275, P6337, DOI 10.1074/jbc.275.9.6337; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; Bai CB, 2002, DEVELOPMENT, V129, P4753; Bikle DD, 2001, MOL CELL ENDOCRINOL, V177, P161, DOI 10.1016/S0303-7207(01)00452-X; Bonifas JM, 2001, J INVEST DERMATOL, V116, P739, DOI 10.1046/j.1523-1747.2001.01315.x; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Chopra A, 1998, J INVEST DERMATOL, V110, P52, DOI 10.1046/j.1523-1747.1998.00089.x; Deng H, 1997, NAT BIOTECHNOL, V15, P1388, DOI 10.1038/nbt1297-1388; Ding Q, 1998, DEVELOPMENT, V125, P2533; Duman-Scheel M, 2002, NATURE, V417, P299, DOI 10.1038/417299a; Fan HR, 1999, J CELL BIOL, V147, P71, DOI 10.1083/jcb.147.1.71; Garach-Jehoshua O, 1998, BRIT J DERMATOL, V139, P950; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jee SH, 2001, ONCOGENE, V20, P198, DOI 10.1038/sj.onc.1204076; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; Kenney AM, 2000, MOL CELL BIOL, V20, P9055, DOI 10.1128/MCB.20.23.9055-9067.2000; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Martin KJ, 2001, P NATL ACAD SCI USA, V98, P2646, DOI 10.1073/pnas.041622398; Matise MP, 1998, DEVELOPMENT, V125, P2759; Medvedev A, 1999, J BIOL CHEM, V274, P3887, DOI 10.1074/jbc.274.6.3887; Mill P, 2003, GENE DEV, V17, P282, DOI 10.1101/gad.1038103; Morasso MI, 1996, J CELL BIOL, V135, P1879, DOI 10.1083/jcb.135.6.1879; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Mullor JL, 2002, TRENDS CELL BIOL, V12, P562, DOI 10.1016/S0962-8924(02)02405-4; Nickoloff BJ, 2002, CELL DEATH DIFFER, V9, P842, DOI 10.1038/sj.cdd.4401036; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Park HL, 2000, DEVELOPMENT, V127, P1593; Regl G, 2002, ONCOGENE, V21, P5529, DOI 10.1038/sj.onc.1205748; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Rutberg SE, 1996, ONCOGENE, V13, P167; Sasaki H, 1999, DEVELOPMENT, V126, P3915; SAVOIA P, 1993, J INVEST DERMATOL, V101, P352, DOI 10.1111/1523-1747.ep12365531; Schoop VM, 1999, J INVEST DERMATOL, V112, P343, DOI 10.1046/j.1523-1747.1999.00524.x; Sheng H, 2002, CANCER RES, V62, P5308; Sherr CJ, 2000, CANCER RES, V60, P3689; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Takahashi H, 1997, J INVEST DERMATOL, V108, P843, DOI 10.1111/1523-1747.ep12292575; Toftgard R, 2000, CELL MOL LIFE SCI, V57, P1720, DOI 10.1007/PL00000654; Tuominen H, 1997, J CUTAN PATHOL, V24, P590, DOI 10.1111/j.1600-0560.1997.tb01089.x; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Varani J, 2000, BRIT J CANCER, V82, P657, DOI 10.1054/bjoc.1999.0978; Watanabe R, 1998, J BIOL CHEM, V273, P9651, DOI 10.1074/jbc.273.16.9651; Weiner HL, 2002, CANCER RES, V62, P6385; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; Werner S, 2001, TRENDS CELL BIOL, V11, P143, DOI 10.1016/S0962-8924(01)01955-9; Wetmore C, 2003, CURR OPIN GENET DEV, V13, P34, DOI 10.1016/S0959-437X(03)00002-9; Xie JW, 2001, P NATL ACAD SCI USA, V98, P9255, DOI 10.1073/pnas.151173398; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yoon JW, 2002, J BIOL CHEM, V277, P5548, DOI 10.1074/jbc.M105708200; ZETTERGREN JG, 1984, P NATL ACAD SCI-BIOL, V81, P238, DOI 10.1073/pnas.81.1.238	60	70	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1263	1274		10.1038/sj.onc.1207240	http://dx.doi.org/10.1038/sj.onc.1207240			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14691458				2022-12-25	WOS:000188892200011
J	Herold, CL; Qi, AD; Harden, TK; Nicholas, RA				Herold, CL; Qi, AD; Harden, TK; Nicholas, RA			Agonist versus antagonist action of ATP at the P2Y(4) receptor is determined by the second extracellular loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PROTEIN-COUPLED RECEPTOR; ADP RECEPTOR; CRYSTAL-STRUCTURE; PHOSPHOLIPASE-C; AMINO-ACIDS; EXPRESSION; IDENTIFICATION; CLONING; RHODOPSIN	UTP is a potent full agonist at both the human P2Y(4) (hP2Y(4)) and rat P2Y(4) (rP2Y(4)) receptor. In contrast, ATP is a potent full agonist at the rP2Y(4) receptor but is a similarly potent competitive antagonist at the hP2Y(4) receptor. To delineate the structural determinants of agonism versus antagonism in these species homologues, we expressed a series of human/rat P2Y(4) receptor chimeras in 1321N1 human astrocytoma cells and assessed the capacity of ATP and UTP to mobilize intracellular Ca2+. Replacement of the NH2 terminus of the hP2Y(4) receptor with the corresponding region of the rP2Y(4) receptor resulted in a receptor that was activated weakly by ATP, whereas replacement of the second extracellular loop (EL2) of the hP2Y(4) receptor with that of the rP2Y(4) receptor yielded a chimeric receptor that was activated fully by UTP and near fully by ATP, albeit with lower potencies than those observed at the rP2Y(4) receptor. These potencies were increased, and ATP was converted to a full agonist by replacing both the NH2 terminus and EL2 in the hP2Y(4) receptor with the corresponding regions from the rP2Y(4) receptor. Mutational analysis of the five divergent amino acids in EL2 between the two receptors revealed that three amino acids, Asn-177, Ile-183, and Leu-190, contribute to the capacity of EL2 to impart ATP agonism. Taken together, these results suggest that the second extracellular loop and the NH2 terminus form a functional motif that plays a key role in determining whether ATP functions as an agonist or antagonist at mammalian P2Y(4) receptors.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Nicholas, RA (corresponding author), Univ N Carolina, Dept Pharmacol, CB 7365, Chapel Hill, NC 27599 USA.	nicholas@med.unc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038213] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL071131, HL71131] Funding Source: Medline; NIGMS NIH HHS [GM38213, R01 GM038213] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI H, 1994, J BIOL CHEM, V269, P24557; Archer E, 2003, TRENDS PHARMACOL SCI, V24, P36, DOI 10.1016/S0165-6147(02)00009-3; Berthold M, 1997, NEUROCHEM RES, V22, P1023, DOI 10.1023/A:1022483027858; Brown EM, 1999, AM J MED, V106, P238, DOI 10.1016/S0002-9343(98)00418-5; Chambers JK, 2000, J BIOL CHEM, V275, P10767, DOI 10.1074/jbc.275.15.10767; Communi D, 1999, BRIT J PHARMACOL, V128, P1199, DOI 10.1038/sj.bjp.0702909; Communi D, 2001, J BIOL CHEM, V276, P41479, DOI 10.1074/jbc.M105912200; Communi D, 1997, J BIOL CHEM, V272, P31969, DOI 10.1074/jbc.272.51.31969; Comstock K E, 1997, Methods Mol Biol, V62, P207; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; ERB L, 1995, J BIOL CHEM, V270, P4185, DOI 10.1074/jbc.270.9.4185; Foster CJ, 2001, J CLIN INVEST, V107, P1591, DOI 10.1172/JCI12242; Harden TK, 1998, DEV CARDIOVASC MED, V209, P187; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hoffmann C, 1999, J BIOL CHEM, V274, P14639, DOI 10.1074/jbc.274.21.14639; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Jiang QL, 1997, MOL PHARMACOL, V52, P499, DOI 10.1124/mol.52.3.499; Kenakin T, 1996, PHARMACOL REV, V48, P413; Kennedy C, 2000, MOL PHARMACOL, V57, P926; King BF, 1998, TRENDS PHARMACOL SCI, V19, P506, DOI 10.1016/S0165-6147(98)01271-1; Li Q, 1998, MOL PHARMACOL, V54, P541, DOI 10.1124/mol.54.3.541; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parnot C, 2000, P NATL ACAD SCI USA, V97, P7615, DOI 10.1073/pnas.110142297; Parnot C, 2002, TRENDS ENDOCRIN MET, V13, P336, DOI 10.1016/S1043-2760(02)00628-8; Qi AD, 2001, MOL PHARMACOL, V60, P1375, DOI 10.1124/mol.60.6.1375; Qi AD, 2001, BRIT J PHARMACOL, V132, P318, DOI 10.1038/sj.bjp.0703788; Ralevic V, 1998, PHARMACOL REV, V50, P413; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Schachter JB, 1997, BRIT J PHARMACOL, V122, P1021, DOI 10.1038/sj.bjp.0701479; Schachter JB, 1996, BRIT J PHARMACOL, V118, P167, DOI 10.1111/j.1476-5381.1996.tb15381.x; Takasaki J, 2001, MOL PHARMACOL, V60, P432; Van Rhee A M, 1995, Drug Des Discov, V13, P133; Whistler JL, 2002, TRAFFIC, V3, P866, DOI 10.1034/j.1600-0854.2002.31203.x; Zambon AC, 2001, MOL PHARMACOL, V60, P26, DOI 10.1124/mol.60.1.26; Zhang FL, 2001, J BIOL CHEM, V276, P8608, DOI 10.1074/jbc.M009718200	41	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11456	11464		10.1074/jbc.M301734200	http://dx.doi.org/10.1074/jbc.M301734200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14670966	hybrid, Green Accepted, Green Submitted			2022-12-25	WOS:000220157600076
J	Tsunoda, SP; Wiesner, B; Lorenz, D; Rosenthal, W; Pohl, P				Tsunoda, SP; Wiesner, B; Lorenz, D; Rosenthal, W; Pohl, P			Aquaporin-1, nothing but a water channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANAR LIPID BILAYERS; STRUCTURAL DETERMINANTS; CYCLIC-AMP; ION; PERMEATION; PERMEABILITY; DYNAMICS; PROTEIN; CELLS	Aquaporin-1 (AQP1) is a membrane channel that allows rapid water movement driven by a transmembrane osmotic gradient. It was claimed to have a secondary function as a cyclic nucleotide-gated ion channel. However, upon reconstitution into planar bilayers, the ion channel exhibited a 10-fold lower open probability (<10(-6)) of doubtful physiological significance (Saparov, S. M., Kozono, D., Rothe, U., Agre, P., and Pohl, P. (2001) J. Biol. Chem. 276, 31515-31520). Investigating AQP1 expressed in human embryonic kidney cells, we now have shown that the discrepancy is not due to alterations of AQP1 properties upon reconstitution into bilayers but rather to regulatory processes of the oocyte expression system that may have been misinterpreted as AQP1 ion channel activity. As confirmed by laser scanning reflection microscopy, from 0.8 to 1.4 x 10(6) AQP1 copies/cell contributed to osmotic cell swelling. The proper plasma membrane localization was confirmed by observing the fluorescence of the N-terminal yellow fluorescent protein tag. Whole-cell patch clamp experiments of wild type or tagged AQP1-expressing cells revealed that neither cGMP nor cAMP mediated ion channel activity. The lack of significant CNG ion channels in cellular signal transduction.	Forschungsinst Mol Pharmakol, D-13125 Berlin, Germany; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany; Humboldt Univ, Inst Biol, D-10115 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin	Pohl, P (corresponding author), Forschungsinst Mol Pharmakol, Robert Roessle Str 10, D-13125 Berlin, Germany.	pohl@fmp-berlin.de	Tsunoda, Satoshi/AAN-7023-2021; Pohl, Peter/A-5361-2008	Pohl, Peter/0000-0002-1792-2314; Tsunoda, Satoshi/0000-0003-3636-1521				Agre P, 1997, SCIENCE, V275, P1490, DOI 10.1126/science.275.5305.1490; Anthony TL, 2000, MOL PHARMACOL, V57, P576, DOI 10.1124/mol.57.3.576; Boassa D, 2002, TRENDS PHARMACOL SCI, V23, P558, DOI 10.1016/S0165-6147(02)02112-0; BONDY C, 1993, P NATL ACAD SCI USA, V90, P4500, DOI 10.1073/pnas.90.10.4500; de Groot BL, 2001, SCIENCE, V294, P2353, DOI 10.1126/science.1062459; Fotiadis D, 2002, J MOL BIOL, V318, P1381, DOI 10.1016/S0022-2836(02)00143-2; Hatakeyama S, 2001, BIOCHEM BIOPH RES CO, V287, P814, DOI 10.1006/bbrc.2001.5661; Hoque ATMS, 2000, CANCER GENE THER, V7, P476, DOI 10.1038/sj.cgt.7700146; Ikeda M, 2002, J BIOL CHEM, V277, P39873, DOI 10.1074/jbc.M207008200; JUNG JS, 1994, J BIOL CHEM, V269, P14648; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; Kozono D, 2002, J CLIN INVEST, V109, P1395, DOI 10.1172/JCI200215851; Lorenz D, 2003, EMBO REP, V4, P88, DOI 10.1038/sj.embor.embor711; Maric K, 2001, BIOPHYS J, V80, P1783, DOI 10.1016/S0006-3495(01)76148-6; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; Nielsen S, 2002, PHYSIOL REV, V82, P205, DOI 10.1152/physrev.00024.2001; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; Pohl P, 2001, P NATL ACAD SCI USA, V98, P9624, DOI 10.1073/pnas.161299398; Saparov SM, 2001, J BIOL CHEM, V276, P31515, DOI 10.1074/jbc.M104267200; Verkman AS, 2000, AM J PHYSIOL-RENAL, V278, pF13, DOI 10.1152/ajprenal.2000.278.1.F13; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; Yool AJ, 1996, SCIENCE, V273, P1216, DOI 10.1126/science.273.5279.1216; Yool AJ, 2002, NEWS PHYSIOL SCI, V17, P68, DOI 10.1152/nips.01372.2001; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002	25	46	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11364	11367		10.1074/jbc.M310881200	http://dx.doi.org/10.1074/jbc.M310881200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701836	hybrid			2022-12-25	WOS:000220157600065
J	Usatyuk, PV; Natarajan, V				Usatyuk, PV; Natarajan, V			Role of mitogen-activated protein kinases in 4-hydroxy-2-nonenal-induced actin remodeling and barrier function in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-D ACTIVATION; P38 MAP KINASE; LIPID-PEROXIDATION PRODUCT; OXIDATIVE STRESS; 4-HYDROXYNONENAL-INDUCED APOPTOSIS; GENE-EXPRESSION; INHIBITION; INVOLVEMENT; ALDEHYDE; CA2+	In vivo and in vitro studies indicate that 4-hydroxy-2-nonenal (4-HNE), generated by cellular lipid peroxidation or after oxidative stress, affects endothelial permeability and vascular tone. However, the mechanism(s) of 4-HNE-induced endothelial barrier function is not well defined. Here we provide evidence for the first time on the involvement of mitogen-activated protein kinases (MAPKs) in 4-HNE-mediated actin stress fiber formation and barrier function in lung endothelial cells. Treatment of bovine lung microvascular endothelial cells with hydrogen peroxide (H2O2), as a model oxidant, resulted in accumulation of 4-HNE as evidenced by the formation of 4-HNE-Michael protein adducts. Exposure of cells to 4-HNE, in a dose- and time-dependent manner, decreased endothelial cell permeability measured as transendothelial electrical resistance. The 4-HNE-induced permeability changes were not because of cytotoxicity or endothelial cell apoptosis, which occurred after prolonged treatment and at higher concentrations of 4-HNE. 4-HNE-induced changes in transendothelial electrical resistance were calcium independent, as 4-HNE did not alter intracellular free calcium levels as compared with H2O2 or diperoxovanadate. Stimulation of quiescent cells with 4-HNE (1-100 muM) resulted in phosphorylation of ERK1/2, JNK, and p38 MAPKs, and actin cytoskeleton remodeling. Furthermore, pretreatment of bovine lung microvascular endothelial cells with PD 98059 (25 muM), an inhibitor of MEK1/2, or SP 600125 (25 muM), an inhibitor of JNK, or SB 202190 (25 muM), an inhibitor of p38 MAPK, partially attenuated 4-HNE-mediated barrier function and cytoskeletal remodeling. These results suggest that the activation of ERK, JNK, and p38 MAP kinases is involved in 4-HNE-mediated actin remodeling and endothelial barrier function.	Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD 21224 USA	Johns Hopkins University	Natarajan, V (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Mason F Lord Bldg,Ctr Tower,Rm 675,5200 Eastern A, Baltimore, MD 21224 USA.	vnataraj@jhmi.edu			NHLBI NIH HHS [R01 HL 69909] Funding Source: Medline; PHS HHS [P01 58064] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069909] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRERA G, 1994, BIOCHEM BIOPH RES CO, V203, P553, DOI 10.1006/bbrc.1994.2218; Barrera G, 1996, BIOCHEM BIOPH RES CO, V227, P589, DOI 10.1006/bbrc.1996.1550; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Carini R, 1996, BIOCHEM BIOPH RES CO, V218, P772, DOI 10.1006/bbrc.1996.0137; Cheng JZ, 2001, ARCH BIOCHEM BIOPHYS, V392, P197, DOI 10.1006/abbi.2001.2452; Compton CN, 1998, J TRAUMA, V44, P783, DOI 10.1097/00005373-199805000-00007; Dianzani Mario Umberto, 2003, Molecular Aspects of Medicine, V24, P263; Dickinson DA, 2002, ANN NY ACAD SCI, V973, P488, DOI 10.1111/j.1749-6632.2002.tb04690.x; Doorn JA, 2002, CHEM RES TOXICOL, V15, P1445, DOI 10.1021/tx025590o; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Eaton P, 1999, AM J PHYSIOL-HEART C, V276, pH935, DOI 10.1152/ajpheart.1999.276.3.H935; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Fischer TA, 2001, HYPERTENSION, V37, P1222, DOI 10.1161/01.HYP.37.5.1222; Fleuranceau-Morel P, 1999, NEUROSCI LETT, V277, P91, DOI 10.1016/S0304-3940(99)00652-7; Garcia JGN, 2002, FASEB J, V16, P1064, DOI 10.1096/fj.01-0895com; GIAEVER I, 1993, NATURE, V366, P591, DOI 10.1038/366591a0; GIAEVER I, 1991, P NATL ACAD SCI USA, V88, P7896, DOI 10.1073/pnas.88.17.7896; Goldberg PL, 2002, AM J PHYSIOL-LUNG C, V282, pL146, DOI 10.1152/ajplung.2002.282.1.L146; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hamilton RF, 1998, AM J PHYSIOL-LUNG C, V274, pL8, DOI 10.1152/ajplung.1998.274.1.L8; Herbst U, 1999, J CELL PHYSIOL, V181, P295, DOI 10.1002/(SICI)1097-4652(199911)181:2<295::AID-JCP11>3.0.CO;2-I; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; Ji C, 2001, J BIOL CHEM, V276, P18223, DOI 10.1074/jbc.M101266200; Koh YH, 2000, FREE RADICAL RES, V33, P739, DOI 10.1080/10715760000301261; Kyaw M, 2001, HYPERTENS RES, V24, P251, DOI 10.1291/hypres.24.251; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Leonarduzzi G, 2000, FREE RADICAL BIO MED, V28, P1370, DOI 10.1016/S0891-5849(00)00216-1; Liu RM, 2001, AM J RESP CELL MOL, V24, P499, DOI 10.1165/ajrcmb.24.4.4307; Lu CB, 2002, J BIOL CHEM, V277, P24368, DOI 10.1074/jbc.M201924200; Lum H, 2001, AM J PHYSIOL-CELL PH, V280, pC719; Mark RJ, 1997, J NEUROCHEM, V68, P255; McConnell EJ, 2002, ENDOTHELIUM-J ENDOTH, V9, P45, DOI 10.1080/10623320210708; Mertsch K, 2001, NEUROSCI LETT, V314, P135, DOI 10.1016/S0304-3940(01)02299-6; Mikalsen SO, 1998, J BIOL CHEM, V273, P10036, DOI 10.1074/jbc.273.16.10036; Minekura H, 2001, BIOCHEM BIOPH RES CO, V282, P557, DOI 10.1006/bbrc.2001.4586; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; Natarajan V, 1997, AM J RESP CELL MOL, V17, P251, DOI 10.1165/ajrcmb.17.2.2623; NATARAJAN V, 1993, FREE RADICAL BIO MED, V15, P365, DOI 10.1016/0891-5849(93)90036-T; Natarajan V, 2001, AM J PHYSIOL-LUNG C, V281, pL435, DOI 10.1152/ajplung.2001.281.2.L435; Neely MD, 2002, CHEM RES TOXICOL, V15, P40, DOI 10.1021/tx010115w; Nitti M, 2002, BIOCHEM BIOPH RES CO, V294, P547, DOI 10.1016/S0006-291X(02)00512-0; Ogihara T, 1999, ARCH DIS CHILD-FETAL, V80, pF21, DOI 10.1136/fn.80.1.F21; Parinandi NL, 1999, ANTIOXID REDOX SIGN, V1, P193, DOI 10.1089/ars.1999.1.2-193; Parola M, 1998, J CLIN INVEST, V102, P1942, DOI 10.1172/JCI1413; Pross M, 2000, SURG ENDOSC, V14, P1180, DOI 10.1007/s004640000189; Rahman I, 2002, AM J RESP CRIT CARE, V166, P490, DOI 10.1164/rccm.2110101; Reagan LP, 2000, BRAIN RES, V862, P292, DOI 10.1016/S0006-8993(00)02212-5; Schaphorst KL, 2003, AM J PHYSIOL-LUNG C, V285, pL258, DOI 10.1152/ajplung.00311.2002; SHANKAR HNR, 1993, MOL CELL BIOCHEM, V129, P9, DOI 10.1007/BF00926572; Shi S, 2000, AM J PHYSIOL-LUNG C, V279, pL441, DOI 10.1152/ajplung.2000.279.3.L441; Sittipunt C, 2001, AM J RESP CRIT CARE, V163, P503, DOI 10.1164/ajrccm.163.2.2004187; Soh YJ, 2000, MOL PHARMACOL, V58, P535, DOI 10.1124/mol.58.3.535; STEVENSON MA, 1994, CANCER RES, V54, P12; Tsukagoshi H, 2002, TOXICOL APPL PHARM, V184, P127, DOI 10.1006/taap.2002.9514; Uchida K, 2000, FREE RADICAL BIO MED, V28, P1685, DOI 10.1016/S0891-5849(00)00226-4; Uchida K, 1999, J BIOL CHEM, V274, P2234, DOI 10.1074/jbc.274.4.2234; Usatyuk PV, 2003, ANTIOXID REDOX SIGN, V5, P723, DOI 10.1089/152308603770380025; Usatyuk PV, 2003, AM J PHYSIOL-LUNG C, V285, pL1006, DOI 10.1152/ajplung.00408.2002; Vepa S, 1999, AM J PHYSIOL-LUNG C, V277, pL150, DOI 10.1152/ajplung.1999.277.1.L150; Wang Q, 2001, J IMMUNOL, V166, P6877, DOI 10.4049/jimmunol.166.11.6877	62	121	130	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11789	11797		10.1074/jbc.M311184200	http://dx.doi.org/10.1074/jbc.M311184200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699126	hybrid			2022-12-25	WOS:000220157600116
J	Veach, RA; Liu, DY; Yao, S; Chen, YL; Liu, XY; Downs, S; Hawiger, J				Veach, RA; Liu, DY; Yao, S; Chen, YL; Liu, XY; Downs, S; Hawiger, J			Receptor/transporter-independent targeting of functional peptides across the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-PENETRATING PEPTIDES; PROTEIN TRANSDUCTION DOMAINS; NF-KAPPA-B; NUCLEAR-LOCALIZATION SEQUENCE; ENDOPLASMIC-RETICULUM; SIGNAL SEQUENCES; MECHANISM; LIPOSOMES; TRANSLOCATION; ENDOCYTOSIS	Targeting of peptides, proteins, and other functional cargo into living cells is contingent upon efficient transport across the plasma membrane barrier. We have harnessed the signal sequence hydrophobic region (SSHR) to deliver functional cargoes to cultured cells and to experimental animals. We now report evidence that two chirally distinct forms of SSHR composed of all L or all D amino acids showed similar membrane-translocating activity as assessed by confocal microscopy, flow cytometry, and direct fluorescence measurement. An attached nuclear localization sequence ferried by the SSHR enantiomers displayed similar intracellular function by inhibiting inducible nuclear import of transcription factor nuclear factor kappa B and suppressing nuclear factor kappa B-dependent gene expression of cytokines. A nuclear localization sequence comprised of a positively charged cluster of amino acids was rapidly translocated by SSHR enantiomers to the interior of unilamellar phospholipid vesicles. These findings indicate that the SSHR translocates functional peptides directly through the plasma membrane phospholipid bilayer without involving chirally specific receptor/transporter mechanisms. This mechanism of SSHR translocation is suitable for facile delivery of biologically active peptides for cell-based and animal-based functional proteomic studies.	Vanderbilt Univ, Med Ctr, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA	Vanderbilt University	Hawiger, J (corresponding author), Vanderbilt Univ, Med Ctr, Sch Med, Dept Microbiol & Immunol, A-5321 MCN,1161 21st Ave S, Nashville, TN 37232 USA.	jacek.hawiger@vanderbilt.edu		Veach, Ruth Ann/0000-0003-0038-8802	NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062356, P01HL068744, R43HL069542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054072] Funding Source: NIH RePORTER; NCI NIH HHS [2P30 CA68485] Funding Source: Medline; NHLBI NIH HHS [HL 69542, HL 62356, HL 68744] Funding Source: Medline; NIDDK NIH HHS [DK 54072] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200; Croce K, 1999, J BIOL CHEM, V274, P36321, DOI 10.1074/jbc.274.51.36321; DEGIER J, 1968, BIOCHIM BIOPHYS ACTA, V150, P666, DOI 10.1016/0005-2736(68)90056-4; DEVRIJE GJ, 1990, MOL MICROBIOL, V4, P143; DONALD R, 1995, J BIOL CHEM, V270, P9, DOI 10.1074/jbc.270.1.9; Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; Hawiger J, 1999, CURR OPIN CHEM BIOL, V3, P89, DOI 10.1016/S1367-5931(99)80016-7; Hawiger J, 1997, CURR OPIN IMMUNOL, V9, P189, DOI 10.1016/S0952-7915(97)80134-3; HAWIGER J, 1969, NATURE, V222, P276, DOI 10.1038/222276a0; Jo DW, 2001, NAT BIOTECHNOL, V19, P929, DOI 10.1038/nbt1001-929; KAJSTURA J, 1989, FOLIA HISTOCHEM CYTO, V27, P39; KILLIAN JA, 1990, EMBO J, V9, P815, DOI 10.1002/j.1460-2075.1990.tb08178.x; Kowarik M, 2002, MOL CELL, V10, P769, DOI 10.1016/S1097-2765(02)00685-8; Kramer SD, 2003, BBA-BIOMEMBRANES, V1609, P161, DOI 10.1016/S0005-2736(02)00683-1; Leifert JA, 2002, GENE THER, V9, P1422, DOI 10.1038/sj.gt.3301819; Lewis TS, 2000, MOL CELL, V6, P1343, DOI 10.1016/S1097-2765(00)00132-5; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Liu XY, 2000, J BIOL CHEM, V275, P16774; Liu XY, 1996, P NATL ACAD SCI USA, V93, P11819, DOI 10.1073/pnas.93.21.11819; Looger LL, 2003, NATURE, V423, P185, DOI 10.1038/nature01556; Lundberg M, 2003, MOL THER, V8, P143, DOI 10.1016/S1525-0016(03)00135-7; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; OHNOIWASHITA Y, 1983, J BIOL CHEM, V258, P1895; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Penefsky H S, 1979, Methods Enzymol, V56, P527; Peuvot J, 1999, J THEOR BIOL, V198, P173, DOI 10.1006/jtbi.1999.0908; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; SWANSON ST, 1992, BIOCHEMISTRY-US, V31, P5746, DOI 10.1021/bi00140a009; Takiguchi K, 2002, CHEMPHYSCHEM, V3, P571, DOI 10.1002/1439-7641(20020715)3:7<571::AID-CPHC571>3.0.CO;2-A; Thoren PEG, 2003, BIOCHEM BIOPH RES CO, V307, P100, DOI 10.1016/S0006-291X(03)01135-5; Torgerson TR, 1998, J IMMUNOL, V161, P6084; Torok Z, 2003, P NATL ACAD SCI USA, V100, P3131, DOI 10.1073/pnas.0438003100; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WICKNER W, 1979, ANNU REV BIOCHEM, V48, P23, DOI 10.1146/annurev.bi.48.070179.000323; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Ziegler A, 2003, BIOCHEMISTRY-US, V42, P9185, DOI 10.1021/bi0346805	43	44	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11425	11431		10.1074/jbc.M311089200	http://dx.doi.org/10.1074/jbc.M311089200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699109	hybrid			2022-12-25	WOS:000220157600073
J	Kiessling, S; Muller-Newen, G; Leeb, SN; Hausmann, M; Rath, HC; Strater, J; Spottl, T; Schlottmann, K; Grossmann, J; Montero-Julian, FA; Scholmerich, J; Andus, T; Buschauer, A; Heinrich, PC; Rogler, G				Kiessling, S; Muller-Newen, G; Leeb, SN; Hausmann, M; Rath, HC; Strater, J; Spottl, T; Schlottmann, K; Grossmann, J; Montero-Julian, FA; Scholmerich, J; Andus, T; Buschauer, A; Heinrich, PC; Rogler, G			Functional expression of the interleukin-11 receptor alpha-chain and evidence of antiapoptotic effects in human colonic epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN INTERLEUKIN-11; SIGNAL TRANSDUCER GP130; SMALL-INTESTINAL-MUCOSA; ACTIVE CROHNS-DISEASE; FACTOR-KAPPA-B; GROWTH-FACTOR; MOLECULAR-CLONING; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC CYTOKINE; ENDOTHELIAL-CELLS	A tissue-protective effect of interleukin-11 (IL-11) for the intestinal mucosa has been postulated from animal models of inflammatory bowel disease (IBD). Despite the fact that the clinical usefulness of the anti-inflammatory effects of this cytokine is presently investigated in patients with IBD, there are no data available regarding the target cells of IL-11 action and the mechanisms of tissue protection within the human colonic mucosa. IL-11 responsiveness is restricted to cells that express the interleukin-11 receptor alpha-chain (IL-11Ralpha) and an additional signal-transducing subunit (gp130). In this study, we identified the target cells for IL-11 within the human colon with a new IL-11Ralpha monoclonal antibody and investigated the functional expression of the receptor and downstream effects of IL-11-induced signaling. Immunohistochemistry revealed expression of the IL-11Ralpha selectively on colonic epithelial cells. HT-29 and colonic epithelial cells (CEC) constitutively expressed IL-11Ralpha mRNA and protein. Co-expression of the signal-transducing subunit gp130 was also demonstrated. IL-11 induced signaling through triggering activation of the Jak-STAT pathway without inducing antiinflammatory or proliferative effects in colonic epithelial cells. However, IL-11 stimulation resulted in a dose-dependent tyrosine phosphorylation of Akt, a decreased activation of caspase-9, and a reduced induction of apoptosis in cultured CEC. In HLA-B27 transgenic rats treated with IL-11, a reduction of apoptotic cell numbers was found. This study demonstrates functional expression of the IL-11Ralpha restricted on CEC within the human colonic mucosa. IL-11 induced signaling through triggering activation of the Jak-STAT pathway, without inducing anti-inflammatory or proliferative effects. The beneficial effects of IL-11 therapy are likely to be mediated by CEC via activation of the Akt-survival pathway, mediating antiapoptotic effects to support mucosal integrity.	Univ Regensburg, Dept Internal Med 1, D-93042 Regensburg, Germany; Univ Regensburg, Inst Pharmaceut Chem, D-93040 Regensburg, Germany; Rhein Westfal TH Aachen, Inst Biochem, D-52074 Aachen, Germany; Imunotech, F-13276 Marseille 9, France; Univ Ulm, Inst Pathol, D-89081 Ulm, Germany	University of Regensburg; University of Regensburg; RWTH Aachen University; Ulm University	Rogler, G (corresponding author), Univ Regensburg, Dept Internal Med 1, Franz Josef Str Allee 11, D-93042 Regensburg, Germany.	gerhard.rogler@klinik.uni-regensburg.de	Rogler, Gerhard/O-5308-2015; Buschauer, Armin/D-2861-2009	Rogler, Gerhard/0000-0002-1733-9188; 				Akira S, 1997, INT J BIOCHEM CELL B, V29, P1401, DOI 10.1016/S1357-2725(97)00063-0; Alavi K, 2000, J PEDIATR SURG, V35, P371, DOI 10.1016/S0022-3468(00)90043-5; Barton VA, 2000, J BIOL CHEM, V275, P36197, DOI 10.1074/jbc.M004648200; BERGER LC, 1994, BIOCHEM BIOPH RES CO, V202, P596, DOI 10.1006/bbrc.1994.1970; Blanc C, 2000, J IMMUNOL METHODS, V241, P43, DOI 10.1016/S0022-1759(00)00194-0; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; CHEREL M, 1995, BLOOD, V86, P2534; Chung TDK, 2000, PROSTATE, V42, P1; Dahmen H, 1998, BIOCHEM J, V331, P695, DOI 10.1042/bj3310695; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davidson AJ, 1997, STEM CELLS, V15, P119, DOI 10.1002/stem.150119; Du XX, 1997, AM J PHYSIOL-GASTR L, V272, pG545, DOI 10.1152/ajpgi.1997.272.3.G545; DU XX, 1994, BLOOD, V83, P33; DU XX, 1994, BLOOD, V83, P2023; Du XX, 1997, BLOOD, V89, P3897, DOI 10.1182/blood.V89.11.3897; FOURCIN M, 1994, EUR J IMMUNOL, V24, P277, DOI 10.1002/eji.1830240143; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; Greenwood-Van Meerveld B, 2000, LAB INVEST, V80, P1269, DOI 10.1038/labinvest.3780135; Grosfeld JL, 1999, JPEN-PARENTER ENTER, V23, pS67, DOI 10.1177/014860719902300517; Grossmann J, 2001, CELL GROWTH DIFFER, V12, P147; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KEITH JC, 1994, STEM CELLS, V12, P79; KISHIMOTO T, 1994, STEM CELLS, V12, P37; Krajewski S, 1996, CANCER RES, V56, P2849; Kuenzler KA, 2002, J SURG RES, V108, P268, DOI 10.1006/jsre.2002.6542; Lebeau B, 1997, FEBS LETT, V407, P141, DOI 10.1016/S0014-5793(97)00326-8; Leng SX, 1997, J IMMUNOL, V159, P2161; Mahboubi K, 2001, LAB INVEST, V81, P327, DOI 10.1038/labinvest.3780241; Mahboubi K, 2000, J IMMUNOL, V164, P3837, DOI 10.4049/jimmunol.164.7.3837; Nandurkar HH, 1996, ONCOGENE, V12, P585; Opal SM, 2000, J INFECT DIS, V181, P754, DOI 10.1086/315247; Orazi A, 1996, LAB INVEST, V75, P33; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; Peterson RL, 1998, LAB INVEST, V78, P1503; Peterson RL, 1996, AM J PATHOL, V149, P895; PODOLSKY DK, 1993, AM J PHYSIOL, V264, pG179, DOI 10.1152/ajpgi.1993.264.2.G179; Potten CS, 1996, STEM CELLS, V14, P452, DOI 10.1002/stem.140452; Qiu BS, 1996, DIGEST DIS SCI, V41, P1625, DOI 10.1007/BF02087911; Rogler G, 1998, GASTROENTEROLOGY, V115, P357, DOI 10.1016/S0016-5085(98)70202-1; Rogler G, 1998, LAB INVEST, V78, P889; Ropeleski MJ, 2003, GASTROENTEROLOGY, V124, P1358, DOI 10.1016/S0016-5085(03)00282-8; Sands BE, 2002, ALIMENT PHARM THERAP, V16, P399, DOI 10.1046/j.1365-2036.2002.01179.x; Sands BE, 1999, GASTROENTEROLOGY, V117, P58, DOI 10.1016/S0016-5085(99)70550-0; Schwertschlag US, 1999, LEUKEMIA, V13, P1307, DOI 10.1038/sj.leu.2401514; SONIS S, 1995, ORAL ONCOL, V31B, P261, DOI 10.1016/0964-1955(95)00015-A; Sonis ST, 1997, CYTOKINE, V9, P605, DOI 10.1006/cyto.1997.0208; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Strater J, 1997, GASTROENTEROLOGY, V113, P160, DOI 10.1016/S0016-5085(97)70091-X; Strater J, 1996, GASTROENTEROLOGY, V110, P1776, DOI 10.1053/gast.1996.v110.pm8964403; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; TIDBALL CS, 1971, AM J DIG DIS, V16, P745, DOI 10.1007/BF02239605; Trepicchio WL, 1999, J CLIN INVEST, V104, P1527, DOI 10.1172/JCI6910; Trepicchio WL, 1996, J IMMUNOL, V157, P3627; Trepicchio WL, 1997, J IMMUNOL, V159, P5661; WEINSTEIN WM, 1974, MED CLIN N AM, V58, P1375, DOI 10.1016/S0025-7125(16)32078-8; Yang YC, 1995, ANN NY ACAD SCI, V762, P31; YIN TG, 1993, J IMMUNOL, V151, P2555; YIN TG, 1994, EXP HEMATOL, V22, P467; ZHANG XG, 1994, J EXP MED, V179, P1337, DOI 10.1084/jem.179.4.1337; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	64	52	61	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10304	10315		10.1074/jbc.M312757200	http://dx.doi.org/10.1074/jbc.M312757200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701802	hybrid			2022-12-25	WOS:000220050400079
J	Kim, JE; Tannenbaum, SR				Kim, JE; Tannenbaum, SR			S-nitrosation regulates the activation of endogenous procaspase-9 in HT-29 human colon carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; CYTOCHROME-C RELEASE; CASPASE ACTIVATION; INHIBITS APOPTOSIS; NITROSYLATION; PROTEASE; DEATH; CLEAVAGE; FAS; PROTEINS	Nitric oxide-mediated signals have been suggested to regulate the activity of caspases negatively, yet literature has provided little direct evidence. We show in this paper that cytokines and nitric-oxide synthase ( NOS) inhibitors regulate S-nitrosation of an initiator caspase, procaspase-9, in a human colon adenocarcinoma cell line, HT-29. A NOS inhibitor, N-G-methyl-L-arginine, enhanced the tumor necrosis factor-alpha (TNF-alpha)-induced cleavage of procaspase-9, procaspase-3, and poly-(ADPribose) polymerase, as well as the level of apoptosis. N-G-Methyl-L-arginine, however, did not affect the cleavage of procaspase-8. These results suggest that nitric oxide regulates the cleavage of procaspase-9 and its downstream proteins and, subsequently, apoptosis in HT-29 cells. Labeling S-nitrosated cysteines with a biotin tag enabled us to reveal S-nitrosation of endogenous procaspase-9 that was immunoprecipitated from the HT-29 cell extracts. Furthermore, the treatment with TNF-alpha, as well as NOS inhibitors, decreased interferon-gamma induced S-nitrosation in procaspase-9. Our results show that S-nitrosation of endogenous procaspase-9 occurs in the HT-29 cells under normal conditions and that denitrosation of procaspase-9 enhances its cleavage and consequent apoptosis. We, therefore, suggest that S-nitrosation regulates activation of endogenous procaspase-9 in HT-29 cells.	MIT, Div Biol Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Tannenbaum, SR (corresponding author), MIT, Div Biol Engn, 77 Massachusetts Ave,Rm 56-731, Cambridge, MA 02139 USA.	srt@mit.edu			NIGMS NIH HHS [1-P50-GM68762-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM068762] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Buendia B, 1999, J CELL SCI, V112, P1743; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; Choi YB, 2000, NAT NEUROSCI, V3, P15, DOI 10.1038/71090; Deora AA, 2000, BIOCHEMISTRY-US, V39, P9901, DOI 10.1021/bi992954b; Deora AA, 1998, J BIOL CHEM, V273, P29923, DOI 10.1074/jbc.273.45.29923; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Elfering SL, 2002, J BIOL CHEM, V277, P38079, DOI 10.1074/jbc.M205256200; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Haendeler J, 2002, NAT CELL BIOL, V4, P743, DOI 10.1038/ncb851; Hess DT, 2001, NAT CELL BIOL, V3, pE46, DOI 10.1038/35055152; Hoffmann J, 2001, J BIOL CHEM, V276, P41383, DOI 10.1074/jbc.M107566200; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Jaffrey S R, 2001, Sci STKE, V2001, ppl1, DOI 10.1126/stke.2001.86.pl1; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kim PKM, 2001, INT IMMUNOPHARMACOL, V1, P1421, DOI 10.1016/S1567-5769(01)00088-1; Kim YM, 1998, J BIOL CHEM, V273, P31437, DOI 10.1074/jbc.273.47.31437; Kim YM, 2000, HEPATOLOGY, V32, P770, DOI 10.1053/jhep.2000.18291; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; KOLIOS G, 1995, BRIT J PHARMACOL, V116, P2866, DOI 10.1111/j.1476-5381.1995.tb15938.x; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kroncke KD, 2001, INT IMMUNOPHARMACOL, V1, P1407, DOI 10.1016/S1567-5769(01)00087-X; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Lacza Z, 2003, FREE RADICAL BIO MED, V35, P1217, DOI 10.1016/S0891-5849(03)00510-0; Lacza Z, 2001, FREE RADICAL BIO MED, V31, P1609, DOI 10.1016/S0891-5849(01)00754-7; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; LANE P, 2001, SCI STKE, pRE1; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li JR, 1999, J BIOL CHEM, V274, P17325, DOI 10.1074/jbc.274.24.17325; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mannick JB, 2001, J CELL BIOL, V154, P1111, DOI 10.1083/jcb.200104008; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Marshall HE, 2002, J BIOL CHEM, V277, P34223, DOI 10.1074/jbc.M201638200; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Martins LM, 1998, BLOOD, V92, P3042, DOI 10.1182/blood.V92.9.3042.421k55_3042_3049; Melino G, 1997, NATURE, V388, P432, DOI 10.1038/41237; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; O'Connell J, 2000, J CELL PHYSIOL, V185, P331, DOI 10.1002/1097-4652(200012)185:3<331::AID-JCP3>3.0.CO;2-V; Ogura T, 1997, BIOCHEM BIOPH RES CO, V236, P365, DOI 10.1006/bbrc.1997.6948; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; Park HS, 2000, P NATL ACAD SCI USA, V97, P14382, DOI 10.1073/pnas.97.26.14382; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Rossig L, 1999, J BIOL CHEM, V274, P6823, DOI 10.1074/jbc.274.11.6823; Rudel T, 1998, J IMMUNOL, V160, P7; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schonhoff CM, 2002, BIOCHEMISTRY-US, V41, P13570, DOI 10.1021/bi026262q; Schonhoff CM, 2003, J BIOL CHEM, V278, P18265, DOI 10.1074/jbc.M212459200; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Tatoyan A, 1998, J BIOL CHEM, V273, P11044, DOI 10.1074/jbc.273.18.11044; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Torok NJ, 2002, CANCER RES, V62, P1648; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Xu XL, 1998, CANCER RES, V58, P2832; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zech B, 1999, J BIOL CHEM, V274, P20931, DOI 10.1074/jbc.274.30.20931; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	84	58	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9758	9764		10.1074/jbc.M312722200	http://dx.doi.org/10.1074/jbc.M312722200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701803	hybrid			2022-12-25	WOS:000220050400014
J	MacKenzie, JA; Payne, RM				MacKenzie, JA; Payne, RM			Ribosomes specifically bind to mammalian mitochondria via protease-sensitive proteins on the outer membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SIGNAL-RECOGNITION PARTICLE; BOUND CYTOPLASMIC POLYSOMES; YEAST MITOCHONDRIA; RAT-LIVER; IN-VIVO; MICROSOMAL-MEMBRANES; NASCENT POLYPEPTIDES; RIBONUCLEIC-ACID; TRANSIT PEPTIDE	The interaction of ribosomes with specific components of membranes is one of the central themes to the co-translational targeting and import of proteins. To examine ribosome binding to mammalian mitochondria, we used ribosome-nascent chain complexes (RNCs) to follow the in vitro binding of ribosomes that correspond to the initial targeting stage of proteins. Mitochondria were found to contain a limited number of RNC binding sites on the outer membrane. It required more than twice the amount of non-translating ribosomes to inhibit RNC binding by one-half, indicating that RNCs have a competitive binding advantage. In addition, we found that RNCs bind mainly through the ribosomal component and not the nascent chain. RNCs bind via protease-sensitive proteins on the outer membrane, as well as by protease-insensitive components suggesting that two classes of receptors exist. We also show that binding is sensitive to cation conditions. Nearly all of the binding was inhibited in 0.5 M KCl, indicating that they interact with the membrane primarily through electrostatic interactions. In addition, disruption of RNC structure by removing magnesium causes the complete inhibition of binding under normal binding conditions indicating that it is the intact ribosome that is crucial for binding and not the nascent chain. These findings support the hypothesis that the outer mitochondrial membrane contains receptors specific for ribosomes, which would support the conditions necessary for co-translational import.	Wake Forest Univ, Bowman Gray Sch Med, Dept Pediat, Cardiol Sect, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Sect Mol Med, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Payne, RM (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Pediat, Cardiol Sect, Med Ctr Blvd, Winston Salem, NC 27157 USA.	mpayne@wfubmc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055765] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK55765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADELMAN MR, 1973, J CELL BIOL, V56, P206, DOI 10.1083/jcb.56.1.206; ADES IZ, 1980, J BIOL CHEM, V255, P9918; Bacher G, 1996, NATURE, V381, P248, DOI 10.1038/381248a0; Beckmann R, 2001, CELL, V107, P361, DOI 10.1016/S0092-8674(01)00541-4; Beddoe T, 2002, BBA-MOL CELL RES, V1592, P35, DOI 10.1016/S0167-4889(02)00262-8; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; BORGESE N, 1974, J MOL BIOL, V88, P559, DOI 10.1016/0022-2836(74)90408-2; CHU TW, 1987, J BIOL CHEM, V262, P12806; COLLINS PG, 1991, J CELL BIOL, V114, P639, DOI 10.1083/jcb.114.4.639; Corsi AK, 1996, J BIOL CHEM, V271, P30299, DOI 10.1074/jbc.271.48.30299; COX RA, 1976, BIOCHEM J, V160, P505, DOI 10.1042/bj1600505; Crowley KS, 1998, J BIOL CHEM, V273, P17278, DOI 10.1074/jbc.273.27.17278; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; Donzeau M, 2000, CELL, V101, P401, DOI 10.1016/S0092-8674(00)80850-8; Driessen AJM, 2001, NAT STRUCT BIOL, V8, P492, DOI 10.1038/88549; EDELMAN IS, 1960, BIOCHIM BIOPHYS ACTA, V43, P393, DOI 10.1016/0006-3002(60)90464-9; FUJIKI M, 1991, J BIOL CHEM, V266, P6841; FUJIKI M, 1993, J BIOL CHEM, V268, P1914; Funfschilling U, 1999, MOL BIOL CELL, V10, P3289, DOI 10.1091/mbc.10.10.3289; George R, 2002, FEBS LETT, V516, P213, DOI 10.1016/S0014-5793(02)02528-0; George R, 1998, P NATL ACAD SCI USA, V95, P2296, DOI 10.1073/pnas.95.5.2296; GILMORE R, 1991, METHOD CELL BIOL, V34, P223; Hanes J, 1997, P NATL ACAD SCI USA, V94, P4937, DOI 10.1073/pnas.94.10.4937; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KELLEMS RE, 1972, J BIOL CHEM, V247, P8043; KELLEMS RE, 1974, J BIOL CHEM, V249, P3297; KELLEMS RE, 1975, J CELL BIOL, V65, P1, DOI 10.1083/jcb.65.1.1; KELLEMS RE, 1974, J BIOL CHEM, V249, P3304; LAURING B, 1995, P NATL ACAD SCI USA, V92, P9435, DOI 10.1073/pnas.92.21.9435; Lithgow T, 2000, FEBS LETT, V476, P22, DOI 10.1016/S0014-5793(00)01663-X; Liu MQ, 2000, J BIOL CHEM, V275, P29400, DOI 10.1074/jbc.M002173200; Menetret JF, 2000, MOL CELL, V6, P1219, DOI 10.1016/S1097-2765(00)00118-0; MINAMI EI, 1984, ARCH BIOCHEM BIOPHYS, V235, P562, DOI 10.1016/0003-9861(84)90230-3; Morrow MW, 2001, TRAFFIC, V2, P705, DOI 10.1034/j.1600-0854.2001.21005.x; Murphy EC, 1997, J CELL BIOL, V136, P1213, DOI 10.1083/jcb.136.6.1213; Neuhof A, 1998, MOL BIOL CELL, V9, P103, DOI 10.1091/mbc.9.1.103; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Ni L, 1999, J BIOL CHEM, V274, P12685, DOI 10.1074/jbc.274.18.12685; Nicchitta CV, 1997, J CELL BIOL, V139, P1697, DOI 10.1083/jcb.139.7.1697; Nobumoto M, 1998, J BIOCHEM, V123, P128; NOLAN RD, 1969, EUR J BIOCHEM, V10, P96; PICKETT CB, 1980, EXP CELL RES, V128, P343, DOI 10.1016/0014-4827(80)90070-1; Prinz A, 2000, EMBO J, V19, P1900, DOI 10.1093/emboj/19.8.1900; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Stan T, 2000, EMBO J, V19, P4895, DOI 10.1093/emboj/19.18.4895; SUISSA M, 1982, J BIOL CHEM, V257, P3048; UNDERHAY E, 1956, J BIOPHYS BIOCHEM CY, V2, P635, DOI 10.1083/jcb.2.5.635; van Voorst F, 2000, BIOCHEM J, V347, P601, DOI 10.1042/bj3470601; VERNER K, 1993, TRENDS BIOCHEM SCI, V18, P366, DOI 10.1016/0968-0004(93)90090-A; WALTER P, 1983, METHOD ENZYMOL, V96, P84	53	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9803	9810		10.1074/jbc.M307167200	http://dx.doi.org/10.1074/jbc.M307167200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14668341	hybrid			2022-12-25	WOS:000220050400019
J	Verloo, P; Kocken, CHM; Van der Wel, A; Tilly, BC; Hogema, BM; Sinaasappel, M; Thomas, AW; De Jonge, HR				Verloo, P; Kocken, CHM; Van der Wel, A; Tilly, BC; Hogema, BM; Sinaasappel, M; Thomas, AW; De Jonge, HR			Plasmodium falciparum-activated chloride channels are defective in erythrocytes from cystic fibrosis patients	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; RED-BLOOD-CELLS; TRANSMEMBRANE CONDUCTANCE REGULATOR; MALARIA-INFECTED ERYTHROCYTES; ANION CHANNEL; PARASITE; MEMBRANE; CFTR; CAMP; ATP	An inwardly rectifying anion channel in malaria-infected red blood cells has been proposed to function as the "new permeation pathway" for parasite nutrient acquisition. As the channel shares several properties with the cystic fibrosis transmembrane conductance regulator (CFTR), we tested their interrelationship by whole-cell current measurements in Plasmodium falciparum-infected and uninfected red blood cells from control and cystic fibrosis (CF) patients. A CFTR-like linear chloride conductance as well as a malaria parasite-induced and a shrinkage-activated endogenous inwardly rectifying chloride conductance with properties identical to the malaria-induced channel were all found to be defective in CF erythrocytes. Surprisingly, the absence of the inwardly rectifying chloride conductance in CF erythrocytes had no gross effect on in vitro parasite growth or new permeation pathway activity, supporting an argument against a close association between the Plasmodium-activated chloride channel and the new permeation pathway. The functional expression of CFTR in red blood cells opens new perspectives to exploit the erythrocyte as a readily available cell type in electrophysiological, diagnostic, and therapeutic studies of CF.	Erasmus Univ, Med Ctr, Dept Biochem, NL-3000 DR Rotterdam, Netherlands; Biomed Primate Res Ctr, Dept Parasitol, NL-2280 GH Rijswijk, Netherlands; Erasmus Univ, Sophia Childrens Hosp, Med Ctr, NL-3015 GJ Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital	De Jonge, HR (corresponding author), Erasmus Univ, Med Ctr, Dept Biochem, POB 1738, NL-3000 DR Rotterdam, Netherlands.	h.dejonge@erasmusmc.nl		Verloo, Patrick/0000-0003-2077-0275; Voorberg - van der Wel, Annemarie/0000-0001-9403-0515; Kocken, Clemens/0000-0002-4784-1734				ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; Baumeister S, 2003, MOL BIOCHEM PARASIT, V132, P35, DOI 10.1016/j.molbiopara.2003.08.003; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BRAUNBRETON C, 1988, NATURE, V332, P457, DOI 10.1038/332457a0; Cohn JV, 2003, MOL BIOCHEM PARASIT, V132, P27, DOI 10.1016/j.molbiopara.2003.08.001; Deng WS, 2003, BIOCHEM J, V374, P559, DOI 10.1042/BJ20030474; Deng WS, 2002, MOL MICROBIOL, V44, P1141, DOI 10.1046/j.1365-2958.2002.02948.x; Desai SA, 2000, NATURE, V406, P1001, DOI 10.1038/35023000; Donald RGK, 2002, EUKARYOT CELL, V1, P317, DOI 10.1128/EC.1.3.317-328.2002; Egee S, 2002, J PHYSIOL-LONDON, V542, P795, DOI 10.1113/jphysiol.2002.022970; GINSBURG H, 1987, BIOSCIENCE REP, V7, P455, DOI 10.1007/BF01116501; Ginsburg Hagai, 1999, Novartis Foundation Symposium, V226, P99; Huber SM, 2002, EMBO J, V21, P22, DOI 10.1093/emboj/21.1.22; KIRK K, 1993, FEBS LETT, V323, P123, DOI 10.1016/0014-5793(93)81462-9; Kirk K, 1999, Novartis Found Symp, V226, P55; Kirk K, 2000, NATURE, V406, P949, DOI 10.1038/35023209; Kirk K, 2001, PHYSIOL REV, V81, P495, DOI 10.1152/physrev.2001.81.2.495; KUTNER S, 1982, BIOCHIM BIOPHYS ACTA, V687, P113, DOI 10.1016/0005-2736(82)90178-X; Li JL, 2000, MOL BIOCHEM PARASIT, V109, P157, DOI 10.1016/S0166-6851(00)00242-5; Ogura T, 2002, FASEB J, V16, P863, DOI 10.1096/fj.01-0845fje; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; Reddy MM, 2003, NATURE, V423, P756, DOI 10.1038/nature01694; Sprague RS, 2001, AM J PHYSIOL-CELL PH, V281, pC1158, DOI 10.1152/ajpcell.2001.281.4.C1158; Sprague RS, 1998, AM J PHYSIOL-HEART C, V275, pH1726, DOI 10.1152/ajpheart.1998.275.5.H1726; Staines HM, 2003, J PHYSIOL-LONDON, V552, P177, DOI 10.1113/jphysiol.2003.051169; Staines HM, 2001, AM J PHYSIOL-CELL PH, V280, pC1576, DOI 10.1152/ajpcell.2001.280.6.C1576; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; von Lindern M, 1999, BLOOD, V94, P550, DOI 10.1182/blood.V94.2.550.414k39_550_559; Wagner MA, 2003, BIOPHYS J, V84, P116, DOI 10.1016/S0006-3495(03)74836-X	29	68	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10316	10322		10.1074/jbc.M311540200	http://dx.doi.org/10.1074/jbc.M311540200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14679190	hybrid			2022-12-25	WOS:000220050400080
J	Clark, JA; Black, AR; Leontieva, OV; Frey, MR; Pysz, MA; Kunneva, L; Woloszynska-Read, A; Roy, D; Black, JD				Clark, JA; Black, AR; Leontieva, OV; Frey, MR; Pysz, MA; Kunneva, L; Woloszynska-Read, A; Roy, D; Black, JD			Involvement of the ERK signaling cascade in protein kinase C-mediated cell cycle arrest in intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; MAP-KINASE; PHORBOL ESTER; BRYOSTATIN 1; INDUCED DIFFERENTIATION; INDUCED PROLIFERATION; SUSTAINED ACTIVATION; DOWN-REGULATION; CANCER CELLS; PC12 CELLS	We have reported previously that protein kinase C (PKC) signaling can mediate a program of cell cycle withdrawal in IEC-18 nontransformed intestinal crypt cells, involving rapid disappearance of cyclin D1, increased expression of Cip/Kip cyclin-dependent kinase inhibitors, and activation of the growth suppressor function of pocket proteins (Frey, M. R., Clark, J. A., Leontieva, O., Uronis, J. M., Black, A. R., and Black, J. D. (2000) J. Cell Biol. 151, 763 - 777). In the current study, we present evidence to support a requisite role for PKC alpha in mediating these effects. Furthermore, analysis of the signaling events linking PKC/PKC alpha activation to changes in the cell cycle regulatory machinery implicate the Ras/Raf/MEK/ERK cascade. PKC/PKC alpha activity promoted GTP loading of Ras, activation of Raf-1, and phosphorylation/activation of ERK. ERK activation was found to be required for critical downstream effects of PKC/PKC alpha activation, including cyclin D1 down-regulation, p21(Waf1/Cip1) induction, and cell cycle arrest. PKC-induced ERK activation was strong and sustained relative to that produced by proliferative signals, and the growth inhibitory effects of PKC agonists were dominant over proliferative events when these opposing stimuli were administered simultaneously. PKC signaling promoted cytoplasmic and nuclear accumulation of ERK activity, whereas growth factor-induced phospho-ERK was localized only in the cytoplasm. Comparison of the effects of PKC agonists that differ in their ability to sustain PKC alpha activation and growth arrest in IEC-18 cells, together with the use of selective kinase inhibitors, indicated that the length of PKC-mediated cell cycle exit is dictated by the magnitude/duration of input signal (i.e. PKC alpha activity) and of activation of the ERK cascade. The extent/duration of phospho-ERK nuclear localization may also be important determinants of the duration of PKC agonist-induced growth arrest in this system. Taken together, the data point to PKC alpha and the Ras/Raf/MEK/ERK cascade as key regulators of cell cycle withdrawal in intestinal epithelial cells.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Black, JD (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.	jennifer.black@roswellpark.org	Frey, Mark/M-1739-2019; Frey, Mark/G-3691-2015	Frey, Mark/0000-0002-2561-5402; Frey, Mark/0000-0002-2561-5402	NCI NIH HHS [CA16056] Funding Source: Medline; NIDDK NIH HHS [DK54909, DK60632] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060632, R01DK054909, R56DK060632] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIHARA H, 1991, P NATL ACAD SCI USA, V88, P11062, DOI 10.1073/pnas.88.24.11062; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bikle DD, 2001, MOL CELL ENDOCRINOL, V177, P161, DOI 10.1016/S0303-7207(01)00452-X; Black JD, 2000, FRONT BIOSCI-LANDMRK, V5, pD406, DOI 10.2741/Black; BLUMBERG PM, 1994, PROG CLIN BIOL RES, V387, P3; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; CELANO P, 1993, CELL GROWTH DIFFER, V4, P341; Chen AP, 1999, J BIOL CHEM, V274, P35505, DOI 10.1074/jbc.274.50.35505; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Chiloeches A, 1999, J BIOL CHEM, V274, P19762, DOI 10.1074/jbc.274.28.19762; CLEMENS MJ, 1992, J CELL SCI, V103, P881; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Corbit KC, 2003, J BIOL CHEM, V278, P13061, DOI 10.1074/jbc.M210015200; Corbit KC, 1999, MOL CELL BIOL, V19, P4209; Das D, 2000, FEBS LETT, V472, P50, DOI 10.1016/S0014-5793(00)01416-2; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8; Duncia JV, 1998, BIOORG MED CHEM LETT, V8, P2839, DOI 10.1016/S0960-894X(98)00522-8; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Frey MR, 2000, J CELL BIOL, V151, P763, DOI 10.1083/jcb.151.4.763; Frey MR, 1997, J BIOL CHEM, V272, P9424; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; Gschwend JE, 2000, MOL PHARMACOL, V57, P1224; Harada T, 2001, NAT CELL BIOL, V3, P453, DOI 10.1038/35074516; HOCEVAR BA, 1992, J CELL SCI, V101, P671; Irie N, 2002, BIOCHEM BIOPH RES CO, V298, P738, DOI 10.1016/S0006-291X(02)02531-7; Kaiser GC, 1999, EXP CELL RES, V249, P349, DOI 10.1006/excr.1999.4488; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee HW, 1997, MOL PHARMACOL, V51, P439; Leontieva OV, 2004, J BIOL CHEM, V279, P5788, DOI 10.1074/jbc.M308375200; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Paramio JM, 1998, ONCOGENE, V17, P949, DOI 10.1038/sj.onc.1202031; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Quaroni A, 1980, Methods Cell Biol, V21B, P403; Ravi RK, 1998, J CLIN INVEST, V101, P153, DOI 10.1172/JCI831; Ray RM, 1999, AM J PHYSIOL-CELL PH, V276, pC684, DOI 10.1152/ajpcell.1999.276.3.C684; Rivard N, 1999, AM J PHYSIOL-CELL PH, V277, pC652, DOI 10.1152/ajpcell.1999.277.4.C652; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SAXON ML, 1994, J CELL BIOL, V126, P747, DOI 10.1083/jcb.126.3.747; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Tibudan SS, 2002, J INVEST DERMATOL, V119, P1282, DOI 10.1046/j.1523-1747.2002.19625.x; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Tsukada Y, 2001, J BIOL CHEM, V276, P40968, DOI 10.1074/jbc.M010890200; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Weinstein-Oppenheimer CR, 2000, PHARMACOL THERAPEUT, V88, P229, DOI 10.1016/S0163-7258(00)00085-1; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YAMAGUCHI K, 1995, BIOCHEM BIOPH RES CO, V210, P639, DOI 10.1006/bbrc.1995.1708; YEE AS, 1998, FRONT BIOSCI, V3, P532; Zezula J, 1997, J BIOL CHEM, V272, P29967, DOI 10.1074/jbc.272.47.29967	75	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9233	9247		10.1074/jbc.M312268200	http://dx.doi.org/10.1074/jbc.M312268200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14670956	hybrid			2022-12-25	WOS:000189265900085
J	Santiago, TC; Zufferey, R; Mehra, RS; Coleman, RA; Ben Mamoun, C				Santiago, TC; Zufferey, R; Mehra, RS; Coleman, RA; Ben Mamoun, C			The Plasmodium falciparum PfGatp is an endoplasmic reticulum membrane protein important for the initial step of malarial glycerolipid synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PFNT1 NUCLEOSIDE TRANSPORTER; PHOSPHATIDIC-ACID; SN-GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; DIHYDROXYACETONE PHOSPHATE; INFECTED ERYTHROCYTES; LIPID PARTICLES; BIOSYNTHESIS; GENE; LOCALIZATION; CHOLINE	During its 48-h asexual life cycle within human erythrocytes, Plasmodium falciparum grows to many times its own size and divides to produce 16-32 new parasites. This rapid multiplication requires active synthesis of new membranes and is fueled by phospholipid precursors and fatty acids that are scavenged from the human host. Plasmodium membrane biogenesis relies heavily on the expression of parasite enzymes that incorporate these precursors into phospholipids. However, little is known about the genes involved in membrane biogenesis or where this process takes place within the parasite. Here, we describe the analysis in P. falciparum of the first step of phospholipid biosynthesis that controls acylation of glycerol 3-phosphate (GPAT) at the sn-1 position. We show that this activity is of parasite origin and is specific for glycerol 3-phosphate substrate. We have identified the gene, PfGAT, encoding this activity in P. falciparum and reconstituted its codon composition for optimal expression in the yeast Saccharomyces cerevisiae. PfGAT complements the lethality of a yeast double mutant gat1Deltagat2Delta, lacking GPAT activity. Biochemical analysis revealed that PfGatp is a low affinity GPAT enzyme with a high specificity for C16:0 and C16:1 substrates. PfGatp is an integral membrane protein of the endoplasmic reticulum expressed throughout the intraerythrocytic life cycle of the parasite but induced mainly at the trophozoite stage. This study, which describes the first protozoan GPAT gene, reveals an important role for the endoplasmic reticulum in the initial step of Plasmodium membrane biogenesis.	Univ Connecticut, Ctr Hlth, Ctr Microbial Pathogenesis, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Dept Pathol, Farmington, CT 06030 USA; Univ N Carolina, Dept Nutr, Chapel Hill, NC 27599 USA	University of Connecticut; University of Connecticut; University of Connecticut; University of North Carolina; University of North Carolina Chapel Hill	Ben Mamoun, C (corresponding author), Univ Connecticut, Ctr Hlth, Ctr Microbial Pathogenesis, 263 Farmington Ave,MC3710, Farmington, CT 06030 USA.	choukri@up.uchc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR006192] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056598] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR06192] Funding Source: Medline; NIDDK NIH HHS [DK56598] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANCELIN ML, 1986, BIOCHIM BIOPHYS ACTA, V875, P52, DOI 10.1016/0005-2760(86)90010-X; ANCELIN ML, 1986, FEBS LETT, V202, P217, DOI 10.1016/0014-5793(86)80690-1; Athenstaedt K, 1999, J BACTERIOL, V181, P1458, DOI 10.1128/JB.181.5.1458-1463.1999; Athenstaedt K, 1999, EUR J BIOCHEM, V266, P1, DOI 10.1046/j.1432-1327.1999.00822.x; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; Bozdech Z, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-r9; Carter NS, 2000, J BIOL CHEM, V275, P10683, DOI 10.1074/jbc.275.14.10683; CHRISTIANSEN K, 1978, BIOCHIM BIOPHYS ACTA, V530, P78, DOI 10.1016/0005-2760(78)90128-5; Coleman RA, 2000, ANNU REV NUTR, V20, P77, DOI 10.1146/annurev.nutr.20.1.77; Dircks L, 1999, PROG LIPID RES, V38, P461, DOI 10.1016/S0163-7827(99)00012-0; ELMENDORF HG, 1993, EMBO J, V12, P4763, DOI 10.1002/j.1460-2075.1993.tb06165.x; Foth BJ, 2003, SCIENCE, V299, P705, DOI 10.1126/science.1078599; Foth BJ, 2003, INT REV CYTOL, V224, P57, DOI 10.1016/S0074-7696(05)24003-2; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Hanada K, 2002, J EXP MED, V195, P23, DOI 10.1084/jem.20010724; HOLZ GG, 1977, B WORLD HEALTH ORGAN, V55, P237; KELLEY MJ, 1987, J BIOL CHEM, V262, P14563; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; KUMAR N, 1991, MOL BIOCHEM PARASIT, V48, P47, DOI 10.1016/0166-6851(91)90163-Z; Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025; Lehner R, 1996, PROG LIPID RES, V35, P169, DOI 10.1016/0163-7827(96)00005-7; Lewin TM, 1999, BIOCHEMISTRY-US, V38, P5764, DOI 10.1021/bi982805d; Mamoun CB, 2001, MOL MICROBIOL, V39, P26, DOI 10.1046/j.1365-2958.2001.02222.x; Miller CA, 1998, NUCLEIC ACIDS RES, V26, P3577, DOI 10.1093/nar/26.15.3577; Mitamura T, 2003, MICROBES INFECT, V5, P545, DOI 10.1016/S1286-4579(03)00070-4; Mitamura T, 2000, PARASITOL INT, V49, P219, DOI 10.1016/S1383-5769(00)00048-9; Prigge ST, 2003, BIOCHEMISTRY-US, V42, P1160, DOI 10.1021/bi026847k; Rager N, 2001, J BIOL CHEM, V276, P41095, DOI 10.1074/jbc.M107037200; SHERMAN IW, 1979, MICROBIOL REV, V43, P453, DOI 10.1128/MMBR.43.4.453-495.1979; Sorger D, 2003, APPL MICROBIOL BIOT, V61, P289, DOI 10.1007/s00253-002-1212-4; Sorger D, 2002, J BACTERIOL, V184, P519, DOI 10.1128/JB.184.2.519-524.2002; TILLMAN TS, 1986, J BIOL CHEM, V261, P9144; Toke DA, 1998, J BIOL CHEM, V273, P3278, DOI 10.1074/jbc.273.6.3278; Toke DA, 1998, J BIOL CHEM, V273, P14331, DOI 10.1074/jbc.273.23.14331; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Vial H., 1998, MALARIA PARASITE BIO, P159; VIAL HJ, 1990, BLOOD CELLS, V16, P531; VIAL HJ, 1992, MEM I OSWALDO CRUZ, V87, P251, DOI 10.1590/S0074-02761992000700042; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Wengelnik K, 2002, SCIENCE, V295, P1311, DOI 10.1126/science.1067236; WHO Expert Committee on Malaria, 2000, WHO TECH REP SER, V892, P1; Zaremberg V, 2002, J BIOL CHEM, V277, P39035, DOI 10.1074/jbc.M207753200; Zheng ZF, 2001, J BIOL CHEM, V276, P41710, DOI 10.1074/jbc.M104749200	43	37	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9222	9232		10.1074/jbc.M310502200	http://dx.doi.org/10.1074/jbc.M310502200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14668349	hybrid			2022-12-25	WOS:000189265900084
J	Ligeti, E; Dagher, MC; Hernandez, SE; Koleske, AJ; Settleman, J				Ligeti, E; Dagher, MC; Hernandez, SE; Koleske, AJ; Settleman, J			Phospholipids can switch the GTPase substrate preference of a GTPase-activating protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO; RAS; PHOSPHORYLATION; IDENTIFICATION; ASSOCIATION; INHIBITION; DOMAIN; LIPIDS; FAMILY; ARF	The major cellular inhibitors of the small GTPases of the Ras superfamily are the GTPase-activating proteins ( GAPs), which stimulate the intrinsic GTP hydrolyzing activity of GTPases, thereby inactivating them. The catalytic activity of several GAPs is reportedly inhibited or stimulated by various phospholipids and fatty acids in vitro, indicating a likely physiological role for lipids in regulating small GTPases. We find that the p190 RhoGAP, a potent GAP for the Rho and Rac GTPases, is similarly sensitive to phospholipids. Interestingly, however, several of the tested phospholipids were found to effectively inhibit the RhoGAP activity of p190 but stimulate its RacGAP activity. Thus, phospholipids have the ability to "switch" the GTPase substrate preference of a GAP, thereby providing a novel regulatory mechanism for the small GTPases.	Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Semmelweis Univ, Dept Physiol, H-1444 Budapest, Hungary; CEA Grenoble, Biochim Lab, F-38054 Grenoble, France; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Semmelweis University; CEA; Yale University; Harvard University	Settleman, J (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA.	Settleman@helix.mgh.harvard.edu		DAGHER, Marie-Claire/0000-0001-6878-3169	NINDS NIH HHS [R01 NS039475] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039475] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHMED S, 1995, METHOD ENZYMOL, V256, P114; Bernards A, 2003, BBA-REV CANCER, V1603, P47, DOI 10.1016/S0304-419X(02)00082-3; Burbelo PD, 1995, J BIOL CHEM, V270, P30919, DOI 10.1074/jbc.270.52.30919; FUCHS A, 1994, EUR J BIOCHEM, V226, P587, DOI 10.1111/j.1432-1033.1994.tb20084.x; Kam JL, 2000, J BIOL CHEM, V275, P9653, DOI 10.1074/jbc.275.13.9653; Krugmann S, 2002, MOL CELL, V9, P95, DOI 10.1016/S1097-2765(02)00434-3; LIGETI E, 1993, EUR J BIOCHEM, V216, P813, DOI 10.1111/j.1432-1033.1993.tb18202.x; Lockyer PJ, 1999, CURR BIOL, V9, P265, DOI 10.1016/S0960-9822(99)80116-X; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; Miura K, 2002, MOL CELL, V9, P109, DOI 10.1016/S1097-2765(02)00428-8; Molnar G, 2001, BIOCHEMISTRY-US, V40, P10542, DOI 10.1021/bi011158e; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; Nie ZZ, 2002, J BIOL CHEM, V277, P48965, DOI 10.1074/jbc.M202969200; SERTH J, 1991, EMBO J, V10, P1325, DOI 10.1002/j.1460-2075.1991.tb07651.x; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; Sordella R, 2003, CELL, V113, P147, DOI 10.1016/S0092-8674(03)00271-X; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260	17	52	54	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5055	5058		10.1074/jbc.C300547200	http://dx.doi.org/10.1074/jbc.C300547200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14699145	hybrid			2022-12-25	WOS:000188776500003
J	Xue, LY; Chiu, SM; Fiebig, A; Andrews, DW; Oleinick, NL				Xue, LY; Chiu, SM; Fiebig, A; Andrews, DW; Oleinick, NL			Photodamage to multiple Bcl-xL isoforms by photodynamic therapy with the phthalocyanine photosensitizer Pc 4	ONCOGENE			English	Article						Bcl-xL; Bcl-2; apoptosis; photodynamic; therapy; Pc 4	ENDOPLASMIC-RETICULUM; INDUCED APOPTOSIS; CELLS; BCL-X(L); OVEREXPRESSION; ONCOPROTEIN; RESISTANCE; INDUCTION; MEMBERS; FAMILY	The antiapoptotic oncoprotein Bcl-2 is now a recognized phototarget of photodynamic therapy (PDT) with the phthalocyanine Pc 4 and with other mitochondrion-targeting photosensitizers. Photodamage, observed on Western blots as the loss of the native 26-kDa Bcl-2 protein, is PDT dose dependent and occurs in multiple cell lines, in the cold, and immediately upon photoirradiation. In our initial study, no photochemical damage was observed to Bcl-xL, in spite of its similarity in size, sequence, location and function to Bcl-2. The original study used a commercial anti-Bcl-xS/L antibody. We have revisited this issue by examining Western blots developed using one of three epitope-specific anti-Bcl-xL antibodies from commercial sources, a polyclonal antibody generated to the entire protein, as well as the antibody used previously. All five Bcl-xL antibodies recognized bacterially expressed Bcl-xL, but not Bcl-2, whereas an anti-Bcl-2 antibody recognized Bcl-2 and not Bcl-xL. All five Bcl-xL antibodies recognized at least one protein migrating at similar to30 kDa; two of the antibodies recognized an additional band, migrating at similar to33 or similar to24 kDa. We now observe Pc 4-PDT-induced photo-damage to all Bcl-xL-related proteins, except the 33-kDa species, in several human cancer cell lines. The results indicate that, in addition to the expected quantitative differences that may reflect exposure of individual epitopes, the antibodies also detect proteins of different apparent molecular weights that may be distinct isoforms or post-translationally modified forms of Bcl-xL. No evidence for PDT-induced phosphorylation or degradation was observed. Bcl-xL localized to mitochondria was considerably more sensitive to photodamage than was Bcl-xL in the cytosol, indicating that as previously found for Bcl-2, Bcl-xL must be membrane localized to be photosensitive.	Case Western Reserve Univ, Sch Med BRB324, Dept Radiat Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, CWRU Ireland Comprehens Canc Ctr, Cleveland, OH USA; McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada	Case Western Reserve University; Case Western Reserve University; McMaster University	Oleinick, NL (corresponding author), Case Western Reserve Univ, Sch Med BRB324, Dept Radiat Oncol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	nlo@po.cwru.edu		Andrews, David/0000-0002-9266-7157	NATIONAL CANCER INSTITUTE [R01CA083917, P01CA048735, P30CA043703] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA83917, P01 CA48735, P30 CA43703] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; FANG W, 1994, J IMMUNOL, V153, P4388; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Granville DJ, 1999, BRIT J CANCER, V79, P95, DOI 10.1038/sj.bjc.6690017; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; He J, 1996, PHOTOCHEM PHOTOBIOL, V64, P845, DOI 10.1111/j.1751-1097.1996.tb01845.x; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Kessel D, 1999, CELL DEATH DIFFER, V6, P28, DOI 10.1038/sj.cdd.4400446; Kessel D, 2001, PHOTOCHEM PHOTOBIOL, V74, P318, DOI 10.1562/0031-8655(2001)074<0318:ETBITT>2.0.CO;2; Kim HRC, 1999, CANCER RES, V59, P3429; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lam M, 2001, J BIOL CHEM, V276, P47379, DOI 10.1074/jbc.M107678200; Li XY, 2001, CANCER RES, V61, P1699; Liu QY, 1997, CLIN CANCER RES, V3, P2039; MOAN J, 1991, PHOTOCHEM PHOTOBIOL, V53, P549, DOI 10.1111/j.1751-1097.1991.tb03669.x; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; OLEINICK NL, 1993, PHOTOCHEM PHOTOBIOL, V57, P242, DOI 10.1111/j.1751-1097.1993.tb02282.x; Oleinick NL, 2002, PHOTOCH PHOTOBIO SCI, V1, P1, DOI 10.1039/b108586g; REED JC, 1995, HEMATOL ONCOL CLIN N, V9, P451, DOI 10.1016/S0889-8588(18)30104-7; Srivastava M, 2001, J BIOL CHEM, V276, P15481, DOI 10.1074/jbc.M006920200; Trivedi NS, 2000, PHOTOCHEM PHOTOBIOL, V71, P634, DOI 10.1562/0031-8655(2000)071<0634:QAOPLI>2.0.CO;2; Usuda J, 2003, PHOTOCHEM PHOTOBIOL, V78, P1, DOI 10.1562/0031-8655(2003)078<0001:ABTPLO>2.0.CO;2; Usuda J, 2003, J BIOL CHEM, V278, P2021, DOI 10.1074/jbc.M205219200; Wang NS, 2001, J BIOL CHEM, V276, P44117, DOI 10.1074/jbc.M101958200; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Xue LY, 2001, ONCOGENE, V20, P3420, DOI 10.1038/sj.onc.1204441; Ye QR, 2002, J EXP MED, V196, P87, DOI 10.1084/jem.20012084	32	53	55	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2003	22	58					9197	9204		10.1038/sj.onc.1207019	http://dx.doi.org/10.1038/sj.onc.1207019			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755JU	14681679				2022-12-25	WOS:000187400400001
J	Iliev, AI; Stringaris, AK; Nau, R; Neumann, H				Iliev, AI; Stringaris, AK; Nau, R; Neumann, H			Neuronal injury mediated via stimulation of microglial toll-like receptor-9 (TLR9)	FASEB JOURNAL			English	Article						microglia, neurons; toll-like receptor-9; CpG-DNA; neurite damage; neuroinflammation; meningitis; TNF-alpha; NO	NITRIC-OXIDE; BACTERIAL-DNA; NEURODEGENERATIVE DISEASE; MULTIPLE-SCLEROSIS; INNATE IMMUNITY; AXONAL INJURY; CPG MOTIFS; ACTIVATION; CELLS; NEUROTOXICITY	Innate immune cells express toll-like receptor-9 (TLR9) and respond to unmethylated, CG dinucleotide motif-rich DNA released from bacteria during infection or endogenous cells during autoimmune tissue injury. Oligonucleotides containing CG dinucleotide (CpG-DNA) mimic the effect of unmethylated DNA and stimulate TLR9. CpG-DNA was cytotoxic to neurons in organotypic brain cultures. Neurotoxicity of CpG-DNA was mediated via microglial cells and started primarily from neurites as determined by time-lapse imaging of enhanced green fluorescent protein (EGFP)-transfected neurons. Cultured brain microglial cells expressed TLR9 and responded to CpG-DNA by production of the inflammatory mediators nitric oxide (NO) and tumor necrosis factor-alpha (TNF-alpha). Blockade of NO synthase and TNF-alpha prevented damage of neurites and neurotoxicity of CpG-DNA. The data suggest that stimulation of microglia via TLR9 and subsequent release of NO and TNF-alpha is a major source of neurotoxicity in bacterial and autoimmune brain tissue injury.	Univ Gottingen, Dept Neurol, D-37075 Gottingen, Germany; European Neurosci Inst Gottingen, Neuroimmunol Unit, D-37073 Gottingen, Germany	University of Gottingen	Nau, R (corresponding author), Univ Gottingen, Dept Neurol, Robert Koch Str 40, D-37075 Gottingen, Germany.	rnau@gwdg.de	Nau, Roland/F-8234-2015; Stringaris, Argyris/N-1135-2017; Neumann, Harald/A-9718-2010; Iliev, Asparouh/D-2222-2015	Neumann, Harald/0000-0002-5071-5202; 				Bal-Price A, 2001, J NEUROSCI, V21, P6480; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; Bitsch A, 2000, BRAIN, V123, P1174, DOI 10.1093/brain/123.6.1174; Bottcher T, 2003, NEUROSCI LETT, V344, P17, DOI 10.1016/S0304-3940(03)00404-X; CHAO CC, 1992, J IMMUNOL, V149, P2736; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; Dalpke AH, 2002, J IMMUNOL, V168, P4854, DOI 10.4049/jimmunol.168.10.4854; DAWSON TM, 1994, J NEUROSCI, V14, P5147; DAWSON VL, 1994, NEUROPHARMACOLOGY, V33, P1425, DOI 10.1016/0028-3908(94)90045-0; Deng GM, 2001, J IMMUNOL, V167, P4616, DOI 10.4049/jimmunol.167.8.4616; Gerber J, 2001, EUR J CLIN MICROBIOL, V20, P490; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Ii M, 1996, BRAIN RES, V720, P93, DOI 10.1016/0006-8993(96)00156-4; Kingham PJ, 1999, J NEUROCHEM, V73, P538, DOI 10.1046/j.1471-4159.1999.0730538.x; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100; Malipiero U, 1999, EUR J IMMUNOL, V29, P3053, DOI 10.1002/(SICI)1521-4141(199910)29:10<3053::AID-IMMU3053>3.0.CO;2-I; Medana IM, 2002, AM J PATHOL, V160, P655, DOI 10.1016/S0002-9440(10)64885-7; Nau R, 2002, TRENDS NEUROSCI, V25, P38, DOI 10.1016/S0166-2236(00)02024-5; Neumann H, 1998, P NATL ACAD SCI USA, V95, P5779, DOI 10.1073/pnas.95.10.5779; Neumann H, 2003, CURR OPIN NEUROL, V16, P267, DOI 10.1097/00019052-200306000-00004; Neumann H, 2002, J NEUROSCI, V22, P854, DOI 10.1523/JNEUROSCI.22-03-00854.2002; Nguyen MD, 2002, NAT REV NEUROSCI, V3, P216, DOI 10.1038/nrn752; Perry VH, 2003, NAT REV NEUROSCI, V4, P103, DOI 10.1038/nrn1032; Peterson JW, 2001, ANN NEUROL, V50, P389, DOI 10.1002/ana.1123; Ronaghy A, 2002, J IMMUNOL, V168, P51, DOI 10.4049/jimmunol.168.1.51; Schluesener HJ, 2001, J NEUROIMMUNOL, V113, P89, DOI 10.1016/S0165-5728(00)00428-8; Sparwasser T, 1997, EUR J IMMUNOL, V27, P1671, DOI 10.1002/eji.1830270712; Takeshita S, 2001, NEUROREPORT, V12, P3029, DOI 10.1097/00001756-200110080-00010; Vinuesa CG, 2002, NATURE, V416, P595, DOI 10.1038/416595a; Wagner H, 1999, ADV IMMUNOL, V73, P329, DOI 10.1016/S0065-2776(08)60790-7; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8	33	140	145	2	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					412	+		10.1096/fj.03-0670fje	http://dx.doi.org/10.1096/fj.03-0670fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14688201				2022-12-25	WOS:000188067500007
J	Matsuo, H; Morita, E; Tatham, AS; Morimoto, K; Horikawa, T; Osuna, H; Ikezawa, Z; Kaneko, S; Kohno, K; Dekio, S				Matsuo, H; Morita, E; Tatham, AS; Morimoto, K; Horikawa, T; Osuna, H; Ikezawa, Z; Kaneko, S; Kohno, K; Dekio, S			Identification of the IgE-binding epitope in omega-5 gliadin, a major allergen in wheat-dependent exercise-induced anaphylaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTEN PROTEINS; GAMMA-GLIADIN; GENE FAMILY; PRESUMPTIVE ALLERGEN; SEQUENCES; SECALINS; CHILDREN	Wheat-dependent exercise-induced anaphylaxis (WDEIA) is a severe IgE-mediated allergic reaction provoked by the combination of wheat-ingestion with intensive physical exercise over the next few hours. Among wheat proteins, omega-5 gliadin, which is one of the components of fast omega-gliadin, has been reported as a major allergen in the anaphylaxis. In this study, we detected IgE-binding epitopes within the primary sequence of omega-5 gliadin using arrays of overlapping peptides synthesized on derivatized cellulose membranes. Sera from four patients with WDEIA having specific IgE to the fast omega-gliadin were used to probe the membrane. Seven epitopes, QQIPQQQ, QQLPQQQ, QQFPQQQ, QQSPEQQ, QQSPQQQ, QQYPQQQ, and PYPP, were detected within the primary sequence of omega-5 gliadin. By using sera of 15 patients, 4 of them, QQIPQQQ, QQFPQQQ, QQSPEQQ, and QQSPQQQ, were found to be dominant epitopes. Mutational analysis of the QQIPQQQ and QQFPQQQ indicated that amino acids at positions Gln(1), Pro(4), Gln(5), Gln(6), and Gln(7) were critical for IgE binding. These results will provide a useful tool for developing safer wheat products in addition to diagnostic and immunotherapy techniques for WDEIA.	Shimane Univ, Sch Med, Dept Dermatol, Izumo, Shimane 6938501, Japan; Dstl, Biomed Sci, Salisbury SP4 0JQ, Wilts, England; Hiroshima Univ, Grad Sch Med, Dept Dermatol, Minami Ku, Hiroshima 7348551, Japan; Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Dermatol,Chuo Ku, Kobe, Hyogo 6500017, Japan; Yokohama City Univ, Grad Sch Med, Dept Environm Immunodermatol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan	Shimane University; Defence Science & Technology Laboratory; Hiroshima University; Kobe University; Yokohama City University	Matsuo, H (corresponding author), Shimane Univ, Sch Med, Dept Dermatol, 89-1 Enya Cho, Izumo, Shimane 6938501, Japan.	hmatsuo@med.shimane-u.ac.jp	Matsuo, Hiroaki/B-4290-2008	Matsuo, Hiroaki/0000-0002-8730-5389; Tatham, Arthur/0000-0001-5080-5585				Amano M, 1998, BIOCHEM J, V330, P1229, DOI 10.1042/bj3301229; Anderson OD, 1997, THEOR APPL GENET, V95, P59, DOI 10.1007/s001220050532; Anderson OD, 2001, THEOR APPL GENET, V103, P323, DOI 10.1007/s00122-001-0551-3; Busse PJ, 2002, INT ARCH ALLERGY IMM, V129, P93, DOI 10.1159/000065178; Cassidy BG, 1998, THEOR APPL GENET, V96, P743, DOI 10.1007/s001220050797; Cocco RR, 2003, J ALLERGY CLIN IMMUN, V112, P433, DOI 10.1067/mai.2003.1617; DOHI M, 1991, J ALLERGY CLIN IMMUN, V87, P34, DOI 10.1016/0091-6749(91)90210-F; DuPont FM, 2000, CEREAL CHEM, V77, P607, DOI 10.1094/CCHEM.2000.77.5.607; Hsia CC, 2001, THEOR APPL GENET, V103, P37, DOI 10.1007/s00122-001-0552-2; KASARDA DD, 1983, BIOCHIM BIOPHYS ACTA, V747, P138, DOI 10.1016/0167-4838(83)90132-2; KIDD JM, 1983, J ALLERGY CLIN IMMUN, V71, P407, DOI 10.1016/0091-6749(83)90070-2; Maruyama N, 1998, EUR J BIOCHEM, V255, P739, DOI 10.1046/j.1432-1327.1998.2550739.x; MCNEIL D, 1988, ANN ALLERGY, V61, P440; Mine Y, 2002, BIOCHEM BIOPH RES CO, V292, P1070, DOI 10.1006/bbrc.2002.6725; Morita E, 2000, BRIT J DERMATOL, V143, P1059, DOI 10.1046/j.1365-2133.2000.03844.x; Morita E, 2003, J DERMATOL SCI, V33, P99, DOI 10.1016/S0923-1811(03)00156-7; Morita E, 2001, BRIT J DERMATOL, V145, P182, DOI 10.1046/j.1365-2133.2001.04314.x; MUNOZ FM, 1994, ALLERGY, V49, P314, DOI 10.1111/j.1398-9995.1994.tb02274.x; Noma T, 2001, ASIAN PAC J ALLERGY, V19, P283; Nowak-Wegrzyn A, 2003, PEDIATRICS, V111, P1672; Palosuo K, 1999, J ALLERGY CLIN IMMUN, V103, P912, DOI 10.1016/S0091-6749(99)70438-0; Palosuo K, 2003, J ALLERGY CLIN IMMUN, V111, P1386, DOI 10.1067/mai.2003.1498; Palosuo K, 2001, CLIN EXP ALLERGY, V31, P466, DOI 10.1046/j.1365-2222.2001.01023.x; Palosuo K, 2001, J ALLERGY CLIN IMMUN, V108, P634, DOI 10.1067/mai.2001.118602; Pauls JD, 1998, J ALLERGY CLIN IMMUN, V101, P853, DOI 10.1016/S0091-6749(98)70317-3; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; Sander I, 2001, J ALLERGY CLIN IMMUN, V107, P907, DOI 10.1067/mai.2001.113761; Sandiford CP, 1997, CLIN EXP ALLERGY, V27, P1120, DOI 10.1046/j.1365-2222.1997.1310936.x; Seilmeier W, 2001, EUR FOOD RES TECHNOL, V212, P355, DOI 10.1007/s002170000260; SIGURS N, 1994, J ALLERGY CLIN IMMUN, V94, P757, DOI 10.1016/0091-6749(94)90184-8; SILVERSTEIN S R, 1986, Journal of Emergency Medicine, V4, P195, DOI 10.1016/0736-4679(86)90040-5; Tanabe S, 1996, BIOCHEM BIOPH RES CO, V219, P290, DOI 10.1006/bbrc.1996.0225; TATHAM AS, 1985, J CEREAL SCI, V3, P103, DOI 10.1016/S0733-5210(85)80021-7; WATANABE M, 1995, BIOSCI BIOTECH BIOCH, V59, P1596, DOI 10.1271/bbb.59.1596; Wieser H, 2000, EUR FOOD RES TECHNOL, V211, P262, DOI 10.1007/s002170000165; Xiang P, 2002, ARCH BIOCHEM BIOPHYS, V408, P51, DOI 10.1016/S0003-9861(02)00534-9; Yamashita H, 2002, BIOSCI BIOTECH BIOCH, V66, P2487, DOI 10.1271/bbb.66.2487	37	134	143	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12135	12140		10.1074/jbc.M311340200	http://dx.doi.org/10.1074/jbc.M311340200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14699123	hybrid			2022-12-25	WOS:000220334900019
J	Frank, C; Burkhardt, C; Imhof, D; Ringel, J; Zschornig, O; Wieligmann, K; Zacharias, M; Bohmer, FD				Frank, C; Burkhardt, C; Imhof, D; Ringel, J; Zschornig, O; Wieligmann, K; Zacharias, M; Bohmer, FD			Effective dephosphorylation of Src substrates by SHP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; GROWTH-FACTOR RECEPTOR; SH2 DOMAIN; SIGNAL-TRANSDUCTION; NEGATIVE REGULATION; CRYSTAL-STRUCTURE; NUCLEAR-LOCALIZATION; MEDIATED ACTIVATION; SYNTHETIC PEPTIDES; HOMOLOGY-2 DOMAINS	The protein-tyrosine phosphatase SHP-1 is a negative regulator of multiple signal transduction pathways. We observed that SHP-1 effectively antagonized Src-dependent phosphorylations in HEK293 cells. This occurred by dephosphorylation of Src substrates, because Src activity was unaffected in the presence of SHP-1. One reason for efficient dephosphorylation was activation of SHP-1 by Src. Recombinant SHP-1 had elevated activity subsequent to phosphorylation by Src in vitro, and SHP-1 variants with mutated phosphorylation sites in the C terminus, SHP-1 Y538F, and SHP-1 Y538F, Y566F were less active toward Src-generated phosphoproteins in intact cells. A second reason for efficient dephosphorylation is the substrate selectivity of SHP-1. Pull-down experiments with different GST-SHP-1 fusion proteins revealed efficient interaction of Src-generated phosphoproteins with the SHP-1 catalytic domain rather than with the SH2 domains. Phosphopeptides that correspond to good Src substrates were efficiently dephosphorylated by SHP-1 in vitro. Phosphorylated "optimal Src substrate" AEEEIpYGEFEA (where pY is phosphotyrosine) and a phosphopeptide corresponding to a recently identified Src phosphorylation site in p120 catenin, DDLDpY(296)GMMSD, were excellent SHP-1 substrates. Docking of these phosphopeptides into the catalytic domain of SHP-1 by molecular modeling was consistent with the biochemical data and explains the efficient interaction. Acidic residues N-terminal of the phosphotyrosine seem to be of major importance for efficient substrate interaction. Residues C-terminal of the phosphotyrosine probably contribute to the substrate selectivity of SHP-1. We propose that activation of SHP-1 by Src and complementary substrate specificities of SHP-1 and Src may lead to very transient Src signals in the presence of SHP-1.	Univ Jena, Fac Med, Inst Mol Cell Biol, D-07747 Jena, Germany; Univ Jena, Fac Biol & Pharm, Inst Biochem & Biophys, D-07747 Jena, Germany; Univ Leipzig, Inst Med Phys & Biophys, D-04103 Leipzig, Germany; Inst Mol Biotechnol, D-07745 Jena, Germany	Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Leipzig University	Bohmer, FD (corresponding author), Univ Jena, Fac Med, Inst Mol Cell Biol, Drackendorfer Str 1, D-07747 Jena, Germany.	i5frbo@rz.uni-jena.de	Imhof, Diana/AAD-7491-2019	Imhof, Diana/0000-0003-4163-7334				Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; Barford D, 1999, BIOCHEM SOC T, V27, P751, DOI 10.1042/bst0270751; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Beebe KD, 2000, BIOCHEMISTRY-US, V39, P13251, DOI 10.1021/bi0014397; Burshtyn DN, 1997, J BIOL CHEM, V272, P13066, DOI 10.1074/jbc.272.20.13066; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Chiang GG, 2001, J BIOL CHEM, V276, P23173, DOI 10.1074/jbc.M101219200; CHO HJ, 1993, PROTEIN SCI, V2, P977, DOI 10.1002/pro.5560020611; Craggs G, 2001, J BIOL CHEM, V276, P23719, DOI 10.1074/jbc.M102846200; Cuevas B, 1999, J BIOL CHEM, V274, P27583, DOI 10.1074/jbc.274.39.27583; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DECHERT U, 1995, EUR J BIOCHEM, V231, P673, DOI 10.1111/j.1432-1033.1995.0673d.x; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Frank C, 1999, BIOCHEMISTRY-US, V38, P11993, DOI 10.1021/bi982586w; HARDER KW, 1994, BIOCHEM J, V298, P395, DOI 10.1042/bj2980395; Heinrich R, 2002, MOL CELL, V9, P957, DOI 10.1016/S1097-2765(02)00528-2; HIPPEN KL, 1993, BIOCHEMISTRY-US, V32, P12405, DOI 10.1021/bi00097a019; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Holsinger LJ, 2002, ONCOGENE, V21, P7067, DOI 10.1038/sj.onc.1205858; Huyer G, 1998, ANAL BIOCHEM, V258, P19, DOI 10.1006/abio.1997.2541; Jin YJ, 1999, J BIOL CHEM, V274, P28301, DOI 10.1074/jbc.274.40.28301; Johnson TM, 1997, J PEPT RES, V50, P365; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; Keilhack H, 2001, J CELL BIOL, V152, P325, DOI 10.1083/jcb.152.2.325; Keilhack H, 2000, J BIOL CHEM, V275, P26376, DOI 10.1074/jbc.M001315200; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kozlowski M, 1998, MOL CELL BIOL, V18, P2089, DOI 10.1128/MCB.18.4.2089; Krautwald S, 1996, MOL CELL BIOL, V16, P5955; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; Lorenz U, 1996, J EXP MED, V184, P1111, DOI 10.1084/jem.184.3.1111; Lorenz U, 1996, P NATL ACAD SCI USA, V93, P9624, DOI 10.1073/pnas.93.18.9624; Mariner DJ, 2001, J BIOL CHEM, V276, P28006, DOI 10.1074/jbc.M102443200; Myers MP, 2001, J BIOL CHEM, V276, P47771, DOI 10.1074/jbc.C100583200; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; Paulson RF, 1996, NAT GENET, V13, P309, DOI 10.1038/ng0796-309; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; Persson C, 2002, FEBS LETT, V517, P27, DOI 10.1016/S0014-5793(02)02570-X; Peters GH, 2000, J BIOL CHEM, V275, P18201, DOI 10.1074/jbc.M910273199; PINNA LA, 1994, BBA-MOL CELL RES, V1222, P415, DOI 10.1016/0167-4889(94)90050-7; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Tenev T, 2000, EUR J CELL BIOL, V79, P261, DOI 10.1078/S0171-9335(04)70029-1; Tenev T, 1997, J BIOL CHEM, V272, P5966, DOI 10.1074/jbc.272.9.5966; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; Umeda S, 1999, AM J PATHOL, V155, P223, DOI 10.1016/S0002-9440(10)65116-4; Wang P, 2002, BIOCHEMISTRY-US, V41, P6202, DOI 10.1021/bi025591f; Wishcamper CA, 2001, J COMP NEUROL, V441, P118; Wu L, 1997, J BIOL CHEM, V272, P6994, DOI 10.1074/jbc.272.11.6994; Yang J, 2003, J BIOL CHEM, V278, P6516, DOI 10.1074/jbc.M210430200; Yang J, 2000, J BIOL CHEM, V275, P4066, DOI 10.1074/jbc.275.6.4066; Yang WT, 1998, BLOOD, V91, P3746; Yang WT, 2002, BLOOD CELL MOL DIS, V28, P63, DOI 10.1006/bcmd.2002.0485; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X; Zhang JY, 2000, SEMIN IMMUNOL, V12, P361, DOI 10.1006/smim.2000.0223; Zhang ZS, 2003, J BIOL CHEM, V278, P4668, DOI 10.1074/jbc.M210028200; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHANG ZY, 1993, ANAL BIOCHEM, V211, P7, DOI 10.1006/abio.1993.1224; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; Zondag GCM, 2000, J BIOL CHEM, V275, P11264, DOI 10.1074/jbc.275.15.11264	69	68	68	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11375	11383		10.1074/jbc.M309096200	http://dx.doi.org/10.1074/jbc.M309096200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699166	hybrid			2022-12-25	WOS:000220157600067
J	Shridhar, R; Zhang, J; Song, J; Booth, BA; Kevil, CG; Sotiropoulou, G; Fsloane, B; Keppler, D				Shridhar, R; Zhang, J; Song, J; Booth, BA; Kevil, CG; Sotiropoulou, G; Fsloane, B; Keppler, D			Cystatin M suppresses the malignant phenotype of human MDA-MB-435S cells	ONCOGENE			English	Article						cystatins; cathepsins; lysosomal proteases; protease inhibitors; tumor progression	CYSTEINE PROTEINASE-INHIBITOR; SQUAMOUS CARCINOMA-CELLS; CATHEPSIN-B; BREAST-CANCER; MAMMALIAN LEGUMAIN; PLASMINOGEN-ACTIVATOR; PROTEASE INHIBITORS; CHICKEN CYSTATIN; M/E EXPRESSION; TUMOR-CELLS	Proteases are involved in many aspects of tumor progression, including cell survival and proliferation, escape from immune surveillance, cell adhesion and migration, remodeling and invasion of the extracellular matrix. Several lysosomal cysteine proteases have been cloned and shown to be overexpressed in cancer; yet, despite the great potential for development of novel therapeutics, we still know little about the regulation of their proteolytic activity. Cystatins such as cystatin M are potent endogenous protein inhibitors of lysosomal cysteine proteases. Cystatin M is expressed in normal and premalignant human epithelial cells, but not in many cancer cell lines. Here, we examined the effects of cystatin M expression on malignant properties of human breast carcinoma MDA-MB-435S cells. Cystatin M was found to significantly reduce in vitro: cell proliferation, migration, Matrigel invasion, and adhesion to endothelial cells. Reduction of cell proliferation and adhesion to an endothelial cell monolayer were both independent of the inhibition of lysosomal cysteine proteases. In contrast, cell migration and matrix invasion seemed to rely on lysosomal cysteine proteases, as both recombinant cystatin M and E64 were able to block these processes. This study provides the first evidence that cystatin M may play important roles in safeguarding against human breast cancer.	LSUHSC, Sch Med, Dept Cellular Biol & Anat, Shreveport, LA 71130 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Pathol, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA; Univ Patras, Dept Pharm, Patras 26500, Greece; Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Wayne State University; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Patras; Barbara Ann Karmanos Cancer Institute; Wayne State University	Keppler, D (corresponding author), LSUHSC, Sch Med, Dept Cellular Biol & Anat, 1501 Kings Highway,POB 33932, Shreveport, LA 71130 USA.	dkeppl@lsuhsc.edu	Zhang, Jun/AAN-4970-2021; Kevil, Christopher/G-9318-2011; Keppler, Daniel/B-4309-2012	Zhang, Jun/0000-0001-7886-6187; Kevil, Christopher/0000-0003-0863-7260	NATIONAL CANCER INSTITUTE [R21CA091785, R01CA036481] Funding Source: NIH RePORTER; NCI NIH HHS [CA91785, CA36481] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMSON M, 1994, METHOD ENZYMOL, V244, P685; ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282; Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429; Alvarez-Fernandez M, 1999, J BIOL CHEM, V274, P19195, DOI 10.1074/jbc.274.27.19195; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; BELL ET, 1989, ARCH BIOCHEM BIOPHYS, V271, P359, DOI 10.1016/0003-9861(89)90285-3; Boike G, 1992, Melanoma Res, V1, P333, DOI 10.1097/00008390-199201000-00004; Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; Bromme D, 2002, CURR PHARM DESIGN, V8, P1639, DOI 10.2174/1381612023394179; Brunner N, 1994, Cancer Treat Res, V71, P299; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; BUTTLE DJ, 1992, ARCH BIOCHEM BIOPHYS, V299, P377, DOI 10.1016/0003-9861(92)90290-D; Chapman HA, 1997, ANNU REV PHYSIOL, V59, P63, DOI 10.1146/annurev.physiol.59.1.63; Chen JM, 2001, BIOL CHEM, V382, P777, DOI 10.1515/BC.2001.093; Chen JM, 1997, J BIOL CHEM, V272, P8090, DOI 10.1074/jbc.272.12.8090; Coulibaly S, 1999, INT J CANCER, V83, P526, DOI 10.1002/(SICI)1097-0215(19991112)83:4<526::AID-IJC15>3.3.CO;2-D; DECLERCK YA, 1994, EUR J CANCER, V30A, P2170, DOI 10.1016/0959-8049(94)00460-M; Ekiel I, 1997, J MOL BIOL, V271, P266, DOI 10.1006/jmbi.1997.1150; GORETZKI L, 1992, FEBS LETT, V297, P112, DOI 10.1016/0014-5793(92)80339-I; GUINEC N, 1993, BIOL CHEM H-S, V374, P1135, DOI 10.1515/bchm3.1993.374.7-12.1135; Guo M, 2002, J BIOL CHEM, V277, P14829, DOI 10.1074/jbc.M108180200; HENDRIX MJC, 1987, CANCER LETT, V38, P137, DOI 10.1016/0304-3835(87)90209-6; Hulkower KI, 2000, EUR J BIOCHEM, V267, P4165, DOI 10.1046/j.1432-1327.2000.01458.x; KEMBHAVI AA, 1993, ARCH BIOCHEM BIOPHYS, V303, P208, DOI 10.1006/abbi.1993.1274; Keppler D, 1997, MECH AGEING DEV, V98, P151, DOI 10.1016/S0047-6374(97)00080-8; Keppler D, 1996, ENZYME PROTEIN, V49, P94, DOI 10.1159/000468619; Keppler D, 1996, BIOCHEM CELL BIOL, V74, P799, DOI 10.1139/o96-086; KEPPLER D, 1994, BBA-MOL BASIS DIS, V1226, P117, DOI 10.1016/0925-4439(94)90018-3; Kevil CG, 1998, J BIOL CHEM, V273, P15099, DOI 10.1074/jbc.273.24.15099; Kevil CG, 2001, AM J PHYSIOL-CELL PH, V281, pC1442, DOI 10.1152/ajpcell.2001.281.5.C1442; KOBAYASHI H, 1992, CANCER RES, V52, P3610; Kolkhorst V, 1998, J CANCER RES CLIN, V124, P598, DOI 10.1007/s004320050221; Konduri SD, 2002, ONCOGENE, V21, P8705, DOI 10.1038/sj.onc.1205949; LABER B, 1989, FEBS LETT, V248, P162, DOI 10.1016/0014-5793(89)80453-3; LEUNGTACK J, 1990, EXP CELL RES, V188, P16, DOI 10.1016/0014-4827(90)90272-C; Lin R, 2002, MOL ENDOCRINOL, V16, P1243, DOI 10.1210/me.16.6.1243; Linebaugh BE, 1999, EUR J BIOCHEM, V264, P100, DOI 10.1046/j.1432-1327.1999.00582.x; LIOTTA LA, 1991, CANCER RES, V51, pS5054; Liu C, 2003, CANCER RES, V63, P2957; Liu ZD, 1997, BIOCHEM BIOPH RES CO, V231, P283, DOI 10.1006/bbrc.1997.6083; MACIEWICZ RA, 1990, FEBS LETT, V269, P189, DOI 10.1016/0014-5793(90)81151-D; Mai JX, 2002, BIOL CHEM, V383, P1407, DOI 10.1515/BC.2002.159; Mason RW, 2002, BIOL CHEM, V383, P1113, DOI 10.1515/BC.2002.120; Merz GS, 1997, J CELL PHYSIOL, V173, P423; Ni J, 1997, J BIOL CHEM, V272, P10853; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; PRICE JE, 1990, CANCER METAST REV, V8, P285, DOI 10.1007/BF00052605; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; REDWOOD SM, 1992, CANCER, V69, P1212; Roshy S, 2003, CANCER METAST REV, V22, P271, DOI 10.1023/A:1023007717757; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; Sameni M, 2000, NEOPLASIA, V2, P496, DOI 10.1038/sj.neo.7900116; Sexton PS, 1997, MELANOMA RES, V7, P97, DOI 10.1097/00008390-199704000-00002; Sotiropoulou G, 1997, J BIOL CHEM, V272, P903, DOI 10.1074/jbc.272.2.903; SUN Q, 1989, EXP CELL RES, V180, P150, DOI 10.1016/0014-4827(89)90219-X; Taupin P, 2000, NEURON, V28, P385, DOI 10.1016/S0896-6273(00)00119-7; TAVERA C, 1992, BIOCHEM BIOPH RES CO, V182, P1082, DOI 10.1016/0006-291X(92)91842-E; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; Vigneswaran N, 2003, ORAL ONCOL, V39, P559, DOI 10.1016/S1368-8375(03)00038-1; Villadangos JA, 1999, IMMUNOL REV, V172, P109, DOI 10.1111/j.1600-065X.1999.tb01360.x; Zeeuwen PLJM, 2002, BRIT J DERMATOL, V147, P87, DOI 10.1046/j.1365-2133.2002.04785.x; Zeeuwen PLJM, 2001, J INVEST DERMATOL, V116, P693, DOI 10.1046/j.1523-1747.2001.01309.x	63	71	73	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2206	2215		10.1038/sj.onc.1207340	http://dx.doi.org/10.1038/sj.onc.1207340			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14676833				2022-12-25	WOS:000220280900010
J	Pirneskoski, A; Klappa, P; Lobell, M; Williamson, RA; Byrne, L; Alanen, HI; Salo, KEH; Kivirikko, KI; Freedman, RB; Ruddock, LW				Pirneskoski, A; Klappa, P; Lobell, M; Williamson, RA; Byrne, L; Alanen, HI; Salo, KEH; Kivirikko, KI; Freedman, RB; Ruddock, LW			Molecular characterization of the principal substrate binding site of the ubiquitous folding catalyst protein disulfide isomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; FUNCTIONAL-CHARACTERIZATION; DOMAIN; CHAPERONE; FAMILY	Disulfide bond formation in the endoplasmic reticulum of eukaryotes is catalyzed by the ubiquitously expressed enzyme protein disulfide isomerase (PDI). The effectiveness of PDI as a catalyst of native disulfide bond formation in folding polypeptides depends on the ability to catalyze disulfide-dithiol exchange, to bind non-native proteins, and to trigger conformational changes in the bound substrate, allowing access to buried cysteine residues. It is known that the b' domain of PDI provides the principal peptide binding site of PDI and that this domain is critical for catalysis of isomerization but not oxidation reactions in protein substrates. Here we use homology modeling to define more precisely the boundaries of the b' domain and show the existence of an intradomain linker between the b' and a' domains. We have expressed the recombinant b' domain thus defined; the stability and conformational properties of the recombinant product confirm the validity of the domain boundaries. We have modeled the tertiary structure of the b' domain and identified the primary substrate binding site within it. Mutations within this site, expressed both in the isolated domain and in full-length PDI, greatly reduce the binding affinity for small peptide substrates, with the greatest effect being I272W, a mutation that appears to have no structural effect.	Univ Oulu, Bioctr Oulu, Collagen Res Unit, FIN-90014 Oulu, Finland; Univ Oulu, Dept Biochem, FIN-90014 Oulu, Finland; Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland; Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England	University of Oulu; Finland National Institute for Health & Welfare; University of Oulu; University of Oulu; University of Kent	Ruddock, LW (corresponding author), Univ Oulu, Bioctr Oulu, Collagen Res Unit, POB 3000, FIN-90014 Oulu, Finland.	lloyd.ruddock@oulu.fi		Ruddock, Lloyd/0000-0002-6247-686X				Alanen HI, 2003, ANTIOXID REDOX SIGN, V5, P367, DOI 10.1089/152308603768295096; Alanen HI, 2003, J BIOL CHEM, V278, P28912, DOI 10.1074/jbc.M304598200; Anelli T, 2002, EMBO J, V21, P835, DOI 10.1093/emboj/21.4.835; Blank J, 2003, ANTIOXID REDOX SIGN, V5, P359, DOI 10.1089/152308603768295087; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Cunnea PM, 2003, J BIOL CHEM, V278, P1059, DOI 10.1074/jbc.M206995200; Darby NJ, 1998, J MOL BIOL, V276, P239, DOI 10.1006/jmbi.1997.1504; Dyson HJ, 1997, BIOCHEMISTRY-US, V36, P2622, DOI 10.1021/bi961801a; Ferrari DM, 1998, EUR J BIOCHEM, V255, P570, DOI 10.1046/j.1432-1327.1998.2550570.x; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; FORMANKAY JD, 1991, BIOCHEMISTRY-US, V30, P2685, DOI 10.1021/bi00224a017; Freedman RB, 2002, EMBO REP, V3, P136, DOI 10.1093/embo-reports/kvf035; Freedman RB, 1998, BIOL CHEM, V379, P321, DOI 10.1515/bchm.1998.379.3.321; Frishman D, 1997, PROTEINS, V27, P329, DOI 10.1002/(SICI)1097-0134(199703)27:3<329::AID-PROT1>3.0.CO;2-8; GANE PG, 1996, THESIS U KENT CANTER; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; Kanai S, 1998, J MOL EVOL, V47, P200, DOI 10.1007/PL00006377; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; Kemmink J, 1999, J BIOMOL NMR, V13, P357, DOI 10.1023/A:1008341820489; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; Klappa P, 2000, J BIOL CHEM, V275, P13213, DOI 10.1074/jbc.275.18.13213; Klappa P, 1997, EUR J BIOCHEM, V248, P37, DOI 10.1111/j.1432-1033.1997.t01-1-00037.x; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; Klappa P, 2001, BIOCHEM J, V354, P553, DOI 10.1042/0264-6021:3540553; Koivunen P, 1999, EMBO J, V18, P65, DOI 10.1093/emboj/18.1.65; Lappi AK, 2004, J MOL BIOL, V335, P283, DOI 10.1016/j.jmb.2003.10.051; LeMaster DM, 1997, J BIOL CHEM, V272, P29998, DOI 10.1074/jbc.272.48.29998; Lumb RA, 2002, EMBO J, V21, P6763, DOI 10.1093/emboj/cdf685; Rost B, 1996, METHOD ENZYMOL, V266, P525; Ruddock LW, 2000, PROTEIN SCI, V9, P758; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6	34	132	135	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10374	10381		10.1074/jbc.M312193200	http://dx.doi.org/10.1074/jbc.M312193200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14684740	hybrid			2022-12-25	WOS:000220050400087
J	Richer, MJ; Juliano, L; Hashimoto, C; Jean, F				Richer, MJ; Juliano, L; Hashimoto, C; Jean, F			Serpin mechanism of hepatitis C virus nonstructural 3 (NS3) protease inhibition - Induced fit as a mechanism for narrow specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE-CENTER LOOP; NS3-NS4A SERINE PROTEINASE; ACTIVE-SITE; VIRAL PROTEASES; NS4A COFACTOR; IN-VITRO; ACTIVATION; DOMAIN; FURIN; SUBSTRATE	Hepatitis C virus (HCV) nonstructural 3 (NS3) serine protease disrupts important cellular antiviral signaling pathways and plays a pivotal role in the proteolytic maturation of the HCV polyprotein precursor. This recent discovery has fostered the search for NS3 protease inhibitors. However, the enzyme's unusual induced fit behavior and peculiar molecular architecture have imposed considerable obstacles to the development of small molecule inhibitors. In this article, we demonstrate that such unique induced fit behavior and the chymotrypsin-like catalytic domain can provide the structural plasticity necessary to generate protein-based inhibitors of the NS3 protease. We took advantage of the macromolecular scaffold of a Drosophila serpin, SP6, which intrinsically supports chymotrypsin-like enzyme inhibition, to design a novel class of potent and selective inhibitors. We show that altering the SP6 reactive site loop (RSL) resulted in the development of the first effective (K-i of 34 nM) and selective serpin, SP6(EVC/S), directed at the NS3 protease. SP6(EVC/S) operates as a suicide substrate inhibitor, and its partitioning between the complex-forming and proteolytic pathways for the NS3 protease is HCV NS4A cofactor-dependent and - specific. Once bound to the protease active site, SP6(EVC/S) partitions with equal probability to undergo proteolysis by NS3 at the C-terminal site of the engineered RSL, (P-6) Glu-Ile-( P-4) Val-Met-Thr-(P-1) Cys- down arrow-(P-1') Ser, or to form a covalent acyl-enzyme complex characteristic of cognate protease-serpin pairs. Our results also reveal a novel cofactor-induced serpin mechanism of enzyme inhibition that could be explored for developing effective and selective inhibitors of other important induced fit viral proteases of the Flaviviridae family such as the West Nile virus NS3 endoprotease.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; Escola Paulista Med, Dept Biophys, BR-04044020 Sao Paulo, Brazil; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA	University of British Columbia; Universidade Federal de Sao Paulo (UNIFESP); Yale University	Jean, F (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 300-6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.	fjean@interchange.ubc.ca	Juliano, Luiz/D-7204-2012	Juliano, Luiz/0000-0002-5589-2822	NIGMS NIH HHS [GM49370] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049370] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barbato G, 2000, EMBO J, V19, P1195, DOI 10.1093/emboj/19.6.1195; Barbato G, 1999, J MOL BIOL, V289, P371, DOI 10.1006/jmbi.1999.2745; Bartenschlager R, 1999, J VIRAL HEPATITIS, V6, P165, DOI 10.1046/j.1365-2893.1999.00152.x; Bianchi E, 1999, BIOCHEMISTRY-US, V38, P13844, DOI 10.1021/bi991220w; Bianchi E, 2002, BIOPOLYMERS, V66, P101, DOI 10.1002/bip.10230; De Francesco R, 2003, ANTIVIR RES, V58, P1, DOI 10.1016/S0166-3542(03)00028-7; De Francesco R, 2000, CURR TOP MICROBIOL, V242, P149; Foy E, 2003, SCIENCE, V300, P1145, DOI 10.1126/science.1082604; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; Han JH, 2000, FEBS LETT, V468, P194, DOI 10.1016/S0014-5793(00)01224-2; Ingallinella P, 2000, BIOCHEMISTRY-US, V39, P12898, DOI 10.1021/bi001590g; Jean F, 2000, P NATL ACAD SCI USA, V97, P2864, DOI 10.1073/pnas.050504297; JEAN F, 1995, BIOCHEM J, V307, P689, DOI 10.1042/bj3070689; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; JEAN F, 1995, J BIOL CHEM, V270, P19225, DOI 10.1074/jbc.270.33.19225; KNIGHT CG, 1995, METHOD ENZYMOL, V248, P85; Koch JO, 1996, VIROLOGY, V221, P54, DOI 10.1006/viro.1996.0352; KURZCHALIA TV, 1992, J BIOL CHEM, V267, P18419; Landro JA, 1997, BIOCHEMISTRY-US, V36, P9340, DOI 10.1021/bi963054n; LIN C, 1995, J VIROL, V69, P4373, DOI 10.1128/JVI.69.7.4373-4380.1995; LIN C, 1994, J VIROL, V68, P8147, DOI 10.1128/JVI.68.12.8147-8157.1994; LIN C, 1995, P NATL ACAD SCI USA, V92, P7622, DOI 10.1073/pnas.92.17.7622; Love RA, 1998, CLIN DIAGN VIROL, V10, P151, DOI 10.1016/S0928-0197(98)00036-1; Narjes F, 2003, EXPERT OPIN INV DRUG, V12, P153, DOI 10.1517/eoid.12.2.153.21407; Pimenta DC, 2003, BIOCHEM J, V371, P1021, DOI 10.1042/BJ20021952; PO A, 2001, PEPTIDES WAVE FUTURE, P563; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; Rosenberg S, 2001, J MOL BIOL, V313, P451, DOI 10.1006/jmbi.2001.5055; Ryan MD, 1998, J GEN VIROL, V79, P947, DOI 10.1099/0022-1317-79-5-947; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; Tan SL, 2002, NAT REV DRUG DISCOV, V1, P867, DOI 10.1038/nrd937; Tellinghuisen TL, 2002, CURR OPIN MICROBIOL, V5, P419, DOI 10.1016/S1369-5274(02)00341-7; Tong L, 2002, CHEM REV, V102, P4609, DOI 10.1021/cr010184f; Vishnuvardhan D, 1997, FEBS LETT, V402, P209, DOI 10.1016/S0014-5793(96)01532-3; Zhou AW, 2001, J BIOL CHEM, V276, P27541, DOI 10.1074/jbc.M102594200	36	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10222	10227		10.1074/jbc.M313852200	http://dx.doi.org/10.1074/jbc.M313852200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701815	hybrid			2022-12-25	WOS:000220050400069
J	Rossignol, P; Ho-Tin-Noe, B; Vranckx, R; Bouton, MC; Meilhac, O; Lijnen, HR; Guillin, MC; Michel, JB; Angles-Cano, E				Rossignol, P; Ho-Tin-Noe, B; Vranckx, R; Bouton, MC; Meilhac, O; Lijnen, HR; Guillin, MC; Michel, JB; Angles-Cano, E			Protease nexin-1 inhibits plasminogen activation-induced apoptosis of adherent cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; GLIA-DERIVED NEXIN; RECOMBINANT HUMAN-PLASMINOGEN; NEURITE-PROMOTING FACTOR; SINGLE-CHAIN UROKINASE; HAMSTER OVARY CELLS; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; SERINE PROTEASES; MAMMALIAN-CELLS	Degradation of adhesive glycoproteins by plasmin is implicated in cell migration. In this study, we further explored the role of plasminogen activation in cell adhesion and survival and show that uncontrolled plasminogen activation at the cell surface may induce cell detachment and apoptosis. We hypothesized that this process could be prevented in adherent cells by expression of protease nexin-1, a potent serpin able to inhibit thrombin, plasmin, and plasminogen activators. Using two- and three-dimensional culture systems, we demonstrate that Chinese hamster ovary fibroblasts constitutively express tissue-type plasminogen activator and efficiently activate exogenously added plasminogen in a specific and saturable manner (K-m = 46 nM). The formation of plasmin results in proteolysis of fibronectin and laminin, which is followed by cell detachment and apoptosis. Protease nexin-1 expressed by transfected cells significantly inhibited the activity of plasmin and tissue-type plasminogen activator via the formation of inhibitory complexes and prevented cell detachment and apoptosis. In conclusion, protease nexin-1 may be an important anti-apoptotic factor for adherent cells. This cell model could be a useful tool to evaluate therapeutic agents such as serpins in vascular pathologies involving pericellular protease-protease inhibitor imbalance.	Ctr Hosp Univ Bichat Claude Bernard, INSERM, U460, F-75877 Paris 18, France; Univ Paris 07, INSERM, EMI 348, Unite Format Rech Med, F-75870 Paris 18, France; Katholieke Univ Leuven, Ctr Mol & Vasc Biol, B-3000 Louvain, Belgium	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; KU Leuven	Angles-Cano, E (corresponding author), Ctr Hosp Univ Bichat Claude Bernard, INSERM, U460, 46 Rue Henri Huchard, F-75877 Paris 18, France.	angles@infobiogen.fr	Michel, Jean-Baptiste/AAH-9336-2020; ANGLES-CANO, Eduardo/G-2311-2012; Bouton, Marie-Christine/L-1583-2017; Ho-Tin-Noé, Benoit/U-8059-2018; Lijnen, Roger/AAA-4085-2020; ANGLES-CANO, Eduardo/ABA-1739-2020; Meilhac, Olivier/N-4385-2017	ANGLES-CANO, Eduardo/0000-0001-7891-3975; Ho-Tin-Noé, Benoit/0000-0002-7428-1760; ANGLES-CANO, Eduardo/0000-0001-7891-3975; BOUTON, Marie-Christine/0000-0001-5092-7363; Meilhac, Olivier/0000-0002-3740-7539				Abbott A, 2003, NATURE, V424, P870, DOI 10.1038/424870a; Adderley SR, 2000, J BIOL CHEM, V275, P5760, DOI 10.1074/jbc.275.8.5760; ALESSI MC, 1988, EUR J BIOCHEM, V175, P531, DOI 10.1111/j.1432-1033.1988.tb14225.x; Alexander CM, 1996, J CELL BIOL, V135, P1669, DOI 10.1083/jcb.135.6.1669; Badier-Commander C, 2000, J PATHOL, V192, P105, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH670>3.0.CO;2-1; BAKER JB, 1986, SEMIN THROMB HEMOST, V12, P216, DOI 10.1055/s-2007-1003554; BAKER JB, 1980, CELL, V21, P37, DOI 10.1016/0092-8674(80)90112-9; BERGMAN BL, 1986, P NATL ACAD SCI USA, V83, P996, DOI 10.1073/pnas.83.4.996; BEZEAUD A, 1985, EUR J BIOCHEM, V153, P491, DOI 10.1111/j.1432-1033.1985.tb09328.x; BJORK I, 1972, European Journal of Biochemistry, V29, P579, DOI 10.1111/j.1432-1033.1972.tb02024.x; Bonnefoy A, 2000, THROMB RES, V98, P323, DOI 10.1016/S0049-3848(99)00242-X; Bouton MC, 2003, ARTERIOSCL THROM VAS, V23, P142, DOI 10.1161/01.ATV.0000047867.98019.2D; BUSBY SJ, 1991, J BIOL CHEM, V266, P15286; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; CHOI BH, 1990, AM J PATHOL, V137, P741; Chung CY, 1997, J CELL SCI, V110, P1413; Cook GA, 1999, EXP CELL RES, V251, P356, DOI 10.1006/excr.1999.4596; CUNNINGHAM DD, 1989, J CELL BIOCHEM, V39, P55, DOI 10.1002/jcb.240390107; Davis GE, 2001, J CELL SCI, V114, P917; Davis J, 2003, J BIOL CHEM, V278, P19054, DOI 10.1074/jbc.M301398200; DECLERCK PJ, 1990, THROMB RES, P3; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; EATON DL, 1983, J CELL PHYSIOL, V117, P175, DOI 10.1002/jcp.1041170207; Edman P, 1975, PROTEIN SEQUENCE DET, P232; FLEURY V, 1993, J BIOL CHEM, V268, P18554; Fontaine V, 2002, AM J PATHOL, V161, P1701, DOI 10.1016/S0002-9440(10)64447-1; Fowler B, 1998, THROMB HAEMOSTASIS, V80, P148, DOI 10.1055/s-0037-1615154; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; GAUSSEM P, 1993, J BIOL CHEM, V268, P12150; GLOOR S, 1986, CELL, V47, P687; Guan HC, 2003, VIROLOGY, V309, P114, DOI 10.1016/S0042-6822(02)00135-6; GUTTRIDGE DC, 1993, J BIOL CHEM, V268, P18966; HARPER PA, 1983, J CELL SCI, V63, P287; HERVIO L, 1993, BLOOD, V82, P392; HOUENOU LJ, 1995, P NATL ACAD SCI USA, V92, P895, DOI 10.1073/pnas.92.3.895; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ikari Y, 2001, J BIOL CHEM, V276, P11798, DOI 10.1074/jbc.M008503200; Knauer MF, 1997, J BIOL CHEM, V272, P29039, DOI 10.1074/jbc.272.46.29039; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Lee E, 1996, CIRC RES, V78, P44, DOI 10.1161/01.RES.78.1.44; Lijnen HR, 2001, ANN NY ACAD SCI, V936, P226; LOW DA, 1981, P NATL ACAD SCI-BIOL, V78, P2340, DOI 10.1073/pnas.78.4.2340; MANSUY IM, 1993, DEVELOPMENT, V119, P1119; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; Meilhac O, 2003, FASEB J, V17, P1301, DOI 10.1096/fj.02-0687fje; Michel JB, 2001, ARTERIOSCL THROM VAS, V21, P1389; MONARD D, 1973, P NATL ACAD SCI USA, V70, P1894, DOI 10.1073/pnas.70.6.1894; MONARD D, 1992, ANN NY ACAD SCI, V674, P237, DOI 10.1111/j.1749-6632.1992.tb27492.x; MONARD D, 1988, TRENDS NEUROSCI, V11, P541, DOI 10.1016/0166-2236(88)90182-8; Montes R, 1996, BRIT J HAEMATOL, V92, P979, DOI 10.1046/j.1365-2141.1996.416951.x; MOORE A, 1995, CYTOTECHNOLOGY, V17, P1, DOI 10.1007/BF00749215; Mtairag EM, 2002, ARTERIOSCL THROM VAS, V22, P1824, DOI 10.1161/01.ATV.0000037102.31086.F4; PUCK TT, 1958, J EXP MED, V108, P945, DOI 10.1084/jem.108.6.945; RAJARAMAN R, 1984, CELL BIOL INT REP, V8, P383, DOI 10.1016/0309-1651(84)90141-3; RAO JS, 1989, MUSCLE NERVE, V12, P640, DOI 10.1002/mus.880120805; Reijerkerk A, 2003, MOL CANCER RES, V1, P561; REINARTZ J, 1995, EXP CELL RES, V220, P274, DOI 10.1006/excr.1995.1316; Schechner JS, 2000, P NATL ACAD SCI USA, V97, P9191, DOI 10.1073/pnas.150242297; Scott KK, 2003, DNA CELL BIOL, V22, P95, DOI 10.1089/104454903321515904; SCOTT RW, 1985, J BIOL CHEM, V260, P7029; SOMMER J, 1987, BIOCHEMISTRY-US, V26, P6407, DOI 10.1021/bi00394a016; SOMMER J, 1989, GENE, V85, P453, DOI 10.1016/0378-1119(89)90439-3; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; STONE SR, 1987, ARCH BIOCHEM BIOPHYS, V252, P237, DOI 10.1016/0003-9861(87)90028-2; Tarui T, 2002, J BIOL CHEM, V277, P33564, DOI 10.1074/jbc.M205514200; Thelin-Jarnum S, 1999, INT J CANCER, V83, P30, DOI 10.1002/(SICI)1097-0215(19990924)83:1<30::AID-IJC6>3.0.CO;2-4; VAUGHAN PJ, 1993, J BIOL CHEM, V268, P3720; Vitale M, 1999, FEBS LETT, V462, P57, DOI 10.1016/S0014-5793(99)01512-4; WHITE EA, 1993, THROMB HAEMOSTASIS, V69, P119; Zhang X, 2003, MOL VIS, V9, P238; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	78	76	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10346	10356		10.1074/jbc.M310964200	http://dx.doi.org/10.1074/jbc.M310964200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699093	hybrid			2022-12-25	WOS:000220050400084
J	Weeks, DL; Gushansky, G; Scott, DR; Sachs, G				Weeks, DL; Gushansky, G; Scott, DR; Sachs, G			Mechanism of proton gating of a urea channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELICOBACTER-PYLORI UREASE; ACID RESISTANCE; EXPRESSION; PROTEIN; PH; COLONIZATION; ACTIVATION; GENES; H+	The size and complexity of many pH-gated channels have frustrated the development of specific structural models. The small acid-activated six-membrane segment urea channel of Helicobacter hepaticus (HhUreI), homologous to the essential UreI of the gastric pathogen Helicobacter pylori, enables identification of all the periplasmic sites of proton gating by site-directed mutagenesis. Exposure to external acidity enhances [C-14]urea uptake by Xenopus oocytes expressing HhUreI, with half-maximal activity (pH(0.5)) at pH 6.8. A downward shift of pH(0.5) in single site mutants identified four of six protonatable periplasmic residues (His-50 at the boundary of the second transmembrane segment TM2, Glu-56 in the first periplasmic loop, Asp-59 at the boundary of TM3, and His-170 at the boundary of TM6) that affect proton gating. Asp-59 was the only site at which a protonatable residue appeared to be essential for pH gating. Mutation of Glu-110 or Glu-114 in PL2 did not affect the pH(0.5) of gating. A chimera, where the entire periplasmic domain of HhUreI was fused to the membrane domain of Streptococcus salivarius UreI (SsUreI), retained the pH-independent properties of SsUreI. Hence, proton gating of HhUreI likely depends upon the formation of hydrogen bonds by periplasmic residues that in turn produce conformational changes of the transmembrane domain. Further studies on HhUreI may facilitate understanding of other physiologically important pH-responsive channels.	Dept Vet Affairs Greater Los Angeles Healthcare S, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles	Sachs, G (corresponding author), Wadsworth Vet Affairs Hosp, Bldg 113,Rm 324, Los Angeles, CA 90073 USA.	gsachs@ucla.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058333, R56DK058333] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58333] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Auzanneau C, 2003, J BIOL CHEM, V278, P19230, DOI 10.1074/jbc.M301096200; Avdonin V, 2003, BIOPHYS J, V84, P2969, DOI 10.1016/S0006-3495(03)70023-X; Bagnasco SM, 2003, AM J PHYSIOL-RENAL, V284, pF3, DOI 10.1152/ajprenal.00260.2002; Beckwith CS, 2001, INFECT IMMUN, V69, P5914, DOI 10.1128/IAI.69.9.5914-5920.2001; Bury-Mone S, 2001, MOL MICROBIOL, V42, P1021, DOI 10.1046/j.1365-2958.2001.02689.x; Chen YYM, 1998, J BACTERIOL, V180, P5769, DOI 10.1128/JB.180.21.5769-5775.1998; CUSSAC V, 1992, J BACTERIOL, V174, P2466, DOI 10.1128/jb.174.8.2466-2473.1992; DelVecchio VG, 2002, VET MICROBIOL, V90, P587, DOI 10.1016/S0378-1135(02)00238-9; Flagg TP, 2002, J PHYSIOL-LONDON, V544, P351, DOI 10.1113/jphysiol.2002.027581; Immke DC, 2003, NEURON, V37, P75, DOI 10.1016/S0896-6273(02)01130-3; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; Low CM, 2003, MOL PHARMACOL, V63, P1212, DOI 10.1124/mol.63.6.1212; McGee DJ, 1999, J BACTERIOL, V181, P2477, DOI 10.1128/JB.181.8.2477-2484.1999; MeyerRosberg K, 1996, GASTROENTEROLOGY, V111, P886, DOI 10.1016/S0016-5085(96)70056-2; MOLLENHAUER M, 2002, THESIS U KONSTANZ KO; Mollenhauer-Rektorschek M, 2002, RES MICROBIOL, V153, P659, DOI 10.1016/S0923-2508(02)01380-3; Rektorschek M, 2000, MOL MICROBIOL, V36, P141, DOI 10.1046/j.1365-2958.2000.01835.x; Scott DR, 2000, INFECT IMMUN, V68, P470, DOI 10.1128/IAI.68.2.470-477.2000; Scott DR, 1998, GASTROENTEROLOGY, V114, P58, DOI 10.1016/S0016-5085(98)70633-X; Sebbane F, 2002, MOL MICROBIOL, V45, P1165, DOI 10.1046/j.1365-2958.2002.03096.x; Skouloubris S, 1998, INFECT IMMUN, V66, P4517; Spencer RH, 2002, ANNU REV BIOPH BIOM, V31, P207, DOI 10.1146/annurev.biophys.31.082901.134329; Stroffekova K, 1998, AM J PHYSIOL, V275, P1113; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Weeks DL, 2000, SCIENCE, V287, P482, DOI 10.1126/science.287.5452.482; Weeks DL, 2001, MOL MICROBIOL, V40, P1249, DOI 10.1046/j.1365-2958.2001.02466.x; Xu HX, 2001, J BIOL CHEM, V276, P38690, DOI 10.1074/jbc.M106595200; Zeuthen T, 1999, J BIOL CHEM, V274, P21631, DOI 10.1074/jbc.274.31.21631	28	23	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9944	9950		10.1074/jbc.M312680200	http://dx.doi.org/10.1074/jbc.M312680200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701805	hybrid			2022-12-25	WOS:000220050400036
J	Lewis, J; Burstein, E; Reffey, SB; Bratton, SB; Roberts, AB; Duckett, CS				Lewis, J; Burstein, E; Reffey, SB; Bratton, SB; Roberts, AB; Duckett, CS			Uncoupling of the signaling and caspase-inhibitory properties of X-linked inhibitor of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SERINE-PROTEASE OMI/HTRA2; STRUCTURAL BASIS; CYTOCHROME-C; BIR DOMAIN; BACULOVIRAL-INHIBITOR; ENDOTHELIAL-CELLS; NMR STRUCTURE; XIAP; IAP	In addition to its well described function as an enzymatic inhibitor of specific caspases, X-linked inhibitor of apoptosis (X-linked IAP or XIAP) can function as a cofactor in Smad, NF-kappaB, and JNK signaling pathways. However, caspases themselves have been shown to regulate the activity of a number of signaling cascades, raising the possibility that the effect of XIAP in these pathways is indirect. Here we examine this question by introducing point mutations in XIAP predicted to disrupt the ability of the molecule to bind to and inhibit caspases. We show that whereas these mutant variants of XIAP lost caspase-inhibitory activity, they maintained their ability to activate Smad, NF-kappaB, and JNK signaling pathways. Indeed, the signaling properties of the molecule were mapped to domains not directly involved in caspase binding and inhibition. The activation of NF-kappaB by XIAP was dependent on the E3 ubiquitin ligase activity of the RING domain. On the other hand, the ability of XIAP to activate Smad-dependent signaling was mapped to the third baculoviral IAP repeat (BIR) and loop regions of the molecule. Thus, the antiapoptotic and signaling properties of XIAP can be uncoupled.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Sci Applicat Int Corp, Conressionally Directed Med Res Program, Biomed Technol Div, MCMRPLF, Ft Detrick, MD 21702 USA; Univ Texas, Coll Pharm, Ctr Mol & Cellular Toxicol, Austin, TX 78718 USA; NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Science Applications International Corporation (SAIC); University of Texas System; University of Texas Austin; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Duckett, CS (corresponding author), Rm 5315,1301 Catherine, Ann Arbor, MI 48109 USA.	colind@umich.edu	Burstein, Ezra/B-7247-2016	Burstein, Ezra/0000-0003-4341-6367; Duckett, Colin/0000-0001-9413-2263; Bratton, Shawn/0000-0003-2895-5020				Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; Barkett M, 2001, BBA-GEN SUBJECTS, V1526, P25, DOI 10.1016/S0304-4165(01)00092-7; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; Bolton MA, 2002, MOL BIOL CELL, V13, P3064, DOI 10.1091/mbc.E02-02-0092; Bratton SB, 2002, CELL DEATH DIFFER, V9, P881, DOI 10.1038/sj.cdd.4401069; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; Duckett CS, 1998, MOL CELL BIOL, V18, P608, DOI 10.1128/MCB.18.1.608; Fraser AG, 1999, CURR BIOL, V9, P292, DOI 10.1016/S0960-9822(99)80137-7; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hinds MG, 1999, NAT STRUCT BIOL, V6, P648; Hofer-Warbinek R, 2000, J BIOL CHEM, V275, P22064, DOI 10.1074/jbc.M910346199; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Levkau B, 2001, CIRC RES, V88, P282, DOI 10.1161/01.RES.88.3.282; Li FZ, 2000, J BIOL CHEM, V275, P6707, DOI 10.1074/jbc.275.10.6707; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Newton K, 2003, GENE DEV, V17, P819, DOI 10.1101/gad.1077403; Reffey SB, 2001, J BIOL CHEM, V276, P26542, DOI 10.1074/jbc.M100331200; Reuther JY, 1999, J BIOL CHEM, V274, P20664, DOI 10.1074/jbc.274.29.20664; Richter BWM, 2001, MOL CELL BIOL, V21, P4292, DOI 10.1128/MCB.21.13.4292-4301.2001; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Sanna MG, 2002, MOL CELL BIOL, V22, P1754, DOI 10.1128/MCB.22.6.1754-1766.2002; Sanna MG, 1998, P NATL ACAD SCI USA, V95, P6015, DOI 10.1073/pnas.95.11.6015; SANNA MG, 2002, J BIOL CHEM; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srinivasula SM, 2003, J BIOL CHEM, V278, P31469, DOI 10.1074/jbc.C300240200; Stoven S, 2003, P NATL ACAD SCI USA, V100, P5991, DOI 10.1073/pnas.1035902100; Sun CH, 2000, J BIOL CHEM, V275, P33777, DOI 10.1074/jbc.M006226200; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2001, GENOME BIOL, V2; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874	51	84	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9023	9029		10.1074/jbc.M312891200	http://dx.doi.org/10.1074/jbc.M312891200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14701799	hybrid			2022-12-25	WOS:000189265900062
J	Tsunematsu, R; Nakayama, K; Oike, Y; Nishiyama, M; Ishida, N; Hatakeyama, S; Bessho, Y; Kageyama, R; Suda, T; Nakayama, KI				Tsunematsu, R; Nakayama, K; Oike, Y; Nishiyama, M; Ishida, N; Hatakeyama, S; Bessho, Y; Kageyama, R; Suda, T; Nakayama, KI			Mouse Fbw7/Sel-10/Cdc4 is required for Notch degradation during vascular development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; F-BOX PROTEIN; CYCLIN-E; CAENORHABDITIS-ELEGANS; NEOPLASTIC TRANSFORMATION; ENDOTHELIAL-CELLS; UBIQUITIN LIGASE; MICE; EXPRESSION; SEL-10	Mammalian Fbw7 (also known as Sel-10, hCdc4, or hAgo) is the F-box protein component of an SCF (Skp1-Cul1-F-box protein-Rbx1)-type ubiquitin ligase, and the mouse Fbw7 is expressed prominently in the endothelial cell lineage of embryos. We generated mice deficient in Fbw7 and found that the embryos died in utero at embryonic day 10.5-11.5, manifesting marked abnormalities in vascular development. Vascular remodeling was impaired in the brain and yolk sac, and the major trunk veins were not formed. In vitro para-aortic splanchnopleural explant cultures from Fbw7(-/-) embryos also manifested an impairment of vascular network formation. Notch4, which is the product of the proto-oncogene Int3 and an endothelial cell-specific mammalian isoform of Notch, accumulated in Fbw7(-/-) embryos, resulting in an increased expression of Hey1, which encodes a transcriptional repressor that acts downstream of Notch signaling and is implicated in vascular development. Expression of Notch1, -2, or -3 or of cyclin E was unaffected in Fbw7(-/-) embryos. Mammalian Fbw7 thus appears to play an indispensable role in negative regulation of the Notch4-Hey1 pathway and is required for vascular development.	Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol Genet, Fukuoka 8128582, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan; Keio Univ, Sch Med, Dept Cell Differentiat, Shinjuku Ku, Tokyo 1608582, Japan; Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan	Kyushu University; Kyushu University; Japan Science & Technology Agency (JST); Keio University; Kyoto University	Nakayama, KI (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	nakayak1@bioreg.kyushu-u.ac.jp	Suda, Toshio/H-6761-2013; Nishiyama, Masaaki/GWU-5575-2022; Hatakeyama, Shigetsugu/C-8333-2012	Suda, Toshio/0000-0001-7540-1771; Hatakeyama, Shigetsugu/0000-0002-2150-9979				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Callahan R, 2001, J MAMMARY GLAND BIOL, V6, P23, DOI 10.1023/A:1009512414430; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Craig KL, 1999, PROG BIOPHYS MOL BIO, V72, P299, DOI 10.1016/S0079-6107(99)00010-3; Daniel B, 1997, J GEN VIROL, V78, P1095, DOI 10.1099/0022-1317-78-5-1095; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Donovan J, 2002, CURR BIOL, V12, P1605, DOI 10.1016/S0960-9822(02)01149-1; ELLEDGE SJ, 1998, BIOCHIM BIOPHYS ACTA, V1377, P61; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; Gessler M, 2002, CURR BIOL, V12, P1601, DOI 10.1016/S0960-9822(02)01150-8; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Henderson AM, 2001, J BIOL CHEM, V276, P6169, DOI 10.1074/jbc.M008506200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hoemann CD, 2000, MOL CELL BIOL, V20, P3831, DOI 10.1128/MCB.20.11.3831-3842.2000; Hubbard EJA, 1997, GENE DEV, V11, P3182, DOI 10.1101/gad.11.23.3182; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Jundt F, 2002, BLOOD, V99, P3398, DOI 10.1182/blood.V99.9.3398; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Krebs LT, 2000, GENE DEV, V14, P1343; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; Lai EC, 2002, CURR BIOL, V12, pR74, DOI 10.1016/S0960-9822(01)00679-0; Lawson ND, 2001, DEVELOPMENT, V128, P3675; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; Maruyama S, 2001, GENOMICS, V78, P214, DOI 10.1006/geno.2001.6658; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Nakagawa O, 2000, P NATL ACAD SCI USA, V97, P13655, DOI 10.1073/pnas.250485597; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; OsumiYamashita N, 1997, DEV GROWTH DIFFER, V39, P53; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Rae FK, 2000, INT J CANCER, V88, P726, DOI 10.1002/1097-0215(20001201)88:5<726::AID-IJC7>3.0.CO;2-H; REAUME AG, 1992, DEV BIOL, V154, P377, DOI 10.1016/0012-1606(92)90076-S; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Shirane M, 2003, NAT CELL BIOL, V5, P28, DOI 10.1038/ncb894; Shirayoshi Y, 1997, GENES CELLS, V2, P213, DOI 10.1046/j.1365-2443.1997.d01-310.x; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; SUNDARAM M, 1993, GENETICS, V135, P765; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; Tohda S, 2001, LEUKEMIA LYMPHOMA, V42, P467, DOI 10.3109/10428190109064603; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; Uyttendaele H, 2001, P NATL ACAD SCI USA, V98, P5643, DOI 10.1073/pnas.091584598; Villa N, 2001, MECH DEVELOP, V108, P161, DOI 10.1016/S0925-4773(01)00469-5; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; WEINSTEIN BM, 1995, NAT MED, V1, P1143, DOI 10.1038/nm1195-1143; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Wu GY, 1998, P NATL ACAD SCI USA, V95, P15787, DOI 10.1073/pnas.95.26.15787; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414; Zhang XQ, 2001, BLOOD, V98, P1028, DOI 10.1182/blood.V98.4.1028; Zhong TP, 2000, SCIENCE, V287, P1820, DOI 10.1126/science.287.5459.1820; Zhong TP, 2001, NATURE, V414, P216, DOI 10.1038/35102599	61	201	208	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9417	9423		10.1074/jbc.M312337200	http://dx.doi.org/10.1074/jbc.M312337200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14672936	hybrid			2022-12-25	WOS:000189265900107
J	Udagawa, T; Shimizu, Y; Ueda, T				Udagawa, T; Shimizu, Y; Ueda, T			Evidence for the translation initiation of leaderless mRNAs by the intact 70 S ribosome without its dissociation into subunits in eubacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5'-TERMINAL START CODONS; ESCHERICHIA-COLI; FACTORS IF2; PROTEIN S1; SELECTION; RECRUITMENT; BACTERIA	In eubacteria, the dissociation of the 70 S ribosome into the 30 S and 50 S subunits is the essential first step for the translation initiation of canonical mRNAs that possess 5'-leader sequences. However, a number of leaderless mRNAs that start with the initiation codon have been identified in some eubacteria. These have been shown to be translated efficiently in vivo. Here we investigated the process by which leaderless mRNA translation is initiated by using a highly reconstituted cell-free translation system from Escherichia coli. We found that leaderless mRNAs bind preferentially to 70 S ribosomes and that the leaderless mRNA . 70 S . fMet-tRNA complex can transit from the initiation to the elongation phase even in the absence of initiation factors ( IFs). Moreover, leaderless mRNA translation proceeds more efficiently if the intact 70 S ribosome is involved compared with the 30 S subunit. Furthermore, excess amounts of IF3 inhibit leaderless mRNA translation, probably because it promotes the disassembly of the 70 S ribosome into subunits. Finally, excess amounts of fMet-tRNA facilitate the IF-independent translation of leaderless mRNA. These observations strongly suggest that leaderless mRNA translation is initiated by the assembled 70 S ribosome and thereby bypasses the dissociation process.	Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Kashiwa, Chiba 2778562, Japan	University of Tokyo	Ueda, T (corresponding author), Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, FSB401,5-1-5 Kashiwanoha, Kashiwa, Chiba 2778562, Japan.	ueda@k.u-tokyo.ac.jp	Shimizu, Yoshihiro/A-6472-2016; Ueda, Takuya/K-5217-2014	Shimizu, Yoshihiro/0000-0003-3499-1394; Ueda, Takuya/0000-0002-7760-8271				BALAKIN AG, 1992, NUCLEIC ACIDS RES, V20, P563, DOI 10.1093/nar/20.3.563; Brock S, 1998, MOL MICROBIOL, V29, P409, DOI 10.1046/j.1365-2958.1998.00893.x; Carter AP, 2001, SCIENCE, V291, P498, DOI 10.1126/science.1057766; Dallas A, 2001, MOL CELL, V8, P855, DOI 10.1016/S1097-2765(01)00356-2; Grill S, 2000, EMBO J, V19, P4101, DOI 10.1093/emboj/19.15.4101; Grill S, 2001, FEBS LETT, V495, P167, DOI 10.1016/S0014-5793(01)02378-X; Gualerzi CO, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P477; GUALERZI CO, 1990, BIOCHEMISTRY-US, V29, P5881, DOI 10.1021/bi00477a001; HARTZ D, 1989, GENE DEV, V3, P1899, DOI 10.1101/gad.3.12a.1899; JANSSEN GR, 1993, INDUSTRIAL MICROORGANISMS: BASIC AND APPLIED MOLECULAR GENETICS, P59; JONES RL, 1992, J BACTERIOL, V174, P4753, DOI 10.1128/JB.174.14.4753-4760.1992; La Teana A, 2001, RNA, V7, P1173, DOI 10.1017/S1355838201010366; Malhotra A, 1998, J MOL BIOL, V280, P103, DOI 10.1006/jmbi.1998.1859; Moll I, 2002, MOL MICROBIOL, V43, P239, DOI 10.1046/j.1365-2958.2002.02739.x; Moll I, 2002, MOL MICROBIOL, V44, P1387, DOI 10.1046/j.1365-2958.2002.02971.x; Moll I, 1998, FEBS LETT, V436, P213, DOI 10.1016/S0014-5793(98)01131-4; O'Donnell SA, 2002, J BACTERIOL, V184, P6730, DOI 10.1128/JB.184.23.6730-6733.2002; Petrelli D, 2001, EMBO J, V20, P4560, DOI 10.1093/emboj/20.16.4560; Shimizu Y, 2001, NAT BIOTECHNOL, V19, P751, DOI 10.1038/90802; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SOFFIENTINI A, 1994, PROTEIN EXPRES PURIF, V5, P118, DOI 10.1006/prep.1994.1018; SPEDDING G, 1990, RIBOSOMES PROTEIN SY, P1; SURYANARAYANA T, 1983, BIOCHEMISTRY-US, V22, P2715, DOI 10.1021/bi00280a020; Tedin K, 1997, MOL MICROBIOL, V25, P189, DOI 10.1046/j.1365-2958.1997.4421810.x; Tedin K, 1999, MOL MICROBIOL, V31, P67, DOI 10.1046/j.1365-2958.1999.01147.x; Van Etten WJ, 1998, MOL MICROBIOL, V27, P987, DOI 10.1046/j.1365-2958.1998.00744.x; Wu CJ, 1996, MOL MICROBIOL, V22, P339, DOI 10.1046/j.1365-2958.1996.00119.x; Wu XQ, 1996, EMBO J, V15, P4734, DOI 10.1002/j.1460-2075.1996.tb00850.x	28	88	91	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8539	8546		10.1074/jbc.M308784200	http://dx.doi.org/10.1074/jbc.M308784200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14670970	hybrid			2022-12-25	WOS:000189265900004
J	Thomas, M; Dadgar, N; Aphale, A; Harrell, JM; Kunkel, R; Pratt, WB; Lieberman, AP				Thomas, M; Dadgar, N; Aphale, A; Harrell, JM; Kunkel, R; Pratt, WB; Lieberman, AP			Androgen receptor acetylation site mutations cause trafficking defects, misfolding, and aggregation similar to expanded glutamine tracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING PROTEIN; HEAT-SHOCK PROTEINS; POLYGLUTAMINE; NEURODEGENERATION; DISEASE; DROSOPHILA; ATAXIN-1; MODEL; CHIP	Kennedy's disease is a degenerative disorder of motor neurons caused by the expansion of a glutamine tract near the amino terminus of the androgen receptor (AR). Ligand binding to the receptor is associated with several post-translational modifications, but it is poorly understood whether these affect the toxicity of the mutant protein. Our studies now demonstrate that mutation of lysine residues in wild-type AR that are normally acetylated in a ligand-dependent manner mimics the effects of the expanded glutamine tract on receptor trafficking, misfolding, and aggregation. Mutation of lysines 630 or 632 and 633 to alanine markedly delays ligand-dependent nuclear translocation. The K632A/K633A mutant also undergoes ligand-dependent misfolding and aggregation similar to the expanded glutamine tract AR. This acetylation site mutant exhibits ligand-dependent 1C2 immunoreactivity, forms aggregates that co-localize with Hsp40, Hsp70, and the ubiquitin-protein isopeptide ligase (E3) ubiquitin ligase carboxyl terminus of Hsc70-interacting protein (CHIP), and inhibits proteasome function. Ligand-dependent nuclear translocation of the wild-type receptor and misfolding and aggregation of the K632A/K633A mutant are blocked by radicicol, an Hsp90 inhibitor. These data identify a novel role for the acetylation site as a regulator of androgen receptor subcellular distribution and folding and indicate that ligand-dependent aggregation is dependent upon intact Hsp90 function.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Lieberman, AP (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1301 Catherine,4233 Med Sci 1, Ann Arbor, MI 48109 USA.	liebermn@umich.edu			NCI NIH HHS [CA28010] Funding Source: Medline; NINDS NIH HHS [NS044047] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K02NS044047] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Becker M, 2000, J CELL BIOL, V149, P255, DOI 10.1083/jcb.149.2.255; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Chen HK, 2003, CELL, V113, P457, DOI 10.1016/S0092-8674(03)00349-0; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Emamian ES, 2003, NEURON, V38, P375, DOI 10.1016/S0896-6273(03)00258-7; Fu MF, 2002, MOL CELL BIOL, V22, P3373, DOI 10.1128/MCB.22.10.3373-3388.2002; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Galigniana MD, 2001, J BIOL CHEM, V276, P14884, DOI 10.1074/jbc.M010809200; Gaughan L, 2002, J BIOL CHEM, V277, P25904, DOI 10.1074/jbc.M203423200; Georget V, 2002, BIOCHEMISTRY-US, V41, P11824, DOI 10.1021/bi0259150; JENSTER G, 1993, BIOCHEM J, V293, P761, DOI 10.1042/bj2930761; Katsuno M, 2002, NEURON, V35, P843, DOI 10.1016/S0896-6273(02)00834-6; Lieberman AP, 2002, HUM MOL GENET, V11, P1967, DOI 10.1093/hmg/11.17.1967; Lieberman AP, 2000, MUSCLE NERVE, V23, P843, DOI 10.1002/(SICI)1097-4598(200006)23:6<843::AID-MUS2>3.0.CO;2-8; McCampbell A, 2001, P NATL ACAD SCI USA, V98, P15179, DOI 10.1073/pnas.261400698; McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197; Orr HT, 2001, GENE DEV, V15, P925, DOI 10.1101/gad.888401; Piccioni F, 2002, FASEB J, V16, P1418, DOI 10.1096/fj.01-1035fje; Poukka H, 2000, J CELL SCI, V113, P2991; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Szebenyi G, 2003, NEURON, V40, P41, DOI 10.1016/S0896-6273(03)00569-5; Takeyama K, 2002, NEURON, V35, P855, DOI 10.1016/S0896-6273(02)00875-9; Taylor JP, 2003, GENE DEV, V17, P1463, DOI 10.1101/gad.1087503; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	25	93	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8389	8395		10.1074/jbc.M311761200	http://dx.doi.org/10.1074/jbc.M311761200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14670946	hybrid			2022-12-25	WOS:000189103300121
J	Malnou, CE; Werner, A; Borman, AM; Westhof, E; Kean, KM				Malnou, CE; Werner, A; Borman, AM; Westhof, E; Kean, KM			Effects of vaccine strain mutations in domain V of the internal ribosome entry segment compared in the wild type poliovirus type 1 context	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATION INITIATION-FACTOR; RNA SECONDARY STRUCTURE; TRACT-BINDING PROTEIN; HUMAN NEURO-BLASTOMA; INVITRO TRANSLATION; CLEAVAGE PRODUCTS; MESSENGER-RNAS; REGION; EIF4G; SITE	Initiation of poliovirus (PV) protein synthesis is governed by an internal ribosome entry segment structured into several domains including domain V, which is accepted to be important in PV neurovirulence because it harbors an attenuating mutation in each of the vaccine strains developed by A. Sabin. To better understand how these single point mutations exert their effects, we placed each of them into the same genomic context, that of PV type 1. Only the mutation equivalent to the Sabin type 3 strain mutation resulted in significantly reduced viral growth both in HeLa and neuroblastoma cells. This correlated with poor translation efficiency in vitro and could be explained by a structural perturbation of the domain V of the internal ribosome entry segment, as evidenced by RNA melting experiments. We demonstrated that reduced cell death observed during infection by this mutant is due to the absence of inhibition of host cell translation. We confirmed that this shut-off is correlated principally with cleavage of eIF4GII and not eIF4GI and that this cleavage is significantly impaired in the case of the defective mutant. These data support the previously reported conclusion that the 2A protease has markedly different affinities for the two eIF4G isoforms.	Inst Pasteur, CNRS URA 1966, Unite Regulat Traduct Eucaryote & Virale, F-75724 Paris 15, France; Hlth Protect Agcy, Mycol Reference Lab, Bristol BS2 8EL, Avon, England; Inst Biol Mol & Cellulaire, Lab CNRS UPR 9002, F-67084 Strasbourg, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Health Protection Agency; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB)	Kean, KM (corresponding author), Inst Pasteur, CNRS URA 1966, Unite Regulat Traduct Eucaryote & Virale, 25 Rue Dr Roux, F-75724 Paris 15, France.	kathiemb@pasteur.fr	Borman, Andy/H-3663-2019; MALNOU, Cécile/O-9970-2019; MALNOU, Cécile E/K-1569-2014	Borman, Andy/0000-0003-0585-5721; MALNOU, Cécile/0000-0002-1223-0247; MALNOU, Cécile E/0000-0002-1223-0247				AGOL VI, 1989, J VIROL, V63, P4034, DOI 10.1128/JVI.63.9.4034-4038.1989; BELLOCQ C, 1984, VIROLOGY, V139, P403, DOI 10.1016/0042-6822(84)90386-6; Blondel B, 1998, J NEUROVIROL, V4, P1, DOI 10.3109/13550289809113478; BORMAN AM, 1994, EMBO J, V13, P3149, DOI 10.1002/j.1460-2075.1994.tb06613.x; Borman AM, 1997, RNA, V3, P186; Brion P, 1999, RNA, V5, P947, DOI 10.1017/S1355838299990477; DORNER AJ, 1984, J VIROL, V50, P507, DOI 10.1128/JVI.50.2.507-514.1984; GABARRO J, 1978, ANAL BIOCHEM, V91, P309, DOI 10.1016/0003-2697(78)90845-X; Gradi A, 1998, P NATL ACAD SCI USA, V95, P11089, DOI 10.1073/pnas.95.19.11089; Gutierrez AL, 1997, J VIROL, V71, P3826; HALLER AA, 1992, J VIROL, V66, P5075, DOI 10.1128/JVI.66.8.5075-5086.1992; HELLEN CUT, 1994, J VIROL, V68, P941, DOI 10.1128/JVI.68.2.941-950.1994; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; Jackson RJ, 1995, RNA, V1, P985; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMONICA N, 1989, J VIROL, V63, P2357, DOI 10.1128/JVI.63.5.2357-2360.1989; LE SY, 1990, J MOL BIOL, V216, P729, DOI 10.1016/0022-2836(90)90395-3; Leontis NB, 2003, CURR OPIN STRUC BIOL, V13, P300, DOI 10.1016/S0959-440X(03)00076-9; MACADAM AJ, 1992, VIROLOGY, V189, P415, DOI 10.1016/0042-6822(92)90565-7; Malnou CE, 2002, J VIROL, V76, P10617, DOI 10.1128/JVI.76.21.10617-10626.2002; MALNOU CE, 2004, IN PRESS CURR TOPICS; MARC D, 1989, EMBO J, V8, P2661, DOI 10.1002/j.1460-2075.1989.tb08406.x; MARTIN A, 1991, VIROLOGY, V180, P648, DOI 10.1016/0042-6822(91)90078-P; MINOR PD, 1992, J GEN VIROL, V73, P3065, DOI 10.1099/0022-1317-73-12-3065; Minor Philip D., 1997, P555; Morley SJ, 1997, RNA, V3, P1085; Ochs K, 2003, J VIROL, V77, P115, DOI 10.1128/JVI.77.1.115-122.2003; Ochs K, 2002, J VIROL, V76, P2113, DOI 10.1128/JVI.76.5.2113-2122.2002; Perales C, 2003, FEBS LETT, V533, P89, DOI 10.1016/S0014-5793(02)03764-X; PILIPENKO EV, 1989, VIROLOGY, V168, P201, DOI 10.1016/0042-6822(89)90259-6; RACANIELLO VR, 1993, BIOLOGICALS, V21, P365, DOI 10.1006/biol.1993.1097; REED L. J., 1938, AMER JOUR HYG, V27, P493; RIVERA VM, 1988, VIROLOGY, V165, P42, DOI 10.1016/0042-6822(88)90656-3; SABIN A. B., 1973, Journal of Biology, V1, P115, DOI 10.1016/0092-1157(73)90048-6; SALK JE, 1960, LANCET, V2, P715; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SKINNER MA, 1989, J MOL BIOL, V207, P379, DOI 10.1016/0022-2836(89)90261-1; Stewart SR, 1998, NUCLEIC ACIDS RES, V26, P5318, DOI 10.1093/nar/26.23.5318; SVITKIN YV, 1985, VIROLOGY, V147, P243, DOI 10.1016/0042-6822(85)90127-8; SVITKIN YV, 1990, VIROLOGY, V175, P103, DOI 10.1016/0042-6822(90)90190-3; SVITKIN YV, 1988, VIROLOGY, V166, P394, DOI 10.1016/0042-6822(88)90510-7; TETERINA NL, 1992, J GEN VIROL, V73, P1977, DOI 10.1099/0022-1317-73-8-1977; Ventoso I, 1998, FEBS LETT, V435, P79, DOI 10.1016/S0014-5793(98)01027-8; WIMMER E, 1993, ANNU REV GENET, V27, P353, DOI 10.1146/annurev.ge.27.120193.002033; ZIEGLER E, 1995, VIROLOGY, V213, P549; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	47	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10261	10269		10.1074/jbc.M307806200	http://dx.doi.org/10.1074/jbc.M307806200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14672927	hybrid			2022-12-25	WOS:000220050400074
J	Schulze, WX; Mann, M				Schulze, WX; Mann, M			A novel proteomic screen for peptide-protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; ADAPTER-PROTEIN; DIFFERENTIAL INTERACTIONS; ACCESSORY PROTEIN; INTERACTION MAPS; BINDING-SITES; CELL-CULTURE; AMINO-ACIDS; SH2 DOMAINS; RECEPTOR	Regulated interactions between short, unstructured amino acid sequences and modular protein domains are central to cell signaling. Here we use synthetic peptides in "active" (e.g. phosphorylated) and "control" (e.g. nonphosphorylated) forms as baits in affinity pull-down experiments to determine such interactions by quantitative proteomics. Stable isotope labeling by amino acids in cell culture distinguishes specific binders directly by the isotope ratios determined by mass spectrometry (Blagoev, B., Kratchmarova, I., Ong, S.-E., Nielsen, M., Foster, L. J., and Mann, M. ( 2003) Nat. Biotechnol. 21, 315 - 318). A tyrosine-phosphorylated peptide of the epidermal growth factor receptor specifically retrieved the Src homology domain (SH) 2- and SH3 domain-containing adapter protein Grb2. A proline-rich sequence of Son of Sevenless also specifically bound Grb2, demonstrating that the screen maintains specificity with low affinity interactions. The proline-rich Sos peptide retrieved only SH3 domain containing proteins as specific binding partners. Two of these, Pacsin 3 and Sorting Nexin 9, were confirmed by immunoprecipitation. Our data are consistent with a change in the role of Sos from Ras-dependent signaling to actin remodeling/endocytic signaling events by a proline-SH3 domain switch.	Univ So Denmark, Dept Biochem & Mol Biol, Ctr Expt Bioinformat, DK-5230 Odense M, Denmark	University of Southern Denmark	Mann, M (corresponding author), Univ So Denmark, Dept Biochem & Mol Biol, Ctr Expt Bioinformat, Campusvej 55, DK-5230 Odense M, Denmark.	mann@bmb.sdu.dk	Mann, Matthias/A-3454-2013; Schulze, Waltraud X/E-9800-2011	Mann, Matthias/0000-0003-1292-4799; Schulze, Waltraud X/0000-0001-9957-7245				BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Blagoev B, 2003, NAT BIOTECHNOL, V21, P315, DOI 10.1038/nbt790; Bradshaw JM, 2003, ADV PROTEIN CHEM, V61, P161; Brett TJ, 2002, STRUCTURE, V10, P797, DOI 10.1016/S0969-2126(02)00784-0; Cesareni G, 2002, FEBS LETT, V513, P38, DOI 10.1016/S0014-5793(01)03307-5; Chook YM, 1996, J BIOL CHEM, V271, P30472, DOI 10.1074/jbc.271.48.30472; Dikic I, 2002, FEBS LETT, V529, P110, DOI 10.1016/S0014-5793(02)03188-5; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Espejo A, 2002, BIOCHEM J, V367, P697, DOI 10.1042/BJ20020860; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; GOUDREAU N, 1994, NAT STRUCT BIOL, V1, P898, DOI 10.1038/nsb1294-898; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Holt KH, 1996, J BIOL CHEM, V271, P8300, DOI 10.1074/jbc.271.14.8300; Innocenti M, 2002, J CELL BIOL, V156, P125, DOI 10.1083/jcb.200108035; Ishihama Y, 2002, J CHROMATOGR A, V979, P233, DOI 10.1016/S0021-9673(02)01402-4; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Kay BK, 2001, METHODS, V24, P240, DOI 10.1006/meth.2001.1185; Kirsch KH, 1999, P NATL ACAD SCI USA, V96, P6211, DOI 10.1073/pnas.96.11.6211; Legrain P, 2000, FEBS LETT, V480, P32, DOI 10.1016/S0014-5793(00)01774-9; Lundmark R, 2002, BIOCHEM J, V362, P597, DOI 10.1042/0264-6021:3620597; Mayer BJ, 2001, J CELL SCI, V114, P1253; Modregger J, 2000, J CELL SCI, V113, P4511; Mulder NJ, 2003, NUCLEIC ACIDS RES, V31, P315, DOI 10.1093/nar/gkg046; NIMNUAL A, 2002, SCI STKE; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Ong SE, 2003, J PROTEOME RES, V2, P173, DOI 10.1021/pr0255708; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Qian XL, 2000, EMBO J, V19, P642, DOI 10.1093/emboj/19.4.642; Qualmann B, 2000, J CELL BIOL, V148, P1047, DOI 10.1083/jcb.148.5.1047; Ranish JA, 2003, NAT GENET, V33, P349, DOI 10.1038/ng1101; Rappsilber J, 2003, ANAL CHEM, V75, P663, DOI 10.1021/ac026117i; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Sumoy L, 2001, GENE, V262, P199, DOI 10.1016/S0378-1119(00)00531-X; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Vidal M, 1998, J BIOL CHEM, V273, P5343, DOI 10.1074/jbc.273.9.5343; Walhout AJM, 2001, NAT REV MOL CELL BIO, V2, P55, DOI 10.1038/35048107; Ward CW, 1996, J BIOL CHEM, V271, P5603, DOI 10.1074/jbc.271.10.5603; Wasiak S, 2001, J BIOL CHEM, V276, P26622, DOI 10.1074/jbc.M100591200; Watanabe S, 2000, BIOCHEM BIOPH RES CO, V278, P167, DOI 10.1006/bbrc.2000.3760; Worby CA, 2002, NAT REV MOL CELL BIO, V3, P919, DOI 10.1038/nrm974; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yaffe MB, 2002, NAT REV MOL CELL BIO, V3, P177, DOI 10.1038/nrm759; YANG SS, 1995, J BIOL CHEM, V270, P18212, DOI 10.1074/jbc.270.31.18212; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	48	244	258	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10756	10764		10.1074/jbc.M309909200	http://dx.doi.org/10.1074/jbc.M309909200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14679214	hybrid			2022-12-25	WOS:000220050400131
J	Shirakawa, R; Higashi, T; Tabuchi, A; Yoshioka, A; Nishioka, H; Fukuda, M; Kita, T; Horiuchi, H				Shirakawa, R; Higashi, T; Tabuchi, A; Yoshioka, A; Nishioka, H; Fukuda, M; Kita, T; Horiuchi, H			Munc13-4 is a GTP-Rab27-binding protein regulating dense core granule secretion in platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-INDUCED ALPHA-GRANULE; RAB5 EFFECTOR EEA1; MYOSIN-VA; MOLECULAR-MECHANISMS; GRISCELLI-SYNDROME; MEMBRANE-FUSION; BINDING DOMAIN; BOVINE BRAIN; ASHEN MICE; KINASE-C	Platelets store self-agonists such as ADP and serotonin in dense core granules. Although exocytosis of these granules is crucial for hemostasis and thrombosis, the underlying mechanism is not fully understood. Here, we show that incubation of permeabilized platelets with unprenylated active mutant Rab27A-Q78L, wild type Rab27A, and Rab27B inhibited the secretion, whereas inactive mutant Rab27A-T23N and other GTPases had no effects. Furthermore, we affinity-purified a GTP-Rab27A-binding protein in platelets and identified it as Munc13-4, a homologue of Munc13-1 known as a priming factor for neurotransmitter release. Recombinant Munc13-4 directly bound to GTP-Rab27A and - Rab27B in vitro, but not other GTPases, and enhanced secretion in an in vitro assay. The inhibition of secretion by unprenylated Rab27A was rescued by the addition of Munc13-4, suggesting that Munc13-4 mediates the function of GTP-Rab27. Thus, Rab27 regulates the dense core granule secretion in platelets by employing its binding protein, Munc13-4.	Kyoto Univ, Grad Sch Med, Dept Geriatr Med, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Kyoto 6068507, Japan; RIKEN, Fukuda Initiat Res Unit, Wako, Saitama 3510198, Japan	Kyoto University; Kyoto University; RIKEN	Horiuchi, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Geriatr Med, Kyoto 6068507, Japan.	horiuchi@kuhp.kyoto-u.ac.jp	Higashi, Tomohito/AHE-7942-2022; Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853; Higashi, Tomohito/0000-0001-5616-1477				AKAYAMA M, 1986, CELL STRUCT FUNCT, V11, P259, DOI 10.1247/csf.11.259; Ashery U, 2000, EMBO J, V19, P3586, DOI 10.1093/emboj/19.14.3586; Augustin I, 1999, BIOCHEM J, V337, P363, DOI 10.1042/0264-6021:3370363; Augustin I, 1999, NATURE, V400, P457, DOI 10.1038/22768; Barral DC, 2002, J CLIN INVEST, V110, P247, DOI 10.1172/JCI200215058; Brass L. F, 2000, HEMATOLOGY BASIC PRI, P1753; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; Brose N, 2000, CURR OPIN NEUROBIOL, V10, P303, DOI 10.1016/S0959-4388(00)00105-7; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; Chen D, 2000, BLOOD, V95, P921, DOI 10.1182/blood.V95.3.921.003k17_921_929; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Haddad EK, 2001, J CELL BIOL, V152, P835, DOI 10.1083/jcb.152.4.835; Hume AN, 2002, TRAFFIC, V3, P193, DOI 10.1034/j.1600-0854.2002.030305.x; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; KNIGHT DE, 1980, THROMB RES, V20, P437, DOI 10.1016/0049-3848(80)90282-0; Knight JB, 2000, ENDOCRINOLOGY, V141, P208, DOI 10.1210/en.141.1.208; Koch H, 2000, BIOCHEM J, V349, P247, DOI 10.1042/0264-6021:3490247; Kuroda TS, 2003, MOL CELL BIOL, V23, P5245, DOI 10.1128/MCB.23.15.5245-5255.2003; Kuroda TS, 2002, BIOCHEM BIOPH RES CO, V293, P899, DOI 10.1016/S0006-291X(02)00320-0; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MATSUI Y, 1990, BIOCHEM BIOPH RES CO, V166, P1010, DOI 10.1016/0006-291X(90)90911-6; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; Menasche G, 2003, BLOOD, V101, P2736, DOI 10.1182/blood-2002-09-2789; Nagashima K, 2002, FEBS LETT, V517, P233, DOI 10.1016/S0014-5793(02)02634-0; NAGATA K, 1990, FEBS LETT, V275, P29, DOI 10.1016/0014-5793(90)81431-M; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; Nielsen E, 2000, J CELL BIOL, V151, P601, DOI 10.1083/jcb.151.3.601; Novak EK, 2002, BLOOD, V100, P128, DOI 10.1182/blood.V100.1.128; NUOFFER C, 1995, METHOD ENZYMOL, V257, P3; Palmer M, 1998, EMBO J, V17, P1598, DOI 10.1093/emboj/17.6.1598; Pereira-Leal JB, 2001, FEBS LETT, V498, P197, DOI 10.1016/S0014-5793(01)02483-8; Price A, 2000, J CELL BIOL, V148, P1231, DOI 10.1083/jcb.148.6.1231; Provance DW, 2002, TRAFFIC, V3, P124, DOI 10.1034/j.1600-0854.2002.030205.x; Richmond JE, 2001, NATURE, V412, P338, DOI 10.1038/35085583; Sassa T, 1999, J NEUROSCI, V19, P4772; Schoch S, 2002, NATURE, V415, P321, DOI 10.1038/415321a; Shirakawa R, 2000, J BIOL CHEM, V275, P33844, DOI 10.1074/jbc.M002834200; Simonsen A, 1999, J BIOL CHEM, V274, P28857, DOI 10.1074/jbc.274.41.28857; Stinchcombe JC, 2001, IMMUNITY, V15, P751, DOI 10.1016/S1074-7613(01)00234-5; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Varoqueaux F, 2002, P NATL ACAD SCI USA, V99, P9037, DOI 10.1073/pnas.122623799; Wilson SM, 2000, P NATL ACAD SCI USA, V97, P7933, DOI 10.1073/pnas.140212797; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247; Yoshioka A, 2001, ANN NY ACAD SCI, V947, P403; Yoshioka A, 2001, J BIOL CHEM, V276, P39379, DOI 10.1074/jbc.M102933200; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	54	162	167	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10730	10737		10.1074/jbc.M309426200	http://dx.doi.org/10.1074/jbc.M309426200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699162	Green Submitted, hybrid			2022-12-25	WOS:000220050400128
J	Gao, RP; Brigstock, DR				Gao, RP; Brigstock, DR			Connective tissue growth factor (CCN2) induces adhesion of rat activated hepatic stellate cells by binding of its C-terminal domain to integrin alpha(v)beta(3) and heparan sulfate proteoglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SKIN FIBROBLASTS; ENDOTHELIAL-CELLS; HUMAN LIVER; MATRICELLULAR PROTEINS; FACTOR CTGF; MYOBLAST DIFFERENTIATION; CYR61 CCN1; EXPRESSION; SURFACE; ALPHA(6)BETA(1)	Connective tissue growth factor (CCN2, also known as CTGF) is a matricellular protein that appears to play an important role in hepatic stellate cell (HSC)-mediated fibrogenesis. After signal peptide cleavage, the full-length CCN2 molecule comprises four structural modules (CCN2(1-4)) and is susceptible to proteolysis by HSC yielding isoforms comprising essentially modules 3 and 4 (CCN2(3-4)) or module 4 alone (CCN2(4)). In this study we show that rat activated HSC are capable of adhesion to all three CCN2 isoforms via the binding of module 4 to integrin alpha(v)beta(3), a process that is dependent on interactions between module 4 and cell surface heparan sulfate proteoglycans (HSPGs). These findings are based on several lines of evidence. First, integrin alpha(v)beta(3) was detected in HSC lysates by immunoprecipitation and Western blot, and CCN2(4)-mediated HSC adhesion was blocked by anti-integrin alpha(v)beta(3) antibody. Second, as assessed by immunoprecipitation and solid phase binding assay, CCN2(4) bound directly to integrin alpha(v)beta(3) in cell-free systems. Third, destruction or inhibition of synthesis of cell surface HSPGs with, respectively, heparinase or sodium chlorate abrogated HSC adhesion to CCN2(4). Fourth, prior occupancy of heparin-binding sites on CCN2(4) with soluble heparin completely blocked HSC adhesion. These findings indicate that integrin alpha(v)beta(3) functions as a co-receptor with HSPGs for CCN2(4)-mediated HSC adhesion. Furthermore, by peptide mapping and site-directed mutagenesis we demonstrated that the sequence IRTPKISKPIKFELSG within CCN2(4) is a unique binding domain for integrin alpha(v)beta(3) that is sufficient to mediate integrin alpha(v)beta(3)- and HSPG-dependent HSC adhesion. These findings offer the possibility of developing novel antifibrotic therapies that target the integrin-binding domain.	Childrens Res Inst, Ctr Cell & Vasc Biol, Columbus, OH 43205 USA; Ohio State Univ, Dept Surg, Columbus, OH 43212 USA; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43212 USA	University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Brigstock, DR (corresponding author), Childrens Res Inst, Ctr Cell & Vasc Biol, Rm WA 2022,700 Childrens Dr, Columbus, OH 43205 USA.	brigstod@pediatrics.ohio-state.edu			NIAAA NIH HHS [R01 AA12817] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012817] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Abou-Shady M, 2000, LIVER, V20, P296, DOI 10.1034/j.1600-0676.2000.020004296.x; Babic AM, 1999, MOL CELL BIOL, V19, P2958; Ball DK, 2003, REPRODUCTION, V125, P271, DOI 10.1530/rep.0.1250271; Ball DK, 2003, J ENDOCRINOL, V176, pR1, DOI 10.1677/joe.0.176R001; Beauvais DM, 2003, EXP CELL RES, V286, P219, DOI 10.1016/S0014-4827(03)00126-5; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; Bornstein P, 2000, MATRIX BIOL, V19, P555, DOI 10.1016/S0945-053X(00)00103-7; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brigstock DR, 1997, J BIOL CHEM, V272, P20275, DOI 10.1074/jbc.272.32.20275; Brigstock DR, 2003, J CLIN PATHOL-MOL PA, V56, P127, DOI 10.1136/mp.56.2.127; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Caldwell EEO, 1996, INT J BIOCHEM CELL B, V28, P203, DOI 10.1016/1357-2725(95)00123-9; Carey DJ, 1997, BIOCHEM J, V327, P1; Carloni V, 1996, GASTROENTEROLOGY, V110, P1127, DOI 10.1053/gast.1996.v110.pm8613002; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Chen CC, 2001, J BIOL CHEM, V276, P47329, DOI 10.1074/jbc.M107666200; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; Ellis PD, 2003, J VASC RES, V40, P234, DOI 10.1159/000071887; Feitsma K, 2000, J BIOL CHEM, V275, P9396, DOI 10.1074/jbc.275.13.9396; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; GALLAGHER JT, 1985, BIOCHEM J, V230, P665, DOI 10.1042/bj2300665; Gao RP, 2003, HEPATOL RES, V27, P214, DOI 10.1016/S1386-6346(03)00241-9; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; Grzeszkiewicz TM, 2002, ENDOCRINOLOGY, V143, P1441, DOI 10.1210/en.143.4.1441; Grzeszkiewicz TM, 2001, J BIOL CHEM, V276, P21943, DOI 10.1074/jbc.M100978200; Herndon ME, 1999, GLYCOBIOLOGY, V9, P143, DOI 10.1093/glycob/9.2.143; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Iwamoto H, 1998, J HEPATOL, V29, P752, DOI 10.1016/S0168-8278(98)80256-0; Kerr JS, 2001, DRUG NEWS PERSPECT, V14, P143; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Leu SJ, 2003, J BIOL CHEM, V278, P33801, DOI 10.1074/jbc.M305862200; Leu SJ, 2002, J BIOL CHEM, V277, P46248, DOI 10.1074/jbc.M209288200; MENDENDEZ JA, 2003, ENDOCR RELAT CANCER, V10, P139; Mould AP, 2002, J BIOL CHEM, V277, P19800, DOI 10.1074/jbc.M201571200; Moussad EEDA, 2000, MOL GENET METAB, V71, P276, DOI 10.1006/mgme.2000.3059; Paradis V, 2002, LAB INVEST, V82, P767, DOI 10.1097/01.LAB.0000017365.18894.D3; Paradis V, 1999, HEPATOLOGY, V30, P968, DOI 10.1002/hep.510300425; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Perbal B, 1999, P NATL ACAD SCI USA, V96, P869, DOI 10.1073/pnas.96.3.869; Perbal B, 2003, J CLIN PATHOL-MOL PA, V56, P80, DOI 10.1136/mp.56.2.80; PIALI L, 1995, J CELL BIOL, V130, P451, DOI 10.1083/jcb.130.2.451; Rachfal AW, 2003, HEPATOL RES, V26, P1, DOI 10.1016/S1386-6346(03)00115-3; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Roberts MS, 2003, J BIOL CHEM, V278, P1975, DOI 10.1074/jbc.M208607200; Roskams T, 1996, HEPATOLOGY, V24, P524, DOI 10.1053/jhep.1996.v24.pm0008781318; Rusnati M, 1997, MOL BIOL CELL, V8, P2449, DOI 10.1091/mbc.8.12.2449; Sakamoto K, 2002, J BIOL CHEM, V277, P29399, DOI 10.1074/jbc.M203727200; Schober JM, 2002, BLOOD, V99, P4457, DOI 10.1182/blood.V99.12.4457; SCHOBER JM, 2003, J BIOL CHEM; SMITH JW, 1994, J BIOL CHEM, V269, P960; van der Pauw MTM, 2002, J PERIODONTAL RES, V37, P317, DOI 10.1034/j.1600-0765.2002.00349.x; VYAS SK, 1995, GASTROENTEROLOGY, V109, P889, DOI 10.1016/0016-5085(95)90399-2; Weiner OH, 1996, CELL TISSUE RES, V285, P11, DOI 10.1007/s004410050615; Williams EJ, 2000, J HEPATOL, V32, P754, DOI 10.1016/S0168-8278(00)80244-5	58	191	207	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8848	8855		10.1074/jbc.M313204200	http://dx.doi.org/10.1074/jbc.M313204200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14684735	hybrid			2022-12-25	WOS:000189265900040
J	Lew, JL; Zhao, A; Yu, JH; Huang, L; de Pedro, N; Pelaez, F; Wright, SD; Cui, JS				Lew, JL; Zhao, A; Yu, JH; Huang, L; de Pedro, N; Pelaez, F; Wright, SD; Cui, JS			The farnesoid X receptor controls gene expression in a ligand- and promoter-selective fashion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTOR; NEGATIVE FEEDBACK-REGULATION; SALT EXPORT PUMP; BILE-ACIDS; PROTEIN GENE; LIVER; FXR; IDENTIFICATION; TRANSCRIPTION; TRANSPORTER	Farnesoid X receptor (FXR) is a nuclear receptor for bile acids. Ligand activated-FXR regulates transcription of genes to allow feedback control of bile acid synthesis and secretion. There are five major bile acids in humans. We have previously demonstrated that lithocholate acts as an FXR antagonist, and here we show that the other four bile acids, chenodeoxycholate (CDCA), deoxycholate (DCA), cholate (CA), and ursodeoxycholate (UDCA), act as selective FXR agonists in a gene-specific fashion. In an in vitro coactivator association assay, CDCA fully activated FXR, whereas CA partially activated FXR and DCA and UDCA had negligible activities. Similar results were also obtained from a glutathione S-transferase pull-down assay in which only CDCA and the synthetic FXR agonist GW4064 significantly increased the interaction of SRC-1 with FXR. In FXR transactivation assays with a bile salt export pump (BSEP) promoter-driven luciferase construct, bile acids showed distinct abilities to activate the BSEP promoter: CDCA, DCA, CA, and UDCA increased luciferase activity by 25-, 20-, 18-, and 8-fold, respectively. Consistently, CDCA increased BSEP mRNA by 750-fold in HepG2 cells, whereas DCA, CA, and UDCA induced BSEP mRNA by 250-, 75-, and 15-fold, respectively. Despite the partial induction of BSEP mRNA, CA, DCA, and UDCA effectively repressed expression of cholesterol 7alpha-hydroxylase, another FXR target. We further showed that all four bile acids significantly increased FXR protein, suggesting the existence of an auto-regulatory loop in FXR signaling pathways. In conclusion, these results suggest that the binding of each bile acid results in a different FXR conformations, which in turn differentially regulates expression of individual FXR targets.	Merck Res Labs, Dept Atherosclerosis & Endocrinol, Rahway, NJ 07065 USA; Merck Sharp & Dohme Espana, Madrid 28027, Spain	Merck & Company; Merck & Company	Cui, JS (corresponding author), Merck Res Labs, Dept Atherosclerosis & Endocrinol, 126 E Lincoln Ave,POB 2000,RY80W-107, Rahway, NJ 07065 USA.	jisong_cui@merck.com	Pelaez, Fernando/K-1790-2014	Pelaez, Fernando/0000-0002-4861-586X				Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; Bramlett KS, 2000, MOL GENET METAB, V71, P609, DOI 10.1006/mgme.2000.3106; Camp HS, 1999, FEBS LETT, V447, P186, DOI 10.1016/S0014-5793(99)00268-9; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; Claudel T, 2002, J CLIN INVEST, V109, P961; Cui J, 2003, J BIOL CHEM, V278, P10214, DOI 10.1074/jbc.M209323200; Cui J, 2002, J BIOL CHEM, V277, P25963, DOI 10.1074/jbc.M200824200; Denson LA, 2001, GASTROENTEROLOGY, V121, P140, DOI 10.1053/gast.2001.25503; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; Gupta S, 2001, J BIOL CHEM, V276, P15816, DOI 10.1074/jbc.M010878200; Hofmann AF, 1999, ARCH INTERN MED, V159, P2647, DOI 10.1001/archinte.159.22.2647; Kast HR, 2001, MOL ENDOCRINOL, V15, P1720, DOI 10.1210/me.15.10.1720; Kerr TA, 2002, DEV CELL, V2, P713, DOI 10.1016/S1534-5807(02)00154-5; Li Y, 2002, MOL ENDOCRINOL, V16, P506, DOI 10.1210/me.16.3.506; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Mak PA, 2002, J LIPID RES, V43, P2037, DOI 10.1194/jlr.C200014-JLR200; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Maloney PR, 2000, J MED CHEM, V43, P2971, DOI 10.1021/jm0002127; Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Song CS, 2001, J BIOL CHEM, V276, P42549, DOI 10.1074/jbc.M107557200; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; Takeyama K, 1996, BIOCHEM BIOPH RES CO, V222, P395, DOI 10.1006/bbrc.1996.0755; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; Xu GR, 2002, J BIOL CHEM, V277, P50491, DOI 10.1074/jbc.M209176200; Yu JH, 2002, J BIOL CHEM, V277, P31441, DOI 10.1074/jbc.M200474200; Zhang M, 2001, J BIOL CHEM, V276, P41690, DOI 10.1074/jbc.M105117200; Zhou GC, 1998, MOL ENDOCRINOL, V12, P1594, DOI 10.1210/me.12.10.1594	32	154	159	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8856	8861		10.1074/jbc.M306422200	http://dx.doi.org/10.1074/jbc.M306422200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14684751	hybrid			2022-12-25	WOS:000189265900041
J	Martin-Puig, S; Temes, E; Olmos, G; Jones, DR; Aragones, J; Landazuri, MO				Martin-Puig, S; Temes, E; Olmos, G; Jones, DR; Aragones, J; Landazuri, MO			Role of iron (II)-2-oxoglutarate-dependent dioxygenases in the generation of hypoxia-induced phosphatidic acid through HIF-1/2 and von Hippel-Lindau-independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR-I; STRESS FIBER FORMATION; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; MAMMALIAN TARGET; HIF-ALPHA; OXYGEN; PROLYL; ACTIVATION; PROTEIN	Hypoxia-inducible factors ( HIF-1/HIF-2) govern the expression of critical genes for cellular adaptation to low oxygen tensions. We have previously reported that the intracellular level of phosphatidic acid (PA) rises in response to hypoxia (1% O-2). In this report, we have explored whether components of the canonical HIF/von Hippel-Lindau (VHL) pathway are involved in the induction of PA. We found that hypoxia induces PA in a cell line constitutively expressing a stable version of HIF-1alpha. PA induction was also found in HIF-1alpha- and 2alpha-negative CHO Ka13 cells, as well as in HIF-beta-negative HepaC4 cells. These data indicate that HIF activity is neither sufficient nor necessary for oxygen-dependent PA accumulation. PA generation was also detected in cells deficient for the tumor suppressor VHL, indicating that the presence of VHL was not required for the induction of PA. Here we show that PA accumulation also occurs at moderate hypoxia (5% O-2), although to a lesser extent to that seen at 1% O-2, revealing that PA is induced at the same hypoxia range required to activate HIF-1. Prolyl hydroxylases (PHD) and asparaginyl hydroxylase (FIH) belong to the iron (II) and 2-oxoglutarate- dependent dioxygenase family and have been proposed as oxygen sensors involved in the regulation of HIFs. Chemical inhibition of these activities by treatment with iron chelators or 2-oxoglutarate analogs also results in a marked PA accumulation similar to that observed in hypoxia. Together these data show that PA accumulation in response to hypoxia is both HIF-1/2- and VHL-independent and indicate a role of iron (II)-2-oxoglutarate-dependent dioxygenases in the oxygen-sensing mechanisms involved in hypoxia-driven phospholipid regulation.	Univ Autonoma Madrid, Hosp Princesa, Serv Inmunol, Madrid 28006, Spain	Autonomous University of Madrid; Hospital de La Princesa	Landazuri, MO (corresponding author), Univ Autonoma Madrid, Hosp Princesa, Serv Inmunol, Diego de Leon 62, Madrid 28006, Spain.	mortiz.hlpr@salud.madrid.org		Aragones Lopez, Julian/0000-0002-0193-4679; Martin-Puig, Silvia/0000-0003-3048-6729; Olmos Centenera, Gemma/0000-0003-4835-0846				Andresen BT, 2002, FEBS LETT, V531, P65, DOI 10.1016/S0014-5793(02)03483-X; Aragones J, 2001, J BIOL CHEM, V276, P10548, DOI 10.1074/jbc.M006180200; Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; del Peso L, 2003, J BIOL CHEM, V278, P48690, DOI 10.1074/jbc.M308862200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; Gassmann M, 1997, KIDNEY INT, V51, P567, DOI 10.1038/ki.1997.81; Ghosh S, 2003, J BIOL CHEM, V278, P45690, DOI 10.1074/jbc.M302933200; Ghosh S, 1997, FASEB J, V11, P45, DOI 10.1096/fasebj.11.1.9034165; Gong PF, 2001, J BIOL CHEM, V276, P27018, DOI 10.1074/jbc.M103658200; Gu YZ, 1998, GENE EXPRESSION, V7, P205; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Hodgkin MN, 1998, TRENDS BIOCHEM SCI, V23, P200, DOI 10.1016/S0968-0004(98)01200-6; Hofbauer KH, 2003, EUR J BIOCHEM, V270, P4515, DOI 10.1046/j.1432-1033.2003.03846.x; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Humar R, 2002, FASEB J, V16, DOI 10.1096/fj.01-0658com; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Ivanov SV, 1998, P NATL ACAD SCI USA, V95, P12596, DOI 10.1073/pnas.95.21.12596; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jung F, 2002, CIRC RES, V91, P38, DOI 10.1161/01.RES.0000024412.24491.CA; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kam Y, 2001, MOL CELL BIOL, V21, P4055, DOI 10.1128/MCB.21.12.4055-4066.2001; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kishikawa K, 1999, J BIOL CHEM, V274, P21335, DOI 10.1074/jbc.274.30.21335; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; LIM HK, 2003, J BIOL CHEM, V12, P123; Lopez-Barneo J, 1999, RESP PHYSIOL, V115, P215, DOI 10.1016/S0034-5687(99)00016-X; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; MAJAMAA K, 1986, J BIOL CHEM, V261, P7819; Masson N, 2003, J CELL SCI, V116, P3041, DOI 10.1242/jcs.00655; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; MCCAFFREY TA, 1995, J CLIN INVEST, V95, P446, DOI 10.1172/JCI117684; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Ryan HE, 2000, CANCER RES, V60, P4010; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Safran M, 2003, J CLIN INVEST, V111, P779, DOI 10.1172/JCI200318181; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; SETA KA, 2002, SCI STKE, V146, pRE11, DOI DOI 10.1126/STKE.2002.146.RE11; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Warnecke C, 2003, FASEB J, V17, P1186, DOI 10.1096/fj.02-1062fje; Wenger RH, 2000, J EXP BIOL, V203, P1253; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030; Zhu H, 2001, SCIENCE, V292, P449, DOI 10.1126/science.1060849	57	10	12	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9504	9511		10.1074/jbc.M310658200	http://dx.doi.org/10.1074/jbc.M310658200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14681229	hybrid			2022-12-25	WOS:000189265900117
J	Mukhopadhyay, D; SundarRaj, S; Alok, A; Karande, AA				Mukhopadhyay, D; SundarRaj, S; Alok, A; Karande, AA			Glycodelin A, not glycodelin S, is apoptotically active - Relevance of sialic acid modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL PROTEIN-14; SEMINAL-VESICLES; T-CELLS; EXPRESSION; OLIGOSACCHARIDES; APOPTOSIS	Glycodelin, previously known as PP14 ( placental protein-14), is a kernel lipocalin secreted by the glandular epithelium of the endometrium upon progesterone stimulation and by the seminal vesicles. The isoform of the protein present in female reproductive tissue, glycodelin A (GdA), and the male counterpart, glycodelin S (GdS), have identical amino acid sequences, but strikingly different N-linked glycans. It is well documented in literature that GdA is an immunosuppressive protein, and we have shown that this activity is due to its ability to induce apoptosis in activated T cells. The precise role of GdS in seminal plasma is not known. In this study, we report that GdS is not apoptotically active. We observe that the apoptotic activity requires the presence of sialic acid residues on the complex glycans, as in the case of GdA; however, complex glycans of GdS are nonsialylated. We have expressed the wild-type protein in Pichia pastoris, which does not add sialic acid to the secreted proteins, and confirmed our observations that the protein is apoptotically inactive in the non-sialylated form. Our results indicate that differential glycosylation modulates the function of the different glycodelin isoforms.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Karande, AA (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	anjali@biochem.iisc.ernet.in	Karande, Anjali/C-4880-2009					AMR S, 1982, BIOCHEM BIOPH RES CO, V109, P146, DOI 10.1016/0006-291X(82)91577-7; Barteri M, 2000, BBA-PROTEIN STRUCT M, V1479, P255, DOI 10.1016/S0167-4838(00)00021-2; Bohn H, 1982, Placenta Suppl, V4, P67; BOLTON AE, 1987, LANCET, V1, P593; BOYUM A, 1964, NATURE, V204, P793, DOI 10.1038/204793a0; Celis JE, 1998, CELL BIOLOGY - A LABOARATORY HANDBOOK, 2ND EDITION, VOL 4, P375; Chotigeat W, 2000, J BIOTECHNOL, V81, P55, DOI 10.1016/S0168-1656(00)00268-6; Crocker PR, 2001, TRENDS IMMUNOL, V22, P337, DOI 10.1016/S1471-4906(01)01930-5; DELL A, 1995, J BIOL CHEM, V270, P24116, DOI 10.1074/jbc.270.41.24116; Dutta B, 1998, PROTEIN EXPRES PURIF, V14, P327, DOI 10.1006/prep.1998.0961; FRIEDMAN ML, 1986, BIOCHEM J, V236, P149, DOI 10.1042/bj2360149; Gonzales GF, 2001, ASIAN J ANDROL, V3, P251; Haque ME, 1999, EUR J BIOCHEM, V259, P269, DOI 10.1046/j.1432-1327.1999.00062.x; Harlow E., 1988, ANTIBODIES LABORATOR, P310; Jayachandran R, 2004, J BIOL CHEM, V279, P8585, DOI 10.1074/jbc.M310480200; Jerzak M, 1998, AM J REPROD IMMUNOL, V40, P130; JULKUNEN M, 1986, ENDOCRINOLOGY, V118, P1782, DOI 10.1210/endo-118-5-1782; JULKUNEN M, 1988, P NATL ACAD SCI USA, V85, P8845, DOI 10.1073/pnas.85.23.8845; Kamarainen M, 1997, LAB INVEST, V77, P565; Karri T, 2000, HISTOCHEM J, V32, P711, DOI 10.1023/A:1004144909714; Koistinen H, 1999, FEBS LETT, V450, P158, DOI 10.1016/S0014-5793(99)00490-1; Koistinen H, 1996, MOL HUM REPROD, V2, P759, DOI 10.1093/molehr/2.10.759; Logdberg L, 2000, BBA-PROTEIN STRUCT M, V1482, P284, DOI 10.1016/S0167-4838(00)00164-3; Morris HR, 1996, J BIOL CHEM, V271, P32159, DOI 10.1074/jbc.271.50.32159; Mukhopadhyay D, 2001, J BIOL CHEM, V276, P28268, DOI 10.1074/jbc.M010487200; OEHNINGER S, 1995, FERTIL STERIL, V63, P377; Schauer R, 1988, Adv Exp Med Biol, V228, P47; Seppala M, 1998, TUMOR BIOL, V19, P213, DOI 10.1159/000030009; SEPPALA M, 1985, ANN NY ACAD SCI, V442, P212, DOI 10.1111/j.1749-6632.1985.tb37522.x; Song MQ, 2001, P NATL ACAD SCI USA, V98, P9265, DOI 10.1073/pnas.151151198; TULPPALA M, 1995, FERTIL STERIL, V63, P792, DOI 10.1016/S0015-0282(16)57483-4	31	43	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8577	8584		10.1074/jbc.M306673200	http://dx.doi.org/10.1074/jbc.M306673200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14679205	hybrid			2022-12-25	WOS:000189265900008
J	Stuhlmeier, KM; Pollaschek, C				Stuhlmeier, KM; Pollaschek, C			Differential effect of transforming growth factor beta (TGF-beta) on the genes encoding hyaluronan synthases and utilization of the p38 MAPK pathway in TGF-beta-induced hyaluronan synthase 1 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PATHWAYS; RHEUMATOID-ARTHRITIS; ANGIOGENIC OLIGOSACCHARIDES; SYNOVIAL-FLUID; SIGNAL-TRANSDUCTION; MURINE MACROPHAGES; DISEASE-ACTIVITY; PRIMARY ADHESION; DENDRITIC CELLS; CANCER CELLS	Unfettered hyaluronan (HA) production is a hallmark of rheumatoid arthritis. The discovery of three genes encoding hyaluronan synthases (HASs) allows for the investigation of the signaling pathways leading to the activation of these genes. Our objective is to further understanding of the regulation of these genes as well as to find ways to prevent undesired gene activation. Human fibroblast-like synoviocytes were used in these experiments. mRNA levels of HAS were monitored by reverse transcriptase-PCR. A series of specific kinase inhibitors were used to investigate intracellular pathways leading to the up-regulation of HAS1. Our experiments, testing a series of stimuli including tumor necrosis factor alpha (TNFalpha), demonstrate that TGF-beta is the most potent stimulus for HAS1 transcription. TGF-beta activates HAS1 in a dose-dependent manner with a maximum effect at a concentration of 0.5-1 ng/ml. TGF-beta-induced HAS1 mRNA can be detected within 60 min and reaches maximal levels at 6 h. Furthermore, TGF-beta treatment leads to an increase in synthase activity as determined by HA ELISA and by in vitro HA synthase assays. In contrast to the activatory effect on HAS1, TGF-beta dose-dependently suppresses HAS3 mRNA. As to the mode of action of TGF-beta-induced HAS1 mRNA activation, our experiments reveal that blocking p38 MAPK inhibited the TGF-beta effect by 90%, blocking the MEK pathway led to an inhibition by 40%, and blocking the JNK pathway had no effect. The presented data might contribute to a better understanding of the role of TGF-beta and of HA in the pathology of diseases.	Ludwig Boltzmann Inst Rheumatol & Balneol, A-1107 Vienna, Austria	Ludwig Boltzmann Institute	Stuhlmeier, KM (corresponding author), Ludwig Boltzmann Inst Rheumatol & Balneol, Kurbadstr 10,POB 78, A-1107 Vienna, Austria.	karlms@excite.com						Agren UM, 1997, FREE RADICAL BIO MED, V23, P996, DOI 10.1016/S0891-5849(97)00098-1; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Bucht A, 1996, CLIN EXP IMMUNOL, V103, P357; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Catterall JB, 1997, GLYCOCONJUGATE J, V14, P867, DOI 10.1023/A:1018598223579; Chen Wanjun, 2002, Curr Dir Autoimmun, V5, P62; CHICHIBU K, 1989, CLIN CHIM ACTA, V181, P317, DOI 10.1016/0009-8981(89)90237-4; Cuff CA, 2001, J CLIN INVEST, V108, P1031, DOI 10.1172/JCI12455; de la Motte CA, 1999, J BIOL CHEM, V274, P30747, DOI 10.1074/jbc.274.43.30747; DeGrendele HC, 1997, J IMMUNOL, V159, P2549; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; ELLIS I, 1995, GROWTH FACTORS, V12, P211, DOI 10.3109/08977199509036881; Emlen W, 1996, J RHEUMATOL, V23, P974; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; Estess P, 1998, J CLIN INVEST, V102, P1173, DOI 10.1172/JCI4235; Finlay GA, 2000, J BIOL CHEM, V275, P27650; Gerdin B, 1997, J INTERN MED, V242, P49, DOI 10.1046/j.1365-2796.1997.00173.x; Goldberg PL, 2002, AM J PHYSIOL-LUNG C, V282, pL146, DOI 10.1152/ajplung.2002.282.1.L146; Goumans MJ, 2000, INT J DEV BIOL, V44, P253; HAKANSSON L, 1985, J IMMUNOL, V135, P2735; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; HASCALL VC, 1974, J BIOL CHEM, V249, P4232; HAUBECK HD, 1995, ARTHRITIS RHEUM-US, V38, P669, DOI 10.1002/art.1780380515; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Horton MR, 2000, AM J PHYSIOL-LUNG C, V279, pL707, DOI 10.1152/ajplung.2000.279.4.L707; Kosaki R, 1999, CANCER RES, V59, P1141; Laurent TC, 1996, ANN MED, V28, P241, DOI 10.3109/07853899609033126; LEES VC, 1995, LAB INVEST, V73, P259; Lettesjo H, 1998, SCAND J IMMUNOL, V48, P286; Louthrenoo Worawit, 2001, Journal of the Medical Association of Thailand, V84, P622; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MATUCCICERINIC M, 1990, ANN RHEUM DIS, V49, P598, DOI 10.1136/ard.49.8.598; McKee CM, 1997, J BIOL CHEM, V272, P8013, DOI 10.1074/jbc.272.12.8013; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; Meyer K, 1934, J BIOL CHEM, V107, P629; Mohamadzadeh M, 1998, J CLIN INVEST, V101, P97, DOI 10.1172/JCI1604; Noble PW, 1996, J EXP MED, V183, P2373, DOI 10.1084/jem.183.5.2373; OGUCHI T, 2001, POST SESS RHEUM ARTH, pO642; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROONEY P, 1995, INT J CANCER, V60, P632, DOI 10.1002/ijc.2910600511; Ropponen K, 1998, CANCER RES, V58, P342; SATTAR A, 1994, J INVEST DERMATOL, V103, P576, DOI 10.1111/1523-1747.ep12396880; Setala LP, 1999, BRIT J CANCER, V79, P1133, DOI 10.1038/sj.bjc.6690180; Slevin M, 1998, LAB INVEST, V78, P987; Spicer A P, 2001, Methods Mol Biol, V171, P373; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Termeer CC, 2000, J IMMUNOL, V165, P1863, DOI 10.4049/jimmunol.165.4.1863; UNDERHILL C, 1992, J CELL SCI, V103, P293; WAHL SM, 1990, J IMMUNOL, V145, P2514; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang JY, 2002, P NATL ACAD SCI USA, V99, P14362, DOI 10.1073/pnas.222536599; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; WEIGEL PH, 1989, CIBA F SYMP, V143, P248; WEIGEL PH, 1986, J THEOR BIOL, V119, P219, DOI 10.1016/S0022-5193(86)80076-5; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Xiao YQ, 2002, J BIOL CHEM, V277, P14884, DOI 10.1074/jbc.M111718200; Yamada H, 2000, ARCH ORTHOP TRAUM SU, V120, P521, DOI 10.1007/s004029900131; Yonekura A, 1999, ENDOCR J, V46, P545, DOI 10.1507/endocrj.46.545; Yoshida M, 2000, J BIOL CHEM, V275, P497, DOI 10.1074/jbc.275.1.497	62	99	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8753	8760		10.1074/jbc.M303945200	http://dx.doi.org/10.1074/jbc.M303945200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676202	hybrid			2022-12-25	WOS:000189265900029
J	Nielsen, FC; Jager, AC; Lutzen, A; Bundgaard, JR; Juel, L; Rasmussen, LJ				Nielsen, FC; Jager, AC; Lutzen, A; Bundgaard, JR; Juel, L; Rasmussen, LJ			Characterization of human exonuclease 1 in complex with mismatch repair proteins, subcellular localization and association with PCNA	ONCOGENE			English	Article						hEXO1; hMSH2; hMLH1; PCNA; DNA mismatch repair; HNPCC	CELL NUCLEAR ANTIGEN; DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE EXO1; NUCLEOTIDE EXCISION-REPAIR; MEIOTIC CROSSING-OVER; DNA POLYMERASE-DELTA; COLORECTAL-CANCER; WERNER-SYNDROME; S-PHASE; REPLICATION FACTORIES	Human exonuclease 1 ( hEXO1) has been implicated in DNA mismatch repair (MMR), replication, and recombination, but the nature of its interaction with these cellular processes is still ambiguous. We show that hEXO1 colocalizes with proliferating cell nuclear antigen ( PCNA) at DNA replication sites and that the C-terminal region of hEXO1 is sufficient for this localization. We also show that both hMLH1-hPMS2 (MutLalpha) and hMLH1 hEXO1 complexes are formed in a reaction mixture containing all three proteins. Moreover, hEXO1 50 double-stranded exonuclease activity on a homoduplex substrate but not on a substrate containing a G/T mismatch was inhibited by complex formation with hMSH2-hMSH6 (MutSalpha) or MutLalpha. Taken together, the results support a model in which hEXO1 plays a role in events at the replication sites as well as a functional role in the MMR and/or recombination processes.	Roskilde Univ Ctr, Dept Chem & Life Sci, DK-4000 Roskilde, Denmark; Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark	Roskilde University; Rigshospitalet; University of Copenhagen	Rasmussen, LJ (corresponding author), Roskilde Univ Ctr, Dept Chem & Life Sci, DK-4000 Roskilde, Denmark.	ljr@ruc.dk	Nielsen, Finn Cilius/AAA-4926-2020	Rasmussen, Lene Juel/0000-0001-6864-963X				Amin NS, 2001, MOL CELL BIOL, V21, P5142, DOI 10.1128/MCB.21.15.5142-5155.2001; Aquilina G, 2001, J CELL PHYSIOL, V187, P145, DOI 10.1002/jcp.1067; Argueso JL, 2002, GENETICS, V160, P909; Baker SM, 1998, CANCER RES, V58, P1087; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; BRENOTBOSC F, 1995, CHROMOSOMA, V103, P517, DOI 10.1007/BF00355316; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CELIS JE, 1985, P NATL ACAD SCI USA, V82, P3262, DOI 10.1073/pnas.82.10.3262; Datta A, 2000, MOL CELL, V6, P593, DOI 10.1016/S1097-2765(00)00058-7; de Wind N, 2001, CURR BIOL, V11, pR545, DOI 10.1016/S0960-9822(01)00338-4; de Wind N, 1999, NAT GENET, V23, P359, DOI 10.1038/15544; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Digilio FA, 1996, DEV BIOL, V178, P90, DOI 10.1006/dbio.1996.0200; Drotschmann K, 1999, P NATL ACAD SCI USA, V96, P2970, DOI 10.1073/pnas.96.6.2970; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Edelmann W, 2000, CANCER RES, V60, P803; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Fiorentini P, 1997, MOL CELL BIOL, V17, P2764, DOI 10.1128/MCB.17.5.2764; Fuss J, 2002, J BIOL CHEM, V277, P8658, DOI 10.1074/jbc.M110615200; Genschel J, 2002, J BIOL CHEM, V277, P13302, DOI 10.1074/jbc.M111854200; Heyer J, 1999, ONCOGENE, V18, P5325, DOI 10.1038/sj.onc.1203036; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; Hsieh P, 2001, MUTAT RES-DNA REPAIR, V486, P71, DOI 10.1016/S0921-8777(01)00088-X; Jager AC, 2001, ONCOGENE, V20, P3590, DOI 10.1038/sj.onc.1204467; Kamath-Loeb AS, 2001, J BIOL CHEM, V276, P16439, DOI 10.1074/jbc.M100253200; Karran P, 2001, CARCINOGENESIS, V22, P1931, DOI 10.1093/carcin/22.12.1931; Kawamura K, 2000, ANAL QUANT CYTOL, V22, P107; Khazanehdari KA, 2000, CHROMOSOMA, V109, P94, DOI 10.1007/s004120050416; Kirkpatrick DT, 2000, GENETICS, V156, P1549; Kleczkowska HE, 2001, GENE DEV, V15, P724, DOI 10.1101/gad.191201; Kondo E, 2001, NUCLEIC ACIDS RES, V29, P1695, DOI 10.1093/nar/29.8.1695; Leach FS, 1996, CANCER RES, V56, P235; Lebel M, 2001, CELL MOL LIFE SCI, V58, P857, DOI 10.1007/s00018-001-8398-y; Lee BI, 1999, J BIOL CHEM, V274, P37763, DOI 10.1074/jbc.274.53.37763; Lee BI, 1999, NUCLEIC ACIDS RES, V27, P4114, DOI 10.1093/nar/27.20.4114; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; Lin YL, 1998, J BIOL CHEM, V273, P1453, DOI 10.1074/jbc.273.3.1453; Marra G, 1996, ONCOGENE, V13, P2189; Marra G, 1999, BIOCHEM J, V338, P1, DOI 10.1042/0264-6021:3380001; Michel B, 2001, P NATL ACAD SCI USA, V98, P8181, DOI 10.1073/pnas.111008798; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; Nielsen FC, 2002, J CELL SCI, V115, P2087; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; OKEEFE RT, 1992, J CELL BIOL, V116, P1095, DOI 10.1083/jcb.116.5.1095; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Rasmussen LJ, 2000, MUTAT RES-DNA REPAIR, V460, P41, DOI 10.1016/S0921-8777(00)00012-4; Rasmussen LJ, 2000, EXP CELL RES, V257, P127, DOI 10.1006/excr.2000.4865; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Rothstein R, 2000, GENE DEV, V14, P1; Schmutte C, 1998, CANCER RES, V58, P4537; Schmutte C, 2001, J BIOL CHEM, V276, P33011, DOI 10.1074/jbc.M102670200; Sharma S, 2003, J BIOL CHEM, V278, P23487, DOI 10.1074/jbc.M212798200; Shcherbakova PV, 2001, MOL CELL BIOL, V21, P940, DOI 10.1128/MCB.21.3.940-951.2001; Smith BT, 2001, MOL CELL, V8, P1197, DOI 10.1016/S1097-2765(01)00402-6; Sokolsky T, 2000, GENETICS, V155, P589; Somanathan S, 2001, J CELL BIOCHEM, V81, P56, DOI 10.1002/1097-4644(20010401)81:1<56::AID-JCB1023>3.0.CO;2-#; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; Sun XM, 2002, CANCER RES, V62, P6026; SZANKASI P, 1995, SCIENCE, V267, P1166, DOI 10.1126/science.7855597; Thomas David C., 1995, Methods (Orlando), V7, P187, DOI 10.1006/meth.1995.1024; Tishkoff DX, 1998, CANCER RES, V58, P5027; Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487; Tran HT, 1999, MOL CELL BIOL, V19, P2000; Tran PT, 2002, DNA REPAIR, V1, P895, DOI 10.1016/S1568-7864(02)00114-3; Tsubouchi H, 2000, MOL BIOL CELL, V11, P2221, DOI 10.1091/mbc.11.7.2221; Wang Y, 2000, GENE DEV, V14, P927; Wilson DM, 1998, NUCLEIC ACIDS RES, V26, P3762, DOI 10.1093/nar/26.16.3762; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238; Wu Y, 2001, GASTROENTEROLOGY, V120, P1580, DOI 10.1053/gast.2001.25117	74	63	69	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1457	1468		10.1038/sj.onc.1207265	http://dx.doi.org/10.1038/sj.onc.1207265			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14676842				2022-12-25	WOS:000189035800013
J	Ro, TB; Holt, RU; Brenne, AT; Hjorth-Hansen, H; Waage, A; Hjertner, O; Sundan, A; Borset, M				Ro, TB; Holt, RU; Brenne, AT; Hjorth-Hansen, H; Waage, A; Hjertner, O; Sundan, A; Borset, M			Bone morphogenetic protein-5,-6 and-7 inhibit growth and induce apoptosis in human myeloma cells	ONCOGENE			English	Article						BMP-5; BMP-6; BMP-7; myeloma; apoptosis	HEMATOPOIETIC STEM-CELLS; MULTIPLE-MYELOMA; OSTEOGENIC PROTEIN-1; SERINE/THREONINE KINASE; SIGNALING PATHWAYS; I RECEPTORS; ACTIVIN; DIFFERENTIATION; EXPRESSION; CANDIDATE	Previously, bone morphogenetic protein (BMP)-2 and -4 have been shown to inhibit proliferation and induce apoptosis in human myeloma cells. BMP-2 and -4 belong to a subgroup of BMPs using the BMP receptors Alk-3 or -6. In this study, we examined the effects on human myeloma cells of BMP-6 and -7, members of a different BMP subgroup, which mainly utilize Alk-2 as their receptor. All cell lines examined expressed mRNA for the BMP-6 and -7 receptor Alk-2. We did not detect transcripts for the BMP-2 and -4 receptors Alk-3 or Alk-6 in INA-6 and RPMI-8226 cells by RT-PCR. Accordingly, the intracellular signalling molecules Smad-1, -5 and -8 were not phosphorylated by BMP-4 in INA-6 and RPMI-8226 cells. The expression patterns of various BMP receptors in the myeloma cell lines explained the differences in responses to the various BMPs. Alk-2-expressing cell lines responded with growth inhibition and apoptosis to BMP-6 and -7, whereas cell lines lacking both Alk-3 and -6 were resistant to BMP-4. Soluble Alk-3 and -6 were able to neutralize the BMP-4 effects in BMP-4-responsive cell lines. All BMPs reduced viability in more than 70% of purified primary myeloma cell samples. BMPs have intriguing antitumor effects in vitro. Importantly, myeloma cells not responsive to BMP-2 and -4 may still be sensitive to BMP-6 or -7. It is possible that therapeutic use of BMP or BMP analogues could have an impact on both myeloma bone disease and myeloma cell growth.	Norwegian Univ Sci & Technol, Dept Canc Res & Mol Med, MTFS, N-7489 Trondheim, Norway; St Olavs Hosp, Dept Hematol, N-7005 Trondheim, Norway	Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU)	Ro, TB (corresponding author), Norwegian Univ Sci & Technol, Dept Canc Res & Mol Med, MTFS, N-7489 Trondheim, Norway.	torstein.ro@medisin.ntnu.no	Waage, Anders/D-7705-2013; Borset, Magne/AAY-1713-2021; Rø, Torstein/I-2340-2013	Ro, Torstein/0000-0002-5258-500X; Borset, Magne/0000-0001-5179-2835				Beck HN, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471-2202-2-12; Bhatia M, 1999, J EXP MED, V189, P1139, DOI 10.1084/jem.189.7.1139; BORSET M, 1994, EUR J HAEMATOL, V53, P31; Borset M, 1996, BLOOD, V88, P3998, DOI 10.1182/blood.V88.10.3998.bloodjournal88103998; Brenne AT, 2002, BLOOD, V99, P3756, DOI 10.1182/blood.V99.10.3756; Chang CF, 2003, STROKE, V34, P558, DOI 10.1161/01.STR.0000051507.64423.00; DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U; Ebisawa T, 1999, J CELL SCI, V112, P3519; Franzen A, 2001, BIOCHEM BIOPH RES CO, V285, P773; Friedlaender GE, 2001, J BONE JOINT SURG AM, V83A, pS151; Gazitt Y, 1999, LEUKEMIA, V13, P1817, DOI 10.1038/sj.leu.2401501; Gilboa L, 2000, MOL BIOL CELL, V11, P1023, DOI 10.1091/mbc.11.3.1023; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hallahan AR, 2003, NAT MED, V9, P1033, DOI 10.1038/nm904; Hjertner O, 2001, BLOOD, V97, P516, DOI 10.1182/blood.V97.2.516; JACKSON N, 1989, CLIN EXP IMMUNOL, V75, P93; JERNBERGWIKLUND H, 1991, EUR J HAEMATOL, V46, P231; Kawamura C, 2000, BLOOD, V96, P2005, DOI 10.1182/blood.V96.6.2005.h8002005a_2005_2011; Kim IY, 2000, CANCER RES, V60, P2840; NISHIHARA T, 1993, BIOCHEM BIOPH RES CO, V197, P985, DOI 10.1006/bbrc.1993.2576; Nohe A, 2002, J BIOL CHEM, V277, P5330, DOI 10.1074/jbc.M102750200; Paine-Saunders S, 2002, J BIOL CHEM, V277, P2089, DOI 10.1074/jbc.M109151200; Rodriguez-Leon J, 1999, NAT CELL BIOL, V1, P125, DOI 10.1038/10098; Seidel C, 2000, BLOOD, V95, P388, DOI 10.1182/blood.V95.2.388; SHIMA Y, 1995, BLOOD, V85, P757, DOI 10.1182/blood.V85.3.757.bloodjournal853757; Tarte K, 2003, BLOOD, V102, P592, DOI 10.1182/blood-2002-10-3161; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; Tsuchida K, 1996, MOL CELL NEUROSCI, V7, P467, DOI 10.1006/mcne.1996.0034; Urashima M, 1996, BLOOD, V87, P1928; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Wach S, 2001, ONCOGENE, V20, P7761, DOI 10.1038/sj.onc.1204962; Wozney J M, 1989, Prog Growth Factor Res, V1, P267, DOI 10.1016/0955-2235(89)90015-X; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; Zavadil J, 1997, LEUKEMIA, V11, P1187, DOI 10.1038/sj.leu.2400750; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	36	96	104	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3024	3032		10.1038/sj.onc.1207386	http://dx.doi.org/10.1038/sj.onc.1207386			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	14691444				2022-12-25	WOS:000220845200006
J	Brajenovic, M; Joberty, G; Kuster, B; Bouwmeester, T; Drewes, G				Brajenovic, M; Joberty, G; Kuster, B; Bouwmeester, T; Drewes, G			Comprehensive proteomic analysis of human par protein complexes reveals an interconnected protein network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY-REGULATING KINASE; C-ELEGANS EMBRYOS; CELL-POLARITY; SEQUENCE DATABASES; EPITHELIAL TIGHT; DROSOPHILA; GENE; IDENTIFICATION; LKB1; CDC42	The polarization of eukaryotic cells is controlled by the concerted activities of asymmetrically localized proteins. The PAR proteins, first identified in Caenorhabditis elegans, are common regulators of cell polarity conserved from nematode and flies to man. However, little is known about the molecular mechanisms by which these proteins and protein complexes establish cell polarity in mammals. We have mapped multiprotein complexes formed around the putative human Par orthologs MARK4 (microtubule-associated protein/microtubule affinity-regulating kinase 4) (Par-1), Par-3, LKB1 (Par-4), 14-3-3zeta and eta(Par-5), Par-6a, -b, -c, and PKClambda (PKC3). We employed a proteomic approach comprising tandem affinity purification (TAP) of protein complexes from cultured cells and protein sequencing by tandem mass spectrometry. From these data we constructed a highly interconnected protein network consisting of three core complex "modules" formed around MARK4 (Par-1), Par-3.Par-6, and LKB1 (Par-4). The network confirms most previously reported interactions. In addition we identified more than 50 novel interactors, some of which, like the 14-3-3 phospho-protein scaffolds, occur in more than one distinct complex. We demonstrate that the complex formation between LKB1.Par-4, PAPK, and Mo25 results in the translocation of LKB1 from the nucleus to the cytoplasm and to tight junctions and show that the LKB1 complex may activate MARKs, which are known to introduce 14-3-3 binding sites into several substrates. Our findings suggest co-regulation and/or signaling events between the distinct Par complexes and provide a basis for further elucidation of the molecular mechanisms that govern cell polarity.	Cellzome AG, D-69117 Heidelberg, Germany	GlaxoSmithKline; Cellzome GmbH	Bouwmeester, T (corresponding author), Cellzome AG, Meyerhofstr 1, D-69117 Heidelberg, Germany.	Tewis.Bouwmeester@Cellzome.com; Gerard.Drewes@Cellzome.com	Kuster, Bernhard/Q-6031-2016	Kuster, Bernhard/0000-0002-9094-1677; Drewes, Gerard/0000-0003-0575-6766				Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Benton R, 2002, DEV CELL, V3, P659, DOI 10.1016/S1534-5807(02)00320-9; Bohm H, 1997, CURR BIOL, V7, P603, DOI 10.1016/S0960-9822(06)00260-0; Boudeau J, 2003, FEBS LETT, V546, P159, DOI 10.1016/S0014-5793(03)00642-2; Brown AJH, 1999, MOL CELL NEUROSCI, V13, P119, DOI 10.1006/mcne.1999.0736; Clark KA, 2003, DEVELOPMENT, V130, P2611, DOI 10.1242/dev.00492; Cuenca AA, 2003, DEVELOPMENT, V130, P1255, DOI 10.1242/dev.00284; DREWES G, 1995, J BIOL CHEM, V270, P7679, DOI 10.1074/jbc.270.13.7679; Drewes G, 2003, FEBS LETT, V554, P45, DOI 10.1016/S0014-5793(03)01080-9; Drewes G, 2003, CURR OPIN CELL BIOL, V15, P199, DOI 10.1016/S0955-0674(03)00005-X; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Gao L, 2002, CURR BIOL, V12, P221, DOI 10.1016/S0960-9822(01)00663-7; Gao L, 2002, GENE, V294, P99, DOI 10.1016/S0378-1119(02)00681-9; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; Jan YN, 1998, NATURE, V392, P775, DOI 10.1038/33854; Jarvik JW, 1998, ANNU REV GENET, V32, P601, DOI 10.1146/annurev.genet.32.1.601; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Keller R, 2002, SCIENCE, V298, P1950, DOI 10.1126/science.1079478; Kemphues K, 2000, CELL, V101, P345, DOI 10.1016/S0092-8674(00)80844-2; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Martin SG, 2003, NATURE, V421, P379, DOI 10.1038/nature01296; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; Mollinari C, 2002, BIOL CELL, V94, P1, DOI 10.1016/S0248-4900(02)01181-4; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morton DG, 2002, DEV BIOL, V241, P47, DOI 10.1006/dbio.2001.0489; Muller J, 2001, MOL CELL, V8, P983, DOI 10.1016/S1097-2765(01)00383-5; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; Nishigaki K, 2003, J BIOL CHEM, V278, P13520, DOI 10.1074/jbc.M208601200; Nozaki M, 1996, DNA CELL BIOL, V15, P505, DOI 10.1089/dna.1996.15.505; O'Kelly I, 2002, CELL, V111, P577, DOI 10.1016/S0092-8674(02)01040-1; Pellettieri J, 2002, SCIENCE, V298, P1946, DOI 10.1126/science.1072162; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Schirle M, 2003, MOL CELL PROTEOMICS, V2, P1297, DOI 10.1074/mcp.M300087-MCP200; SCHNEIDER A, 2004, IN PRESS J NEUROCHEM; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Sontag E, 1999, J BIOL CHEM, V274, P25490, DOI 10.1074/jbc.274.36.25490; Tabuse Y, 1998, DEVELOPMENT, V125, P3607; Trinczek B, 2004, J BIOL CHEM, V279, P5915, DOI 10.1074/jbc.M304528200; Vaccari T, 2002, CURR BIOL, V12, P1524, DOI 10.1016/S0960-9822(02)01079-5; Watts JL, 1996, DEVELOPMENT, V122, P3133; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6; Yamanaka T, 2001, GENES CELLS, V6, P721, DOI 10.1046/j.1365-2443.2001.00453.x	58	148	158	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12804	12811		10.1074/jbc.M312171200	http://dx.doi.org/10.1074/jbc.M312171200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14676191	hybrid			2022-12-25	WOS:000220334900095
J	Harwell, RM; Mull, BB; Porter, DC; Keyomarsi, K				Harwell, RM; Mull, BB; Porter, DC; Keyomarsi, K			Activation of cyclin-dependent kinase 2 by full length and low molecular weight forms of cyclin E in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE-TRANSITION; PROTEIN; PROLIFERATION; EXPRESSION; PHOSPHORYLATION; OVEREXPRESSION; P40(MO15); P34(CDC2); P27(KIP1)	Cyclin E, a positive regulator of the cell cycle, controls the transition of cells from G(1) to S phase. Deregulation of the G(1)-S checkpoint contributes to uncontrolled cell division, a hallmark of cancer. We have reported previously that cyclin E is overexpressed in breast cancer and such overexpression is usually accompanied by the appearance of low molecular weight isoforms of cyclin E protein, which are not present in normal cells. Furthermore, we have shown that the expression of cyclin E low molecular weight isoforms can be used as a reliable prognostic marker for breast cancer to predict patient outcome. In this study we examined the role of cyclin E in directly activating cyclin-dependent kinase (CDK) 2. For this purpose, a series of N-terminal deleted forms of cyclin E corresponding to the low molecular weight forms detected only in cancer cells were translated in vitro and mixed with cell extracts. These tumor-specific N-terminal deleted forms of cyclin E are able to activate CDK2. Addition of cyclin E into both normal and tumor cell extracts was shown to increase the levels of CDK2 activity, along with an increase in the amount of phosphorylated CDK2. The increase in CDK2 activity was because of cyclin E binding to endogenous CDK2 in complex with endogenous cyclin E, cyclin A, or unbound CDK2. The increase in CDK2 phosphorylation was through a pathway involving cyclin-activating kinase, but addition of cyclin E to an extract containing unphosphorylated CDK2 can still lead to increase in CDK2 activity. Our data suggest that the ability of high levels of full-length and low molecular weight forms of cyclin E to activate CDK2 may be one mechanism that leads to the constitutive activation of cyclin E.CDK2 complexes leading to G(1)/S deregulation and tumor progression.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; SUNY Albany, Wadsworth Ctr, Div Mol Med, Albany, NY 12201 USA; Univ Texas, MD Anderson Canc Ctr, Breast Canc Res Program, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Wadsworth Center; University of Texas System; UTMD Anderson Cancer Center	Keyomarsi, K (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, 1515 Holcombe Blvd,Box 66, Houston, TX 77030 USA.	kkeyomar@mdanderson.org	Keyomarsi, Khandan/H-2716-2016	Keyomarsi, Khandan/0000-0002-5440-0849; Mull, Benjamin/0000-0001-8379-873X	NCI NIH HHS [R01 CA 87548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087548] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		COULONVAL K, 2003, J BIOL CHEM; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; Donnellan R, 1999, FASEB J, V13, P773, DOI 10.1096/fasebj.13.8.773; DOU QP, 1993, CANCER RES, V53, P1493; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Harwell RM, 2000, CANCER RES, V60, P481; Horton LE, 1997, ONCOGENE, V14, P491, DOI 10.1038/sj.onc.1200851; KEYOMARSI K, 1994, CANCER RES, V54, P380; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Keyomarsi K, 2003, NAT MED, V9, P152, DOI 10.1038/nm0203-152; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; Porter DC, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.23.e101; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; Sclafani RA, 1996, CURR OPIN CELL BIOL, V8, P788, DOI 10.1016/S0955-0674(96)80079-2; Sgambato A, 1996, CANCER RES, V56, P1389; Sgambato A, 1997, CLIN CANCER RES, V3, P1879; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; TSAI LH, 1993, ONCOGENE, V8, P1593; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103	35	27	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12695	12705		10.1074/jbc.M313407200	http://dx.doi.org/10.1074/jbc.M313407200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14701826	hybrid			2022-12-25	WOS:000220334900083
J	Kondapalli, J; Flozak, AS; Albuquerque, MLC				Kondapalli, J; Flozak, AS; Albuquerque, MLC			Laminar shear stress differentially modulates gene expression of p120 catenin, Kaiso transcription factor, and vascular endothelial cadherin in human coronary artery endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WOUND CLOSURE; LOCALIZATION; SIGNAL; P120(CTN); PATTERNS; ADHESION; PROTEIN; BINDING; FLOW; RNA	We demonstrated previously that laminar shear stress (LSS) enhances human coronary artery endothelial cell (HCAEC) wound closure via a vascular endothelial cadherin (VE-cadherin)-dependent mechanism. VE-cadherin can interact with p120 catenin (p120(ctn)) to mediate cell locomotion and proliferation. In this study, we hypothesized that p120(ctn) and an interacting protein, Kaiso, a transcriptional factor with which p120(ctn) may interact, would be expressed differentially at the wound border and away from the wound border in HCAEC exposed to LSS. One of the major goals in this study was to assess the differential gene expression of p120(ctn), Kaiso, and VE-cadherin in HCAEC at specific locations along the wound border to further our understanding of the molecular mechanisms involved in wound closure. We combined the technique of laser capture microdissection with quantitative real time PCR to compare p120(ctn), Kaiso, and VE-cadherin mRNA expression in HCAEC at and away from the wound border under LSS. Total RNA was isolated from 200-1,000 laser-captured HCAEC and reverse transcribed into cDNA. Detection of p120(ctn), Kaiso, and VE-cadherin mRNA was carried out using quantitative real time PCR. Normalization of cDNA templates was achieved by glyceraldehyde-3-phosphate dehydrogenase (GAPDH) quantification. Quantitative real time PCR analysis revealed p120(ctn): GAPDH ratios, Kaiso: GAPDH ratios, and VE-cadherin:GAPDH ratios, relative to static control for each set, of 0.99-4.18 ( mean +/- S. E., 1.94 +/- 0.404), 1.0-5.24 ( 2.11 +/- 0.51), and 0.99-1.42 ( 1.09 +/- 0.09) after 3 h of LSS, respectively. With these techniques, we found that p120(ctn) and Kaiso transcripts were increased in laser-captured HCAEC at the wound border compared with HCAEC away from the wound border. In addition, differential expression of p120(ctn) and Kaiso mRNA was observed in HCAEC depending on how LSS was applied in relation to the wounding process. These techniques may have wide applicability for studying wound healing because gene expression of key adhesion molecules in HCAEC may now be determined from select regions of the endothelial wound border.	Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60611 USA; Childrens Mem Hosp, Div Crit Care Med, Crit Care Lab Vasc Res, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago	Albuquerque, MLC (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Pediat, W-140,Ward 12-108,303 E Chicago Ave, Chicago, IL 60611 USA.	malbuquerque@northwestern.edu			NIGMS NIH HHS [R01 GM59931] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059931] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albuquerque MLC, 2003, J CELL PHYSIOL, V195, P50, DOI 10.1002/jcp.10228; Albuquerque MLC, 2002, EXP BIOL MED, V227, P1006, DOI 10.1177/153537020222701109; Albuquerque MLC, 2001, EXP CELL RES, V270, P223, DOI 10.1006/excr.2001.5351; Albuquerque MLC, 2000, AM J PHYSIOL-HEART C, V279, pH293, DOI 10.1152/ajpheart.2000.279.1.H293; Bao XP, 1999, ARTERIOSCL THROM VAS, V19, P996, DOI 10.1161/01.ATV.19.4.996; BONNER RF, 1997, SCIENCE, V278, P1482; Boylan S, 2001, LAB INVEST, V81, P1167, DOI 10.1038/labinvest.3780329; Brooks AR, 2002, PHYSIOL GENOMICS, V9, P27, DOI 10.1152/physiolgenomics.00075.2001; Chien S, 1998, HYPERTENSION, V31, P162, DOI 10.1161/01.HYP.31.1.162; Chiu JJ, 1999, CIRC RES, V85, P238, DOI 10.1161/01.RES.85.3.238; Chiu JJ, 2003, BLOOD, V101, P2667, DOI 10.1182/blood-2002-08-2560; Daniel JM, 2002, NUCLEIC ACIDS RES, V30, P2911, DOI 10.1093/nar/gkf398; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; Ferber A, 2002, EXP CELL RES, V274, P35, DOI 10.1006/excr.2001.5436; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Navarro P, 1995, J BIOL CHEM, V270, P30965, DOI 10.1074/jbc.270.52.30965; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Passerini AG, 2003, J VASC SURG, V37, P182, DOI 10.1067/mva.2003.66; Peters DG, 2002, PHYSIOL GENOMICS, V12, P25, DOI 10.1152/physiolgenomics.00016.2002; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; Reynolds AB, 1996, EXP CELL RES, V225, P328, DOI 10.1006/excr.1996.0183; SHYY YJ, 1994, P NATL ACAD SCI USA, V91, P4678, DOI 10.1073/pnas.91.11.4678; Simone NL, 1998, TRENDS GENET, V14, P272, DOI 10.1016/S0168-9525(98)01489-9; Suzuki T, 2000, BIOTECHNIQUES, V29, P332, DOI 10.2144/00292rv02; Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; van Hengel J, 1999, P NATL ACAD SCI USA, V96, P7980, DOI 10.1073/pnas.96.14.7980; Wang WH, 2001, MOL VIS, V7, P89	28	18	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11417	11424		10.1074/jbc.M306057200	http://dx.doi.org/10.1074/jbc.M306057200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699141	hybrid			2022-12-25	WOS:000220157600072
J	Pasqualato, S; Senic-Matuglia, F; Renault, L; Goud, B; Salamero, J; Cherfils, J				Pasqualato, S; Senic-Matuglia, F; Renault, L; Goud, B; Salamero, J; Cherfils, J			The structural GDP/GTP cycle of Rab11 reveals a novel interface involved in the dynamics of recycling endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-DISSOCIATION INHIBITOR; GTP-BINDING PROTEINS; TRANS-GOLGI NETWORK; CRYSTAL-STRUCTURE; NUCLEOTIDE EXCHANGE; MEMBRANE-TRANSPORT; EFFECTOR PROTEIN; MYOSIN VB; GTPASES; FAMILY	The small GTP-binding protein Rab11 is an essential regulator of the dynamics of recycling endosomes. Here we report the crystallographic analysis of the GDP/GTP cycle of human Rab11a, and a structure-based mutagenesis study that identifies a novel mutant phenotype. The crystal structures show that the nucleotide-sensitive switch 1 and 2 regions differ from those of other Rab proteins. In Rab11-GDP, they contribute to a close packed symmetrical dimer, which may associate to membranes in the cell and allow Rab11 to undergo GDP/GTP cycles without recycling to the cytosol. The structure of active Rab11 delineates a three-dimensional site that includes switch 1 and is separate from the site defined by the Rab3/Rabphilin interface. It is proposed to form a novel interface for a Rab11 partner compatible with the simultaneous binding of another partner at the Rabphilin interface. Mutation of Ser(29) to Phe in this epitope resulted in morphological modifications of the recycling compartment that are distinct from those induced by the classical dominant-negative and constitutively active Rab11 mutants. Recycling endosomes condensed in the perinuclear region where they retained recycling transferrin, and they clustered Rab11- and EEA1-positive membranes. Altogether, our study suggests that this mutation impairs a specific subset of Rab11 interactions, possibly those involved in cytoskeleton-based movements driving the slow recycling pathway.	Inst Curie Rech, CNRS, UMR 144, Lab Mecanismes Mol Transport Intracellulaire, F-75248 Paris 05, France; CNRS, UPR 9063, Lab Enxymol & Biochim Struct, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Salamero, J (corresponding author), Inst Curie Rech, CNRS, UMR 144, Lab Mecanismes Mol Transport Intracellulaire, 12 Rue Lhomond, F-75248 Paris 05, France.	salamero@curie.fr	Senic-Matuglia, Francesca/AAQ-3815-2020; Goud, Bruno/GWC-4807-2022; Pasqualato, Sebastiano/G-1032-2011	Pasqualato, Sebastiano/0000-0002-9038-7768; salamero, jean/0000-0002-2610-5826; RENAULT, Louis/0000-0003-1722-074X				Barbero P, 2002, J CELL BIOL, V156, P511, DOI 10.1083/jcb.200109030; BERANGER F, 1994, J BIOL CHEM, V269, P13637; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; Calhoun BC, 1998, AM J PHYSIOL-CELL PH, V275, pC163, DOI 10.1152/ajpcell.1998.275.1.C163; Casanova JE, 1999, MOL BIOL CELL, V10, P47, DOI 10.1091/mbc.10.1.47; Chattopadhyay D, 2000, ACTA CRYSTALLOGR D, V56, P937, DOI 10.1107/S0907444900007575; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Chen W, 1998, MOL BIOL CELL, V9, P3241, DOI 10.1091/mbc.9.11.3241; Constantinescu AT, 2002, STRUCTURE, V10, P569, DOI 10.1016/S0969-2126(02)00737-2; Corbett KD, 2001, TRENDS BIOCHEM SCI, V26, P710, DOI 10.1016/S0968-0004(01)01974-0; Cox D, 2000, P NATL ACAD SCI USA, V97, P680, DOI 10.1073/pnas.97.2.680; De Renzis S, 2002, NAT CELL BIOL, V4, P124, DOI 10.1038/ncb744; Dumas JJ, 1999, STRUCTURE, V7, P413, DOI 10.1016/S0969-2126(99)80054-9; Esters H, 2000, J MOL BIOL, V298, P111, DOI 10.1006/jmbi.2000.3645; Hales CM, 2001, J BIOL CHEM, V276, P39067, DOI 10.1074/jbc.M104831200; Hales CM, 2002, J BIOL CHEM, V277, P50415, DOI 10.1074/jbc.M209270200; Hammer JA, 2002, CURR OPIN CELL BIOL, V14, P69, DOI 10.1016/S0955-0674(01)00296-4; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Holtta-Vuori M, 2002, MOL BIOL CELL, V13, P3107, DOI 10.1091/mbc.E02-01-0025; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; Janin J, 1995, PROTEINS, V23, P580, DOI 10.1002/prot.340230413; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lapierre LA, 2001, MOL BIOL CELL, V12, P1843, DOI 10.1091/mbc.12.6.1843; Lindsay AJ, 2002, J BIOL CHEM, V277, P12190, DOI 10.1074/jbc.M108665200; Lippe R, 2001, MOL BIOL CELL, V12, P2219, DOI 10.1091/mbc.12.7.2219; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Merithew E, 2001, J BIOL CHEM, V276, P13982, DOI 10.1074/jbc.M009771200; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mohrmann K, 2002, J BIOL CHEM, V277, P32029, DOI 10.1074/jbc.M203064200; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pereira-Leal JB, 2001, J MOL BIOL, V313, P889, DOI 10.1006/jmbi.2001.5072; Pereira-Leal JB, 2003, BIOCHEM BIOPH RES CO, V301, P92, DOI 10.1016/S0006-291X(02)02963-7; Pereira-Leal JB, 2001, FEBS LETT, V498, P197, DOI 10.1016/S0014-5793(01)02483-8; Pereira-Leal JB, 2000, J MOL BIOL, V301, P1077, DOI 10.1006/jmbi.2000.4010; Pfeffer S, 2003, CELL, V112, P507, DOI 10.1016/S0092-8674(03)00118-1; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Rak A, 2003, SCIENCE, V302, P646, DOI 10.1126/science.1087761; Ren MD, 1998, P NATL ACAD SCI USA, V95, P6187, DOI 10.1073/pnas.95.11.6187; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; Simonsen A, 1999, J BIOL CHEM, V274, P28857, DOI 10.1074/jbc.274.41.28857; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Smythe E, 2002, MOL CELL, V9, P205, DOI 10.1016/S1097-2765(02)00462-8; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; Stroupe C, 2000, J MOL BIOL, V304, P585, DOI 10.1006/jmbi.2000.4236; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Wallace DM, 2002, BIOCHEM BIOPH RES CO, V292, P909, DOI 10.1006/bbrc.2002.6736; Wallace DME, 2002, BIOCHEM BIOPH RES CO, V299, P770, DOI 10.1016/S0006-291X(02)02720-1; Wilcke M, 2000, J CELL BIOL, V151, P1207, DOI 10.1083/jcb.151.6.1207; Wurmser AE, 2000, J CELL BIOL, V151, P551, DOI 10.1083/jcb.151.3.551; Zeng JB, 1999, P NATL ACAD SCI USA, V96, P2840, DOI 10.1073/pnas.96.6.2840; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhu GY, 2003, J BIOL CHEM, V278, P2452, DOI 10.1074/jbc.M211042200; Zhu ZY, 2001, BIOCHEMISTRY-US, V40, P15699, DOI 10.1021/bi0116792	58	67	71	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11480	11488		10.1074/jbc.M310558200	http://dx.doi.org/10.1074/jbc.M310558200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699104	hybrid			2022-12-25	WOS:000220157600079
J	Soltoff, SP				Soltoff, SP			Evidence that tyrphostins AG10 and AG18 are mitochondrial uncouplers that alter phosphorylation-dependent cell signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PAROTID ACINAR-CELLS; TRANSMEMBRANE CONDUCTANCE REGULATOR; DELTA TYROSINE PHOSPHORYLATION; RAT SUBMANDIBULAR-GLAND; ION-TRANSPORT; EXTRACELLULAR ATP; SUBSTANCE-P; PKC-DELTA; C-DELTA	Receptor agonists that initiate fluid secretion in salivary gland epithelial cells also increase protein phosphorylation. To assess contributions of tyrosine phosphorylation to secretion, changes in muscarinic receptor-initiated secretion (estimated from sodium pump-dependent increases in oxygen consumption) were measured in parotid acinar cells exposed to tyrosine kinase inhibitors. However, like the mitochondrial uncoupler carbonyl cyanide p-trifluoromethoxyphenyl hydrazone, tyrphostins AG10 and AG18 increased the rate of oxygen consumption and reduced cellular ATP by similar to90% in the absence of the muscarinic agonist carbachol, indicating that these tyrphostins uncouple mitochondria. Exposure of isolated mitochondria to five structurally related tyrphostins demonstrated that their relative potencies as uncouplers differed from their in vitro kinase-inhibitory potencies due to different molecular requirements for the two effects. AG10 and AG18 blocked parotid phosphorylation events only at concentrations that reduced ATP content. The tyrosine kinase inhibitor genistein reduced ATP content by 15-20% and weakly uncoupled isolated mitochondria, but its inhibition of carbachol-mediated protein kinase Cdelta tyrosine phosphorylation and ERK1/2 activation appeared attributable to blocking tyrosine kinases directly. Carbachol itself rapidly reduced ATP content by 15-20%. Carbachol, 3'-O-(4-benzoyl)benzoyl adenosine 5'-triphosphate (P2X(7) receptor agonist), AG10, AG18, and carbonyl cyanide p-trifluoromethoxyphenyl hydrazone rapidly activated the fuel sensor AMP-activated protein kinase (AMPK); however, only AMPK activation by carbachol and BzATP was due to sodium pump stimulation. AG10 and AG18 also activated AMPK and/or uncoupled mitochondria in PC12, HeLa, and HEK293 cells. These studies demonstrate that some tyrosine kinase inhibitors produce cellular effects that are mechanistically different from their primary in vitro characterizations and, as do salivary secretory stimuli, promote rapid metabolic alterations that initiate secondary signaling events.	Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Soltoff, SP (corresponding author), Beth Israel Deaconess Med Ctr, Div Signal Transduct, New Res Bldg,Rm 1030 J,330 Brookline Ave, Boston, MA 02215 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010877] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE10877] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Arreola J, 2003, J PHYSIOL-LONDON, V547, P197, DOI 10.1113/jphysiol.2002.028373; BALABAN RS, 1980, P NATL ACAD SCI-BIOL, V77, P447, DOI 10.1073/pnas.77.1.447; Benes C, 2001, AM J PHYSIOL-CELL PH, V280, pC1498, DOI 10.1152/ajpcell.2001.280.6.C1498; Bradford MD, 2002, BIOCHEM J, V366, P745, DOI 10.1042/BJ20020358; Bradford MD, 1998, EUR J MORPHOL, V36, P176; BURGER AM, 1995, CANCER RES, V55, P2794; Davies SP, 1995, FEBS LETT, V377, P421, DOI 10.1016/0014-5793(95)01368-7; DUAN RG, 1994, AM J PHYSIOL, V266, pG303, DOI 10.1152/ajpgi.1994.266.2.G303; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; Hallows KR, 2003, J BIOL CHEM, V278, P998, DOI 10.1074/jbc.M210621200; Hallows KR, 2000, J CLIN INVEST, V105, P1711, DOI 10.1172/JCI9622; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; KAPAS S, 1995, BIOCHEM J, V305, P433, DOI 10.1042/bj3050433; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDEL LJ, 1981, AM J PHYSIOL, V240, pF357, DOI 10.1152/ajprenal.1981.240.5.F357; Mouria M, 2002, INT J CANCER, V98, P761, DOI 10.1002/ijc.10202; MURAKAMI M, 1990, J PHYSIOL-LONDON, V426, P127, DOI 10.1113/jphysiol.1990.sp018130; Niisato N, 1999, J PHYSIOL-LONDON, V518, P417, DOI 10.1111/j.1469-7793.1999.0417p.x; Niisato N, 2001, BIOCHEM BIOPH RES CO, V285, P880, DOI 10.1006/bbrc.2001.5251; Palumbo GA, 1997, CANCER RES, V57, P2434; PURUSHOTHAM KR, 1995, CRIT REV ORAL BIOL M, V6, P119, DOI 10.1177/10454411950060020201; Sagara Y, 2002, J BIOL CHEM, V277, P36204, DOI 10.1074/jbc.M203895200; SEGER R, 1995, J BIOL CHEM, V270, P28325; SEO Y, 1991, BIOCHIM BIOPHYS ACTA, V971, P289; SMAJE LH, 1986, PFLUGERS ARCH, V406; SOLTOFF SP, 1990, J GEN PHYSIOL, V95, P319, DOI 10.1085/jgp.95.2.319; Soltoff SP, 2001, J BIOL CHEM, V276, P37986; SOLTOFF SP, 1984, J GEN PHYSIOL, V84, P643, DOI 10.1085/jgp.84.4.643; SOLTOFF SP, 1987, SEMIN NEPHROL, V7, P20; SOLTOFF SP, 1992, AM J PHYSIOL, V262, pC934, DOI 10.1152/ajpcell.1992.262.4.C934; SOLTOFF SP, 1989, J GEN PHYSIOL, V93, P285, DOI 10.1085/jgp.93.2.285; SOLTOFF SP, 1995, J BIOL CHEM, V270, P13490, DOI 10.1074/jbc.270.22.13490; SOLTOFF SP, 1990, ANN NY ACAD SCI, V603, P76; STEWART DJ, 1983, AM J PHYSIOL, V245, pG364, DOI 10.1152/ajpgi.1983.245.3.G364; TERADA H, 1990, ENVIRON HEALTH PERSP, V87, P213, DOI 10.2307/3431027; Turner R. J., 1993, BIOL SALIVARY GLANDS, P105; Turner RJ, 2002, ORAL DIS, V8, P3, DOI 10.1034/j.1601-0825.2002.10815.x; Yoon HS, 2000, BIOCHEM BIOPH RES CO, V276, P151, DOI 10.1006/bbrc.2000.3445; YOUNG SW, 1993, FEBS LETT, V316, P278, DOI 10.1016/0014-5793(93)81308-M; Zeng WZ, 1997, J BIOL CHEM, V272, P32956, DOI 10.1074/jbc.272.52.32956; Zheng JB, 2000, BRIT J PHARMACOL, V130, P1115, DOI 10.1038/sj.bjp.0703397; Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599	45	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10910	10918		10.1074/jbc.M305396200	http://dx.doi.org/10.1074/jbc.M305396200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14688271	hybrid			2022-12-25	WOS:000220157600012
J	Benson, MA; Tinsley, CL; Blake, DJ				Benson, MA; Tinsley, CL; Blake, DJ			Myospryn is a novel binding partner for dysbindin in muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; LYSOSOME-RELATED ORGANELLES; HERMANSKY-PUDLAK-SYNDROME; SYNDROME GENE-PRODUCT; OPITZ-SYNDROME; REGULATORY SUBUNIT; ALPHA-DYSTROBREVIN; CONTAINING PROTEIN; BETA-DYSTROBREVIN; PHOSPHATASE 2A	Dysbindin is a coiled-coil-containing protein that was initially identified in a screen for dystrobrevin-interacting proteins. Recently, dysbindin has been shown to be involved in the biogenesis of lysosome-related organelles and is also a major schizophrenia susceptibility factor. Although dysbindin has been implicated in a number of different cellular processes, little is known about its function. To determine the function of dysbindin in muscle, we performed a yeast two-hybrid screen to identify potential interacting proteins. Here we show that dysbindin binds to a novel 413-kDa protein, myospryn, which is expressed in cardiac and skeletal muscle. The transcript encoding myospryn encompasses genethonin-3, a transcript that is down-regulated in muscle from Duchenne muscular dystrophy patients and stretch-responsive protein 553, which is up-regulated in experimental muscle hypertrophy. The C terminus of myospryn contains BBC, FN3, and SPRY domains in a configuration reminiscent of the tripartite motif protein family, as well as the dysbindin-binding site and a region mediating self-association. Dysbindin and myospryn co-immunoprecipitate from muscle extracts and are extensively co-localized. These data demonstrate for the first time that there are tissue-specific ligands for dysbindin that may play important roles in the different disease states involving this protein.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England	University of Oxford	Blake, DJ (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.	derek.blake@pharm.ox.ac.uk		Benson, Matthew/0000-0003-4459-0439				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Benson MA, 2001, J BIOL CHEM, V276, P24232, DOI 10.1074/jbc.M010418200; Blake Derek J., 1992, Human Molecular Genetics, V1, P103, DOI 10.1093/hmg/1.2.103; Blake DJ, 1998, P NATL ACAD SCI USA, V95, P241, DOI 10.1073/pnas.95.1.241; Blake DJ, 1999, J CELL BIOL, V147, P645, DOI 10.1083/jcb.147.3.645; Blake DJ, 2002, NEUROMUSCULAR DISORD, V12, pS110, DOI 10.1016/S0960-8966(02)00091-3; Blake DJ, 2002, PHYSIOL REV, V82, P291, DOI 10.1152/physrev.00028.2001; Bray NJ, 2003, HUM GENET, V113, P149, DOI 10.1007/s00439-003-0956-y; Bredt DS, 1999, NAT CELL BIOL, V1, pE89, DOI 10.1038/12085; Buchner G, 1999, HUM MOL GENET, V8, P1397, DOI 10.1093/hmg/8.8.1397; Burgueno J, 2003, J BIOL CHEM, V278, P37545, DOI 10.1074/jbc.M302809200; Cainarca S, 1999, HUM MOL GENET, V8, P1387, DOI 10.1093/hmg/8.8.1387; Carim-Todd L, 2001, BBA-GENE STRUCT EXPR, V1518, P200, DOI 10.1016/S0167-4781(01)00178-6; CHU A, 1988, METHOD ENZYMOL, V157, P36; Dell'Angelica EC, 2000, FASEB J, V14, P1265, DOI 10.1096/fj.14.10.1265; Falcon-Perez JM, 2002, J BIOL CHEM, V277, P28191, DOI 10.1074/jbc.M204011200; Grady RM, 1999, NAT CELL BIOL, V1, P215, DOI 10.1038/12034; Harrison PJ, 2003, LANCET, V361, P417, DOI 10.1016/S0140-6736(03)12379-3; Huizing M, 2000, TRAFFIC, V1, P823, DOI 10.1034/j.1600-0854.2000.011103.x; Kemp TJ, 2000, GENOMICS, V66, P229, DOI 10.1006/geno.2000.6213; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; Li W, 2003, NAT GENET, V35, P84, DOI 10.1038/ng1229; Li YK, 2001, J BIOL CHEM, V276, P40824, DOI 10.1074/jbc.M106141200; Liu J, 2001, P NATL ACAD SCI USA, V98, P6650, DOI 10.1073/pnas.111154698; Moriyama K, 2002, TRAFFIC, V3, P666, DOI 10.1034/j.1600-0854.2002.30908.x; Nawrotzki R, 1998, J CELL SCI, V111, P2595; Newey SE, 2000, CURR BIOL, V10, P1295, DOI 10.1016/S0960-9822(00)00760-0; Peng HZ, 2002, J MOL BIOL, V320, P629, DOI 10.1016/S0022-2836(02)00477-1; Perry J, 1999, GENOMICS, V62, P385, DOI 10.1006/geno.1999.6043; Peters MF, 1997, J BIOL CHEM, V272, P31561, DOI 10.1074/jbc.272.50.31561; Quaderi NA, 1997, NAT GENET, V17, P285, DOI 10.1038/ng1197-285; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Schwab SG, 2003, AM J HUM GENET, V72, P185, DOI 10.1086/345463; Schweiger S, 1999, P NATL ACAD SCI USA, V96, P2794, DOI 10.1073/pnas.96.6.2794; Short KM, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-1; Sillitoe RV, 2003, J NEUROSCI, V23, P6576; Stein PA, 2002, J CELL SCI, V115, P3389; Straub RE, 2002, AM J HUM GENET, V71, P337, DOI 10.1086/341750; Swank RT, 2000, PIGM CELL RES, V13, P59, DOI 10.1034/j.1600-0749.13.s8.12.x; Tkatchenko AV, 2001, NEUROMUSCULAR DISORD, V11, P269, DOI 10.1016/S0960-8966(00)00198-X; Trockenbacher A, 2001, NAT GENET, V29, P287, DOI 10.1038/ng762	42	54	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10450	10458		10.1074/jbc.M312664200	http://dx.doi.org/10.1074/jbc.M312664200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688250	hybrid			2022-12-25	WOS:000220050400096
J	Liu, CH; Chopra, R; Swanberg, S; Olland, S; O'Connell, J; Herrmann, S				Liu, CH; Chopra, R; Swanberg, S; Olland, S; O'Connell, J; Herrmann, S			Elongation of synthetic RNA templates by hepatitis C virus NS5B polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO INITIATION; CRYSTAL-STRUCTURE; MECHANISM; IDENTIFICATION; REQUIREMENTS	Here we examine the ability of seven, 3'-related, short synthetic RNAs to serve as templates for the hepatitis C virus (HCV) polymerase, non-structural protein 5B (NS5B). These RNAs, termed HL, range from 8 to 16 nucleotides in length, each with ACC at the 3' terminus. Interestingly HL12 and longer templates have a predicted secondary structure. Those with one or two unpaired adenylates at the 5'-end of a stem were increased in size by one or two nucleotides, respectively, following incubation with NS5B and UTP. Using labeled template RNA and cold UTP, extension in size could be inhibited by addition of non-labeled template of the same size. This template elongation was not inhibited by cold linear HL10 template unless pGpG was added. Fluorescence anisotropy demonstrated HL14, a template with secondary structure, bound with an apparent K-d of 22 nM. A linear template, HL10, plus pGpG primer was bound by NS5B with a Kd of 45 nM, whereas HL10 alone bound with an apparent Kd of 182 nM. The amplitude of the template extension product was increased by a brief preincubation at 4 degreesC followed by incubation at 23 or 30 degreesC. The nucleotide- mediated increase in size occurred for both templates that required a mismatch or bulge at the 3'-end as well as for those without the mismatch. These results suggest an NS5B active site pocket can readily accommodate short templates with four or five base stems and initiate copy-back replication in the presence of a one nucleotide mismatch.	Wyeth Res, Cambridge, MA 02140 USA; Wyeth Res, Pearl River, NY 10965 USA	Pfizer; Pfizer	Herrmann, S (corresponding author), Wyeth Res, 87 Cambridge Pk Dr, Cambridge, MA 02140 USA.	shermann@wyeth.com						Adachi T, 2002, BBA-PROTEINS PROTEOM, V1601, P38, DOI 10.1016/S1570-9639(02)00433-8; Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3; [Anonymous], 1999, J Hepatol, V30, P956; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; Carroll SS, 2000, BIOCHEMISTRY-US, V39, P8243, DOI 10.1021/bi991992s; Hong Z, 2001, VIROLOGY, V285, P6, DOI 10.1006/viro.2001.0948; HOUGHTON M, 1996, FIELDS VIROLOGY, P1035; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Johnson RB, 2000, ARCH BIOCHEM BIOPHYS, V377, P129, DOI 10.1006/abbi.2000.1749; Kao CC, 2001, VIROLOGY, V287, P251, DOI 10.1006/viro.2001.1039; Kao CC, 1999, VIROLOGY, V253, P1, DOI 10.1006/viro.1998.9517; Kao CC, 2000, J VIROL, V74, P11121, DOI 10.1128/JVI.74.23.11121-11128.2000; Kim MJ, 2000, J VIROL, V74, P10312, DOI 10.1128/JVI.74.22.10312-10322.2000; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Leveque VJP, 2003, J VIROL, V77, P9020, DOI 10.1128/JVI.77.16.9020-9028.2003; Lohmann V, 2000, J VIRAL HEPATITIS, V7, P167; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; Luo GX, 2000, J VIROL, V74, P851, DOI 10.1128/JVI.74.2.851-863.2000; Oh JW, 1999, J VIROL, V73, P7694, DOI 10.1128/JVI.73.9.7694-7702.1999; Ranjith-Kumar CT, 2002, J VIROL, V76, P12513, DOI 10.1128/JVI.76.24.12513-12525.2002; Ranjith-Kumar CT, 2001, J VIROL, V75, P8615, DOI 10.1128/JVI.75.18.8615-8623.2001; Sun XL, 2000, BIOCHEM BIOPH RES CO, V268, P798, DOI 10.1006/bbrc.2000.2120; Tomei L, 2000, J GEN VIROL, V81, P759, DOI 10.1099/0022-1317-81-3-759; Zhong WD, 2000, J VIROL, V74, P2017, DOI 10.1128/JVI.74.4.2017-2022.2000; Zhong WD, 2000, J VIROL, V74, P9134, DOI 10.1128/JVI.74.19.9134-9143.2000	28	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10738	10746		10.1074/jbc.M310062200	http://dx.doi.org/10.1074/jbc.M310062200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688285	hybrid			2022-12-25	WOS:000220050400129
J	Roccisana, JL; Kawanabe, N; Kajiya, H; Koide, M; Roodman, GD; Reddy, SV				Roccisana, JL; Kawanabe, N; Kajiya, H; Koide, M; Roodman, GD; Reddy, SV			Functional role for heat shock factors in the transcriptional regulation of human RANK ligand gene expression in stromal/osteoblast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; KAPPA-B-LIGAND; OSTEOCLAST DIFFERENTIATION FACTOR; NECROSIS-FACTOR-ALPHA; BONE-MARROW CULTURES; RECEPTOR ACTIVATOR; OSTEOBLASTIC CELLS; NUCLEAR-FACTOR; PARATHYROID-HORMONE; PAGETS-DISEASE	RANK Ligand (RANKL) is a critical osteoclastogenic factor that is expressed on stromal cells and osteoblasts. Most resorption stimuli induce osteoclast formation by modulating RANKL gene expression in marrow stromal/osteoblast cells. However, it is unclear how these stimuli modulate RANKL gene expression in the bone microenvironment. To characterize the transcriptional control of human RANKL gene expression in stromal/osteoblast cells, we PCR-amplified and cloned a 2-kb 5'-flanking sequence of the RANKL gene, using normal human osteoblast derived genomic DNA as a template. Sequence analysis identified the presence of several potential Heat Shock Factor (HSF) responsive elements (HSE) in the human RANKL gene promoter region. Co-expression of HSF-1 or HSF-2 with the RANKL gene promoter-luciferase reporter plasmid in human osteoblastic cells (NOBC) demonstrated a 2-fold and 4.5-fold increase in promoter activity, respectively. RT-PCR analysis for HSF-1 and 2 mRNA expression in human bone marrow-derived stromal cells (SAKA-T) and osteoblast cells detected only HSF-2 expression. As evident from EMSA analysis, in contrast to 1,25(OH)(2)D-3 SAKA-T cells treated with b-FGF demonstrated increased levels of HSF-2 binding to the HSE present in the RANKL gene promoter region. Immunocytochemical staining further confirmed nuclear localization of HSF-2 in both SAKA-T transformed stromal cells and human bone marrow derived primary stromal/preosteoblastic cells in response to b-FGF treatment. Furthermore, b-FGF treatment of SAKA-T cells transfected with the luciferase reporter plasmid containing the hRANKL HSE region (-2 kb to -1275 bp) upstream to a heterologous promoter showed increased levels of transactivation. Western blot analysis further demonstrated enhanced levels of RANKL expression and HSP-27 phosphorylation in SAKA-T cells treated with b-FGF. In addition, overexpression of HSF-2 in SAKA-T cells resulted in a 5-fold increase in the levels of RANKL expression in these cells. These data further suggest that HSF-2 is a downstream target of b-FGF to induce RANKL expression in stromal/osteoblast cells, and that HSF may play an important role in modulating RANKL gene expression in the bone microenvironment.	Univ Pittsburgh, Div Hematol, Dept Med, Pittsburgh, PA 15213 USA; Vet Affairs Med Ctr, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Reddy, SV (corresponding author), Univ Pittsburgh, Div Hematol Oncol, Dept Med, Liliane S Kaufmann Bldg,Suite 301,3471 5th Ave, Pittsburgh, PA 15213 USA.	reddysv@msx.upmc.edu		Kajiya, Hiroshi/0000-0003-3275-3632; Roccisana, Jennifer/0000-0003-3631-9040; Koide, Masanori/0000-0002-6511-9999	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR049363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012603] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 049363] Funding Source: Medline; NIDCR NIH HHS [DE12603] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Carmeliet G, 1997, J BONE MINER RES, V12, P786, DOI 10.1359/jbmr.1997.12.5.786; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLINOSDOBY P, 2002, J BONE MINER RES, pM134; Darimont C, 2002, CELL GROWTH DIFFER, V13, P59; FERNANDES M, 1994, NUCLEIC ACIDS RES, V22, P167, DOI 10.1093/nar/22.2.167; Geoffroy V, 2002, MOL CELL BIOL, V22, P6222, DOI 10.1128/MCB.22.17.6222-6233.2002; Gronthos S, 2003, J BONE MINER RES, V18, P716, DOI 10.1359/jbmr.2003.18.4.716; Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756-3282(99)00162-3; Hong YL, 1999, J BIOL CHEM, V274, P12967, DOI 10.1074/jbc.274.19.12967; Hurley MM, 1998, BONE, V22, P309, DOI 10.1016/S8756-3282(97)00292-5; Hurley MM, 1999, J BONE MINER RES, V14, P776, DOI 10.1359/jbmr.1999.14.5.776; Ikeda T, 2001, ENDOCRINOLOGY, V142, P1419, DOI 10.1210/en.142.4.1419; Ishida A, 2002, J BIOL CHEM, V277, P26217, DOI 10.1074/jbc.M111093200; Ishijima M, 2001, J EXP MED, V193, P399, DOI 10.1084/jem.193.3.399; Kang KI, 1999, P NATL ACAD SCI USA, V96, P1439, DOI 10.1073/pnas.96.4.1439; Kawaguchi H, 2000, J BONE MINER RES, V15, P466, DOI 10.1359/jbmr.2000.15.3.466; Kawazoe Y, 1998, EUR J BIOCHEM, V255, P356, DOI 10.1046/j.1432-1327.1998.2550356.x; Kikuchi T, 2001, J IMMUNOL, V166, P3574, DOI 10.4049/jimmunol.166.5.3574; Kitazawa R, 1999, BBA-GENE STRUCT EXPR, V1445, P134, DOI 10.1016/S0167-4781(99)00032-9; Kitazawa R, 2002, BIOCHEM BIOPH RES CO, V290, P650, DOI 10.1006/bbrc.2001.6251; Kozawa O, 2001, CELL SIGNAL, V13, P535, DOI 10.1016/S0898-6568(01)00180-2; Kozawa O, 2001, ARCH BIOCHEM BIOPHYS, V388, P237, DOI 10.1006/abbi.2000.2290; Lee SK, 2002, J IMMUNOL, V169, P2374, DOI 10.4049/jimmunol.169.5.2374; Martin I, 1997, ENDOCRINOLOGY, V138, P4456, DOI 10.1210/en.138.10.4456; Mathew A, 2001, MOL CELL BIOL, V21, P7163, DOI 10.1128/MCB.21.21.7163-7171.2001; McMillan DR, 2002, MOL CELL BIOL, V22, P8005, DOI 10.1128/MCB.22.22.8005-8014.2002; Menaa C, 2000, J CLIN INVEST, V105, P1833, DOI 10.1172/JCI9133; Mills BG, 1997, CALCIFIED TISSUE INT, V61, P16, DOI 10.1007/s002239900285; Mizuno A, 2002, J BONE MINER METAB, V20, P337, DOI 10.1007/s007740200049; Montero A, 2000, J CLIN INVEST, V105, P1085, DOI 10.1172/JCI8641; Nakagawa N, 1999, BIOCHEM BIOPH RES CO, V265, P158, DOI 10.1006/bbrc.1999.1601; Nakashima T, 2000, BIOCHEM BIOPH RES CO, V275, P768, DOI 10.1006/bbrc.2000.3379; O'Brien CA, 2002, BONE, V30, P453, DOI 10.1016/S8756-3282(01)00692-5; Okada Y, 2003, J BIOL CHEM, V278, P21258, DOI 10.1074/jbc.M302113200; Okada Y, 2000, J CLIN INVEST, V105, P823, DOI 10.1172/JCI8195; Quinn JMW, 2000, J BONE MINER RES, V15, P1459, DOI 10.1359/jbmr.2000.15.8.1459; Reddy SV, 2000, J BONE MINER RES, V15, pS370; REDDY SV, 1995, J BONE MINER RES, V10, P601; Reffitt DM, 2003, BONE, V32, P127, DOI 10.1016/S8756-3282(02)00950-X; Roux S, 2002, BRIT J HAEMATOL, V117, P86, DOI 10.1046/j.1365-2141.2002.03417.x; SHAKOORI AR, 1992, J CELL BIOCHEM, V48, P277, DOI 10.1002/jcb.240480308; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; Singh IS, 2000, J BIOL CHEM, V275, P9841, DOI 10.1074/jbc.275.13.9841; Snoeckx LHEH, 2001, PHYSIOL REV, V81, P1461, DOI 10.1152/physrev.2001.81.4.1461; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; TAKAHASHI S, 1995, ENDOCRINOLOGY, V136, P1441, DOI 10.1210/en.136.4.1441; Thomas GP, 2001, J ENDOCRINOL, V170, P451, DOI 10.1677/joe.0.1700451; Wang RX, 2002, EUR J IMMUNOL, V32, P1090, DOI 10.1002/1521-4141(200204)32:4<1090::AID-IMMU1090>3.0.CO;2-P; Xie Y, 2002, J BIOL CHEM, V277, P11802, DOI 10.1074/jbc.M109296200; YANG XL, 1995, J STEROID BIOCHEM, V52, P415, DOI 10.1016/0960-0760(94)00191-N	52	36	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10500	10507		10.1074/jbc.M303727200	http://dx.doi.org/10.1074/jbc.M303727200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699143	hybrid			2022-12-25	WOS:000220050400102
J	Adler, J; Bibi, E				Adler, J; Bibi, E			Determinants of substrate recognition by the Escherichia coli multidrug transporter MdfA identified on both sides of the membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SCANNING MUTAGENESIS; RESISTANCE P-GLYCOPROTEIN; LACTOSE PERMEASE; GENOME SEQUENCE; BINDING SITE; PROTEIN; MUTATIONS; MECHANISM; RESIDUE; LEAFLET	The Escherichia coli multidrug transporter MdfA contains a membrane-embedded charged residue (Glu-26) that was shown to play an important role in substrate recognition. To identify additional determinants of multidrug recognition we isolated 58 intragenic second-site mutations that restored the function of inactive MdfA E26X mutants. In addition, two single-site mutations that enhanced the activity of wild-type MdfA were identified. Most of the mutations were found in two regions, the cytoplasmic half of transmembrane segments (TMs) 4, 5, and 6 (cluster 1) and the periplasmic half of TM 1 and 2 ( cluster 2). The identified residues were mutated to cysteines in the background of a functional cysteineless MdfA, and substrate protection against alkylation was analyzed. The results support the suggestion that the two clusters are involved in substrate recognition. Using inverted membrane vesicles we observed that a proton electrochemical gradient (Delta(mu) over tilde (H+), inside positive and acidic) enhanced the substrate-protective effect in the cytoplasmic region, whereas it largely reduced this effect in the periplasmic side of MdfA. Therefore, we propose that substrates interact with two sites in MdfA, one in the cytoplasmic leaflet of the membrane and the other in the periplasmic leaflet. Theoretically, these domains could constitute a large part of the multidrug pathway through MdfA.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Bibi, E (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	e.bibi@weizmann.ac.il		Bibi, Eitan/0000-0003-3700-2707				Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Adler J, 2004, BIOCHEMISTRY-US, V43, P518, DOI 10.1021/bi035485t; Adler J, 2002, J BACTERIOL, V184, P3313, DOI 10.1128/JB.184.12.3313-3320.2002; BIBI E, 1993, P NATL ACAD SCI USA, V90, P9209, DOI 10.1073/pnas.90.19.9209; Bibi E, 2001, J MOL MICROB BIOTECH, V3, P171; Bohn C, 1998, J BACTERIOL, V180, P6072, DOI 10.1128/JB.180.22.6072-6075.1998; Bolhuis H, 1996, EMBO J, V15, P4239, DOI 10.1002/j.1460-2075.1996.tb00798.x; Edgar R, 1997, J BACTERIOL, V179, P2274, DOI 10.1128/jb.179.7.2274-2280.1997; Edgar R, 1999, EMBO J, V18, P822, DOI 10.1093/emboj/18.4.822; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; Gruol DJ, 2002, MOL PHARMACOL, V62, P1238, DOI 10.1124/mol.62.5.1238; Gruol DJ, 2001, MOL PHARMACOL, V60, P104, DOI 10.1124/mol.60.1.104; Hirai T, 2003, J BACTERIOL, V185, P1712, DOI 10.1128/JB.185.5.1712-1718.2003; Hirai T, 2002, NAT STRUCT BIOL, V9, P597, DOI 10.1038/nsb821; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Jin Q, 2002, NUCLEIC ACIDS RES, V30, P4432, DOI 10.1093/nar/gkf566; KABACK HR, 1978, BIOCHEMISTRY-US, V17, P1640, DOI 10.1021/bi00602a010; Kwaw I, 2001, BIOCHEMISTRY-US, V40, P10491, DOI 10.1021/bi010866x; Levy SB, 2002, J APPL MICROBIOL, V92, p65S, DOI 10.1046/j.1365-2672.92.5s1.4.x; Lewinson O, 2003, P NATL ACAD SCI USA, V100, P1667, DOI 10.1073/pnas.0435544100; Lewinson O, 2001, BIOCHEMISTRY-US, V40, P12612, DOI 10.1021/bi011040y; Loo TW, 2002, J BIOL CHEM, V277, P44332, DOI 10.1074/jbc.M208433200; Loo TW, 2001, J BIOL CHEM, V276, P14972, DOI 10.1074/jbc.M100407200; Loo TW, 2000, J BIOL CHEM, V275, P39272, DOI 10.1074/jbc.M007741200; Mine T, 1998, J BIOCHEM-TOKYO, V124, P187, DOI 10.1093/oxfordjournals.jbchem.a022078; Mordoch SS, 1999, J BIOL CHEM, V274, P19480, DOI 10.1074/jbc.274.27.19480; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; Nikaido H, 1998, CURR OPIN MICROBIOL, V1, P516, DOI 10.1016/S1369-5274(98)80083-0; Nilsen IW, 1996, J BACTERIOL, V178, P3188, DOI 10.1128/jb.178.11.3188-3193.1996; Parkhill J, 2001, NATURE, V413, P848, DOI 10.1038/35101607; Parkhill J, 2001, NATURE, V413, P523, DOI 10.1038/35097083; Poole K, 2001, CURR OPIN MICROBIOL, V4, P500, DOI 10.1016/S1369-5274(00)00242-3; Saier MH, 2001, SEMIN CELL DEV BIOL, V12, P205, DOI 10.1006/scdb.2000.0246; Schumacher MA, 2001, SCIENCE, V294, P2158, DOI 10.1126/science.1066020; Shapiro AB, 1997, EUR J BIOCHEM, V250, P122, DOI 10.1111/j.1432-1033.1997.00122.x; Tamura N, 2001, J BIOL CHEM, V276, P20330, DOI 10.1074/jbc.M007993200; VANIWAARDEN PR, 1992, BIOCHIM BIOPHYS ACTA, V1113, P161, DOI 10.1016/0304-4157(92)90037-B; Venkatesan P, 2000, BIOCHEMISTRY-US, V39, P10649, DOI 10.1021/bi0004394; Venkatesan P, 2000, BIOCHEMISTRY-US, V39, P10656, DOI 10.1021/bi0004403; Vo QD, 1999, J BIOL CHEM, V274, P20318, DOI 10.1074/jbc.274.29.20318; Yerushalmi H, 2000, J BIOL CHEM, V275, P5264, DOI 10.1074/jbc.275.8.5264; Zgurskaya HI, 2002, INT J MED MICROBIOL, V292, P95, DOI 10.1078/1438-4221-00195	44	54	58	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8957	8965		10.1074/jbc.M313422200	http://dx.doi.org/10.1074/jbc.M313422200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14688269	hybrid			2022-12-25	WOS:000189265900054
J	Hinton, A; Gatti, DL; Ackerman, SH				Hinton, A; Gatti, DL; Ackerman, SH			The molecular chaperone, Atp12p, from Homo sapiens - In vitro studies with purified wild type and mutant (E240K) proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL F-1-ATPASE; CITRATE SYNTHASE; YEAST; IDENTIFICATION; F1-ATPASE; SUBUNIT; STABILITY; DOMAINS	Work in Saccharomyces cerevisiae has shown that Atp12p binds to unassembled alpha subunits of F-1 and in so doing prevents the alpha subunit from associating with itself in non-productive complexes during assembly of the F-1 moiety of the mitochondrial ATP synthase. We have developed a method to prepare recombinant Atp12p after expression of its human cDNA in bacterial cells. The molecular chaperone activity of HuAtp12p was studied using citrate synthase as a model substrate. Wild type HuAtp12p suppresses the aggregation of thermally inactivated citrate synthase. In contrast, the mutant protein HuAtp12p(E240K), which harbors a lysine at the position of the highly conserved Glu-240, fails to prevent citrate synthase aggregation at 43 degreesC. No significant differences were observed between the wild type and the mutant proteins as judged by sedimentation analysis, cysteine titration, tryptophan emission spectra, or limited proteolysis, which suggests that the E240K mutation alters the activity of HuAtp12p with minimal effects on the physical integrity of the protein. An additional important finding of this work is that the equilibrium chemical denaturation curve of HuAtp12p shows two components, the first of which is associated with protein aggregation. This result is consistent with a model for Atp12p structure in which there is a hydrophobic chaperone domain that is buried within the protein interior.	Wayne State Univ, Sch Med, Dept Surg, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University; Wayne State University	Ackerman, SH (corresponding author), Wayne State Univ, Sch Med, Dept Surg, 421 E Canfield Ave, Detroit, MI 48201 USA.	sackerm@med.wayne.edu			NIGMS NIH HHS [F31 GM65068, R01 GM48157, R01 GM069840] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069840, F31GM065068, R01GM048157] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; Ackerman SH, 2002, BBA-BIOENERGETICS, V1555, P101, DOI 10.1016/S0005-2728(02)00262-1; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; BOWMAN S, 1991, J BIOL CHEM, V266, P7517; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BURNS DJ, 1986, J BIOL CHEM, V261, P2066; CLARKE J, 1993, BIOCHEMISTRY-US, V32, P4322, DOI 10.1021/bi00067a022; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; ILLINTON A, 2003, J BIOL CHEM, V278, P34110; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lefebvre-Legendre L, 2001, J BIOL CHEM, V276, P6789, DOI 10.1074/jbc.M009557200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Nozaki Y, 1972, Methods Enzymol, V26, P43; PAUL MF, 1994, J BIOL CHEM, V269, P26158; ROYER CA, 1993, PROTEIN SCI, V2, P1844, DOI 10.1002/pro.5560021106; Sastry MSR, 2002, J BIOL CHEM, V277, P46026, DOI 10.1074/jbc.M205800200; Sheluho D, 2001, J BIOL CHEM, V276, P39945, DOI 10.1074/jbc.M107252200; SINGH M, 1970, J BIOL CHEM, V245, P4636; SRERE PA, 1966, J BIOL CHEM, V241, P2157; Wang ZG, 1998, J BIOL CHEM, V273, P2993, DOI 10.1074/jbc.273.5.2993; Wang ZG, 2000, EMBO J, V19, P1486, DOI 10.1093/emboj/19.7.1486; Wang ZG, 1996, J BIOL CHEM, V271, P4887; Wang ZG, 2001, J BIOL CHEM, V276, P30773, DOI 10.1074/jbc.M104133200; ZHI W, 1991, BIOCHEMISTRY-US, V30, P9281, DOI 10.1021/bi00102a021	28	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9016	9022		10.1074/jbc.M312631200	http://dx.doi.org/10.1074/jbc.M312631200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14701807	hybrid			2022-12-25	WOS:000189265900061
J	Koishi, R; Xu, HX; Ren, DJ; Navarro, B; Spiller, BW; Shi, Q; Clapham, DE				Koishi, R; Xu, HX; Ren, DJ; Navarro, B; Spiller, BW; Shi, Q; Clapham, DE			A superfamily of voltage-gated sodium channels in bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRIVEN FLAGELLAR MOTORS; ALKALOPHILIC BACILLUS; NA+-DRIVEN; SP-NOV.; STRAIN; NEURONS; VIBRIO; INACTIVATION; CURRENTS; MOTILITY	NaChBac, a six-alpha-helical transmembrane- spanning protein cloned from Bacillus halodurans, is the first functionally characterized bacterial voltage-gated Na+-selective channel (Ren, D., Navarro, B., Xu, H., Yue, L., Shi, Q., and Clapham, D. E. ( 2001) Science 294, 2372 2375). As a highly expressing ion channel protein, NaChBac is an ideal candidate for high resolution structural determination and structure-function studies. The biological role of NaChBac, however, is still unknown. In this report, another 11 structurally related bacterial proteins are described. Two of these functionally expressed as voltage-dependent Na+ channels (Na(V)PZ from Paracoccus zeaxanthinifaciens and NaVSP from Silicibacter pomeroyi). Na(V)PZ and NaVSP share similar to40% amino acid sequence identity with NaChBac. When expressed in mammalian cell lines, both Na(V)PZ and NaVSP were Na+-selective and voltage-dependent. However, their kinetics and voltage dependence differ significantly. These single six-alpha-helical transmembrane-spanning subunits constitute a widely distributed superfamily (Na(V)Bac) of channels in bacteria, implying a fundamental prokaryotic function. The degree of sequence homology (22 - 54%) is optimal for future comparisons of Na(V)Bac structure and function of similarity and dissimilarity among Na(V)Bac proteins. Thus, the Na(V)Bac superfamily is fertile ground for crystallographic, electrophysiological, and microbiological studies.	Harvard Univ, Sch Med, Childrens Hosp, Howard Hughes Med Inst,Dept Cardiovasc Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Childrens Hosp, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Clapham, DE (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Howard Hughes Med Inst,Dept Cardiovasc Res, 320 Longwood Ave, Boston, MA 02115 USA.	dclapham@enders.tch.harvard.edu	Clapham, David/S-1123-2019; Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428; 				Akopian AN, 1996, NATURE, V379, P257, DOI 10.1038/379257a0; Asai Y, 2003, J MOL BIOL, V327, P453, DOI 10.1016/S0022-2836(03)00096-2; AUSUBEL FM, 1995, CURRENT PROTOCOLS MO, V1, P24; Berry A, 2003, INT J SYST EVOL MICR, V53, P231, DOI 10.1099/ijs.0.02368-0; Booth IR, 2003, BIOCHEMISTRY-US, V42, P10045, DOI 10.1021/bi034953w; Catterall MA, 2001, SCIENCE, V294, P2306, DOI 10.1126/science.1067417; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Do MTH, 2003, NEURON, V39, P109, DOI 10.1016/S0896-6273(03)00360-X; Goldin AL, 2000, NEURON, V28, P365, DOI 10.1016/S0896-6273(00)00116-1; Gonzalez JM, 2003, INT J SYST EVOL MICR, V53, P1261, DOI 10.1099/ijs.0.02491-0; Gonzalez JM, 2000, INT J SYST EVOL MICR, V50, P831, DOI 10.1099/00207713-50-2-831; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; HIROTA N, 1983, J BIOL CHEM, V258, P577; IMAE Y, 1986, METHOD ENZYMOL, V125, P582; IMAE Y, 1989, J BIOENERG BIOMEMBR, V21, P705, DOI 10.1007/BF00762688; Junge K, 2003, APPL ENVIRON MICROB, V69, P4282, DOI 10.1128/AEM.69.7.4282-4284.2003; Kojima S, 1999, J BACTERIOL, V181, P1927, DOI 10.1128/JB.181.6.1927-1930.1999; Krulwich TA, 1996, BBA-BIOENERGETICS, V1275, P21, DOI 10.1016/0005-2728(96)00044-8; Krulwich TA, 2001, BBA-BIOENERGETICS, V1505, P158, DOI 10.1016/S0005-2728(00)00285-1; Liu J, 2002, J GEN PHYSIOL, V120, P723, DOI 10.1085/jgp.20028687; Lu J, 2001, FEMS MICROBIOL LETT, V205, P291, DOI 10.1111/j.1574-6968.2001.tb10963.x; McCarter LL, 2001, MICROBIOL MOL BIOL R, V65, P445, DOI 10.1128/MMBR.65.3.445-462.2001; MCCARTHY AJ, 1984, J GEN MICROBIOL, V130, P5; MELDRUM FC, 1993, P ROY SOC B-BIOL SCI, V251, P231, DOI 10.1098/rspb.1993.0034; MOORE RL, 1984, INT J SYST BACTERIOL, V34, P71, DOI 10.1099/00207713-34-1-71; Perriere G, 1996, BIOCHIMIE, V78, P364, DOI 10.1016/0300-9084(96)84768-7; Ren DJ, 2001, SCIENCE, V294, P2372, DOI 10.1126/science.1065635; Strom MS, 2000, MICROBES INFECT, V2, P177, DOI 10.1016/S1286-4579(00)00270-7; SUGIYAMA S, 1985, FEBS LETT, V182, P265, DOI 10.1016/0014-5793(85)80312-4; Sun YM, 1997, J GEN PHYSIOL, V110, P693, DOI 10.1085/jgp.110.6.693; Taddese A, 2002, NEURON, V33, P587, DOI 10.1016/S0896-6273(02)00574-3; Takami H, 2000, EXTREMOPHILES, V4, P99, DOI 10.1007/s007920050143; VASSILEV PM, 1988, SCIENCE, V241, P1658, DOI 10.1126/science.2458625; Yamagishi T, 2001, J GEN PHYSIOL, V118, P171, DOI 10.1085/jgp.118.2.171; Yellen G, 2002, NATURE, V419, P35, DOI 10.1038/nature00978; Yorimitsu T, 2001, BBA-BIOENERGETICS, V1505, P82, DOI 10.1016/S0005-2728(00)00279-6; Yue LX, 2002, J GEN PHYSIOL, V120, P845, DOI 10.1085/jgp.20028699	37	127	129	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9532	9538		10.1074/jbc.M313100200	http://dx.doi.org/10.1074/jbc.M313100200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14665618	hybrid			2022-12-25	WOS:000189265900120
J	Lu, M; Sautin, YY; Holliday, LS; Gluck, SL				Lu, M; Sautin, YY; Holliday, LS; Gluck, SL			The glycolytic enzyme aldolase mediates assembly, expression, and activity of vacuolar H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY FRUCTOSE INTOLERANCE; SACCHAROMYCES-CEREVISIAE; V-ATPASE; MOLECULAR-CLONING; PROTON PUMP; A-SUBUNIT; INTERACTS; ISOFORMS; MUTANTS; CELLS	Vacuolar H+-ATPases (V-ATPases) are a family of highly conserved proton pumps that couple hydrolysis of cytosolic ATP to proton transport out of the cytosol. How ATP is supplied for V-ATPase-mediated hydrolysis and for coupling of proton transport is poorly understood. We have reported that the glycolytic enzyme aldolase physically associates with V-ATPase ( Lu, M., Holliday, L. S., Zhang, L., Dunn, W. A., and Gluck, S. L. (2001) J. Biol. Chem. 276, 30407 - 30413). Here we show that aldolase interacts with three different subunits of V-ATPase ( subunits a, B, and E). The binding sites for the V-ATPase subunits on aldolase appear to be on distinct interfaces of the glycolytic enzyme. Aldolase deletion mutant cells were able to grow in medium buffered at pH 5.5 but not at pH 7.5, displaying a growth phenotype similar to that observed in V-ATPase subunit deletion mutants. Abnormalities in V-ATPase assembly and protein expression observed in aldolase deletion mutant cells could be fully rescued by aldolase complementation. The interaction between aldolase and V-ATPase increased dramatically in the presence of glucose, suggesting that aldolase may act as a glucose sensor for V-ATPase regulation. Taken together, these findings provide functional evidence that the ATP-generating glycolytic pathway is directly coupled to the ATP-hydrolyzing proton pump through physical interaction between aldolase and V-ATPase.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Florida, Coll Dent, Dept Orthodont, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	University of California System; University of California San Francisco; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Lu, M (corresponding author), Univ Calif San Francisco, Dept Med, HSE 672,Box 0532,513 Parnassus Ave, San Francisco, CA 94143 USA.	minglu@medicine.ucsf.edu	Holliday, Lexie/GYQ-4972-2022	Holliday, Lexie/0000-0002-0844-1965; Sautin, Yuri/0000-0003-3618-5134	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK064977, R01DK064095] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK64095, DK64977] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI I, 1990, J BIOL CHEM, V265, P960; Alberts B, 1989, MOL BIOL CELL, P41; Ali M, 1998, J MED GENET, V35, P353, DOI 10.1136/jmg.35.5.353; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Forster C, 2000, J BIOL CHEM, V275, P38245, DOI 10.1074/jbc.M006650200; FOURY F, 1990, J BIOL CHEM, V265, P18554; Gluck SL, 1996, ANNU REV PHYSIOL, V58, P427, DOI 10.1146/annurev.physiol.58.1.427; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HSU SC, 1991, J BIOL CHEM, V266, P21745; Kane PM, 2000, FEBS LETT, V469, P137, DOI 10.1016/S0014-5793(00)01265-5; KANE PM, 1995, J BIOL CHEM, V270, P17025; LOBO Z, 1984, J BACTERIOL, V160, P222, DOI 10.1128/JB.160.1.222-226.1984; Lu M, 2002, J BIOL CHEM, V277, P38409, DOI 10.1074/jbc.M203521200; Lu M, 2001, J BIOL CHEM, V276, P30407, DOI 10.1074/jbc.M008768200; MORRIS RC, 1968, J CLIN INVEST, V47, P1389, DOI 10.1172/JCI105830; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824; OHYA Y, 1991, J BIOL CHEM, V266, P13971; Oka T, 2001, J BIOL CHEM, V276, P40050, DOI 10.1074/jbc.M106488200; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; Rolland F, 2001, TRENDS BIOCHEM SCI, V26, P310, DOI 10.1016/S0968-0004(01)01805-9; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; Smardon AM, 2002, J BIOL CHEM, V277, P13831, DOI 10.1074/jbc.M200682200; Smith AN, 2001, J BIOL CHEM, V276, P42382, DOI 10.1074/jbc.M107267200; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Su Y, 2003, J BIOL CHEM, V278, P20013, DOI 10.1074/jbc.M210077200; Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760; WANG ZQ, 1990, J BIOL CHEM, V265, P21957; Wu K, 1997, P NATL ACAD SCI USA, V94, P13273, DOI 10.1073/pnas.94.24.13273	29	147	149	3	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8732	8739		10.1074/jbc.M303871200	http://dx.doi.org/10.1074/jbc.M303871200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14672945	hybrid			2022-12-25	WOS:000189265900026
J	Roisin, A; Robin, JP; Dereuddre-Bosquet, N; Vitte, AL; Dormont, D; Clayette, P; Jalinot, P				Roisin, A; Robin, JP; Dereuddre-Bosquet, N; Vitte, AL; Dormont, D; Clayette, P; Jalinot, P			Inhibition of HIV-1 replication by cell-penetrating peptides binding Rev	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NUCLEAR EXPORT SIGNAL; NUCLEOPORIN-LIKE PROTEIN; RESPONSE RNA DECOY; TAT TRANSACTIVATOR; TYPE-1 REV; IN-VIVO; FUNCTIONAL INTERACTION; TRANSCRIPTION FACTOR; TERMINAL DOMAIN	New therapeutic agents able to block HIV-1 replication are eagerly sought after to increase the possibilities of treatment of resistant viral strains. In this report, we describe a rational strategy to identify small peptide sequences owning the dual property of penetrating within lymphocytes and of binding to a protein target. Such sequences were identified for two important HIV-1 regulatory proteins, Tat and Rev. Their association to a stabilizing domain consisting of human small ubiquitin-related modifier-1 (SUMO-1) allowed the generation of small proteins named SUMO-1 heptapeptide protein transduction domain for binding Tat (SHPT) and SUMO-1 heptapeptide protein transduction domain for binding Rev (SHPR), which are stable and efficiently penetrate within primary lymphocytes. Analysis of the antiviral activity of these proteins showed that one SHPR is active in both primary lymphocytes and macrophages, whereas one SHPT is active only in the latter cells. These proteins may represent prototypes of new therapeutic agents targeting the crucial functions exerted by both viral regulatory factors.	Ecole Normale Super Lyon, Lab Biol Mol Cellule, CNRS, UMR5161, F-69364 Lyon 07, France; Univ Paris 11, EPHE, CRSSA,DRM,DSV, CEA,Serv Neurovirol,Soc Pharmacol & Immunol BIO, F-92265 Fontenay Aux Roses, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet; CEA; UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Universite Paris Saclay	Jalinot, P (corresponding author), Ecole Normale Super Lyon, Lab Biol Mol Cellule, CNRS, UMR5161, 46 Allee Italie, F-69364 Lyon 07, France.	pjalinot@ens-lyon.fr						Askjaer P, 1998, J BIOL CHEM, V273, P33414, DOI 10.1074/jbc.273.50.33414; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; Bohjanen PR, 1997, NUCLEIC ACIDS RES, V25, P4481, DOI 10.1093/nar/25.22.4481; Bres V, 2002, EMBO J, V21, P6811, DOI 10.1093/emboj/cdf669; Browning CM, 1999, J VIROL, V73, P5191, DOI 10.1128/JVI.73.6.5191-5195.1999; Chen D, 2002, EMBO J, V21, P6801, DOI 10.1093/emboj/cdf683; Coburn GA, 2002, J VIROL, V76, P9225, DOI 10.1128/JVI.76.18.9225-9231.2002; Cujec TP, 1997, GENE DEV, V11, P2645, DOI 10.1101/gad.11.20.2645; Cujec TP, 1997, MOL CELL BIOL, V17, P1817, DOI 10.1128/MCB.17.4.1817; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; EMERMAN M, 1987, EMBO J, V6, P3755, DOI 10.1002/j.1460-2075.1987.tb02710.x; Farjot G, 1999, J BIOL CHEM, V274, P17309, DOI 10.1074/jbc.274.24.17309; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fraisier C, 1998, GENE THER, V5, P1665, DOI 10.1038/sj.gt.3300780; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; Fujinaga K, 1998, J VIROL, V72, P7154, DOI 10.1128/JVI.72.9.7154-7159.1998; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; HOPE TJ, 1991, J VIROL, V65, P6001, DOI 10.1128/JVI.65.11.6001-6007.1991; Izmailova E, 2003, NAT MED, V9, P191, DOI 10.1038/nm822; Jacque JM, 2002, NATURE, V418, P435, DOI 10.1038/nature00896; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; JEANG KT, 1993, J VIROL, V67, P6224, DOI 10.1128/JVI.67.10.6224-6233.1993; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Konopka K, 2000, GENE, V255, P235, DOI 10.1016/S0378-1119(00)00334-6; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; LISZIEWICZ J, 1993, P NATL ACAD SCI USA, V90, P8000, DOI 10.1073/pnas.90.17.8000; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; PEPINSKY RB, 1994, DNA CELL BIOL, V13, P1011, DOI 10.1089/dna.1994.13.1011; Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; VENKATESH LK, 1990, VIROLOGY, V176, P39, DOI 10.1016/0042-6822(90)90228-J; Venkatesh LK, 2003, J VIROL, V77, P7236, DOI 10.1128/JVI.77.13.7236-7243.2003; VESCHAMBRE P, 1995, J MOL BIOL, V250, P169, DOI 10.1006/jmbi.1995.0368; Veschambre P, 1997, J GEN VIROL, V78, P2235, DOI 10.1099/0022-1317-78-9-2235; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; YANG MJ, 1995, NUCLEIC ACIDS RES, V23, P1152, DOI 10.1093/nar/23.7.1152; Yang YD, 2003, J VIROL, V77, P6700, DOI 10.1128/JVI.77.12.6700-6708.2003; Yi R, 2002, RNA, V8, P180, DOI 10.1017/S1355838202012384; Yi R, 2002, J VIROL, V76, P2036, DOI 10.1128/JVI.76.5.2036-2042.2002; Zolotukhin AS, 1999, J VIROL, V73, P120, DOI 10.1128/JVI.73.1.120-127.1999	59	27	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9208	9214		10.1074/jbc.M311594200	http://dx.doi.org/10.1074/jbc.M311594200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14668323	Green Published, hybrid			2022-12-25	WOS:000189265900082
J	Wang, K; Hackett, JT; Cox, ME; van Hoek, M; Lindstrom, JM; Parsons, SJ				Wang, K; Hackett, JT; Cox, ME; van Hoek, M; Lindstrom, JM; Parsons, SJ			Regulation of the neuronal nicotinic acetylcholine receptor by Src family tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; ACTIVATED PROTEIN-KINASE; EPIDERMAL-GROWTH-FACTOR; C-SRC; CATECHOLAMINE SECRETION; NMDA RECEPTORS; SIGNALING COMPLEX; MOLECULAR-BIOLOGY; NEURAL TISSUES; GENE-PRODUCT	Src family kinases (SFKs) are abundant in chromaffin cells that reside in the adrenal medulla and respond to cholinergic stimulation by secreting catecholamines. Our previous work indicated that SFKs regulate acetyl-choline- or nicotine-induced secretion, but the site of modulatory action was unclear. Using whole cell recordings, we found that inhibition of SFK tyrosine kinase activity by PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo(3,4-d)pyrimidine) treatment or expression of a kinase-defective c-Src reduced the peak amplitude of nicotine-induced currents in chromaffin cells or in human embryonic kidney cells ectopically expressing functional neuronal alpha3beta4alpha5 acetylcholine receptors (AChRs). Conversely, the phosphotyrosine phosphatase inhibitor, sodium vanadate, or expression of mutationally activated c-Src resulted in enhanced current amplitudes. These results suggest that SFKs and putative phosphotyrosine phosphatases regulate the activity of AChRs by opposing actions. This proposed model was supported further by the findings that SFKs physically associate with the receptor and that the AChR is tyrosine-phosphorylated.	Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Ctr Canc, Charlottesville, VA 22908 USA; Univ Virginia, Dept Physiol, Charlottesville, VA 22908 USA; Univ Penn, Dept Neurosci, Philadelphia, PA 19104 USA; George Mason Univ, Ctr Biodef, Manassas, VA 20110 USA	University of Virginia; University of Virginia; University of Virginia; University of Pennsylvania; George Mason University	Parsons, SJ (corresponding author), Univ Virginia Hlth Syst, Dept Microbiol, POB 800734, Charlottesville, VA 22908 USA.	sap@virginia.edu	van Hoek, Monique/E-1629-2011	van Hoek, Monique/0000-0003-1679-4899	NCI NIH HHS [P01 CA40042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040042] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; ALESSI DR, 1993, ONCOGENE, V8, P2015; Allen CM, 1996, J NEUROSCI RES, V44, P421, DOI 10.1002/(SICI)1097-4547(19960601)44:5<421::AID-JNR2>3.0.CO;2-H; Amico C, 1998, NEUROSCIENCE, V84, P529, DOI 10.1016/S0306-4522(97)00555-1; BOKSA P, 1984, J NEUROCHEM, V42, P607, DOI 10.1111/j.1471-4159.1984.tb02726.x; Brandon NJ, 2001, NEUROPHARMACOLOGY, V41, P745, DOI 10.1016/S0028-3908(01)00121-6; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CamposCaro A, 1997, J NEUROCHEM, V68, P488; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; CHANGEUX JP, 1984, SCIENCE, V225, P1335, DOI 10.1126/science.6382611; Cheek TR, 1991, CURR OPIN CELL BIOL, V3, P199, DOI 10.1016/0955-0674(91)90139-P; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; Cox ME, 1997, J NEUROCHEM, V69, P1119; Cox ME, 1996, J NEUROCHEM, V66, P1103; CREUTZ CE, 1987, J BIOL CHEM, V262, P1860; CRIADO M, 1992, NEUROCHEM RES, V17, P281, DOI 10.1007/BF00966671; Di Angelantonio S, 2003, EUR J NEUROSCI, V17, P2313, DOI 10.1046/j.1460-9568.2003.02669.x; DOUGLAS WW, 1968, BRIT J PHARMACOL, V34, P451, DOI 10.1111/j.1476-5381.1968.tb08474.x; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; FLY CM, 1994, J NEUROCHEM, V62, P923; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; Free RB, 2003, BRAIN RES, V974, P60, DOI 10.1016/S0006-8993(03)02551-4; GRANDORI C, 1988, J CELL BIOL, V107, P2125, DOI 10.1083/jcb.107.6.2125; Gu HJ, 1996, J NEUROCHEM, V66, P1454; Haskell MD, 2001, CHEM REV, V101, P2425, DOI 10.1021/cr0002341; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; HUGANIR RL, 1989, CRIT REV BIOCHEM MOL, V24, P183, DOI 10.3109/10409238909082553; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KATAGIRI T, 1989, MOL CELL BIOL, V9, P4914, DOI 10.1128/MCB.9.11.4914; Kobayashi H, 2002, ANN NY ACAD SCI, V971, P127, DOI 10.1111/j.1749-6632.2002.tb04446.x; LEE K, 1992, N-S ARCH PHARMACOL, V345, P363; LEVY JB, 1993, J BIOL CHEM, V268, P10573; Liao GY, 2001, MOL PHARMACOL, V59, P960, DOI 10.1124/mol.59.5.960; MacFarlane SN, 2000, J NEUROSCI, V20, P5245, DOI 10.1523/JNEUROSCI.20-14-05245.2000; McPherson PS, 1999, CELL SIGNAL, V11, P229, DOI 10.1016/S0898-6568(98)00059-X; MOSS SJ, 1995, NATURE, V377, P344, DOI 10.1038/377344a0; Nelson ME, 2001, J GEN PHYSIOL, V118, P563, DOI 10.1085/jgp.118.5.563; Nitabach MN, 2001, P NATL ACAD SCI USA, V98, P705, DOI 10.1073/pnas.031446198; Nong Y, 2003, NATURE, V422, P302, DOI 10.1038/nature01497; ODDIE KM, 1989, J NEUROSCI RES, V24, P38, DOI 10.1002/jnr.490240107; Paradiso K, 1998, J NEUROSCI, V18, P9227; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PARSONS SJ, 1986, BIOCHEM BIOPH RES CO, V134, P736, DOI 10.1016/S0006-291X(86)80482-X; PENG ZY, 1995, ONCOGENE, V11, P1955; Picciotto MR, 2000, NEUROPSYCHOPHARMACOL, V22, P451, DOI 10.1016/S0893-133X(99)00146-3; Ratcliffe CF, 2000, NAT NEUROSCI, V3, P437, DOI 10.1038/74805; REUTER CWM, 1995, METHOD ENZYMOL, V255, P245; ROSS CA, 1988, P NATL ACAD SCI USA, V85, P9831, DOI 10.1073/pnas.85.24.9831; Salter MW, 1998, BIOCHEM PHARMACOL, V56, P789, DOI 10.1016/S0006-2952(98)00124-5; SAPRU MK, 1994, J BIOL CHEM, V269, P27811; Smart TG, 1997, CURR OPIN NEUROBIOL, V7, P358, DOI 10.1016/S0959-4388(97)80063-3; SUGRUE MM, 1990, J NEUROSCI, V10, P2513; SWOPE SL, 1995, ANN NY ACAD SCI, V757, P197, DOI 10.1111/j.1749-6632.1995.tb17476.x; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tiran Z, 2003, J BIOL CHEM, V278, P17509, DOI 10.1074/jbc.M212766200; VANHOEK M, 1999, RRD NEUROCHEMISTRY 1, V2, P315; vanHoek ML, 1997, BIOCHEM J, V326, P271, DOI 10.1042/bj3260271; VERNALLIS AB, 1993, NEURON, V10, P451, DOI 10.1016/0896-6273(93)90333-M; Wang F, 1998, J BIOL CHEM, V273, P28721, DOI 10.1074/jbc.273.44.28721; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; WHITING P, 1986, J NEUROSCI, V6, P3061; Wijetunge S, 1995, BIOCHEM BIOPH RES CO, V217, P1039, DOI 10.1006/bbrc.1995.2874; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; YAGI T, 1993, ONCOGENE, V8, P3343; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; ZHAO YH, 1991, ONCOGENE, V6, P1725; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	69	52	53	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8779	8786		10.1074/jbc.M309652200	http://dx.doi.org/10.1074/jbc.M309652200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14679211	hybrid			2022-12-25	WOS:000189265900032
J	Zhang, MS; Coffino, P				Zhang, MS; Coffino, P			Repeat sequence of Epstein-Barr virus-encoded nuclear antigen 1 protein interrupts proteasome substrate processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLY-ALA REPEAT; KAPPA-B-ALPHA; ORNITHINE-DECARBOXYLASE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; DEGRADATION; INHIBITION; MECHANISM; STABILIZATION; ATPASE	The Epstein-Barr virus thwarts immune surveillance through a Gly-Ala repeat (GAr) within the viral Epstein-Barr virus-encoded nuclear antigen 1 protein. The GAr inhibits proteasome processing, an early step in antigen peptide presentation, but the mechanism of proteasome inhibition has been unclear. By embedding a GAr within ornithine decarboxylase, a natural proteasome substrate that does not require ubiquitin conjugation, we now demonstrate inhibition in a purified system, excluding involvement of ubiquitin conjugation or of proteins extraneous to substrate and proteasome. We show further that the GAr acts as a stop-transfer signal in proteasome substrate processing, resulting in vivo in partial proteolysis that halts just short of the GAr. Similarly, introducing a GAr into green fluorescent protein destabilized by the ornithine decarboxylase degradation domain also stops the progress of proteolysis, leading to the accumulation of partial degradation products. We postulate that the ATP motor of the proteasome slips when it encounters the GAr, impeding further insertion and, in this way, halting degradation.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Coffino, P (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, 513 Parnassus Ave, San Francisco, CA 94143 USA.	pcoffin@itsa.ucsf.edu		Coffino, Philip/0000-0003-0344-5083	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045335] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM-45335] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akopian TN, 1997, J BIOL CHEM, V272, P1791, DOI 10.1074/jbc.272.3.1791; Almrud JJ, 2000, J MOL BIOL, V295, P7, DOI 10.1006/jmbi.1999.3331; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; Ben-Shahar S, 1999, J BIOL CHEM, V274, P21963, DOI 10.1074/jbc.274.31.21963; CARDOZO C, 1994, BIOCHEMISTRY-US, V33, P6483, DOI 10.1021/bi00187a014; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; Dantuma NP, 2000, P NATL ACAD SCI USA, V97, P8381, DOI 10.1073/pnas.140217397; Dantuma NP, 2002, FEBS LETT, V529, P22, DOI 10.1016/S0014-5793(02)03252-0; FALK K, 1995, J GEN VIROL, V76, P779, DOI 10.1099/0022-1317-76-4-779; Fleming JA, 2002, P NATL ACAD SCI USA, V99, P1461, DOI 10.1073/pnas.032516399; Gaczynska M, 2003, BIOCHEMISTRY-US, V42, P8663, DOI 10.1021/bi034784f; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Heessen S, 2002, P NATL ACAD SCI USA, V99, P1532, DOI 10.1073/pnas.022306499; Hewitt EW, 2003, IMMUNOLOGY, V110, P163, DOI 10.1046/j.1365-2567.2003.01738.x; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; Hoyt MA, 2003, J BIOL CHEM, V278, P12135, DOI 10.1074/jbc.M211802200; Kenniston JA, 2003, CELL, V114, P511, DOI 10.1016/S0092-8674(03)00612-3; Kern AD, 1999, STRUCTURE, V7, P567, DOI 10.1016/S0969-2126(99)80073-2; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; Kohler A, 2001, MOL CELL, V7, P1143, DOI 10.1016/S1097-2765(01)00274-X; LAUX G, 1988, EMBO J, V7, P769, DOI 10.1002/j.1460-2075.1988.tb02874.x; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; Leight ER, 2000, REV MED VIROL, V10, P83, DOI 10.1002/(SICI)1099-1654(200003/04)10:2&lt;83::AID-RMV262&gt;3.0.CO;2-T; Leonchiks A, 1998, FEBS LETT, V440, P365, DOI 10.1016/S0014-5793(98)01488-4; Levitskaya J, 1997, P NATL ACAD SCI USA, V94, P12616, DOI 10.1073/pnas.94.23.12616; LEVITSKAYA J, 1995, NATURE, V375, P685, DOI 10.1038/375685a0; Li XQ, 1998, J BIOL CHEM, V273, P34970, DOI 10.1074/jbc.273.52.34970; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; MIYAZAKI Y, 1993, EUR J BIOCHEM, V214, P837, DOI 10.1111/j.1432-1033.1993.tb17987.x; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Navon A, 2001, MOL CELL, V8, P1339, DOI 10.1016/S1097-2765(01)00407-5; Niwa H, 2002, STRUCTURE, V10, P1415, DOI 10.1016/S0969-2126(02)00855-9; Oster G, 2003, TRENDS CELL BIOL, V13, P114, DOI 10.1016/S0962-8924(03)00004-7; Rape M, 2002, NAT CELL BIOL, V4, pE113, DOI 10.1038/ncb0502-e113; Sambrook J, 2001, MOL CLONING LAB MANU; Sharipo A, 1998, NAT MED, V4, P939, DOI 10.1038/nm0898-939; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Tellam J, 2001, J BIOL CHEM, V276, P33353, DOI 10.1074/jbc.M104535200; Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861; Toth C, 1999, J BIOL CHEM, V274, P25921, DOI 10.1074/jbc.274.36.25921; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Yin Y, 2003, SCIENCE, V301, P1371, DOI 10.1126/science.1088902; Zhang MS, 2003, EMBO J, V22, P1488, DOI 10.1093/emboj/cdg158	48	58	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8635	8641		10.1074/jbc.M310449200	http://dx.doi.org/10.1074/jbc.M310449200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14688254	hybrid			2022-12-25	WOS:000189265900015
J	Bullard, B; Ferguson, C; Minajeva, A; Leake, MC; Gautel, M; Labeit, D; Ding, LL; Labeit, S; Horwitz, J; Leonard, KR; Linke, WA				Bullard, B; Ferguson, C; Minajeva, A; Leake, MC; Gautel, M; Labeit, D; Ding, LL; Labeit, S; Horwitz, J; Leonard, KR; Linke, WA			Association of the chaperone alpha B-crystallin with titin in heart muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN C; SHOCK-PROTEIN; CARDIAC MYOFIBRILS; A-CRYSTALLIN; QUATERNARY STRUCTURE; MOLECULAR CHAPERONE; PASSIVE TENSION; 2-MODE BINDING; Z-LINE; DOMAIN	alphaB-crystallin, a major component of the vertebrate lens, is a chaperone belonging to the family of small heat shock proteins. These proteins form oligomers that bind to partially unfolded substrates and prevent denaturation. alphaB-crystallin in cardiac muscle binds to myofibrils under conditions of ischemia, and previous work has shown that the protein binds to titin in the I-band of cardiac fibers (Golenhofen, N., Arbeiter, A., Koob, R., and Drenckhahn, D. ( 2002) J. Mol. Cell. Cardiol. 34, 309 319). This part of titin extends as muscles are stretched and is made up of immunoglobulin-like modules and two extensible regions (N2B and PEVK) that have no well defined secondary structure. We have followed the position of alphaB-crystallin in stretched cardiac fibers relative to a known part of the titin sequence. alphaB-crystallin bound to a discrete region of the I-band that moved away from the Z-disc as sarcomeres were extended. In the physiological range of sarcomere lengths, alphaB-crystallin bound in the position of the N2B region of titin, but not to PEVK. In overstretched myofibrils, it was also in the Ig region between N2B and the Z-disc. Binding between alphaB-crystallin and N2B was confirmed using recombinant titin fragments. The Ig domains in an eight-domain fragment were stabilized by alphaB-crystallin; atomic force microscopy showed that higher stretching forces were needed to unfold the domains in the presence of the chaperone. Reversible association with alphaB-crystallin would protect I-band titin from stress liable to cause domain unfolding until conditions are favorable for refolding to the native state.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Heidelberg Univ, Inst Physiol & Pathophysiol, D-69120 Heidelberg, Germany; Univ Klinikum Mannheim, Inst Anasthesiol & Operat Intens Med, D-68135 Mannheim, Germany; Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90024 USA	European Molecular Biology Laboratory (EMBL); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; University of California System; University of California Los Angeles	Bullard, B (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	bullard@embl.de	Minajeva, Ave/F-6977-2017; Gautel, Mathias/AAB-9860-2019; Leake, Mark/C-1245-2011; Linke, Wolfgang A/E-8662-2012	Leake, Mark/0000-0002-1715-1249; Gautel, Mathias/0000-0003-4027-9803; Linke, Wolfgang/0000-0003-0801-3773; Minajeva, Ave/0000-0003-0256-1410				Bang ML, 2001, CIRC RES, V89, P1065, DOI 10.1161/hh2301.100981; Barbato R, 1996, CIRC RES, V78, P821, DOI 10.1161/01.RES.78.5.821; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; Carrion-Vazquez M, 1999, P NATL ACAD SCI USA, V96, P3694, DOI 10.1073/pnas.96.7.3694; Derham BK, 1999, PROG RETIN EYE RES, V18, P463, DOI 10.1016/S1350-9462(98)00030-5; Freiburg A, 2000, CIRC RES, V86, P1114; FURST DO, 1988, J CELL BIOL, V106, P1563, DOI 10.1083/jcb.106.5.1563; Gautel M, 1996, J MUSCLE RES CELL M, V17, P449, DOI 10.1007/BF00123361; Golenhofen N, 1999, J MOL CELL CARDIOL, V31, P569, DOI 10.1006/jmcc.1998.0892; Golenhofen N, 2002, J MOL CELL CARDIOL, V34, P309, DOI 10.1006/jmcc.2001.1513; Granzier H, 2002, J PHYSIOL-LONDON, V541, P335, DOI 10.1113/jphysiol.2001.014381; Gregorio CC, 1999, CURR OPIN CELL BIOL, V11, P18, DOI 10.1016/S0955-0674(99)80003-9; Gruen M, 1999, FEBS LETT, V453, P254, DOI 10.1016/S0014-5793(99)00727-9; Haley DA, 1998, J MOL BIOL, V277, P27, DOI 10.1006/jmbi.1997.1611; Helmes M, 1999, CIRC RES, V84, P1339, DOI 10.1161/01.RES.84.11.1339; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 2003, EXP EYE RES, V76, P145, DOI 10.1016/S0014-4835(02)00278-6; Horwitz J, 1998, METHOD ENZYMOL, V290, P365, DOI 10.1016/S0076-6879(98)90032-5; Horwitz J, 2000, SEMIN CELL DEV BIOL, V11, P53, DOI 10.1006/scdb.1999.0351; Ito K, 2001, J BIOL CHEM, V276, P5346, DOI 10.1074/jbc.M009004200; Jaenicke R, 2001, CRIT REV BIOCHEM MOL, V36, P435, DOI 10.1080/20014091074237; KANTOROW M, 1994, P NATL ACAD SCI USA, V91, P3112, DOI 10.1073/pnas.91.8.3112; Kentish JC, 2001, CIRC RES, V88, P1059, DOI 10.1161/hh1001.091640; Kim R, 1998, P NATL ACAD SCI USA, V95, P9129, DOI 10.1073/pnas.95.16.9129; Koteiche HA, 2003, J BIOL CHEM, V278, P10361, DOI 10.1074/jbc.M211851200; Koteiche HA, 1999, J MOL BIOL, V294, P561, DOI 10.1006/jmbi.1999.3242; Kulke M, 2001, CIRC RES, V89, P874, DOI 10.1161/hh2201.099453; Kunst G, 2000, CIRC RES, V86, P51, DOI 10.1161/01.RES.86.1.51; LAKEY A, 1990, EMBO J, V9, P3459, DOI 10.1002/j.1460-2075.1990.tb07554.x; Lange S, 2002, J CELL SCI, V115, P4925, DOI 10.1242/jcs.00181; Leake MC, 2003, FEBS LETT, V535, P55, DOI 10.1016/S0014-5793(02)03857-7; Li HB, 2002, NATURE, V418, P998, DOI 10.1038/nature00938; Linke WA, 2002, J MUSCLE RES CELL M, V23, P483, DOI 10.1023/A:1023462507254; Linke WA, 2002, J STRUCT BIOL, V137, P194, DOI 10.1006/jsbi.2002.4468; Linke WA, 1997, BIOPHYS J, V73, P905, DOI 10.1016/S0006-3495(97)78123-2; Linke WA, 1999, J CELL BIOL, V146, P631, DOI 10.1083/jcb.146.3.631; Linke WA, 1996, J MOL BIOL, V261, P62, DOI 10.1006/jmbi.1996.0441; Martin JL, 1997, CIRCULATION, V96, P4343; Mchaourab HS, 2002, J BIOL CHEM, V277, P40557, DOI 10.1074/jbc.M206250200; Mornon JP, 1998, INT J BIOL MACROMOL, V22, P219, DOI 10.1016/S0141-8130(98)00019-1; Neagoe C, 2002, CIRCULATION, V106, P1333, DOI 10.1161/01.CIR.0000029803.93022.93; Ray PS, 2001, FASEB J, V15, P393, DOI 10.1096/fj.00-0199com; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; SOTERIOU A, 1993, J CELL SCI, V104, P119; Tskhovrebova L, 1997, NATURE, V387, P308, DOI 10.1038/387308a0; van de Klundert FAJM, 1998, EUR J CELL BIOL, V75, P38, DOI 10.1016/S0171-9335(98)80044-7; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; VANDENOETELAAR PJM, 1990, BIOCHEMISTRY-US, V29, P3488, DOI 10.1021/bi00466a010; Watanabe K, 2002, J STRUCT BIOL, V137, P248, DOI 10.1006/jsbi.2002.4458; Yamasaki R, 2002, CIRC RES, V90, P1181, DOI 10.1161/01.RES.0000021115.24712.99; Yamasaki R, 2001, BIOPHYS J, V81, P2297, DOI 10.1016/S0006-3495(01)75876-6	52	123	127	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7917	7924		10.1074/jbc.M307473200	http://dx.doi.org/10.1074/jbc.M307473200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14676215	hybrid			2022-12-25	WOS:000189103300069
J	Li, DS; Yamada, T; Wang, F; Vulin, AI; Samuels, HH				Li, DS; Yamada, T; Wang, F; Vulin, AI; Samuels, HH			Novel roles of retinoid X receptor (RXR) and RXR ligand in dynamically modulating the activity of the thyroid hormone receptor/RXR heterodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTORS; FUNCTIONAL EVIDENCE; ALLOSTERIC CONTROL; RESPONSE ELEMENTS; ACID RECEPTORS; BINDING DOMAIN; CO-REPRESSOR; DNA; MEDIATE; TRANSCRIPTION	Many members of the type II nuclear receptor subfamily function as heterodimers with the retinoid X receptor (RXR). A permissive heterodimer (e.g. peroxisome proliferator-activated receptor/RXR) allows for ligand binding by both partners of the receptor complex. In contrast, RXR has been thought to be incapable of ligand binding in a nonpermissive heterodimer, such as that of thyroid hormone receptor (TR)/RXR, where it has been referred to as a silent partner. However, we recently presented functional evidence suggesting that RXR in the TR/RXR heterodimer can bind its natural ligand 9-cis-RA in cells. Here we extended our study of the interrelationship of TR and RXR. We examined the potential modulatory effect of RXR and its ligand on the activity of TR, primarily using a Gal4-TR chimera. This study led to several novel and unexpected findings: 1) heterodimerization of apo-RXRalpha (in the absence of 9-cis-RA) with Gal4-TR inhibits T3-mediated transactivation; 2) the inhibition of Gal4-TR activity by RXRalpha is further enhanced by 9-cis-RA; 3) two different RXR subtypes (alpha and beta) differentially modulate the activity of Gal4-TR; 4) the N-terminal A/B domains of RXR alpha and beta are largely responsible for their differential modulation of TR activity; and 5) the RXR ligand 9-cis-RA appears to differentially affect T3-mediated transactivation from the Gal4-TR/RXRalpha (which is inhibited by 9-cis-RA) and TRE-bound TR/RXRalpha(which is further activated by 9-cis-RA) heterodimers. Taken together, these results further support our recent proposal that the RXR component in a TR/RXR heterodimer is not silent and, more importantly, reveal novel aspects of regulation of the activity of the TR/RXR heterodimer by RXR and RXR ligand.	NYU, Sch Med, Dept Pharmacol, MSB 424, New York, NY 10016 USA	New York University	Li, DS (corresponding author), NYU, Sch Med, Dept Pharmacol, MSB 424, 550 1st Ave, New York, NY 10016 USA.	lid01@med.nyu.edu; herbert.samuels@med.nyu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK016636, R01DK016636, F32DK009581, R37DK016636] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09581, DK16636] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Blumberg B, 1998, GENE DEV, V12, P3149, DOI 10.1101/gad.12.20.3149; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; FORMAN BM, 1991, GENE, V105, P9, DOI 10.1016/0378-1119(91)90507-8; Germain P, 2002, NATURE, V415, P187, DOI 10.1038/415187a; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Kastner P, 1997, DEVELOPMENT, V124, P313; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kastner P, 1997, DEVELOPMENT, V124, P4749; Kersten S, 1996, BIOCHEMISTRY-US, V35, P3816, DOI 10.1021/bi952737k; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Krezel W, 1996, P NATL ACAD SCI USA, V93, P9010, DOI 10.1073/pnas.93.17.9010; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; Lala DS, 1996, NATURE, V383, P450, DOI 10.1038/383450a0; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Li DS, 2002, MOL CELL BIOL, V22, P5782, DOI 10.1128/MCB.22.16.5782-5792.2002; Li DS, 1999, MOL CELL BIOL, V19, P7191; Li DS, 2001, MOL CELL BIOL, V21, P8371, DOI 10.1128/MCB.21.24.8371-8384.2001; Mak HY, 1999, MOL CELL BIOL, V19, P3895; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; Mathur M, 2001, MOL CELL BIOL, V21, P2298, DOI 10.1128/MCB.21.7.2298-2311.2001; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; Minucci S, 1997, MOL CELL BIOL, V17, P644, DOI 10.1128/MCB.17.2.644; NELSON CC, 1994, MOL ENDOCRINOL, V8, P829, DOI 10.1210/me.8.7.829; QI JS, 1995, MOL CELL BIOL, V15, P1817; ROY DY, 1995, MOL CELL BIOL, V15, P6481; SAMUELS HH, 1982, RECENT PROG HORM RES, V38, P557; Schulman IG, 1997, GENE DEV, V11, P299, DOI 10.1101/gad.11.3.299; TITCOMB MW, 1994, MOL ENDOCRINOL, V8, P870, DOI 10.1210/me.8.7.870; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Wan YJY, 2000, MOL CELL BIOL, V20, P4436, DOI 10.1128/MCB.20.12.4436-4444.2000; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Zhang JS, 1997, MOL CELL BIOL, V17, P6887, DOI 10.1128/MCB.17.12.6887	42	34	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7427	7437		10.1074/jbc.M311596200	http://dx.doi.org/10.1074/jbc.M311596200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14668324	hybrid			2022-12-25	WOS:000189103300009
J	Shen, WH; Yin, YX; Broussard, SR; McCusker, RH; Freund, GG; Dantzer, R; Kelley, KW				Shen, WH; Yin, YX; Broussard, SR; McCusker, RH; Freund, GG; Dantzer, R; Kelley, KW			Tumor necrosis factor alpha inhibits cyclin A expression and retinoblastoma hyperphosphorylation triggered by insulin-like growth factor-I induction of new E2F-1 synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; UBIQUITIN-PROTEASOME PATHWAY; S-PHASE ENTRY; RECEPTOR SUBSTRATE-1; NEOPLASTIC TRANSFORMATION; TYROSINE PHOSPHORYLATION; GAMMA-INTERFERON; FAMILY PROTEINS; CARCINOMA CELLS; GENE-PRODUCT	Cyclin A is required for cell cycle S phase entry, and its overexpression contributes to tumorigenesis. Release of pre-existing E2Fs from inactive complexes of E2F and hypophosphorylated retinoblastoma (RB) is the prevailing dogma for E2F transcriptional activation of target genes such as cyclin A. Here we explored the hypothesis that new synthesis of E2F-1 is required for insulin-like growth factor-I (IGF-I) to induce cyclin A accumulation and RB hyperphosphorylation, events that are targeted by tumor necrosis factor alpha (TNFalpha) to arrest cell cycle progression. We first established that IGF-I increases expression of cyclin A, causes hyperphosphorylation of RB, and augments the mass of E2F-1 in a time-dependent manner. As expected, E2F-1 small interfering RNA blocks the ability of IGF-I to increase synthesis of E2F-1. Most important, this E2F-1 small interfering RNA also blocks the ability of IGF-I to increase cyclin A accumulation and to hyperphosphorylate RB. We next established that TNFalpha dose-dependently inhibits IGF-I-induced phosphorylation of both RB and histone H1 by cyclin A-dependent cyclin-dependent kinases. Cyclin-dependent kinase 2 (Cdk2) mediates this suppression because co-immunoprecipitation experiments revealed that TNFalpha reduces the amount of IGF-I-induced cyclin A that binds Cdk2, leading to a reduction in Cdk2 enzymatic activity. TNFalpha antagonizes the ability of IGF-I to increase mass of both E2F-1 and cyclin A but not cyclin E or D1. The cytostatic property of TNFalpha is also shown by its ability to block IGF-I-stimulated luciferase activity of a cyclin A promoter reporter. Deletion of an E2F recognition site from this reporter eliminates the regulatory effects of both IGF-I and TNFalpha on cyclin A transcription, indicating the essential role of E2F-1 in mediating their cross-talk. Collectively, these results establish that TNFalpha targets IGF-I-induced E2F-1 synthesis, leading to inhibition of the subsequent accumulation in cyclin A, formation of cyclin A-Cdk2 complexes, hyperphosphorylation of RB, and cell cycle arrest.	Univ Illinois, Dept Anim Sci, Immunophysiol Lab, Edward R Madigan Lab 207, Urbana, IL 61801 USA; Columbia Univ Coll Phys & Surg, Dept Radiat Oncol, New York, NY 10032 USA; Univ Illinois, Coll Med, Dept Pathol, Urbana, IL 61801 USA; Inst Francois Magendie Neurosci, UMR INRA Bordeaux 2, FRE CNRS, F-33077 Bordeaux, France	University of Illinois System; University of Illinois Urbana-Champaign; Columbia University; University of Illinois System; University of Illinois Urbana-Champaign; Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite de Bordeaux	Kelley, KW (corresponding author), Univ Illinois, Dept Anim Sci, Immunophysiol Lab, Edward R Madigan Lab 207, 1201 W Gregory Dr, Urbana, IL 61801 USA.	kwkelley@uiuc.edu		Dantzer, Robert/0000-0001-9399-6107; Kelley, Keith W./0000-0002-6837-8793; SHEN, WEN/0000-0002-5830-6518	NIAID NIH HHS [AI50442] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Beletsky IP, 2002, BIOCHEMISTRY-MOSCOW+, V67, P312, DOI 10.1023/A:1014884400144; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; BORTNER DM, 1995, CELL GROWTH DIFFER, V6, P1579; Brantl S, 2002, BBA-GENE STRUCT EXPR, V1575, P15, DOI 10.1016/S0167-4781(02)00280-4; Broussard SR, 2003, ENDOCRINOLOGY, V144, P2988, DOI 10.1210/en.2003-0087; Bukholm IRK, 2001, INT J CANCER, V93, P283, DOI 10.1002/ijc.1311; Buolamwini JK, 2000, CURR PHARM DESIGN, V6, P379, DOI 10.2174/1381612003400948; BURKE TW, 1993, IN VITRO CELL DEV-AN, V29A, P391; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; Chakravarthy MV, 2000, J BIOL CHEM, V275, P35942, DOI 10.1074/jbc.M005832200; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Dormond O, 2002, ANTICANCER RES, V22, P3159; Dupont J, 2000, J BIOL CHEM, V275, P35893, DOI 10.1074/jbc.M006741200; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Greene MW, 2003, J BIOL CHEM, V278, P8199, DOI 10.1074/jbc.M209153200; Hamelers IHL, 2002, J BIOL CHEM, V277, P47645, DOI 10.1074/jbc.M208727200; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Hu XT, 2002, J BIOL CHEM, V277, P16528, DOI 10.1074/jbc.M109929200; Jackson JG, 2001, ONCOGENE, V20, P7318, DOI 10.1038/sj.onc.1204920; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; Lassak A, 2002, J BIOL CHEM, V277, P17231, DOI 10.1074/jbc.M110885200; Liu Q, 1999, MOL CELL BIOL, V19, P6229; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Mauro L, 2003, J CELL PHYSIOL, V194, P108, DOI 10.1002/jcp.10207; Moneo V, 2003, J CELL BIOCHEM, V89, P484, DOI 10.1002/jcb.10529; Muller H, 1997, MOL CELL BIOL, V17, P5508; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; O'Connor JC, 2003, METABOLISM, V52, P666, DOI 10.1016/S0026-0495(03)00026-X; Orlovsky K, 2002, ONCOGENE, V21, P4997, DOI 10.1038/sj.onc.1205624; Pederson TM, 2001, DIABETES, V50, P24, DOI 10.2337/diabetes.50.1.24; PEEPER DS, 1995, ONCOGENE, V10, P39; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pollak M, 2000, EUR J CANCER, V36, P1224, DOI 10.1016/S0959-8049(00)00102-7; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; *SAS I INC, 2001, STAT AN SYST; SATOMOTO K, 1995, BIOCHEM BIOPH RES CO, V213, P1115, DOI 10.1006/bbrc.1995.2242; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Shen WH, 2002, CANCER RES, V62, P4746; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; Stevens C, 2003, ARCH BIOCHEM BIOPHYS, V412, P157, DOI 10.1016/S0003-9861(03)00054-7; SUTHERLAND RL, 1983, CANCER RES, V43, P3998; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Varma H, 2002, CANCER RES, V62, P3985; Venters HD, 1999, P NATL ACAD SCI USA, V96, P9879, DOI 10.1073/pnas.96.17.9879; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; Vincent AM, 2002, GROWTH HORM IGF RES, V12, P193, DOI 10.1016/S1096-6374(02)00017-5; Vivo C, 2001, ONCOGENE, V20, P1085, DOI 10.1038/sj.onc.1204199; Welniak LA, 2002, J LEUKOCYTE BIOL, V71, P381; Yam CH, 2002, CELL MOL LIFE SCI, V59, P1317, DOI 10.1007/s00018-002-8510-y; You H, 2002, J CELL BIOCHEM, V84, P211, DOI 10.1002/jcb.10037; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472	64	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7438	7446		10.1074/jbc.M310264200	http://dx.doi.org/10.1074/jbc.M310264200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14681231	hybrid			2022-12-25	WOS:000189103300010
J	Shimamoto, Y; Ishida, J; Yamagata, K; Saito, T; Kato, H; Matsuoka, T; Hirota, K; Daitoku, H; Nangaku, M; Yamagata, K; Fujii, H; Takeda, J; Fukamizu, A				Shimamoto, Y; Ishida, J; Yamagata, K; Saito, T; Kato, H; Matsuoka, T; Hirota, K; Daitoku, H; Nangaku, M; Yamagata, K; Fujii, H; Takeda, J; Fukamizu, A			Inhibitory effect of the small heterodimer partner on hepatocyte nuclear factor-4 mediates bile acid-induced repression of the human angiotensinogen gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION INITIATION SITE; ENHANCER CORE ELEMENT; DNA-BINDING DOMAIN; DUCT LIGATION; RECEPTOR SHP; X-RECEPTOR; TRANSGENIC MICE; TATA BOX; EXPRESSION; PROMOTER	Bile acids function as transcriptional regulators for the genes important in bile acid synthesis and cholesterol homeostasis. In this study, we identified angiotensinogen (ANG), the precursor of vasoactive octapeptide angiotensin II, as a novel target gene of bile acids. In human ANG transgenic mice, administration of cholic acid resulted in the down-regulation of human ANG gene expression in the liver. ANG gene expression in HepG2 cells was also repressed by chenodeoxycholic acid. Because the expression of small heterodimer partner (SHP) mRNA was induced by chenodeoxycholic acid in HepG2 cells, we analyzed the effects of SHP on the human ANG promoter. Promoter mutation analysis demonstrated that SHP repressed human ANG promoter activity through the element, which has been previously determined as a binding site for hepatocyte nuclear factor-4 (HNF-4). SHP repressed human ANG promoter activity only when the HNF-4 expression vector was cotransfected in HeLa cells. Furthermore, we found that SHP bound to the HNF-4 N-terminal region including the DNA-binding domain and activation function-1 and that SHP prevented HNF-4 from binding to the human ANG promoter. These results suggest that bile acids negatively regulate the human ANG gene through the inhibitory effect of SHP on HNF-4.	Univ Tsukuba, Inst Appl Biochem, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tokyo, Sch Med, Div Nephrol & Endocrinol, Bunkyo Ku, Tokyo 1138655, Japan; Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, Osaka 5650871, Japan; Niigata Univ, Sch Med, Dept Biochem, Niigata 951, Japan; Gunma Univ, Inst Mol & Cellular Regulat, Dept Cell Biol, Mol Genet Lab, Gunma 3718512, Japan	University of Tsukuba; University of Tokyo; Osaka University; Niigata University; Gunma University	Fukamizu, A (corresponding author), Univ Tsukuba, Inst Appl Biochem, Ctr Tsukuba Adv Res Alliance, Ten Noudai 1-1-1, Tsukuba, Ibaraki 3058577, Japan.	akif@tara.tsukuba.ac.jp	Nangaku, Masaomi/A-5300-2010; fukamizu, akiyoshi/J-5350-2012	fukamizu, akiyoshi/0000-0002-8786-6020; YAMAGATA, Kazuyuki/0000-0002-5804-6090				Chiang JYL, 2003, AM J PHYSIOL-GASTR L, V284, pG349, DOI 10.1152/ajpgi.00417.2002; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Corvol P, 1997, ENDOCR REV, V18, P662, DOI 10.1210/er.18.5.662; De Fabiani E, 2003, J BIOL CHEM, V278, P39124, DOI 10.1074/jbc.M305079200; FUKAMIZU A, 1990, J BIOL CHEM, V265, P7576; FUKAMIZU A, 1993, J BIOL CHEM, V268, P11617; Gines P, 1999, J AM SOC NEPHROL, V10, P1833; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Gupta S, 2001, J BIOL CHEM, V276, P15816, DOI 10.1074/jbc.M010878200; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; Hirota K, 2003, J BIOL CHEM, V278, P13056, DOI 10.1074/jbc.C200553200; Jiang GQ, 1997, MOL CELL BIOL, V17, P6546, DOI 10.1128/MCB.17.11.6546; Johansson L, 1999, J BIOL CHEM, V274, P345, DOI 10.1074/jbc.274.1.345; KOKUBU T, 1972, BIOCHEM PHARMACOL, V21, P209; Kovacic A, 2004, MOL ENDOCRINOL, V18, P252, DOI 10.1210/me.2003-0211; KUIPERS OP, 1991, NUCLEIC ACIDS RES, V19, P4558, DOI 10.1093/nar/19.16.4558; KullakUblick GA, 1996, HEPATOLOGY, V23, P1053; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Masuda N, 1997, BBA-GENE STRUCT EXPR, V1350, P27, DOI 10.1016/S0167-4781(96)00196-0; NAVEH Y, 1988, J HEPATOL, V6, P57, DOI 10.1016/S0168-8278(88)80462-8; NIBU Y, 1994, J BIOL CHEM, V269, P28598; NIBU Y, 1994, BIOCHEM BIOPH RES CO, V205, P1102, DOI 10.1006/bbrc.1994.2779; Nishizawa H, 2002, J BIOL CHEM, V277, P1586, DOI 10.1074/jbc.M104301200; Ourlin JC, 2003, MOL ENDOCRINOL, V17, P1693, DOI 10.1210/me.2002-0383; Rajas F, 2002, J BIOL CHEM, V277, P15736, DOI 10.1074/jbc.M200971200; Seel WG, 1998, MOL ENDOCRINOL, V12, P1551, DOI 10.1210/mend.12.10.0184; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Seol W, 1997, MOL CELL BIOL, V17, P7126, DOI 10.1128/MCB.17.12.7126; SHASHA SM, 1976, CLIN SCI MOL MED, V50, P533, DOI 10.1042/cs0500533; SHIMADA S, 1995, ENDOCRINE, V3, P543, DOI 10.1007/BF02738831; TAKAHASHI S, 1991, BIOCHEM BIOPH RES CO, V180, P1103, DOI 10.1016/S0006-291X(05)81180-5; UBEDA M, 1994, HEPATOLOGY, V19, P1431, DOI 10.1016/0270-9139(94)90239-9; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Yanai K, 1996, J BIOL CHEM, V271, P15981, DOI 10.1074/jbc.271.27.15981; Yanai K, 1997, BIOCHEM BIOPH RES CO, V237, P158, DOI 10.1006/bbrc.1997.7000; Yanai K, 1997, FEBS LETT, V412, P285, DOI 10.1016/S0014-5793(97)00802-8; Yanai K, 1999, J BIOL CHEM, V274, P34605, DOI 10.1074/jbc.274.49.34605; Yanai K, 1997, J BIOL CHEM, V272, P30558, DOI 10.1074/jbc.272.48.30558; Yoshida E, 1997, BIOCHEM BIOPH RES CO, V241, P664, DOI 10.1006/bbrc.1997.7871; Zhao A, 2003, J BIOL CHEM, V278, P28765, DOI 10.1074/jbc.M304568200	41	26	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7770	7776		10.1074/jbc.M310577200	http://dx.doi.org/10.1074/jbc.M310577200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14672953	hybrid			2022-12-25	WOS:000189103300050
J	Shan, SQ; Robson, ND; Cao, YT; Qiao, T; Li, CY; Kontos, CD; Garcia-Blanco, M; Dewhirst, MW				Shan, SQ; Robson, ND; Cao, YT; Qiao, T; Li, CY; Kontos, CD; Garcia-Blanco, M; Dewhirst, MW			Responses of vascular endothelial cells to angiogenic signaling are important for tumor cell survival	FASEB JOURNAL			English	Article						murine mammary carcinoma; murine melanoma; basic fibroblast growth factor; soluble Tie-2; green fluorescence protein	FIBROBLAST-GROWTH-FACTOR; SKIN WINDOW CHAMBERS; FACTOR RECEPTORS; TIE2 RECEPTOR; IN-VIVO; EXPRESSION; ANGIOPOIETIN-1; CANCER; VEGF; INHIBITION	Neoplastic cells overexpress several angiogenic cytokines, which stimulate neovascularization. Whether the responses of the host endothelial cells to these signaling molecules affect tumor cells during early tumorigenesis has not been investigated. We investigated pre-angiogenic tumor cell survival and angiogenesis initiation by two murine tumor lines (4T1 mammary carcinoma and B16 melanoma), which constitutively expressed GFP, in dorsal skin-fold window chambers of mice treated with extracellular domain of Tie-2 (ExTek) or bFGF. ExTek reduced tumor cell survival, retarded tumor growth, and inhibited angiogenesis onset compared with controls. bFGF increased tumor cell survival and promoted earlier angiogenesis and tumor growth. Neither bFGF nor ExTek affected cell proliferation in vitro. RT-PCR showed mRNA expression of bFGF receptor 2 (FGFR2)IIIB, which does not bind bFGF efficiently, by 4T1 cells and B16 cells express FGFR1 but not FGFR2. B16 cells expressed angiopoietin (Ang) 2, but neither cell line expresses Ang1. Both tumor lines express VEGF. These findings suggested that effects of bFGF and ExTek on tumor cell survival and angiogenesis were not due to direct action but were instead a result of paracrine factors secreted by endothelial cells. These subsequent signals form endothelial cells promote early survival and proliferation of disseminated tumor cells before onset of angiogenesis.	Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Genet, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Dewhirst, MW (corresponding author), Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA.	dewhirst@radonc.duke.edu	Dewhirst, Mark/Q-1302-2019; Li, Chuan-Yuan/H-4148-2013	Dewhirst, Mark/0000-0003-3459-6546; Kontos, Christopher/0000-0002-8056-3115				Abe Mayumi, 2001, Angiogenesis, V4, P289, DOI 10.1023/A:1016018617152; Ankoma-Sey V, 1998, ONCOGENE, V17, P115, DOI 10.1038/sj.onc.1201912; ASAHARA T, 1995, CIRCULATION, V92, P365, DOI 10.1161/01.CIR.92.9.365; Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233; BOOCOCK CA, 1995, JNCI-J NATL CANCER I, V87, P506, DOI 10.1093/jnci/87.7.506; Browder T, 2000, CANCER RES, V60, P1878; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Da Silva-Azevedo L, 2002, BIOCHEM BIOPH RES CO, V297, P1270, DOI 10.1016/S0006-291X(02)02370-7; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Dow JK, 2000, UROLOGY, V55, P800, DOI 10.1016/S0090-4295(00)00457-X; DUBOIS NA, 1991, EXP CELL RES, V196, P302, DOI 10.1016/0014-4827(91)90265-V; Folkman J, 2000, JNCI-J NATL CANCER I, V92, P94, DOI 10.1093/jnci/92.2.94; Folkman J, 2001, SCIENCE, V293, P227, DOI 10.1126/science.1062892; Friedl P, 1997, CANCER RES, V57, P2061; Garcia-Barros M, 2003, SCIENCE, V300, P1155, DOI 10.1126/science.1082504; GOTO F, 1993, LAB INVEST, V69, P508; Graeven U, 2001, CANCER RES, V61, P7282; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Holash J, 1999, ONCOGENE, V18, P5356, DOI 10.1038/sj.onc.1203035; Huang Q, 1999, NAT BIOTECHNOL, V17, P1033, DOI 10.1038/13736; INGBER D, 1991, J CELL BIOCHEM, V47, P236, DOI 10.1002/jcb.240470309; Jackson MW, 2002, CANCER RES, V62, P854; Kumar-Singh S, 1999, J PATHOL, V189, P72, DOI 10.1002/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0; Laurie R, 2001, LIBRARY, V2, P83, DOI 10.1093/library/2.1.83; Li CY, 2000, JNCI-J NATL CANCER I, V92, P143, DOI 10.1093/jnci/92.2.143; Lin PN, 1998, CELL GROWTH DIFFER, V9, P49; Lin PN, 1997, J CLIN INVEST, V100, P2072, DOI 10.1172/JCI119740; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Masood R, 1997, P NATL ACAD SCI USA, V94, P979, DOI 10.1073/pnas.94.3.979; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Oh H, 1999, J BIOL CHEM, V274, P15732, DOI 10.1074/jbc.274.22.15732; Papapetropoulos A, 1999, LAB INVEST, V79, P213; Peters KG, 1998, BRIT J CANCER, V77, P51, DOI 10.1038/bjc.1998.8; POLVERINI PJ, 1991, ASSAY PURIFICATION N, V198; RAK JW, 1995, ANTI-CANCER DRUG, V6, P3, DOI 10.1097/00001813-199502000-00001; Riedel F, 2000, HEAD NECK-J SCI SPEC, V22, P183, DOI 10.1002/(SICI)1097-0347(200003)22:2<183::AID-HED11>3.0.CO;2-R; Rofstad EK, 2000, CANCER RES, V60, P4932; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Segall JE, 1996, CLIN EXP METASTAS, V14, P61, DOI 10.1007/BF00157687; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; SHAN S, 1997, BRIT J CANCER, V46, P429; Shan SQ, 2001, CLIN CANCER RES, V7, P2590; Siemeister G, 1999, CANCER RES, V59, P3185; STAVRI GT, 1995, CIRCULATION, V92, P11, DOI 10.1161/01.CIR.92.1.11; Stratmann A, 1998, AM J PATHOL, V153, P1459, DOI 10.1016/S0002-9440(10)65733-1; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; White RR, 2003, P NATL ACAD SCI USA, V100, P5028, DOI 10.1073/pnas.0831159100; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; Yuan HT, 1999, J AM SOC NEPHROL, V10, P1722	51	32	33	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					326	+		10.1096/fj.03-0765fje	http://dx.doi.org/10.1096/fj.03-0765fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14688196				2022-12-25	WOS:000188067500002
J	Soudais, C; Skander, N; Kremer, EJ				Soudais, C; Skander, N; Kremer, EJ			Long-term in vivo transduction of neurons throughout the rat central nervous system using novel helper-dependent CAV-2 vectors	FASEB JOURNAL			English	Article						adenovirus; gutless; gene therapy; neurodegenerative disorders; canine	CAPACITY ADENOVIRAL VECTORS; VIRAL CODING SEQUENCES; MEDIATED GENE-TRANSFER; BASAL NUCLEUS; CANINE ADENOVIRUS; SENILE DEMENTIA; PARKINSONS-DISEASE; PACKAGING SIGNAL; THERAPY; MEYNERT	Numerous genetic and environmental causes, variable pathophysiologies, and the blood-brain barrier create a formidable challenge for the study and treatment of neurodegenerative diseases affecting the central nervous system. Although there are many intracellular strategies to address neurodegeneration, for example, which transgene to use, one fundamental criterion for the long-term survival of neurons may be their genetic modification. Here, we describe the generation and in vivo efficacy of helper-dependent canine adenovirus (CAV-2) vectors that preferentially transduced neurons and efficiently trafficked via axonal retrograde transport. We used a flexible strategy and the synergy between Cre/loxP and nonlethal packaging-defective helper vectors to generate high titer helper-dependent vector stocks. One year after striatal injections in the rat brain, we found stable, high-level expression in striatal neurons, similar to50% of the dopaminergic neurons of the substantia nigra, and the cholinergic neurons in the basal nuclei of Meynert. Due to the intrinsic properties of helper-dependent CAV-2 vectors (27-kb cloning capacity; low preexisting, innate, and induced immunogenicity; retrograde transport; and long-term transgene expression), they will aid fundamental and applied studies in neurobiology. Moreover, helper-dependent CAV-2 vectors may be clinically relevant for the treatment of many neurodegenerative diseases.	CNRS, UMR 5535, IGMM, F-34293 Montpellier, France; Fac Med Necker enfants malad, INSERM, U550, F-75015 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Kremer, EJ (corresponding author), CNRS, UMR 5535, IGMM, IFR 122,1919 Route de Mende, F-34293 Montpellier, France.	kremer@igm.cnrs-mop.fr	Kremer, EJ/P-9838-2019; Kremer, Eric J/D-3734-2013; soudais, claire/F-9756-2016	Kremer, EJ/0000-0001-6114-7530; soudais, claire/0000-0002-4387-6649				AKLI S, 1993, NAT GENET, V3, P224, DOI 10.1038/ng0393-224; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Amalfitano Andrea, 2002, Current Gene Therapy, V2, P111, DOI 10.2174/1566523024605618; ANDERS K H, 1990, Pediatric Neurosurgery, V16, P316, DOI 10.1159/000120551; Bergen K, 1997, COPEIA, P275, DOI 10.2307/1447747; BOTH GW, 2002, ADENOVIRAL VECTORS G, P447; Brooks AI, 2002, P NATL ACAD SCI USA, V99, P6216, DOI 10.1073/pnas.082011999; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; Chillon M, 2001, HUM GENE THER, V12, P1815, DOI 10.1089/104303401750476302; Conner JM, 2003, NEURON, V38, P819, DOI 10.1016/S0896-6273(03)00288-5; Ehrengruber MU, 2002, MOL NEUROBIOL, V26, P183, DOI 10.1385/MN:26:2-3:183; FLOMENBERG P, 1995, J INFECT DIS, V171, P1090, DOI 10.1093/infdis/171.5.1090; GLUZMAN Y, 1983, J VIROL, V45, P91, DOI 10.1128/JVI.45.1.91-103.1983; Greber UF, 2002, CELL MOL LIFE SCI, V59, P608, DOI 10.1007/s00018-002-8453-3; Hartigan-O'Connor D, 2002, HUM GENE THER, V13, P519, DOI 10.1089/10430340252809810; Hartigan-O'Connor D, 2002, METHOD ENZYMOL, V346, P224; Hehir KM, 1996, J VIROL, V70, P8459, DOI 10.1128/JVI.70.12.8459-8467.1996; Hsich G, 2002, HUM GENE THER, V13, P579, DOI 10.1089/10430340252837198; Keriel A, 2003, M S-MED SCI, V19, P1048, DOI 10.1051/medsci/200319111048; Kilgard M, 2003, NEURON, V38, P678, DOI 10.1016/S0896-6273(03)00327-1; Kochanek S, 1999, HUM GENE THER, V10, P2451, DOI 10.1089/10430349950016807; Kochanek S, 1996, P NATL ACAD SCI USA, V93, P5731, DOI 10.1073/pnas.93.12.5731; Kochanek S, 2001, CURR OPIN MOL THER, V3, P454; Korczyn A. D., 2001, J NEUROL S3, V248, P1, DOI DOI 10.1007/PL00022916; Kremer EJ, 2000, J VIROL, V74, P505, DOI 10.1128/JVI.74.1.505-512.2000; KREMER EJ, 2004, IN PRESS J GENE MED; Lilley C. E., 2001, Current Gene Therapy, V1, P339, DOI 10.2174/1566523013348346; Loser P, 1998, J VIROL, V72, P180; Loser Peter, 2002, Curr Gene Ther, V2, P161, DOI 10.2174/1566523024605555; Lowenstein PR, 2002, TRENDS IMMUNOL, V23, P23, DOI 10.1016/S1471-4906(01)02063-4; Lowenstein PR, 2002, METHOD ENZYMOL, V346, P292; Martinez-Serrano A, 2000, NAT MED, V6, P483, DOI 10.1038/74918; Mittereder N, 1996, J VIROL, V70, P7498, DOI 10.1128/JVI.70.11.7498-7509.1996; Morante-Oria J, 2003, P NATL ACAD SCI USA, V100, P12468, DOI 10.1073/pnas.1633692100; Morsy MA, 1998, P NATL ACAD SCI USA, V95, P7866, DOI 10.1073/pnas.95.14.7866; Morsy MA, 1999, MOL MED TODAY, V5, P18, DOI 10.1016/S1357-4310(98)01376-8; Nabel GJ, 1999, P NATL ACAD SCI USA, V96, P324, DOI 10.1073/pnas.96.2.324; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; Ng P, 2002, J VIROL, V76, P4181, DOI 10.1128/JVI.76.9.4181-4189.2002; O'Neal VK, 2000, MOL MED, V6, P179, DOI 10.1007/BF03402113; Oorschot DE, 1996, J COMP NEUROL, V366, P580, DOI 10.1002/(SICI)1096-9861(19960318)366:4<580::AID-CNE3>3.0.CO;2-0; Parks RJ, 1996, P NATL ACAD SCI USA, V93, P13565, DOI 10.1073/pnas.93.24.13565; Passini MA, 2002, J NEUROSCI, V22, P6437; PEARSON RCA, 1983, BRAIN RES, V289, P375, DOI 10.1016/0006-8993(83)90046-X; PEARSON RCA, 1983, BRAIN RES, V261, P321, DOI 10.1016/0006-8993(83)90637-6; Reddy PS, 2002, MOL THER, V5, P63, DOI 10.1006/mthe.2001.0510; ROSSOR MN, 1982, NEUROSCI LETT, V28, P217, DOI 10.1016/0304-3940(82)90155-0; Sandig V, 2000, P NATL ACAD SCI USA, V97, P1002, DOI 10.1073/pnas.97.3.1002; Sapolsky RM, 2003, NAT REV NEUROSCI, V4, P61, DOI 10.1038/nrn1006; Sato M, 2002, GENE THER, V9, P472, DOI 10.1038/sj.gt.3301668; Schiedner G, 2002, J VIROL, V76, P1600, DOI 10.1128/JVI.76.4.1600-1609.2002; ShammahLagnado SJ, 1996, J COMP NEUROL, V376, P489, DOI 10.1002/(SICI)1096-9861(19961216)376:3<489::AID-CNE10>3.0.CO;2-H; Shu SY, 2003, J NEUROSCI RES, V71, P751, DOI 10.1002/jnr.10518; Soudais C, 2000, J VIROL, V74, P10639, DOI 10.1128/JVI.74.22.10639-10649.2000; Soudais C, 2001, FASEB J, V15, P2283, DOI 10.1096/fj.01-0321fje; Soudais C, 2001, MOL THER, V3, P631, DOI 10.1006/mthe.2001.0263; Stripecke R, 1999, GENE THER, V6, P1305, DOI 10.1038/sj.gt.3300951; TAGLIAVINI F, 1984, ACTA NEUROL SCAND, V70, P20; TAGLIAVINI F, 1983, ACTA NEUROPATHOL, V61, P157, DOI 10.1007/BF00697397; TAGLIAVINI F, 1983, LANCET, V1, P469; TAGLIAVINI F, 1985, ACTA NEUROPATHOL, V66, P127, DOI 10.1007/BF00688687; Tsuchiya K, 2002, NEUROPATHOLOGY, V22, P77, DOI 10.1046/j.1440-1789.2002.00429.x; Worgall S, 1997, HUM GENE THER, V8, P1675, DOI 10.1089/hum.1997.8.14-1675	63	89	92	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					391	+		10.1096/fj.03-0438fje	http://dx.doi.org/10.1096/fj.03-0438fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14688208				2022-12-25	WOS:000188067500014
J	Niu, JG; Li, ZK; Peng, BL; Chiao, PJ				Niu, JG; Li, ZK; Peng, BL; Chiao, PJ			Identification of an autoregulatory feedback pathway involving interleukin-1 alpha in induction of constitutive NF-kappa B activation in pancreatic cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; TRANSCRIPTION FACTOR; EXPRESSION; ADENOCARCINOMA; GROWTH; AP-1; PROTEINS; ENHANCER; LINE; GENE	We previously reported that NF-kappaB is constitutively activated in most human pancreatic cancer tissues and cell lines but not in normal pancreatic tissues and immortalized pancreatic ductal epithelial cells. IkappaBalphaM-mediated inhibition of constitutive NF-kappaB activity in human pancreatic cancer cells suppressed tumorigenesis and liver metastasis in an orthotopic nude mouse model, suggesting that constitutive NF-kappaB activation plays an important role in pancreatic tumor progression and metastasis. However, the underlying mechanism by which NF-kappaB is activated in pancreatic cancer remains to be elucidated. In this study, we found that an autocrine mechanism accounts for the constitutive activation of NF-kappaB in metastatic human pancreatic cancer cell lines. Further investigation showed that interleukin-1alpha was the primary cytokine secreted by these cells that activates NF-kappaB. Neutralization of interleukin-1alpha activity suppressed the constitutive activation of NF-kappaB and the expression of its downstream target gene, urokinase-type plasminogen activator, in metastatic pancreatic cancer cell lines. Our results demonstrate that regulation of interleukin-1alpha expression is primarily dependent on AP-1 activity, which is in part induced by signaling pathways that are epidermal growth factor receptor-dependent and - independent. In conclusion, our findings suggest a possible mechanism for the constitutive activation of NF-kappaB in metastatic human pancreatic cancer cells and a possible missing mechanistic link between inflammation and cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Unit 107, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, Houston Hlth Sci Ctr, Grad Sch Biomed Sci, Program Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston	Chiao, PJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Unit 107, 1515 Holcombe Blvd, Houston, TX 77030 USA.	pjchiao@mdanderson.org			NCI NIH HHS [CA78778-01, CA097159, CA73675-01] Funding Source: Medline; PHS HHS [R21PA-98-029] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097159, P01CA078778, R29CA073675] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andersen K, 1998, ANTICANCER RES, V18, P3299; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Apte RN, 2002, SEMIN CANCER BIOL, V12, P277, DOI 10.1016/S1044-579X(02)00014-7; Arend WR, 2002, CYTOKINE GROWTH F R, V13, P323, DOI 10.1016/S1359-6101(02)00020-5; Arlt A, 2002, CANCER RES, V62, P910; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Bailly S, 1996, EUR CYTOKINE NETW, V7, P125; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Breslin TM, 2001, ANN SURG ONCOL, V8, P123, DOI 10.1007/s10434-001-0123-4; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CASTELLI C, 1994, CANCER RES, V54, P4785; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; DEMETRI GD, 1990, J CLIN INVEST, V86, P1261, DOI 10.1172/JCI114833; Dong QG, 2002, ONCOGENE, V21, P6510, DOI 10.1038/sj.onc.1205848; Emmerich F, 1999, BLOOD, V94, P3129, DOI 10.1182/blood.V94.9.3129.421k03_3129_3134; Frazier ML, 1996, INT J PANCREATOL, V19, P31, DOI 10.1007/BF02788373; FRAZIER ML, 1990, PANCREAS, V5, P8, DOI 10.1097/00006676-199001000-00002; Fujioka S, 2003, ONCOGENE, V22, P1365, DOI 10.1038/sj.onc.1206323; Fujioka S, 2003, CLIN CANCER RES, V9, P346; FURUTANI Y, 1986, NUCLEIC ACIDS RES, V14, P3167, DOI 10.1093/nar/14.8.3167; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilmore TD, 1996, ONCOGENE, V13, P1367; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Li JX, 2003, ONCOGENE, V22, P211, DOI 10.1038/sj.onc.1206102; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Lotem J, 2002, ONCOGENE, V21, P3284, DOI 10.1038/sj.onc.1205319; Matsuda K, 2002, CANCER RES, V62, P5611; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; Mori N, 1996, BLOOD, V87, P3410, DOI 10.1182/blood.V87.8.3410.bloodjournal8783410; Nguyen M, 1997, AM J PATHOL, V150, P1307; Ondrey FG, 1999, MOL CARCINOGEN, V26, P119, DOI 10.1002/(SICI)1098-2744(199910)26:2<119::AID-MC6>3.0.CO;2-N; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Panozzo MP, 1996, INT J CLIN LAB RES, V26, P240, DOI 10.1007/BF02602956; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; Sawai H, 2001, PANCREAS, V23, P399, DOI 10.1097/00006676-200111000-00011; Schmid-Alliana A, 1998, J BIOL CHEM, V273, P3394, DOI 10.1074/jbc.273.6.3394; Sclabas GM, 2003, J GASTROINTEST SURG, V7, P37, DOI 10.1016/S1091-255X(02)00088-4; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SMITH JJ, 1987, P NATL ACAD SCI USA, V84, P7567, DOI 10.1073/pnas.84.21.7567; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Vale T, 2001, CANCER RES, V61, P602; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; Wang WX, 1999, ONCOGENE, V18, P4554, DOI 10.1038/sj.onc.1202833; Wang WX, 1999, CLIN CANCER RES, V5, P119; Wilson J, 2002, SEMIN CANCER BIOL, V12, P113, DOI 10.1006/scbi.2001.0419; Wolf JS, 2001, CLIN CANCER RES, V7, P1812; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506	58	89	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16452	16462		10.1074/jbc.M309789200	http://dx.doi.org/10.1074/jbc.M309789200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14679213	hybrid			2022-12-25	WOS:000220747900093
J	de Avalos, SV; Okamoto, Y; Hannun, YA				de Avalos, SV; Okamoto, Y; Hannun, YA			Activation and localization of inositol phosphosphingolipid phospholipase C, Isc1p, to the mitochondria during growth of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTRAL SPHINGOMYELINASE; ENDOPLASMIC-RETICULUM; CERAMIDE; YEAST; CELL; MEMBRANE; PROTEIN; STRESS; SPHINGOLIPIDS; CLONING	Sphingomyelinases (SMases) generate ceramides, which are known to regulate cell cycle and growth. Only one enzyme that belongs to the extended family of SMases is present in S. cerevisiae, Isc1p; however, little is known about its regulation or physiologic function. Deletion of ISC1 in S. cerevisiae resulted in a growth defect, and the slow growth phenotype was rescued by plasmid-borne expression of Isc1, confirming its role in growth. The levels of phytoceramide exhibited an Isc1p-dependent increase of similar to4-fold after 24 h of growth. In addition, the specific activity of Isc1p was significantly elevated (>3-fold) between the early logarithmic and the late logarithmic/start of stationary phases of growth. The activation of the enzyme was not associated with increased levels of the protein, indicating that the mechanism is independent of transcription/translation. Interestingly, this activation was lost upon delipidation of the enzyme, raising the possibility of regulation by associated lipids. Confocal microscopy revealed that the enzyme was predominantly in the ER during early growth but became associated with mitochondria in late logarithmic growth. These results were also supported by differential centrifugation and isolation of mitochondria and further confirmed in mitochondria purified using sucrose gradients at the different stages of growth. These results reveal that the activity and localization of Isc1p are regulated in a growth-dependent manner. A novel mechanism for activation of Isc1p through localization to mitochondria is proposed. The results also suggest a role for Isc1p-generated ceramides in optimal regulation of growth.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA.	hannun@musc.edu	OKAMOTO, Yasuo/J-8438-2015		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Achleitner G, 1999, EUR J BIOCHEM, V264, P545, DOI 10.1046/j.1432-1327.1999.00658.x; Andrieu-Abadie N, 2001, FREE RADICAL BIO MED, V31, P717, DOI 10.1016/S0891-5849(01)00655-4; Bielawska A, 2000, METHOD ENZYMOL, V311, P518; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; Bligh E.G., 1959, CAN J BIOCH PHYSL, V37; Boldogh IR, 2001, P NATL ACAD SCI USA, V98, P3162, DOI 10.1073/pnas.051494698; Borgese N, 2001, MOL BIOL CELL, V12, P2482, DOI 10.1091/mbc.12.8.2482; Chalfant CE, 2001, J BIOL CHEM, V276, P44848, DOI 10.1074/jbc.M106291200; Chung N, 2000, J BIOL CHEM, V275, P17229, DOI 10.1074/jbc.C000229200; de Avalos SV, 2002, J BIOL CHEM, V277, P639, DOI 10.1074/jbc.M109037200; DEAVALOS SV, 2004, IN PRESS BIOACTIVE L; DICKSON RC, 1990, MOL CELL BIOL, V10, P2176, DOI 10.1128/MCB.10.5.2176; Egner A, 2002, P NATL ACAD SCI USA, V99, P3370, DOI 10.1073/pnas.052545099; Feoktistova A, 2001, GENETICS, V158, P1397; FOLCH J, 1957, J BIOL CHEM, V226, P497; GAIGG B, 1995, BBA-BIOMEMBRANES, V1234, P214, DOI 10.1016/0005-2736(94)00287-Y; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HOFFMANN HP, 1973, SCIENCE, V181, P749, DOI 10.1126/science.181.4101.749; Hofmann K, 2000, P NATL ACAD SCI USA, V97, P5895, DOI 10.1073/pnas.97.11.5895; Jazwinski SM, 2002, INT J BIOCHEM CELL B, V34, P1491, DOI 10.1016/S1357-2725(02)00044-4; Jenkins GM, 2001, J BIOL CHEM, V276, P8574, DOI 10.1074/jbc.M007425200; Kaiser CA, 2002, METHOD ENZYMOL, V351, P325; Kinner A, 2003, FEBS LETT, V549, P135, DOI 10.1016/S0014-5793(03)00801-9; Liu B, 1998, J BIOL CHEM, V273, P34472, DOI 10.1074/jbc.273.51.34472; Mao CG, 2000, J BIOL CHEM, V275, P31369, DOI 10.1074/jbc.M003683200; Marchesini N, 2003, J BIOL CHEM, V278, P13775, DOI 10.1074/jbc.M212262200; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; Mizutani Y, 2000, BBA-MOL CELL BIOL L, V1485, P236, DOI 10.1016/S1388-1981(00)00059-7; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; Okamoto Y, 2003, BIOCHEMISTRY-US, V42, P7855, DOI 10.1021/bi0341354; Okamoto Y, 2002, J BIOL CHEM, V277, P46470, DOI 10.1074/jbc.M207779200; Onyango P, 2002, P NATL ACAD SCI USA, V99, P13653, DOI 10.1073/pnas.222538099; Perry David K, 2003, Cancer Treat Res, V115, P345; Perry DK, 2000, METHOD ENZYMOL, V312, P22; RIEDER E, 2000, CURRENT PROTOCOLS CE; Ruvolo PP, 2002, J BIOL CHEM, V277, P22847, DOI 10.1074/jbc.M201830200; Sawai H, 2000, J BIOL CHEM, V275, P39793, DOI 10.1074/jbc.M007721200; Schumacher MM, 2002, J BIOL CHEM, V277, P51033, DOI 10.1074/jbc.M205301200; Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200; WALWORTH NC, 1989, METHOD CELL BIOL, V31, P335; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627; Zanolari B, 2000, EMBO J, V19, P2824, DOI 10.1093/emboj/19.12.2824; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	45	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11537	11545		10.1074/jbc.M309586200	http://dx.doi.org/10.1074/jbc.M309586200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699160	hybrid			2022-12-25	WOS:000220157600086
J	Ido, H; Harada, K; Futaki, S; Hayashi, Y; Nishiuchi, R; Natsuka, Y; Li, SL; Wada, Y; Combs, AC; Ervasti, JM; Sekiguchi, K				Ido, H; Harada, K; Futaki, S; Hayashi, Y; Nishiuchi, R; Natsuka, Y; Li, SL; Wada, Y; Combs, AC; Ervasti, JM; Sekiguchi, K			Molecular dissection of the alpha-dystroglycan- and integrin-binding sites within the globular domain of human laminin-10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTES CELL-ADHESION; CHAIN-G-DOMAIN; LG MODULES; MAJOR HEPARIN; MIGRATION; IDENTIFICATION; ALPHA-3-BETA-1; ALPHA(3)BETA(1); ALPHA-6-BETA-1; PURIFICATION	The adhesive interactions of cells with laminins are mediated by integrins and non-integrin-type receptors such as alpha-dystroglycan and syndecans. Laminins bind to these receptors at the C-terminal globular domain of their alpha chains, but the regions recognized by these receptors have not been mapped precisely. In this study, we sought to locate the binding sites of laminin-10 (alpha5beta1gamma1) for alpha(3)beta(1) and alpha(6)beta(1) integrins and alpha-dystroglycan through the production of a series of recombinant laminin-10 proteins with deletions of the LG (laminin G-like) modules within the globular domain. We found that deletion of the LG4-5 modules did not compromise the binding of laminin-10 to alpha(3)beta(1) and alpha(6)beta(1) integrins but completely abrogated its binding to alpha-dystroglycan. Further deletion up to the LG3 module resulted in loss of its binding to the integrins, underlining the importance of LG3 for integrin binding by laminin-10. When expressed individually as fusion proteins with glutathione S-transferase or the N-terminal 70-kDa region of fibronectin, only LG4 was capable of binding to alpha-dystroglycan, whereas neither LG3 nor any of the other LG modules retained the ability to bind to the integrins. Site-directed mutagenesis of the LG3 and LG4 modules indicated that Asp-3198 in the LG3 module is involved in the integrin binding by laminin-10, whereas multiple basic amino acid residues in the putative loop regions are involved synergistically in the alpha-dystroglycan binding by the LG4 module.	Osaka Univ, Inst Prot Res, Div Prot Chem, Suita, Osaka 5650871, Japan; Aichi Med Univ, Japan Sci & Technol Agcy, ERATO, Sekiguchi Biomatrix Signaling Project, Aichi 4801195, Japan; Osaka Med Ctr Maternal & Child Hlth, Res Inst, Osaka 5941101, Japan; Univ Wisconsin, Sch Med, Dept Physiol, Madison, WI 53706 USA	Osaka University; Aichi Medical University; Japan Science & Technology Agency (JST); University of Wisconsin System; University of Wisconsin Madison	Sekiguchi, K (corresponding author), Osaka Univ, Inst Prot Res, Div Prot Chem, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.	sekiguch@protein.osaka-u.ac.jp	Ervasti, James/AAZ-4786-2020; Hayashi, Yoshitaka/I-6168-2014	Hayashi, Yoshitaka/0000-0002-7557-4303				Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; Andac Z, 1999, J MOL BIOL, V287, P253, DOI 10.1006/jmbi.1999.2606; AOTA S, 1994, J BIOL CHEM, V269, P24756; BRANCACCIO A, 1995, FEBS LETT, V368, P139, DOI 10.1016/0014-5793(95)00628-M; Chiba A, 1997, J BIOL CHEM, V272, P2156; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; DEUTZMANN R, 1990, EUR J BIOCHEM, V191, P513, DOI 10.1111/j.1432-1033.1990.tb19151.x; Doi M, 2002, J BIOL CHEM, V277, P12741, DOI 10.1074/jbc.M111228200; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Fujiwara H, 2001, J BIOL CHEM, V276, P17550, DOI 10.1074/jbc.M010155200; GEE SH, 1993, J BIOL CHEM, V268, P14972; Gu JG, 2002, J BIOL CHEM, V277, P19922, DOI 10.1074/jbc.M200383200; Gu JG, 2001, J BIOL CHEM, V276, P27090, DOI 10.1074/jbc.M102284200; Hayashi Y, 2002, BIOCHEM BIOPH RES CO, V299, P498, DOI 10.1016/S0006-291X(02)02642-6; Henry MD, 1998, CELL, V95, P859, DOI 10.1016/S0092-8674(00)81708-0; Henry MD, 1999, CURR OPIN CELL BIOL, V11, P602, DOI 10.1016/S0955-0674(99)00024-1; Hirosaki T, 2000, J BIOL CHEM, V275, P22495, DOI 10.1074/jbc.M001326200; Hirosaki T, 2002, J BIOL CHEM, V277, P49287, DOI 10.1074/jbc.M111096200; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; HUMPHRIES MJ, 1990, J CELL SCI, V97, P585; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kariya Y, 2003, J CELL BIOCHEM, V88, P506, DOI 10.1002/jcb.10350; Kikkawa Y, 1998, J BIOL CHEM, V273, P15854, DOI 10.1074/jbc.273.25.15854; Kikkawa Y, 2000, J CELL SCI, V113, P869; KUNNEKEN K, 2003, J BIOL CHEM; Li J, 2003, EMBO J, V22, P2400, DOI 10.1093/emboj/cdg239; MARINKOVICH MP, 1992, J CELL BIOL, V119, P695, DOI 10.1083/jcb.119.3.695; MATSUYAMA S, 1994, J BIOCHEM, V116, P898, DOI 10.1093/oxfordjournals.jbchem.a124613; McDearmon EL, 1998, J BIOL CHEM, V273, P24139, DOI 10.1074/jbc.273.37.24139; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Miner JH, 1998, J CELL BIOL, V143, P1713, DOI 10.1083/jcb.143.6.1713; Mizushima H, 1997, CELL GROWTH DIFFER, V8, P979; Nielsen PK, 2000, J BIOL CHEM, V275, P14517, DOI 10.1074/jbc.275.19.14517; Nishiuchi R, 2003, J BIOCHEM, V134, P497, DOI 10.1093/jb/mvg185; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; Okamoto O, 2003, J BIOL CHEM, V278, P44168, DOI 10.1074/jbc.M300726200; Okazaki I, 2002, J BIOL CHEM, V277, P37070, DOI 10.1074/jbc.M201672200; Pall EA, 1996, J BIOL CHEM, V271, P3817; Shang ML, 2001, J BIOL CHEM, V276, P33045, DOI 10.1074/jbc.M100798200; Smirnov SP, 2002, J BIOL CHEM, V277, P18928, DOI 10.1074/jbc.M201880200; Talts JF, 2000, J BIOL CHEM, V275, P35192, DOI 10.1074/jbc.M003261200; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; Timpl R, 2000, MATRIX BIOL, V19, P309, DOI 10.1016/S0945-053X(00)00072-X; Utani A, 2001, J BIOL CHEM, V276, P28779, DOI 10.1074/jbc.M101420200; Yamaguchi H, 2000, J BIOL CHEM, V275, P29458, DOI 10.1074/jbc.M003103200; Yu H, 2003, BIOCHEM J, V371, P289, DOI 10.1042/BJ20021500	47	97	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10946	10954		10.1074/jbc.M313626200	http://dx.doi.org/10.1074/jbc.M313626200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701821	hybrid, Green Published			2022-12-25	WOS:000220157600016
J	Sorenson, CM				Sorenson, CM			Interaction of bcl-2 with paxillin through its BH4 domain is important during ureteric bud branching	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING PATHWAY; RENAL DEVELOPMENT; CYSTIC KIDNEYS; CELL-DEATH; EXPRESSION; APOPTOSIS; PROTEINS; BINDING; MOUSE; PHOSPHORYLATION	bcl-2 protects cells from apoptosis initiated by a variety of stimuli including loss of cell adhesion. Mice deficient in bcl-2 ( bcl-2-/-) develop renal hypoplastic/cystic dysplasia, a condition that leads to significant morbidity and mortality in children. The precise mechanism of action of bcl-2 has not been elucidated. bcl-2 may merely facilitate survival of precursor cells and/or may play a more "active" role during morphogenesis by interacting with other proteins such as paxillin. Recent work in this laboratory demonstrated that bcl-2 directly associates with paxillin. The data presented here demonstrate that the bcl-2 homology 4 (BH4) domain, specifically amino acids 17-31, is necessary for the bcl-2 interaction with paxillin. Paxillin also associated with the BH4 domains of more closely related bcl-2 family members, bcl-xL and bcl-w, compared with that from the non-mammalian homologue ced9. Tyrosines 21 and 28 in the bcl-2 BH4 domain were essential for interaction with paxillin. In embryonic kidney organ culture, incubation with the bcl-2 BH4 domain resulted in inhibition of ureteric bud branching. Therefore, these data suggest that the interaction of bcl-2 with paxillin plays an important role during nephrogenesis.	Univ Wisconsin, Dept Pediat, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Sorenson, CM (corresponding author), Univ Wisconsin, Dept Pediat, H4-444 CSC,600 Highland Ave, Madison, WI 53792 USA.	cmsorenson@wisc.edu						CHANDLER D, 1994, HUM PATHOL, V25, P789, DOI 10.1016/0046-8177(94)90248-8; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Hagel M, 2002, MOL CELL BIOL, V22, P901, DOI 10.1128/MCB.22.3.901-915.2002; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; LU PJ, 1995, J CELL BIOL, V129, P1363, DOI 10.1083/jcb.129.5.1363; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; Nor JE, 2001, CANCER RES, V61, P2183; NOVACK DV, 1994, AM J PATHOL, V145, P61; Reed JC, 1996, ADV EXP MED BIOL, V406, P99; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Sakai T, 2003, NATURE, V423, P876, DOI 10.1038/nature01712; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Sorenson CM, 1996, AM J PHYSIOL-RENAL, V271, pF234, DOI 10.1152/ajprenal.1996.271.1.F234; Sorenson CM, 1996, AM J PHYSIOL-RENAL, V271, pF184, DOI 10.1152/ajprenal.1996.271.1.F184; Sorenson CM, 2002, AM J PHYSIOL-RENAL, V282, pF442, DOI 10.1152/ajprenal.00184.2001; Sorenson CM, 2002, AM J PHYSIOL-RENAL, V283, pF1085, DOI 10.1152/ajprenal.00380.2001; SORENSON CM, 1995, AM J PHYSIOL-RENAL, V268, pF73, DOI 10.1152/ajprenal.1995.268.1.F73; Sorenson CM, 1999, AM J PHYSIOL-RENAL, V276, pF210, DOI 10.1152/ajprenal.1999.276.2.F210; Sorenson CM, 1999, DEV DYNAM, V215, P371, DOI 10.1002/(SICI)1097-0177(199908)215:4<371::AID-AJA8>3.3.CO;2-8; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; TURNER CE, 1994, J CELL SCI, V107, P1583; Vance BA, 1996, J BIOL CHEM, V271, P30811, DOI 10.1074/jbc.271.48.30811; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; WANG H, 1996, CELL, V4, P589	29	34	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11368	11374		10.1074/jbc.M310079200	http://dx.doi.org/10.1074/jbc.M310079200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699151	hybrid			2022-12-25	WOS:000220157600066
J	Lee, MR; Kim, SH; Cho, HJ; Lee, KY; Moon, AR; Jeong, HG; Lee, JS; Hyun, JW; Chung, MH; You, HJ				Lee, MR; Kim, SH; Cho, HJ; Lee, KY; Moon, AR; Jeong, HG; Lee, JS; Hyun, JW; Chung, MH; You, HJ			Transcription factors NF-YA regulate the induction of human OGG1 following DNA-alkylating agent methylmethane sulfonate (MMS) treatment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE MGMT; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; POLYMERASE-BETA; MESSENGER-RNA; DAMAGED DNA; LUNG-CANCER; 7-METHYLGUANINE RESIDUES; SUBSTRATE-SPECIFICITY	A human 8-oxoguanine- DNA glycosylase (hOGG1) is the main enzyme that repairs 8-oxoG, which is a critical mutagenic lesion. There is a great deal of interest in the up- or down-regulation of OGG1 expression after DNA damage. In this study, we investigated the effect of a DNA-alkylating agent, methylmethane sulfonate (MMS), on hOGG1 expression level and found that MMS treatment resulted in an increase in the functional hOGG1 expression in HCT116 cells. A region between -121 and -61 of the hOGG1 promoter was found to be crucial for this induction by MMS. Site-directed mutations of the two inverted CCAAT motifs substantially abrogated the induction of the hOGG1 promoter as a result of MMS treatment. In addition, the NF-YA protein ( binding to the inverted CCAAT box) was induced after exposing cells to MMS. Moreover, gel shift and supershift analyses with the nuclear extracts prepared from HCT116 cells identified NF-YA as the transcription factor interacting with the inverted CCAAT box. Mutations of the inverted CCAAT box either prevented the binding of this factor or abolished its activation as a result of MMS treatment. Finally, this study showed that hOGG1-expressing HCT116 cells exhibited increased hOGG1 repair activity and resistance to MMS. Overall, these results demonstrate that MMS can up- regulate hOGG1 expression through the induction of the transcription factor, NFYA, and increased transcription level of the hOGG1 gene correlates with an increase in enzyme activity providing functional protection from MMS.	Chosun Univ, Res Ctr Prot Mat, Kwangju 501759, South Korea; Chosun Univ, Sch Med, Dept Pharmacol, Kwangju 501759, South Korea; Cheju Natl Univ, Coll Med, Dept Biochem, Jeju, South Korea; Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 110799, South Korea	Chosun University; Chosun University; Jeju National University; Seoul National University (SNU)	You, HJ (corresponding author), Chosun Univ, Res Ctr Prot Mat, 375 Seosuk Dong, Kwangju 501759, South Korea.	hjyou@mail.chosun.ac.kr		Jeong, Hye Gwang/0000-0002-8020-8914; You, Ho Jin/0000-0002-0530-4017				Aburatani H, 1997, CANCER RES, V57, P2151; Arai K, 1997, ONCOGENE, V14, P2857, DOI 10.1038/sj.onc.1201139; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; Blons H, 1999, MOL CARCINOGEN, V26, P254; Boiteux S, 2000, ARCH BIOCHEM BIOPHYS, V377, P1, DOI 10.1006/abbi.2000.1773; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; BREIMER LH, 1990, MOL CARCINOGEN, V3, P188, DOI 10.1002/mc.2940030405; Cadet J, 1997, Rev Physiol Biochem Pharmacol, V131, P1; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHETSANGA CJ, 1979, NUCLEIC ACIDS RES, V6, P3673, DOI 10.1093/nar/6.11.3673; Chevillard S, 1998, ONCOGENE, V16, P3083, DOI 10.1038/sj.onc.1202096; Cho HJ, 2002, J BIOL CHEM, V277, P19358, DOI 10.1074/jbc.M200933200; Davis BM, 1997, CANCER RES, V57, P5093; Deutsch WA, 1997, J BIOL CHEM, V272, P32857, DOI 10.1074/jbc.272.52.32857; Dhenaut A, 2000, MUTAT RES-DNA REPAIR, V461, P109, DOI 10.1016/S0921-8777(00)00042-2; DIZDAROGLU M, 1991, FREE RADICAL BIO MED, V10, P225, DOI 10.1016/0891-5849(91)90080-M; Dobson AW, 2002, AM J PHYSIOL-LUNG C, V283, pL205, DOI 10.1152/ajplung.00443.2001; Dosch J, 1996, ONCOGENE, V13, P1927; FEIG DI, 1994, CANCER RES, V54, pS1890; Fritz G, 2001, J BIOL CHEM, V276, P3115, DOI 10.1074/jbc.M005058200; Gill RD, 1996, CANCER RES, V56, P3721; GOMBAR CT, 1980, BIOCHEM PHARMACOL, V29, P2639, DOI 10.1016/0006-2952(80)90079-9; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; HALLIWELL B, 1991, FEBS LETT, V281, P9, DOI 10.1016/0014-5793(91)80347-6; Hansen WK, 2000, J PHARMACOL EXP THER, V295, P1; HIBI K, 1992, ONCOGENE, V7, P445; Hodges NJ, 2002, CARCINOGENESIS, V23, P55, DOI 10.1093/carcin/23.1.55; HOSOE S, 1994, LUNG CANCER-J IASLC, V10, P297, DOI 10.1016/0169-5002(94)90659-9; Ishida T, 1999, CYTOGENET CELL GENET, V85, P232, DOI 10.1159/000015299; Ishida T, 1999, INT J CANCER, V80, P18; Jin SQ, 2001, ONCOGENE, V20, P2683, DOI 10.1038/sj.onc.1204390; KAINA B, 1993, ENVIRON MOL MUTAGEN, V22, P283, DOI 10.1002/em.2850220418; Karahalil B, 1998, NUCLEIC ACIDS RES, V26, P1228, DOI 10.1093/nar/26.5.1228; Kim HN, 2001, CARCINOGENESIS, V22, P265, DOI 10.1093/carcin/22.2.265; KLETZIEN RF, 1994, FASEB J, V8, P174, DOI 10.1096/fasebj.8.2.8119488; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Kobune M, 2001, CANCER RES, V61, P5116; Koc ON, 1999, CANCER GENE THER, V6, P340, DOI 10.1038/sj.cgt.7700067; Kohno T, 1998, ONCOGENE, V16, P3219, DOI 10.1038/sj.onc.1201872; Kuo FC, 1997, J EXP MED, V186, P1547, DOI 10.1084/jem.186.9.1547; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Matuoka K, 1999, EXP CELL RES, V253, P365, DOI 10.1006/excr.1999.4605; Maze R, 1996, P NATL ACAD SCI USA, V93, P206, DOI 10.1073/pnas.93.1.206; MICHAELS ML, 1990, NUCLEIC ACIDS RES, V18, P3841, DOI 10.1093/nar/18.13.3841; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Minowa O, 2000, P NATL ACAD SCI USA, V97, P4156, DOI 10.1073/pnas.050404497; MULLER N, 1985, CHEM-BIOL INTERACT, V53, P173, DOI 10.1016/S0009-2797(85)80094-6; NAKAYAMA T, 1985, NATURE, V314, P462, DOI 10.1038/314462a0; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; Nishioka K, 1999, MOL BIOL CELL, V10, P1637, DOI 10.1091/mbc.10.5.1637; Ochs K, 2002, CANCER RES, V62, P1524; Ochs K, 1999, CANCER RES, V59, P1544; OCONNOR TR, 1988, NUCLEIC ACIDS RES, V16, P5879, DOI 10.1093/nar/16.13.5879; Phillips WP, 1997, CANCER RES, V57, P4817; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Singer B, 1975, Prog Nucleic Acid Res Mol Biol, V15, P219, DOI 10.1016/S0079-6603(08)60121-X; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Souza-Pinto NC, 1999, NUCLEIC ACIDS RES, V27, P1935, DOI 10.1093/nar/27.8.1935; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; TCHOU J, 1993, MUTAT RES, V299, P277, DOI 10.1016/0165-1218(93)90104-L; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; Thomas D, 1997, MOL GEN GENET, V254, P171, DOI 10.1007/s004380050405; Tsurudome Y, 1999, CARCINOGENESIS, V20, P1573, DOI 10.1093/carcin/20.8.1573; Tsuruya K, 2003, DNA REPAIR, V2, P211, DOI 10.1016/S1568-7864(02)00214-8; VANDELFT JHM, 1993, ENVIRON HEALTH PERSP, V99, P25, DOI 10.2307/3431453; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; Xu Y, 2001, J PHARMACOL EXP THER, V296, P825; YOKOTA J, 1993, FASEB J, V7, P920, DOI 10.1096/fasebj.7.10.8344488	78	40	43	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9857	9866		10.1074/jbc.M311132200	http://dx.doi.org/10.1074/jbc.M311132200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688259	hybrid			2022-12-25	WOS:000220050400025
J	Wikstrom, M; Xie, J; Bogdanov, M; Mileykovskaya, E; Heacock, P; Wieslander, A; Dowhan, W				Wikstrom, M; Xie, J; Bogdanov, M; Mileykovskaya, E; Heacock, P; Wieslander, A; Dowhan, W			Monoglucosyldiacylglycerol, a foreign lipid, can substitute for phosphatidylethanolamine in essential membrane-associated functions in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID COMPOSITION; ACHOLEPLASMA-LAIDLAWII; PHOSPHOLIPID-COMPOSITION; 1,2-DIACYLGLYCEROL 3-GLUCOSYLTRANSFERASE; TRANSPORT-SYSTEM; IN-VITRO; LACKING PHOSPHATIDYLETHANOLAMINE; STRUCTURAL FEATURES; NONBILAYER LIPIDS; LACTOSE PERMEASE	The mechanisms by which lipid bilayer properties govern or influence membrane protein functions are little understood, but a liquid-crystalline state and the presence of anionic and nonbilayer (NB)-prone lipids seem important. An Escherichia coli mutant lacking the major membrane lipid phosphatidylethanolamine (NB-prone) requires divalent cations for viability and cell integrity and is impaired in several membrane functions that are corrected by introduction of the "foreign" NB-prone neutral glycolipid alpha-monoglucosyldiacylglycerol (MGlcDAG) synthesized by the MGlcDAG synthase from Acholeplasma laidlawii. Dependence on Mg2+ was reduced, and cellular yields and division malfunction were greatly improved. The increased passive membrane permeability of the mutant was not abolished, but protein-mediated osmotic stress adaptation to salts and sucrose was recovered by the presence of MGlcDAG. MGlcDAG also restored tryptophan prototrophy and active transport function of lactose permease, both critically dependent on phosphatidylethanolamine. Three mechanisms can explain the observed effects: NB-prone MGlcDAG improves the quenched lateral pressure profile across the bilayer; neutral MGlcDAG dilutes the high anionic lipid surface charge; MGlcDAG provides a neutral lipid that can hydrogen bond and/or partially ionize. The reduced dependence on Mg2+ and lack of correction by high monovalent salts strongly support the essential nature of the NB properties of MGlcDAG.	Stockholm Univ, Dept Biochem & Biophys, S-10691 Stockholm, Sweden; Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA	Stockholm University; University of Texas System	Wieslander, A (corresponding author), Stockholm Univ, Dept Biochem & Biophys, S-10691 Stockholm, Sweden.	ake@dbb.su.se; William.Dowhan@uth.tmc.edu	Bogdanov, Mikhail/J-3695-2017	Xie, Jun/0000-0001-6943-0330; Mileykovskaya, Eugenia/0000-0002-8775-4467	NIGMS NIH HHS [GM20487] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arechaga I, 2000, FEBS LETT, V482, P215, DOI 10.1016/S0014-5793(00)02054-8; Attard GS, 2000, P NATL ACAD SCI USA, V97, P9032, DOI 10.1073/pnas.160260697; Belrhali H, 1999, STRUCTURE, V7, P909, DOI 10.1016/S0969-2126(99)80118-X; Berg S, 2001, J BIOL CHEM, V276, P22056, DOI 10.1074/jbc.M102576200; Bogdanov M, 2002, EMBO J, V21, P2107, DOI 10.1093/emboj/21.9.2107; Bogdanov M, 1999, J BIOL CHEM, V274, P12339, DOI 10.1074/jbc.274.18.12339; Bogdanov M, 1996, J BIOL CHEM, V271, P11615, DOI 10.1074/jbc.271.20.11615; BOGDANOV M, 1995, J BIOL CHEM, V270, P732, DOI 10.1074/jbc.270.2.732; Booth PJ, 2001, CRIT REV BIOCHEM MOL, V36, P501, DOI 10.1080/20014091074246; Botelho AV, 2002, BIOCHEMISTRY-US, V41, P6354, DOI 10.1021/bi011995g; BRABETZ W, 1993, J BACTERIOL, V175, P7488, DOI 10.1128/JB.175.22.7488-7491.1993; BRYSZEWSKA M, 1988, BIOCHIM BIOPHYS ACTA, V943, P485, DOI 10.1016/0005-2736(88)90381-1; Cantor RS, 1999, CHEM PHYS LIPIDS, V101, P45, DOI 10.1016/S0009-3084(99)00054-7; Crooke E, 2001, BIOCHIMIE, V83, P19, DOI 10.1016/S0300-9084(00)01224-4; DAWSON RMC, 1986, DATA BIOCH RES, P456; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P10710; Dormann P, 2002, TRENDS PLANT SCI, V7, P112, DOI 10.1016/S1360-1385(01)02216-6; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; DRIESSEN AJM, 1988, BIOCHEMISTRY-US, V27, P865, DOI 10.1021/bi00403a005; EATON LC, 1981, J BACTERIOL, V146, P1151, DOI 10.1128/JB.146.3.1151-1153.1981; Edman M, 2003, J BIOL CHEM, V278, P8420, DOI 10.1074/jbc.M211492200; Errington J, 2003, MICROBIOL MOL BIOL R, V67, P52, DOI 10.1128/MMBR.67.1.52-65.2003; Fishov I, 1999, MOL MICROBIOL, V32, P1166, DOI 10.1046/j.1365-2958.1999.01425.x; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; GANGOLA P, 1987, J BIOL CHEM, V262, P12570; Herskovits AA, 2002, J CELL BIOL, V159, P403, DOI 10.1083/jcb.200204144; HIRAOKA S, 1993, FEBS LETT, V336, P221, DOI 10.1016/0014-5793(93)80807-7; Johnson JE, 1999, MOL MEMBR BIOL, V16, P217, DOI 10.1080/096876899294544; Karlsson OP, 1997, J BIOL CHEM, V272, P929, DOI 10.1074/jbc.272.2.929; KENNEDY EP, 1982, P NATL ACAD SCI-BIOL, V79, P1092, DOI 10.1073/pnas.79.4.1092; KENNEDY EP, 1996, ESCHERICHIA COLI SAL, V1, P1064; KILLIAN JA, 1994, BBA-BIOMEMBRANES, V1189, P225; Laan EVDD, 2003, J BACTERIOL, V185, P3773, DOI 10.1128/JB.185.3773.3779.2003; Lewis BE, 2003, J AM CHEM SOC, V125, P7872, DOI 10.1021/ja034983m; Li L, 2003, BIOCHEMISTRY-US, V42, P9677, DOI 10.1021/bi034360l; LINDBLOM G, 1986, BIOCHEMISTRY-US, V25, P7502, DOI 10.1021/bi00371a037; LUSK JE, 1969, J BIOL CHEM, V244, P1653; Lutkenhaus J, 2002, CURR OPIN MICROBIOL, V5, P548, DOI 10.1016/S1369-5274(02)00376-4; Mannock DA, 2001, EUR BIOPHYS J BIOPHY, V30, P537, DOI 10.1007/s002490010185z; Mileykovskaya E, 2003, J BIOL CHEM, V278, P22193, DOI 10.1074/jbc.M302603200; Mileykovskaya E, 1997, J BACTERIOL, V179, P1029, DOI 10.1128/jb.179.4.1029-1034.1997; Mileykovskaya E, 1998, J BACTERIOL, V180, P4252, DOI 10.1128/JB.180.16.4252-4257.1998; Mileykovskaya E, 2000, J BACTERIOL, V182, P1172, DOI 10.1128/JB.182.4.1172-1175.2000; Morein S, 1996, J BIOL CHEM, V271, P6801, DOI 10.1074/jbc.271.12.6801; NAGATA S, 1995, MICROBIOL-UK, V141, P729, DOI 10.1099/13500872-141-3-729; NESMEYANOVA MA, 1991, WORLD J MICROB BIOT, V7, P394, DOI 10.1007/BF00329408; Niemi AE, 1997, EUR BIOPHYS J BIOPHY, V26, P485, DOI 10.1007/s002490050103; NIKAIDO H, 1981, J GEN PHYSIOL, V77, P121, DOI 10.1085/jgp.77.2.121; NOORDAM PC, 1980, CHEM PHYS LIPIDS, V27, P221, DOI 10.1016/0009-3084(80)90037-7; Pogliano J, 1999, MOL MICROBIOL, V31, P1149, DOI 10.1046/j.1365-2958.1999.01255.x; Poolman B, 2002, MOL MICROBIOL, V44, P889, DOI 10.1046/j.1365-2958.2002.02894.x; RAETZ CRH, 1977, J BIOL CHEM, V252, P5911; RICHEY B, 1987, J BIOL CHEM, V262, P7157; RIETVELD AG, 1993, J BIOL CHEM, V268, P12427; SEIMIYA T, 1978, CHEM PHYS LIPIDS, V22, P221, DOI 10.1016/0009-3084(78)90028-2; SIKKEMA J, 1995, MICROBIOL REV, V59, P201, DOI 10.1128/MMBR.59.2.201-222.1995; SILVER S, 1996, ESCHERICHIA COLI SAL, V1, P1091; SPROTT GD, 1984, METHODS GEN MOL BACT, P72; Storm P, 2003, EUR J BIOCHEM, V270, P1699, DOI 10.1046/j.1432-1033.2003.03527.x; Szeto TH, 2002, P NATL ACAD SCI USA, V99, P15693, DOI 10.1073/pnas.232590599; Urban F, 1932, J BIOL CHEM, V94, P697; van den Brink-van der Laan E, 2001, BIOCHEMISTRY-US, V40, P9677, DOI 10.1021/bi002903a; van der Does C, 2000, J BIOL CHEM, V275, P2472, DOI 10.1074/jbc.275.4.2472; van der Heide T, 2001, EMBO J, V20, P7022, DOI 10.1093/emboj/20.24.7022; Vanounou S, 2003, MOL MICROBIOL, V49, P1067, DOI 10.1046/j.1365-2958.2003.03614.x; VANVEEN HW, 1993, J BIOL CHEM, V268, P19377; VIITANEN P, 1986, METHOD ENZYMOL, V125, P429; Wang XY, 2002, EMBO J, V21, P5673, DOI 10.1093/emboj/cdf571; Weber FJ, 1996, BBA-REV BIOMEMBRANES, V1286, P225, DOI 10.1016/S0304-4157(96)00010-X; WEISSBORN AC, 1992, J BACTERIOL, V174, P4856, DOI 10.1128/JB.174.14.4856-4859.1992; WIESLANDER A, 1995, EUR J BIOCHEM, V227, P734, DOI 10.1111/j.1432-1033.1995.tb20196.x; WIESLANDER A, 1986, BIOCHEMISTRY-US, V25, P7511, DOI 10.1021/bi00371a038; WILKISON WO, 1988, J BIOL CHEM, V263, P14505; Wood JM, 1999, MICROBIOL MOL BIOL R, V63, P230, DOI 10.1128/MMBR.63.1.230-262.1999; Yang L, 2003, BIOCHEMISTRY-US, V42, P6631, DOI 10.1021/bi0344836; YOUNG K, 1991, J BACTERIOL, V173, P3609, DOI 10.1128/JB.173.12.3609-3614.1991; Yue AWB, 2003, BIOCHEMISTRY-US, V42, P1309, DOI 10.1021/bi026923j; Zhang W, 2003, J BIOL CHEM, V278, P50128, DOI 10.1074/jbc.M309840200; Zhukov AV, 1996, CHEM PHYS LIPIDS, V82, P1, DOI 10.1016/0009-3084(96)02538-8	80	60	62	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10484	10493		10.1074/jbc.M310183200	http://dx.doi.org/10.1074/jbc.M310183200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688287	hybrid			2022-12-25	WOS:000220050400100
J	Lee, JY; Kim, JH; Hong, SH; Lee, JY; Cherny, RA; Bush, AI; Palmiter, RD; Koh, JY				Lee, JY; Kim, JH; Hong, SH; Lee, JY; Cherny, RA; Bush, AI; Palmiter, RD; Koh, JY			Estrogen decreases zinc transporter 3 expression and synaptic vesicle zinc levels in mouse brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTOCHEMICALLY-REACTIVE ZINC; ALZHEIMER A-BETA; POSTMENOPAUSAL WOMEN; PRECURSOR PROTEIN; AMYLOID PLAQUES; DISEASE; INDUCTION; BOUTONS; COPPER; MOSSY	Previous studies suggest that female sex hormones modulate synaptic zinc levels, which may influence amyloid plaque formation and Alzheimer's disease progression. We examined the effects of ovariectomy and estrogen supplement on the levels of synaptic zinc and zinc transporter protein Znt3 in the brain. Ovariectomy was performed on 5-month-old mice, and 2 weeks later, pellets containing vehicle, low (0.18 mg/pellet), or high dose (0.72 mg) 17beta-estradiol were implanted. After 4 weeks, animals were decapitated, and blood and brain were collected for analysis. Blood analysis indicated that estrogen implants altered plasma estrogen levels in a dose-dependent manner. Analysis of brain tissue showed that ovariectomy raised hippocampal synaptic vesicle zinc levels, whereas estrogen replacement lowered these zinc levels. Western blots revealed that Znt3 levels in the brain were modulated in parallel with synaptic zinc levels, whereas no change was detected in the levels of Znt3 mRNA, as determined by Northern blot and reverse transcriptase-PCR analysis. However, mRNA levels of the delta subunit of adaptor protein complex (AP)-3, which modulates the level of Znt3 levels, were altered by estrogen depletion or replacement. These data demonstrate that estrogen alters the levels of Znt3 and synaptic vesicle zinc in female mice, probably through changing AP-3 delta expression. Since synaptic zinc may play a key role in neuronal death in acute brain injury as well as in plaque formation in Alzheimer's disease, and since estrogen may be beneficial in both conditions, our results may provide new insights into the effects of estrogen on the brain.	Univ Ulsan, Coll Med, Natl Creat Res Initiat Ctr Study Cent Nervous Sys, Seoul 138736, South Korea; Univ Ulsan, Coll Med, Dept Neurol, Seoul 138736, South Korea; Univ Ulsan, Coll Med, Dept Obstet & Gynecol, Seoul 138736, South Korea; Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; Univ Melbourne, Mental Hlth Res Inst Victoria, Parkville, Vic 3052, Australia; Harvard Univ, Sch Med, Dept Psychiat, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Lab Oxidat Biol, Genet & Aging Res Unit, Charlestown, MA 02129 USA; Univ Washington, Dept Biochem, Howard Hughes Med Inst, Seattle, WA 98195 USA	University of Ulsan; University of Ulsan; University of Ulsan; University of Melbourne; University of Melbourne; Harvard University; Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Koh, JY (corresponding author), Univ Ulsan, Coll Med, Natl Creat Res Initiat Ctr Study Cent Nervous Sys, 388-1 Poongnapdong, Seoul 138736, South Korea.	jkko@www.amc.seoul.kr	Lee, Joo-Yong/F-4545-2014; Koh, Jae-Young/C-9014-2011; Bush, Ashley/Y-2457-2019; Bush, Ashley I/A-1186-2007	Koh, Jae-Young/0000-0002-4318-495X; Bush, Ashley/0000-0001-8259-9069; Bush, Ashley I/0000-0001-8259-9069				Amateau SK, 2002, J NEUROSCI, V22, P8586; ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; Asthana S, 2001, NEUROLOGY, V57, P605, DOI 10.1212/WNL.57.4.605; Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Callahan MJ, 2001, AM J PATHOL, V158, P1173, DOI 10.1016/S0002-9440(10)64064-3; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Cherny RA, 1999, J BIOL CHEM, V274, P23223, DOI 10.1074/jbc.274.33.23223; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; Cole TB, 1999, P NATL ACAD SCI USA, V96, P1716, DOI 10.1073/pnas.96.4.1716; Danscher G, 1997, J NEUROSCI METH, V76, P53, DOI 10.1016/S0165-0270(97)00079-4; Deibel MA, 1996, J NEUROL SCI, V143, P137, DOI 10.1016/S0022-510X(96)00203-1; Dong J, 2003, BIOCHEMISTRY-US, V42, P2768, DOI 10.1021/bi0272151; FREDERICKSON CJ, 1987, J NEUROSCI METH, V20, P91, DOI 10.1016/0165-0270(87)90042-2; FREDERICKSON CJ, 1989, BRAIN RES, V480, P317, DOI 10.1016/0006-8993(89)90199-6; Greenfield JP, 2002, J BIOL CHEM, V277, P12128, DOI 10.1074/jbc.M110009200; Harris-White ME, 2001, NEUROCHEM INT, V39, P435, DOI 10.1016/S0197-0186(01)00051-1; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; JORM AF, 1987, ACTA PSYCHIAT SCAND, V76, P465, DOI 10.1111/j.1600-0447.1987.tb02906.x; Kantheti P, 2003, MAMM GENOME, V14, P157, DOI 10.1007/s00335-002-2238-8; Kantheti P, 1998, NEURON, V21, P111, DOI 10.1016/S0896-6273(00)80519-X; Koh JY, 2001, MOL NEUROBIOL, V24, P99, DOI 10.1385/MN:24:1-3:099; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Lee JY, 1999, J NEUROSCI, V19, DOI 10.1523/jneurosci.19-11-j0002.1999; Lee JY, 2002, P NATL ACAD SCI USA, V99, P7705, DOI 10.1073/pnas.092034699; Li Y, 2001, J NEUROSCI, V21, P8015, DOI 10.1523/JNEUROSCI.21-20-08015.2001; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; Manthey D, 2001, EUR J BIOCHEM, V268, P4285, DOI 10.1046/j.1432-1327.2001.02346.x; MARTINEZGUIJARRO FJ, 1991, J NEUROCYTOL, V20, P834, DOI 10.1007/BF01191734; MOUTON PR, 2001, SOC NEUR ABSTR, V27; Murphy DD, 1998, P NATL ACAD SCI USA, V95, P11412, DOI 10.1073/pnas.95.19.11412; Owens CT, 2002, ANN PHARMACOTHER, V36, P1273; Payami H, 1996, AM J HUM GENET, V58, P803; PEREZCLAUSELL J, 1985, BRAIN RES, V337, P91, DOI 10.1016/0006-8993(85)91612-9; Schonknecht P, 2001, NEUROSCI LETT, V307, P122, DOI 10.1016/S0304-3940(01)01896-1; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Suh SW, 2000, BRAIN RES, V852, P274, DOI 10.1016/S0006-8993(99)02096-X; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Ueno S, 2002, J CELL BIOL, V158, P215, DOI 10.1083/jcb.200204066; Valente T, 2002, MOL CELL NEUROSCI, V21, P189, DOI 10.1006/mcne.2002.1159; Weiss JH, 2000, TRENDS PHARMACOL SCI, V21, P395, DOI 10.1016/S0165-6147(00)01541-8; Wenzel HJ, 1997, P NATL ACAD SCI USA, V94, P12676, DOI 10.1073/pnas.94.23.12676; Xu HX, 1998, NAT MED, V4, P447, DOI 10.1038/nm0498-447; Yaffe K, 1998, JAMA-J AM MED ASSOC, V279, P688, DOI 10.1001/jama.279.9.688; Yang DS, 2000, EUR J BIOCHEM, V267, P6692, DOI 10.1046/j.1432-1327.2000.01767.x; Yang SH, 2000, STROKE, V31, P745, DOI 10.1161/01.STR.31.3.745	49	118	126	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8602	8607		10.1074/jbc.M309730200	http://dx.doi.org/10.1074/jbc.M309730200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14681234	hybrid			2022-12-25	WOS:000189265900011
J	Su, H; McClarty, G; Dong, F; Hatch, GM; Pan, ZXK; Zhong, GM				Su, H; McClarty, G; Dong, F; Hatch, GM; Pan, ZXK; Zhong, GM			Activation of Raf/MEK/ERK/cPLA2 signaling pathway is essential for chlamydial acquisition of host glycerophospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTED CELLS; TRACHOMATIS INFECTION; PHOSPHOLIPASE A(2); REGULATED KINASE; GENOME SEQUENCE; PROTEIN-KINASE; HEP-2 CELLS; PNEUMONIAE; INHIBITION; IDENTIFICATION	Chlamydiae, a diverse group of obligate intracellular pathogens replicating within cytoplasmic vacuoles of eukaryotic cells, are able to acquire lipids from host cells. Here we report that activation of the host Raf-MEK-ERK-cPLA2 signaling cascade is required for the chlamydial uptake of host glycerophospholipids. Both the MAP kinase pathway (Ras/Raf/MEK/ERK) and Ca2+-dependent cytosolic phospholipase A2 (cPLA2) were activated in chlamydia-infected cells. The inhibition of cPLA2 activity resulted in the blockade of the chlamydial uptake of host glycerophospholipids and impairment in chlamydial growth. Blocking either c-Raf-1 or MEK1/2 activity prevented the chlamydial activation of ERK1/2, leading to the suppression of both chlamydial activation of the host cPLA2 and uptake of glycerophospholipids from the host cells. The chlamydia-induced phosphorylation of cPLA2 was also blocked by a dominant negative ERK2. Furthermore, activation of both ERK1/2 and cPLA2 was dependent on chlamydial growth and restricted within chlamydia-infected cells, suggesting an active manipulation of the host ERK-cPLA2 signaling pathway by chlamydiae.	Univ Texas, Hlth Sci Ctr, Dept Microbiol & Immunol, San Antonio, TX 78229 USA; Univ Manitoba, Dept Med Microbiol, Winnipeg, MB R3E OW3, Canada; Univ Manitoba, Dept Pharmacol & Therapeut, Winnipeg, MB R3E OW3, Canada; Med Coll Ohio, Dept Microbiol & Immunol, Toledo, OH 43614 USA	University of Texas System; University of Texas Health San Antonio; University of Manitoba; University of Manitoba	Zhong, GM (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Microbiol & Immunol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	Zhongg@UTHSCSA.EDU			NHLBI NIH HHS [R01HL64883] Funding Source: Medline; NIAID NIH HHS [R01AI47997] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064883] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047997] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Al-Younes HM, 2001, CELL MICROBIOL, V3, P427, DOI 10.1046/j.1462-5822.2001.00125.x; Barber GN, 2001, CELL DEATH DIFFER, V8, P113, DOI 10.1038/sj.cdd.4400823; BEATTY WL, 1994, INFECT IMMUN, V62, P3705, DOI 10.1128/IAI.62.9.3705-3711.1994; Belland RJ, 2003, P NATL ACAD SCI USA, V100, P8478, DOI 10.1073/pnas.1331135100; Belland RJ, 2001, P NATL ACAD SCI USA, V98, P13984, DOI 10.1073/pnas.241377698; Burgert HG, 2002, CURR TOP MICROBIOL, V269, P273; Caldwell HD, 2003, J CLIN INVEST, V111, P1757, DOI [10.1172/JCI200317993, 10.1172/JCI17993]; Carabeo RA, 2003, P NATL ACAD SCI USA, V100, P6771, DOI 10.1073/pnas.1131289100; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen LY, 2002, J IMMUNOL, V169, P3934, DOI 10.4049/jimmunol.169.7.3934; Coombes BK, 2002, CELL MICROBIOL, V4, P447, DOI 10.1046/j.1462-5822.2002.00203.x; DAWSON JM, 1984, ANAL BIOCHEM, V140, P391, DOI 10.1016/0003-2697(84)90183-0; FAN HZ, 1992, J CLIN INVEST, V90, P1803, DOI 10.1172/JCI116055; Fan T, 1998, J EXP MED, V187, P487, DOI 10.1084/jem.187.4.487; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fields KA, 2002, ANNU REV CELL DEV BI, V18, P221, DOI 10.1146/annurev.cellbio.18.012502.105845; Greene W, 2003, J INFECTION, V47, P45, DOI 10.1016/S0163-4453(03)00039-2; Hackstadt T, 1996, EMBO J, V15, P964, DOI 10.1002/j.1460-2075.1996.tb00433.x; Hatch GM, 1998, INFECT IMMUN, V66, P3727, DOI 10.1128/IAI.66.8.3727-3735.1998; HATCH GM, 1992, J BIOL CHEM, V267, P12443; Hatch GM, 1998, BIOCHEM BIOPH RES CO, V243, P356, DOI 10.1006/bbrc.1998.8101; Heuer D, 2003, CELL MICROBIOL, V5, P315, DOI 10.1046/j.1462-5822.2003.00278.x; Hiller G, 1999, CELL SIGNAL, V11, P863, DOI 10.1016/S0898-6568(99)00058-3; Hu H, 1999, J CLIN INVEST, V103, P747, DOI 10.1172/JCI4582; Iliffe-Lee ER, 2000, MOL MICROBIOL, V38, P20, DOI 10.1046/j.1365-2958.2000.02102.x; Kalayoglu MV, 2002, JAMA-J AM MED ASSOC, V288, P2724, DOI 10.1001/jama.288.21.2724; Kalman S, 1999, NAT GENET, V21, P385, DOI 10.1038/7716; Kirchner JT, 2000, POSTGRAD MED, V107, P55, DOI 10.3810/pgm.2000.01.815; Luo HL, 2002, J VIROL, V76, P3365, DOI 10.1128/JVI.76.7.3365-3373.2002; MCCLARTY G, 1991, J BACTERIOL, V173, P4922, DOI 10.1128/jb.173.16.4922-4931.1991; McClarty G, 1999, CHLAMYDIA, P69; MCCLARTY G, 1993, FEMS MICROBIOL LETT, V108, P325, DOI 10.1111/j.1574-6968.1993.tb06123.x; MORRISON RP, 1989, J EXP MED, V169, P663, DOI 10.1084/jem.169.3.663; Murakami M, 2002, J BIOCHEM, V131, P285, DOI 10.1093/oxfordjournals.jbchem.a003101; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Ojcius DM, 1998, J BIOL CHEM, V273, P7052, DOI 10.1074/jbc.273.12.7052; Pantoja LG, 2001, INFECT IMMUN, V69, P7927, DOI 10.1128/IAI.69.12.7927-7932.2001; Papp JR, 1997, J REPROD IMMUNOL, V34, P185, DOI 10.1016/S0165-0378(97)00035-1; Pleschka S, 2001, NAT CELL BIOL, V3, P301, DOI 10.1038/35060098; Rasmussen SJ, 1997, J CLIN INVEST, V99, P77, DOI 10.1172/JCI119136; Read TD, 2003, NUCLEIC ACIDS RES, V31, P2134, DOI 10.1093/nar/gkg321; Read TD, 2000, NUCLEIC ACIDS RES, V28, P1397, DOI 10.1093/nar/28.6.1397; SCHACHTER J, 1980, ANNU REV MICROBIOL, V34, P285, DOI 10.1146/annurev.mi.34.100180.001441; Shaw AC, 2002, CELL MICROBIOL, V4, P411, DOI 10.1046/j.1462-5822.2002.00200.x; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; Stephens RS, 2003, TRENDS MICROBIOL, V11, P44, DOI 10.1016/S0966-842X(02)00011-2; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue TJ, 2003, CELL SIGNAL, V15, P455, DOI 10.1016/S0898-6568(02)00112-2; TIPPLES G, 1993, MOL MICROBIOL, V8, P1105, DOI 10.1111/j.1365-2958.1993.tb01655.x; Wolf K, 2001, CELL MICROBIOL, V3, P145, DOI 10.1046/j.1462-5822.2001.00098.x; Wylie JL, 1997, J BACTERIOL, V179, P7233, DOI 10.1128/jb.179.23.7233-7242.1997; Wyrick PB, 2000, CELL MICROBIOL, V2, P275, DOI 10.1046/j.1462-5822.2000.00059.x; Xia MS, 2003, J INFECT DIS, V187, P424, DOI 10.1086/367962; Xu JF, 2002, J NEUROCHEM, V83, P259, DOI 10.1046/j.1471-4159.2002.01145.x; Zhong GM, 1999, J EXP MED, V189, P1931, DOI 10.1084/jem.189.12.1931; ZHONG GM, 1988, INFECT IMMUN, V56, P283, DOI 10.1128/IAI.56.1.283-286.1988; Zhong GM, 1997, P NATL ACAD SCI USA, V94, P13856, DOI 10.1073/pnas.94.25.13856; Zhong GM, 1996, J EXP MED, V184, P2061, DOI 10.1084/jem.184.5.2061; Zhong GM, 2001, J EXP MED, V193, P935, DOI 10.1084/jem.193.8.935; Zhong GM, 2000, J EXP MED, V191, P1525, DOI 10.1084/jem.191.9.1525; Zhu XD, 2002, J LEUKOCYTE BIOL, V72, P1046	62	131	146	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9409	9416		10.1074/jbc.M312008200	http://dx.doi.org/10.1074/jbc.M312008200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676189	hybrid			2022-12-25	WOS:000189265900106
J	Yang, EJ; Yoon, JH; Min, DS; Chung, KC				Yang, EJ; Yoon, JH; Min, DS; Chung, KC			LIM kinase 1 activates cAMP-responsive element-binding protein during the neuronal differentiation of immortalized hippocampal progenitor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; NERVOUS-SYSTEM; CREB; GROWTH; PHOSPHORYLATION; IDENTIFICATION; FAMILY; RAS; RHO; SUFFICIENT	LIM kinase 1 (LIMK1), a novel member of a subclass of the protein-serine/threonine kinases, is known to play a role in the development and maintenance of neuronal circuits that mediate cognitive function. Genetic studies have implicated a mutation of LIMK1 as a causative factor in the impairment of visuospatial cognition in a neurodevelopmental disorder, Williams syndrome. A transcriptional factor, cAMP-responsive element-binding protein (CREB), is thought to be involved in the formation of many types of synaptic plasticity involving learning and memory. In the present study we show that the LIMK1 activity is markedly induced during the differentiation of immortalized hippocampal progenitor (H19-7) cells. We found that the addition of neurogenic growth factor to H19-7 cells induces specific binding between LIMK1 and active CREB, that LIMK1 directly phosphorylates CREB, and that this leads to the stimulation of subsequent cAMP-responsive element-mediated gene transcription during H19-7 cell neuronal differentiation. In addition, we also found that LIMK1 activation occurs through Rac/Cdc42- and p21-activated kinase-mediated signaling pathways. Moreover, when the plasmid encoding kinase-inactive LIMK1 was transfected to block the activation of endogenous LIMK1, the neuronal differentiation of H19-7 cells was significantly suppressed. These findings suggest that LIMK1 activation and subsequent CREB phosphorylation are important in the neuronal differentiation of central nervous system hippocampal progenitor cells.	Yonsei Univ, Coll Sci, Dept Biol, Seoul 120749, South Korea; Yonsei Univ, Coll Med, Dept Med Sci, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Dept Otorhinolaryngol, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul 120752, South Korea; Catholic Univ Korea, Coll Med, Dept Physiol, Seoul 137701, South Korea	Yonsei University; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Catholic University of Korea	Chung, KC (corresponding author), Yonsei Univ, Coll Sci, Dept Biol, Shinchon Dong 134, Seoul 120749, South Korea.	kchung@yonsei.ac.kr	Yoon, Joo-Heon/E-5781-2016	Yoon, Joo-Heon/0000-0003-2404-7156				AltunGultekin ZF, 1996, J NEUROSCI RES, V44, P308, DOI 10.1002/(SICI)1097-4547(19960515)44:4<308::AID-JNR2>3.0.CO;2-G; Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; Bayatti N, 2001, J NEUROCHEM, V78, P972, DOI 10.1046/j.1471-4159.2001.00464.x; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; BEUREN AJ, 1964, AM J CARDIOL, V13, P471, DOI 10.1016/0002-9149(64)90154-7; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; Carlier MF, 1999, J BIOL CHEM, V274, P33827, DOI 10.1074/jbc.274.48.33827; Chao MV, 2000, J NEUROSCI RES, V59, P353, DOI 10.1002/(SICI)1097-4547(20000201)59:3<353::AID-JNR8>3.3.CO;2-J; Chung KC, 1998, MOL CELL BIOL, V18, P2272, DOI 10.1128/MCB.18.4.2272; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Edwards DC, 1999, J BIOL CHEM, V274, P11352, DOI 10.1074/jbc.274.16.11352; EVES EM, 1994, BRAIN RES, V656, P396, DOI 10.1016/0006-8993(94)91484-2; EVES EM, 1992, P NATL ACAD SCI USA, V89, P4373, DOI 10.1073/pnas.89.10.4373; Fimia GM, 2000, MOL CELL BIOL, V20, P8613, DOI 10.1128/MCB.20.22.8613-8622.2000; Frangiskakis JM, 1996, CELL, V86, P59, DOI 10.1016/S0092-8674(00)80077-X; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; Higuchi O, 1996, FEBS LETT, V396, P81, DOI 10.1016/0014-5793(96)01072-1; Higuchi O, 1997, ONCOGENE, V14, P1819, DOI 10.1038/sj.onc.1201020; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Kuo WL, 1996, MOL CELL BIOL, V16, P1458; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Meng YH, 2002, NEURON, V35, P121, DOI 10.1016/S0896-6273(02)00758-4; MIZUNO K, 1994, ONCOGENE, V9, P1605; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Mori T, 1997, MOL BRAIN RES, V45, P247, DOI 10.1016/S0169-328X(96)00257-4; Morris CA, 2000, ANNU REV GENOM HUM G, V1, P461; OHASHI K, 1994, J BIOCHEM, V116, P636, DOI 10.1093/oxfordjournals.jbchem.a124573; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; Parker D, 1996, MOL CELL BIOL, V16, P694; Prigent SA, 2000, METH MOL B, V124, P251; PROSCHEL C, 1996, NAT GENET, V13, P272; Radhakrishnan I, 1998, FEBS LETT, V430, P317, DOI 10.1016/S0014-5793(98)00680-2; Sarmiere PD, 2002, NEURON, V35, P3, DOI 10.1016/S0896-6273(02)00759-6; Sebok A, 1999, J NEUROCHEM, V73, P949, DOI 10.1046/j.1471-4159.1999.0730949.x; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Sung JY, 2001, J BIOL CHEM, V276, P13858, DOI 10.1074/jbc.M010610200; Sung JY, 2001, J NEUROCHEM, V78, P1044, DOI 10.1046/j.1471-4159.2001.00491.x; TASSABEHJI M, 2002, J BIOL CHEM, V277, P22093; TRAYNOR AE, 1984, DEV BRAIN RES, V14, P205; Volterra V, 1996, CORTEX, V32, P663, DOI 10.1016/S0010-9452(96)80037-2; Wang JY, 1998, J BIOL CHEM, V273, P20525, DOI 10.1074/jbc.273.32.20525; WILLIAMS JC, 1961, CIRCULATION, V24, P1311, DOI 10.1161/01.CIR.24.6.1311; XIE HJ, 1995, J IMMUNOL, V154, P1717; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yamaguchi Y, 2001, J BIOL CHEM, V276, P18977, DOI 10.1074/jbc.M100254200; Yang EJ, 2004, J BIOL CHEM, V279, P1827, DOI 10.1074/jbc.M308722200; Yang EJ, 2001, J BIOL CHEM, V276, P39819, DOI 10.1074/jbc.M104091200; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yang N, 1999, BIOCHEM J, V338, P793, DOI 10.1042/0264-6021:3380793; Yang N, 1998, EXP CELL RES, V241, P242, DOI 10.1006/excr.1998.4053	60	47	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8903	8910		10.1074/jbc.M311913200	http://dx.doi.org/10.1074/jbc.M311913200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14684741	hybrid			2022-12-25	WOS:000189265900048
J	Zheng, QL; Yin, GY; Yan, C; Cavet, M; Berk, BC				Zheng, QL; Yin, GY; Yan, C; Cavet, M; Berk, BC			14-3-3 beta binds to big mitogen-activated protein kinase 1 (BMK1/ERK5) and regulates BMK1 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED ASK1 ACTIVATION; PROTEIN-KINASE; GROWTH-FACTOR; ERK5; EXPRESSION; DISSOCIATION; ERK5/BMK1	Big mitogen-activated kinase 1 (BMK1/ ERK5) is a member of the MAPK family activated by growth factors that mediates cell growth and survival. Previous data show that BMK1 can be activated by steady laminar flow and is atheroprotective by preventing endothelial cells from undergoing apoptosis. The primary structure of BMK1 is distinct from other MAPK members by virtue of a unique long C-tail, suggesting specific mechanisms of regulation. To characterize regulatory mechanisms for BMK1 function, we identified binding proteins by yeast two-hybrid analysis. Among these proteins, the scaffolding protein 14-3-3 was identified. BMK1 bound to 14-3-3beta in vitro and in vivo as demonstrated by glutathione S-transferase (GST)-14-3-3beta fusion protein pull-down assays and coimmunoprecipitation. Phosphorylation of BMK1 was most likely required for this interaction. GST-14-3-3beta pull-down assays using truncated constructs of BMK1 and site-directed BMK1 mutants demonstrated that the interaction requires serine 486 within the C terminus of BMK1. BMK1 bound to 14-3-3beta basally, and the interaction was greatly abrogated when BMK1 was activated. The interaction of 14-3-3beta and BMK1 inhibited kinase activities stimulated by constitutively active (CA)-MEK5 and epidermal growth factor. Mutation of serine 486 (BMK1-S486A) prevented the interaction with 14-3-3beta and enhanced BMK1 activity upon epidermal growth factor stimulation. These data demonstrate an inhibitory function for 14-3-3beta binding to BMK1 and show that serine 486 phosphorylation represents a novel regulatory mechanism for BMK1.	Univ Rochester, Sch Med & Dent, Aab Inst Biomed Sci, Cardiovasc Res Ctr, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Aab Inst Biomed Sci, Dept Med, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Berk, BC (corresponding author), Univ Rochester, Sch Med & Dent, Aab Inst Biomed Sci, Cardiovasc Res Ctr, 601 Elmwood Ave,Box 679, Rochester, NY 14642 USA.	bradford_berk@urmc.rochester.edu		Berk, Bradford/0000-0002-2767-4115; Yan, Chen/0000-0002-1397-6358				Cavet ME, 2003, J BIOL CHEM, V278, P18376, DOI 10.1074/jbc.M208475200; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; Kasler HG, 2000, MOL CELL BIOL, V20, P8382, DOI 10.1128/MCB.20.22.8382-8389.2000; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Liu YM, 2001, J CLIN INVEST, V107, P917, DOI 10.1172/JCI11947; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; PI X, 2004, IN PRESS CIRC RES; Regan CP, 2002, P NATL ACAD SCI USA, V99, P9248, DOI 10.1073/pnas.142293999; Sohn SJ, 2002, J BIOL CHEM, V277, P43344, DOI 10.1074/jbc.M207573200; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yan C, 2001, J BIOL CHEM, V276, P10870, DOI 10.1074/jbc.M009286200; Yan C, 1999, J BIOL CHEM, V274, P143, DOI 10.1074/jbc.274.1.143; Yang CC, 1998, NUCLEIC ACIDS RES, V26, P4771, DOI 10.1093/nar/26.20.4771; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhang R, 2003, J CLIN INVEST, V111, P1933, DOI 10.1172/JCI200317790; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	21	18	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8787	8791		10.1074/jbc.M310212200	http://dx.doi.org/10.1074/jbc.M310212200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14679215	hybrid			2022-12-25	WOS:000189265900033
J	Fukunaga, R; Fukai, S; Ishitani, R; Nureki, O; Yokoyama, S				Fukunaga, R; Fukai, S; Ishitani, R; Nureki, O; Yokoyama, S			Crystal structures of the CP1 domain from Thermus thermophilus isoleucyl-tRNA synthetase and its complex with L-valine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS; ESCHERICHIA-COLI; DIFFRACTION DATA; AMINO-ACIDS; AMINOACYLATION; ERRORS; SIEVE; DISCRIMINATION; THREONINE; SELECTION	Isoleucyl-tRNA synthetase (IleRS) links tRNA(Ile) with not only its cognate isoleucine but also the nearly cognate valine. The CP1 domain of IleRS deacylates, or edits, the mischarged Val-tRNA(Ile). We determined the crystal structures of the Thermus thermophilus IleRS CP1 domain alone, and in its complex with valine at 1.8- and 2.0-Angstrom resolutions, respectively. In the complex structure, the Asp(328) residue, which was shown to be critical for the editing reaction against Val-tRNA(Ile) by a previous mutational analysis, recognizes the valine NH3+ group. The valine side chain binding pocket is only large enough to accommodate valine, and the placement of an isoleucine model in this location revealed that the additional methylene group of isoleucine would clash with His(319). The H319A mutant of Escherichia coli IleRS reportedly deacylates the cognate Ile-tRNA(Ile) in addition to Val-tRNA(Ile), indicating that the valine-binding mode found in this study represents that in the Val-tRNA(Ile) editing reaction. Analyses of the Val-tRNA(Ile) editing activities of T. thermophilus IleRS mutants revealed the importance of Thr(228), Thr(229), Thr(230), and Asp(328), which are coordinated with water molecules in the present structure. The structural model for the Val-adenosine moiety of Val-tRNA(Ile) bound in the IleRS editing site revealed some interesting differences in the substrate binding and recognizing mechanisms between IleRS and T. thermophilus leucyl-tRNA synthetase. For example, the carbonyl oxygens of the amino acids are located opposite to each other, relative to the adenosine ribose ring, and are differently recognized.	Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol, PRESTO, Kawaguchi, Saitama 3320012, Japan; RIKEN Genom Sci Ctr, Yokohama, Kanagawa 2300045, Japan; RIKEN Harima Inst, Cellular Signaling Lab, Mikazuki, Hyogo 6795148, Japan	University of Tokyo; Japan Science & Technology Agency (JST); RIKEN; RIKEN	Yokoyama, S (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	yokoyama@biochem.s.u-tokyo.ac.jp	Yokoyama, Shigeyuki/N-6911-2015; Fukunaga, Ryuya/AAK-8609-2020; Fukai, Shuya/X-4838-2018	Yokoyama, Shigeyuki/0000-0003-3133-7338; Fukunaga, Ryuya/0000-0002-5814-8206; Fukai, Shuya/0000-0002-1241-1443				BALDWIN AN, 1966, J BIOL CHEM, V241, P839; Bishop AC, 2002, P NATL ACAD SCI USA, V99, P585, DOI 10.1073/pnas.012611299; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cusack S, 2000, EMBO J, V19, P2351, DOI 10.1093/emboj/19.10.2351; ENGLISCH S, 1986, NUCLEIC ACIDS RES, V14, P7529, DOI 10.1093/nar/14.19.7529; FERSHT AR, 1977, BIOCHEMISTRY-US, V16, P1025, DOI 10.1021/bi00624a034; FERSHT AR, 1976, BIOCHEMISTRY-US, V15, P3342, DOI 10.1021/bi00660a026; FREIST W, 1988, EUR J BIOCHEM, V173, P27, DOI 10.1111/j.1432-1033.1988.tb13962.x; Fukai S, 2000, CELL, V103, P793, DOI 10.1016/S0092-8674(00)00182-3; GIEGE R, 1974, EUR J BIOCHEM, V45, P351, DOI 10.1111/j.1432-1033.1974.tb03560.x; Hale SP, 1997, SCIENCE, V276, P1250, DOI 10.1126/science.276.5316.1250; Hendrickson TL, 2000, BIOCHEMISTRY-US, V39, P8180, DOI 10.1021/bi0004798; Hendrickson TL, 2002, MOL CELL, V9, P353, DOI 10.1016/S1097-2765(02)00449-5; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P28; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Lin L, 1996, NATURE, V384, P33, DOI 10.1038/384033b0; Lincecum TL, 2003, MOL CELL, V11, P951, DOI 10.1016/S1097-2765(03)00098-4; Nordin BE, 2002, J BIOL CHEM, V277, P20510, DOI 10.1074/jbc.M202023200; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pauling L., 1957, FESTSCHRIFT ARTHUR S, P597; SCHMIDT E, 1994, SCIENCE, V264, P265, DOI 10.1126/science.8146659; Silvian LF, 1999, SCIENCE, V285, P1074, DOI 10.1126/science.285.5430.1074; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766	26	42	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8396	8402		10.1074/jbc.M312830200	http://dx.doi.org/10.1074/jbc.M312830200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14672940	hybrid			2022-12-25	WOS:000189103300122
J	Nishiyama, Y; Bhatia, G; Bangale, Y; Planque, S; Mitsuda, Y; Taguchi, H; Karle, S; Paul, S				Nishiyama, Y; Bhatia, G; Bangale, Y; Planque, S; Mitsuda, Y; Taguchi, H; Karle, S; Paul, S			Toward selective covalent inactivation of pathogenic antibodies - A phosphonate diester analog of vasoactive intestinal peptide that inactivates catalytic autoantibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SERUM ALBUMIN; SERINE PROTEASES; LIGHT-CHAIN; IRREVERSIBLE INHIBITORS; REACTIVITY; CLEAVAGE; DERIVATIVES; ESTERS; MICE; ACID	We report the selective inactivation of proteolytic antibodies (Abs) to an autoantigen, the neuropeptide vasoactive intestinal peptide (VIP), by a covalently reactive analog (CRA) of VIP containing an electrophilic phosphonate diester at the Lys(20) residue. The VIP-CRA was bound irreversibly by a monoclonal Ab that catalyzes the hydrolysis of VIP. The reaction with the VIP-CRA proceeded more rapidly than with a hapten CRA devoid of the VIP sequence. The covalent binding occurred preferentially at the light chain subunit of the Ab. Covalent VIP-CRA binding was inhibited by VIP devoid of the phosphonate diester group. These results indicate the importance of noncovalent VIP recognition in guiding Ab nucleophilic attack on the phosphonate group. Consistent with the covalent binding data, the VIP-CRA inhibited catalysis by the recombinant light chain of this Ab with potency greater than the hapten-CRA. Catalytic hydrolysis of VIP by a polyclonal VIPase autoantibody preparation that cleaves multiple peptide bonds located between residues 7 and 22 essentially was inhibited completely by the VIP-CRA, suggesting that the electrophilic phosphonate at Lys(20) enjoys sufficient conformational freedom to react covalently with Abs that cleave different peptide bonds in VIP. These results suggest a novel route to antigen-specific covalent targeting of pathogenic Abs.	Univ Texas, Houston Med Sch, Dept Pathol & Lab Med, Chem Immunol & Therapeut Res Ctr, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Nishiyama, Y (corresponding author), Univ Texas, Houston Med Sch, Dept Pathol & Lab Med, Chem Immunol & Therapeut Res Ctr, 6431 Fannin, Houston, TX 77030 USA.	Yasuhiro.Nishiyama@uth.tmc.edu; Sudhir.Paul@uth.tmc.edu			NIAID NIH HHS [AI31268] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031268, R21AI031268] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALETRAS A, 1995, INT J PEPT PROT RES, V45, P488; Bangale Y, 2003, FASEB J, V17, P628, DOI 10.1096/fj.02-0475com; Berisha HI, 2002, PULM PHARMACOL THER, V15, P121, DOI 10.1006/pupt.2001.0337; GAO QS, 1995, J MOL BIOL, V253, P658, DOI 10.1006/jmbi.1995.0580; Gilles JGG, 2000, SEMIN THROMB HEMOST, V26, P151, DOI 10.1055/s-2000-9817; Hatiuchi K, 2003, IMMUNOL LETT, V86, P249, DOI 10.1016/S0165-2478(03)00030-0; KAARTINEN M, 1986, EUR J IMMUNOL, V16, P98, DOI 10.1002/eji.1830160119; Kolesnikov AV, 2000, P NATL ACAD SCI USA, V97, P13526, DOI 10.1073/pnas.200360497; Lacroix-Desmazes S, 1999, NAT MED, V5, P1044, DOI 10.1038/12483; MAGGI CA, 1995, PHYSIOL REV, V75, P277, DOI 10.1152/physrev.1995.75.2.277; Marangoni A.G., 2003, ENZYME KINETICS MODE; Matsuura K, 1996, BIOL CHEM, V377, P587, DOI 10.1515/bchm3.1996.377.9.587; MEANS GE, 1979, ARCH BIOCHEM BIOPHYS, V194, P526, DOI 10.1016/0003-9861(79)90647-7; MITCHELL T J, 1990, Peptide Research, V3, P277; Nishiyama Y, 2002, ARCH BIOCHEM BIOPHYS, V402, P281, DOI 10.1016/S0003-9861(02)00087-5; OLEKSYSZYN J, 1994, J MED CHEM, V37, P226, DOI 10.1021/jm00028a004; OLEKSYSZYN J, 1994, METHOD ENZYMOL, V244, P423; OLEKSYSZYN J, 1991, BIOCHEMISTRY-US, V30, P485, DOI 10.1021/bi00216a026; PAUL S, 1991, J BIOL CHEM, V266, P16128; Paul S, 2003, J BIOL CHEM, V278, P20429, DOI 10.1074/jbc.M300870200; PAUL S, 1989, SCIENCE, V244, P1158, DOI 10.1126/science.2727702; PAUL S, 1992, J BIOL CHEM, V267, P13142; Paul S, 2001, J BIOL CHEM, V276, P28314, DOI 10.1074/jbc.M102530200; Planque S, 2003, J BIOL CHEM, V278, P20436, DOI 10.1074/jbc.M301468200; PLANQUE S, 2004, J BIOL CHEM     0115; Rekvig OP, 2003, ARTHRITIS RHEUM-US, V48, P300, DOI 10.1002/art.10739; SAMPSON NS, 1991, BIOCHEMISTRY-US, V30, P2255, DOI 10.1021/bi00222a031; SCHWARTZ M, 1982, CLIN CHIM ACTA, V124, P213, DOI 10.1016/0009-8981(82)90389-8; SHUSTER AM, 1992, SCIENCE, V256, P665, DOI 10.1126/science.1585181; SUN M, 1994, J BIOL CHEM, V269, P734; Sun M, 1997, J MOL BIOL, V271, P374, DOI 10.1006/jmbi.1997.1196; Tomer Y, 1997, CLIN IMMUNOL IMMUNOP, V82, P3, DOI 10.1006/clin.1996.4243; Vincent A, 2002, NAT REV IMMUNOL, V2, P797, DOI 10.1038/nri916; Voice JK, 2002, REGUL PEPTIDES, V109, P199, DOI 10.1016/S0167-0115(02)00182-9; Voice JK, 2003, J IMMUNOL, V170, P308, DOI 10.4049/jimmunol.170.1.308; Wellings DA, 1997, METHOD ENZYMOL, V289, P44	36	16	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7877	7883		10.1074/jbc.M310950200	http://dx.doi.org/10.1074/jbc.M310950200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14676184	hybrid			2022-12-25	WOS:000189103300064
J	Tremeau-Bravard, A; Riedl, T; Egly, JM; Dahmus, ME				Tremeau-Bravard, A; Riedl, T; Egly, JM; Dahmus, ME			Fate of RNA polymerase II stalled at a cisplatin lesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPAIR COUPLING FACTOR; TERMINAL DOMAIN PHOSPHATASE; NUCLEOTIDE EXCISION-REPAIR; CYCLOBUTANE PYRIMIDINE DIMER; TRANSCRIBED DNA STRAND; XERODERMA-PIGMENTOSUM; ELONGATION COMPLEXES; FACTOR CSB/ERCC6; THYMINE DIMER; TEMPLATE DNA	Elongating RNA polymerase II blocked by DNA damage in the transcribed DNA strand is thought to initiate the transcription-coupled repair process. The objective of this study is to better understand the sequence of events that occurs during repair from the time RNA polymerase II first encounters the lesion. This study establishes that an immobilized DNA template containing a unique cisplatin lesion can serve as an in vitro substrate for both transcription and DNA repair. RNA polymerase II is quantitatively stalled at the cisplatin lesion during transcription and can be released from the template, along with the nascent transcript, in an ATP-dependent manner. RNA polymerase II stalled at a lesion and containing a dephosphorylated repetitive carboxyl-terminal domain (CTD) appears to be more sensitive toward release. However, a dephosphorylated CTD can become readily phosphorylated in front of the lesion by CTD kinases in the presence of ATP. The observation that RNA polymerase II and transcript release occurs in a TFIIH-deficient repair extract but not in a reconstituted repair system demonstrates that disassembly of the elongation complex can occur independently of the repair process and vice versa. Indeed, the presence of RNA polymerase II at the lesion does not prevent dual incision from occurring. Finally, we also propose that the Cockayne's syndrome B protein factor, believed to be the mammalian transcription repair coupling factor, is neither involved in transcript release nor required for dual incision in the presence of lesion-stalled RNA polymerase II in vitro. More likely, it prevents RNA polymerase from backing up when it encounters the lesion. The ability to transcribe and repair the same damaged DNA molecule fixed on beads, along with the fact that the reaction conditions can be freely altered, provides a powerful tool to study the fate of RNA polymerase II blocked on the cisplatin lesion.	Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	University of California System; University of California Davis; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Dahmus, ME (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, 1 Shields Ave, Davis, CA 95616 USA.	medahmus@ucdavis.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033300] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33300] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Araujo SJ, 2000, GENE DEV, V14, P349; Berneburg M, 2001, ADV GENET, V43, P71, DOI 10.1016/S0065-2660(01)43004-5; Bradsher J, 2002, MOL CELL, V10, P819, DOI 10.1016/S1097-2765(02)00678-0; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; EILAT D, 1982, P NATL ACAD SCI-BIOL, V79, P3818, DOI 10.1073/pnas.79.12.3818; Friedberg EC, 2003, NATURE, V421, P436, DOI 10.1038/nature01408; Frit P, 2002, MOL CELL, V10, P1391, DOI 10.1016/S1097-2765(02)00732-3; GERARD M, 1991, J BIOL CHEM, V266, P20940; Hara R, 1999, J BIOL CHEM, V274, P24779, DOI 10.1074/jbc.274.35.24779; JOHNSON RT, 1985, J CELL SCI, V76, P115; Kalogeraki VS, 2003, J BIOL CHEM, V278, P19558, DOI 10.1074/jbc.M301060200; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P23, DOI 10.1016/S0027-5107(01)00141-5; Lehman AL, 2000, J BIOL CHEM, V275, P14923, DOI 10.1074/jbc.275.20.14923; Lindahl T, 1997, CURR OPIN GENET DEV, V7, P158, DOI 10.1016/S0959-437X(97)80124-4; Liu MY, 1998, J BIOL CHEM, V273, P25541, DOI 10.1074/jbc.273.40.25541; Marshall NF, 2000, J BIOL CHEM, V275, P32430, DOI 10.1074/jbc.M005898200; Marshall NF, 1998, J BIOL CHEM, V273, P31726, DOI 10.1074/jbc.273.48.31726; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; MAY A, 1993, J BIOL CHEM, V268, P1650; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; Park JS, 2002, CELL, V109, P757, DOI 10.1016/S0092-8674(02)00769-9; REINES D, 1992, J BIOL CHEM, V267, P3795; Selby CP, 1997, NUCLEIC ACIDS RES, V25, P787, DOI 10.1093/nar/25.4.787; Selby CP, 1997, P NATL ACAD SCI USA, V94, P11205, DOI 10.1073/pnas.94.21.11205; Selby CP, 1997, J BIOL CHEM, V272, P1885, DOI 10.1074/jbc.272.3.1885; SELBY CP, 1995, J BIOL CHEM, V270, P4882, DOI 10.1074/jbc.270.9.4882; Shivji MKK, 1999, METH MOL B, V113, P373; Svejstrup JQ, 2003, J CELL SCI, V116, P447, DOI 10.1242/jcs.00271; Svejstrup JQ, 2002, MOL CELL, V9, P1151, DOI 10.1016/S1097-2765(02)00553-1; Svejstrup JQ, 2002, NAT REV MOL CELL BIO, V3, P21, DOI 10.1038/nrm703; TAKAYAMA K, 1995, CANCER RES, V55, P5656; Tantin D, 1997, MOL CELL BIOL, V17, P6803, DOI 10.1128/MCB.17.12.6803; Tornaletti S, 2003, J BIOL CHEM, V278, P35791, DOI 10.1074/jbc.M305394200; Tornaletti S, 1999, J BIOL CHEM, V274, P24124, DOI 10.1074/jbc.274.34.24124; van den Boom V, 2002, BIOESSAYS, V24, P780, DOI 10.1002/bies.10150; Woudstra EC, 2002, NATURE, V415, P929, DOI 10.1038/415929a; ZHEN WP, 1993, CARCINOGENESIS, V14, P919, DOI 10.1093/carcin/14.5.919; Zorio DAR, 2001, CURR BIOL, V11, pR144, DOI 10.1016/S0960-9822(01)00063-X	41	56	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7751	7759		10.1074/jbc.M309853200	http://dx.doi.org/10.1074/jbc.M309853200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14672951	hybrid			2022-12-25	WOS:000189103300048
J	Weernink, PAO; Meletiadis, K; Hommeltenberg, S; Hinz, M; Ishihara, H; Schmidt, M; Jakobs, KH				Weernink, PAO; Meletiadis, K; Hommeltenberg, S; Hinz, M; Ishihara, H; Schmidt, M; Jakobs, KH			Activation of type I phosphatidylinositol 4-phosphate 5-kinase isoforms by the Rho GTPases, RhoA, Rac1, and Cdc42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-D STIMULATION; ACTIN STRESS FIBERS; LIPID KINASE FAMILY; DIFFICILE TOXIN-B; PLASMA-MEMBRANE; PHOSPHATE KINASE; 3T3 FIBROBLASTS; 4,5-BISPHOSPHATE; RECEPTOR; BINDING	Type I phosphatidylinositol 4-phosphate 5-kinase (PIP5K) catalyzes the formation of the phospholipid, phosphatidylinositol 4,5-bisphosphate (PIP2), which is implicated in many cellular processes. The Rho GTPases, RhoA and Rac1, have been shown previously to activate PIP5K and to bind PIP5K. Three type I PIP5K isoforms ( Ialpha, Ibeta, and Igamma) have been identified; however, it is unclear whether these isoforms are differentially or even sequentially regulated by Rho GTPases. Here we show that RhoA and Rac1, as well as Cdc42, but not the Ras-like GTPases, RalA and Rap1A, markedly stimulate PIP2 synthesis by all three PIP5K isoforms expressed in human embryonic kidney 293 cells, both in vitro and in vivo. RhoA-stimulated PIP2 synthesis by the PIP5K isoforms was mediated by the RhoA effector, Rho-kinase. Stimulation of PIP5K isoforms by Rac1 and Cdc42 was apparently independent of and additive with RhoA- and Rho-kinase, as shown by studies with C3 transferase and Rho-kinase mutants. RhoA, and to a lesser extent Rac1, but not Cdc42, interacted in a nucleotide-independent form with all three PIP5K isoforms. Binding of PIP5K isoforms to GTP-bound, but not GDP-bound, RhoA could be displaced by Rho-kinase, suggesting a direct and constitutive PIP5K-Rho GTPase binding, which, however, does not trigger PIP5K activation. In summary, our findings indicate that synthesis of PIP2 by the three PIP5K isoforms is controlled by RhoA, acting via Rho-kinase, as well as Rac1 and Cdc42, implicating that regulation of PIP2 synthesis has a central position in signaling by these three Rho GTPases.	Univ Klinikum Essen, Inst Pharmakol, D-45122 Essen, Germany; Tohoku Univ, Grad Sch Med, Div Mol Metab & Diabet, Sendai, Miyagi 9808575, Japan	University of Duisburg Essen; Tohoku University	Weernink, PAO (corresponding author), Univ Klinikum Essen, Inst Pharmakol, Hufelandstr 55, D-45122 Essen, Germany.	paschal.oudeweernink@uni-essen.de						Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1999, J BIOL CHEM, V274, P32418, DOI 10.1074/jbc.274.45.32418; Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Blomquist A, 2000, BIOCHEM J, V352, P319, DOI 10.1042/0264-6021:3520319; Chatah NEH, 2001, J BIOL CHEM, V276, P34059, DOI 10.1074/jbc.M104917200; CHILVERS ER, 1991, BIOCHEM J, V275, P373, DOI 10.1042/bj2750373; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; Doughman RL, 2003, J BIOL CHEM, V278, P23036, DOI 10.1074/jbc.M211397200; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Exton JH, 2002, FEBS LETT, V531, P58, DOI 10.1016/S0014-5793(02)03405-1; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Gasteier JE, 2003, J BIOL CHEM, V278, P38902, DOI 10.1074/jbc.M306229200; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Gratacap MP, 2001, J BIOL CHEM, V276, P47906, DOI 10.1074/jbc.M104442200; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Holz RW, 2000, J BIOL CHEM, V275, P17878, DOI 10.1074/jbc.M000925200; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; Itoh T, 2000, J BIOL CHEM, V275, P19389, DOI 10.1074/jbc.M000426200; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; Ma L, 1998, J CELL BIOL, V140, P1125; Malecz N, 2000, CURR BIOL, V10, P1383, DOI 10.1016/S0960-9822(00)00778-8; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; Matsui T, 1999, CURR BIOL, V9, P1259, DOI 10.1016/S0960-9822(99)80508-9; Padron D, 2003, J CELL BIOL, V162, P693, DOI 10.1083/jcb.200302051; Park SJ, 2001, J BIOL CHEM, V276, P4781, DOI 10.1074/jbc.M010177200; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; Ren XD, 1998, CURR OPIN GENET DEV, V8, P63, DOI 10.1016/S0959-437X(98)80063-4; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Schmidt M, 1996, EUR J BIOCHEM, V240, P707, DOI 10.1111/j.1432-1033.1996.0707h.x; Schmidt M, 1996, N-S ARCH PHARMACOL, V354, P87, DOI 10.1007/BF00178707; SCHMIDT M, 1994, EUR J BIOCHEM, V225, P667, DOI 10.1111/j.1432-1033.1994.00667.x; Schmidt M, 1999, J BIOL CHEM, V274, P14648, DOI 10.1074/jbc.274.21.14648; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; Toker A, 2002, CELL MOL LIFE SCI, V59, P761, DOI 10.1007/s00018-002-8465-z; Tolias KF, 2000, CURR BIOL, V10, P153, DOI 10.1016/S0960-9822(00)00315-8; Tolias KF, 1998, MOL CELL BIOL, V18, P762, DOI 10.1128/MCB.18.2.762; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Tsuji T, 2002, J CELL BIOL, V157, P819, DOI 10.1083/jcb.200112107; van Hennik PB, 2003, J BIOL CHEM, V278, P39166, DOI 10.1074/jbc.M307001200; van Horck FPG, 2002, CURR BIOL, V12, P241, DOI 10.1016/S0960-9822(01)00660-1; Weernink PAO, 2000, EUR J BIOCHEM, V267, P5237, DOI 10.1046/j.1432-1327.2000.01599.x; Weernink PAO, 2000, J BIOL CHEM, V275, P10168, DOI 10.1074/jbc.275.14.10168; Wenk MR, 2001, NEURON, V32, P79, DOI 10.1016/S0896-6273(01)00456-1; Whiteford CC, 1997, BIOCHEM J, V323, P597, DOI 10.1042/bj3230597; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105; Yamamoto M, 2001, J CELL BIOL, V152, P867, DOI 10.1083/jcb.152.5.867; Yamazaki M, 2002, J BIOL CHEM, V277, P17226, DOI 10.1074/jbc.M109795200; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756	64	132	137	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7840	7849		10.1074/jbc.M312737200	http://dx.doi.org/10.1074/jbc.M312737200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14681219	hybrid			2022-12-25	WOS:000189103300060
J	Robbins, JB; Murphy, MC; White, BA; Mackie, RI; Ha, T; Cann, IKO				Robbins, JB; Murphy, MC; White, BA; Mackie, RI; Ha, T; Cann, IKO			Functional analysis of multiple single-stranded DNA-binding proteins from Methanosarcina acetivorans and their effects on DNA synthesis by DNA polymerase BI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARCHAEON SULFOLOBUS-SOLFATARICUS; THERMOAUTOTROPHICUM DELTA-H; RESONANCE ENERGY-TRANSFER; REPLICATION FACTOR-C; ESCHERICHIA-COLI; PYROCOCCUS-FURIOSUS; CLAMP-LOADER; IDENTIFICATION; SSB; GENOME	Single-stranded DNA-binding proteins and their functional homologs, replication protein X are essential components of cellular DNA replication, repair and recombination. We describe here the isolation and characterization of multiple replication protein A homologs, RPA1, RPA2, and RPA3, from the archaeon Methanosarcina acetivorans. RPA1 comprises four single-stranded DNA-binding domains, while RPA2 and RPA3 are each composed of two such domains and a zinc finger domain. Gel filtration analysis suggested that RPA1 exists as homotetramers and homodimers in solution, while RPA2 and RPA3 form only homodimers. Unlike the multiple RPA proteins found in other Archaea and eukaryotes, each of the M. acetivorans RPAs can act as a distinct single-stranded DNA-binding protein. Fluorescence resonance energy transfer and fluorescence polarization anisotropy studies revealed that the M. acetivorans RPAs bind to as few as 10 single-stranded DNA bases. However, more stable binding is achieved with single-stranded DNA of 18-23 bases, and for such substrates the estimated K-d was 3.82 +/- 0.28 nm, 173.6 +/- 105.17 nm, and 5.92 +/- 0.23 nm, for RPA1, RPA2, and RPA3, respectively. The architectures of the M. acetivorans RPAs are different from those of hitherto reported homologs. Thus, these proteins may represent novel forms of replication protein A. Most importantly, our results show that the three RPAs and their combinations highly stimulate the primer extension capacity of M. acetivorans DNA polymerase BI. Although bacterial SSB and eukaryotic RPA have been shown to stimulate DNA synthesis by their cognate DNA polymerases, our findings provide the first in vitro biochemical evidence for the conservation of this property in an archaeon.	Univ Illinois, Dept Anim Sci, Urbana, IL 61801 USA; Univ Illinois, Dept Phys, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Cann, IKO (corresponding author), Univ Illinois, Dept Anim Sci, 1207 W Gregory Dr, Urbana, IL 61801 USA.	icann@uiuc.edu	Ha, Taekjip/B-9506-2009	Ha, Taekjip/0000-0003-2195-6258	NIGMS NIH HHS [R01 GM065367, 5T32GM08276, GM65367] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008276, R01GM065367] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bar-Ziv R, 2001, P NATL ACAD SCI USA, V98, P9068, DOI 10.1073/pnas.151242898; Cann IKO, 2001, J BACTERIOL, V183, P2614, DOI 10.1128/JB.183.8.2614-2623.2001; Cann IKO, 1999, J BACTERIOL, V181, P6591, DOI 10.1128/JB.181.21.6591-6599.1999; Cann IKO, 1999, GENETICS, V152, P1249; Chedin F, 1998, TRENDS BIOCHEM SCI, V23, P273, DOI 10.1016/S0968-0004(98)01243-2; Cheng W, 2001, J MOL BIOL, V310, P327, DOI 10.1006/jmbi.2001.4758; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; De Felice M, 1999, J MOL BIOL, V291, P47, DOI 10.1006/jmbi.1999.2939; Deppenmeier U, 2002, J MOL MICROB BIOTECH, V4, P453; FAY PJ, 1981, J BIOL CHEM, V256, P976; Galagan JE, 2002, GENOME RES, V12, P532, DOI 10.1101/gr.223902; Haseltine CA, 2002, MOL MICROBIOL, V43, P1505, DOI 10.1046/j.1365-2958.2002.02807.x; Ishino Y, 1998, GENES GENET SYST, V73, P323, DOI 10.1266/ggs.73.323; Karsten R., 1997, BIF FUTURA, V12, P20; Kelly TJ, 1998, P NATL ACAD SCI USA, V95, P14634, DOI 10.1073/pnas.95.25.14634; Kelman Z, 2000, J BIOL CHEM, V275, P7327, DOI 10.1074/jbc.275.10.7327; Kelman Z, 1999, J BIOL CHEM, V274, P28751, DOI 10.1074/jbc.274.40.28751; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; Komori K, 2001, J BIOL CHEM, V276, P25654, DOI 10.1074/jbc.M102423200; Kozlov AG, 2002, BIOCHEMISTRY-US, V41, P11611, DOI 10.1021/bi020361m; Krejci L, 2002, STRUCTURE, V10, P601, DOI 10.1016/S0969-2126(02)00765-7; Lakowicz JR, 1999, PRINCIPLES FLUORESCE, P291, DOI 10.1007/978-1-4757-3061-6; Lilley DMJ, 2000, CURR OPIN CHEM BIOL, V4, P507, DOI 10.1016/S1367-5931(00)00124-1; Lin YL, 1998, J BIOL CHEM, V273, P1453, DOI 10.1074/jbc.273.3.1453; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; MACKIE RI, 1992, ENCY MICROBIOLOGY, V3, P97; Perler FB, 1996, ADV PROTEIN CHEM, V48, P377; Pisani FM, 2000, J MOL BIOL, V301, P61, DOI 10.1006/jmbi.2000.3964; Raghunathan S, 2000, NAT STRUCT BIOL, V7, P648, DOI 10.1038/77943; Selvin PR, 2000, NAT STRUCT BIOL, V7, P730, DOI 10.1038/78948; Wadsworth RIM, 2001, NUCLEIC ACIDS RES, V29, P914, DOI 10.1093/nar/29.4.914; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P5088; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Zhou ZHS, 1999, BIOCHEMISTRY-US, V38, P15915, DOI 10.1021/bi992062b	35	36	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6315	6326		10.1074/jbc.M304491200	http://dx.doi.org/10.1074/jbc.M304491200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14676214	hybrid			2022-12-25	WOS:000188969200016
J	Jacob, R; Heine, M; Eikemeyer, J; Frerker, N; Zimmer, KP; Rescher, U; Gerke, V; Naim, HY				Jacob, R; Heine, M; Eikemeyer, J; Frerker, N; Zimmer, KP; Rescher, U; Gerke, V; Naim, HY			Annexin II is required for apical transport in polarized epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; LACTASE-PHLORHIZIN HYDROLASE; GPI-ANCHORED PROTEINS; MDCK CELLS; INTRACELLULAR-TRANSPORT; CYTOPLASMIC DOMAIN; EARLY ENDOSOMES; SORTING SIGNAL; GOLGI NETWORK; MEMBRANE	The sorting of apical proteins comprises an initial recognition step in the trans Golgi network and a final partitioning of the apical pool of proteins into at least two different types of vesicular carriers. One criteria of these carriers is the association or non-association of the protein content with lipid rafts. We have previously characterized a population containing the raft-associated sucrase-isomaltase-carrying vesicles (SAVs) and another one, the non-raft-associated lactase-phlorizin hydrolase-carrrying vesicles (LAVs) that are targeted separately to the apical membrane. Here, we demonstrate biochemically and by employing confocal laser microscopy that the annexin II-S100A10 complex is a component of SAVs and is absent from LAVs. The unequivocal role of annexin II in the apical targeting of SI is clearly demonstrated when down-regulation of this protein by annexin II-specific small interfering RNA drastically decreases the apical delivery of SI in the epithelial cell line Madin-Darby canine kidney. The annexin II-S100A10 complex plays therefore a crucial role in routing SAVs to the apical membrane of epithelial cells.	Univ Marburg, Dept Cell Biol & Cell Pathol, D-35033 Marburg, Germany; Hannover Sch Vet Med, Dept Physiol Chem, Hannover, Germany; Univ Childrens Hosp Muenster, Munster, Germany; Univ Munster, Inst Med Biochem, Munster, Germany	Philipps University Marburg; University of Veterinary Medicine Hannover, Foundation; University of Munster; University of Munster	Jacob, R (corresponding author), Univ Marburg, Dept Cell Biol & Cell Pathol, Robert Koch Str 6, D-35033 Marburg, Germany.	jacob@staff.uni-marburg.de	Zimmer, Klaus-Peter/AAY-9351-2020; Heine, Martin/C-6285-2011; Jacob, Ralf/B-8163-2011; Zimmer, Klaus-Peter/AAY-9261-2020					BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; Chuang JZ, 1998, J CELL BIOL, V142, P1245, DOI 10.1083/jcb.142.5.1245; DANIELSEN EM, 1995, BIOCHEMISTRY-US, V34, P1596, DOI 10.1021/bi00005a016; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; FIEDLER K, 1995, J CELL BIOL, V128, P1043, DOI 10.1083/jcb.128.6.1043; Filipenko NR, 2001, J BIOL CHEM, V276, P5310, DOI 10.1074/jbc.M009710200; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; GERKE V, 1985, J BIOL CHEM, V260, P1688; Girard C, 2002, EMBO J, V21, P4439, DOI 10.1093/emboj/cdf469; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HARDER T, 1993, J CELL BIOL, V123, P1119, DOI 10.1083/jcb.123.5.1119; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; Jacob R, 2000, J BIOL CHEM, V275, P6566, DOI 10.1074/jbc.275.9.6566; Jacob R, 2003, CURR BIOL, V13, P607, DOI 10.1016/S0960-9822(03)00188-X; Jacob R, 1999, J BIOL CHEM, V274, P8061, DOI 10.1074/jbc.274.12.8061; Jacob R, 2001, CURR BIOL, V11, P1444, DOI 10.1016/S0960-9822(01)00446-8; JACOB R, 1994, J BIOL CHEM, V269, P2712; Jost M, 1997, J CELL SCI, V110, P221; Lafont F, 1998, J CELL BIOL, V142, P1413, DOI 10.1083/jcb.142.6.1413; Lin SS, 1998, J CELL BIOL, V142, P51, DOI 10.1083/jcb.142.1.51; LISANTI MP, 1990, J MEMBRANE BIOL, V113, P155, DOI 10.1007/BF01872889; MAIURI L, 1991, GASTROENTEROLOGY, V100, P359, DOI 10.1016/0016-5085(91)90203-W; Mostov K, 2003, NAT CELL BIOL, V5, P287, DOI 10.1038/ncb0403-287; NEUHOFF V, 1990, ELECTROPHORESIS, V11, P101, DOI 10.1002/elps.1150110202; Okuse K, 2002, NATURE, V417, P653, DOI 10.1038/nature00781; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; OSBORN M, 1988, EXP CELL RES, V175, P81, DOI 10.1016/0014-4827(88)90257-1; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; Simmen T, 2002, NAT CELL BIOL, V4, P154, DOI 10.1038/ncb745; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; Van de Graaf SFJ, 2003, EMBO J, V22, P1478, DOI 10.1093/emboj/cdg162; Zheng XL, 1999, J BIOL CHEM, V274, P1596, DOI 10.1074/jbc.274.3.1596; Zobiack N, 2003, MOL BIOL CELL, V14, P4896, DOI 10.1091/mbc.E03-06-0387	39	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3680	3684		10.1074/jbc.C300503200	http://dx.doi.org/10.1074/jbc.C300503200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14670963	hybrid			2022-12-25	WOS:000188379600067
J	Mateo-Lozano, S; Tirado, OM; Notario, V				Mateo-Lozano, S; Tirado, OM; Notario, V			Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation	ONCOGENE			English	Article						mTOR; rapamycin; EWS/FLI-1; Ewing's sarcoma	TRANSFORMING-GROWTH-FACTOR; II RECEPTOR; EWS-FLI1; FAMILY; EXPRESSION; TARGET; EWS; ONCOPROTEINS; PATHWAY	Ewing's sarcoma (ES) is the prototype of a family of tumors (ESFT) of neuroectodermal origin formed by small, round cells with limited neural differentiation, which arise most frequently within bones in children or adolescents. The proliferation of ESFT cells is highly dependent on the establishment of, and signaling through several growth factor-mediated autocrine loops. The mammalian target of rapamycin (mTOR) is a central regulator of translation and cell proliferation, involved in the cellular response to various nutritional, stress and mitogenic effectors. As mTOR has recently been associated with certain human cancers, we investigated the possibility that mTOR played a role in the regulation of ES cell proliferation. Results showed that ES cell lines carrying EWS/FLI-1 alleles of different types expressed different levels of total and phosphorylated mTOR protein. We demonstrate that rapamycin, an mTOR inhibitor, efficiently blocked the proliferation of all cell lines by promoting cell cycle arrest at the G(1) phase. This was paralleled by the downregulation of the levels of the EWS/FLI-1 proteins, regardless of their fusion type, and the concomitant restoration of the expression of the TGF-beta type 2 receptor (TGFbeta RII), which is known to be repressed by several EWS-ETS fusion proteins. The expression of a rapamycin-resistant mTOR construct prevented both the proliferation blockade and the EWS/FLI-1 downregulation. These data demonstrate that mTOR signaling plays a central role in ES cell pathobiology and strongly suggest that the use of rapamycin as a cytostatic agent may be an efficient tool for the treatment of ES patients.	Georgetown Univ, Med Ctr, Dept Radiat Med, Expt Carcinogenesis Lab, Washington, DC 20057 USA	Georgetown University	Notario, V (corresponding author), Georgetown Univ, Med Ctr, Dept Radiat Med, Expt Carcinogenesis Lab, Res Bldg,Room E215,3970 Reservoir Rd NW, Washington, DC 20057 USA.	notariov@georgetown.edu	/AAB-6461-2022; /AFP-0764-2022; Tirado, Oscar Martínez/R-9604-2019	Tirado, Oscar Martínez/0000-0002-4666-2822; Mateo, Silvia/0000-0002-2365-1573	NATIONAL CANCER INSTITUTE [P30CA051008, P01CA074175] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA74175, P30-CA51008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 1998, CURR OPIN IMMUNOL, V10, P330, DOI 10.1016/S0952-7915(98)80172-6; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; Aryee DNT, 2000, LAB INVEST, V80, P1833, DOI 10.1038/labinvest.3780194; Benini S, 2001, CLIN CANCER RES, V7, P1790; Daniels G A, 2001, Expert Rev Anticancer Ther, V1, P211, DOI 10.1586/14737140.1.2.211; de Alava E, 2000, AM J PATHOL, V156, P849, DOI 10.1016/S0002-9440(10)64953-X; Decker T, 2003, BLOOD, V101, P278, DOI 10.1182/blood-2002-01-0189; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Deneen B, 2001, ONCOGENE, V20, P6731, DOI 10.1038/sj.onc.1204875; Elit Laurie, 2002, Curr Opin Investig Drugs, V3, P1249; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Girnita L, 2000, ONCOGENE, V19, P4298, DOI 10.1038/sj.onc.1203755; Grolleau A, 2002, J BIOL CHEM, V277, P22175, DOI 10.1074/jbc.M202014200; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Im YH, 2000, CANCER RES, V60, P1536; Kim J, 1999, PHYSIOL GENOMICS, V1, P127, DOI 10.1152/physiolgenomics.1999.1.3.127; Kovar H, 2001, CANCER RES, V61, P5992; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Lin PP, 1999, CANCER RES, V59, P1428; Luan FL, 2003, KIDNEY INT, V63, P917, DOI 10.1046/j.1523-1755.2003.00805.x; Matsumoto Y, 2001, BRIT J CANCER, V84, P768, DOI 10.1054/bjoc.2000.1652; Nakatani F, 2003, J BIOL CHEM, V278, P15105, DOI 10.1074/jbc.M211470200; Rodriguez-Galindo C, 2003, MED PEDIATR ONCOL, V40, P276, DOI 10.1002/mpo.10240; Sausville EA, 1999, PHARMACOL THERAPEUT, V82, P285, DOI 10.1016/S0163-7258(98)00062-X; Scotlandi K, 1998, CANCER RES, V58, P4127; Seufferlein T, 1996, CANCER RES, V56, P3895; Shah SA, 2001, J SURG RES, V97, P123, DOI 10.1006/jsre.2001.6145; Toretsky JA, 1999, CANCER RES, V59, P5745; Uren A, 2003, ONCOGENE, V22, P2334, DOI 10.1038/sj.onc.1206330; van der Poel HG, 2003, UROL RES, V30, P380, DOI 10.1007/s00240-002-0282-1; Visner GA, 2003, CIRCULATION, V107, P911, DOI 10.1161/01.CIR.0000048191.75585.60; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x; Zwerner JP, 2001, ONCOGENE, V20, P626, DOI 10.1038/sj.onc.1204133	35	78	96	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2003	22	58					9282	9287		10.1038/sj.onc.1207081	http://dx.doi.org/10.1038/sj.onc.1207081			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755JU	14681687				2022-12-25	WOS:000187400400010
J	Morito, N; Yoh, K; Itoh, K; Hirayama, A; Koyama, A; Yamamoto, M; Takahashi, S				Morito, N; Yoh, K; Itoh, K; Hirayama, A; Koyama, A; Yamamoto, M; Takahashi, S			Nrf2 regulates the sensitivity of death receptor signals by affecting intracellular glutathione levels	ONCOGENE			English	Article						Nrf2; oxidative stress; apoptosis; fas; TNF-receptor I	TUMOR-NECROSIS-FACTOR; PLANAR AROMATIC-COMPOUNDS; OXIDATIVE STRESS; INDUCIBLE EXPRESSION; APOPTOSIS; MICE; DEPLETION; IDENTIFICATION; ACETAMINOPHEN; ELEMENTS	Nrf2 is a basic leucine zipper transcriptional activator that is essential for the coordinate transcriptional induction of various antioxidant drug-metabolizing enzymes. Numerous studies have firmly established Nrf2's importance in protection from oxidative stress and certain chemical insults. Given the protective function of Nrf2, surprisingly few studies have focused on the relationship between Nrf2 and apoptosis. Therefore, we analysed how Nrf2 influences Fas signaling using Nrf2-deficient T cells. At a concentration of 1 mug/ml, the anti-Fas antibody induced 60% of cell death in Nrf2-deficient cultured thymocytes while, using the same treatment, only 40% of Nrf2 wildtype thymocytes died (P < 0.05). Nrf2 deficiency enhances the sensitivity of Fas-mediated apoptosis in T cells. Next we examined the effect of Nrf2 deficiency during hepatocellular apoptosis in vivo. In comparison to wildtype mice, Nrf2-deficient mice displayed more severe hepatitis after induction with the anti-Fas antibody or tumor necrosis factor (TNF)-alpha. The enhanced sensitivity to anti-Fas or TNF-alpha stimulation was restored by preadministration of glutathione ethyl monoester, a compound capable of passing the cell membrane and upregulating the intracellular levels of glutathione. The results indicated that Nrf2 activity regulates the sensitivity of death signals by means of intracellular glutathione levels.	Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Inst Clin Med, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Lab Anim Resource Ctr, Tsukuba, Ibaraki 3058575, Japan	University of Tsukuba; University of Tsukuba; University of Tsukuba; University of Tsukuba	Takahashi, S (corresponding author), Univ Tsukuba, Inst Basic Med Sci, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	satoruta@md.tsukuba.ac.jp	Itoh, Ken/B-9506-2013; Yamamoto, Masayuki/A-4873-2010; Hirayama, Aki/G-7842-2017	Itoh, Ken/0000-0002-5518-0729; Yamamoto, Masayuki/0000-0002-9073-9436; Hirayama, Aki/0000-0001-5777-4208				Anderson M E, 1997, Adv Pharmacol, V38, P65; Chan D, 2000, AUSTRALAS J AGEING, V19, P26; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; Chen TS, 2000, MECH AGEING DEV, V120, P127, DOI 10.1016/S0047-6374(00)00214-1; Chiba T, 1996, EUR J IMMUNOL, V26, P1164, DOI 10.1002/eji.1830260530; Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501; Colell A, 1998, GASTROENTEROLOGY, V115, P1541, DOI 10.1016/S0016-5085(98)70034-4; DROGE W, 1994, FASEB J, V8, P1131; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Hall AG, 1999, EUR J CLIN INVEST, V29, P238; Haouzi D, 2001, HEPATOLOGY, V33, P1181, DOI 10.1053/jhep.2001.24235; Hentze H, 1999, HEPATOLOGY, V30, P177, DOI 10.1002/hep.510300111; Hentze H, 2000, AM J PATHOL, V156, P2045, DOI 10.1016/S0002-9440(10)65076-6; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1999, FREE RADICAL RES, V31, P319, DOI 10.1080/10715769900300881; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; JONES TW, 1986, ARCH TOXICOL, P259; Kotlo KU, 2003, ONCOGENE, V22, P797, DOI 10.1038/sj.onc.1206077; Leist M, 1996, MOL MED, V2, P109, DOI 10.1007/BF03402207; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MEISTER A, 1992, BIOCHEM PHARMACOL, V44, P1905, DOI 10.1016/0006-2952(92)90091-V; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; PRESTERA T, 1995, MOL MED, V1, P827, DOI 10.1007/BF03401897; Rahman I, 2001, BIOCHEM PHARMACOL, V62, P787, DOI 10.1016/S0006-2952(01)00702-X; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Srivastava SK, 2000, CANCER LETT, V153, P35, DOI 10.1016/S0304-3835(00)00333-5; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; UHLIG S, 1992, LIFE SCI, V51, P1083, DOI 10.1016/0024-3205(92)90509-N; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Xu Y, 1998, GASTROENTEROLOGY, V115, P1229, DOI 10.1016/S0016-5085(98)70095-2; Yoh K, 2001, KIDNEY INT, V60, P1343, DOI 10.1046/j.1523-1755.2001.00939.x; Zhivotovsky B, 1997, BIOCHEM BIOPH RES CO, V230, P481, DOI 10.1006/bbrc.1996.6016	40	90	96	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2003	22	58					9275	9281		10.1038/sj.onc.1207024	http://dx.doi.org/10.1038/sj.onc.1207024			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755JU	14681686	Green Submitted, Bronze			2022-12-25	WOS:000187400400009
J	Durr, M; Harder, F; Merkel, A; Bug, G; Henschler, R; Muller, AM				Durr, M; Harder, F; Merkel, A; Bug, G; Henschler, R; Muller, AM			Chimaerism and erythroid marker expression after microinjection of human acute myeloid leukaemia cells into murine blastocysts	ONCOGENE			English	Article						acute myeloid leukaemia (AML); embryonic microenvironment	TERATOCARCINOMA CELLS; EMBRYONAL CARCINOMA; RETINOIC ACID; MOUSE EMBRYOS; STEM-CELLS; DIFFERENTIATION; FUSION; CANCER; LINES; LIVER	It has been suggested that the embryonic microenvironment can control the survival and the transformed phenotype of tumour cells. Here, we addressed the hypothesis that the murine embryonic microenvironment can induce the differentiation of human tumour cells. To examine such interactions, we injected human leukaemic cells into preimplantation murine blastocysts at embryonic day 3.5 of gestation (E3.5). Microinjection of human KG-1 myeloid leukaemia cells and primary human acute myeloid leukaemia (AML) cells led to the generation of chimaeric embryos and adults. We observed that in E12.5 murine embryos, KG-1 cells were preferentially detected in yolk sac and peripheral blood, while primary AML cells mainly seeded the aorta gonad mesonephros region of chimaeric embryos. Analysis of the donor contribution in 15 different adult tissues showed that progeny of primary AML cells seeded to various haematopoietic and non-haematopoietic tissues. Chimaeric embryos and adults showed no apparent tumour formation. Furthermore, analysis of chimaeric E12.5 embryos revealed that the progeny of human KG-1 cells activated erythroid-specific human globin and glycophorin A expression. In summary, our data indicate that human AML cells activate markers of erythroid differentiation after injection into early murine embryos.	Univ Wurzburg, Inst Med Radiat & Cell Res MSZ, D-97078 Wurzburg, Germany; Red Cross Blood Ctr, Inst Transfus Med & Immune Haematol, D-60528 Frankfurt, Germany; Univ Frankfurt, Dept Med 3, D-60590 Frankfurt, Germany	University of Wurzburg; Goethe University Frankfurt	Muller, AM (corresponding author), Univ Wurzburg, Inst Med Radiat & Cell Res MSZ, Versbacherstr 5,D-2, D-97078 Wurzburg, Germany.		Bug, Gesine/H-8827-2013					Alcalay M, 2001, ONCOGENE, V20, P5680, DOI 10.1038/sj.onc.1204642; BARKER JE, 1970, NATURE, V228, P1305, DOI 10.1038/2281305a0; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; BRINSTER RL, 1974, J EXP MED, V140, P1049, DOI 10.1084/jem.140.4.1049; Bungert J, 1995, GENE DEV, V9, P3083, DOI 10.1101/gad.9.24.3083; DRACH J, 1993, CANCER RES, V53, P2100; Geiger H, 1998, CELL, V93, P1055, DOI 10.1016/S0092-8674(00)81210-6; GERSCHENSON M, 1986, P NATL ACAD SCI USA, V83, P7307, DOI 10.1073/pnas.83.19.7307; GOOTWINE E, 1982, NATURE, V299, P63, DOI 10.1038/299063a0; Harder F, 2002, BLOOD, V99, P719, DOI 10.1182/blood.V99.2.719; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; ILLMENSEE K, 1976, P NATL ACAD SCI USA, V73, P549, DOI 10.1073/pnas.73.2.549; JUNGHAHN I, 2001, BLOOD, V98; Kirchhof N, 2002, CELLS TISSUES ORGANS, V171, P77, DOI 10.1159/000057693; KOEFFLER HP, 1978, SCIENCE, V200, P1153, DOI 10.1126/science.306682; KOEFFLER HP, 1981, CANCER RES, V41, P919; Li L, 2003, CANCER RES, V63, P2733; Lichtenberger C, 1999, J IMMUNOL METHODS, V227, P75, DOI 10.1016/S0022-1759(99)00076-9; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585; MINTZ B, 1975, TERATOMAS DIFFERENTI, P59; MULLER AM, 1994, IMMUNITY, V1, P291, DOI 10.1016/1074-7613(94)90081-7; OUTRAM S, 1988, LEUKEMIA RES, V12, P651, DOI 10.1016/0145-2126(88)90099-9; PAPAIOANNOU VE, 1975, NATURE, V258, P70, DOI 10.1038/258070a0; PIERCE GB, 1979, P NATL ACAD SCI USA, V76, P6649, DOI 10.1073/pnas.76.12.6649; PIERCE GB, 1982, CANCER RES, V42, P1082; PODESTA AH, 1984, P NATL ACAD SCI-BIOL, V81, P7608, DOI 10.1073/pnas.81.23.7608; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROBINSON J, 1981, NATURE, V289, P68, DOI 10.1038/289068a0; ROSSANT J, 1985, EXP CELL RES, V156, P213, DOI 10.1016/0014-4827(85)90275-7; SACHS L, 1980, J NATL CANCER I, V65, P675, DOI 10.1093/jnci/65.4.675; SAITO H, 1985, BLOOD, V66, P1233; Sawyers CL, 2002, CURR OPIN GENET DEV, V12, P111, DOI 10.1016/S0959-437X(01)00273-8; Stevens L C, 1967, Adv Morphog, V6, P1; Tavian M, 1996, BLOOD, V87, P67, DOI 10.1182/blood.V87.1.67.bloodjournal87167; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; TERSTAPPEN LWMM, 1992, LEUKEMIA, V6, P993; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; WARBURTON PE, 1991, GENOMICS, V11, P324, DOI 10.1016/0888-7543(91)90139-6; WATERS BK, 1986, J EMBRYOL EXP MORPH, V98, P99; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729	43	22	27	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2003	22	57					9185	9191		10.1038/sj.onc.1207134	http://dx.doi.org/10.1038/sj.onc.1207134			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	752FJ	14668800				2022-12-25	WOS:000187149100009
J	Cheng, L; Mahon, GM; Kostenko, EV; Whitehead, IP				Cheng, L; Mahon, GM; Kostenko, EV; Whitehead, IP			Pleckstrin homology domain-mediated activation of the Rho-specific guanine nucleotide exchange factor Dbs by Rac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; ACTIN STRESS FIBERS; TRANSFORMING ACTIVITY; RAS TRANSFORMATION; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; FAMILY GTPASES; CELL-ADHESION; CDC42 GTPASES; PH DOMAIN	Dbs is a Rho-specific guanine nucleotide exchange factor that was identified in a screen for proteins whose expression causes deregulated growth in NIH 3T3 mouse fibroblasts. Although Rac1 has not been shown to be a substrate for Dbs in either in vitro or in vivo assays, the Rat ortholog of Dbs (Ost) has been shown to bind specifically to GTP.Rac1 in vitro. The dependence of the Rac1/Dbs interaction on GTP suggests that Dbs may in fact be an effector for Rac1. Here we show that the interaction between activated Rac1 and Dbs can be recapitulated in mammalian cells and that the Rac1 docking site resides within the pleckstrin homology domain of Dbs. This interaction is specific for Rac1 and is not observed between Rac1 and several other members of the Rho-specific guanine nucleotide exchange factor family. Co-expression of Dbs with activated Rac1 causes enhanced focus forming activity and elevated levels of GTP.RhoA in NIH 3T3 cells, indicating that Dbs is activated by the interaction. Consistent with this, activated Rac1 co-localizes with Dbs in NIH 3T3 cells, and natively expressed Rac1 relocalizes in response to Dbs expression. To summarize, we have characterized a surprisingly direct pleckstrin homology domain-mediated mechanism through which Rho GTPases can become functionally linked.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Whitehead, IP (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, 225 Warren St, Newark, NJ 07103 USA.	whiteip@umdnj.edu			NATIONAL CANCER INSTITUTE [R01CA097066] Funding Source: NIH RePORTER; NCI NIH HHS [CA 097066] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Baumeister MA, 2003, J BIOL CHEM, V278, P11457, DOI 10.1074/jbc.M211901200; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; Cheng L, 2002, MOL CELL BIOL, V22, P6895, DOI 10.1128/MCB.22.19.6895-6905.2002; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Chimini G, 2000, NAT CELL BIOL, V2, pE191, DOI 10.1038/35036454; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Crompton AM, 2000, J BIOL CHEM, V275, P25751, DOI 10.1074/jbc.M002050200; Evers EE, 2000, METHOD ENZYMOL, V325, P403; Fuentes EJ, 2003, J BIOL CHEM, V278, P21188, DOI 10.1074/jbc.M211792200; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HART MJ, 1994, J BIOL CHEM, V269, P62; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kim O, 2002, J BIOL CHEM, V277, P30066, DOI 10.1074/jbc.M201713200; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Lorenzi MV, 1999, ONCOGENE, V18, P4742, DOI 10.1038/sj.onc.1202851; Mahon GM, 2003, CURR BIOL, V13, P437, DOI 10.1016/S0960-9822(03)00090-3; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, COLD SPRING HARB SYM, V57, P661, DOI 10.1101/SQB.1992.057.01.072; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1991, NEW BIOL, V3, P372; Rossman KL, 2003, J BIOL CHEM, V278, P18393, DOI 10.1074/jbc.M300127200; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Russo C, 2001, J BIOL CHEM, V276, P19524, DOI 10.1074/jbc.M009742200; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Snyder JT, 2001, J BIOL CHEM, V276, P45868, DOI 10.1074/jbc.M106731200; Snyder JT, 2003, J BIOL CHEM, V278, P21099, DOI 10.1074/jbc.M301418200; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; VAN AL, 1997, GENE DEV, V11, P2295; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014	47	24	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12786	12793		10.1074/jbc.M313099200	http://dx.doi.org/10.1074/jbc.M313099200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14701795	hybrid			2022-12-25	WOS:000220334900093
J	Nomaguchi, M; Teramoto, T; Yu, L; Markoff, L; Padmanabhan, R				Nomaguchi, M; Teramoto, T; Yu, L; Markoff, L; Padmanabhan, R			Requirements for West Nile virus (-)- and (+)-strand subgenomic RNA synthesis in vitro by the viral RNA-dependent RNA polymerase expressed in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-C VIRUS; PUTATIVE METHYLTRANSFERASE DOMAIN; FLAVIVIRUS GENOMIC RNA; 3' UNTRANSLATED REGION; NEGATIVE-STRAND RNA; DE-NOVO SYNTHESIS; DENGUE VIRUS; SECONDARY STRUCTURE; NS3 PROTEIN; NTPASE ACTIVITY	RNA-dependent RNA polymerases (RdRPs) of the Flaviviridae family catalyze replication of positive (+)strand viral RNA through synthesis of minus (-)- and progeny (+)- strand RNAs. West Nile virus (WNV), a mosquito-borne member, is a rapidly re-emerging human pathogen in the United States since its first outbreak in 1999. To study the replication of the WNV RNA in vitro, an assay is described here that utilizes the WNV RdRP and subgenomic (-)- and (+)- strand template RNAs containing 5'- and 3'-terminal regions (TR) with the conserved sequence elements. Our results show that both 5'- and 3'-TRs of the (+)- strand RNA template including the wild type cyclization (CYC) motifs are important for RNA synthesis. However, the 3'-TR of the (-)- strand RNA template alone is sufficient for RNA synthesis. Mutational analysis of the CYC motifs revealed that the (+)- strand 5'- CYC motif is critical for (+)- strand RNA synthesis but neither the (-)- strand 5'- nor 3'-CYC motif is important for the (+)- strand RNA synthesis. Moreover, the 5'- cap inhibits the (+)- strand RNA synthesis from the 3' fold-back structure of (+)- strand RNA template without affecting the de novo synthesis of RNA. These results support a model that "cyclization" of the viral RNA play a role for (-)- strand RNA synthesis but not for (+)- strand RNA synthesis.	Georgetown Univ, Med Ctr, Dept Microbiol & Immunol, Washington, DC 20057 USA; US FDA, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA	Georgetown University; US Food & Drug Administration (FDA)	Padmanabhan, R (corresponding author), Georgetown Univ, Med Ctr, Dept Microbiol & Immunol, SW309 Med Dent Bldg,3900 Reservoir Rd, Washington, DC 20057 USA.	rp55@georgetown.edu			NIAID NIH HHS [AI 32078] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI032078, R01AI032078] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ackermann M, 2001, J BIOL CHEM, V276, P39926, DOI 10.1074/jbc.M104248200; Asnis DS, 2000, CLIN INFECT DIS, V30, P413, DOI 10.1086/313737; Bartelma G, 2002, VIROLOGY, V299, P122, DOI 10.1006/viro.2002.1504; Barton DJ, 2001, EMBO J, V20, P1439, DOI 10.1093/emboj/20.6.1439; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; BLACKWELL JL, 1995, J VIROL, V69, P5650, DOI 10.1128/JVI.69.9.5650-5658.1995; Borowski P, 2001, J VIROL, V75, P3220, DOI 10.1128/JVI.75.7.3220-3229.2001; Bredenbeek PJ, 2003, J GEN VIROL, V84, P1261, DOI 10.1099/vir.0.18860-0; BRINTON MA, 1986, VIROLOGY, V153, P113, DOI 10.1016/0042-6822(86)90012-7; Brinton MA, 2001, ANN NY ACAD SCI, V951, P207; Brinton MA, 2002, ANNU REV MICROBIOL, V56, P371, DOI 10.1146/annurev.micro.56.012302.160654; BRINTON MA, 1988, VIROLOGY, V162, P290, DOI 10.1016/0042-6822(88)90468-0; CALISHER CH, 1989, J GEN VIROL, V70, P37, DOI 10.1099/0022-1317-70-1-37; Campbell GL, 2002, LANCET INFECT DIS, V2, P519, DOI 10.1016/S1473-3099(02)00368-7; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; Corver J, 2003, J VIROL, V77, P2265, DOI 10.1128/JVI.77.3.2265-2270.2003; Cui TA, 1998, VIROLOGY, V246, P409, DOI 10.1006/viro.1998.9213; De Nova-Ocampo M, 2002, VIROLOGY, V295, P337, DOI 10.1006/viro.2002.1407; Egloff MP, 2002, EMBO J, V21, P2757, DOI 10.1093/emboj/21.11.2757; Guyatt KJ, 2001, J VIROL METHODS, V92, P37, DOI 10.1016/S0166-0934(00)00270-6; HAHN CS, 1987, J MOL BIOL, V198, P33, DOI 10.1016/0022-2836(87)90455-4; Herold J, 2001, MOL CELL, V7, P581, DOI 10.1016/S1097-2765(01)00205-2; Khromykh AA, 2001, J VIROL, V75, P6719, DOI 10.1128/JVI.75.14.6719-6728.2001; Kim DW, 1997, VIRUS RES, V49, P17, DOI 10.1016/S0168-1702(97)01452-4; KOONIN EV, 1993, J GEN VIROL, V74, P733, DOI 10.1099/0022-1317-74-4-733; Kuo MD, 1996, J GEN VIROL, V77, P2077, DOI 10.1099/0022-1317-77-9-2077; Li HT, 1999, J VIROL, V73, P3108, DOI 10.1128/JVI.73.4.3108-3116.1999; Lo MK, 2003, J VIROL, V77, P10004, DOI 10.1128/JVI.77.18.10004-10014.2003; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; Luo GX, 2000, J VIROL, V74, P851, DOI 10.1128/JVI.74.2.851-863.2000; Lyons T, 2001, J VIROL, V75, P10696, DOI 10.1128/JVI.75.22.10696-10708.2001; Meek J, 2002, CURR OPIN PEDIATR, V14, P72, DOI 10.1097/00008480-200202000-00013; MEN R, 1996, J VIROL, V70, P3390; MOHAN PM, 1991, GENE, V108, P185, DOI 10.1016/0378-1119(91)90433-C; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; Nash D, 2001, NEW ENGL J MED, V344, P1807, DOI 10.1056/NEJM200106143442401; Nomaguchi M, 2003, J VIROL, V77, P8831, DOI 10.1128/JVI.77.16.8831-8842.2003; O'Reilly EK, 1998, VIROLOGY, V252, P287, DOI 10.1006/viro.1998.9463; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; Ranjith-Kumar CT, 2001, J VIROL, V75, P8615, DOI 10.1128/JVI.75.18.8615-8623.2001; Rappole JH, 2000, EMERG INFECT DIS, V6, P319, DOI 10.3201/eid0604.000401; Reigadas S, 2001, EUR J BIOCHEM, V268, P5857, DOI 10.1046/j.0014-2956.2001.02532.x; RICE CM, 1996, FIELDS VIROLOGY, P931; Roehrig JT, 2002, CURR TOP MICROBIOL, V267, P223; ROZANOV MN, 1992, J GEN VIROL, V73, P2129, DOI 10.1099/0022-1317-73-8-2129; Shi PY, 1996, BIOCHEMISTRY-US, V35, P4222, DOI 10.1021/bi952398v; Shi PY, 1996, J VIROL, V70, P6278, DOI 10.1128/JVI.70.9.6278-6287.1996; SMITHBURN K. C, 1940, AMER JOUR TROP MED, V20, P471; Steffens S, 1999, J GEN VIROL, V80, P2583, DOI 10.1099/0022-1317-80-10-2583; Tan BH, 1996, VIROLOGY, V216, P317, DOI 10.1006/viro.1996.0067; WARRENER P, 1993, J VIROL, V67, P989, DOI 10.1128/JVI.67.2.989-996.1993; WENGLER G, 1991, VIROLOGY, V184, P707, DOI 10.1016/0042-6822(91)90440-M; WENGLER G, 1993, VIROLOGY, V197, P265, DOI 10.1006/viro.1993.1587; WESTAWAY EG, 1968, J IMMUNOL, V100, P569; Westaway EG, 2002, CURR TOP MICROBIOL, V267, P323; Yamashita T, 1998, J BIOL CHEM, V273, P15479, DOI 10.1074/jbc.273.25.15479; Yocupicio-Monroy RME, 2003, J VIROL, V77, P3067, DOI 10.1128/JVI.77.5.3067-3076.2003; You S, 1999, J BIOL CHEM, V274, P33714, DOI 10.1074/jbc.274.47.33714; You SY, 2001, J BIOL CHEM, V276, P15581, DOI 10.1074/jbc.M010923200; Zeng LL, 1998, J VIROL, V72, P7510, DOI 10.1128/JVI.72.9.7510-7522.1998	60	45	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12141	12151		10.1074/jbc.M310839200	http://dx.doi.org/10.1074/jbc.M310839200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14699096	hybrid			2022-12-25	WOS:000220334900020
J	Ahmad, N; Gabius, HJ; Andre, S; Kaltner, H; Sabesan, S; Roy, R; Liu, BC; Macaluso, F; Brewer, CF				Ahmad, N; Gabius, HJ; Andre, S; Kaltner, H; Sabesan, S; Roy, R; Liu, BC; Macaluso, F; Brewer, CF			Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGE-BINDING PROTEIN; RECOMBINANT POLYPEPTIDE; NEGATIVE REGULATION; CELL-GROWTH; LECTIN; EXPRESSION; OLIGOSACCHARIDES; APOPTOSIS; FAMILY; IDENTIFICATION	Galectin-3 is unique among the galectin family of animal lectins in its biological activities and structure. Most members of the galectin family including galectin-1 possess apoptotic activities, whereas galectin-3 possesses anti-apoptotic activity. Galectin-3 is also the only chimera type galectin and consists of a nonlectin N-terminal domain and a C-terminal carbohydrate-binding domain. Recent sedimentation equilibrium and velocity studies show that murine galectin-3 is a monomer in the absence and presence of LacNAc, a monovalent sugar. However, quantitative precipitation studies in the present report indicate that galectin-3 precipitates as a pentamer with a series of divalent pentasaccharides with terminal LacNAc residues. Furthermore, the kinetics of precipitation are fast, on the order of seconds. This indicates that although the majority of galectin-3 in solution is a monomer, a rapid equilibrium exists between the monomer and a small percentage of pentamer. The latter, in turn, precipitates with the divalent oligosaccharides, resulting in rapid conversion of monomer to pentamer by mass action equilibria. Mixed quantitative precipitation experiments and electron microscopy suggest that galectin-3 forms heterogenous, disorganized cross-linking complexes with the multivalent carbohydrates. This contrasts with galectin-1 and many plant lectins that form homogeneous, organized cross-linked complexes. The results are discussed in terms of the biological properties of galectin-3.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol & Microbiol & Immunol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Univ Munich, Inst Physiol Chem, D-80539 Munich, Germany; DuPont Co Inc, Wilmington, DE 19880 USA; Univ Ottawa, Dept Chem, Ctr Res Biopharmaceut, Ottawa, ON K1N 6N5, Canada	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Munich; DuPont; University of Ottawa	Brewer, CF (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol & Microbiol & Immunol, Bronx, NY 10461 USA.	brewer@aecom.yu.edu		Kaltner, Herbert/0000-0003-4680-8411; Andre, Sabine/0000-0003-0850-0432; Gabius, Hans-Joachim/0000-0003-3467-3900	NCI NIH HHS [CA-16054, P30 CA-13330] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330, R01CA016054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGRWAL N, 1993, J BIOL CHEM, V268, P14932; Ahmad N, 2002, CAN J CHEM, V80, P1096, DOI 10.1139/V02-162; BAO Q, 1995, J CELL SCI, V108, P2791; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BHATTACHARYYA L, 1990, BIOCHEMISTRY-US, V29, P7523, DOI 10.1021/bi00484a022; BOURNE Y, 1994, NAT STRUCT BIOL, V1, P863, DOI 10.1038/nsb1294-863; Bresalier RS, 1998, GASTROENTEROLOGY, V115, P287, DOI 10.1016/S0016-5085(98)70195-7; Camby I, 2001, BRAIN PATHOL, V11, P12; Cooper DNW, 2002, BBA-GEN SUBJECTS, V1572, P209, DOI 10.1016/S0304-4165(02)00310-0; DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213; Demetriou M, 2001, NATURE, V409, P733, DOI 10.1038/35055582; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FRIGERI LG, 1990, J BIOL CHEM, V265, P20763; FRIGERI LG, 1993, BIOCHEMISTRY-US, V32, P7644, DOI 10.1021/bi00081a007; Gabius HJ, 1997, EUR J BIOCHEM, V243, P543, DOI 10.1111/j.1432-1033.1997.t01-1-00543.x; GREEN ED, 1988, J BIOL CHEM, V263, P18253; GUPTA D, 1994, BIOCHEMISTRY-US, V33, P7495, DOI 10.1021/bi00190a001; GUPTA D, 1994, BIOCHEMISTRY-US, V33, P5526, DOI 10.1021/bi00184a022; GUPTA D, 1994, CURR TOPICS PEPTIDE, V1, P177; HSU DK, 1992, J BIOL CHEM, V267, P14167; JIA SH, 1988, J BIOL CHEM, V263, P6009; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; KNIBBS RN, 1993, J BIOL CHEM, V268, P14940; Kopitz J, 2001, J BIOL CHEM, V276, P35917, DOI 10.1074/jbc.M105135200; Kuklinski S, 1998, J NEUROCHEM, V70, P814; Kuwabara I, 1996, J IMMUNOL, V156, P3939; Lahm H, 2001, J CANCER RES CLIN, V127, P375, DOI 10.1007/s004320000207; LAING JG, 1988, BIOCHEMISTRY-US, V27, P5329, DOI 10.1021/bi00414a057; Leonidas DD, 1998, BIOCHEMISTRY-US, V37, P13930, DOI 10.1021/bi981056x; Liu FT, 2000, CLIN IMMUNOL, V97, P79, DOI 10.1006/clim.2000.4912; Liu FT, 2002, BBA-GEN SUBJECTS, V1572, P263, DOI 10.1016/S0304-4165(02)00313-6; Lobsanov YD, 1997, TRENDS GLYCOSCI GLYC, V9, P145, DOI 10.4052/tigg.9.145; MASSA SM, 1993, BIOCHEMISTRY-US, V32, P260, DOI 10.1021/bi00052a033; MEHUL B, 1994, J BIOL CHEM, V269, P18250; MORRIS S, 2004, IN PRESS GLYCOBIOLOG; MOUTSATSOS IK, 1987, P NATL ACAD SCI USA, V84, P6452, DOI 10.1073/pnas.84.18.6452; Nangia-Makker P, 2000, AM J PATHOL, V156, P899, DOI 10.1016/S0002-9440(10)64959-0; NILSSON B, 1979, J BIOL CHEM, V254, P4545; OCHIENG J, 1993, BIOCHEMISTRY-US, V32, P4455, DOI 10.1021/bi00067a038; Pace KE, 1999, J IMMUNOL, V163, P3801; Pace KE, 2000, J IMMUNOL, V165, P2331, DOI 10.4049/jimmunol.165.5.2331; Parikh I, 1974, Methods Enzymol, V34, P77; Rabinovich GA, 2002, BBA-GEN SUBJECTS, V1572, P274, DOI 10.1016/S0304-4165(02)00314-8; SABESAN S, 1992, J AM CHEM SOC, V114, P8363, DOI 10.1021/ja00048a004; SAHA SK, 1994, CARBOHYD RES, V254, P157; Seetharaman J, 1998, J BIOL CHEM, V273, P13047, DOI 10.1074/jbc.273.21.13047; SPIRO RG, 1960, J BIOL CHEM, V235, P2860; Vespa GNR, 1999, J IMMUNOL, V162, P799; YAMAOKA A, 1995, J IMMUNOL, V154, P3479; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; Yang RY, 1998, BIOCHEMISTRY-US, V37, P4086, DOI 10.1021/bi971409c	52	405	415	2	54	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10841	10847		10.1074/jbc.M312834200	http://dx.doi.org/10.1074/jbc.M312834200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14672941	hybrid			2022-12-25	WOS:000220157600004
J	Liu, ZY; Shi, WB; Ji, XH; Sun, CX; Jee, WSS; Wu, YL; Mao, ZK; Nagy, TR; Li, QN; Cao, X				Liu, ZY; Shi, WB; Ji, XH; Sun, CX; Jee, WSS; Wu, YL; Mao, ZK; Nagy, TR; Li, QN; Cao, X			Molecules mimicking Smad1 interacting with hox stimulate bone formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MARROW STROMAL CELLS; HOMEOBOX GENE; IN-VIVO; PROTEIN; REPRESSION; TRANSCRIPTION; DIFFERENTIATION; HOMEODOMAIN; EXPRESSION	Bone morphogenetic proteins (BMPs) induce osteoblast differentiation and bone formation. Smads, a group of functionally and structurally related intracellular effectors, mediate signaling initiated by BMPs and regulate cell definite commitment. Previously, we showed that Smad1 activates osteopontin and osteoprotegerin gene expression by dislodging Hoxc-8 from its DNA binding sites. A domain of Smad1, termed Smad1C, was characterized as interacting with Hoxc-8 and then crippling its DNA-binding ability. Ectopic expression of Smad1C is able to bypass BMP signaling in the induction of osteoblast differentiation and bone formation in vitro. To test the function of Smad1C on osteogenesis in vivo, we generated transgenic mice in which Smad1C expression was induced with doxycycline and localized in bone by using a tetracycline-inducible expression system (Tet-on) modified with a bone-specific gene promoter, type I collagen alpha1. The mice expressing Smad1C showed increased skeletal bone mineral density compared with their littermates. Bone histomorphometric analysis of mouse tibiae showed that Smad1C significantly increases trabecular bone area and length of trabecular surface covered with osteoid and up-regulates bone marker gene (OPN, Cbfa1, Col I alpha1, BSP, ALP) expression in vivo. Moreover, stromal cells isolated from mice expressing Smad1C displayed a higher potential for differentiating into osteoblasts than the other mice. These results indicate that Smad1C mimics BMPs in the induction of osteogenesis in vivo. Most important, using a high throughput screening assay based on mimicking Smad1C's displacement of Hoxc-8 binding to DNA, we identified chemical entities that exhibit bone anabolic activity in cell and bone organ cultures, suggesting the possibility that the compounds may be used as bone anabolic agents to treat bone pathologies.	Univ Alabama Birmingham, Sch Med, Dept Pathol, Birmingham, AL 35294 USA; Procter & Gamble Pharmaceut, Div Radiobiol, Mason, OH 45040 USA; Univ Utah, Salt Lake City, UT 84108 USA; Univ Alabama Birmingham, Sch Hlth Related Profess, Dept Nutr Sci, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Sch Hlth Related Profess, Clin Nutr Res Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; Procter & Gamble; Utah System of Higher Education; University of Utah; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Cao, X (corresponding author), 1670 Univ Blvd VH G002, Birmingham, AL 35294 USA.	cao@path.uab.edu		Shi, Weibin/0000-0002-8267-2796; Nagy, Tim/0000-0002-2371-7114	NIAMS NIH HHS [P30AR46301] Funding Source: Medline; NIDDK NIH HHS [P30DK56336, DK57501] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056336] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEGLEY CT, 1993, BONE, V14, P661, DOI 10.1016/8756-3282(93)90089-S; BELLOWS CG, 1986, CALCIFIED TISSUE INT, V38, P143, DOI 10.1007/BF02556874; CATRON KM, 1995, MOL CELL BIOL, V15, P861; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Dirr MJ, 2000, J BONE MINER RES, V15, pS462; Emery JG, 2001, TRENDS PHARMACOL SCI, V22, P233, DOI 10.1016/S0165-6147(00)01661-8; Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Kim JY, 2003, EXP CELL RES, V290, P217, DOI 10.1016/S0014-4827(03)00319-7; Kopp JB, 2002, KIDNEY INT, V61, P351, DOI 10.1046/j.1523-1755.2002.00126.x; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Ladher R, 1996, DEVELOPMENT, V122, P2385; LEMOUELLIC H, 1988, GENE DEV, V2, P125, DOI 10.1101/gad.2.1.125; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miyazono K, 1999, BONE, V25, P91, DOI 10.1016/S8756-3282(99)00113-1; Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946; Nagy TR, 2000, OBES RES, V8, P392, DOI 10.1038/oby.2000.47; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; Pearson KL, 1999, BBA-GENE STRUCT EXPR, V1489, P354, DOI 10.1016/S0167-4781(99)00166-9; Pereira RF, 1998, P NATL ACAD SCI USA, V95, P1142, DOI 10.1073/pnas.95.3.1142; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Schnabel CA, 1996, MOL CELL BIOL, V16, P2678; Shi XM, 1999, J BIOL CHEM, V274, P13711, DOI 10.1074/jbc.274.19.13711; Shimamoto T, 1999, J EXP ZOOL, V283, P186; SIMEONE A, 1987, P NATL ACAD SCI USA, V84, P4914, DOI 10.1073/pnas.84.14.4914; Tang SJ, 1998, DEVELOPMENT, V125, P1877; Thickett Christopher, 2002, Gene Expression Patterns, V2, P5, DOI 10.1016/S0925-4773(02)00353-2; Traianedes K, 1998, ENDOCRINOLOGY, V139, P3178, DOI 10.1210/en.139.7.3178; VIOLETTE SM, 1992, P NATL ACAD SCI USA, V89, P3805, DOI 10.1073/pnas.89.9.3805; Wan M, 2001, J BIOL CHEM, V276, P10119, DOI 10.1074/jbc.M006918200; Wang YJ, 2003, CELL, V114, P299, DOI 10.1016/S0092-8674(03)00603-2; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Wu JW, 2002, CELL, V111, P357, DOI 10.1016/S0092-8674(02)01006-1; Yang X., 2001, METH MOL B, V177, P163; Yang XL, 2000, J BIOL CHEM, V275, P1065, DOI 10.1074/jbc.275.2.1065; Yin JL, 2001, IMMUNOL CELL BIOL, V79, P213, DOI 10.1046/j.1440-1711.2001.01002.x; Yueh YG, 1998, P NATL ACAD SCI USA, V95, P9956, DOI 10.1073/pnas.95.17.9956; Zhao M, 2002, J CELL BIOL, V157, P1049, DOI 10.1083/jcb.200109012	41	36	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11313	11319		10.1074/jbc.M312731200	http://dx.doi.org/10.1074/jbc.M312731200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14672939	hybrid			2022-12-25	WOS:000220157600059
J	Xing, L; Huhtala, M; Pietiainen, V; Kapyla, J; Vuorinen, K; Marjomaki, V; Heino, J; Johnson, MS; Hyypia, T; Cheng, RH				Xing, L; Huhtala, M; Pietiainen, V; Kapyla, J; Vuorinen, K; Marjomaki, V; Heino, J; Johnson, MS; Hyypia, T; Cheng, RH			Structural and functional analysis of integrin alpha I-2 domain interaction with echovirus 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUTH-DISEASE VIRUS; DEPENDENT ADHESION SITE; INTEGRIN ALPHA-2 BETA-1; I-DOMAIN; CELLULAR RECEPTOR; CRYSTAL-STRUCTURE; EXTRACELLULAR SEGMENT; VITRONECTIN RECEPTOR; PICORNAVIRUS GROUP; COXSACKIEVIRUS A9	Integrins are cell surface receptors for several microbial pathogens including echovirus 1 (EV1), a picornavirus. Cryo-electron microscopy revealed that the functional domain (alpha(2)I) of human alpha(2)beta(1) integrin binds to a surface depression on the EV1 capsid. This three-dimensional structure of EV1 bound to alpha(2)I domain provides the first structural details of an integrin interacting with a picornavirus. The model indicates that alpha(2)beta(1) integrin cannot simultaneously bind both EV1 and the physiological ligand collagen. Compared with collagen binding to the alpha(2)I domain, the virus binds with a 10-fold higher affinity but in vitro uncoating of EV1 was not observed as a result of attachment of alpha(2)I. A molecular model, constructed on the basis of the EV1-integrin complex, shows that multiple alpha(2)beta(1) heterodimers can bind at adjacent sites around the virus 5-fold symmetry axes without steric hindrance. In agreement with this, virus attachment to alpha(2)beta(1) integrin on the cell surface was found to result in integrin clustering, which can give rise to signaling and facilitate the initiation of the viral entry process that takes place via caveolae-mediated endocytosis.	Karolinska Inst, Dept Biosci, S-14157 Huddinge, Sweden; Abo Akad Univ, Dept Biochem & Pharm, SF-20500 Turku, Finland; Univ Helsinki, Haartman Inst, Dept Virol, FIN-00014 Helsinki, Finland; Univ Jyvaskyla, Dept Cell Biol, SF-40351 Jyvaskyla, Finland; Univ Oulu, Dept Med Microbiol, Oulu 90014, Finland	Karolinska Institutet; Abo Akademi University; University of Helsinki; University of Jyvaskyla; University of Oulu	Cheng, RH (corresponding author), Univ Calif Davis, Dept Mol & Cellular Biol, Davis, CA 95616 USA.	rhch@ucdavis.edu	Cheng, Holland/A-8973-2008	Marjomaki, Varpu/0000-0002-4592-5926; Pietiainen, Vilja/0000-0003-3125-2406; Kapyla, Jarmo/0000-0003-3036-713X; Huhtala, Mikko/0000-0001-6070-7604				Akula SM, 2002, CELL, V108, P407, DOI 10.1016/S0092-8674(02)00628-1; Belnap DM, 2000, P NATL ACAD SCI USA, V97, P73, DOI 10.1073/pnas.97.1.73; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; BERGELSON JM, 1992, SCIENCE, V255, P1718, DOI 10.1126/science.1553561; BERGELSON JM, 1993, J CLIN INVEST, V92, P232, DOI 10.1172/JCI116555; BERINSTEIN A, 1995, J VIROL, V69, P2664, DOI 10.1128/JVI.69.4.2664-2666.1995; CHANG KH, 1989, J GEN VIROL, V70, P3269, DOI 10.1099/0022-1317-70-12-3269; Dickeson SK, 1999, J BIOL CHEM, V274, P32182, DOI 10.1074/jbc.274.45.32182; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Filman DJ, 1998, ACTA CRYSTALLOGR D, V54, P1261, DOI 10.1107/S0907444998002790; FOX G, 1989, J GEN VIROL, V70, P625, DOI 10.1099/0022-1317-70-3-625; Grist N R, 1978, Prog Med Virol, V24, P114; He YN, 2002, P NATL ACAD SCI USA, V99, P10325, DOI 10.1073/pnas.152161599; He YN, 2000, P NATL ACAD SCI USA, V97, P79, DOI 10.1073/pnas.97.1.79; Hendry E, 1999, STRUCT FOLD DES, V7, P1527, DOI 10.1016/S0969-2126(00)88343-4; Hewat EA, 2000, EMBO J, V19, P6317, DOI 10.1093/emboj/19.23.6317; HOOVERLITTY H, 1993, J VIROL, V67, P390, DOI 10.1128/JVI.67.1.390-397.1993; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; HYYPIA T, 1992, P NATL ACAD SCI USA, V89, P8847, DOI 10.1073/pnas.89.18.8847; Ivaska J, 1999, J CELL BIOL, V147, P401, DOI 10.1083/jcb.147.2.401; Johnson MS, 1996, METHOD ENZYMOL, V266, P575; JOHNSON MS, 1993, J MOL BIOL, V233, P716, DOI 10.1006/jmbi.1993.1548; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KAPLAN G, 1990, J VIROL, V64, P4697, DOI 10.1128/JVI.64.10.4697-4702.1990; King SL, 1997, J BIOL CHEM, V272, P28518, DOI 10.1074/jbc.272.45.28518; KING SL, 1995, J VIROL, V69, P3237, DOI 10.1128/JVI.69.5.3237-3239.1995; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; LOGAN D, 1993, NATURE, V362, P566, DOI 10.1038/362566a0; Marjomaki V, 2002, J VIROL, V76, P1856, DOI 10.1128/JVI.76.4.1856-1865.2002; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Nemerow GR, 1999, MICROBIOL MOL BIOL R, V63, P725, DOI 10.1128/MMBR.63.3.725-734.1999; OLSON NH, 1993, P NATL ACAD SCI USA, V90, P507, DOI 10.1073/pnas.90.2.507; Pentikainen O, 1999, J BIOL CHEM, V274, P31493, DOI 10.1074/jbc.274.44.31493; ROIVAINEN M, 1994, VIROLOGY, V203, P357, DOI 10.1006/viro.1994.1494; Rossmann MG, 2002, TRENDS MICROBIOL, V10, P324, DOI 10.1016/S0966-842X(02)02383-1; Segerman A, 2003, J VIROL, V77, P9183, DOI 10.1128/JVI.77.17.9183-9191.2003; STANWAY G, 1994, J VIROL, V68, P8232, DOI 10.1128/JVI.68.12.8232-8238.1994; Tulla M, 2001, J BIOL CHEM, V276, P48206, DOI 10.1074/jbc.M104058200; Upla P, 2004, MOL BIOL CELL, V15, P625, DOI 10.1091/mbc.E03-08-0588; Xing L, 2000, EMBO J, V19, P1207, DOI 10.1093/emboj/19.6.1207; Xing L, 2003, J VIROL, V77, P6101, DOI 10.1128/JVI.77.11.6101-6107.2003; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Zimmermann H, 1997, VIROLOGY, V233, P149, DOI 10.1006/viro.1997.8601	46	45	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11632	11638		10.1074/jbc.M312441200	http://dx.doi.org/10.1074/jbc.M312441200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701832	hybrid			2022-12-25	WOS:000220157600097
J	Dementin, S; Burlat, B; De Lacey, AL; Pardo, A; Adryanczyk-Perrier, G; Guigliarelli, B; Fernandez, VM; Rousset, M				Dementin, S; Burlat, B; De Lacey, AL; Pardo, A; Adryanczyk-Perrier, G; Guigliarelli, B; Fernandez, VM; Rousset, M			A glutamate is the essential proton transfer gate during the catalytic cycle of the [NiFe] hydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-GIGAS HYDROGENASE; SITE-DIRECTED MUTAGENESIS; DENSITY-FUNCTIONAL THEORY; NICKEL-IRON HYDROGENASE; ACTIVE-SITE; CRYSTAL-STRUCTURE; FE HYDROGENASES; KINETIC CHARACTERIZATION; ANGSTROM RESOLUTION; CARBON-MONOXIDE	Kinetic, EPR, and Fourier transform infrared spectroscopic analysis of Desulfovibrio fructosovorans [NiFe] hydrogenase mutants targeted to Glu-25 indicated that this amino acid participates in proton transfer between the active site and the protein surface during the catalytic cycle. Replacement of that glutamic residue by a glutamine did not modify the spectroscopic properties of the enzyme but cancelled the catalytic activity except the para-H-2/ortho-H-2 conversion. This mutation impaired the fast proton transfer from the active site that allows high turnover numbers for the oxidation of hydrogen. Replacement of the glutamic residue by the shorter aspartic acid slowed down this proton transfer, causing a significant decrease of H-2 oxidation and hydrogen isotope exchange activities, but did not change the para-H-2/ortho-H-2 conversion activity. The spectroscopic properties of this mutant were totally different, especially in the reduced state in which a non-photosensitive nickel EPR spectrum was obtained.	CNRS, Unite Bioenerget & Ingn Prot, Inst Biol Struct & Microbiol, F-13402 Marseille 20, France; CSIC, Inst Catalisis, Madrid 28049, Spain	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Catalisis y Petroleoquimica (ICP)	Rousset, M (corresponding author), CNRS, Unite Bioenerget & Ingn Prot, Inst Biol Struct & Microbiol, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	rousset@ibsm.cnrs-mrs.fr	De Lacey, Antonio L/H-3311-2015	De Lacey, Antonio L/0000-0002-9347-0452; Dementin, Sebastien/0000-0001-6168-5371				ALBRACHT SPJ, 1994, BBA-BIOENERGETICS, V1188, P167, DOI 10.1016/0005-2728(94)90036-1; Amara P, 1999, J AM CHEM SOC, V121, P4468, DOI 10.1021/ja983971b; Bertrand P, 2000, J BIOL INORG CHEM, V5, P682, DOI 10.1007/s007750000152; Bleijlevens B, 2001, J BIOL INORG CHEM, V6, P763, DOI 10.1007/s007750100252; Burgdorf T, 2002, J BACTERIOL, V184, P6280, DOI 10.1128/JB.184.22.6280-6288.2002; BUTT JN, 1993, J AM CHEM SOC, V115, P12587, DOI 10.1021/ja00079a049; CAMMACK R, 1987, BIOCHIM BIOPHYS ACTA, V912, P98, DOI 10.1016/0167-4838(87)90252-4; CAMMACK R, 2001, HYDROGEN FUEL, P159; Carepo M, 2002, J AM CHEM SOC, V124, P281, DOI 10.1021/ja010204v; Cleland WW, 1998, J BIOL CHEM, V273, P25529, DOI 10.1074/jbc.273.40.25529; Darensbourg MY, 2000, COORDIN CHEM REV, V206, P533, DOI 10.1016/S0010-8545(00)00268-X; De Gioia L, 1999, INORG CHEM, V38, P2658, DOI 10.1021/ic9811446; De Lacey AL, 2000, BBA-PROTEIN STRUCT M, V1481, P371, DOI 10.1016/S0167-4838(00)00180-1; deLacey AL, 1997, J AM CHEM SOC, V119, P7181, DOI 10.1021/ja963802w; DeLacey AL, 2003, J BIOL INORG CHEM, V8, P129, DOI 10.1007/s00775-002-0397-4; DeLacey AL, 2002, J BIOL INORG CHEM, V7, P318, DOI 10.1007/s00775-001-0301-7; Dole F, 1996, BIOCHEMISTRY-US, V35, P16399, DOI 10.1021/bi961662x; Dole F, 1997, BIOCHEMISTRY-US, V36, P7847, DOI 10.1021/bi963171i; FAUQUE G, 1988, FEMS MICROBIOL LETT, V54, P299, DOI 10.1111/j.1574-6968.1988.tb02748.x; FERNANDEZ VM, 1985, BIOCHIM BIOPHYS ACTA, V832, P69, DOI 10.1016/0167-4838(85)90175-X; Fontecilla-Camps J. C., 2001, HYDROGEN FUEL, P93; Garcin E, 1999, STRUCT FOLD DES, V7, P557, DOI 10.1016/S0969-2126(99)80072-0; Goldman CM, 1995, COMMENT INORG CHEM, V18, P1, DOI 10.1080/02603599508033861; GUIGLIARELLI B, 1995, BIOCHEMISTRY-US, V34, P4781, DOI 10.1021/bi00014a036; Happe RP, 1997, NATURE, V385, P126, DOI 10.1038/385126a0; Hartmann GC, 1996, J BIOL INORG CHEM, V1, P446, DOI 10.1007/s007750050077; Higuchi Y, 1999, STRUCT FOLD DES, V7, P549, DOI 10.1016/S0969-2126(99)80071-9; Higuchi Y, 1999, BIOCHEM BIOPH RES CO, V255, P295, DOI 10.1006/bbrc.1999.0210; KRASNA AI, 1954, J AM CHEM SOC, V76, P3015, DOI 10.1021/ja01640a045; Maroney MJ, 2001, J BIOL INORG CHEM, V6, P453, DOI 10.1007/s007750100225; Matias PM, 2001, J BIOL INORG CHEM, V6, P63, DOI 10.1007/s007750000167; Medina M, 1996, BBA-BIOENERGETICS, V1275, P227, DOI 10.1016/0005-2728(96)00007-2; Montet Y, 1997, NAT STRUCT BIOL, V4, P523, DOI 10.1038/nsb0797-523; MOURA JJG, 1982, BIOCHEM BIOPH RES CO, V108, P1388, DOI 10.1016/S0006-291X(82)80060-0; Nicolet Y, 1999, STRUCTURE, V7, P13, DOI 10.1016/S0969-2126(99)80005-7; Ogata H, 2002, J AM CHEM SOC, V124, P11628, DOI 10.1021/ja012645k; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Peters JW, 1998, SCIENCE, V282, P1853, DOI 10.1126/science.282.5395.1853; Rousset M, 1998, P NATL ACAD SCI USA, V95, P11625, DOI 10.1073/pnas.95.20.11625; Rousset M, 1998, PLASMID, V39, P114, DOI 10.1006/plas.1997.1321; ROUSSET M, 1991, MOL MICROBIOL, V5, P1735, DOI 10.1111/j.1365-2958.1991.tb01922.x; Sellmann D, 2000, ANGEW CHEM INT EDIT, V39, P561, DOI 10.1002/(SICI)1521-3773(20000204)39:3<561::AID-ANIE561>3.0.CO;2-3; Volbeda A, 2002, INT J HYDROGEN ENERG, V27, P1449, DOI 10.1016/S0360-3199(02)00072-1; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; Volbeda A, 1996, J AM CHEM SOC, V118, P12989, DOI 10.1021/ja962270g; WILLIAMS RJP, 1995, NATURE, V376, P643, DOI 10.1038/376643a0; YAGI T, 1973, J BIOCHEM-TOKYO, V73, P1069, DOI 10.1093/oxfordjournals.jbchem.a130161	47	111	114	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10508	10513		10.1074/jbc.M312716200	http://dx.doi.org/10.1074/jbc.M312716200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688251				2022-12-25	WOS:000220050400103
J	Honda, S; Marumoto, T; Hirota, T; Nitta, M; Arima, Y; Ogawa, M; Saya, H				Honda, S; Marumoto, T; Hirota, T; Nitta, M; Arima, Y; Ogawa, M; Saya, H			Activation of m-calpain is required for chromosome alignment on the metaphase plate during mitosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; CHROMOKINESIN KID; CYSTEINE PROTEASE; TUMOR-SUPPRESSOR; MITOTIC SPINDLE; MAMMALIAN-CELLS; INHIBITOR; CALCIUM; COMPLEX; KINETOCHORES	Calpains form a superfamily of Ca2+-dependent intracellular cysteine proteases with various isoforms. Two isoforms, mu- and m-calpains, are ubiquitously expressed and known as conventional calpains. It has been previously shown that the mammalian calpains are activated during mitosis by transient increases in cytosolic Ca2+ concentration. However, it is still unknown whether the activation of calpains contributes to particular events in mitosis. With the use of RNA interference (RNAi), we investigated the roles of calpains in mitosis. Cells reduced the levels of m- calpain, but not mu-calpain, arrested at prometaphase and failed to align their chromosomes at the spindle equator. Specific peptidyl calpain inhibitors also induced aberrant mitosis with chromosome misalignment. Although both m- calpain RNAi and calpain inhibitors affected neither the separation of centrosomes nor the assembly of bipolar spindles, Mad2 was detected on the kinetochores of the misaligned chromosomes, indicating that the prometaphase arrest induced by calpain inhibition is due to activation of the spindle assembly checkpoint. Furthermore, when calpain activity was inhibited in cells having monopolar spindles, chromosomes were clustered adjacent to the centrosome, suggesting that calpain activity is involved in a polar ejection force for metaphase alignment of chromosomes. Based on these findings, we propose that activation of m- calpain during mitosis is required for cells to establish the chromosome alignment by regulating some molecules that generate polar ejection force.	Kumamoto Univ, Dept Tumor Genet & Biol, Grad Sch Med Sci, Kumamoto 8608556, Japan; Kumamoto Univ, Dept Surg Gastroenterol, Grad Sch Med Sci, Kumamoto 8608556, Japan	Kumamoto University; Kumamoto University	Saya, H (corresponding author), Kumamoto Univ, Dept Tumor Genet & Biol, Grad Sch Med Sci, 1-1-1 Honjo, Kumamoto 8608556, Japan.	hsaya@gpo.kumamoto-u.ac.jp	Saya, Hideyuki/J-4325-2013; Arima, Yoshimi/J-8057-2013	Arima, Yoshimi/0000-0002-2384-1406				Antonio C, 2000, CELL, V102, P425, DOI 10.1016/S0092-8674(00)00048-9; Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Bhatt A, 2002, J CELL SCI, V115, P3415; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Cox EA, 1998, MICROSC RES TECHNIQ, V43, P412, DOI 10.1002/(SICI)1097-0029(19981201)43:5<412::AID-JEMT7>3.0.CO;2-F; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Funabiki H, 2000, CELL, V102, P411, DOI 10.1016/S0092-8674(00)00047-7; Hata S, 2001, FEBS LETT, V501, P111, DOI 10.1016/S0014-5793(01)02611-4; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Kapoor TM, 2002, J CELL BIOL, V157, P551, DOI 10.1083/jcb.200202073; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; Kimura Y, 1998, NAT MED, V4, P915, DOI 10.1038/nm0898-915; LANE RD, 1992, EXP CELL RES, V203, P5, DOI 10.1016/0014-4827(92)90033-5; Levesque AA, 2001, J CELL BIOL, V154, P1135, DOI 10.1083/jcb.200106093; Nitta M, 2002, GENES CELLS, V7, P151, DOI 10.1046/j.1356-9597.2001.00509.x; Ohsugi M, 2003, EMBO J, V22, P2091, DOI 10.1093/emboj/cdg208; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; Santella L, 1998, BIOCHEM BIOPH RES CO, V244, P317, DOI 10.1006/bbrc.1998.8086; Santella L, 2000, EXP CELL RES, V259, P117, DOI 10.1006/excr.2000.4969; Santella L, 1998, CELL CALCIUM, V23, P123, DOI 10.1016/S0143-4160(98)90110-5; SHERWOOD SW, 1993, P NATL ACAD SCI USA, V90, P3353, DOI 10.1073/pnas.90.8.3353; SKIBBENS RV, 1993, J CELL BIOL, V122, P859, DOI 10.1083/jcb.122.4.859; Tanaka TU, 2002, CELL, V108, P317, DOI 10.1016/S0092-8674(02)00633-5; Tokai N, 1996, EMBO J, V15, P457, DOI 10.1002/j.1460-2075.1996.tb00378.x; Topper LM, 2001, J CELL BIOL, V154, P707, DOI 10.1083/jcb.200104130; Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748; Xu Y, 2002, J BIOL CHEM, V277, P21474, DOI 10.1074/jbc.M111689200; Yajima J, 2003, EMBO J, V22, P1067, DOI 10.1093/emboj/cdg102; YAMAGUCHI R, 1994, FEBS LETT, V356, P114, DOI 10.1016/0014-5793(94)01246-6	30	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10615	10623		10.1074/jbc.M308841200	http://dx.doi.org/10.1074/jbc.M308841200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688278	hybrid			2022-12-25	WOS:000220050400115
J	Mueckler, M; Makepeace, C				Mueckler, M; Makepeace, C			Analysis of transmembrane segment 8 of the GLUT1 glucose transporter by cysteine-scanning mutagenesis and substituted cysteine accessibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE SUGAR-TRANSPORT; EXOFACIAL LIGAND-BINDING; XENOPUS-OOCYTES; PERMEATION PATHWAY; ESCHERICHIA-COLI; SYSTEM; FAMILY; SITE; MECHANISM; KINETICS	The GLUT1 glucose transporter has been proposed to form an aqueous substrate translocation pathway via the clustering of several amphipathic transmembrane helices (Mueckler, M., Caruso, C., Baldwin, S. A., Panico, M., Blench, I., Morris, H. R., Allard, W. J., Lienhard, G. E., and Lodish, H. F. (1985) Science 229, 941-945). The possible role of transmembrane helix 8 in the formation of this permeation pathway was investigated using cysteine-scanning mutagenesis and the membrane-impermeant sulfhydryl-specific reagent, p-chloromercuribenzenesulfonate (pCMBS). Twenty-one GLUT1 mutants were created from a fully functional cysteine-less parental GLUT1 molecule by successively changing each residue along transmembrane segment 8 to a cysteine. The mutant proteins were then expressed in Xenopus oocytes, and their membrane concentrations, 2-deoxyglucose uptake activities, and sensitivities to pCMBS were determined. Four positions within helix 8, alanine 309, threonine 310, serine 313, and glycine 314, were accessible to pCMBS as judged by the inhibition of transport activity. All four of these residues are clustered along one face of a putative alpha-helix. These results suggest that transmembrane segment 8 of GLUT1 forms part of the sugar permeation pathway. Updated two-dimensional models for the orientation of the 12 transmembrane helices and the conformation of the exofacial glucose binding site of GLUT1 are proposed that are consistent with existing experimental data and homology modeling based on the crystal structures of two bacterial membrane transporters.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Mueckler, M (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	mike@cellbio.wustl.edu	Mueckler, Mike M/F-6115-2012		NIDDK NIH HHS [DK43695] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043695] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; APPLEMAN JR, 1985, J BIOL CHEM, V260, P4575; APPLEMAN JR, 1989, BIOCHEMISTRY-US, V28, P8221, DOI 10.1021/bi00446a038; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; BARNETT JEG, 1973, BIOCHEM J, V131, P211, DOI 10.1042/bj1310211; BARNETT JEG, 1975, BIOCHEM J, V145, P417, DOI 10.1042/bj1450417a; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; Cloherty EK, 1996, BIOCHEMISTRY-US, V35, P10411, DOI 10.1021/bi953077m; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; HASHIRAMOTO M, 1992, J BIOL CHEM, V267, P17502; HRESKO RC, 1994, J BIOL CHEM, V269, P32110; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; Hruz PW, 2000, BIOCHEMISTRY-US, V39, P9367, DOI 10.1021/bi000821g; Hruz PW, 2001, MOL MEMBR BIOL, V18, P183; Hruz PW, 1999, J BIOL CHEM, V274, P36176, DOI 10.1074/jbc.274.51.36176; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; JUNG EKY, 1986, J BIOL CHEM, V261, P9155; KELLER K, 1989, J BIOL CHEM, V264, P18884; LOWE AG, 1989, RED BLOOD CELL MEMBR, V11, P597; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; Mueckler M, 1999, J BIOL CHEM, V274, P10923, DOI 10.1074/jbc.274.16.10923; Mueckler M, 1997, BIOCHEM SOC T, V25, P951, DOI 10.1042/bst0250951; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; Mueckler M, 2002, J BIOL CHEM, V277, P3498, DOI 10.1074/jbc.M109157200; MUECKLER M, 1994, J BIOL CHEM, V269, P20533; Mueckler M, 1997, J BIOL CHEM, V272, P30141, DOI 10.1074/jbc.272.48.30141; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; Olsowski A, 2000, BIOCHEMISTRY-US, V39, P2469, DOI 10.1021/bi992160x; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; Seatter MJ, 1998, BIOCHEMISTRY-US, V37, P1322, DOI 10.1021/bi972322u; VIDAVER GA, 1966, J THEOR BIOL, V10, P301, DOI 10.1016/0022-5193(66)90128-7; WELLNER M, 1995, FEBS LETT, V370, P19, DOI 10.1016/0014-5793(95)00783-6	33	38	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10494	10499		10.1074/jbc.M310786200	http://dx.doi.org/10.1074/jbc.M310786200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688257	hybrid			2022-12-25	WOS:000220050400101
J	Kovtun, IV; Welch, G; Guthrie, HD; Hafner, KL; McMurray, CT				Kovtun, IV; Welch, G; Guthrie, HD; Hafner, KL; McMurray, CT			CAG repeat lengths in X- and Y-bearing sperm indicate that gender bias during transmission of Huntington's disease gene is determined in the embryo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLOW CYTOMETRIC SEPARATION; CHROMOSOME-BEARING; MUTATION; INSTABILITY; MOUSE; PRESELECTION; PHENOTYPE; EXPANSION; ATROPHY; LOCUS	The size of the CAG tract at the Huntington's disease (HD) locus upon transmission depends on the gender of the parent. However, the basis for the parent-of-origin effect is unknown. To test whether expansion and contraction in HD are "imprinted" in the germ cells, we isolated the X- and Y-bearing sperm of HD transgenic mice. Here we show that CAG repeat distributions in the X- and Y-bearing spermatozoa of founding fathers do not differ. These data show that gender-dependent changes in CAG repeat length arise in the embryo.	Mayo Clin & Mayo Fdn, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mol Neurosci Program, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Cytogenet, Rochester, MN 55905 USA; USDA, Germplasm & Gamete Physiol Lab, Beltsville, MD 20705 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; United States Department of Agriculture (USDA)	McMurray, CT (corresponding author), Mayo Clin & Mayo Fdn, Dept Mol Pharmacol & Expt Therapeut, 200 1st St SW, Rochester, MN 55905 USA.	mcmurray.cynthia@mayo.edu	Kovtun, Irina/ABA-8484-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040738] Funding Source: NIH RePORTER; NINDS NIH HHS [NS4073802S1] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Giovannone B, 1997, HUM MUTAT, V10, P458, DOI 10.1002/(SICI)1098-1004(1997)10:6<458::AID-HUMU7>3.0.CO;2-9; Ikeuchi T, 1996, AM J HUM GENET, V58, P730; JOHNSON LA, 1993, HUM REPROD, V8, P1733, DOI 10.1093/oxfordjournals.humrep.a137925; Johnson LA, 1995, REPROD FERT DEVELOP, V7, P893, DOI 10.1071/RD9950893; Kennedy L, 2003, HUM MOL GENET, V12, P3359, DOI 10.1093/hmg/ddg352; Kennedy L, 2000, HUM MOL GENET, V9, P2539, DOI 10.1093/hmg/9.17.2539; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; Kovtun IV, 2001, NAT GENET, V27, P407, DOI 10.1038/86906; Kovtun IV, 2000, HUM MOL GENET, V9, P2767, DOI 10.1093/hmg/9.18.2767; LASPADA AR, 1992, NAT GENET, V2, P301, DOI 10.1038/ng1292-301; Leeflang EP, 1999, HUM MOL GENET, V8, P173, DOI 10.1093/hmg/8.2.173; Leeflang EP, 1996, AM J HUM GENET, V59, P896; Malter HE, 1997, NAT GENET, V15, P165, DOI 10.1038/ng0297-165; Mangiarini L, 1997, NAT GENET, V15, P197, DOI 10.1038/ng0297-197; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Rens W, 1998, CYTOMETRY, V33, P476, DOI 10.1002/(SICI)1097-0320(19981201)33:4<476::AID-CYTO12>3.0.CO;2-B; REYNIERS E, 1993, NAT GENET, V4, P143, DOI 10.1038/ng0693-143; RIDLEY RM, 1988, J MED GENET, V25, P589, DOI 10.1136/jmg.25.9.589; TROTTIER Y, 1994, J MED GENET, V31, P377, DOI 10.1136/jmg.31.5.377; Wheeler VC, 1999, HUM MOL GENET, V8, P115, DOI 10.1093/hmg/8.1.115; Zhang Y, 2002, HUM MOL GENET, V11, P791, DOI 10.1093/hmg/11.7.791	22	19	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9389	9391		10.1074/jbc.M313080200	http://dx.doi.org/10.1074/jbc.M313080200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14688268	hybrid			2022-12-25	WOS:000189265900103
J	Fasshauer, D; Margittai, M				Fasshauer, D; Margittai, M			A transient N-terminal interaction of SNAP-25 and syntaxin nucleates SNARE assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; COMPLEX	The SNARE proteins syntaxin, SNAP-25, and synaptobrevin play a central role during Ca2+-dependent exocytosis at the nerve terminal. Whereas syntaxin and SNAP-25 are located in the plasma membrane, synaptobrevin resides in the membrane of synaptic vesicles. It is thought that gradual assembly of these proteins into a membrane-bridging ternary SNARE complex ultimately leads to membrane fusion. According to this model, syntaxin and SNAP-25 constitute an acceptor complex for synaptobrevin. In vitro, however, syntaxin and SNAP-25 form a stable complex that contains two syntaxin molecules, one of which is occupying and possibly obstructing the binding site of synaptobrevin. To elucidate the assembly pathway of the synaptic SNAREs, we have now applied a combination of fluorescence and CD spectroscopy. We found that SNARE assembly begins with the slow and rate-limiting interaction of syntaxin and SNAP-25. Their interaction was prevented by N-terminal but not by C-terminal truncations, suggesting that for productive assembly all three participating helices must come together simultaneously. This suggests a complicated nucleation process that might be the reason for the observed slow assembly rate. N-terminal truncations of SNAP-25 and syntaxin also prevented the formation of the ternary complex, whereas neither N- nor C-terminal shortened synaptobrevin helices lost their ability to interact. This suggests that binding of synaptobrevin occurs after the establishment of the syntaxin-SNAP-25 interaction. Moreover, binding of synaptobrevin was inhibited by an excess of syntaxin, suggesting that a 1: 1 interaction of syntaxin and SNAP-25 serves as the on-pathway SNARE assembly intermediate.	Max Planck Inst Biophys Chem, Dept Neurobiol, D-37077 Gottingen, Germany	Max Planck Society	Fasshauer, D (corresponding author), Max Planck Inst Biophys Chem, Dept Neurobiol, Fassberg 11, D-37077 Gottingen, Germany.	dfassha@mpibpc.gwdg.de	Margittai, Martin/D-5039-2014; Fasshauer, Dirk/B-1563-2013	Margittai, Martin/0000-0003-1903-5927; Fasshauer, Dirk/0000-0002-1040-4282				Antonin W, 2002, NAT STRUCT BIOL, V9, P107, DOI 10.1038/nsb746; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 2003, BBA-MOL CELL RES, V1641, P87, DOI 10.1016/S0167-4889(03)00090-9; Fasshauer D, 2002, NAT STRUCT BIOL, V9, P144, DOI 10.1038/nsb750; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; Hazzard J, 1999, J BIOMOL NMR, V14, P203, DOI 10.1023/A:1008382027065; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Kweon DH, 2003, NAT STRUCT BIOL, V10, P440, DOI 10.1038/nsb928; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Margittai M, 2001, J BIOL CHEM, V276, P13169, DOI 10.1074/jbc.M010653200; Misura KMS, 2001, J BIOL CHEM, V276, P41301, DOI 10.1074/jbc.M106853200; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; Rice LM, 1997, FEBS LETT, V415, P49, DOI 10.1016/S0014-5793(97)01091-0; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Ungar D, 2003, ANNU REV CELL DEV BI, V19, P493, DOI 10.1146/annurev.cellbio.19.110701.155609; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xiao WZ, 2001, NAT STRUCT BIOL, V8, P308, DOI 10.1038/86174; Zhang F, 2002, J BIOL CHEM, V277, P24294, DOI 10.1074/jbc.M201200200	27	130	133	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7613	7621		10.1074/jbc.M312064200	http://dx.doi.org/10.1074/jbc.M312064200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14665625	Green Published, hybrid			2022-12-25	WOS:000189103300031
J	Kaeser, MD; Pebernard, S; Iggo, RD				Kaeser, MD; Pebernard, S; Iggo, RD			Regulation of p53 stability and function in HCT116 colon cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN LIGASE ACTIVITY; APOPTOTIC RESPONSE; TUMOR-SUPPRESSOR; DNA-BINDING; PHOSPHORYLATION; MDM2; GENE; STABILIZATION; ACETYLATION; ACTIVATION	We have used a lentiviral vector to stably express p53 at a physiological level in p53 knockout HCT116 cells. Cells transduced with wild type p53 responded to genotoxic stress by stabilizing p53 and expressing p53 target genes. The reconstituted cells underwent G(1) arrest or apoptosis appropriately depending on the type of stress, albeit less efficiently than parental wild type cells. Compared with cells expressing exogenous wild type p53, the apoptotic response to 5-fluorouracil (5FU) was >50% reduced in cells expressing S15A or S20A mutant p53, and even more reduced by combined mutation of serines 6, 9, 15, 20, 33, and 37 (N6A). Among a panel of p53 target genes tested by quantitative PCR, the gene showing the largest defect in induction by 5FU was BBC3 (PUMA), which was induced 4-fold by wild type p53 and 2-fold by the N6A mutant. Mutation of N-terminal phosphorylation sites did not prevent p53 stabilization by doxorubicin or 5FU. MDM2 silencing by RNA interference activated p53 target gene expression in normal fibroblasts but not in HCT116 cells, and exogenous p53 could be stabilized in HCT116 knockout cells despite combined mutation of p53 phosphorylation sites and silencing of MDM2 expression. The MDM2 feedback loop is thus defective, and other mechanisms must exist to regulate p53 stability and function in this widely used tumor cell line.	Swiss Inst Expt Canc Res, Oncogene Grp, CH-1066 Epalinges, Switzerland	Swiss Institute Experimental Cancer Research	Iggo, RD (corresponding author), Swiss Inst Expt Canc Res, Oncogene Grp, Ch Boveresses 155, CH-1066 Epalinges, Switzerland.	Richard.Iggo@isrec.unil.ch	Iggo, Richard/G-3546-2014; Käser-Pébernard, Stéphanie GM/C-4219-2014	Käser-Pébernard, Stéphanie GM/0000-0002-6035-6979; Kaeser, Matthias/0000-0003-0050-9408				ANDERSON CW, 2003, HDB CELL SIGNALING, V3, P237; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Blattner C, 2002, MOL CELL BIOL, V22, P6170, DOI 10.1128/MCB.22.17.6170-6182.2002; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burri N, 2001, LAB INVEST, V81, P217, DOI 10.1038/labinvest.3780230; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Chao C, 2003, J BIOL CHEM, V278, P41028, DOI 10.1074/jbc.M306938200; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chene P, 2000, J MOL BIOL, V299, P245, DOI 10.1006/jmbi.2000.3738; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Saito S, 2003, J BIOL CHEM, V278, P37536, DOI 10.1074/jbc.M305135200; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Saller E, 1999, EMBO J, V18, P4424, DOI 10.1093/emboj/18.16.4424; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shieh SY, 2000, GENE DEV, V14, P289; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Wu ZQ, 2002, MOL CELL BIOL, V22, P2441, DOI 10.1128/MCB.22.8.2441-2449.2002; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhao RB, 2000, GENE DEV, V14, P981	55	91	91	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7598	7605		10.1074/jbc.M311732200	http://dx.doi.org/10.1074/jbc.M311732200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14665630	hybrid			2022-12-25	WOS:000189103300029
J	Khursigara, CM; De Crescenzo, G; Pawelek, PD; Coulton, JW				Khursigara, CM; De Crescenzo, G; Pawelek, PD; Coulton, JW			Enhanced binding of TonB to a ligand-loaded outer membrane receptor - Role of the oligomeric state of TonB in formation of a functional FhuA center dot TonB complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COBALAMIN TRANSPORTER BTUB; FERRICHROME-IRON RECEPTOR; ESCHERICHIA-COLI K-12; IN-VIVO EVIDENCE; CRYSTAL-STRUCTURE; CONFORMATIONAL-CHANGE; CYTOPLASMIC MEMBRANE; ACTIVE-TRANSPORT; PROTEIN TONB; REVEALS	The (f) under bar erric (h) under bar ydroxymate (u) under bar ptake (FhuA) receptor from Escherichia coli facilitates transport of siderophores ferricrocin and ferrichrome and siderophore-antibiotic conjugates such as albomycin and rifamycin CGP 4832. FhuA is also the receptor for phages T5, T1, Phi80, UC-1, for colicin M and for the antimicrobial peptide microcin MccJ21. Energy for transport is provided by the cytoplasmic membrane complex TonB.ExbB.ExbD, which uses the proton motive force of the cytoplasmic membrane to transduce energy to the outer membrane. To accomplish energy transfer, TonB contacts outer membrane receptors. However, the stoichiometry of TonB.receptor complexes and their sites of interaction remain uncertain. In this study, analyses of FhuA interactions with two recombinant TonB proteins by analytical ultracentrifugation revealed that TonB forms a 2:1 complex with FhuA. The presence of the FhuA-specific ligand ferricrocin enhanced the amounts of complex but is not essential for its formation. Surface plasmon resonance experiments demonstrated that FhuA.TonB interactions are multiple and have apparent affinities in the nanomolar range. TonB also possesses two distinct binding regions: one in the C terminus of the protein, for which binding to FhuA is ferricrocin-independent, and a higher affinity region outside the C terminus, for which ferricrocin enhances interactions with FhuA. Together these experiments establish that FhuA.TonB interactions are more intricate than originally predicted, that the TonB.FhuA stoichiometry is 2:1, and that ferricrocin modulates binding of FhuA to TonB at regions outside the C-terminal domain of TonB.	McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada; McGill Univ, Sheldon Biotechnol Ctr, Prot Prot Interact Facil, Montreal, PQ H3A 2B4, Canada	McGill University; McGill University	Coulton, JW (corresponding author), McGill Univ, Dept Microbiol & Immunol, 3775 Univ St, Montreal, PQ H3A 2B4, Canada.	james.coulton@mcgill.ca	Pawelek, Peter/E-7950-2014	Pawelek, Peter/0000-0002-8361-6593				Boulanger P, 1996, BIOCHEMISTRY-US, V35, P14216, DOI 10.1021/bi9608673; Braun V, 1998, MET IONS BIOL SYST, V35, P67; Braun V, 2002, CURR OPIN MICROBIOL, V5, P194, DOI 10.1016/S1369-5274(02)00298-9; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; Cadieux N, 1999, P NATL ACAD SCI USA, V96, P10673, DOI 10.1073/pnas.96.19.10673; Cadieux N, 2000, J BACTERIOL, V182, P5954, DOI 10.1128/JB.182.21.5954-5961.2000; Chang CS, 2001, J BIOL CHEM, V276, P27535, DOI 10.1074/jbc.M102778200; Chimento DP, 2003, J MOL BIOL, V332, P999, DOI 10.1016/j.jmb.2003.07.005; Chimento DP, 2003, NAT STRUCT BIOL, V10, P394, DOI 10.1038/nsb914; De Crescenzo G, 2001, J BIOL CHEM, V276, P29632, DOI 10.1074/jbc.M009765200; De Crescenzo G, 2000, BIOCHEMISTRY-US, V39, P9466, DOI 10.1021/bi992987r; EVANS JS, 1986, FEBS LETT, V208, P211, DOI 10.1016/0014-5793(86)81020-1; Ferguson AD, 1998, PROTEIN SCI, V7, P1636, DOI 10.1002/pro.5560070719; Ferguson AD, 2002, SCIENCE, V295, P1715, DOI 10.1126/science.1067313; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; FERGUSON AD, 2001, HDB METALLOPROTEINS, P834; GUNTER K, 1990, FEBS LETT, V274, P85, DOI 10.1016/0014-5793(90)81335-L; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Larsen RA, 2003, MOL MICROBIOL, V49, P211, DOI 10.1046/j.1365-2958.2003.03579.x; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; Moeck GS, 1996, MOL MICROBIOL, V22, P459, DOI 10.1046/j.1365-2958.1996.00112.x; Moeck GS, 1997, J BIOL CHEM, V272, P28391, DOI 10.1074/jbc.272.45.28391; Moeck GS, 1998, MOL MICROBIOL, V28, P675, DOI 10.1046/j.1365-2958.1998.00817.x; Moeck GS, 2001, J BACTERIOL, V183, P2755, DOI 10.1128/JB.183.9.2755-2764.2001; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; Postle K, 2003, MOL MICROBIOL, V49, P869, DOI 10.1046/j.1365-2958.2003.03629.x; Rich RL, 2000, CURR OPIN BIOTECH, V11, P54, DOI 10.1016/S0958-1669(99)00054-3; Sauter A, 2003, J BACTERIOL, V185, P5747, DOI 10.1128/JB.185.19.5747-5754.2003; SCHOFFLER H, 1989, MOL GEN GENET, V217, P378, DOI 10.1007/BF02464907; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SKARE JT, 1993, J BIOL CHEM, V268, P16302; ZHAO YF, 2003, BIOCHIM BIOPHYS ACTA, V1614, P201	32	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7405	7412		10.1074/jbc.M311784200	http://dx.doi.org/10.1074/jbc.M311784200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14668326	hybrid			2022-12-25	WOS:000189103300006
J	Hacker, S; Krebber, H				Hacker, S; Krebber, H			Differential export requirements for shuttling serine/arginine-type mRNA-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION ELONGATION; ARGININE METHYLATION; YEAST; COMPLEX; PHOSPHORYLATION; CYTOPLASM; TRANSPORT; DOMAIN	Messenger RNAs are transported to the cytoplasm bound to several shuttling mRNA-binding proteins. Here, we present the characterization of Hrb1, a novel component of the transported ribonucleoprotein complex in Saccharomyces cerevisiae. The protein is similar to the other two serine/arginine (SR)-type proteins in yeast, Gbp2 and Np13. Hrb1 is nuclear at steady state and its import is mediated by the karyopherin Mtr10. Hrb1 binds to poly(A)(+) RNA in vivo and its binding is significantly increased in MTR10 mutants, suggesting a role for Mtr10 in dissociating Hrb1 from the mRNAs. Interestingly, by comparing the export requirements of all three SR proteins we find similarities but also striking differences. While the export of all three proteins is dependent on the export of mRNAs in general, as no transport is observed in mutants defective in transcription (rpb1-1) or mRNA export (mex67-5), we find specific requirements for components of the THO complex, involved in transcription elongation. While both Hrb1 and Gbp2 depend on Mft1 and Hpr1 for their nuclear export, Np13 is exported independently of both proteins. These findings suggest that Hrb1 and Gbp2, but not Np13, might be loaded onto the growing mRNA via the THO complex components Mtf1 and Hrp1.	Univ Marburg, Inst Mol Biol & Tumorforsch, D-35037 Marburg, Germany	Philipps University Marburg	Krebber, H (corresponding author), Univ Marburg, Inst Mol Biol & Tumorforsch, Emil Mannkopff Str 2, D-35037 Marburg, Germany.	krebber@imt.uni-marburg.de						Afonina E, 1998, J BIOL CHEM, V273, P13015, DOI 10.1074/jbc.273.21.13015; ANDERSON JT, 1993, MOL CELL BIOL, V13, P2730, DOI 10.1128/MCB.13.5.2730; Barry DM, 2000, ESSAYS BIOCHEM, V36, P89, DOI 10.1042/bse0360089; Chavez S, 2000, EMBO J, V19, P5824, DOI 10.1093/emboj/19.21.5824; Clouse KN, 2001, NAT CELL BIOL, V3, P97, DOI 10.1038/35050625; Dasso M, 2001, CELL, V104, P321, DOI 10.1016/S0092-8674(01)00218-5; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Estruch F, 2003, MOL BIOL CELL, V14, P1664, DOI 10.1091/mbc.E02-09-0602; FLACH J, 1994, MOL CELL BIOL, V14, P8399, DOI 10.1128/MCB.14.12.8399; Fried H, 2003, CELL MOL LIFE SCI, V60, P1659, DOI 10.1007/s00018-003-3070-3; Gilbert W, 2001, RNA, V7, P302, DOI 10.1017/S1355838201002369; Green DM, 2003, P NATL ACAD SCI USA, V100, P1010, DOI 10.1073/pnas.0336594100; Henry MF, 1996, MOL CELL BIOL, V16, P3668; Kessler MM, 1997, GENE DEV, V11, P2545, DOI 10.1101/gad.11.19.2545; Krebber H, 1999, GENE DEV, V13, P1994, DOI 10.1101/gad.13.15.1994; Lei EP, 2001, GENE DEV, V15, P1771, DOI 10.1101/gad.892401; Lei EP, 2002, DEV CELL, V2, P261, DOI 10.1016/S1534-5807(02)00134-X; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; McBride AE, 2000, J BIOL CHEM, V275, P3128, DOI 10.1074/jbc.275.5.3128; Piruat JI, 1998, EMBO J, V17, P4859, DOI 10.1093/emboj/17.16.4859; Reed R, 2002, CELL, V108, P523, DOI 10.1016/S0092-8674(02)00627-X; Rondon AG, 2003, J BIOL CHEM, V278, P39037, DOI 10.1074/jbc.M305718200; RUSSELL I, 1995, EUR J CELL BIOL, V66, P293; Santos-Rosa H, 1998, MOL CELL BIOL, V18, P6826, DOI 10.1128/MCB.18.11.6826; Senger B, 1998, EMBO J, V17, P2196, DOI 10.1093/emboj/17.8.2196; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; Siebel CW, 1996, P NATL ACAD SCI USA, V93, P13641, DOI 10.1073/pnas.93.24.13641; Snay-Hodge CA, 1998, EMBO J, V17, P2663, DOI 10.1093/emboj/17.9.2663; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Strasser K, 2001, NATURE, V413, P648, DOI 10.1038/35098113; Tacke R, 1997, P NATL ACAD SCI USA, V94, P1148, DOI 10.1073/pnas.94.4.1148; Tseng SSL, 1998, EMBO J, V17, P2651, DOI 10.1093/emboj/17.9.2651; Visa N, 1996, J CELL BIOL, V133, P5, DOI 10.1083/jcb.133.1.5; Windgassen M, 2003, EMBO REP, V4, P278, DOI 10.1038/sj.embor.embor763; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; Yun CY, 2000, J CELL BIOL, V150, P707, DOI 10.1083/jcb.150.4.707; Zenklusen D, 2002, MOL CELL BIOL, V22, P8241, DOI 10.1128/MCB.22.23.8241-8253.2002; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999	38	35	36	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5049	5052		10.1074/jbc.C300522200	http://dx.doi.org/10.1074/jbc.C300522200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14676199	hybrid			2022-12-25	WOS:000188776500001
J	Gu, J; Zhang, LD; Swisher, SG; Liu, JS; Roth, JA; Fang, BL				Gu, J; Zhang, LD; Swisher, SG; Liu, JS; Roth, JA; Fang, BL			Induction of p53-regulated genes in lung cancer cells: implications of the mechanism for adenoviral p53-mediated apoptosis	ONCOGENE			English	Article						lung cancer; real-time PCR; p53; apoptosis; siRNA	P53-DEPENDENT APOPTOSIS; P53-INDUCED APOPTOSIS; BINDING PROTEIN; BCL-2 FAMILY; P53 PROTEIN; BAX; TRANSCRIPTION; SEQUENCE; DEATH; PUMA	The p53 gene is the most frequently mutated gene in human cancers. Loss of functional p53 leads to impaired responses of cancer cells to apoptosis induction and to poor prognosis in patients with certain types of cancer. Cancer gene therapies using ectopic expression of wildtype p53 to force cancer cells through the apoptotic pathway have been tested extensively preclinically and clinically, and genes in various cell lines have been reported to be regulated upon ectopic p53 overexpression. However, the effect of p53 on many other p53-dependent and apoptosis-related genes remains unclear, as does the mechanism of p53-induced apoptosis in human cancers. In this study, we used real-time reverse transcription polymerase chain reaction to evaluate the changes in expression of various p53-dependent and apoptosis-related genes in five human non-small-cell lung cancer cell lines with varying p53 statuses after adenoviral p53 treatment. We found that Ad/p53 induced the expression of the proapoptotic genes PUMA, Bak, Bax, and Fas in a cell type- and time-dependent manner. Among these genes, PUMA was upregulated the most dramatically and broadly. However, when a specific siRNA construct against PUMA was employed, we observed no attenuation of apoptosis in H1299 cells. Our data suggest that Ad-p53 induces the expression of a variety of proapoptotic genes and that lack of induction in one of these genes does not block Ad/p53-mediated cell killing in human lung cancer cells.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fang, BL (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, 1515 Holcombe Blvd, Houston, TX 77030 USA.	bfang@mdanderson.org	Gu, Jian/Q-4780-2018	Gu, Jian/0000-0003-3499-0973	NATIONAL CANCER INSTITUTE [R01CA092487, R01CA098582, P01CA078778] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 098582-01A1, R01 CA 092487-01A1, 2P50-CA70970-04, P01 CA78778-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Clayman GL, 1998, J CLIN ONCOL, V16, P2221, DOI 10.1200/JCO.1998.16.6.2221; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; EL DW, 1993, CELL, V75, P817; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lane DP, 2002, TRENDS MOL MED, V8, pS38, DOI 10.1016/S1471-4914(02)02309-2; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MIYASHITA T, 1995, CELL, V80, P293; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nemunaitis J, 2000, J CLIN ONCOL, V18, P609, DOI 10.1200/JCO.2000.18.3.609; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; QUINLAN DC, 1992, CANCER RES, V52, P4828; Reinke V, 1997, ONCOGENE, V15, P1527, DOI 10.1038/sj.onc.1201316; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Swisher SG, 1999, J NATL CANCER I, V91, P763, DOI 10.1093/jnci/91.9.763; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; Xiang H, 1998, J NEUROSCI, V18, P1363; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; ZHANG WW, 1993, BIOTECHNIQUES, V15, P868; Zhao RB, 2000, GENE DEV, V14, P981	39	17	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1300	1307		10.1038/sj.onc.1207239	http://dx.doi.org/10.1038/sj.onc.1207239			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14676844				2022-12-25	WOS:000188892200015
J	Chelbi-alix, MK; Bobe, P; Benoit, G; Canova, A; Pine, R				Chelbi-alix, MK; Bobe, P; Benoit, G; Canova, A; Pine, R			Arsenic enhances the activation of Stat1 by interferon gamma leading to synergistic expression of IRF-1	ONCOGENE			English	Article						interferon; IRF-1; Stat1; apoptosis; APL	ACUTE PROMYELOCYTIC LEUKEMIA; SIGNALING CROSS-TALK; I-TRANSFORMED-CELLS; TRANS-RETINOIC ACID; PML-RAR-ALPHA; APL CELLS; REGULATORY FACTOR-1; IFN-GAMMA; NB4 CELLS; KAPPA-B	Arsenic trioxide (As2O3) can induce clinical remission in patients with acute promyelocytic leukemia (APL), including those who have relapsed after treatment with all-trans-retinoic acid (RA). In vitro studies with the APL-derived NB4 cell line showed that As2O3 exerts a dose-dependent dual effect, which induces apoptosis at 1 muM, whereas at a lower concentration of 0.1 muM, a partial differentiation of APL is observed. In non-APL cells, interferon (IFN) alpha and 1 muM As2O3 act synergistically to induce apoptosis. In this report, we show that in NB4 cells and in two RA-resistant NB4-derived cell lines, NB4-R1 and NB4-R2, IFNalpha or IFNgamma combined with 0.1 muM As2O3 lead to an increased maturation effect. Moreover, IFNgamma alone is able to differentiate RA-sensitive and -resistant cells with a higher maturation effect on NB4-R2 cells. In contrast, all these cells underwent apoptosis in the presence of the cytokine and a higher concentration of As2O3. IFNgamma boosted As2O3-induced apoptosis in APL cells as tested by TUNEL, Annexin V staining and activation of caspase 3. As2O3 differently altered IFN-induced gene products; it downregulated PML/RARalpha and PML, did not alter PKR and Stat1, and upregulated interferon regulatory family (IRF)-1. Synergism by IFNgamma and arsenic on IRF-1 expression is mediated by a composite element in the IRF-1 promoter that includes an IFNgamma-activation site (GAS) overlapped by a nonconsensus site for nuclear factor kappa B (NFkappaB). Arsenic has no effect on NFkappaB, whereas it enhances the activation of Stat1 by IFNgamma in NB4 cells leading to an increase in IRF-1 expression.	Inst Lwoff, UPR9045, F-94801 Villejuif, France; Hop St Louis, INSERM, U496, F-75010 Paris, France; Publ Hlth Res Inst, Newark, NJ 07103 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Chelbi-alix, MK (corresponding author), Inst Lwoff, UPR9045, 7 Rue Guy Moquet, F-94801 Villejuif, France.			BENOIT, Gerard/0000-0001-9462-6570; Bobe, Pierre/0000-0002-8835-6786				Bazarbachi A, 1999, BLOOD, V93, P278, DOI 10.1182/blood.V93.1.278.401k22_278_283; Chelbi-Alix MK, 1999, LEUKEMIA, V13, P1167, DOI 10.1038/sj.leu.2401469; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; Chen GQ, 1997, BLOOD, V89, P3345; Chen Z, 1997, PHARMACOL THERAPEUT, V76, P141, DOI 10.1016/S0163-7258(97)00090-9; DANIEL MT, 1993, BLOOD, V82, P1858; de The H, 2001, ONCOGENE, V20, P7136, DOI 10.1038/sj.onc.1204851; Duprez E, 2000, LEUKEMIA, V14, P255, DOI 10.1038/sj.leu.2401683; Duprez E, 1996, ONCOGENE, V12, P2451; DUPREZ E, 1992, LEUKEMIA, V6, P1281; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; El-Sabban ME, 2000, BLOOD, V96, P2849; Foss GS, 1999, J BIOL CHEM, V274, P35196, DOI 10.1074/jbc.274.49.35196; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; Gil J, 2000, APOPTOSIS, V5, P107, DOI 10.1023/A:1009664109241; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KROGER A, 2002, J INTERFERON CYTOKIN, V1, P5; LANOTTE M, 1991, BLOOD, V77, P1080; MARUYAMA M, 1989, NUCLEIC ACIDS RES, V17, P3292, DOI 10.1093/nar/17.8.3292; MILLER WH, 1995, BLOOD, V85, P3021, DOI 10.1182/blood.V85.11.3021.bloodjournal85113021; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; Ohmori Y, 1997, J BIOL CHEM, V272, P14899, DOI 10.1074/jbc.272.23.14899; Pelicano L, 1999, ONCOGENE, V18, P3944, DOI 10.1038/sj.onc.1202802; Pelicano L, 1997, ONCOGENE, V15, P2349, DOI 10.1038/sj.onc.1201410; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; Percario ZA, 1999, CELL GROWTH DIFFER, V10, P263; Pine R, 1997, NUCLEIC ACIDS RES, V25, P4346, DOI 10.1093/nar/25.21.4346; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; Stadler M, 1995, ONCOGENE, V11, P2565; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; TANIGUCHI T, 1997, BIOCHIM BIOPHYS ACTA, V1333, P9; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Yoshida H, 1996, CANCER RES, V56, P2945; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978; Zhu Q, 2002, BLOOD, V99, P1014	43	20	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2003	22	57					9121	9130		10.1038/sj.onc.1207090	http://dx.doi.org/10.1038/sj.onc.1207090			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	752FJ	14668793				2022-12-25	WOS:000187149100002
J	Laux, WHG; Pande, P; Shoshani, I; Gao, JY; Boudou-Vivet, V; Gosselin, G; Johnson, RA				Laux, WHG; Pande, P; Shoshani, I; Gao, JY; Boudou-Vivet, V; Gosselin, G; Johnson, RA			Pro-nucleotide inhibitors of adenylyl cyclases in intact cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-MEDIATED INHIBITION; PHOSPHATE-PROTECTING GROUPS; HUMAN-IMMUNODEFICIENCY; CYCLIC-AMP; NUCLEOSIDE 3-POLYPHOSPHATES; PHOSPHOTRIESTER DERIVATIVES; MONONUCLEOTIDE PRODRUGS; INTRACELLULAR DELIVERY; ANTIVIRAL EVALUATION; POTENT INHIBITORS	Substituted adenine derivatives with protected phosphoryl groups were synthesized and tested as inhibitors of adenylyl cyclase in isolated enzyme and intact cell systems. Protected 3'-phosphoryl derivatives of 2', 5'-dideoxyadenosine (2',5'-dd-Ado) and beta-L-2',5'-dd-Ado, protected 5'-phosphoryl derivatives of beta-L-2', 3'-dd-Ado, and protected phosphoryl derivatives of two 9-(2-phosphonomethoxy- acyl)-adenines were synthesized. Protection was afforded by two cyclosaligenyl- or three S-acyl-2-thioethyl-substituents. These pro-nucleotides were tested for their capacity to block forskolin-induced increases in [H-3] cAMP in OB1771 and F442A preadipocytes and human macrophages prelabeled with [H-3] adenine. A striking selectivity for 2', 5'- dd-Ado- 3'-phosphoryl derivatives was observed. Cyclosaligenyl-derivatives (IC50 similar to2 muM) were much less potent than S-acyl-2-thioethyl- derivatives. Best studied of these was 2', 5'-dd-Ado- 3'-O-bis(S-pivaloyl-2-thioethyl)-phosphate, which blocked [H-3] cAMP formation in preadipocytes (IC50 similar to30 nM) and suppressed opening of cAMP-dependent Cl- channels in cardiac myocytes (IC50 similar to 800 nM). None of the pro-nucleotides inhibited adenylyl cyclase per se, whether isolated from rat brain or OB1771 cells. These compounds exhibit the hallmarks of prodrugs. Data suggest they are taken up, are deprotected, and are converted to a potent inhibitory form to inhibit adenylyl cyclase, but only by intact cells. The availability and characteristics of these prodrugs should make them useful for blocking cAMP-mediated pathways in intact cell systems, in biochemical, pharmacological, and potentially therapeutic contexts.	SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; Univ Montpellier 2, Lab Chim Organ Biomol Synth, CNRS, UMR 5625, F-34095 Montpellier 5, France	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Johnson, RA (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.	roger.johnson@sunysb.edu			NIDDK NIH HHS [DK38828] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038828] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER P, 1994, COLLECT CZECH CHEM C, V59, P2127, DOI 10.1135/cccc19942127; Beltran T, 2001, BIOORG MED CHEM LETT, V11, P1775, DOI 10.1016/S0960-894X(01)00299-2; Benzaria S, 1996, J MED CHEM, V39, P4958, DOI 10.1021/jm960289o; Bolon PJ, 1996, BIOORG MED CHEM LETT, V6, P1657, DOI 10.1016/0960-894X(96)00293-4; CHENG WL, 1995, AM J PHYSIOL-ENDOC M, V269, pE642, DOI 10.1152/ajpendo.1995.269.4.E642; CLAUS TH, 1982, MOL CELL ENDOCRINOL, V26, P269, DOI 10.1016/0303-7207(82)90116-2; DECLERCQ E, 1997, CLIN MICROBIOL REV, V10, P1; DESAUBRY L, 1995, TETRAHEDRON LETT, V36, P995, DOI 10.1016/0040-4039(94)02424-A; DESAUBRY L, 1995, NUCLEOS NUCLEOT, V14, P1453, DOI 10.1080/15257779508010705; Desaubry L, 1996, J BIOL CHEM, V271, P14028, DOI 10.1074/jbc.271.24.14028; Desaubry L, 1998, J BIOL CHEM, V273, P24972, DOI 10.1074/jbc.273.38.24972; Desaubry L, 1996, J BIOL CHEM, V271, P2380, DOI 10.1074/jbc.271.5.2380; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; DILLINGHAM MA, 1985, J MEMBRANE BIOL, V88, P277, DOI 10.1007/BF01871091; Doronin S, 1999, J BIOL CHEM, V274, P34745, DOI 10.1074/jbc.274.49.34745; Egron D, 2001, NUCLEOS NUCLEOT NUCL, V20, P751, DOI 10.1081/NCN-100002422; FAIN JN, 1972, J BIOL CHEM, V247, P6866; Friedman D L, 1976, Adv Cyclic Nucleotide Res, V7, P69; GAO J, 1992, J PHYSIOL-LONDON, V449, P689, DOI 10.1113/jphysiol.1992.sp019109; GARBERS DL, 1975, J BIOL CHEM, V250, P8449; GARTNER R, 1985, MOL CELL ENDOCRINOL, V42, P145, DOI 10.1016/0303-7207(85)90102-9; GREGA DS, 1987, J NEUROSCI, V7, P700; HARVEY RD, 1990, J GEN PHYSIOL, V95, P1077, DOI 10.1085/jgp.95.6.1077; HASLAM RJ, 1972, LIFE SCI 2-BIOCH GEN, V11, P1143, DOI 10.1016/0024-3205(72)90269-X; HASLAM RJ, 1978, BIOCHEM J, V176, P83, DOI 10.1042/bj1760083; HOLY A, 1987, COLLECT CZECH CHEM C, V52, P2801, DOI 10.1135/cccc19872801; HOLY A, 1995, COLLECT CZECH CHEM C, V60, P1196, DOI 10.1135/cccc19951196; HWANG TC, 1992, J GEN PHYSIOL, V99, P465, DOI 10.1085/jgp.99.4.465; Ibrahimi A, 1999, AM J PHYSIOL-CELL PH, V276, pC487, DOI 10.1152/ajpcell.1999.276.2.C487; JOHNSON RA, 1989, MOL PHARMACOL, V35, P681; Johnson RA, 1997, J BIOL CHEM, V272, P8962; JOHNSON RA, 1994, METHOD ENZYMOL, V238, P31; JONES RJ, 1995, ANTIVIR RES, V27, P1, DOI 10.1016/0166-3542(95)00011-A; LEFEBVRE I, 1995, J MED CHEM, V38, P3941, DOI 10.1021/jm00020a007; LONDOS C, 1977, P NATL ACAD SCI USA, V74, P5482, DOI 10.1073/pnas.74.12.5482; MCGUIGAN C, 1992, ANTIVIR RES, V17, P311, DOI 10.1016/0166-3542(92)90026-2; MCGUIGAN C, 1993, J MED CHEM, V36, P1048, DOI 10.1021/jm00060a013; Meier C, 1996, ANGEW CHEM INT EDIT, V35, P70, DOI 10.1002/anie.199600701; Meier C, 1997, BIOORG MED CHEM LETT, V7, P99, DOI 10.1016/S0960-894X(96)00597-5; Meier C, 1998, J MED CHEM, V41, P1417, DOI 10.1021/jm970664s; Meier C, 1997, BIOORG MED CHEM LETT, V7, P1577, DOI 10.1016/S0960-894X(97)00265-5; Meier C, 2002, MINI-REV MED CHEM, V2, P219, DOI 10.2174/1389557023406205; NAESENS L, 1994, REV MED VIROL, V4, P147, DOI 10.1002/rmv.1980040302; Naesens L, 1997, ANTIVIR CHEM CHEMOTH, V8, P1; NEYTS J, 1994, BIOCHEM PHARMACOL, V47, P39, DOI 10.1016/0006-2952(94)90435-9; PERIGAUD C, 1993, BIOORG MED CHEM LETT, V3, P2521, DOI 10.1016/S0960-894X(01)80709-5; PERIGAUD C, 1996, ADV ANTIV D, V2, P147; Peyrottes S, 2001, NUCLEOS NUCLEOT NUCL, V20, P315, DOI 10.1081/NCN-100002302; PIERRA C, 1997, THESIS U MONTPELLIER; REID IR, 1990, AM J PHYSIOL, V258, pE708, DOI 10.1152/ajpendo.1990.258.4.E708; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SASTRY JK, 1992, MOL PHARMACOL, V41, P441; Shoshani I, 1999, J BIOL CHEM, V274, P34742, DOI 10.1074/jbc.274.49.34742; Shoshani I, 1999, J BIOL CHEM, V274, P34735, DOI 10.1074/jbc.274.49.34735; Tesmer JJG, 2000, BIOCHEMISTRY-US, V39, P14464, DOI 10.1021/bi0015562; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; Thomas CA, 1997, BLOOD, V90, P3760, DOI 10.1182/blood.V90.9.3760; Wagner CR, 2000, MED RES REV, V20, P417, DOI 10.1002/1098-1128(200011)20:6<417::AID-MED1>3.0.CO;2-Z; WEINRYB I, 1974, BIOCHIM BIOPHYS ACTA, V334, P218, DOI 10.1016/0005-2744(74)90165-X; WOLFF J, 1981, ADV CYCL NUCL RES<D>, V14, P199	60	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13317	13332		10.1074/jbc.M309535200	http://dx.doi.org/10.1074/jbc.M309535200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14699161	hybrid			2022-12-25	WOS:000220478500008
J	Nery, FC; Passos, DO; Garcia, VS; Kobarg, J				Nery, FC; Passos, DO; Garcia, VS; Kobarg, J			Ki-1/57 interacts with RACK1 and is a substrate for the phosphorylation by phorbol 12-myristate 13-acetate-activated protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN-REMODELING FACTOR; HISTONE DEACETYLASE; SCAFFOLD PROTEIN; HODGKINS-DISEASE; BINDING-PROTEIN; BETA-SUBUNIT; PKC-BETA; RECEPTOR; ANTIGEN; FAMILY	Ki-1/57, the 57-kDa human protein antigen recognized by the CD30 antibody Ki-1, is a cytoplasmic and nuclear protein that is phosphorylated on serine and threonine residues. When isolated from the Hodgkin's lymphoma analogous cell line L540 Ki-1/57 co-immunoprecipitated with a Thr/Ser protein kinase activity. It has been also found to interact with hyaluronic acid and has therefore been termed intracellular IHABP4 (hyaluronan-binding protein 4). Recent studies demonstrated, however, that Ki-1/57 engages in specific interaction with the chromo-helicase-DNA-binding domain protein 3, a nuclear protein involved in chromatin remodeling and transcription regulation. We used the yeast two-hybrid system to find proteins interacting with Ki-1/57 and identified the adaptor protein RACK1 (receptor of activated kinase 1). Next, we confirmed this interaction in vitro and in vivo, performed detailed mapping studies of the interaction sites of Ki-1/57 and RACK-1, and demonstrated that Ki-1/57 also co-precipitates with protein kinase C (PKC) when isolated from phorbol 12-myristate 13-acetate (PMA)-activated L540 tumor cells and is a substrate for PKC phosphorylation in vitro and in vivo. Interestingly, the interaction of Ki-1/57 with RACK1 is abolished upon activation of L540 cells with PMA, which results in the phosphorylation of Ki-1/57 and its exit from the nucleus. Taken together, our data suggest that Ki-1/57 forms a stable complex with RACK-1 in unstimulated cells and upon PMA stimulation gets phosphorylated on threonine residues located at its extreme C terminus. These events associate Ki-1/57 with the RACK1/PKC pathway and may be important for the regulation of its cellular functions.	Lab Nacl Luz Sincrotron, Ctr Biol Mol Estrutural, BR-13084971 Campinas, SP, Brazil; Univ Estadual Campinas, Dept Genet & Evolucao, BR-13083970 Campinas, SP, Brazil; Univ Estadual Campinas, Dept Bioquim, BR-13083970 Campinas, SP, Brazil	Laboratorio Nacional de Luz Sincrotron (LNLS); Universidade Estadual de Campinas; Universidade Estadual de Campinas	Kobarg, J (corresponding author), Lab Nacl Luz Sincrotron, Ctr Biol Mol Estrutural, Rua Giuseppe Maximo Scolfaro 10-000,CP 6192, BR-13084971 Campinas, SP, Brazil.	jkobarg@lnls.br	Kobarg, Jörg/T-4736-2019	Kobarg, Jörg/0000-0002-9419-0145; Rinaldi, Vera/0000-0002-0051-1754				Aubry F, 1998, EUR J BIOCHEM, V254, P558, DOI 10.1046/j.1432-1327.1998.2540558.x; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Baumann M, 2000, EUR J BIOCHEM, V267, P3891, DOI 10.1046/j.1432-1327.2000.01430.x; Berns H, 2000, FASEB J, V14, P2549, DOI 10.1096/fj.99-1038com; Cavalli G, 1998, CURR OPIN CELL BIOL, V10, P354, DOI 10.1016/S0955-0674(98)80011-2; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; Cox EA, 2003, MOL BIOL CELL, V14, P658, DOI 10.1091/mbc.E02-03-0142; Croze E, 2000, J IMMUNOL, V165, P5127, DOI 10.4049/jimmunol.165.9.5127; Csukai M, 1999, PHARMACOL RES, V39, P253, DOI 10.1006/phrs.1998.0418; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; Dequiedt F, 2003, IMMUNITY, V18, P687, DOI 10.1016/S1074-7613(03)00109-2; DIEHL V, 1981, J CANCER RES CLIN, V101, P111, DOI 10.1007/BF00405072; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; Fischle W, 2001, J BIOL CHEM, V276, P35826, DOI 10.1074/jbc.M104935200; FROESE P, 1987, J IMMUNOL, V139, P2081; Gallina A, 2001, VIROLOGY, V283, P7, DOI 10.1006/viro.2001.0855; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; Geijsen N, 1999, ONCOGENE, V18, P5126, DOI 10.1038/sj.onc.1202896; GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104; HANSEN H, 1990, RES IMMUNOL, V141, P13, DOI 10.1016/0923-2494(90)90098-J; HANSEN H, 1989, BIOL CHEM H-S, V370, P409, DOI 10.1515/bchm3.1989.370.1.409; Heaton JH, 2001, J BIOL CHEM, V276, P3341, DOI 10.1074/jbc.M006538200; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Huang L, 2000, J BIOL CHEM, V275, P29829, DOI 10.1074/jbc.M002737200; Kobarg J, 1997, EXP CLIN IMMUNOGENET, V14, P273; KOONIN EV, 1995, NUCLEIC ACIDS RES, V23, P4229, DOI 10.1093/nar/23.21.4229; Kuroda S, 1999, J CELL BIOL, V144, P403, DOI 10.1083/jcb.144.3.403; Lemos TA, 2003, FEBS LETT, V533, P14, DOI 10.1016/S0014-5793(02)03737-7; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Machado EL, 2002, PHYTOCHEMISTRY, V61, P835, DOI 10.1016/S0031-9422(02)00429-6; McCahill A, 2002, MOL PHARMACOL, V62, P1261, DOI 10.1124/mol.62.6.1261; Moraes KCM, 2003, BIOL CHEM, V384, P25, DOI 10.1515/BC.2003.004; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; Ogas J, 1999, P NATL ACAD SCI USA, V96, P13839, DOI 10.1073/pnas.96.24.13839; Ozaki T, 2003, ONCOGENE, V22, P3231, DOI 10.1038/sj.onc.1206382; Padanilam BJ, 1997, AM J PHYSIOL-RENAL, V272, pF160, DOI 10.1152/ajprenal.1997.272.2.F160; Pass JM, 2001, AM J PHYSIOL-HEART C, V281, pH2500, DOI 10.1152/ajpheart.2001.281.6.H2500; ROHDE D, 1992, AM J PATHOL, V140, P473; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Sang NL, 2001, J BIOL CHEM, V276, P27026, DOI 10.1074/jbc.M010346200; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; Tcherkasowa AE, 2002, J IMMUNOL, V169, P5161, DOI 10.4049/jimmunol.169.9.5161; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; USACHEWA A, 2001, J BIOL CHEM, V27, P22948; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Woodage T, 1997, P NATL ACAD SCI USA, V94, P11472, DOI 10.1073/pnas.94.21.11472; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	53	25	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11444	11455		10.1074/jbc.M306672200	http://dx.doi.org/10.1074/jbc.M306672200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699138	hybrid			2022-12-25	WOS:000220157600075
J	Oxford, JT; DeScala, J; Morris, N; Gregory, K; Medeck, R; Irwin, K; Oxford, R; Brown, R; Mercer, L; Cusack, S				Oxford, JT; DeScala, J; Morris, N; Gregory, K; Medeck, R; Irwin, K; Oxford, R; Brown, R; Mercer, L; Cusack, S			Interaction between amino propeptides of type XI procollagen alpha 1 chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN TYPE-XI; NONCOLLAGENOUS DOMAIN; CARTILAGE; ORGANIZATION; FORMS; IX; MORPHOGENESIS; MEMBRANE; FIBRILS; GENE	Type XI collagen is a quantitatively minor yet essential constituent of the cartilage extracellular matrix. The amino propeptide of the alpha1 chain remains attached to the rest of the molecule for a longer period of time after synthesis than the other amino propeptides of type XI collagen and has been localized to the surface of thin collagen fibrils. Yeast two-hybrid system was used to demonstrate that a homodimer of alpha1(XI) amino propeptide (alpha1(XI)Npp) could form in vivo. Interaction was also confirmed using multi-angle laser light scattering, detecting an absolute weight average molar mass ranging from the size of a monomer to the size of a dimer (25,000 50,000 g/mol), respectively. Binding was shown to be saturable by ELISA. An interaction between recombinant alpha1(XI)Npp and the endogenous alpha1(XI)Npp was observed, and specificity for alpha1(XI)Npp but not alpha2(XI)Npp was demonstrated by co-precipitation. The interaction between the recombinant form of alpha1(XI)Npp and the endogenous alpha1(XI)Npp resulted in a stable association during the regeneration of cartilage extracellular matrix by fetal bovine chondrocytes maintained in pellet culture, generating a protein that migrated with an apparent molecular mass of 50-60 kDa on an SDS-polyacrylamide gel.	Boise State Univ, Dept Biol, Boise, ID 83725 USA; Shriners Hosp Children, Portland, OR 97201 USA; Robert W Franz Canc Res Ctr, Portland, OR 97213 USA	Idaho; Boise State University	Oxford, JT (corresponding author), Boise State Univ, Dept Biol, Boise, ID 83725 USA.	joxford@boiststate.edu	Oxford, Julia Thom/AAH-2842-2019	Oxford, Julia Thom/0000-0002-4850-3569; Keller, Kate/0000-0002-1616-972X	NCRR NIH HHS [P20RR16454, P20 RR016454-096114, P20 RR016454-086155, P20 RR016454] Funding Source: Medline; NIAMS NIH HHS [K02 AR048672-02, K02 AR048672-05, K02 AR048672-01, R01 AR047985-05, R01 AR047985-03, R01AR47985, R01 AR047985-02, R01 AR047985, K02 AR048672-04, K02 AR048672-03, K02AR48672, K02 AR048672, R01 AR047985-01, R01 AR047985-04] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047985, K02AR048672] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BALLOCK RT, 1994, J CELL BIOL, V126, P1311, DOI 10.1083/jcb.126.5.1311; Barber RE, 1996, BIOCHEM J, V320, P479, DOI 10.1042/bj3200479; Davies GBM, 1998, DEV DYNAM, V213, P12, DOI 10.1002/(SICI)1097-0177(199809)213:1<12::AID-AJA2>3.0.CO;2-0; Douglas SP, 1998, MATRIX BIOL, V16, P497, DOI 10.1016/S0945-053X(98)90020-8; EIKENBERRY EF, 1982, ARTICULAR CARTILAGE, P133; Eyre D, 1987, STRUCTURE FUNCTION C, P261; Frischholz S, 1998, J BIOL CHEM, V273, P4547, DOI 10.1074/jbc.273.8.4547; Gregory KE, 2000, J BIOL CHEM, V275, P11498, DOI 10.1074/jbc.275.15.11498; Imamura Y, 1998, J BIOL CHEM, V273, P27511, DOI 10.1074/jbc.273.42.27511; KEENE DR, 1995, J HISTOCHEM CYTOCHEM, V43, P967, DOI 10.1177/43.10.7560887; KWAN APL, 1991, J CELL BIOL, V114, P597, DOI 10.1083/jcb.114.3.597; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; Medeck RJ, 2003, BIOCHEM J, V376, P361, DOI 10.1042/BJ20030894; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; Moradi-Ameli M, 1998, MATRIX BIOL, V17, P393, DOI 10.1016/S0945-053X(98)90091-9; MORADIAMELI M, 1994, MATRIX BIOL, V14, P233, DOI 10.1016/0945-053X(94)90187-2; NEAME PJ, 1990, J BIOL CHEM, V265, P20401; OXFORD JT, 1995, J BIOL CHEM, V270, P9478, DOI 10.1074/jbc.270.16.9478; Rousseau JC, 1996, J BIOL CHEM, V271, P23743, DOI 10.1074/jbc.271.39.23743; SAWADA H, 1990, J CELL BIOL, V110, P219, DOI 10.1083/jcb.110.1.219; SMITH GN, 1987, COLLAGEN REL RES, V7, P17; SONI R, 1993, CURR GENET, V24, P455, DOI 10.1007/BF00351857; SUSSMAN M D, 1984, Journal of Orthopaedic Research, V2, P134, DOI 10.1002/jor.1100020204; THOM JR, 1991, J BIOL CHEM, V266, P7262; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; WU JJ, 1995, J BIOL CHEM, V270, P18865, DOI 10.1074/jbc.270.32.18865; YURCHENCO PD, 1984, BIOCHEMISTRY-US, V23, P1839, DOI 10.1021/bi00303a040	27	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10939	10945		10.1074/jbc.M310291200	http://dx.doi.org/10.1074/jbc.M310291200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699108	Green Accepted, hybrid			2022-12-25	WOS:000220157600015
J	Favari, E; Lee, M; Calabresi, L; Franceschini, G; Zimetti, F; Bernini, F; Kovanen, PT				Favari, E; Lee, M; Calabresi, L; Franceschini, G; Zimetti, F; Bernini, F; Kovanen, PT			Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1-but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR CHOLESTEROL EFFLUX; APOLIPOPROTEIN-A-I; MACROPHAGE FOAM CELLS; AORTIC INTIMAL FLUID; MAST-CELLS; APOA-I; INTERSTITIAL FLUID; FATTY STREAKS; HDL; PLASMA	The ATP-binding cassette transporter A1 (ABCA1) mediates the efflux of cellular unesterified cholesterol and phospholipid to lipid-poor apolipoprotein A-I. Chymase, a protease secreted by mast cells, selectively cleaves pre-beta-migrating particles from high density lipoprotein (HDL)(3) and reduces the efflux of cholesterol from macrophages. To evaluate whether this effect is the result of reduction of ABCA1-dependent or -independent pathways of cholesterol efflux, in this study we examined the efflux of cholesterol to preparations of chymase-treated HDL3 in two types of cell: 1) in J774 murine macrophages endogenously expressing low levels of scavenger receptor class B, type I (SR-BI), and high levels of ABCA1 upon treatment with cAMP; and 2) in Fu5AH rat hepatoma cells endogenously expressing high levels of the SR-BI and low levels of ABCA1. Treatment of HDL3 with the human chymase resulted in rapid depletion of pre-beta-HDL and a concomitant decrease in the efflux of cholesterol and phospholipid (2-fold and 3-fold, respectively) from the ABCA1-expressing J774 cells. In contrast, efflux of free cholesterol from Fu5AH to chymase-treated and to untreated HDL3 was similar. Incubation of HDL3 with phospholipid transfer protein led to an increase in pre-beta-HDL contents as well as in ABCA1-mediated cholesterol efflux. A decreased cholesterol efflux to untreated HDL3 but not to chymase-treated HDL3 was observed in ABCA1-expressing J774 with probucol, an inhibitor of cholesterol efflux to lipid-poor apoA-I. Similar results were obtained using brefeldin and gliburide, two inhibitors of ABCA1-mediated efflux. These results indicate that chymase treatment of HDL3 specifically impairs the ABCA1-dependent pathway without influencing either aqueous or SR-BI-facilitated diffusion and that this effect is caused by depletion of lipid-poor pre-beta-migrating particles in HDL3. Our results are compatible with the view that HDL3 promotes ABCA1-mediated lipid efflux entirely through its lipid-poor fraction with pre-beta mobility.	Wihuri Res Inst, SF-00140 Helsinki, Finland; Univ Parma, Dept Pharmacol & Biol Sci, I-43100 Parma, Italy; Univ Havana, Dept Biochem, Havana H10400, Cuba; Univ Milan, Dept Pharmacol Sci, Ctr E Grossi Paoletti, I-30126 Milan, Italy	Wihuri Research Institute; University of Parma; Universidad de la Habana; University of Milan	Kovanen, PT (corresponding author), Wihuri Res Inst, Kalliolinnantie 4, SF-00140 Helsinki, Finland.	petri.kovanen@wri.fi	Bernini, Franco/B-6740-2011; 应, 宁宁/G-9472-2011; Favari, Elda/B-6830-2011	Favari, Elda/0000-0002-5901-2482; FRANCESCHINI, GUIDO/0000-0003-2687-1771; Calabresi, Laura/0000-0001-5042-9532; Zimetti, Francesca/0000-0002-6665-263X				ASZATALOS BF, 1993, BIOCHIM BIOPHYS ACTA, V1169, P301; Attie AD, 2001, J LIPID RES, V42, P1717; Bernini F, 1996, BBA-LIPID LIPID MET, V1299, P103, DOI 10.1016/0005-2760(95)00200-6; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Favari E, 2002, BIOCHEM BIOPH RES CO, V299, P801, DOI 10.1016/S0006-291X(02)02745-6; FIELDING CJ, 1995, J LIPID RES, V36, P211; Fielding CJ, 2001, BBA-MOL CELL BIOL L, V1533, P175, DOI 10.1016/S1388-1981(01)00162-7; FIELDING CJ, 1991, CURR OPIN LIPIDOL, V2, P376; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; Fournier N, 2000, ARTERIOSCL THROM VAS, V20, P1283, DOI 10.1161/01.ATV.20.5.1283; FRANCESCHINI G, 1985, J BIOL CHEM, V260, P6321; Ghalim N, 1996, INT J CLIN LAB RES, V26, P224, DOI 10.1007/BF02602953; HUANG YD, 1993, ARTERIOSCLER THROMB, V13, P445, DOI 10.1161/01.ATV.13.3.445; JAUHIAINEN M, 1993, J BIOL CHEM, V268, P4032; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JONAS A, 1991, BIOCHIM BIOPHYS ACTA, V1084, P205, DOI 10.1016/0005-2760(91)90062-M; KAARTINEN M, 1994, ARTERIOSCLER THROMB, V14, P966, DOI 10.1161/01.ATV.14.6.966; KOKKONEN JO, 1986, J BIOL CHEM, V261, P6067; Kovanen PT, 1996, CURR OPIN LIPIDOL, V7, P281, DOI 10.1097/00041433-199610000-00004; Lee M, 1999, ARTERIOSCL THROM VAS, V19, P1066, DOI 10.1161/01.ATV.19.4.1066; Lee M, 2003, J BIOL CHEM, V278, P13539, DOI 10.1074/jbc.M210847200; Lee M, 2003, J LIPID RES, V44, P539, DOI 10.1194/jlr.M200420-JLR200; Lee M, 2002, ARTERIOSCL THROM VAS, V22, P2086, DOI 10.1161/01.ATV.0000041405.07367.B5; Lee M, 2002, ARTERIOSCL THROM VAS, V22, P1475, DOI 10.1161/01.ATV.0000029782.84357.68; Lee M, 2000, J LIPID RES, V41, P975; Lindstedt L, 1996, J CLIN INVEST, V97, P2174, DOI 10.1172/JCI118658; Lindstedt L, 1999, J BIOL CHEM, V274, P22627, DOI 10.1074/jbc.274.32.22627; Lindstedt L, 2001, ATHEROSCLEROSIS, V155, P87, DOI 10.1016/S0021-9150(00)00544-X; Lindstedt L, 2000, BIOCHEM BIOPH RES CO, V277, P552, DOI 10.1006/bbrc.2000.3704; Mendez AJ, 1997, BBA-LIPID LIPID MET, V1346, P285, DOI 10.1016/S0005-2760(97)00031-3; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Panagotopulos SE, 2002, J BIOL CHEM, V277, P39477, DOI 10.1074/jbc.M207005200; Porsch-Ozcurumez M, 2001, J BIOL CHEM, V276, P12427, DOI 10.1074/jbc.M100218200; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rothblat GH, 2002, ATHEROSCLEROSIS, V163, P1, DOI 10.1016/S0021-9150(01)00713-4; Sakr SW, 1999, BBA-MOL CELL BIOL L, V1438, P85, DOI 10.1016/S1388-1981(99)00041-4; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SLOOP CH, 1987, J LIPID RES, V28, P225; Sviridov D, 2002, ARTERIOSCL THROM VAS, V22, P1482, DOI 10.1161/01.ATV.0000029120.44088.FE; Tsujita M, 1996, BIOCHEMISTRY-US, V35, P13011, DOI 10.1021/bi960734h; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; YANCEY PG, 1995, BIOCHEMISTRY-US, V34, P7955, DOI 10.1021/bi00024a021; Yancey PG, 2003, ARTERIOSCL THROM VAS, V23, P712, DOI 10.1161/01.ATV.0000057572.97137.DD; Yancey PG, 2000, J BIOL CHEM, V275, P36596, DOI 10.1074/jbc.M006924200; Yokoyama S, 1998, BBA-LIPID LIPID MET, V1392, P1, DOI 10.1016/S0005-2760(98)00032-0	50	110	115	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9930	9936		10.1074/jbc.M312476200	http://dx.doi.org/10.1074/jbc.M312476200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14701812	hybrid			2022-12-25	WOS:000220050400034
J	Salicioni, AM; Gaultier, A; Brownlee, C; Cheezum, MK; Gonias, SL				Salicioni, AM; Gaultier, A; Brownlee, C; Cheezum, MK; Gonias, SL			Low density lipoprotein receptor-related protein-1 promotes beta(1) integrin maturation and transport to the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; CYTOPLASMIC DOMAIN; CYTOSOLIC ADAPTER; LRP; MODULATION; EXPRESSION; ADHESION; BETA-1-INTEGRIN; ACTIVATION; CATABOLISM	Low density lipoprotein receptor-related protein-1 (LRP-1) mediates the endocytosis of multiple plasma membrane proteins and thereby models the composition of the cell surface. LRP-1 also functions as a catabolic receptor for fibronectin, limiting fibronectin accumulation in association with cells. The goal of the present study was to determine whether LRP-1 regulates cell surface levels of the beta(1) integrin subunit. We hypothesized that LRP-1 may down-regulate cell surface beta(1) by promoting its internalization; however, unexpectedly, LRP-1 expression was associated with a substantial increase in cell surface beta(1) integrin in two separate cell lines, murine embryonic fibroblasts (MEFs) and CHO cells. The total amount of beta(1) integrin was unchanged because LRP-1-deficient cells retained increased amounts of beta(1) in the endoplasmic reticulum (ER). Expression of human LRP-1 in LRP-1-deficient MEFs reversed the shift in subcellular beta(1) integrin distribution. Metabolic labeling experiments demonstrated that the precursor form of newly synthesized beta(1) integrin (p105) is converted into mature beta(1) (p125) more slowly in LRP-1-deficient cells. Although low levels of cell surface beta(1) integrin, in LRP-1-deficient MEFs, were associated with decreased adhesion to fibronectin, the subcellular distribution of beta(1) integrin was most profoundly dependent on LRP-1 only after the cell cultures became confluent. A mutagen-treated CHO cell line, in which LRP-1 is expressed but retained in the secretory pathway, also demonstrated nearly complete ER retention of beta(1) integrin. These studies support a model in which LRP-1 either directly or indirectly promotes maturation of beta(1) integrin precursor and thereby increases the level of beta(1) integrin at the cell surface.	Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Biochem, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Mol Genet, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Gonias, SL (corresponding author), Univ Virginia, Sch Med, Dept Pathol, Box 800214, Charlottesville, VA 22908 USA.	slg2t@virginia.edu	Salicioni, Ana Maria/ABD-8384-2021	Salicioni, Ana Maria/0000-0002-8951-3587	NHLBI NIH HHS [R01 HL60551] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060551] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA SK, 1987, J BIOL CHEM, V262, P17536; Alais S, 2001, J CELL SCI, V114, P1847; Arandjelovic S, 2003, BIOCHEMISTRY-US, V42, P6121, DOI 10.1021/bi0342158; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; Barnes H, 2001, J BIOL CHEM, V276, P19119, DOI 10.1074/jbc.M011437200; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Bellis SL, 1999, J CELL PHYSIOL, V181, P33, DOI 10.1002/(SICI)1097-4652(199910)181:1<33::AID-JCP4>3.0.CO;2-#; Boucher P, 2003, SCIENCE, V300, P329, DOI 10.1126/science.1082095; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; Chang DD, 2002, J BIOL CHEM, V277, P8140, DOI 10.1074/jbc.M109031200; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; COPPOLINO M, 1995, J BIOL CHEM, V270, P23132, DOI 10.1074/jbc.270.39.23132; Culi J, 2003, CELL, V112, P343, DOI 10.1016/S0092-8674(02)01279-5; Czekay RP, 2003, J CELL BIOL, V160, P781, DOI 10.1083/jcb.200208117; DESTROOPER B, 1991, EUR J BIOCHEM, V199, P25; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; FITZGERALD DJ, 1995, J CELL BIOL, V129, P1533, DOI 10.1083/jcb.129.6.1533; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; HEINO J, 1989, J BIOL CHEM, V264, P380; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; HOTCHIN NA, 1995, J CELL BIOL, V128, P1209, DOI 10.1083/jcb.128.6.1209; Hsieh JC, 2003, CELL, V112, P355, DOI 10.1016/S0092-8674(03)00045-X; Huang SS, 2003, FASEB J, V17, P2068, DOI 10.1096/fj.03-0256com; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; LENTER M, 1994, J BIOL CHEM, V269, P12263; Lutz C, 2002, J BIOL CHEM, V277, P43143, DOI 10.1074/jbc.M204426200; LYSIAK JJ, 1995, J BIOL CHEM, V270, P21919, DOI 10.1074/jbc.270.37.21919; Ma Z, 2002, J CELL BIOL, V159, P1061, DOI 10.1083/jcb.200207070; Martel V, 2000, J CELL SCI, V113, P1951; Mizejewski GJ, 1999, P SOC EXP BIOL MED, V222, P124, DOI 10.1046/j.1525-1373.1999.d01-122.x; NARITA M, 1995, J BIOL CHEM, V270, P24800, DOI 10.1074/jbc.270.42.24800; Pietrzik CU, 2002, EMBO J, V21, P5691, DOI 10.1093/emboj/cdf568; Salicioni AM, 2002, J BIOL CHEM, V277, P16160, DOI 10.1074/jbc.M201401200; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Strickland DK, 2002, TRENDS ENDOCRIN MET, V13, P66, DOI 10.1016/S1043-2760(01)00526-4; Tran H, 2002, J CELL SCI, V115, P2031; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; Weaver AM, 1996, J BIOL CHEM, V271, P24894, DOI 10.1074/jbc.271.40.24894; Webb DJ, 2000, J CELL SCI, V113, P123; Webb DJ, 1999, J BIOL CHEM, V274, P7412, DOI 10.1074/jbc.274.11.7412; WILLNOW TE, 1994, J CELL SCI, V107, P719	46	66	67	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10005	10012		10.1074/jbc.M306625200	http://dx.doi.org/10.1074/jbc.M306625200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699139	hybrid			2022-12-25	WOS:000220050400044
J	Dong, Z; Wang, JZ				Dong, Z; Wang, JZ			Hypoxia selection of death-resistant cells - A role for Bcl-X-L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR; FAMILY-MEMBERS; PROTEIN FAMILY; APOPTOSIS; MITOCHONDRIA; EXPRESSION; ACTIVATION; OLIGOMERIZATION; ANGIOGENESIS; INHIBITION	Under hypoxia, some cells are irreversibly injured and die, whereas others can adapt to the stress and survive. The molecular and genetic basis underlying cellular sensitivity to hypoxic injury is unclear. Here we have selected death-resistant cells by repeated episodes of hypoxia. The selected cells are cross-resistant to apoptosis induced by staurosporine, azide, and cisplatin. These cells up-regulate Bcl-X-L, an anti-apoptotic protein. Bcl-X-L interacts with the pro-apoptotic molecule Bax and abrogates its toxicity in mitochondria, resulting in the preservation of mitochondrial integrity, cytochrome c, and cell viability. Down-regulation of Bcl-X-L by antisense oligonucleotides or the newly identified Bcl-X-L inhibitor chelerythrine restores cellular sensitivity to injury and death. Thus, Bcl-X-L is a key molecule for hypoxia selection of death resistance. These findings may have important implications for the development of solid tumors where hypoxia selects for death-resistant cells that are inert to cancer therapy.	Med Coll Georgia, Dept Cellular Biol & Anat, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Dong, Z (corresponding author), Med Coll Georgia, Dept Cellular Biol & Anat, 1459 Laney Walker Blvd, Augusta, GA 30912 USA.	zdong@mail.mcg.edu						Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Brown JM, 1999, CANCER RES, V59, P5863; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chan SL, 2003, J BIOL CHEM, V278, P20453, DOI 10.1074/jbc.C300138200; Dong Z, 2000, BIOCHEM J, V347, P669, DOI 10.1042/0264-6021:3470669; Dong Z, 2003, AM J PATHOL, V163, P663, DOI 10.1016/S0002-9440(10)63693-0; Dong Z, 2001, J BIOL CHEM, V276, P18702, DOI 10.1074/jbc.M011774200; Foreman KE, 1996, AM J PATHOL, V149, P795; Gottlieb RA, 2002, METHODS, V26, P341, DOI 10.1016/S1046-2023(02)00040-3; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; Kaelin WG, 2002, GENE DEV, V16, P1441, DOI 10.1101/gad.1003602; Krajewska M, 1996, CANCER RES, V56, P2422; Maecker HL, 2000, CANCER RES, V60, P4638; Mahajan NP, 1998, NAT BIOTECHNOL, V16, P547, DOI 10.1038/nbt0698-547; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Maxwell PH, 2001, CURR OPIN GENET DEV, V11, P293, DOI 10.1016/S0959-437X(00)00193-3; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Pollman MJ, 1998, NAT MED, V4, P222, DOI 10.1038/nm0298-222; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Saikumar P, 1998, ONCOGENE, V17, P3401, DOI 10.1038/sj.onc.1202590; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Semenza GL, 2000, ADV EXP MED BIOL, V475, P123; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Tu YP, 1998, CANCER RES, V58, P256; Wang XD, 2001, GENE DEV, V15, P2922; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Yi XL, 2003, J BIOL CHEM, V278, P16992, DOI 10.1074/jbc.M300039200	41	78	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9215	9221		10.1074/jbc.M312225200	http://dx.doi.org/10.1074/jbc.M312225200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676192	hybrid			2022-12-25	WOS:000189265900083
J	Ley, R; Ewings, KE; Hadfield, K; Howes, E; Balmanno, K; Cook, SJ				Ley, R; Ewings, KE; Hadfield, K; Howes, E; Balmanno, K; Cook, SJ			Extracellular signal-regulated kinases 1/2 are serum-stimulated "Bim(EL) kinases" that bind to the BH3-only protein Bim(EL) causing its phosphorylation and turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBER; CELL-CYCLE ARREST; C-JUN; PROAPOPTOTIC ACTIVITY; BIM EXPRESSION; SURVIVAL; ACTIVATION; GENE; JNK; BAX	Bim, a "BH3-only" protein, is expressed de novo following withdrawal of serum survival factors and promotes cell death. We have shown previously that activation of the ERK1/2 pathway promotes phosphorylation of Bim(EL), targeting it for degradation via the proteasome. However, the nature of the kinase responsible for Bim(EL) phosphorylation remained unclear. We now show that Bim(EL) is phosphorylated on at least three sites in response to activation of the ERK1/2 pathway. By using the peptidylprolyl isomerase, Pin1, as a probe for proline-directed phosphorylation, we show that ERK1/2-dependent phosphorylation of Bim(EL) occurs at (S/T) P motifs. ERK1/2 phosphorylates Bim(EL), but not Bim(S) or Bim(L), in vitro, and mutation of Ser(65) to alanine blocks the phosphorylation of Bim(EL) by ERK1/2 in vitro and in vivo and prevents the degradation of the protein following activation of the ERK1/2 pathway. We also find that ERK1/2, but not JNK, can physically associate with GST-Bim(EL), but not GST-Bim(L) or GST-Bim(S), in vitro. ERK1/2 also binds to full-length Bim(EL) in vivo, and we have localized a potential ERK1/2 "docking domain" lying within a 27-amino acid stretch of the Bim(EL) protein. Our findings provide new insights into the post-translational regulation of Bim(EL) and the role of the ERK1/2 pathway in cell survival signaling.	Babraham Inst, Signalling Programme, Mol Signalling Lab, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Cook, SJ (corresponding author), Babraham Inst, Signalling Programme, Mol Signalling Lab, Cambridge CB2 4AT, England.	simon.cook@bbsrc.ac.uk		Balmanno, Kathryn/0000-0002-6417-3889	Biotechnology and Biological Sciences Research Council [BBS/E/B/0000C199, BBS/E/B/0000H457] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Biswas SC, 2002, J BIOL CHEM, V277, P49511, DOI 10.1074/jbc.M208086200; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Garner AP, 2002, ONCOGENE, V21, P8089, DOI 10.1038/sj.onc.1206000; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; He JQ, 2003, ONCOGENE, V22, P4524, DOI 10.1038/sj.onc.1206767; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Holland PM, 1999, CURR BIOL, V9, pR329, DOI 10.1016/S0960-9822(99)80205-X; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1432, DOI 10.1210/me.12.9.1432; Hsu T, 2001, NAT CELL BIOL, V3, P538, DOI 10.1038/35078508; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; May GHW, 1998, J BIOL CHEM, V273, P33429, DOI 10.1074/jbc.273.50.33429; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; Seward RJ, 2003, MOL IMMUNOL, V39, P983, DOI 10.1016/S0161-5890(03)00047-6; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Squires MS, 2002, BIOCHEM J, V366, P673, DOI 10.1042/BJ20020372; Tanoue T, 2002, PHARMACOL THERAPEUT, V93, P193, DOI 10.1016/S0163-7258(02)00188-2; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Weston CR, 2003, ONCOGENE, V22, P1281, DOI 10.1038/sj.onc.1206261; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740	43	172	177	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8837	8847		10.1074/jbc.M311578200	http://dx.doi.org/10.1074/jbc.M311578200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14681225	hybrid			2022-12-25	WOS:000189265900039
J	Traub, S; Kubasch, N; Morath, S; Kresse, M; Hartung, T; Schmidt, RR; Hermann, C				Traub, S; Kubasch, N; Morath, S; Kresse, M; Hartung, T; Schmidt, RR; Hermann, C			Structural requirements of synthetic muropeptides to synergize with lipopolysaccharide in cytokine induction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL-CELL WALL; TUMOR-NECROSIS-FACTOR; MURAMYL-DIPEPTIDE; ANAPHYLACTOID REACTIONS; HUMAN MONOCYTES; ACID; INTERLEUKIN-1; ENDOTOXIN; ENHANCEMENT; RESPONSES	Muropeptides contribute to the recognition of bacteria by modulating immune responses: the structural requirements for adjuvant activity were described in the seventies. During the last years, our knowledge of bacterial pattern recognition has increased dramatically and the importance of the absence of contaminations in both muropeptide preparations and other bacterial stimuli has become clear. We investigated a panel of 15 synthetic Limulus-negative muropeptides, four of them synthesized for the first time, as to their potency to synergize with lipopolysaccharide (LPS) in cytokine induction in human whole blood. No muropeptide was capable of stimulating cytokine release from human blood. However, as little as 20 nM of the muropeptides N-acetyl-muramyl-L-alanyl-D-isoglutamine (muramyl dipeptide, M(ADiQ)), N-acetyl-glucosamine-muramyl dipeptide GM(ADiQ), or C18M(ADiQ), which carries a non-natural additional fatty acid, sufficed to induce an up to 3 log-order shift in tumor necrosis factor alpha-release in response to 100 pg/ml LPS. The release of interleukin-1beta, interleukin-6, and interleukin-10 was also significantly enhanced although to a lesser extent. The synergistic effect was stereoselective with M( ADiQ) being the minimal active principle. Synergy was also observed on the transcriptional level by means of real-time PCR. Smaller molecules like N-acetylmuramic acid (M), AM, carrying a naturally occurring 1,6-anhydro-bound in M or M(A), containing only the amino acid L-alanine neither synergized with LPS nor influenced the synergy of other muropeptides with LPS. In conclusion, these data show that nanomolar quantities of muropeptides dramatically potentiate LPS-induced monocyte activation. This has implications for pyrogenicity testing and endotoxemia in patients.	Univ Konstanz, Dept Biochem Pharmacol, D-78457 Constance, Germany; Univ Konstanz, Dept Chim Organ, D-78457 Constance, Germany	University of Konstanz; University of Konstanz	Hermann, C (corresponding author), Univ Konstanz, Dept Biochem Pharmacol, POB M655, D-78457 Constance, Germany.	Corinna.Hermann@uni-konstanz.de						ADAM A, 1988, ISI ATLAS-IMMUNOL, V1, P205; Alper PB, 1996, TETRAHEDRON LETT, V37, P6029, DOI 10.1016/0040-4039(96)01307-X; AZUMA I, 1992, VACCINE, V10, P1000, DOI 10.1016/0264-410X(92)90108-V; BAHR GM, 1987, CELL IMMUNOL, V107, P443, DOI 10.1016/0008-8749(87)90251-6; BERGMEYER HU, 1972, CLIN CHEM, V18, P1305; COSTE J, 1990, TETRAHEDRON LETT, V31, P205, DOI 10.1016/S0040-4039(00)94371-5; CZERNECKI S, 1992, TETRAHEDRON LETT, V33, P221, DOI 10.1016/0040-4039(92)88055-A; DINARELLO CA, 1986, FASEB J, V45, P2545; DOKTER WHA, 1994, J BIOL CHEM, V269, P4201; Dzierzbicka K, 2003, J MED CHEM, V46, P183, DOI 10.1021/jm020991m; ELLOUZ F, 1974, BIOCHEM BIOPH RES CO, V59, P1317, DOI 10.1016/0006-291X(74)90458-6; Flak TA, 2000, INFECT IMMUN, V68, P1235, DOI 10.1128/IAI.68.3.1235-1242.2000; Fosset S, 2003, PHYSIOL BEHAV, V79, P173, DOI 10.1016/S0031-9384(03)00065-9; Gao Y, 1998, J ORG CHEM, V63, P2133, DOI 10.1021/jo972133h; HARTUNG T, 1995, BLOOD, V85, P2482, DOI 10.1182/blood.V85.9.2482.bloodjournal8592482; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; HOLCOMB RC, 1994, TETRAHEDRON LETT, V35, P7005, DOI 10.1016/0040-4039(94)88210-X; HOLTJE JV, 1989, PROG IND M, V27, P101; HOLTJE JV, 1987, 18 WORKSH C HOECHST; Kalyuzhin OV, 2002, B EXP BIOL MED+, V134, P281, DOI 10.1023/A:1021519921125; KINZY W, 1985, LIEBIGS ANN CHEM, P1537; KINZY W, 1987, TETRAHEDRON LETT, V28, P1981, DOI 10.1016/S0040-4039(00)96025-8; KINZY W, 1987, LIEBIGS ANN CHEM, P407; KOTANI S, 1986, FASEB J, V45, P2534; Kubasch N, 2002, EUR J ORG CHEM, V2002, P2710, DOI 10.1002/1099-0690(200208)2002:16<2710::AID-EJOC2710>3.0.CO;2-8; KUSUMOTO S, 1976, B CHEM SOC JPN, V49, P533, DOI 10.1246/bcsj.49.533; Langford MP, 2002, MOL CELL BIOCHEM, V236, P63, DOI 10.1023/A:1016110429204; LECONTEL C, 1993, J IMMUNOL, V150, P4541; OREILLY T, 1992, CLIN INFECT DIS, V14, P1100, DOI 10.1093/clinids/14.5.1100; PARANT MA, 1995, INFECT IMMUN, V63, P110, DOI 10.1128/IAI.63.1.110-115.1995; PAULSEN H, 1986, LIEBIGS ANN CHEM, P664; Rossi Sergio, 2003, Dendrochronologia, V21, P33, DOI 10.1078/1125-7865-00034; Safavi KE, 2000, J ENDODONT, V26, P153, DOI 10.1097/00004770-200003000-00006; SCHMIDT U, 1984, SYNTHESIS-STUTTGART, P53, DOI 10.1055/s-1984-30730; SUZUKI K, 1994, IMMUNOPHARMACOLOGY, V28, P31, DOI 10.1016/0162-3109(94)90036-1; TAILLER D, 1992, J CHEM SOC PERK T 1, P3163, DOI 10.1039/p19920003163; TAKADA H, 1987, INFECT IMMUN, V55, P409, DOI 10.1128/IAI.55.2.409-413.1987; Takada H, 2002, J ENDOTOXIN RES, V8, P337, DOI 10.1179/096805102125000669; Takada H, 1996, INFECT IMMUN, V64, P657, DOI 10.1128/IAI.64.2.657-659.1996; TERMIN A, 1992, LIEBIGS ANN CHEM, P527; TERMIN A, 1989, LIEBIGS ANN CHEM, P789; VERMEULEN MW, 1987, J IMMUNOL, V139, P7; Wang JE, 2001, SHOCK, V16, P178, DOI 10.1097/00024382-200116030-00002; Wolfert MA, 2002, J BIOL CHEM, V277, P39179, DOI 10.1074/jbc.M204885200; Yang SH, 2001, INFECT IMMUN, V69, P2045, DOI 10.1128/IAI.69.4.2045-2053.2001; ZOLLER U, 1975, TETRAHEDRON, V31, P863, DOI 10.1016/0040-4020(75)80092-5	46	53	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8694	8700		10.1074/jbc.M310556200	http://dx.doi.org/10.1074/jbc.M310556200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14668350	hybrid			2022-12-25	WOS:000189265900021
J	Baskakov, IV				Baskakov, IV			Autocatalytic conversion of recombinant prion proteins displays a species barrier	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE EXPRESSING HUMAN; YEAST PRION; CONFORMATIONAL CONVERSION; SCRAPIE; PROPAGATION; STRAIN; PRP; BSE; FIBRILLIZATION; AGGREGATION	The most unorthodox feature of the prion disease is the existence of an abnormal infectious isoform of the prion protein, PrPSc. According to the "protein-only" hypothesis, PrPSc propagates its abnormal conformation in an autocatalytic manner using the normal isoform, PrPC, as a substrate. Because autocatalytic conversion is considered a key element of prion replication, in this study I tested whether in vitro conversion of recombinant PrP into abnormal isoform displays specific features of an autocatalytic process. I found that recombinant human PrP formed two distinct beta-sheet rich isoforms, the beta-oligomer and the amyloid fibrils. The kinetics of the fibrils formation measured at different pH values were consistent with a model in which the beta-oligomer was not on the kinetic pathway to the fibrillar form. As judged by electron microscopy, an acidic pH favored to the long fibrils, whereas short fibrils morphologically similar to "prion rods" were formed at neutral pH. At neutral pH the conversion to the fibrils can be seeded with small aliquots of preformed fibrils. As small as 0.001% aliquot displayed seeding activity. The conversion of human PrP was seeded with high efficacy only with the preformed fibrils of human but not mouse PrP and vice versa. These studies illustrate that in vitro conversion of recombinant PrP displays specific features of an autocatalytic process and mimics the transmission barrier of prion propagation observed in vivo. I speculate that this model can be used as a rapid assay for assessing the intrinsic propensities of prion transmission between different species.	Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Baskakov, IV (corresponding author), 725 W Lombard St, Baltimore, MD 21201 USA.	Baskakov@umbi.umd.edu						Asante EA, 2002, EMBO J, V21, P6358, DOI 10.1093/emboj/cdf653; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; Baskakov IV, 2001, J BIOL CHEM, V276, P19687, DOI 10.1074/jbc.C100180200; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; Chien P, 2001, NATURE, V410, P223, DOI 10.1038/35065632; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; DePace AH, 1998, CELL, V93, P1241, DOI 10.1016/S0092-8674(00)81467-1; GAJDUSEK DC, 1988, J NEUROIMMUNOL, V20, P95; Hill AF, 1999, J GEN VIROL, V80, P11, DOI 10.1099/0022-1317-80-1-11; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; Kazlauskaite J, 2003, BIOCHEMISTRY-US, V42, P3295, DOI 10.1021/bi026872q; Kirby L, 2003, J GEN VIROL, V84, P1013, DOI 10.1099/vir.0.18903-0; Kundu B, 2003, P NATL ACAD SCI USA, V100, P12069, DOI 10.1073/pnas.2033281100; Lee S, 2003, NAT STRUCT BIOL, V10, P725, DOI 10.1038/nsb961; Lu BY, 2001, BIOCHEMISTRY-US, V40, P13390, DOI 10.1021/bi011111t; Maddelein ML, 2002, P NATL ACAD SCI USA, V99, P7402, DOI 10.1073/pnas.072199199; MASTERS CL, 1979, ANN NEUROL, V5, P177, DOI 10.1002/ana.410050212; Mehlhorn I, 1996, BIOCHEMISTRY-US, V35, P5528, DOI 10.1021/bi952965e; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PATTISON IH, 1968, RES VET SCI, V9, P408; Peretz D, 2002, NEURON, V34, P921, DOI 10.1016/S0896-6273(02)00726-2; Prusiner SB, 2001, NEW ENGL J MED, V344, P1516, DOI 10.1056/NEJM200105173442006; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; RAEBER AJ, 1992, J VIROL, V66, P6155, DOI 10.1128/JVI.66.10.6155-6163.1992; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Santoso A, 2000, CELL, V100, P277, DOI 10.1016/S0092-8674(00)81565-2; Scott MR, 1997, J VIROL, V71, P9032, DOI 10.1128/JVI.71.12.9032-9044.1997; Sparrer HE, 2000, SCIENCE, V289, P595, DOI 10.1126/science.289.5479.595; Swietnicki W, 2000, BIOCHEMISTRY-US, V39, P424, DOI 10.1021/bi991967m; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; TURK E, 1988, EUR J BIOCHEM, V176, P21, DOI 10.1111/j.1432-1033.1988.tb14246.x; Vanik DL, 2002, J BIOL CHEM, V277, P49065, DOI 10.1074/jbc.M207511200; Welker E, 2002, J BIOL CHEM, V277, P33477, DOI 10.1074/jbc.M204273200; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wickner RB, 1995, YEAST, V11, P1671, DOI 10.1002/yea.320111609	37	71	74	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7671	7677		10.1074/jbc.M310594200	http://dx.doi.org/10.1074/jbc.M310594200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14668351	hybrid			2022-12-25	WOS:000189103300038
J	Vanden Berghe, T; van Loo, G; Saelens, X; van Gurp, M; Brouckaert, G; Kalai, M; Declercq, W; Vandenabeele, P				Vanden Berghe, T; van Loo, G; Saelens, X; van Gurp, M; Brouckaert, G; Kalai, M; Declercq, W; Vandenabeele, P			Differential signaling to apoptotic and necrotic cell death by Fas-associated death domain protein FADD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; MAMMALIAN-CELLS; KINASE RIP; FACTOR TNF; ACTIVATION; PATHWAY; CASPASE-8; COMPLEX; MITOCHONDRIA; INHIBITION	Two general pathways for cell death have been defined, apoptosis and necrosis. Previous studies in Jurkat cells have demonstrated that the Fas-associated death domain (FADD) is required for Fas-mediated signaling to apoptosis and necrosis. Here we developed L929rTA cell lines that allow Tet-on inducible expression and FK506-binding protein ( FKBP)-mediated dimerization of FADD, FADD-death effector domain (FADD-DED), or FADD-death domain (FADD-DD). We show that expression and dimerization of FADD leads to necrosis. However, pretreatment of the cells with the Hsp90 inhibitor geldanamycin, which leads to proteasome-mediated degradation of receptor interacting protein 1 (RIP1), reverts FKBP-FADD-induced necrosis to apoptosis. Expression and dimerization of FADD-DD mediates necrotic cell death. We found that FADD-DD is able to bind RIP1, another protein necessary for Fas-mediated necrosis. Expression and dimerization of FADD-DED initiates apoptosis. Remarkably, in the presence of caspase inhibitors, FADD-DED mediates necrotic cell death. Coimmunoprecipitation studies revealed that FADD-DED in the absence procaspase-8 C/A is also capable of recruiting RIP1. However, when procaspase-8 C/A and RIP1 are expressed simultaneously, FADD-DED preferentially recruits procaspase-8 C/A.	Flanders Interuniv Inst Biotechnol VIB, Dept Mol Biomed Res, Mol Signalling & Cell Death Unit, B-9052 Zwijnaarde, Belgium; State Univ Ghent, B-9052 Zwijnaarde, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University	Vandenabeele, P (corresponding author), Flanders Interuniv Inst Biotechnol VIB, Dept Mol Biomed Res, Mol Signalling & Cell Death Unit, Technol Pk 927, B-9052 Zwijnaarde, Belgium.	peter.vandenabeele@dmbr.UGent.be	van Loo, Geert/C-1505-2009; Vanden Berghe, Tom/C-4916-2009; , van Loo Geert/AAD-1220-2019; Saelens, Xavier/N-5728-2015; Vandenabeele, Peter/AAD-5793-2022; Vandenabeele, Peter/C-8597-2009; Berghe, Tom Vanden/N-2902-2019	Vanden Berghe, Tom/0000-0002-1633-0974; , van Loo Geert/0000-0002-8427-4775; Vandenabeele, Peter/0000-0002-6669-8822; Berghe, Tom Vanden/0000-0002-1633-0974; , Xavier/0000-0002-3861-6965				Amara JF, 1997, P NATL ACAD SCI USA, V94, P10618, DOI 10.1073/pnas.94.20.10618; Berglund H, 2000, J MOL BIOL, V302, P171, DOI 10.1006/jmbi.2000.4011; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Boone E, 2000, J BIOL CHEM, V275, P37596, DOI 10.1074/jbc.M007166200; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Denecker G, 2001, CELL MOL LIFE SCI, V58, P356, DOI 10.1007/PL00000863; Denecker G, 2001, CELL DEATH DIFFER, V8, P829, DOI 10.1038/sj.cdd.4400883; Fan LF, 1999, HUM GENE THER, V10, P2273, DOI 10.1089/10430349950016924; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Freundlieb S, 1999, J GENE MED, V1, P4, DOI 10.1002/(SICI)1521-2254(199901/02)1:1<4::AID-JGM4>3.0.CO;2-Y; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Harper N, 2003, J BIOL CHEM, V278, P25534, DOI 10.1074/jbc.M303399200; Hill JM, 2004, J BIOL CHEM, V279, P1474, DOI 10.1074/jbc.M304996200; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Jeong EJ, 1999, J BIOL CHEM, V274, P16337, DOI 10.1074/jbc.274.23.16337; Kalai M, 2002, CELL DEATH DIFFER, V9, P981, DOI 10.1038/sj.cdd.4401051; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Khwaja A, 1999, J BIOL CHEM, V274, P36817, DOI 10.1074/jbc.274.51.36817; Kim JW, 2000, ONCOGENE, V19, P4491, DOI 10.1038/sj.onc.1203796; LAMKANFI M, 2003, CASPASES THEIR ROLE, P1; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martinon F, 2000, FEBS LETT, V468, P134, DOI 10.1016/S0014-5793(00)01212-6; Matsumura H, 2000, J CELL BIOL, V151, P1247, DOI 10.1083/jcb.151.6.1247; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Schotte P, 2001, J BIOL CHEM, V276, P25939, DOI 10.1074/jbc.M104014200; Spencer DM, 1996, CURR BIOL, V6, P839, DOI 10.1016/S0960-9822(02)00607-3; Vanden Berghe T, 2003, J BIOL CHEM, V278, P5622, DOI 10.1074/jbc.M208925200; Vandevoorde V, 1997, J CELL BIOL, V137, P1627, DOI 10.1083/jcb.137.7.1627; VANHOENACKER P, 1999, GENE THER MOL BIOL, V3, P301; Varfolomeev EE, 1996, J EXP MED, V183, P1271, DOI 10.1084/jem.183.3.1271; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Vercammen D, 1997, CYTOKINE, V9, P801, DOI 10.1006/cyto.1997.0252; Wyllie A H, 1980, Int Rev Cytol, V68, P251	38	88	93	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7925	7933		10.1074/jbc.M307807200	http://dx.doi.org/10.1074/jbc.M307807200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14668343	hybrid			2022-12-25	WOS:000189103300070
J	di San Filippo, CA; Longo, N				di San Filippo, CA; Longo, N			Tyrosine residues affecting sodium stimulation of carnitine transport in the OCTN2 carnitine/organic cation transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC CATION/CARNITINE TRANSPORTER; GLUCOSE COTRANSPORTER; ESCHERICHIA-COLI; DEFICIENCY; MUTATIONS; PHENOTYPE; MECHANISM; DEFECTS	Primary carnitine deficiency is a disorder of fatty acid oxidation caused by mutations in the Na+-dependent carnitine/organic cation transporter OCTN2. Studies with tyrosyl group-modifying reagents support the involvement of tyrosine residues in Na+ binding by sodium-coupled transporters. Here we report two new patients with carnitine deficiency caused by mutations affecting tyrosyl residues (Y447C and Y449D) close to a residue (Glu-452) previously shown to affect sodium stimulation of carnitine transport. Kinetic analysis indicated that the Y449D substitution, when expressed in Chinese hamster ovary cells, increased the concentration of sodium required to half-maximally stimulate carnitine transport from 14.8 +/- 1.8 to 34.9 +/- 5.8 mm (p < 0.05), whereas Y447C completely abolished carnitine transport. Substitution of these tyrosine residues with phenylalanine restored normal carnitine transport in Y449F but resulted in markedly impaired carnitine transport by Y447F. This was associated with an increase in the concentration of sodium required to half-maximally stimulate carnitine transport to 57.8 +/- 7.4 mm (p < 0.01 versus normal OCTN2). The Y447F and Y449D mutant transporters retained their ability to transport the organic cation tetraethylammonium indicating that their effect on carnitine transport was specific and likely associated with the impaired sodium stimulation of carnitine transport. By contrast, the Y447C natural mutation abolished the transport of organic cations in addition to carnitine. Confocal microscopy of OCTN2 transporters tagged with green fluorescent protein indicated that the Y447C mutant transporters failed to reach the plasma membrane, whereas Y447F, Y449D, and Y449F had normal membrane localization. These natural mutations identify tyrosine residues possibly involved in coupling the sodium electrochemical gradient to transmembrane solute transfer in the sodium-dependent co-transporter OCTN2.	Univ Utah, Dept Pediat, Div Med Genet, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Longo, N (corresponding author), Univ Utah, Dept Pediat, Div Med Genet, 2C 412 SOM,50 N Med Dr, Salt Lake City, UT 84132 USA.	Nicola.Longo@hse.utah.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053824] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 53824] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; GANAPATHY V, 1989, J PHARMACOL EXP THER, V251, P9; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; KOEPSELL H, 2003, IN PRESS PFLUEGERS A; KULANTHAIVEL P, 1989, BIOCHIM BIOPHYS ACTA, V985, P139, DOI 10.1016/0005-2736(89)90358-1; Martin MG, 1996, NAT GENET, V12, P216, DOI 10.1038/ng0296-216; Meyer-Wentrup F, 1998, BIOCHEM BIOPH RES CO, V248, P673, DOI 10.1006/bbrc.1998.9034; Ohashi R, 2002, J PHARMACOL EXP THER, V302, P1286, DOI 10.1124/jpet.102.036004; Ohashi R, 2001, MOL PHARMACOL, V59, P358, DOI 10.1124/mol.59.2.358; PEERCE BE, 1985, J BIOL CHEM, V260, P6026; PEERCE BE, 1984, J BIOL CHEM, V259, P4105; Scaglia F, 1999, ARCH BIOCHEM BIOPHYS, V364, P99, DOI 10.1006/abbi.1999.1118; Scaglia F, 1999, SEMIN PERINATOL, V23, P152, DOI 10.1016/S0146-0005(99)80047-0; Segel, 1975, ENZYME KINETICS BEHA, P274; Seth P, 1999, J BIOL CHEM, V274, P33388, DOI 10.1074/jbc.274.47.33388; Tamai I, 1998, J BIOL CHEM, V273, P20378, DOI 10.1074/jbc.273.32.20378; Vockley J, 2000, MOL GENET METAB, V71, P10, DOI 10.1006/mgme.2000.3066; Wang YH, 2000, HUM MUTAT, V16, P401, DOI 10.1002/1098-1004(200011)16:5<401::AID-HUMU4>3.0.CO;2-J; Wang YH, 2000, HUM MUTAT, V15, P238, DOI 10.1002/(SICI)1098-1004(200003)15:3<238::AID-HUMU4>3.0.CO;2-3; Wang YH, 2000, J BIOL CHEM, V275, P20782, DOI 10.1074/jbc.M000194200; Wang YH, 1999, P NATL ACAD SCI USA, V96, P2356, DOI 10.1073/pnas.96.5.2356; Wang YH, 2001, GENET MED, V3, P387, DOI 10.1097/00125817-200111000-00002; Wu X, 1998, BIOCHEM BIOPH RES CO, V246, P589, DOI 10.1006/bbrc.1998.8669; Wu X, 1999, J PHARMACOL EXP THER, V290, P1482	24	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7247	7253		10.1074/jbc.M309171200	http://dx.doi.org/10.1074/jbc.M309171200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14665638	hybrid			2022-12-25	WOS:000188969200126
J	Malanga, M; Althaus, FR				Malanga, M; Althaus, FR			Poly(ADP-ribose) reactivates stalled DNA topoisomerase I and induces DNA strand break resealing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEXES; CAMPTOTHECIN; DOMAINS; LINKER; PARP-2; ASSOCIATION; COVALENT; CLEAVAGE; REPAIR; BINDS	Regulating the topological state of DNA is a vital function of the enzyme DNA topoisomerase I. However, when acting on damaged DNA, topoisomerase I may get trapped in a covalent complex with nicked DNA (stalled topoisomerase I), that, if unrepaired, may lead to genomic instability or cell death. Here we show that ADP-ribose polymers target specific domains of topoisomerase I and reprogram the enzyme to remove itself from cleaved DNA and close the resulting gap. Two members of the poly(ADP-ribose) polymerase family, PARP-1 and 2, act as poly(ADP-ribose) carriers to stalled topoisomerase I sites and induce efficient repair of enzyme-associated DNA strand breaks. Thus, by counteracting topoisomerase I-induced DNA damage, PARP-1 and PARP-2 act as positive regulators of genomic stability in eukaryotic cells.	Univ Zurich, Inst Pharmacol & Toxicol, CH-8057 Zurich, Switzerland	University of Zurich	Althaus, FR (corresponding author), Univ Zurich, Inst Pharmacol & Toxicol, Winterthurerstr 260, CH-8057 Zurich, Switzerland.	fra@vetpharm.unizh.ch						Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Beneke S, 2000, EXP GERONTOL, V35, P989, DOI 10.1016/S0531-5565(00)00134-0; Bowman KJ, 2001, BRIT J CANCER, V84, P106, DOI 10.1054/bjoc.2000.1555; Caldecott KW, 2003, CELL, V112, P7, DOI 10.1016/S0092-8674(02)01247-3; Chatterjee S, 1989, Cancer Commun, V1, P389; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; de Murcia JMN, 2003, EMBO J, V22, P2255, DOI 10.1093/emboj/cdg206; Fiorani P, 2003, J BIOL CHEM, V278, P43268, DOI 10.1074/jbc.M303899200; Gagne JP, 2003, BIOCHEM J, V371, P331, DOI 10.1042/BJ20021675; Ireton GC, 2000, J BIOL CHEM, V275, P25820, DOI 10.1074/jbc.M002144200; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; MALANGA M, 1995, ANAL BIOCHEM, V228, P245, DOI 10.1006/abio.1995.1346; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; Mao YH, 2000, CANCER RES, V60, P4538; Miknyoczki SJ, 2003, MOL CANCER THER, V2, P371; OGATA N, 1981, J BIOL CHEM, V256, P4135; Okano S, 2003, MOL CELL BIOL, V23, P3974, DOI 10.1128/MCB.23.11.3974-3981.2003; PANZETER PL, 1993, J BIOL CHEM, V268, P17662; PANZETER PL, 1990, NUCLEIC ACIDS RES, V18, P2194, DOI 10.1093/nar/18.8.2194; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Postow L, 2001, P NATL ACAD SCI USA, V98, P8219, DOI 10.1073/pnas.111006998; Pourquier P, 1999, J BIOL CHEM, V274, P8516, DOI 10.1074/jbc.274.13.8516; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; Pourquier P, 2001, ADV CANCER RES, V80, P189, DOI 10.1016/S0065-230X(01)80016-6; REALINI CA, 1992, J BIOL CHEM, V267, P18858; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; Shuman S, 2000, METH MOL B, V95, P65; Soe K, 2001, NUCLEIC ACIDS RES, V29, P3195, DOI 10.1093/nar/29.15.3195; Staker BL, 2002, P NATL ACAD SCI USA, V99, P15387, DOI 10.1073/pnas.242259599; Stewart L, 1999, J BIOL CHEM, V274, P32950, DOI 10.1074/jbc.274.46.32950; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; TANIZAWA A, 1995, BIOCHEMISTRY-US, V34, P7200, DOI 10.1021/bi00021a035; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Yang SW, 1996, P NATL ACAD SCI USA, V93, P11534, DOI 10.1073/pnas.93.21.11534; Yang Z, 2002, J BIOL CHEM, V277, P30815, DOI 10.1074/jbc.M205302200	36	108	115	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5244	5248		10.1074/jbc.C300437200	http://dx.doi.org/10.1074/jbc.C300437200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14699148	hybrid, Green Accepted			2022-12-25	WOS:000188776500026
J	Liu, BY; Kim, YC; Leatherberry, V; Cowin, P; Alexander, CM				Liu, BY; Kim, YC; Leatherberry, V; Cowin, P; Alexander, CM			Mammary gland development requires syndecan-1 to create a beta-catenin/TCF-responsive mammary epithelial subpopulation	ONCOGENE			English	Article						Wnt-1; syndecan; mouse mammary gland; beta-catenin	HEPARAN-SULFATE PROTEOGLYCANS; SIGNAL-TRANSDUCTION; COLORECTAL-CANCER; WNT/BETA-CATENIN; TGF-BETA; WNT; WINGLESS; DROSOPHILA; PATHWAYS; PROTEIN	Mice with a null mutation in the cell surface heparan sulfate (HS) proteoglycan, syndecan-1 (Sdc1), develop almost normally, but resist mammary tumor development in response to Wnt-1. Here, we test the hypothesis that Sdc1 promotes Wnt-1- induced tumor development by interacting with the Wnt cell surface signaling complex. Thus, the response of Sdc1 -/- mammary epithelial cells (mecs) to the intracellular, activated Wnt signal transducer, DeltaNbeta-catenin, was assayed both in vitro and in vivo, to test whether beta-catenin/TCF transactivation was Sdc1-independent. Surprisingly, we found that the expression of a canonical Wnt pathway reporter, TOP-FLASH, was reduced by 50% in both unstimulated Sdc1-/- mecs and in stimulated cells responding to Wnt1 or DeltaNbeta-catenin. Tumor development in response to DeltaNbeta-catenin was also significantly delayed on a Sdc1-/- background. Furthermore, the average beta-catenin/TCF transactivation per cell was normal in Sdc1-/- mec cultures, but the number of responsive cells was reduced by 50%. Sdc1-/- mecs show compensatory changes that maintain the number of HS chains, hence these experiments cannot test the coreceptor activity of HS for Wnt signaling. We propose that TCF-dependent transactivational activity is suppressed in 50% of cells in Sdc1-/- glands, and conclude that the major effect of Sdc1 does not map to the activity of the Wnt signaling complex, but to another pathway to create or stabilize the beta-catenin/TCF-responsive tumor precursor cells in mouse mammary gland.	Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA; NYU Med Ctr, Dept Cell Biol, New York, NY 10016 USA	University of Wisconsin System; University of Wisconsin Madison; New York University	Alexander, CM (corresponding author), Univ Wisconsin, Sch Med, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.			Kim, Young Chul/0000-0002-6782-2186; Cowin, Pamela/0000-0002-1827-1154	NCI NIH HHS [P30 CA14520, T32 CA09135, CA 90877-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009135, R01CA090877, P30CA014520] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander CM, 2000, NAT GENET, V25, P329, DOI 10.1038/77108; Baeg GH, 2001, DEVELOPMENT, V128, P87; Baeg GH, 2000, CURR OPIN CELL BIOL, V12, P575, DOI 10.1016/S0955-0674(00)00134-4; Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Behrens J, 2000, J CELL SCI, V113, P911; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; Brantjes H, 2002, BIOL CHEM, V383, P255, DOI 10.1515/BC.2002.027; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; Chan SK, 2002, CELL, V111, P265, DOI 10.1016/S0092-8674(02)01037-1; Clevers H, 2000, NAT GENET, V24, P206, DOI 10.1038/73396; Cumberledge S, 1997, TRENDS GENET, V13, P421, DOI 10.1016/S0168-9525(97)01275-4; EMERMAN JT, 1988, ADV CELL CULT, V6, P137; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; Ishitani T, 2003, MOL CELL BIOL, V23, P1379, DOI 10.1128/MCB.23.4.1379-1389.2003; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Letamendia A, 2001, J BONE JOINT SURG AM, V83A, pS31; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lin XH, 1999, DEVELOPMENT, V126, P3715; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Payre F, 1999, NATURE, V400, P271, DOI 10.1038/22330; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Polakis P, 2000, GENE DEV, V14, P1837; Rasmussen SB, 2000, METHODS MAMMARY GLAN; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Stepp MA, 2002, J CELL SCI, V115, P4517, DOI 10.1242/jcs.00128; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0	38	54	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	2003	22	58					9243	9253		10.1038/sj.onc.1207217	http://dx.doi.org/10.1038/sj.onc.1207217			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755JU	14681683				2022-12-25	WOS:000187400400006
J	Koshikawa, N; Schenk, S; Moeckel, G; Sharabi, A; Miyazaki, K; Gardner, H; Zent, R; Quaranta, V				Koshikawa, N; Schenk, S; Moeckel, G; Sharabi, A; Miyazaki, K; Gardner, H; Zent, R; Quaranta, V			Proteolytic processing of laminin-5 by MT1-MMP in tissues and its effects on epithelial cell morphology	FASEB JOURNAL			English	Article						matrix metalloproteinase; MT1-MMP KO mouse; extracellular matrix; cell migration; laminin-5 gamma 2	MATRIX METALLOPROTEINASES; GAMMA-2 CHAIN; MT-MMPS; MEMBRANE; KIDNEY; ALPHA-6-BETA-4; EXPRESSION; INTEGRINS; KERATINOCYTES; MORPHOGENESIS	The extracellular matrix macromolecule laminin-5 (Ln-5) is converted by matrix metalloproteinases (MMP) MT1-MMP and MMP-2 into a migration-promoting substrate in vitro. We now report that cleavage of Ln-5 by MT1-MMP occurs in vivo and affects epithelial tissue organization and probably Ln-5 turnover. In MT1-MMP knockout (KO) mice, the kidneys showed increased levels of total Ln-5 gamma2 subunit, but significantly reduced amounts of gamma2', an amino-terminal truncated proteolytic form of gamma2. The kidney tubular epithelia of KO animals were poorly differentiated, a phenotype reminiscent of human congenital mixed hypoplastic/dysplastic disorders. To establish a better link between Ln-5 proteolytic cleavage and epithelial morphology, MT1-MMP expression was reconstituted by transfection of MT1-MMP into a Ln-5 positive, MT1-MMP deficient epithelial cell line. MT1-MMP transfectants demonstrated increased levels of processed Ln-5 gamma2 chain and enhanced spreading on Ln-5, but not fibronectin. Recombinant MT1-MMP cleaved gamma2 constructs in vitro at a known in vivo gamma2 gamma2' processing site. These results strongly indicate that Ln-5 is a physiological substrate of MT1-MMP in vivo. Proteolytic processing of gamma2 subunit by MT1-MMP may influence Ln-5 turnover in epithelial basement membranes and affect epithelial morphogenesis.	Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Ctr Matrix Biol, Nashville, TN 37232 USA; Scripps Res Inst, La Jolla, CA USA; Vanderbilt Univ, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA; Vet Affairs Hosp, Nashville, TN USA; Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Yokohama, Kanagawa 232, Japan	Vanderbilt University; Vanderbilt University; Scripps Research Institute; Vanderbilt University; Vanderbilt University; Yokohama City University	Quaranta, V (corresponding author), Vanderbilt Univ, Med Ctr, Dept Canc Biol, 771 Preston Bldg, Nashville, TN 37232 USA.	vito.quaranta@vanderbilt.edu	Koshikawa, Naohiko/S-7306-2017; Quaranta, Vito/G-6512-2016	Koshikawa, Naohiko/0000-0002-4539-888X; Quaranta, Vito/0000-0001-7491-8672; Sharabi, Andrew/0000-0003-2075-1197; Moeckel, Gilbert/0000-0002-6059-0837				Airenne T, 2000, CELL TISSUE RES, V300, P129, DOI 10.1007/s004410050054; Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; Baker SE, 1996, J CELL SCI, V109, P2509; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CARTER DA, 1991, RESTOR NEUROL NEUROS, V3, P65, DOI 10.3233/RNN-1991-3203; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; Cosgrove D, 1996, GENE DEV, V10, P2981, DOI 10.1101/gad.10.23.2981; De Arcangelis A, 2000, TRENDS GENET, V16, P389, DOI 10.1016/S0168-9525(00)02074-6; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Engvall E, 1996, J CELL BIOCHEM, V61, P493; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Gilles C, 2001, J CELL SCI, V114, P2967; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; JONES JCR, 1991, CELL REGUL, V2, P427, DOI 10.1091/mbc.2.6.427; Kanwar YS, 1999, AM J PHYSIOL-RENAL, V277, pF934, DOI 10.1152/ajprenal.1999.277.6.F934; Kinoh H, 1996, J CELL SCI, V109, P953; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Kreidberg JA, 1996, DEVELOPMENT, V122, P3537; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; Miner JH, 2000, DEV BIOL, V217, P278, DOI 10.1006/dbio.1999.9546; Miosge N, 2002, ANAT EMBRYOL, V205, P355, DOI 10.1007/s00429-002-0256-7; MIYAZAKI K, 1993, P NATL ACAD SCI USA, V90, P11767, DOI 10.1073/pnas.90.24.11767; Mizushima H, 1998, HORM RES, V50, P7, DOI 10.1159/000053118; NIESSEN CM, 1994, EXP CELL RES, V211, P360, DOI 10.1006/excr.1994.1099; Pirila E, 2003, BIOCHEM BIOPH RES CO, V303, P1012, DOI 10.1016/S0006-291X(03)00452-2; Plopper GE, 1998, BREAST CANCER RES TR, V51, P57, DOI 10.1023/A:1006086218174; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; RYAN MC, 1994, J BIOL CHEM, V269, P22779; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Schenk S, 2003, J CELL BIOL, V161, P197, DOI 10.1083/jcb.200208145; Shofuda K, 1997, J BIOL CHEM, V272, P9749; SILVA FG, 1993, ARCH PATHOL LAB MED, V117, P1233; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; TRUONG LD, 1988, HISTOCHEMISTRY, V90, P51, DOI 10.1007/BF00495707; UITTO J, 1994, J INVEST DERMATOL, V103, pS39, DOI 10.1111/1523-1747.ep12398967; Uitto J, 1996, MOL BIOL REP, V23, P35, DOI 10.1007/BF00357071; Utani A, 2001, J BIOL CHEM, V276, P28779, DOI 10.1074/jbc.M101420200; VAILLY J, 1994, EUR J BIOCHEM, V219, P209, DOI 10.1111/j.1432-1033.1994.tb19932.x; Veitch DP, 2003, J BIOL CHEM, V278, P15661, DOI 10.1074/jbc.M210588200; Wahlgren J, 2003, J ORAL PATHOL MED, V32, P100, DOI 10.1034/j.1600-0714.2003.00075.x; Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431; YURCHENCO PD, 1994, CURR OPIN CELL BIOL, V6, P674, DOI 10.1016/0955-0674(94)90093-0; Zent R, 2001, DEV BIOL, V238, P289, DOI 10.1006/dbio.2001.0391	45	60	62	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					364	+		10.1096/fj.03-0584fje	http://dx.doi.org/10.1096/fj.03-0584fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14688206				2022-12-25	WOS:000188067500012
J	Fishman, P; Bar-Yehuda, S; Ohana, G; Barer, F; Ochaion, A; Erlanger, A; Madi, L				Fishman, P; Bar-Yehuda, S; Ohana, G; Barer, F; Ochaion, A; Erlanger, A; Madi, L			An agonist to the A(3) adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B	ONCOGENE			English	Article						A(3) adenosine receptor; CF101; colon carcinoma; beta-catenin; GSK-3 beta	BIOCHEMICAL-CHARACTERIZATION; PROGNOSTIC MARKER; SIGNALING PATHWAY; CANCER-THERAPY; CELL GROWTH; MELANOMA; TUMOR; PHOSPHORYLATION; OVEREXPRESSION; ACTIVATION	A(3) adenosine receptor (A(3)AR) activation with the specific agonist CF101 has been shown to inhibit the development of colon carcinoma growth in syngeneic and xenograft murine models. In the present study, we looked into the effect of CF101 on the molecular mechanisms involved in the inhibition of HCT-116 colon carcinoma in mice. In tumor lesions derived from CF101-treated mice, a decrease in the expression level of protein kinase A (PKA) and an increase in glycogen synthase kinase-3beta (GSK-3beta) was observed. This gave rise to downregulation of beta-catenin and its transcriptional gene products cyclin D1 and c-Myc. Further mechanistic studies in vitro revealed that these responses were counteracted by the selective A(3)AR antagonist MRS 1523 and by the GSK-3beta inhibitors lithium and SB216763, confirming that the observed effects were A(3)AR and GSK-3beta mediated. CF101 downregulated PKB/Akt expression level, resulting in a decrease in the level and DNA-binding capacity of NF-kappaB, both in vivo and in vitro. Furthermore, the PKA and PKB/Akt inhibitors H89 and Worthmannin mimicked the effect of CF101, supporting their involvement in mediating the response to the agonist. This is the first demonstration that A(3)AR activation induces colon carcinoma growth inhibition via the modulation of the key proteins GSK-3beta and NF-kappaB.	Can Fite Biopharma Ltd, IL-49170 Kiryat Matalon, Petach Tikva, Israel; Tel Aviv Univ, Sackler Fac Med, Rabin Med Ctr, Felsenstein Med Res Ctr,Lab Clin & Tumor Immunol, Petah Tiqwa, Israel	Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Fishman, P (corresponding author), Can Fite Biopharma Ltd, IL-49170 Kiryat Matalon, Petach Tikva, Israel.	pnina@canfite.co.il						Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Chana JS, 2002, BRIT J PLAST SURG, V55, P623, DOI 10.1054/bjps.2002.3964; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Ferkey DM, 2000, DEV BIOL, V225, P471, DOI 10.1006/dbio.2000.9816; Fishman P, 2003, ANTICANCER RES, V23, P2077; Fishman P, 2002, ANTI-CANCER DRUG, V13, P437, DOI 10.1097/00001813-200206000-00001; Fishman P, 2002, ONCOGENE, V21, P4060, DOI 10.1038/sj.onc.1205531; Fishman P, 2001, EXP CELL RES, V269, P230, DOI 10.1006/excr.2001.5327; Gessi S, 2001, BRIT J PHARMACOL, V134, P116, DOI 10.1038/sj.bjp.0704254; Hosokawa Y, 1998, GENE CHROMOSOME CANC, V22, P66, DOI 10.1002/(SICI)1098-2264(199805)22:1<66::AID-GCC9>3.0.CO;2-5; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Joyce D, 2001, CYTOKINE GROWTH F R, V12, P73, DOI 10.1016/S1359-6101(00)00018-6; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kolligs FT, 2002, DIGESTION, V66, P131, DOI 10.1159/000066755; Lovig T, 2002, SCAND J GASTROENTERO, V37, P1184, DOI 10.1080/003655202760373407; Madi L, 2003, J BIOL CHEM, V278, P42121, DOI 10.1074/jbc.M301243200; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Masuda M, 2002, CANCER RES, V62, P3351; Merighi S, 2001, BRIT J PHARMACOL, V134, P1215, DOI 10.1038/sj.bjp.0704352; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Nguyen DC, 2003, INT J ONCOL, V22, P1285; Ohana G, 2003, BRIT J CANCER, V89, P1552, DOI 10.1038/sj.bjc.6601315; Ohana G, 2001, J CELL PHYSIOL, V186, P19, DOI 10.1002/1097-4652(200101)186:1<19::AID-JCP1011>3.0.CO;2-3; Olah ME, 2000, PHARMACOL THERAPEUT, V85, P55, DOI 10.1016/S0163-7258(99)00051-0; Parrella P, 2001, INVEST OPHTH VIS SCI, V42, P1679; Poulsen SA, 1998, BIOORGAN MED CHEM, V6, P619, DOI 10.1016/S0968-0896(98)00038-8; Schulte G, 2002, MOL PHARMACOL, V62, P1137, DOI 10.1124/mol.62.5.1137; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Suh BC, 2001, BRIT J PHARMACOL, V134, P132, DOI 10.1038/sj.bjp.0704218; Trincavelli ML, 2002, MOL PHARMACOL, V62, P1373, DOI 10.1124/mol.62.6.1373; Trincavelli ML, 2002, BBA-MOL CELL RES, V1591, P55, DOI 10.1016/S0167-4889(02)00248-3; VanWardenburg RCAM, 1997, INT J CANCER, V73, P544, DOI 10.1002/(SICI)1097-0215(19971114)73:4<544::AID-IJC15>3.3.CO;2-C	33	85	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2465	2471		10.1038/sj.onc.1207355	http://dx.doi.org/10.1038/sj.onc.1207355			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14691449				2022-12-25	WOS:000220558000004
J	Horiuchi, J; Jiang, W; Zhou, H; Wu, P; Yin, JCP				Horiuchi, J; Jiang, W; Zhou, H; Wu, P; Yin, JCP			Phosphorylation of conserved casein kinase sites regulates cAMP-response element-binding protein DNA binding in Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED GENE-EXPRESSION; TRANSCRIPTION FACTORS; CREB PHOSPHORYLATION; CALCIUM REGULATION; CIRCADIAN CLOCK; II INTERACTS; MULTIPLE; ACTIVATOR; MEMORY; HIPPOCAMPUS	The Drosophila homolog of cAMP-response element-binding protein (CREB), dCREB2, exists with serine 231, equivalent to mammalian serine 133, in a predominantly phosphorylated state. Thus, unlike the mammalian protein, the primary regulation of dCREB2 may occur at a different step from serine 231 phosphorylation. Although bacterially expressed dCREB2 bound cAMP-response element sites, protein from Drosophila extracts was unable to do so unless treated with phosphatase. Phosphorylation of recombinant protein by casein kinase (CK) I or II, but not calcium-calmodulin kinase II or protein kinase A, inhibited DNA binding. Up to four conserved CK sites likely to be phosphorylated in vivo were responsible for this effect, and these sites were phosphorylated by a kinase present in Drosophila cell extracts that biochemically resembles CKII. We propose that the relative importance of different signaling pathways in regulating CREB activity may differ between Drosophila and mammals. In Drosophila, the dephosphorylation of CK sites appears to be the major regulatory step, while phosphorylation of serine 231 is necessary but secondary.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Horiuchi, J (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	jcyin@wisc.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH067774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035575] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R21DA015753] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH067774] Funding Source: Medline; NINDS NIH HHS [NS 35575] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Belvin MP, 1999, NEURON, V22, P777, DOI 10.1016/S0896-6273(00)80736-9; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Blendy JA, 1996, EMBO J, V15, P1098, DOI 10.1002/j.1460-2075.1996.tb00447.x; BOHM S, 1993, J BIOL CHEM, V268, P3952; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; Deisseroth K, 2002, NEURON, V34, P179, DOI 10.1016/S0896-6273(02)00664-5; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; Gau D, 2002, NEURON, V34, P245, DOI 10.1016/S0896-6273(02)00656-6; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Grimes CA, 2001, J NEUROCHEM, V78, P1219, DOI 10.1046/j.1471-4159.2001.00495.x; Harlow E., 1988, ANTIBODIES LAB MANUA; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; Impey S, 1998, NAT NEUROSCI, V1, P595, DOI 10.1038/2830; Impey S, 1996, NEURON, V16, P973, DOI 10.1016/S0896-6273(00)80120-8; Kornhauser JM, 2002, NEURON, V34, P221, DOI 10.1016/S0896-6273(02)00655-4; Lieberman DN, 1999, NAT NEUROSCI, V2, P125, DOI 10.1038/5680; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; Liu XG, 2002, ACTA PHARMACOL SIN, V23, P556; Lonze BE, 2002, NEURON, V34, P371, DOI 10.1016/S0896-6273(02)00686-4; MARSHAK DR, 1994, CELL MOL BIOL RES, V40, P513; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Moussazadeh M, 2000, CELL MOL BIOL, V46, P1265; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; Obrietan K, 1999, J BIOL CHEM, V274, P17748, DOI 10.1074/jbc.274.25.17748; Parker D, 1996, MOL CELL BIOL, V16, P694; Pittenger C, 2002, NEURON, V34, P447, DOI 10.1016/S0896-6273(02)00684-0; Redmond L, 2002, NEURON, V34, P999, DOI 10.1016/S0896-6273(02)00737-7; Saeki K, 1999, BIOCHEM J, V338, P49, DOI 10.1042/0264-6021:3380049; Shaywitz AJ, 2000, MOL CELL BIOL, V20, P9409, DOI 10.1128/MCB.20.24.9409-9422.2000; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Trott RL, 2001, J BIOL CHEM, V276, P2159, DOI 10.1074/jbc.M005996200; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; Waddell S, 2001, TRENDS GENET, V17, P719, DOI 10.1016/S0168-9525(01)02526-4; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; Yamaguchi Y, 1998, NUCLEIC ACIDS RES, V26, P3854, DOI 10.1093/nar/26.16.3854; YIN JCP, 1995, MOL CELL BIOL, V15, P5123; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5	44	27	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12117	12125		10.1074/jbc.M212839200	http://dx.doi.org/10.1074/jbc.M212839200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14676200	Green Accepted, hybrid			2022-12-25	WOS:000220334900017
J	Li, QX; Cheon, YP; Kannan, A; Shanker, S; Bagchi, IC; Bagchi, MK				Li, QX; Cheon, YP; Kannan, A; Shanker, S; Bagchi, IC; Bagchi, MK			A novel pathway involving progesterone receptor, 12/15-lipoxygenase-derived eicosanoids, and peroxisome proliferator-activated receptor gamma regulates implantation in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; GENE-EXPRESSION; MOUSE UTERUS; TARGETED DISRUPTION; EMBRYO IMPLANTATION; NUCLEAR RECEPTORS; FATTY-ACIDS; GROWTH; ALPHA; LIPOXYGENASES	The 12/15-lipoxygenases (12/15-LOX) catalyze the stereospecific oxygenation of arachidonic and linoleic acids into a complex series of signaling molecules, including the hydroxyeicosatetraenoic acids (HETEs) and hydroxyoctadecadienoic acids (HODEs). Our previous studies, using high density oligonucleotide microarrays, suggested a novel link between progesterone receptor ( PR) signaling and 12/15-LOX-mediated fatty acid metabolism in preimplantation mouse uterus. In this paper, using PR knockout mice, we established that the transcripts encoding leukocyte-12/15-LOX (L-12/15-LOX) and epidermal-12/15-LOX (E-12/15-LOX) are indeed downstream targets of regulation by PR in the uterine surface epithelium. Maximal induction of both L- and E-12/15-LOX on the day of implantation resulted in a marked increase in the uterine levels of the eicosanoids, 12-HETE, 15-HETE, and 13-HODE. Mice with null mutation in L-12/15-LOX had significantly reduced uterine levels of arachidonic acid metabolites and exhibited a partial impairment in implantation. Complete blockade of uterine 12/15-LOX activity by a specific inhibitor led to greater than 80% reduction in a number of implantation sites relative to untreated controls. Cell-based assays indicated that 12-HETE, 15-HETE, and 13-HODE function as activating ligands of peroxisome proliferator-activated receptor gamma (PPARgamma), suggesting that this nuclear receptor could be a downstream target of 12/15LOX-derived metabolites in the preimplantation uterus. Consistent with this hypothesis, administration of rosiglitazone, a potent PPARgamma-selective agonist, efficiently reversed inhibition of implantation by the 12/15-LOX-specific inhibitor. Rosiglitazone also induced a number of potential target genes of 12/15-LOX-derived metabolites in the pregnant uterus, indicating their regulation by PPARgamma. Collectively, our results uncovered a novel signaling pathway in which progesterone-induced synthesis of the 12/15-LOX-derived lipid mediators activates PPARgamma and its downstream gene networks, which in turn function as critical regulators of implantation in the mouse.	Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Univ Illinois, Dept Vet Biosci, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Bagchi, MK (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, 534 Burrill Hall,MC-114,407 S Goodwin Ave, Urbana, IL 61801 USA.	mbagchi@life.uiuc.edu			NICHD NIH HHS [R01 HD39291, R01 HD44611, R01 HD43381] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD039291, R01HD044611, R01HD043381] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AIZU E, 1986, CARCINOGENESIS, V7, P1809, DOI 10.1093/carcin/7.11.1809; Barak Y, 2002, P NATL ACAD SCI USA, V99, P303, DOI 10.1073/pnas.012610299; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BAULIEU EE, 1991, TRENDS ENDOCRIN MET, V2, P233, DOI 10.1016/1043-2760(91)90030-Q; Blais C, 2000, PEPTIDES, V21, P1903, DOI 10.1016/S0196-9781(00)00348-X; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; Campos MM, 2000, NEUROPEPTIDES, V34, P314, DOI 10.1054/npep.2000.0823; Carson DD, 2000, DEV BIOL, V223, P217, DOI 10.1006/dbio.2000.9767; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Cheon YP, 2002, MOL ENDOCRINOL, V16, P2853, DOI 10.1210/me.2002-0270; Conrad DJ, 1999, CLIN REV ALLERG IMMU, V17, P71, DOI 10.1007/BF02737598; Dailey LA, 1999, CURR MED CHEM, V6, P389; DAS SK, 1992, ENDOCRINOLOGY, V130, P3459, DOI 10.1210/en.130.6.3459; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; DRINKWATER CC, 1987, BIOCHEMISTRY-US, V26, P6750, DOI 10.1021/bi00395a026; Espey Lawrence L., 1994, P725; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Funk CD, 1996, BBA-LIPID LIPID MET, V1304, P65, DOI 10.1016/S0005-2760(96)00107-5; Gidley-Baird A A, 1981, J Reprod Fertil Suppl, V29, P97; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Kuhn H, 1999, ADV EXP MED BIOL, V447, P5; KUSHNER I, 1988, METHOD ENZYMOL, V163, P373; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; McDonnell M, 2001, PROSTAG OTH LIPID M, V63, P93, DOI 10.1016/S0090-6980(00)00100-3; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Mikuni M, 1998, BIOL REPROD, V58, P1211, DOI 10.1095/biolreprod58.5.1211; Mirochnitchenko O, 2000, CIRC RES, V87, P289, DOI 10.1161/01.RES.87.4.289; MIYAZAKI Y, 1989, NUCLEIC ACIDS RES, V17, P3298, DOI 10.1093/nar/17.8.3298; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NAKADATE T, 1985, J PHARM PHARMACOL, V37, P71, DOI 10.1111/j.2042-7158.1985.tb04938.x; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; Nibbs RJB, 1997, J BIOL CHEM, V272, P12495, DOI 10.1074/jbc.272.19.12495; PARIA BC, 1993, P NATL ACAD SCI USA, V90, P10159, DOI 10.1073/pnas.90.21.10159; Parr MB., 1989, BIOL UTERUS, P233; Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000; Philibert D, 1985, ANTIPROGESTIN STEROI, P49; Pinto FM, 2001, EUR J PHARMACOL, V425, pR1, DOI 10.1016/S0014-2999(01)01186-4; PSYCHOYOS A, 1973, HDB PHYSL, P187; REICH R, 1983, PROSTAGLANDINS, V26, P1011, DOI 10.1016/0090-6980(83)90161-2; Schild RL, 2002, J CLIN ENDOCR METAB, V87, P1105, DOI 10.1210/jc.87.3.1105; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; Sun DX, 1996, J BIOL CHEM, V271, P24055, DOI 10.1074/jbc.271.39.24055; TAKAHASHI T, 1994, CELL GROWTH DIFFER, V5, P919; THOMAS T, 1995, BBA-GENE STRUCT EXPR, V1261, P77, DOI 10.1016/0167-4781(94)00224-Q; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Weitlauf H. M., 1994, P391; YOSHINAG.K, 1966, J REPROD FERTIL, V12, P593, DOI 10.1530/jrf.0.0120593; YOSHINAGA K, 1988, ANN NY ACAD SCI, V541, P424, DOI 10.1111/j.1749-6632.1988.tb22279.x; Zhu LJ, 1998, ENDOCRINOLOGY, V139, P3923, DOI 10.1210/en.139.9.3923	57	66	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11570	11581		10.1074/jbc.M311773200	http://dx.doi.org/10.1074/jbc.M311773200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14688261	hybrid			2022-12-25	WOS:000220157600090
J	Batten, ML; Imanishi, Y; Maeda, T; Tu, DC; Moise, AR; Bronson, D; Possin, D; Van Gelder, RN; Baehr, W; Palczewski, K				Batten, ML; Imanishi, Y; Maeda, T; Tu, DC; Moise, AR; Bronson, D; Possin, D; Van Gelder, RN; Baehr, W; Palczewski, K			Lecithin-retinol acyltransferase is essential for accumulation of all-trans-retinyl esters in the eye and in the liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT RETINITIS-PIGMENTOSA; DIETARY VITAMIN-A; VISUAL PIGMENT; MOUSE MODEL; BINDING PROTEIN; CIS-RETINOLS; RAT-LIVER; OPSIN; GENE; REGENERATION	Lecithin-retinol acyltransferase (LRAT), an enzyme present mainly in the retinal pigmented epithelial cells and liver, converts all-trans-retinol into all-trans-retinyl esters. In the retinal pigmented epithelium, LRAT plays a key role in the retinoid cycle, a two-cell recycling system that replenishes the 11-cis-retinal chromophore of rhodopsin and cone pigments. We disrupted mouse Lrat gene expression by targeted recombination and generated a homozygous Lrat knock-out (Lrat-/-) mouse. Despite the expression of LRAT in multiple tissues, the Lrat-/- mouse develops normally. The histological analysis and electron microscopy of the retina for 6-8-week-old Lrat-/- mice revealed that the rod outer segments are similar to35% shorter than those of Lrat+/+ mice, whereas other neuronal layers appear normal. Lrat-/- mice have trace levels of all-trans-retinyl esters in the liver, lung, eye, and blood, whereas the circulating all-trans-retinol is reduced only slightly. Scotopic and photopic electroretinograms as well as pupillary constriction analyses revealed that rod and cone visual functions are severely attenuated at an early age. We conclude that Lrat-/- mice may serve as an animal model with early onset severe retinal dystrophy and severe retinyl ester deprivation.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Utah, Dept Ophthalmol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Neurobiol & Anat, Salt Lake City, UT 84112 USA; Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Washington University (WUSTL); Washington University (WUSTL)	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, Box 356485, Seattle, WA 98195 USA.	palczews@u.washington.edu	Imanishi, Yoshikazu/E-8178-2010; Moise, Alexander R/C-9498-2009; Van Gelder, Russell/ABB-4225-2021; AR, Moise/P-2474-2019; Moise, Alexander/A-7186-2008	Imanishi, Yoshikazu/0000-0003-4696-4836; Moise, Alexander R/0000-0003-2307-6035; Van Gelder, Russell/0000-0001-5368-3659; AR, Moise/0000-0003-2307-6035; 	NEI NIH HHS [R01 EY014988, R01 EY009339, EYK0800403, EY14988, EY08123, EY09339, EY13385, R01 EY008123, R01 EY013385] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013385, K08EY000403, R01EY014988, R01EY008123, R01EY009339] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ablonczy Z, 2002, J BIOL CHEM, V277, P40491, DOI 10.1074/jbc.M205507200; ADAMUS G, 1989, IN VITRO CELL DEV B, V25, P1141; ANANTHARAMAN V, 2003, GENOME BIOL; Ball SL, 2002, INVEST OPHTH VIS SCI, V43, P1595; BOK D, 1985, INVEST OPHTH VIS SCI, V26, P1659; Dawson MI, 2000, CURR PHARM DESIGN, V6, P311, DOI 10.2174/1381612003401190; Driessen CAGG, 2000, MOL CELL BIOL, V20, P4275, DOI 10.1128/MCB.20.12.4275-4287.2000; Fortuna VA, 2001, J NUTR BIOCHEM, V12, P610, DOI 10.1016/S0955-2863(01)00179-6; Gottesman ME, 2001, BIOESSAYS, V23, P409, DOI 10.1002/bies.1059; Haeseleer F, 2002, J BIOL CHEM, V277, P45537, DOI 10.1074/jbc.M208882200; Hattar S, 2003, NATURE, V424, P76, DOI 10.1038/nature01761; Hetling JR, 1999, J PHYSIOL-LONDON, V516, P593, DOI 10.1111/j.1469-7793.1999.0593v.x; Jager S, 1996, BIOCHEMISTRY-US, V35, P2901, DOI 10.1021/bi9524068; Jahng WJ, 2003, BIOCHEMISTRY-US, V42, P12805, DOI 10.1021/bi035370p; Jang GF, 2001, J BIOL CHEM, V276, P32456, DOI 10.1074/jbc.M104949200; Kuksa V, 2002, J BIOL CHEM, V277, P42315, DOI 10.1074/jbc.M206014200; LI ZY, 1994, EXP EYE RES, V58, P397, DOI 10.1006/exer.1994.1032; Lucas RJ, 2001, NAT NEUROSCI, V4, P621, DOI 10.1038/88443; MACDONALD PN, 1988, BIOCHEM BIOPH RES CO, V156, P157, DOI 10.1016/S0006-291X(88)80818-0; MACDONALD PN, 1988, J BIOL CHEM, V263, P12478; Maeda T, 2003, J NEUROCHEM, V85, P944, DOI 10.1046/j.1471-4159.2003.01741.x; McBee JK, 2000, BIOCHEMISTRY-US, V39, P11370, DOI 10.1021/bi001061c; McBee JK, 2001, J BIOL CHEM, V276, P48483, DOI 10.1074/jbc.M105840200; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Melia TJ, 1997, BIOPHYS J, V73, P3182, DOI 10.1016/S0006-3495(97)78344-9; Mondal MS, 2001, FEBS LETT, V489, P14, DOI 10.1016/S0014-5793(00)02428-5; Mondal MS, 2000, BIOCHEMISTRY-US, V39, P5215, DOI 10.1021/bi9929554; NAASH MI, 1993, P NATL ACAD SCI USA, V90, P5499, DOI 10.1073/pnas.90.12.5499; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; ONG DE, 1988, J BIOL CHEM, V263, P5789; Palczewski K, 1999, BIOCHEMISTRY-US, V38, P12012, DOI 10.1021/bi990504d; Panda S, 2003, SCIENCE, V301, P525, DOI 10.1126/science.1086179; Perrault I, 1999, MOL GENET METAB, V68, P200, DOI 10.1006/mgme.1999.2906; Provencio I, 1998, P NATL ACAD SCI USA, V95, P340, DOI 10.1073/pnas.95.1.340; RANDO RR, 1991, BIOCHEMISTRY-US, V30, P595, DOI 10.1021/bi00217a001; Rattner A, 1999, ANNU REV GENET, V33, P89, DOI 10.1146/annurev.genet.33.1.89; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Ruiz A, 2001, INVEST OPHTH VIS SCI, V42, P31; Ruiz A, 1999, J BIOL CHEM, V274, P3834, DOI 10.1074/jbc.274.6.3834; Saari JC, 2000, INVEST OPHTH VIS SCI, V41, P337; Saari JC, 1998, VISION RES, V38, P1325, DOI 10.1016/S0042-6989(97)00198-3; SAARI JC, 1993, BIOCHEM J, V291, P697, DOI 10.1042/bj2910697; SCHMITT MC, 1993, BIOL REPROD, V49, P972, DOI 10.1095/biolreprod49.5.972; Seeliger MW, 2001, NAT GENET, V29, P70, DOI 10.1038/ng712; SURYA A, 1995, J BIOL CHEM, V270, P5024, DOI 10.1074/jbc.270.10.5024; Thompson CL, 2001, P NATL ACAD SCI USA, V98, P11708, DOI 10.1073/pnas.201301498; Thompson DA, 2001, NAT GENET, V28, P123, DOI 10.1038/88828; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297; Van Hooser JP, 2002, J BIOL CHEM, V277, P19173, DOI 10.1074/jbc.M112384200; Wald G, 1936, J GEN PHYSIOL, V19, P781, DOI 10.1085/jgp.19.5.781; Woodruff ML, 2003, NAT GENET, V35, P158, DOI 10.1038/ng1246; Zolfaghari R, 2002, BIOCHEM J, V368, P621, DOI 10.1042/BJ20020918; Zolfaghari R, 2002, J NUTR, V132, P1160, DOI 10.1093/jn/132.6.1160; Zolfaghari R, 2000, J LIPID RES, V41, P2024	54	268	280	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10422	10432		10.1074/jbc.M312410200	http://dx.doi.org/10.1074/jbc.M312410200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14684738	Green Accepted, hybrid			2022-12-25	WOS:000220050400093
J	Kubitz, R; Saha, N; Kuhlkamp, T; Dutta, S; vom Dahl, S; Wettstein, M; Haussinger, DH				Kubitz, R; Saha, N; Kuhlkamp, T; Dutta, S; vom Dahl, S; Wettstein, M; Haussinger, DH			Ca2+-dependent protein kinase C Isoforms induce cholestasis in rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE PROTEIN-2; CONJUGATE EXPORT PUMP; SUBSTRATE MARCKS PROTEIN; CANALICULAR MEMBRANE; SIGNAL-TRANSDUCTION; PHORBOL ESTERS; DOWN-REGULATION; BILE SECRETION; HEPG2 CELLS; CYCLIC-AMP	Bile secretion is regulated by different signaling transduction pathways including protein kinase C (PKC). However, the role of different PKC isoforms for bile formation is still controversial. This study investigates the effects of PKC isoform selective activators and inhibitors on PKC translocation, bile secretion, bile acid uptake, and subcellular transporter localization in rat liver, isolated rat hepatocytes and in HepG2 cells. In rat liver activation of Ca2+-dependent cPKCalpha and Ca2+-independent PKCepsilon by phorbol 12-myristate 13-acetate (PMA, 10 nmol/liter) is associated with their translocation to the plasma membrane. PMA also induced translocation of the cloned rat PKCepsilon fused to a yellow fluorescent protein (YFP), which was transfected into HepG2 cells. In the perfused liver, PMA induced marked cholestasis. The PKC inhibitors Go6850 (1 mumol/liter) and Go6976 (0.2 mumol/liter), a selective inhibitor of Ca2+-dependent PKC isoforms, diminished the PMA effect by 50 and 60%, respectively. Thymeleatoxin (Ttx,) a selective activator of Ca2+-dependent cPKCs, did not translocate rat PKCepsilon-YFP transfected in HepG2 cells. However, Ttx (0.5-10 nmol/liter) induced cholestasis similar to PMA and led to a retrieval of Bsep from the canalicular membrane in rat liver while taurocholate-uptake in isolated hepatocytes was not affected. Go6976 completely blocked the cholestatic effect of Ttx but had no effect on tauroursodeoxycholate-induced choleresis. The data identify Ca2+-dependent PKC isoforms as inducers of cholestasis. This is mainly due to inhibition of taurocholate excretion involving transporter retrieval from the canalicular membrane.	Univ Dusseldorf, Dept Gastroenterol Hepatol & Infectiol, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Kubitz, R (corresponding author), Univ Dusseldorf, Dept Gastroenterol Hepatol & Infectiol, Moorenstr 5, D-40225 Dusseldorf, Germany.	Kubitz@med.uni-duesseldorf.de	Dahl, Stephan vom/AAF-8456-2021; Saha, Nirmalendu/J-8100-2014; Saha, Nirmalendu/AAH-7792-2021	Dahl, Stephan vom/0000-0003-0481-0601; Saha, Nirmalendu/0000-0002-9635-3024; Saha, Nirmalendu/0000-0002-9635-3024				Beuers U, 1996, GASTROENTEROLOGY, V110, P1553, DOI 10.1053/gast.1996.v110.pm8613063; Beuers U, 2001, HEPATOLOGY, V33, P1206, DOI 10.1053/jhep.2001.24034; Beuers U, 1999, HEPATOLOGY, V29, P477, DOI 10.1002/hep.510290227; Bouscarel B, 1999, GASTROENTEROLOGY, V117, P433, DOI 10.1053/gast.1999.0029900433; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CORASANTI JG, 1989, HEPATOLOGY, V10, P8, DOI 10.1002/hep.1840100103; Croquet F, 1996, BBA-MOL BASIS DIS, V1315, P163, DOI 10.1016/0925-4439(95)00124-7; DIMITRIJEVIC SM, 1995, MOL PHARMACOL, V48, P259; DIVALD A, 1994, HEPATOLOGY, V20, P159, DOI 10.1002/hep.1840200124; Dombrowski F, 2000, BIOCHEM J, V348, P183, DOI 10.1042/0264-6021:3480183; DURONIO V, 1990, J CELL PHYSIOL, V145, P381, DOI 10.1002/jcp.1041450225; Gekeler V, 1996, BRIT J CANCER, V74, P897, DOI 10.1038/bjc.1996.454; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; GRUNE S, 1993, J BIOL CHEM, V268, P17734; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; Hansra G, 1999, BIOCHEM J, V342, P337, DOI 10.1042/0264-6021:3420337; Haussinger D, 2000, SEMIN LIVER DIS, V20, P307, DOI 10.1055/s-2000-9386; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; Keppler D, 2000, SEMIN LIVER DIS, V20, P265, DOI 10.1055/s-2000-9391; KIM JY, 1994, J BIOL CHEM, V269, P28214; Kubitz R, 2001, HEPATOLOGY, V34, P340, DOI 10.1053/jhep.2001.25959; Kubitz R, 1997, GASTROENTEROLOGY, V113, P1438, DOI 10.1053/gast.1997.v113.pm9352844; Kubitz R, 1999, GASTROENTEROLOGY, V116, P401, DOI 10.1016/S0016-5085(99)70138-1; KUHN WF, 1988, AM J PHYSIOL, V254, pG732, DOI 10.1152/ajpgi.1988.254.5.G732; Kurz AK, 2001, GASTROENTEROLOGY, V121, P407, DOI 10.1053/gast.2001.26262; Llosas MD, 1996, BIOCHEM J, V315, P1049; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Meier PJ, 2002, ANNU REV PHYSIOL, V64, P635, DOI 10.1146/annurev.physiol.64.082201.100300; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Mottino AD, 2002, HEPATOLOGY, V35, P1409, DOI 10.1053/jhep.2002.33327; Muller M, 2000, SEMIN LIVER DIS, V20, P323, DOI 10.1055/s-2000-9387; NATHANSON MH, 1992, AM J PHYSIOL, V262, pG1079, DOI 10.1152/ajpgi.1992.262.6.G1079; NATHANSON MH, 1992, HEPATOLOGY, V15, P107, DOI 10.1002/hep.1840150119; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; Noe J, 2001, HEPATOLOGY, V33, P1223, DOI 10.1053/jhep.2001.24171; Ohmori S, 2000, J BIOL CHEM, V275, P26449, DOI 10.1074/jbc.M003588200; ORR JW, 1992, J BIOL CHEM, V267, P15263; PERLETTI GP, 1994, J BIOCHEM BIOPH METH, V28, P195, DOI 10.1016/0165-022X(94)90016-7; ROELOFSEN H, 1991, BIOCHEM J, V278, P637, DOI 10.1042/bj2780637; ROIVAINEN R, 1993, FEBS LETT, V319, P31, DOI 10.1016/0014-5793(93)80031-O; Rost D, 1999, HEPATOLOGY, V29, P814, DOI 10.1002/hep.510290319; RYVES WJ, 1991, FEBS LETT, V288, P5, DOI 10.1016/0014-5793(91)80989-G; Schliess F, 1997, GASTROENTEROLOGY, V113, P1306, DOI 10.1053/gast.1997.v113.pm9322526; Schmitt M, 2000, BIOL CHEM, V381, P487, DOI 10.1515/BC.2000.063; SHOJI M, 1986, BIOCHEM BIOPH RES CO, V135, P1144, DOI 10.1016/0006-291X(86)91047-8; Suzuki H, 2000, SEMIN LIVER DIS, V20, P251, DOI 10.1055/s-2000-8408; SWIERCZYNSKI SL, 1995, J BIOL CHEM, V270, P13436, DOI 10.1074/jbc.270.22.13436; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; Trauner M, 2001, Semin Gastrointest Dis, V12, P66; Trauner M, 1998, NEW ENGL J MED, V339, P1217, DOI 10.1056/NEJM199810223391707	51	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10323	10330		10.1074/jbc.M306242200	http://dx.doi.org/10.1074/jbc.M306242200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14679204	hybrid			2022-12-25	WOS:000220050400081
J	Ohhashi, Y; Hasegawa, K; Naiki, H; Goto, Y				Ohhashi, Y; Hasegawa, K; Naiki, H; Goto, Y			Optimum amyloid fibril formation of a peptide fragment suggests the amyloidogenic preference of beta(2)-microglobulin under physiological conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-2-MICROGLOBULIN REVEALS; SOLID-STATE NMR; DISULFIDE BOND; NEUTRAL PH; IN-VITRO; PROTEIN AGGREGATION; PRION PROTEIN; BETA-SHEET; REDUCTION; DISEASES	beta(2)-Microglobulin (beta(2)m) is a major component of amyloid fibrils deposited in patients with dialysis-related amyloidosis. Although full-length beta(2)m readily forms amyloid fibrils in vitro by seed-dependent extension with a maximum at pH 2.5, fibril formation under physiological conditions as detected in patients has been difficult to reproduce. A 22-residue K3 peptide of beta(2)m, Ser(20)-Lys(41), obtained by digestion with Acromobacter protease I, forms amyloid fibrils without seeding. To obtain further insight into the mechanism of fibril formation, we studied the pH dependence of fibril formation of the K3 peptide and its morphology using a ThT fluorescence assay and electron microscopy, respectively. K3 peptide formed amyloid fibrils over a wide range of pH values with an optimum around pH 7 and contrasted with the pH profile of the seed-dependent extension reaction of full-length beta(2)m. This suggests that once the rigid native-fold of beta(2)m is unfolded and additional factors triggering the nucleation process are provided, full-length beta(2)m discloses an intrinsic potential to form amyloid fibrils at neutral pH. The fibril formation was strongly promoted by dimerization of K3 through Cys(25). The morphology of the fibrils varied depending on the fibril formation conditions and the presence or absence of a disulfide bond. Various fibrils had the potential to seed fibril formation of full-length beta(2)m accompanied with a characteristic lag phase, suggesting that the internal structures are similar.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Japan Sci Corp, CREST, Suita, Osaka 5650871, Japan; Univ Fukui, Fac Med Sci, Fukui 9101193, Japan; Japan Sci Corp, CREST, Fukui 9101193, Japan	Osaka University; Japan Science & Technology Agency (JST); University of Fukui; Japan Science & Technology Agency (JST)	Goto, Y (corresponding author), Osaka Univ, Inst Prot Res, Yamadaoka 3-2, Suita, Osaka 5650871, Japan.	ygoto@protein.osaka-u.ac.jp	Naiki, Hironobu/G-5599-2014					Balbach JJ, 2000, BIOCHEMISTRY-US, V39, P13748, DOI 10.1021/bi0011330; Ban T, 2003, J BIOL CHEM, V278, P16462, DOI 10.1074/jbc.C300049200; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; Chiba T, 2003, J BIOL CHEM, V278, P47016, DOI 10.1074/jbc.M304473200; Chiti F, 2003, NATURE, V424, P805, DOI 10.1038/nature01891; Chiti F, 2002, NAT STRUCT BIOL, V9, P137, DOI 10.1038/nsb752; Chiti F, 2001, PROTEIN SCI, V10, P2541, DOI 10.1110/ps.ps.10201; Chiti F, 2001, J MOL BIOL, V307, P379, DOI 10.1006/jmbi.2000.4478; de la Paz ML, 2002, P NATL ACAD SCI USA, V99, P16052, DOI 10.1073/pnas.252340199; Dobson CM, 2002, NATURE, V418, P729, DOI 10.1038/418729a; Esposito G, 2000, PROTEIN SCI, V9, P831, DOI 10.1110/ps.9.5.831; Fandrich M, 2002, EMBO J, V21, P5682, DOI 10.1093/emboj/cdf573; Gejyo F, 1990, Contrib Nephrol, V78, P47; GEJYO F, 1985, BIOCHEM BIOPH RES CO, V129, P701, DOI 10.1016/0006-291X(85)91948-5; Gillmore JD, 1997, BRIT J HAEMATOL, V99, P245, DOI 10.1046/j.1365-2141.1997.303194.x; Gozu M, 2003, J BIOCHEM, V133, P731, DOI 10.1093/jb/mvg094; Hammarstrom P, 2002, P NATL ACAD SCI USA, V99, P16427, DOI 10.1073/pnas.202495199; Hasegawa K, 2003, BIOCHEM BIOPH RES CO, V304, P101, DOI 10.1016/S0006-291X(03)00543-6; Heegaard NHH, 2001, J BIOL CHEM, V276, P32657, DOI 10.1074/jbc.M104452200; Herrmann LM, 1998, NEUROREPORT, V9, P2457, DOI 10.1097/00001756-199808030-00006; Hirota-Nakaoka N, 2003, J BIOCHEM, V134, P159, DOI 10.1093/jb/mvg124; Hong DP, 2002, J BIOL CHEM, V277, P21554, DOI 10.1074/jbc.M200188200; Hoshino M, 2002, NAT STRUCT BIOL, V9, P332, DOI 10.1038/nsb792; HURLE MR, 1994, P NATL ACAD SCI USA, V91, P5446, DOI 10.1073/pnas.91.12.5446; Jones S, 2003, J MOL BIOL, V330, P935, DOI 10.1016/S0022-2836(03)00688-0; Jones S, 2003, J MOL BIOL, V325, P249, DOI 10.1016/S0022-2836(02)01227-5; Kad NM, 2003, J MOL BIOL, V330, P785, DOI 10.1016/S0022-2836(03)00583-7; Kad NM, 2001, J MOL BIOL, V313, P559, DOI 10.1006/jmbi.2001.5071; Katou H, 2002, PROTEIN SCI, V11, P2218, DOI 10.1110/ps.0213202; Khurana R, 2001, BIOCHEMISTRY-US, V40, P3525, DOI 10.1021/bi001782b; Koo EH, 1999, P NATL ACAD SCI USA, V96, P9989, DOI 10.1073/pnas.96.18.9989; Kozhukh GV, 2002, J BIOL CHEM, V277, P1310, DOI 10.1074/jbc.M108753200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krebs MRH, 2000, J MOL BIOL, V300, P541, DOI 10.1006/jmbi.2000.3862; Krishnan S, 2003, BIOCHEMISTRY-US, V42, P829, DOI 10.1021/bi026528t; Lee S, 2003, NAT STRUCT BIOL, V10, P725, DOI 10.1038/nsb961; MacPhee CE, 2000, J MOL BIOL, V297, P1203, DOI 10.1006/jmbi.2000.3600; McParland VJ, 2002, NAT STRUCT BIOL, V9, P326, DOI 10.1038/nsb791; Monti M, 2002, PROTEIN SCI, V11, P2362, DOI 10.1110/ps.0206902; Morgan CJ, 2001, J MOL BIOL, V309, P339, DOI 10.1006/jmbi.2001.4661; Naiki H, 1997, AMYLOID, V4, P223, DOI 10.3109/13506129709003833; Ohhashi Y, 2002, J BIOCHEM, V131, P45, DOI 10.1093/oxfordjournals.jbchem.a003076; Ohnishi S, 2000, J MOL BIOL, V301, P477, DOI 10.1006/jmbi.2000.3980; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; SIPE JD, 1992, ANNU REV BIOCHEM, V61, P947, DOI 10.1146/annurev.bi.61.070192.004503; Smith DP, 2003, J MOL BIOL, V330, P943, DOI 10.1016/S0022-2836(03)00687-9; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; Takahashi Y, 2000, STRUCTURE, V8, P915, DOI 10.1016/S0969-2126(00)00183-0; Trinh CH, 2002, P NATL ACAD SCI USA, V99, P9771, DOI 10.1073/pnas.152337399; Verdone G, 2002, PROTEIN SCI, V11, P487, DOI 10.1110/ps.29002; Welker E, 2001, P NATL ACAD SCI USA, V98, P4334, DOI 10.1073/pnas.071066598; West MW, 1999, P NATL ACAD SCI USA, V96, P11211, DOI 10.1073/pnas.96.20.11211; Yamaguchi I, 2001, BIOCHEMISTRY-US, V40, P8499, DOI 10.1021/bi0027128; Zurdo J, 2001, J MOL BIOL, V311, P325, DOI 10.1006/jmbi.2001.4858	55	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10814	10821		10.1074/jbc.M310334200	http://dx.doi.org/10.1074/jbc.M310334200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14699107	Green Published, hybrid			2022-12-25	WOS:000220050400137
J	Zhang, XC; Shan, PY; Jiang, DH; Noble, PW; Abraham, NG; Kappas, A; Lee, PJ				Zhang, XC; Shan, PY; Jiang, DH; Noble, PW; Abraham, NG; Kappas, A; Lee, PJ			Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PATHWAY; ENDOTHELIAL-CELLS; MAMMALIAN-CELLS; TRANSGENIC MICE; GENE; INJURY; DELIVERY; INHIBITION; EXPRESSION	Heme oxygenase-1 (HO-1) is emerging as an important cytoprotective enzyme system in a variety of injury models. To optimize future therapeutic applications of HO-1, it is necessary to delineate the precise functions and mechanisms as well as modes of externally regulating HO-1 expression. Investigations have been limited by difficulties with the generation of HO-1 null mice and the lack of specific HO-1 inhibitors. Lung ischemia-reperfusion (I-R) injury is the inciting event in acute lung failure following transplantation, surgery, and shock. To study the function of HO-1 in I-R-induced lung injury, we designed small interfering RNA ( siRNA) sequences that effectively suppress HO-1 expression both in vitro and in vivo in an organ-specific manner. In this study we show that there is enhanced apoptosis, via increased Fas expression and caspase 3 activity, in the presence of HO-1 siRNA in endothelial cells and mouse lung during I-R injury, whereas HO-1 overexpression attenuates apoptosis. To the best of our knowledge, we are the first to demonstrate that lung-specific siRNA delivery can be achieved by intranasal administration without the need for viral vectors or transfection agents in vivo, thereby obviating potential concerns for toxicity if siRNA technology is to have clinical application in the future.	Yale Univ, Sch Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA; New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA; Rockefeller Univ, New York, NY 10021 USA	Yale University; New York Medical College; Rockefeller University	Lee, PJ (corresponding author), Yale Univ, Sch Med, Pulm & Crit Care Med Sect, POB 208057, New Haven, CT 06520 USA.	patty.lee@yale.edu	zhang, xu/GYE-3558-2022; Jiang, Dianhua/B-1421-2009	Zhang, Xuchen/0000-0002-1484-4672; Jiang, Dianhua/0000-0002-4508-3829	NHLBI NIH HHS [HL004034, HL34300, HL55601, HL31069] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL031069, R01HL031069, P01HL034300, R37HL031069] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbas-Terki T, 2002, HUM GENE THER, V13, P2197, DOI 10.1089/104303402320987888; ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; Barton GM, 2002, P NATL ACAD SCI USA, V99, P14943, DOI 10.1073/pnas.242594499; Calvillo L, 2003, P NATL ACAD SCI USA, V100, P4802, DOI 10.1073/pnas.0630444100; Cao GD, 2002, J NEUROSCI, V22, P5423; Chanalaris A, 2003, J MOL CELL CARDIOL, V35, P257, DOI 10.1016/S0022-2828(03)00003-8; Devroe Eric, 2002, BMC Biotechnol, V2, P15, DOI 10.1186/1472-6750-2-15; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Hasuwa H, 2002, FEBS LETT, V532, P227, DOI 10.1016/S0014-5793(02)03680-3; Jozkowicz A, 2003, ACTA BIOCHIM POL, V50, P69, DOI 10.18388/abp.2003_3715; KAPPAS A, 2002, HEME OXYGENASE BIOL, P3; LEE PJ, 2003, LUNG BIOL HEALTH DIS, V170, P117; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; McCaffrey AP, 2003, NAT BIOTECHNOL, V21, P639, DOI 10.1038/nbt824; Otterbein LE, 1999, J CLIN INVEST, V103, P1047, DOI 10.1172/JCI5342; Otterbein LE, 2000, AM J PHYSIOL-LUNG C, V279, pL1029, DOI 10.1152/ajplung.2000.279.6.L1029; Quan SO, 2001, P NATL ACAD SCI USA, V98, P12203, DOI 10.1073/pnas.211399398; Reich S, 2003, MOL VIS, V9, P210; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; SARDANA MK, 1987, P NATL ACAD SCI USA, V84, P2464, DOI 10.1073/pnas.84.8.2464; Shen CX, 2003, FEBS LETT, V539, P111, DOI 10.1016/S0014-5793(03)00209-6; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; Sorensen DR, 2003, J MOL BIOL, V327, P761, DOI 10.1016/S0022-2836(03)00181-5; Stammberger U, 2000, ANN THORAC SURG, V69, P1532, DOI 10.1016/S0003-4975(00)01228-5; Yang LM, 1999, AM J PHYSIOL-LUNG C, V277, pL127, DOI 10.1152/ajplung.1999.277.1.L127; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276; Zender L, 2003, P NATL ACAD SCI USA, V100, P7797, DOI 10.1073/pnas.1330920100; Zhang XC, 2003, J BIOL CHEM, V278, P22061, DOI 10.1074/jbc.M301858200; Zhang XC, 2003, J BIOL CHEM, V278, P1248, DOI 10.1074/jbc.M208419200; Zhang XC, 2002, AM J PHYSIOL-LUNG C, V283, pL815, DOI 10.1152/ajplung.00485.2001	33	217	262	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10677	10684		10.1074/jbc.M312941200	http://dx.doi.org/10.1074/jbc.M312941200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688267	hybrid			2022-12-25	WOS:000220050400122
J	Golden, JW; Bahe, JA; Lucas, WT; Nibert, ML; Schiff, LA				Golden, JW; Bahe, JA; Lucas, WT; Nibert, ML; Schiff, LA			Cathepsin S supports acid-independent infection by some reoviruses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							MHC CLASS-II; INTESTINAL M-CELLS; MOUSE L-CELLS; CREUTZFELDT-JAKOB-DISEASE; CAPSID PROTEIN SIGMA-3; CENTRAL-NERVOUS-SYSTEM; CYSTEINE PROTEASES; MAMMALIAN REOVIRUSES; INVARIANT CHAIN; IN-VITRO	In murine fibroblasts, efficient proteolysis of reovirus outer capsid protein sigma3 during cell entry by virions requires the acid-dependent lysosomal cysteine protease cathepsin L. The importance of cathepsin L for infection of other cell types is unknown. Here we report that the acid-independent lysosomal cysteine protease cathepsin S mediates outer capsid processing in macrophage-like P388D cells. P388D cells supported infection by virions of strain Lang, but not strain c43. Genetic studies revealed that this difference is determined by S4, the viral gene segment that encodes sigma3. c43-derived subvirion particles that lack sigma3 replicated normally in P388D cells, suggesting that the difference in infectivity of Lang and c43 virions is at the level of sigma3 processing. Infection of P388D cells with Lang virions was inhibited by the broad spectrum cysteine protease inhibitor trans-epoxysuccinyl-L-leucylamido-(4-guanidino) butane but not by NH4Cl, which raises the endocytic pH and thereby inhibits acid-dependent proteases such as cathepsins L and B. Outer capsid processing and infection of P388D cells with Lang virions were also inhibited by a cathepsin S-specific inhibitor. Furthermore, in the presence of NH4Cl, cell lines engineered to express cathepsin S supported infection by Lang, but not c43, virions. Our results thus indicate that differences in susceptibility to cathepsin S-mediated sigma3 processing are responsible for strain differences in reovirus infection of macrophage-like P388D cells and other cathepsin S-expressing cells. Additionally, our data suggest that the acid dependence of reovirus infections of most other cell types may reflect the low pH requirement for the activities of most other lysosomal proteases rather, than some other acid-dependent aspect of cell entry.	Univ Minnesota, Dept Microbiol, Mayo Mail Code 196,420 Delaware St SE, Minneapolis, MN 55455 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	University of Minnesota System; University of Minnesota Twin Cities; Harvard University; Harvard Medical School	Schiff, LA (corresponding author), Univ Minnesota, Dept Microbiol, Mayo Mail Code 196,420 Delaware St SE, Minneapolis, MN 55455 USA.	schiff@lenti.med.umn.edu		Golden, Joseph/0000-0002-9709-313X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045990, R01AI046440] Funding Source: NIH RePORTER; NIAID NIH HHS [2T32 AI-0742, AI-45990, AI-46440] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMERONGEN HM, 1994, J VIROL, V68, P8428, DOI 10.1128/JVI.68.12.8428-8432.1994; Baer GS, 1999, J VIROL, V73, P9532, DOI 10.1128/JVI.73.11.9532-9543.1999; Baer GS, 1997, J VIROL, V71, P4921, DOI 10.1128/JVI.71.7.4921-4928.1997; Baker CA, 1999, J VIROL, V73, P5089, DOI 10.1128/JVI.73.6.5089-5097.1999; Baker CA, 2002, J VIROL, V76, P10905, DOI 10.1128/JVI.76.21.10905-10913.2002; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; Barton ES, 2001, CELL, V104, P441, DOI 10.1016/S0092-8674(01)00231-8; BASS DM, 1988, LAB INVEST, V58, P226; BASS DM, 1990, J VIROL, V64, P1830, DOI 10.1128/JVI.64.4.1830-1833.1990; BEATTIE E, 1995, J VIROL, V69, P499, DOI 10.1128/JVI.69.1.499-505.1995; Beers C, 2003, J EXP MED, V197, P169, DOI 10.1084/jem.20020978; BODKIN DK, 1989, J VIROL, V63, P4676, DOI 10.1128/JVI.63.11.4676-4681.1989; BODKIN DK, 1989, J VIROL, V63, P1188, DOI 10.1128/JVI.63.3.1188-1193.1989; BORSA J, 1973, J VIROL, V11, P1017, DOI 10.1128/JVI.11.6.1017-1019.1973; BORSA J, 1979, J GEN VIROL, V45, P161, DOI 10.1099/0022-1317-45-1-161; BORSA J, 1973, J VIROL, V11, P552, DOI 10.1128/JVI.11.4.552-564.1973; BORSA J, 1981, VIROLOGY, V111, P191, DOI 10.1016/0042-6822(81)90664-4; Broering TJ, 2000, J VIROL, V74, P5516, DOI 10.1128/JVI.74.12.5516-5524.2000; Buhling F, 2000, ADV EXP MED BIOL, V477, P241; CANNING WM, 1983, SCIENCE, V219, P987, DOI 10.1126/science.6297010; Chandran K, 1998, J VIROL, V72, P467, DOI 10.1128/JVI.72.1.467-475.1998; Chandran K, 1999, J VIROL, V73, P3941, DOI 10.1128/JVI.73.5.3941-3950.1999; CHANG CT, 1971, VIROLOGY, V46, P544, DOI 10.1016/0042-6822(71)90058-4; Chapman HA, 1997, ANNU REV PHYSIOL, V59, P63, DOI 10.1146/annurev.physiol.59.1.63; Chappell JD, 1997, J VIROL, V71, P1834, DOI 10.1128/JVI.71.3.1834-1841.1997; Chappell JD, 2000, J VIROL, V74, P8472, DOI 10.1128/JVI.74.18.8472-8479.2000; Coombs KM, 1998, VIROLOGY, V243, P218, DOI 10.1006/viro.1998.9061; DANIS C, 1992, VIROLOGY, V190, P494, DOI 10.1016/0042-6822(92)91241-L; Denisova E, 1999, J VIROL, V73, P3147, DOI 10.1128/JVI.73.4.3147-3153.1999; DERMODY TS, 1990, J VIROL, V64, P5173, DOI 10.1128/JVI.64.10.5173-5176.1990; DRYDEN KA, 1993, J CELL BIOL, V122, P1023, DOI 10.1083/jcb.122.5.1023; Ebert DH, 2002, J BIOL CHEM, V277, P24609, DOI 10.1074/jbc.M201107200; Ebert DH, 2001, J VIROL, V75, P3197, DOI 10.1128/JVI.75.7.3197-3206.2001; ESTES MK, 1981, J VIROL, V39, P879, DOI 10.1128/JVI.39.3.879-888.1981; Fiebiger E, 2001, J EXP MED, V193, P881, DOI 10.1084/jem.193.8.881; FURLONG DB, 1988, J VIROL, V62, P246, DOI 10.1128/JVI.62.1.246-256.1988; Golden JW, 2002, J VIROL, V76, P7430, DOI 10.1128/JVI.76.15.7430-7443.2002; HAZELTON PR, 1995, VIROLOGY, V207, P46, DOI 10.1006/viro.1995.1050; Hooper JW, 1996, J VIROL, V70, P672, DOI 10.1128/JVI.70.1.672-677.1996; Hooper JW, 1996, J VIROL, V70, P459, DOI 10.1128/JVI.70.1.459-467.1996; Hsieh CS, 2002, J IMMUNOL, V168, P2618, DOI 10.4049/jimmunol.168.6.2618; IMANI F, 1988, P NATL ACAD SCI USA, V85, P7887, DOI 10.1073/pnas.85.21.7887; Jane-Valbuena J, 2002, J VIROL, V76, P5184, DOI 10.1128/JVI.76.10.5184-5197.2002; Jane-Valbuena J, 1999, J VIROL, V73, P2963; JOKLIK WK, 1972, VIROLOGY, V49, P700, DOI 10.1016/0042-6822(72)90527-2; Kang JX, 1998, P NATL ACAD SCI USA, V95, P13687, DOI 10.1073/pnas.95.23.13687; KAUFFMAN RS, 1983, VIROLOGY, V124, P403, DOI 10.1016/0042-6822(83)90356-2; KEDL R, 1995, J VIROL, V69, P552, DOI 10.1128/JVI.69.1.552-559.1995; Kido H, 1999, MOL CELLS, V9, P235; Kido H, 1996, ADV EXP MED BIOL, V389, P233; KIRSCHKE H, 1989, BIOCHEM J, V264, P467, DOI 10.1042/bj2640467; Kirschke H, 1998, LYSOSOMAL CYSTEINE P; Kothandaraman S, 1998, VIROLOGY, V251, P264, DOI 10.1006/viro.1998.9434; Kreusch S, 2000, EUR J BIOCHEM, V267, P2965; Lazure C, 2002, CURR PHARM DESIGN, V8, P511, DOI 10.2174/1381612023395691; LEE PWK, 1981, VIROLOGY, V108, P156, DOI 10.1016/0042-6822(81)90535-3; LEMERE CA, 1995, AM J PATHOL, V146, P848; Liuzzo JP, 1999, MOL MED, V5, P320, DOI 10.1007/BF03402068; LUCIAJANDRIS P, 1993, J VIROL, V67, P5339, DOI 10.1128/JVI.67.9.5339-5345.1993; Martinez CG, 1996, J VIROL, V70, P576; McGrath ME, 1999, ANNU REV BIOPH BIOM, V28, P181, DOI 10.1146/annurev.biophys.28.1.181; Montaser M, 2002, BIOL CHEM, V383, P1305, DOI 10.1515/BC.2002.147; MORGAN EM, 1974, VIROLOGY, V59, P556, DOI 10.1016/0042-6822(74)90465-6; Morin MJ, 1996, J VIROL, V70, P541, DOI 10.1128/JVI.70.1.541-548.1996; MORRISON LA, 1991, P NATL ACAD SCI USA, V88, P3852, DOI 10.1073/pnas.88.9.3852; MORTON PA, 1995, J IMMUNOL, V154, P137; MUNGER JS, 1995, BIOCHEM J, V311, P299, DOI 10.1042/bj3110299; MURATA M, 1991, FEBS LETT, V280, P307, DOI 10.1016/0014-5793(91)80318-W; NIBERT ML, 1991, J CLIN INVEST, V88, P727, DOI 10.1172/JCI115369; NIBERT ML, 1991, J VIROL, V65, P1960, DOI 10.1128/JVI.65.4.1960-1967.1991; Nibert ML, 1998, CURR TOP MICROBIOL, V233, P1; NIBERT ML, 1992, J VIROL, V66, P6408, DOI 10.1128/JVI.66.11.6408-6418.1992; Nibert ML., 2001, FIELDS VIROLOGY, P1679; Olland AM, 2001, EMBO J, V20, P979, DOI 10.1093/emboj/20.5.979; PALMER JT, 1995, J MED CHEM, V38, P3193, DOI 10.1021/jm00017a002; Petanceska S, 1996, J BIOL CHEM, V271, P4403; Pierre P, 1998, CELL, V93, P1135, DOI 10.1016/S0092-8674(00)81458-0; PORTNOY DA, 1986, J BIOL CHEM, V261, P4697; RAMIG RF, 1977, SCIENCE, V195, P406, DOI 10.1126/science.831284; REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849; Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074-7613(00)80249-6; ROSEN L, 1960, AM J HYG, V71, P242, DOI 10.1093/oxfordjournals.aje.a120107; ROSEN L, 1960, AM J HYG, V71, P258, DOI 10.1093/oxfordjournals.aje.a120109; RUBIN DH, 1985, J VIROL, V53, P391, DOI 10.1128/JVI.53.2.391-398.1985; SHARPE AH, 1978, VIROLOGY, V84, P63, DOI 10.1016/0042-6822(78)90218-0; SHATKIN AJ, 1972, J VIROL, V10, P698, DOI 10.1128/JVI.10.4.698-706.1972; SHEPARD DA, 1995, J VIROL, V69, P8180, DOI 10.1128/JVI.69.12.8180-8184.1995; SHERRY B, 1989, J VIROL, V63, P4850, DOI 10.1128/JVI.63.11.4850-4856.1989; SHERRY B, 1989, J VIROL, V63, P4840, DOI 10.1128/JVI.63.11.4840-4849.1989; SHI GP, 1992, J BIOL CHEM, V267, P7258; Shi GP, 2003, CIRC RES, V92, P493, DOI 10.1161/01.RES.0000060485.20318.96; SHI GP, 1994, J BIOL CHEM, V269, P11530; Shing M, 1996, VIRUS RES, V46, P19, DOI 10.1016/S0168-1702(96)01372-X; SILVERSTEIN SC, 1972, VIROLOGY, V47, P797, DOI 10.1016/0042-6822(72)90571-5; STURZENBECKER LJ, 1987, J VIROL, V61, P2351, DOI 10.1128/JVI.61.8.2351-2361.1987; TOSTESON MT, 1993, P NATL ACAD SCI USA, V90, P10549, DOI 10.1073/pnas.90.22.10549; TOWATARI T, 1991, FEBS LETT, V280, P311, DOI 10.1016/0014-5793(91)80319-X; Tyler K.L., 2001, FIELDS VIROLOGY, P1729; TYLER KL, 1985, NEUROLOGY, V35, P88, DOI 10.1212/WNL.35.1.88; Villadangos JA, 1997, J EXP MED, V186, P549, DOI 10.1084/jem.186.4.549; VIRGIN HW, 1988, J VIROL, V62, P4594, DOI 10.1128/JVI.62.12.4594-4604.1988; WEINER HL, 1980, J INFECT DIS, V141, P609, DOI 10.1093/infdis/141.5.609; Wetzel JD, 1997, J VIROL, V71, P1362, DOI 10.1128/JVI.71.2.1362-1369.1997; WIENER JR, 1989, VIROLOGY, V169, P293, DOI 10.1016/0042-6822(89)90154-2; WIENER JR, 1989, VIROLOGY, V169, P194, DOI 10.1016/0042-6822(89)90055-X; WILSON GAR, 1994, J VIROL, V68, P6458, DOI 10.1128/JVI.68.10.6458-6465.1994; Wilson GJ, 2002, J VIROL, V76, P9832, DOI 10.1128/JVI.76.19.9832-9843.2002; WOLF JL, 1983, GASTROENTEROLOGY, V85, P291; WOLF JL, 1981, SCIENCE, V212, P471, DOI 10.1126/science.6259737; YOUNG JAT, 2001, FIELDS VIROLOGY, P87; Yue ZY, 1997, VIROLOGY, V234, P364, DOI 10.1006/viro.1997.8664; ZAR JH, 1984, BIOSTAT ANAL, P138	112	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8547	8557		10.1074/jbc.M309758200	http://dx.doi.org/10.1074/jbc.M309758200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14670972	hybrid, Green Published			2022-12-25	WOS:000189265900005
J	Roberts, JA; Evans, RJ				Roberts, JA; Evans, RJ			ATP binding at human P2X(1) receptors - Contribution of aromatic and basic amino acids revealed using mutagenesis and partial agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION-PI INTERACTIONS; SENSORY NEURONS; URINARY-BLADDER; HUMAN PLATELETS; ION CHANNELS; PURINOCEPTOR; ACTIVATION; RESIDUES; RAT; RECOGNITION	P2X receptors comprise a family of ATP-gated ion channels with the basic amino acids Lys-68, Arg-292, and Lys-309 (P2X(1) receptor numbering) contributing to agonist potency. In many ATP-binding proteins aromatic amino acids coordinate the binding of the adenine group. There are 20 conserved aromatic amino acids in the extracellular ligand binding loop of at least 6 of the 7 P2X receptors. We used alanine replacement mutagenesis to determine the effects of individual conserved aromatic residues on the properties of human P2X(1) receptors expressed in Xenopus oocytes. ATP evoked concentration-dependent (EC50 similar to1 muM) desensitizing currents at wild-type receptors and for the majority of mutants there was no change (10 residues) or a < 6-fold decrease in ATP potency (6 mutants). Mutants F195A and W259A failed to form detectable channels at the cell surface. F185A and F291A produced 10- and 160-fold decreases in ATP potency. The partial agonists 2', 3'-O-(4-benzoyl)- ATP (BzATP) and P-1, P-5-di(adenosine 5')-pentaphosphate (Ap(5)A) were tested on a range of mutants that decreased ATP potency to determine whether this resulted predominantly from changes in agonist binding or gating of the channel. At K68A and K309A receptors BzATP and Ap5A had essentially no agonist activity but antagonized, or for R292A potentiated, ATP responses. At F185A receptors BzATP was an antagonist but Ap5A no longer showed affinity for the receptor. These results suggest that residues Lys-68, Phe-185, Phe-291, Arg-292, and Lys-309 contribute to ligand binding at P2X(1) receptors, with Phe- 185 and Phe- 291 coordinating the binding of the adenine ring of ATP.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	University of Leicester	Evans, RJ (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, Univ Rd, Leicester LE1 9HN, Leics, England.	rje6@le.ac.uk	Roberts, Jon/A-6771-2012					ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Armstrong N, 2003, P NATL ACAD SCI USA, V100, P5736, DOI 10.1073/pnas.1037393100; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; BEAN BP, 1990, J NEUROSCI, V10, P1; Beene DL, 2002, BIOCHEMISTRY-US, V41, P10262, DOI 10.1021/bi020266d; BO XN, 1995, FEBS LETT, V375, P129, DOI 10.1016/0014-5793(95)01203-Q; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; Cockayne DA, 2000, NATURE, V407, P1011, DOI 10.1038/35039519; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Ennion S, 2000, J BIOL CHEM, V275, P29361, DOI 10.1074/jbc.M003637200; Ennion SJ, 2002, MOL PHARMACOL, V61, P303, DOI 10.1124/mol.61.2.303; Ennion SJ, 2001, BIOCHEM BIOPH RES CO, V289, P700, DOI 10.1006/bbrc.2001.6034; EVANS RJ, 1995, MOL PHARMACOL, V48, P178; EVANS RJ, 1992, NATURE, V357, P503, DOI 10.1038/357503a0; Hechler B, 2003, J EXP MED, V198, P661, DOI 10.1084/jem.20030144; Jiang LH, 2000, J BIOL CHEM, V275, P34190, DOI 10.1074/jbc.M005481200; Jin RS, 2003, NAT NEUROSCI, V6, P803, DOI 10.1038/nn1091; Knofel T, 2001, J MOL BIOL, V309, P239, DOI 10.1006/jmbi.2001.4656; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; Lewis CJ, 2000, BRIT J PHARMACOL, V129, P124, DOI 10.1038/sj.bjp.0702993; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; Mahaut-Smith MP, 2000, BRIT J PHARMACOL, V131, P108, DOI 10.1038/sj.bjp.0703517; Michel AD, 1996, BRIT J PHARMACOL, V117, P1254, DOI 10.1111/j.1476-5381.1996.tb16723.x; Mulryan K, 2000, NATURE, V403, P86, DOI 10.1038/47495; Nakazawa K, 2002, NEUROSCI LETT, V324, P141, DOI 10.1016/S0304-3940(02)00234-3; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Rettinger J, 2003, J GEN PHYSIOL, V121, P451, DOI 10.1085/jgp.200208730; SURPRENANT A, 1995, TRENDS NEUROSCI, V18, P224, DOI 10.1016/0166-2236(95)93907-F; Tanner NK, 2003, MOL CELL, V11, P127, DOI 10.1016/S1097-2765(03)00006-6; Theis K, 1999, EMBO J, V18, P6899, DOI 10.1093/emboj/18.24.6899; Vial C, 2000, BRIT J PHARMACOL, V131, P1489, DOI 10.1038/sj.bjp.0703720; Vial C, 2002, BRIT J PHARMACOL, V135, P363, DOI 10.1038/sj.bjp.0704486	34	86	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9043	9055		10.1074/jbc.M308964200	http://dx.doi.org/10.1074/jbc.M308964200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14699168	hybrid			2022-12-25	WOS:000189265900065
J	Verges, M; Bensadoun, A; Herz, J; Belcher, JD; Havel, RJ				Verges, M; Bensadoun, A; Herz, J; Belcher, JD; Havel, RJ			Endocytosis of hepatic lipase and lipoprotein lipase into rat liver Hepatocytes in vivo is mediated by the low density lipoprotein receptor-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; 3 ENDOSOMAL FRACTIONS; CHYLOMICRON REMNANTS; BINDING-PROTEIN; ALPHA-2-MACROGLOBULIN RECEPTOR; APOLIPOPROTEIN-B; HIGH-AFFINITY; CELLS; CATABOLISM; DEGRADATION	In isolated cell studies, the internalization and degradation of hepatic lipase (HL) has been linked to its binding to the low density lipoprotein receptor-related protein (LRP). We have utilized the receptor-associated protein ( RAP), a universal inhibitor of high affinity ligand binding to LRP, to evaluate the participation of LRP in the endocytosis of HL and lipoprotein lipase (LPL). We isolated a total endosome fraction from rat livers after a 30-min infusion of recombinant RAP, administered as a glutathione S-transferase conjugate (GST-RAP). GST-RAP infusion had no effect on the concentration of HL in liver homogenates, but its concentration in blood plasma increased progressively by 20%, and enrichment over homogenate of HL in endosomes was reduced by 50% as compared with infusion of GST alone. The concentrations of LPL in liver and plasma were 1.4 and 0.5%, respectively, those of HL, but endosomal enrichment of the two enzymes was similar (similar to10-fold). GST-RAP infusion had no effect on the concentration of LPL in liver but increased its concentration in blood plasma by 250% and reduced its endosomal enrichment by 95% or greater. GST-RAP infusion also reduced endosomal enrichment of LRP by 40%, but enrichment of several other endocytic receptors was unaffected. Endosomal enrichment of several membrane trafficking proteins associated with the endocytic pathway in hepatocytes was unaffected by GST-RAP with the exception of early endosome endosome antigen 1, which was reduced by 85%. We conclude that HL is partially and LPL almost exclusively taken up into rat hepatocytes after binding to the endocytic receptor LRP.	Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; Cornell Univ, Dept Anat & Biochem & Biophys, Ithaca, NY 14853 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA	University of California System; University of California San Francisco; Cornell University; Cornell University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Havel, RJ (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA.	havelr@itsa.ucsf.edu	Verges, Marcel/L-5784-2014	Verges, Marcel/0000-0002-2606-223X	NHLBI NIH HHS [R37 HL063762, HL20948, HL63762, HL14850] Funding Source: Medline; NIAID NIH HHS [AI36953, AI125144] Funding Source: Medline; NINDS NIH HHS [NS43408] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063762, R37HL063762, P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043408] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; BELCHER JD, 1987, P NATL ACAD SCI USA, V84, P6785, DOI 10.1073/pnas.84.19.6785; BELCHER JD, 1985, BIOCHEM J, V229, P343, DOI 10.1042/bj2290343; BELCHER JD, 1988, CIRCULATION, V28, P145; Bergeron N, 1998, P NATL ACAD SCI USA, V95, P15647, DOI 10.1073/pnas.95.26.15647; BRASAEMLE DL, 1993, J LIPID RES, V34, P455; Breedveld B, 1997, BIOCHEM J, V321, P425, DOI 10.1042/bj3210425; Breedveld B, 1998, BIOCHEM J, V330, P785, DOI 10.1042/bj3300785; BUCOLO G, 1973, CLIN CHEM, V19, P476; Callaghan J, 1999, BIOCHEM J, V338, P539, DOI 10.1042/0264-6021:3380539; Cavalli V, 2001, MOL CELL, V7, P421, DOI 10.1016/S1097-2765(01)00189-7; Chappell DA, 1998, PROG LIPID RES, V37, P393, DOI 10.1016/S0163-7827(98)00017-4; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHENG CF, 1981, J BIOL CHEM, V256, P2893; CISAR LA, 1985, J LIPID RES, V26, P380; CISAR LA, 1989, J BIOL CHEM, V264, P1767; DEMANT T, 1988, J LIPID RES, V29, P1603; Enrich C, 1996, HEPATOLOGY, V24, P226, DOI 10.1002/hep.510240136; FURUKAWA T, 1990, J BIOCHEM-TOKYO, V108, P297, DOI 10.1093/oxfordjournals.jbchem.a123197; Gardai SJ, 2003, CELL, V115, P13, DOI 10.1016/S0092-8674(03)00758-X; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HAMILTON RL, 1965, DISSERT ABSTR, V26, P1; HARFORD J, 1982, J BIOL CHEM, V257, P2685; HAVEL RJ, 1988, HEPATOLOGY, V8, P1689, DOI 10.1002/hep.1840080637; Havel RJ, 1998, ATHEROSCLEROSIS, V141, pS1; HERZ J, 1995, P NATL ACAD SCI USA, V92, P4611, DOI 10.1073/pnas.92.10.4611; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HORNICK CA, 1985, J CELL BIOL, V100, P1558, DOI 10.1083/jcb.100.5.1558; JACKLE S, 1991, J LIPID RES, V32, P485; JACKLE S, 1991, J BIOL CHEM, V266, P1396; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JACKSON RL, 1983, ENZYMES, V16, P141; JANSEN H, 1978, BIOCHEM BIOPH RES CO, V85, P148, DOI 10.1016/S0006-291X(78)80022-9; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; Krapp A, 1996, J LIPID RES, V37, P926; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Lawe DC, 2002, J BIOL CHEM, V277, P8611, DOI 10.1074/jbc.M109239200; LUND H, 1989, P NATL ACAD SCI USA, V86, P9318, DOI 10.1073/pnas.86.23.9318; MARTEAU C, 1988, LIFE SCI, V42, P533, DOI 10.1016/0024-3205(88)90094-X; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; Melman L, 2001, J BIOL CHEM, V276, P29338, DOI 10.1074/jbc.M103717200; MOKUNO H, 1994, J BIOL CHEM, V269, P13238; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; ORLANDO RA, 1994, P NATL ACAD SCI USA, V91, P3161, DOI 10.1073/pnas.91.8.3161; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PETERSON J, 1985, BIOCHIM BIOPHYS ACTA, V837, P262, DOI 10.1016/0005-2760(85)90049-9; Qiu SQ, 1998, J LIPID RES, V39, P1661; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; Sanan DA, 1997, J LIPID RES, V38, P1002; SCHOONDERWOERD K, 1994, BIOCHEM J, V302, P717, DOI 10.1042/bj3020717; SHAFI S, 1994, J LIPID RES, V35, P709; van Vlijmen BJM, 1999, J BIOL CHEM, V274, P35219, DOI 10.1074/jbc.274.49.35219; VANDRIEL IR, 1987, J BIOL CHEM, V262, P17443; VASSILIOU G, 1994, J BIOL CHEM, V269, P15172; Verges M, 1999, P NATL ACAD SCI USA, V96, P10146, DOI 10.1073/pnas.96.18.10146; VILARO S, 1988, BIOCHIM BIOPHYS ACTA, V959, P106, DOI 10.1016/0005-2760(88)90021-5; WALLINDER L, 1984, BIOCHIM BIOPHYS ACTA, V795, P513, DOI 10.1016/0005-2760(84)90181-4	60	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9030	9036		10.1074/jbc.M312908200	http://dx.doi.org/10.1074/jbc.M312908200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14701798	hybrid			2022-12-25	WOS:000189265900063
J	Grimminger, V; Richter, K; Imhof, A; Buchner, J; Walter, S				Grimminger, V; Richter, K; Imhof, A; Buchner, J; Walter, S			The prion curing agent guanidinium chloride specifically inhibits ATP hydrolysis by Hsp104	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; YEAST PRIONS; PROTEIN HSP104; PSI+ PRION; PROPAGATION; CHAPERONE; HYDROCHLORIDE; INHERITANCE; PSI(+); URE3	The molecular chaperone Hsp104 from Saccharomyces cerevisiae dissolves protein aggregates in the cell and is thus of crucial importance for the thermotolerance of yeast. In addition to this disaggregase activity, Hsp104 has a key function in yeast prion propagation, as Hsp104 was found to be essential for the maintenance of the associated phenotypes. In vivo data suggest that Hsp104 function is affected by guanidinium chloride. Adding small amounts of this compound to yeast medium causes curing of the prions: cells lose their prion-related phenotype. Guanidinium chloride was also found to impair heat shock resistance. Here, we present a detailed in vitro analysis showing that guanidinium chloride is an uncompetitive inhibitor of Hsp104. Micromolar concentrations of this agent reduce the ATPase activity of Hsp104 to similar to35% of its normal activity. This inhibition is not related to the denaturing properties of this compound, because Hsp104 was not affected by urea. Guanidinium ions selectively bind to the nucleotide-bound, hexameric state of the molecular chaperone. Thus, they increase the affinity of Hsp104 for adenine nucleotides and promote the nucleotide-dependent oligomerization of the chaperone. Our findings strongly suggest that guanidinium chloride causes curing of yeast prions by perturbing the ATPase of Hsp104, which is essential for both prion propagation and thermotolerance.	Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany; Univ Munich, Adolf Butenandt Inst, D-80336 Munich, Germany	Technical University of Munich; University of Munich	Walter, S (corresponding author), Tech Univ Munich, Inst Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.	stefan.walter@ch.tum.de	Richter, Klaus/A-2673-2010; Imhof, Axel/AAU-5313-2021; Buchner, Johannes/A-2651-2010	Richter, Klaus/0000-0002-8952-9642; Imhof, Axel/0000-0003-2993-8249; Buchner, Johannes/0000-0003-1282-7737				CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; COX BS, 1988, YEAST, V4, P159, DOI 10.1002/yea.320040302; Derkatch IL, 1997, GENETICS, V147, P507; Eaglestone SS, 2000, P NATL ACAD SCI USA, V97, P240, DOI 10.1073/pnas.97.1.240; Ferreira PC, 2001, MOL MICROBIOL, V40, P1357, DOI 10.1046/j.1365-2958.2001.02478.x; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Hattendorf DA, 2002, EMBO J, V21, P12, DOI 10.1093/emboj/21.1.12; Jung GM, 2002, P NATL ACAD SCI USA, V99, P9936, DOI 10.1073/pnas.152333299; Jung GM, 2001, CURR MICROBIOL, V43, P7, DOI 10.1007/s002840010251; Kushnirov VV, 2000, CURR BIOL, V10, P1443, DOI 10.1016/S0960-9822(00)00802-2; Moriyama H, 2000, MOL CELL BIOL, V20, P8916, DOI 10.1128/MCB.20.23.8916-8922.2000; Narayanan S, 2003, P NATL ACAD SCI USA, V100, P9286, DOI 10.1073/pnas.1233535100; Ness F, 2002, MOL CELL BIOL, V22, P5593, DOI 10.1128/MCB.22.15.5593-5605.2002; Neuwald AF, 1999, GENOME RES, V9, P27; NORBY JG, 1988, METHOD ENZYMOL, V156, P116; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; Santoso A, 2000, CELL, V100, P277, DOI 10.1016/S0092-8674(00)81565-2; Schirmer EC, 1998, METHOD ENZYMOL, V290, P430, DOI 10.1016/S0076-6879(98)90036-2; Schirmer EC, 2001, P NATL ACAD SCI USA, V98, P914, DOI 10.1073/pnas.031568098; Schirmer EC, 1998, J BIOL CHEM, V273, P15546, DOI 10.1074/jbc.273.25.15546; Segel I.H., 1993, ENZYME KINETICS, P136; Sondheimer N, 2000, MOL CELL, V5, P163, DOI 10.1016/S1097-2765(00)80412-8; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; Tuite MF, 1996, TRENDS GENET, V12, P467, DOI 10.1016/0168-9525(96)10045-7; TUITE MF, 1981, GENETICS, V98, P691; Wegrzyn RD, 2001, MOL CELL BIOL, V21, P4656, DOI 10.1128/MCB.21.14.4656-4669.2001; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wickner RB, 1995, YEAST, V11, P1671, DOI 10.1002/yea.320111609	33	109	112	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7378	7383		10.1074/jbc.M312403200	http://dx.doi.org/10.1074/jbc.M312403200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14668331	hybrid			2022-12-25	WOS:000189103300003
J	Falciatori, I; Borsellino, G; Haliassos, N; Boitani, C; Corallini, S; Battistini, L; Bernardi, G; Stefanini, M; Vicini, E				Falciatori, I; Borsellino, G; Haliassos, N; Boitani, C; Corallini, S; Battistini, L; Bernardi, G; Stefanini, M; Vicini, E			Identification and enrichment of spermatogonial stem cells displaying side-population phenotype in immature mouse testis	FASEB JOURNAL			English	Article						spermatogenesis; germ cell transplantation; seminiferous epithelium wave	GLYCOPROTEIN GENE LEADS; BONE-MARROW-CELLS; C-KIT; SELF-RENEWAL; GERM-CELLS; DYE EFFLUX; EXPRESSION; SPERMATOGENESIS; TRANSPLANTATION; COLONIZATION	In mammals, spermatogenesis is maintained by spermatogonial stem cells (SSC). In their niche, SSC divide to self-maintain and to produce a transit-amplifying population that eventually enters the meiotic cycle to give rise to spermatozoa. The low number of SSC and the lack of specific markers hinder their isolation and enrichment. Stem cells in several adult tissues can be identified by using their verapamil-sensitive Hoechst dye-effluxing properties, which define the characteristic "side population" (SP). Here we show, by multicolor flow cytometric analysis, that immature mouse testis contains a "side-population" (T-SP), which is Sca-l(pos), Ep-CAM(pos), EE2 (pos), alpha6-integrin (pos), and alphav-integrin(neg). A 13-fold enrichment in SSC activity was observed when sorted T-SP cells from ROSA 26 mice were transplanted in busulfan-treated mouse testis. Whereas an incomplete range of spermatogenic stages was encountered two months after transplantation of unsorted testicular cells, the transplantation of T-SP cells generated all associations of mouse germ cells representing the full range of spermatogenic stages. These data suggest that Hoechst staining and cell sorting might provide a novel approach to SSC enrichment in mammals.	Univ Roma La Sapienza, Dept Histol & Med Embryol, I-00161 Rome, Italy; Santa Lucia Fdn Sci Inst IRCCS, Neuroimmunol & Flor Cytometry Unit, Rome, Italy; Univ Roma Tor Vergata, Dept Neurosci, Rome, Italy	Sapienza University Rome; IRCCS Santa Lucia; University of Rome Tor Vergata	Vicini, E (corresponding author), Univ Roma La Sapienza, Dept Histol & Med Embryol, Via Antonio Scarpa 14, I-00161 Rome, Italy.	elena.vicini@uniroma1.it	Battistini, luca/ABE-1882-2021; Borsellino, Giovanna/K-3074-2016; Haliasos, Nikolaos/G-6352-2010; Battistini, Luca/D-6920-2014	Borsellino, Giovanna/0000-0002-4227-6481; Battistini, Luca/0000-0002-6488-4891; Vicini, Elena/0000-0003-0399-0145; Haliasos, Nikolaos/0000-0003-3204-1483				Anderson R, 1999, J REPROD FERTIL, V116, P379, DOI 10.1530/jrf.0.1160379; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11298, DOI 10.1073/pnas.91.24.11298; Bunting KD, 2000, BLOOD, V96, P902, DOI 10.1182/blood.V96.3.902.015k40_902_909; Bunting KD, 1998, BLOOD, V92, P2269, DOI 10.1182/blood.V92.7.2269.2269_2269_2279; De Rooij DG, 2000, J ANDROL, V21, P776; Dobrinski I, 1999, MOL REPROD DEV, V53, P142, DOI 10.1002/(SICI)1098-2795(199906)53:2&lt;142::AID-MRD3&gt;3.0.CO;2-O; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Kanatsu-Shinohara M, 2003, BIOL REPROD, V68, P1801, DOI 10.1095/biolreprod.102.012575; KLEIN J, 1986, NATURAL HIST MAJOR H, P152; KOSHIMIZU U, 1995, MOL REPROD DEV, V40, P221, DOI 10.1002/mrd.1080400211; Kubota H, 2003, P NATL ACAD SCI USA, V100, P6487, DOI 10.1073/pnas.0631767100; McLean DJ, 2002, BIOL REPROD, V66, P1374, DOI 10.1095/biolreprod66.5.1374; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; Morena AR, 1996, J ANDROL, V17, P708; Nagano M, 1999, BIOL REPROD, V60, P1429, DOI 10.1095/biolreprod60.6.1429; OAKBERG EF, 1956, AM J ANAT, V99, P507, DOI 10.1002/aja.1000990307; Ogawa T, 2003, BIOL REPROD, V68, P316, DOI 10.1095/biolreprod.102.004549; Ogawa T, 1997, INT J DEV BIOL, V41, P111; Ohta H, 2000, DEVELOPMENT, V127, P2125; Ohta H, 2000, DEV GROWTH DIFFER, V42, P105; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Russell L. D., 1990, HISTOLOGICAL HISTOPA; Schinkel AH, 1997, P NATL ACAD SCI USA, V94, P4028, DOI 10.1073/pnas.94.8.4028; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; Schrans-Stassen BHGJ, 1999, ENDOCRINOLOGY, V140, P5894, DOI 10.1210/en.140.12.5894; Shinohara T, 2000, DEV BIOL, V220, P401, DOI 10.1006/dbio.2000.9655; Shinohara T, 2001, P NATL ACAD SCI USA, V98, P6186, DOI 10.1073/pnas.111158198; Shinohara T, 2000, P NATL ACAD SCI USA, V97, P8346, DOI 10.1073/pnas.97.15.8346; Shinohara T, 2000, INT J ANDROL, V23, P89, DOI 10.1046/j.1365-2605.2000.00025.x; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; SORRENTINO V, 1991, ONCOGENE, V6, P149; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; Storms RW, 2000, BLOOD, V96, P2125; TEGELENBOSCH RAJ, 1993, MUTAT RES, V290, P193; VANDERIJN M, 1989, P NATL ACAD SCI USA, V86, P4634; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Ventela S, 2002, BIOL REPROD, V66, P1422, DOI 10.1095/biolreprod66.5.1422; Welm BE, 2002, DEV BIOL, V245, P42, DOI 10.1006/dbio.2002.0625; YOSHINAGA K, 1991, DEVELOPMENT, V113, P689; Zhou CS, 2001, BMC BIOCHEM, V2, DOI 10.1186/1471-2091-2-7; Zhou S, 2002, P NATL ACAD SCI USA, V99, P12339, DOI 10.1073/pnas.192276999	46	87	96	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					376	+		10.1096/fj.03-0744fje	http://dx.doi.org/10.1096/fj.03-0744fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14688197				2022-12-25	WOS:000188067500003
J	Keren, Z; Diamant, E; Ostrovsky, O; Bengal, E; Melamed, D				Keren, Z; Diamant, E; Ostrovsky, O; Bengal, E; Melamed, D			Modification of ligand-independent B cell receptor tonic signals activates receptor editing in immature B lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN-RECEPTOR; CLONAL SELECTION; POSITIVE SELECTION; CD19; EXPRESSION; DEFICIENT; MICE; IMMUNOGLOBULIN; PROTEIN; KINASE	Maturation of B lymphocytes strictly depends on the signaling competence of the B cell antigen receptor (BCR). Autoreactive receptors undergo negative selection and can be replaced by receptor editing. In addition, the process of maturation of non-self B cells and migration to the spleen, referred to as positive selection, is limited by the signaling competence of the BCR. Using 3-83Tg mice deficient of CD19 we have shown that signaling incompetence not only blocks positive selection but also activates receptor editing. Here we study the role of ligand-independent BCR tonic tyrosine phosphorylation signals in activation of receptor editing. We find that editing, immature 3-83Tg B cells deficient of CD19 have elevated BCR tonic signals and that lowering these tonic signals effectively suppresses receptor editing. Furthermore, we show that elevation of BCR tonic signals in non-editing, immature 3-83Tg B cells stimulates significant receptor editing. We also show that positive selection and developmental progression from the bone marrow to the spleen are limited to cells capable of establishing appropriate tonic signals, as in contrast to immature cells, splenic 3-83Tg B cells deficient of CD19 have BCR tonic signals similar to those of the control 3-83Tg cells. This developmental progression is accompanied by activation of molecules signaling for growth and survival. Hence, we suggest that ligand-independent BCR tonic signals are required for promoting positive selection and suppressing the receptor-editing mechanism in immature B cells.	Technion Israel Inst Technol, Fac Med, Dept Immunol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Dept Biochem, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Melamed, D (corresponding author), Technion Israel Inst Technol, Fac Med, Dept Immunol, IL-31096 Haifa, Israel.	melamedd@tx.technion.ac.il						Bannish G, 2001, J EXP MED, V194, P1583, DOI 10.1084/jem.194.11.1583; BILLIPS LG, 1995, J EXP MED, V182, P973, DOI 10.1084/jem.182.4.973; Brauweiler AM, 2000, IMMUNOL REV, V176, P69; Buhl AM, 1997, J EXP MED, V186, P1897, DOI 10.1084/jem.186.11.1897; Buhl AM, 2000, IMMUNOL REV, V176, P141; Casellas R, 2001, SCIENCE, V291, P1541, DOI 10.1126/science.1056600; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; Fleming HE, 2001, IMMUNITY, V15, P521, DOI 10.1016/S1074-7613(01)00216-3; Fujimoto M, 1999, IMMUNITY, V11, P191, DOI 10.1016/S1074-7613(00)80094-1; Fujimoto M, 2000, IMMUNOL RES, V22, P281, DOI 10.1385/IR:22:2-3:281; Han A, 2003, IMMUNITY, V19, P621, DOI 10.1016/S1074-7613(03)00275-9; Healy JI, 1998, ANNU REV IMMUNOL, V16, P645, DOI 10.1146/annurev.immunol.16.1.645; Jumaa H, 1999, IMMUNITY, V11, P547, DOI 10.1016/S1074-7613(00)80130-2; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; Klinman NR, 1996, IMMUNITY, V5, P189, DOI 10.1016/S1074-7613(00)80314-3; Kouskoff V, 2000, P NATL ACAD SCI USA, V97, P7435, DOI 10.1073/pnas.130182597; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; Leider N, 2003, J IMMUNOL, V171, P2446, DOI 10.4049/jimmunol.171.5.2446; Li XL, 1998, J IMMUNOL, V161, P5901; Loder F, 1999, J EXP MED, V190, P75, DOI 10.1084/jem.190.1.75; Martin F, 2000, IMMUNITY, V12, P39, DOI 10.1016/S1074-7613(00)80157-0; Meade J, 2002, EUR J IMMUNOL, V32, P1029, DOI 10.1002/1521-4141(200204)32:4<1029::AID-IMMU1029>3.0.CO;2-M; Meffre E, 2000, NAT IMMUNOL, V1, P379, DOI 10.1038/80816; Melamed D, 1997, J IMMUNOL, V159, P1233; Melamed D, 1998, CELL, V92, P173, DOI 10.1016/S0092-8674(00)80912-5; MELAMED D, 1993, EUR J IMMUNOL, V23, P935, DOI 10.1002/eji.1830230426; Melchers F, 2000, IMMUNOL REV, V175, P33, DOI 10.1111/j.1600-065X.2000.imr017510.x; Monroe RJ, 1999, IMMUNITY, V11, P201, DOI 10.1016/S1074-7613(00)80095-3; Nemazee D, 2000, J EXP MED, V191, P1813, DOI 10.1084/jem.191.11.1813; Nemazee D, 2000, ANNU REV IMMUNOL, V18, P19, DOI 10.1146/annurev.immunol.18.1.19; Niiro H, 2002, J EXP MED, V195, P143, DOI 10.1084/jem.20011524; Niiro H, 2002, NAT REV IMMUNOL, V2, P945, DOI 10.1038/nri955; Okada T, 2002, J EXP MED, V196, P65, DOI 10.1084/jem.20020201; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Otero DC, 2003, J IMMUNOL, V170, P73, DOI 10.4049/jimmunol.170.1.73; Otero DC, 2001, J BIOL CHEM, V276, P1474, DOI 10.1074/jbc.M003918200; Penninger JM, 2001, NAT IMMUNOL, V2, P389, DOI 10.1038/87687; Phee H, 2001, MOL CELL BIOL, V21, P8615, DOI 10.1128/MCB.21.24.8615-8625.2001; Polic B, 2001, P NATL ACAD SCI USA, V98, P8744, DOI 10.1073/pnas.141218898; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Reichlin A, 2001, J EXP MED, V193, P13, DOI 10.1084/jem.193.1.13; Reth M, 2000, IMMUNOL REV, V176, P10; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; Sato S, 1997, P NATL ACAD SCI USA, V94, P13158, DOI 10.1073/pnas.94.24.13158; Shivtiel S, 2002, EUR J IMMUNOL, V32, P2264, DOI 10.1002/1521-4141(200208)32:8<2264::AID-IMMU2264>3.0.CO;2-E; Shivtiel S, 2002, J IMMUNOL, V168, P5596, DOI 10.4049/jimmunol.168.11.5596; Tedford K, 2001, NAT IMMUNOL, V2, P548, DOI 10.1038/88756; Wienands J, 1996, P NATL ACAD SCI USA, V93, P7865, DOI 10.1073/pnas.93.15.7865; Yamanashi Y, 2000, GENE DEV, V14, P11; Yu W, 1999, NATURE, V400, P682, DOI 10.1038/23287	50	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13418	13424		10.1074/jbc.M311970200	http://dx.doi.org/10.1074/jbc.M311970200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14668327	hybrid			2022-12-25	WOS:000220478500019
J	Toy-Miou-Leong, M; Cortes, CL; Beaudet, A; Rostene, W; Forgez, P				Toy-Miou-Leong, M; Cortes, CL; Beaudet, A; Rostene, W; Forgez, P			Receptor trafficking via the perinuclear recycling compartment accompanied by cell division is necessary for permanent neurotensin cell sensitization and leads to chronic mitogen-activated protein kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDUCED INTERNALIZATION; LUNG-CANCER CELLS; COUPLED RECEPTOR; INTRACELLULAR TRAFFICKING; TRANSDUCTION PATHWAYS; BINDING-PROPERTIES; SMALL-INTESTINE; MESSENGER-RNA; RAT; EXPRESSION	Most G protein-coupled receptors are internalized after interaction with their respective ligand, a process that subsequently contributes to cell desensitization, receptor endocytosis, trafficking, and finally cell resensitization. Although cellular mechanisms leading to cell desensitization have been widely studied, those responsible for cell resensitization are still poorly understood. We examined here the traffic of the high affinity neurotensin receptor (NT1 receptor) following prolonged exposure to high agonist concentration. Fluorescence and confocal microscopy of Chinese hamster ovary, human neuroblastoma (CHP 212), and murine neuroblastoma (N1E-115) cells expressing green fluorescent protein-tagged NT1 receptor revealed that under prolonged treatment with saturating concentrations of neurotensin (NT) agonist, NT1 receptor and NT transiently accumulated in the perinuclear recycling compartment ( PNRC). During this cellular event, cell surface receptors remained markedly depleted as detected by both confocal microscopy and I-125-NT binding assays. In dividing cells, we observed that following prolonged NT agonist stimulation, NT1 receptors were removed from the PNRC, accumulated in dispersed vesicles inside the cytoplasm, and subsequently reappeared at the cell surface. This NT binding recovery allowed for constant cell sensitization and led to a chronic activation of mitogen-activated protein kinases p42 and p44. Under these conditions, the constant activation of NT1 receptor generates an oncogenic regulation. These observations support the potent role for neuropeptides, such as NT, in cancer progression.	Hop St Antoine, INSERM, U482, F-75012 Paris, France; Coll France, INSERM, U36, F-75005 Paris, France; McGill Univ, Montreal Neurol Inst, Montreal, PQ H2A 2B4, Canada; Hop St Antoine, INSERM, EMI 0350, F-75012 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; McGill University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Forgez, P (corresponding author), Hop St Antoine, INSERM, U482, 184 Rue Faubourg, F-75012 Paris, France.	forgez@st-antoine.inserm.fr	Llorens-Cortes, Catherine/E-5839-2016; FORGEZ, Patricia/N-2960-2018; Rostene, William/F-2754-2017; Llorens-Cortès, catherine/AAL-3893-2021	Llorens-Cortes, Catherine/0000-0002-7667-0401; Llorens-Cortès, catherine/0000-0002-7667-0401; ROSTENE, WILLIAM/0000-0003-0409-5361				AMAR S, 1987, J NEUROCHEM, V49, P999, DOI 10.1111/j.1471-4159.1987.tb09986.x; Botto JM, 1998, BIOCHEM BIOPH RES CO, V243, P585, DOI 10.1006/bbrc.1997.8071; BOUDIN H, 1995, BIOCHEM J, V305, P277, DOI 10.1042/bj3050277; Bremnes T, 2000, J BIOL CHEM, V275, P17596, DOI 10.1074/jbc.M000142200; CARRAWAY R, 1976, J BIOL CHEM, V251, P7045; CHABRY J, 1995, J BIOL CHEM, V270, P2439, DOI 10.1074/jbc.270.6.2439; Chalon P, 1996, FEBS LETT, V386, P91, DOI 10.1016/0014-5793(96)00397-3; CUSACK B, 1991, EUR J PHARM-MOLEC PH, V206, P339, DOI 10.1016/0922-4106(91)90119-3; DOULUT S, 1992, PEPTIDE RES, V5, P30; Elek J, 2000, ANTICANCER RES, V20, P53; EVERS BM, 1992, ANN SURG, V216, P423, DOI 10.1097/00000658-199210000-00005; FAURE MP, 1995, J NEUROSCI, V15, P4140; FAURE MP, 1995, NEUROSCIENCE, V68, P519, DOI 10.1016/0306-4522(95)00145-9; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; FEURLE GE, 1981, DIGEST DIS SCI, V26, P1125, DOI 10.1007/BF01295980; Gullo L, 1998, GASTROEN CLIN BIOL, V22, P25; Heasley LE, 2001, ONCOGENE, V20, P1563, DOI 10.1038/sj.onc.1204183; HELMSTAEDTER V, 1977, HISTOCHEMISTRY, V53, P35, DOI 10.1007/BF00511208; Hermans E, 1997, NEUROCHEM INT, V31, P291, DOI 10.1016/S0197-0186(96)00155-6; Huang S, 2002, EXP CELL RES, V275, P255, DOI 10.1006/excr.2002.5504; Innamorati G, 2001, J BIOL CHEM, V276, P13096, DOI 10.1074/jbc.M009780200; JENNES L, 1982, J COMP NEUROL, V210, P211, DOI 10.1002/cne.902100302; Jones SM, 2000, ONCOGENE, V19, P5558, DOI 10.1038/sj.onc.1203858; Karbowski M, 2001, J CELL SCI, V114, P281; Keezer SM, 2002, EXP CELL RES, V273, P54, DOI 10.1006/excr.2001.5421; KEYOMARSI K, 1991, CANCER RES, V51, P3602; Lenkei Z, 2000, J HISTOCHEM CYTOCHEM, V48, P1553, DOI 10.1177/002215540004801112; Maoret JJ, 1999, INT J CANCER, V80, P448, DOI 10.1002/(SICI)1097-0215(19990129)80:3<448::AID-IJC19>3.0.CO;2-N; Martin S, 2002, J CELL SCI, V115, P165; Mazella J, 1998, J BIOL CHEM, V273, P26273, DOI 10.1074/jbc.273.41.26273; Moody TW, 2001, PEPTIDES, V22, P109, DOI 10.1016/S0196-9781(00)00362-4; Najimi M, 1998, J BIOL CHEM, V273, P21634, DOI 10.1074/jbc.273.34.21634; Navarro V, 2001, FEBS LETT, V495, P100, DOI 10.1016/S0014-5793(01)02367-5; Nouel D, 1997, J NEUROSCI, V17, P1795; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; PoinotChazel G, 1996, BIOCHEM J, V320, P145, DOI 10.1042/bj3200145; PRESLEY JF, 1993, J CELL BIOL, V122, P1231, DOI 10.1083/jcb.122.6.1231; Rao S, 1998, ONCOGENE, V17, P2393, DOI 10.1038/sj.onc.1202322; Reubi JC, 1998, GUT, V42, P546, DOI 10.1136/gut.42.4.546; Reubi JC, 1999, INT J CANCER, V82, P213, DOI 10.1002/(SICI)1097-0215(19990719)82:2<213::AID-IJC11>3.0.CO;2-8; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; SEHGAL I, 1994, P NATL ACAD SCI USA, V91, P4673, DOI 10.1073/pnas.91.11.4673; SETHI T, 1992, CANCER RES, V52, pS2737; Signoret N, 2000, J CELL BIOL, V151, P1281, DOI 10.1083/jcb.151.6.1281; Souaze F, 1997, J BIOL CHEM, V272, P10087; TANAKA K, 1990, NEURON, V4, P847, DOI 10.1016/0896-6273(90)90137-5; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Uthayakumar S, 1995, CELL MOL BIOL RES, V41, P405; Vandenbulcke F, 2000, J CELL SCI, V113, P2963; Vincent JP, 1995, CELL MOL NEUROBIOL, V15, P501, DOI 10.1007/BF02071313; Wang L, 2000, CLIN CANCER RES, V6, P566; WOOD SM, 1981, J CLIN ENDOCR METAB, V53, P1310, DOI 10.1210/jcem-53-6-1310; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; Zhao DZ, 2001, J BIOL CHEM, V276, P44464, DOI 10.1074/jbc.M104942200	55	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12636	12646		10.1074/jbc.M303384200	http://dx.doi.org/10.1074/jbc.M303384200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14699144	hybrid			2022-12-25	WOS:000220334900077
J	Chung, L; Ng, YC				Chung, L; Ng, YC			Altered expression of apoptosis-related proteins in aged skeletal muscle	FASEB JOURNAL			English	Meeting Abstract	Experimental Biology 2004 Meeting	APR 17-21, 2004	Washington, DC						Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health				Rader, Christoph/0000-0001-9955-3454					0	17	24	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR 23	2004	18	4		S			A345	A345		10.1096/fj.03-0586fje	http://dx.doi.org/10.1096/fj.03-0586fje			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806ZA	14688205				2022-12-25	WOS:000220470601661
J	Deterding, LJ; Ramirez, DC; Dubin, JR; Mason, RP; Tomer, KB				Deterding, LJ; Ramirez, DC; Dubin, JR; Mason, RP; Tomer, KB			Identification of free radicals on hemoglobin from its self-peroxidation using mass spectrometry and immuno-spin trapping - Observation of a histidinyl radical	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING; CYTOCHROME-C; MYOGLOBIN; SITE; METMYOGLOBIN; SUPEROXIDE; PEPTIDE; DISEASE	In an effort to understand the mechanism of radical formation on heme proteins, the formation of radicals on hemoglobin was initiated by reaction with hydrogen peroxide in the presence of the spin trap 5,5-dimethyl-1-pyrroline N-oxide (DMPO). The DMPO nitrone adducts were analyzed by mass spectrometry (MS) and immuno-spin trapping. The spin-trapped protein adducts were then subjected to tryptic digestion and MS analyses. When hemoglobin was reacted with hydrogen peroxide (H2O2) in the presence of DMPO, a DMPO nitrone adduct could be detected by immuno-spin trapping. To verify that DMPO adducts of the protein free radicals had been formed, the reaction mixtures were analyzed by flow injection electrospray ionization mass spectrometry (ESI/MS). The ESI mass spectrum of the hemoglobin/H2O2/DMPO sample shows one adduct each on both the alpha chain and the beta chain of hemoglobin which corresponds in mass to the addition of one DMPO molecule. The nature of the radicals formed on hemoglobin was explored using proteolysis techniques followed by liquid chromatography/mass spectrometry (LC/MS) and tandem mass spectrometry (MS/MS) analyses. The following sites of DMPO addition were identified on hemoglobin: Cys-93 of the beta chain, and Tyr-42, Tyr-24, and His-20 of the alpha chain. Because of the pi-pi interaction of Tyr-24 and His-20, the unpaired electron is apparently delocalized on both the tyrosine and histidine residue (pi-pi stacked pair radical).	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Deterding, LJ (corresponding author), NIEHS, Struct Biol Lab, NIH, POB 12233,MD F0-03, Res Triangle Pk, NC 27709 USA.	deterdi2@niehs.nih.gov	RAMIREZ, DARIO C/K-3312-2013; Tomer, Kenneth B/E-8018-2013; Mason, Ronald P/G-5967-2019	RAMIREZ, DARIO C/0000-0001-6725-3326; Mason, Ronald P/0000-0002-1859-9109	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050153, Z01ES050139, ZIAES050139] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alayash AI, 2001, ANTIOXID REDOX SIGN, V3, P313, DOI 10.1089/152308601300185250; Alayash AI, 1999, NAT BIOTECHNOL, V17, P545, DOI 10.1038/9849; Barr DP, 1996, J BIOL CHEM, V271, P15498, DOI 10.1074/jbc.271.26.15498; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; Borchers C, 1999, J CHROMATOGR A, V854, P119, DOI 10.1016/S0021-9673(99)00479-3; Brigellius R., 1985, OXIDATIVE STRESS, P243; BUETTNER GR, 1990, FREE RADICAL RES COM, V10, P11, DOI 10.3109/10715769009145928; Deterding LJ, 1998, J BIOL CHEM, V273, P12863, DOI 10.1074/jbc.273.21.12863; Detweiler CD, 2002, FREE RADICAL BIO MED, V33, P364, DOI 10.1016/S0891-5849(02)00895-X; Dunford H. B., 1999, HEME PEROXIDASES; Everse J, 1997, FREE RADICAL BIO MED, V22, P1075, DOI 10.1016/S0891-5849(96)00499-6; FAJER J, 1975, P NATL ACAD SCI USA, V72, P4956, DOI 10.1073/pnas.72.12.4956; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; Giulivi C, 2001, J BIOL CHEM, V276, P24129, DOI 10.1074/jbc.M010697200; Gunther MR, 1998, BIOCHEM J, V330, P1293; Gunther MR, 2002, J BIOL CHEM, V277, P9160, DOI 10.1074/jbc.M107342200; Harris MN, 2002, CHEM RES TOXICOL, V15, P1589, DOI 10.1021/tx025594t; Hawkins CL, 2001, BBA-BIOENERGETICS, V1504, P196, DOI 10.1016/S0005-2728(00)00252-8; He YY, 2003, PHOTOCHEM PHOTOBIOL, V77, P585, DOI 10.1562/0031-8655(2003)077<0585:UHRDBI>2.0.CO;2; JANSSEN YMW, 1993, LAB INVEST, V69, P261; Kappus H., 1985, OXIDATIVE STRESS, V40, P273, DOI [DOI 10.1016/B978-0-12-642760-8.50016-8, 10.1016/B978-0-12-642760-8.50016-8]; KIM YM, 1995, FREE RADICAL RES, V22, P11, DOI 10.3109/10715769509147524; MAPLES KR, 1990, ARCH BIOCHEM BIOPHYS, V277, P402, DOI 10.1016/0003-9861(90)90596-Q; MCARTHUR KM, 1993, BIOCHIM BIOPHYS ACTA, V1202, P173, DOI 10.1016/0167-4838(93)90002-9; Nagababu E, 2002, BIOCHEMISTRY-US, V41, P7407, DOI 10.1021/bi0121048; Navaratnam S, 1998, J CHEM SOC FARADAY T, V94, P2577, DOI 10.1039/a803477j; Ramirez DC, 2003, FREE RADICAL BIO MED, V34, P830, DOI 10.1016/S0891-5849(02)01437-5; RICHTER C, 1995, BBA-MOL BASIS DIS, V1271, P67, DOI 10.1016/0925-4439(95)00012-S; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Romero N, 2003, J BIOL CHEM, V278, P44049, DOI 10.1074/jbc.M305895200; Shishehbor MH, 2003, JAMA-J AM MED ASSOC, V289, P1675, DOI 10.1001/jama.289.13.1675; TEW D, 1988, J BIOL CHEM, V263, P17880; Thillet J, 1985, Free Radic Res Commun, V1, P89, DOI 10.3109/10715768509056541; Webber AN, 2001, BBA-BIOENERGETICS, V1507, P61, DOI 10.1016/S0005-2728(01)00198-0; Witting PK, 2001, J BIOL CHEM, V276, P16540, DOI 10.1074/jbc.M011707200; Wright PJ, 2003, J AM CHEM SOC, V125, P8655, DOI 10.1021/ja0291888; Zhang HM, 2002, BIOCHEMISTRY-US, V41, P13507, DOI 10.1021/bi026122g	37	104	106	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11600	11607		10.1074/jbc.M310704200	http://dx.doi.org/10.1074/jbc.M310704200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699100	hybrid			2022-12-25	WOS:000220157600093
J	Hesselager, M; Timmermann, DB; Ahring, PK				Hesselager, M; Timmermann, DB; Ahring, PK			pH dependency and desensitization kinetics of heterologously expressed combinations of acid-sensing ion channel subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPERIMENTAL TISSUE ACIDOSIS; SENSORY NEURONS; MOLECULAR-CLONING; GATED CHANNELS; HUMAN SKIN; PROTON; CELLS; PAIN; CURRENTS; MEMBRANE	The exact subunit combinations of functional native acid-sensing ion channels (ASICs) have not been established yet, but both homomeric and heteromeric channels are likely to exist. To determine the ability of different subunits to assemble into heteromeric channels, a number of ASIC1a-, ASIC1b-, ASIC2a-, ASIC2b-, and ASIC3-containing homo- and heteromeric channels were studied by whole-cell patch clamp recordings with respect to pH sensitivity, desensitization kinetics, and level of sustained current normalized to peak current. Analyzing and comparing data for these three features demonstrated unique heteromeric channels in a number of co-expression experiments. Formation of heteromeric ASIC1a + 2a and ASIC1b + 2a channels was foremost supported by the desensitization characteristics that were independent of proton concentration, a feature none of the respective homomeric channels has. Several lines of evidence supported formation of ASIC1a + 3, ASIC1b + 3, and ASIC2a + 3 heteromeric channels. The most compelling was the desensitization characteristics, which, besides being proton-independent, were faster than those of any of the respective homomeric channels. ASIC2b, which homomerically expressed is not activated by protons per se, did not appear to form unique heteromeric combinations with other subunits and in fact appeared to suppress the function of ASIC1b. Co-expression of three subunits such as ASIC1a + 2a + 3 and ASIC1b + 2a + 3 resulted in data that could best be explained by coexistence of multiple channel populations within the same cell. This observation seems to be in good agreement with the fact that ASIC-expressing sensory neurons display a variety of acid-evoked currents.	NeuroSearch AS, DK-2750 Ballerup, Denmark		Ahring, PK (corresponding author), NeuroSearch AS, Pederstrupvej 93, DK-2750 Ballerup, Denmark.	pka@neurosearch.dk	Harms, Hauke/I-4406-2012	Harms, Hauke/0000-0002-7316-7341; Ahring, Joergen Philip Kiaer/0000-0003-1807-3331				Akopian AN, 2000, NEUROREPORT, V11, P2217, DOI 10.1097/00001756-200007140-00031; Babinski K, 1999, J NEUROCHEM, V72, P51, DOI 10.1046/j.1471-4159.1999.0720051.x; Babinski K, 2000, J BIOL CHEM, V275, P28519, DOI 10.1074/jbc.M004114200; Bassler EL, 2001, J BIOL CHEM, V276, P33782, DOI 10.1074/jbc.M104030200; Benson CJ, 2002, P NATL ACAD SCI USA, V99, P2338, DOI 10.1073/pnas.032678399; BEVAN S, 1991, J PHYSIOL-LONDON, V433, P145, DOI 10.1113/jphysiol.1991.sp018419; Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240; Coscoy S, 1998, J BIOL CHEM, V273, P8317, DOI 10.1074/jbc.273.14.8317; de la Rosa DA, 2002, P NATL ACAD SCI USA, V99, P2326, DOI 10.1073/pnas.042688199; Escoubas P, 2000, J BIOL CHEM, V275, P25116, DOI 10.1074/jbc.M003643200; Grunder S, 2000, NEUROREPORT, V11, P1607; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; KRISHTAL OA, 1981, NEUROSCIENCE, V6, P2599, DOI 10.1016/0306-4522(81)90105-6; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; Petruska JC, 2000, J NEUROPHYSIOL, V84, P2365, DOI 10.1152/jn.2000.84.5.2365; STEEN KH, 1993, NEUROSCI LETT, V154, P113, DOI 10.1016/0304-3940(93)90184-M; Steen KH, 1996, PAIN, V66, P163, DOI 10.1016/0304-3959(96)03034-5; STEEN KH, 1995, NEUROSCI LETT, V199, P29, DOI 10.1016/0304-3940(95)12002-L; Sutherland SP, 2001, P NATL ACAD SCI USA, V98, P711, DOI 10.1073/pnas.011404498; Voilley N, 2001, J NEUROSCI, V21, P8026, DOI 10.1523/JNEUROSCI.21-20-08026.2001; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Xie JH, 2002, J NEUROPHYSIOL, V87, P2835, DOI 10.1152/jn.2002.87.6.2835	24	250	256	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11006	11015		10.1074/jbc.M313507200	http://dx.doi.org/10.1074/jbc.M313507200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701823	hybrid			2022-12-25	WOS:000220157600023
J	Logan, IR; Sapountzi, V; Gaughan, L; Neal, DE; Robson, CN				Logan, IR; Sapountzi, V; Gaughan, L; Neal, DE; Robson, CN			Control of human PIRH2 protein stability - Involvement of TIP60 and the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE COMPLEX; UBIQUITIN LIGASE ACTIVITY; RING-FINGER DOMAIN; EARLY EMBRYONIC LETHALITY; TUMOR-SUPPRESSOR P53; ANDROGEN RECEPTOR; PROSTATE-CANCER; MDM2-DEFICIENT MICE; MDM2 DEGRADATION; GENE-EXPRESSION	Murine PIRH2 (mPIRH2) was recently identified as a RING finger-containing ubiquitin-protein isopeptide ligase that interacts with both p53 and the human androgen receptor. mpirh2 is a p53-responsive gene that is up-regulated by UV, and mPIRH2 protein has the capacity to polyubiquitylate p53, perhaps leading to p53 destruction. mpirh2 therefore has properties similar to those of the oncogene mdm2. Here, we have identified human PIRH2 (hPIRH2) as a TIP60-interacting protein. To investigate its regulation, we characterized hPIRH2 in parallel with hPIRH2 variants possessing mutations of conserved RING finger residues. We observed that wild-type hPIRH2 is an unstable protein with a short half-life and is a target for RING domain-dependent proteasomal degradation. Accordingly, we found that hPIRH2 was ubiquitylated in cells. The TIP60-hPIRH2 association appeared to regulate hPIRH2 stability; co-expression of TIP60 enhanced hPIRH2 protein stability and altered hPIRH2 subcellular localization. These results suggest that hPIRH2 activities can be controlled, at the post-translational level, in multiple ways.	Univ Newcastle, Sch Med, No Inst Canc Res, Sch Surg & Reprod Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Addenbrookes Hosp, Ctr Oncol, Cambridge CB2 2QQ, England	Newcastle University - UK; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Robson, CN (corresponding author), Univ Newcastle, Sch Med, No Inst Canc Res, Sch Surg & Reprod Sci, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	C.N.Robson@ncl.ac.uk		Neal, David/0000-0002-6033-5086				Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Beitel LK, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290041; Bird AW, 2002, NATURE, V419, P411, DOI 10.1038/nature01035; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Cai Y, 2003, J BIOL CHEM, V278, P42733, DOI 10.1074/jbc.C300389200; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; de Rozieres S, 2000, ONCOGENE, V19, P1691, DOI 10.1038/sj.onc.1203468; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Fu MF, 2003, MOL CELL BIOL, V23, P8563, DOI 10.1128/MCB.23.23.8563-8575.2003; Galarneau L, 2000, MOL CELL, V5, P927, DOI 10.1016/S1097-2765(00)80258-0; Gaughan L, 2002, J BIOL CHEM, V277, P25904, DOI 10.1074/jbc.M203423200; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Gu JJ, 2001, MOL CELL BIOL, V21, P8533, DOI 10.1128/MCB.21.24.8533-8546.2001; Halkidou K, 2003, ONCOGENE, V22, P2466, DOI 10.1038/sj.onc.1206342; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Kimura A, 1998, GENES CELLS, V3, P789, DOI 10.1046/j.1365-2443.1998.00229.x; LEACH FS, 1993, CANCER RES, V53, P2231; Lee AH, 2003, P NATL ACAD SCI USA, V100, P9946, DOI 10.1073/pnas.1334037100; Legube G, 2002, EMBO J, V21, P1704, DOI 10.1093/emboj/21.7.1704; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Li LM, 2001, P NATL ACAD SCI USA, V98, P1619, DOI 10.1073/pnas.98.4.1619; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; LUNA RMD, 1995, NATURE, V378, P203; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Mayo LD, 1997, CANCER RES, V57, P5013; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Nordentoft I, 2003, BIOCHEM J, V374, P165, DOI 10.1042/BJ20030087; O'Keefe K, 2003, MOL CELL BIOL, V23, P6396, DOI 10.1128/MCB.23.18.6396-6405.2003; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; QUELLE DE, 1995, CELL, V83, P993; Ruland J, 2001, P NATL ACAD SCI USA, V98, P1859, DOI 10.1073/pnas.98.4.1859; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Xiao H, 2003, J BIOL CHEM, V278, P11197, DOI 10.1074/jbc.M210816200; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	65	54	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11696	11704		10.1074/jbc.M312712200	http://dx.doi.org/10.1074/jbc.M312712200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14701804	hybrid			2022-12-25	WOS:000220157600105
J	Mooney, LM; Whitmarsh, AJ				Mooney, LM; Whitmarsh, AJ			Docking interactions in the c-Jun N-terminal kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; SCAFFOLD PROTEIN; MAP KINASES; JNK; IDENTIFICATION; STRESS; PHOSPHORYLATION; ACTIVATION	The c-JunN-terminal kinase (JNK) signaling pathway is a major mediator of stress responses in cells. Similar to other mitogen-activated protein kinases (MAPKs), JNK activity is controlled by a cascade of protein kinases and by protein phosphatases, including dual-specificity MAPK phosphatases. Components of the JNK pathway associate with scaffold proteins that modulate their activities and cellular localization. The JNK-interacting protein-1 (JIP-1) scaffold protein specifically binds JNK, MAPK kinase 7 (MKK7), and members of the mixed lineage kinase (MLK) family, and regulates JNK activation in neurons. In this study we demonstrate that distinct regions within the N termini of MKK7 and the MLK family member dual leucine zipper kinase (DLK) mediate their binding to JIP-1. We have also identified amino acids in JNK required for: (a) binding to JIP-1 and for JIP-1-mediated JNK activation, (b) docking to MAPK kinase 4 (MKK4) and efficient phosphorylation by MKK4, and (c) docking to its substrate c-Jun and efficient c-Jun phosphorylation. None of the amino acids identified were essential for JNK docking to MKK7 or the dual-specificity phosphatase MAPK phosphatase 7 (MKP7). These findings uncover molecular determinants of JIP-1 scaffold complex assembly and demonstrate that there are overlapping, but also distinct, binding determinants within JNK that mediate interactions with scaffold proteins, activators, phosphatases, and substrates.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Whitmarsh, AJ (corresponding author), Univ Manchester, Sch Biol Sci, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	alan.j.whitmarsh@man.ac.uk		Whitmarsh, Alan/0000-0003-1184-6610				Bardwell AJ, 2003, BIOCHEM J, V370, P1077, DOI 10.1042/BJ20021806; Bardwell AJ, 2001, J BIOL CHEM, V276, P10374, DOI 10.1074/jbc.M010271200; Barr RK, 2002, J BIOL CHEM, V277, P10987, DOI 10.1074/jbc.M107565200; Buchsbaum RJ, 2002, MOL CELL BIOL, V22, P4073, DOI 10.1128/MCB.22.12.4073-4085.2002; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; DAI TN, 1995, ONCOGENE, V10, P849; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Enslen H, 2001, BIOL CELL, V93, P5, DOI 10.1016/S0248-4900(01)01156-X; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Haefliger JA, 2003, J CELL SCI, V116, P1463, DOI 10.1242/jcs.00356; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ho DT, 2003, J BIOL CHEM, V278, P32662, DOI 10.1074/jbc.M304229200; Im JY, 2003, J NEUROSCI RES, V74, P326, DOI 10.1002/jnr.10761; Ito M, 1999, MOL CELL BIOL, V19, P7539; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kelkar N, 2003, P NATL ACAD SCI USA, V100, P9843, DOI 10.1073/pnas.1733944100; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Masuda K, 2003, J BIOL CHEM, V278, P32448, DOI 10.1074/jbc.M213254200; Matsuura H, 2002, J BIOL CHEM, V277, P40703, DOI 10.1074/jbc.M202004200; Merritt SE, 1999, J BIOL CHEM, V274, P10195, DOI 10.1074/jbc.274.15.10195; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Nihalani D, 2000, J BIOL CHEM, V275, P7273, DOI 10.1074/jbc.275.10.7273; Nihalani D, 2001, EMBO J, V20, P3447, DOI 10.1093/emboj/20.13.3447; Nihalani D, 2003, J BIOL CHEM, V278, P28694, DOI 10.1074/jbc.M304212200; Robinson FL, 2002, J BIOL CHEM, V277, P14844, DOI 10.1074/jbc.M107776200; Schoorlemmer J, 2001, CURR BIOL, V11, P793, DOI 10.1016/S0960-9822(01)00232-9; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tanoue TJ, 2003, CELL SIGNAL, V15, P455, DOI 10.1016/S0898-6568(02)00112-2; Thompson NA, 2001, J BIOL CHEM, V276, P27745, DOI 10.1074/jbc.C100222200; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Tu Z, 2003, CELL SIGNAL, V15, P65, DOI 10.1016/S0898-6568(02)00056-6; Vacratsis PO, 2000, J BIOL CHEM, V275, P27893; Waeber G, 2000, NAT GENET, V24, P291, DOI 10.1038/73523; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Whitmarsh AJ, 2001, GENE DEV, V15, P2421, DOI 10.1101/gad.922801; Willoughby EA, 2003, J BIOL CHEM, V278, P10731, DOI 10.1074/jbc.M207324200; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Xie XL, 1998, STRUCTURE, V6, P983, DOI 10.1016/S0969-2126(98)00100-2; Xu BE, 2001, J BIOL CHEM, V276, P26509, DOI 10.1074/jbc.M102769200; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zhang JL, 2003, J BIOL CHEM, V278, P29901, DOI 10.1074/jbc.M303909200	54	60	66	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11843	11852		10.1074/jbc.M311841200	http://dx.doi.org/10.1074/jbc.M311841200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14699111	hybrid			2022-12-25	WOS:000220157600121
J	Ding, M; Lu, YJ; Bowman, L; Huang, CS; Leonard, S; Wang, LY; Vallyathan, V; Castranova, V; Shi, XL				Ding, M; Lu, YJ; Bowman, L; Huang, CS; Leonard, S; Wang, LY; Vallyathan, V; Castranova, V; Shi, XL			Inhibition of AP-1 and neoplastic transformation by fresh apple peel extract	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR PROTEIN-1 ACTIVATION; SIGNAL-TRANSDUCTION PATHWAYS; CANCER CHEMOPREVENTION; ANTIOXIDANT ACTIVITY; CRYSTALLINE SILICA; RESPONSE ELEMENT; TUMOR PROMOTION; PHORBOL ESTER; RETINOIC ACID; JB6 CELLS	Consumption of fruits and vegetables has been associated with a low incidence of cancers and other chronic diseases. Previous studies suggested that fresh apples inhibit tumor cell proliferation. Here we report that oral administration of apple peel extracts decreased the number of nonmalignant and malignant skin tumors per mouse induced by 12-O-tetradecanolyphorbol-13-acetate (TPA) in 7,12-dimethylbenz(a) anthracene-initiated mouse skin. ESR analysis indicated that apple extract strongly scavenged hydroxyl (OH) and superoxide (O-2(radical anion)) radicals. Mechanistic studies showed that pretreatment with apple peel extract inhibited AP-1 transactivation induced by ultraviolet B irradiation or TPA in JB6 cells and AP-1-luciferase reporter transgenic mice. This inhibitory effect appears to be mediated by the inhibition of ERKs and JNK activity. The results provide the first evidence that an extract from fresh apple peel extract may inhibit tumor promoter-induced carcinogenesis and associated cell signaling, and suggest that the chemopreventive effects of fresh apple may be through its antioxidant properties by blocking reactive oxygen species-mediated AP-1-MAPK activation.	NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, Morgantown, WV 26505 USA; NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY 10987 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); New York University	Ding, M (corresponding author), NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, Morgantown, WV 26505 USA.	mid5@cdc.gov	Shi, Xianglin/B-8588-2012	Huang, Chuanshu/0000-0003-4133-5096				Adler V, 1996, J BIOL CHEM, V271, P23304, DOI 10.1074/jbc.271.38.23304; [Anonymous], 1996, CA Cancer J Clin, V46, P325; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BLOCK G, 1992, NUTR CANCER, V18, P1, DOI 10.1080/01635589209514201; BUSCHER M, 1988, ONCOGENE, V3, P301; Cao GH, 1998, AM J CLIN NUTR, V68, P1081, DOI 10.1093/ajcn/68.5.1081; Carlton PS, 2000, CANCER LETT, V159, P113, DOI 10.1016/S0304-3835(00)00464-X; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Ding M, 1999, J BIOL CHEM, V274, P30611, DOI 10.1074/jbc.274.43.30611; Ding M, 2001, J BIOL CHEM, V276, P9108, DOI 10.1074/jbc.M007666200; Eberhardt MV, 2000, NATURE, V405, P903, DOI 10.1038/35016148; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; JANZEN EG, 1968, J AM CHEM SOC, V90, P5909, DOI 10.1021/ja01023a051; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Keli SO, 1996, ARCH INTERN MED, V156, P637, DOI 10.1001/archinte.156.6.637; Kresty LA, 2001, CANCER RES, V61, P6112; Krishnan K, 1998, PRIMARY CARE, V25, P361, DOI 10.1016/S0095-4543(05)70069-5; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; La Vecchia C, 1998, EUR J CANCER PREV, V7, P3, DOI 10.1097/00008469-199802001-00002; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Li JJ, 1996, CANCER RES, V56, P483; Li JJ, 1997, CANCER RES, V57, P3569; Lu YP, 2002, P NATL ACAD SCI USA, V99, P12455, DOI 10.1073/pnas.182429899; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORSE MA, 1993, CARCINOGENESIS, V14, P1737, DOI 10.1093/carcin/14.9.1737; Mukhtar H, 1999, TOXICOL APPL PHARM, V158, P207, DOI 10.1006/taap.1999.8721; NAITO M, 1988, CARCINOGENESIS, V9, P639, DOI 10.1093/carcin/9.4.639; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; Rock CL, 1998, HEMATOL ONCOL CLIN N, V12, P975, DOI 10.1016/S0889-8588(05)70037-X; SHI XL, 1988, BIOCHEM BIOPH RES CO, V156, P137, DOI 10.1016/S0006-291X(88)80815-5; SHI XL, 1990, ARCH BIOCHEM BIOPHYS, V277, P342, DOI 10.1016/0003-9861(90)90589-Q; Wattenberg LW, 1997, P SOC EXP BIOL MED, V216, P133; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wolfe K, 2003, J AGR FOOD CHEM, V51, P609, DOI 10.1021/jf020782a; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827	38	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10670	10676		10.1074/jbc.M311465200	http://dx.doi.org/10.1074/jbc.M311465200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14665633	hybrid			2022-12-25	WOS:000220050400121
J	Mascarell, L; Auger, R; Alcover, A; Ojcius, DM; Jungas, T; Cadet-Daniel, V; Kanellopoulos, JM; Truffa-Bachi, P				Mascarell, L; Auger, R; Alcover, A; Ojcius, DM; Jungas, T; Cadet-Daniel, V; Kanellopoulos, JM; Truffa-Bachi, P			Characterization of a gene encoding two isoforms of a mitochondrial protein up-regulated by cyclosporin a in activated T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS; CALCINEURIN; CYCLOPHILIN; MEMBRANE; BINDING; IMPORT; EXPRESSION; RECEPTOR; CANCER; NFATP	Cyclosporin A (CSA) is an immunosuppressor used in organ transplantation. A recent proteomic analysis has revealed that activation of T cells in the presence of CSA induces the synthesis of hundreds of new proteins. Here we used representational difference analysis to characterize some of the corresponding induced genes. After cDNA bank screening we focused on one of these genes, which we named CSA-conditional, T cell activation-dependent (CSTAD) gene. This gene produces two mRNAs resulting from alternative splicing events. They encode two proteins of 104 and 141 amino acids, CSTADp-S and CSTADp-L, for the short and long forms, respectively. FK506 had the same effect as CSA, whereas rapamycin did not affect the level of CSTAD gene expression, demonstrating that inhibition of the calcineurin activation pathway is involved in CSTAD gene up-regulation. CSA also led to overexpression of CSTAD in mice immunized in the presence of CSA, confirming the in vitro analysis. Microscopic and cytofluorimetric analysis of cells expressing green fluorescent protein-tagged CSTADp-L and CSTADp-S showed that both proteins colocalize with mitochondrial markers and depolarize the mitochondrial transmembrane potential without causing release of cytochrome c, apoptosis, or necrosis. Both CSTADp isoforms are sensitive to proteinase K, implying that they are located in the mitochondrial outer membrane. These data reveal a new mechanism of action for CSA, which involves up-regulation of a gene whose products are sorted to mitochondria and depolarize the mitochondrial membrane.	Univ Paris 11, IBBMC, CNRS UMR 8619, Lab Activat Cellulaire & Transduct Signaux, F-91405 Orsay, France; Inst Pasteur, CNRS, Unite Biol Populat Lymphocytaires, URA 2582, F-75724 Paris 15, France; Inst Pasteur, CNRS, Unite Biol Interact Cellulaires, URA 2582, F-75724 Paris 15, France; Univ Paris 07, Inst Jacques Monod, CNRS, UMR 7592, F-75721 Paris 5, France	UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	Kanellopoulos, JM (corresponding author), Univ Paris 11, IBBMC, CNRS UMR 8619, Lab Activat Cellulaire & Transduct Signaux, F-91405 Orsay, France.	Jean.Kanellopoulos@ibbmc.u-psud.fr	Ojcius, David/ABE-6557-2020	Alcover, Andres/0000-0002-9507-3450; Ojcius, David/0000-0003-1461-4495	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054624] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI054624] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bellosillo B, 2002, BLOOD, V100, P1810, DOI 10.1182/blood-2001-12-0327; Bemer V, 1996, EUR J IMMUNOL, V26, P1481, DOI 10.1002/eji.1830260712; Bernardi P, 1996, BBA-BIOENERGETICS, V1275, P5, DOI 10.1016/0005-2728(96)00041-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONNERN CP, 1994, BIOCHEM J, V302, P321, DOI 10.1042/bj3020321; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; Frazer JK, 1997, J IMMUNOL METHODS, V207, P1, DOI 10.1016/S0022-1759(97)00091-4; Halestrap AP, 1997, MOL CELL BIOCHEM, V174, P167, DOI 10.1023/A:1006879618176; Ho S, 1996, CLIN IMMUNOL IMMUNOP, V80, pS40, DOI 10.1006/clin.1996.0140; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Johnson N, 1999, EUR J BIOCHEM, V263, P353, DOI 10.1046/j.1432-1327.1999.00490.x; Kawai J, 2001, NATURE, V409, P685, DOI 10.1038/35055500; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; Khanna A, 1997, TRANSPLANTATION, V63, P1037, DOI 10.1097/00007890-199704150-00026; Khanna AK, 1999, TRANSPLANTATION, V67, P882, DOI 10.1097/00007890-199903270-00016; Mascarell L, 2002, IMMUNOL LETT, V84, P137, DOI 10.1016/S0165-2478(02)00157-8; Mascarell L, 2000, TRANSPLANTATION, V70, P340, DOI 10.1097/00007890-200007270-00019; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; Morton RS, 1999, J PERIODONTOL, V70, P1464, DOI 10.1902/jop.1999.70.12.1464; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Perfettini JL, 2002, METHOD ENZYMOL, V358, P334; PFANNER N, 1987, EUR J BIOCHEM, V169, P289, DOI 10.1111/j.1432-1033.1987.tb13610.x; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RAO A, 1995, J LEUKOCYTE BIOL, V57, P536, DOI 10.1002/jlb.57.4.536; Roumier A, 2001, IMMUNITY, V15, P715, DOI 10.1016/S1074-7613(01)00225-4; Rovira P, 2000, CURR MED CHEM, V7, P673, DOI 10.2174/0929867003374778; SMAGULA C, 1988, J BIOL CHEM, V263, P6783; STEWART T, 1995, LANCET, V346, P796, DOI 10.1016/S0140-6736(95)91618-0; Teague TK, 1999, P NATL ACAD SCI USA, V96, P12691, DOI 10.1073/pnas.96.22.12691; THIEL G, 1994, TRANSPLANT P, V26, P2493; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; WILLIAMSON MS, 1994, J PERIODONTOL, V65, P895, DOI 10.1902/jop.1994.65.10.895; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	39	4	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10556	10563		10.1074/jbc.M313770200	http://dx.doi.org/10.1074/jbc.M313770200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14684732	Green Published, hybrid			2022-12-25	WOS:000220050400109
J	Yosef, I; Irihimovitch, V; Knopf, JA; Cohen, I; Orr-Dahan, I; Nahum, E; Keasar, C; Shapira, M				Yosef, I; Irihimovitch, V; Knopf, JA; Cohen, I; Orr-Dahan, I; Nahum, E; Keasar, C; Shapira, M			RNA binding activity of the ribulose-1,5-bisphosphate carboxylase/oxygenase large subunit from Chlamydomonas reinhardtii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-BISPHOSPHATE CARBOXYLASE; CHLOROPLAST GENE-EXPRESSION; PROTEIN DISULFIDE-ISOMERASE; PSBC MESSENGER-RNA; CRYSTAL-STRUCTURE; TRANSLATIONAL REGULATION; GREEN-ALGA; LIGHT; RUBISCO; THYLAKOIDS	Transfer of the green algae Chlamydomonas reinhardtii from low light to high light generated an oxidative stress that led to a dramatic arrest in the synthesis of the large subunit (LSU) of ribulose-1,5-bisphosphate carboxylase/ oxygenase ( Rubisco). The translational arrest correlated with transient changes in the intracellular levels of reactive oxygen species and with shifting the glutathione pool toward its oxidized form (Irihimovitch, V., and Shapira, M. ( 2000) J. Biol. Chem. 275, 16289 - 16295). Here we examined how the redox potential of glutathione affected the RNA-protein interactions with the 5'-untranslated region of rbcL. This RNA region specifically binds a group of proteins with molecular masses of 81, 62, 51, and 47 kDa in UV-cross-linking experiments under reducing conditions. Binding of these proteins was interrupted by exposure to oxidizing conditions ( GSSG), and a new protein of 55 kDa was shown to interact with the RNA. The 55-kDa protein comigrated with Rubisco LSU in one- and two-dimensional gels, and its RNA binding activity was further verified by using the purified protein in UV-cross-linking experiments under oxidizing conditions. However, the LSU of purified and oxidized Rubisco bound to RNA in a sequence-independent manner. A remarkable structural similarity was found between the amino-terminal domain of Rubisco LSU in C. reinhardtii and the RNA binding domain, a highly prevailing motif among RNA-binding proteins. It appears from the crystal structure of Rubisco that the amino terminus of LSU is buried within the holoenzyme. We propose that under oxidizing conditions it is exposed to the surface and can, therefore, bind RNA. Accordingly, a recombinant form of the polypeptide domain that corresponds to the amino terminus of LSU was found to bind RNA in vitro with or without GSSG.	Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Dept Comp Sci, IL-84105 Beer Sheva, Israel	Ben Gurion University; Ben Gurion University	Shapira, M (corresponding author), Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel.	shapiram@bgumail.bgu.ac.il	Keasar, Chen/J-8413-2012; Cohen‬, ‪Idan/AAD-6997-2021; KEASAR, CHEN/HGB-9794-2022	Cohen‬, ‪Idan/0000-0001-6933-9385; Shapira, Michal/0000-0002-6164-7874; Keasar, Chen/0000-0003-0994-1520				Auchincloss AH, 2002, J CELL BIOL, V157, P953, DOI 10.1083/jcb.200201060; Bae WH, 2000, P NATL ACAD SCI USA, V97, P7784, DOI 10.1073/pnas.97.14.7784; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; Boudreau E, 2000, EMBO J, V19, P3366, DOI 10.1093/emboj/19.13.3366; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Choquet Y, 1998, P NATL ACAD SCI USA, V95, P4380, DOI 10.1073/pnas.95.8.4380; Cristofari G, 2002, PROG NUCLEIC ACID RE, V72, P223, DOI 10.1016/S0079-6603(02)72071-0; Danon A, 1997, PLANT PHYSIOL, V115, P1293, DOI 10.1104/pp.115.4.1293; DANON A, 1991, EMBO J, V10, P3993, DOI 10.1002/j.1460-2075.1991.tb04974.x; DRON M, 1982, J MOL BIOL, V162, P775, DOI 10.1016/0022-2836(82)90547-2; Ferre-D'Amare AR, 1998, NATURE, V395, P567, DOI 10.1038/26912; FICHTNER K, 1993, PLANTA, V190, P1, DOI 10.1007/BF00195668; Foyer CH, 1997, PHYSIOL PLANTARUM, V100, P241, DOI 10.1034/j.1399-3054.1997.1000205.x; GORLACH M, 1994, J BIOL CHEM, V269, P23074; GUTTERIDGE S, 1995, PLANT CELL, V7, P809, DOI 10.1105/tpc.7.7.809; Hauser CR, 1996, J BIOL CHEM, V271, P1486, DOI 10.1074/jbc.271.3.1486; Irihimovitch V, 2000, J BIOL CHEM, V275, P16289, DOI 10.1074/jbc.275.21.16289; Ishida H, 1999, J BIOL CHEM, V274, P5222, DOI 10.1074/jbc.274.8.5222; Karlson D, 2002, J BIOL CHEM, V277, P35248, DOI 10.1074/jbc.M205774200; Kim JM, 1997, SCIENCE, V278, P1954, DOI 10.1126/science.278.5345.1954; Lopez C, 2000, VIROLOGY, V269, P462, DOI 10.1006/viro.2000.0235; Marcus Y, 2003, J BACTERIOL, V185, P1509, DOI 10.1128/JB.185.5.1509-1517.2003; MEHTA RA, 1992, J BIOL CHEM, V267, P2810; Mizohata E, 2002, J MOL BIOL, V316, P679, DOI 10.1006/jmbi.2001.5381; Mohr S, 2002, CELL, V109, P769, DOI 10.1016/S0092-8674(02)00771-7; Moreno J, 1999, J BIOL CHEM, V274, P26789, DOI 10.1074/jbc.274.38.26789; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nagai K, 1996, CURR OPIN STRUC BIOL, V6, P53, DOI 10.1016/S0959-440X(96)80095-9; Noctor G, 2002, J EXP BOT, V53, P1283, DOI 10.1093/jexbot/53.372.1283; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Osmond CB, 1994, PHOTOINHIBITION PHOT, P1; PRASIL O, 1992, PHOTOSYSTEMS STRUCTU, P295, DOI DOI 10.1016/B978-0-444-89440-3.50017-5; Rochaix JD, 1996, PLANT MOL BIOL, V32, P327, DOI 10.1007/BF00039389; Rodermel S, 1996, P NATL ACAD SCI USA, V93, P3881, DOI 10.1073/pnas.93.9.3881; Sambrook J, 2001, MOL CLONING LAB MANU; Severson W, 1999, J BIOL CHEM, V274, P33732, DOI 10.1074/jbc.274.47.33732; Shapira M, 1997, PLANT MOL BIOL, V33, P1001, DOI 10.1023/A:1005814800641; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; Siomi H, 1997, CURR OPIN GENET DEV, V7, P345, DOI 10.1016/S0959-437X(97)80148-7; SPREITZER RJ, 1985, P NATL ACAD SCI USA, V82, P5460, DOI 10.1073/pnas.82.16.5460; Taylor TC, 2001, J BIOL CHEM, V276, P48159, DOI 10.1074/jbc.M107765200; Thirumalai D, 2001, ANNU REV BIOPH BIOM, V30, P245, DOI 10.1146/annurev.biophys.30.1.245; Trebitsh T, 2001, J BIOL CHEM, V276, P4564, DOI 10.1074/jbc.M005950200; Trebitsh T, 2000, MOL CELL BIOL, V20, P1116, DOI 10.1128/MCB.20.4.1116-1123.2000; Vaistij FE, 2000, P NATL ACAD SCI USA, V97, P14813, DOI 10.1073/pnas.97.26.14813; Yohn CB, 1998, P NATL ACAD SCI USA, V95, P2238, DOI 10.1073/pnas.95.5.2238; Zerges W, 1998, J CELL BIOL, V140, P101, DOI 10.1083/jcb.140.1.101; Zerges W, 1997, MOL CELL BIOL, V17, P3440, DOI 10.1128/MCB.17.6.3440; Zerges W, 2002, PLANT MOL BIOL, V50, P573, DOI 10.1023/A:1020246007858; Zerges W, 2000, BIOCHIMIE, V82, P583, DOI 10.1016/S0300-9084(00)00603-9	50	44	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10148	10156		10.1074/jbc.M308602200	http://dx.doi.org/10.1074/jbc.M308602200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14679208	hybrid			2022-12-25	WOS:000220050400061
J	Zhang, XY; Zhang, XD; Borrow, JM; Nguyen, T; Hersey, P				Zhang, XY; Zhang, XD; Borrow, JM; Nguyen, T; Hersey, P			Translational control of tumor necrosis factor-related apoptosis-inducing ligand death receptor expression in melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAIL-INDUCED APOPTOSIS; DECOY RECEPTORS; TRANSCRIPTION INITIATION; PROTEIN EXPRESSION; KILLER/DR5 GENE; RICH ELEMENTS; SEQUENCE; REGION; MEMBER	In the present study, it was found that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-R2 protein expression did not correlate with mRNA expression in melanoma cell lines. In particular, early passage primary cultures from patients had low TRAIL-R2 protein expression compared with later passage cultures although TRAIL-R2 mRNA expression was similar in early and late passages. Similarly, cell lines made resistant to TRAIL by cultures in TRAIL had low TRAIL-R2 protein expression but normal levels of mRNA for TRAIL-R2. Expression from a luciferase reporter gene construct with the 3'-untranslated region (UTR) ( but not the 5'-UTR) of TRAIL-R2 was suppressed when transfected into the TRAIL-selected ( resistant) melanoma lines compared with that seen in the parental ( sensitive) lines. Similar results were seen in early passage ( resistant) cultures compared with late passage ( sensitive) primary melanoma cultures. RNA gel shift assays demonstrated protein(s) binding to the 3'-UTR of TRAIL-R2 mRNA that were more evident in TRAIL-resistant cultures with low TRAIL-R2 protein expression. A 23-base fragment of the 3'-UTR inhibited binding of the proteins to the 3'-UTR, and a probe using this fragment bound to proteins in TRAIL-selected melanoma lines and early passage isolates of melanoma. Binding of the 3'-UTR probe to the cytosolic protein( s) was induced by exposure to TRAIL and was lost from the TRAIL selected lines 2 - 3 days after withdrawal of TRAIL from the cultures. These results are consistent with post-transcriptional regulation of TRAIL-R2 expression by cytosolic proteins induced by TRAIL that bind to the 3'-UTR region of TRAIL-R2 mRNA.	Immunol & Oncol Unit, Newcastle, NSW 2300, Australia		Hersey, P (corresponding author), Immunol & Oncol Unit, David Maddison Bldg,Corner King & Watt St, Newcastle, NSW 2300, Australia.	Peter.Hersey@newcastle.edu.au	zhang, xian/GYA-0290-2022; zhang, xu/GYE-3558-2022; Zhang, xiaoyu/GXA-3206-2022; zhang, xu/GRX-9733-2022	Zhang, Xu Dong/0000-0001-9457-8003				Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Bollig F, 2003, BIOCHEM BIOPH RES CO, V301, P665, DOI 10.1016/S0006-291X(03)00015-9; Cazzola M, 2000, BLOOD, V95, P3280, DOI 10.1182/blood.V95.11.3280.011k41_3280_3288; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Giles KM, 2003, J BIOL CHEM, V278, P2937, DOI 10.1074/jbc.M208439200; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1999, J IMMUNOL, V162, P2597; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Guan BX, 2002, ONCOGENE, V21, P3121, DOI 10.1038/sj.onc.1205430; Guan BX, 2001, J CELL PHYSIOL, V188, P98, DOI 10.1002/jcp.1101; Gura T, 1997, SCIENCE, V277, P768, DOI 10.1126/science.277.5327.768; Iyer S, 2000, J BIOL CHEM, V275, P17051, DOI 10.1074/jbc.M909219199; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kasashima K, 2002, NUCLEIC ACIDS RES, V30, P4519, DOI 10.1093/nar/gkf567; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Meng RD, 2001, EXP CELL RES, V262, P154, DOI 10.1006/excr.2000.5073; Neininger A, 2002, J BIOL CHEM, V277, P3065, DOI 10.1074/jbc.C100685200; Nguyen T, 2001, CLIN CANCER RES, V7, p966S; Phillips TA, 1999, J IMMUNOL, V162, P6053; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; SHARROW CO, 1996, CURRENT PROTOCOLS IM; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheikh MS, 2000, LEUKEMIA, V14, P1509, DOI 10.1038/sj.leu.2401865; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Thomas WD, 1998, J IMMUNOL, V161, P2195; WALKER J, 1998, METHODS MOL BIOL; Wang EH, 1997, CANCER RES, V57, P5426; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yoshida T, 2001, FEBS LETT, V507, P381, DOI 10.1016/S0014-5793(01)02947-7; Zhang T, 2002, BIOCHEM SOC T, V30, P952, DOI 10.1042/BST0300952; Zhang XD, 2000, FEBS LETT, V482, P193, DOI 10.1016/S0014-5793(00)02042-1; Zhang XD, 2000, J IMMUNOL, V164, P3961, DOI 10.4049/jimmunol.164.8.3961; Zhang XD, 1999, CANCER RES, V59, P2747	34	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10606	10614		10.1074/jbc.M308211200	http://dx.doi.org/10.1074/jbc.M308211200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688276	hybrid			2022-12-25	WOS:000220050400114
J	Eskiw, CH; Dellaire, G; Bazett-Jones, DP				Eskiw, CH; Dellaire, G; Bazett-Jones, DP			Chromatin contributes to structural integrity of promyelocytic leukemia bodies through a SUMO-1-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PML NUCLEAR-BODIES; COVALENT MODIFICATION; RAR-ALPHA; PROTEIN; INTERPHASE; DOMAINS; ND10; DAXX; DNA; CONDENSATION	Promyelocytic leukemia (PML) protein is implicated in transcriptional regulation, apoptosis, DNA repair, and tumor suppression. It is not known, however, whether PML and other components of PML bodies function within the vicinity of the bodies or elsewhere in the nucleoplasm. In this study, we demonstrate that chromatin organization around PML bodies influences their morphology, dynamics, and structural integrity by a SUMO-1-independent mechanism. Following transcriptional inhibition and during early apoptosis, chromatin retracts from the periphery of PML bodies, coinciding with the formation of new PML-containing structures through fission of supramolecular PML-containing microbodies. Both fission and fusion of microbodies with parental PML bodies indicate a loss of structural integrity of the bodies, dependent on the state of the surrounding chromatin. This is supported by the observation that treatment of live cells with DNase I could reproduce the structural instability of PML bodies. In addition, PML bodies, which are normally surrounded by chromatin and are positionally stable, become more dynamic following these treatments, presumably due to the loss of chromatin contacts. Overexpression of SUMO-1, a modification required for PML body formation, did not prevent PML body fission, indicating that chromatin-based integrity of PML body structure occurs through a SUMO-1-independent mechanism.	Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Bazett-Jones, DP (corresponding author), Hosp Sick Children, Cell Biol Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	dbjones@sickkids.ca	Dellaire, Graham/L-9948-2014	Dellaire, Graham/0000-0002-3466-6316				Bazett-Jones DP, 1999, METHODS, V17, P188, DOI 10.1006/meth.1998.0729; Bazett-Jones DP, 1999, MICRON, V30, P151, DOI 10.1016/S0968-4328(99)00019-0; Beaudouin J, 2002, CELL, V108, P83, DOI 10.1016/S0092-8674(01)00627-4; Boddy MN, 1996, ONCOGENE, V13, P971; Boisvert FM, 2000, J CELL BIOL, V148, P283, DOI 10.1083/jcb.148.2.283; Boisvert FM, 2001, J CELL BIOL, V152, P1099, DOI 10.1083/jcb.152.5.1099; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; Cohen N, 2001, EMBO J, V20, P4547, DOI 10.1093/emboj/20.16.4547; Dostie J, 2000, J CELL BIOL, V148, P239, DOI 10.1083/jcb.148.2.239; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; Drouin A, 2001, EXP CELL RES, V271, P277, DOI 10.1006/excr.2001.5377; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Eskiw CH, 2003, J CELL SCI, V116, P4455, DOI 10.1242/jcs.00758; Hayakawa T, 2003, J CELL SCI, V116, P3327, DOI 10.1242/jcs.00635; Hendzel MJ, 1998, J BIOL CHEM, V273, P24470, DOI 10.1074/jbc.273.38.24470; HENDZEL MJ, 1991, BIOCHEM J, V273, P753, DOI 10.1042/bj2730753; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Kentsis A, 2002, P NATL ACAD SCI USA, V99, P15404, DOI 10.1073/pnas.202608799; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Lehming N, 1998, P NATL ACAD SCI USA, V95, P7322, DOI 10.1073/pnas.95.13.7322; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Louria-Hayon I, 2003, J BIOL CHEM, V278, P33134, DOI 10.1074/jbc.M301264200; Maul GG, 1995, J CELL BIOCHEM, V59, P498, DOI 10.1002/jcb.240590410; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; Muratani M, 2002, NAT CELL BIOL, V4, P106, DOI 10.1038/ncb740; Nefkens I, 2003, J CELL SCI, V116, P513, DOI 10.1242/jcs.00253; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; Plehn-Dujowich D, 2000, CHROMOSOMA, V109, P266, DOI 10.1007/s004120000073; Ren Y, 2003, J HISTOCHEM CYTOCHEM, V51, P605, DOI 10.1177/002215540305100506; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Shiels C, 2001, J CELL SCI, V114, P3705; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Sun YJ, 2003, GENOMICS, V82, P250, DOI 10.1016/S0888-7543(03)00075-2; von Mikecz A, 2000, J CELL BIOL, V150, P265, DOI 10.1083/jcb.150.1.265; Wang ZG, 1998, BLOOD, V92, P1497, DOI 10.1182/blood.V92.5.1497.417k41_1497_1504; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wiesmeijer K, 2002, J STRUCT BIOL, V140, P180, DOI 10.1016/S1047-8477(02)00529-4; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001	43	75	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9577	9585		10.1074/jbc.M312580200	http://dx.doi.org/10.1074/jbc.M312580200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14672938	hybrid			2022-12-25	WOS:000189265900125
J	Ohnishi, H; Miyata, T; Yasuda, H; Satoh, Y; Hanatsuka, K; Kita, H; Ohashi, A; Tamada, K; Makita, N; Iiri, T; Ueda, N; Mashima, H; Sugano, K				Ohnishi, H; Miyata, T; Yasuda, H; Satoh, Y; Hanatsuka, K; Kita, H; Ohashi, A; Tamada, K; Makita, N; Iiri, T; Ueda, N; Mashima, H; Sugano, K			Distinct roles of Smad2-, Smad3-, and ERK-dependent pathways in transforming growth factor-beta(1) regulation of pancreatic stellate cellular functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; SIGNAL-TRANSDUCTION; EXTRACELLULAR-MATRIX; TARGETED DISRUPTION; ACTIVIN-A; CELLS; RAT; ACTIVATION; PHOSPHORYLATION; IDENTIFICATION	Pancreatic stellate cells (PSCs) play a major role in promoting pancreatic fibrosis. Transforming growth factor-beta(1) (TGF-beta(1)) regulates PSC activation and proliferation in an autocrine manner. The intracellular signaling pathways of the regulation were examined in this study. Immunoprecipitation and immunocytochemistry revealed that Smad2, Smad3, and Smad4 were functionally expressed in PSCs. Adenovirus-mediated expression of Smad2, Smad3, or dominant-negative Smad2/3 did not alter TGF-beta(1) mRNA expression level or the amount of autocrine TGF-beta(1) peptide. However, expression of dominant-negative Smad2/3 inhibited PSC activation and enhanced their proliferation. Co-expression of Smad2 with dominant-negative Smad2/3 restored PSC activation inhibited by dominant-negative Smad2/3 expression without changing their proliferation. By contrast, co-expression of Smad3 with dominant- negative Smad2/3 attenuated PSC proliferation enhanced by dominant- negative Smad2/3 expression without altering their activation. Exogenous TGF-beta(1) increased TGFbeta(1) mRNA expression in PSCs. However, PD98059, a specific inhibitor of mitogen-activated protein kinase kinase (MEK1), inhibited ERK activation by TGF-beta(1), and consequently attenuated TGF-beta(1) enhancement of its own mRNA expression in PSCs. We propose that TGF-beta(1) differentially regulates PSC activation, proliferation, and TGF-beta(1) mRNA expression through Smad2-, Smad3-, and ERK-dependent pathways, respectively.	Jichi Med Sch, Dept Gastroenterol, Minami Kawachi, Tochigi 3290498, Japan; Showa Univ, Fujigaoka Hosp, Div Gastroenterol, Kanagawa 2278501, Japan; Univ Tokyo, Sch Med, Dept Endocrinol & Nephrol, Tokyo 1138655, Japan; Univ Tokyo, Sch Med, Dept Gastroenterol, Tokyo 1138655, Japan	Jichi Medical University; Showa University; University of Tokyo; University of Tokyo	Ohnishi, H (corresponding author), Jichi Med Sch, Dept Gastroenterol, 3311-1 Yakushiji, Minami Kawachi, Tochigi 3290498, Japan.	hohnishi@jichi.ac.jp	Mashima, Hirosato/ABE-6412-2020					Apte MV, 1999, GUT, V44, P534, DOI 10.1136/gut.44.4.534; Apte MV, 1998, GUT, V43, P128, DOI 10.1136/gut.43.1.128; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Bachem MG, 1998, GASTROENTEROLOGY, V115, P421, DOI 10.1016/S0016-5085(98)70209-4; Datto MB, 1999, MOL CELL BIOL, V19, P2495; Goto D, 1998, FEBS LETT, V430, P201, DOI 10.1016/S0014-5793(98)00658-9; Haber PS, 1999, AM J PATHOL, V155, P1087, DOI 10.1016/S0002-9440(10)65211-X; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Kanamaru C, 2001, J BIOL CHEM, V276, P45636, DOI 10.1074/jbc.M105302200; KIM SJ, 1989, J BIOL CHEM, V264, P7041; Kruse ML, 2000, REGUL PEPTIDES, V90, P47, DOI 10.1016/S0167-0115(00)00104-X; LEE MS, 1995, AM J PATHOL, V147, P42; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Menke A, 1997, GASTROENTEROLOGY, V113, P295, DOI 10.1016/S0016-5085(97)70107-0; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; OHNISHI H, 1995, J CLIN INVEST, V95, P2304, DOI 10.1172/JCI117922; Ohnishi H, 1997, J BIOL CHEM, V272, P16056, DOI 10.1074/jbc.272.25.16056; Ohnishi H, 1999, GASTROENTEROLOGY, V116, P943, DOI 10.1016/S0016-5085(99)70078-8; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Schnabl B, 2001, HEPATOLOGY, V34, P89, DOI 10.1053/jhep.2001.25349; Suzuki J, 2001, J CLIN INVEST, V107, P363, DOI 10.1172/JCI10254; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; Weinstein M, 1998, P NATL ACAD SCI USA, V95, P9378, DOI 10.1073/pnas.95.16.9378; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Yue JB, 2000, J BIOL CHEM, V275, P30765, DOI 10.1074/jbc.M000039200	27	82	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8873	8878		10.1074/jbc.M309698200	http://dx.doi.org/10.1074/jbc.M309698200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14688282	hybrid			2022-12-25	WOS:000189265900044
J	Vila, R; Kurosaki, M; Barzago, MM; Kolek, M; Bastone, A; Colombo, L; Salmona, M; Terao, M; Garattini, E				Vila, R; Kurosaki, M; Barzago, MM; Kolek, M; Bastone, A; Colombo, L; Salmona, M; Terao, M; Garattini, E			Regulation and biochemistry of mouse molybdo-flavoenzymes - The DBA/2 mouse is selectively deficient in the expression of aldehyde oxidase homologues 1 and 2 and represents a unique source for the purification and characterization of aldehyde oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID SYNTHESIS; XANTHINE-OXIDOREDUCTASE; ALCOHOL-DEHYDROGENASE; MOLECULAR-CLONING; GUINEA-PIG; TISSUE DISTRIBUTION; ESCHERICHIA-COLI; MAMMARY-GLAND; LIVER-INJURY; IN-VIVO	Mouse molybdo-flavoenzymes consist of xanthine oxidoreductase, aldehyde oxidase (AOX1), and two recently identified proteins, AOH1 and AOH2 ( aldehyde oxidase homologues 1 and 2). Here we demonstrate that CD-1, C57BL/6, 129/Sv, and other mouse strains synthesize high levels of AOH1 in the liver and AOH2 in the skin. By contrast, the DBA/2 and CBA strains are unique, having a selective deficit in the expression of the AOH1 and AOH2 genes. DBA/2 animals synthesize trace amounts of a catalytically active AOH1 protein. However, relative to CD-1 animals, an over 2 log reduction in the steady-state levels of liver AOH1 mRNA, protein, and enzymatic activity is observed in basal conditions and following administration of testosterone. The DBA/2 mouse represents a unique opportunity to purify AOX1 and compare its enzymatic characteristics to those of the AOH1 protein. The spectroscopy and biochemistry of AOX1 are very similar to those of AOH1 except for a differential sensitivity to the non-competitive inhibitory effect of norharmane. AOX1 and AOH1 oxidize an overlapping set of aldehydes and heterocycles. For most compounds, the substrate efficiency (V-max/K-m) of AOX1 is superior to that of AOH1. Alkylic alcohols and acetaldehyde, the toxic metabolite of ethanol, are poor substrates of both enzymes. Consistent with this, the levels of acetaldehyde in the livers of ethanol administered CD-1 and DBA/2 mice are similar, indicating that neither enzyme is involved in the in vivo biotransformation of acetaldehyde.	Mario Negri Inst Pharmacol Res, Ctr Catullo & Daniele Borgomainerio, Mol Biol Lab, Dept Mol Pharmacol & Biochem, I-20157 Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Garattini, E (corresponding author), Mario Negri Inst Pharmacol Res, Ctr Catullo & Daniele Borgomainerio, Mol Biol Lab, Dept Mol Pharmacol & Biochem, Via Eritrea 62, I-20157 Milan, Italy.	egarattini@marionegri.it	KUROSAKI, Mami/ABG-2224-2020; Terao, Mineko/AAA-6415-2020; terao, mineko/AAU-8089-2020; Garattini, Enrico/AAI-1998-2019; Barzago, Maria Monica/AAA-6402-2020; salmona, mario/ABI-4066-2020; colombo, laura/AAA-6716-2020; salmona, mario/AAA-7116-2020	KUROSAKI, Mami/0000-0001-8231-713X; Terao, Mineko/0000-0002-9976-9869; Barzago, Maria Monica/0000-0002-6952-0069; colombo, laura/0000-0002-3243-0270; salmona, mario/0000-0002-9098-9873; Garattini, Enrico/0000-0001-8983-886X				BADWEY JA, 1981, J BIOL CHEM, V256, P3479; Baylin SB, 1998, ADV CANCER RES, V72, P141; Calzi ML, 1995, J BIOL CHEM, V270, P31037, DOI 10.1074/jbc.270.52.31037; CARPANI G, 1990, ARCH BIOCHEM BIOPHYS, V279, P237, DOI 10.1016/0003-9861(90)90487-J; Demontis S, 1999, BBA-GENE STRUCT EXPR, V1489, P207, DOI 10.1016/S0167-4781(99)00174-8; Doehner W, 2002, CIRCULATION, V105, P2619, DOI 10.1161/01.CIR.0000017502.58595.ED; Duester G, 1999, ADV EXP MED BIOL, V463, P311; Enroth C, 2000, P NATL ACAD SCI USA, V97, P10723, DOI 10.1073/pnas.97.20.10723; Eriksson CJP, 2001, ALCOHOL CLIN EXP RES, V25, p15S, DOI 10.1111/j.1530-0277.2001.tb02369.x; FORTEMCROBBIE CM, 1986, J BIOL CHEM, V261, P2154; Garattini E, 2003, BIOCHEM J, V372, P15, DOI 10.1042/BJ20030121; Harrison R, 2002, FREE RADICAL BIO MED, V33, P774, DOI 10.1016/S0891-5849(02)00956-5; Holmes R S, 1980, Adv Exp Med Biol, V132, P57; HOLMES RS, 1978, COMP BIOCHEM PHYS B, V61, P339, DOI 10.1016/0305-0491(78)90134-7; HOLMES RS, 1979, BIOCHEM GENET, V17, P517, DOI 10.1007/BF00498887; HOLMES RS, 1981, ANIM BLOOD GROUPS BI, V12, P193; HUANG DY, 1994, BIOCHEM BIOPH RES CO, V205, P1278, DOI 10.1006/bbrc.1994.2803; JOHNS DG, 1967, J CLIN INVEST, V46, P1492, DOI 10.1172/JCI105641; Jordan CGM, 1999, J PHARM PHARMACOL, V51, P411, DOI 10.1211/0022357991772619; Kurosaki M, 1996, BIOCHEM J, V319, P801, DOI 10.1042/bj3190801; Kurosaki M, 1999, BIOCHEM J, V341, P71, DOI 10.1042/0264-6021:3410071; KUROSAKI M, 1995, BIOCHEM J, V306, P225, DOI 10.1042/bj3060225; Kuwabara Y, 2003, P NATL ACAD SCI USA, V100, P8170, DOI 10.1073/pnas.1431485100; LEE MO, 1991, BIOCHEM PHARMACOL, V42, P1279, DOI 10.1016/0006-2952(91)90266-8; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; McManaman JL, 2002, J PHYSIOL-LONDON, V545, P567, DOI 10.1113/jphysiol.2002.027185; MIRA L, 1995, ARCH BIOCHEM BIOPHYS, V318, P53, DOI 10.1006/abbi.1995.1203; Molotkov A, 2002, P NATL ACAD SCI USA, V99, P5337, DOI 10.1073/pnas.082093299; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; Niederreither K, 2002, P NATL ACAD SCI USA, V99, P16111, DOI 10.1073/pnas.252626599; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Shambrook J, 1989, MOL CLONING LAB MANU; SHAW S, 1990, BIOCHEM J, V268, P579, DOI 10.1042/bj2680579; SHAW S, 1992, LIFE SCI, V50, P2045, DOI 10.1016/0024-3205(92)90570-F; STELL JGP, 1989, J CHROMATOGR, V475, P363, DOI 10.1016/S0021-9673(01)89690-4; STODDART AM, 1992, BIOCHEM PHARMACOL, V43, P2227, DOI 10.1016/0006-2952(92)90182-I; Sugihara K, 1999, BIOL PHARM BULL, V22, P1246; Terao M, 2000, J BIOL CHEM, V275, P30690, DOI 10.1074/jbc.M005355200; Terao M, 1998, BIOCHEM J, V332, P383, DOI 10.1042/bj3320383; TERAO M, 1992, BIOCHEM J, V283, P863, DOI 10.1042/bj2830863; Terao M, 2001, J BIOL CHEM, V276, P46347, DOI 10.1074/jbc.M105744200; TSUJITA M, 1994, BBA-PROTEIN STRUCT M, V1204, P108, DOI 10.1016/0167-4838(94)90039-6; Tuma DJ, 2002, FREE RADICAL BIO MED, V32, P303, DOI 10.1016/S0891-5849(01)00742-0; Vorbach C, 2002, GENE DEV, V16, P3223, DOI 10.1101/gad.1032702; Wang XS, 1996, J BIOL CHEM, V271, P16288, DOI 10.1074/jbc.271.27.16288; Wingender E, 1997, NUCLEIC ACIDS RES, V25, P265, DOI 10.1093/nar/25.1.265; Yoshihara S, 1997, ARCH BIOCHEM BIOPHYS, V338, P29, DOI 10.1006/abbi.1996.9774; YOSHIHARA S, 1985, ARCH BIOCHEM BIOPHYS, V242, P213, DOI 10.1016/0003-9861(85)90495-3	48	38	41	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8668	8683		10.1074/jbc.M308137200	http://dx.doi.org/10.1074/jbc.M308137200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14665639	hybrid			2022-12-25	WOS:000189265900019
